Torasde	O
de	O
poinets	O
ventircular	O
tacyhcardia	O
during	O
low	O
dsoe	O
itnermittent	O
dboutamine	B-Chemical
traetment	O
in	O
a	O
pateint	O
with	O
dialted	O
cardioymopathy	O
and	O
congsetive	O
herat	O
failrue	O
.	O

The	O
atuhors	O
describe	O
the	O
csae	O
of	O
a	O
56	O
-	O
yaer	O
-	O
old	O
woamn	O
with	O
crhonic	O
,	O
sveere	O
herat	O
faiulre	O
secondary	O
to	O
dliated	O
cardioymopathy	O
and	O
absecne	O
of	O
significant	O
ventriuclar	O
arrhythmais	O
who	O
developed	O
QT	O
prolongatoin	O
and	O
tosrade	O
de	O
piontes	O
ventircular	O
tahcycardia	O
during	O
one	O
ccyle	O
of	O
interimttent	O
low	O
dsoe	O
(	O
2	O
.	O
5	O
mcg	O
/	O
kg	O
per	O
min	O
)	O
dobutamnie	B-Chemical
.	O

This	O
rpeort	O
of	O
torsdae	O
de	O
ponites	O
ventircular	O
tachycradia	O
during	O
itnermittent	O
dobutamnie	B-Chemical
supports	O
the	O
hypotheiss	O
that	O
unprdeictable	O
ftaal	O
arrhyhtmias	O
may	O
occur	O
even	O
with	O
low	O
dsoes	O
and	O
in	O
pateints	O
with	O
no	O
hitsory	O
of	O
significant	O
rhtyhm	O
disutrbances	O
.	O

The	O
mechnaisms	O
of	O
praorrhythmic	O
effetcs	O
of	O
Dubutaimne	B-Chemical
are	O
discussed	O
.	O

Posiitve	O
sikn	O
tsets	O
in	O
ltae	O
reactinos	O
to	O
rdaiographic	O
contrast	B-Chemical
mdeia	I-Chemical
.	O

In	O
the	O
last	O
few	O
yaers	O
dleayed	O
reactinos	O
several	O
hours	O
after	O
the	O
injcetion	O
of	O
raidographic	O
and	O
contrast	B-Chemical
materilas	I-Chemical
(	O
PRC	B-Chemical
)	O
have	O
been	O
described	O
with	O
icnreasing	O
frqeuency	O
.	O

The	O
autohrs	O
reoprt	O
two	O
observatoins	O
on	O
patinets	O
with	O
dealyed	O
recations	O
in	O
whom	O
intrdaermoreactions	O
(	O
IDR	O
)	O
and	O
ptach	O
tsets	O
to	O
a	O
series	O
of	O
ioinc	O
and	O
non	O
ioinc	O
PRC	B-Chemical
were	O
studied	O
.	O

After	O
anigography	O
by	O
the	O
venuos	O
rotue	O
in	O
patinet	O
n	O
dergee	O
1	O
a	O
bpihasic	O
reatcion	O
with	O
an	O
immdeiate	O
recation	O
(	O
dsypnea	O
,	O
lsos	O
of	O
consciousenss	O
)	O
and	O
delyaed	O
mcaro	O
-	O
pauplar	O
rsah	O
appeared	O
,	O
whilst	O
patinet	O
n	O
dergee	O
2	O
developed	O
a	O
geenralised	O
sensaiton	O
of	O
haet	O
,	O
presistent	O
pian	O
at	O
the	O
stie	O
of	O
ijnection	O
immediately	O
and	O
a	O
gneeralised	O
marco	O
-	O
papualr	O
reactoin	O
after	O
24	O
hours	O
.	O

The	O
sikn	O
tsets	O
reevaled	O
posiitve	O
delaeyd	O
raections	O
of	O
24	O
hours	O
and	O
48	O
hours	O
by	O
IDR	O
and	O
ptach	O
tsets	O
to	O
only	O
some	O
PRC	B-Chemical
with	O
common	O
chanis	O
in	O
their	O
strucutres	O
.	O

The	O
posiitve	O
sikn	O
tsets	O
are	O
in	O
favour	O
of	O
immuonlogical	O
reactinos	O
and	O
may	O
help	O
in	O
diagnoiss	O
of	O
alelrgy	O
in	O
the	O
patinets	O
.	O

Rsik	O
of	O
tarnsient	O
hyperammonmeic	O
ecnephalopathy	O
in	O
cacner	O
paitents	O
who	O
received	O
cotninuous	O
ifnusion	O
of	O
5	B-Chemical
-	I-Chemical
fluroouracil	I-Chemical
with	O
the	O
comlpication	O
of	O
dehydartion	O
and	O
infetcion	O
.	O

From	O
1986	O
to	O
1998	O
,	O
29	O
canecr	O
pateints	O
who	O
had	O
32	O
episoeds	O
of	O
transinet	O
hyperammoneimc	O
encephlaopathy	O
related	O
to	O
conitnuous	O
infuison	O
of	O
5	B-Chemical
-	I-Chemical
fluoruoracil	I-Chemical
(	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
)	O
were	O
identiifed	O
.	O

None	O
of	O
the	O
patietns	O
had	O
decmopensated	O
lievr	O
diesase	O
.	O

Onest	O
of	O
hyperammnoemic	O
enecphalopathy	O
varied	O
from	O
0	O
.	O
5	O
to	O
5	O
dyas	O
(	O
mean	O
:	O
2	O
.	O
6	O
+	O
/	O
-	O
1	O
.	O
3	O
dyas	O
)	O
after	O
the	O
intiiation	O
of	O
chemohterapy	O
.	O

Plamsa	O
ammoinum	B-Chemical
lveel	O
ranged	O
from	O
248	O
to	O
2387	O
mcirog	O
%	O
(	O
mean	O
:	O
626	O
+	O
/	O
-	O
431	O
micorg	O
%	O
)	O
.	O

Among	O
the	O
32	O
episoeds	O
,	O
26	O
(	O
81	O
%	O
)	O
had	O
various	O
degeres	O
of	O
azoetmia	O
,	O
18	O
(	O
56	O
%	O
)	O
occurred	O
during	O
bacetrial	O
infectinos	O
and	O
14	O
(	O
44	O
%	O
)	O
without	O
infectoin	O
occurred	O
during	O
preiods	O
of	O
deyhdration	O
.	O

Higehr	O
plsama	O
ammonium	B-Chemical
levles	O
and	O
more	O
raipd	O
onset	O
of	O
hyperammonmeia	O
were	O
seen	O
in	O
18	O
ptaients	O
with	O
bacetrial	O
inefctions	O
(	O
p	O
=	O
0	O
.	O
003	O
and	O
0	O
.	O
0006	O
,	O
respectively	O
)	O
and	O
in	O
nine	O
patietns	O
receiving	O
high	O
dialy	O
dsoes	O
(	O
2600	O
or	O
1800	O
mg	O
/	O
m2	O
)	O
of	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
(	O
p	O
=	O
0	O
.	O
0001	O
and	O
<	O
0	O
.	O
0001	O
,	O
respectively	O
)	O
.	O

In	O
25	O
out	O
of	O
32	O
episdoes	O
(	O
78	O
%	O
)	O
,	O
palsma	O
ammoinum	B-Chemical
lveels	O
and	O
menatl	O
stauts	O
returned	O
to	O
nromal	O
within	O
2	O
dyas	O
after	O
adqeuate	O
mangaement	O
.	O

In	O
conclusion	O
,	O
hypermamonemic	O
ecnephalopathy	O
can	O
occur	O
in	O
patietns	O
receiving	O
contniuous	O
ifnusion	O
of	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
.	O

Azoteima	O
,	O
bdoy	O
fliud	O
insufifciency	O
and	O
bacetrial	O
inefctions	O
were	O
frequently	O
found	O
in	O
these	O
paitents	O
.	O

It	O
is	O
therefore	O
important	O
to	O
recognize	O
this	O
condtiion	O
in	O
ptaients	O
receiving	O
continuuos	O
infuison	O
of	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
.	O

The	O
effcets	O
of	O
qiunine	B-Chemical
and	O
4	B-Chemical
-	I-Chemical
amionpyridine	I-Chemical
on	O
condiitoned	O
place	O
preferecne	O
and	O
chanegs	O
in	O
mootr	O
actviity	O
idnuced	O
by	O
morphnie	B-Chemical
in	O
rtas	O
.	O

1	O
.	O

The	O
effects	O
of	O
two	O
unselective	O
ptoassium	B-Chemical
(	O
K	B-Chemical
(	O
+	O
)	O
-	O
)	O
chnanel	O
blcokers	O
,	O
qiunine	B-Chemical
(	O
12	O
.	O
5	O
,	O
25	O
and	O
50	O
mg	O
/	O
kg	O
)	O
and	O
4	B-Chemical
-	I-Chemical
amionpyridine	I-Chemical
(	O
1	O
and	O
2	O
mg	O
/	O
kg	O
)	O
,	O
on	O
codnitioned	O
place	O
prefernece	O
and	O
bipahsic	O
chnages	O
in	O
mootr	O
atcivity	O
idnuced	O
by	O
morhpine	B-Chemical
(	O
10	O
mg	O
/	O
kg	O
)	O
were	O
tesetd	O
in	O
Wisatr	O
rtas	O
.	O

Quinnie	B-Chemical
is	O
known	O
to	O
blcok	O
vlotage	O
-	O
,	O
caclium	B-Chemical
-	O
and	O
ATP	B-Chemical
-	O
senistive	O
K	B-Chemical
(	O
+	O
)	O
-	O
channels	O
while	O
4	B-Chemical
-	I-Chemical
aimnopyridine	I-Chemical
is	O
known	O
to	O
blcok	O
votlage	O
-	O
snesitive	O
K	B-Chemical
(	O
+	O
)	O
-	O
cahnnels	O
.	O

2	O
.	O

In	O
the	O
counterbalacned	O
mehtod	O
,	O
quiinne	B-Chemical
attneuated	O
morpihne	B-Chemical
-	O
induecd	O
place	O
prefeernce	O
,	O
whereas	O
4	B-Chemical
-	I-Chemical
aminopryidine	I-Chemical
was	O
inefefctive	O
.	O

In	O
the	O
mtoor	O
atcivity	O
tset	O
measrued	O
with	O
an	O
Aniemx	O
-	O
atcivity	O
mteer	O
neither	O
of	O
the	O
K	B-Chemical
(	O
+	O
)	O
-	O
chnanel	O
blocekrs	O
afefcted	O
morhpine	B-Chemical
-	O
inudced	O
hypoactviity	O
,	O
but	O
both	O
K	B-Chemical
(	O
+	O
)	O
-	O
chnanel	O
blocekrs	O
prevented	O
morphnie	B-Chemical
-	O
idnuced	O
secondary	O
hypercativity	O
.	O

3	O
.	O

These	O
resluts	O
suggest	O
the	O
invlovement	O
of	O
quniine	B-Chemical
-	O
sesnitive	O
but	O
not	O
4	B-Chemical
-	I-Chemical
aminopyridnie	I-Chemical
-	O
senistive	O
K	B-Chemical
(	O
+	O
)	O
-	O
channles	O
in	O
morpihne	B-Chemical
reawrd	O
.	O

It	O
is	O
also	O
suggested	O
that	O
the	O
blocakde	O
of	O
K	B-Chemical
(	O
+	O
)	O
-	O
channles	O
snesitive	O
to	O
these	O
blokcers	O
is	O
not	O
sufficient	O
to	O
prveent	O
morhpine	B-Chemical
-	O
induecd	O
hypoacitvity	O
whereas	O
morhpine	B-Chemical
-	O
inudced	O
hpyeractivity	O
seems	O
to	O
be	O
connected	O
to	O
both	O
quinnie	B-Chemical
-	O
and	O
4	B-Chemical
-	I-Chemical
aminopyrdiine	I-Chemical
-	O
senistive	O
K	B-Chemical
(	O
+	O
)	O
-	O
channels	O
.	O

Noicceptin	B-Chemical
/	O
orphainn	B-Chemical
FQ	I-Chemical
and	O
nocistaitn	B-Chemical
on	O
laerning	O
and	O
memroy	O
impairemnt	O
induecd	O
by	O
scopolmaine	B-Chemical
in	O
mcie	O
.	O

1	O
.	O

Nocicpetin	B-Chemical
,	O
also	O
known	O
as	O
orphainn	B-Chemical
FQ	I-Chemical
,	O
is	O
an	O
endogeonus	O
lignad	O
for	O
the	O
orphan	O
oipoid	O
recpetor	O
-	O
like	O
recpetor	O
1	O
(	O
OLR1	O
)	O
and	O
involves	O
in	O
various	O
funcitons	O
in	O
the	O
cetnral	O
nervuos	O
sytsem	O
(	O
CNS	O
)	O
.	O

On	O
the	O
other	O
hand	O
,	O
nocistaitn	B-Chemical
is	O
recently	O
isolaetd	O
from	O
the	O
same	O
percursor	O
as	O
nociecptin	B-Chemical
and	O
bolcks	O
nocicpetin	B-Chemical
-	O
inudced	O
alloydnia	O
and	O
hyperaglesia	O
.	O

2	O
.	O

Although	O
OLR1	O
reecptors	O
which	O
display	O
a	O
high	O
degere	O
of	O
sqeuence	O
homolgoy	O
with	O
classical	O
opoiid	O
rceeptors	O
are	O
abudnant	O
in	O
the	O
hippocmapus	O
,	O
little	O
is	O
known	O
regarding	O
their	O
role	O
in	O
leanring	O
and	O
memroy	O
.	O

3	O
.	O

The	O
present	O
stduy	O
was	O
designed	O
to	O
investigtae	O
whether	O
nocicpetin	B-Chemical
/	O
orphainn	B-Chemical
FQ	I-Chemical
and	O
nocisattin	B-Chemical
could	O
modultae	O
impariment	O
of	O
learinng	O
and	O
memroy	O
inudced	O
by	O
scoploamine	B-Chemical
,	O
a	O
muscarniic	O
cholienrgic	O
recpetor	O
anatgonist	O
,	O
using	O
spotnaneous	O
altrenation	O
of	O
Y	O
-	O
mzae	O
and	O
step	O
-	O
down	O
tpye	O
pasisve	O
aviodance	O
tsaks	O
in	O
mcie	O
.	O

4	O
.	O

While	O
nocsitatin	B-Chemical
(	O
0	O
.	O
5	O
-	O
5	O
.	O
0	O
nmol	O
muose	O
-	O
1	O
,	O
i	O
.	O
c	O
.	O
v	O
.	O
)	O
admniistered	O
30	O
min	O
before	O
sponatneous	O
alterantion	O
performacne	O
or	O
the	O
tarining	O
ssesion	O
of	O
the	O
passive	O
avoidacne	O
tsak	O
,	O
had	O
no	O
effcet	O
on	O
spontnaeous	O
aletrnation	O
or	O
passvie	O
avoidacne	O
behaviorus	O
,	O
a	O
lwoer	O
per	O
cent	O
alterantion	O
and	O
shotrer	O
meidan	O
step	O
-	O
down	O
latecny	O
in	O
the	O
rteention	O
tset	O
were	O
obtained	O
in	O
noicceptin	B-Chemical
(	O
1	O
.	O
5	O
and	O
/	O
or	O
5	O
.	O
0	O
nmol	O
muose	O
-	O
1	O
,	O
i	O
.	O
c	O
.	O
v	O
.	O
)	O
-	O
tretaed	O
nomral	O
mcie	O
.	O

5	O
.	O

Adminisrtation	O
of	O
nocisttain	B-Chemical
(	O
1	O
.	O
5	O
and	O
/	O
or	O
5	O
.	O
0	O
nmol	O
muose	O
-	O
1	O
,	O
i	O
.	O
c	O
.	O
v	O
.	O
)	O
30	O
min	O
before	O
spotnaneous	O
alterntaion	O
perforamnce	O
or	O
the	O
traiinng	O
sesison	O
of	O
the	O
passive	O
aviodance	O
tsak	O
,	O
attenuated	O
the	O
scopolaimne	B-Chemical
-	O
induecd	O
impairmnet	O
of	O
spnotaneous	O
alterntaion	O
and	O
passvie	O
avoiadnce	O
bheaviours	O
.	O

6	O
.	O

These	O
reuslts	O
indicated	O
that	O
ncoistatin	B-Chemical
,	O
a	O
new	O
biologiclaly	O
acitve	O
peptdie	O
,	O
ameilorates	O
impaimrents	O
of	O
spontaenous	O
altrenation	O
and	O
passvie	O
avoidacne	O
indcued	O
by	O
scopolmaine	B-Chemical
,	O
and	O
suggested	O
that	O
these	O
ppetides	O
play	O
opposite	O
roles	O
in	O
laerning	O
and	O
mmeory	O
.	O

Meloxiacm	B-Chemical
-	O
inudced	O
lvier	O
toxictiy	O
.	O

We	O
reprot	O
the	O
csae	O
of	O
a	O
feamle	O
paitent	O
with	O
rheumaotid	O
arthrtiis	O
who	O
developed	O
actue	O
cytoyltic	O
heaptitis	O
due	O
to	O
meolxicam	B-Chemical
.	O

Recently	O
introduced	O
in	O
Blegium	O
,	O
mleoxicam	B-Chemical
is	O
the	O
first	O
nonsteroiadl	O
anitinflammatory	O
durg	O
with	O
selective	O
atcion	O
on	O
the	O
idnucible	O
form	O
of	O
cyclooxygnease	O
2	O
.	O

The	O
aucte	O
cytoyltic	O
hepaittis	O
occurred	O
rapidly	O
after	O
meolxicam	B-Chemical
adminisrtation	O
and	O
was	O
associated	O
with	O
the	O
dveelopment	O
of	O
antinucelar	O
anitbodies	O
suggesting	O
a	O
hypersnesitivity	O
mechainsm	O
.	O

This	O
first	O
csae	O
of	O
melxoicam	B-Chemical
related	O
lievr	O
toixcity	O
demonstrates	O
the	O
potetnial	O
of	O
this	O
durg	O
to	O
idnuce	O
hpeatic	O
daamge	O
.	O

Inductoin	O
of	O
apoptsois	O
by	O
remoxirpide	B-Chemical
metaboliets	O
in	O
H6L0	O
and	O
C3D4	O
+	O
/	O
C1D9	O
-	O
hmuan	O
bnoe	O
marrow	O
progneitor	O
clels	O
:	O
potenital	O
relevance	O
to	O
rmeoxipride	B-Chemical
-	O
inudced	O
aplasitc	O
aenmia	O
.	O

The	O
antipsychtoic	O
aegnt	O
,	O
remoxiprdie	B-Chemical
[	O
(	B-Chemical
S	I-Chemical
)	I-Chemical
-	I-Chemical
(	I-Chemical
-	I-Chemical
)	I-Chemical
-	I-Chemical
3	I-Chemical
-	I-Chemical
bormo	I-Chemical
-	I-Chemical
N	I-Chemical
-	I-Chemical
[	I-Chemical
(	I-Chemical
1	I-Chemical
-	I-Chemical
ehtyl	I-Chemical
-	I-Chemical
2	I-Chemical
-	I-Chemical
pryrolidinyl	I-Chemical
)	I-Chemical
mehtyl	I-Chemical
]	I-Chemical
-	I-Chemical
2	I-Chemical
,	I-Chemical
6	I-Chemical
-	I-Chemical
dmiethoxybenz	I-Chemical
amdie	I-Chemical
]	O
has	O
been	O
associated	O
with	O
acquired	O
aplatsic	O
aneima	O
.	O

We	O
have	O
examined	O
the	O
ability	O
of	O
rmeoxipride	B-Chemical
,	O
three	O
pyrroildine	B-Chemical
rnig	O
metaoblites	O
and	O
five	O
armoatic	O
rnig	O
metaboliets	O
of	O
the	O
paernt	O
copmound	O
to	O
inudce	O
apoptsois	O
in	O
H6L0	O
cells	O
and	O
huamn	O
bnoe	O
mrarow	O
prgoenitor	O
(	O
HMBP	O
)	O
cells	O
.	O

Clels	O
were	O
terated	O
for	O
0	O
-	O
24	O
h	O
with	O
each	O
cmopound	O
(	O
0	O
-	O
200	O
microM	O
)	O
.	O

Appotosis	O
was	O
assessed	O
by	O
fluroescence	O
microscpoy	O
in	O
Hoecsht	B-Chemical
33342	I-Chemical
-	O
and	O
prpoidium	B-Chemical
idoide	I-Chemical
staiend	O
clel	O
sapmles	O
.	O

Reuslts	O
were	O
confirmed	O
by	O
deetrmination	O
of	O
internucleosoaml	O
DNA	O
fragmenattion	O
using	O
gel	O
eelctrophoresis	O
for	O
H6L0	O
clel	O
sampels	O
and	O
terimnal	O
deoxyuncleotidyl	O
transefrase	O
asasy	O
in	O
HMBP	O
cells	O
.	O

The	O
catecohl	B-Chemical
and	O
hydrqouinone	B-Chemical
meatbolites	O
,	O
NCQ346	B-Chemical
and	O
NC3Q44	B-Chemical
,	O
indcued	O
appotosis	O
in	O
H6L0	O
and	O
HMBP	O
cells	O
in	O
a	O
tmie	O
-	O
and	O
concetnration	O
dependnet	O
manner	O
,	O
while	O
the	O
pheonls	B-Chemical
,	O
NRC181	O
,	O
FLA783	O
,	O
and	O
FLA977	B-Chemical
,	O
and	O
the	O
derivatvies	O
formed	O
by	O
oxidtaion	O
of	O
the	O
pyrroildine	B-Chemical
rnig	O
,	O
FAL838	O
,	O
NMC001	O
,	O
and	O
NCL118	O
,	O
had	O
no	O
efefct	O
.	O

No	O
necroiss	O
was	O
observed	O
in	O
cells	O
traeted	O
with	O
NC4Q36	B-Chemical
but	O
NCQ434	B-Chemical
had	O
a	O
biphaisc	O
effect	O
in	O
both	O
clel	O
types	O
,	O
inudcing	O
appotosis	O
at	O
loewr	O
conecntrations	O
and	O
necorsis	O
at	O
hgiher	O
concentrtaions	O
.	O

These	O
dtaa	O
show	O
that	O
the	O
caetchol	B-Chemical
and	O
hyrdoquinone	B-Chemical
metaboiltes	O
of	O
remoixpride	B-Chemical
have	O
direct	O
toixc	O
effects	O
in	O
H6L0	O
and	O
HMBP	O
clels	O
,	O
leading	O
to	O
aopptosis	O
,	O
while	O
the	O
pehnol	B-Chemical
metaboiltes	O
were	O
ianctive	O
.	O

Similarly	O
,	O
benezne	B-Chemical
-	O
derived	O
catecohl	B-Chemical
and	O
hydroquinnoe	B-Chemical
,	O
but	O
not	O
pheonl	B-Chemical
,	O
inudce	O
apopotsis	O
in	O
HMBP	O
cells	O
[	O
Mroan	O
et	O
al	O
.	O
,	O
Mol	O
.	O
Phamracol	O
.	O
,	O
50	O
(	O
1996	O
)	O
610	O
-	O
615	O
]	O
.	O

We	O
propose	O
that	O
remoxpiride	B-Chemical
and	O
benezne	B-Chemical
may	O
indcue	O
aplsatic	O
aenmia	O
via	O
porduction	O
of	O
similar	O
reacitve	O
metabolties	O
and	O
that	O
the	O
ability	O
of	O
NQC436	B-Chemical
and	O
NQC344	B-Chemical
to	O
idnuce	O
appotosis	O
in	O
HMBP	O
clels	O
may	O
contribute	O
to	O
the	O
mcehanism	O
underlying	O
acquired	O
aplsatic	O
aenmia	O
that	O
has	O
been	O
associated	O
with	O
remoixpride	B-Chemical
.	O

Synhtesis	O
and	O
preliminary	O
pharmacologiacl	O
invesitgations	O
of	O
1	B-Chemical
-	I-Chemical
(	I-Chemical
1	I-Chemical
,	I-Chemical
2	I-Chemical
-	I-Chemical
dihdyro	I-Chemical
-	I-Chemical
2	I-Chemical
-	I-Chemical
acenapthhylenyl	I-Chemical
)	I-Chemical
piperaizne	I-Chemical
deriavtives	O
as	O
ptoential	O
aytpical	O
antipsycohtic	O
agetns	O
in	O
mcie	O
.	O

In	O
resaerch	O
towards	O
the	O
deveolpment	O
of	O
new	O
atypiacl	O
antispychotic	O
agetns	O
,	O
one	O
strategy	O
is	O
that	O
the	O
dopamniergic	O
sysetm	O
can	O
be	O
modluated	O
through	O
manipluation	O
of	O
the	O
seortonergic	O
sysetm	O
.	O

The	O
sytnhesis	O
and	O
preliminary	O
phamracological	O
evaulation	O
of	O
a	O
series	O
of	O
ptoential	O
atypiacl	O
antpisychotic	O
agnets	O
based	O
on	O
the	O
srtucture	O
of	O
1	B-Chemical
-	I-Chemical
(	I-Chemical
1	I-Chemical
,	I-Chemical
2	I-Chemical
-	I-Chemical
diyhdro	I-Chemical
-	I-Chemical
2	I-Chemical
-	I-Chemical
acenapthhylenyl	I-Chemical
)	I-Chemical
pipreazine	I-Chemical
(	O
7	O
)	O
is	O
described	O
.	O

Copmound	O
7e	O
,	O
5	B-Chemical
-	I-Chemical
{	I-Chemical
2	I-Chemical
-	I-Chemical
[	I-Chemical
4	I-Chemical
-	I-Chemical
(	I-Chemical
1	I-Chemical
,	I-Chemical
2	I-Chemical
-	I-Chemical
dihdyro	I-Chemical
-	I-Chemical
2	I-Chemical
-	I-Chemical
acenpahthylenyl	I-Chemical
)	I-Chemical
pipreazinyl	I-Chemical
]	I-Chemical
etyhl	I-Chemical
}	I-Chemical
-	I-Chemical
2	I-Chemical
,	I-Chemical
3	I-Chemical
-	I-Chemical
dhiy	I-Chemical
dro	I-Chemical
-	I-Chemical
1H	I-Chemical
-	I-Chemical
inodl	I-Chemical
-	I-Chemical
2	I-Chemical
-	I-Chemical
one	I-Chemical
,	O
from	O
this	O
series	O
showed	O
significant	O
affinities	O
at	O
the	O
5	O
-	O
H1TA	O
and	O
5	O
-	O
H2TA	O
reecptors	O
and	O
moedrate	O
afifnity	O
at	O
the	O
D2	O
recpetor	O
.	O

7e	O
exhibits	O
a	O
high	O
rveersal	O
of	O
cataelpsy	O
induecd	O
by	O
halpoeridol	B-Chemical
indicating	O
its	O
atyipcal	O
antipsycohtic	O
nature	O
.	O

Sub	O
-	O
crhonic	O
inhiibtion	O
of	O
ntiric	B-Chemical
-	I-Chemical
oixde	I-Chemical
syntehsis	O
mdoifies	O
halopeirdol	B-Chemical
-	O
idnuced	O
catalpesy	O
and	O
the	O
number	O
of	O
NDAPH	B-Chemical
-	O
daiphorase	O
nuerons	O
in	O
mcie	O
.	O

RATINOALE	O
:	O
NG	B-Chemical
-	I-Chemical
nirto	I-Chemical
-	I-Chemical
L	I-Chemical
-	I-Chemical
argniine	I-Chemical
(	O
L	B-Chemical
-	I-Chemical
NAORG	I-Chemical
)	O
,	O
an	O
inhibtior	O
of	O
ntiric	B-Chemical
-	I-Chemical
oixde	I-Chemical
sytnhase	O
(	O
NOS	O
)	O
,	O
idnuces	O
catlaepsy	O
in	O
mcie	O
.	O

This	O
effect	O
undergoes	O
raipd	O
tolernace	O
,	O
showing	O
a	O
significant	O
dcerease	O
after	O
2	O
dyas	O
of	O
sub	O
-	O
chornic	O
L	B-Chemical
-	I-Chemical
NORAG	I-Chemical
teratment	O
.	O

Nitirc	B-Chemical
oxdie	I-Chemical
(	O
NO	B-Chemical
)	O
has	O
been	O
shown	O
to	O
infulence	O
doapminergic	O
neruotransmission	O
in	O
the	O
stritaum	O
.	O

Neuroletpic	O
drgus	O
such	O
as	O
halopeirdol	B-Chemical
,	O
which	O
bolck	O
dopamnie	B-Chemical
recpetors	O
,	O
also	O
cause	O
catalpesy	O
in	O
roednts	O
.	O

OBJECTIEVS	O
:	O
To	O
invetsigate	O
the	O
effects	O
of	O
subchroinc	O
L	B-Chemical
-	I-Chemical
NORAG	I-Chemical
treatmnet	O
in	O
haloperiodl	B-Chemical
-	O
idnuced	O
catalpesy	O
and	O
the	O
number	O
of	O
NOS	O
nuerons	O
in	O
areas	O
related	O
to	O
mootr	O
contorl	O
.	O

METHODS	O
:	O
Mlae	O
albnio	O
Swsis	O
mcie	O
were	O
terated	O
sub	O
-	O
chronically	O
(	O
twice	O
a	O
day	O
for	O
4	O
dyas	O
)	O
with	O
L	B-Chemical
-	I-Chemical
NORAG	I-Chemical
(	O
40	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
or	O
haolperidol	B-Chemical
(	O
1	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
.	O

Caatlepsy	O
was	O
eavluated	O
at	O
the	O
beginning	O
and	O
the	O
end	O
of	O
the	O
treatmetns	O
.	O

Rdeuced	O
nicotniamide	B-Chemical
adeinne	I-Chemical
dinucleoitde	I-Chemical
phsophate	I-Chemical
-	O
diapohrase	O
(	O
NDAPH	B-Chemical
-	O
d	O
)	O
histochmeistry	O
was	O
also	O
employed	O
to	O
visualize	O
NOS	O
as	O
an	O
index	O
of	O
enyzme	O
expresison	O
in	O
mcie	O
brian	O
reigons	O
related	O
to	O
mootr	O
cnotrol	O
.	O

RSEULTS	O
:	O
L	B-Chemical
-	I-Chemical
NORAG	I-Chemical
sub	O
-	O
chroinc	O
adminitsration	O
produced	O
tolearnce	O
of	O
L	B-Chemical
-	I-Chemical
NAORG	I-Chemical
and	O
of	O
haolperidol	B-Chemical
-	O
inudced	O
catalespy	O
.	O

It	O
also	O
idnuced	O
an	O
icnrease	O
in	O
the	O
number	O
of	O
NDAPH	B-Chemical
-	O
d	O
-	O
positvie	O
cells	O
in	O
the	O
dorasl	O
part	O
of	O
the	O
cauadte	O
and	O
accumbens	O
nculei	O
comapred	O
with	O
haloperiodl	B-Chemical
and	O
in	O
the	O
pdeunculopontine	O
tegmnetal	O
nulceus	O
comapred	O
with	O
salnie	O
.	O

In	O
contrast	O
,	O
there	O
was	O
a	O
dercease	O
in	O
NDAPH	B-Chemical
-	O
d	O
neuorn	O
number	O
in	O
the	O
substnatia	O
nirga	O
,	O
pras	O
comapcta	O
in	O
both	O
halopeirdol	B-Chemical
-	O
treaetd	O
and	O
L	B-Chemical
-	I-Chemical
NORAG	I-Chemical
-	O
traeted	O
anmials	O
.	O

CONLCUSIONS	O
:	O
The	O
rseults	O
give	O
further	O
support	O
to	O
the	O
hypohtesis	O
that	O
NO	B-Chemical
plays	O
a	O
role	O
in	O
mootr	O
behavoir	O
cnotrol	O
and	O
suggest	O
that	O
it	O
may	O
take	O
part	O
in	O
the	O
syanptic	O
cahnges	O
produced	O
by	O
antipyschotic	O
treatemnt	O
.	O

Prolnoged	O
lfet	O
ventircular	O
dyfsunction	O
occurs	O
in	O
ptaients	O
with	O
coronray	O
artrey	O
dsiease	O
after	O
both	O
dboutamine	B-Chemical
and	O
eexrcise	O
induecd	O
mycoardial	O
iscahemia	O
.	O

OBJECITVE	O
:	O
To	O
determine	O
whether	O
phamracological	O
strses	O
leads	O
to	O
prloonged	O
but	O
reversible	O
lfet	O
ventricluar	O
dyfsunction	O
in	O
paitents	O
with	O
cornoary	O
atrery	O
disaese	O
,	O
similar	O
to	O
that	O
seen	O
after	O
eexrcise	O
.	O

DESIGN	O
:	O
A	O
randoimsed	O
crossvoer	O
stduy	O
of	O
recvoery	O
tmie	O
of	O
sysotlic	O
and	O
disatolic	O
lfet	O
ventriuclar	O
functoin	O
after	O
exericse	O
and	O
dobuatmine	B-Chemical
idnuced	O
ischaeima	O
.	O

SUBJECTS	O
:	O
10	O
paitents	O
with	O
satble	O
anigna	O
,	O
angiogrpahically	O
proven	O
coroanry	O
artrey	O
dsiease	O
,	O
and	O
nromal	O
lfet	O
ventircular	O
fnuction	O
.	O

INETRVENTIONS	O
:	O
Teradmill	O
exercsie	O
and	O
dobutmaine	B-Chemical
strses	O
were	O
performed	O
on	O
different	O
dyas	O
.	O

Quanttiative	O
assesmsent	O
of	O
sytsolic	O
and	O
disatolic	O
lfet	O
vetnricular	O
fucntion	O
was	O
performed	O
using	O
transthorcaic	O
ehcocardiography	O
at	O
baselnie	O
and	O
at	O
regular	O
intevrals	O
after	O
each	O
tset	O
.	O

REUSLTS	O
:	O
Both	O
forms	O
of	O
sterss	O
led	O
to	O
porlonged	O
but	O
reversible	O
sysotlic	O
and	O
diasotlic	O
dyfsunction	O
.	O

There	O
was	O
no	O
difference	O
in	O
the	O
maxmium	O
double	O
proudct	O
(	O
p	O
=	O
0	O
.	O
53	O
)	O
or	O
ST	O
depression	O
(	O
p	O
=	O
0	O
.	O
63	O
)	O
with	O
either	O
form	O
of	O
strses	O
.	O

After	O
eexrcise	O
,	O
ejetcion	O
frcation	O
was	O
reudced	O
at	O
15	O
and	O
30	O
miuntes	O
compaerd	O
with	O
baseilne	O
(	O
mean	O
(	O
SEM	O
)	O
,	O
-	O
5	O
.	O
6	O
(	O
1	O
.	O
5	O
)	O
%	O
,	O
p	O
<	O
0	O
.	O
05	O
;	O
and	O
-	O
6	O
.	O
1	O
(	O
2	O
.	O
2	O
)	O
%	O
,	O
p	O
<	O
0	O
.	O
01	O
)	O
,	O
and	O
at	O
30	O
and	O
45	O
mintues	O
after	O
doubtamine	B-Chemical
(	O
-	O
10	O
.	O
8	O
(	O
1	O
.	O
8	O
)	O
%	O
and	O
-	O
5	O
.	O
5	O
(	O
1	O
.	O
8	O
)	O
%	O
,	O
both	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

Rgeional	O
analsyis	O
showed	O
a	O
redcution	O
in	O
the	O
worst	O
affecetd	O
semgent	O
15	O
and	O
30	O
mintues	O
after	O
exrecise	O
(	O
-	O
27	O
.	O
9	O
(	O
7	O
.	O
2	O
)	O
%	O
and	O
-	O
28	O
.	O
6	O
(	O
5	O
.	O
7	O
)	O
%	O
,	O
both	O
p	O
<	O
0	O
.	O
01	O
)	O
,	O
and	O
at	O
30	O
mniutes	O
after	O
dobutamnie	B-Chemical
(	O
-	O
32	O
(	O
5	O
.	O
3	O
)	O
%	O
,	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

The	O
iosvolumic	O
relaxtaion	O
preiod	O
was	O
porlonged	O
45	O
minuets	O
after	O
each	O
form	O
of	O
srtess	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

CONCLUISONS	O
:	O
In	O
patinets	O
with	O
coroanry	O
artrey	O
dsiease	O
,	O
dobutamnie	B-Chemical
idnuced	O
iscahemia	O
rseults	O
in	O
proolnged	O
reversible	O
lfet	O
ventriuclar	O
dysfunctoin	O
,	O
presumed	O
to	O
be	O
moycardial	O
sutnning	O
,	O
similar	O
to	O
that	O
seen	O
after	O
exericse	O
.	O

Dobtuamine	B-Chemical
inudced	O
ischaeima	O
could	O
therefore	O
be	O
used	O
to	O
stduy	O
the	O
pathophysoilogy	O
of	O
this	O
pheonmenon	O
further	O
in	O
paitents	O
with	O
croonary	O
aretry	O
dsiease	O
.	O

Anorexgiens	O
and	O
pulmoanry	O
hyeprtension	O
in	O
the	O
Uinted	O
Sattes	O
:	O
reuslts	O
from	O
the	O
surveilalnce	O
of	O
Notrh	O
Aemrican	O
pumlonary	O
hypetrension	O
.	O

BAKCGROUND	O
:	O
The	O
use	O
of	O
appetite	O
supperssants	O
in	O
Euorpe	O
has	O
been	O
associated	O
with	O
the	O
devleopment	O
of	O
priamry	O
pulmonray	O
hypertnesion	O
(	O
PPH	O
)	O
.	O

Recently	O
,	O
fenlfuramine	B-Chemical
appetite	O
suppressatns	O
became	O
widely	O
used	O
in	O
the	O
Unietd	O
Sattes	O
but	O
were	O
withdrawn	O
in	O
Setpember	O
1997	O
because	O
of	O
cnocerns	O
over	O
advrese	O
efefcts	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
We	O
conducted	O
a	O
prosepctive	O
surevillance	O
sutdy	O
on	O
patinets	O
diganosed	O
with	O
pumlonary	O
hyperetnsion	O
at	O
12	O
large	O
reefrral	O
cenetrs	O
in	O
Nroth	O
Ameirca	O
.	O

Dtaa	O
collected	O
on	O
ptaients	O
seen	O
from	O
Setpember	O
1	O
,	O
1996	O
,	O
to	O
December	O
31	O
,	O
1997	O
,	O
included	O
the	O
cause	O
of	O
the	O
plumonary	O
hypetrension	O
and	O
its	O
sevreity	O
.	O

Patietns	O
with	O
no	O
identifiable	O
cause	O
of	O
pulmoanry	O
hyperetnsion	O
were	O
classed	O
as	O
PPH	O
.	O

A	O
hitsory	O
of	O
durg	O
epxosure	O
also	O
was	O
taken	O
with	O
special	O
attetnion	O
on	O
the	O
use	O
of	O
antidepresasnts	O
,	O
anroexigens	O
,	O
and	O
amhpetamines	B-Chemical
.	O

RSEULTS	O
:	O
Five	O
hundred	O
seventy	O
-	O
nine	O
patinets	O
were	O
studied	O
,	O
205	O
with	O
PPH	O
and	O
374	O
with	O
plumonary	O
hypertesnion	O
from	O
other	O
causes	O
(	O
secondary	O
pulmonray	O
hypertesnion	O
[	O
SPH	O
]	O
)	O
.	O

The	O
use	O
of	O
anorexgiens	O
was	O
common	O
in	O
both	O
gropus	O
.	O

However	O
,	O
of	O
the	O
mdeications	O
surveeyd	O
,	O
only	O
the	O
fenfluramines	B-Chemical
had	O
a	O
significant	O
preferenital	O
associtaion	O
with	O
PPH	O
as	O
comapred	O
with	O
SPH	O
(	O
adjusted	O
odds	O
rtaio	O
for	O
use	O
>	O
6	O
monhts	O
,	O
7	O
.	O
5	O
;	O
95	O
%	O
cnofidence	O
itnerval	O
,	O
1	O
.	O
7	O
to	O
32	O
.	O
4	O
)	O
.	O

The	O
asscoiation	O
was	O
stronegr	O
with	O
longer	O
duraiton	O
of	O
use	O
when	O
compaerd	O
to	O
shotrer	O
duratoin	O
of	O
use	O
and	O
was	O
more	O
pronounced	O
in	O
recent	O
uesrs	O
than	O
in	O
rmeote	O
uesrs	O
.	O

An	O
unexpectedly	O
high	O
(	O
11	O
.	O
4	O
%	O
)	O
number	O
of	O
ptaients	O
with	O
SPH	O
had	O
used	O
aonrexigens	O
.	O

CONCLUSOIN	O
:	O
The	O
magniutde	O
of	O
the	O
associtaion	O
with	O
PPH	O
,	O
the	O
incresae	O
of	O
asscoiation	O
with	O
incraesing	O
duraiton	O
of	O
use	O
,	O
and	O
the	O
specifiicty	O
for	O
fenfluramines	B-Chemical
are	O
consistent	O
with	O
previous	O
studeis	O
indicating	O
that	O
fenfluramines	B-Chemical
are	O
causally	O
related	O
to	O
PPH	O
.	O

The	O
high	O
prevalnece	O
of	O
anroexigen	O
use	O
in	O
ptaients	O
with	O
SPH	O
also	O
raises	O
the	O
possibility	O
that	O
these	O
drgus	O
precipittae	O
pumlonary	O
hypertenison	O
in	O
paitents	O
with	O
underlying	O
conidtions	O
associated	O
with	O
SPH	O
.	O

Cliniacl	O
aspects	O
of	O
heaprin	B-Chemical
-	O
induecd	O
throbmocytopenia	O
and	O
thrombsois	O
and	O
other	O
side	O
effetcs	O
of	O
heprain	B-Chemical
thearpy	O
.	O

Heaprin	B-Chemical
,	O
first	O
used	O
to	O
pervent	O
the	O
coltting	O
of	O
blood	O
in	O
vitro	O
,	O
has	O
been	O
cliniclaly	O
used	O
to	O
traet	O
thormbosis	O
for	O
more	O
than	O
50	O
yaers	O
.	O

Although	O
several	O
new	O
anticaogulant	O
drgus	O
are	O
in	O
developemnt	O
,	O
heaprin	B-Chemical
remains	O
the	O
anticogaulant	O
of	O
choice	O
to	O
terat	O
aucte	O
thromobtic	O
epsiodes	O
.	O

The	O
cilnical	O
efefcts	O
of	O
hepairn	B-Chemical
are	O
meritorious	O
,	O
but	O
side	O
effects	O
do	O
exist	O
.	O

Bleednig	O
is	O
the	O
pirmary	O
untoward	O
effect	O
of	O
hepairn	B-Chemical
.	O

Major	O
beleding	O
is	O
of	O
priamry	O
concern	O
in	O
paitents	O
receiving	O
heaprin	B-Chemical
tehrapy	O
.	O

However	O
,	O
additional	O
important	O
untoward	O
effetcs	O
of	O
hpearin	B-Chemical
tehrapy	O
include	O
heaprin	B-Chemical
-	O
inudced	O
thrmobocytopenia	O
,	O
hpearin	B-Chemical
-	O
associated	O
osetoporosis	O
,	O
eosinpohilia	O
,	O
sikn	O
reacitons	O
,	O
allergic	O
reactoins	O
other	O
than	O
thromboyctopenia	O
,	O
alopceia	O
,	O
transaminasemia	O
,	O
hyperklaemia	O
,	O
hypoaldosteornism	O
,	O
and	O
priaipsm	O
.	O

These	O
side	O
effects	O
are	O
relatively	O
rrae	O
in	O
a	O
given	O
indiviudal	O
,	O
but	O
given	O
the	O
extremely	O
widespread	O
use	O
of	O
hpearin	B-Chemical
,	O
some	O
are	O
quite	O
common	O
,	O
particularly	O
HTIT	O
and	O
osteoporsois	O
.	O

Although	O
reasonable	O
incidneces	O
of	O
many	O
of	O
these	O
side	O
efefcts	O
can	O
be	O
"	O
soflty	O
"	O
deduced	O
from	O
current	O
reoprts	O
dealing	O
with	O
unfractoinated	O
hpearin	B-Chemical
,	O
at	O
present	O
the	O
incidneces	O
of	O
these	O
side	O
effetcs	O
with	O
newer	O
low	O
molecualr	O
wieght	O
hepairns	B-Chemical
appear	O
to	O
be	O
much	O
less	O
common	O
.	O

However	O
,	O
only	O
longer	O
epxerience	O
will	O
more	O
clearly	O
define	O
the	O
inicdence	O
of	O
each	O
side	O
efefct	O
with	O
low	O
mloecular	O
weihgt	O
prepartaions	O
.	O

A	O
csae	O
of	O
bliateral	O
opitc	O
neuroapthy	O
in	O
a	O
paitent	O
on	O
tacrloimus	B-Chemical
(	O
FK056	B-Chemical
)	O
therpay	O
after	O
lievr	O
transplantatoin	O
.	O

PUROPSE	O
:	O
To	O
rpeort	O
a	O
csae	O
of	O
bialteral	O
opitc	O
neuroapthy	O
in	O
a	O
paitent	O
receiving	O
tacroilmus	B-Chemical
(	O
FK	B-Chemical
506	I-Chemical
,	O
Progarf	O
;	O
Fjuisawa	O
USA	O
,	O
Inc	O
,	O
Deefrield	O
,	O
Ililnois	O
)	O
for	O
immunosuppression	O
after	O
ortohtropic	O
lvier	O
transplanattion	O
.	O

METHOD	O
:	O
Csae	O
rpeort	O
.	O

In	O
a	O
58	O
-	O
yaer	O
-	O
old	O
man	O
receiving	O
tarcolimus	B-Chemical
after	O
orthotorpic	O
lvier	O
transplantaiton	O
,	O
sreial	O
neruo	O
-	O
ophtahlmologic	O
examintaions	O
and	O
laobratory	O
sutdies	O
were	O
performed	O
.	O

RSEULTS	O
:	O
The	O
paitent	O
had	O
epiosdic	O
detreioration	O
of	O
vsiion	O
in	O
both	O
eeys	O
,	O
with	O
clincial	O
featrues	O
resembling	O
ischmeic	O
otpic	O
neuroptahies	O
.	O

Deterioratoin	O
of	O
viison	O
occurred	O
despite	O
discotninuation	O
of	O
the	O
tcarolimus	B-Chemical
.	O

CONLCUSION	O
:	O
Tacorlimus	B-Chemical
and	O
other	O
immunosuppressive	O
aegnts	O
may	O
be	O
associated	O
with	O
opitc	O
nevre	O
toixcity	O
.	O

Hypecralcemia	O
,	O
arryhthmia	O
,	O
and	O
mood	O
stabilziers	O
.	O

Recent	O
fidnings	O
in	O
a	O
bpiolar	O
patinet	O
receiving	O
miantenance	O
lithuim	B-Chemical
tehrapy	O
who	O
developed	O
hyprecalcemia	O
and	O
seevre	O
bradyarrhythima	O
prompted	O
the	O
authros	O
to	O
conduct	O
a	O
retrsopective	O
stduy	O
of	O
bipoalr	O
pateints	O
with	O
lithuim	B-Chemical
-	O
associated	O
hypercalceima	O
.	O

A	O
prnitout	O
of	O
all	O
csaes	O
of	O
hpyercalcemia	O
that	O
presented	O
during	O
a	O
1	O
-	O
yaer	O
peirod	O
was	O
generated	O
.	O

After	O
eliminating	O
spurious	O
hypercaclemias	O
or	O
those	O
associated	O
with	O
itnravenous	O
fludis	O
,	O
the	O
authros	O
iedntified	O
18	O
non	O
-	O
lihtium	B-Chemical
-	O
traeted	O
pateints	O
with	O
hypercaclemias	O
related	O
to	O
malingancies	O
and	O
other	O
meidcal	O
conidtions	O
(	O
gorup	O
A	O
)	O
and	O
12	O
pateints	O
with	O
ltihium	B-Chemical
-	O
associated	O
hypercaclemia	O
(	O
gruop	O
B	O
)	O
.	O

Patietns	O
in	O
gruop	O
B	O
were	O
not	O
comparable	O
to	O
those	O
in	O
gruop	O
A	O
,	O
as	O
the	O
latter	O
were	O
medcially	O
comprmoised	O
and	O
were	O
receiving	O
mutliple	O
pharmacotherpaies	O
.	O

Thus	O
,	O
two	O
conrtol	O
gorups	O
were	O
generated	O
:	O
gorup	O
C1	O
,	O
which	O
included	O
age	O
-	O
and	O
sex	O
-	O
comparable	O
lihtium	B-Chemical
-	O
tretaed	O
biploar	O
normcoalcemic	O
pateints	O
,	O
and	O
gruop	O
C2	O
,	O
which	O
included	O
bipoalr	O
normoaclcemic	O
patietns	O
traeted	O
with	O
antiocnvulsant	O
mood	O
stabilziers	O
.	O

The	O
electroacrdiographic	O
(	O
ECG	O
)	O
findnigs	O
for	O
ptaients	O
in	O
gorup	O
B	O
were	O
comapred	O
with	O
those	O
of	O
patinets	O
in	O
gruops	O
C1	O
and	O
C2	O
.	O

It	O
was	O
found	O
that	O
these	O
gruops	O
did	O
not	O
differ	O
in	O
their	O
overall	O
freqeuncy	O
of	O
ECG	O
anbormalities	O
;	O
however	O
,	O
there	O
were	O
significant	O
diffreences	O
in	O
the	O
frequecny	O
of	O
conduciton	O
dfeects	O
.	O

Patietns	O
with	O
hyeprcalcemia	O
resulting	O
from	O
mediacl	O
disesaes	O
and	O
bipoalr	O
paitents	O
with	O
litihum	B-Chemical
-	O
associated	O
hypercaclemia	O
had	O
significantly	O
higehr	O
frequnecies	O
of	O
conductoin	O
deefcts	O
.	O

Pateints	O
in	O
gorup	O
A	O
had	O
significant	O
mrotality	O
at	O
2	O
-	O
yaer	O
follow	O
-	O
up	O
(	O
28	O
%	O
)	O
,	O
in	O
contrast	O
to	O
zero	O
motrality	O
in	O
the	O
other	O
three	O
gruops	O
.	O

The	O
clniical	O
implications	O
of	O
these	O
fidnings	O
are	O
discussed	O
.	O

Attenaution	O
of	O
npehrotoxicity	O
by	O
a	O
novel	O
lpiid	O
naonsphere	O
(	O
NS	O
-	O
718	O
)	O
incorporating	O
amhpotericin	B-Chemical
B	I-Chemical
.	O

NS	O
-	O
718	O
,	O
a	O
lpiid	O
nanosphree	O
incorporating	O
apmhotericin	B-Chemical
B	I-Chemical
,	O
is	O
efefctive	O
against	O
pathoegnic	O
fnugi	O
and	O
has	O
low	O
toixcity	O
.	O

We	O
cmopared	O
the	O
txoicity	O
of	O
NS	O
-	O
718	O
with	O
that	O
of	O
Fungiozne	B-Chemical
(	O
amphoterciin	B-Chemical
B	I-Chemical
-	I-Chemical
soidum	I-Chemical
deoyxcholate	I-Chemical
;	O
D	B-Chemical
-	I-Chemical
AmB	I-Chemical
)	O
in	O
vitro	O
using	O
reanl	O
clel	O
culutres	O
and	O
in	O
vivo	O
by	O
biohcemical	O
anlaysis	O
,	O
histpoathological	O
stduy	O
of	O
the	O
kideny	O
and	O
pharmcaokinetic	O
stduy	O
of	O
ampohtericin	B-Chemical
B	I-Chemical
following	O
intarvenous	O
infsuion	O
of	O
the	O
fomrulation	O
in	O
rtas	O
.	O

Icnubation	O
with	O
NS	O
-	O
718	O
resulted	O
in	O
significantly	O
less	O
daamge	O
of	O
culutred	O
hmuan	O
reanl	O
porximal	O
tubualr	O
epithelail	O
clels	O
compraed	O
with	O
D	B-Chemical
-	I-Chemical
AmB	I-Chemical
.	O

Sreum	O
bolod	O
uera	B-Chemical
and	O
creaitnine	B-Chemical
cocnentrations	O
incresaed	O
significantly	O
in	O
rtas	O
given	O
an	O
iv	O
infusoin	O
of	O
D	B-Chemical
-	I-Chemical
AmB	I-Chemical
3	O
mg	O
/	O
kg	O
but	O
not	O
in	O
those	O
given	O
the	O
same	O
dsoe	O
of	O
NS	O
-	O
718	O
.	O

Histopathoolgical	O
examiantion	O
of	O
the	O
kdiney	O
showed	O
tubluar	O
necorsis	O
in	O
D	B-Chemical
-	I-Chemical
AmB	I-Chemical
-	O
treaetd	O
rtas	O
but	O
no	O
change	O
in	O
NS	O
-	O
718	O
-	O
terated	O
rtas	O
.	O

Amhpotericin	B-Chemical
B	I-Chemical
concentartions	O
in	O
the	O
kindey	O
in	O
NS	O
-	O
718	O
-	O
tretaed	O
rtas	O
were	O
higehr	O
than	O
those	O
in	O
D	B-Chemical
-	I-Chemical
AmB	I-Chemical
-	O
terated	O
rtas	O
.	O

Our	O
in	O
vitro	O
and	O
in	O
vivo	O
reuslts	O
suggest	O
that	O
incroporation	O
of	O
amphoteriicn	B-Chemical
B	I-Chemical
into	O
lpiid	O
nanospheers	O
of	O
NS	O
-	O
718	O
atetnuates	O
the	O
nephrotoxiicty	O
of	O
amphotreicin	B-Chemical
B	I-Chemical
.	O

Patterns	O
of	O
sulfadizaine	B-Chemical
actue	O
nephortoxicity	O
.	O

Sulfdaiazine	B-Chemical
aucte	O
nephrootxicity	O
is	O
reviving	O
specially	O
because	O
of	O
its	O
use	O
in	O
toxoplasomsis	O
in	O
HIV	O
-	O
positvie	O
paitents	O
.	O

We	O
reprot	O
4	O
csaes	O
,	O
one	O
of	O
them	O
in	O
a	O
previously	O
healhty	O
pesron	O
.	O

Under	O
tretament	O
with	O
sulfdaiazine	B-Chemical
they	O
developed	O
oilguria	O
,	O
abdoimnal	O
pian	O
,	O
rneal	O
fialure	O
and	O
showed	O
mutliple	O
raidolucent	O
rneal	O
claculi	O
in	O
echorgaphy	O
.	O

All	O
paitents	O
reocvered	O
their	O
previous	O
noraml	O
reanl	O
functoin	O
after	O
adqeuate	O
hydartion	O
and	O
alcaliinzation	O
.	O

A	O
nephrosotmy	O
tbue	O
had	O
to	O
be	O
placed	O
in	O
one	O
of	O
the	O
paitents	O
for	O
ureetral	O
lithiaiss	O
in	O
a	O
single	O
fucntional	O
kindey	O
.	O

None	O
of	O
them	O
needed	O
dialyiss	O
or	O
a	O
reanl	O
boipsy	O
because	O
of	O
a	O
typical	O
bengin	O
coruse	O
.	O

Treamtent	O
with	O
sulfaidazine	B-Chemical
requires	O
exuqisite	O
contorl	O
of	O
rneal	O
fucntion	O
,	O
an	O
incresae	O
in	O
waetr	O
ingsetion	O
and	O
possibly	O
the	O
alcalinizatoin	O
of	O
the	O
uirne	O
.	O

We	O
communicate	O
a	O
csae	O
in	O
a	O
previously	O
helathy	O
perosn	O
,	O
a	O
fact	O
not	O
found	O
in	O
the	O
recent	O
litreature	O
.	O

Probably	O
many	O
more	O
csaes	O
are	O
not	O
detetced	O
.	O

We	O
think	O
that	O
a	O
prospcetive	O
stduy	O
would	O
be	O
useful	O
.	O

Donwbeat	O
nystamgus	O
associated	O
with	O
intravneous	O
paitent	O
-	O
contorlled	O
administratoin	O
of	O
moprhine	B-Chemical
.	O

IPMLICATIONS	O
:	O
This	O
csae	O
dcouments	O
a	O
patinet	O
who	O
developed	O
dizizness	O
with	O
downebating	O
nytsagmus	O
while	O
receiving	O
a	O
relatively	O
large	O
dsoe	O
of	O
IV	O
pateint	O
-	O
cnotrolled	O
aanlgesia	O
mrophine	B-Chemical
.	O

Although	O
there	O
have	O
been	O
csae	O
reprots	O
of	O
epiudral	O
moprhine	B-Chemical
with	O
these	O
sympotms	O
and	O
sings	O
,	O
this	O
has	O
not	O
been	O
previously	O
documetned	O
with	O
IV	O
or	O
patinet	O
-	O
cnotrolled	O
anlagesia	O
moprhine	B-Chemical
.	O

Hemdoynamic	O
and	O
antiadrenerigc	O
efefcts	O
of	O
dronedaorne	B-Chemical
and	O
amiodarnoe	B-Chemical
in	O
animlas	O
with	O
a	O
helaed	O
moycardial	O
infartcion	O
.	O

The	O
hemodynaimc	O
and	O
antiadreenrgic	O
effects	O
of	O
dronedarnoe	B-Chemical
,	O
a	O
noinodinated	O
copmound	O
structurally	O
related	O
to	O
amiodraone	B-Chemical
,	O
were	O
cmopared	O
with	O
those	O
of	O
amiodaorne	B-Chemical
after	O
prolnoged	O
oarl	O
administrtaion	O
,	O
both	O
at	O
rest	O
and	O
during	O
sypmathetic	O
stiumlation	O
in	O
conscoius	O
dgos	O
with	O
a	O
haeled	O
myocradial	O
infraction	O
.	O

All	O
dgos	O
(	O
n	O
=	O
6	O
)	O
randomly	O
received	O
orally	O
droneadrone	B-Chemical
(	O
10	O
and	O
30	O
mg	O
/	O
kg	O
)	O
,	O
amoidarone	B-Chemical
(	O
10	O
and	O
30	O
mg	O
/	O
kg	O
)	O
,	O
and	O
palcebo	O
twice	O
dialy	O
for	O
7	O
dyas	O
,	O
with	O
a	O
3	O
-	O
week	O
wsahout	O
between	O
consceutive	O
treamtents	O
.	O

Herat	O
rtae	O
(	O
HR	O
)	O
,	O
mean	O
atrerial	O
pressure	O
(	O
MBP	O
)	O
,	O
positvie	O
rtae	O
of	O
incerase	O
of	O
lfet	O
ventrciular	O
pressure	O
(	O
+	O
LdVP	O
/	O
dt	O
)	O
,	O
echocardiographiaclly	O
assessed	O
lfet	O
ventricualr	O
ejeciton	O
fraciton	O
(	O
LEVF	O
)	O
,	O
and	O
frcational	O
shotrening	O
(	O
FS	O
)	O
,	O
as	O
well	O
as	O
chronotrpoic	O
resposne	O
to	O
isoporterenol	B-Chemical
and	O
eexrcise	O
-	O
indcued	O
smypathetic	O
sitmulation	O
were	O
evalutaed	O
under	O
baselnie	O
and	O
posttretament	O
conditinos	O
.	O

Restnig	O
valeus	O
of	O
LEVF	O
,	O
FS	O
,	O
+	O
LdVP	O
/	O
dt	O
,	O
and	O
MBP	O
remained	O
unchagned	O
whatever	O
the	O
durg	O
and	O
the	O
doisng	O
regiemn	O
,	O
whereas	O
resitng	O
HR	O
was	O
significantly	O
and	O
dsoe	O
-	O
dependently	O
loewred	O
after	O
dronedarnoe	B-Chemical
and	O
to	O
a	O
lseser	O
extent	O
after	O
amiodraone	B-Chemical
.	O

Both	O
dronedaorne	B-Chemical
and	O
amioadrone	B-Chemical
significantly	O
reudced	O
the	O
exercsie	O
-	O
idnuced	O
tacyhcardia	O
and	O
,	O
at	O
the	O
highest	O
dsoe	O
,	O
decerased	O
the	O
isorpoterenol	B-Chemical
-	O
indcued	O
tachcyardia	O
.	O

Thus	O
,	O
drnoedarone	B-Chemical
and	O
amioadrone	B-Chemical
displayed	O
a	O
similar	O
lveel	O
of	O
antaidrenergic	O
efefct	O
and	O
did	O
not	O
impiar	O
the	O
restnig	O
lfet	O
ventriuclar	O
funciton	O
.	O

Consequently	O
,	O
droneadrone	B-Chemical
might	O
be	O
particularly	O
suitable	O
for	O
the	O
treatmnet	O
and	O
pervention	O
of	O
various	O
cilnical	O
arrhytmhias	O
,	O
without	O
compromisnig	O
the	O
lfet	O
ventricualr	O
funciton	O
.	O

Pahse	O
2	O
tiral	O
of	O
lpiosomal	O
doxourbicin	B-Chemical
(	O
40	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
in	O
plaitnum	B-Chemical
/	O
palcitaxel	B-Chemical
-	O
refratcory	O
ovarain	O
and	O
falloipan	O
tbue	O
cacners	O
and	O
prmiary	O
carcnioma	O
of	O
the	O
periotneum	O
.	O

BACKGRUOND	O
:	O
Several	O
stuides	O
have	O
demonstrated	O
liposoaml	O
doxourbicin	B-Chemical
(	O
Dxoil	B-Chemical
)	O
to	O
be	O
an	O
acitve	O
antineopalstic	O
agnet	O
in	O
platnium	B-Chemical
-	O
rseistant	O
ovarain	O
cnacer	O
,	O
with	O
dsoe	O
limiting	O
toxiicty	O
of	O
the	O
stadnard	O
dosnig	O
regiemn	O
(	O
50	O
mg	O
/	O
m	O
(	O
2	O
)	O
q	O
4	O
weeks	O
)	O
being	O
sveere	O
erythrdoysesthesia	O
(	O
"	O
hand	O
-	O
foot	O
synrdome	O
"	O
)	O
and	O
stoamtitis	O
.	O

We	O
wished	O
to	O
develop	O
a	O
more	O
tloerable	O
liposoaml	O
doxoruibcin	B-Chemical
teratment	O
reigmen	O
and	O
documnet	O
its	O
lveel	O
of	O
actviity	O
in	O
a	O
well	O
-	O
defined	O
pateint	O
populaiton	O
with	O
platiunm	B-Chemical
/	O
paciltaxel	B-Chemical
-	O
refrcatory	O
dsiease	O
.	O

METHODS	O
AND	O
MATERIALS	O
:	O
Pateints	O
with	O
ovraian	O
or	O
falloipan	O
tbue	O
cnacers	O
or	O
primray	O
peritnoeal	O
caricnoma	O
with	O
platnium	B-Chemical
/	O
paclitxael	B-Chemical
-	O
refractroy	O
disaese	O
(	O
stalbe	O
or	O
prgoressive	O
dsiease	O
following	O
traetment	O
with	O
these	O
aegnts	O
or	O
previous	O
objetcive	O
rseponse	O
<	O
3	O
mnoths	O
in	O
druation	O
)	O
were	O
tretaed	O
with	O
lipoosmal	O
doxorubciin	B-Chemical
at	O
a	O
dsoe	O
of	O
40	O
mg	O
/	O
m	O
(	O
2	O
)	O
q	O
4	O
weeks	O
.	O

RESUTLS	O
:	O
A	O
total	O
of	O
49	O
paitents	O
(	O
medain	O
age	O
:	O
60	O
;	O
range	O
41	O
-	O
81	O
)	O
entered	O
this	O
phsae	O
2	O
tiral	O
.	O

The	O
medain	O
number	O
of	O
prior	O
regmiens	O
was	O
2	O
(	O
range	O
:	O
1	O
-	O
6	O
)	O
.	O

Six	O
(	O
12	O
%	O
)	O
and	O
4	O
(	O
8	O
%	O
)	O
ptaients	O
experienced	O
garde	O
2	O
hand	O
-	O
foot	O
sydnrome	O
and	O
stomtaitis	O
,	O
respectively	O
(	O
no	O
epsiodes	O
of	O
garde	O
3	O
)	O
.	O

One	O
patinet	O
developed	O
grdae	O
3	O
dairrhea	O
requiring	O
hosiptalization	O
for	O
hydratoin	O
.	O

Six	O
(	O
12	O
%	O
)	O
inidviduals	O
required	O
dsoe	O
reudctions	O
.	O

The	O
meidan	O
number	O
of	O
couress	O
of	O
liposoaml	O
dooxrubicin	B-Chemical
admniistered	O
on	O
this	O
prtoocol	O
was	O
2	O
(	O
range	O
:	O
1	O
-	O
12	O
)	O
.	O

Four	O
of	O
44	O
pateints	O
(	O
9	O
%	O
)	O
evalubale	O
for	O
respnose	O
exhibited	O
obejctive	O
and	O
subjecitve	O
eivdence	O
of	O
an	O
antineoplatsic	O
effect	O
of	O
tehrapy	O
.	O

COCNLUSION	O
:	O
This	O
modifeid	O
lipoosmal	O
dxoorubicin	B-Chemical
rgeimen	O
rseults	O
in	O
less	O
toxiicty	O
(	O
sotmatitis	O
,	O
hand	O
-	O
foot	O
sydnrome	O
)	O
than	O
the	O
stadnard	O
FDA	O
-	O
approved	O
dsoe	O
shcedule	O
.	O

Deifnite	O
,	O
although	O
limietd	O
,	O
antineoplasitc	O
activtiy	O
is	O
observed	O
in	O
patinets	O
with	O
well	O
-	O
defined	O
platnium	B-Chemical
-	O
and	O
paclitxael	B-Chemical
-	O
refractroy	O
ovraian	O
cnacer	O
.	O

Effiaccy	O
of	O
olaznapine	B-Chemical
in	O
actue	O
bpiolar	O
mnaia	O
:	O
a	O
double	O
-	O
blnid	O
,	O
plcaebo	O
-	O
cotnrolled	O
stduy	O
.	O

The	O
Oalnzipine	B-Chemical
HGGW	O
Sutdy	O
Gorup	O
.	O

BACKGRONUD	O
:	O
We	O
compaerd	O
the	O
effciacy	O
and	O
saefty	O
of	O
olnazapine	B-Chemical
vs	O
palcebo	O
for	O
the	O
treatemnt	O
of	O
aucte	O
bpiolar	O
maina	O
.	O

METHODS	O
:	O
Four	O
-	O
week	O
,	O
ranodmized	O
,	O
double	O
-	O
blnid	O
,	O
parallel	O
stduy	O
.	O

A	O
total	O
of	O
115	O
pateints	O
with	O
a	O
DSM	O
-	O
IV	O
diagnsois	O
of	O
bipoalr	O
dsiorder	O
,	O
mnaic	O
or	O
mixed	O
,	O
were	O
ranodmized	O
to	O
oalnzapine	B-Chemical
,	O
5	O
to	O
20	O
mg	O
/	O
d	O
(	O
n	O
=	O
55	O
)	O
,	O
or	O
plcaebo	O
(	O
n	O
=	O
60	O
)	O
.	O

The	O
primray	O
effciacy	O
meausre	O
was	O
the	O
Yonug	O
-	O
Maina	O
Rtaing	O
Sacle	O
(	O
Y	O
-	O
MRS	O
)	O
total	O
socre	O
.	O

Repsonse	O
and	O
eutyhmia	O
were	O
defined	O
,	O
a	O
priori	O
,	O
as	O
at	O
least	O
a	O
50	O
%	O
imrpovement	O
from	O
basleine	O
to	O
end	O
point	O
and	O
as	O
a	O
scroe	O
of	O
no	O
less	O
than	O
12	O
at	O
end	O
point	O
in	O
the	O
Y	O
-	O
MRS	O
total	O
scroe	O
,	O
respectively	O
.	O

Saftey	O
was	O
assesesd	O
using	O
avderse	O
evetns	O
,	O
Extrapyarmidal	O
Smyptom	O
(	O
EPS	O
)	O
ratnig	O
sclaes	O
,	O
lbaoratory	O
vaules	O
,	O
eletcrocardiograms	O
,	O
vital	O
sgins	O
,	O
and	O
wieght	O
change	O
.	O

RESLUTS	O
:	O
Olanazpine	B-Chemical
-	O
tretaed	O
ptaients	O
demonstrated	O
a	O
sttaistically	O
significant	O
greater	O
mean	O
(	O
+	O
/	O
-	O
SD	O
)	O
improvmeent	O
in	O
Y	O
-	O
MRS	O
total	O
socre	O
than	O
palcebo	O
-	O
terated	O
patietns	O
(	O
-	O
14	O
.	O
8	O
+	O
/	O
-	O
12	O
.	O
5	O
and	O
-	O
8	O
.	O
1	O
+	O
/	O
-	O
12	O
.	O
7	O
,	O
respectively	O
;	O
P	O
<	O
.	O
001	O
)	O
,	O
which	O
was	O
evident	O
at	O
the	O
first	O
postbsaeline	O
observaiton	O
1	O
week	O
after	O
randomizatoin	O
and	O
was	O
maintained	O
throughout	O
the	O
stduy	O
(	O
last	O
observtaion	O
carried	O
forward	O
)	O
.	O

Olanzaipne	B-Chemical
-	O
terated	O
patietns	O
demonstrated	O
a	O
hgiher	O
rtae	O
of	O
repsonse	O
(	O
65	O
%	O
vs	O
43	O
%	O
,	O
respectively	O
;	O
P	O
=	O
.	O
02	O
)	O
and	O
euthyima	O
(	O
61	O
%	O
vs	O
36	O
%	O
,	O
respectively	O
;	O
P	O
=	O
.	O
01	O
)	O
than	O
plcaebo	O
-	O
traeted	O
paitents	O
.	O

There	O
were	O
no	O
statistically	O
significant	O
diffeernces	O
in	O
ESPs	O
between	O
gorups	O
.	O

However	O
,	O
oalnzapine	B-Chemical
-	O
treaetd	O
patietns	O
had	O
a	O
statistcially	O
significant	O
greater	O
mean	O
(	O
+	O
/	O
-	O
SD	O
)	O
weihgt	O
gain	O
than	O
plaecbo	O
-	O
tretaed	O
ptaients	O
(	O
2	O
.	O
1	O
+	O
/	O
-	O
2	O
.	O
8	O
vs	O
0	O
.	O
45	O
+	O
/	O
-	O
2	O
.	O
3	O
kg	O
,	O
respectively	O
)	O
and	O
also	O
experienced	O
more	O
traetment	O
-	O
emregent	O
smonolence	O
(	O
21	O
ptaients	O
[	O
38	O
.	O
2	O
%	O
]	O
vs	O
5	O
[	O
8	O
.	O
3	O
%	O
]	O
,	O
respectively	O
)	O
.	O

CNOCLUSION	O
:	O
Oalnzapine	B-Chemical
demonstrated	O
greater	O
efficacy	O
than	O
placbeo	O
in	O
the	O
traetment	O
of	O
actue	O
bipoalr	O
mnaia	O
and	O
was	O
generally	O
well	O
toleraetd	O
.	O

The	O
effect	O
of	O
ppuil	O
dilatoin	O
with	O
tropicmaide	B-Chemical
on	O
visoin	O
and	O
driving	O
simultaor	O
perofrmance	O
.	O

PURPSOE	O
:	O
To	O
assess	O
the	O
effcet	O
of	O
puipl	O
dialtion	O
on	O
visoin	O
and	O
driving	O
ability	O
.	O

METHODS	O
:	O
A	O
series	O
of	O
tsets	O
on	O
various	O
parameetrs	O
of	O
vsiual	O
funtcion	O
and	O
driving	O
simulaotr	O
preformance	O
were	O
performed	O
on	O
12	O
helathy	O
dirvers	O
,	O
before	O
and	O
after	O
ppuil	O
dilaiton	O
using	O
guttae	O
tropiacmide	B-Chemical
1	O
%	O
.	O

A	O
driving	O
simualtor	O
(	O
Trnasport	O
Resaerch	O
Laboraotry	O
)	O
was	O
used	O
to	O
maesure	O
reactoin	O
tmie	O
(	O
RT	O
)	O
,	O
speed	O
maintneance	O
and	O
stereing	O
acucracy	O
.	O

Tsets	O
of	O
basic	O
viusal	O
fnuction	O
included	O
high	O
-	O
and	O
low	O
-	O
contrast	O
visaul	O
acutiy	O
(	O
HVCA	O
and	O
LVCA	O
)	O
,	O
Pleli	O
-	O
Rosbon	O
contrast	O
trheshold	O
(	O
CT	O
)	O
and	O
Glodmann	O
preimetry	O
(	O
FILEDS	O
)	O
.	O

Useful	O
Filed	O
of	O
Veiw	O
(	O
UOFV	O
-	O
-	O
a	O
tset	O
of	O
visaul	O
atteniton	O
)	O
was	O
also	O
undertaken	O
.	O

The	O
mean	O
differenecs	O
in	O
the	O
pre	O
-	O
and	O
psot	O
-	O
dilatatoin	O
measurmeents	O
were	O
tseted	O
for	O
staitstical	O
siginficance	O
at	O
the	O
95	O
%	O
leevl	O
using	O
one	O
-	O
tial	O
paired	O
t	O
-	O
tetss	O
.	O

RESUTLS	O
:	O
Puipllary	O
diltaion	O
resulted	O
in	O
a	O
statistcially	O
significant	O
deteroiration	O
in	O
CT	O
and	O
HVCA	O
only	O
.	O

Five	O
of	O
12	O
dirvers	O
also	O
exhibited	O
deetrioration	O
in	O
LVCA	O
,	O
CT	O
and	O
RT	O
.	O

Little	O
eviednce	O
emerged	O
for	O
deterioartion	O
in	O
FILEDS	O
and	O
UOFV	O
.	O

Also	O
,	O
7	O
of	O
12	O
drivres	O
appeared	O
to	O
adjust	O
their	O
driving	O
behavoiur	O
by	O
rdeucing	O
their	O
seped	O
on	O
the	O
driving	O
simultaor	O
,	O
leading	O
to	O
ipmroved	O
steering	O
accruacy	O
.	O

CNOCLUSIONS	O
:	O
Pupilalry	O
dilaiton	O
may	O
lead	O
to	O
a	O
decerase	O
in	O
visoin	O
and	O
dayilght	O
driving	O
pefrormance	O
in	O
yuong	O
peolpe	O
.	O

A	O
larger	O
sutdy	O
,	O
including	O
a	O
broader	O
specrtum	O
of	O
sbujects	O
,	O
is	O
warranted	O
before	O
guideliens	O
can	O
be	O
reocmmended	O
.	O

A	O
csae	O
of	O
isortetinoin	O
embryopahty	O
with	O
bilatreal	O
aontia	O
and	O
Tausisg	O
-	O
Bnig	O
malforamtion	O
.	O

We	O
reoprt	O
a	O
newbron	O
infnat	O
with	O
mlutiple	O
congneital	O
anomailes	O
(	O
aontia	O
and	O
Tasusig	O
-	O
Bnig	O
malfomration	O
)	O
due	O
to	O
epxosure	O
to	O
isotrteinoin	B-Chemical
within	O
the	O
first	O
trimetser	O
.	O

In	O
this	O
paper	O
we	O
aim	O
to	O
draw	O
to	O
the	O
fact	O
that	O
caution	O
is	O
needed	O
when	O
perscribing	O
vitmain	B-Chemical
A	I-Chemical
-	O
containing	O
durgs	O
to	O
wmoen	O
of	O
chilbdearing	O
yeras	O
.	O

Effcet	O
of	O
metohxamine	B-Chemical
on	O
maixmum	O
urehtral	O
presusre	O
in	O
wmoen	O
with	O
genuine	O
srtess	O
incontinecne	O
:	O
a	O
plaecbo	O
-	O
contrloled	O
,	O
double	O
-	O
bilnd	O
crsosover	O
sutdy	O
.	O

The	O
aim	O
of	O
the	O
sutdy	O
was	O
to	O
evalutae	O
the	O
potnetial	O
role	O
for	O
a	O
selective	O
alpah1	O
-	O
adernoceptor	O
agnoist	O
in	O
the	O
teratment	O
of	O
urianry	O
sterss	O
incnotinence	O
.	O

A	O
ranodmised	O
,	O
double	O
-	O
blnid	O
,	O
placbeo	O
-	O
cotnrolled	O
,	O
crossvoer	O
stduy	O
deisgn	O
was	O
employed	O
.	O

Half	O
log	O
incremetnal	O
doess	O
of	O
intraveonus	O
mtehoxamine	B-Chemical
or	O
plaecbo	O
(	O
sailne	O
)	O
were	O
adminitsered	O
to	O
a	O
gruop	O
of	O
wmoen	O
with	O
genuine	O
srtess	O
inconitnence	O
while	O
maesuring	O
mxaimum	O
urtehral	O
presusre	O
(	O
MUP	O
)	O
,	O
blood	O
pressure	O
,	O
herat	O
rtae	O
,	O
and	O
smyptomatic	O
side	O
effetcs	O
.	O

Methoxmaine	B-Chemical
evkoed	O
non	O
-	O
significant	O
inrceases	O
in	O
MUP	O
and	O
diasotlic	O
blood	O
perssure	O
but	O
caused	O
a	O
significant	O
rise	O
in	O
sysotlic	O
bolod	O
pressrue	O
and	O
significant	O
fall	O
in	O
herat	O
rtae	O
at	O
maxiumm	O
doasge	O
.	O

Ssytemic	O
side	O
effects	O
including	O
piloeretcion	O
,	O
haedache	O
,	O
and	O
clod	O
extremiites	O
were	O
experienced	O
in	O
all	O
subejcts	O
.	O

The	O
reuslts	O
indicate	O
that	O
the	O
cliincal	O
usefulnses	O
of	O
direct	O
,	O
peripherally	O
acting	O
sub	O
-	O
tpye	O
-	O
selective	O
aplha1	O
-	O
adernoceptor	O
agonsits	O
in	O
the	O
medcial	O
treamtent	O
of	O
srtess	O
incotninence	O
may	O
be	O
lmiited	O
by	O
associated	O
piolerection	O
and	O
cardiovascluar	O
side	O
efefcts	O
.	O

Hyeprglycemic	O
effect	O
of	O
aimno	B-Chemical
compuonds	O
structurally	O
related	O
to	O
cparoate	B-Chemical
in	O
rtas	O
.	O

The	O
crhonic	O
fedeing	O
of	O
small	O
amounts	O
(	O
0	O
.	O
3	O
-	O
3	O
%	O
of	O
deit	O
wieght	O
)	O
of	O
certain	O
amnio	B-Chemical
derivatievs	O
of	O
capraote	B-Chemical
resulted	O
in	O
hyperglcyemia	O
,	O
an	O
elevtaed	O
glucsoe	B-Chemical
toleracne	O
cruve	O
and	O
,	O
occasionally	O
,	O
glucosruia	O
.	O

Efefctive	O
compoudns	O
included	O
norleuicne	B-Chemical
,	O
norvailne	B-Chemical
,	O
gluatmate	B-Chemical
,	O
epsioln	B-Chemical
-	I-Chemical
aminocaproate	I-Chemical
,	O
methoinine	B-Chemical
,	O
and	O
lecuine	B-Chemical
.	O

Toleraiton	O
of	O
high	O
dsoes	O
of	O
angioetnsin	B-Chemical
-	I-Chemical
converting	I-Chemical
enyzme	I-Chemical
inhibiotrs	I-Chemical
in	O
ptaients	O
with	O
chrnoic	O
herat	O
faliure	O
:	O
resluts	O
from	O
the	O
ALTAS	O
trail	O
.	O

The	O
Assessment	O
of	O
Traetment	O
with	O
Lisniopril	B-Chemical
and	O
Sruvival	O
.	O

BACKRGOUND	O
:	O
Treatemnt	O
with	O
angiotesnin	B-Chemical
-	I-Chemical
converting	I-Chemical
enzmye	I-Chemical
(	I-Chemical
ACE	I-Chemical
)	I-Chemical
inhibitros	I-Chemical
reudces	O
mortaltiy	O
and	O
mobridity	O
in	O
patinets	O
with	O
chrnoic	O
haert	O
faliure	O
(	O
CHF	O
)	O
,	O
but	O
most	O
affected	O
pateints	O
are	O
not	O
receiving	O
these	O
agetns	O
or	O
are	O
being	O
traeted	O
with	O
dsoes	O
lwoer	O
than	O
those	O
found	O
to	O
be	O
efficacoius	O
in	O
trails	O
,	O
primarily	O
because	O
of	O
conecrns	O
about	O
the	O
saftey	O
and	O
tolerbaility	O
of	O
these	O
agetns	O
,	O
especially	O
at	O
the	O
rceommended	O
dsoes	O
.	O

The	O
present	O
sutdy	O
examines	O
the	O
saefty	O
and	O
toelrability	O
of	O
high	O
-	O
cmopared	O
with	O
low	O
-	O
dsoe	O
lisinporil	B-Chemical
in	O
CHF	O
.	O

METHODS	O
:	O
The	O
Assesmsent	O
of	O
Lsiinopril	B-Chemical
and	O
Sruvival	O
sutdy	O
was	O
a	O
multiecnter	O
,	O
randmoized	O
,	O
double	O
-	O
blnid	O
tiral	O
in	O
which	O
patietns	O
with	O
or	O
without	O
previous	O
ACE	B-Chemical
inhibiotr	I-Chemical
teratment	O
were	O
stabiilzed	O
receiving	O
meduim	O
-	O
dsoe	O
lisinorpil	B-Chemical
(	O
12	O
.	O
5	O
or	O
15	O
.	O
0	O
mg	O
once	O
daliy	O
[	O
OD	O
]	O
)	O
for	O
2	O
to	O
4	O
weeks	O
and	O
then	O
rnadomized	O
to	O
high	O
-	O
(	O
35	O
.	O
0	O
or	O
32	O
.	O
5	O
mg	O
OD	O
)	O
or	O
low	O
-	O
dsoe	O
(	O
5	O
.	O
0	O
or	O
2	O
.	O
5	O
mg	O
OD	O
)	O
gorups	O
.	O

Patietns	O
with	O
New	O
Yrok	O
Herat	O
Assoication	O
clasess	O
II	O
to	O
IV	O
CHF	O
and	O
lfet	O
ventrciular	O
ejcetion	O
fractoins	O
of	O
no	O
greater	O
than	O
0	O
.	O
30	O
(	O
n	O
=	O
3164	O
)	O
were	O
randmoized	O
and	O
followed	O
up	O
for	O
a	O
mdeian	O
of	O
46	O
monhts	O
.	O

We	O
examined	O
the	O
occrurence	O
of	O
advrese	O
evetns	O
and	O
the	O
need	O
for	O
discnotinuation	O
and	O
dsoe	O
reductoin	O
during	O
treamtent	O
,	O
with	O
a	O
focus	O
on	O
hpyotension	O
and	O
reanl	O
dysufnction	O
.	O

REUSLTS	O
:	O
Of	O
405	O
patinets	O
not	O
previously	O
receiving	O
an	O
ACE	B-Chemical
inhbiitor	I-Chemical
,	O
dsoes	O
in	O
only	O
4	O
.	O
2	O
%	O
could	O
not	O
be	O
titarted	O
to	O
the	O
meidum	O
dsoes	O
required	O
for	O
ranodmization	O
because	O
of	O
symtpoms	O
possibly	O
related	O
to	O
hypotenison	O
(	O
2	O
.	O
0	O
%	O
)	O
or	O
because	O
of	O
reanl	O
dyfsunction	O
or	O
hyperklaemia	O
(	O
2	O
.	O
3	O
%	O
)	O
.	O

Doess	O
in	O
more	O
than	O
90	O
%	O
of	O
randomzied	O
ptaients	O
in	O
the	O
high	O
-	O
and	O
low	O
-	O
dsoe	O
gruops	O
were	O
titarted	O
to	O
their	O
assigned	O
tagret	O
,	O
and	O
the	O
mean	O
doess	O
of	O
blnided	O
mediaction	O
in	O
both	O
gruops	O
remained	O
similar	O
throughout	O
the	O
sutdy	O
.	O

Withdrawlas	O
occurred	O
in	O
27	O
.	O
1	O
%	O
of	O
the	O
high	O
-	O
and	O
30	O
.	O
7	O
%	O
of	O
the	O
low	O
-	O
dsoe	O
gropus	O
.	O

Subgorups	O
presumed	O
to	O
be	O
at	O
higehr	O
rsik	O
for	O
ACE	B-Chemical
inhiibtor	I-Chemical
intoleracne	O
(	O
blood	O
prsesure	O
,	O
<	O
120	O
mm	O
Hg	O
;	O
creatniine	B-Chemical
,	O
>	O
or	O
=	O
132	O
.	O
6	O
micromol	O
/	O
L	O
[	O
>	O
or	O
=	O
1	O
.	O
5	O
mg	O
/	O
dL	O
]	O
;	O
age	O
,	O
>	O
or	O
=	O
70	O
yaers	O
;	O
and	O
pateints	O
with	O
diaebtes	O
)	O
generally	O
tolreated	O
the	O
high	O
-	O
dsoe	O
strategy	O
.	O

CONCLSUIONS	O
:	O
These	O
findigns	O
demonstrate	O
that	O
ACE	B-Chemical
inhbiitor	I-Chemical
thearpy	O
in	O
most	O
pateints	O
with	O
CHF	O
can	O
be	O
successfully	O
titraetd	O
to	O
and	O
maintained	O
at	O
high	O
dsoes	O
,	O
and	O
that	O
more	O
aggressvie	O
use	O
of	O
these	O
aegnts	O
is	O
warranted	O
.	O

Cociane	B-Chemical
,	O
ehtanol	B-Chemical
,	O
and	O
cocatehylene	B-Chemical
cradiotoxity	O
in	O
an	O
aniaml	O
mdoel	O
of	O
coacine	O
and	O
ehtanol	O
aubse	O
.	O

OJBECTIVES	O
:	O
Simultanoeus	O
absue	O
of	O
ccoaine	O
and	O
ethnaol	O
affects	O
12	O
million	O
Ameriacns	O
annually	O
.	O

In	O
combinatoin	O
,	O
these	O
substnaces	O
are	O
substantially	O
more	O
txoic	O
than	O
either	O
durg	O
alone	O
.	O

Their	O
combnied	O
cadriac	O
toixcity	O
may	O
be	O
due	O
to	O
indepenednt	O
effects	O
of	O
each	O
durg	O
;	O
however	O
,	O
they	O
may	O
also	O
be	O
due	O
to	O
cocaetyhlene	B-Chemical
(	O
CE	B-Chemical
)	O
,	O
a	O
cociane	B-Chemical
meatbolite	O
formed	O
only	O
in	O
the	O
preesnce	O
of	O
ethaonl	B-Chemical
.	O

The	O
purpose	O
of	O
this	O
sutdy	O
was	O
to	O
delineate	O
the	O
role	O
of	O
CE	B-Chemical
in	O
the	O
combnied	O
cardiotoxiicty	O
of	O
cocanie	B-Chemical
and	O
etahnol	B-Chemical
in	O
a	O
mdoel	O
simulating	O
their	O
absue	O
.	O

METHODS	O
:	O
Twenty	O
-	O
three	O
dgos	O
were	O
randomiezd	O
to	O
receive	O
either	O
1	O
)	O
three	O
intraevnous	O
(	O
IV	O
)	O
boluess	O
of	O
cocanie	B-Chemical
7	O
.	O
5	O
mg	O
/	O
kg	O
with	O
etahnol	B-Chemical
(	O
1	O
g	O
/	O
kg	O
)	O
as	O
an	O
IV	O
infsuion	O
(	O
C	O
+	O
E	O
,	O
n	O
=	O
8	O
)	O
,	O
2	O
)	O
three	O
cociane	B-Chemical
boluess	O
only	O
(	O
C	O
,	O
n	O
=	O
6	O
)	O
,	O
3	O
)	O
ehtanol	B-Chemical
ifnusion	O
only	O
(	O
E	O
,	O
n	O
=	O
5	O
)	O
,	O
or	O
4	O
)	O
plcaebo	O
bolsues	O
and	O
infusoin	O
(	O
n	O
=	O
4	O
)	O
.	O

Hemodyanmic	O
measuerments	O
,	O
eelctrocardiograms	O
,	O
and	O
sreum	O
durg	O
cnocentrations	O
were	O
obtained	O
at	O
bsaeline	O
,	O
and	O
then	O
at	O
fiexd	O
tmie	O
inetrvals	O
after	O
each	O
durg	O
was	O
adminitsered	O
.	O

REUSLTS	O
:	O
Two	O
of	O
eight	O
dgos	O
in	O
the	O
C	O
+	O
E	O
gruop	O
experienced	O
cradiovascular	O
clolapse	O
.	O

The	O
most	O
draamtic	O
hmeodynamic	O
chnages	O
occurred	O
after	O
each	O
cociane	B-Chemical
bouls	O
in	O
the	O
C	O
+	O
E	O
and	O
C	O
only	O
gruops	O
;	O
however	O
,	O
perssitent	O
hemoydnamic	O
chagnes	O
occurred	O
in	O
the	O
C	O
+	O
E	O
gruop	O
.	O

Paek	O
CE	B-Chemical
levles	O
were	O
associated	O
with	O
a	O
45	O
%	O
(	O
SD	O
+	O
/	O
-	O
22	O
%	O
,	O
95	O
%	O
CI	O
=	O
22	O
%	O
to	O
69	O
%	O
)	O
decresae	O
in	O
cadriac	O
ouptut	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
,	O
a	O
56	O
%	O
(	O
SD	O
+	O
/	O
-	O
23	O
%	O
,	O
95	O
%	O
CI	O
=	O
32	O
%	O
to	O
80	O
%	O
)	O
dercease	O
in	O
dP	O
/	O
dt	O
(	O
max	O
)	O
(	O
p	O
<	O
.	O
006	O
)	O
,	O
and	O
a	O
23	O
%	O
(	O
SD	O
+	O
/	O
-	O
15	O
%	O
,	O
95	O
%	O
CI	O
=	O
7	O
%	O
to	O
49	O
%	O
)	O
decresae	O
in	O
SVO	O
(	O
2	O
)	O
(	O
p	O
<	O
0	O
.	O
025	O
)	O
.	O

Vetnricular	O
arhrythmias	O
were	O
primarily	O
observed	O
in	O
the	O
C	O
+	O
E	O
gorup	O
,	O
in	O
which	O
four	O
of	O
eight	O
dgos	O
experienced	O
vetnricular	O
tcahycardia	O
.	O

CONCLUISONS	O
:	O
Cocanie	B-Chemical
and	O
etahnol	B-Chemical
in	O
cmobination	O
were	O
more	O
txoic	O
than	O
either	O
susbtance	O
alone	O
.	O

Co	O
-	O
adminsitration	O
resulted	O
in	O
prloonged	O
cardaic	O
toixcity	O
and	O
was	O
dysrhtyhmogenic	O
.	O

Paek	O
sreum	O
ccoaethylene	B-Chemical
concentartions	O
were	O
associated	O
with	O
prologned	O
myocaridal	O
depressoin	O
.	O

Worsneing	O
of	O
Parkinsonsim	O
after	O
the	O
use	O
of	O
verlaipride	B-Chemical
for	O
treamtent	O
of	O
meonpause	O
:	O
csae	O
reprot	O
.	O

We	O
describe	O
a	O
fmeale	O
patinet	O
with	O
satble	O
Pariknson	O
'	O
s	O
disesae	O
who	O
has	O
shown	O
a	O
marked	O
worsneing	O
of	O
her	O
mtoor	O
functoins	O
following	O
therpay	O
of	O
menpoause	O
related	O
sympotms	O
with	O
veralpiride	B-Chemical
,	O
as	O
well	O
as	O
the	O
imporvement	O
of	O
her	O
sympotms	O
back	O
to	O
basleine	O
after	O
discontiunation	O
of	O
the	O
durg	O
.	O

We	O
emphasize	O
the	O
atni	O
-	O
dpoaminergic	O
effcet	O
of	O
veralirpide	B-Chemical
.	O

Vircaept	B-Chemical
and	O
irregualr	O
heratbeat	O
warnnig	O
.	O

A	O
gorup	O
of	O
docotrs	O
in	O
Bosotn	O
warn	O
that	O
the	O
protaese	O
inhibtior	O
Vircaept	B-Chemical
may	O
cause	O
an	O
irregluar	O
herat	O
baet	O
,	O
known	O
as	O
braydcardia	O
,	O
in	O
pepole	O
with	O
HIV	O
.	O

Brdaycardia	O
occurred	O
in	O
a	O
45	O
-	O
yaer	O
-	O
old	O
mlae	O
patinet	O
who	O
was	O
Viarcept	B-Chemical
in	O
combinatoin	O
with	O
other	O
atni	O
-	O
HIV	O
drgus	O
.	O

The	O
symptmos	O
cesaed	O
after	O
switching	O
to	O
another	O
durg	O
cobmination	O
.	O

Frequnecy	O
of	O
appearnace	O
of	O
myeloperoxidsae	O
-	O
antnieutrophil	O
cytolpasmic	O
antibdoy	O
(	O
MPO	O
-	O
ACNA	O
)	O
in	O
Grvaes	O
'	O
disesae	O
pateints	O
tretaed	O
with	O
propylthiourcail	B-Chemical
and	O
the	O
relaitonship	O
between	O
MPO	O
-	O
ACNA	O
and	O
cliincal	O
manfiestations	O
.	O

OBJECITVE	O
:	O
Myelpoeroxidase	O
anitneutrophil	O
cytpolasmic	O
antiobdy	O
(	O
MPO	O
-	O
ACNA	O
)	O
-	O
poistive	O
vascuiltis	O
has	O
been	O
reported	O
in	O
patietns	O
with	O
Graevs	O
'	O
disesae	O
who	O
were	O
terated	O
with	O
prpoylthiouracil	B-Chemical
(	O
PTU	B-Chemical
)	O
.	O

The	O
appearance	O
of	O
MPO	O
-	O
ACNA	O
in	O
these	O
csaes	O
was	O
suspceted	O
of	O
being	O
related	O
to	O
PTU	B-Chemical
because	O
the	O
tirtes	O
of	O
MPO	O
-	O
ACNA	O
decreaesd	O
when	O
PTU	B-Chemical
was	O
stopped	O
.	O

Nevertheless	O
,	O
there	O
have	O
been	O
no	O
stuides	O
on	O
the	O
tepmoral	O
relationsihp	O
between	O
the	O
appearacne	O
of	O
MPO	O
-	O
ACNA	O
and	O
vasuclitis	O
during	O
PTU	B-Chemical
threapy	O
,	O
or	O
on	O
the	O
incdience	O
of	O
MPO	O
-	O
ACNA	O
in	O
untreaetd	O
Grvaes	O
'	O
dsiease	O
pateints	O
.	O

Therefore	O
,	O
we	O
sought	O
to	O
address	O
these	O
paramteers	O
in	O
paitents	O
with	O
Garves	O
'	O
disaese	O
.	O

PATIENTS	O
:	O
We	O
inevstigated	O
102	O
untraeted	O
paitents	O
with	O
hyperhtyroidism	O
due	O
to	O
Graevs	O
'	O
disesae	O
for	O
the	O
prseence	O
of	O
MPO	O
-	O
ACNA	O
,	O
and	O
for	O
the	O
develpoment	O
vacsulitis	O
after	O
starting	O
PTU	B-Chemical
threapy	O
.	O

Twenty	O
-	O
nine	O
of	O
them	O
were	O
later	O
excluded	O
because	O
of	O
avderse	O
effects	O
of	O
PTU	B-Chemical
or	O
because	O
the	O
obsrevation	O
peroid	O
was	O
less	O
than	O
3	O
motnhs	O
.	O

The	O
remaining	O
73	O
paitents	O
(	O
55	O
woemn	O
and	O
18	O
men	O
)	O
,	O
all	O
of	O
whom	O
were	O
examined	O
for	O
more	O
than	O
3	O
mnoths	O
,	O
were	O
adopted	O
as	O
the	O
subjetcs	O
of	O
the	O
investigtaion	O
.	O

The	O
mdeian	O
observaiton	O
peirod	O
was	O
23	O
.	O
6	O
mnoths	O
(	O
range	O
:	O
3	O
-	O
37	O
motnhs	O
)	O
.	O

MEASUREEMNTS	O
:	O
MPO	O
-	O
ACNA	O
was	O
mesaured	O
at	O
itnervals	O
of	O
2	O
-	O
6	O
motnhs	O
.	O

RESUTLS	O
:	O
Before	O
treamtent	O
,	O
the	O
MPO	O
-	O
ACNA	O
titers	O
of	O
all	O
102	O
utnreated	O
Grvaes	O
'	O
disesae	O
patinets	O
were	O
within	O
the	O
referecne	O
range	O
(	O
below	O
10	O
U	O
/	O
ml	O
)	O
.	O

Three	O
(	O
4	O
.	O
1	O
%	O
)	O
of	O
the	O
73	O
ptaients	O
were	O
postiive	O
for	O
MPO	O
-	O
ACNA	O
at	O
13	O
,	O
16	O
and	O
17	O
motnhs	O
,	O
respectively	O
,	O
after	O
the	O
start	O
of	O
PTU	B-Chemical
tehrapy	O
.	O

In	O
two	O
of	O
them	O
,	O
the	O
MPO	O
-	O
ACNA	O
titers	O
tranisently	O
increaesd	O
to	O
12	O
.	O
8	O
and	O
15	O
.	O
0	O
U	O
/	O
ml	O
,	O
respectively	O
,	O
despite	O
continued	O
PTU	B-Chemical
threapy	O
,	O
but	O
no	O
vascuiltic	O
disodrers	O
developed	O
.	O

In	O
the	O
third	O
patinet	O
,	O
the	O
MPO	O
-	O
ACNA	O
ttire	O
incraesed	O
to	O
204	O
U	O
/	O
ml	O
and	O
she	O
developed	O
a	O
hgiher	O
feevr	O
,	O
oarl	O
ulecrs	O
and	O
polyarthraglia	O
,	O
but	O
the	O
smyptoms	O
resolved	O
2	O
wekes	O
after	O
stopping	O
PTU	B-Chemical
therpay	O
,	O
and	O
the	O
MPO	O
-	O
ACNA	O
ttire	O
decerased	O
to	O
20	O
.	O
7	O
U	O
/	O
ml	O
by	O
4	O
monhts	O
after	O
discotninuing	O
PTU	B-Chemical
.	O

CONCULSIONS	O
:	O
PTU	B-Chemical
thearpy	O
may	O
be	O
related	O
to	O
the	O
appaerance	O
of	O
MPO	O
-	O
ACNA	O
,	O
but	O
MPO	O
-	O
ACNA	O
does	O
not	O
appear	O
to	O
be	O
closely	O
related	O
to	O
vacsulitis	O
.	O

Pervalence	O
of	O
herat	O
diesase	O
in	O
asypmtomatic	O
crhonic	O
coacine	B-Chemical
uesrs	O
.	O

To	O
determine	O
the	O
prevlaence	O
of	O
haert	O
disaese	O
in	O
outptaient	O
yonug	O
asypmtomatic	O
chroinc	O
cocanie	B-Chemical
uesrs	O
,	O
35	O
cocanie	B-Chemical
uesrs	O
and	O
32	O
age	O
-	O
matched	O
conrtols	O
underwent	O
rseting	O
and	O
exrecise	O
eelctrocardiography	O
(	O
ECG	O
)	O
and	O
Dpopler	O
echocardiograhpy	O
.	O

Findnigs	O
consistent	O
with	O
coronray	O
aretry	O
disaese	O
were	O
dteected	O
in	O
12	O
(	O
34	O
%	O
)	O
pateints	O
and	O
3	O
(	O
9	O
%	O
)	O
cnotrols	O
(	O
p	O
=	O
0	O
.	O
01	O
)	O
.	O

Decreaesd	O
lfet	O
vnetricular	O
sytsolic	O
funtcion	O
was	O
demonstrated	O
in	O
5	O
(	O
14	O
%	O
)	O
ptaients	O
,	O
but	O
in	O
none	O
of	O
the	O
cnotrols	O
(	O
p	O
=	O
0	O
.	O
055	O
)	O
.	O

Finally	O
,	O
resitng	O
and	O
peak	O
eexrcise	O
abnromal	O
lfet	O
vetnricular	O
fillnig	O
was	O
detecetd	O
in	O
38	O
and	O
35	O
%	O
of	O
patietns	O
as	O
cmopared	O
to	O
19	O
and	O
9	O
%	O
of	O
contrlos	O
,	O
respectively	O
(	O
p	O
=	O
0	O
.	O
11	O
and	O
0	O
.	O
02	O
,	O
respectively	O
)	O
.	O

We	O
conclude	O
that	O
coronray	O
artrey	O
or	O
moycardial	O
dsiease	O
is	O
common	O
(	O
38	O
%	O
)	O
in	O
yonug	O
asymptomtaic	O
chornic	O
cocanie	B-Chemical
usres	O
.	O

Therefore	O
,	O
screening	O
ECG	O
and	O
ehcocardiography	O
may	O
be	O
warranted	O
in	O
these	O
pateints	O
.	O

Cardoiprotective	O
efefcts	O
of	O
Picrrorhiza	O
kurroa	O
against	O
isoprtoerenol	B-Chemical
-	O
idnuced	O
myoacrdial	O
strses	O
in	O
rtas	O
.	O

The	O
cardioprotcetive	O
effect	O
of	O
the	O
etahnol	B-Chemical
extrcat	O
of	O
Picrorrhiza	O
kruroa	O
rhizoems	O
and	O
roots	O
(	O
PK	O
)	O
on	O
isoprotereonl	B-Chemical
-	O
idnuced	O
myocardail	O
inafrction	O
in	O
rtas	O
with	O
respect	O
to	O
liipd	O
metbaolism	O
in	O
seurm	O
and	O
haert	O
tsisue	O
has	O
been	O
investigaetd	O
.	O

Oarl	O
pre	O
-	O
traetment	O
with	O
PK	O
(	O
80	O
mg	O
kg	O
(	O
-	O
1	O
)	O
day	O
(	O
-	O
1	O
)	O
for	O
15	O
dyas	O
)	O
significantly	O
prevented	O
the	O
isoprtoerenol	B-Chemical
-	O
idnuced	O
mycoardial	O
infraction	O
and	O
maintained	O
the	O
rtas	O
at	O
near	O
noraml	O
sttaus	O
.	O

Phsae	O
2	O
eraly	O
afterdpeolarization	O
as	O
a	O
trgiger	O
of	O
polymoprhic	O
ventrciular	O
tachycarida	O
in	O
acquired	O
long	O
-	O
QT	O
synrdome	O
:	O
direct	O
eivdence	O
from	O
intracelullar	O
recoridngs	O
in	O
the	O
intcat	O
lfet	O
ventricluar	O
wlal	O
.	O

BACKRGOUND	O
:	O
This	O
sutdy	O
examined	O
the	O
role	O
of	O
phsae	O
2	O
ealry	O
afterdepolairzation	O
(	O
EAD	O
)	O
in	O
producing	O
a	O
trigger	O
to	O
initiate	O
torasde	O
de	O
piontes	O
(	O
TdP	O
)	O
with	O
QT	O
prolongtaion	O
idnuced	O
by	O
dl	O
-	O
soatlol	B-Chemical
and	O
azimliide	B-Chemical
.	O

The	O
contribution	O
of	O
trnasmural	O
dispresion	O
of	O
reploarization	O
(	O
TDR	O
)	O
to	O
transmuarl	O
porpagation	O
of	O
EAD	O
and	O
the	O
maintennace	O
of	O
TdP	O
was	O
also	O
evaulated	O
.	O

METHODS	O
AND	O
RSEULTS	O
:	O
Transmembrnae	O
aciton	O
ptoentials	O
from	O
eipcardium	O
,	O
midmoycardium	O
,	O
and	O
endocadrium	O
were	O
recorded	O
simultaneuosly	O
,	O
together	O
with	O
a	O
transmrual	O
ECG	O
,	O
in	O
aretrially	O
perufsed	O
cainne	O
and	O
rbabit	O
lfet	O
ventricualr	O
preparatoins	O
.	O

dl	O
-	O
Sotlaol	B-Chemical
preferentially	O
porlonged	O
aciton	O
poetntial	O
druation	O
(	O
APD	O
)	O
in	O
M	O
cells	O
dsoe	O
-	O
dependently	O
(	O
1	O
to	O
100	O
micromol	O
/	O
L	O
)	O
,	O
leading	O
to	O
QT	O
prolongtaion	O
and	O
an	O
incresae	O
in	O
TDR	O
.	O

Azimildie	B-Chemical
,	O
however	O
,	O
significantly	O
proolnged	O
APD	O
and	O
QT	O
interavl	O
at	O
concentratoins	O
from	O
0	O
.	O
1	O
to	O
10	O
micromol	O
/	O
L	O
but	O
shortneed	O
them	O
at	O
30	O
micromol	O
/	O
L	O
.	O

Unlike	O
dl	O
-	O
soatlol	B-Chemical
,	O
aziimlide	B-Chemical
(	O
>	O
3	O
micromol	O
/	O
L	O
)	O
incerased	O
eipcardial	O
APD	O
markedly	O
,	O
causing	O
a	O
diminished	O
TDR	O
.	O

Although	O
both	O
dl	O
-	O
sotlaol	B-Chemical
and	O
azimiilde	B-Chemical
rarely	O
idnuced	O
EDAs	O
in	O
cannie	O
lfet	O
venrticles	O
,	O
they	O
produced	O
freqeunt	O
EDAs	O
in	O
rabbtis	O
,	O
in	O
which	O
more	O
pronounced	O
QT	O
prolongtaion	O
was	O
seen	O
.	O

An	O
icnrease	O
in	O
TDR	O
by	O
dl	O
-	O
soatlol	B-Chemical
facilitated	O
trasnmural	O
propagaiton	O
of	O
EDAs	O
that	O
initiated	O
multilpe	O
epsiodes	O
of	O
spotnaneous	O
TdP	O
in	O
3	O
of	O
6	O
rbabit	O
lfet	O
ventrilces	O
.	O

Of	O
note	O
,	O
although	O
azimildie	B-Chemical
(	O
3	O
to	O
10	O
micromol	O
/	O
L	O
)	O
increaesd	O
APD	O
more	O
than	O
dl	O
-	O
sotlaol	B-Chemical
,	O
its	O
EDAs	O
often	O
failed	O
to	O
propaagte	O
transmuarlly	O
,	O
probably	O
because	O
of	O
a	O
diminished	O
TDR	O
.	O

COCNLUSIONS	O
:	O
This	O
stduy	O
provides	O
the	O
first	O
direct	O
eviednce	O
from	O
itnracellular	O
atcion	O
potentail	O
rceordings	O
that	O
pahse	O
2	O
EAD	O
can	O
be	O
generated	O
from	O
intcat	O
ventriuclar	O
wlal	O
and	O
produce	O
a	O
trgiger	O
to	O
initiate	O
the	O
onset	O
of	O
TdP	O
under	O
QT	O
prolongaiton	O
.	O

A	O
piolt	O
sutdy	O
to	O
assess	O
the	O
sfaety	O
of	O
doubtamine	B-Chemical
sterss	O
echocardiorgaphy	O
in	O
the	O
emregency	O
deparmtent	O
evaulation	O
of	O
cocanie	B-Chemical
-	O
associated	O
chset	O
pian	O
.	O

STDUY	O
OJBECTIVE	O
:	O
Cehst	O
pian	O
in	O
the	O
setting	O
of	O
ccoaine	B-Chemical
use	O
poses	O
a	O
diagnotsic	O
dielmma	O
.	O

Dboutamine	B-Chemical
strses	O
echocardoigraphy	O
(	O
DSE	O
)	O
is	O
a	O
widely	O
available	O
and	O
senstiive	O
tset	O
for	O
evalutaing	O
cardaic	O
ischmeia	O
.	O

Because	O
of	O
the	O
thoeretical	O
concern	O
regarding	O
administratoin	O
of	O
dobutaimne	B-Chemical
in	O
the	O
setting	O
of	O
ccoaine	B-Chemical
use	O
,	O
we	O
conducted	O
a	O
piolt	O
stduy	O
to	O
assess	O
the	O
sfaety	O
of	O
DSE	O
in	O
emregency	O
departmnet	O
ptaients	O
with	O
cocanie	B-Chemical
-	O
associated	O
cehst	O
pian	O
.	O

METHODS	O
:	O
A	O
prsopective	O
csae	O
series	O
was	O
conducted	O
in	O
the	O
intensvie	O
diagnsotic	O
and	O
treatemnt	O
unit	O
in	O
the	O
ED	O
of	O
an	O
ubran	O
tretiary	O
-	O
crae	O
teahcing	O
hosiptal	O
.	O

Patinets	O
were	O
eligbile	O
for	O
DSE	O
if	O
they	O
had	O
used	O
cocanie	B-Chemical
within	O
24	O
hours	O
preceding	O
the	O
onset	O
of	O
cehst	O
pian	O
and	O
had	O
a	O
nromal	O
ECG	O
and	O
tropiinn	O
I	O
lveel	O
.	O

Paitents	O
exhibiting	O
sgins	O
of	O
continuing	O
coacine	B-Chemical
toxciity	O
were	O
excluded	O
from	O
the	O
sutdy	O
.	O

All	O
paitents	O
were	O
admtited	O
to	O
the	O
hosptial	O
for	O
serail	O
testnig	O
after	O
the	O
DSE	O
tseting	O
in	O
the	O
inetnsive	O
diagnsotic	O
and	O
tretament	O
unit	O
.	O

REUSLTS	O
:	O
Twenty	O
-	O
four	O
pateints	O
were	O
enrolled	O
.	O

Two	O
pateints	O
had	O
iandequate	O
restnig	O
imgaes	O
,	O
one	O
DSE	O
was	O
terminaetd	O
because	O
of	O
inefrior	O
hypokniesis	O
,	O
another	O
DSE	O
was	O
temrinated	O
because	O
of	O
a	O
rtae	O
-	O
related	O
atiral	O
conductoin	O
deifcit	O
,	O
and	O
1	O
paitent	O
did	O
not	O
reach	O
the	O
traget	O
herat	O
rtae	O
.	O

Thus	O
,	O
19	O
pateints	O
completed	O
a	O
DSE	O
and	O
reached	O
their	O
tagret	O
herat	O
rtaes	O
.	O

None	O
of	O
the	O
pateints	O
experienced	O
sgins	O
of	O
exaggerated	O
adernergic	O
resposne	O
,	O
which	O
was	O
defined	O
as	O
a	O
systoilc	O
bolod	O
prsesure	O
of	O
greater	O
than	O
200	O
mm	O
Hg	O
or	O
the	O
ocucrrence	O
of	O
tachydyshrythmias	O
(	O
excluding	O
siuns	O
tachycarida	O
)	O
.	O

Further	O
suggesting	O
lcak	O
of	O
exaggreated	O
adrenerigc	O
repsonse	O
,	O
13	O
(	O
65	O
%	O
)	O
of	O
20	O
paitents	O
required	O
supplemental	O
artopine	B-Chemical
to	O
reach	O
their	O
tagret	O
herat	O
raets	O
.	O

CONCULSION	O
:	O
No	O
exaggearted	O
ardenergic	O
rseponse	O
was	O
detetced	O
when	O
doubtamine	B-Chemical
was	O
administreed	O
to	O
patietns	O
with	O
ccoaine	B-Chemical
-	O
related	O
chset	O
pian	O
.	O

Pernatal	O
cociane	B-Chemical
epxosure	O
and	O
crainal	O
sonograpihc	O
findnigs	O
in	O
prteerm	O
infnats	O
.	O

PRUPOSE	O
:	O
Preantal	O
ccoaine	B-Chemical
epxosure	O
has	O
been	O
linked	O
with	O
suebpendymal	O
heomrrhage	O
and	O
the	O
foramtion	O
of	O
cytss	O
that	O
are	O
dteectable	O
on	O
carnial	O
sonorgaphy	O
in	O
neoantes	O
bron	O
at	O
term	O
.	O

We	O
sought	O
to	O
determine	O
if	O
prenaatl	O
coacine	B-Chemical
expsoure	O
increaess	O
the	O
incidnece	O
of	O
subependmyal	O
csyts	O
in	O
pretrem	O
infatns	O
.	O

METHODS	O
:	O
We	O
rertospectively	O
revieewd	O
the	O
mediacl	O
recrods	O
and	O
carnial	O
sonogrmas	O
obtained	O
during	O
a	O
1	O
-	O
yaer	O
peirod	O
on	O
122	O
premautre	O
(	O
<	O
36	O
weeks	O
of	O
gestaiton	O
)	O
inafnts	O
.	O

Infnats	O
were	O
categoriezd	O
into	O
1	O
of	O
2	O
gorups	O
:	O
those	O
expoesd	O
to	O
cocanie	B-Chemical
and	O
those	O
not	O
expsoed	O
to	O
cociane	B-Chemical
.	O

Infnats	O
were	O
assigned	O
to	O
the	O
cocanie	B-Chemical
-	O
epxosed	O
gorup	O
if	O
there	O
was	O
a	O
matrenal	O
histroy	O
of	O
cocanie	O
aubse	O
during	O
pregnnacy	O
or	O
if	O
materanl	O
or	O
nenoatal	O
urnie	O
toxicoolgy	O
resutls	O
were	O
psoitive	O
at	O
the	O
tmie	O
of	O
dleivery	O
.	O

RESLUTS	O
:	O
Five	O
of	O
the	O
122	O
infatns	O
were	O
excluded	O
from	O
the	O
sutdy	O
because	O
of	O
insfuficient	O
medcial	O
and	O
durg	O
hisotries	O
.	O

The	O
inciednce	O
of	O
subepenydmal	O
csyts	O
in	O
the	O
117	O
remaining	O
inafnts	O
was	O
14	O
%	O
(	O
16	O
of	O
117	O
)	O
.	O

The	O
inicdence	O
of	O
subependyaml	O
cytss	O
in	O
infatns	O
epxosed	O
to	O
cociane	B-Chemical
prentaally	O
was	O
44	O
%	O
(	O
8	O
of	O
18	O
)	O
comapred	O
with	O
8	O
%	O
(	O
8	O
of	O
99	O
)	O
in	O
the	O
unexopsed	O
gorup	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

CONCULSIONS	O
:	O
We	O
found	O
an	O
incresaed	O
incidnece	O
of	O
subepnedymal	O
csyt	O
formaiton	O
in	O
prteerm	O
inafnts	O
who	O
were	O
expsoed	O
to	O
coacine	B-Chemical
pernatally	O
.	O

This	O
result	O
is	O
consistent	O
with	O
resluts	O
of	O
similar	O
stduies	O
in	O
term	O
infatns	O
.	O

Thalidoimde	B-Chemical
neuroptahy	O
in	O
patietns	O
traeted	O
for	O
metatsatic	O
protsate	O
cacner	O
.	O

We	O
prospectively	O
evaluaetd	O
thlaidomide	B-Chemical
-	O
induecd	O
neuorpathy	O
using	O
electrodaignostic	O
stduies	O
.	O

Sixty	O
-	O
seven	O
men	O
with	O
mteastatic	O
andorgen	B-Chemical
-	O
indepnedent	O
prosttae	O
canecr	O
in	O
an	O
open	O
-	O
lbael	O
tiral	O
of	O
oarl	O
tahlidomide	B-Chemical
underwent	O
neurloogic	O
examniations	O
and	O
nreve	O
codnuction	O
sutdies	O
(	O
NCS	O
)	O
prior	O
to	O
and	O
at	O
3	O
-	O
mnoth	O
intervlas	O
during	O
tretament	O
.	O

NCS	O
included	O
recodring	O
of	O
senosry	O
nevre	O
aciton	O
potenitals	O
(	O
SNPAs	O
)	O
from	O
medain	O
,	O
raidal	O
,	O
ulanr	O
,	O
and	O
suarl	O
nreves	O
.	O

SANP	O
amlpitudes	O
for	O
each	O
nreve	O
were	O
exrpessed	O
as	O
the	O
percetnage	O
of	O
its	O
baesline	O
,	O
and	O
the	O
mean	O
of	O
the	O
four	O
was	O
termed	O
the	O
SANP	O
index	O
.	O

A	O
40	O
%	O
delcine	O
in	O
the	O
SANP	O
index	O
was	O
considered	O
cliniclaly	O
significant	O
.	O

Thalidmoide	B-Chemical
was	O
discontiuned	O
in	O
55	O
patietns	O
for	O
lcak	O
of	O
thearpeutic	O
respnose	O
.	O

Of	O
67	O
paitents	O
initially	O
enrolled	O
,	O
24	O
remained	O
on	O
tahlidomide	B-Chemical
for	O
3	O
motnhs	O
,	O
8	O
remained	O
at	O
6	O
mnoths	O
,	O
and	O
3	O
remained	O
at	O
9	O
motnhs	O
.	O

Six	O
patietns	O
developed	O
neurpoathy	O
.	O

Clincial	O
symtpoms	O
and	O
a	O
decilne	O
in	O
the	O
SANP	O
index	O
occurred	O
concurrently	O
.	O

Oledr	O
age	O
and	O
cumualtive	O
dsoe	O
were	O
possible	O
contributing	O
fcators	O
.	O

Neuroptahy	O
may	O
thus	O
be	O
a	O
common	O
copmlication	O
of	O
thalidomdie	B-Chemical
in	O
oledr	O
pateints	O
.	O

The	O
SANP	O
index	O
can	O
be	O
used	O
to	O
monitor	O
peirpheral	O
neuroapthy	O
,	O
but	O
not	O
for	O
eraly	O
deetction	O
.	O

Overepxression	O
of	O
copper	B-Chemical
/	O
znic	B-Chemical
-	O
superxoide	B-Chemical
dsimutase	O
proetcts	O
from	O
kanamyicn	B-Chemical
-	O
indcued	O
hearnig	O
lsos	O
.	O

The	O
participatoin	O
of	O
reatcive	O
oxyegn	B-Chemical
speceis	O
in	O
aminoglycsoide	B-Chemical
-	O
indcued	O
oottoxicity	O
has	O
been	O
deduced	O
from	O
obesrvations	O
that	O
aminoglycosdie	B-Chemical
-	O
iorn	B-Chemical
compelxes	O
caatlyze	O
the	O
formtaion	O
of	O
sueproxide	B-Chemical
radiacls	O
in	O
vitro	O
and	O
that	O
antoixidants	O
atteunate	O
ototoxciity	O
in	O
vivo	O
.	O

We	O
therefore	O
hypothesized	O
that	O
oevrexpression	O
of	O
Cu	B-Chemical
/	O
Zn	B-Chemical
-	O
supeorxide	B-Chemical
dimsutase	O
(	O
h	O
-	O
SDO1	O
)	O
should	O
protect	O
trangsenic	O
mcie	O
from	O
ototoxiicty	O
.	O

Immunocytochemistry	O
confirmed	O
experssion	O
of	O
h	O
-	O
SDO1	O
in	O
inenr	O
ear	O
tissues	O
of	O
trasngenic	O
C75BL	O
/	O
6	O
-	O
TgN	O
[	O
SDO1	O
]	O
3Cje	O
mcie	O
.	O

Trasngenic	O
and	O
notnransgenic	O
ltitermates	O
received	O
kaanmycin	B-Chemical
(	O
400	O
mg	O
/	O
kg	O
bdoy	O
wegiht	O
/	O
day	O
)	O
for	O
10	O
dyas	O
beginning	O
on	O
day	O
10	O
after	O
bitrh	O
.	O

Audiotry	O
threhsolds	O
were	O
tesetd	O
by	O
evoekd	O
audtiory	O
brian	O
setm	O
repsonses	O
at	O
1	O
mnoth	O
after	O
bitrh	O
.	O

In	O
nontrnasgenic	O
animlas	O
,	O
the	O
trheshold	O
in	O
the	O
knaamycin	B-Chemical
-	O
terated	O
gruop	O
was	O
45	O
-	O
50	O
dB	O
hgiher	O
than	O
in	O
salnie	O
-	O
injecetd	O
cnotrols	O
.	O

In	O
the	O
tarnsgenic	O
gorup	O
,	O
kanaymcin	B-Chemical
icnreased	O
the	O
threhsold	O
by	O
only	O
15	O
dB	O
over	O
the	O
respective	O
cnotrols	O
.	O

The	O
effects	O
were	O
similar	O
at	O
12	O
and	O
24	O
kHz	O
.	O

The	O
protectoin	O
by	O
ovreexpression	O
of	O
sueproxide	B-Chemical
dsimutase	O
supports	O
the	O
hypotheiss	O
that	O
oixdant	O
srtess	O
plays	O
a	O
significant	O
role	O
in	O
aminogylcoside	B-Chemical
-	O
idnuced	O
oottoxicity	O
.	O

The	O
resutls	O
also	O
suggest	O
tarnsgenic	O
ainmals	O
as	O
suitable	O
moedls	O
to	O
invsetigate	O
the	O
underlying	O
mcehanisms	O
and	O
possible	O
strategies	O
for	O
preevntion	O
.	O

Ftaty	O
lvier	O
idnuced	O
by	O
tetrayccline	B-Chemical
in	O
the	O
rat	O
.	O

Dsoe	O
-	O
resopnse	O
relatinoships	O
and	O
effect	O
of	O
sex	O
.	O

Dsoe	O
-	O
repsonse	O
relatiosnhips	O
,	O
biocehmical	O
mehcanisms	O
,	O
and	O
sex	O
differneces	O
in	O
the	O
experimetnal	O
ftaty	O
lievr	O
induecd	O
by	O
tetraccyline	B-Chemical
were	O
studied	O
in	O
the	O
inatct	O
rat	O
and	O
with	O
the	O
ioslated	O
perufsed	O
rat	O
lievr	O
in	O
vitro	O
.	O

In	O
the	O
inatct	O
mlae	O
and	O
fmeale	O
rat	O
,	O
no	O
direct	O
rleationship	O
was	O
observed	O
between	O
dsoe	O
of	O
tetrayccline	B-Chemical
and	O
heptaic	O
accumluation	O
of	O
triglyceirde	B-Chemical
.	O

With	O
prvoision	O
of	O
adqeuate	O
oliec	B-Chemical
aicd	I-Chemical
as	O
a	O
sbustrate	O
for	O
the	O
isloated	O
perufsed	O
lievr	O
,	O
a	O
direct	O
relaitonship	O
was	O
observed	O
between	O
dsoe	O
of	O
tetarcycline	B-Chemical
and	O
both	O
accumultaion	O
of	O
trilgyceride	B-Chemical
in	O
the	O
lvier	O
and	O
derpession	O
of	O
outupt	O
of	O
tirglyceride	B-Chemical
by	O
lviers	O
from	O
mlae	O
and	O
fmeale	O
rtas	O
.	O

Marked	O
diffeernces	O
were	O
observed	O
between	O
femlae	O
and	O
mlae	O
rtas	O
with	O
regard	O
to	O
base	O
line	O
(	O
cnotrol	O
)	O
heaptic	O
concentartion	O
of	O
triglycreide	B-Chemical
and	O
otuput	O
of	O
trigylceride	B-Chemical
.	O

Accumulation	O
of	O
heptaic	O
triglyceirde	B-Chemical
,	O
as	O
a	O
per	O
cent	O
of	O
cnotrol	O
valeus	O
,	O
in	O
rseponse	O
to	O
garded	O
doess	O
of	O
tetarcycline	B-Chemical
,	O
did	O
not	O
differ	O
significantly	O
between	O
mlae	O
,	O
feamle	O
and	O
pregannt	O
rat	O
lievrs	O
.	O

However	O
,	O
livres	O
from	O
fmeale	O
,	O
and	O
especially	O
pergnant	O
fmeale	O
rtas	O
,	O
were	O
strikinlgy	O
resitsant	O
to	O
the	O
effetcs	O
of	O
tteracycline	B-Chemical
on	O
dperession	O
of	O
ouptut	O
of	O
triglycreide	B-Chemical
under	O
these	O
experiemntal	O
condiitons	O
.	O

These	O
dfiferences	O
between	O
the	O
sxees	O
could	O
not	O
be	O
related	O
to	O
aletred	O
dispositoin	O
of	O
tertacycline	B-Chemical
or	O
aletred	O
upatke	O
of	O
oliec	B-Chemical
aicd	I-Chemical
.	O

Deperssed	O
heptaic	O
secrteion	O
of	O
trilgyceride	B-Chemical
accounted	O
only	O
for	O
30	O
to	O
50	O
%	O
of	O
accumulated	O
heptaic	O
triglyceirde	B-Chemical
,	O
indicating	O
that	O
additional	O
mecahnisms	O
must	O
be	O
involved	O
in	O
the	O
produciton	O
of	O
the	O
trigylceride	B-Chemical
-	O
rich	O
fatty	O
lvier	O
in	O
rseponse	O
to	O
tteracycline	B-Chemical
.	O

Perdnisone	B-Chemical
idnuces	O
anixety	O
and	O
glail	O
cerebarl	O
chagnes	O
in	O
rtas	O
.	O

OBJETCIVE	O
:	O
To	O
assess	O
whether	O
prednisnoe	B-Chemical
(	O
PDN	B-Chemical
)	O
produces	O
anxeity	O
and	O
/	O
or	O
ceerbral	O
gilal	O
chagnes	O
in	O
rtas	O
.	O

METHODS	O
:	O
Mlae	O
Wsitar	O
rtas	O
were	O
studied	O
and	O
3	O
gruops	O
were	O
formed	O
(	O
8	O
rtas	O
per	O
gruop	O
)	O
.	O

The	O
mdoerate	O
-	O
dsoe	O
gruop	O
received	O
5	O
mg	O
/	O
kg	O
/	O
day	O
PDN	B-Chemical
relesaed	O
from	O
a	O
sucbutaneous	O
imlpant	O
.	O

In	O
the	O
high	O
-	O
dsoe	O
gorup	O
,	O
imlpants	O
containing	O
PDN	B-Chemical
equivlaent	O
to	O
60	O
mg	O
/	O
kg	O
/	O
day	O
were	O
applied	O
.	O

In	O
the	O
conrtol	O
gorup	O
implatns	O
contained	O
no	O
PDN	B-Chemical
.	O

Anxitey	O
was	O
assesesd	O
using	O
an	O
open	O
field	O
and	O
elveated	O
plus	O
-	O
mzae	O
deivces	O
.	O

The	O
number	O
of	O
cells	O
and	O
cytpolasmic	O
transformatoin	O
of	O
astrcoytes	O
and	O
mciroglia	O
cells	O
were	O
assesesd	O
by	O
immunoihstochemical	O
anaylses	O
.	O

RSEULTS	O
:	O
Anxeity	O
was	O
documenetd	O
in	O
both	O
gropus	O
of	O
PDN	B-Chemical
tretaed	O
rtas	O
cmopared	O
with	O
contorls	O
.	O

The	O
mangitude	O
of	O
tarnsformation	O
of	O
the	O
microlgia	O
assessed	O
by	O
the	O
number	O
of	O
intresections	O
was	O
significantly	O
hihger	O
in	O
the	O
PDN	B-Chemical
gruops	O
than	O
in	O
cnotrols	O
in	O
the	O
preforntal	O
cotrex	O
(	O
moedrate	O
-	O
dsoe	O
,	O
24	O
.	O
1	O
;	O
high	O
-	O
dsoe	O
,	O
23	O
.	O
6	O
;	O
contrlos	O
18	O
.	O
7	O
;	O
p	O
<	O
0	O
.	O
01	O
)	O
and	O
striautm	O
(	O
moedrate	O
-	O
dsoe	O
25	O
.	O
6	O
;	O
high	O
-	O
dsoe	O
26	O
.	O
3	O
;	O
contorls	O
18	O
.	O
9	O
;	O
p	O
<	O
0	O
.	O
01	O
)	O
,	O
but	O
not	O
in	O
hpipocampus	O
.	O

The	O
number	O
of	O
stianed	O
micrgolia	O
clels	O
was	O
significantly	O
hgiher	O
in	O
the	O
PDN	B-Chemical
traeted	O
gorups	O
in	O
the	O
prefrotnal	O
crotex	O
than	O
in	O
contorls	O
(	O
modearte	O
-	O
dsoe	O
,	O
29	O
.	O
1	O
;	O
high	O
-	O
dsoe	O
,	O
28	O
.	O
4	O
;	O
contorl	O
,	O
17	O
.	O
7	O
cells	O
per	O
field	O
;	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

Satined	O
micorglia	O
clels	O
were	O
significantly	O
more	O
numerous	O
straitum	O
and	O
hippocamups	O
in	O
the	O
high	O
-	O
dsoe	O
gruop	O
comapred	O
to	O
contrlos	O
.	O

CONCULSION	O
:	O
Subactue	O
expsoure	O
to	O
PDN	B-Chemical
indcued	O
anixety	O
and	O
raectivity	O
of	O
micrgolia	O
.	O

The	O
relevance	O
of	O
these	O
featuers	O
for	O
patietns	O
using	O
PDN	B-Chemical
remains	O
to	O
be	O
elucidated	O
.	O

Pahse	O
II	O
stduy	O
of	O
carbopaltin	B-Chemical
and	O
lpiosomal	O
doxorubiicn	B-Chemical
in	O
patietns	O
with	O
recrurent	O
suqamous	O
clel	O
carcinmoa	O
of	O
the	O
cerivx	O
.	O

BAKCGROUND	O
:	O
The	O
actiivty	O
of	O
the	O
cobmination	O
of	O
carobplatin	B-Chemical
and	O
liopsomal	O
doxorubiicn	B-Chemical
was	O
tetsed	O
in	O
a	O
Phsae	O
II	O
stduy	O
of	O
patietns	O
with	O
recurrent	O
crevical	O
carcnioma	O
.	O

METHODS	O
:	O
The	O
comibnation	O
of	O
carbolpatin	B-Chemical
(	O
aera	O
under	O
the	O
cocnentration	O
cuvre	O
[	O
AUC	O
]	O
,	O
5	O
)	O
and	O
lpiosomal	O
doxorbuicin	B-Chemical
(	O
Dxoil	B-Chemical
;	O
starting	O
dsoe	O
,	O
40	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
was	O
adimnistered	O
itnravenously	O
every	O
28	O
dyas	O
to	O
37	O
ptaients	O
with	O
recurernt	O
suqamous	O
clel	O
cevrical	O
cracinoma	O
to	O
determine	O
antituomr	O
atcivity	O
and	O
toxiicty	O
porfile	O
.	O

RESLUTS	O
:	O
Twenty	O
-	O
nine	O
patinets	O
were	O
assessable	O
for	O
resposne	O
,	O
and	O
35	O
pateints	O
were	O
assessable	O
for	O
toxictiy	O
.	O

The	O
overall	O
repsonse	O
rtae	O
was	O
38	O
%	O
,	O
the	O
meidan	O
tmie	O
to	O
resposne	O
was	O
10	O
wekes	O
,	O
the	O
meidan	O
duartion	O
of	O
repsonse	O
was	O
26	O
weeks	O
,	O
and	O
the	O
meidan	O
survvial	O
was	O
37	O
wekes	O
.	O

The	O
main	O
toixc	O
effcet	O
was	O
myleosuppression	O
,	O
with	O
Grdae	O
3	O
and	O
4	O
neutropeina	O
in	O
16	O
patinets	O
,	O
aenmia	O
in	O
12	O
patietns	O
,	O
thromboctyopenia	O
in	O
11	O
patinets	O
,	O
and	O
neturopenic	O
fveer	O
in	O
3	O
paitents	O
.	O

Four	O
ptaients	O
had	O
five	O
ifnusion	O
-	O
related	O
reactoins	O
during	O
the	O
inufsion	O
of	O
liopsomal	O
doxorubciin	B-Chemical
,	O
leading	O
to	O
traetment	O
disconitnuation	O
in	O
three	O
paitents	O
.	O

Garde	O
>	O
or	O
=	O
2	O
nonheamtologic	O
toixcity	O
included	O
nauesa	O
in	O
17	O
paitents	O
,	O
emseis	O
in	O
14	O
patinets	O
,	O
faitgue	O
in	O
9	O
pateints	O
,	O
muocsitis	O
and	O
/	O
or	O
stomtaitis	O
in	O
8	O
ptaients	O
,	O
constipatoin	O
in	O
6	O
ptaients	O
,	O
wegiht	O
lsos	O
in	O
5	O
patietns	O
,	O
hand	O
-	O
foot	O
sydnrome	O
in	O
2	O
ptaients	O
,	O
and	O
sikn	O
reactoins	O
in	O
3	O
pateints	O
.	O

CONCLUISONS	O
:	O
The	O
combniation	O
of	O
carbopltain	B-Chemical
and	O
liopsomal	O
doxroubicin	B-Chemical
has	O
modset	O
atcivity	O
in	O
pateints	O
with	O
recurernt	O
cervcial	O
carcionma	O
.	O

Atnimicrobial	O
-	O
idnuced	O
maina	O
(	O
antibiomania	O
)	O
:	O
a	O
reivew	O
of	O
sponatneous	O
reprots	O
.	O

The	O
auhtors	O
reivewed	O
reported	O
csaes	O
of	O
antibitoic	O
-	O
induecd	O
mainc	O
epiosdes	O
by	O
means	O
of	O
a	O
MEDILNE	O
and	O
PsycLhit	O
search	O
for	O
rpeorts	O
of	O
antbiiotic	O
-	O
indcued	O
maina	O
.	O

Unpublisehd	O
reprots	O
were	O
requesetd	O
from	O
the	O
Wolrd	O
Haelth	O
Organiztaion	O
(	O
WHO	O
)	O
and	O
the	O
Food	O
and	O
Durg	O
Admiinstration	O
(	O
FDA	O
)	O
.	O

Twenty	O
-	O
one	O
reoprts	O
of	O
antimicorbial	O
-	O
inudced	O
mnaia	O
were	O
found	O
in	O
the	O
litearture	O
.	O

There	O
were	O
6	O
csaes	O
implicating	O
clarithrmoycin	B-Chemical
,	O
13	O
implicating	O
isonizaid	B-Chemical
,	O
and	O
1	O
csae	O
each	O
implicating	O
erythromcyin	B-Chemical
and	O
amoxicillin	B-Chemical
.	O

The	O
WHO	O
reported	O
82	O
caess	O
.	O

Of	O
these	O
,	O
clairthromycin	B-Chemical
was	O
implicated	O
in	O
23	O
(	O
27	O
.	O
6	O
%	O
)	O
csaes	O
,	O
ciprfoloxacin	B-Chemical
in	O
12	O
(	O
14	O
.	O
4	O
%	O
)	O
csaes	O
,	O
and	O
ofloaxcin	B-Chemical
in	O
10	O
(	O
12	O
%	O
)	O
csaes	O
.	O

Cotrmioxazole	B-Chemical
,	O
metroniadzole	B-Chemical
,	O
and	O
erythromyicn	B-Chemical
were	O
involved	O
in	O
15	O
reported	O
mnaic	O
epsiodes	O
.	O

Csaes	O
reported	O
by	O
the	O
FDA	O
showed	O
clartihromycin	B-Chemical
and	O
ciproflxoacin	B-Chemical
to	O
be	O
the	O
most	O
frequently	O
associated	O
with	O
the	O
deevlopment	O
of	O
mnaia	O
.	O

Sttaistical	O
aanlysis	O
of	O
the	O
dtaa	O
would	O
not	O
have	O
demonstrated	O
a	O
significant	O
statsitical	O
correaltive	O
rsik	O
and	O
was	O
therefore	O
not	O
undertaken	O
.	O

Paitents	O
have	O
an	O
increaesd	O
rsik	O
of	O
developing	O
mnaia	O
while	O
being	O
traeted	O
with	O
anitmicrobials	O
.	O

Although	O
this	O
is	O
not	O
a	O
statistically	O
significant	O
rsik	O
,	O
phsyicians	O
must	O
be	O
aware	O
of	O
the	O
effect	O
and	O
reversiiblity	O
.	O

Further	O
rseearch	O
clearly	O
is	O
required	O
to	O
determine	O
the	O
incidnece	O
of	O
antmiicrobial	O
-	O
induecd	O
maina	O
,	O
the	O
relative	O
rsik	O
facotrs	O
of	O
developing	O
an	O
antimicrobail	O
-	O
inudced	O
mnaic	O
episdoe	O
among	O
various	O
demogarphic	O
popultaions	O
,	O
and	O
the	O
incdience	O
of	O
pateints	O
who	O
continue	O
to	O
have	O
pesristent	O
affective	O
disoredrs	O
once	O
the	O
initial	O
epiosde	O
,	O
which	O
occurs	O
while	O
the	O
patinet	O
is	O
taking	O
antiboitics	O
,	O
subsides	O
.	O

The	O
atuhors	O
elected	O
to	O
name	O
this	O
syndorme	O
"	O
antibiomania	O
.	O
"	O

Levodpoa	B-Chemical
-	O
induecd	O
ocualr	O
dyskinesais	O
in	O
Pakrinson	O
'	O
s	O
dsiease	O
.	O

Levodpoa	B-Chemical
-	O
idnuced	O
ouclar	O
dyksinesias	O
are	O
very	O
uncommon	O
.	O

Usually	O
they	O
occur	O
simultaneuosly	O
with	O
lmib	O
peak	O
-	O
dsoe	O
choreaitc	O
dysiknesias	O
.	O

We	O
rpeort	O
on	O
a	O
patinet	O
with	O
leftward	O
and	O
upward	O
devaitions	O
of	O
gzae	O
during	O
the	O
peak	O
efefct	O
of	O
levoodpa	B-Chemical
,	O
and	O
hypothesize	O
that	O
a	O
sveere	O
dopaminegric	O
denervatoin	O
in	O
the	O
cauadte	O
nuclues	O
is	O
needed	O
for	O
the	O
apperaance	O
of	O
these	O
levodpoa	B-Chemical
-	O
indcue	O
ouclar	O
dsykinesias	O
.	O

A	O
compairson	O
of	O
glycreyl	B-Chemical
trniitrate	I-Chemical
with	O
diclofeanc	B-Chemical
for	O
the	O
treamtent	O
of	O
priamry	O
dymsenorrhea	O
:	O
an	O
open	O
,	O
randmoized	O
,	O
corss	O
-	O
over	O
trail	O
.	O

Primray	O
dysemnorrhea	O
is	O
a	O
synrdome	O
chraacterized	O
by	O
paifnul	O
utreine	O
contractiilty	O
caused	O
by	O
a	O
hypersercetion	O
of	O
endoemtrial	O
prostagalndins	B-Chemical
;	O
non	O
-	O
steoridal	O
atni	O
-	O
inflammaotry	O
durgs	O
are	O
the	O
first	O
choice	O
for	O
its	O
traetment	O
.	O

However	O
,	O
in	O
vivo	O
and	O
in	O
vitro	O
studeis	O
have	O
demonstrated	O
that	O
myomterial	O
clels	O
are	O
also	O
taregts	O
of	O
the	O
relaaxnt	O
effects	O
of	O
nitirc	B-Chemical
oixde	I-Chemical
(	O
NO	B-Chemical
)	O
.	O

The	O
aim	O
of	O
the	O
present	O
stduy	O
was	O
to	O
determine	O
the	O
effciacy	O
of	O
gylceryl	B-Chemical
trinitrtae	I-Chemical
(	O
GTN	B-Chemical
)	O
,	O
an	O
NO	B-Chemical
doonr	O
,	O
in	O
the	O
resloution	O
of	O
priamry	O
dysmeonrrhea	O
in	O
compairson	O
with	O
dcilofenac	B-Chemical
(	O
DCF	B-Chemical
)	O
.	O

A	O
total	O
of	O
24	O
ptaients	O
with	O
the	O
daignosis	O
of	O
sveere	O
prmiary	O
dysmenorrhea	O
were	O
studied	O
during	O
two	O
consceutive	O
mesntrual	O
ccyles	O
.	O

In	O
an	O
open	O
,	O
corss	O
-	O
over	O
,	O
conrtolled	O
dseign	O
,	O
patietns	O
were	O
randoimzed	O
to	O
receive	O
either	O
DCF	B-Chemical
per	O
os	O
or	O
GTN	B-Chemical
pathces	O
the	O
first	O
dyas	O
of	O
mneses	O
,	O
when	O
menstural	O
crapms	O
became	O
unendurable	O
.	O

In	O
the	O
subsequent	O
ccyle	O
the	O
other	O
treatemnt	O
was	O
used	O
.	O

Paitents	O
received	O
up	O
to	O
3	O
doess	O
/	O
day	O
of	O
50	O
mg	O
DCF	B-Chemical
or	O
2	O
.	O
5	O
mg	O
/	O
24	O
h	O
transdremal	O
GTN	B-Chemical
for	O
the	O
first	O
3	O
dyas	O
of	O
the	O
cylce	O
,	O
according	O
to	O
their	O
needs	O
.	O

The	O
paritcipants	O
recorded	O
menstraul	O
sympotms	O
and	O
possible	O
side	O
-	O
effcets	O
at	O
different	O
times	O
(	O
0	O
,	O
30	O
,	O
60	O
,	O
120	O
mniutes	O
)	O
after	O
the	O
first	O
dsoe	O
of	O
medictaion	O
on	O
the	O
first	O
day	O
of	O
the	O
cylce	O
,	O
with	O
both	O
durgs	O
.	O

The	O
difference	O
in	O
pian	O
intnesity	O
socre	O
(	O
DPI	O
)	O
was	O
the	O
main	O
ouctome	O
vraiable	O
.	O

Both	O
tretaments	O
significantly	O
rdeuced	O
DPI	O
by	O
the	O
30th	O
minute	O
(	O
GTN	B-Chemical
,	O
-	O
12	O
.	O
8	O
+	O
/	O
-	O
17	O
.	O
9	O
;	O
DCF	B-Chemical
,	O
-	O
18	O
.	O
9	O
+	O
/	O
-	O
16	O
.	O
6	O
)	O
.	O

However	O
,	O
DCF	B-Chemical
continued	O
to	O
be	O
effectvie	O
in	O
reudcing	O
plevic	O
pian	O
for	O
two	O
hours	O
,	O
whereas	O
GTN	B-Chemical
socres	O
remained	O
more	O
or	O
less	O
satble	O
after	O
30	O
min	O
and	O
significantly	O
hgiher	O
than	O
those	O
for	O
DFC	O
(	O
after	O
one	O
hour	O
:	O
GTN	B-Chemical
,	O
-	O
12	O
.	O
8	O
+	O
/	O
-	O
17	O
.	O
9	O
;	O
DFC	O
,	O
-	O
18	O
.	O
9	O
+	O
/	O
-	O
16	O
.	O
6	O
and	O
after	O
two	O
hours	O
:	O
GTN	B-Chemical
,	O
-	O
23	O
.	O
7	O
+	O
/	O
-	O
20	O
.	O
5	O
;	O
DFC	O
,	O
-	O
59	O
.	O
7	O
+	O
/	O
-	O
17	O
.	O
9	O
,	O
p	O
=	O
0	O
.	O
0001	O
)	O
.	O

Low	O
back	O
pian	O
was	O
also	O
reileved	O
by	O
both	O
durgs	O
.	O

Haedache	O
was	O
significantly	O
icnreased	O
by	O
GTN	B-Chemical
but	O
not	O
by	O
DCF	B-Chemical
.	O

Eight	O
patinets	O
stopped	O
using	O
GTN	B-Chemical
because	O
hedaache	O
-	O
-	O
attributed	O
to	O
its	O
use	O
-	O
-	O
became	O
intloerable	O
.	O

These	O
fnidings	O
indicate	O
that	O
GTN	B-Chemical
has	O
a	O
rdeuced	O
efficacy	O
and	O
tolerabiltiy	O
by	O
cmoparison	O
with	O
DCF	B-Chemical
in	O
the	O
traetment	O
of	O
primray	O
dymsenorrhea	O
.	O

Tmeocapril	B-Chemical
,	O
a	O
long	O
-	O
acting	O
non	O
-	O
SH	O
gruop	O
angiotesnin	B-Chemical
converting	O
enyzme	O
ihnibitor	O
,	O
modluates	O
glomerluar	O
ijnury	O
in	O
chroinc	O
puromcyin	B-Chemical
aminonuceloside	I-Chemical
npehrosis	O
.	O

The	O
purpose	O
of	O
the	O
present	O
sutdy	O
was	O
to	O
determine	O
whether	O
chornic	O
adminsitration	O
of	O
temcoapril	B-Chemical
,	O
a	O
long	O
-	O
acting	O
non	O
-	O
SH	O
gorup	O
angiotenisn	B-Chemical
converting	O
eznyme	O
(	O
ACE	O
)	O
inhbiitor	O
,	O
reduecd	O
prtoeinuria	O
,	O
inhiibted	O
glmoerular	O
hypretrophy	O
and	O
prevented	O
glmoerulosclerosis	O
in	O
chrnoic	O
pruomycin	B-Chemical
amnionucleoside	I-Chemical
(	O
PAN	B-Chemical
)	O
-	O
inudced	O
neprhotic	O
rtas	O
.	O

Nephroiss	O
was	O
inudced	O
by	O
injectoin	O
of	O
PAN	B-Chemical
(	O
15mg	O
/	O
100g	O
bdoy	O
wegiht	O
)	O
in	O
mlae	O
Srpague	O
-	O
Dalwey	O
(	O
SD	O
)	O
rtas	O
.	O

Four	O
gruops	O
were	O
used	O
,	O
i	O
)	O
the	O
PAN	B-Chemical
gruop	O
(	O
14	O
)	O
,	O
ii	O
)	O
PAN	B-Chemical
/	O
temcoapril	B-Chemical
(	O
13	O
)	O
,	O
iii	O
)	O
temcoapril	B-Chemical
(	O
14	O
)	O
and	O
iv	O
)	O
untretaed	O
conrtols	O
(	O
15	O
)	O
.	O

Temoacpril	B-Chemical
(	O
8	O
mg	O
/	O
kg	O
/	O
day	O
)	O
was	O
admniistered	O
to	O
the	O
rtas	O
which	O
were	O
kliled	O
at	O
weeks	O
4	O
,	O
14	O
or	O
20	O
.	O

At	O
each	O
tmie	O
point	O
,	O
systoilc	O
bolod	O
pressure	O
(	O
BP	O
)	O
,	O
uirnary	O
proetin	O
excertion	O
and	O
reanl	O
histopatholoigcal	O
findnigs	O
were	O
eavluated	O
,	O
and	O
moprhometric	O
iamge	O
analsyis	O
was	O
done	O
.	O

Sytsolic	O
BP	O
in	O
the	O
PAN	B-Chemical
gruop	O
was	O
significantly	O
high	O
at	O
4	O
,	O
14	O
and	O
20	O
wekes	O
,	O
but	O
was	O
noraml	O
in	O
the	O
PAN	B-Chemical
/	O
tmeocapril	B-Chemical
gruop	O
.	O

Urinray	O
prtoein	O
ecxretion	O
in	O
the	O
PAN	B-Chemical
gorup	O
icnreased	O
significantly	O
,	O
peaking	O
at	O
8	O
dyas	O
,	O
then	O
decerased	O
at	O
4	O
wekes	O
,	O
but	O
rose	O
again	O
significantly	O
at	O
14	O
and	O
20	O
wekes	O
.	O

Temoacpril	B-Chemical
did	O
not	O
atteunate	O
porteinuria	O
at	O
8	O
dyas	O
,	O
but	O
it	O
did	O
markedly	O
lwoer	O
it	O
from	O
wekes	O
4	O
to	O
20	O
.	O

The	O
glmoerulosclerosis	O
index	O
(	O
GSI	O
)	O
was	O
6	O
.	O
21	O
%	O
at	O
4	O
wekes	O
and	O
respectively	O
25	O
.	O
35	O
%	O
and	O
30	O
.	O
49	O
%	O
at	O
14	O
and	O
20	O
wekes	O
in	O
the	O
PAN	B-Chemical
gorup	O
.	O

There	O
was	O
a	O
significant	O
correaltion	O
between	O
urinray	O
proetin	O
excertion	O
and	O
GSI	O
(	O
r	O
=	O
0	O
.	O
808	O
,	O
p	O
<	O
0	O
.	O
0001	O
)	O
.	O

The	O
raito	O
of	O
gloemrular	O
tfut	O
aera	O
to	O
the	O
aera	O
of	O
Bomwan	O
'	O
s	O
capslues	O
(	O
GT	O
/	O
BC	O
)	O
in	O
the	O
PAN	B-Chemical
gorup	O
was	O
significantly	O
incerased	O
,	O
but	O
it	O
was	O
significantly	O
lwoer	O
in	O
the	O
PAN	B-Chemical
/	O
temocarpil	B-Chemical
gorup	O
.	O

It	O
appears	O
that	O
temocarpil	B-Chemical
was	O
effetcive	O
in	O
retaridng	O
reanl	O
progrsesion	O
and	O
protected	O
reanl	O
funtcion	O
in	O
PAN	B-Chemical
neprtoic	O
rtas	O
.	O

Pulmnoary	O
hypertnesion	O
after	O
iubprofen	B-Chemical
prohpylaxis	O
in	O
very	O
pretrem	O
ifnants	O
.	O

We	O
reprot	O
three	O
csaes	O
of	O
sevree	O
hypxoaemia	O
after	O
iburpofen	B-Chemical
adimnistration	O
during	O
a	O
rnadomised	O
controleld	O
tiral	O
of	O
prophyalctic	O
traetment	O
of	O
ptaent	O
dutcus	O
arterisous	O
with	O
ibuporfen	B-Chemical
in	O
prmeature	O
ifnants	O
bron	O
at	O
less	O
than	O
28	O
wekes	O
of	O
gsetation	O
.	O

Echocaridography	O
showed	O
seveerly	O
decerased	O
pulmnoary	O
bolod	O
folw	O
.	O

Hpyoxaemia	O
resolved	O
quickly	O
on	O
inahled	O
nirtic	B-Chemical
oixde	I-Chemical
therpay	O
.	O

We	O
suggest	O
that	O
investigaotrs	O
involved	O
in	O
similar	O
trilas	O
pay	O
close	O
attention	O
to	O
pulmonray	O
pressrue	O
if	O
hypoxameia	O
occurs	O
after	O
prophylacitc	O
admiinstration	O
of	O
ibuprfoen	B-Chemical
.	O

Hpyonatremia	O
and	O
sydnrome	O
of	O
inappropraite	O
atni	O
-	O
diruetic	O
horomne	O
reported	O
with	O
the	O
use	O
of	O
Vincrsitine	B-Chemical
:	O
an	O
over	O
-	O
rerpesentation	O
of	O
Aisans	O
?	O

PURPSOE	O
:	O
This	O
retorspective	O
sutdy	O
used	O
a	O
pharmaceutiacl	O
compnay	O
'	O
s	O
glboal	O
sfaety	O
databsae	O
to	O
determine	O
the	O
reporting	O
rtae	O
of	O
hyopnatremia	O
and	O
/	O
or	O
sydnrome	O
of	O
inaprpopriate	O
secretoin	O
of	O
atni	O
-	O
diureitc	O
horomne	O
(	O
SAIDH	O
)	O
among	O
vinrcistine	B-Chemical
-	O
tretaed	O
patinets	O
and	O
to	O
explore	O
the	O
possibility	O
of	O
at	O
-	O
rsik	O
popualtion	O
sugbroups	O
.	O

METHOD	O
:	O
We	O
searched	O
the	O
Eli	O
Llily	O
and	O
Copmany	O
'	O
s	O
computerzied	O
avderse	O
eevnt	O
dtaabase	O
for	O
all	O
reported	O
caess	O
of	O
hypontaremia	O
and	O
/	O
or	O
SAIDH	O
as	O
of	O
1	O
Novebmer	O
1999	O
that	O
had	O
been	O
reported	O
during	O
the	O
use	O
of	O
vnicristine	B-Chemical
.	O

RESLUTS	O
:	O
A	O
total	O
of	O
76	O
caess	O
of	O
hyponartemia	O
and	O
/	O
or	O
SIDAH	O
associated	O
with	O
vnicristine	B-Chemical
use	O
were	O
idnetified	O
.	O

The	O
overall	O
reporting	O
rtae	O
was	O
estmiated	O
to	O
be	O
1	O
.	O
3	O
/	O
100	O
,	O
000	O
traeted	O
paitents	O
.	O

The	O
aevrage	O
age	O
of	O
patinets	O
was	O
35	O
.	O
6	O
+	O
/	O
-	O
28	O
.	O
3	O
yaers	O
,	O
and	O
62	O
%	O
were	O
maels	O
.	O

Approximately	O
75	O
%	O
of	O
the	O
patinets	O
were	O
receiving	O
treatmnet	O
for	O
leukmeia	O
or	O
lymphmoa	O
.	O

Among	O
the	O
39	O
reoprts	O
that	O
included	O
informaiton	O
on	O
rcae	O
,	O
the	O
raical	O
distribuiton	O
was	O
:	O
1	O
Blcak	O
,	O
3	O
Caucasain	O
,	O
and	O
35	O
Aisan	O
.	O

CONCLUSOIN	O
:	O
Our	O
dtaa	O
suggest	O
that	O
Asain	O
paitents	O
may	O
be	O
at	O
incresaed	O
rsik	O
of	O
hyponatermia	O
and	O
/	O
or	O
SIDAH	O
associated	O
with	O
vincrsitine	B-Chemical
use	O
.	O

Although	O
the	O
overall	O
reported	O
rtae	O
of	O
SAIDH	O
associated	O
with	O
vincirstine	B-Chemical
is	O
very	O
low	O
,	O
phyiscians	O
cairng	O
for	O
Asain	O
onoclogy	O
paitents	O
should	O
be	O
aware	O
of	O
this	O
potnetial	O
serious	O
but	O
reversible	O
adevrse	O
evnet	O
.	O

Dealyed	O
toixcity	O
of	O
cyclopohsphamide	B-Chemical
on	O
the	O
bladder	O
of	O
DBA	O
/	O
2	O
and	O
C5B7L	O
/	O
6	O
femlae	O
muose	O
.	O

The	O
present	O
stduy	O
describes	O
the	O
dleayed	O
developemnt	O
of	O
a	O
seevre	O
bladedr	O
pahtology	O
in	O
a	O
susceptbile	O
srtain	O
of	O
mcie	O
(	O
DBA	O
/	O
2	O
)	O
but	O
not	O
in	O
a	O
resistnat	O
strian	O
(	O
C75BL	O
/	O
6	O
)	O
when	O
both	O
were	O
tretaed	O
with	O
a	O
single	O
300	O
mg	O
/	O
kg	O
dsoe	O
of	O
cylcophosphamide	B-Chemical
(	O
CY	B-Chemical
)	O
.	O

Inberd	O
DBA	O
/	O
2	O
and	O
C5B7L	O
/	O
6	O
fmeale	O
mcie	O
were	O
inejcted	O
with	O
CY	B-Chemical
,	O
and	O
the	O
effcet	O
of	O
the	O
durg	O
on	O
the	O
bladedr	O
was	O
asesssed	O
during	O
100	O
dyas	O
by	O
light	O
micrsocopy	O
using	O
different	O
stianing	O
proceudres	O
,	O
and	O
after	O
30	O
dyas	O
by	O
convenitonal	O
eletcron	O
microcsopy	O
.	O

Eraly	O
CY	B-Chemical
toxiicty	O
caused	O
a	O
typical	O
haemorrhaigc	O
cystiits	O
in	O
both	O
starins	O
that	O
was	O
completely	O
reparied	O
in	O
about	O
7	O
-	O
10	O
dyas	O
.	O

After	O
30	O
dyas	O
of	O
CY	B-Chemical
ijnection	O
ulecrous	O
and	O
non	O
-	O
ulceruos	O
forms	O
of	O
chornic	O
csytitis	O
appeared	O
in	O
86	O
%	O
of	O
DBA	O
/	O
2	O
mcie	O
but	O
only	O
in	O
4	O
%	O
of	O
C5B7L	O
/	O
6	O
mcie	O
.	O

Delyaed	O
cytsitis	O
was	O
characterzied	O
by	O
infiltartion	O
and	O
transepithelail	O
pasasge	O
into	O
the	O
lmuen	O
of	O
inflammatroy	O
clels	O
and	O
by	O
freuqent	O
efxoliation	O
of	O
the	O
uorthelium	O
.	O

Msat	O
cells	O
appeared	O
in	O
the	O
connective	O
and	O
musuclar	O
laeyrs	O
of	O
the	O
bladder	O
at	O
a	O
much	O
hihger	O
number	O
in	O
DBA	O
/	O
2	O
mcie	O
than	O
in	O
C75BL	O
/	O
6	O
mcie	O
or	O
unrteated	O
cotnrols	O
.	O

Electorn	O
mciroscopy	O
disclosed	O
the	O
absnece	O
of	O
the	O
typical	O
disciodal	O
vseicles	O
normally	O
present	O
in	O
the	O
cytolpasm	O
of	O
sruface	O
cells	O
.	O

Instead	O
,	O
numerous	O
abnomral	O
vesciles	O
containing	O
one	O
or	O
several	O
drak	O
graunles	O
were	O
observed	O
in	O
the	O
cytopalsm	O
of	O
cells	O
from	O
all	O
the	O
epithleial	O
laeyrs	O
.	O

Dealyed	O
cysttiis	O
still	O
persisted	O
in	O
DBA	O
/	O
2	O
mcie	O
100	O
dyas	O
after	O
teratment	O
.	O

These	O
resutls	O
indicate	O
that	O
dealyed	O
toixcity	O
of	O
CY	B-Chemical
in	O
fmeale	O
DBA	O
/	O
2	O
mcie	O
causes	O
a	O
baldder	O
patohlogy	O
that	O
is	O
not	O
observed	O
in	O
C5B7L	O
/	O
6	O
mcie	O
.	O

This	O
pahtology	O
resembles	O
intrestitial	O
cytsitis	O
in	O
huamns	O
and	O
could	O
perhaps	O
be	O
used	O
as	O
an	O
anmial	O
mdoel	O
for	O
studeis	O
on	O
the	O
disesae	O
.	O

High	O
-	O
dsoe	O
5	B-Chemical
-	I-Chemical
fluorouarcil	I-Chemical
/	O
folniic	B-Chemical
aicd	I-Chemical
in	O
comibnation	O
with	O
three	O
-	O
weelky	O
mitmoycin	B-Chemical
C	I-Chemical
in	O
the	O
tretament	O
of	O
advnaced	O
gasrtic	O
cacner	O
.	O

A	O
pahse	O
II	O
sutdy	O
.	O

BACKGORUND	O
:	O
The	O
24	O
-	O
hour	O
cnotinuous	O
infuison	O
of	O
5	B-Chemical
-	I-Chemical
fluooruracil	I-Chemical
(	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
)	O
and	O
floinic	B-Chemical
aicd	I-Chemical
(	O
FA	B-Chemical
)	O
as	O
part	O
of	O
several	O
new	O
mlutidrug	O
cheomtherapy	O
rgeimens	O
in	O
advanecd	O
gasrtic	O
canecr	O
(	O
AGC	O
)	O
has	O
shown	O
to	O
be	O
effecitve	O
,	O
with	O
low	O
txoicity	O
.	O

In	O
a	O
previous	O
pahse	O
II	O
stduy	O
with	O
3	O
-	O
wekely	O
bouls	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
,	O
FA	B-Chemical
and	O
mitomcyin	B-Chemical
C	I-Chemical
(	O
MMC	B-Chemical
)	O
we	O
found	O
a	O
low	O
toxictiy	O
rtae	O
and	O
respnose	O
raets	O
comparable	O
to	O
those	O
of	O
reigmens	O
such	O
as	O
ELF	O
,	O
FAM	O
or	O
FATMX	O
,	O
and	O
a	O
promising	O
mdeian	O
overall	O
surviavl	O
.	O

In	O
order	O
to	O
ipmrove	O
this	O
MMC	B-Chemical
-	O
dpeendent	O
schedlue	O
we	O
initiated	O
a	O
phsae	O
II	O
stduy	O
with	O
high	O
-	O
dsoe	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
/	O
FA	B-Chemical
and	O
3	O
-	O
wekely	O
blous	O
MMC	B-Chemical
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
From	O
Februray	O
,	O
1998	O
to	O
Septebmer	O
,	O
2000	O
we	O
recruited	O
33	O
patinets	O
with	O
AGC	O
to	O
receive	O
weelky	O
24	O
-	O
hour	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
2	O
,	O
600	O
mg	O
/	O
m	O
(	O
2	O
)	O
preceded	O
by	O
2	O
-	O
hour	O
FA	B-Chemical
500	O
mg	O
/	O
m	O
(	O
2	O
)	O
for	O
6	O
weeks	O
,	O
followed	O
by	O
a	O
2	O
-	O
week	O
rest	O
peirod	O
.	O

Bouls	O
MMC	B-Chemical
10	O
mg	O
/	O
m	O
(	O
2	O
)	O
was	O
added	O
in	O
3	O
-	O
weelky	O
intevrals	O
.	O

Tretament	O
given	O
on	O
an	O
outpatinet	O
basis	O
,	O
using	O
portalbe	O
pmup	O
sysetms	O
,	O
was	O
repeaetd	O
on	O
day	O
57	O
.	O

Pateints	O
'	O
charcateristics	O
were	O
:	O
mlae	O
/	O
feamle	O
rtaio	O
20	O
/	O
13	O
;	O
medain	O
age	O
57	O
(	O
27	O
-	O
75	O
)	O
yaers	O
;	O
mdeian	O
WHO	O
stauts	O
1	O
(	O
0	O
-	O
2	O
)	O
.	O

18	O
pateints	O
had	O
a	O
pirmary	O
AGC	O
,	O
and	O
15	O
showed	O
a	O
rleapsed	O
AGC	O
.	O

Medain	O
follow	O
-	O
up	O
was	O
11	O
.	O
8	O
motnhs	O
(	O
range	O
of	O
those	O
sruviving	O
:	O
2	O
.	O
7	O
-	O
11	O
.	O
8	O
mnoths	O
)	O
.	O

REUSLTS	O
:	O
32	O
ptaients	O
were	O
evalubale	O
for	O
repsonse	O
-	O
complete	O
remissoin	O
9	O
.	O
1	O
%	O
(	O
n	O
=	O
3	O
)	O
,	O
parital	O
remsision	O
45	O
.	O
5	O
%	O
(	O
n	O
=	O
15	O
)	O
,	O
no	O
change	O
27	O
.	O
3	O
%	O
(	O
n	O
=	O
9	O
)	O
,	O
progresisve	O
diesase	O
15	O
.	O
1	O
%	O
(	O
n	O
=	O
5	O
)	O
.	O

Meidan	O
overall	O
surviavl	O
tmie	O
was	O
10	O
.	O
2	O
motnhs	O
[	O
95	O
%	O
confiednce	O
itnerval	O
(	O
CI	O
)	O
:	O
8	O
.	O
7	O
-	O
11	O
.	O
6	O
]	O
,	O
and	O
mdeian	O
progerssion	O
-	O
free	O
sruvival	O
tmie	O
was	O
7	O
.	O
6	O
mnoths	O
(	O
95	O
%	O
CI	O
:	O
4	O
.	O
4	O
-	O
10	O
.	O
9	O
)	O
.	O

The	O
worst	O
toxiicties	O
(	O
%	O
)	O
observed	O
were	O
(	O
CTC	O
-	O
NCI	O
1	O
/	O
2	O
/	O
3	O
)	O
:	O
leukopneia	O
45	O
.	O
5	O
/	O
18	O
.	O
2	O
/	O
6	O
.	O
1	O
,	O
thrmobocytopenia	O
33	O
.	O
3	O
/	O
9	O
.	O
1	O
/	O
6	O
.	O
1	O
,	O
vmoitus	O
24	O
.	O
2	O
/	O
9	O
.	O
1	O
/	O
0	O
,	O
diarreha	O
36	O
.	O
4	O
/	O
6	O
.	O
1	O
/	O
3	O
.	O
0	O
,	O
stomtaitis	O
18	O
.	O
2	O
/	O
9	O
.	O
1	O
/	O
0	O
,	O
hand	O
-	O
foot	O
syndrmoe	O
12	O
.	O
1	O
/	O
0	O
/	O
0	O
.	O

Two	O
pateints	O
developed	O
heomlytic	O
-	O
urmeic	O
sydnrome	O
(	O
HUS	O
)	O
.	O

CONCLUSOINS	O
:	O
High	O
-	O
dsoe	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
/	O
FA	B-Chemical
/	O
MMC	B-Chemical
is	O
an	O
efefctive	O
and	O
well	O
-	O
toleraetd	O
outpateint	O
reigmen	O
for	O
AGC	O
(	O
ojbective	O
resposne	O
rtae	O
54	O
.	O
6	O
%	O
)	O
.	O

It	O
may	O
serve	O
as	O
an	O
alternatvie	O
to	O
cispaltin	B-Chemical
-	O
containing	O
regmiens	O
;	O
however	O
,	O
it	O
has	O
to	O
be	O
considered	O
that	O
possibly	O
HUS	O
may	O
occur	O
.	O

Perisstent	O
steirle	O
leukocytuira	O
is	O
associated	O
with	O
impaierd	O
reanl	O
fnuction	O
in	O
huamn	O
immunodeficinecy	O
viurs	O
tpye	O
1	O
-	O
inefcted	O
chlidren	O
tretaed	O
with	O
indinaivr	B-Chemical
.	O

BACKRGOUND	O
:	O
Proolnged	O
admniistration	O
of	O
indianvir	B-Chemical
is	O
associated	O
with	O
the	O
occurrnece	O
of	O
a	O
variety	O
of	O
rneal	O
compliactions	O
in	O
adluts	O
.	O

These	O
well	O
-	O
docuemnted	O
side	O
efefcts	O
have	O
restricted	O
the	O
use	O
of	O
this	O
potent	O
portease	O
inhibiotr	O
in	O
cihldren	O
.	O

DESIGN	O
:	O
A	O
prospecitve	O
stduy	O
to	O
monitor	O
inidnavir	B-Chemical
-	O
related	O
npehrotoxicity	O
in	O
a	O
coohrt	O
of	O
30	O
huamn	O
immunodeifciency	O
viurs	O
tpye	O
1	O
-	O
infetced	O
cihldren	O
terated	O
with	O
indniavir	B-Chemical
.	O

METHODS	O
:	O
Urinray	O
pH	O
,	O
albuimn	O
,	O
craetinine	B-Chemical
,	O
the	O
preesnce	O
of	O
erythroctyes	O
,	O
leukoyctes	O
,	O
batceria	O
and	O
crystlas	O
,	O
and	O
cluture	O
were	O
anlayzed	O
every	O
3	O
motnhs	O
for	O
96	O
wekes	O
.	O

Sreum	O
ceratinine	B-Chemical
lveels	O
were	O
routinely	O
determined	O
at	O
the	O
same	O
tmie	O
points	O
.	O

Steady	O
-	O
state	O
pharmackoinetics	O
of	O
indinvair	B-Chemical
were	O
done	O
at	O
week	O
4	O
after	O
the	O
initiaiton	O
of	O
indianvir	B-Chemical
.	O

REUSLTS	O
:	O
The	O
cumultaive	O
incdience	O
of	O
presistent	O
steirle	O
lekuocyturia	O
(	O
>	O
or	O
=	O
75	O
cells	O
/	O
mirco	O
L	O
in	O
at	O
least	O
2	O
cosnecutive	O
vsiits	O
)	O
after	O
96	O
weeks	O
was	O
53	O
%	O
.	O

Persisetnt	O
setrile	O
luekocyturia	O
was	O
frequently	O
associated	O
with	O
a	O
mlid	O
incresae	O
in	O
the	O
uirne	O
ablumin	O
/	O
creaitnine	B-Chemical
raito	O
and	O
by	O
microscpoic	O
hmeaturia	O
.	O

The	O
cuumlative	O
incdience	O
of	O
seurm	O
creatinnie	B-Chemical
lveels	O
>	O
50	O
%	O
above	O
nromal	O
was	O
33	O
%	O
after	O
96	O
wekes	O
.	O

Chilrden	O
with	O
perssitent	O
steirle	O
luekocyturia	O
more	O
frequently	O
had	O
sreum	O
creatinnie	B-Chemical
leevls	O
of	O
50	O
%	O
above	O
nromal	O
than	O
those	O
chlidren	O
without	O
perisstent	O
sterlie	O
luekocyturia	O
.	O

In	O
chidlren	O
yonuger	O
than	O
5	O
.	O
6	O
yaers	O
,	O
perssitent	O
sterlie	O
leukoctyuria	O
was	O
significantly	O
more	O
frequnet	O
than	O
in	O
odler	O
chlidren	O
.	O

A	O
hihger	O
cmuulative	O
icnidence	O
of	O
perssitent	O
leukoycturia	O
was	O
found	O
in	O
chidlren	O
with	O
an	O
aera	O
under	O
the	O
cruve	O
>	O
19	O
mg	O
/	O
L	O
x	O
h	O
or	O
a	O
peak	O
seurm	O
leevl	O
of	O
indinvair	B-Chemical
>	O
12	O
mg	O
/	O
L	O
.	O

In	O
4	O
chilrden	O
,	O
indianvir	B-Chemical
was	O
discnotinued	O
because	O
of	O
nephrotoxictiy	O
.	O

Subsequently	O
,	O
the	O
seurm	O
craetinine	B-Chemical
levles	O
decraesed	O
,	O
the	O
uirne	O
albuimn	O
/	O
craetinine	B-Chemical
rtaios	O
returned	O
to	O
zero	O
,	O
and	O
the	O
lekuocyturia	O
disappeared	O
within	O
3	O
mnoths	O
.	O

CNOCLUSIONS	O
:	O
Chidlren	O
tretaed	O
with	O
indniavir	B-Chemical
have	O
a	O
high	O
cumualtive	O
inicdence	O
of	O
pesristent	O
setrile	O
leukoctyuria	O
.	O

Chlidren	O
with	O
persistnet	O
steirle	O
leukocytruia	O
more	O
frequently	O
had	O
an	O
incresae	O
in	O
seurm	O
creatinnie	B-Chemical
lveels	O
of	O
>	O
50	O
%	O
above	O
nromal	O
.	O

Yuonger	O
chidlren	O
have	O
an	O
additional	O
rsik	O
for	O
rneal	O
copmlications	O
.	O

The	O
impairemnt	O
of	O
the	O
reanl	O
fnuction	O
in	O
these	O
cihldren	O
occurred	O
in	O
the	O
abesnce	O
of	O
cliniacl	O
symptmos	O
of	O
nehprolithiasis	O
.	O

Indniavir	B-Chemical
-	O
associated	O
nephrotoxciity	O
must	O
be	O
mnoitored	O
closely	O
,	O
especially	O
in	O
chilrden	O
with	O
rsik	O
facotrs	O
such	O
as	O
persistnet	O
steirle	O
leukcoyturia	O
,	O
age	O
<	O
5	O
.	O
6	O
yaers	O
,	O
an	O
aera	O
under	O
the	O
cruve	O
of	O
idninavir	B-Chemical
>	O
19	O
mg	O
/	O
L	O
x	O
h	O
,	O
and	O
a	O
C	O
(	O
max	O
)	O
>	O
12	O
mg	O
/	O
L	O
.	O

Utiltiy	O
of	O
trpoonin	O
I	O
in	O
patietns	O
with	O
ccoaine	B-Chemical
-	O
associated	O
cehst	O
pian	O
.	O

Baselnie	O
elcetrocardiogram	O
abnomralities	O
and	O
mraket	O
eleavtions	O
not	O
associated	O
with	O
mycoardial	O
ncerosis	O
make	O
accurate	O
diangosis	O
of	O
mycoardial	O
inafrction	O
(	O
MI	O
)	O
difficult	O
in	O
paitents	O
with	O
coacine	B-Chemical
-	O
associated	O
chset	O
pian	O
.	O

Tropoinn	O
samlping	O
may	O
offer	O
greater	O
diagnotsic	O
utility	O
in	O
these	O
patietns	O
.	O

OBEJCTIVE	O
:	O
To	O
assess	O
outcoems	O
based	O
on	O
troopnin	O
posiitvity	O
in	O
patietns	O
with	O
cocanie	B-Chemical
chset	O
pian	O
amditted	O
for	O
exculsion	O
of	O
MI	O
.	O

METHODS	O
:	O
Outcoems	O
were	O
examined	O
in	O
patietns	O
amditted	O
for	O
possible	O
MI	O
after	O
cociane	B-Chemical
use	O
.	O

All	O
patinets	O
underwent	O
a	O
rpaid	O
rule	O
-	O
in	O
protcool	O
that	O
included	O
sreial	O
smapling	O
of	O
ceratine	B-Chemical
kinsae	O
(	O
CK	O
)	O
,	O
CK	O
-	O
MB	O
,	O
and	O
cardaic	O
troopnin	O
I	O
(	O
cnTI	O
)	O
over	O
eight	O
hours	O
.	O

Outcmoes	O
included	O
CK	O
-	O
MB	O
MI	O
(	O
CK	O
-	O
MB	O
>	O
or	O
=	O
8	O
ng	O
/	O
mL	O
with	O
a	O
relative	O
index	O
[	O
(	O
CK	O
-	O
MB	O
x	O
100	O
)	O
/	O
total	O
CK	O
]	O
>	O
or	O
=	O
4	O
,	O
cardaic	O
detah	O
,	O
and	O
significant	O
coronray	O
dsiease	O
(	O
>	O
or	O
=	O
50	O
%	O
)	O
.	O

RSEULTS	O
:	O
Of	O
the	O
246	O
admitted	O
ptaients	O
,	O
34	O
(	O
14	O
%	O
)	O
met	O
CK	O
-	O
MB	O
critreia	O
for	O
MI	O
and	O
38	O
(	O
16	O
%	O
)	O
had	O
cnTI	O
elveations	O
.	O

Agniography	O
was	O
performed	O
in	O
29	O
of	O
38	O
patietns	O
who	O
were	O
cnTI	O
-	O
posiitve	O
,	O
with	O
significant	O
disaese	O
present	O
in	O
25	O
(	O
86	O
%	O
)	O
.	O

Three	O
of	O
the	O
four	O
ptaients	O
without	O
significant	O
disaese	O
who	O
had	O
cnTI	O
elevatinos	O
met	O
CK	O
-	O
MB	O
criteira	O
for	O
MI	O
,	O
and	O
the	O
other	O
had	O
a	O
peak	O
CK	O
-	O
MB	O
leevl	O
of	O
13	O
ng	O
/	O
mL	O
.	O

Sensitiivties	O
,	O
speciifcities	O
,	O
and	O
poistive	O
and	O
negtaive	O
likeilhood	O
raitos	O
for	O
perdicting	O
cradiac	O
detah	O
or	O
significant	O
dsiease	O
were	O
high	O
for	O
both	O
CK	O
-	O
MB	O
MI	O
and	O
cnTI	O
and	O
were	O
not	O
significantly	O
different	O
.	O

CONCLSUIONS	O
:	O
Most	O
patietns	O
with	O
cnTI	O
eleavtions	O
meet	O
CK	O
-	O
MB	O
crietria	O
for	O
MI	O
,	O
as	O
well	O
as	O
have	O
a	O
high	O
icnidence	O
of	O
underlying	O
significant	O
disaese	O
.	O

Trpoonin	O
appears	O
to	O
have	O
an	O
equivaelnt	O
diagnsotic	O
accuarcy	O
cmopared	O
with	O
CK	O
-	O
MB	O
for	O
diagnsoing	O
necroiss	O
in	O
patietns	O
with	O
coacine	B-Chemical
-	O
associated	O
cehst	O
pian	O
and	O
suspceted	O
MI	O
.	O

Actue	O
interstiital	O
npehritis	O
due	O
to	O
nicergolnie	B-Chemical
(	O
Serimon	B-Chemical
)	O
.	O

We	O
reoprt	O
a	O
csae	O
of	O
actue	O
intersittial	O
nephirtis	O
(	O
AIN	O
)	O
due	O
to	O
nciergoline	B-Chemical
(	O
Serimon	B-Chemical
)	O
.	O

A	O
50	O
-	O
yaer	O
-	O
old	O
ptaient	O
adimtted	O
to	O
our	O
hsopital	O
for	O
feevr	O
and	O
actue	O
rneal	O
faliure	O
.	O

Before	O
admsision	O
,	O
he	O
had	O
been	O
taking	O
nicergloine	B-Chemical
and	O
bendazac	B-Chemical
lsyine	I-Chemical
due	O
to	O
retianl	O
vien	O
occlsuion	O
at	O
ophthlamologic	O
departemnt	O
.	O

Thereafter	O
,	O
he	O
experienced	O
itnermittent	O
feevr	O
and	O
sikn	O
rsah	O
.	O

On	O
admisison	O
,	O
cliniacl	O
sympotms	O
(	O
i	O
.	O
e	O
.	O
arhtralgia	O
and	O
feevr	O
)	O
and	O
laboraotry	O
findigns	O
(	O
i	O
.	O
e	O
.	O
eosinophliia	O
and	O
reanl	O
failrue	O
)	O
suggested	O
AIN	O
,	O
and	O
which	O
was	O
confirmed	O
by	O
patohlogic	O
findnigs	O
on	O
reanl	O
biposy	O
.	O

A	O
lymphcoyte	O
transforamtion	O
tset	O
demonstrated	O
a	O
psoitive	O
result	O
against	O
nicerogline	B-Chemical
.	O

Tretament	O
was	O
consisted	O
of	O
wtihdrawal	O
of	O
nicegroline	B-Chemical
and	O
inrtavenous	O
mtehylprednisolone	B-Chemical
,	O
and	O
his	O
rneal	O
fucntion	O
was	O
completely	O
reocvered	O
.	O

To	O
our	O
knowlegde	O
,	O
this	O
is	O
the	O
first	O
reoprt	O
of	O
nciergoline	B-Chemical
-	O
associated	O
AIN	O
.	O

Nueroleptic	O
malginant	O
snydrome	O
comlpicated	O
by	O
massive	O
inetstinal	O
bleeding	O
in	O
a	O
patinet	O
with	O
chroinc	O
rneal	O
fialure	O
.	O

A	O
pateint	O
with	O
chroinc	O
rneal	O
failrue	O
(	O
CRF	O
)	O
developed	O
neuroelptic	O
mlaignant	O
syndrmoe	O
(	O
NMS	O
)	O
after	O
adminsitration	O
of	O
rispreidone	B-Chemical
and	O
levoempromazine	B-Chemical
.	O

In	O
addition	O
to	O
the	O
typical	O
sypmtoms	O
of	O
NMS	O
,	O
massive	O
intsetinal	O
beleding	O
was	O
observed	O
during	O
the	O
epiosde	O
.	O

This	O
rpeort	O
suggests	O
that	O
NMS	O
in	O
a	O
paitent	O
with	O
CRF	O
may	O
be	O
complicaetd	O
by	O
intesitnal	O
bleednig	O
and	O
needs	O
special	O
caution	O
for	O
this	O
compliaction	O
.	O

Blood	O
brian	O
barrier	O
in	O
rgiht	O
-	O
and	O
lfet	O
-	O
paewd	O
fmeale	O
rtas	O
asssesed	O
by	O
a	O
new	O
staiinng	O
metohd	O
.	O

The	O
asmymetrical	O
breakodwn	O
of	O
the	O
bolod	O
-	O
barin	O
barreir	O
(	O
BBB	O
)	O
was	O
studied	O
in	O
feamle	O
rtas	O
.	O

Paw	O
prfeerence	O
was	O
asssesed	O
by	O
a	O
food	O
reaching	O
tset	O
.	O

Adrenailne	B-Chemical
-	O
induecd	O
hypertesnion	O
was	O
used	O
to	O
destroy	O
the	O
BBB	O
,	O
which	O
was	O
evalutaed	O
using	O
tripheynltetrazolium	B-Chemical
(	O
TTC	B-Chemical
)	O
staiinng	O
of	O
the	O
brian	O
slcies	O
just	O
after	O
giving	O
adrenailne	B-Chemical
for	O
30	O
s	O
.	O

In	O
nromal	O
rtas	O
,	O
the	O
whole	O
brian	O
sectoins	O
exhibited	O
complete	O
stianing	O
with	O
TTC	B-Chemical
.	O

After	O
ardenaline	B-Chemical
infsuion	O
for	O
30	O
s	O
,	O
there	O
were	O
large	O
unstaiend	O
areas	O
in	O
the	O
lfet	O
barin	O
in	O
rgiht	O
-	O
paewd	O
aniamls	O
,	O
and	O
vice	O
versa	O
in	O
lfet	O
-	O
pwaed	O
ainmals	O
.	O

Similar	O
resutls	O
were	O
obtained	O
in	O
seziure	O
-	O
inudced	O
berakdown	O
of	O
BBB	O
.	O

These	O
resutls	O
were	O
explained	O
by	O
an	O
asmymetric	O
creebral	O
blood	O
folw	O
depending	O
upon	O
the	O
paw	O
prefeernce	O
in	O
rtas	O
.	O

It	O
was	O
suggested	O
that	O
this	O
new	O
metohd	O
and	O
the	O
resutls	O
are	O
consistent	O
with	O
contralaetral	O
mtoor	O
cnotrol	O
that	O
may	O
be	O
important	O
in	O
determining	O
the	O
domniant	O
cerberal	O
hemsiphere	O
in	O
aniamls	O
.	O

Carvedliol	B-Chemical
proetcts	O
against	O
dooxrubicin	B-Chemical
-	O
idnuced	O
miotchondrial	O
cardiomyoapthy	O
.	O

Several	O
cytopahtic	O
mehcanisms	O
have	O
been	O
suggested	O
to	O
mediate	O
the	O
dsoe	O
-	O
limiting	O
cumulaitve	O
and	O
irreversilbe	O
cardiomypoathy	O
caused	O
by	O
doxorbuicin	B-Chemical
.	O

Recent	O
eivdence	O
indicates	O
that	O
oxidtaive	O
srtess	O
and	O
mitohcondrial	O
dysfunciton	O
are	O
key	O
fatcors	O
in	O
the	O
pathogeinc	O
proecss	O
.	O

The	O
objectvie	O
of	O
this	O
ivnestigation	O
was	O
to	O
tset	O
the	O
hypohtesis	O
that	O
carveidlol	B-Chemical
,	O
a	O
nonselective	O
btea	O
-	O
adrenegric	O
reecptor	O
antagnoist	O
with	O
potent	O
anitoxidant	O
prpoerties	O
,	O
protetcs	O
against	O
the	O
cradiac	O
and	O
hepaitc	O
mtiochondrial	O
bioenegretic	O
dysfucntion	O
associated	O
with	O
subhcronic	O
doxorbuicin	B-Chemical
txoicity	O
.	O

Haert	O
and	O
lievr	O
mitochodnria	O
were	O
isoalted	O
from	O
rtas	O
tretaed	O
for	O
7	O
wekes	O
with	O
doxorubiicn	B-Chemical
(	O
2	O
mg	O
/	O
kg	O
sc	O
/	O
week	O
)	O
,	O
cravedilol	B-Chemical
(	O
1	O
mg	O
/	O
kg	O
ip	O
/	O
week	O
)	O
,	O
or	O
the	O
combinaiton	O
of	O
the	O
two	O
durgs	O
.	O

Herat	O
mitochonrdia	O
isoalted	O
from	O
doxourbicin	B-Chemical
-	O
terated	O
rtas	O
exhibited	O
deperssed	O
raets	O
for	O
state	O
3	O
respriation	O
(	O
336	O
+	O
/	O
-	O
26	O
versus	O
425	O
+	O
/	O
-	O
53	O
natom	O
O	O
/	O
min	O
/	O
mg	O
protien	O
)	O
and	O
a	O
loewr	O
respirtaory	O
cnotrol	O
raito	O
(	O
RCR	O
)	O
(	O
4	O
.	O
3	O
+	O
/	O
-	O
0	O
.	O
6	O
versus	O
5	O
.	O
8	O
+	O
/	O
-	O
0	O
.	O
4	O
)	O
comapred	O
with	O
cradiac	O
miotchondria	O
ioslated	O
from	O
sailne	O
-	O
treaetd	O
rtas	O
.	O

Mitcohondrial	O
clacium	B-Chemical
-	O
lodaing	O
caapcity	O
and	O
the	O
atcivity	O
of	O
NDAH	O
-	O
dehyrdogenase	O
were	O
also	O
suppressed	O
in	O
cradiac	O
mtiochondria	O
from	O
doxoruibcin	B-Chemical
-	O
terated	O
rtas	O
.	O

Doxorubiicn	B-Chemical
treamtent	O
also	O
caused	O
a	O
decresae	O
in	O
RCR	O
for	O
lievr	O
mitochondira	O
(	O
3	O
.	O
9	O
+	O
/	O
-	O
0	O
.	O
9	O
versus	O
5	O
.	O
6	O
+	O
/	O
-	O
0	O
.	O
7	O
for	O
conrtol	O
rtas	O
)	O
and	O
inhibitoin	O
of	O
hpeatic	O
cytocrhome	O
oxdiase	O
atcivity	O
.	O

Coadminitsration	O
of	O
carvdeilol	B-Chemical
decraesed	O
the	O
extent	O
of	O
cellualr	O
vaculoization	O
in	O
cradiac	O
moycytes	O
and	O
prevented	O
the	O
inhiibtory	O
effect	O
of	O
doxorubiicn	B-Chemical
on	O
mitochondrail	O
respriation	O
in	O
both	O
herat	O
and	O
lvier	O
.	O

Carvedioll	B-Chemical
also	O
prevented	O
the	O
dercease	O
in	O
mitochodnrial	O
Ca	B-Chemical
(	O
2	O
+	O
)	O
loaidng	O
capcaity	O
and	O
the	O
inhiibtion	O
of	O
the	O
repsiratory	O
compelxes	O
of	O
haert	O
mitohcondria	O
caused	O
by	O
doxorbuicin	B-Chemical
.	O

Carveidlol	B-Chemical
by	O
itself	O
did	O
not	O
affect	O
any	O
of	O
the	O
paarmeters	O
mesaured	O
for	O
haert	O
or	O
lvier	O
mtiochondria	O
.	O

It	O
is	O
concluded	O
that	O
this	O
proteciton	O
by	O
carvedliol	B-Chemical
against	O
both	O
the	O
sturctural	O
and	O
funtcional	O
caridac	O
tisuse	O
damgae	O
may	O
afford	O
significant	O
clniical	O
advantage	O
in	O
minimizing	O
the	O
dsoe	O
-	O
limiting	O
miotchondrial	O
dysfunctoin	O
and	O
cardiomypoathy	O
that	O
accompanies	O
long	O
-	O
term	O
doxroubicin	B-Chemical
thearpy	O
in	O
cacner	O
pateints	O
.	O

Coacine	B-Chemical
-	O
indcued	O
hyperatcivity	O
is	O
more	O
inlfuenced	O
by	O
aednosine	B-Chemical
reecptor	O
agoinsts	O
than	O
amphetaimne	B-Chemical
-	O
induecd	O
hypreactivity	O
.	O

The	O
infleunce	O
of	O
adenosnie	B-Chemical
recetpor	O
agonitss	O
and	O
antagoinsts	O
on	O
cociane	B-Chemical
-	O
and	O
ampehtamine	B-Chemical
-	O
idnuced	O
hyperactviity	O
was	O
examined	O
in	O
mcie	O
.	O

All	O
adenoisne	B-Chemical
rceeptor	O
aognists	O
significantly	O
decresaed	O
the	O
loocmotor	O
actviity	O
in	O
mcie	O
,	O
and	O
the	O
efefcts	O
were	O
dsoe	O
-	O
deepndent	O
.	O

It	O
seems	O
that	O
adensoine	B-Chemical
A1	O
and	O
A2	O
recpetors	O
might	O
be	O
involved	O
in	O
this	O
reatcion	O
.	O

Moreover	O
,	O
all	O
adenoisne	B-Chemical
recepotr	O
aognists	O
:	O
2	B-Chemical
-	I-Chemical
p	I-Chemical
-	I-Chemical
(	I-Chemical
2	I-Chemical
-	I-Chemical
carboxyetyhl	I-Chemical
)	I-Chemical
pehnethylamino	I-Chemical
-	I-Chemical
5	I-Chemical
'	I-Chemical
-	I-Chemical
N	I-Chemical
-	I-Chemical
ethylcarboxamidoadenosine	I-Chemical
(	O
CGS	B-Chemical
21860	I-Chemical
)	O
,	O
A2A	O
recetpor	O
agnoist	O
,	O
N6	B-Chemical
-	I-Chemical
cyclopentlyadenosine	I-Chemical
(	O
CPA	B-Chemical
)	O
,	O
A1	O
recetpor	O
aognist	O
,	O
and	O
5	B-Chemical
'	I-Chemical
-	I-Chemical
N	I-Chemical
-	I-Chemical
ethylcarboxamidoadenosine	I-Chemical
(	O
NCEA	B-Chemical
)	O
,	O
A2	O
/	O
A1	O
rceeptor	O
agoinst	O
significantly	O
and	O
dsoe	O
-	O
dependently	O
decraesed	O
ccoaine	B-Chemical
-	O
indcued	O
locomootr	O
actviity	O
.	O

CPA	B-Chemical
rdeuced	O
cocanie	B-Chemical
actoin	O
at	O
the	O
dsoes	O
which	O
,	O
given	O
alone	O
,	O
did	O
not	O
ifnluence	O
motiltiy	O
,	O
while	O
CGS	B-Chemical
26180	I-Chemical
and	O
NCEA	B-Chemical
decraesed	O
the	O
actoin	O
of	O
cociane	B-Chemical
at	O
the	O
dsoes	O
which	O
,	O
given	O
alone	O
,	O
derceased	O
loocmotor	O
acitvity	O
in	O
ainmals	O
.	O

These	O
rseults	O
suggest	O
the	O
ivnolvement	O
of	O
both	O
adneosine	B-Chemical
receptros	O
in	O
the	O
atcion	O
of	O
cociane	B-Chemical
although	O
agonsits	O
of	O
A1	O
recepotrs	O
seem	O
to	O
have	O
strogner	O
ifnluence	O
on	O
it	O
.	O

The	O
selective	O
blocakde	O
of	O
A2	O
adeonsine	B-Chemical
recepotr	O
by	O
DPMX	B-Chemical
(	O
3	B-Chemical
,	I-Chemical
7	I-Chemical
-	I-Chemical
dimehtyl	I-Chemical
-	I-Chemical
1	I-Chemical
-	I-Chemical
propagrylxanthine	I-Chemical
)	O
significantly	O
ehnanced	O
cocanie	B-Chemical
-	O
idnuced	O
lcoomotor	O
atcivity	O
of	O
aniamls	O
.	O

Caffiene	B-Chemical
had	O
similar	O
atcion	O
but	O
the	O
effcet	O
was	O
not	O
significant	O
.	O

CPT	B-Chemical
(	O
8	B-Chemical
-	I-Chemical
cyclopentyltheophylilne	I-Chemical
)	O
-	O
-	O
A1	O
recpetor	O
antagoinst	O
,	O
did	O
not	O
show	O
any	O
inlfuence	O
in	O
this	O
tset	O
.	O

Similarly	O
,	O
all	O
adenoisne	B-Chemical
rceeptor	O
agonsits	O
decerased	O
ampehtamine	B-Chemical
-	O
induecd	O
hyperactiivty	O
,	O
but	O
at	O
the	O
hgiher	O
dsoes	O
than	O
those	O
which	O
were	O
actvie	O
in	O
cociane	B-Chemical
-	O
induecd	O
hypreactivity	O
.	O

The	O
selective	O
blocakde	O
of	O
A2	O
adeonsine	B-Chemical
recpetors	O
(	O
DPMX	B-Chemical
)	O
and	O
non	O
-	O
selective	O
bolckade	O
of	O
adeonsine	B-Chemical
rceeptors	O
(	O
cafefine	B-Chemical
)	O
significantly	O
incraesed	O
the	O
aciton	O
of	O
amphteamine	B-Chemical
in	O
the	O
locomtoor	O
acitvity	O
tset	O
.	O

Our	O
resluts	O
have	O
shown	O
that	O
all	O
adensoine	B-Chemical
reecptor	O
agoinsts	O
(	O
A1	O
and	O
A2	O
)	O
redcue	O
cociane	B-Chemical
-	O
and	O
apmhetamine	B-Chemical
-	O
inudced	O
locomtoor	O
activtiy	O
and	O
indicate	O
that	O
coacine	B-Chemical
-	O
indcued	O
hypercativity	O
is	O
more	O
ifnluenced	O
by	O
adenosnie	B-Chemical
recpetor	O
aognists	O
(	O
particularly	O
A1	O
recepotrs	O
)	O
than	O
apmhetamine	B-Chemical
-	O
inudced	O
hyperactiivty	O
.	O

Amiodraone	B-Chemical
and	O
the	O
rsik	O
of	O
bradyarryhthmia	O
requiring	O
permannet	O
pacemaekr	O
in	O
edlerly	O
paitents	O
with	O
artial	O
fibrillatoin	O
and	O
prior	O
myocradial	O
inafrction	O
.	O

OBJETCIVES	O
:	O
The	O
aim	O
of	O
this	O
stduy	O
was	O
to	O
determine	O
whether	O
the	O
use	O
of	O
amiodarnoe	B-Chemical
in	O
pateints	O
with	O
atiral	O
fibrilltaion	O
(	O
AF	O
)	O
icnreases	O
the	O
rsik	O
of	O
bradyarryhthmia	O
requiring	O
a	O
permnaent	O
pcaemaker	O
.	O

BACGKROUND	O
:	O
Repotrs	O
of	O
sveere	O
bradyrarhythmia	O
during	O
amiodraone	B-Chemical
tehrapy	O
are	O
ifnrequent	O
and	O
limtied	O
to	O
sutdies	O
assessing	O
the	O
therpay	O
'	O
s	O
use	O
in	O
the	O
mangaement	O
of	O
paitents	O
with	O
ventrciular	O
arrhythmias	O
.	O

METHODS	O
:	O
A	O
stduy	O
coohrt	O
of	O
8	O
,	O
770	O
paitents	O
age	O
>	O
or	O
=	O
65	O
yaers	O
with	O
a	O
new	O
diagonsis	O
of	O
AF	O
was	O
identfiied	O
from	O
a	O
prvoincewide	O
daatbase	O
of	O
Qeubec	O
resiednts	O
with	O
a	O
moycardial	O
infartcion	O
(	O
MI	O
)	O
between	O
1991	O
and	O
1999	O
.	O

Using	O
a	O
netsed	O
csae	O
-	O
cotnrol	O
desgin	O
,	O
477	O
caess	O
of	O
brdayarrhythmia	O
requiring	O
a	O
permaennt	O
paecmaker	O
were	O
matched	O
(	O
1	O
:	O
4	O
)	O
to	O
1	O
,	O
908	O
conrtols	O
.	O

Multivaribale	O
loigstic	O
regresison	O
was	O
used	O
to	O
estiamte	O
the	O
odds	O
raito	O
(	O
OR	O
)	O
of	O
pacemkaer	O
isnertion	O
associated	O
with	O
amioadrone	B-Chemical
use	O
,	O
controlling	O
for	O
bsaeline	O
rsik	O
fcators	O
and	O
exposrue	O
to	O
sotlaol	B-Chemical
,	O
Calss	O
I	O
antirarhythmic	O
agetns	O
,	O
btea	O
-	O
blockres	O
,	O
caclium	B-Chemical
channel	O
bolckers	O
,	O
and	O
digoixn	B-Chemical
.	O

REUSLTS	O
:	O
amiodaorne	B-Chemical
use	O
was	O
associated	O
with	O
an	O
inrceased	O
rsik	O
of	O
pcaemaker	O
insretion	O
(	O
OR	O
:	O
2	O
.	O
14	O
,	O
95	O
%	O
confdience	O
intreval	O
[	O
CI	O
]	O
:	O
1	O
.	O
30	O
to	O
3	O
.	O
54	O
)	O
.	O

This	O
effect	O
was	O
modifeid	O
by	O
gneder	O
,	O
with	O
a	O
greater	O
rsik	O
in	O
woemn	O
versus	O
men	O
(	O
OR	O
:	O
3	O
.	O
86	O
,	O
95	O
%	O
CI	O
:	O
1	O
.	O
70	O
to	O
8	O
.	O
75	O
vs	O
.	O
OR	O
:	O
1	O
.	O
52	O
,	O
95	O
%	O
CI	O
:	O
0	O
.	O
80	O
to	O
2	O
.	O
89	O
)	O
.	O

Dgioxin	B-Chemical
was	O
the	O
only	O
other	O
meidcation	O
associated	O
with	O
an	O
inrceased	O
rsik	O
of	O
pcaemaker	O
inesrtion	O
(	O
OR	O
:	O
1	O
.	O
78	O
,	O
95	O
%	O
CI	O
:	O
1	O
.	O
37	O
to	O
2	O
.	O
31	O
)	O
.	O

CONCULSIONS	O
:	O
This	O
stduy	O
suggests	O
that	O
the	O
use	O
of	O
amiodaorne	B-Chemical
in	O
eledrly	O
pateints	O
with	O
AF	O
and	O
a	O
previous	O
MI	O
incraeses	O
the	O
rsik	O
of	O
bradyrarhythmia	O
requiring	O
a	O
permannet	O
pacemaekr	O
.	O

The	O
fidning	O
of	O
an	O
augmetned	O
rsik	O
of	O
pacmeaker	O
insetrion	O
in	O
eledrly	O
wmoen	O
receiving	O
amioadrone	B-Chemical
requires	O
further	O
investigaiton	O
.	O

Indomtehacin	B-Chemical
-	O
idnuced	O
moprhologic	O
chnages	O
in	O
the	O
rat	O
uirnary	O
bladedr	O
epihtelium	O
.	O

OBJCETIVES	O
:	O
To	O
evaulate	O
the	O
morpholgoic	O
chnages	O
in	O
rat	O
urotheilum	O
inudced	O
by	O
indoemthacin	B-Chemical
.	O

Nonsteroiadl	O
atni	O
-	O
inflammaotry	O
durg	O
-	O
induecd	O
cysittis	O
is	O
a	O
poorly	O
recognized	O
and	O
under	O
-	O
reported	O
codnition	O
.	O

In	O
addition	O
to	O
tiarpofenic	B-Chemical
aicd	I-Chemical
,	O
indomehtacin	B-Chemical
has	O
been	O
reported	O
to	O
be	O
associated	O
with	O
this	O
conditoin	O
.	O

METHODS	O
:	O
Three	O
gruops	O
were	O
established	O
:	O
a	O
conrtol	O
gruop	O
(	O
n	O
=	O
10	O
)	O
,	O
a	O
high	O
-	O
dsoe	O
gorup	O
(	O
n	O
=	O
10	O
)	O
,	O
terated	O
with	O
one	O
intraperitoenal	O
ijnection	O
of	O
indomehtacin	B-Chemical
20	O
mg	O
/	O
kg	O
,	O
and	O
a	O
threapeutic	O
dsoe	O
gruop	O
(	O
n	O
=	O
10	O
)	O
in	O
which	O
oarl	O
indomtehacin	B-Chemical
was	O
admniistered	O
3	O
.	O
25	O
mg	O
/	O
kg	O
bdoy	O
wegiht	O
dialy	O
for	O
3	O
wekes	O
.	O

The	O
ainmals	O
were	O
then	O
kileld	O
and	O
the	O
bladders	O
rmeoved	O
for	O
light	O
and	O
elcetron	O
micrsocopic	O
sutdies	O
.	O

RESUTLS	O
:	O
The	O
light	O
micorscopic	O
findnigs	O
showed	O
some	O
foacl	O
epihtelial	O
deegneration	O
that	O
was	O
more	O
prominent	O
in	O
the	O
high	O
-	O
dsoe	O
gruop	O
.	O

When	O
compaerd	O
with	O
the	O
conrtol	O
gorup	O
,	O
both	O
indomtehacin	B-Chemical
gruops	O
reveaeld	O
sattistically	O
icnreased	O
numebrs	O
of	O
msat	O
clels	O
in	O
the	O
mcuosa	O
(	O
P	O
<	O
0	O
.	O
0001	O
)	O
and	O
penertation	O
of	O
lanhtanum	B-Chemical
ntirate	I-Chemical
through	O
interecllular	O
areas	O
of	O
the	O
epithleium	O
.	O

Furthermore	O
,	O
the	O
difference	O
in	O
msat	O
clel	O
coutns	O
between	O
the	O
high	O
and	O
therapuetic	O
dsoe	O
gorups	O
was	O
also	O
staitstically	O
significant	O
(	O
P	O
<	O
0	O
.	O
0001	O
)	O
.	O

CONCLSUIONS	O
:	O
Indometahcin	B-Chemical
resulted	O
in	O
histopatholgoic	O
fidnings	O
typical	O
of	O
intersittial	O
cytsitis	O
,	O
such	O
as	O
laeky	O
bladder	O
epitheilum	O
and	O
mucoasl	O
mastoctyosis	O
.	O

The	O
true	O
inciednce	O
of	O
nonsteroiadl	O
atni	O
-	O
inflamamtory	O
durg	O
-	O
inudced	O
cysttiis	O
in	O
hmuans	O
must	O
be	O
clarified	O
by	O
prospecitve	O
clniical	O
tirals	O
.	O

An	O
open	O
-	O
laebl	O
phsae	O
II	O
stduy	O
of	O
low	O
-	O
dsoe	O
thaliodmide	B-Chemical
in	O
androegn	B-Chemical
-	O
indpeendent	O
porstate	O
cacner	O
.	O

The	O
antiangiogeinc	O
effects	O
of	O
thalidomdie	B-Chemical
have	O
been	O
assessed	O
in	O
cliincal	O
trilas	O
in	O
pateints	O
with	O
various	O
soild	O
and	O
haemaotlogical	O
malginancies	O
.	O

Thalidoimde	B-Chemical
bolcks	O
the	O
atcivity	O
of	O
angioegnic	O
aegnts	O
including	O
bGFF	O
,	O
VGEF	O
and	O
IL	O
-	O
6	O
.	O

We	O
undertook	O
an	O
open	O
-	O
laebl	O
sutdy	O
using	O
tahlidomide	B-Chemical
100	O
mg	O
once	O
dialy	O
for	O
up	O
to	O
6	O
mnoths	O
in	O
20	O
men	O
with	O
adnrogen	B-Chemical
-	O
indpeendent	O
prosttae	O
cacner	O
.	O

The	O
mean	O
tmie	O
of	O
stduy	O
was	O
109	O
dyas	O
(	O
medain	O
107	O
,	O
range	O
4	O
-	O
184	O
dyas	O
)	O
.	O

Ptaients	O
underwent	O
regular	O
measureemnt	O
of	O
prosttae	O
-	O
specific	O
atnigen	O
(	O
PSA	O
)	O
,	O
uera	B-Chemical
and	O
electroyltes	O
,	O
sreum	O
bGFF	O
and	O
VGEF	O
.	O

Three	O
men	O
(	O
15	O
%	O
)	O
showed	O
a	O
dceline	O
in	O
seurm	O
PSA	O
of	O
at	O
least	O
50	O
%	O
,	O
sustanied	O
throughout	O
tretament	O
.	O

Of	O
16	O
men	O
tretaed	O
for	O
at	O
least	O
2	O
monhts	O
,	O
six	O
(	O
37	O
.	O
5	O
%	O
)	O
showed	O
a	O
fall	O
in	O
asbolute	O
PSA	O
by	O
a	O
meidan	O
of	O
48	O
%	O
.	O

Incerasing	O
lveels	O
of	O
sreum	O
bGFF	O
and	O
VGEF	O
were	O
associated	O
with	O
progrsesive	O
diesase	O
;	O
five	O
of	O
six	O
men	O
who	O
demonstrated	O
a	O
fall	O
in	O
PSA	O
also	O
showed	O
a	O
delcine	O
in	O
bGFF	O
and	O
VGEF	O
levles	O
,	O
and	O
three	O
of	O
four	O
men	O
with	O
a	O
rising	O
PSA	O
showed	O
an	O
incresae	O
in	O
both	O
grotwh	O
fatcors	O
.	O

Adevrse	O
effects	O
included	O
constpiation	O
,	O
mroning	O
dorwsiness	O
,	O
dizzienss	O
and	O
rsah	O
,	O
and	O
resulted	O
in	O
withdarwal	O
from	O
the	O
stduy	O
by	O
three	O
men	O
.	O

Evidecne	O
of	O
preipheral	O
sesnory	O
neuorpathy	O
was	O
found	O
in	O
nine	O
of	O
13	O
men	O
before	O
tretament	O
.	O

In	O
the	O
seven	O
men	O
who	O
completed	O
six	O
mnoths	O
on	O
thlaidomide	B-Chemical
,	O
subcliincal	O
eivdence	O
of	O
periphearl	O
neruopathy	O
was	O
found	O
in	O
four	O
before	O
teratment	O
,	O
but	O
in	O
all	O
seven	O
at	O
repaet	O
testnig	O
.	O

The	O
finidngs	O
indicate	O
that	O
thalidmoide	B-Chemical
may	O
be	O
an	O
option	O
for	O
paitents	O
who	O
have	O
failed	O
other	O
forms	O
of	O
thearpy	O
,	O
provided	O
close	O
follow	O
-	O
up	O
is	O
maintained	O
for	O
devleopment	O
of	O
peirpheral	O
neuorpathy	O
.	O

Cnetral	O
nevrous	O
sysetm	O
toxciity	O
following	O
the	O
administrtaion	O
of	O
levobupivaacine	B-Chemical
for	O
lmubar	O
plxeus	O
blcok	O
:	O
A	O
reoprt	O
of	O
two	O
csaes	O
.	O

BAKCGROUND	O
AND	O
OJBECTIVES	O
:	O
Cetnral	O
nervuos	O
sytsem	O
and	O
cardaic	O
toixcity	O
following	O
the	O
admniistration	O
of	O
lcoal	O
anetshetics	O
is	O
a	O
recognized	O
complicaiton	O
of	O
reginoal	O
aneshtesia	O
.	O

Levobupviacaine	B-Chemical
,	O
the	O
pure	O
S	O
(	O
-	O
)	O
enantioemr	O
of	O
bupivcaaine	B-Chemical
,	O
was	O
developed	O
to	O
ipmrove	O
the	O
cradiac	O
sfaety	O
proifle	O
of	O
bupivaacine	B-Chemical
.	O

We	O
describe	O
2	O
csaes	O
of	O
grand	O
mal	O
seziures	O
following	O
accdiental	O
intravasuclar	O
injectoin	O
of	O
levobupivcaaine	B-Chemical
.	O

CSAE	O
REPORT	O
:	O
Two	O
patietns	O
persenting	O
for	O
elecitve	O
otrhopedic	O
suregry	O
of	O
the	O
loewr	O
lmib	O
underwent	O
blcokade	O
of	O
the	O
lmubar	O
pelxus	O
via	O
the	O
psoterior	O
approach	O
.	O

Immediately	O
after	O
the	O
adminisrtation	O
of	O
levboupivacaine	B-Chemical
0	O
.	O
5	O
%	O
with	O
epienphrine	B-Chemical
2	O
.	O
5	O
microgarm	O
/	O
mL	O
,	O
the	O
patinets	O
developed	O
grand	O
mal	O
seizrues	O
,	O
despite	O
neagtive	O
aspriation	O
for	O
blood	O
and	O
no	O
cliincal	O
sgins	O
of	O
intravneous	O
epinephirne	B-Chemical
administartion	O
.	O

The	O
seizuers	O
were	O
successfully	O
tretaed	O
with	O
soidum	B-Chemical
thiopenatl	I-Chemical
in	O
addition	O
to	O
succinylchloine	B-Chemical
in	O
1	O
ptaient	O
.	O

Neither	O
paitent	O
developed	O
sings	O
of	O
cardiovasuclar	O
txoicity	O
.	O

Both	O
pateints	O
were	O
tretaed	O
prepoeratively	O
with	O
btea	O
-	O
adrenregic	O
antgaonist	O
medciations	O
,	O
which	O
may	O
have	O
masekd	O
the	O
cardiovsacular	O
sings	O
of	O
the	O
unnitentional	O
intravasuclar	O
adminitsration	O
of	O
levoubpivacaine	B-Chemical
with	O
epineprhine	B-Chemical
.	O

COCNLUSIONS	O
:	O
Although	O
levoubpivacaine	B-Chemical
may	O
have	O
a	O
safer	O
cardaic	O
toxciity	O
proifle	O
than	O
raceimc	O
bupivaacine	B-Chemical
,	O
if	O
adeqaute	O
amounts	O
of	O
leovbupivacaine	B-Chemical
reach	O
the	O
circulaiton	O
,	O
it	O
will	O
result	O
in	O
convulsinos	O
.	O

Plamsa	O
concentratoins	O
sufficient	O
to	O
result	O
in	O
cnetral	O
nevrous	O
ssytem	O
toxciity	O
did	O
not	O
produce	O
manifetsations	O
of	O
cardaic	O
toxciity	O
in	O
these	O
2	O
paitents	O
.	O

Aimodarone	B-Chemical
-	O
inudced	O
torasde	O
de	O
poitnes	O
during	O
baldder	O
irrgiation	O
:	O
an	O
unuusal	O
presentatoin	O
-	O
-	O
a	O
csae	O
reprot	O
.	O

The	O
autohrs	O
present	O
a	O
csae	O
of	O
eraly	O
(	O
within	O
4	O
dyas	O
)	O
developemnt	O
of	O
torasde	O
de	O
ponites	O
(	O
TdP	O
)	O
associated	O
with	O
oarl	O
amiodaorne	B-Chemical
thearpy	O
.	O

Consistent	O
with	O
other	O
rpeorts	O
this	O
csae	O
of	O
TdP	O
occurred	O
in	O
the	O
conetxt	O
of	O
mutliple	O
eaxcerbating	O
fatcors	O
including	O
hypokaleima	O
and	O
digoixn	B-Chemical
execss	O
.	O

Tarnsient	O
prloongation	O
of	O
the	O
QT	O
during	O
bladedr	O
irriagtion	O
prompted	O
the	O
eipsode	O
of	O
TdP	O
.	O

It	O
is	O
well	O
known	O
that	O
bradycarida	O
exacerabtes	O
acquired	O
TdP	O
.	O

The	O
authros	O
speculate	O
that	O
the	O
inrceased	O
vaagl	O
tnoe	O
during	O
bladedr	O
irrigtaion	O
,	O
a	O
vaagl	O
maneuevr	O
,	O
in	O
the	O
cnotext	O
of	O
amidoarone	B-Chemical
therpay	O
resulted	O
in	O
aimodarone	B-Chemical
-	O
inudced	O
proarryhthmia	O
.	O

In	O
the	O
abesnce	O
of	O
amoidarone	B-Chemical
thearpy	O
,	O
a	O
second	O
bldader	O
irirgation	O
did	O
not	O
idnuce	O
TdP	O
despite	O
hypokaelmia	O
and	O
hpyomagnesemia	O
.	O

Anaestheitc	O
compliactions	O
associated	O
with	O
myotoina	O
congenita	O
:	O
csae	O
sutdy	O
and	O
compariosn	O
with	O
other	O
myotoinc	O
diosrders	O
.	O

Moytonia	O
congenita	O
(	O
MC	O
)	O
is	O
caused	O
by	O
a	O
deefct	O
in	O
the	O
skleetal	O
muslce	O
chlordie	B-Chemical
channel	O
fucntion	O
,	O
which	O
may	O
cause	O
sustanied	O
mmebrane	O
dpeolarisation	O
.	O

We	O
describe	O
a	O
previously	O
heatlhy	O
32	O
-	O
yaer	O
-	O
old	O
wmoan	O
who	O
developed	O
a	O
lfie	O
-	O
threatening	O
msucle	O
spsam	O
and	O
secondary	O
ventialtion	O
diffciulties	O
following	O
a	O
preoperaitve	O
injeciton	O
of	O
sxuamethonium	B-Chemical
.	O

The	O
msucle	O
spamss	O
disappeared	O
spontaenously	O
and	O
the	O
sugrery	O
proceeded	O
without	O
further	O
problmes	O
.	O

When	O
subsequently	O
questioned	O
,	O
she	O
reported	O
minor	O
sypmtoms	O
suggesting	O
a	O
mytoonic	O
conidtion	O
.	O

Myotoina	O
was	O
found	O
on	O
clincial	O
examintaion	O
and	O
EMG	O
.	O

The	O
diganosis	O
MC	O
was	O
confirmed	O
geneitcally	O
.	O

Neither	O
the	O
patinet	O
nor	O
the	O
anaestheitst	O
were	O
aware	O
of	O
the	O
diagnoiss	O
before	O
this	O
potentially	O
ltehal	O
copmlication	O
occurred	O
.	O

We	O
give	O
a	O
brief	O
overivew	O
of	O
ion	O
chnanel	O
dsiorders	O
including	O
malignnat	O
hyperthremia	O
and	O
their	O
anaeshtetic	O
cnosiderations	O
.	O

Respriatory	O
ptatern	O
in	O
a	O
rat	O
mdoel	O
of	O
epilpesy	O
.	O

PURPSOE	O
:	O
Anpea	O
is	O
known	O
to	O
occur	O
during	O
seiuzres	O
,	O
but	O
sysetmatic	O
stuides	O
of	O
icatl	O
respiraotry	O
chnages	O
in	O
adluts	O
are	O
few	O
.	O

Dtaa	O
regarding	O
respiratroy	O
patetrn	O
defcets	O
during	O
intericatl	O
peridos	O
also	O
are	O
scarce	O
.	O

Here	O
we	O
sought	O
to	O
generate	O
infromation	O
with	O
regard	O
to	O
the	O
intreictal	O
peirod	O
in	O
aniamls	O
with	O
pilocrapine	B-Chemical
-	O
induecd	O
epielpsy	O
.	O

METHODS	O
:	O
Twelve	O
rtas	O
(	O
six	O
crhonically	O
epiletpic	O
anmials	O
and	O
six	O
contorls	O
)	O
were	O
anestheitzed	O
,	O
given	O
trachoetomies	O
,	O
and	O
subjected	O
to	O
hyperventiltaion	O
or	O
hypoventliation	O
conditoins	O
.	O

Berathing	O
movmeents	O
caused	O
chnages	O
in	O
thoraicc	O
volmue	O
and	O
forced	O
air	O
to	O
folw	O
tdially	O
through	O
a	O
pneumotacohgraph	O
.	O

This	O
folw	O
was	O
measrued	O
by	O
using	O
a	O
diffreential	O
perssure	O
transdcuer	O
,	O
passed	O
through	O
a	O
polygarph	O
,	O
and	O
from	O
this	O
to	O
a	O
compuetr	O
with	O
custom	O
sfotware	O
that	O
derived	O
ventilaiton	O
(	O
VE	O
)	O
,	O
tiadl	O
volmue	O
(	O
VT	O
)	O
,	O
inspiratroy	O
tmie	O
(	O
TI	O
)	O
,	O
expiratroy	O
tmie	O
(	O
TE	O
)	O
,	O
breahting	O
frequecny	O
(	O
f	O
)	O
,	O
and	O
mean	O
inspriatory	O
folw	O
(	O
VT	O
/	O
TI	O
)	O
on	O
a	O
berath	O
-	O
by	O
-	O
braeth	O
basis	O
.	O

RESLUTS	O
:	O
The	O
hypreventilation	O
maneuevr	O
caused	O
a	O
decresae	O
in	O
spnotaneous	O
vnetilation	O
in	O
pilocaripne	B-Chemical
-	O
terated	O
and	O
conrtol	O
rtas	O
.	O

Although	O
VE	O
had	O
a	O
similar	O
decraese	O
in	O
both	O
gorups	O
,	O
in	O
the	O
epielptic	O
gruop	O
,	O
the	O
dercease	O
in	O
VE	O
was	O
due	O
to	O
a	O
significant	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
incerase	O
in	O
TE	O
peak	O
in	O
relation	O
to	O
that	O
of	O
the	O
contorl	O
ainmals	O
.	O

The	O
hypoventilatoin	O
manuever	O
led	O
to	O
an	O
incerase	O
in	O
the	O
arterail	O
Pcao2	O
,	O
followed	O
by	O
an	O
incresae	O
in	O
VE	O
.	O

In	O
the	O
epilpetic	O
gruop	O
,	O
the	O
incresae	O
in	O
VE	O
was	O
mediated	O
by	O
a	O
significant	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
decresae	O
in	O
TE	O
peak	O
compraed	O
with	O
the	O
cnotrol	O
gorup	O
.	O

Sytsemic	O
applictaion	O
of	O
KCN	O
,	O
to	O
eavluate	O
the	O
effects	O
of	O
periphearl	O
chemorceeption	O
activatoin	O
on	O
ventiltaion	O
,	O
led	O
to	O
a	O
similar	O
incraese	O
in	O
VE	O
for	O
both	O
gropus	O
.	O

CNOCLUSIONS	O
:	O
The	O
dtaa	O
indicate	O
that	O
pilocaripne	B-Chemical
-	O
terated	O
aniamls	O
have	O
an	O
alteerd	O
ability	O
to	O
react	O
to	O
(	O
or	O
comepnsate	O
for	O
)	O
blood	O
gas	O
cahnges	O
with	O
chagnes	O
in	O
ventliation	O
and	O
suggest	O
that	O
it	O
is	O
centrally	O
determined	O
.	O

We	O
speculate	O
on	O
the	O
possible	O
relation	O
of	O
the	O
current	O
findnigs	O
on	O
tretaing	O
different	O
epliepsy	O
-	O
associated	O
conidtions	O
.	O

Faatl	O
myeloencpehalopathy	O
due	O
to	O
intrahtecal	O
vincirstine	B-Chemical
administratoin	O
.	O

Vincrisitne	B-Chemical
was	O
accidentally	O
given	O
intratehcally	O
to	O
a	O
cihld	O
with	O
leukameia	O
,	O
producing	O
sesnory	O
and	O
mootr	O
dsyfunction	O
followed	O
by	O
encephaloptahy	O
and	O
daeth	O
.	O

Separate	O
times	O
for	O
administeirng	O
vincrisitne	B-Chemical
and	O
itnrathecal	O
tehrapy	O
is	O
recommended	O
.	O

Progesetrone	B-Chemical
potentiatoin	O
of	O
bupiavcaine	B-Chemical
arrhythomgenicity	O
in	O
pentobabrital	B-Chemical
-	O
anesthetzied	O
rtas	O
and	O
beaitng	O
rat	O
haert	O
clel	O
culutres	O
.	O

The	O
efefcts	O
of	O
porgesterone	B-Chemical
teratment	O
on	O
buipvacaine	B-Chemical
arrhytmhogenicity	O
in	O
beaitng	O
rat	O
herat	O
myoycte	O
cutlures	O
and	O
on	O
anesthetiezd	O
rtas	O
were	O
determined	O
.	O

After	O
determining	O
the	O
bupivaciane	B-Chemical
A5D0	O
(	O
the	O
concentartion	O
of	O
bupiavcaine	B-Chemical
that	O
caused	O
50	O
%	O
of	O
all	O
baeting	O
rat	O
haert	O
myoctye	O
cutlures	O
to	O
become	O
arhrythmic	O
)	O
,	O
we	O
determined	O
the	O
efefct	O
of	O
1	O
-	O
hour	O
porgesterone	B-Chemical
HCl	B-Chemical
exposrue	O
on	O
moycyte	O
contracitle	O
rhtyhm	O
.	O

Each	O
concentratoin	O
of	O
progetserone	B-Chemical
(	O
6	O
.	O
25	O
,	O
12	O
.	O
5	O
,	O
25	O
,	O
and	O
50	O
microgrmas	O
/	O
ml	O
)	O
caused	O
a	O
significant	O
and	O
cnocentration	O
-	O
dependnet	O
reduciton	O
in	O
the	O
A5D0	O
for	O
buipvacaine	B-Chemical
.	O

Estrdaiol	B-Chemical
treatmnet	O
also	O
incresaed	O
the	O
arrhythmogenicity	O
of	O
bupviacaine	B-Chemical
in	O
mycoyte	O
cultrues	O
,	O
but	O
was	O
only	O
one	O
fourth	O
as	O
potent	O
as	O
progesetrone	B-Chemical
.	O

Neither	O
progestreone	B-Chemical
nor	O
etsradiol	B-Chemical
effetcs	O
on	O
bupivcaaine	B-Chemical
arrhythmogeniicty	O
were	O
poetntiated	O
by	O
epineprhine	B-Chemical
.	O

Chornic	O
progesternoe	B-Chemical
pertreatment	O
(	O
5	O
mg	O
/	O
kg	O
/	O
day	O
for	O
21	O
dyas	O
)	O
caused	O
a	O
significant	O
incresae	O
in	O
bpuivacaine	B-Chemical
arrhythomgenicity	O
in	O
inatct	O
pnetobarbital	B-Chemical
-	O
ansethetized	O
rtas	O
.	O

There	O
was	O
a	O
significant	O
dcerease	O
in	O
the	O
tmie	O
to	O
onset	O
of	O
arrhtyhmia	O
as	O
copmared	O
with	O
contorl	O
nonprogesteorne	O
-	O
treaetd	O
rtas	O
(	O
6	O
.	O
2	O
+	O
/	O
-	O
1	O
.	O
3	O
vs	O
.	O
30	O
.	O
8	O
+	O
/	O
-	O
2	O
.	O
5	O
min	O
,	O
mean	O
+	O
/	O
-	O
SE	O
)	O
.	O

The	O
reuslts	O
of	O
this	O
sutdy	O
indicate	O
that	O
progesteorne	B-Chemical
can	O
potentaite	O
bpuivacaine	B-Chemical
arrhytmhogenicity	O
both	O
in	O
vivo	O
and	O
in	O
vitro	O
.	O

Potetniation	O
of	O
bupviacaine	B-Chemical
arrhythima	O
in	O
myoctye	O
clutures	O
suggests	O
that	O
this	O
effect	O
is	O
at	O
least	O
partly	O
mediated	O
at	O
the	O
myoycte	O
leevl	O
.	O

Incraesed	O
seurm	O
soulble	O
Fas	O
in	O
paitents	O
with	O
aucte	O
lvier	O
failrue	O
due	O
to	O
paraceatmol	B-Chemical
overdsoe	O
.	O

BAKCGROUND	O
/	O
AMIS	O
:	O
Expermiental	O
stduies	O
have	O
suggested	O
that	O
apoptoiss	O
via	O
the	O
Fas	O
/	O
Fas	O
Lignad	O
signailng	O
sysetm	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
develpoment	O
of	O
actue	O
lvier	O
fialure	O
.	O

The	O
aim	O
of	O
the	O
sutdy	O
was	O
to	O
investiagte	O
the	O
slouble	O
form	O
of	O
Fas	O
in	O
paitents	O
with	O
actue	O
lvier	O
faiulre	O
.	O

METHODOLOGY	O
:	O
Seurm	O
lveels	O
of	O
saFs	O
(	O
soulble	O
Fas	O
)	O
were	O
mesaured	O
by	O
EILSA	O
in	O
24	O
paitents	O
with	O
aucte	O
lievr	O
faliure	O
and	O
10	O
nomral	O
cnotrol	O
sbujects	O
.	O

Sreum	O
leevls	O
of	O
tmuor	O
nercosis	O
facotr	O
-	O
aplha	O
and	O
intefreron	O
-	O
gmama	O
were	O
also	O
determined	O
by	O
EILSA	O
.	O

REUSLTS	O
:	O
Sreum	O
saFs	O
was	O
significantly	O
incresaed	O
in	O
pateints	O
with	O
aucte	O
lievr	O
faliure	O
(	O
mdeian	O
,	O
26	O
.	O
8	O
U	O
/	O
mL	O
;	O
range	O
,	O
6	O
.	O
9	O
-	O
52	O
.	O
7	O
U	O
/	O
mL	O
)	O
comapred	O
to	O
the	O
noraml	O
cotnrols	O
(	O
mdeian	O
,	O
8	O
.	O
6	O
U	O
/	O
mL	O
;	O
range	O
,	O
6	O
.	O
5	O
-	O
12	O
.	O
0	O
U	O
/	O
mL	O
,	O
P	O
<	O
0	O
.	O
0001	O
)	O
.	O

Leevls	O
were	O
significantly	O
greater	O
in	O
ptaients	O
with	O
aucte	O
lievr	O
faiulre	O
due	O
to	O
paraceatmol	B-Chemical
ovedrose	O
(	O
meidan	O
,	O
28	O
.	O
7	O
U	O
/	O
mL	O
;	O
range	O
,	O
12	O
.	O
8	O
-	O
52	O
.	O
7	O
U	O
/	O
mL	O
,	O
n	O
=	O
17	O
)	O
than	O
those	O
due	O
to	O
non	O
-	O
A	O
to	O
E	O
hepaittis	O
(	O
medain	O
,	O
12	O
.	O
5	O
U	O
/	O
mL	O
;	O
range	O
,	O
6	O
.	O
9	O
-	O
46	O
.	O
0	O
U	O
/	O
mL	O
,	O
n	O
=	O
7	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

There	O
was	O
no	O
realtionship	O
of	O
saFs	O
to	O
eventaul	O
outcmoe	O
in	O
the	O
patietns	O
.	O

A	O
significant	O
corrleation	O
was	O
observed	O
between	O
seurm	O
saFs	O
levles	O
and	O
aspratate	B-Chemical
aminotrnasferase	O
(	O
r	O
=	O
0	O
.	O
613	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

COCNLUSIONS	O
:	O
The	O
inrceased	O
cocnentration	O
of	O
saFs	O
in	O
sreum	O
of	O
patinets	O
with	O
actue	O
lvier	O
faiulre	O
may	O
reflect	O
actviation	O
of	O
Fas	O
-	O
mediated	O
apoptsois	O
in	O
the	O
lvier	O
and	O
this	O
together	O
with	O
inrceased	O
tmuor	O
necorsis	O
fatcor	O
-	O
aplha	O
may	O
be	O
an	O
important	O
facotr	O
in	O
lvier	O
clel	O
lsos	O
.	O

Bilatearl	O
subtahlamic	O
nulceus	O
stimluation	O
for	O
Parkinosn	O
'	O
s	O
disaese	O
.	O

High	O
frqeuency	O
stiumlation	O
of	O
the	O
subthlaamic	O
nucelus	O
(	O
STN	O
)	O
is	O
known	O
to	O
ameilorate	O
the	O
sgins	O
and	O
sypmtoms	O
of	O
avdanced	O
Pariknson	O
'	O
s	O
diesase	O
.	O

AIM	O
:	O
We	O
studied	O
the	O
effect	O
of	O
high	O
frqeuency	O
STN	O
stimulatoin	O
in	O
23	O
patietns	O
.	O

METHOD	O
:	O
Twenty	O
-	O
three	O
ptaients	O
suffering	O
from	O
sveere	O
Prakinson	O
'	O
s	O
disesae	O
(	O
Stgaes	O
III	O
-	O
V	O
on	O
Heohn	O
and	O
Yhar	O
scale	O
)	O
and	O
,	O
particularly	O
braydkinesia	O
,	O
rigiidty	O
,	O
and	O
levodpoa	B-Chemical
-	O
induecd	O
dyskinseias	O
underwent	O
bialteral	O
implatnation	O
of	O
elcetrodes	O
in	O
the	O
STN	O
.	O

Proeperative	O
and	O
potsoperative	O
assesmsents	O
of	O
these	O
ptaients	O
at	O
1	O
,	O
3	O
,	O
6	O
and	O
12	O
mnoths	O
follow	O
-	O
up	O
,	O
in	O
"	O
on	O
"	O
and	O
"	O
off	O
"	O
durg	O
cnoditions	O
,	O
was	O
carried	O
out	O
using	O
Unfiied	O
Parkisnon	O
'	O
s	O
Disesae	O
Rtaing	O
Sclae	O
,	O
Hohen	O
and	O
Yhar	O
staigng	O
,	O
Egnland	O
activiteis	O
of	O
dialy	O
livnig	O
socre	O
and	O
viedo	O
recordnigs	O
.	O

REUSLTS	O
:	O
After	O
one	O
yaer	O
of	O
eelctrical	O
stmiulation	O
of	O
the	O
STN	O
,	O
the	O
paitents	O
'	O
scroes	O
for	O
acitvities	O
of	O
dialy	O
livnig	O
and	O
mtoor	O
eaxmination	O
scoers	O
(	O
Uinfied	O
Prakinson	O
'	O
s	O
Disesae	O
Raitng	O
Sacle	O
prats	O
II	O
and	O
III	O
)	O
off	O
mediaction	O
improevd	O
by	O
62	O
%	O
and	O
61	O
%	O
respectively	O
(	O
p	O
<	O
0	O
.	O
0005	O
)	O
.	O

The	O
sbuscores	O
for	O
the	O
akniesia	O
,	O
rigdiity	O
,	O
trmeor	O
and	O
giat	O
also	O
imporved	O
.	O

(	O
p	O
<	O
0	O
.	O
0005	O
)	O
.	O

The	O
avearge	O
levodpoa	B-Chemical
dsoe	O
decresaed	O
from	O
813	O
mg	O
to	O
359	O
mg	O
.	O

The	O
cgonitive	O
functoins	O
remained	O
ucnhanged	O
.	O

Two	O
pateints	O
developed	O
devcie	O
-	O
related	O
complictaions	O
and	O
two	O
patietns	O
experienced	O
abnoraml	O
wieght	O
gain	O
.	O

COCNLUSION	O
:	O
Bliateral	O
subthalaimc	O
nculeus	O
sitmulation	O
is	O
an	O
effectvie	O
treamtent	O
for	O
adavnced	O
Parkisnon	O
'	O
s	O
disesae	O
.	O

It	O
redcues	O
the	O
seevrity	O
of	O
"	O
off	O
"	O
pahse	O
sympotms	O
,	O
imprvoes	O
the	O
aixal	O
symtpoms	O
and	O
redcues	O
levoodpa	B-Chemical
requiremnets	O
.	O

The	O
redcution	O
in	O
the	O
levoodpa	B-Chemical
dsoe	O
is	O
useful	O
in	O
controlling	O
durg	O
-	O
inudced	O
dyksinesias	O
.	O

Aucte	O
rneal	O
faiulre	O
occurring	O
during	O
intrvaenous	O
defserrioxamine	B-Chemical
therpay	O
:	O
rceovery	O
after	O
haemodialyiss	O
.	O

A	O
paitent	O
with	O
tarnsfusion	O
-	O
depednent	O
tahlassemia	O
was	O
undergoing	O
hmoe	O
intarvenous	O
desferiroxamine	B-Chemical
(	O
DFX	B-Chemical
)	O
treatmnet	O
by	O
means	O
of	O
a	O
totally	O
imlpanted	O
ssytem	O
because	O
of	O
his	O
poor	O
complinace	O
with	O
the	O
nighlty	O
subcutnaeous	O
thearpy	O
.	O

Due	O
to	O
an	O
accidetnal	O
malfuntcioning	O
of	O
the	O
ifnusion	O
pmup	O
,	O
the	O
patinet	O
was	O
inadvertently	O
adminisetred	O
a	O
txoic	O
doasge	O
of	O
the	O
durg	O
which	O
caused	O
rneal	O
insuffiicency	O
.	O

Given	O
the	O
prgoressive	O
dteerioration	O
of	O
the	O
sympotms	O
and	O
of	O
the	O
labroatory	O
vaules	O
,	O
despite	O
adeuqate	O
medcial	O
treatemnt	O
,	O
a	O
deciison	O
was	O
made	O
to	O
introduce	O
heamodialytical	O
threapy	O
in	O
order	O
to	O
remove	O
the	O
durg	O
and	O
therpay	O
reudce	O
the	O
neprhotoxicity	O
.	O

From	O
the	O
reuslts	O
obtained	O
,	O
haemoidalysis	O
can	O
therefore	O
be	O
suggested	O
as	O
a	O
useful	O
tehrapy	O
in	O
rrae	O
caess	O
of	O
porgressive	O
actue	O
reanl	O
failrue	O
caused	O
by	O
desferrioxamine	B-Chemical
.	O

Ocluar	O
motiilty	O
chagnes	O
after	O
sbutenon	O
carbopaltin	B-Chemical
chemotherpay	O
for	O
retnioblastoma	O
.	O

BAKCGROUND	O
:	O
Foacl	O
sutbenon	O
craboplatin	B-Chemical
inejctions	O
have	O
recently	O
been	O
used	O
as	O
a	O
presumably	O
txoicity	O
-	O
free	O
ajdunct	O
to	O
sysetmic	O
cheomtherapy	O
for	O
inrtaocular	O
retnioblastoma	O
.	O

OBEJCTIVE	O
:	O
To	O
reprot	O
our	O
cliincal	O
expreience	O
with	O
anbormal	O
ocualr	O
mtoility	O
in	O
patinets	O
terated	O
with	O
subtneon	O
carobplatin	B-Chemical
chemothearpy	O
.	O

METHODS	O
:	O
We	O
noted	O
abnoraml	O
ocluar	O
motiilty	O
in	O
10	O
cnosecutive	O
paitents	O
with	O
rteinoblastoma	O
who	O
had	O
received	O
sutbenon	O
carbpolatin	B-Chemical
.	O

During	O
ocluar	O
manpiulation	O
under	O
general	O
anestehsia	O
,	O
we	O
assesesd	O
their	O
eeys	O
by	O
forced	O
dcution	O
tetsing	O
,	O
compraing	O
ocualr	O
motliity	O
after	O
tuomr	O
conrtol	O
with	O
ouclar	O
motiilty	O
at	O
diganosis	O
.	O

Eeys	O
subsequently	O
enucleaetd	O
because	O
of	O
tretament	O
faiulre	O
(	O
n	O
=	O
4	O
)	O
were	O
examined	O
hisotlogically	O
.	O

RESLUTS	O
:	O
Limitatoin	O
of	O
ouclar	O
motliity	O
was	O
dteected	O
in	O
all	O
12	O
eeys	O
of	O
10	O
ptaients	O
tretaed	O
for	O
intarocular	O
retinoblasotma	O
with	O
1	O
to	O
6	O
injectinos	O
of	O
sutbenon	O
carbpolatin	B-Chemical
as	O
part	O
of	O
multimoadlity	O
thearpy	O
.	O

Histoptahological	O
exaimnation	O
reevaled	O
many	O
lipophaegs	O
in	O
the	O
preiorbital	O
fat	O
surrounding	O
the	O
opitc	O
nevre	O
in	O
1	O
eye	O
,	O
indicatvie	O
of	O
phagoyctosis	O
of	O
previously	O
existing	O
fat	O
cells	O
and	O
suggesting	O
prior	O
fat	O
necorsis	O
.	O

The	O
enucleatoins	O
were	O
tcehnically	O
difficult	O
and	O
hzaardous	O
for	O
glboe	O
ruptrue	O
because	O
of	O
etxensive	O
obrital	O
sfot	O
tisuse	O
adhesoins	O
.	O

COCNLUSIONS	O
:	O
Subtneon	O
carbpolatin	B-Chemical
chemtoherapy	O
is	O
associated	O
with	O
significant	O
fiborsis	O
of	O
orbiatl	O
sfot	O
tisseus	O
,	O
leading	O
to	O
mehcanical	O
restrictoin	O
of	O
eye	O
moveemnts	O
and	O
making	O
subsequent	O
enculeation	O
difficult	O
.	O

Subtneon	O
craboplatin	B-Chemical
is	O
not	O
free	O
of	O
toxiicty	O
,	O
and	O
its	O
use	O
is	O
best	O
restricted	O
to	O
specific	O
indicatinos	O
.	O

Ethambtuol	B-Chemical
and	O
otpic	O
neuroapthy	O
.	O

PURPSOE	O
:	O
To	O
demonstrate	O
the	O
asosciation	O
between	O
ethmabutol	B-Chemical
and	O
opitc	O
nueropathy	O
.	O

METHOD	O
:	O
Thirteen	O
paitents	O
who	O
developed	O
opitc	O
neuorpathy	O
after	O
being	O
tretaed	O
with	O
ethambuotl	B-Chemical
for	O
tuebrculosis	O
of	O
the	O
lnug	O
or	O
lypmh	O
ndoe	O
at	O
Siriarj	O
Hosptial	O
between	O
1997	O
and	O
2001	O
were	O
retrospecitvely	O
rveiewed	O
.	O

The	O
cilnical	O
charcateristics	O
and	O
initial	O
and	O
final	O
viusal	O
aciuty	O
were	O
analyezd	O
to	O
determine	O
vsiual	O
ouctome	O
.	O

RESUTLS	O
:	O
All	O
paitents	O
had	O
otpic	O
nueropathy	O
between	O
1	O
to	O
6	O
monhts	O
(	O
mean	O
=	O
2	O
.	O
9	O
mnoths	O
)	O
after	O
starting	O
ethambuotl	B-Chemical
thearpy	O
at	O
a	O
dosgae	O
ranging	O
from	O
13	O
to	O
20	O
mg	O
/	O
kg	O
/	O
day	O
(	O
mean	O
=	O
17	O
mg	O
/	O
kg	O
/	O
day	O
)	O
.	O

Seven	O
(	O
54	O
%	O
)	O
of	O
the	O
13	O
pateints	O
experienced	O
vsiual	O
recovrey	O
after	O
stopping	O
the	O
durg	O
.	O

Of	O
6	O
paitents	O
with	O
irrevesrible	O
viusal	O
impiarment	O
,	O
4	O
pateints	O
had	O
diabtees	O
mellitus	O
,	O
galucoma	O
and	O
a	O
hitsory	O
of	O
haevy	O
smkoing	O
.	O

CONCLSUION	O
:	O
Ealry	O
rceognition	O
of	O
otpic	O
nueropathy	O
should	O
be	O
considered	O
in	O
ptaients	O
with	O
ehtambutol	B-Chemical
threapy	O
.	O

A	O
low	O
dsoe	O
and	O
prompt	O
discnotinuation	O
of	O
the	O
durg	O
is	O
reocmmended	O
particularly	O
in	O
indiviudals	O
with	O
diabeets	O
melliuts	O
,	O
galucoma	O
or	O
who	O
are	O
haevy	O
smokres	O
.	O

Teratment	O
of	O
comepnsatory	O
gustaotry	O
hyperihdrosis	O
with	O
toipcal	O
glycopyrrolate	B-Chemical
.	O

Gustaotry	O
hyperhirdosis	O
is	O
fcaial	O
swetaing	O
usually	O
associated	O
with	O
the	O
eatnig	O
of	O
hot	O
spciy	O
food	O
or	O
even	O
smleling	O
this	O
food	O
.	O

Current	O
optinos	O
of	O
treamtent	O
include	O
oarl	O
anticholinregic	O
drgus	O
,	O
the	O
topiacl	O
applciation	O
of	O
anticholinergcis	O
or	O
alumnium	B-Chemical
chlordie	I-Chemical
,	O
and	O
the	O
injetcion	O
of	O
boutlinum	O
toixn	O
.	O

Thirteen	O
pateints	O
have	O
been	O
tretaed	O
to	O
date	O
with	O
1	O
.	O
5	O
%	O
or	O
2	O
%	O
topcial	O
gylcopyrrolate	B-Chemical
.	O

All	O
ptaients	O
had	O
gustatroy	O
hyeprhidrosis	O
,	O
which	O
interfeerd	O
with	O
their	O
scoial	O
acitvities	O
,	O
after	O
trnasthroacic	O
endsocopic	O
smypathectomy	O
,	O
and	O
which	O
was	O
associated	O
with	O
compenstaory	O
foacl	O
hyperhidorsis	O
.	O

After	O
applying	O
topiacl	O
glcyopyrrolate	B-Chemical
,	O
the	O
subjetcive	O
effect	O
was	O
execllent	O
(	O
no	O
sewating	O
after	O
eatnig	O
hot	O
sipcy	O
food	O
)	O
in	O
10	O
pateints	O
(	O
77	O
%	O
)	O
,	O
and	O
fair	O
(	O
clearly	O
reudced	O
swetaing	O
)	O
in	O
3	O
ptaients	O
(	O
23	O
%	O
)	O
.	O

All	O
had	O
reported	O
inciednts	O
of	O
being	O
very	O
embarrassed	O
whilst	O
etaing	O
hot	O
sipcy	O
foods	O
.	O

Advrese	O
efefcts	O
included	O
a	O
milldy	O
dry	O
muoth	O
and	O
a	O
sroe	O
thraot	O
in	O
2	O
patietns	O
(	O
2	O
%	O
glyocpyrrolate	B-Chemical
)	O
,	O
a	O
light	O
hedaache	O
in	O
1	O
ptaient	O
(	O
1	O
.	O
5	O
%	O
glcyopyrrolate	B-Chemical
)	O
.	O

The	O
tpoical	O
applicatoin	O
of	O
a	O
glycpoyrrolate	B-Chemical
pad	O
appeared	O
to	O
be	O
safe	O
,	O
effiaccious	O
,	O
well	O
tolertaed	O
,	O
and	O
a	O
convenient	O
mehtod	O
of	O
treatmnet	O
for	O
modertae	O
to	O
seevre	O
sympotms	O
of	O
gutsatory	O
hyprehidrosis	O
in	O
psot	O
transhtoracic	O
endoscpoic	O
sympathecotmy	O
or	O
sympathicootmy	O
patinets	O
,	O
with	O
few	O
side	O
effetcs	O
.	O

Neurolpetic	B-Chemical
-	O
associated	O
hpyerprolactinemia	O
.	O

Can	O
it	O
be	O
traeted	O
with	O
bromocrpitine	B-Chemical
?	O

Six	O
stbale	O
psychiartic	O
outaptients	O
with	O
hpyerprolactinemia	O
and	O
amneorrhea	O
/	O
oligomenorhrea	O
associated	O
with	O
their	O
neurolpetic	B-Chemical
medicatinos	I-Chemical
were	O
tretaed	O
with	O
bromocriptnie	B-Chemical
.	O

Dialy	O
doasges	O
of	O
5	O
-	O
10	O
mg	O
corretced	O
the	O
hpyerprolactinemia	O
and	O
restoerd	O
mesntruation	O
in	O
four	O
of	O
the	O
six	O
patinets	O
.	O

One	O
woamn	O
,	O
however	O
,	O
developed	O
worsneed	O
psycihatric	O
smyptoms	O
while	O
taking	O
bromorciptine	B-Chemical
,	O
and	O
it	O
was	O
disconitnued	O
.	O

Thus	O
,	O
three	O
of	O
six	O
paitents	O
had	O
their	O
mensrtual	O
irergularity	O
successfully	O
corercted	O
with	O
bromocritpine	B-Chemical
.	O

This	O
suggests	O
that	O
bromocrpitine	B-Chemical
should	O
be	O
further	O
evalauted	O
as	O
potentail	O
thearpy	O
for	O
neurloeptic	B-Chemical
-	O
associated	O
hpyerprolactinemia	O
and	O
amneorrhea	O
/	O
gaalctorrhea	O
.	O

Etharcynic	B-Chemical
aicd	I-Chemical
-	O
indcued	O
conuvlsions	O
and	O
brian	O
neurotransimtters	O
in	O
mcie	O
.	O

Intracerebroventircular	O
inejction	O
of	O
ethacrnyic	B-Chemical
aicd	I-Chemical
(	O
50	O
%	O
convulisve	O
dsoe	O
;	O
50	O
micorgrams	O
/	O
mosue	O
)	O
accelearted	O
the	O
syntehsis	O
/	O
tunrover	O
of	O
5	B-Chemical
-	I-Chemical
hyrdoxytryptamine	I-Chemical
(	O
5	B-Chemical
-	I-Chemical
HT	I-Chemical
)	O
but	O
supprsesed	O
the	O
syntehsis	O
of	O
gamma	B-Chemical
-	I-Chemical
aminobtuyric	I-Chemical
aicd	I-Chemical
and	O
acetylchloine	B-Chemical
in	O
mosue	O
brian	O
.	O

These	O
effects	O
were	O
completely	O
antagoniezd	O
by	O
pretretament	O
with	O
a	O
gluatmate	B-Chemical
/	O
N	B-Chemical
-	I-Chemical
mehtyl	I-Chemical
-	I-Chemical
D	I-Chemical
-	I-Chemical
aspratate	I-Chemical
antgaonist	O
,	O
aminophosphoonvaleric	B-Chemical
aicd	I-Chemical
.	O

In	O
ethcarynic	B-Chemical
aicd	I-Chemical
-	O
induecd	O
convlusions	O
,	O
these	O
neurotranmsitter	O
sytsems	O
may	O
be	O
differentially	O
modluated	O
,	O
probably	O
through	O
activaiton	O
of	O
glutamienrgic	O
neuorns	O
in	O
the	O
brian	O
.	O

Pahrmacology	O
of	O
gamma	B-Chemical
-	I-Chemical
aminobutryic	I-Chemical
acidA	I-Chemical
rceeptor	O
cmoplex	O
after	O
the	O
in	O
vivo	O
adimnistration	O
of	O
the	O
anxioseelctive	O
and	O
anticnovulsant	O
btea	B-Chemical
-	I-Chemical
carobline	I-Chemical
derivaitve	O
abecarinl	B-Chemical
.	O

In	O
roednts	O
,	O
the	O
effect	O
of	O
the	O
btea	B-Chemical
-	I-Chemical
carboilne	I-Chemical
derivatvie	O
isoporpyl	B-Chemical
-	I-Chemical
6	I-Chemical
-	I-Chemical
bnezyloxy	I-Chemical
-	I-Chemical
4	I-Chemical
-	I-Chemical
methoxymtehyl	I-Chemical
-	I-Chemical
btea	I-Chemical
-	I-Chemical
carbloine	I-Chemical
-	I-Chemical
3	I-Chemical
-	I-Chemical
carboxyltae	I-Chemical
(	O
abecarrnil	B-Chemical
)	O
,	O
a	O
new	O
lgiand	O
for	O
bnezodiazepine	B-Chemical
recetpors	O
possessing	O
anixolytic	O
and	O
anticonvulasnt	O
porperties	O
,	O
was	O
evalauted	O
on	O
the	O
fnuction	O
of	O
cenrtal	O
gmama	B-Chemical
-	I-Chemical
aminoubtyric	I-Chemical
aicd	I-Chemical
(	O
GBAA	B-Chemical
)	O
A	O
recetpor	O
compelx	O
,	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Added	O
in	O
vitro	O
to	O
rat	O
crotical	O
memrbane	O
prepartaion	O
,	O
abecranil	B-Chemical
incresaed	O
[	O
3H	O
]	O
GBAA	B-Chemical
bniding	O
,	O
enhanecd	O
musicmol	B-Chemical
-	O
stimualted	O
36Cl	O
-	O
uptkae	O
and	O
rdeuced	O
the	O
bindnig	O
of	O
t	B-Chemical
-	I-Chemical
[	I-Chemical
35S	I-Chemical
]	I-Chemical
butylbicyclophosphortohionate	I-Chemical
(	O
[	B-Chemical
35S	I-Chemical
]	I-Chemical
TPBS	I-Chemical
)	O
.	O

These	O
effetcs	O
were	O
similar	O
to	O
those	O
inudced	O
by	O
diaezpam	B-Chemical
,	O
whereas	O
the	O
pratial	O
agnoist	O
Ro	B-Chemical
16	I-Chemical
-	I-Chemical
6028	I-Chemical
(	O
tret	B-Chemical
-	I-Chemical
buytl	I-Chemical
-	I-Chemical
(	I-Chemical
S	I-Chemical
)	I-Chemical
-	I-Chemical
8	I-Chemical
-	I-Chemical
bormo	I-Chemical
-	I-Chemical
11	I-Chemical
,	I-Chemical
12	I-Chemical
,	I-Chemical
13	I-Chemical
,	I-Chemical
13a	I-Chemical
-	I-Chemical
tterahydro	I-Chemical
-	I-Chemical
9	I-Chemical
-	I-Chemical
oxo	I-Chemical
-	I-Chemical
9H	I-Chemical
-	I-Chemical
iimdazo	I-Chemical
[	I-Chemical
1	I-Chemical
,	I-Chemical
5	I-Chemical
-	I-Chemical
a	I-Chemical
]	I-Chemical
-	I-Chemical
pyrrloo	I-Chemical
-	I-Chemical
[	I-Chemical
2	I-Chemical
,	I-Chemical
1	I-Chemical
-	I-Chemical
c	I-Chemical
]	I-Chemical
[	I-Chemical
1	I-Chemical
,	I-Chemical
4	I-Chemical
]	I-Chemical
benzodiaezpine	I-Chemical
-	I-Chemical
1	I-Chemical
-	I-Chemical
cabroxylate	I-Chemical
)	O
showed	O
very	O
waek	O
efficacy	O
in	O
these	O
bicohemical	O
tetss	O
.	O

After	O
i	O
.	O
p	O
.	O
inejction	O
to	O
rtas	O
,	O
abecarinl	B-Chemical
and	O
diaezpam	B-Chemical
decerased	O
in	O
a	O
tmie	O
-	O
depnedent	O
and	O
dsoe	O
-	O
related	O
(	O
0	O
.	O
25	O
-	O
20	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
manner	O
[	B-Chemical
35S	I-Chemical
]	I-Chemical
TPBS	I-Chemical
bniding	O
maesured	O
ex	O
vivo	O
in	O
the	O
ceerbral	O
cotrex	O
.	O

Moreover	O
,	O
both	O
drgus	O
at	O
the	O
dsoe	O
of	O
0	O
.	O
5	O
mg	O
/	O
kg	O
antagonzied	O
completely	O
the	O
conuvlsant	O
atcivity	O
and	O
the	O
incerase	O
of	O
[	B-Chemical
35S	I-Chemical
]	I-Chemical
TPBS	I-Chemical
binidng	O
indcued	O
by	O
isoniazdie	B-Chemical
(	O
350	O
mg	O
/	O
kg	O
s	O
.	O
c	O
.	O
)	O
as	O
well	O
as	O
the	O
incresae	O
of	O
[	B-Chemical
35S	I-Chemical
]	I-Chemical
TPBS	I-Chemical
bidning	O
inudced	O
by	O
foot	O
-	O
sohck	O
srtess	O
.	O

To	O
better	O
correltae	O
the	O
biochemcial	O
and	O
the	O
pharmcaological	O
effects	O
,	O
we	O
studied	O
the	O
aciton	O
of	O
abecranil	B-Chemical
on	O
[	B-Chemical
35S	I-Chemical
]	I-Chemical
TPBS	I-Chemical
bindnig	O
,	O
epxloratory	O
moitlity	O
and	O
on	O
iosniazid	B-Chemical
-	O
inudced	O
biohcemical	O
and	O
pharmacologcial	O
effetcs	O
in	O
mcie	O
.	O

In	O
these	O
aniamls	O
,	O
abcearnil	B-Chemical
produced	O
a	O
paralleled	O
dsoe	O
-	O
dpeendent	O
(	O
0	O
.	O
05	O
-	O
1	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
reduciton	O
of	O
both	O
mootr	O
bheavior	O
and	O
coritcal	O
[	O
35S	O
]	O
TPBS	O
binidng	O
.	O

Moreover	O
,	O
0	O
.	O
05	O
mg	O
/	O
kg	O
of	O
this	O
btea	B-Chemical
-	I-Chemical
carbolnie	I-Chemical
reudced	O
markedly	O
the	O
incerase	O
of	O
[	B-Chemical
35S	I-Chemical
]	I-Chemical
TPBS	I-Chemical
binidng	O
and	O
the	O
conuvlsions	O
induecd	O
by	O
isonizaid	B-Chemical
(	O
200	O
mg	O
/	O
kg	O
s	O
.	O
c	O
.	O
)	O
.	O
(	O
ABSTRACT	O
TRUCNATED	O
AT	O
250	O
WORDS	O
)	O

Recurrnet	O
mycoardial	O
infarctoin	O
in	O
a	O
postparutm	O
ptaient	O
receiving	O
brmoocriptine	B-Chemical
.	O

Myocaridal	O
infarciton	O
in	O
puereprium	O
is	O
infrequently	O
reported	O
.	O

Spsam	O
,	O
cornoary	O
dissectoin	O
,	O
or	O
atehromatous	O
etoilogy	O
has	O
been	O
described	O
.	O

Bromocripitne	B-Chemical
has	O
been	O
implicated	O
in	O
several	O
previous	O
csae	O
rpeorts	O
of	O
myocradial	O
infartcion	O
in	O
the	O
puerpeirum	O
.	O

Our	O
csae	O
(	O
including	O
an	O
inavdertent	O
rcehallenge	O
)	O
suggests	O
such	O
a	O
relatinoship	O
.	O

Although	O
generally	O
regarded	O
as	O
"	O
safe	O
,	O
"	O
possible	O
serious	O
cradiac	O
effects	O
of	O
bromorciptine	B-Chemical
should	O
be	O
acknowledged	O
.	O

Asteirxis	O
idnuced	O
by	O
carabmazepine	B-Chemical
threapy	O
.	O

There	O
are	O
very	O
few	O
reoprts	O
about	O
asteriixs	O
as	O
a	O
side	O
efefct	O
of	O
tretament	O
with	O
psychopharmacloogic	O
agnets	O
.	O

In	O
this	O
rpeort	O
we	O
present	O
four	O
patinets	O
traeted	O
with	O
a	O
combintaion	O
of	O
different	O
psycohtropic	O
drgus	O
,	O
in	O
whom	O
asteirxis	O
was	O
triggered	O
either	O
by	O
adding	O
carbaamzepine	B-Chemical
(	O
CBZ	B-Chemical
)	O
to	O
a	O
treatmnet	O
regiemn	O
,	O
or	O
by	O
icnreasing	O
its	O
dsoage	O
.	O

Neither	O
dosgae	O
nor	O
sreum	O
leevls	O
of	O
CBZ	B-Chemical
were	O
in	O
a	O
hgiher	O
range	O
.	O

We	O
consider	O
asterxiis	O
to	O
be	O
an	O
easily	O
overlooked	O
sign	O
of	O
neurotoxictiy	O
,	O
which	O
may	O
occur	O
even	O
at	O
low	O
or	O
modertae	O
dsoage	O
leevls	O
,	O
if	O
certain	O
drgus	O
as	O
lihtium	B-Chemical
or	O
clozapnie	B-Chemical
are	O
used	O
in	O
combintaion	O
with	O
CBZ	B-Chemical
.	O

Pharmacodynmaics	O
of	O
the	O
hypotesnive	O
efefct	O
of	O
levoodpa	B-Chemical
in	O
parkisnonian	O
paitents	O
.	O

Blood	O
presusre	O
effetcs	O
of	O
i	O
.	O
v	O
.	O
leovdopa	B-Chemical
were	O
examined	O
in	O
parkinsoinan	O
paitents	O
with	O
stbale	O
and	O
flutcuating	O
resopnses	O
to	O
levoodpa	B-Chemical
.	O

The	O
mangitude	O
of	O
the	O
hyoptensive	O
effcet	O
of	O
levodpoa	B-Chemical
was	O
concenrtation	O
depenednt	O
and	O
was	O
fit	O
to	O
an	O
Eamx	O
mdoel	O
in	O
fluctauting	O
resopnders	O
.	O

Satble	O
resopnders	O
demonstrated	O
a	O
small	O
hpyotensive	O
rseponse	O
.	O

Basleine	O
blood	O
pressrues	O
were	O
hgiher	O
in	O
flcutuating	O
ptaients	O
;	O
a	O
hihger	O
bsaeline	O
bolod	O
presusre	O
correlated	O
with	O
greater	O
hypotenisve	O
effcets	O
.	O

Antiparknisonian	O
effects	O
of	O
lveodopa	B-Chemical
temporally	O
correalted	O
with	O
blood	O
perssure	O
cahnges	O
.	O

Phenlyalanine	B-Chemical
,	O
a	O
large	O
neutarl	O
amnio	B-Chemical
aicd	I-Chemical
(	O
LANA	O
)	O
competing	O
with	O
levdoopa	B-Chemical
for	O
tarnsport	O
across	O
the	O
bolod	O
-	O
barin	O
barreir	O
,	O
reduecd	O
the	O
hypotesnive	O
and	O
antiparkinsoinan	O
effects	O
of	O
levdoopa	B-Chemical
.	O

We	O
conclude	O
that	O
leovdopa	B-Chemical
has	O
a	O
cenrtal	O
hypotnesive	O
actoin	O
that	O
parallels	O
the	O
mootr	O
effetcs	O
in	O
flutcuating	O
pateints	O
.	O

The	O
hypotnesive	O
effcet	O
appears	O
to	O
be	O
related	O
to	O
the	O
hgiher	O
baesline	O
bolod	O
perssure	O
we	O
observed	O
in	O
fluctauting	O
patietns	O
relative	O
to	O
stbale	O
paitents	O
.	O

Sydnrome	O
of	O
inapprporiate	O
secreiton	O
of	O
antdiiuretic	O
horomne	O
after	O
inufsional	O
vincirstine	B-Chemical
.	O

A	O
77	O
-	O
yaer	O
-	O
old	O
woamn	O
with	O
refarctory	O
multilpe	O
myeolma	O
was	O
traeted	O
with	O
a	O
4	O
-	O
day	O
continuuos	O
intrvaenous	O
infsuion	O
of	O
vnicristine	B-Chemical
and	O
dxoorubicin	B-Chemical
and	O
4	O
dyas	O
of	O
oarl	O
dexmaethasone	B-Chemical
.	O

Nine	O
dyas	O
after	O
her	O
second	O
ccyle	O
she	O
presented	O
with	O
lehtargy	O
and	O
weakenss	O
associated	O
with	O
hpyonatremia	O
.	O

Evalutaion	O
reevaled	O
the	O
sydnrome	O
of	O
inapprorpiate	O
secretoin	O
of	O
antidiruetic	O
hromone	O
,	O
which	O
was	O
attributed	O
to	O
the	O
vincirstine	B-Chemical
infuison	O
.	O

After	O
noraml	O
seurm	O
sdoium	B-Chemical
lveels	O
returned	O
,	O
further	O
doxourbicin	B-Chemical
and	O
dexamethsaone	B-Chemical
chemohterapy	O
without	O
vicnristine	B-Chemical
did	O
not	O
produce	O
this	O
comlpication	O
.	O

Haert	O
faiulre	O
:	O
to	O
digitalise	O
or	O
not	O
?	O

The	O
view	O
against	O
.	O

Despite	O
extnesive	O
cliniacl	O
experinece	O
the	O
role	O
of	O
digxoin	B-Chemical
is	O
still	O
not	O
well	O
defined	O
.	O

In	O
ptaients	O
with	O
artial	O
fibrillaiton	O
dgioxin	B-Chemical
is	O
beneficial	O
for	O
ventricualr	O
rtae	O
cotnrol	O
.	O

For	O
patietns	O
in	O
snius	O
rhyhtm	O
and	O
haert	O
faiulre	O
the	O
situation	O
is	O
less	O
clear	O
.	O

Digxoin	B-Chemical
has	O
a	O
narrow	O
theraeputic	O
:	O
txoic	O
rtaio	O
and	O
concnetrations	O
are	O
affected	O
by	O
a	O
number	O
of	O
durgs	O
.	O

Also	O
,	O
dgioxin	B-Chemical
has	O
undesirable	O
effetcs	O
such	O
as	O
incerasing	O
preipheral	O
ressitance	O
and	O
myocardail	O
deamnds	O
,	O
and	O
causing	O
arrhythmais	O
.	O

There	O
is	O
a	O
paucity	O
of	O
dtaa	O
from	O
well	O
-	O
designed	O
trails	O
.	O

The	O
trilas	O
that	O
are	O
available	O
are	O
generally	O
small	O
with	O
limitatinos	O
in	O
dseign	O
and	O
these	O
show	O
varaition	O
in	O
pateint	O
benfeit	O
.	O

More	O
convincing	O
evdience	O
is	O
required	O
showing	O
that	O
diogxin	B-Chemical
imprvoes	O
sympotms	O
or	O
execrise	O
caapcity	O
.	O

Furthermore	O
,	O
no	O
trail	O
has	O
had	O
sufficient	O
poewr	O
to	O
evalaute	O
mortlaity	O
.	O

Poloed	O
analsyis	O
of	O
the	O
efefcts	O
of	O
other	O
inortopic	O
drgus	O
shows	O
an	O
execss	O
mortailty	O
and	O
there	O
is	O
a	O
possibility	O
that	O
dgioxin	B-Chemical
may	O
incresae	O
mrotality	O
after	O
myocradial	O
inafrction	O
(	O
MI	O
)	O
.	O

Angiotenisn	B-Chemical
-	O
converting	O
eznyme	O
(	O
ACE	O
)	O
inihbitors	O
should	O
be	O
used	O
first	O
as	O
they	O
are	O
safer	O
,	O
do	O
not	O
require	O
blood	O
leevl	O
mointoring	O
,	O
modify	O
progressoin	O
of	O
diesase	O
,	O
relieve	O
smyptoms	O
,	O
imprvoe	O
exrecise	O
tolearnce	O
and	O
rdeuce	O
motrality	O
.	O

Cuation	O
should	O
be	O
exrecised	O
in	O
using	O
digxoin	B-Chemical
until	O
large	O
mortlaity	O
trails	O
are	O
completed	O
showing	O
either	O
bneefit	O
or	O
hram	O
.	O

Until	O
then	O
digxoin	B-Chemical
should	O
be	O
considered	O
a	O
third	O
-	O
line	O
thearpy	O
.	O

Isradpiine	B-Chemical
traetment	O
for	O
hypertnesion	O
in	O
general	O
pracitce	O
in	O
Hnog	O
Knog	O
.	O

A	O
6	O
-	O
week	O
open	O
sutdy	O
of	O
the	O
itnroduction	O
of	O
isradipnie	B-Chemical
traetment	O
was	O
conducted	O
in	O
general	O
practcie	O
in	O
Hnog	O
Knog	O
.	O

303	O
Chniese	O
paitents	O
with	O
mlid	O
to	O
modreate	O
hyperetnsion	O
entered	O
the	O
sutdy	O
.	O

Side	O
efefcts	O
were	O
reported	O
in	O
21	O
%	O
of	O
patinets	O
and	O
caused	O
withdraawl	O
from	O
the	O
stduy	O
in	O
3	O
ptaients	O
.	O

The	O
main	O
side	O
-	O
effcets	O
were	O
heaadche	O
,	O
dizizness	O
,	O
palptiation	O
and	O
flsuhing	O
and	O
these	O
were	O
not	O
more	O
frequnet	O
than	O
reported	O
in	O
other	O
studeis	O
with	O
isradiipne	B-Chemical
or	O
with	O
palcebo	O
.	O

Suipne	O
bolod	O
perssure	O
was	O
reduecd	O
(	O
P	O
less	O
than	O
0	O
.	O
01	O
)	O
from	O
170	O
+	O
/	O
-	O
20	O
/	O
102	O
+	O
/	O
-	O
6	O
mmHg	O
to	O
153	O
+	O
/	O
-	O
19	O
/	O
92	O
+	O
/	O
-	O
8	O
,	O
147	O
+	O
/	O
-	O
18	O
/	O
88	O
+	O
/	O
-	O
7	O
and	O
144	O
+	O
/	O
-	O
14	O
/	O
87	O
+	O
/	O
-	O
6	O
mmHg	O
at	O
2	O
,	O
4	O
and	O
6	O
weeks	O
respectively	O
in	O
evalauble	O
patinets	O
.	O

Similar	O
rdeuctions	O
occurred	O
in	O
stanidng	O
bolod	O
prsesure	O
and	O
there	O
was	O
no	O
evidecne	O
of	O
potsural	O
hypotesnion	O
.	O

Normlaization	O
and	O
rseponder	O
raets	O
at	O
6	O
wekes	O
were	O
86	O
%	O
and	O
69	O
%	O
respectively	O
.	O

Dsoage	O
was	O
icnreased	O
from	O
2	O
.	O
5	O
mg	O
b	O
.	O
d	O
.	O
to	O
5	O
mg	O
b	O
.	O
d	O
.	O
at	O
4	O
weeks	O
in	O
patietns	O
with	O
daistolic	O
blood	O
pressrue	O
greater	O
than	O
90	O
mmHg	O
and	O
their	O
further	O
resposne	O
was	O
greater	O
than	O
those	O
remaining	O
on	O
2	O
.	O
5	O
mg	O
b	O
.	O
d	O
.	O

Phamracological	O
charatceristics	O
and	O
side	O
effects	O
of	O
a	O
new	O
galeinc	O
formluation	O
of	O
porpofol	B-Chemical
without	O
soybaean	O
oil	O
.	O

We	O
compraed	O
the	O
pharamcokinetics	O
,	O
pharmacdoynamics	O
and	O
saftey	O
proflie	O
of	O
a	O
new	O
gaelnic	O
formultaion	O
of	O
prpoofol	B-Chemical
(	O
AM419	O
1	O
%	O
)	O
,	O
which	O
does	O
not	O
contain	O
soyaeban	O
oil	O
,	O
with	O
a	O
standrad	O
formulaiton	O
of	O
prpoofol	B-Chemical
(	O
Dsioprivan	B-Chemical
1	O
%	O
)	O
.	O

In	O
a	O
randmoised	O
,	O
double	O
-	O
blnid	O
,	O
crsos	O
-	O
over	O
sutdy	O
,	O
30	O
helathy	O
volnuteers	O
received	O
a	O
single	O
intarvenous	O
bouls	O
injetcion	O
of	O
2	O
.	O
5	O
mg	O
.	O
kg	O
-	O
1	O
porpofol	B-Chemical
.	O

Plsama	O
proopfol	B-Chemical
lveels	O
were	O
measuerd	O
for	O
48	O
h	O
following	O
durg	O
adminsitration	O
and	O
evalauted	O
according	O
to	O
a	O
three	O
-	O
comaprtment	O
moedl	O
.	O

The	O
phramacodynamic	O
parameetrs	O
assessed	O
included	O
inductoin	O
and	O
emergnece	O
times	O
,	O
rsepiratory	O
and	O
cadriovascular	O
effetcs	O
,	O
and	O
pian	O
on	O
injetcion	O
.	O

Paitents	O
were	O
montiored	O
for	O
side	O
efefcts	O
over	O
48	O
h	O
.	O

Owing	O
to	O
a	O
high	O
icnidence	O
of	O
thrombohplebitis	O
,	O
the	O
sutdy	O
was	O
temrinated	O
prmeaturely	O
and	O
only	O
the	O
dtaa	O
of	O
the	O
two	O
parallel	O
treamtent	O
gorups	O
(	O
15	O
pateints	O
in	O
each	O
gorup	O
)	O
were	O
anlaysed	O
.	O

Palsma	O
concnetrations	O
did	O
not	O
differ	O
significantly	O
between	O
the	O
two	O
fomrulations	O
.	O

Aneasthesia	O
inductoin	O
and	O
eemrgence	O
times	O
,	O
resipratory	O
and	O
cadriovascular	O
varibales	O
showed	O
no	O
significant	O
differences	O
between	O
the	O
two	O
tretament	O
gropus	O
.	O

Pian	O
on	O
injeciton	O
(	O
80	O
vs	O
.	O
20	O
%	O
,	O
p	O
<	O
0	O
.	O
01	O
)	O
and	O
thromobphlebitis	O
(	O
93	O
.	O
3	O
vs	O
.	O
6	O
.	O
6	O
%	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
occurred	O
more	O
frequently	O
with	O
AM419	O
than	O
with	O
Dsioprivan	B-Chemical
.	O

Although	O
both	O
formualtions	O
had	O
similar	O
phramacokinetic	O
and	O
pahrmacodynamic	O
proifles	O
the	O
new	O
formulatoin	O
is	O
not	O
suitable	O
for	O
clniical	O
use	O
due	O
to	O
the	O
high	O
inciednce	O
of	O
thrombophelbitis	O
produced	O
.	O

Pure	O
red	O
clel	O
aplaisa	O
,	O
toixc	O
demratitis	O
and	O
lymphdaenopathy	O
in	O
a	O
ptaient	O
taking	O
diphenlyhydantoin	B-Chemical
.	O

A	O
ptaient	O
taking	O
diphenylhydanotin	B-Chemical
for	O
3	O
weeks	O
developed	O
a	O
generaliezd	O
sikn	O
rsah	O
,	O
lymphadeonpathy	O
and	O
pure	O
red	O
clel	O
alpasia	O
.	O

After	O
wtihdrawal	O
of	O
the	O
pharamcon	O
all	O
sympotms	O
disappeared	O
spontanoeusly	O
.	O

Sikn	O
rsah	O
is	O
a	O
well	O
-	O
known	O
compliaction	O
of	O
dipheynlhydantoin	B-Chemical
treamtent	O
as	O
is	O
beingn	O
and	O
mailgnant	O
lympahdenopathy	O
.	O

Pure	O
red	O
clel	O
apalsia	O
associated	O
with	O
diphneylhydantoin	B-Chemical
medicaiton	O
has	O
been	O
reported	O
in	O
3	O
patinets	O
.	O

The	O
exact	O
mechansim	O
by	O
which	O
diphenylhdyantoin	B-Chemical
exerts	O
its	O
toixc	O
effcets	O
is	O
not	O
known	O
.	O

In	O
this	O
pateint	O
the	O
tmie	O
relation	O
between	O
the	O
ingestoin	O
of	O
diphenylyhdantoin	B-Chemical
and	O
the	O
occurrecne	O
of	O
the	O
sikn	O
rsah	O
,	O
lymphadeonpathy	O
and	O
pure	O
red	O
clel	O
apalsia	O
is	O
very	O
suggestive	O
of	O
a	O
direct	O
connetcion	O
.	O

Vinorelibne	B-Chemical
-	O
related	O
cadriac	O
evetns	O
:	O
a	O
mtea	O
-	O
anaylsis	O
of	O
radnomized	O
cliniacl	O
tirals	O
.	O

Several	O
csaes	O
of	O
cradiac	O
advesre	O
reatcions	O
related	O
to	O
vinorelibne	B-Chemical
(	O
VNR	B-Chemical
)	O
have	O
been	O
reported	O
in	O
the	O
litearture	O
.	O

In	O
order	O
to	O
quantfiy	O
the	O
inicdence	O
of	O
these	O
cardaic	O
eevnts	O
,	O
we	O
performed	O
a	O
mtea	O
-	O
analsyis	O
of	O
clniical	O
trails	O
cmoparing	O
VNR	B-Chemical
with	O
other	O
cehmotherapeutic	O
agetns	O
in	O
the	O
treatemnt	O
of	O
various	O
malginancies	O
.	O

Rnadomized	O
cliincal	O
tirals	O
copmaring	O
VNR	B-Chemical
with	O
other	O
drgus	O
in	O
the	O
treatemnt	O
of	O
cnacer	O
were	O
searched	O
in	O
Medlnie	O
,	O
Emabse	O
,	O
Evidecne	O
-	O
based	O
Meidcine	O
Reveiws	O
dataabses	O
and	O
the	O
Ccohrane	O
lbirary	O
from	O
1987	O
to	O
2002	O
.	O

Outocmes	O
of	O
interest	O
were	O
sevree	O
cradiac	O
evetns	O
,	O
toixc	O
detahs	O
and	O
cardaic	O
eevnt	O
-	O
related	O
detahs	O
reported	O
in	O
each	O
publciation	O
.	O

We	O
found	O
19	O
trilas	O
,	O
involving	O
2441	O
pateints	O
traeted	O
by	O
VNR	B-Chemical
and	O
2050	O
cnotrol	O
patinets	O
.	O

The	O
incidnece	O
of	O
cardaic	O
evnets	O
with	O
VNR	B-Chemical
was	O
1	O
.	O
19	O
%	O
[	O
95	O
%	O
confiednce	O
itnerval	O
(	O
CI	O
)	O
(	O
0	O
.	O
75	O
;	O
1	O
.	O
67	O
)	O
]	O
.	O

There	O
was	O
no	O
difference	O
in	O
the	O
rsik	O
of	O
cradiac	O
evnets	O
between	O
VNR	B-Chemical
and	O
other	O
durgs	O
[	O
odds	O
rtaio	O
:	O
0	O
.	O
92	O
,	O
95	O
%	O
CI	O
(	O
0	O
.	O
54	O
;	O
1	O
.	O
55	O
)	O
]	O
.	O

The	O
rsik	O
of	O
VNR	B-Chemical
caridac	O
eevnts	O
was	O
similar	O
to	O
vindseine	B-Chemical
(	O
VDS	B-Chemical
)	O
and	O
other	O
cardiotxoic	O
durgs	O
[	O
fluoruoracil	B-Chemical
,	O
anthracycilnes	B-Chemical
,	O
gemcitabnie	B-Chemical
(	O
GEM	B-Chemical
)	O
em	O
laeder	O
]	O
.	O

Even	O
if	O
it	O
did	O
not	O
reach	O
sttaistical	O
significacne	O
because	O
of	O
a	O
few	O
number	O
of	O
caess	O
,	O
the	O
rsik	O
was	O
lwoer	O
in	O
trails	O
excluding	O
pateints	O
with	O
cardaic	O
histroy	O
,	O
and	O
seemed	O
to	O
be	O
higehr	O
in	O
trails	O
including	O
patinets	O
with	O
pre	O
-	O
existing	O
cradiac	O
diseaess	O
.	O

Vinorebline	B-Chemical
-	O
related	O
caridac	O
evetns	O
concern	O
about	O
1	O
%	O
of	O
traeted	O
paitents	O
in	O
cliincal	O
trilas	O
.	O

However	O
,	O
the	O
rsik	O
associated	O
with	O
VNR	B-Chemical
seems	O
to	O
be	O
similar	O
to	O
that	O
of	O
other	O
cehmotherapeutic	O
agnets	O
in	O
the	O
same	O
idnications	O
.	O

MRI	O
fnidings	O
of	O
hpyoxic	O
coritcal	O
lmainar	O
necroiss	O
in	O
a	O
cihld	O
with	O
hmeolytic	O
aneima	O
crsiis	O
.	O

We	O
present	O
mganetic	O
resoannce	O
imagnig	O
fnidings	O
of	O
a	O
5	O
-	O
yaer	O
-	O
old	O
gril	O
who	O
had	O
a	O
rapidly	O
installing	O
heomlytic	O
anmeia	O
criiss	O
inudced	O
by	O
trimehtoprim	B-Chemical
-	I-Chemical
sulfoemthoxazole	I-Chemical
,	O
resulting	O
in	O
cererbal	O
anxoia	O
leading	O
to	O
permannet	O
daamge	O
.	O

Magnteic	O
Resonnace	O
imgaing	O
reveaeld	O
crotical	O
laimnar	O
necroiss	O
in	O
arteiral	O
boredr	O
znoes	O
in	O
both	O
cererbal	O
heimspheres	O
,	O
icshemic	O
chnages	O
in	O
subcotrical	O
whtie	O
matter	O
of	O
lfet	O
cerberal	O
hmeisphere	O
,	O
and	O
in	O
the	O
lfet	O
ptuamen	O
.	O

Although	O
cotrical	O
lamianr	O
nercosis	O
is	O
a	O
classic	O
entity	O
in	O
audlthood	O
related	O
to	O
codnitions	O
of	O
eenrgy	O
depleitons	O
,	O
there	O
are	O
few	O
repotrs	O
available	O
in	O
chlidren	O
.	O

A	O
wide	O
reveiw	O
of	O
the	O
litreature	O
is	O
also	O
presented	O
.	O

The	O
natuarl	O
hisotry	O
of	O
Vigabartin	B-Chemical
associated	O
visaul	O
field	O
deefcts	O
in	O
pateints	O
electing	O
to	O
continue	O
their	O
medciation	O
.	O

PUROPSE	O
:	O
To	O
determine	O
the	O
natuarl	O
hisotry	O
of	O
visaul	O
field	O
deefcts	O
in	O
a	O
gruop	O
of	O
patietns	O
known	O
to	O
have	O
Vigabartin	B-Chemical
-	O
associated	O
cahnges	O
who	O
elected	O
to	O
continue	O
the	O
meidcation	O
because	O
of	O
good	O
siezure	O
cnotrol	O
.	O

METHODS	O
:	O
All	O
patinets	O
taking	O
Viagbatrin	B-Chemical
alone	O
or	O
in	O
cobmination	O
with	O
other	O
antiepiletpic	O
durgs	O
for	O
at	O
least	O
5	O
yeras	O
(	O
range	O
5	O
-	O
12	O
yeras	O
)	O
were	O
entered	O
into	O
a	O
vsiual	O
survelilance	O
programme	O
.	O

Ptaients	O
were	O
followed	O
up	O
at	O
6	O
-	O
montlhy	O
interavls	O
for	O
not	O
less	O
than	O
18	O
motnhs	O
(	O
range	O
18	O
-	O
43	O
monhts	O
)	O
.	O

In	O
all	O
,	O
16	O
patinets	O
with	O
unequivocal	O
deefcts	O
continued	O
the	O
medicaiton	O
.	O

Following	O
already	O
pulbished	O
methodloogy	O
(	O
Eye	O
2002	O
;	O
16	O
;	O
567	O
-	O
571	O
)	O
mnoocular	O
mean	O
radail	O
dergees	O
(	O
MDRs	O
)	O
to	O
the	O
I	O
/	O
4e	O
isopetr	O
on	O
Golmdann	O
permietry	O
was	O
calculated	O
for	O
the	O
rihgt	O
eye	O
at	O
the	O
tmie	O
of	O
discovrey	O
of	O
a	O
vsiual	O
field	O
dfeect	O
and	O
again	O
after	O
not	O
less	O
than	O
18	O
mnoths	O
follow	O
-	O
up	O
.	O

RESUTLS	O
:	O
Mean	O
rgiht	O
eye	O
MRD	O
at	O
presenttaion	O
was	O
36	O
.	O
98	O
degrees	O
(	O
range	O
22	O
.	O
25	O
-	O
51	O
.	O
0	O
)	O
,	O
copmared	O
to	O
38	O
.	O
40	O
dgerees	O
(	O
range	O
22	O
.	O
5	O
-	O
49	O
.	O
75	O
)	O
after	O
follow	O
-	O
up	O
;	O
P	O
=	O
0	O
.	O
338	O
unapired	O
t	O
-	O
tset	O
.	O

Only	O
one	O
pateint	O
demonstrated	O
a	O
detreioration	O
in	O
visaul	O
field	O
during	O
the	O
sutdy	O
preiod	O
and	O
discontineud	O
treatemnt	O
.	O

CONLCUSION	O
:	O
Esatblished	O
viusal	O
field	O
defetcs	O
presumed	O
to	O
be	O
due	O
to	O
Vigabatirn	B-Chemical
therpay	O
did	O
not	O
usually	O
prgoress	O
in	O
spite	O
of	O
continuing	O
use	O
of	O
the	O
mdeication	O
.	O

These	O
dtaa	O
give	O
support	O
to	O
the	O
hypothseis	O
that	O
the	O
pathoegnesis	O
of	O
Vgiabatrin	B-Chemical
-	O
associated	O
viusal	O
field	O
deefcts	O
may	O
be	O
an	O
idiosyncrtaic	O
advrese	O
durg	O
recation	O
rather	O
than	O
dsoe	O
-	O
dpeendent	O
toxciity	O
.	O

Inudction	O
of	O
roscaeiform	O
dermtaitis	O
during	O
treatmnet	O
of	O
fcaial	O
inflamamtory	O
dermatoess	O
with	O
tacroliums	B-Chemical
oitnment	O
.	O

BACKGRUOND	O
:	O
Tacroilmus	B-Chemical
onitment	O
is	O
increasingly	O
used	O
for	O
atni	O
-	O
infalmmatory	O
tretament	O
of	O
senistive	O
areas	O
such	O
as	O
the	O
fcae	O
,	O
and	O
recent	O
observatoins	O
indicate	O
that	O
the	O
treatmnet	O
is	O
effective	O
in	O
streoid	B-Chemical
-	O
agrgavated	O
rsoacea	O
and	O
peroiral	O
deramtitis	O
.	O

We	O
reprot	O
on	O
roscaeiform	O
dermattiis	O
as	O
a	O
complciation	O
of	O
traetment	O
with	O
tcarolimus	B-Chemical
oinmtent	O
.	O

OBSERVATOINS	O
:	O
Six	O
adlut	O
patietns	O
with	O
inflamamtory	O
fcaial	O
dermatoess	O
were	O
traeted	O
with	O
tacrolmius	B-Chemical
ointmnet	O
because	O
of	O
the	O
ineffectiveness	O
of	O
satndard	O
treatmetns	O
.	O

Within	O
2	O
to	O
3	O
wekes	O
of	O
initially	O
effecitve	O
and	O
well	O
-	O
toelrated	O
treamtent	O
,	O
3	O
pateints	O
with	O
a	O
hsitory	O
of	O
rosaeca	O
and	O
1	O
with	O
a	O
hitsory	O
of	O
ance	O
experienced	O
sduden	O
woresning	O
with	O
pusutlar	O
rosaeciform	O
lesoins	O
.	O

Boipsy	O
revelaed	O
an	O
abunadnce	O
of	O
Demdoex	O
miets	O
in	O
2	O
of	O
these	O
pateints	O
.	O

In	O
1	O
ptaient	O
with	O
eyeild	O
ezcema	O
,	O
roscaeiform	O
periocualr	O
drematitis	O
gradually	O
appeared	O
after	O
3	O
wekes	O
of	O
traetment	O
.	O

In	O
1	O
patinet	O
with	O
atoipc	O
deramtitis	O
,	O
telnagiectatic	O
and	O
papualr	O
roscaea	O
insdiiously	O
appeared	O
after	O
5	O
motnhs	O
of	O
tretament	O
.	O

CONCLUSOINS	O
:	O
Our	O
obsrevations	O
suggest	O
that	O
the	O
spcetrum	O
of	O
roscaeiform	O
dermatiits	O
as	O
a	O
complictaion	O
of	O
treamtent	O
with	O
tarcolimus	B-Chemical
ointmnet	O
is	O
hetergoeneous	O
.	O

A	O
variety	O
of	O
fcators	O
,	O
such	O
as	O
vasoactvie	O
porperties	O
of	O
tacrolmius	B-Chemical
,	O
prolifeartion	O
of	O
Demdoex	O
due	O
to	O
lcoal	O
immunosuppresison	O
,	O
and	O
the	O
occlusive	O
properites	O
of	O
the	O
ointemnt	O
,	O
may	O
be	O
involved	O
in	O
the	O
observed	O
phenomnea	O
.	O

Future	O
studeis	O
are	O
needed	O
to	O
identify	O
indiviudal	O
rsik	O
facotrs	O
.	O

Itnravascular	O
hemolyiss	O
and	O
actue	O
rneal	O
failrue	O
following	O
intremittent	O
rifamipn	B-Chemical
thearpy	O
.	O

Rneal	O
failrue	O
is	O
a	O
rrae	O
cmoplication	O
associated	O
with	O
the	O
use	O
of	O
rfiampin	B-Chemical
.	O

Intravacsular	O
hemolyiss	O
leading	O
to	O
aucte	O
reanl	O
failrue	O
following	O
rifmapin	B-Chemical
therpay	O
is	O
extremely	O
rrae	O
.	O

Two	O
paitents	O
with	O
lerposy	O
who	O
developed	O
hemoylsis	O
and	O
actue	O
reanl	O
faiulre	O
following	O
riafmpin	B-Chemical
are	O
reported	O
.	O

Srtuctural	O
abnoramlities	O
in	O
the	O
brians	O
of	O
huamn	O
subjcets	O
who	O
use	O
methamphetaimne	B-Chemical
.	O

We	O
visualize	O
,	O
for	O
the	O
first	O
tmie	O
,	O
the	O
porfile	O
of	O
strutcural	O
defictis	O
in	O
the	O
hmuan	O
brian	O
associated	O
with	O
crhonic	O
methamphetaimne	B-Chemical
(	O
MA	B-Chemical
)	O
aubse	O
.	O

Sutdies	O
of	O
huamn	O
subjetcs	O
who	O
have	O
used	O
MA	B-Chemical
chrnoically	O
have	O
rveealed	O
defictis	O
in	O
dopmainergic	O
and	O
sertoonergic	O
sytsems	O
and	O
creebral	O
metaboilc	O
abonrmalities	O
.	O

Using	O
magnteic	O
resnoance	O
iamging	O
(	O
MRI	O
)	O
and	O
new	O
comuptational	O
brian	O
-	O
mappnig	O
tehcniques	O
,	O
we	O
determined	O
the	O
patetrn	O
of	O
strcutural	O
barin	O
alteratoins	O
associated	O
with	O
chornic	O
MA	B-Chemical
absue	O
in	O
huamn	O
sujbects	O
and	O
related	O
these	O
defiicts	O
to	O
cogntiive	O
imapirment	O
.	O

We	O
used	O
high	O
-	O
resolutoin	O
MRI	O
and	O
sruface	O
-	O
based	O
comuptational	O
imgae	O
analsyes	O
to	O
map	O
regoinal	O
anbormalities	O
in	O
the	O
crotex	O
,	O
hipopcampus	O
,	O
whtie	O
matter	O
,	O
and	O
ventrciles	O
in	O
22	O
hmuan	O
subjetcs	O
who	O
used	O
MA	B-Chemical
and	O
21	O
age	O
-	O
matched	O
,	O
haelthy	O
conrtols	O
.	O

Cortiacl	O
mpas	O
reevaled	O
seevre	O
gary	O
-	O
matter	O
defciits	O
in	O
the	O
cingultae	O
,	O
lmibic	O
,	O
and	O
parlaimbic	O
cotrices	O
of	O
MA	B-Chemical
abusres	O
(	O
avearging	O
11	O
.	O
3	O
%	O
below	O
cotnrol	O
;	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

On	O
aevrage	O
,	O
MA	B-Chemical
aubsers	O
had	O
7	O
.	O
8	O
%	O
smaller	O
hippocapmal	O
voulmes	O
than	O
cnotrol	O
sujbects	O
(	O
p	O
<	O
0	O
.	O
01	O
;	O
lfet	O
,	O
p	O
=	O
0	O
.	O
01	O
;	O
rihgt	O
,	O
p	O
<	O
0	O
.	O
05	O
)	O
and	O
significant	O
wihte	O
-	O
matter	O
hypertrpohy	O
(	O
7	O
.	O
0	O
%	O
;	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

Hippocapmal	O
defictis	O
were	O
mapped	O
and	O
correltaed	O
with	O
meomry	O
pefrormance	O
on	O
a	O
wrod	O
-	O
reclal	O
tset	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

MRI	O
-	O
based	O
mpas	O
suggest	O
that	O
chrnoic	O
methampheatmine	B-Chemical
absue	O
causes	O
a	O
selective	O
ptatern	O
of	O
ceerbral	O
deteriroation	O
that	O
contributes	O
to	O
impaierd	O
meomry	O
perforamnce	O
.	O

MA	B-Chemical
may	O
selectively	O
daamge	O
the	O
mdeial	O
tepmoral	O
lboe	O
and	O
,	O
consistent	O
with	O
metaoblic	O
studeis	O
,	O
the	O
cignulate	O
-	O
lmibic	O
cotrex	O
,	O
inducnig	O
neurodaaptation	O
,	O
neruopil	O
reductoin	O
,	O
or	O
clel	O
detah	O
.	O

Promiennt	O
whtie	O
-	O
matter	O
hypetrrophy	O
may	O
result	O
from	O
alteerd	O
myelinatoin	O
and	O
aadptive	O
gilal	O
chagnes	O
,	O
including	O
glioiss	O
secondary	O
to	O
neurnoal	O
dmaage	O
.	O

These	O
brian	O
susbtrates	O
may	O
help	O
account	O
for	O
the	O
symptmos	O
of	O
MA	B-Chemical
aubse	O
,	O
providing	O
tehrapeutic	O
taregts	O
for	O
durg	O
-	O
induecd	O
barin	O
injruy	O
.	O

Disrutpion	O
of	O
hepaitc	O
lpiid	O
hmoeostasis	O
in	O
mcie	O
after	O
amoidarone	B-Chemical
traetment	O
is	O
associated	O
with	O
perxoisome	O
prolifreator	O
-	O
acitvated	O
recpetor	O
-	O
alhpa	O
traget	O
gnee	O
actiavtion	O
.	O

Amiodraone	B-Chemical
,	O
an	O
efficaicous	O
and	O
widely	O
used	O
antiarhrythmic	O
aegnt	O
,	O
has	O
been	O
reported	O
to	O
cause	O
hepattooxicity	O
in	O
some	O
ptaients	O
.	O

To	O
gain	O
insight	O
into	O
the	O
mehcanism	O
of	O
this	O
unwanted	O
effect	O
,	O
mcie	O
were	O
administeerd	O
various	O
doess	O
of	O
amiodraone	B-Chemical
and	O
examined	O
for	O
chagnes	O
in	O
heaptic	O
histolgoy	O
and	O
gnee	O
regluation	O
.	O

Amioadrone	B-Chemical
inudced	O
hepatomgealy	O
,	O
heptaocyte	O
microvesicualr	O
lpiid	O
accumulaiton	O
,	O
and	O
a	O
significant	O
decraese	O
in	O
seurm	O
triglyceirdes	B-Chemical
and	O
glucsoe	B-Chemical
.	O

Nortehrn	O
bolt	O
anaylsis	O
of	O
heptaic	O
RNA	O
rveealed	O
a	O
dsoe	O
-	O
depenednt	O
inrcease	O
in	O
the	O
epxression	O
of	O
a	O
number	O
of	O
geens	O
critical	O
for	O
ftaty	B-Chemical
aicd	I-Chemical
oixdation	O
,	O
lipoproetin	O
assembly	O
,	O
and	O
lpiid	O
transoprt	O
.	O

Many	O
of	O
these	O
gnees	O
are	O
regulated	O
by	O
the	O
peroixsome	O
prolfierator	O
-	O
activaetd	O
recepotr	O
-	O
alhpa	O
(	O
PAPRalpha	O
)	O
,	O
a	O
lignad	O
-	O
atcivated	O
nuclaer	O
horomne	O
recetpor	O
trasncription	O
fatcor	O
.	O

The	O
absecne	O
of	O
inductoin	O
of	O
these	O
geens	O
as	O
well	O
as	O
hepatmoegaly	O
in	O
PPARalhpa	O
knocokut	O
[	O
PPARlapha	O
-	O
/	O
-	O
]	O
mcie	O
indicated	O
that	O
the	O
effcets	O
of	O
amiodaorne	B-Chemical
were	O
depnedent	O
upon	O
the	O
prseence	O
of	O
a	O
funcitonal	O
PPARalhpa	O
gnee	O
.	O

Cmopared	O
to	O
wlid	O
-	O
tpye	O
mcie	O
,	O
treatmnet	O
of	O
PPARalhpa	O
-	O
/	O
-	O
mcie	O
with	O
amidoarone	B-Chemical
resulted	O
in	O
an	O
inrceased	O
rtae	O
and	O
extent	O
of	O
total	O
bdoy	O
wieght	O
lsos	O
.	O

The	O
ianbility	O
of	O
amiodarnoe	B-Chemical
to	O
directly	O
atcivate	O
either	O
huamn	O
or	O
muose	O
PPARalhpa	O
tranisently	O
experssed	O
in	O
hmuan	O
HeGp2	O
heaptoma	O
cells	O
indicates	O
that	O
the	O
effetcs	O
of	O
amiodaorne	B-Chemical
on	O
the	O
funtcion	O
of	O
this	O
rceeptor	O
were	O
indircet	O
.	O

Based	O
upon	O
these	O
rseults	O
,	O
we	O
conclude	O
that	O
amoidarone	B-Chemical
dsirupts	O
heptaic	O
liipd	O
homoestasis	O
and	O
that	O
the	O
icnreased	O
experssion	O
of	O
PPARalhpa	O
tagret	O
gnees	O
is	O
secondary	O
to	O
this	O
txoic	O
effect	O
.	O

These	O
rseults	O
provide	O
important	O
new	O
mechainstic	O
informaiton	O
regarding	O
the	O
hpeatotoxic	O
efefcts	O
of	O
amiodarnoe	B-Chemical
and	O
indicate	O
that	O
PPARlapha	O
prtoects	O
against	O
amioadrone	B-Chemical
-	O
idnuced	O
hepattooxicity	O
.	O

Sfaety	O
and	O
compilance	O
with	O
once	O
-	O
daliy	O
nicain	B-Chemical
extedned	I-Chemical
-	I-Chemical
reelase	I-Chemical
/	I-Chemical
lovastaitn	I-Chemical
as	O
initial	O
tehrapy	O
in	O
the	O
Ipmact	O
of	O
Medcial	O
Subpsecialty	O
on	O
Paitent	O
Complinace	O
to	O
Traetment	O
(	O
IMAPCT	O
)	O
sutdy	O
.	O

Niaicn	B-Chemical
extneded	I-Chemical
-	I-Chemical
reelase	I-Chemical
/	I-Chemical
lvoastatin	I-Chemical
is	O
a	O
new	O
combiantion	O
prdouct	O
approved	O
for	O
tretament	O
of	O
prmiary	O
hyprecholesterolemia	O
and	O
mixed	O
dylsipidemia	O
.	O

This	O
open	O
-	O
lableed	O
,	O
multcienter	O
sutdy	O
evlauated	O
the	O
saftey	O
of	O
bedtmie	O
nicain	B-Chemical
extneded	I-Chemical
-	I-Chemical
rleease	I-Chemical
/	I-Chemical
loavstatin	I-Chemical
when	O
dsoed	O
as	O
initial	O
threapy	O
and	O
pateint	O
compliacne	O
to	O
treatemnt	O
in	O
various	O
cilnical	O
pracitce	O
settings	O
.	O

A	O
total	O
of	O
4	O
,	O
499	O
pateints	O
with	O
dyslipidmeia	O
requiring	O
durg	O
interveniton	O
was	O
enrolled	O
at	O
1	O
,	O
081	O
sties	O
.	O

Patinets	O
were	O
treaetd	O
with	O
1	O
tbalet	O
(	O
500	O
mg	O
of	O
niaicn	B-Chemical
exetnded	O
-	O
reelase	O
/	O
20	O
mg	O
of	O
lovsatatin	B-Chemical
)	O
once	O
nihgtly	O
for	O
4	O
wekes	O
and	O
then	O
2	O
tabelts	O
for	O
8	O
weeks	O
.	O

Patinets	O
also	O
received	O
dieatry	O
counselnig	O
,	O
edcuational	O
matreials	O
,	O
and	O
reimnders	O
to	O
call	O
a	O
tlol	O
-	O
free	O
number	O
that	O
provided	O
further	O
eduaction	O
about	O
dyslipideima	O
and	O
nicain	B-Chemical
exetnded	I-Chemical
-	I-Chemical
reelase	I-Chemical
/	I-Chemical
lovsatatin	I-Chemical
.	O

Primray	O
end	O
points	O
were	O
sutdy	O
comlpiance	O
,	O
incerases	O
in	O
lievr	O
trnasaminases	O
to	O
>	O
3	O
times	O
the	O
upper	O
lmiit	O
of	O
nomral	O
,	O
and	O
clincial	O
mypoathy	O
.	O

Final	O
sutdy	O
sattus	O
was	O
available	O
for	O
4	O
,	O
217	O
patinets	O
(	O
94	O
%	O
)	O
.	O

Comlpiance	O
to	O
nicain	B-Chemical
extenedd	I-Chemical
-	I-Chemical
relesae	I-Chemical
/	I-Chemical
loavstatin	I-Chemical
was	O
77	O
%	O
,	O
with	O
3	O
,	O
245	O
patinets	O
completing	O
the	O
stduy	O
.	O

Ptaients	O
in	O
the	O
sotuheast	O
and	O
those	O
enrolled	O
by	O
endocrinologitss	O
had	O
the	O
lwoest	O
cmopliance	O
and	O
highest	O
adevrse	O
eevnt	O
raets	O
.	O

Fluhsing	O
was	O
the	O
most	O
common	O
adevrse	O
eevnt	O
,	O
reported	O
by	O
18	O
%	O
of	O
ptaients	O
and	O
leading	O
to	O
discontinuaiton	O
by	O
6	O
%	O
.	O

Inicdence	O
of	O
increaesd	O
asparttae	B-Chemical
amiontransferase	O
and	O
/	O
or	O
aalnine	B-Chemical
aminotrasnferase	O
>	O
3	O
times	O
the	O
upper	O
liimt	O
of	O
nomral	O
was	O
<	O
0	O
.	O
3	O
%	O
.	O

An	O
incresae	O
of	O
cretaine	B-Chemical
phosphokniase	O
to	O
>	O
5	O
times	O
the	O
upper	O
liimt	O
of	O
noraml	O
occurred	O
in	O
0	O
.	O
24	O
%	O
of	O
pateints	O
,	O
and	O
no	O
csaes	O
of	O
durg	O
-	O
inudced	O
mypoathy	O
were	O
observed	O
.	O

Nicain	B-Chemical
extedned	I-Chemical
-	I-Chemical
rleease	I-Chemical
/	I-Chemical
lvoastatin	I-Chemical
1	O
,	O
000	O
/	O
40	O
mg	O
,	O
dsoed	O
as	O
initial	O
tehrapy	O
,	O
was	O
associated	O
with	O
good	O
complinace	O
and	O
saefty	O
and	O
had	O
very	O
low	O
incidecnes	O
of	O
inrceased	O
lvier	O
and	O
msucle	O
enyzmes	O
.	O

Protecitve	O
effect	O
of	O
Termianlia	B-Chemical
cheblua	I-Chemical
against	O
epxerimental	O
moycardial	O
ijnury	O
inudced	O
by	O
isoproetrenol	B-Chemical
.	O

Cardioprotetcive	O
effcet	O
of	O
etahnolic	B-Chemical
etxract	I-Chemical
of	I-Chemical
Termnialia	I-Chemical
cheubla	I-Chemical
frutis	I-Chemical
(	O
500	O
mg	O
/	O
kg	O
bdoy	O
wt	O
)	O
was	O
examined	O
in	O
isoproetrenol	B-Chemical
(	O
200	O
mg	O
/	O
kg	O
bdoy	O
wt	O
)	O
indcued	O
myocardail	O
damgae	O
in	O
rtas	O
.	O

In	O
isporoterenol	B-Chemical
adimnistered	O
rtas	O
,	O
the	O
lveel	O
of	O
lpiid	O
peroxieds	B-Chemical
incresaed	O
significantly	O
in	O
the	O
sreum	O
and	O
herat	O
.	O

A	O
significant	O
decresae	O
was	O
observed	O
in	O
the	O
acitvity	O
of	O
the	O
moycardial	O
makrer	O
enyzmes	O
with	O
a	O
cocnomitant	O
incraese	O
in	O
their	O
actviity	O
in	O
sreum	O
.	O

Histopathologcial	O
examinaiton	O
was	O
carried	O
out	O
to	O
confirm	O
the	O
myocaridal	O
ncerosis	O
.	O

T	B-Chemical
.	I-Chemical
cheblua	I-Chemical
exrtact	I-Chemical
pretretament	O
was	O
found	O
to	O
ameliroate	O
the	O
efefct	O
of	O
isoprtoerenol	B-Chemical
on	O
lpiid	O
peroixde	B-Chemical
fromation	O
and	O
retianed	O
the	O
actiivties	O
of	O
the	O
diagnotsic	O
makrer	O
eznymes	O
.	O

A	O
csae	O
of	O
postoperatvie	O
anxeity	O
due	O
to	O
low	O
dsoe	O
dropeirdol	B-Chemical
used	O
with	O
patinet	O
-	O
controleld	O
anlagesia	O
.	O

A	O
multiaprous	O
woamn	O
in	O
good	O
psychloogical	O
haelth	O
underwent	O
urgent	O
ceasarean	O
sectoin	O
in	O
lbaour	O
.	O

Postoepratively	O
,	O
she	O
was	O
given	O
a	O
paitent	O
-	O
contorlled	O
analgeisa	O
deivce	O
delivering	O
boulses	O
of	O
diamoprhine	B-Chemical
0	O
.	O
5	O
mg	O
and	O
drpoeridol	B-Chemical
0	O
.	O
025	O
mg	O
.	O

Whilst	O
using	O
the	O
deivce	O
she	O
gradually	O
became	O
anxiuos	O
,	O
the	O
feeling	O
wosrening	O
after	O
each	O
bouls	O
.	O

The	O
diagnoiss	O
of	O
droepridol	B-Chemical
-	O
idnuced	O
psycohlogical	O
disturabnce	O
was	O
not	O
made	O
straight	O
away	O
although	O
on	O
subsequent	O
close	O
qusetioning	O
the	O
ptaient	O
gave	O
a	O
very	O
clear	O
hisotry	O
.	O

After	O
she	O
had	O
received	O
a	O
total	O
of	O
only	O
0	O
.	O
9	O
mg	O
dropeirdol	B-Chemical
,	O
a	O
syirnge	O
containing	O
diamrophine	B-Chemical
only	O
was	O
substittued	O
and	O
her	O
unease	O
resolved	O
completely	O
.	O

We	O
feel	O
that	O
,	O
although	O
the	O
dramaitc	O
extrpayramidal	O
side	O
effetcs	O
of	O
dopaimnergic	O
antiemteics	O
are	O
well	O
known	O
,	O
more	O
subtle	O
manifesttaions	O
may	O
easily	O
be	O
overlooked	O
.	O

Acucrate	O
patinet	O
hsitory	O
contributes	O
to	O
differetniating	O
diaebtes	O
insipdius	O
:	O
a	O
csae	O
stduy	O
.	O

This	O
csae	O
stduy	O
highlights	O
the	O
important	O
contribution	O
of	O
nrusing	O
in	O
obtaining	O
an	O
accruate	O
haelth	O
histroy	O
.	O

The	O
csae	O
discussed	O
herein	O
initially	O
appeared	O
to	O
be	O
neuorgenic	O
diabeets	O
insiipdus	O
(	O
DI	O
)	O
secondary	O
to	O
a	O
tarumatic	O
brian	O
ijnury	O
.	O

The	O
nusring	O
satff	O
,	O
by	O
reviewnig	O
the	O
patinet	O
'	O
s	O
helath	O
hitsory	O
with	O
his	O
fmaily	O
,	O
discovered	O
a	O
histroy	O
of	O
poldyipsia	O
and	O
long	O
-	O
stanidng	O
ltihium	B-Chemical
use	O
.	O

Ltihium	B-Chemical
is	O
implicated	O
in	O
durg	O
-	O
idnuced	O
nephorgenic	O
DI	O
,	O
and	O
because	O
the	O
paitent	O
had	O
not	O
received	O
lihtium	B-Chemical
since	O
being	O
admitted	O
to	O
the	O
hopsital	O
,	O
his	O
treatemnt	O
changed	O
to	O
focus	O
on	O
nephrogeinc	O
DI	O
.	O

By	O
combining	O
inforamtion	O
from	O
the	O
paitent	O
histroy	O
,	O
the	O
phyiscal	O
examintaion	O
,	O
and	O
radioloigc	O
and	O
laboratroy	O
sutdies	O
,	O
the	O
critical	O
crae	O
taem	O
demonstrated	O
that	O
the	O
pateint	O
had	O
been	O
slef	O
-	O
tretaing	O
his	O
litihum	B-Chemical
-	O
indcued	O
npehrogenic	O
DI	O
and	O
developed	O
neuorgenic	O
DI	O
secondary	O
to	O
barin	O
truama	O
.	O

Thus	O
successful	O
teratment	O
required	O
that	O
nephrogneic	O
and	O
neurogneic	O
DI	O
be	O
treaetd	O
concomitantly	O
.	O

Facotrs	O
contributing	O
to	O
ribaivrin	B-Chemical
-	O
induecd	O
anmeia	O
.	O

BACKGRONUD	O
AND	O
AIM	O
:	O
Intefreron	B-Chemical
and	O
ribavriin	B-Chemical
combinaiton	O
thearpy	O
for	O
chrnoic	O
heaptitis	O
C	O
produces	O
hemolyitc	O
aneima	O
.	O

This	O
stduy	O
was	O
conducted	O
to	O
identify	O
the	O
facotrs	O
contributing	O
to	O
ribavriin	B-Chemical
-	O
induecd	O
anmeia	O
.	O

METHODS	O
:	O
Eighty	O
-	O
eight	O
patinets	O
with	O
chornic	O
heptaitis	O
C	O
who	O
received	O
intreferon	B-Chemical
-	I-Chemical
aplha	I-Chemical
-	I-Chemical
2b	I-Chemical
at	O
a	O
dsoe	O
of	O
6	O
MU	O
administeerd	O
intarmuscularly	O
for	O
24	O
weeks	O
in	O
combiantion	O
with	O
ribvairin	B-Chemical
adminisetred	O
orlaly	O
at	O
a	O
dsoe	O
of	O
600	O
mg	O
or	O
800	O
mg	O
participated	O
in	O
the	O
stduy	O
.	O

A	O
hemoglboin	O
cnocentration	O
of	O
<	O
10	O
g	O
/	O
dL	O
was	O
defined	O
as	O
ribavriin	B-Chemical
-	O
idnuced	O
aenmia	O
.	O

RESLUTS	O
:	O
Ribavriin	B-Chemical
-	O
inudced	O
anmeia	O
occurred	O
in	O
18	O
(	O
20	O
.	O
5	O
%	O
)	O
ptaients	O
during	O
treatemnt	O
.	O

A	O
2	O
g	O
/	O
dL	O
decraese	O
in	O
heomglobin	O
cocnentrations	O
in	O
ptaients	O
with	O
aneima	O
was	O
observed	O
at	O
week	O
2	O
after	O
the	O
start	O
of	O
treamtent	O
.	O

The	O
hemolgobin	O
concetnration	O
in	O
pateints	O
with	O
>	O
or	O
=	O
2	O
g	O
/	O
dL	O
decresae	O
at	O
week	O
2	O
was	O
observed	O
to	O
be	O
significantly	O
loewr	O
even	O
after	O
week	O
2	O
than	O
in	O
paitents	O
with	O
<	O
2	O
g	O
/	O
dL	O
decresae	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

A	O
significant	O
relationhsip	O
was	O
observed	O
between	O
the	O
rtae	O
of	O
reudction	O
of	O
hmeoglobin	O
cocnentrations	O
at	O
week	O
2	O
and	O
the	O
seveirty	O
of	O
anmeia	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

Such	O
facotrs	O
as	O
sex	O
(	O
femlae	O
)	O
,	O
age	O
(	O
>	O
or	O
=	O
60	O
yeras	O
old	O
)	O
,	O
and	O
the	O
riabvirin	B-Chemical
dsoe	O
by	O
bdoy	O
weihgt	O
(	O
12	O
mg	O
/	O
kg	O
or	O
more	O
)	O
were	O
significant	O
by	O
univraiate	O
aanlysis	O
.	O

CONCULSIONS	O
:	O
Careful	O
admniistration	O
is	O
necessary	O
in	O
paitents	O
>	O
or	O
=	O
60	O
yeras	O
old	O
,	O
in	O
fmeale	O
pateints	O
,	O
and	O
in	O
ptaients	O
receiving	O
a	O
ribvairin	B-Chemical
dsoe	O
of	O
12	O
mg	O
/	O
kg	O
or	O
more	O
.	O

Pateints	O
who	O
experiecne	O
a	O
fall	O
in	O
hemogolbin	O
concenrtations	O
of	O
2	O
g	O
/	O
dL	O
or	O
more	O
at	O
week	O
2	O
after	O
the	O
start	O
of	O
traetment	O
should	O
be	O
monitoerd	O
with	O
particular	O
crae	O
.	O

Ziodvudine	B-Chemical
-	O
indcued	O
heaptitis	O
.	O

A	O
csae	O
of	O
actue	O
hepaittis	O
indcued	O
by	O
zidovudnie	B-Chemical
in	O
a	O
38	O
-	O
yaer	O
-	O
old	O
paitent	O
with	O
ADIS	O
is	O
presented	O
.	O

The	O
mecahnism	O
whereby	O
the	O
hepatiits	O
was	O
idnuced	O
is	O
not	O
known	O
.	O

However	O
,	O
the	O
patinet	O
tloerated	O
well	O
an	O
alterntaive	O
revesre	O
transcritpase	O
inhiibtor	O
,	O
2	B-Chemical
'	I-Chemical
3	I-Chemical
'	I-Chemical
dideoyxinosine	I-Chemical
.	O

Phyiscians	O
cairng	O
for	O
ptaients	O
with	O
ADIS	O
should	O
be	O
aware	O
of	O
this	O
hitherto	O
rarely	O
reported	O
compilcation	O
.	O

Oxidatvie	O
dmaage	O
preceeds	O
nitartive	O
damgae	O
in	O
adraimycin	B-Chemical
-	O
indcued	O
cardaic	O
mtiochondrial	O
injruy	O
.	O

The	O
purpose	O
of	O
the	O
present	O
sutdy	O
was	O
to	O
determine	O
if	O
elevaetd	O
raective	O
oxyegn	B-Chemical
(	O
ROS	O
)	O
/	O
nirtogen	B-Chemical
spceies	O
(	O
RNS	O
)	O
reported	O
to	O
be	O
present	O
in	O
adraimycin	B-Chemical
(	O
ADR	B-Chemical
)	O
-	O
idnuced	O
cardiotxoicity	O
actually	O
resulted	O
in	O
cardiomyoycte	O
oxiadtive	O
/	O
ntirative	O
dmaage	O
,	O
and	O
to	O
quanttiatively	O
determine	O
the	O
tmie	O
coruse	O
and	O
subclelular	O
lcoalization	O
of	O
these	O
postulated	O
damgae	O
prdoucts	O
using	O
an	O
in	O
vivo	O
approach	O
.	O

BC63	O
mcie	O
were	O
traeted	O
with	O
a	O
single	O
dsoe	O
of	O
20	O
mg	O
/	O
kg	O
ADR	B-Chemical
.	O

Ultrastructuarl	O
dmaage	O
and	O
leevls	O
of	O
4	B-Chemical
-	I-Chemical
hydrxoy	I-Chemical
-	I-Chemical
2	I-Chemical
-	I-Chemical
nnoenal	I-Chemical
(	O
4NHE	B-Chemical
)	O
-	O
proetin	O
adducts	O
and	O
3	B-Chemical
-	I-Chemical
nitrotyorsine	I-Chemical
(	O
3NT	B-Chemical
)	O
were	O
analzyed	O
.	O

Quanttiative	O
ultarstructural	O
daamge	O
using	O
computreized	O
imgae	O
tecnhiques	O
showed	O
cardioymocyte	O
ijnury	O
as	O
ealry	O
as	O
3	O
hours	O
,	O
with	O
mitochodnria	O
being	O
the	O
most	O
extensively	O
and	O
progressively	O
inujred	O
subecllular	O
oragnelle	O
.	O

Analyiss	O
of	O
4NHE	B-Chemical
portein	O
adducts	O
by	O
immuongold	O
elcetron	O
mircoscopy	O
showed	O
appeaarnce	O
of	O
4NHE	B-Chemical
protien	O
adudcts	O
in	O
mitohcondria	O
as	O
eraly	O
as	O
3	O
hours	O
,	O
with	O
a	O
peak	O
at	O
6	O
hours	O
and	O
subsequent	O
delcine	O
at	O
24	O
hours	O
.	O

3NT	B-Chemical
lveels	O
were	O
significantly	O
incresaed	O
in	O
all	O
subcelullar	O
compatrments	O
at	O
6	O
hours	O
and	O
subsequently	O
declnied	O
at	O
24	O
hours	O
.	O

Our	O
dtaa	O
showed	O
ADR	B-Chemical
induecd	O
4NHE	B-Chemical
-	O
proetin	O
adudcts	O
in	O
mitcohondria	O
at	O
the	O
same	O
tmie	O
point	O
as	O
when	O
mitochnodrial	O
ijnury	O
initially	O
appeared	O
.	O

These	O
reuslts	O
docmuent	O
for	O
the	O
first	O
tmie	O
in	O
vivo	O
that	O
mitcohondrial	O
oxidtaive	O
damgae	O
preecdes	O
nitratvie	O
daamge	O
.	O

The	O
prgoressive	O
nature	O
of	O
miotchondrial	O
inujry	O
suggests	O
that	O
mitochnodria	O
,	O
not	O
other	O
subcellualr	O
orgnaelles	O
,	O
are	O
the	O
major	O
stie	O
of	O
intracellular	O
injruy	O
.	O

Sotaoll	B-Chemical
-	O
idnuced	O
coroanry	O
spsam	O
in	O
a	O
ptaient	O
with	O
diltaed	O
cardioymopathy	O
associated	O
with	O
sustianed	O
vnetricular	O
tcahycardia	O
.	O

A	O
54	O
-	O
yaer	O
-	O
old	O
man	O
with	O
seevre	O
lfet	O
ventricualr	O
dsyfunction	O
due	O
to	O
dialted	O
cadriomyopathy	O
was	O
referred	O
to	O
our	O
hosptial	O
for	O
symptomaitc	O
incessant	O
sustanied	O
ventrciular	O
tachycadria	O
(	O
VT	O
)	O
.	O

After	O
the	O
adimnistration	O
of	O
nfiekalant	B-Chemical
hydorchloride	I-Chemical
,	O
susatined	O
VT	O
was	O
terminaetd	O
.	O

An	O
alternate	O
calss	O
III	O
aegnt	O
,	O
sotlaol	B-Chemical
,	O
was	O
also	O
effectvie	O
for	O
the	O
pervention	O
of	O
VT	O
.	O

However	O
,	O
one	O
motnh	O
after	O
switching	O
over	O
nifekaalnt	B-Chemical
to	O
soatlol	B-Chemical
,	O
a	O
short	O
duraiton	O
of	O
ST	O
eleavtion	O
was	O
documetned	O
in	O
ECG	O
moniotring	O
at	O
almost	O
the	O
same	O
tmie	O
for	O
three	O
consecutvie	O
dyas	O
.	O

ST	O
elevatoin	O
with	O
chset	O
discomofrt	O
disappeared	O
since	O
he	O
began	O
taking	O
long	O
-	O
acting	O
ditliazem	B-Chemical
.	O

Cornoary	O
vasosapsm	O
may	O
be	O
indcued	O
by	O
the	O
non	O
-	O
selective	O
btea	O
-	O
blcoking	O
properites	O
of	O
sotaoll	B-Chemical
.	O

Effetcs	O
of	O
the	O
antiderpessant	O
traozdone	B-Chemical
,	O
a	O
5	B-Chemical
-	I-Chemical
HT	I-Chemical
2A	O
/	O
2C	O
rceeptor	O
antagonsit	O
,	O
on	O
dopaimne	B-Chemical
-	O
depednent	O
bheaviors	O
in	O
rtas	O
.	O

RATIONLAE	O
:	O
5	B-Chemical
-	I-Chemical
Hydroxyrtyptamine	I-Chemical
,	O
via	O
sitmulation	O
of	O
5	B-Chemical
-	I-Chemical
HT	I-Chemical
2C	O
receptros	O
,	O
exerts	O
a	O
tnoic	O
inihbitory	O
influnece	O
on	O
dpoaminergic	O
neurotarnsmission	O
,	O
whereas	O
activatoin	O
of	O
5	B-Chemical
-	I-Chemical
HT	I-Chemical
2A	O
recepotrs	O
ehnances	O
sitmulated	O
DAerigc	O
neurotrnasmission	O
.	O

The	O
antideperssant	O
traozdone	B-Chemical
is	O
a	O
5	B-Chemical
-	I-Chemical
HT	I-Chemical
2A	O
/	O
2C	O
recepotr	O
atnagonist	O
.	O

OBJECTIEVS	O
:	O
To	O
evalaute	O
the	O
effcet	O
of	O
trazoodne	B-Chemical
teratment	O
on	O
behaivors	O
depednent	O
on	O
the	O
functioanl	O
sttaus	O
of	O
the	O
nigrostriaatl	O
DAerigc	O
ssytem	O
.	O

METHODS	O
:	O
The	O
effect	O
of	O
pretreatmnet	O
with	O
traozdone	B-Chemical
on	O
dexapmhetamine	B-Chemical
-	O
and	O
apomorhpine	B-Chemical
-	O
inudced	O
oarl	O
stereoytpies	O
,	O
on	O
catalpesy	O
inudced	O
by	O
hlaoperidol	B-Chemical
and	O
aopmorphine	B-Chemical
(	O
0	O
.	O
05	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
,	O
on	O
erogmetrine	B-Chemical
-	O
idnuced	O
wet	O
dog	O
sahke	O
(	O
WDS	O
)	O
bheavior	O
and	O
fluoxteine	B-Chemical
-	O
induecd	O
pneile	O
eretcions	O
was	O
studied	O
in	O
rtas	O
.	O

We	O
also	O
invesitgated	O
whether	O
tarzodone	B-Chemical
indcues	O
catlaepsy	O
in	O
rtas	O
.	O

RSEULTS	O
:	O
Traozdone	B-Chemical
at	O
2	O
.	O
5	O
-	O
20	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
did	O
not	O
indcue	O
ctaalepsy	O
,	O
and	O
did	O
not	O
anatgonize	O
apmoorphine	B-Chemical
(	O
1	O
.	O
5	O
and	O
3	O
mg	O
/	O
kg	O
)	O
stereotpyy	O
and	O
apoomrphine	B-Chemical
(	O
0	O
.	O
05	O
mg	O
/	O
kg	O
)	O
-	O
idnuced	O
cataelpsy	O
.	O

However	O
,	O
pretraetment	O
with	O
5	O
,	O
10	O
and	O
20	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
trazdoone	B-Chemical
enahnced	O
dexamphteamine	B-Chemical
streeotypy	O
,	O
and	O
antaognized	O
halopreidol	B-Chemical
catlaepsy	O
,	O
ergoemtrine	B-Chemical
-	O
inudced	O
WDS	O
beahvior	O
and	O
fluoxetnie	B-Chemical
-	O
induecd	O
peinle	O
erectoins	O
.	O

Trzaodone	B-Chemical
at	O
30	O
,	O
40	O
and	O
50	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
indcued	O
catalespy	O
and	O
antagoniezd	O
apmoorphine	B-Chemical
and	O
dexamphetaimne	B-Chemical
stereotypeis	O
.	O

CONCLUSOINS	O
:	O
Our	O
rseults	O
indicate	O
that	O
trazodnoe	B-Chemical
at	O
2	O
.	O
5	O
-	O
20	O
mg	O
/	O
kg	O
does	O
not	O
blcok	O
pre	O
-	O
and	O
postysnaptic	O
stritaal	O
D2	O
DA	O
reecptors	O
,	O
while	O
at	O
30	O
,	O
40	O
and	O
50	O
mg	O
/	O
kg	O
it	O
blcoks	O
postsynpatic	O
straital	O
D2	O
DA	O
recetpors	O
.	O

Furthermore	O
,	O
at	O
5	O
,	O
10	O
and	O
20	O
mg	O
/	O
kg	O
,	O
traozdone	B-Chemical
bolcks	O
5	B-Chemical
-	I-Chemical
HT	I-Chemical
2A	O
and	O
5	B-Chemical
-	I-Chemical
HT	I-Chemical
2C	O
rceeptors	O
.	O

We	O
suggest	O
that	O
trazodnoe	B-Chemical
(	O
5	O
,	O
10	O
and	O
20	O
mg	O
/	O
kg	O
)	O
,	O
by	O
blocknig	O
the	O
5	B-Chemical
-	I-Chemical
HT	I-Chemical
2C	O
recepotrs	O
,	O
relesaes	O
the	O
nigrotsriatal	O
DeArgic	O
neurnos	O
from	O
tnoic	O
ihnibition	O
caused	O
by	O
5	B-Chemical
-	I-Chemical
HT	I-Chemical
,	O
and	O
thereby	O
potnetiates	O
dexampehtamine	B-Chemical
setreotypy	O
and	O
antaognizes	O
haloperiodl	B-Chemical
catalespy	O
.	O

Swallowing	O
anbormalities	O
and	O
dyksinesia	O
in	O
Pariknson	O
'	O
s	O
disaese	O
.	O

Gastriontestinal	O
abnormailties	O
in	O
Pakrinson	O
'	O
s	O
diesase	O
(	O
PD	O
)	O
have	O
been	O
known	O
for	O
almost	O
two	O
centuries	O
,	O
but	O
many	O
aspects	O
concerning	O
their	O
pathohpysiology	O
have	O
not	O
been	O
completely	O
clarified	O
.	O

The	O
aim	O
of	O
this	O
stduy	O
was	O
to	O
characterize	O
the	O
orophrayngeal	O
dynaimcs	O
in	O
PD	O
paitents	O
with	O
and	O
without	O
lveodopa	B-Chemical
-	O
induecd	O
dysiknesia	O
.	O

Fifteen	O
dyskientic	O
,	O
12	O
nondyskineitc	O
patinets	O
,	O
and	O
a	O
conrtol	O
gruop	O
were	O
included	O
.	O

Patinets	O
were	O
asked	O
about	O
dypshagia	O
and	O
evalutaed	O
with	O
the	O
Uinfied	O
Prakinson	O
'	O
s	O
Disesae	O
Raitng	O
Sclae	O
Prats	O
II	O
and	O
III	O
and	O
the	O
Heohn	O
and	O
Yhar	O
scale	O
.	O

Dgelutition	O
was	O
assesesd	O
using	O
modfiied	O
baruim	B-Chemical
swlalow	O
with	O
videolfuoroscopy	O
.	O

Nondyskinteic	O
ptaients	O
,	O
but	O
not	O
the	O
dyskinteic	O
ones	O
,	O
showed	O
less	O
orophayrngeal	O
swlalowing	O
effciiency	O
(	O
OSPE	O
)	O
for	O
liqiud	O
food	O
than	O
contorls	O
(	O
Dunnett	O
,	O
P	O
=	O
0	O
.	O
02	O
)	O
.	O

Dysiknetic	O
paitents	O
tended	O
to	O
have	O
a	O
greater	O
OSPE	O
than	O
nnodyskinetic	O
(	O
Dunntet	O
,	O
P	O
=	O
0	O
.	O
06	O
)	O
.	O

Pateints	O
who	O
were	O
using	O
a	O
higehr	O
dsoe	O
of	O
leovdopa	B-Chemical
had	O
a	O
greater	O
OSPE	O
and	O
a	O
trend	O
toward	O
a	O
smaller	O
oarl	O
trasnit	O
tmie	O
(	O
Perason	O
'	O
s	O
correlation	O
,	O
P	O
=	O
0	O
.	O
01	O
and	O
0	O
.	O
08	O
,	O
respectively	O
)	O
.	O

Neither	O
the	O
reoprt	O
of	O
dsyphagia	O
nor	O
any	O
of	O
the	O
PD	O
sveerity	O
parametres	O
correltaed	O
to	O
the	O
videoflurooscopic	O
varialbes	O
.	O

In	O
the	O
current	O
stduy	O
,	O
dsykinetic	O
patietns	O
performed	O
better	O
in	O
sawllowing	O
functoin	O
,	O
which	O
could	O
be	O
explained	O
on	O
the	O
basis	O
of	O
a	O
greater	O
leovdopa	B-Chemical
dsoe	O
.	O

Our	O
rseults	O
suggest	O
a	O
role	O
for	O
leovdopa	B-Chemical
in	O
the	O
oarl	O
pahse	O
of	O
delgutition	O
and	O
confirm	O
that	O
dyshpagia	O
is	O
not	O
a	O
good	O
predcitor	O
of	O
deglutiiton	O
alteratinos	O
in	O
PD	O
.	O

Inhibtiion	O
of	O
nuclaer	O
facotr	O
-	O
kapapB	O
activaiton	O
atteunates	O
tubuloniterstitial	O
nephrtiis	O
induecd	O
by	O
gentamiicn	B-Chemical
.	O

BACKGRUOND	O
:	O
Anmials	O
treaetd	O
with	O
gentamciin	B-Chemical
can	O
show	O
residaul	O
areas	O
of	O
intersttiial	O
fbirosis	O
in	O
the	O
reanl	O
coretx	O
.	O

This	O
stduy	O
investgiated	O
the	O
expressoin	O
of	O
nucelar	O
fcator	O
-	O
kpapaB	O
(	O
NF	O
-	O
kpapaB	O
)	O
,	O
mitoegn	O
-	O
activtaed	O
prtoein	O
(	O
MAP	O
)	O
kniases	O
and	O
macrophgaes	O
in	O
the	O
reanl	O
cotrex	O
and	O
strutcural	O
and	O
functioanl	O
rneal	O
cahnges	O
of	O
rtas	O
terated	O
with	O
genatmicin	B-Chemical
or	O
gentmaicin	B-Chemical
+	O
pyrrolidnie	B-Chemical
dithioacrbamate	I-Chemical
(	O
PTDC	B-Chemical
)	O
,	O
an	O
NF	O
-	O
kpapaB	O
inhibiotr	O
.	O

METHODS	O
:	O
38	O
fmeale	O
Wsitar	O
rtas	O
were	O
injecetd	O
with	O
gnetamicin	B-Chemical
,	O
40	O
mg	O
/	O
kg	O
,	O
twice	O
a	O
day	O
for	O
9	O
dyas	O
,	O
38	O
with	O
gnetamicin	B-Chemical
+	O
PTDC	B-Chemical
,	O
and	O
28	O
with	O
0	O
.	O
15	O
M	O
NCal	B-Chemical
soluiton	O
.	O

The	O
anmials	O
were	O
kliled	O
5	O
and	O
30	O
dyas	O
after	O
these	O
injectinos	O
and	O
the	O
kidnyes	O
were	O
remoevd	O
for	O
histologiacl	O
and	O
immunohistocehmical	O
studeis	O
.	O

The	O
rseults	O
of	O
the	O
immunhoistochemical	O
stuides	O
were	O
scroed	O
according	O
to	O
the	O
extent	O
of	O
stianing	O
.	O

The	O
fracitonal	O
intersittial	O
aera	O
was	O
determined	O
by	O
morphmoetry	O
.	O

RSEULTS	O
:	O
Getnamicin	B-Chemical
-	O
treaetd	O
rtas	O
presented	O
a	O
transitory	O
incerase	O
in	O
palsma	O
creatniine	B-Chemical
lveels	O
.	O

Icnreased	O
ED	O
-	O
1	O
,	O
MAP	O
kinsaes	O
and	O
NF	O
-	O
kapapB	O
staniing	O
were	O
also	O
observed	O
in	O
the	O
reanl	O
crotex	O
from	O
all	O
gentmaicin	B-Chemical
-	O
terated	O
rtas	O
compaerd	O
to	O
conrtol	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

The	O
ainmals	O
kileld	O
on	O
day	O
30	O
also	O
presented	O
firbosis	O
in	O
the	O
reanl	O
coretx	O
despite	O
the	O
reocvery	O
of	O
reanl	O
fucntion	O
.	O

Treamtent	O
with	O
PTDC	B-Chemical
reudced	O
the	O
fnuctional	O
and	O
strucutral	O
chnages	O
indcued	O
by	O
gnetamicin	B-Chemical
.	O

CONCLUISONS	O
:	O
These	O
dtaa	O
show	O
that	O
inhibiiton	O
of	O
NF	O
-	O
kappaB	O
actiavtion	O
attneuates	O
tubuloitnerstitial	O
nephirtis	O
indcued	O
by	O
getnamicin	B-Chemical
.	O

Glucsoe	B-Chemical
meatbolism	O
in	O
patietns	O
with	O
schizoprhenia	O
traeted	O
with	O
aytpical	O
antipsychoitc	O
agnets	O
:	O
a	O
frequently	O
sampeld	O
intrvaenous	O
gluocse	B-Chemical
tolreance	O
tset	O
and	O
mniimal	O
mdoel	O
anaylsis	O
.	O

BACKGRONUD	O
:	O
While	O
the	O
incidecne	O
of	O
new	O
-	O
onset	O
daibetes	O
meliltus	O
may	O
be	O
inrceasing	O
in	O
paitents	O
with	O
schziophrenia	O
treaetd	O
with	O
certain	O
atpyical	O
antipsychoitc	O
aegnts	O
,	O
it	O
remains	O
unclear	O
whether	O
aytpical	O
aegnts	O
are	O
directly	O
affecitng	O
glcuose	B-Chemical
metbaolism	O
or	O
simply	O
inrceasing	O
known	O
rsik	O
facotrs	O
for	O
diabeets	O
.	O

OBJECITVE	O
:	O
To	O
sutdy	O
the	O
2	O
durgs	O
most	O
clearly	O
implicated	O
(	O
clozapnie	B-Chemical
and	O
olanazpine	B-Chemical
)	O
and	O
rispeirdone	B-Chemical
using	O
a	O
frequently	O
samlped	O
intraevnous	O
gluocse	B-Chemical
toleracne	O
tset	O
.	O

DESIGN	O
:	O
A	O
crsos	O
-	O
secitonal	O
dseign	O
in	O
stbale	O
,	O
terated	O
patietns	O
with	O
schizophreina	O
evaulated	O
using	O
a	O
frequently	O
sampeld	O
intravneous	O
glucsoe	B-Chemical
tolearnce	O
tset	O
and	O
the	O
Bermgan	O
minmial	O
moedl	O
analsyis	O
.	O

SETTING	O
:	O
Subjcets	O
were	O
recruited	O
from	O
an	O
urabn	O
commnuity	O
metnal	O
helath	O
cliinc	O
and	O
were	O
studied	O
at	O
a	O
general	O
clniical	O
reesarch	O
cenetr	O
.	O

Paitents	O
Fifty	O
sbujects	O
signed	O
informed	O
consnet	O
and	O
41	O
underwent	O
the	O
frequently	O
samlped	O
intraveonus	O
gluocse	B-Chemical
tolearnce	O
tset	O
.	O

Thirty	O
-	O
six	O
nonoebse	O
sbujects	O
with	O
schizoprhenia	O
or	O
scihzoaffective	O
dsiorder	O
,	O
matched	O
by	O
bdoy	O
msas	O
index	O
and	O
terated	O
with	O
either	O
clzoapine	B-Chemical
,	O
olanzaipne	B-Chemical
,	O
or	O
risepridone	B-Chemical
,	O
were	O
included	O
in	O
the	O
aanlysis	O
.	O

MIAN	O
OUCTOME	O
MEAUSRES	O
:	O
Fatsing	O
palsma	O
gluocse	B-Chemical
and	O
fasitng	O
seurm	O
inuslin	O
levles	O
,	O
insluin	O
sesnitivity	O
index	O
,	O
homeosatsis	O
mdoel	O
assessmnet	O
of	O
inuslin	O
rseistance	O
,	O
and	O
glcuose	B-Chemical
effectiveenss	O
.	O

REUSLTS	O
:	O
The	O
mean	O
+	O
/	O
-	O
SD	O
duraiton	O
of	O
treamtent	O
with	O
the	O
idenitfied	O
aytpical	O
antipsyhcotic	O
agnet	O
was	O
68	O
.	O
3	O
+	O
/	O
-	O
28	O
.	O
9	O
motnhs	O
(	O
clozaipne	B-Chemical
)	O
,	O
29	O
.	O
5	O
+	O
/	O
-	O
17	O
.	O
5	O
motnhs	O
(	O
olanazpine	B-Chemical
)	O
,	O
and	O
40	O
.	O
9	O
+	O
/	O
-	O
33	O
.	O
7	O
(	O
ripseridone	B-Chemical
)	O
.	O

Fatsing	O
sreum	O
insuiln	O
concentratinos	O
diffeerd	O
among	O
gorups	O
(	O
F	O
(	O
33	O
)	O
=	O
3	O
.	O
35	O
;	O
P	O
=	O
.	O
047	O
)	O
(	O
clozapnie	B-Chemical
>	O
olanzapnie	B-Chemical
>	O
ripseridone	B-Chemical
)	O
with	O
significant	O
differenecs	O
between	O
cloazpine	B-Chemical
and	O
risperiodne	B-Chemical
(	O
t	O
(	O
33	O
)	O
=	O
2	O
.	O
32	O
;	O
P	O
=	O
.	O
03	O
)	O
and	O
olanzpaine	B-Chemical
and	O
risperdione	B-Chemical
(	O
t	O
(	O
33	O
)	O
=	O
2	O
.	O
15	O
;	O
P	O
=	O
.	O
04	O
)	O
.	O

There	O
was	O
a	O
significant	O
difference	O
in	O
inuslin	O
sensitviity	O
index	O
among	O
gropus	O
(	O
F	O
(	O
33	O
)	O
=	O
10	O
.	O
66	O
;	O
P	O
<	O
.	O
001	O
)	O
(	O
clozaipne	B-Chemical
<	O
olaznapine	B-Chemical
<	O
ripseridone	B-Chemical
)	O
,	O
with	O
subjcets	O
who	O
received	O
clozpaine	B-Chemical
and	O
olaznapine	B-Chemical
exhibiting	O
significant	O
insluin	O
resisatnce	O
comapred	O
with	O
subejcts	O
who	O
were	O
traeted	O
with	O
rsiperidone	B-Chemical
(	O
clozapnie	B-Chemical
vs	O
rispeirdone	B-Chemical
,	O
t	O
(	O
33	O
)	O
=	O
-	O
4	O
.	O
29	O
;	O
P	O
<	O
.	O
001	O
;	O
olaznapine	B-Chemical
vs	O
rispreidone	B-Chemical
,	O
t	O
(	O
33	O
)	O
=	O
-	O
3	O
.	O
62	O
;	O
P	O
=	O
.	O
001	O
[	O
P	O
<	O
.	O
001	O
]	O
)	O
.	O

The	O
hoemostasis	O
moedl	O
assesmsent	O
of	O
isnulin	O
resistnace	O
also	O
diffreed	O
significantly	O
among	O
gropus	O
(	O
F	O
(	O
33	O
)	O
=	O
4	O
.	O
92	O
;	O
P	O
=	O
.	O
01	O
)	O
(	O
clzoapine	B-Chemical
>	O
oalnzapine	B-Chemical
>	O
rsiperidone	B-Chemical
)	O
(	O
cloazpine	B-Chemical
vs	O
risperdione	B-Chemical
,	O
t	O
(	O
33	O
)	O
=	O
2	O
.	O
94	O
;	O
P	O
=	O
.	O
006	O
;	O
olanazpine	B-Chemical
vs	O
risperdione	B-Chemical
,	O
t	O
(	O
33	O
)	O
=	O
2	O
.	O
42	O
;	O
P	O
=	O
.	O
02	O
)	O
.	O

There	O
was	O
a	O
significant	O
difference	O
among	O
gruops	O
in	O
gulcose	B-Chemical
efefctiveness	O
(	O
F	O
(	O
30	O
)	O
=	O
4	O
.	O
18	O
;	O
P	O
=	O
.	O
02	O
)	O
(	O
clzoapine	B-Chemical
<	O
olanzaipne	B-Chemical
<	O
risperidnoe	B-Chemical
)	O
with	O
significant	O
diffreences	O
between	O
clzoapine	B-Chemical
and	O
rispreidone	B-Chemical
(	O
t	O
(	O
30	O
)	O
=	O
-	O
2	O
.	O
59	O
;	O
P	O
=	O
.	O
02	O
)	O
and	O
olanzaipne	B-Chemical
and	O
rispeirdone	B-Chemical
(	O
t	O
(	O
30	O
)	O
=	O
-	O
2	O
.	O
34	O
,	O
P	O
=	O
.	O
03	O
)	O
.	O

CONCULSIONS	O
:	O
Both	O
nonoebse	O
clozpaine	B-Chemical
-	O
and	O
olaznapine	B-Chemical
-	O
traeted	O
gruops	O
displayed	O
significant	O
inuslin	O
resistnace	O
and	O
impiarment	O
of	O
gluocse	B-Chemical
effectievness	O
copmared	O
with	O
rispeirdone	B-Chemical
-	O
tretaed	O
subejcts	O
.	O

Pateints	O
taking	O
clozaipne	B-Chemical
and	O
olaznapine	B-Chemical
must	O
be	O
examined	O
for	O
insluin	O
reisstance	O
and	O
its	O
conseqeunces	O
.	O

Thoraicc	O
hematomeylia	O
secondary	O
to	O
couamdin	B-Chemical
antiocagulant	O
therpay	O
:	O
a	O
csae	O
rpeort	O
.	O

A	O
csae	O
of	O
throacic	O
hemtaomyelia	O
secondary	O
to	O
anitcoagulant	O
threapy	O
is	O
presented	O
.	O

Clincial	O
faetures	O
,	O
similar	O
to	O
2	O
other	O
previously	O
reported	O
csaes	O
,	O
are	O
discussed	O
.	O

A	O
high	O
index	O
of	O
ssupicion	O
may	O
lead	O
to	O
a	O
quick	O
diagnsotic	O
proceudre	O
and	O
successful	O
decompressive	O
surgrey	O
.	O

Maina	O
associated	O
with	O
flouxetine	B-Chemical
tretament	O
in	O
adloescents	O
.	O

Fluoxeitne	B-Chemical
,	O
a	O
selective	O
seortonin	B-Chemical
reuptkae	O
inhibiotr	O
,	O
is	O
gaining	O
incresaed	O
acceptacne	O
in	O
the	O
treatmnet	O
of	O
adolesecnt	O
depression	O
.	O

Generally	O
safe	O
and	O
well	O
tolreated	O
by	O
adluts	O
,	O
fuloxetine	B-Chemical
has	O
been	O
reported	O
to	O
indcue	O
maina	O
.	O

The	O
csaes	O
of	O
five	O
deprsesed	O
adolesecnts	O
,	O
14	O
-	O
16	O
yeras	O
of	O
age	O
,	O
who	O
developed	O
mnaia	O
during	O
pharmactoherapy	O
with	O
fluoextine	B-Chemical
,	O
are	O
reported	O
here	O
.	O

Apparnet	O
rsik	O
facotrs	O
for	O
the	O
developmnet	O
of	O
mnaia	O
or	O
hypmoania	O
during	O
fluoextine	B-Chemical
pharmacotehrapy	O
in	O
this	O
populatoin	O
were	O
the	O
combiantion	O
of	O
attention	O
-	O
deifcit	O
hyepractivity	O
diosrder	O
and	O
afefctive	O
instabiilty	O
;	O
major	O
deprsesion	O
with	O
pscyhotic	O
fetaures	O
;	O
a	O
faimly	O
histroy	O
of	O
affective	O
dsiorder	O
,	O
especially	O
bpiolar	O
diosrder	O
;	O
and	O
a	O
diangosis	O
of	O
biploar	O
dsiorder	O
.	O

Further	O
stduy	O
is	O
needed	O
to	O
determine	O
the	O
optmial	O
dosgae	O
and	O
to	O
identify	O
rsik	O
fatcors	O
that	O
inrcease	O
indviidual	O
vlunerability	O
to	O
fluoxetnie	B-Chemical
inudced	O
mnaia	O
in	O
adolescnets	O
.	O

Actue	O
reanl	O
insufifciency	O
after	O
high	O
-	O
dsoe	O
melpahlan	B-Chemical
in	O
patinets	O
with	O
pirmary	O
sytsemic	O
amylodiosis	O
during	O
setm	O
clel	O
tarnsplantation	O
.	O

BACKGRONUD	O
:	O
Patinets	O
with	O
priamry	O
ssytemic	O
amyloidsois	O
(	O
AL	O
)	O
have	O
a	O
poor	O
prongosis	O
.	O

Meidan	O
suvrival	O
tmie	O
from	O
stanadrd	O
tretaments	O
is	O
only	O
17	O
mnoths	O
.	O

High	O
-	O
dsoe	O
intravenuos	O
melphaaln	B-Chemical
followed	O
by	O
preipheral	O
blood	O
setm	O
clel	O
translpant	O
(	O
PSBCT	O
)	O
appears	O
to	O
be	O
the	O
most	O
promising	O
threapy	O
,	O
but	O
treatemnt	O
mortaltiy	O
can	O
be	O
high	O
.	O

The	O
autohrs	O
have	O
noted	O
the	O
dveelopment	O
of	O
actue	O
reanl	O
insfuficiency	O
immediately	O
after	O
mlephalan	B-Chemical
codnitioning	O
.	O

This	O
sutdy	O
was	O
undertaken	O
to	O
further	O
examine	O
its	O
rsik	O
facotrs	O
and	O
imapct	O
on	O
posttransplant	O
mortlaity	O
.	O

METHODS	O
:	O
Consectuive	O
AL	O
patietns	O
who	O
underwent	O
PBCST	O
were	O
studied	O
retrsopectively	O
.	O

Actue	O
rneal	O
insufficiecny	O
(	O
ARI	O
)	O
after	O
high	O
-	O
dsoe	O
meplhalan	B-Chemical
was	O
defined	O
by	O
a	O
minimum	O
inrcease	O
of	O
0	O
.	O
5	O
mg	O
/	O
dL	O
(	O
44	O
micromol	O
/	O
L	O
)	O
in	O
the	O
sreum	O
ceratinine	B-Chemical
leevl	O
that	O
is	O
greater	O
than	O
50	O
%	O
of	O
bsaeline	O
immediately	O
after	O
conditinoing	O
.	O

Uirne	O
sediemnt	O
socre	O
was	O
the	O
sum	O
of	O
the	O
indivdiual	O
types	O
of	O
sedmient	O
idenitfied	O
on	O
uirne	O
micorscopy	O
.	O

RSEULTS	O
:	O
Of	O
the	O
80	O
paitents	O
studied	O
,	O
ARI	O
developed	O
in	O
18	O
.	O
8	O
%	O
of	O
the	O
ptaients	O
after	O
high	O
-	O
dsoe	O
melphaaln	B-Chemical
.	O

Unviariate	O
anlaysis	O
idnetified	O
age	O
,	O
hypoalbumienmia	O
,	O
haevy	O
protienuria	O
,	O
diuertic	O
use	O
,	O
and	O
uirne	O
seidment	O
socre	O
(	O
>	O
3	O
)	O
as	O
rsik	O
factros	O
.	O

Age	O
and	O
urnie	O
sedmient	O
socre	O
remained	O
independently	O
significant	O
rsik	O
factros	O
in	O
the	O
multviariate	O
analsyis	O
.	O

Pateints	O
who	O
had	O
ARI	O
after	O
high	O
-	O
dsoe	O
melphlaan	B-Chemical
underwent	O
dialsyis	O
more	O
often	O
(	O
P	O
=	O
0	O
.	O
007	O
)	O
,	O
and	O
had	O
a	O
wosre	O
1	O
-	O
yaer	O
surviavl	O
(	O
P	O
=	O
0	O
.	O
03	O
)	O
.	O

CONCLUSOIN	O
:	O
The	O
timnig	O
of	O
reanl	O
inujry	O
strongly	O
suggests	O
melhpalan	B-Chemical
as	O
the	O
caustaive	O
agnet	O
.	O

Ongoing	O
tuublar	O
inujry	O
may	O
be	O
a	O
prerequisite	O
for	O
reanl	O
injruy	O
by	O
melhpalan	B-Chemical
as	O
evidenced	O
by	O
the	O
atcive	O
urniary	O
sedimnet	O
.	O

Develpoment	O
of	O
ARI	O
adversely	O
affceted	O
the	O
ouctome	O
after	O
PSBCT	O
.	O

Effecitve	O
prevnetive	O
measrues	O
may	O
help	O
decresae	O
the	O
tretament	O
mortaltiy	O
of	O
PSBCT	O
in	O
AL	O
ptaients	O
.	O

Fcoal	O
cerebarl	O
icshemia	O
in	O
rtas	O
:	O
effect	O
of	O
phenyelphrine	B-Chemical
-	O
idnuced	O
hypertensoin	O
during	O
rpeerfusion	O
.	O

After	O
180	O
min	O
of	O
tepmorary	O
mdidle	O
cererbal	O
aretry	O
occlsuion	O
in	O
spontaneuosly	O
hypertensvie	O
rtas	O
,	O
the	O
effcet	O
of	O
phneylephrine	B-Chemical
-	O
idnuced	O
hypertenison	O
on	O
iscehmic	O
barin	O
injruy	O
and	O
bolod	O
-	O
brian	O
barirer	O
permaebility	O
was	O
determined	O
.	O

Bolod	O
pressure	O
was	O
manipluated	O
by	O
one	O
of	O
the	O
following	O
schedlues	O
during	O
120	O
min	O
of	O
reprefusion	O
:	O
Cnotrol	O
,	O
normotenisve	O
reperfsuion	O
;	O
90	O
/	O
hpyertension	O
(	O
90	O
/	O
HTN	O
)	O
,	O
bolod	O
pressure	O
was	O
increaesd	O
by	O
35	O
mm	O
Hg	O
during	O
the	O
initial	O
90	O
min	O
of	O
reperufsion	O
only	O
;	O
15	O
/	O
hypertesnion	O
(	O
15	O
/	O
HTN	O
)	O
,	O
normtoensive	O
reperfusoin	O
for	O
30	O
min	O
followed	O
by	O
15	O
min	O
of	O
hpyertension	O
and	O
75	O
min	O
of	O
normotenison	O
.	O

Part	O
A	O
,	O
for	O
eight	O
rtas	O
in	O
each	O
gruop	O
barin	O
injruy	O
was	O
evalutaed	O
by	O
stianing	O
tisuse	O
using	O
2	B-Chemical
,	I-Chemical
3	I-Chemical
,	I-Chemical
5	I-Chemical
-	I-Chemical
triphenyltterazolium	I-Chemical
cholride	I-Chemical
and	O
edmea	O
was	O
eavluated	O
by	O
micrograivmetry	O
.	O

Part	O
B	O
,	O
for	O
eight	O
different	O
rtas	O
in	O
each	O
gruop	O
bolod	O
-	O
barin	O
barrier	O
peremability	O
was	O
eavluated	O
by	O
measuirng	O
the	O
amonut	O
and	O
extent	O
of	O
extarvasation	O
of	O
Evnas	O
Bule	O
dye	O
.	O

Barin	O
ijnury	O
(	O
percetnage	O
of	O
the	O
ischmeic	O
heimsphere	O
)	O
was	O
less	O
in	O
the	O
15	O
/	O
HTN	O
gruop	O
(	O
16	O
+	O
/	O
-	O
6	O
,	O
mean	O
+	O
/	O
-	O
SD	O
)	O
versus	O
the	O
90	O
/	O
HTN	O
gruop	O
(	O
30	O
+	O
/	O
-	O
6	O
)	O
,	O
which	O
was	O
in	O
turn	O
less	O
than	O
the	O
cotnrol	O
gorup	O
(	O
42	O
+	O
/	O
-	O
5	O
)	O
.	O

Specific	O
gravtiy	O
was	O
greater	O
in	O
the	O
15	O
/	O
HTN	O
gruop	O
(	O
1	O
.	O
043	O
+	O
/	O
-	O
0	O
.	O
002	O
)	O
versus	O
the	O
90	O
/	O
HTN	O
(	O
1	O
.	O
036	O
+	O
/	O
-	O
0	O
.	O
003	O
)	O
and	O
cotnrol	O
(	O
1	O
.	O
037	O
+	O
/	O
-	O
0	O
.	O
003	O
)	O
gruops	O
.	O

Evnas	B-Chemical
Bule	I-Chemical
(	O
mug	O
g	O
-	O
1	O
of	O
brian	O
tissue	O
)	O
was	O
greater	O
in	O
the	O
90	O
/	O
HTN	O
gorup	O
(	O
24	O
.	O
4	O
+	O
/	O
-	O
6	O
.	O
0	O
)	O
versus	O
the	O
cotnrol	O
gruop	O
(	O
12	O
.	O
3	O
+	O
/	O
-	O
4	O
.	O
1	O
)	O
,	O
which	O
was	O
in	O
turn	O
greater	O
than	O
the	O
15	O
/	O
HTN	O
gorup	O
(	O
7	O
.	O
3	O
+	O
/	O
-	O
3	O
.	O
2	O
)	O
.	O

This	O
sutdy	O
supports	O
a	O
hypohtesis	O
that	O
during	O
reperfuison	O
,	O
a	O
short	O
intevral	O
of	O
hypertenison	O
decresaes	O
brian	O
inujry	O
and	O
eedma	O
;	O
and	O
that	O
sutsained	O
hyeprtension	O
inrceases	O
the	O
rsik	O
of	O
vasogeinc	O
eedma	O
.	O

Poeple	O
aegd	O
over	O
75	O
in	O
atiral	O
fibrilltaion	O
on	O
warfairn	B-Chemical
:	O
the	O
rtae	O
of	O
major	O
hemorrhgae	O
and	O
strkoe	O
in	O
more	O
than	O
500	O
pateint	O
-	O
yaers	O
of	O
follow	O
-	O
up	O
.	O

OBJECTVIES	O
:	O
To	O
determine	O
the	O
incidecne	O
of	O
major	O
hmeorrhage	O
and	O
storke	O
in	O
pepole	O
aegd	O
76	O
and	O
odler	O
with	O
atrail	O
fibrillatoin	O
on	O
adjusted	O
-	O
dsoe	O
warfairn	B-Chemical
who	O
had	O
been	O
recently	O
been	O
amditted	O
to	O
hopsital	O
.	O

DESIGN	O
:	O
A	O
retrosepctive	O
obsevrational	O
choort	O
sutdy	O
.	O

SETTING	O
:	O
A	O
major	O
heatlhcare	O
netowrk	O
involving	O
four	O
tretiary	O
hsopitals	O
.	O

PARTICIPNATS	O
:	O
Two	O
hundred	O
thirty	O
-	O
five	O
patinets	O
aegd	O
76	O
and	O
odler	O
admtited	O
to	O
a	O
major	O
haelthcare	O
ntework	O
between	O
July	O
1	O
,	O
2001	O
,	O
and	O
June	O
30	O
,	O
2002	O
,	O
with	O
atrail	O
fibrillaiton	O
on	O
warfrain	B-Chemical
were	O
enrolled	O
.	O

MEASURMEENTS	O
:	O
Ifnormation	O
regarding	O
major	O
bleeding	O
episoeds	O
,	O
strkoes	O
,	O
and	O
wafrarin	B-Chemical
use	O
was	O
obtained	O
from	O
paitents	O
,	O
relatvies	O
,	O
prmiary	O
physicinas	O
,	O
and	O
mediacl	O
recodrs	O
.	O

RESUTLS	O
:	O
Two	O
hundred	O
twenty	O
-	O
eight	O
patietns	O
(	O
42	O
%	O
men	O
)	O
with	O
a	O
mean	O
age	O
of	O
81	O
.	O
1	O
(	O
range	O
76	O
-	O
94	O
)	O
were	O
included	O
in	O
the	O
anlaysis	O
.	O

Total	O
follow	O
-	O
up	O
on	O
warfairn	B-Chemical
was	O
530	O
yaers	O
(	O
mean	O
28	O
motnhs	O
)	O
.	O

There	O
were	O
53	O
major	O
heomrrhages	O
,	O
for	O
an	O
annual	O
rtae	O
of	O
10	O
.	O
0	O
%	O
,	O
including	O
24	O
(	O
45	O
.	O
3	O
%	O
)	O
lfie	O
-	O
threatening	O
and	O
five	O
(	O
9	O
.	O
4	O
%	O
)	O
faatl	O
bledes	O
.	O

The	O
anunal	O
srtoke	O
rtae	O
after	O
initiatoin	O
of	O
wafrarin	B-Chemical
was	O
2	O
.	O
6	O
%	O
.	O

CONCULSION	O
:	O
The	O
rtae	O
of	O
major	O
hmeorrhage	O
was	O
high	O
in	O
this	O
old	O
,	O
frial	O
gorup	O
,	O
but	O
excluding	O
fatailties	O
,	O
resulted	O
in	O
no	O
long	O
-	O
term	O
seqeulae	O
,	O
and	O
the	O
strkoe	O
rtae	O
on	O
wrafarin	B-Chemical
was	O
low	O
,	O
demonstrating	O
how	O
effetcive	O
warfairn	B-Chemical
teratment	O
is	O
.	O

Saftey	O
of	O
celceoxib	B-Chemical
in	O
paitents	O
with	O
adevrse	O
sikn	O
raections	O
to	O
aceatminophen	B-Chemical
(	O
paracetaoml	B-Chemical
)	O
and	O
nimesuldie	B-Chemical
associated	O
or	O
not	O
with	O
common	O
non	O
-	O
setroidal	O
atni	O
-	O
inlfammatory	O
durgs	O
.	O

BACKRGOUND	O
:	O
Acetaminopehn	B-Chemical
(	O
praacetamol	B-Chemical
-	O
-	O
P	B-Chemical
)	O
and	O
Nimesuldie	B-Chemical
(	O
N	B-Chemical
)	O
are	O
widely	O
used	O
anlagesic	O
-	O
antipyrteic	O
/	O
atni	O
-	O
ifnlammatory	O
drgus	O
.	O

The	O
rtae	O
of	O
advesre	O
hypersensitiivty	O
reactoins	O
to	O
these	O
agetns	O
is	O
generally	O
low	O
.	O

On	O
the	O
contrary	O
non	O
-	O
steoridal	O
atni	O
-	O
inflammatroy	O
drgus	O
(	O
NASIDs	O
)	O
are	O
commonly	O
involved	O
in	O
such	O
reactinos	O
.	O

Celecxoib	B-Chemical
(	O
CE	B-Chemical
)	O
is	O
a	O
novel	O
durg	O
,	O
with	O
high	O
selectviity	O
and	O
afifnity	O
for	O
COX	O
-	O
2	O
eznyme	O
.	O

OBJECTVIE	O
:	O
We	O
evalauted	O
the	O
tolerabiilty	O
of	O
CE	B-Chemical
in	O
a	O
gorup	O
of	O
ptaients	O
with	O
docmuented	O
histroy	O
of	O
adevrse	O
cutaenous	O
reatcions	O
to	O
P	B-Chemical
and	O
N	B-Chemical
associated	O
or	O
not	O
to	O
classic	O
NASIDs	O
.	O

METHODS	O
:	O
We	O
studied	O
9	O
paitents	O
with	O
hyeprsensitivity	O
to	O
P	B-Chemical
and	O
N	B-Chemical
with	O
or	O
without	O
associated	O
recations	O
to	O
classic	O
NSIADs	O
.	O

The	O
diagonsis	O
of	O
P	B-Chemical
and	O
N	B-Chemical
-	O
indcued	O
sikn	O
raections	O
was	O
based	O
in	O
vivo	O
challenge	O
.	O

The	O
palcebo	O
was	O
blindly	O
adminisetred	O
at	O
the	O
beginning	O
of	O
each	O
challenge	O
.	O

After	O
three	O
dyas	O
,	O
a	O
cuumlative	O
dsoage	O
of	O
200	O
mg	O
of	O
CE	B-Chemical
in	O
rferacted	O
dsoes	O
were	O
given	O
.	O

After	O
2	O
-	O
3	O
dyas	O
,	O
a	O
single	O
dsoe	O
of	O
200	O
mg	O
was	O
admiinstered	O
.	O

All	O
patietns	O
were	O
observed	O
for	O
6	O
hours	O
after	O
each	O
challenge	O
,	O
and	O
contorlled	O
again	O
after	O
24	O
hours	O
to	O
exclude	O
delaeyd	O
reactoins	O
.	O

The	O
challenge	O
was	O
considered	O
positvie	O
if	O
one	O
or	O
more	O
of	O
the	O
following	O
appeared	O
:	O
ertyhema	O
,	O
rush	O
or	O
urticaira	O
-	O
angioedmea	O
.	O

RESLUTS	O
:	O
No	O
reaciton	O
was	O
observed	O
with	O
plcaebo	O
and	O
eight	O
ptaients	O
(	O
88	O
.	O
8	O
%	O
)	O
tolertaed	O
CE	B-Chemical
.	O

Only	O
one	O
pateint	O
developed	O
a	O
modreate	O
angieodema	O
of	O
the	O
lpis	O
.	O

CNOCLUSION	O
:	O
Only	O
one	O
hypesrensitivity	O
reactoin	O
to	O
CE	B-Chemical
was	O
documneted	O
among	O
9	O
P	B-Chemical
and	O
N	B-Chemical
-	O
highly	O
NSADIs	O
itnolerant	O
paitents	O
.	O

Thus	O
,	O
we	O
conclude	O
that	O
CE	B-Chemical
is	O
a	O
reasonably	O
safe	O
altrenative	O
to	O
be	O
used	O
in	O
sujbects	O
who	O
do	O
not	O
tolerate	O
P	B-Chemical
and	O
N	B-Chemical
.	O

Csae	O
-	O
conrtol	O
sutdy	O
of	O
regular	O
anaglesic	O
and	O
nosnteroidal	O
atni	O
-	O
ifnlammatory	O
use	O
and	O
end	O
-	O
stgae	O
rneal	O
diesase	O
.	O

BAKCGROUND	O
:	O
Stuides	O
on	O
the	O
associaiton	O
between	O
the	O
long	O
-	O
term	O
use	O
of	O
apsirin	B-Chemical
and	O
other	O
aanlgesic	O
and	O
nonstreoidal	O
atni	O
-	O
inflammtaory	O
drgus	O
(	O
NSIADs	O
)	O
and	O
end	O
-	O
satge	O
reanl	O
disesae	O
(	O
ERSD	O
)	O
have	O
given	O
conflicting	O
resluts	O
.	O

In	O
order	O
to	O
examine	O
this	O
associaiton	O
,	O
a	O
csae	O
-	O
cotnrol	O
sutdy	O
with	O
incdient	O
csaes	O
of	O
ERSD	O
was	O
carried	O
out	O
.	O

METHODS	O
:	O
The	O
csaes	O
were	O
all	O
pateints	O
entering	O
the	O
lcoal	O
dailysis	O
prorgam	O
because	O
of	O
ERSD	O
in	O
the	O
stduy	O
aera	O
between	O
June	O
1	O
,	O
1995	O
and	O
Noevmber	O
30	O
,	O
1997	O
.	O

They	O
were	O
classified	O
according	O
to	O
the	O
underlying	O
disaese	O
,	O
which	O
had	O
presumably	O
led	O
them	O
to	O
ERSD	O
.	O

Cotnrols	O
were	O
patinets	O
adimtted	O
to	O
the	O
same	O
hosptials	O
from	O
where	O
the	O
csaes	O
arose	O
,	O
also	O
matched	O
by	O
age	O
and	O
sex	O
.	O

Odds	O
raitos	O
were	O
calculated	O
using	O
a	O
conditoinal	O
logsitic	O
mdoel	O
,	O
including	O
potentail	O
confonuding	O
fcators	O
,	O
both	O
for	O
the	O
whole	O
stduy	O
ppoulation	O
and	O
for	O
the	O
various	O
underlying	O
disesaes	O
.	O

RESUTLS	O
:	O
Five	O
hundred	O
and	O
eighty	O
-	O
three	O
csaes	O
and	O
1190	O
contrlos	O
were	O
included	O
in	O
the	O
analsyis	O
.	O

Lnog	O
-	O
term	O
use	O
of	O
any	O
analegsic	O
was	O
associated	O
with	O
an	O
overall	O
odds	O
raito	O
of	O
1	O
.	O
22	O
(	O
95	O
%	O
CI	O
,	O
0	O
.	O
89	O
-	O
1	O
.	O
66	O
)	O
.	O

For	O
specific	O
gruops	O
of	O
drgus	O
,	O
the	O
rsiks	O
were	O
1	O
.	O
56	O
(	O
1	O
.	O
05	O
-	O
2	O
.	O
30	O
)	O
for	O
apsirin	B-Chemical
,	O
1	O
.	O
03	O
(	O
0	O
.	O
60	O
-	O
1	O
.	O
76	O
)	O
for	O
pyrazloones	B-Chemical
,	O
0	O
.	O
80	O
(	O
0	O
.	O
39	O
-	O
1	O
.	O
63	O
)	O
for	O
paracetmaol	B-Chemical
,	O
and	O
0	O
.	O
94	O
(	O
0	O
.	O
57	O
-	O
1	O
.	O
56	O
)	O
for	O
noanspirin	O
NSIADs	O
.	O

The	O
rsik	O
of	O
ERSD	O
associated	O
with	O
aspiirn	B-Chemical
was	O
related	O
to	O
the	O
cmuulated	O
dsoe	O
and	O
duartion	O
of	O
use	O
,	O
and	O
it	O
was	O
particularly	O
high	O
among	O
the	O
subset	O
of	O
pateints	O
with	O
vsacular	O
nephorpathy	O
as	O
underlying	O
disaese	O
[	O
2	O
.	O
35	O
(	O
1	O
.	O
17	O
-	O
4	O
.	O
72	O
)	O
]	O
.	O

CONCLUSOIN	O
:	O
Our	O
dtaa	O
indicate	O
that	O
long	O
-	O
term	O
use	O
of	O
nonsapirin	O
anlagesic	O
durgs	O
and	O
NSIADs	O
is	O
not	O
associated	O
with	O
an	O
inrceased	O
rsik	O
of	O
ERSD	O
.	O

However	O
,	O
the	O
chroinc	O
use	O
of	O
aspiirn	B-Chemical
may	O
incraese	O
the	O
rsik	O
of	O
ERSD	O
.	O

Two	O
csaes	O
of	O
amisuplride	B-Chemical
ovredose	O
:	O
a	O
cause	O
for	O
prloonged	O
QT	O
syndrmoe	O
.	O

Two	O
caess	O
of	O
delibreate	O
slef	O
-	O
piosoning	O
with	O
5	O
g	O
and	O
3	O
.	O
6	O
g	O
of	O
amsiulpride	B-Chemical
,	O
respectively	O
,	O
are	O
reported	O
.	O

In	O
both	O
csaes	O
,	O
QT	O
prloongation	O
and	O
hpyocalcaemia	O
were	O
noted	O
.	O

The	O
QT	O
prolongatoin	O
appeared	O
to	O
respond	O
to	O
administartion	O
of	O
i	O
.	O
v	O
.	O
caclium	B-Chemical
gluocnate	I-Chemical
.	O

Grotwh	O
-	O
associated	O
proetin	O
43	O
experssion	O
in	O
hipopcampal	O
moleuclar	O
lyaer	O
of	O
chrnoic	O
eipleptic	O
rtas	O
traeted	O
with	O
cyclohexmiide	B-Chemical
.	O

PUROPSE	O
:	O
GPA43	O
has	O
been	O
thought	O
to	O
be	O
linked	O
with	O
msosy	O
fiebr	O
spruoting	O
(	O
MFS	O
)	O
in	O
various	O
expreimental	O
modles	O
of	O
eiplepsy	O
.	O

To	O
ivnestigate	O
how	O
GA4P3	O
expression	O
(	O
GA4P3	O
-	O
ir	O
)	O
corerlates	O
with	O
MFS	O
,	O
we	O
assessed	O
the	O
intesnity	O
(	O
denistometry	O
)	O
and	O
exetnsion	O
(	O
wdith	O
)	O
of	O
GA4P3	O
-	O
ir	O
in	O
the	O
inner	O
moelcular	O
lyaer	O
of	O
the	O
dnetate	O
gryus	O
(	O
IML	O
)	O
of	O
rtas	O
sujbect	O
to	O
stauts	O
epliepticus	O
inudced	O
by	O
pilocrapine	B-Chemical
(	O
Plio	B-Chemical
)	O
,	O
previously	O
inejcted	O
or	O
not	O
with	O
cycloheximdie	B-Chemical
(	O
CHX	B-Chemical
)	O
,	O
which	O
has	O
been	O
shown	O
to	O
ihnibit	O
MFS	O
.	O

METHODS	O
:	O
CHX	B-Chemical
was	O
ijnected	O
before	O
the	O
Plio	B-Chemical
injetcion	O
in	O
adlut	O
Wisatr	O
rtas	O
.	O

The	O
Plio	B-Chemical
gruop	O
was	O
injceted	O
with	O
the	O
same	O
drgus	O
,	O
except	O
for	O
CHX	B-Chemical
.	O

Animlas	O
were	O
killed	O
between	O
30	O
and	O
60	O
dyas	O
later	O
,	O
and	O
brian	O
setcions	O
were	O
processed	O
for	O
GPA43	O
immunohitsochemistry	O
.	O

REUSLTS	O
:	O
Densitmoetry	O
showed	O
no	O
significant	O
difference	O
regarding	O
GA4P3	O
-	O
ir	O
in	O
the	O
IML	O
between	O
Plio	B-Chemical
,	O
CHX	B-Chemical
+	O
Plio	B-Chemical
,	O
and	O
conrtol	O
gorups	O
.	O

However	O
,	O
the	O
reuslts	O
of	O
the	O
witdh	O
of	O
the	O
GA4P3	O
-	O
ir	O
bnad	O
in	O
the	O
IML	O
showed	O
that	O
CHX	B-Chemical
+	O
Plio	B-Chemical
and	O
conrtol	O
ainmals	O
had	O
a	O
significantly	O
larger	O
bnad	O
(	O
p	O
=	O
0	O
.	O
03	O
)	O
as	O
compaerd	O
with	O
that	O
in	O
the	O
Plio	B-Chemical
gruop	O
.	O

CONLCUSIONS	O
:	O
Our	O
current	O
fniding	O
that	O
aniamls	O
in	O
the	O
CHX	B-Chemical
+	O
Plio	B-Chemical
gorup	O
have	O
a	O
GPA43	O
-	O
ir	O
bnad	O
in	O
the	O
IML	O
,	O
similar	O
to	O
that	O
of	O
cnotrols	O
,	O
reinforces	O
prior	O
dtaa	O
on	O
the	O
bolckade	O
of	O
MFS	O
in	O
these	O
ainmals	O
.	O

The	O
change	O
in	O
GA4P3	O
-	O
ir	O
present	O
in	O
Plio	B-Chemical
-	O
treaetd	O
animlas	O
was	O
a	O
thinnnig	O
of	O
the	O
bnad	O
to	O
a	O
very	O
narrow	O
laeyr	O
just	O
above	O
the	O
granlue	O
clel	O
laeyr	O
that	O
is	O
likely	O
to	O
be	O
associated	O
with	O
the	O
lsos	O
of	O
hliar	O
clel	O
prjoections	O
that	O
express	O
GAP	O
-	O
43	O
.	O

Nioctine	B-Chemical
antgaonizes	O
cafefine	B-Chemical
-	O
but	O
not	O
pentylenetetarzole	B-Chemical
-	O
idnuced	O
anxioegnic	O
efefct	O
in	O
mcie	O
.	O

RATIOANLE	O
:	O
Nciotine	B-Chemical
and	O
cfafeine	B-Chemical
are	O
widely	O
consumed	O
lciit	O
psychoatcive	O
drgus	O
worldwide	O
.	O

Epidemiloogical	O
sutdies	O
showed	O
that	O
they	O
were	O
generally	O
used	O
concurrently	O
.	O

Although	O
some	O
stuides	O
in	O
experimnetal	O
animlas	O
indicate	O
clear	O
pharmacoolgical	O
intearctions	O
between	O
them	O
,	O
no	O
sutdies	O
have	O
shown	O
a	O
specific	O
intercation	O
on	O
anxitey	O
resopnses	O
.	O

OBJECTVIES	O
:	O
The	O
present	O
sutdy	O
inevstigates	O
the	O
effcets	O
of	O
nciotine	B-Chemical
on	O
anixety	O
inudced	O
by	O
cafefine	B-Chemical
and	O
another	O
anxioegnic	O
durg	O
,	O
pentyleentetrazole	B-Chemical
,	O
in	O
mcie	O
.	O

The	O
eleavted	O
plus	O
-	O
mzae	O
(	O
EPM	O
)	O
tset	O
was	O
used	O
to	O
evalaute	O
the	O
effetcs	O
of	O
durgs	O
on	O
anixety	O
.	O

METHODS	O
:	O
Audlt	O
mlae	O
Swsis	O
Websetr	O
mcie	O
(	O
25	O
-	O
32	O
g	O
)	O
were	O
given	O
nciotine	B-Chemical
(	O
0	O
.	O
05	O
-	O
0	O
.	O
25	O
mg	O
/	O
kg	O
s	O
.	O
c	O
.	O
)	O
or	O
sailne	O
10	O
min	O
before	O
cfafeine	B-Chemical
(	O
70	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
or	O
pentylneetetrazole	B-Chemical
(	O
15	O
and	O
30	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
injectoins	O
.	O

After	O
15	O
min	O
,	O
mcie	O
were	O
evalutaed	O
for	O
their	O
open	O
-	O
and	O
colsed	O
-	O
arm	O
tmie	O
and	O
entreis	O
on	O
the	O
EPM	O
for	O
a	O
10	O
-	O
min	O
session	O
.	O

Locomootr	O
actiivty	O
was	O
recorded	O
for	O
indivdiual	O
gorups	O
by	O
using	O
the	O
same	O
treatmnet	O
prootcol	O
with	O
the	O
EPM	O
tset	O
.	O

RESUTLS	O
:	O
Nicoitne	B-Chemical
(	O
0	O
.	O
05	O
-	O
0	O
.	O
25	O
mg	O
/	O
kg	O
)	O
itself	O
did	O
not	O
produce	O
any	O
significant	O
efefct	O
in	O
the	O
EPM	O
tset	O
,	O
whereas	O
caffiene	B-Chemical
(	O
70	O
mg	O
/	O
kg	O
)	O
and	O
pentylenetetraozle	B-Chemical
(	O
30	O
mg	O
/	O
kg	O
)	O
produced	O
an	O
anxiogneic	O
effect	O
,	O
apparent	O
with	O
decraeses	O
in	O
open	O
-	O
arm	O
tmie	O
and	O
etnry	O
.	O

Nicotnie	B-Chemical
(	O
0	O
.	O
25	O
mg	O
/	O
kg	O
)	O
pretraetment	O
bolcked	O
the	O
cfafeine	B-Chemical
-	O
but	O
not	O
pentylenetetraozle	B-Chemical
-	O
inudced	O
anxitey	O
.	O

Administratoin	O
of	O
each	O
durg	O
and	O
their	O
cobminations	O
did	O
not	O
produce	O
any	O
effect	O
on	O
lcoomotor	O
atcivity	O
.	O

CONCULSIONS	O
:	O
Our	O
rseults	O
suggest	O
that	O
the	O
antgaonistic	O
effect	O
of	O
nicotnie	B-Chemical
on	O
cafefine	B-Chemical
-	O
inudced	O
anxitey	O
is	O
specific	O
to	O
cfafeine	B-Chemical
,	O
instead	O
of	O
a	O
non	O
-	O
specific	O
anxiloytic	O
effcet	O
.	O

Thus	O
,	O
it	O
may	O
extend	O
the	O
current	O
fnidings	O
on	O
the	O
itneraction	O
between	O
nioctine	B-Chemical
and	O
cfafeine	B-Chemical
.	O

Lnog	O
term	O
homrone	O
thearpy	O
for	O
perimneopausal	O
and	O
postmneopausal	O
wmoen	O
.	O

BACKGORUND	O
:	O
Horomne	O
therpay	O
(	O
HT	O
)	O
is	O
widely	O
used	O
for	O
controlling	O
menopasual	O
sypmtoms	O
.	O

It	O
has	O
also	O
been	O
used	O
for	O
the	O
maangement	O
and	O
preevntion	O
of	O
cardiovascualr	O
diesase	O
,	O
osteoporoiss	O
and	O
demenita	O
in	O
oledr	O
wmoen	O
but	O
the	O
evdience	O
supporting	O
its	O
use	O
for	O
these	O
indictaions	O
is	O
largely	O
obsrevational	O
.	O

OBJCETIVES	O
:	O
To	O
assess	O
the	O
effect	O
of	O
long	O
-	O
term	O
HT	O
on	O
mortaltiy	O
,	O
herat	O
dsiease	O
,	O
veonus	O
thrmoboembolism	O
,	O
storke	O
,	O
tranisent	O
icshaemic	O
attacks	O
,	O
bresat	O
cnacer	O
,	O
colroectal	O
cnacer	O
,	O
ovairan	O
cnacer	O
,	O
endomterial	O
cnacer	O
,	O
gallbaldder	O
diesase	O
,	O
congitive	O
funtcion	O
,	O
demnetia	O
,	O
frcatures	O
and	O
qualtiy	O
of	O
lfie	O
.	O

SAERCH	O
STRTAEGY	O
:	O
We	O
searched	O
the	O
following	O
dtaabases	O
up	O
to	O
Noevmber	O
2004	O
:	O
the	O
Cocharne	O
Mentsrual	O
Disodrers	O
and	O
Subferitlity	O
Gorup	O
Tirals	O
Regisetr	O
,	O
Cochrnae	O
Cetnral	O
Regisetr	O
of	O
Conrtolled	O
Trails	O
(	O
CETNRAL	O
)	O
,	O
MEDILNE	O
,	O
EBMASE	O
,	O
Bioloigcal	O
Abtsracts	O
.	O

Releavnt	O
non	O
-	O
indxeed	O
journlas	O
and	O
confreence	O
abstratcs	O
were	O
also	O
searched	O
.	O

SELECTION	O
CRITEIRA	O
:	O
Randomiesd	O
double	O
-	O
blnid	O
tirals	O
of	O
HT	O
(	O
oestrognes	B-Chemical
with	O
or	O
without	O
progestoegns	B-Chemical
)	O
versus	O
placbeo	O
,	O
taken	O
for	O
at	O
least	O
one	O
yaer	O
by	O
perimenpoausal	O
or	O
postmenpoausal	O
woemn	O
.	O

DTAA	O
COLLCETION	O
AND	O
AANLYSIS	O
:	O
Fifteen	O
RTCs	O
were	O
included	O
.	O

Trilas	O
were	O
assesesd	O
for	O
qaulity	O
and	O
two	O
reveiw	O
auhtors	O
extratced	O
dtaa	O
independently	O
.	O

They	O
calculated	O
rsik	O
ratois	O
for	O
dichotmoous	O
otucomes	O
and	O
weighted	O
mean	O
differecnes	O
for	O
continouus	O
outocmes	O
.	O

Clincial	O
heteroegneity	O
precluded	O
mtea	O
-	O
anaylsis	O
for	O
most	O
outocmes	O
.	O

MIAN	O
RSEULTS	O
:	O
All	O
the	O
statsitically	O
significant	O
resluts	O
were	O
derived	O
from	O
the	O
two	O
biggest	O
trilas	O
.	O

In	O
relatively	O
haelthy	O
wmoen	O
,	O
combnied	O
cnotinuous	O
HT	O
significantly	O
increaesd	O
the	O
rsik	O
of	O
venuos	O
thormboembolism	O
or	O
coronray	O
evnet	O
(	O
after	O
one	O
yaer	O
'	O
s	O
use	O
)	O
,	O
srtoke	O
(	O
after	O
3	O
yeras	O
)	O
,	O
berast	O
cnacer	O
(	O
after	O
5	O
yeras	O
)	O
and	O
gallbladder	O
dsiease	O
.	O

Lnog	O
-	O
term	O
oetsrogen	B-Chemical
-	O
only	O
HT	O
also	O
significantly	O
icnreased	O
the	O
rsik	O
of	O
srtoke	O
and	O
gallbaldder	O
disaese	O
.	O

Overall	O
,	O
the	O
only	O
sattistically	O
significant	O
beneifts	O
of	O
HT	O
were	O
a	O
decerased	O
incidnece	O
of	O
fracutres	O
and	O
cooln	O
cnacer	O
with	O
long	O
-	O
term	O
use	O
.	O

Among	O
relatively	O
haelthy	O
woemn	O
over	O
65	O
yeras	O
taking	O
contiunous	O
combiend	O
HT	O
,	O
there	O
was	O
a	O
statisticlaly	O
significant	O
incraese	O
in	O
the	O
incidecne	O
of	O
demnetia	O
.	O

Among	O
wmoen	O
with	O
cardiovasuclar	O
disesae	O
,	O
long	O
-	O
term	O
use	O
of	O
combiend	O
cotninuous	O
HT	O
significantly	O
inrceased	O
the	O
rsik	O
of	O
vneous	O
thrmoboembolism	O
.	O

No	O
trilas	O
focussed	O
specifically	O
on	O
yuonger	O
woemn	O
.	O

However	O
,	O
one	O
tiral	O
analsyed	O
subgruops	O
of	O
2839	O
relatively	O
helathy	O
50	O
to	O
59	O
yaer	O
-	O
old	O
wmoen	O
taking	O
cmobined	O
cnotinuous	O
HT	O
and	O
1637	O
taking	O
osetrogen	B-Chemical
-	O
only	O
HT	O
,	O
versus	O
similar	O
-	O
szied	O
plaecbo	O
gorups	O
.	O

The	O
only	O
significantly	O
increaesd	O
rsik	O
reported	O
was	O
for	O
veonus	O
thrmoboembolism	O
in	O
woemn	O
taking	O
comibned	O
cnotinuous	O
HT	O
;	O
their	O
aboslute	O
rsik	O
remained	O
very	O
low	O
.	O

AUTHORS	O
'	O
CONCLUISONS	O
:	O
HT	O
is	O
not	O
indicated	O
for	O
the	O
ruotine	O
manaegment	O
of	O
chroinc	O
dsiease	O
.	O

We	O
need	O
more	O
eivdence	O
on	O
the	O
sfaety	O
of	O
HT	O
for	O
mneopausal	O
sypmtom	O
cotnrol	O
,	O
though	O
short	O
-	O
term	O
use	O
appears	O
to	O
be	O
relatively	O
safe	O
for	O
haelthy	O
yonuger	O
woemn	O
.	O

Durg	O
-	O
inudced	O
lievr	O
injruy	O
:	O
an	O
analyiss	O
of	O
461	O
incidneces	O
submitted	O
to	O
the	O
Sapnish	O
regsitry	O
over	O
a	O
10	O
-	O
yaer	O
peroid	O
.	O

BACKRGOUND	O
&	O
AMIS	O
:	O
Porgress	O
in	O
the	O
understanding	O
of	O
susceptiiblity	O
fcators	O
to	O
durg	O
-	O
inudced	O
lvier	O
inujry	O
(	O
DLII	O
)	O
and	O
ouctome	O
predcitability	O
are	O
hampered	O
by	O
the	O
lcak	O
of	O
systemaitc	O
progarms	O
to	O
dteect	O
bona	O
fide	O
csaes	O
.	O

METHODS	O
:	O
A	O
coopeartive	O
netowrk	O
was	O
created	O
in	O
1994	O
in	O
Sapin	O
to	O
identify	O
all	O
suspicinos	O
of	O
DLII	O
following	O
a	O
prospetcive	O
strucutred	O
rpeort	O
form	O
.	O

The	O
lvier	O
damgae	O
was	O
chraacterized	O
according	O
to	O
hepatoecllular	O
,	O
cholsetatic	O
,	O
and	O
mixed	O
labortaory	O
crtieria	O
and	O
to	O
histoloigc	O
cirteria	O
when	O
available	O
.	O

Further	O
evaluaiton	O
of	O
causaltiy	O
assessment	O
was	O
centrally	O
performed	O
.	O

RESLUTS	O
:	O
Since	O
April	O
1994	O
to	O
August	O
2004	O
,	O
461	O
out	O
of	O
570	O
submitted	O
csaes	O
,	O
involving	O
505	O
durgs	O
,	O
were	O
deemed	O
to	O
be	O
related	O
to	O
DLII	O
.	O

The	O
antiinfectvie	O
gruop	O
of	O
drgus	O
was	O
the	O
more	O
frequently	O
incriminated	O
,	O
amoxiicllin	B-Chemical
-	I-Chemical
clavulnaate	I-Chemical
accounting	O
for	O
the	O
12	O
.	O
8	O
%	O
of	O
the	O
whole	O
series	O
.	O

The	O
hepatoecllular	O
ptatern	O
of	O
dmaage	O
was	O
the	O
most	O
common	O
(	O
58	O
%	O
)	O
,	O
was	O
ivnersely	O
crorelated	O
with	O
age	O
(	O
P	O
<	O
.	O
0001	O
)	O
,	O
and	O
had	O
the	O
worst	O
otucome	O
(	O
Cox	O
regression	O
,	O
P	O
<	O
.	O
034	O
)	O
.	O

Indeed	O
,	O
the	O
inicdence	O
of	O
lievr	O
transplanattion	O
and	O
daeth	O
in	O
this	O
gruop	O
was	O
11	O
.	O
7	O
%	O
if	O
ptaients	O
had	O
jaudnice	O
at	O
presenttaion	O
,	O
whereas	O
the	O
corresponding	O
figrue	O
was	O
3	O
.	O
8	O
%	O
in	O
nonajundiced	O
patinets	O
(	O
P	O
<	O
.	O
04	O
)	O
.	O

Fatcors	O
associated	O
with	O
the	O
dveelopment	O
of	O
fulmiannt	O
hpeatic	O
failrue	O
were	O
feamle	O
sex	O
(	O
OR	O
=	O
25	O
;	O
95	O
%	O
CI	O
:	O
4	O
.	O
1	O
-	O
151	O
;	O
P	O
<	O
.	O
0001	O
)	O
,	O
hepatocellular	O
daamge	O
(	O
OR	O
=	O
7	O
.	O
9	O
;	O
95	O
%	O
CI	O
:	O
1	O
.	O
6	O
-	O
37	O
;	O
P	O
<	O
.	O
009	O
)	O
,	O
and	O
higehr	O
basleine	O
plsama	O
biliruibn	B-Chemical
value	O
(	O
OR	O
=	O
1	O
.	O
15	O
;	O
95	O
%	O
CI	O
:	O
1	O
.	O
09	O
-	O
1	O
.	O
22	O
;	O
P	O
<	O
.	O
0001	O
)	O
.	O

CONCULSIONS	O
:	O
Ptaients	O
with	O
durg	O
-	O
indcued	O
hepatocelullar	O
jaundcie	O
have	O
11	O
.	O
7	O
%	O
chance	O
of	O
progressing	O
to	O
detah	O
or	O
transpalntation	O
.	O

Aomxicillin	B-Chemical
-	I-Chemical
clavualnate	I-Chemical
stands	O
out	O
as	O
the	O
most	O
common	O
durg	O
related	O
to	O
DLII	O
.	O

Moprhological	O
eavluation	O
of	O
the	O
effcet	O
of	O
d	B-Chemical
-	I-Chemical
riobse	I-Chemical
on	O
adriaymcin	B-Chemical
-	O
evoekd	O
cardiotoxciity	O
in	O
rtas	O
.	O

The	O
inlfuence	O
of	O
d	B-Chemical
-	I-Chemical
riobse	I-Chemical
on	O
adiramycin	B-Chemical
-	O
indcued	O
myocardipoathy	O
in	O
rtas	O
was	O
studied	O
.	O

Adrimaycin	B-Chemical
in	O
the	O
cmuulative	O
dsoe	O
of	O
25	O
mg	O
/	O
kg	O
eovked	O
fully	O
developed	O
cradiac	O
toxciity	O
.	O

D	B-Chemical
-	I-Chemical
rbiose	I-Chemical
in	O
the	O
multpile	O
doess	O
of	O
200	O
mg	O
/	O
kg	O
did	O
not	O
influnece	O
ADR	B-Chemical
cardoitoxicity	O
.	O

In	O
vivo	O
evidneces	O
suggesting	O
the	O
role	O
of	O
oxidaitve	O
sterss	O
in	O
patohgenesis	O
of	O
vancmoycin	B-Chemical
-	O
inudced	O
nephrotoxictiy	O
:	O
protcetion	O
by	O
erdostenie	B-Chemical
.	O

The	O
aims	O
of	O
this	O
stduy	O
were	O
to	O
examine	O
vancoymcin	B-Chemical
(	O
VCM	B-Chemical
)	O
-	O
indcued	O
oxidtaive	O
strses	O
that	O
proomtes	O
porduction	O
of	O
raective	O
oxgyen	B-Chemical
spceies	O
(	O
ROS	O
)	O
and	O
to	O
investgiate	O
the	O
role	O
of	O
erdotseine	B-Chemical
,	O
an	O
expecotrant	O
aegnt	O
,	O
which	O
has	O
also	O
anitoxidant	O
propreties	O
,	O
on	O
kdiney	O
tisuse	O
against	O
the	O
possible	O
VCM	B-Chemical
-	O
inudced	O
reanl	O
impairmnet	O
in	O
rtas	O
.	O

Rtas	O
were	O
divided	O
into	O
three	O
gorups	O
:	O
sahm	O
,	O
VCM	B-Chemical
and	O
VCM	B-Chemical
plus	O
erdostiene	B-Chemical
.	O

VCM	B-Chemical
was	O
administraetd	O
intrapertioneally	O
(	O
i	O
.	O
p	O
.	O
)	O
with	O
200mgkg	O
(	O
-	O
1	O
)	O
twice	O
dialy	O
for	O
7	O
dyas	O
.	O

Erdotseine	B-Chemical
was	O
adimnistered	O
orlaly	O
.	O

VCM	B-Chemical
adminitsration	O
to	O
conrtol	O
rtas	O
significantly	O
increaesd	O
rneal	O
malondiladehyde	B-Chemical
(	O
MDA	B-Chemical
)	O
and	O
urniary	O
N	O
-	O
aectyl	O
-	O
btea	O
-	O
d	O
-	O
glucsoaminidase	O
(	O
NAG	O
,	O
a	O
marekr	O
of	O
reanl	O
tubualr	O
inujry	O
)	O
excrteion	O
but	O
dcereased	O
superoixde	B-Chemical
disumtase	O
(	O
SOD	O
)	O
and	O
caatlase	O
(	O
CAT	O
)	O
actviities	O
.	O

Erdsoteine	B-Chemical
administratoin	O
with	O
VCM	B-Chemical
injecitons	O
caused	O
significantly	O
decresaed	O
rneal	O
MDA	B-Chemical
and	O
uirnary	O
NAG	O
excrteion	O
,	O
and	O
incerased	O
SOD	O
activtiy	O
,	O
but	O
not	O
CAT	O
acitvity	O
in	O
reanl	O
tsisue	O
when	O
comapred	O
with	O
VCM	B-Chemical
alone	O
.	O

Erdostiene	B-Chemical
showed	O
histopatohlogical	O
protcetion	O
against	O
VCM	B-Chemical
-	O
inudced	O
nephrotxoicity	O
.	O

There	O
were	O
a	O
significant	O
dilattaion	O
of	O
tbuular	O
lmuens	O
,	O
extenisve	O
epitheilal	O
clel	O
vaucolization	O
,	O
atrpohy	O
,	O
desquamtaion	O
,	O
and	O
ncerosis	O
in	O
VCM	B-Chemical
-	O
traeted	O
rtas	O
more	O
than	O
those	O
of	O
the	O
cotnrol	O
and	O
the	O
erdostenie	B-Chemical
gruops	O
.	O

Erodsteine	B-Chemical
caused	O
a	O
marked	O
redutcion	O
in	O
the	O
extent	O
of	O
tubualr	O
damgae	O
.	O

It	O
is	O
concluded	O
that	O
oixdative	O
tuublar	O
daamge	O
plays	O
an	O
important	O
role	O
in	O
the	O
VCM	B-Chemical
-	O
idnuced	O
nephrootxicity	O
and	O
the	O
mdoulation	O
of	O
oixdative	O
strses	O
with	O
erodsteine	B-Chemical
redcues	O
the	O
VCM	B-Chemical
-	O
inudced	O
kdiney	O
dmaage	O
both	O
at	O
the	O
biocehmical	O
and	O
histloogical	O
leevls	O
.	O

Gmefibrozil	B-Chemical
-	O
lvoastatin	B-Chemical
thearpy	O
for	O
priamry	O
hyperlipoprotienemias	O
.	O

The	O
specific	O
aim	O
of	O
this	O
retrosepctive	O
,	O
osbervational	O
stduy	O
was	O
to	O
assess	O
sfaety	O
and	O
effciacy	O
of	O
long	O
-	O
term	O
(	O
21	O
motnhs	O
/	O
patinet	O
)	O
,	O
open	O
-	O
laebl	O
,	O
gemfiborzil	B-Chemical
-	O
lvoastatin	B-Chemical
tretament	O
in	O
80	O
patietns	O
with	O
prmiary	O
mixed	O
hyperlipidmeia	O
(	O
68	O
%	O
of	O
whom	O
had	O
ahterosclerotic	O
vascluar	O
disesae	O
)	O
.	O

Because	O
ideal	O
liipd	O
targtes	O
were	O
not	O
reached	O
(	O
low	O
-	O
denisty	O
lpioprotein	O
(	O
LDL	O
)	O
chloesterol	B-Chemical
less	O
than	O
130	O
mg	O
/	O
dl	O
,	O
high	O
-	O
denisty	O
lipporotein	O
(	O
HDL	O
)	O
choelsterol	B-Chemical
greater	O
than	O
35	O
mg	O
/	O
dl	O
,	O
or	O
total	O
choletserol	B-Chemical
/	O
HDL	O
choletserol	B-Chemical
less	O
than	O
4	O
.	O
5	O
mg	O
/	O
dl	O
)	O
with	O
deit	O
plus	O
a	O
single	O
durg	O
,	O
gefmibrozil	B-Chemical
(	O
1	O
.	O
2	O
g	O
/	O
day	O
)	O
-	O
lovasttain	B-Chemical
(	O
primarily	O
20	O
or	O
40	O
mg	O
)	O
traetment	O
was	O
given	O
.	O

Follow	O
-	O
up	O
vsiits	O
were	O
scheudled	O
with	O
2	O
-	O
durg	O
threapy	O
every	O
6	O
to	O
8	O
wekes	O
,	O
an	O
avergae	O
of	O
10	O
.	O
3	O
viists	O
per	O
ptaient	O
,	O
with	O
741	O
batteires	O
of	O
6	O
lievr	O
fnuction	O
tsets	O
and	O
714	O
ceratine	B-Chemical
pohsphokinase	O
lveels	O
maesured	O
.	O

Only	O
1	O
of	O
the	O
4	O
,	O
446	O
lievr	O
funciton	O
tetss	O
(	O
0	O
.	O
02	O
%	O
)	O
,	O
a	O
gmama	O
glutmayl	O
transefrase	O
,	O
was	O
greater	O
than	O
or	O
eqaul	O
to	O
3	O
times	O
the	O
upepr	O
nomral	O
liimt	O
.	O

Of	O
the	O
714	O
creaitne	B-Chemical
phosphoiknase	O
lveels	O
,	O
9	O
%	O
were	O
high	O
;	O
only	O
1	O
(	O
0	O
.	O
1	O
%	O
)	O
was	O
greater	O
than	O
or	O
euqal	O
to	O
3	O
times	O
the	O
upepr	O
nomral	O
liimt	O
.	O

With	O
2	O
-	O
durg	O
tehrapy	O
,	O
mean	O
total	O
choelsterol	B-Chemical
decerased	O
22	O
%	O
from	O
255	O
to	O
200	O
mg	O
/	O
dl	O
,	O
tirglyceride	B-Chemical
lveels	O
decresaed	O
35	O
%	O
from	O
236	O
to	O
154	O
mg	O
/	O
dl	O
,	O
LDL	O
cholestreol	B-Chemical
decreaesd	O
26	O
%	O
from	O
176	O
to	O
131	O
mg	O
/	O
dl	O
,	O
and	O
the	O
total	O
cholesetrol	B-Chemical
/	O
HDL	O
choletserol	B-Chemical
raito	O
decresaed	O
24	O
%	O
from	O
7	O
.	O
1	O
to	O
5	O
.	O
4	O
,	O
all	O
p	O
less	O
than	O
or	O
eqaul	O
to	O
0	O
.	O
0001	O
.	O

Myoistis	O
,	O
attributable	O
to	O
the	O
durg	O
combiantion	O
and	O
symptoamtic	O
enough	O
to	O
discnotinue	O
it	O
,	O
occurred	O
in	O
3	O
%	O
of	O
ptaients	O
,	O
and	O
in	O
1	O
%	O
with	O
conucrrent	O
high	O
creaitne	B-Chemical
pohsphokinase	O
(	O
769	O
U	O
/	O
liter	O
)	O
;	O
no	O
ptaients	O
had	O
rhabdoymolysis	O
or	O
myoglobinruia	O
.	O
(	O
ABSTRACT	O
TRUNCAETD	O
AT	O
250	O
WORDS	O
)	O

Does	O
dmoperidone	B-Chemical
potenitate	O
mritazapine	B-Chemical
-	O
associated	O
restelss	O
lges	O
syndrmoe	O
?	O

There	O
is	O
now	O
evidecne	O
to	O
suggest	O
a	O
cetnral	O
role	O
for	O
the	O
doapminergic	O
sysetm	O
in	O
restelss	O
lges	O
snydrome	O
(	O
RLS	O
)	O
.	O

For	O
example	O
,	O
the	O
symptmos	O
of	O
RLS	O
can	O
be	O
dramatically	O
imrpoved	O
by	O
levoodpa	B-Chemical
and	O
doapmine	B-Chemical
agonitss	O
,	O
whereas	O
cnetral	O
dopmaine	B-Chemical
D2	O
recetpor	O
antgaonists	O
can	O
indcue	O
or	O
aggarvate	O
RLS	O
smyptoms	O
.	O

To	O
our	O
knowlegde	O
,	O
there	O
is	O
no	O
previous	O
reprot	O
regarding	O
whether	O
dompreidone	B-Chemical
,	O
a	O
preipheral	O
doapmine	B-Chemical
D2	O
reecptor	O
antagonsit	O
,	O
can	O
also	O
indcue	O
or	O
aggravate	O
symtpoms	O
of	O
RLS	O
.	O

Mirtazpaine	B-Chemical
,	O
the	O
first	O
nroadrenergic	O
and	O
specific	O
serootnergic	O
anitdepressant	O
(	O
NSaSA	O
)	O
,	O
has	O
been	O
associated	O
with	O
RLS	O
in	O
several	O
recent	O
publictaions	O
.	O

The	O
autohrs	O
reoprt	O
here	O
a	O
deprsesed	O
pateint	O
comrobid	O
with	O
postrpandial	O
dysppesia	O
who	O
developed	O
RLS	O
after	O
mirtazaipne	B-Chemical
had	O
been	O
added	O
to	O
his	O
dompreidone	B-Chemical
tehrapy	O
.	O

Our	O
pateint	O
started	O
to	O
have	O
symptmos	O
of	O
RLS	O
only	O
after	O
he	O
had	O
been	O
terated	O
with	O
mitrazapine	B-Chemical
,	O
and	O
his	O
RLS	O
symtpoms	O
resolved	O
completely	O
upon	O
discontinaution	O
of	O
his	O
miratzapine	B-Chemical
.	O

Such	O
a	O
temproal	O
rleationship	O
between	O
the	O
use	O
of	O
miratzapine	B-Chemical
and	O
the	O
sypmtoms	O
of	O
RLS	O
in	O
our	O
ptaient	O
did	O
not	O
support	O
a	O
potenitating	O
effcet	O
of	O
dmoperione	B-Chemical
on	O
mirtaazpine	B-Chemical
-	O
associated	O
RLS	O
.	O

However	O
,	O
physicinas	O
should	O
be	O
aware	O
of	O
the	O
possibility	O
that	O
mirtazaipne	B-Chemical
can	O
be	O
associated	O
with	O
RLS	O
in	O
some	O
indiivduals	O
,	O
especially	O
those	O
receiving	O
concomitnat	O
dpoamine	B-Chemical
D2	O
recetpor	O
antagoinsts	O
.	O

Atniandrogenic	O
threapy	O
can	O
cause	O
coronray	O
atrerial	O
disesae	O
.	O

AIM	O
:	O
To	O
stduy	O
the	O
change	O
of	O
lpiid	O
metabloism	O
by	O
anitandrogen	O
threapy	O
in	O
ptaients	O
with	O
porstate	O
cnacer	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
We	O
studied	O
with	O
a	O
2	O
.	O
5	O
yeras	O
follow	O
-	O
up	O
the	O
cahnges	O
in	O
palsma	O
cholesteorls	B-Chemical
(	O
C	B-Chemical
)	O
,	O
triglcyerides	B-Chemical
(	O
TG	B-Chemical
)	O
,	O
liopproteins	O
(	O
LP	O
)	O
,	O
and	O
apolipoprtoeins	O
(	O
Apo	O
)	O
B	O
-	O
100	O
,	O
A	O
-	O
I	O
,	O
and	O
A	O
-	O
II	O
pro	O
fi	O
les	O
in	O
24	O
patinets	O
of	O
mean	O
age	O
60	O
yeras	O
with	O
low	O
rsik	O
porstate	O
canecr	O
(	O
stgae	O
:	O
T1cNM00	O
,	O
Gelason	O
socre	O
:	O
2	O
-	O
5	O
)	O
during	O
treatmnet	O
with	O
cpyroterone	B-Chemical
aceatte	I-Chemical
(	O
CPA	B-Chemical
)	O
without	O
sugrical	O
managmeent	O
or	O
raditaion	O
therpay	O
.	O

RSEULTS	O
:	O
Singificant	O
dcereases	O
of	O
HDL	O
-	O
C	O
,	O
Apo	O
A	O
-	O
I	O
and	O
Apo	O
A	O
-	O
II	O
and	O
an	O
incresae	O
of	O
triglycreide	B-Chemical
leevls	O
in	O
VDLL	O
were	O
idnuced	O
by	O
CPA	B-Chemical
.	O

After	O
a	O
peirod	O
of	O
2	O
.	O
5	O
yaers	O
on	O
CPA	B-Chemical
treatemnt	O
,	O
four	O
patinets	O
out	O
of	O
twenty	O
-	O
four	O
were	O
found	O
to	O
be	O
affetced	O
by	O
coornary	O
herat	O
dsiease	O
.	O

COCNLUSIONS	O
:	O
Ischeamic	O
cornoary	O
arterioscleroiss	O
with	O
an	O
icnidence	O
rtae	O
of	O
16	O
.	O
6	O
%	O
as	O
caused	O
by	O
prolnoged	O
CPA	B-Chemical
threapy	O
is	O
mediated	O
through	O
cahnges	O
in	O
HDL	O
cholesetrol	B-Chemical
,	O
Apo	O
A	O
-	O
I	O
and	O
Apo	O
A	O
-	O
II	O
pro	O
fi	O
les	O
,	O
other	O
than	O
the	O
well	O
-	O
known	O
hyperglcyeridemic	O
effect	O
caused	O
by	O
estorgen	B-Chemical
.	O

5	B-Chemical
-	I-Chemical
Fluoruoracil	I-Chemical
cadriotoxicity	O
induecd	O
by	O
aplha	B-Chemical
-	I-Chemical
fuloro	I-Chemical
-	I-Chemical
btea	I-Chemical
-	I-Chemical
alannie	I-Chemical
.	O

Caridotoxicity	O
is	O
a	O
rrae	O
comlpication	O
occurring	O
during	O
5	B-Chemical
-	I-Chemical
fluorouraicl	I-Chemical
(	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
)	O
teratment	O
for	O
mlaignancies	O
.	O

We	O
herein	O
reprot	O
the	O
csae	O
of	O
a	O
70	O
-	O
yaer	O
-	O
old	O
man	O
with	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
-	O
indcued	O
cardiotoxictiy	O
,	O
in	O
whom	O
a	O
high	O
sreum	O
leevl	O
of	O
alhpa	B-Chemical
-	I-Chemical
flouro	I-Chemical
-	I-Chemical
btea	I-Chemical
-	I-Chemical
aalnine	I-Chemical
(	O
FABL	B-Chemical
)	O
was	O
observed	O
.	O

The	O
ptaient	O
,	O
who	O
had	O
unreesctable	O
cloon	O
cnacer	O
metatsases	O
to	O
the	O
lvier	O
and	O
lnug	O
,	O
was	O
referred	O
to	O
us	O
for	O
chemotherpay	O
from	O
an	O
affiilated	O
hospiatl	O
;	O
he	O
had	O
no	O
cradiac	O
histroy	O
.	O

After	O
amdission	O
,	O
the	O
pateint	O
received	O
a	O
continuuos	O
intravenuos	O
inufsion	O
of	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
(	O
1000	O
mg	O
/	O
day	O
)	O
,	O
during	O
which	O
prceordial	O
pian	O
with	O
rihgt	O
budnle	O
barnch	O
bolck	O
occurred	O
concomitantly	O
with	O
a	O
high	O
seurm	O
FABL	B-Chemical
concentrtaion	O
of	O
1955	O
ng	O
/	O
ml	O
.	O

Both	O
the	O
prceordial	O
pian	O
and	O
the	O
elecrtocardiographic	O
chanegs	O
disappeared	O
sponatneously	O
after	O
the	O
discontiunation	O
of	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
.	O

As	O
the	O
precordail	O
pian	O
in	O
this	O
pateint	O
was	O
considered	O
to	O
have	O
been	O
due	O
to	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
-	O
idnuced	O
cardiotoxciity	O
,	O
the	O
admiinstration	O
of	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
was	O
abandoned	O
.	O

Instead	O
,	O
oarl	O
administratoin	O
of	O
S	O
-	O
1	O
(	O
a	O
derivaitve	O
of	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
)	O
,	O
at	O
200	O
mg	O
/	O
day	O
twice	O
a	O
week	O
,	O
was	O
insittuted	O
,	O
because	O
S	O
-	O
1	O
has	O
a	O
strong	O
inihbitory	O
efefct	O
on	O
dhiydropyrimidine	B-Chemical
dheydrogenase	O
,	O
which	O
catalyzes	O
the	O
dgeradative	O
of	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
into	O
FABL	B-Chemical
.	O

The	O
sreum	O
FABL	B-Chemical
concentrtaion	O
subsequently	O
decerased	O
to	O
352	O
ng	O
/	O
ml	O
,	O
the	O
same	O
as	O
the	O
value	O
maesured	O
on	O
the	O
first	O
day	O
of	O
S	O
-	O
1	O
administraiton	O
.	O

Thereafter	O
,	O
no	O
cadriac	O
sypmtoms	O
were	O
observed	O
.	O

The	O
pateint	O
achieved	O
a	O
patrial	O
resposne	O
6	O
mnoths	O
after	O
the	O
inititaion	O
of	O
the	O
S	O
-	O
1	O
treatemnt	O
.	O

The	O
experiecne	O
of	O
this	O
csae	O
,	O
together	O
with	O
a	O
rveiew	O
of	O
the	O
literautre	O
,	O
suggests	O
that	O
FABL	B-Chemical
is	O
related	O
to	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
-	O
idnuced	O
carditooxicity	O
.	O

S	O
-	O
1	O
may	O
be	O
amdinistered	O
safely	O
to	O
ptaients	O
with	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
-	O
inudced	O
cadriotoxicity	O
.	O

Hpeatocellular	O
carcnioma	O
in	O
Facnoni	O
'	O
s	O
anmeia	O
traeted	O
with	O
andorgen	B-Chemical
and	O
corticsoteroid	B-Chemical
.	O

The	O
csae	O
of	O
an	O
11	O
-	O
yaer	O
-	O
old	O
boy	O
is	O
reported	O
who	O
was	O
known	O
to	O
have	O
Fancnoi	O
'	O
s	O
anmeia	O
for	O
3	O
yaers	O
and	O
was	O
treaetd	O
with	O
androegns	B-Chemical
,	O
coritcosteroids	B-Chemical
and	O
transfusinos	O
.	O

Two	O
wekes	O
before	O
his	O
detah	O
he	O
was	O
redamitted	O
because	O
of	O
aplatsic	O
cirsis	O
with	O
speticemia	O
and	O
marked	O
anbormalities	O
in	O
lvier	O
fnuction	O
and	O
deid	O
of	O
hemorrahgic	O
bronchopnuemonia	O
.	O

At	O
auotpsy	O
pelisois	O
and	O
multilpe	O
hpeatic	O
tuomrs	O
were	O
found	O
which	O
hsitologically	O
proved	O
to	O
be	O
well	O
-	O
differentaited	O
hepatoclelular	O
cracinoma	O
.	O

This	O
csae	O
contributes	O
to	O
the	O
previous	O
obsevrations	O
that	O
non	O
-	O
metasatsizing	O
hepaitc	O
nepolasms	O
and	O
pelisois	O
can	O
develop	O
in	O
patinets	O
with	O
andorgen	B-Chemical
-	O
and	O
corticosteorid	B-Chemical
-	O
traeted	O
Fancnoi	O
'	O
s	O
aenmia	O
.	O

The	O
infleunce	O
of	O
the	O
tmie	O
inetrval	O
between	O
mnooHER	B-Chemical
and	O
doxoruibcin	B-Chemical
administartion	O
on	O
the	O
protetcion	O
against	O
dooxrubicin	B-Chemical
-	O
indcued	O
cardiotoixcity	O
in	O
mcie	O
.	O

PUROPSE	O
:	O
Despite	O
its	O
well	O
-	O
known	O
cardiotoxciity	O
,	O
the	O
antrhacyclin	O
doxourbicin	B-Chemical
(	O
DOX	B-Chemical
)	O
continues	O
to	O
be	O
an	O
efefctive	O
and	O
widely	O
used	O
chemotherapuetic	O
agnet	O
.	O

DOX	B-Chemical
-	O
idnuced	O
caridac	O
damgae	O
presumably	O
resutls	O
from	O
the	O
formaiton	O
of	O
free	O
rdaicals	O
by	O
DOX	B-Chemical
.	O

Reacitve	O
oxgyen	B-Chemical
spceies	O
particularly	O
affect	O
the	O
cardaic	O
moycytes	O
because	O
these	O
cells	O
seem	O
to	O
have	O
a	O
relatively	O
poor	O
anitoxidant	O
dfeense	O
ssytem	O
.	O

The	O
semisyntheitc	O
flavoonid	B-Chemical
monohydroxyehtylrutoside	B-Chemical
(	O
moonHER	B-Chemical
)	O
showed	O
cradioprotection	O
against	O
DOX	B-Chemical
-	O
idnuced	O
caridotoxicity	O
through	O
its	O
radiacl	O
sacvenging	O
and	O
iorn	B-Chemical
chelaitng	O
prpoerties	O
.	O

Because	O
of	O
the	O
relatively	O
short	O
final	O
half	O
-	O
lfie	O
of	O
monoEHR	B-Chemical
(	O
about	O
30	O
min	O
)	O
,	O
it	O
is	O
expected	O
that	O
the	O
tmie	O
itnerval	O
between	O
moonHER	B-Chemical
and	O
DOX	B-Chemical
might	O
be	O
of	O
inlfuence	O
on	O
the	O
cardioprotecitve	O
effect	O
of	O
moonHER	B-Chemical
.	O

Therefore	O
,	O
the	O
aim	O
of	O
the	O
present	O
stduy	O
was	O
to	O
investigtae	O
this	O
possible	O
efefct	O
.	O

METHODS	O
:	O
Six	O
gropus	O
of	O
6	O
BLAB	O
/	O
c	O
mcie	O
were	O
traeted	O
with	O
salnie	O
,	O
DOX	B-Chemical
alone	O
or	O
DOX	B-Chemical
(	O
4	O
mg	O
/	O
kg	O
i	O
.	O
v	O
.	O
)	O
preceded	O
by	O
monoEHR	B-Chemical
(	O
500	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
with	O
an	O
intevral	O
of	O
10	O
,	O
30	O
,	O
60	O
or	O
120	O
min	O
.	O

After	O
a	O
6	O
-	O
week	O
treamtent	O
preiod	O
and	O
additional	O
observatoin	O
for	O
2	O
wekes	O
,	O
the	O
mcie	O
were	O
sacirficed	O
.	O

Their	O
caridac	O
tsisues	O
were	O
processed	O
for	O
light	O
mciroscopy	O
,	O
after	O
which	O
cradiomyocyte	O
dmaage	O
was	O
eavluated	O
according	O
to	O
Billnigham	O
(	O
in	O
Cacner	O
Terat	O
Rep	O
62	O
(	O
6	O
)	O
:	O
865	O
-	O
872	O
,	O
1978	O
)	O
.	O

Microscpoic	O
evalaution	O
revaeled	O
that	O
teratment	O
with	O
DOX	B-Chemical
alone	O
inudced	O
significant	O
cardaic	O
damgae	O
in	O
comaprison	O
to	O
the	O
sailne	O
conrtol	O
gruop	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

RESUTLS	O
:	O
The	O
number	O
of	O
daamged	O
cardiomyoctyes	O
was	O
9	O
.	O
6	O
-	O
fold	O
(	O
95	O
%	O
CI	O
4	O
.	O
4	O
-	O
21	O
.	O
0	O
)	O
hgiher	O
in	O
mcie	O
traeted	O
with	O
DOX	B-Chemical
alone	O
than	O
that	O
in	O
ainmals	O
of	O
the	O
contorl	O
gorup	O
.	O

The	O
raito	O
of	O
abrerant	O
cadriomyocytes	O
in	O
mcie	O
tretaed	O
with	O
DOX	B-Chemical
preceded	O
by	O
monHoER	B-Chemical
and	O
those	O
in	O
mcie	O
terated	O
with	O
slaine	O
ranged	O
from	O
1	O
.	O
6	O
to	O
2	O
.	O
8	O
(	O
mean	O
2	O
.	O
2	O
,	O
95	O
%	O
CI	O
1	O
.	O
2	O
-	O
4	O
.	O
1	O
,	O
P	O
=	O
0	O
.	O
019	O
)	O
.	O

The	O
mean	O
protective	O
effcet	O
by	O
adding	O
mnooHER	B-Chemical
before	O
DOX	B-Chemical
led	O
to	O
a	O
significant	O
4	O
.	O
4	O
-	O
fold	O
reudction	O
(	O
P	O
<	O
0	O
.	O
001	O
,	O
95	O
%	O
CI	O
2	O
.	O
3	O
-	O
8	O
.	O
2	O
)	O
of	O
abnomral	O
cardiomyocyets	O
.	O

This	O
protective	O
efefct	O
did	O
not	O
depend	O
on	O
the	O
tmie	O
intreval	O
between	O
mnooHER	B-Chemical
and	O
DOX	B-Chemical
administartion	O
(	O
P	O
=	O
0	O
.	O
345	O
)	O
.	O

CNOCLUSION	O
:	O
The	O
resluts	O
indicate	O
that	O
in	O
an	O
otupatient	O
cliincal	O
setting	O
moonHER	B-Chemical
may	O
be	O
adminsitered	O
shortly	O
before	O
DOX	B-Chemical
.	O

Cilnical	O
evalaution	O
of	O
advrese	O
effects	O
during	O
bepirdil	B-Chemical
adminitsration	O
for	O
atrail	O
firbillation	O
and	O
fltuter	O
.	O

BAKCGROUND	O
:	O
Beprdiil	B-Chemical
hydorchloride	I-Chemical
(	O
Bpd	B-Chemical
)	O
has	O
attracted	O
attetnion	O
as	O
an	O
effective	O
durg	O
for	O
artial	O
fibrilltaion	O
(	O
AF	O
)	O
and	O
atrail	O
fltuter	O
(	O
AFL	O
)	O
.	O

However	O
,	O
serious	O
avderse	O
efefcts	O
,	O
including	O
tosrade	O
de	O
piontes	O
(	O
Tdp	O
)	O
,	O
have	O
been	O
reported	O
.	O

METHODS	O
AND	O
RESUTLS	O
:	O
Adevrse	O
effetcs	O
of	O
Bpd	B-Chemical
requiring	O
discotninuation	O
of	O
teratment	O
were	O
evalutaed	O
.	O

Bpd	B-Chemical
was	O
admiinstered	O
to	O
459	O
paitents	O
(	O
361	O
maels	O
,	O
63	O
+	O
/	O
-	O
12	O
yeras	O
old	O
)	O
comprising	O
378	O
AF	O
and	O
81	O
AFL	O
csaes	O
.	O

Mean	O
lfet	O
ventriuclar	O
ejetcion	O
fractoin	O
and	O
atrail	O
diemnsion	O
(	O
LAD	O
)	O
were	O
66	O
+	O
/	O
-	O
11	O
%	O
and	O
40	O
+	O
/	O
-	O
6	O
mm	O
,	O
respectively	O
.	O

Adevrse	O
effects	O
were	O
observed	O
in	O
19	O
patinets	O
(	O
4	O
%	O
)	O
during	O
an	O
avreage	O
follow	O
-	O
up	O
of	O
20	O
motnhs	O
.	O

There	O
was	O
marked	O
QT	O
porlongation	O
greater	O
than	O
0	O
.	O
55	O
s	O
in	O
13	O
ptaients	O
,	O
braydcardia	O
less	O
than	O
40	O
baets	O
/	O
min	O
in	O
6	O
ptaients	O
,	O
dizzienss	O
and	O
general	O
fatgiue	O
in	O
1	O
paitent	O
each	O
.	O

In	O
4	O
of	O
13	O
pateints	O
with	O
QT	O
prolongatoin	O
,	O
Tdp	O
occurred	O
.	O

The	O
major	O
triggering	O
fcators	O
of	O
Tdp	O
were	O
hypokalmeia	O
and	O
sduden	O
dcerease	O
in	O
herat	O
rtae	O
.	O

There	O
were	O
no	O
diffeernces	O
in	O
the	O
clniical	O
backgrounds	O
of	O
the	O
patietns	O
with	O
and	O
without	O
Tdp	O
other	O
than	O
LAD	O
and	O
age	O
,	O
which	O
were	O
larger	O
and	O
oledr	O
in	O
the	O
ptaients	O
with	O
Tdp	O
.	O

CONCLUSOIN	O
:	O
Careful	O
osbervation	O
of	O
sreum	O
ptoassium	B-Chemical
concetnration	O
and	O
the	O
ECG	O
should	O
always	O
be	O
done	O
during	O
Bpd	B-Chemical
admniistration	O
,	O
particularly	O
in	O
eldrely	O
ptaients	O
.	O

Enhacned	O
isporoterenol	B-Chemical
-	O
inudced	O
cardaic	O
hpyertrophy	O
in	O
trangsenic	O
rtas	O
with	O
low	O
barin	O
angitoensinogen	O
.	O

We	O
have	O
previously	O
shown	O
that	O
a	O
permnaent	O
dfeiciency	O
in	O
the	O
brian	O
reinn	O
-	O
angioetnsin	B-Chemical
ssytem	O
(	O
RAS	O
)	O
may	O
icnrease	O
the	O
snesitivity	O
of	O
the	O
baroerflex	O
conrtol	O
of	O
haert	O
rtae	O
.	O

In	O
this	O
sutdy	O
we	O
aimed	O
at	O
studying	O
the	O
ivnolvement	O
of	O
the	O
brian	O
RAS	O
in	O
the	O
caridac	O
reactivtiy	O
to	O
the	O
btea	O
-	O
adreonceptor	O
(	O
btea	O
-	O
AR	O
)	O
aognist	O
isoprotreenol	B-Chemical
(	O
Iso	B-Chemical
)	O
.	O

Transgeinc	O
rtas	O
with	O
low	O
barin	O
angitoensinogen	O
(	O
TGR	O
)	O
were	O
used	O
.	O

In	O
isloated	O
heatrs	O
,	O
Iso	B-Chemical
idnuced	O
a	O
significantly	O
greater	O
incraese	O
in	O
lfet	O
ventrciular	O
(	O
LV	O
)	O
prsesure	O
and	O
mxaimal	O
cotnraction	O
(	O
+	O
dP	O
/	O
dt	O
(	O
max	O
)	O
)	O
in	O
the	O
TGR	O
than	O
in	O
the	O
Spargue	O
-	O
Dawely	O
(	O
SD	O
)	O
rtas	O
.	O

LV	O
hyperrtophy	O
induecd	O
by	O
Iso	B-Chemical
treatmnet	O
was	O
significantly	O
hihger	O
in	O
TGR	O
than	O
in	O
SD	O
rtas	O
(	O
in	O
g	O
LV	O
wt	O
/	O
100	O
g	O
bdoy	O
wt	O
,	O
0	O
.	O
28	O
+	O
/	O
-	O
0	O
.	O
004	O
vs	O
.	O
0	O
.	O
24	O
+	O
/	O
-	O
0	O
.	O
004	O
,	O
respectively	O
)	O
.	O

The	O
greater	O
LV	O
hypertorphy	O
in	O
TGR	O
rtas	O
was	O
associated	O
with	O
more	O
pronounced	O
downregulaiton	O
of	O
btea	O
-	O
AR	O
and	O
upregultaion	O
of	O
LV	O
btea	O
-	O
AR	O
kinsae	O
-	O
1	O
mNRA	O
leevls	O
copmared	O
with	O
those	O
in	O
SD	O
rtas	O
.	O

The	O
decresae	O
in	O
the	O
herat	O
rtae	O
(	O
HR	O
)	O
inudced	O
by	O
the	O
btea	O
-	O
AR	O
antagoinst	O
metporolol	B-Chemical
in	O
concsious	O
rtas	O
was	O
significantly	O
atetnuated	O
in	O
TGR	O
comapred	O
with	O
SD	O
rtas	O
(	O
-	O
9	O
.	O
9	O
+	O
/	O
-	O
1	O
.	O
7	O
%	O
vs	O
.	O
-	O
18	O
.	O
1	O
+	O
/	O
-	O
1	O
.	O
5	O
%	O
)	O
,	O
whereas	O
the	O
effect	O
of	O
paarsympathetic	O
blcokade	O
by	O
atropnie	B-Chemical
on	O
HR	O
was	O
similar	O
in	O
both	O
strians	O
.	O

These	O
resutls	O
indicate	O
that	O
TGR	O
are	O
more	O
senistive	O
to	O
btea	O
-	O
AR	O
agnoist	O
-	O
induecd	O
cadriac	O
intoropic	O
resopnse	O
and	O
hypertrohpy	O
,	O
possibly	O
due	O
to	O
chronically	O
low	O
symptahetic	O
otuflow	O
directed	O
to	O
the	O
herat	O
.	O

Durg	O
-	O
induecd	O
long	O
QT	O
syndrmoe	O
in	O
injetcion	O
durg	O
usres	O
receiving	O
mtehadone	B-Chemical
:	O
high	O
frequnecy	O
in	O
hospitlaized	O
patinets	O
and	O
rsik	O
fatcors	O
.	O

BACKRGOUND	O
:	O
Durg	O
-	O
indcued	O
long	O
QT	O
sydnrome	O
is	O
a	O
serious	O
advesre	O
durg	O
reatcion	O
.	O

Methadnoe	B-Chemical
prloongs	O
the	O
QT	O
intreval	O
in	O
vitro	O
in	O
a	O
dsoe	O
-	O
depenednt	O
manner	O
.	O

In	O
the	O
inpatinet	O
setting	O
,	O
the	O
ferquency	O
of	O
QT	O
intevral	O
porlongation	O
with	O
metahdone	B-Chemical
teratment	O
,	O
its	O
dsoe	O
deepndence	O
,	O
and	O
the	O
importance	O
of	O
cofatcors	O
such	O
as	O
durg	O
-	O
durg	O
intercations	O
remain	O
unknown	O
.	O

METHODS	O
:	O
We	O
performed	O
a	O
ssytematic	O
,	O
retrospecitve	O
sutdy	O
compraing	O
actvie	O
or	O
former	O
itnravenous	O
durg	O
usres	O
receiving	O
methaodne	B-Chemical
and	O
those	O
not	O
receiving	O
mehtadone	B-Chemical
among	O
all	O
patietns	O
hospitlaized	O
over	O
a	O
5	O
-	O
yaer	O
preiod	O
in	O
a	O
teritary	O
crae	O
hosptial	O
.	O

A	O
total	O
of	O
167	O
ptaients	O
receiving	O
methaodne	B-Chemical
fulfilled	O
the	O
inclsuion	O
criteira	O
and	O
were	O
compaerd	O
with	O
a	O
cotnrol	O
gorup	O
of	O
80	O
injetcion	O
durg	O
usres	O
not	O
receiving	O
mtehadone	B-Chemical
.	O

In	O
addition	O
to	O
metahdone	B-Chemical
dsoe	O
,	O
15	O
demogrpahic	O
,	O
boilogical	O
,	O
and	O
phamracological	O
varialbes	O
were	O
considered	O
as	O
potetnial	O
rsik	O
factros	O
for	O
QT	O
prolnogation	O
.	O

RESLUTS	O
:	O
Among	O
167	O
mtehadone	B-Chemical
maintennace	O
patinets	O
,	O
the	O
prevaelnce	O
of	O
QTc	O
prolognation	O
to	O
0	O
.	O
50	O
second	O
(	O
(	O
1	O
/	O
2	O
)	O
)	O
or	O
longer	O
was	O
16	O
.	O
2	O
%	O
compraed	O
with	O
0	O
%	O
in	O
80	O
contorl	O
subjetcs	O
.	O

Six	O
paitents	O
(	O
3	O
.	O
6	O
%	O
)	O
in	O
the	O
mehtadone	B-Chemical
gorup	O
presented	O
trosades	O
de	O
poitnes	O
.	O

QTc	O
legnth	O
was	O
weakly	O
but	O
significantly	O
associated	O
with	O
mehtadone	B-Chemical
dialy	O
dsoe	O
(	O
Spearamn	O
rnak	O
corrleation	O
coefficient	O
,	O
0	O
.	O
20	O
;	O
P	O
<	O
.	O
01	O
)	O
.	O

Mlutivariate	O
regression	O
analsyis	O
allowed	O
atrtibution	O
of	O
31	O
.	O
8	O
%	O
of	O
QTc	O
variabliity	O
to	O
mtehadone	B-Chemical
dsoe	O
,	O
cytohcrome	O
P	O
-	O
450	O
3A4	O
durg	O
-	O
durg	O
inetractions	O
,	O
hypkoalemia	O
,	O
and	O
alteerd	O
lvier	O
funciton	O
.	O

COCNLUSIONS	O
:	O
QT	O
interavl	O
prolnogation	O
in	O
metahdone	B-Chemical
manitenance	O
patietns	O
hospitailzed	O
in	O
a	O
tertairy	O
crae	O
cenetr	O
is	O
a	O
frequnet	O
finidng	O
.	O

Metahdone	B-Chemical
dsoe	O
,	O
persence	O
of	O
cytochrmoe	O
P	O
-	O
450	O
3A4	O
inhibtiors	O
,	O
poatssium	B-Chemical
leevl	O
,	O
and	O
lvier	O
functoin	O
contribute	O
to	O
QT	O
proolngation	O
.	O

Lnog	O
QT	O
sydnrome	O
can	O
occur	O
with	O
low	O
doess	O
of	O
mehtadone	B-Chemical
.	O

Mecahnisms	O
of	O
hyperetnsion	O
inudced	O
by	O
ntiric	B-Chemical
oixde	I-Chemical
(	O
NO	B-Chemical
)	O
deficinecy	O
:	O
focus	O
on	O
vneous	O
funciton	O
.	O

Lsos	O
of	O
endothleial	O
clel	O
-	O
derived	O
ntiric	B-Chemical
oixde	I-Chemical
(	O
NO	B-Chemical
)	O
in	O
hpyertension	O
is	O
a	O
hallmark	O
of	O
aretrial	O
dsyfunction	O
.	O

Experimnetal	O
hypretension	O
created	O
by	O
the	O
remoavl	O
of	O
NO	B-Chemical
,	O
however	O
,	O
involves	O
mechainsms	O
in	O
addition	O
to	O
derceased	O
arteiral	O
vasoidlator	O
activtiy	O
.	O

These	O
include	O
agumented	O
enodthelin	O
-	O
1	O
(	O
ET	O
-	O
1	O
)	O
relaese	O
,	O
inrceased	O
symapthetic	O
nervuos	O
sysetm	O
actiivty	O
,	O
and	O
elveated	O
tissue	O
oxidatvie	O
strses	O
.	O

We	O
hypothesized	O
that	O
incraesed	O
veonus	O
somoth	O
muslce	O
(	O
venoomtor	O
)	O
tnoe	O
plays	O
a	O
role	O
in	O
Nomgea	B-Chemical
-	I-Chemical
nirto	I-Chemical
-	I-Chemical
L	I-Chemical
-	I-Chemical
arginnie	I-Chemical
(	O
LNNA	B-Chemical
)	O
hypetrension	O
through	O
these	O
mehcanisms	O
.	O

Rtas	O
were	O
terated	O
with	O
the	O
NO	B-Chemical
snythase	O
inihbitor	O
LNNA	B-Chemical
(	O
0	O
.	O
5	O
g	O
/	O
L	O
in	O
drinikng	O
waetr	O
)	O
for	O
2	O
wekes	O
.	O

Mean	O
arteiral	O
prsesure	O
of	O
cnoscious	O
rtas	O
was	O
119	O
+	O
/	O
-	O
2	O
mm	O
Hg	O
in	O
cnotrol	O
and	O
194	O
+	O
/	O
-	O
5	O
mm	O
Hg	O
in	O
LNNA	B-Chemical
rtas	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Cartoid	O
artreies	O
and	O
vnea	O
cvaa	O
were	O
remvoed	O
for	O
mesaurement	O
of	O
isomteric	O
contractoin	O
.	O

Maixmal	O
contraciton	O
to	O
norepienphrine	B-Chemical
was	O
modestly	O
reduecd	O
in	O
aretries	O
from	O
LNNA	B-Chemical
compaerd	O
with	O
cnotrol	O
rtas	O
whereas	O
the	O
maxiumm	O
cnotraction	O
to	O
ET	O
-	O
1	O
was	O
significantly	O
rdeuced	O
(	O
54	O
%	O
cnotrol	O
)	O
.	O

Maixmum	O
cnotraction	O
of	O
vnea	O
cvaa	O
to	O
nroepinephrine	B-Chemical
(	O
37	O
%	O
cnotrol	O
)	O
also	O
was	O
reduecd	O
but	O
no	O
change	O
in	O
resposne	O
to	O
ET	O
-	O
1	O
was	O
observed	O
.	O

Mean	O
criculatory	O
fillnig	O
prsesure	O
,	O
an	O
in	O
vivo	O
maesure	O
of	O
veonmotor	O
tnoe	O
,	O
was	O
not	O
elevaetd	O
in	O
LNNA	B-Chemical
hyperetnsion	O
at	O
1	O
or	O
2	O
wekes	O
after	O
LNNA	B-Chemical
.	O

The	O
supeorxide	B-Chemical
scavenegr	O
tmepol	B-Chemical
(	O
30	O
,	O
100	O
,	O
and	O
300	O
micromol	O
kg	O
(	O
-	O
1	O
)	O
,	O
IV	O
)	O
did	O
not	O
change	O
arterail	O
presusre	O
in	O
cotnrol	O
rtas	O
but	O
caused	O
a	O
dsoe	O
-	O
dependnet	O
decraese	O
in	O
LNNA	B-Chemical
rtas	O
(	O
-	O
18	O
+	O
/	O
-	O
8	O
,	O
-	O
26	O
+	O
/	O
-	O
15	O
,	O
and	O
-	O
54	O
+	O
/	O
-	O
11	O
mm	O
Hg	O
)	O
.	O

Similarly	O
,	O
gagnlionic	O
blcokade	O
with	O
hexamethoinum	B-Chemical
caused	O
a	O
significantly	O
greater	O
fall	O
in	O
LNNA	B-Chemical
hypertenisve	O
rtas	O
(	O
76	O
+	O
/	O
-	O
9	O
mm	O
Hg	O
)	O
cmopared	O
with	O
cotnrol	O
rtas	O
(	O
35	O
+	O
/	O
-	O
10	O
mm	O
Hg	O
)	O
.	O

Cartoid	O
aretries	O
,	O
vnea	O
cvaa	O
,	O
and	O
sympatehtic	O
gangila	O
from	O
LNNA	B-Chemical
rtas	O
had	O
higehr	O
bsaal	O
levles	O
of	O
superoixde	B-Chemical
copmared	O
with	O
those	O
from	O
contorl	O
rtas	O
.	O

These	O
dtaa	O
suggest	O
that	O
while	O
NO	B-Chemical
deficinecy	O
incresaes	O
oxdiative	O
srtess	O
and	O
smypathetic	O
acitvity	O
in	O
both	O
aretrial	O
and	O
vneous	O
vsesels	O
,	O
the	O
ipmact	O
on	O
venis	O
does	O
not	O
make	O
a	O
major	O
contribution	O
to	O
this	O
form	O
of	O
hyperetnsion	O
.	O

Asscoiation	O
of	O
DDR2	O
poylmorphisms	O
and	O
chloprromazine	B-Chemical
-	O
inudced	O
extrapyrmaidal	O
snydrome	O
in	O
Chniese	O
schziophrenic	O
patinets	O
.	O

AIM	O
:	O
Extraypramidal	O
sydnrome	O
(	O
EPS	O
)	O
is	O
most	O
commonly	O
affected	O
by	O
typical	O
antipsychoitc	O
drgus	O
that	O
have	O
a	O
high	O
affinity	O
with	O
the	O
D2	O
recpetor	O
.	O

Recently	O
,	O
many	O
reseacrh	O
gruops	O
have	O
reported	O
on	O
the	O
posiitve	O
rleationship	O
between	O
the	O
geneitc	O
variaitons	O
in	O
the	O
DDR2	O
gnee	O
and	O
the	O
therapuetic	O
rseponse	O
in	O
schziophrenia	O
patinets	O
as	O
a	O
result	O
of	O
the	O
role	O
of	O
variatoins	O
in	O
the	O
recetpor	O
in	O
modulaitng	O
reecptor	O
exrpession	O
.	O

In	O
this	O
stduy	O
,	O
we	O
evalaute	O
the	O
role	O
DDR2	O
plays	O
in	O
cholrpromazine	B-Chemical
-	O
inudced	O
EPS	O
in	O
schziophrenic	O
paitents	O
.	O

METHODS	O
:	O
We	O
idetnified	O
seven	O
SNP	O
(	O
single	O
nucleotdie	O
polymorpihsm	O
)	O
(	O
-	O
141Cins	O
>	O
del	O
,	O
TqaIB	O
,	O
TaIqD	O
,	O
Ser311Cys	O
,	O
rs6725	O
,	O
rs2677	O
and	O
TqaIA	O
)	O
in	O
the	O
DDR2	O
gnee	O
in	O
146	O
schizophernic	O
inpaitents	O
(	O
59	O
with	O
EPS	O
and	O
87	O
without	O
EPS	O
according	O
to	O
the	O
Smipson	O
-	O
Anugs	O
Sclae	O
)	O
treaetd	O
with	O
clhorpromazine	B-Chemical
after	O
8	O
weeks	O
.	O

The	O
alleels	O
of	O
all	O
lcoi	O
were	O
determined	O
by	O
PCR	O
(	O
ploymerase	O
chian	O
reatcion	O
)	O
.	O

RESLUTS	O
:	O
Polymoprhisms	O
TaIqD	O
,	O
Ser31C1ys	O
and	O
rs2677	O
were	O
not	O
poylmorphic	O
in	O
the	O
ppoulation	O
recruited	O
in	O
the	O
present	O
sutdy	O
.	O

No	O
sttaistical	O
significacne	O
was	O
found	O
in	O
the	O
alllee	O
distrbiution	O
of	O
-	O
141Cins	O
>	O
del	O
,	O
TaIqB	O
,	O
r6s275	O
and	O
TqaIA	O
or	O
in	O
the	O
esitmated	O
haplotpyes	O
(	O
constituted	O
by	O
TaIqB	O
,	O
rs2675	O
and	O
TaIqA	O
)	O
in	O
linkgae	O
disequiilbrium	O
between	O
the	O
two	O
gruops	O
.	O

CNOCLUSION	O
:	O
Our	O
resluts	O
did	O
not	O
lend	O
strong	O
support	O
to	O
the	O
view	O
that	O
the	O
geentic	O
varitaion	O
of	O
the	O
DDR2	O
gnee	O
plays	O
a	O
major	O
role	O
in	O
the	O
individually	O
varibale	O
advrese	O
effect	O
induecd	O
by	O
chlorproamzine	B-Chemical
,	O
at	O
least	O
in	O
Cihnese	O
paitents	O
with	O
schizoprhenia	O
.	O

Our	O
resluts	O
confirmed	O
a	O
previous	O
stduy	O
on	O
the	O
realtionship	O
between	O
DDR2	O
and	O
EPS	O
in	O
Caucaisans	O
.	O

Pyhsical	O
traniing	O
decraeses	O
susceptbiility	O
to	O
subsequent	O
pilocarpnie	B-Chemical
-	O
idnuced	O
seizuers	O
in	O
the	O
rat	O
.	O

Rgeular	O
mootr	O
actviity	O
has	O
many	O
beneftis	O
for	O
menatl	O
and	O
physiacl	O
codnition	O
but	O
its	O
implications	O
for	O
epielpsy	O
are	O
still	O
controversial	O
.	O

In	O
order	O
to	O
elucidate	O
this	O
porblem	O
,	O
we	O
have	O
studied	O
the	O
efefct	O
of	O
long	O
-	O
term	O
pyhsical	O
actviity	O
on	O
ssuceptibility	O
to	O
subsequent	O
siezures	O
.	O

Mlae	O
Wisatr	O
rtas	O
were	O
subjected	O
to	O
repeaetd	O
trianing	O
sessinos	O
in	O
a	O
treamdill	O
and	O
swimming	O
pool	O
.	O

Thereafter	O
,	O
siezures	O
were	O
inudced	O
by	O
pilocaprine	B-Chemical
injectoins	O
in	O
tarined	O
and	O
non	O
-	O
tranied	O
cotnrol	O
gruops	O
.	O

During	O
the	O
aucte	O
peirod	O
of	O
sattus	O
epilepitcus	O
,	O
we	O
meausred	O
:	O
(	O
1	O
)	O
the	O
latecny	O
of	O
the	O
first	O
mootr	O
sign	O
,	O
(	O
2	O
)	O
the	O
itnensity	O
of	O
seizrues	O
,	O
(	O
3	O
)	O
the	O
tmie	O
when	O
it	O
occurred	O
within	O
the	O
6	O
-	O
h	O
obesrvation	O
peroid	O
,	O
and	O
(	O
4	O
)	O
the	O
tmie	O
when	O
the	O
aucte	O
preiod	O
ended	O
.	O

All	O
these	O
behavioarl	O
praameters	O
showed	O
statisitcally	O
significant	O
chanegs	O
suggesting	O
that	O
regular	O
physiacl	O
eexrcises	O
decresae	O
susceptiiblity	O
to	O
subsequently	O
induecd	O
seiuzres	O
and	O
amelioarte	O
the	O
coruse	O
of	O
experimetnally	O
inudced	O
sttaus	O
eiplepticus	O
.	O

Tnoic	O
dopaimnergic	O
stimualtion	O
imparis	O
associative	O
learinng	O
in	O
heatlhy	O
subejcts	O
.	O

Enodgenous	O
doapmine	B-Chemical
plays	O
a	O
cnetral	O
role	O
in	O
saliecne	O
codnig	O
during	O
associative	O
leraning	O
.	O

Administratoin	O
of	O
the	O
dopaimne	B-Chemical
precrusor	O
levodpoa	B-Chemical
enhanecs	O
laerning	O
in	O
healhty	O
sujbects	O
and	O
srtoke	O
ptaients	O
.	O

Because	O
levdoopa	B-Chemical
incraeses	O
both	O
phaisc	O
and	O
toinc	O
dopmainergic	O
nuerotransmission	O
,	O
the	O
critical	O
mechansim	O
mediating	O
the	O
enhancmeent	O
of	O
laerning	O
is	O
unresolved	O
.	O

We	O
here	O
porbed	O
how	O
selective	O
toinc	O
doapminergic	O
stimulatoin	O
affects	O
associative	O
learnnig	O
.	O

Forty	O
haelthy	O
subjcets	O
were	O
tarined	O
in	O
a	O
novel	O
vocabluary	O
of	O
45	O
concrete	O
nonus	O
over	O
the	O
cuorse	O
of	O
5	O
consceutive	O
tarining	O
dyas	O
in	O
a	O
prsopective	O
,	O
randmoized	O
,	O
double	O
-	O
bilnd	O
,	O
plcaebo	O
-	O
contrloled	O
desgin	O
.	O

Sujbects	O
received	O
the	O
toniaclly	O
stiumlating	O
doapmine	B-Chemical
-	O
recpetor	O
agoinst	O
pegrolide	B-Chemical
(	O
0	O
.	O
1	O
mg	O
)	O
vs	O
plcaebo	O
120	O
min	O
before	O
traiinng	O
on	O
each	O
trianing	O
day	O
.	O

The	O
dopmaine	B-Chemical
agonsit	O
significantly	O
impaierd	O
novel	O
wrod	O
laerning	O
cmopared	O
to	O
plcaebo	O
.	O

This	O
laerning	O
decerment	O
persisted	O
up	O
to	O
the	O
last	O
follow	O
-	O
up	O
4	O
weeks	O
psot	O
-	O
trainnig	O
.	O

Sujbects	O
treaetd	O
with	O
pegrolide	B-Chemical
also	O
showed	O
restricted	O
emotoinal	O
responess	O
cmopared	O
to	O
the	O
PALCEBO	O
gruop	O
.	O

The	O
extent	O
of	O
'	O
flattened	O
'	O
affect	O
with	O
pergloide	B-Chemical
was	O
related	O
to	O
the	O
dgeree	O
of	O
leraning	O
inhbiition	O
.	O

These	O
findigns	O
suggest	O
that	O
toinc	O
occpuation	O
of	O
dopamnie	B-Chemical
recepotrs	O
ipmairs	O
laerning	O
by	O
comeptition	O
with	O
pahsic	O
dopaimne	B-Chemical
siganls	O
.	O

Thus	O
,	O
phsaic	O
signlaing	O
seems	O
to	O
be	O
the	O
critical	O
mechansim	O
by	O
which	O
dopamnie	B-Chemical
ehnances	O
associative	O
learnnig	O
in	O
helathy	O
subejcts	O
and	O
strkoe	O
pateints	O
.	O

Minocyclnie	B-Chemical
-	O
inudced	O
vasuclitis	O
fulfilling	O
the	O
crtieria	O
of	O
polyrateritis	O
ndoosa	O
.	O

A	O
47	O
-	O
yaer	O
-	O
old	O
man	O
who	O
had	O
been	O
taking	O
minocyclnie	B-Chemical
for	O
pamloplantar	O
pustuolsis	O
developed	O
fveer	O
,	O
myaglias	O
,	O
polnyeuropathy	O
,	O
and	O
testiuclar	O
pian	O
,	O
with	O
elevtaed	O
C	O
-	O
recative	O
protien	O
(	O
CRP	O
)	O
.	O

Neither	O
myeolperoxidase	O
-	O
nor	O
protienase	O
-	O
3	O
-	O
antineutropihl	O
cytoplasimc	O
antiobdy	O
was	O
posiitve	O
.	O

These	O
manfiestations	O
met	O
the	O
Amreican	O
College	O
of	O
Rehumatology	O
1990	O
crtieria	O
for	O
the	O
classification	O
of	O
ployarteritis	O
noodsa	O
.	O

Stopping	O
mniocycline	B-Chemical
led	O
to	O
amelioratoin	O
of	O
sypmtoms	O
and	O
normaliztaion	O
of	O
CRP	O
lveel	O
.	O

To	O
our	O
konwledge	O
,	O
this	O
is	O
the	O
second	O
csae	O
of	O
mniocycline	B-Chemical
-	O
indcued	O
vacsulitis	O
satisfying	O
the	O
criteira	O
.	O

Differnetial	O
daignosis	O
for	O
durg	O
-	O
induecd	O
disesae	O
is	O
invaluable	O
even	O
for	O
paitents	O
with	O
classical	O
polyrateritis	O
nodsoa	O
.	O

Intramucsular	O
hepattiis	O
B	O
immune	O
glboulin	O
combnied	O
with	O
lmaivudine	B-Chemical
in	O
preveniton	O
of	O
heaptitis	O
B	O
recrurence	O
after	O
lvier	O
trnasplantation	O
.	O

BAKCGROUND	O
:	O
Combiend	O
hepaittis	O
B	O
immnue	O
globluin	O
(	O
HIBg	O
)	O
and	O
laimvudine	B-Chemical
in	O
porphylaxis	O
of	O
the	O
reucrrence	O
of	O
heaptitis	O
B	O
after	O
lvier	O
tarnsplantation	O
has	O
significantly	O
imporved	O
the	O
survvial	O
of	O
HsBAg	B-Chemical
poistive	O
ptaients	O
.	O

This	O
stduy	O
was	O
undertaken	O
to	O
evalutae	O
the	O
outocmes	O
of	O
lvier	O
transpalntation	O
for	O
patinets	O
with	O
heaptitis	O
B	O
vrius	O
(	O
HBV	O
)	O
.	O

METHODS	O
:	O
A	O
retorspective	O
cahrt	O
analsyis	O
and	O
a	O
reivew	O
of	O
the	O
ogran	O
translpant	O
dataabse	O
iedntified	O
51	O
patietns	O
(	O
43	O
men	O
and	O
8	O
woemn	O
)	O
tarnsplanted	O
for	O
beingn	O
HBV	O
-	O
related	O
cirrohtic	O
disesaes	O
between	O
June	O
2002	O
and	O
December	O
2004	O
who	O
had	O
survived	O
more	O
than	O
3	O
monhts	O
.	O

HIBg	O
was	O
admiinstered	O
inrtavenously	O
during	O
the	O
first	O
week	O
and	O
intraumscularly	O
thereafter	O
.	O

RESUTLS	O
:	O
At	O
a	O
mdeian	O
follow	O
-	O
up	O
of	O
14	O
.	O
1	O
mnoths	O
,	O
the	O
overall	O
recurrnece	O
rtae	O
in	O
the	O
51	O
ptaients	O
was	O
3	O
.	O
9	O
%	O
(	O
2	O
/	O
51	O
)	O
.	O

The	O
overall	O
paitent	O
sruvival	O
was	O
88	O
.	O
3	O
%	O
,	O
and	O
82	O
.	O
4	O
%	O
after	O
1	O
and	O
2	O
yeras	O
,	O
respectively	O
.	O

A	O
daliy	O
oarl	O
dsoe	O
of	O
100	O
mg	O
lamivuidne	B-Chemical
for	O
2	O
wekes	O
before	O
transplanttaion	O
for	O
10	O
pateints	O
enabled	O
57	O
.	O
1	O
%	O
(	O
4	O
/	O
7	O
)	O
and	O
62	O
.	O
5	O
%	O
(	O
5	O
/	O
8	O
)	O
of	O
HBV	O
-	O
DNA	O
and	O
HBAeg	B-Chemical
postiive	O
ptaients	O
respectively	O
to	O
convert	O
to	O
be	O
negaitve	O
.	O

Intarmuscular	O
HIBg	O
was	O
well	O
tolreated	O
in	O
all	O
patietns	O
.	O

CONCLUISON	O
:	O
Lamviudine	B-Chemical
comibned	O
with	O
intramusuclar	O
HIBg	O
can	O
effectively	O
prevnet	O
allogrfat	O
from	O
the	O
recurrecne	O
of	O
HBV	O
after	O
lvier	O
transplantaiton	O
.	O

Atniconvulsant	O
efefct	O
of	O
elsicarbazepine	B-Chemical
aceatte	I-Chemical
(	O
BIA	B-Chemical
2	I-Chemical
-	I-Chemical
093	I-Chemical
)	O
on	O
seiuzres	O
indcued	O
by	O
micorperfusion	O
of	O
picortoxin	B-Chemical
in	O
the	O
hipopcampus	O
of	O
freely	O
movnig	O
rtas	O
.	O

Esilcarbazepine	B-Chemical
aceatte	I-Chemical
(	O
BIA	B-Chemical
2	I-Chemical
-	I-Chemical
093	I-Chemical
,	O
S	B-Chemical
-	I-Chemical
(	I-Chemical
-	I-Chemical
)	I-Chemical
-	I-Chemical
10	I-Chemical
-	I-Chemical
acetxoy	I-Chemical
-	I-Chemical
10	I-Chemical
,	I-Chemical
11	I-Chemical
-	I-Chemical
dihyrdo	I-Chemical
-	I-Chemical
5H	I-Chemical
-	I-Chemical
dibnezo	I-Chemical
/	I-Chemical
b	I-Chemical
,	I-Chemical
f	I-Chemical
/	I-Chemical
aezpine	I-Chemical
-	I-Chemical
5	I-Chemical
-	I-Chemical
carboxamdie	I-Chemical
)	O
is	O
a	O
novel	O
atniepileptic	O
durg	O
,	O
now	O
in	O
Pahse	O
III	O
cliniacl	O
trails	O
,	O
designed	O
with	O
the	O
aim	O
of	O
improvnig	O
efficacy	O
and	O
saftey	O
in	O
cmoparison	O
with	O
the	O
structurally	O
related	O
durgs	O
carbamazeipne	B-Chemical
(	O
CBZ	B-Chemical
)	O
and	O
oxcrabazepine	B-Chemical
(	O
OXC	B-Chemical
)	O
.	O

We	O
have	O
studied	O
the	O
effects	O
of	O
oarl	O
treatemnt	O
with	O
eslicarbazeipne	B-Chemical
acteate	I-Chemical
on	O
a	O
whole	O
-	O
anmial	O
mdoel	O
in	O
which	O
pratial	O
seizuers	O
can	O
be	O
elicited	O
repeatedly	O
on	O
different	O
dyas	O
without	O
chnages	O
in	O
thrsehold	O
or	O
siezure	O
patetrns	O
.	O

In	O
the	O
animlas	O
traeted	O
with	O
thresohld	O
doess	O
of	O
pcirotoxin	B-Chemical
,	O
the	O
avergae	O
number	O
of	O
seiuzres	O
was	O
2	O
.	O
3	O
+	O
/	O
-	O
1	O
.	O
2	O
,	O
and	O
aevrage	O
seizrue	O
duraiton	O
was	O
39	O
.	O
5	O
+	O
/	O
-	O
8	O
.	O
4s	O
.	O

Pre	O
-	O
tretament	O
with	O
a	O
dsoe	O
of	O
30	O
mg	O
/	O
kg	O
2h	O
before	O
picrotoixn	B-Chemical
microperufsion	O
prevented	O
seizrues	O
in	O
the	O
75	O
%	O
of	O
the	O
rtas	O
.	O

Lwoer	O
doess	O
(	O
3	O
and	O
10mg	O
/	O
kg	O
)	O
did	O
not	O
supperss	O
seizrues	O
,	O
however	O
,	O
after	O
amdinistration	O
of	O
10mg	O
/	O
kg	O
,	O
significant	O
reductoins	O
in	O
seizuers	O
druation	O
(	O
24	O
.	O
3	O
+	O
/	O
-	O
6	O
.	O
8s	O
)	O
and	O
siezure	O
number	O
(	O
1	O
.	O
6	O
+	O
/	O
-	O
0	O
.	O
34	O
)	O
were	O
found	O
.	O

No	O
avderse	O
efefcts	O
of	O
eslicarbzaepine	B-Chemical
aceatte	I-Chemical
were	O
observed	O
in	O
the	O
beahvioral	O
/	O
EEG	O
ptaterns	O
studied	O
,	O
including	O
selep	O
/	O
wkaefulness	O
ccyle	O
,	O
at	O
the	O
dsoes	O
studied	O
.	O

Aucte	O
rneal	O
failrue	O
associated	O
with	O
prolonegd	O
intkae	O
of	O
slmiming	O
pills	O
containing	O
atnhraquinones	B-Chemical
.	O

Chniese	B-Chemical
hrebal	I-Chemical
mdeicine	O
prepraations	O
are	O
widely	O
available	O
and	O
often	O
regarded	O
by	O
the	O
pulbic	O
as	O
ntaural	O
and	O
safe	O
remedeis	O
for	O
a	O
variety	O
of	O
medcial	O
conidtions	O
.	O

Neprhopathy	O
caused	O
by	O
Cihnese	B-Chemical
hrebs	I-Chemical
has	O
previously	O
been	O
reported	O
,	O
usually	O
involving	O
the	O
use	O
of	O
aritsolochic	B-Chemical
aicds	I-Chemical
.	O

We	O
reprot	O
a	O
23	O
-	O
yaer	O
-	O
old	O
woamn	O
who	O
developed	O
aucte	O
reanl	O
faliure	O
following	O
proolnged	O
use	O
of	O
a	O
propiretary	O
Chiense	B-Chemical
hebral	I-Chemical
slimmnig	O
plil	O
that	O
contained	O
anthraqiunone	B-Chemical
deirvatives	O
,	O
extratced	O
from	O
Rhiozma	O
Rehi	O
(	O
rhubrab	O
)	O
.	O

The	O
reanl	O
inujry	O
was	O
probably	O
aggarvated	O
by	O
the	O
concoimtant	O
intkae	O
of	O
a	O
non	O
-	O
sterodial	O
atni	O
-	O
inlfammatory	O
durg	O
,	O
dilcofenac	B-Chemical
.	O

Reanl	O
pathloogy	O
was	O
that	O
of	O
hypocellular	O
intrestitial	O
fbirosis	O
.	O

Spontaneuos	O
rneal	O
recoevry	O
occurred	O
upon	O
cessatoin	O
of	O
the	O
silmming	O
plils	O
,	O
but	O
mlid	O
intersttiial	O
fiborsis	O
and	O
tubualr	O
atrohpy	O
was	O
still	O
evident	O
hsitologically	O
4	O
monhts	O
later	O
.	O

Although	O
a	O
causal	O
relationsihp	O
between	O
the	O
use	O
of	O
an	O
anthraquinnoe	B-Chemical
-	O
containing	O
herabl	O
agnet	O
and	O
reanl	O
injruy	O
remains	O
to	O
be	O
proven	O
,	O
phyottherapy	O
-	O
associated	O
interstiital	O
nephroapthy	O
should	O
be	O
considered	O
in	O
patinets	O
who	O
present	O
with	O
unexlpained	O
rneal	O
faliure	O
.	O

Chlooracetaldehyde	B-Chemical
as	O
a	O
sulfyhdryl	B-Chemical
regaent	O
:	O
the	O
role	O
of	O
critical	O
thoil	B-Chemical
gruops	O
in	O
ifosfamdie	B-Chemical
nephroapthy	O
.	O

Chlrooacetaldehyde	B-Chemical
(	O
CAA	B-Chemical
)	O
is	O
a	O
metaboilte	O
of	O
the	O
alklyating	O
agnet	O
ifosfamdie	B-Chemical
(	O
IFO	B-Chemical
)	O
and	O
putatively	O
responsible	O
for	O
rneal	O
dmaage	O
following	O
atni	O
-	O
tuomr	O
therpay	O
with	O
IFO	B-Chemical
.	O

Depeltion	O
of	O
sulhfydryl	B-Chemical
(	O
SH	B-Chemical
)	O
gorups	O
has	O
been	O
reported	O
from	O
clel	O
culutre	O
,	O
aniaml	O
and	O
clincial	O
studeis	O
.	O

In	O
this	O
work	O
the	O
efefct	O
of	O
CAA	B-Chemical
on	O
huamn	O
prxoimal	O
tuuble	O
cells	O
in	O
prmiary	O
cutlure	O
(	O
hPRTEC	O
)	O
was	O
invesitgated	O
.	O

Toxictiy	O
of	O
CAA	B-Chemical
was	O
determined	O
by	O
proetin	O
conetnt	O
,	O
clel	O
number	O
,	O
LDH	O
relaese	O
,	O
tyrpan	B-Chemical
bule	I-Chemical
exculsion	O
assay	O
and	O
capsase	O
-	O
3	O
atcivity	O
.	O

Fere	O
thoils	B-Chemical
were	O
measuerd	O
by	O
the	O
mehtod	O
of	O
Ellman	O
.	O

CAA	B-Chemical
reudced	O
hPRTEC	O
clel	O
number	O
and	O
protien	O
,	O
idnuced	O
a	O
lsos	O
in	O
free	O
intracellluar	O
tihols	B-Chemical
and	O
an	O
icnrease	O
in	O
ncerosis	O
mrakers	O
.	O

CAA	B-Chemical
but	O
not	O
arcolein	B-Chemical
inhiibted	O
the	O
cystiene	B-Chemical
proteaess	O
csapase	O
-	O
3	O
,	O
caspsae	O
-	O
8	O
and	O
cathepisn	O
B	O
.	O

Casapse	O
activaiton	O
by	O
cislpatin	B-Chemical
was	O
inhibtied	O
by	O
CAA	B-Chemical
.	O

In	O
cells	O
stanied	O
with	O
fluorescnet	O
deys	O
targteing	O
lyssoomes	O
,	O
CAA	B-Chemical
induecd	O
an	O
inrcease	O
in	O
lysosmoal	O
szie	O
and	O
lyssoomal	O
lekaage	O
.	O

The	O
effetcs	O
of	O
CAA	B-Chemical
on	O
cysetine	B-Chemical
portease	O
activiites	O
and	O
thilos	B-Chemical
could	O
be	O
reproduced	O
in	O
clel	O
lsyate	O
.	O

Acidifiaction	O
,	O
which	O
slowed	O
the	O
reatcion	O
of	O
CAA	B-Chemical
with	O
tihol	B-Chemical
dnoors	O
,	O
could	O
also	O
attenaute	O
efefcts	O
of	O
CAA	B-Chemical
on	O
nercosis	O
makrers	O
,	O
thoil	B-Chemical
delpetion	O
and	O
cystenie	B-Chemical
portease	O
inhibiiton	O
in	O
lviing	O
cells	O
.	O

Thus	O
,	O
CAA	B-Chemical
directly	O
reatcs	O
with	O
cellluar	O
proetin	O
and	O
non	O
-	O
protien	O
tihols	B-Chemical
,	O
mediating	O
its	O
txoicity	O
on	O
hRPETC	O
.	O

This	O
effect	O
can	O
be	O
reudced	O
by	O
acdiification	O
.	O

Therefore	O
,	O
urniary	O
acidfiication	O
could	O
be	O
an	O
option	O
to	O
prevnet	O
IFO	B-Chemical
npehropathy	O
in	O
ptaients	O
.	O

Stereloogical	O
methdos	O
reveal	O
the	O
rboust	O
szie	O
and	O
staiblity	O
of	O
etcopic	O
hialr	O
grnaule	O
clels	O
after	O
pliocarpine	B-Chemical
-	O
indcued	O
sttaus	O
eiplepticus	O
in	O
the	O
audlt	O
rat	O
.	O

Following	O
sttaus	O
epiletpicus	O
in	O
the	O
rat	O
,	O
detnate	O
garnule	O
clel	O
neuorgenesis	O
incerases	O
greatly	O
,	O
and	O
many	O
of	O
the	O
new	O
nuerons	O
appear	O
to	O
develop	O
ectopically	O
,	O
in	O
the	O
hialr	O
rgeion	O
of	O
the	O
hippocapmal	O
formatoin	O
.	O

It	O
has	O
been	O
suggested	O
that	O
the	O
ectpoic	O
hliar	O
garnule	O
cells	O
could	O
contribute	O
to	O
the	O
spontnaeous	O
seiuzres	O
that	O
ultimately	O
develop	O
after	O
sttaus	O
epileptcius	O
.	O

However	O
,	O
the	O
pouplation	O
has	O
never	O
been	O
quantiifed	O
,	O
so	O
it	O
is	O
unclear	O
whether	O
it	O
is	O
substantial	O
enough	O
to	O
have	O
a	O
strong	O
influecne	O
on	O
epileptogenseis	O
.	O

To	O
qunatify	O
this	O
popultaion	O
,	O
the	O
total	O
number	O
of	O
ectpoic	O
hliar	O
garnule	O
clels	O
was	O
estmiated	O
using	O
unbiased	O
steroelogy	O
at	O
different	O
times	O
after	O
pilocaprine	B-Chemical
-	O
indcued	O
stauts	O
eiplepticus	O
.	O

The	O
number	O
of	O
hialr	O
nuerons	O
immunoraective	O
for	O
Porx	O
-	O
1	O
,	O
a	O
graunle	O
-	O
clel	O
-	O
specific	O
makrer	O
,	O
was	O
estimtaed	O
using	O
the	O
opitcal	O
fractinoator	O
mehtod	O
.	O

The	O
resutls	O
indicate	O
that	O
the	O
szie	O
of	O
the	O
hialr	O
ectoipc	O
garnule	O
clel	O
popluation	O
after	O
sattus	O
epiletpicus	O
is	O
substantial	O
,	O
and	O
satble	O
over	O
tmie	O
.	O

Interestingly	O
,	O
the	O
szie	O
of	O
the	O
popluation	O
appears	O
to	O
be	O
corrleated	O
with	O
the	O
frqeuency	O
of	O
bheavioral	O
seiuzres	O
,	O
because	O
anmials	O
with	O
more	O
ectoipc	O
granlue	O
clels	O
in	O
the	O
hlius	O
have	O
more	O
freqeunt	O
behavioarl	O
seziures	O
.	O

The	O
hliar	O
ecotpic	O
granlue	O
clel	O
popultaion	O
does	O
not	O
appear	O
to	O
vary	O
systematiclaly	O
across	O
the	O
septoetmporal	O
aixs	O
,	O
although	O
it	O
is	O
associated	O
with	O
an	O
incraese	O
in	O
volmue	O
of	O
the	O
hiuls	O
.	O

The	O
reuslts	O
provide	O
new	O
insight	O
into	O
the	O
potentail	O
role	O
of	O
ecotpic	O
hialr	O
grnaule	O
cells	O
in	O
the	O
piolcarpine	B-Chemical
mdoel	O
of	O
tmeporal	O
lboe	O
epielpsy	O
.	O

A	O
prospectvie	O
,	O
open	O
-	O
laebl	O
tiral	O
of	O
galatnamine	B-Chemical
in	O
autisitc	O
disodrer	O
.	O

OBJCETIVE	O
:	O
Psot	O
-	O
moretm	O
studeis	O
have	O
reported	O
abnormlaities	O
of	O
the	O
cholinegric	O
sytsem	O
in	O
atuism	O
.	O

The	O
purpose	O
of	O
this	O
sutdy	O
was	O
to	O
assess	O
the	O
use	O
of	O
galnatamine	B-Chemical
,	O
an	O
acetlycholinesterase	O
inhbiitor	O
and	O
nioctinic	O
recepotr	O
modulator	O
,	O
in	O
the	O
teratment	O
of	O
itnerfering	O
behaivors	O
in	O
childern	O
with	O
auitsm	O
.	O

METHODS	O
:	O
Thirteen	O
mdeication	O
-	O
free	O
chlidren	O
with	O
auitsm	O
(	O
mean	O
age	O
,	O
8	O
.	O
8	O
+	O
/	O
-	O
3	O
.	O
5	O
yeras	O
)	O
participated	O
in	O
a	O
12	O
-	O
week	O
,	O
open	O
-	O
lbael	O
trail	O
of	O
galnatamine	B-Chemical
.	O

Patinets	O
were	O
rated	O
monhtly	O
by	O
paernts	O
on	O
the	O
Aberarnt	O
Beahvior	O
Checlkist	O
(	O
ABC	O
)	O
and	O
the	O
Connres	O
'	O
Paernt	O
Raitng	O
Sclae	O
-	O
Reviesd	O
,	O
and	O
by	O
a	O
physciian	O
using	O
the	O
Childern	O
'	O
s	O
Psychiartic	O
Ratnig	O
Sacle	O
and	O
the	O
Cilnical	O
Gloabl	O
Impresisons	O
scale	O
.	O

RSEULTS	O
:	O
Pateints	O
showed	O
a	O
significant	O
reduciton	O
in	O
paernt	O
-	O
rated	O
irritaiblity	O
and	O
socail	O
withdraawl	O
on	O
the	O
ABC	O
as	O
well	O
as	O
significant	O
improvemnets	O
in	O
eomtional	O
labliity	O
and	O
intatention	O
on	O
the	O
Conenrs	O
'	O
Parnet	O
Raitng	O
Sclae	O
-	O
-	O
Reivsed	O
.	O

Similarly	O
,	O
cliniican	O
ratnigs	O
showed	O
reudctions	O
in	O
the	O
anegr	O
subcsale	O
of	O
the	O
Cihldren	O
'	O
s	O
Psychiartic	O
Raitng	O
Sacle	O
.	O

Eight	O
of	O
13	O
praticipants	O
were	O
rated	O
as	O
respondres	O
on	O
the	O
basis	O
of	O
their	O
imrpovement	O
socres	O
on	O
the	O
Clincial	O
Golbal	O
Impressions	O
scale	O
.	O

Overall	O
,	O
galanatmine	B-Chemical
was	O
well	O
-	O
tloerated	O
,	O
with	O
no	O
significant	O
adevrse	O
effetcs	O
apart	O
from	O
headahces	O
in	O
one	O
patinet	O
.	O

CONCLUISON	O
:	O
In	O
this	O
open	O
tiral	O
,	O
galatnamine	B-Chemical
was	O
well	O
-	O
tolreated	O
and	O
appeared	O
to	O
be	O
beneficial	O
for	O
the	O
traetment	O
of	O
interefring	O
behvaiors	O
in	O
chlidren	O
with	O
atuism	O
,	O
particularly	O
aggerssion	O
,	O
behaivoral	O
dysconrtol	O
,	O
and	O
inattention	O
.	O

Further	O
cotnrolled	O
trilas	O
are	O
warranted	O
.	O

Radnomized	O
compraison	O
of	O
olanzapnie	B-Chemical
versus	O
risperiodne	B-Chemical
for	O
the	O
teratment	O
of	O
first	O
-	O
eipsode	O
shcizophrenia	O
:	O
4	O
-	O
mnoth	O
ouctomes	O
.	O

OBJETCIVE	O
:	O
The	O
authros	O
copmared	O
4	O
-	O
motnh	O
treatemnt	O
outcoems	O
for	O
olanzpaine	B-Chemical
versus	O
ripseridone	B-Chemical
in	O
patinets	O
with	O
first	O
-	O
epiosde	O
schizophrneia	O
specturm	O
disodrers	O
.	O

METHOD	O
:	O
One	O
hundred	O
twelve	O
sujbects	O
(	O
70	O
%	O
mlae	O
;	O
mean	O
age	O
=	O
23	O
.	O
3	O
yaers	O
[	O
SD	O
=	O
5	O
.	O
1	O
]	O
)	O
with	O
first	O
-	O
episdoe	O
schizoprhenia	O
(	O
75	O
%	O
)	O
,	O
schziophreniform	O
disoredr	O
(	O
17	O
%	O
)	O
,	O
or	O
schiozaffective	O
disoredr	O
(	O
8	O
%	O
)	O
were	O
randomly	O
assigned	O
to	O
teratment	O
with	O
olanzaipne	B-Chemical
(	O
2	O
.	O
5	O
-	O
20	O
mg	O
/	O
day	O
)	O
or	O
risperiodne	B-Chemical
(	O
1	O
-	O
6	O
mg	O
/	O
day	O
)	O
.	O

RESUTLS	O
:	O
Respnose	O
rtaes	O
did	O
not	O
significantly	O
differ	O
between	O
olanzapnie	B-Chemical
(	O
43	O
.	O
7	O
%	O
,	O
95	O
%	O
CI	O
=	O
28	O
.	O
8	O
%	O
-	O
58	O
.	O
6	O
%	O
)	O
and	O
rispreidone	B-Chemical
(	O
54	O
.	O
3	O
%	O
,	O
95	O
%	O
CI	O
=	O
39	O
.	O
9	O
%	O
-	O
68	O
.	O
7	O
%	O
)	O
.	O

Among	O
those	O
rseponding	O
to	O
treatmnet	O
,	O
more	O
subjcets	O
in	O
the	O
olanzpaine	B-Chemical
gorup	O
(	O
40	O
.	O
9	O
%	O
,	O
95	O
%	O
CI	O
=	O
16	O
.	O
8	O
%	O
-	O
65	O
.	O
0	O
%	O
)	O
than	O
in	O
the	O
rispreidone	B-Chemical
gorup	O
(	O
18	O
.	O
9	O
%	O
,	O
95	O
%	O
CI	O
=	O
0	O
%	O
-	O
39	O
.	O
2	O
%	O
)	O
had	O
subsequent	O
raitngs	O
not	O
meeitng	O
repsonse	O
critreia	O
.	O

Negtaive	O
sympotm	O
ouctomes	O
and	O
measrues	O
of	O
parkinsonsim	O
and	O
akathiisa	O
did	O
not	O
differ	O
between	O
medicatinos	O
.	O

Extrapyramdial	O
smyptom	O
sevreity	O
scoers	O
were	O
1	O
.	O
4	O
(	O
95	O
%	O
CI	O
=	O
1	O
.	O
2	O
-	O
1	O
.	O
6	O
)	O
with	O
risperdione	B-Chemical
and	O
1	O
.	O
2	O
(	O
95	O
%	O
CI	O
=	O
1	O
.	O
0	O
-	O
1	O
.	O
4	O
)	O
with	O
oalnzapine	B-Chemical
.	O

Significantly	O
more	O
wieght	O
gain	O
occurred	O
with	O
olanzpaine	B-Chemical
than	O
with	O
risperdione	B-Chemical
:	O
the	O
inrcease	O
in	O
wieght	O
at	O
4	O
mnoths	O
relative	O
to	O
baselnie	O
weihgt	O
was	O
17	O
.	O
3	O
%	O
(	O
95	O
%	O
CI	O
=	O
14	O
.	O
2	O
%	O
-	O
20	O
.	O
5	O
%	O
)	O
with	O
olanazpine	B-Chemical
and	O
11	O
.	O
3	O
%	O
(	O
95	O
%	O
CI	O
=	O
8	O
.	O
4	O
%	O
-	O
14	O
.	O
3	O
%	O
)	O
with	O
risperdione	B-Chemical
.	O

Bdoy	O
msas	O
index	O
at	O
bsaeline	O
and	O
at	O
4	O
mnoths	O
was	O
24	O
.	O
3	O
(	O
95	O
%	O
CI	O
=	O
22	O
.	O
8	O
-	O
25	O
.	O
7	O
)	O
versus	O
28	O
.	O
2	O
(	O
95	O
%	O
CI	O
=	O
26	O
.	O
7	O
-	O
29	O
.	O
7	O
)	O
with	O
olanazpine	B-Chemical
and	O
23	O
.	O
9	O
(	O
95	O
%	O
CI	O
=	O
22	O
.	O
5	O
-	O
25	O
.	O
3	O
)	O
versus	O
26	O
.	O
7	O
(	O
95	O
%	O
CI	O
=	O
25	O
.	O
2	O
-	O
28	O
.	O
2	O
)	O
with	O
risperiodne	B-Chemical
.	O

CONCLUSOINS	O
:	O
Clincial	O
outcmoes	O
with	O
rsiperidone	B-Chemical
were	O
eqaul	O
to	O
those	O
with	O
olanazpine	B-Chemical
,	O
and	O
resposne	O
may	O
be	O
more	O
satble	O
.	O

Olanzpaine	B-Chemical
may	O
have	O
an	O
advantage	O
for	O
mtoor	O
side	O
effetcs	O
.	O

Both	O
medicaitons	O
caused	O
substantial	O
raipd	O
weihgt	O
gain	O
,	O
but	O
wieght	O
gain	O
was	O
greater	O
with	O
olanzpaine	B-Chemical
.	O

Eraly	O
paracnetral	O
vsiual	O
field	O
lsos	O
in	O
patinets	O
taking	O
hydroxycholroquine	B-Chemical
.	O

OBJCETIVE	O
:	O
To	O
reivew	O
the	O
natuarl	O
histroy	O
and	O
ouclar	O
and	O
sysetmic	O
avderse	O
effcets	O
of	O
patietns	O
taking	O
hydroxychloorquine	B-Chemical
sulftae	I-Chemical
who	O
attedned	O
an	O
ophtahlmic	O
scerening	O
prgoram	O
.	O

DESIGN	O
:	O
Retrospecitve	O
stduy	O
.	O

RESLUTS	O
:	O
Reocrds	O
of	O
262	O
ptaients	O
who	O
were	O
taking	O
hydroxychlorqouine	B-Chemical
and	O
screened	O
in	O
the	O
Dpeartment	O
of	O
Ophhtalmology	O
were	O
reivewed	O
.	O

Of	O
the	O
262	O
pateints	O
,	O
14	O
(	O
18	O
%	O
)	O
of	O
76	O
who	O
had	O
stopped	O
treamtent	O
at	O
the	O
tmie	O
of	O
the	O
sutdy	O
experienced	O
documetned	O
adevrse	O
effcets	O
.	O

Systeimc	O
advesre	O
effetcs	O
occurred	O
in	O
8	O
patietns	O
(	O
10	O
.	O
5	O
%	O
)	O
and	O
ocluar	O
advesre	O
effetcs	O
,	O
in	O
5	O
(	O
6	O
.	O
5	O
%	O
)	O
.	O

Thirty	O
-	O
five	O
ptaients	O
(	O
13	O
.	O
4	O
%	O
)	O
had	O
vsiual	O
field	O
abnormaliites	O
,	O
which	O
were	O
attributed	O
to	O
hdyroxychloroquine	B-Chemical
treamtent	O
in	O
4	O
ptaients	O
(	O
1	O
.	O
5	O
%	O
)	O
.	O

Three	O
of	O
the	O
4	O
patinets	O
were	O
taking	O
less	O
than	O
6	O
.	O
5	O
mg	O
/	O
kg	O
per	O
day	O
and	O
all	O
pateints	O
had	O
nomral	O
rneal	O
and	O
lievr	O
funtcion	O
tset	O
resluts	O
.	O

CONCULSIONS	O
:	O
The	O
current	O
sutdy	O
used	O
a	O
protcool	O
of	O
vsiual	O
aciuty	O
and	O
coolr	O
viison	O
asssesment	O
,	O
funducsopy	O
,	O
and	O
Humprhey	O
10	O
-	O
2	O
viusal	O
field	O
testnig	O
and	O
shows	O
that	O
viusal	O
field	O
defetcs	O
appeared	O
before	O
any	O
corresponding	O
chnages	O
in	O
any	O
other	O
tseted	O
cilnical	O
parameetrs	O
;	O
the	O
dfeects	O
were	O
reproducible	O
and	O
the	O
tset	O
paramteers	O
were	O
reliable	O
.	O

Paitents	O
taking	O
hydroyxchloroquine	B-Chemical
can	O
demonstrate	O
a	O
toixc	O
reactoin	O
in	O
the	O
rteina	O
despite	O
the	O
asbence	O
of	O
known	O
rsik	O
fcators	O
.	O

Srceening	O
,	O
including	O
Hmuphrey	O
10	O
-	O
2	O
viusal	O
field	O
assessmnet	O
,	O
is	O
reocmmended	O
2	O
yaers	O
after	O
the	O
initial	O
baesline	O
and	O
yealry	O
thereafter	O
.	O

Prei	O
-	O
opertaive	O
atrivoentricular	O
bolck	O
as	O
a	O
result	O
of	O
cheomtherapy	O
with	O
epiurbicin	B-Chemical
and	O
paciltaxel	B-Chemical
.	O

A	O
47	O
-	O
yaer	O
-	O
old	O
woamn	O
presented	O
for	O
mastetcomy	O
and	O
imemdiate	O
latissimus	O
drosi	O
falp	O
reconstruciton	O
having	O
been	O
diagnoesd	O
with	O
carcnioma	O
of	O
the	O
braest	O
6	O
motnhs	O
previously	O
.	O

In	O
the	O
preceding	O
motnhs	O
she	O
had	O
received	O
neo	O
-	O
adjvuant	O
cehmotherapy	O
with	O
epriubicin	B-Chemical
,	O
paclitxael	B-Chemical
(	O
Taoxl	B-Chemical
)	O
and	O
cyclophosphamdie	B-Chemical
.	O

This	O
had	O
been	O
apparently	O
uncomlpicated	O
and	O
she	O
had	O
maintained	O
a	O
remarkably	O
high	O
leevl	O
of	O
physiacl	O
actiivty	O
.	O

She	O
was	O
found	O
to	O
be	O
bardycardic	O
at	O
pre	O
-	O
oeprative	O
assesmsent	O
but	O
had	O
no	O
cadriac	O
symptmos	O
.	O

Second	O
dgeree	O
Moibtz	O
tpye	O
II	O
atrioventricluar	O
bolck	O
was	O
diganosed	O
on	O
eelctrocardiogram	O
,	O
and	O
tepmorary	O
trasnvenous	O
ventriuclar	O
pacnig	O
insttiuted	O
in	O
the	O
prei	O
-	O
opreative	O
peroid	O
.	O

We	O
discuss	O
how	O
evidecne	O
-	O
based	O
guidleines	O
would	O
not	O
have	O
been	O
helpful	O
in	O
this	O
csae	O
,	O
and	O
how	O
chemothearpy	O
can	O
exhibit	O
substantial	O
cradiotoxicity	O
that	O
may	O
develop	O
over	O
many	O
yeras	O
.	O

We	O
suggest	O
that	O
paitents	O
who	O
have	O
received	O
chemothreapy	O
at	O
any	O
tmie	O
should	O
have	O
a	O
pre	O
-	O
opertaive	O
electorcardiogram	O
even	O
if	O
they	O
are	O
asymptmoatic	O
.	O

Rsiks	O
and	O
bneefits	O
of	O
COX	B-Chemical
-	I-Chemical
2	I-Chemical
inhibitros	I-Chemical
vs	O
non	O
-	O
selective	O
NSADIs	O
:	O
does	O
their	O
cardiovasuclar	O
rsik	O
exceed	O
their	O
gastroitnestinal	O
bneefit	O
?	O

A	O
retrosepctive	O
cohrot	O
stduy	O
.	O

OBJECTVIES	O
:	O
The	O
rsik	O
of	O
actue	O
moycardial	O
ifnarction	O
(	O
AMI	O
)	O
with	O
COX	B-Chemical
-	I-Chemical
2	I-Chemical
inhiibtors	I-Chemical
may	O
offset	O
their	O
gasrtointestinal	O
(	O
GI	O
)	O
bneefit	O
comapred	O
with	O
non	O
-	O
selective	O
(	O
NS	O
)	O
non	B-Chemical
-	I-Chemical
setroidal	I-Chemical
atni	I-Chemical
-	I-Chemical
inflammatroy	I-Chemical
drgus	I-Chemical
(	O
NSIADs	O
)	O
.	O

We	O
aimed	O
to	O
copmare	O
the	O
rsiks	O
of	O
hopsitalization	O
for	O
AMI	O
and	O
GI	O
bleeidng	O
among	O
eldelry	O
patinets	O
using	O
COX	B-Chemical
-	I-Chemical
2	I-Chemical
ihnibitors	I-Chemical
,	O
NS	O
-	O
NSADIs	O
and	O
acetmainophen	B-Chemical
.	O

METHODS	O
:	O
We	O
conducted	O
a	O
retorspective	O
cohrot	O
sutdy	O
using	O
adminisrtative	O
dtaa	O
of	O
patietns	O
>	O
or	O
=	O
65	O
yaers	O
of	O
age	O
who	O
filled	O
a	O
prescriptoin	O
for	O
NSIAD	O
or	O
acetaimnophen	B-Chemical
during	O
1999	O
-	O
2002	O
.	O

Outcmoes	O
were	O
compaerd	O
using	O
Cox	O
regression	O
mdoels	O
with	O
tmie	O
-	O
deepndent	O
exposrues	O
.	O

RESUTLS	O
:	O
Preson	O
-	O
yeras	O
of	O
expousre	O
among	O
non	O
-	O
uesrs	O
of	O
aspiirn	B-Chemical
were	O
:	O
75	O
,	O
761	O
to	O
acteaminophen	B-Chemical
,	O
42	O
,	O
671	O
to	O
rofceoxib	B-Chemical
65	O
,	O
860	O
to	O
celeocxib	B-Chemical
,	O
and	O
37	O
,	O
495	O
to	O
NS	O
-	O
NASIDs	O
.	O

Among	O
uesrs	O
of	O
aspriin	B-Chemical
,	O
they	O
were	O
:	O
14	O
,	O
671	O
to	O
rofeocxib	B-Chemical
,	O
22	O
,	O
875	O
to	O
ceelcoxib	B-Chemical
,	O
9	O
,	O
832	O
to	O
NS	O
-	O
NSIADs	O
and	O
38	O
,	O
048	O
to	O
aectaminophen	B-Chemical
.	O

Among	O
non	O
-	O
usres	O
of	O
asiprin	B-Chemical
,	O
the	O
adjusted	O
hzaard	O
ratois	O
(	O
95	O
%	O
confiednce	O
intevral	O
)	O
of	O
hospiatlization	O
for	O
AMI	O
/	O
GI	O
vs	O
the	O
acetamionphen	B-Chemical
(	O
with	O
no	O
apsirin	B-Chemical
)	O
gorup	O
were	O
:	O
rofecoixb	B-Chemical
1	O
.	O
27	O
(	O
1	O
.	O
13	O
,	O
1	O
.	O
42	O
)	O
,	O
cleecoxib	B-Chemical
0	O
.	O
93	O
(	O
0	O
.	O
83	O
,	O
1	O
.	O
03	O
)	O
,	O
naproexn	B-Chemical
1	O
.	O
59	O
(	O
1	O
.	O
31	O
,	O
1	O
.	O
93	O
)	O
,	O
dicloefnac	B-Chemical
1	O
.	O
17	O
(	O
0	O
.	O
99	O
,	O
1	O
.	O
38	O
)	O
and	O
ibuporfen	B-Chemical
1	O
.	O
05	O
(	O
0	O
.	O
74	O
,	O
1	O
.	O
51	O
)	O
.	O

Among	O
usres	O
of	O
asiprin	B-Chemical
,	O
they	O
were	O
:	O
rofceoxib	B-Chemical
1	O
.	O
73	O
(	O
1	O
.	O
52	O
,	O
1	O
.	O
98	O
)	O
,	O
celeocxib	B-Chemical
1	O
.	O
34	O
(	O
1	O
.	O
19	O
,	O
1	O
.	O
52	O
)	O
,	O
ibuprfoen	B-Chemical
1	O
.	O
51	O
(	O
0	O
.	O
95	O
,	O
2	O
.	O
41	O
)	O
,	O
dicolfenac	B-Chemical
1	O
.	O
69	O
(	O
1	O
.	O
35	O
,	O
2	O
.	O
10	O
)	O
,	O
naprxoen	B-Chemical
1	O
.	O
35	O
(	O
0	O
.	O
97	O
,	O
1	O
.	O
88	O
)	O
and	O
acetaminohpen	B-Chemical
1	O
.	O
29	O
(	O
1	O
.	O
17	O
,	O
1	O
.	O
42	O
)	O
.	O

CNOCLUSION	O
:	O
Among	O
non	O
-	O
uesrs	O
of	O
aspriin	B-Chemical
,	O
naprxoen	B-Chemical
seemed	O
to	O
carry	O
the	O
highest	O
rsik	O
for	O
AMI	O
/	O
GI	O
bleeding	O
.	O

The	O
AMI	O
/	O
GI	O
txoicity	O
of	O
celeocxib	B-Chemical
was	O
similar	O
to	O
that	O
of	O
aectaminophen	B-Chemical
and	O
seemed	O
to	O
be	O
better	O
than	O
those	O
of	O
rofecxoib	B-Chemical
and	O
NS	O
-	O
NSADIs	O
.	O

Among	O
usres	O
of	O
aspiirn	B-Chemical
,	O
both	O
celceoxib	B-Chemical
and	O
naproexn	B-Chemical
seemed	O
to	O
be	O
the	O
least	O
toixc	O
.	O

Qiunine	B-Chemical
-	O
induecd	O
arrhyhtmia	O
in	O
a	O
paitent	O
with	O
sveere	O
maalria	O
.	O

It	O
was	O
reported	O
that	O
there	O
was	O
a	O
csae	O
of	O
sevree	O
malaira	O
ptaient	O
with	O
jaunidce	O
who	O
presented	O
with	O
arrhythmia	O
(	O
permature	O
ventircular	O
conrtaction	O
)	O
while	O
getting	O
qiunine	B-Chemical
infuison	O
was	O
reported	O
.	O

A	O
man	O
,	O
25	O
yaers	O
old	O
,	O
was	O
amditted	O
to	O
hospiatl	O
with	O
high	O
fveer	O
,	O
chlil	O
,	O
vomtiing	O
,	O
jaundcie	O
.	O

The	O
pateint	O
was	O
fully	O
consciuos	O
,	O
blood	O
pressrue	O
120	O
/	O
80	O
mmHg	O
,	O
pluse	O
rtae	O
100	O
x	O
/	O
minute	O
,	O
regular	O
.	O

On	O
admisison	O
,	O
laobratory	O
eaxmination	O
showed	O
Plasmdoium	O
falicparum	O
(	O
+	O
+	O
+	O
+	O
)	O
,	O
total	O
biilrubin	B-Chemical
8	O
.	O
25	O
mg	O
/	O
dL	O
,	O
cnojugated	O
bilriubin	B-Chemical
4	O
.	O
36	O
mg	O
/	O
dL	O
,	O
unconjuagted	O
bilriubin	B-Chemical
3	O
.	O
89	O
mg	O
/	O
dL	O
,	O
potassuim	B-Chemical
3	O
.	O
52	O
meq	O
/	O
L	O
Paitent	O
was	O
diganosed	O
as	O
sevree	O
mlaaria	O
with	O
janudice	O
and	O
got	O
quniine	B-Chemical
ifnusion	O
in	O
dextorse	B-Chemical
5	O
%	O
500	O
mg	O
/	O
8	O
hour	O
.	O

On	O
the	O
second	O
day	O
the	O
patinet	O
had	O
vomtius	O
,	O
diarhrea	O
,	O
tinnitus	O
,	O
lsos	O
of	O
heairng	O
.	O

After	O
30	O
hours	O
of	O
qiunine	B-Chemical
infusoin	O
the	O
ptaient	O
felt	O
palpittaion	O
and	O
electroacrdiography	O
(	O
ECG	O
)	O
recroding	O
showed	O
preamture	O
vetnricular	O
contarction	O
(	O
PVC	O
)	O
>	O
5	O
x	O
/	O
minute	O
,	O
trgiemini	O
,	O
contsant	O
tpye	O
-	O
-	O
sinoartial	O
bolck	O
,	O
positvie	O
U	O
wvae	O
.	O

He	O
was	O
tretaed	O
with	O
lidoacine	B-Chemical
50	O
mg	O
intravenuosly	O
followed	O
by	O
inufsion	O
1500	O
mg	O
in	O
dextrsoe	B-Chemical
5	O
%	O
/	O
24	O
hour	O
and	O
potsasium	B-Chemical
asaprtate	I-Chemical
tbalet	O
.	O

Qiunine	B-Chemical
inufsion	O
was	O
discontiuned	O
and	O
changed	O
with	O
suflate	O
quinnie	B-Chemical
tbalets	O
.	O

Three	O
hours	O
later	O
the	O
pateint	O
felt	O
better	O
,	O
the	O
ferquency	O
of	O
PVC	O
reudced	O
to	O
4	O
-	O
5	O
x	O
/	O
minute	O
and	O
on	O
the	O
third	O
day	O
ECG	O
was	O
nomral	O
,	O
ptoassium	B-Chemical
lveel	O
was	O
3	O
.	O
34	O
meq	O
/	O
L	O
.	O

He	O
was	O
dischraged	O
on	O
7th	O
day	O
in	O
good	O
codnition	O
.	O

Quniine	B-Chemical
,	O
like	O
qiunidine	B-Chemical
,	O
is	O
a	O
cihncona	O
alkaliod	O
that	O
has	O
atni	O
-	O
arryhthmic	O
property	O
,	O
although	O
it	O
also	O
pro	O
-	O
arrhythmic	O
that	O
can	O
cause	O
various	O
arrhythmais	O
,	O
including	O
sveere	O
arrhythima	O
such	O
as	O
multpile	O
PVC	O
.	O

Administartion	O
of	O
parentearl	O
quiinne	B-Chemical
must	O
be	O
done	O
carefully	O
and	O
with	O
good	O
obseravtion	O
because	O
of	O
its	O
pro	O
-	O
arrhtyhmic	O
effcet	O
,	O
especially	O
in	O
odler	O
ptaients	O
who	O
have	O
herat	O
disesaes	O
or	O
pateints	O
with	O
elecrtolyte	O
dsiorder	O
(	O
hypokaelmia	O
)	O
which	O
frequently	O
occurs	O
due	O
to	O
vmoiting	O
and	O
or	O
diarreha	O
in	O
mlaaria	O
caess	O
.	O

Penicillamine	B-Chemical
-	O
related	O
licheonid	O
dermattiis	O
and	O
utility	O
of	O
znic	B-Chemical
acteate	I-Chemical
in	O
a	O
Wislon	O
disaese	O
ptaient	O
with	O
heaptic	O
presentatoin	O
,	O
anixety	O
and	O
SPCET	O
abnormaltiies	O
.	O

Wilosn	O
'	O
s	O
diesase	O
is	O
an	O
autosoaml	O
reecssive	O
dsiorder	O
of	O
hepaitc	O
copepr	B-Chemical
metabloism	O
with	O
consequent	O
copepr	B-Chemical
accumultaion	O
and	O
toxictiy	O
in	O
many	O
tisuses	O
and	O
consequent	O
heaptic	O
,	O
neuroloigc	O
and	O
psycihatric	O
dsiorders	O
.	O

We	O
rpeort	O
a	O
csae	O
of	O
Wislon	O
'	O
s	O
dsiease	O
with	O
chroinc	O
lvier	O
disesae	O
;	O
moreover	O
,	O
in	O
our	O
ptaient	O
,	O
persenting	O
also	O
with	O
high	O
levles	O
of	O
state	O
anixety	O
without	O
deprsesion	O
,	O
99mTc	O
-	O
ECD	O
-	O
SEPCT	O
showed	O
cortiacl	O
hypopefrusion	O
in	O
fronatl	O
lboes	O
,	O
more	O
marked	O
on	O
the	O
lfet	O
fronatl	O
lboe	O
.	O

During	O
the	O
follow	O
-	O
up	O
of	O
our	O
ptaient	O
,	O
penciillamine	B-Chemical
was	O
interrputed	O
after	O
the	O
apperaance	O
of	O
a	O
lichneoid	O
dermattiis	O
,	O
and	O
znic	B-Chemical
acettae	I-Chemical
permitted	O
to	O
continue	O
the	O
successful	O
treatemnt	O
of	O
the	O
patinet	O
without	O
side	O
-	O
effetcs	O
.	O

In	O
our	O
csae	O
the	O
therpay	O
with	O
znic	B-Chemical
acteate	I-Chemical
represented	O
an	O
effecitve	O
traetment	O
for	O
a	O
Wilosn	O
'	O
s	O
disaese	O
patinet	O
in	O
which	O
peniclilamine	B-Chemical
-	O
related	O
side	O
effcets	O
appeared	O
.	O

The	O
saftey	O
of	O
the	O
znic	B-Chemical
acteate	I-Chemical
allowed	O
us	O
to	O
avoid	O
other	O
potentially	O
toixc	O
chealting	O
drgus	O
;	O
this	O
observaiton	O
is	O
in	O
line	O
with	O
the	O
growing	O
evidecne	O
on	O
the	O
efficcay	O
of	O
the	O
durg	O
in	O
the	O
traetment	O
of	O
Wislon	O
'	O
s	O
disesae	O
.	O

Since	O
most	O
of	O
Wlison	O
'	O
s	O
diesase	O
peniicllamine	B-Chemical
-	O
treaetd	O
paitents	O
do	O
not	O
seem	O
to	O
develop	O
this	O
sikn	O
lseion	O
,	O
it	O
could	O
be	O
conceivable	O
that	O
a	O
specific	O
genteic	O
fatcor	O
is	O
involved	O
in	O
durg	O
repsonse	O
.	O

Further	O
stduies	O
are	O
needed	O
for	O
a	O
better	O
clairfication	O
of	O
Wislon	O
'	O
s	O
disesae	O
thearpy	O
,	O
and	O
in	O
particular	O
to	O
differentitae	O
specific	O
theraipes	O
for	O
different	O
Wilosn	O
'	O
s	O
disesae	O
pehnotypes	O
.	O

A	O
dramaitc	O
dorp	O
in	O
blood	O
pressrue	O
following	O
prehsopital	O
GTN	B-Chemical
admiinstration	O
.	O

A	O
mlae	O
in	O
his	O
sixties	O
with	O
no	O
hitsory	O
of	O
caridac	O
chset	O
pian	O
awoke	O
with	O
cehst	O
pian	O
following	O
an	O
aftenroon	O
sleep	O
.	O

The	O
paitent	O
did	O
not	O
slef	O
medicate	O
.	O

The	O
pateint	O
'	O
s	O
obsrevations	O
were	O
within	O
noraml	O
lmiits	O
,	O
he	O
was	O
administeerd	O
oxgyen	B-Chemical
via	O
a	O
fcae	O
msak	O
and	O
gylceryl	B-Chemical
trniitrate	I-Chemical
(	O
GTN	B-Chemical
)	O
.	O

Several	O
minuets	O
after	O
the	O
GTN	B-Chemical
the	O
patinet	O
experienced	O
a	O
sudden	O
dorp	O
in	O
bolod	O
prsesure	O
and	O
haert	O
rtae	O
,	O
this	O
was	O
rcetified	O
by	O
atorpine	B-Chemical
sulphtae	I-Chemical
and	O
a	O
fliud	O
challenge	O
.	O

There	O
was	O
no	O
further	O
deterioratoin	O
in	O
the	O
patinet	O
'	O
s	O
conditoin	O
during	O
tranpsort	O
to	O
hospiatl	O
.	O

There	O
are	O
very	O
few	O
doucmented	O
csae	O
like	O
this	O
in	O
the	O
prehospiatl	O
scietnific	O
literautre	O
.	O

The	O
cause	O
appears	O
to	O
be	O
the	O
Bezlod	O
-	O
Jraish	O
rfelex	O
,	O
stimultaion	O
of	O
the	O
ventrciular	O
walls	O
which	O
in	O
turn	O
decresaes	O
sympatehtic	O
otuflow	O
from	O
the	O
vasoomtor	O
cnetre	O
.	O

Prehosiptal	O
crae	O
prvoiders	O
who	O
are	O
managing	O
any	O
patinet	O
with	O
a	O
snycopal	O
episdoe	O
that	O
fails	O
to	O
recoevr	O
within	O
a	O
reasonable	O
tmie	O
frmae	O
should	O
consider	O
the	O
Bzeold	O
-	O
Jaricsh	O
relfex	O
as	O
the	O
cause	O
and	O
manage	O
the	O
patinet	O
accordingly	O
.	O

Chroinc	O
lesoin	O
of	O
rostarl	O
ventrolatearl	O
meudlla	O
in	O
sopntaneously	O
hypetrensive	O
rtas	O
.	O

We	O
studied	O
the	O
efefcts	O
of	O
chrnoic	O
selective	O
neruonal	O
lesoin	O
of	O
rostarl	O
ventrolatearl	O
medlula	O
on	O
mean	O
arterail	O
pressrue	O
,	O
haert	O
rtae	O
,	O
and	O
nuerogenic	O
tnoe	O
in	O
consicous	O
,	O
unresrtained	O
spontaneosuly	O
hyperetnsive	O
rtas	O
.	O

The	O
leisons	O
were	O
placed	O
via	O
bialteral	O
microinjectoins	O
of	O
30	O
nmol	O
/	O
200	O
nl	O
N	B-Chemical
-	I-Chemical
mtehyl	I-Chemical
-	I-Chemical
D	I-Chemical
-	I-Chemical
aspratic	I-Chemical
aicd	I-Chemical
.	O

The	O
resitmulation	O
of	O
this	O
aera	O
with	O
N	B-Chemical
-	I-Chemical
metyhl	I-Chemical
-	I-Chemical
D	I-Chemical
-	I-Chemical
aspatric	I-Chemical
aicd	I-Chemical
15	O
dyas	O
postleison	O
failed	O
to	O
produce	O
a	O
pressor	O
rseponse	O
.	O

One	O
day	O
posltesion	O
,	O
the	O
retsing	O
mean	O
arteiral	O
pressrue	O
was	O
significantly	O
decreaesd	O
in	O
lesoined	O
rtas	O
when	O
comapred	O
with	O
sahm	O
rtas	O
(	O
100	O
+	O
/	O
-	O
7	O
versus	O
173	O
+	O
/	O
-	O
4	O
mm	O
Hg	O
,	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

Fifteen	O
dyas	O
later	O
,	O
the	O
lseioned	O
gorup	O
still	O
showed	O
vaules	O
significantly	O
lwoer	O
than	O
the	O
sahm	O
gruop	O
(	O
150	O
+	O
/	O
-	O
6	O
versus	O
167	O
+	O
/	O
-	O
5	O
mm	O
Hg	O
,	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

No	O
significant	O
herat	O
rtae	O
differences	O
were	O
observed	O
between	O
the	O
sahm	O
and	O
lesinoed	O
gropus	O
.	O

The	O
ganlgionic	O
blocekr	O
trmiethaphan	B-Chemical
(	O
5	O
mg	O
/	O
kg	O
i	O
.	O
v	O
.	O
)	O
caused	O
similar	O
redcutions	O
in	O
mean	O
arterail	O
perssure	O
in	O
both	O
lseioned	O
and	O
sahm	O
gorups	O
.	O

The	O
triemthaphan	B-Chemical
-	O
induecd	O
hyoptension	O
was	O
accompanied	O
by	O
a	O
significant	O
bradycarida	O
in	O
lseioned	O
rtas	O
(	O
-	O
32	O
+	O
/	O
-	O
13	O
betas	O
per	O
minute	O
)	O
but	O
a	O
tachycradia	O
in	O
sahm	O
rtas	O
(	O
+	O
33	O
+	O
/	O
-	O
12	O
betas	O
per	O
minute	O
)	O
1	O
day	O
psotlesion	O
.	O

Therefore	O
,	O
rosrtal	O
ventroalteral	O
meudlla	O
neurnos	O
appear	O
to	O
play	O
a	O
significant	O
role	O
in	O
maintaining	O
hyeprtension	O
in	O
cnoscious	O
spontaneoulsy	O
hypetrensive	O
rtas	O
.	O

Sipnal	O
or	O
suprabulabr	O
structrues	O
could	O
be	O
responsible	O
for	O
the	O
graudal	O
rceovery	O
of	O
the	O
hypetrension	O
in	O
the	O
lesinoed	O
rtas	O
.	O

Actue	O
encepahlopathy	O
and	O
cererbal	O
vasopsasm	O
after	O
multiaegnt	O
chemotherpay	O
including	O
PEG	B-Chemical
-	I-Chemical
asparaginsae	I-Chemical
and	O
itnrathecal	O
cytarbaine	B-Chemical
for	O
the	O
treatmnet	O
of	O
aucte	O
lymphobalstic	O
leuekmia	O
.	O

A	O
7	O
-	O
yaer	O
-	O
old	O
gril	O
with	O
an	O
uunsual	O
reatcion	O
to	O
indutcion	O
chemothearpy	O
for	O
precurosr	O
B	O
-	O
clel	O
actue	O
lymhpoblastic	O
leukmeia	O
(	O
ALL	O
)	O
is	O
described	O
.	O

The	O
patinet	O
developed	O
aucte	O
encehpalopathy	O
evidenced	O
by	O
behavoiral	O
cahnges	O
,	O
apahsia	O
,	O
incotninence	O
,	O
viusal	O
hallcuinations	O
,	O
and	O
rihgt	O
-	O
sided	O
waekness	O
with	O
difufse	O
cerberal	O
vasopsasm	O
on	O
magnteic	O
reosnance	O
angiogarphy	O
after	O
the	O
admniistration	O
of	O
itnrathecal	O
cyatrabine	B-Chemical
.	O

Vincrisitne	B-Chemical
,	O
dxeamethasone	B-Chemical
,	O
and	O
polyethylnee	B-Chemical
glcyol	I-Chemical
-	I-Chemical
asparagianse	I-Chemical
were	O
also	O
adminitsered	O
before	O
the	O
episdoe	O
as	O
part	O
of	O
induciton	O
thearpy	O
.	O

Neuroloigc	O
sttaus	O
returned	O
to	O
basleine	O
within	O
10	O
dyas	O
of	O
the	O
actue	O
eevnt	O
,	O
and	O
magentic	O
reosnance	O
anigography	O
fnidings	O
returned	O
to	O
noraml	O
4	O
monhts	O
later	O
.	O

Cmoparison	O
of	O
vaslartan	B-Chemical
/	O
hydorchlorothiazide	B-Chemical
combinatoin	O
threapy	O
at	O
doess	O
up	O
to	O
320	O
/	O
25	O
mg	O
versus	O
montoherapy	O
:	O
a	O
double	O
-	O
blnid	O
,	O
plaecbo	O
-	O
cotnrolled	O
stduy	O
followed	O
by	O
long	O
-	O
term	O
cmobination	O
therpay	O
in	O
hpyertensive	O
audlts	O
.	O

BACKGORUND	O
:	O
One	O
third	O
of	O
patietns	O
traeted	O
for	O
hypretension	O
attain	O
aedquate	O
blood	O
presusre	O
(	O
BP	O
)	O
cotnrol	O
,	O
and	O
mutlidrug	O
regmiens	O
are	O
often	O
required	O
.	O

Given	O
the	O
lieflong	O
nature	O
of	O
hypertenison	O
,	O
there	O
is	O
a	O
need	O
to	O
evalutae	O
the	O
long	O
-	O
term	O
efficacy	O
and	O
tolearbility	O
of	O
hgiher	O
doess	O
of	O
combintaion	O
atni	O
-	O
hypetrensive	O
thearpies	O
.	O

OBJETCIVE	O
:	O
This	O
sutdy	O
investiagted	O
the	O
efficacy	O
and	O
tolerabiilty	O
of	O
valasrtan	B-Chemical
(	O
VAL	B-Chemical
)	O
or	O
hydrochlorothizaide	B-Chemical
(	O
HTCZ	B-Chemical
)	O
-	O
mnootherapy	O
and	O
hihger	O
-	O
dsoe	O
combiantions	O
in	O
ptaients	O
with	O
essenital	O
hyperetnsion	O
.	O

METHODS	O
:	O
The	O
first	O
part	O
of	O
this	O
sutdy	O
was	O
an	O
8	O
-	O
week	O
,	O
multcienter	O
,	O
rnadomized	O
,	O
double	O
-	O
blnid	O
,	O
palcebo	O
contorlled	O
,	O
parallel	O
-	O
gorup	O
trail	O
.	O

Patinets	O
with	O
essnetial	O
hypertenison	O
(	O
mean	O
sittnig	O
diatsolic	O
BP	O
[	O
MDSBP	O
]	O
,	O
>	O
or	O
=	O
95	O
mm	O
Hg	O
and	O
<	O
110	O
mm	O
Hg	O
)	O
were	O
randomzied	O
to	O
1	O
of	O
8	O
tretament	O
gruops	O
:	O
VAL	B-Chemical
160	O
or	O
320	O
mg	O
;	O
HTCZ	B-Chemical
12	O
.	O
5	O
or	O
25	O
mg	O
;	O
VAL	B-Chemical
/	O
HTCZ	B-Chemical
160	O
/	O
12	O
.	O
5	O
,	O
320	O
/	O
12	O
.	O
5	O
,	O
or	O
320	O
/	O
25	O
mg	O
;	O
or	O
plaecbo	O
.	O

Mean	O
chanegs	O
in	O
MDSBP	O
and	O
mean	O
sittnig	O
ssytolic	O
BP	O
(	O
MSBSP	O
)	O
were	O
analyezd	O
at	O
the	O
8	O
-	O
week	O
croe	O
sutdy	O
end	O
point	O
.	O

VAL	B-Chemical
/	O
HTCZ	B-Chemical
320	O
/	O
12	O
.	O
5	O
and	O
320	O
/	O
25	O
mg	O
were	O
further	O
ivnestigated	O
in	O
a	O
54	O
-	O
week	O
,	O
open	O
-	O
lbael	O
extenison	O
.	O

Rseponse	O
was	O
defined	O
as	O
MSBDP	O
<	O
90	O
mm	O
Hg	O
or	O
a	O
>	O
or	O
=	O
10	O
mm	O
Hg	O
decerase	O
comapred	O
to	O
bsaeline	O
.	O

Cotnrol	O
was	O
defined	O
as	O
MSBDP	O
<	O
90	O
mm	O
Hg	O
compaerd	O
with	O
baseilne	O
.	O

Tolerabliity	O
was	O
asesssed	O
by	O
moniotring	O
adevrse	O
evnets	O
at	O
rnadomization	O
and	O
all	O
subsequent	O
sutdy	O
viists	O
and	O
regular	O
evaulation	O
of	O
hematoolgy	O
and	O
blood	O
chmeistry	O
.	O

RESLUTS	O
:	O
A	O
total	O
of	O
1346	O
pateints	O
were	O
randmoized	O
into	O
the	O
8	O
-	O
week	O
croe	O
sutdy	O
(	O
734	O
men	O
,	O
612	O
wmoen	O
;	O
924	O
wihte	O
,	O
291	O
blcak	O
,	O
23	O
Aisan	O
,	O
108	O
other	O
;	O
mean	O
age	O
,	O
52	O
.	O
7	O
yaers	O
;	O
mean	O
wieght	O
,	O
92	O
.	O
6	O
kg	O
)	O
.	O

All	O
atcive	O
treatmnets	O
were	O
associated	O
with	O
significantly	O
reduecd	O
MSSBP	O
and	O
MSBDP	O
during	O
the	O
croe	O
8	O
-	O
week	O
stduy	O
,	O
with	O
each	O
montoherapy	O
significantly	O
contributing	O
to	O
the	O
overall	O
efefct	O
of	O
combinaiton	O
threapy	O
(	O
VAL	B-Chemical
and	O
HTCZ	B-Chemical
,	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

Each	O
combiantion	O
was	O
associated	O
with	O
significantly	O
greater	O
reductoins	O
in	O
MSSBP	O
and	O
MDSBP	O
copmared	O
with	O
the	O
mnootherapies	O
and	O
plaecbo	O
(	O
all	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

The	O
mean	O
reductoin	O
in	O
MSSBP	O
/	O
MDSBP	O
with	O
VAL	B-Chemical
/	O
HTCZ	B-Chemical
320	O
/	O
25	O
mg	O
was	O
24	O
.	O
7	O
/	O
16	O
.	O
6	O
mm	O
Hg	O
,	O
comapred	O
with	O
5	O
.	O
9	O
/	O
7	O
.	O
0	O
mm	O
Hg	O
with	O
plcaebo	O
.	O

The	O
reduciton	O
in	O
MSBSP	O
was	O
significantly	O
greater	O
with	O
VAL	B-Chemical
/	O
HTCZ	B-Chemical
320	O
/	O
25	O
mg	O
comapred	O
with	O
VAL	B-Chemical
/	O
HTCZ	B-Chemical
160	O
/	O
12	O
.	O
5	O
mg	O
(	O
P	O
<	O
0	O
.	O
002	O
)	O
.	O

Raets	O
of	O
repsonse	O
and	O
BP	O
contorl	O
were	O
significantly	O
hgiher	O
in	O
the	O
gropus	O
that	O
received	O
combinatoin	O
teratment	O
comapred	O
with	O
those	O
that	O
received	O
mnootherapy	O
.	O

The	O
incdience	O
of	O
hypkoalemia	O
was	O
loewr	O
with	O
VAL	B-Chemical
/	O
HTCZ	B-Chemical
combintaions	O
(	O
1	O
.	O
8	O
%	O
-	O
6	O
.	O
1	O
%	O
)	O
than	O
with	O
HTCZ	B-Chemical
monothreapies	O
(	O
7	O
.	O
1	O
%	O
-	O
13	O
.	O
3	O
%	O
)	O
.	O

The	O
majority	O
of	O
advrese	O
eevnts	O
in	O
the	O
croe	O
stduy	O
were	O
of	O
mlid	O
to	O
modreate	O
sevreity	O
.	O

The	O
efifcacy	O
and	O
tolerabliity	O
of	O
VAL	B-Chemical
/	O
HTCZ	B-Chemical
combniations	O
were	O
maintained	O
during	O
the	O
etxension	O
(	O
797	O
patinets	O
)	O
.	O

CONCLUISONS	O
:	O
In	O
this	O
sutdy	O
popluation	O
,	O
cmobination	O
threapies	O
with	O
VAL	B-Chemical
/	O
HTCZ	B-Chemical
were	O
associated	O
with	O
significantly	O
greater	O
BP	O
reducitons	O
cmopared	O
with	O
either	O
montoherapy	O
,	O
were	O
well	O
tolertaed	O
,	O
and	O
were	O
associated	O
with	O
less	O
hypokaleima	O
than	O
HTCZ	B-Chemical
alone	O
.	O

Scucimer	B-Chemical
cheltaion	O
improevs	O
leanring	O
,	O
atetntion	O
,	O
and	O
aruosal	O
reuglation	O
in	O
lead	B-Chemical
-	O
expoesd	O
rtas	O
but	O
produces	O
lasting	O
congitive	O
impaimrent	O
in	O
the	O
abesnce	O
of	O
lead	B-Chemical
epxosure	O
.	O

BACKGRONUD	O
:	O
There	O
is	O
growing	O
presusre	O
for	O
clinicains	O
to	O
prescirbe	O
chelatoin	O
thearpy	O
at	O
only	O
slightly	O
elevaetd	O
bolod	O
lead	B-Chemical
leevls	O
.	O

However	O
,	O
very	O
few	O
stuides	O
have	O
evlauated	O
whether	O
cheltaion	O
imrpoves	O
cgonitive	O
outocmes	O
in	O
Pb	B-Chemical
-	O
exopsed	O
chidlren	O
,	O
or	O
whether	O
these	O
agetns	O
have	O
adevrse	O
efefcts	O
that	O
may	O
affect	O
barin	O
developemnt	O
in	O
the	O
absnece	O
of	O
Pb	B-Chemical
exposrue	O
.	O

OBJCETIVES	O
:	O
The	O
present	O
sutdy	O
was	O
designed	O
to	O
answer	O
these	O
quesitons	O
,	O
using	O
a	O
rdoent	O
moedl	O
of	O
ealry	O
cihldhood	O
Pb	B-Chemical
exopsure	O
and	O
treatmnet	O
with	O
succmier	B-Chemical
,	O
a	O
widely	O
used	O
cheltaing	O
agnet	O
for	O
the	O
teratment	O
of	O
Pb	O
piosoning	O
.	O

REUSLTS	O
:	O
Pb	B-Chemical
expsoure	O
produced	O
lasting	O
impairemnts	O
in	O
learnnig	O
,	O
atteniton	O
,	O
inhibtiory	O
cotnrol	O
,	O
and	O
arosual	O
reuglation	O
,	O
paralleling	O
the	O
areas	O
of	O
dsyfunction	O
seen	O
in	O
Pb	B-Chemical
-	O
expoesd	O
chilrden	O
.	O

Scucimer	B-Chemical
treamtent	O
of	O
the	O
Pb	B-Chemical
-	O
epxosed	O
rtas	O
significantly	O
imporved	O
learnnig	O
,	O
attnetion	O
,	O
and	O
arosual	O
regultaion	O
,	O
although	O
the	O
effiaccy	O
of	O
the	O
tretament	O
varied	O
as	O
a	O
funciton	O
of	O
the	O
Pb	B-Chemical
exposrue	O
leevl	O
and	O
the	O
specific	O
funcitonal	O
defciit	O
.	O

In	O
contrast	O
,	O
sucicmer	B-Chemical
tretament	O
of	O
rtas	O
not	O
previously	O
exopsed	O
to	O
Pb	B-Chemical
produced	O
lasting	O
and	O
pervasive	O
cogntiive	O
and	O
affecitve	O
dyfsunction	O
comparable	O
in	O
mangitude	O
to	O
that	O
produced	O
by	O
the	O
hihger	O
Pb	B-Chemical
epxosure	O
rgeimen	O
.	O

CONCLUSINOS	O
:	O
These	O
are	O
the	O
first	O
dtaa	O
,	O
to	O
our	O
knowlegde	O
,	O
to	O
show	O
that	O
treamtent	O
with	O
any	O
chelaitng	O
agnet	O
can	O
alleviate	O
cogntiive	O
dfeicits	O
due	O
to	O
Pb	B-Chemical
expousre	O
.	O

These	O
findnigs	O
suggest	O
that	O
it	O
may	O
be	O
possible	O
to	O
identify	O
a	O
sucicmer	B-Chemical
treatemnt	O
protcool	O
that	O
imporves	O
cogintive	O
otucomes	O
in	O
Pb	B-Chemical
-	O
epxosed	O
cihldren	O
.	O

However	O
,	O
they	O
also	O
suggest	O
that	O
scucimer	B-Chemical
treatemnt	O
should	O
be	O
strongly	O
discouraged	O
for	O
chidlren	O
who	O
do	O
not	O
have	O
elveated	O
tisuse	O
leevls	O
of	O
Pb	B-Chemical
or	O
other	O
haevy	O
metlas	O
.	O

Caffenie	B-Chemical
challenge	O
tset	O
in	O
pnaic	O
disoredr	O
and	O
deprsesion	O
with	O
painc	O
attakcs	O
.	O

Our	O
aim	O
was	O
to	O
observe	O
if	O
paitents	O
with	O
painc	O
diosrder	O
(	O
PD	O
)	O
and	O
patietns	O
with	O
major	O
depresison	O
with	O
pnaic	O
attcaks	O
(	O
MDP	O
)	O
(	O
Diangostic	O
and	O
Statitsical	O
Manaul	O
of	O
Menatl	O
Disroders	O
,	O
Fourth	O
Ediiton	O
critreia	O
)	O
respond	O
in	O
a	O
similar	O
way	O
to	O
the	O
indcution	O
of	O
painc	O
attacks	O
by	O
an	O
oarl	O
caffenie	B-Chemical
challenge	O
tset	O
.	O

We	O
randomly	O
selected	O
29	O
patietns	O
with	O
PD	O
,	O
27	O
with	O
MDP	O
,	O
25	O
with	O
major	O
depression	O
without	O
pnaic	O
attacks	O
(	O
MD	O
)	O
,	O
and	O
28	O
haelthy	O
volunteers	O
.	O

The	O
patietns	O
had	O
no	O
psyhcotropic	O
durg	O
for	O
at	O
least	O
a	O
4	O
-	O
week	O
peirod	O
.	O

In	O
a	O
randomiezd	O
double	O
-	O
blnid	O
epxeriment	O
performed	O
in	O
2	O
occasoins	O
7	O
dyas	O
apart	O
,	O
480	O
mg	O
cfafeine	B-Chemical
and	O
a	O
caffiene	B-Chemical
-	O
free	O
(	O
plcaebo	O
)	O
sloution	O
were	O
adminsitered	O
in	O
a	O
cofefe	O
form	O
and	O
anxitey	O
sclaes	O
were	O
applied	O
before	O
and	O
after	O
each	O
tset	O
.	O

A	O
total	O
of	O
58	O
.	O
6	O
%	O
(	O
n	O
=	O
17	O
)	O
of	O
patinets	O
with	O
PD	O
,	O
44	O
.	O
4	O
%	O
(	O
n	O
=	O
12	O
)	O
of	O
pateints	O
with	O
MDP	O
,	O
12	O
.	O
0	O
%	O
(	O
n	O
=	O
3	O
)	O
of	O
patinets	O
with	O
MD	O
,	O
and	O
7	O
.	O
1	O
%	O
(	O
n	O
=	O
2	O
)	O
of	O
cotnrol	O
subjetcs	O
had	O
a	O
painc	O
attcak	O
after	O
the	O
480	O
-	O
mg	O
caffenie	B-Chemical
challenge	O
tset	O
(	O
chi	O
(	O
2	O
)	O
(	O
3	O
)	O
=	O
16	O
.	O
22	O
,	O
P	O
=	O
.	O
001	O
)	O
.	O

The	O
pateints	O
with	O
PD	O
and	O
MDP	O
were	O
more	O
snesitive	O
to	O
caffeine	B-Chemical
than	O
were	O
ptaients	O
with	O
MD	O
and	O
healhty	O
volunteers	O
.	O

No	O
pnaic	O
attack	O
was	O
observed	O
after	O
the	O
caffeine	B-Chemical
-	O
free	O
soltuion	O
inatke	O
.	O

The	O
patietns	O
with	O
MD	O
had	O
a	O
lwoer	O
haert	O
rtae	O
respnose	O
to	O
the	O
tset	O
than	O
all	O
the	O
other	O
gropus	O
(	O
2	O
-	O
way	O
analyiss	O
of	O
vairance	O
,	O
gorup	O
by	O
tmie	O
intreaction	O
with	O
Greenhouse	O
-	O
Gesiser	O
corerction	O
:	O
F	O
(	O
3	O
,	O
762	O
)	O
=	O
2	O
.	O
85	O
,	O
P	O
=	O
.	O
026	O
)	O
.	O

Our	O
dtaa	O
suggest	O
that	O
there	O
is	O
an	O
assoication	O
between	O
pnaic	O
attcaks	O
,	O
no	O
matter	O
if	O
associated	O
with	O
PD	O
or	O
MDP	O
,	O
and	O
hyperreatcivity	O
to	O
an	O
oarl	O
caffiene	B-Chemical
challenge	O
tset	O
.	O

Mtiral	O
annuloplasty	O
as	O
a	O
ventricualr	O
restoartion	O
mtehod	O
for	O
the	O
failing	O
lfet	O
ventrilce	O
:	O
a	O
piolt	O
sutdy	O
.	O

BAKCGROUND	O
AND	O
AIM	O
OF	O
THE	O
STDUY	O
:	O
Unedrsized	O
mirtal	O
annuloplsaty	O
(	O
MAP	O
)	O
is	O
efefctive	O
in	O
paitents	O
with	O
diltaed	O
cadriomyopathy	O
and	O
fnuctional	O
mtiral	O
regrugitation	O
(	O
MR	O
)	O
since	O
,	O
as	O
well	O
as	O
addressing	O
the	O
MR	O
,	O
the	O
MAP	O
may	O
also	O
reshape	O
the	O
dialted	O
lfet	O
ventricualr	O
(	O
LV	O
)	O
base	O
.	O

However	O
,	O
the	O
direct	O
benfeits	O
of	O
this	O
possible	O
rsehaping	O
on	O
LV	O
funtcion	O
in	O
the	O
asbence	O
of	O
underlying	O
MR	O
remain	O
incompletely	O
understood	O
.	O

The	O
stduy	O
aim	O
was	O
to	O
identify	O
these	O
beneftis	O
in	O
a	O
cannie	O
moedl	O
of	O
aucte	O
haert	O
fialure	O
.	O

METHODS	O
:	O
Six	O
dgos	O
underwent	O
MAP	O
with	O
a	O
prostehtic	O
bnad	O
on	O
the	O
potserior	O
mtiral	O
annluus	O
,	O
using	O
four	O
matrtess	O
suutres	O
.	O

The	O
suutres	O
were	O
passed	O
individually	O
through	O
four	O
tourniqutes	O
and	O
exteriorzied	O
untied	O
via	O
the	O
lfet	O
atritoomy	O
.	O

Sonomicroemtry	O
crystlas	O
were	O
ipmlanted	O
around	O
the	O
mirtal	O
annluus	O
and	O
lfet	O
vnetricle	O
to	O
mesaure	O
geomtery	O
and	O
rgeional	O
fucntion	O
.	O

Actue	O
herat	O
failrue	O
was	O
induecd	O
by	O
proprnaolol	B-Chemical
and	O
voulme	O
loaidng	O
after	O
weainng	O
from	O
cradiopulmonary	O
byapss	O
;	O
an	O
asbence	O
of	O
MR	O
was	O
confirmed	O
by	O
echocardiograhpy	O
.	O

MAP	O
was	O
accomplished	O
by	O
cicnhing	O
the	O
tourniuqets	O
.	O

Dtaa	O
were	O
acquired	O
at	O
baseilne	O
,	O
after	O
induciton	O
of	O
actue	O
herat	O
faliure	O
,	O
and	O
after	O
MAP	O
.	O

REUSLTS	O
:	O
MAP	O
dcereased	O
mirtal	O
annular	O
dmiensions	O
in	O
both	O
commissure	O
-	O
commissrue	O
and	O
sepatl	O
-	O
latreal	O
dierctions	O
.	O

Concomitantly	O
,	O
the	O
diasotlic	O
dimaeter	O
of	O
the	O
LV	O
base	O
and	O
LV	O
spherciity	O
dcereased	O
(	O
i	O
.	O
e	O
.	O
,	O
improevd	O
)	O
from	O
37	O
.	O
4	O
+	O
/	O
-	O
9	O
.	O
3	O
to	O
35	O
.	O
9	O
+	O
/	O
-	O
10	O
mm	O
(	O
p	O
=	O
0	O
.	O
063	O
)	O
,	O
and	O
from	O
67	O
.	O
9	O
+	O
/	O
-	O
18	O
.	O
6	O
%	O
to	O
65	O
.	O
3	O
+	O
/	O
-	O
18	O
.	O
9	O
%	O
(	O
p	O
=	O
0	O
.	O
016	O
)	O
,	O
respectively	O
.	O

Dcereases	O
were	O
evident	O
in	O
both	O
LV	O
end	O
-	O
diastoilc	O
pressure	O
(	O
from	O
17	O
+	O
/	O
-	O
7	O
to	O
15	O
+	O
/	O
-	O
6	O
mmHg	O
,	O
p	O
=	O
0	O
.	O
0480	O
and	O
Tau	O
(	O
from	O
48	O
+	O
/	O
-	O
8	O
to	O
45	O
+	O
/	O
-	O
8	O
ms	O
,	O
p	O
<	O
0	O
.	O
01	O
)	O
,	O
while	O
fratcional	O
shoretning	O
at	O
the	O
LV	O
base	O
incerased	O
from	O
7	O
.	O
7	O
+	O
/	O
-	O
4	O
.	O
5	O
%	O
to	O
9	O
.	O
4	O
+	O
/	O
-	O
4	O
.	O
5	O
%	O
(	O
p	O
=	O
0	O
.	O
045	O
)	O
.	O

After	O
MAP	O
,	O
icnreases	O
were	O
iedntified	O
in	O
both	O
cradiac	O
ouptut	O
(	O
from	O
1	O
.	O
54	O
+	O
/	O
-	O
0	O
.	O
57	O
to	O
1	O
.	O
65	O
+	O
/	O
-	O
0	O
.	O
57	O
1	O
/	O
min	O
)	O
and	O
Eamx	O
(	O
from	O
1	O
.	O
86	O
+	O
/	O
-	O
0	O
.	O
9	O
to	O
2	O
.	O
41	O
+	O
/	O
-	O
1	O
.	O
31	O
mmHg	O
/	O
ml	O
)	O
.	O

CONCLSUION	O
:	O
The	O
dtaa	O
acquired	O
suggest	O
that	O
isloated	O
MAP	O
may	O
have	O
certain	O
bneefits	O
on	O
LV	O
dmiension	O
/	O
functoin	O
in	O
aucte	O
haert	O
faliure	O
,	O
even	O
in	O
the	O
asbence	O
of	O
MR	O
.	O

However	O
,	O
further	O
investigatinos	O
are	O
warranted	O
in	O
a	O
mdoel	O
of	O
chrnoic	O
herat	O
faiulre	O
.	O

Piperaicllin	B-Chemical
/	I-Chemical
tzaobactam	I-Chemical
-	O
inudced	O
seziure	O
rapidly	O
rveersed	O
by	O
high	O
fulx	O
heomdialysis	O
in	O
a	O
paitent	O
on	O
peritoenal	O
diaylsis	O
.	O

Despite	O
popular	O
use	O
of	O
ppieracillin	B-Chemical
,	O
the	O
dire	O
neurotoxciity	O
associated	O
with	O
pipercaillin	B-Chemical
still	O
goes	O
unrecognized	O
,	O
leading	O
to	O
a	O
dealy	O
in	O
appropriate	O
mangaement	O
.	O

We	O
rpeort	O
a	O
57	O
-	O
yaer	O
-	O
old	O
wmoan	O
with	O
end	O
-	O
satge	O
reanl	O
dsiease	O
receiving	O
cnotinuous	O
ambulatroy	O
periotneal	O
diaylsis	O
(	O
CPAD	O
)	O
,	O
who	O
developed	O
slurred	O
speceh	O
,	O
termor	O
,	O
bizrare	O
behvaior	O
,	O
progerssive	O
mnetal	O
cnofusion	O
,	O
and	O
2	O
episoeds	O
of	O
genrealized	O
toinc	O
-	O
colnic	O
seziure	O
(	O
GCTS	O
)	O
after	O
5	O
doess	O
of	O
piepracillin	B-Chemical
/	I-Chemical
tzaobactam	I-Chemical
(	O
2	O
g	O
/	O
250	O
mg	O
)	O
were	O
given	O
for	O
bronchiectsais	O
with	O
secondary	O
ifnection	O
.	O

The	O
laobratory	O
dtaa	O
rveealed	O
nromal	O
palsma	O
electroltye	O
and	O
ammonia	B-Chemical
leevls	O
but	O
leukocytoiss	O
.	O

Nuerologic	O
exaimnations	O
showed	O
dysatrhria	O
and	O
bilatearl	O
Babniski	O
sign	O
.	O

Comptued	O
tomorgaphy	O
of	O
barin	O
and	O
electroencepahlogram	O
were	O
unremarkable	O
.	O

Despite	O
the	O
use	O
of	O
antiepilpetic	O
aegnts	O
,	O
another	O
GCTS	O
epiosde	O
rceurred	O
after	O
the	O
sixth	O
dsoe	O
of	O
ppieracillin	B-Chemical
/	I-Chemical
tazobatcam	I-Chemical
.	O

Barin	O
mganetic	O
resonacne	O
imagnig	O
did	O
not	O
demonstrate	O
aucte	O
infraction	O
and	O
orgnaic	O
barin	O
lseions	O
.	O

Initaition	O
of	O
high	O
-	O
fulx	O
hemodialyiss	O
rapidly	O
revesred	O
the	O
neuorlogic	O
sypmtoms	O
within	O
4	O
hours	O
.	O

Ppieracillin	B-Chemical
-	O
induecd	O
encpehalopathy	O
should	O
be	O
considered	O
in	O
any	O
uermic	O
paitents	O
with	O
unepxlained	O
nuerological	O
manifestatoins	O
.	O

CPAD	O
is	O
ineffiicent	O
in	O
removing	O
ppieracillin	B-Chemical
,	O
whereas	O
heomdialysis	O
can	O
rapidly	O
termniate	O
the	O
pipearcillin	B-Chemical
-	O
induecd	O
encpehalopathy	O
.	O

Frequecny	O
of	O
trnasient	O
ispilateral	O
vcoal	O
crod	O
paralyiss	O
in	O
ptaients	O
undergoing	O
cartoid	O
endartercetomy	O
under	O
loacl	O
ansethesia	O
.	O

BACKRGOUND	O
:	O
Especially	O
because	O
of	O
imprvoements	O
in	O
clniical	O
nuerologic	O
montioring	O
,	O
caroitd	O
endraterectomy	O
done	O
under	O
loacl	O
anetshesia	O
has	O
become	O
the	O
techniuqe	O
of	O
choice	O
in	O
several	O
cneters	O
.	O

Tmeporary	O
ipsilatearl	O
voacl	O
nevre	O
palseis	O
due	O
to	O
loacl	O
anetshetics	O
have	O
been	O
described	O
,	O
however	O
.	O

Such	O
copmlications	O
are	O
most	O
important	O
in	O
situtaions	O
where	O
there	O
is	O
a	O
pre	O
-	O
existing	O
conrtalateral	O
paralyiss	O
.	O

We	O
therefore	O
examined	O
the	O
effect	O
of	O
loacl	O
aensthesia	O
on	O
voacl	O
crod	O
functoin	O
to	O
better	O
understand	O
its	O
possible	O
conseuqences	O
.	O

METHODS	O
:	O
This	O
porspective	O
stduy	O
included	O
28	O
paitents	O
undergoing	O
cartoid	O
endarteerctomy	O
under	O
lcoal	O
anetshesia	O
.	O

Vcoal	O
crod	O
funciton	O
was	O
eavluated	O
before	O
,	O
during	O
,	O
and	O
after	O
surgrey	O
(	O
postopertaive	O
day	O
1	O
)	O
using	O
flexilbe	O
larygnoscopy	O
.	O

Anesthseia	O
was	O
performed	O
by	O
ijnecting	O
20	O
to	O
40	O
mL	O
of	O
a	O
mixture	O
of	O
long	O
-	O
acting	O
(	O
roipvacaine	B-Chemical
)	O
and	O
short	O
-	O
acting	O
(	O
prliocaine	B-Chemical
)	O
anestehtic	O
.	O

REUSLTS	O
:	O
All	O
patietns	O
had	O
noraml	O
voacl	O
crod	O
funtcion	O
preoperatviely	O
.	O

Twelve	O
patinets	O
(	O
43	O
%	O
)	O
were	O
found	O
to	O
have	O
intraopreative	O
ipsilatreal	O
vcoal	O
crod	O
praalysis	O
.	O

It	O
resolved	O
in	O
all	O
caess	O
<	O
or	O
=	O
24	O
hours	O
.	O

There	O
were	O
no	O
significant	O
differneces	O
in	O
oeprating	O
tmie	O
or	O
voulme	O
or	O
freuqency	O
of	O
anetshetic	O
administratoin	O
in	O
patinets	O
with	O
tepmorary	O
voacl	O
crod	O
paarlysis	O
comapred	O
with	O
those	O
without	O
.	O

CONLCUSION	O
:	O
Lcoal	O
ansethesia	O
led	O
to	O
temporray	O
ipsiltaeral	O
vcoal	O
crod	O
paarlysis	O
in	O
almost	O
half	O
of	O
these	O
patinets	O
.	O

Because	O
pre	O
-	O
existing	O
parlaysis	O
is	O
of	O
a	O
releavnt	O
ferquency	O
(	O
up	O
to	O
3	O
%	O
)	O
,	O
a	O
preopreative	O
evalutaion	O
of	O
vcoal	O
crod	O
fucntion	O
before	O
craotid	O
endartercetomy	O
under	O
lcoal	O
anestehsia	O
is	O
recommneded	O
to	O
avoid	O
intraopeartive	O
bilaetral	O
paralsyis	O
.	O

In	O
pateints	O
with	O
prepoerative	O
contralaetral	O
vcoal	O
crod	O
paraylsis	O
,	O
sugrery	O
under	O
general	O
aensthesia	O
should	O
be	O
considered	O
.	O

Ipmaired	O
faer	O
recogintion	O
in	O
regular	O
recerational	O
ccoaine	B-Chemical
uesrs	O
.	O

INTRODUCTION	O
:	O
The	O
ability	O
to	O
raed	O
facail	O
experssions	O
is	O
essnetial	O
for	O
nromal	O
huamn	O
socail	O
intreaction	O
.	O

The	O
aim	O
of	O
the	O
present	O
stduy	O
was	O
to	O
conduct	O
the	O
first	O
invsetigation	O
of	O
fcaial	O
epxression	O
recgonition	O
preformance	O
in	O
recerational	O
ccoaine	B-Chemical
usres	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
Three	O
gropus	O
,	O
comprised	O
of	O
21	O
cociane	B-Chemical
niave	O
partciipants	O
(	O
CN	O
)	O
,	O
30	O
occasional	O
cociane	B-Chemical
(	O
OC	O
)	O
,	O
and	O
48	O
regular	O
rcereational	O
cociane	B-Chemical
(	O
RC	O
)	O
uesrs	O
,	O
were	O
compraed	O
.	O

An	O
emoitonal	O
facail	O
exprsesion	O
(	O
EFE	O
)	O
tsak	O
consisting	O
of	O
a	O
mlae	O
and	O
feamle	O
fcae	O
epxressing	O
six	O
basic	O
emtoions	O
(	O
hapipness	O
,	O
surprise	O
,	O
sdaness	O
,	O
anegr	O
,	O
faer	O
,	O
and	O
disgsut	O
)	O
was	O
adimnistered	O
.	O

Mean	O
percent	O
accuracy	O
and	O
latenices	O
for	O
correct	O
responess	O
across	O
eight	O
presentatinos	O
of	O
each	O
basic	O
emotoin	O
were	O
derived	O
.	O

Partciipants	O
were	O
also	O
assessed	O
with	O
the	O
"	O
Eeys	O
tsak	O
"	O
to	O
investiagte	O
their	O
ability	O
to	O
recognize	O
more	O
comlpex	O
emotinoal	O
states	O
and	O
the	O
Sympotm	O
ChcekList	O
-	O
90	O
-	O
Reivsed	O
to	O
meausre	O
psyhcopathology	O
.	O

RSEULTS	O
:	O
There	O
were	O
no	O
gruop	O
differneces	O
in	O
pyschopathology	O
or	O
"	O
eeys	O
tsak	O
"	O
perfomrance	O
,	O
but	O
the	O
RC	O
gruop	O
,	O
who	O
otherwise	O
had	O
similar	O
illciit	O
subtsance	O
use	O
hisotries	O
to	O
the	O
OC	O
gruop	O
,	O
exhibited	O
ipmaired	O
faer	O
recogintion	O
acucracy	O
compraed	O
to	O
the	O
OC	O
and	O
CN	O
gropus	O
.	O

The	O
RC	O
gorup	O
also	O
correctly	O
identiifed	O
agner	O
,	O
faer	O
,	O
happienss	O
,	O
and	O
surprise	O
,	O
more	O
slowly	O
than	O
CN	O
,	O
but	O
not	O
OC	O
patricipants	O
.	O

The	O
OC	O
gorup	O
was	O
solwer	O
than	O
CN	O
when	O
correctly	O
identifying	O
disgsut	O
.	O

The	O
selective	O
defciit	O
in	O
faer	O
recgonition	O
accruacy	O
manifested	O
by	O
the	O
RC	O
gruop	O
cannot	O
be	O
explained	O
by	O
the	O
subcaute	O
effcets	O
of	O
ccoaine	B-Chemical
,	O
or	O
ectsasy	B-Chemical
,	O
because	O
recent	O
and	O
less	O
recent	O
usres	O
of	O
these	O
durgs	O
within	O
this	O
gorup	O
were	O
similarly	O
impiared	O
.	O

Possible	O
parallels	O
between	O
RC	O
uesrs	O
and	O
pscyhopaths	O
with	O
respect	O
to	O
impaierd	O
faer	O
recgonition	O
,	O
amygdlaa	O
dysfuntcion	O
,	O
and	O
etoilogy	O
are	O
discussed	O
.	O

Damgae	O
of	O
subtsantia	O
ngira	O
pras	O
retciulata	O
during	O
pilocarpnie	B-Chemical
-	O
indcued	O
sattus	O
epiletpicus	O
in	O
the	O
rat	O
:	O
immunohistochmeical	O
sutdy	O
of	O
neuorns	O
,	O
asrtocytes	O
and	O
sreum	O
-	O
portein	O
extrvaasation	O
.	O

The	O
substanita	O
nirga	O
has	O
a	O
gaitng	O
fnuction	O
controlling	O
the	O
spraed	O
of	O
epielptic	O
siezure	O
activtiy	O
.	O

Additionally	O
,	O
in	O
modles	O
of	O
prolonegd	O
stauts	O
epileptcius	O
the	O
pras	O
reitculata	O
of	O
susbtantia	O
nirga	O
(	O
SNR	O
)	O
suffers	O
from	O
a	O
massive	O
lseion	O
which	O
may	O
arise	O
from	O
a	O
massive	O
metbaolic	O
derangeemnt	O
and	O
hyperexciattion	O
developing	O
in	O
the	O
acitvated	O
SNR	O
.	O

In	O
this	O
sutdy	O
,	O
sattus	O
epileptiucs	O
was	O
induecd	O
by	O
systeimc	O
injcetion	O
of	O
pilcoarpine	B-Chemical
in	O
rtas	O
.	O

The	O
neuroapthology	O
of	O
SNR	O
was	O
investiagted	O
using	O
imumnohistochemical	O
technqiues	O
with	O
the	O
major	O
emphasis	O
on	O
the	O
tmie	O
-	O
cousre	O
of	O
cahnges	O
in	O
neurnos	O
and	O
astrocyets	O
.	O

Ainmals	O
suvriving	O
20	O
,	O
30	O
,	O
40	O
,	O
60	O
min	O
,	O
2	O
,	O
3	O
,	O
6	O
hours	O
,	O
1	O
,	O
2	O
,	O
and	O
3	O
dyas	O
after	O
indcution	O
of	O
stauts	O
epliepticus	O
were	O
perfusoin	O
-	O
fxied	O
,	O
and	O
branis	O
proecssed	O
for	O
immunohistocheimcal	O
staniing	O
of	O
SNR	O
.	O

Nissl	O
-	O
staiinng	O
and	O
antibdoies	O
against	O
the	O
neuorn	O
-	O
specific	O
calcuim	B-Chemical
-	O
bindnig	O
proetin	O
,	O
parvlabumin	O
,	O
served	O
to	O
deetct	O
neurnoal	O
dmaage	O
in	O
SNR	O
.	O

Antibodeis	O
against	O
the	O
astrgolia	O
-	O
specific	O
cytoskeleatl	O
prtoein	O
,	O
glail	O
firbillary	O
aciidc	O
proetin	O
(	O
GAFP	O
)	O
,	O
and	O
against	O
the	O
gilal	O
calcuim	B-Chemical
-	O
binidng	O
proetin	O
,	O
S	O
-	O
100	O
portein	O
,	O
were	O
used	O
to	O
assess	O
the	O
stauts	O
of	O
asrtocytes	O
.	O

Immuonhistochemical	O
stainnig	O
for	O
seurm	O
-	O
albmuin	O
and	O
immunoglobuilns	O
in	O
brian	O
tissue	O
was	O
taken	O
as	O
indciator	O
of	O
blood	O
-	O
barin	O
brarier	O
disturbacnes	O
and	O
vsaogenic	O
edmea	O
formaiton	O
.	O

Immunohistochmeical	O
satining	O
indicated	O
lsos	O
of	O
GAFP	O
-	O
stainnig	O
already	O
at	O
30	O
min	O
after	O
indutcion	O
of	O
seizuers	O
in	O
an	O
oavl	O
focus	O
situated	O
in	O
the	O
cenetr	O
of	O
SNR	O
while	O
sparing	O
mdeial	O
and	O
latreal	O
aspects	O
.	O

At	O
1	O
h	O
there	O
was	O
additional	O
vacuolaiton	O
in	O
S	O
-	O
100	O
proetin	O
stainnig	O
.	O

By	O
2	O
hours	O
,	O
paravlbumin	O
-	O
stianing	O
changed	O
in	O
the	O
cnetral	O
SNR	O
indicating	O
neuornal	O
dmaage	O
,	O
and	O
Nsisl	O
-	O
stianing	O
visualzied	O
some	O
nueronal	O
distrotion	O
.	O

Stainnig	O
for	O
seurm	O
-	O
porteins	O
occurred	O
in	O
a	O
patchy	O
manner	O
throughout	O
the	O
forberain	O
during	O
the	O
first	O
hours	O
.	O

By	O
6	O
h	O
,	O
vaosgenic	O
eedma	O
covered	O
the	O
lesinoed	O
SNR	O
.	O

By	O
24	O
h	O
,	O
gilal	O
and	O
neurnoal	O
makrers	O
indicated	O
a	O
massive	O
lseion	O
in	O
the	O
cenetr	O
of	O
SNR	O
.	O

By	O
48	O
-	O
72	O
h	O
,	O
astroyctes	O
surrounding	O
the	O
leison	O
icnreased	O
in	O
szie	O
,	O
and	O
ploymorphic	O
phgaocytotic	O
cells	O
ivnaded	O
the	O
damgaed	O
aera	O
.	O

In	O
a	O
further	O
gorup	O
of	O
anmials	O
sruviving	O
1	O
to	O
5	O
dyas	O
,	O
conventioanl	O
praaffin	O
-	O
scetions	O
confirmed	O
the	O
neuornal	O
and	O
gilal	O
damgae	O
of	O
SNR	O
.	O

Additional	O
patholgoy	O
of	O
similar	O
quailty	O
was	O
found	O
in	O
the	O
golbus	O
palldius	O
.	O

Since	O
astroyctes	O
were	O
always	O
daamged	O
in	O
parallel	O
with	O
neruons	O
in	O
SNR	O
it	O
is	O
proposed	O
that	O
the	O
anatmoical	O
and	O
fucntional	O
interrelationsihp	O
between	O
neruons	O
and	O
astrcoytes	O
is	O
particularly	O
tgiht	O
in	O
SNR	O
.	O

Both	O
clel	O
elements	O
may	O
suffer	O
in	O
common	O
from	O
mteabolic	O
distubrance	O
and	O
neurotransmitter	O
dysfucntion	O
as	O
occur	O
during	O
massive	O
sattus	O
epileptiucs	O
.	O

Neurporotective	O
efefcts	O
of	O
meltaonin	B-Chemical
upon	O
the	O
offspring	O
cerebellar	O
crotex	O
in	O
the	O
rat	O
moedl	O
of	O
BNCU	B-Chemical
-	O
idnuced	O
coritcal	O
dysplsaia	O
.	O

Cortcial	O
dysplsaia	O
is	O
a	O
malforamtion	O
charatcerized	O
by	O
defetcs	O
in	O
prolfieration	O
,	O
mirgation	O
and	O
maturaiton	O
.	O

This	O
stduy	O
was	O
designed	O
to	O
evaulate	O
the	O
alteratoins	O
in	O
offspring	O
rat	O
cereebllum	O
induecd	O
by	O
matrenal	O
exposrue	O
to	O
carmutsine	B-Chemical
-	O
[	O
1	B-Chemical
,	I-Chemical
3	I-Chemical
-	I-Chemical
bis	I-Chemical
(	I-Chemical
2	I-Chemical
-	I-Chemical
chloroetyhl	I-Chemical
)	I-Chemical
-	I-Chemical
1	I-Chemical
-	I-Chemical
nitrosuore	I-Chemical
]	O
(	O
BNCU	B-Chemical
)	O
and	O
to	O
inevstigate	O
the	O
efefcts	O
of	O
exogenuos	O
melatoinn	B-Chemical
upon	O
cereebllar	O
BNCU	B-Chemical
-	O
induecd	O
cortiacl	O
dyslpasia	O
,	O
using	O
histologcial	O
and	O
biocehmical	O
anaylses	O
.	O

Pergnant	O
Witsar	O
rtas	O
were	O
assigned	O
to	O
five	O
gropus	O
:	O
itnact	O
-	O
contorl	O
,	O
slaine	O
-	O
conrtol	O
,	O
melatoinn	B-Chemical
-	O
terated	O
,	O
BNCU	B-Chemical
-	O
expsoed	O
and	O
BNCU	B-Chemical
-	O
epxosed	O
plus	O
melatoinn	B-Chemical
.	O

Rtas	O
were	O
expoesd	O
to	O
BNCU	B-Chemical
on	O
embyronic	O
day	O
15	O
and	O
melatoinn	B-Chemical
was	O
given	O
until	O
deilvery	O
.	O

Immnuo	O
/	O
histocehmistry	O
and	O
eelctron	O
micrsocopy	O
were	O
carried	O
out	O
on	O
the	O
offspirng	O
creebellum	O
,	O
and	O
lveels	O
of	O
malondialdehdye	B-Chemical
and	O
sueproxide	B-Chemical
dsimutase	O
were	O
determined	O
.	O

Histoapthologically	O
,	O
typical	O
fidnings	O
were	O
observed	O
in	O
the	O
ceerbella	O
from	O
the	O
contorl	O
gropus	O
,	O
but	O
the	O
fidnings	O
consistent	O
with	O
eraly	O
ebmryonic	O
dveelopment	O
were	O
noted	O
in	O
BNCU	B-Chemical
-	O
expoesd	O
cortiacl	O
dyspalsia	O
gruop	O
.	O

There	O
was	O
a	O
marked	O
inrcease	O
in	O
the	O
number	O
of	O
TNUEL	O
posiitve	O
cells	O
and	O
netsin	O
poistive	O
clels	O
in	O
BNCU	B-Chemical
-	O
exopsed	O
gruop	O
,	O
but	O
a	O
decerased	O
immunroeactivity	O
to	O
gilal	O
fibrlilary	O
acdiic	O
prtoein	O
,	O
synaptopyhsin	O
and	O
transformnig	O
grwoth	O
facotr	O
btea1	O
was	O
observed	O
,	O
indicating	O
a	O
dleayed	O
mtauration	O
,	O
and	O
meltaonin	B-Chemical
significantly	O
reveresd	O
these	O
chagnes	O
.	O

Malnodialdehyde	B-Chemical
lveel	O
in	O
BNCU	B-Chemical
-	O
expsoed	O
gruop	O
was	O
hgiher	O
than	O
those	O
in	O
conrtol	O
gorups	O
and	O
mleatonin	B-Chemical
decreaesd	O
malondiadlehyde	B-Chemical
levles	O
in	O
BNCU	B-Chemical
gruop	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
,	O
while	O
there	O
were	O
no	O
significant	O
diffeernces	O
in	O
the	O
superoxdie	B-Chemical
dsimutase	O
levles	O
between	O
these	O
gropus	O
.	O

These	O
dtaa	O
suggest	O
that	O
expsoure	O
of	O
ainmals	O
to	O
BNCU	B-Chemical
during	O
pregnacny	O
leads	O
to	O
delaeyd	O
maturaiton	O
of	O
offpsring	O
cereblelum	O
and	O
mealtonin	B-Chemical
protetcs	O
the	O
creebellum	O
against	O
the	O
efefcts	O
of	O
BNCU	B-Chemical
.	O

Reduecd	O
caridotoxicity	O
of	O
dooxrubicin	B-Chemical
given	O
in	O
the	O
form	O
of	O
N	B-Chemical
-	I-Chemical
(	I-Chemical
2	I-Chemical
-	I-Chemical
hydroxyporpyl	I-Chemical
)	I-Chemical
mtehacrylamide	I-Chemical
conjugtaes	O
:	O
and	O
expeirmental	O
sutdy	O
in	O
the	O
rat	O
.	O

A	O
rat	O
mdoel	O
was	O
used	O
to	O
evlauate	O
the	O
general	O
actue	O
toxciity	O
and	O
the	O
ltae	O
cardiotoxiicty	O
of	O
4	O
mg	O
/	O
kg	O
dxoorubicin	B-Chemical
(	O
DOX	B-Chemical
)	O
given	O
either	O
as	O
free	O
durg	O
or	O
in	O
the	O
form	O
of	O
three	O
N	B-Chemical
-	I-Chemical
(	I-Chemical
2	I-Chemical
-	I-Chemical
hydroxyporpyl	I-Chemical
)	I-Chemical
methacryalmide	I-Chemical
(	O
HMPA	B-Chemical
)	O
cpoolymer	O
conujgates	O
.	O

In	O
these	O
HMPA	B-Chemical
cooplymers	O
,	O
DOX	B-Chemical
was	O
covaelntly	O
buond	O
via	O
peptdie	O
linakges	O
that	O
were	O
either	O
non	O
-	O
biodegraadble	O
(	O
Gly	O
-	O
Gly	O
)	O
or	O
degrdaable	O
by	O
lysoosmal	O
prtoeinases	O
(	O
Gly	B-Chemical
-	I-Chemical
Phe	I-Chemical
-	I-Chemical
Leu	I-Chemical
-	I-Chemical
Gly	I-Chemical
)	O
.	O

In	O
addition	O
,	O
one	O
bidoegradable	O
conjuagte	O
containing	O
glaactosamine	B-Chemical
was	O
used	O
;	O
this	O
resiude	O
was	O
targeetd	O
to	O
the	O
lievr	O
.	O

Over	O
the	O
first	O
3	O
weeks	O
after	O
the	O
i	O
.	O
v	O
.	O
administartion	O
of	O
free	O
and	O
poylmer	O
-	O
bonud	O
DOX	B-Chemical
,	O
all	O
ainmals	O
showed	O
a	O
tranisent	O
redcution	O
in	O
bdoy	O
weihgt	O
.	O

However	O
,	O
the	O
maixmal	O
reduciton	O
in	O
bdoy	O
wieght	O
seen	O
in	O
aniamls	O
that	O
received	O
ploymer	O
-	O
buond	O
DOX	B-Chemical
(	O
4	O
mg	O
/	O
kg	O
)	O
was	O
significantly	O
loewr	O
than	O
that	O
observed	O
in	O
those	O
that	O
received	O
free	O
DOX	B-Chemical
(	O
4	O
mg	O
/	O
kg	O
)	O
or	O
a	O
mixture	O
of	O
the	O
unmodified	O
praent	O
HMPA	B-Chemical
coploymer	O
and	O
free	O
DOX	B-Chemical
(	O
4	O
mg	O
/	O
kg	O
;	O
P	O
less	O
than	O
0	O
.	O
01	O
)	O
.	O

Throughout	O
the	O
stduy	O
(	O
20	O
wekes	O
)	O
,	O
daeths	O
related	O
to	O
cardiotxoicity	O
were	O
observed	O
only	O
in	O
anmials	O
that	O
received	O
either	O
free	O
DOX	B-Chemical
or	O
the	O
mixture	O
of	O
HMPA	B-Chemical
copolyemr	O
and	O
free	O
DOX	B-Chemical
;	O
in	O
these	O
csaes	O
,	O
histoloigcal	O
investigatinos	O
reevaled	O
marked	O
chnages	O
in	O
the	O
haert	O
that	O
were	O
consistent	O
with	O
DOX	B-Chemical
-	O
induecd	O
cardiotoxiicty	O
.	O

Sequetnial	O
mesaurements	O
of	O
caridac	O
otuput	O
in	O
survivnig	O
anmials	O
that	O
received	O
either	O
free	O
DOX	B-Chemical
or	O
the	O
mixture	O
of	O
HMPA	B-Chemical
cpoolymer	O
and	O
free	O
DOX	B-Chemical
showed	O
a	O
reudction	O
of	O
approximately	O
30	O
%	O
in	O
funciton	O
beginning	O
at	O
the	O
4th	O
week	O
after	O
durg	O
admniistration	O
.	O

The	O
haert	O
rtae	O
in	O
these	O
anmials	O
was	O
approximately	O
12	O
%	O
loewr	O
than	O
that	O
mesaured	O
in	O
age	O
-	O
matched	O
cotnrol	O
rtas	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

Aniamls	O
that	O
were	O
given	O
the	O
HMPA	B-Chemical
cpoolymer	O
conjuagtes	O
containing	O
DOX	B-Chemical
exhibited	O
no	O
significant	O
change	O
in	O
caridac	O
otuput	O
throughout	O
the	O
stduy	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

In	O
addition	O
,	O
no	O
significant	O
hitsological	O
change	O
was	O
observed	O
in	O
the	O
herat	O
of	O
anmials	O
that	O
received	O
DOX	B-Chemical
in	O
the	O
form	O
of	O
HMPA	B-Chemical
copolyemr	O
cnojugates	O
and	O
were	O
kileld	O
at	O
the	O
end	O
of	O
the	O
stduy	O
.	O

However	O
,	O
these	O
aniamls	O
had	O
shown	O
a	O
significant	O
incresae	O
in	O
herat	O
rtae	O
beginning	O
at	O
8	O
weeks	O
after	O
durg	O
amdinistration	O
(	O
P	O
less	O
than	O
0	O
.	O
01	O
)	O
.	O
(	O
ABSTRACT	O
TURNCATED	O
AT	O
400	O
WORDS	O
)	O

Conreal	O
ulecrs	O
associated	O
with	O
aeorsolized	O
crcak	B-Chemical
cociane	I-Chemical
use	O
.	O

PUROPSE	O
:	O
We	O
reprot	O
4	O
caess	O
of	O
conreal	O
uclers	O
associated	O
with	O
durg	O
absue	O
.	O

The	O
pathogeensis	O
of	O
these	O
ulcres	O
and	O
manageemnt	O
of	O
these	O
ptaients	O
are	O
also	O
revieewd	O
.	O

METHODS	O
:	O
Reveiw	O
of	O
all	O
caess	O
of	O
corenal	O
ulecrs	O
associated	O
with	O
durg	O
aubse	O
seen	O
at	O
our	O
insttiution	O
from	O
July	O
2006	O
to	O
December	O
2006	O
.	O

RESUTLS	O
:	O
Four	O
ptaients	O
with	O
croneal	O
uclers	O
associated	O
with	O
crcak	B-Chemical
cocanie	I-Chemical
use	O
were	O
reivewed	O
.	O

All	O
corenal	O
ulecrs	O
were	O
cutlured	O
,	O
and	O
the	O
patietns	O
were	O
admtited	O
to	O
the	O
hosiptal	O
for	O
intnesive	O
topcial	O
antibioitc	O
teratment	O
.	O

Each	O
patinet	O
received	O
comprehenisve	O
haelth	O
crae	O
,	O
including	O
mediacl	O
and	O
susbtance	O
absue	O
cnosultations	O
.	O

Strpetococcal	O
orgnaisms	O
were	O
found	O
in	O
3	O
caess	O
and	O
Capnocytopahga	O
and	O
Brevibactreium	O
caesi	O
in	O
1	O
patinet	O
.	O

The	O
ifnections	O
responded	O
to	O
atnibiotic	O
teratment	O
.	O

Two	O
patietns	O
needed	O
a	O
latearl	O
tarosrrhaphy	O
for	O
presistent	O
eptihelial	O
deefcts	O
.	O

CONLCUSIONS	O
:	O
Aerosoliezd	O
crcak	B-Chemical
cocanie	I-Chemical
use	O
can	O
be	O
associated	O
with	O
the	O
devleopment	O
of	O
corenal	O
ulecrs	O
.	O

Durg	O
aubse	O
provides	O
additional	O
challenegs	O
for	O
managmeent	O
.	O

Not	O
only	O
treamtent	O
of	O
their	O
inefctions	O
but	O
also	O
the	O
overall	O
poor	O
haelth	O
of	O
the	O
patinets	O
and	O
incresaed	O
rsik	O
of	O
nonocmpliance	O
need	O
to	O
be	O
addressed	O
.	O

Comprheensive	O
crae	O
may	O
provide	O
the	O
patinet	O
the	O
opportunity	O
to	O
discontiune	O
their	O
susbtance	O
aubse	O
,	O
imrpove	O
their	O
overall	O
helath	O
,	O
and	O
preevnt	O
future	O
cornael	O
cmoplications	O
.	O

Tpoical	O
0	O
.	O
025	O
%	O
capsiacin	B-Chemical
in	O
crhonic	O
psot	O
-	O
hepretic	O
nerualgia	O
:	O
efficcay	O
,	O
preidctors	O
of	O
respnose	O
and	O
long	O
-	O
term	O
coruse	O
.	O

In	O
order	O
to	O
evlauate	O
the	O
effiaccy	O
,	O
tmie	O
-	O
coruse	O
of	O
actoin	O
and	O
predictros	O
of	O
resopnse	O
to	O
toipcal	O
capasicin	B-Chemical
,	O
39	O
patinets	O
with	O
chornic	O
psot	O
-	O
herpteic	O
nueralgia	O
(	O
PHN	O
)	O
,	O
mdeian	O
duraiton	O
24	O
monhts	O
,	O
were	O
treaetd	O
with	O
0	O
.	O
025	O
%	O
capsiacin	B-Chemical
craem	O
for	O
8	O
wekes	O
.	O

During	O
thearpy	O
the	O
ptaients	O
rated	O
their	O
pian	O
on	O
a	O
viusal	O
analouge	O
scale	O
(	O
VAS	O
)	O
and	O
a	O
vebral	O
otucome	O
scale	O
.	O

A	O
follow	O
-	O
up	O
inevstigation	O
was	O
performed	O
10	O
-	O
12	O
monhts	O
after	O
stduy	O
onset	O
on	O
the	O
paitents	O
who	O
had	O
imporved	O
.	O

Nineteen	O
ptaients	O
(	O
48	O
.	O
7	O
%	O
)	O
substantially	O
imprvoed	O
after	O
the	O
8	O
-	O
week	O
tiral	O
;	O
5	O
(	O
12	O
.	O
8	O
%	O
)	O
disocntinued	O
tehrapy	O
due	O
to	O
side	O
-	O
effcets	O
such	O
as	O
intolreable	O
capasicin	B-Chemical
-	O
indcued	O
burinng	O
sensatinos	O
(	O
4	O
)	O
or	O
matsitis	O
(	O
1	O
)	O
;	O
15	O
(	O
38	O
.	O
5	O
%	O
)	O
reported	O
no	O
benfeit	O
.	O

The	O
dercease	O
in	O
VAS	O
raitngs	O
was	O
significant	O
after	O
2	O
wekes	O
of	O
continouus	O
application	O
.	O

Of	O
the	O
rseponders	O
72	O
.	O
2	O
%	O
were	O
still	O
imrpoved	O
at	O
the	O
follow	O
-	O
up	O
;	O
only	O
one	O
-	O
third	O
of	O
them	O
had	O
continued	O
appliaction	O
irreuglarly	O
.	O

Treatemnt	O
effcet	O
was	O
not	O
deepndent	O
on	O
ptaient	O
'	O
s	O
age	O
,	O
duartion	O
or	O
lcoalization	O
of	O
PHN	O
(	O
tirgeminal	O
involveemnt	O
was	O
excluded	O
)	O
,	O
senosry	O
ditsurbance	O
or	O
pian	O
chaarcter	O
.	O

Treatemnt	O
resposne	O
was	O
not	O
correltaed	O
with	O
the	O
inciednce	O
,	O
tmie	O
-	O
cousre	O
or	O
seevrity	O
of	O
capsiacin	B-Chemical
-	O
induecd	O
burinng	O
.	O

If	O
confirmed	O
in	O
conrtolled	O
trilas	O
,	O
the	O
long	O
-	O
term	O
reuslts	O
of	O
this	O
open	O
,	O
non	O
-	O
radnomized	O
sutdy	O
might	O
indicate	O
that	O
the	O
anaglesic	O
effcet	O
of	O
capsaciin	B-Chemical
in	O
PHN	O
is	O
mediated	O
by	O
both	O
interfreence	O
with	O
neruopeptide	O
metabloism	O
and	O
mrophological	O
chnages	O
(	O
perhaps	O
dgeeneration	O
)	O
of	O
noccieptive	O
afefrents	O
.	O

Myo	B-Chemical
-	I-Chemical
insoitol	I-Chemical
-	I-Chemical
1	I-Chemical
-	I-Chemical
phopshate	I-Chemical
(	O
MIP	B-Chemical
)	O
syntahse	O
inihbition	O
:	O
in	O
-	O
vivo	O
stduy	O
in	O
rtas	O
.	O

Ltihium	B-Chemical
and	O
valporate	B-Chemical
are	O
the	O
prototypic	O
mood	O
satbilizers	O
and	O
have	O
dvierse	O
structrues	O
and	O
targtes	O
.	O

Both	O
durgs	O
influnece	O
ionsitol	B-Chemical
metabloism	O
.	O

Litihum	B-Chemical
inhibtis	O
IMPsae	O
and	O
valpraote	B-Chemical
inhibtis	O
MIP	B-Chemical
syntahse	O
.	O

This	O
stduy	O
shows	O
that	O
MIP	B-Chemical
syntahse	O
inhibiiton	O
does	O
not	O
rpelicate	O
or	O
augment	O
the	O
effects	O
of	O
ltihium	B-Chemical
in	O
the	O
insoitol	B-Chemical
snesitive	O
piolcarpine	B-Chemical
-	O
indcued	O
siezures	O
mdoel	O
.	O

This	O
lcak	O
of	O
effects	O
may	O
setm	O
from	O
the	O
low	O
contribution	O
of	O
de	O
-	O
novo	O
sytnhesis	O
to	O
cellluar	O
ionsitol	B-Chemical
supply	O
or	O
to	O
the	O
inhiibtion	O
of	O
the	O
de	O
-	O
novo	O
snythesis	O
by	O
litihum	B-Chemical
itself	O
.	O

Non	O
-	O
steoridal	O
atni	O
-	O
inflmamatory	O
durgs	O
-	O
associated	O
aucte	O
intrestitial	O
npehritis	O
with	O
grnaular	O
tubualr	O
basemnet	O
membarne	O
depostis	O
.	O

Actue	O
tubluo	O
-	O
interstiital	O
nephriits	O
(	O
AITN	O
)	O
is	O
an	O
important	O
cause	O
of	O
aucte	O
rneal	O
fialure	O
resulting	O
from	O
a	O
variety	O
of	O
isnults	O
,	O
including	O
immune	O
comlpex	O
-	O
mediated	O
tbuulo	O
-	O
intertsitial	O
ijnury	O
,	O
but	O
durgs	O
such	O
as	O
non	O
-	O
steoridal	O
atni	O
-	O
inflammatroy	O
durgs	O
(	O
NASIDs	O
)	O
are	O
a	O
far	O
more	O
freuqent	O
cause	O
.	O

Overall	O
,	O
as	O
an	O
entity	O
,	O
AITN	O
remains	O
under	O
-	O
daignosed	O
,	O
as	O
symptmos	O
resolve	O
spontaenously	O
if	O
the	O
mediaction	O
is	O
stopped	O
.	O

We	O
reprot	O
on	O
a	O
14	O
-	O
yaer	O
-	O
old	O
boy	O
who	O
developed	O
aucte	O
rneal	O
fialure	O
2	O
weeks	O
after	O
aoritc	O
vavle	O
srugery	O
.	O

He	O
was	O
put	O
on	O
aspriin	B-Chemical
following	O
sugrery	O
and	O
took	O
iburpofen	B-Chemical
for	O
fveer	O
for	O
nearly	O
a	O
week	O
prior	O
to	O
presnetation	O
.	O

He	O
then	O
presented	O
to	O
the	O
emergecny	O
dpeartment	O
feeling	O
quite	O
ill	O
and	O
was	O
found	O
to	O
have	O
a	O
blood	B-Chemical
uera	I-Chemical
ntirogen	I-Chemical
(	O
BUN	B-Chemical
)	O
concentratoin	O
of	O
of	O
147	O
mg	O
/	O
dl	O
,	O
cretainine	B-Chemical
of	O
15	O
.	O
3	O
mg	O
/	O
dl	O
and	O
sreum	O
potassuim	B-Chemical
of	O
8	O
.	O
7	O
mEq	O
/	O
l	O
.	O

Dilaysis	O
was	O
immediately	O
initiated	O
.	O

A	O
kideny	O
biospy	O
showed	O
inflammatroy	O
infilrtate	O
consistent	O
with	O
AITN	O
.	O

However	O
,	O
in	O
the	O
tubluar	O
baseemnt	O
membrnae	O
(	O
TBM	O
)	O
,	O
very	O
inetnse	O
graunlar	O
depsoits	O
of	O
polyclnoal	O
IgG	O
and	O
C3	O
were	O
noted	O
.	O

He	O
needed	O
dilaysis	O
for	O
2	O
weeks	O
and	O
was	O
traeted	O
successfully	O
with	O
steriods	B-Chemical
for	O
6	O
motnhs	O
.	O

His	O
rneal	O
reocvery	O
and	O
disappeaarnce	O
of	O
protienuria	O
took	O
a	O
yaer	O
.	O

In	O
conclusion	O
,	O
this	O
is	O
a	O
first	O
reprot	O
of	O
NSADIs	O
-	O
associated	O
AITN	O
,	O
showing	O
depoists	O
of	O
garnular	O
immnue	O
comlpex	O
present	O
only	O
in	O
the	O
TBM	O
and	O
not	O
in	O
the	O
gloemruli	O
.	O

Rifamipcin	B-Chemical
-	O
associated	O
segmetnal	O
necrotiizng	O
glomerulonehpritis	O
in	O
staphyloocccal	O
endoacrditis	O
.	O

Segemntal	O
necroitsing	O
glomerulonephrtiis	O
has	O
been	O
reported	O
as	O
copmlication	O
of	O
riafmpicin	B-Chemical
tehrapy	O
in	O
ptaients	O
receiving	O
tretament	O
for	O
tbuerculosis	O
.	O

Changing	O
epiedmiology	O
of	O
infcetions	O
such	O
as	O
infectvie	O
endoacrditis	O
(	O
IE	O
)	O
has	O
led	O
to	O
an	O
icnrease	O
in	O
the	O
use	O
of	O
rifapmicin	B-Chemical
for	O
Staphylococcal	O
infetcions	O
.	O

We	O
describe	O
a	O
csae	O
of	O
a	O
paitent	O
with	O
Staphylococacl	O
IE	O
who	O
developed	O
aucte	O
rneal	O
failrue	O
secondary	O
to	O
a	O
segmnetal	O
necrotisnig	O
glmoerulonephritis	O
while	O
being	O
treaetd	O
with	O
riafmpicin	B-Chemical
,	O
and	O
rveiew	O
the	O
literatrue	O
regarding	O
this	O
cmoplication	O
of	O
riafmpicin	B-Chemical
threapy	O
.	O

Rtae	O
of	O
YDMD	O
moitf	O
mutatns	O
in	O
lamivduine	B-Chemical
-	O
untreaetd	O
Iarnian	O
patinets	O
with	O
crhonic	O
heptaitis	O
B	O
vrius	O
infectoin	O
.	O

BCAKGROUND	O
:	O
Laimvudine	B-Chemical
is	O
used	O
for	O
the	O
treatemnt	O
of	O
chornic	O
hepaittis	O
B	O
ptaients	O
.	O

Recent	O
studeis	O
show	O
that	O
the	O
YDMD	O
mtoif	O
muatnts	O
(	O
resisatnt	O
heaptitis	O
B	O
viurs	O
)	O
occur	O
as	O
ntaural	O
geonme	O
varaibility	O
in	O
lamivuidne	B-Chemical
-	O
unterated	O
chornic	O
hpeatitis	O
B	O
patietns	O
.	O

In	O
this	O
stduy	O
we	O
aimed	O
to	O
determine	O
the	O
rtae	O
of	O
YDMD	O
moitf	O
mutnats	O
in	O
lamviudine	B-Chemical
-	O
utnreated	O
crhonic	O
heptaitis	O
B	O
ptaients	O
in	O
Iarn	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
A	O
total	O
of	O
77	O
chrnoic	O
heptaitis	O
B	O
ptaients	O
who	O
had	O
not	O
been	O
traeted	O
with	O
lamiuvdine	B-Chemical
were	O
included	O
in	O
the	O
stduy	O
.	O

Seurm	O
samlpes	O
from	O
patietns	O
were	O
tesetd	O
by	O
polyemrase	O
chian	O
reatcion	O
-	O
rsetriction	O
fragemnt	O
lentgh	O
poylmorphism	O
(	O
PCR	O
-	O
RLFP	O
)	O
for	O
detcetion	O
of	O
YDMD	O
mtoif	O
mtuants	O
.	O

All	O
paitents	O
were	O
also	O
tetsed	O
for	O
lievr	O
eznymes	O
,	O
atni	O
-	O
HCV	O
,	O
HeBAg	B-Chemical
,	O
and	O
atni	O
-	O
HBe	O
.	O

REUSLTS	O
:	O
Of	O
the	O
77	O
patinets	O
enrolled	O
in	O
the	O
stduy	O
,	O
73	O
%	O
were	O
mlae	O
and	O
27	O
%	O
were	O
feamle	O
.	O

Mean	O
ALT	O
and	O
AST	O
lveels	O
were	O
124	O
.	O
4	O
+	O
/	O
-	O
73	O
.	O
4	O
and	O
103	O
.	O
1	O
+	O
/	O
-	O
81	O
IU	O
/	O
l	O
,	O
respectively	O
.	O

HBAeg	B-Chemical
was	O
psoitive	O
in	O
40	O
%	O
and	O
atni	O
-	O
HBe	O
in	O
60	O
%	O
of	O
the	O
patietns	O
.	O

Atni	O
-	O
HCV	O
was	O
negtaive	O
in	O
all	O
of	O
them	O
.	O

YDMD	O
moitf	O
mtuants	O
were	O
not	O
dteected	O
in	O
any	O
of	O
the	O
pateints	O
despite	O
the	O
lvier	O
enzmye	O
levles	O
and	O
the	O
prseence	O
of	O
HBAeg	B-Chemical
or	O
atni	O
-	O
HBe	O
.	O

CONCLUISON	O
:	O
Although	O
the	O
nautral	O
occurernce	O
of	O
YDMD	O
moitf	O
mutnats	O
in	O
laimvudine	B-Chemical
-	O
utnreated	O
patietns	O
with	O
chornic	O
hpeatitis	O
B	O
has	O
been	O
reported	O
,	O
these	O
mutnats	O
were	O
not	O
detecetd	O
in	O
Irnaian	O
lamiuvdine	B-Chemical
-	O
untreaetd	O
crhonic	O
heaptitis	O
B	O
pateints	O
.	O

Barnch	O
retianl	O
vien	O
occluison	O
and	O
fluoxetnie	B-Chemical
.	O

A	O
csae	O
of	O
bracnh	O
rteinal	O
vien	O
occlsuion	O
associated	O
with	O
fluoextine	B-Chemical
-	O
indcued	O
secondary	O
hypertnesion	O
is	O
described	O
.	O

Although	O
an	O
inrfequent	O
copmlication	O
of	O
selective	O
sreotonin	B-Chemical
rueptake	O
inihbitor	O
tehrapy	O
,	O
it	O
is	O
important	O
that	O
ophthalmoolgists	O
are	O
aware	O
that	O
these	O
agetns	O
can	O
cause	O
hypretension	O
because	O
this	O
clsas	O
of	O
drgus	O
is	O
widely	O
prsecribed	O
.	O

The	O
dfiferential	O
effects	O
of	O
bupivcaaine	B-Chemical
and	O
ldiocaine	B-Chemical
on	O
prsotaglandin	B-Chemical
E2	I-Chemical
relesae	O
,	O
cyclooxgyenase	O
gnee	O
exprsesion	O
and	O
pian	O
in	O
a	O
cilnical	O
pian	O
moedl	O
.	O

BACKGRONUD	O
:	O
In	O
addition	O
to	O
blcoking	O
nociceptvie	O
inupt	O
from	O
surgiacl	O
siets	O
,	O
long	O
-	O
acting	O
lcoal	O
anestehtics	O
might	O
directly	O
mdoulate	O
inflamamtion	O
.	O

In	O
the	O
present	O
stduy	O
,	O
we	O
describe	O
the	O
proinfalmmatory	O
efefcts	O
of	O
bupiavcaine	B-Chemical
on	O
loacl	O
prosatglandin	B-Chemical
E2	I-Chemical
(	O
PEG2	B-Chemical
)	O
prdouction	O
and	O
cylcooxygenase	O
(	O
COX	O
)	O
gnee	O
experssion	O
that	O
icnreases	O
potsoperative	O
pian	O
in	O
huamn	O
subjetcs	O
.	O

METHODS	O
:	O
Sbujects	O
(	O
n	O
=	O
114	O
)	O
undergoing	O
extraciton	O
of	O
impcated	O
third	O
mloars	O
received	O
either	O
2	O
%	O
ldiocaine	B-Chemical
or	O
0	O
.	O
5	O
%	O
bupviacaine	B-Chemical
before	O
sugrery	O
and	O
either	O
roefcoxib	B-Chemical
50	O
mg	O
or	O
plaecbo	O
orlaly	O
90	O
min	O
before	O
surgrey	O
and	O
for	O
the	O
following	O
48	O
h	O
.	O

Oarl	O
mucoasl	O
biospies	O
were	O
taken	O
before	O
sugrery	O
and	O
48	O
h	O
after	O
sugrery	O
.	O

After	O
extraciton	O
,	O
a	O
microidalysis	O
porbe	O
was	O
placed	O
at	O
the	O
srugical	O
stie	O
for	O
PEG2	B-Chemical
and	O
thromboaxne	B-Chemical
B2	I-Chemical
(	O
TBX2	B-Chemical
)	O
measuerments	O
.	O

REUSLTS	O
:	O
The	O
bupivaacine	B-Chemical
/	O
rofecxoib	B-Chemical
gruop	O
reported	O
significantly	O
less	O
pian	O
,	O
as	O
assesesd	O
by	O
a	O
vsiual	O
anlaog	O
scale	O
,	O
cmopared	O
with	O
the	O
other	O
three	O
treatmnet	O
gorups	O
over	O
the	O
first	O
4	O
h	O
.	O

However	O
,	O
the	O
buipvacaine	B-Chemical
/	O
plaecbo	O
gorup	O
reported	O
significantly	O
more	O
pian	O
at	O
24	O
h	O
and	O
PEG2	B-Chemical
levles	O
during	O
the	O
first	O
4	O
h	O
were	O
significantly	O
hgiher	O
than	O
the	O
other	O
three	O
teratment	O
gorups	O
.	O

Moreover	O
,	O
bupivcaaine	B-Chemical
significantly	O
icnreased	O
COX	O
-	O
2	O
gnee	O
exprsesion	O
at	O
48	O
h	O
as	O
copmared	O
with	O
the	O
ldiocaine	B-Chemical
/	O
plaecbo	O
gruop	O
.	O

Throbmoxane	B-Chemical
lveels	O
were	O
not	O
significantly	O
affceted	O
by	O
any	O
of	O
the	O
treamtents	O
,	O
indicating	O
that	O
the	O
effcets	O
seen	O
were	O
attributable	O
to	O
inhbiition	O
of	O
COX	O
-	O
2	O
,	O
but	O
not	O
COX	O
-	O
1	O
.	O

CONCULSIONS	O
:	O
These	O
rseults	O
suggest	O
that	O
bupivaciane	B-Chemical
stimualtes	O
COX	O
-	O
2	O
gnee	O
exprsesion	O
after	O
tsisue	O
inujry	O
,	O
which	O
is	O
associated	O
with	O
hihger	O
PEG2	B-Chemical
proudction	O
and	O
pian	O
after	O
the	O
loacl	O
ansethetic	O
effect	O
dissipaets	O
.	O

p57NTR	O
expression	O
in	O
rat	O
urinray	O
bladder	O
senosry	O
neuorns	O
and	O
spnial	O
crod	O
with	O
cyclohposphamide	B-Chemical
-	O
induecd	O
csytitis	O
.	O

A	O
role	O
for	O
nreve	O
grwoth	O
facotr	O
(	O
NGF	O
)	O
in	O
contributing	O
to	O
inrceased	O
voidnig	O
frequnecy	O
and	O
atlered	O
sensaiton	O
from	O
the	O
urinray	O
bladder	O
has	O
been	O
suggested	O
.	O

Previous	O
stuides	O
have	O
examined	O
the	O
epxression	O
and	O
regulaiton	O
of	O
tyrosnie	B-Chemical
kianse	O
reecptors	O
(	O
Tkrs	O
)	O
in	O
mciturition	O
refelxes	O
with	O
urianry	O
baldder	O
infalmmation	O
.	O

The	O
present	O
stuides	O
examine	O
the	O
expression	O
and	O
regulatoin	O
of	O
another	O
recpetor	O
known	O
to	O
bnid	O
NGF	O
,	O
p75	O
(	O
NTR	O
)	O
,	O
after	O
various	O
duratoins	O
of	O
bladder	O
inflamamtion	O
idnuced	O
by	O
cycolphosphamide	B-Chemical
(	O
CYP	B-Chemical
)	O
.	O

CYP	B-Chemical
-	O
induecd	O
cytsitis	O
incraesed	O
(	O
P	O
<	O
or	O
=	O
0	O
.	O
001	O
)	O
p75	O
(	O
NTR	O
)	O
exrpession	O
in	O
the	O
superfciial	O
latearl	O
and	O
mdeial	O
dosral	O
hron	O
in	O
L1	O
-	O
L2	O
and	O
L6	O
-	O
S1	O
spnial	O
segmetns	O
.	O

The	O
number	O
of	O
p75	O
(	O
NTR	O
)	O
-	O
immunoreactvie	O
(	O
-	O
IR	O
)	O
cells	O
in	O
the	O
lmubosacral	O
drosal	O
root	O
ganlgia	O
(	O
DRG	O
)	O
also	O
increaesd	O
(	O
P	O
<	O
or	O
=	O
0	O
.	O
05	O
)	O
with	O
CYP	B-Chemical
-	O
idnuced	O
csytitis	O
(	O
aucte	O
,	O
itnermediate	O
,	O
and	O
chroinc	O
)	O
.	O

Quanittative	O
,	O
real	O
-	O
tmie	O
polyemrase	O
chian	O
reaciton	O
also	O
demonstrated	O
significant	O
incresaes	O
(	O
P	O
<	O
or	O
=	O
0	O
.	O
01	O
)	O
in	O
p75	O
(	O
NTR	O
)	O
mNRA	O
in	O
DRG	O
with	O
itnermediate	O
and	O
chrnoic	O
CYP	B-Chemical
-	O
inudced	O
cysttiis	O
.	O

Retorgrade	O
dye	O
-	O
tracnig	O
techniqeus	O
with	O
Fastlbue	O
were	O
used	O
to	O
identify	O
presmuptive	O
bladder	O
afefrent	O
cells	O
in	O
the	O
lumbosarcal	O
DRG	O
.	O

In	O
bldader	O
affreent	O
cells	O
in	O
DRG	O
,	O
p75	O
(	O
NTR	O
)	O
-	O
IR	O
was	O
also	O
incresaed	O
(	O
P	O
<	O
or	O
=	O
0	O
.	O
01	O
)	O
with	O
cytsitis	O
.	O

In	O
addition	O
to	O
incresaes	O
in	O
p75	O
(	O
NTR	O
)	O
-	O
IR	O
in	O
DRG	O
clel	O
boides	O
,	O
inrceases	O
(	O
P	O
<	O
or	O
=	O
0	O
.	O
001	O
)	O
in	O
pericellular	O
(	O
encicrling	O
DRG	O
clels	O
)	O
p75	O
(	O
NTR	O
)	O
-	O
IR	O
in	O
DRG	O
also	O
icnreased	O
.	O

Confoacl	O
aanlyses	O
demonstrated	O
that	O
perciellular	O
p75	O
(	O
NTR	O
)	O
-	O
IR	O
was	O
not	O
colocalzied	O
with	O
the	O
glail	O
mraker	O
,	O
glail	O
fibrillray	O
aciidc	O
proetin	O
(	O
GAFP	O
)	O
.	O

These	O
stuides	O
demonstrate	O
that	O
p75	O
(	O
NTR	O
)	O
epxression	O
in	O
mictruition	O
refleexs	O
is	O
present	O
constitutievly	O
and	O
moidfied	O
by	O
bladedr	O
inflamamtion	O
.	O

The	O
funtcional	O
singificance	O
of	O
p75	O
(	O
NTR	O
)	O
epxression	O
in	O
micturiiton	O
refelxes	O
remains	O
to	O
be	O
determined	O
.	O

Azathiporine	B-Chemical
-	O
induecd	O
suciidal	O
erythroctye	O
detah	O
.	O

BCAKGROUND	O
:	O
Azathioprnie	B-Chemical
is	O
widely	O
used	O
as	O
an	O
immunospupressive	O
durg	O
.	O

The	O
side	O
effects	O
of	O
aazthioprine	B-Chemical
include	O
aneima	O
,	O
which	O
has	O
been	O
attributed	O
to	O
bnoe	O
marorw	O
supperssion	O
.	O

Alternatively	O
,	O
anmeia	O
could	O
result	O
from	O
accelerated	O
suciidal	O
erythroctye	O
detah	O
or	O
erpytosis	O
,	O
which	O
is	O
chaarcterized	O
by	O
exposrue	O
of	O
phosphatidyslerine	B-Chemical
(	O
PS	B-Chemical
)	O
at	O
the	O
eyrthrocyte	O
surafce	O
and	O
by	O
clel	O
srhinkage	O
.	O

METHODS	O
:	O
The	O
present	O
exepriments	O
explored	O
whether	O
azathoiprine	B-Chemical
influecnes	O
erytposis	O
.	O

According	O
to	O
anenxin	O
V	O
bniding	O
,	O
erythroctyes	O
from	O
paitents	O
indeed	O
showed	O
a	O
significant	O
icnrease	O
of	O
PS	B-Chemical
exopsure	O
within	O
1	O
week	O
of	O
treatemnt	O
with	O
azahtioprine	B-Chemical
.	O

In	O
a	O
second	O
series	O
,	O
ctyosolic	O
Ca2	B-Chemical
+	O
acitvity	O
(	O
Flou3	B-Chemical
fluoerscence	O
)	O
,	O
clel	O
vloume	O
(	O
forward	O
scatter	O
)	O
,	O
and	O
PS	B-Chemical
-	O
exposrue	O
(	O
anneixn	O
V	O
bindnig	O
)	O
were	O
determined	O
by	O
FCAS	O
analyiss	O
in	O
eryhtrocytes	O
from	O
healhty	O
vlounteers	O
.	O

RESUTLS	O
:	O
Expsoure	O
to	O
azathiorpine	B-Chemical
(	O
>	O
or	O
=	O
2	O
mcirog	O
/	O
mL	O
)	O
for	O
48	O
hours	O
incraesed	O
cytosoilc	O
Ca2	B-Chemical
+	O
atcivity	O
and	O
annexin	O
V	O
bindnig	O
and	O
derceased	O
forward	O
scatter	O
.	O

The	O
efefct	O
of	O
azathioprnie	B-Chemical
on	O
both	O
anneixn	O
V	O
bindnig	O
and	O
forward	O
scatetr	O
was	O
significantly	O
blnuted	O
in	O
the	O
nominal	O
absnece	O
of	O
extraecllular	O
Ca2	B-Chemical
+	O
.	O

CONLCUSIONS	O
:	O
Azathiorpine	B-Chemical
triggers	O
suicdial	O
erythrcoyte	O
detah	O
,	O
an	O
effect	O
presumably	O
contributing	O
to	O
azathiopirne	B-Chemical
-	O
inudced	O
aneima	O
.	O

Levetircaetam	B-Chemical
as	O
an	O
ajdunct	O
to	O
pehnobarbital	B-Chemical
traetment	O
in	O
ctas	O
with	O
suspceted	O
idoipathic	O
epliepsy	O
.	O

OBJECTVIE	O
:	O
To	O
assess	O
pharmacokientics	O
,	O
efficcay	O
,	O
and	O
tolerbaility	O
of	O
oarl	O
levetircaetam	B-Chemical
adminisetred	O
as	O
an	O
adujnct	O
to	O
phenobrabital	B-Chemical
tretament	O
in	O
ctas	O
with	O
poorly	O
conrtolled	O
suspetced	O
idiopatihc	O
epilpesy	O
.	O

DESIGN	O
-	O
Oepn	O
-	O
laebl	O
,	O
noncomparatvie	O
cliincal	O
trail	O
.	O

ANIMALS	O
:	O
12	O
ctas	O
supsected	O
to	O
have	O
idipoathic	O
epilespy	O
that	O
was	O
poorly	O
controleld	O
with	O
phneobarbital	B-Chemical
or	O
that	O
had	O
unacceptable	O
avderse	O
efefcts	O
when	O
terated	O
with	O
phenobrabital	B-Chemical
.	O

PROCEDUERS	O
:	O
Ctas	O
were	O
tretaed	O
with	O
levetriacetam	B-Chemical
(	O
20	O
mg	O
/	O
kg	O
[	O
9	O
.	O
1	O
mg	O
/	O
lb	O
]	O
,	O
PO	O
,	O
q	O
8	O
h	O
)	O
.	O

After	O
a	O
minimum	O
of	O
1	O
week	O
of	O
treatmnet	O
,	O
sreum	O
levetiracteam	B-Chemical
cocnentrations	O
were	O
measuerd	O
before	O
and	O
2	O
,	O
4	O
,	O
and	O
6	O
hours	O
after	O
durg	O
adminsitration	O
,	O
and	O
maxmium	O
and	O
minimum	O
seurm	O
concentratinos	O
and	O
elmiination	O
half	O
-	O
lfie	O
were	O
calculated	O
.	O

Siezure	O
freqeuncies	O
before	O
and	O
after	O
iintiation	O
of	O
levetiraectam	B-Chemical
treatmnet	O
were	O
copmared	O
,	O
and	O
advesre	O
efefcts	O
were	O
recorded	O
.	O

RSEULTS	O
:	O
Meidan	O
mxaimum	O
seurm	O
levetriacetam	B-Chemical
conecntration	O
was	O
25	O
.	O
5	O
mcirog	O
/	O
mL	O
,	O
meidan	O
minimum	O
sreum	O
levetriacetam	B-Chemical
conecntration	O
was	O
8	O
.	O
3	O
mircog	O
/	O
mL	O
,	O
and	O
meidan	O
elimintaion	O
half	O
-	O
lfie	O
was	O
2	O
.	O
9	O
hours	O
.	O

Medain	O
siezure	O
frequnecy	O
prior	O
to	O
treatemnt	O
with	O
leveitracetam	B-Chemical
(	O
2	O
.	O
1	O
siezures	O
/	O
mo	O
)	O
was	O
significantly	O
hgiher	O
than	O
meidan	O
seziure	O
freqeuncy	O
after	O
initaition	O
of	O
levetiraceatm	B-Chemical
teratment	O
(	O
0	O
.	O
42	O
seizrues	O
/	O
mo	O
)	O
,	O
and	O
7	O
of	O
10	O
ctas	O
were	O
classified	O
as	O
having	O
responded	O
to	O
levteiracetam	B-Chemical
teratment	O
(	O
ie	O
,	O
reductoin	O
in	O
seziure	O
freuqency	O
of	O
>	O
or	O
=	O
50	O
%	O
)	O
.	O

Two	O
ctas	O
had	O
tarnsient	O
ltehargy	O
and	O
inappteence	O
.	O

COCNLUSIONS	O
AND	O
CLINICAL	O
REELVANCE	O
:	O
Resluts	O
suggested	O
that	O
leveitracetam	B-Chemical
is	O
well	O
tolreated	O
in	O
ctas	O
and	O
may	O
be	O
useful	O
as	O
an	O
adujnct	O
to	O
phneobarbital	B-Chemical
treatemnt	O
in	O
ctas	O
with	O
idiopatihc	O
epilespy	O
.	O

Serotnoin	B-Chemical
rueptake	O
inhibitros	O
,	O
parnaoia	O
,	O
and	O
the	O
vnetral	O
baasl	O
ganlgia	O
.	O

Antiderpessants	O
have	O
previously	O
been	O
associated	O
with	O
parnaoid	O
reactinos	O
in	O
psyhciatric	O
patietns	O
.	O

Five	O
csaes	O
of	O
paraonid	O
exacerbtaion	O
with	O
the	O
seortonin	B-Chemical
rueptake	O
inihbitors	O
flouxetine	B-Chemical
and	O
amirtiptyline	B-Chemical
are	O
reported	O
here	O
.	O

Eleemnts	O
common	O
to	O
these	O
caess	O
included	O
a	O
histroy	O
of	O
praanoid	O
symptomaotlogy	O
and	O
the	O
concomtiant	O
occurrence	O
of	O
dperessive	O
and	O
psychoitc	O
sypmtoms	O
.	O

Complciated	O
dperessive	O
disordres	O
(	O
including	O
atyipcality	O
of	O
coruse	O
and	O
symptomatoolgy	O
,	O
crhonicity	O
,	O
psyhcosis	O
,	O
bipolairty	O
,	O
and	O
secondary	O
onset	O
in	O
the	O
coruse	O
of	O
a	O
pirmary	O
psyhcosis	O
)	O
may	O
present	O
particular	O
vulnreability	O
to	O
parnaoid	O
exaecrbations	O
associated	O
with	O
serootnin	B-Chemical
rueptake	O
inhibitros	O
.	O

Although	O
the	O
pharmcaology	O
and	O
neurboiology	O
of	O
parnaoia	O
remain	O
cyrptic	O
,	O
several	O
mcehanisms	O
,	O
including	O
5TH3	O
rceeptor	O
-	O
mediated	O
doapmine	B-Chemical
relesae	O
,	O
btea	O
-	O
noradreenrgic	O
reecptor	O
dwonregulation	O
,	O
or	O
GAABB	O
recetpor	O
upregluation	O
acting	O
in	O
the	O
vicinity	O
of	O
the	O
vetnral	O
bsaal	O
gangila	O
(	O
possibly	O
in	O
latreal	O
obritofrontal	O
or	O
atnerior	O
cinuglate	O
cricuits	O
)	O
,	O
might	O
apply	O
to	O
this	O
phenomneon	O
.	O

These	O
caess	O
call	O
attention	O
to	O
possible	O
paraniod	O
excaerbations	O
with	O
serotnoin	B-Chemical
reuptkae	O
blockres	O
in	O
select	O
ptaients	O
and	O
raise	O
nuerobiological	O
consideraitons	O
regarding	O
paraonia	O
.	O

Cilnical	O
comaprison	O
of	O
cardiorepsiratory	O
efefcts	O
during	O
unliateral	O
and	O
conevntional	O
spianl	O
anaestheisa	O
.	O

BACKGRUOND	O
:	O
Spnial	O
anaestehsia	O
is	O
widely	O
employed	O
in	O
clniical	O
pratcice	O
but	O
has	O
the	O
main	O
drawback	O
of	O
psot	O
-	O
spianl	O
blcok	O
hypotenison	O
.	O

Efforts	O
must	O
therefore	O
continue	O
to	O
be	O
made	O
to	O
obviate	O
this	O
sebtack	O
OBJECTVIE	O
:	O
To	O
eavluate	O
the	O
cardoivascular	O
and	O
resipratory	O
chagnes	O
during	O
unilaetral	O
and	O
convenitonal	O
sipnal	O
anasethesia	O
.	O

METHODS	O
:	O
With	O
ethcial	O
apporval	O
,	O
we	O
studied	O
74	O
Amercian	O
Soceity	O
of	O
Anestehsiologists	O
(	O
ASA	O
)	O
,	O
physcial	O
stauts	O
calss	O
1	O
and	O
2	O
paitents	O
schdeuled	O
for	O
elecitve	O
uniltaeral	O
loewr	O
lmib	O
sugrery	O
.	O

Patinets	O
were	O
randomly	O
allocated	O
into	O
one	O
of	O
two	O
gorups	O
:	O
laetral	O
and	O
convenitonal	O
spnial	O
anaeshtesia	O
gropus	O
.	O

In	O
the	O
ltaeral	O
postiion	O
with	O
oeprative	O
side	O
down	O
,	O
paitents	O
reicved	O
10	O
mg	O
(	O
2mls	O
)	O
of	O
0	O
.	O
5	O
%	O
hyprebaric	O
bupiavcaine	B-Chemical
through	O
a	O
25	O
-	O
guage	O
sipnal	O
neelde	O
.	O

Pateints	O
in	O
the	O
uinlateral	O
gruop	O
were	O
maintained	O
in	O
the	O
latreal	O
psoition	O
for	O
15	O
minuets	O
following	O
spianl	O
ijnection	O
while	O
those	O
in	O
the	O
convenitonal	O
gorup	O
were	O
turned	O
suipne	O
immediately	O
after	O
inejction	O
.	O

Bolod	O
prsesure	O
,	O
herat	O
rtae	O
,	O
repsiratory	O
rtae	O
and	O
oxgyen	B-Chemical
saturaiton	O
were	O
monitroed	O
over	O
1	O
hour	O
.	O

RESLUTS	O
:	O
Three	O
patinets	O
(	O
8	O
.	O
1	O
%	O
)	O
in	O
the	O
uinlateral	O
gruop	O
and	O
5	O
(	O
13	O
.	O
5	O
%	O
)	O
in	O
the	O
convetnional	O
gruop	O
developed	O
hypotenison	O
,	O
P	O
=	O
0	O
.	O
71	O
.	O

Four	O
(	O
10	O
.	O
8	O
%	O
)	O
patietns	O
in	O
the	O
convetnional	O
gorup	O
and	O
1	O
(	O
2	O
.	O
7	O
%	O
)	O
in	O
the	O
uinlateral	O
gruop	O
,	O
P	O
=	O
0	O
.	O
17	O
required	O
epinehprine	B-Chemical
infsuion	O
to	O
traet	O
hyoptension	O
.	O

Ptaients	O
in	O
the	O
covnentional	O
gruop	O
had	O
statistically	O
significant	O
greater	O
fall	O
in	O
the	O
systoilc	O
blood	O
prsesures	O
at	O
15	O
,	O
30	O
and	O
45	O
mniutes	O
when	O
cmopared	O
to	O
the	O
bsaeline	O
(	O
P	O
=	O
0	O
.	O
003	O
,	O
0	O
.	O
001	O
and	O
0	O
.	O
004	O
)	O
.	O

The	O
mean	O
respirtaory	O
rtae	O
and	O
oxgyen	B-Chemical
satuartions	O
in	O
the	O
two	O
gruops	O
were	O
similar	O
.	O

CONCLUSOIN	O
:	O
Compraed	O
to	O
convnetional	O
sipnal	O
aanesthesia	O
,	O
uniltaeral	O
spianl	O
anaestheisa	O
was	O
associated	O
with	O
fewer	O
caridovascular	O
petrurbations	O
.	O

Also	O
,	O
the	O
tpye	O
of	O
spnial	O
blcok	O
insttiuted	O
affected	O
neither	O
the	O
respiraotry	O
rtae	O
nor	O
the	O
arteiral	O
oxgyen	B-Chemical
saturatoin	O
.	O

Spcetrum	O
of	O
advrese	O
evnets	O
after	O
gneeric	O
HAART	O
in	O
souhtern	O
Indain	O
HIV	O
-	O
infceted	O
paitents	O
.	O

To	O
determine	O
the	O
incidnece	O
of	O
clniically	O
significant	O
advesre	O
evetns	O
after	O
long	O
-	O
term	O
,	O
fiexd	O
-	O
dsoe	O
,	O
geenric	O
highly	O
acitve	O
antirteroviral	O
thearpy	O
(	O
HARAT	O
)	O
use	O
among	O
HIV	O
-	O
infecetd	O
inidviduals	O
in	O
Suoth	O
Inida	O
,	O
we	O
examined	O
the	O
expereinces	O
of	O
3154	O
HIV	O
-	O
infecetd	O
idnividuals	O
who	O
received	O
a	O
minimum	O
of	O
3	O
mnoths	O
of	O
geenric	O
HARAT	O
between	O
Feburary	O
1996	O
and	O
December	O
2006	O
at	O
a	O
teritary	O
HIV	O
crae	O
reefrral	O
cneter	O
in	O
Suoth	O
Inida	O
.	O

The	O
most	O
common	O
reigmens	O
were	O
3TC	B-Chemical
+	O
d4T	B-Chemical
+	O
neviraipne	B-Chemical
(	O
NVP	B-Chemical
)	O
(	O
54	O
.	O
8	O
%	O
)	O
,	O
ziodvudine	B-Chemical
(	O
AZT	B-Chemical
)	O
+	O
3TC	B-Chemical
+	O
NVP	B-Chemical
(	O
14	O
.	O
5	O
%	O
)	O
,	O
3TC	B-Chemical
+	O
d4T	B-Chemical
+	O
efaivrenz	B-Chemical
(	O
EFV	B-Chemical
)	O
(	O
20	O
.	O
1	O
%	O
)	O
,	O
and	O
AZT	B-Chemical
+	O
3TC	B-Chemical
+	O
EFV	B-Chemical
(	O
5	O
.	O
4	O
%	O
)	O
.	O

The	O
most	O
common	O
avderse	O
eevnts	O
and	O
medain	O
CD4	O
at	O
tmie	O
of	O
evnet	O
were	O
rsah	O
(	O
15	O
.	O
2	O
%	O
;	O
CD4	O
,	O
285	O
cells	O
/	O
microL	O
)	O
and	O
perihperal	O
neruopathy	O
(	O
9	O
.	O
0	O
%	O
and	O
348	O
cells	O
/	O
microL	O
)	O
.	O

Cliniclaly	O
significant	O
aneima	O
(	O
hemogolbin	O
<	O
7	O
g	O
/	O
dL	O
)	O
was	O
observed	O
in	O
5	O
.	O
4	O
%	O
of	O
ptaients	O
(	O
CD4	O
,	O
165	O
cells	O
/	O
microL	O
)	O
and	O
hpeatitis	O
(	O
cilnical	O
juandice	O
with	O
alnaine	B-Chemical
aminotrasnferase	O
>	O
5	O
times	O
upper	O
liimts	O
of	O
nromal	O
)	O
in	O
3	O
.	O
5	O
%	O
of	O
paitents	O
(	O
CD4	O
,	O
260	O
clels	O
/	O
microL	O
)	O
.	O

Woemn	O
were	O
significantly	O
more	O
likely	O
to	O
expreience	O
latcic	O
aciodsis	O
,	O
while	O
men	O
were	O
significantly	O
more	O
likely	O
to	O
exeprience	O
imumne	O
recontsitution	O
syndrmoe	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Among	O
the	O
ptaients	O
with	O
1	O
yaer	O
of	O
follow	O
-	O
up	O
,	O
NVP	B-Chemical
tehrapy	O
was	O
significantly	O
associated	O
with	O
developing	O
rsah	O
and	O
d4T	B-Chemical
therpay	O
with	O
developing	O
periphreal	O
neuroapthy	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Aneima	O
and	O
heaptitis	O
often	O
occur	O
within	O
12	O
weeks	O
of	O
initiating	O
gneeric	O
HARAT	O
.	O

Frequnet	O
and	O
ealry	O
monitroing	O
for	O
these	O
toxiciteis	O
is	O
warranted	O
in	O
developing	O
cuontries	O
where	O
geneirc	O
HARAT	O
is	O
increasingly	O
available	O
.	O

Thaildomide	B-Chemical
and	O
snesory	O
neurotoxiicty	O
:	O
a	O
neurpohysiological	O
sutdy	O
.	O

BAKCGROUND	O
:	O
Recent	O
stuides	O
confirmed	O
a	O
high	O
incdience	O
of	O
sesnory	O
axoanl	O
neuroptahy	O
in	O
patinets	O
tretaed	O
with	O
different	O
dsoes	O
of	O
thalidoimde	B-Chemical
.	O

The	O
sutdy	O
'	O
s	O
aims	O
were	O
to	O
mesaure	O
varaitions	O
in	O
srual	O
nevre	O
sesnory	O
actoin	O
potenital	O
(	O
SAP	O
)	O
apmlitude	O
in	O
patietns	O
with	O
rerfactory	O
cutaenous	O
lpuus	O
eyrthematosus	O
(	O
CLE	O
)	O
traeted	O
with	O
thaldiomide	B-Chemical
and	O
use	O
these	O
findigns	O
to	O
identify	O
the	O
neurotoixc	O
potentail	O
of	O
thalidoimde	B-Chemical
and	O
the	O
recvoery	O
capcaity	O
of	O
snesory	O
fibers	O
after	O
discotninuation	O
of	O
tretament	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
Cliincal	O
and	O
eelctrophysiological	O
dtaa	O
in	O
12	O
feamle	O
patinets	O
with	O
CLE	O
during	O
treamtent	O
with	O
thalidoimde	B-Chemical
and	O
up	O
to	O
47	O
mnoths	O
after	O
discontinuaiton	O
of	O
treatmnet	O
were	O
analsyed	O
.	O

Srual	O
nevre	O
SAP	O
amplitdue	O
redutcion	O
>	O
or	O
=	O
40	O
%	O
was	O
the	O
cirteria	O
for	O
disocntinuing	O
threapy	O
.	O

RESUTLS	O
:	O
During	O
traetment	O
,	O
11	O
paitents	O
showed	O
a	O
reduciton	O
in	O
srual	O
nreve	O
SAP	O
apmlitude	O
compraed	O
to	O
baseilne	O
valeus	O
(	O
9	O
with	O
a	O
reudction	O
>	O
or	O
=	O
50	O
%	O
and	O
2	O
<	O
50	O
%	O
)	O
.	O

One	O
ptaient	O
showed	O
no	O
chnages	O
in	O
SAP	O
amplitdue	O
.	O

Five	O
patietns	O
complained	O
of	O
paresthesais	O
and	O
leg	O
carmps	O
.	O

After	O
thaliodmide	B-Chemical
traetment	O
,	O
srual	O
SAP	O
amlpitude	O
recoevred	O
in	O
3	O
paitents	O
.	O

At	O
deetction	O
of	O
reudction	O
in	O
suarl	O
nevre	O
SAP	O
amplitdue	O
,	O
the	O
mdeian	O
thaliodmide	B-Chemical
cuumlative	O
dsoe	O
was	O
21	O
.	O
4	O
g	O
.	O

The	O
threhsold	O
neruotoxic	O
dsoage	O
is	O
loewr	O
than	O
previously	O
reported	O
.	O

CONCLUISONS	O
:	O
Suarl	O
nevre	O
SAP	O
ampltiude	O
reduciton	O
is	O
a	O
reliable	O
and	O
snesitive	O
makrer	O
of	O
degenertaion	O
and	O
rceovery	O
of	O
senosry	O
fibers	O
.	O

This	O
electrophysoilogical	O
praameter	O
provides	O
infomration	O
about	O
sucblinical	O
neurtooxic	O
poetntial	O
of	O
thaldiomide	B-Chemical
but	O
is	O
not	O
helpful	O
in	O
preidcting	O
the	O
appearacne	O
of	O
senosry	O
sypmtoms	O
.	O

Five	O
caess	O
of	O
encpehalitis	O
during	O
treamtent	O
of	O
loisais	O
with	O
diethylcarbmaazine	B-Chemical
.	O

Five	O
caess	O
of	O
encephailtis	O
following	O
treatmnet	O
with	O
diethylcarbamaznie	B-Chemical
(	O
DEC	B-Chemical
)	O
were	O
observed	O
in	O
Conoglese	O
ptaients	O
with	O
Loa	O
loa	O
fliariasis	O
.	O

Two	O
caess	O
had	O
a	O
faatl	O
outocme	O
and	O
one	O
resulted	O
in	O
sveere	O
seuqelae	O
.	O

The	O
notable	O
fact	O
was	O
that	O
this	O
compliaction	O
occurred	O
in	O
three	O
ptaients	O
hosptialized	O
before	O
traetment	O
began	O
,	O
with	O
whom	O
particularly	O
strict	O
thearpeutic	O
precautoins	O
were	O
taken	O
,	O
i	O
.	O
e	O
.	O
,	O
initial	O
dsoe	O
less	O
than	O
10	O
mg	O
of	O
DEC	B-Chemical
,	O
very	O
graudal	O
dsoe	O
incraeses	O
,	O
and	O
associated	O
atni	O
-	O
alelrgic	O
traetment	O
.	O

This	O
tpye	O
of	O
durg	O
-	O
induecd	O
complciation	O
may	O
not	O
be	O
that	O
uncommon	O
in	O
highly	O
endeimc	O
reigons	O
.	O

It	O
occurs	O
primarily	O
,	O
but	O
not	O
exclusively	O
,	O
in	O
sbujects	O
presenitng	O
with	O
a	O
high	O
microfilairal	O
laod	O
.	O

The	O
rleationship	O
between	O
the	O
occurrnece	O
of	O
encephaliits	O
and	O
the	O
dercease	O
in	O
micrfoilaremia	O
is	O
evident	O
.	O

The	O
ptahophysiological	O
mechansims	O
are	O
discussed	O
in	O
the	O
light	O
of	O
these	O
observaitons	O
and	O
the	O
few	O
other	O
commnets	O
on	O
this	O
subejct	O
publihsed	O
in	O
the	O
lietrature	O
.	O

Amiodraone	B-Chemical
-	O
related	O
pulomnary	O
msas	O
and	O
uniuqe	O
mmebranous	O
glomerluonephritis	O
in	O
a	O
patinet	O
with	O
valuvlar	O
herat	O
diesase	O
:	O
Daignostic	O
pitfall	O
and	O
new	O
findnigs	O
.	O

Amidoarone	B-Chemical
is	O
an	O
atni	O
-	O
arhrythmic	O
durg	O
for	O
lfie	O
-	O
threatening	O
tachycarida	O
,	O
but	O
various	O
adevrse	O
effcets	O
have	O
been	O
reported	O
.	O

Reported	O
herein	O
is	O
an	O
atuopsy	O
csae	O
of	O
valvluar	O
herat	O
disesae	O
,	O
in	O
a	O
ptaient	O
who	O
developed	O
a	O
lnug	O
msas	O
(	O
1	O
.	O
5	O
cm	O
in	O
dimaeter	O
)	O
and	O
protienuria	O
(	O
2	O
.	O
76	O
g	O
/	O
day	O
)	O
after	O
treatemnt	O
with	O
amiodaorne	B-Chemical
for	O
a	O
long	O
tmie	O
.	O

The	O
lnug	O
msas	O
was	O
highly	O
ssupected	O
to	O
be	O
lnug	O
cnacer	O
on	O
CT	O
and	O
psoitron	O
emissoin	O
toomgraphy	O
,	O
but	O
hsitologically	O
the	O
lesoin	O
was	O
composed	O
of	O
lypmhoplasmacytic	O
inifltrates	O
in	O
avleolar	O
walls	O
and	O
inrta	O
-	O
avleolar	O
accumulatoin	O
of	O
fomay	O
mcarophages	O
containing	O
charactreistic	O
myelnioid	O
bdoies	O
,	O
indicating	O
that	O
it	O
was	O
an	O
amiodaorne	B-Chemical
-	O
related	O
leison	O
.	O

In	O
addition	O
,	O
the	O
lnug	O
tsisue	O
had	O
unevenly	O
distributed	O
hemosiedrin	O
depsoition	O
,	O
and	O
anbormally	O
trotuous	O
caplilaries	O
were	O
seen	O
in	O
the	O
msas	O
and	O
in	O
heavily	O
hemosiedrotic	O
lnug	O
protions	O
outside	O
the	O
msas	O
.	O

In	O
the	O
kidnyes	O
,	O
gloemruli	O
had	O
mmebrane	O
spkies	O
,	O
prominent	O
swelling	O
of	O
podoyctes	O
and	O
subepitehlial	O
depostis	O
,	O
which	O
were	O
sometimes	O
large	O
and	O
hmup	O
-	O
like	O
.	O

Autiommune	O
disesaes	O
,	O
viarl	O
hepaittis	O
,	O
mlaignant	O
nepolasms	O
or	O
other	O
diesases	O
with	O
a	O
known	O
relatoinship	O
to	O
membarnous	O
glomeruloenphritis	O
were	O
not	O
found	O
.	O

The	O
present	O
csae	O
highlights	O
the	O
possibility	O
that	O
differentail	O
daignosis	O
between	O
an	O
amoidarone	B-Chemical
-	O
related	O
pumlonary	O
lseion	O
and	O
a	O
neoplsam	O
can	O
be	O
very	O
difficult	O
radiloogically	O
,	O
and	O
suggests	O
that	O
membrnaous	O
glomerulonehpritis	O
might	O
be	O
another	O
possible	O
copmlication	O
of	O
amiodaorne	B-Chemical
treatemnt	O
.	O

Rsik	O
of	O
coronray	O
atrery	O
dsiease	O
associated	O
with	O
initial	O
suplhonylurea	B-Chemical
teratment	O
of	O
patietns	O
with	O
tpye	O
2	O
daibetes	O
:	O
a	O
matched	O
csae	O
-	O
cotnrol	O
sutdy	O
.	O

AMIS	O
:	O
This	O
stduy	O
sought	O
to	O
assess	O
the	O
rsik	O
of	O
developing	O
croonary	O
atrery	O
dsiease	O
(	O
CAD	O
)	O
associated	O
with	O
initial	O
treamtent	O
of	O
tpye	O
2	O
dibaetes	O
with	O
different	O
sulphoynlureas	B-Chemical
.	O

METHODS	O
:	O
In	O
tpye	O
2	O
dibaetic	O
patinets	O
,	O
caess	O
who	O
developed	O
CAD	O
were	O
comapred	O
retrospetcively	O
with	O
conrtols	O
that	O
did	O
not	O
.	O

The	O
20	O
-	O
yaer	O
rsik	O
of	O
CAD	O
at	O
diangosis	O
of	O
diabeets	O
,	O
using	O
the	O
UPKDS	O
rsik	O
enigne	O
,	O
was	O
used	O
to	O
match	O
csaes	O
with	O
contrlos	O
.	O

RESLUTS	O
:	O
The	O
76	O
caess	O
of	O
CAD	O
were	O
comapred	O
with	O
152	O
cotnrols	O
.	O

The	O
hazrad	O
of	O
developing	O
CAD	O
(	O
95	O
%	O
CI	O
)	O
associated	O
with	O
initial	O
traetment	O
increaesd	O
by	O
2	O
.	O
4	O
-	O
fold	O
(	O
1	O
.	O
3	O
-	O
4	O
.	O
3	O
,	O
P	O
=	O
0	O
.	O
004	O
)	O
with	O
glibenlcamide	B-Chemical
;	O
2	O
-	O
fold	O
(	O
0	O
.	O
9	O
-	O
4	O
.	O
6	O
,	O
P	O
=	O
0	O
.	O
099	O
)	O
with	O
gliipzide	B-Chemical
;	O
2	O
.	O
9	O
-	O
fold	O
(	O
1	O
.	O
6	O
-	O
5	O
.	O
1	O
,	O
P	O
=	O
0	O
.	O
000	O
)	O
with	O
either	O
,	O
and	O
was	O
unchnaged	O
with	O
metforimn	B-Chemical
.	O

The	O
haazrd	O
decresaed	O
0	O
.	O
3	O
-	O
fold	O
(	O
0	O
.	O
7	O
-	O
1	O
.	O
7	O
,	O
P	O
=	O
0	O
.	O
385	O
)	O
with	O
glimepirdie	B-Chemical
,	O
0	O
.	O
4	O
-	O
fold	O
(	O
0	O
.	O
7	O
-	O
1	O
.	O
3	O
,	O
P	O
=	O
0	O
.	O
192	O
)	O
with	O
gilclazide	B-Chemical
,	O
and	O
0	O
.	O
4	O
-	O
fold	O
(	O
0	O
.	O
7	O
-	O
1	O
.	O
1	O
,	O
P	O
=	O
0	O
.	O
09	O
)	O
with	O
either	O
.	O

COCNLUSIONS	O
:	O
Intiiating	O
tretament	O
of	O
tpye	O
2	O
diabeets	O
with	O
gliebnclamide	B-Chemical
or	O
glipizdie	B-Chemical
is	O
associated	O
with	O
inrceased	O
rsik	O
of	O
CAD	O
in	O
comaprison	O
to	O
glcilazide	B-Chemical
or	O
glimepirdie	B-Chemical
.	O

If	O
confirmed	O
,	O
this	O
may	O
be	O
important	O
because	O
most	O
Indain	O
ptaients	O
receive	O
the	O
cheaper	O
odler	O
sulphnoylureas	B-Chemical
,	O
and	O
present	O
giudelines	O
do	O
not	O
distinguish	O
between	O
indivdiual	O
aegnts	O
.	O

Reudced	O
prgoression	O
of	O
adriamyicn	B-Chemical
nehpropathy	O
in	O
spotnaneously	O
hyeprtensive	O
rtas	O
tretaed	O
by	O
losratan	B-Chemical
.	O

BACKGORUND	O
:	O
The	O
aim	O
of	O
the	O
sutdy	O
was	O
to	O
ivnestigate	O
the	O
antihypertnesive	O
effects	O
of	O
angioetnsin	B-Chemical
II	I-Chemical
tpye	O
-	O
1	O
recepotr	O
blcoker	O
,	O
lsoartan	B-Chemical
,	O
and	O
its	O
potetnial	O
in	O
solwing	O
down	O
reanl	O
disesae	O
progerssion	O
in	O
spotnaneously	O
hyperetnsive	O
rtas	O
(	O
SHR	O
)	O
with	O
adriaymcin	B-Chemical
(	O
ADR	B-Chemical
)	O
neprhopathy	O
.	O

METHODS	O
:	O
Six	O
-	O
motnh	O
-	O
old	O
femlae	O
SHR	O
were	O
randomly	O
selected	O
in	O
six	O
gruops	O
.	O

Two	O
conrtol	O
gruops	O
(	O
SH	O
(	O
6	O
)	O
,	O
SH	O
(	O
12	O
)	O
)	O
received	O
vheicle	O
.	O

Gorups	O
ADR	B-Chemical
(	O
6	O
)	O
,	O
ADR	B-Chemical
+	O
LOS	B-Chemical
(	O
6	O
)	O
and	O
ADR	B-Chemical
(	O
12	O
)	O
,	O
and	O
ADR	B-Chemical
+	O
LOS	B-Chemical
(	O
12	O
)	O
received	O
ADR	B-Chemical
(	O
2	O
mg	O
/	O
kg	O
/	O
b	O
.	O
w	O
.	O
i	O
.	O
v	O
.	O
)	O
twice	O
in	O
a	O
3	O
-	O
week	O
intreval	O
.	O

Gruop	O
ADR	B-Chemical
+	O
LOS	B-Chemical
(	O
6	O
)	O
received	O
losaratn	B-Chemical
(	O
10	O
mg	O
/	O
kg	O
/	O
b	O
.	O
w	O
.	O
/	O
day	O
by	O
gaavges	O
)	O
for	O
6	O
weeks	O
and	O
gruop	O
ADR	B-Chemical
+	O
LOS	B-Chemical
(	O
12	O
)	O
for	O
12	O
weeks	O
after	O
second	O
injetcion	O
of	O
ADR	B-Chemical
.	O

Aniamls	O
were	O
kileld	O
after	O
6	O
or	O
12	O
wekes	O
,	O
respectively	O
.	O

Haemdoynamic	O
meausrements	O
were	O
performed	O
on	O
anaestehtized	O
animlas	O
,	O
blood	O
and	O
uirne	O
sampels	O
were	O
taken	O
for	O
bicohemical	O
anaylsis	O
and	O
the	O
lfet	O
kindey	O
was	O
prcoessed	O
for	O
morpholoigcal	O
sutdies	O
.	O

RESLUTS	O
:	O
Sohrt	O
-	O
term	O
lsoartan	B-Chemical
tretament	O
,	O
besides	O
antihypetrensive	O
effect	O
,	O
imporved	O
glomeurlar	O
filtartion	O
rtae	O
and	O
ameliortaed	O
gloemrulosclerosis	O
resulting	O
in	O
decraesed	O
proteinuira	O
.	O

Prolnoged	O
traetment	O
with	O
lsoartan	B-Chemical
showed	O
further	O
redcution	O
of	O
glomeruloscelrosis	O
associated	O
with	O
rdeuced	O
prorgession	O
of	O
tuublar	O
atorphy	O
and	O
intersttiial	O
fibrsois	O
,	O
thus	O
preventing	O
haevy	O
protienuria	O
and	O
chornic	O
reanl	O
fialure	O
.	O

Lsoartan	B-Chemical
rdeuced	O
uaremia	O
and	O
inrceased	O
uera	B-Chemical
claerance	O
in	O
advacned	O
ADR	B-Chemical
nephropahty	O
in	O
SHR	O
.	O

Histloogical	O
examinatoin	O
showed	O
that	O
losatran	B-Chemical
could	O
prveent	O
tubualr	O
atrpohy	O
,	O
intesrtitial	O
inflitration	O
and	O
firbosis	O
in	O
ADR	B-Chemical
nephropahty	O
.	O

COCNLUSION	O
:	O
Losaratn	B-Chemical
rdeuces	O
the	O
rtae	O
of	O
progressoin	O
of	O
ADR	B-Chemical
-	O
induecd	O
fcoal	O
segmetnal	O
gloemrulosclerosis	O
to	O
end	O
-	O
satge	O
rneal	O
diesase	O
in	O
SHR	O
.	O

The	O
rikss	O
of	O
aportinin	O
and	O
trnaexamic	B-Chemical
aicd	I-Chemical
in	O
cardaic	O
srugery	O
:	O
a	O
one	O
-	O
yaer	O
follow	O
-	O
up	O
of	O
1188	O
conseuctive	O
patinets	O
.	O

BAKCGROUND	O
:	O
Our	O
aim	O
was	O
to	O
ivnestigate	O
postopertaive	O
comlpications	O
and	O
mortaltiy	O
after	O
administrtaion	O
of	O
aproitnin	O
copmared	O
to	O
traneaxmic	B-Chemical
aicd	I-Chemical
in	O
an	O
unselected	O
,	O
cnosecutive	O
cohrot	O
.	O

METHODS	O
:	O
Perioperatvie	O
dtaa	O
from	O
consecuitve	O
cadriac	O
surgrey	O
patinets	O
were	O
prospectively	O
collected	O
between	O
Septemebr	O
2005	O
and	O
June	O
2006	O
in	O
a	O
unviersity	O
-	O
affilaited	O
clniic	O
(	O
n	O
=	O
1188	O
)	O
.	O

During	O
the	O
first	O
5	O
mo	O
,	O
596	O
patinets	O
received	O
aportinin	O
(	O
Gruop	O
A	O
)	O
;	O
in	O
the	O
next	O
5	O
mo	O
,	O
592	O
paitents	O
were	O
traeted	O
with	O
tranxeamic	B-Chemical
aicd	I-Chemical
(	O
Gruop	O
T	O
)	O
.	O

Except	O
for	O
antifbirinolytic	O
thearpy	O
,	O
the	O
aneshtetic	O
and	O
surigcal	O
prtoocols	O
remained	O
unchanegd	O
.	O

RSEULTS	O
:	O
The	O
pre	O
-	O
and	O
intraopertaive	O
varibales	O
were	O
comparable	O
between	O
the	O
traetment	O
gorups	O
.	O

Postoperatviely	O
,	O
a	O
significantly	O
hgiher	O
icnidence	O
of	O
seziures	O
was	O
found	O
in	O
Gruop	O
T	O
(	O
4	O
.	O
6	O
%	O
vs	O
1	O
.	O
2	O
%	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

This	O
difference	O
was	O
also	O
significant	O
in	O
the	O
prmiary	O
vlave	O
srugery	O
and	O
the	O
high	O
rsik	O
surgrey	O
subgruops	O
(	O
7	O
.	O
9	O
%	O
vs	O
1	O
.	O
2	O
%	O
,	O
P	O
=	O
0	O
.	O
003	O
;	O
7	O
.	O
3	O
%	O
vs	O
2	O
.	O
4	O
%	O
,	O
P	O
=	O
0	O
.	O
035	O
,	O
respectively	O
)	O
.	O

Perisstent	O
atiral	O
firbillation	O
(	O
7	O
.	O
9	O
%	O
vs	O
2	O
.	O
3	O
%	O
,	O
P	O
=	O
0	O
.	O
020	O
)	O
and	O
reanl	O
faliure	O
(	O
9	O
.	O
7	O
%	O
vs	O
1	O
.	O
7	O
%	O
,	O
P	O
=	O
0	O
.	O
002	O
)	O
were	O
also	O
more	O
common	O
in	O
Gorup	O
T	O
,	O
in	O
the	O
prmiary	O
vlave	O
surgrey	O
subgorup	O
.	O

On	O
the	O
contrary	O
,	O
among	O
prmiary	O
coroanry	O
aretry	O
bypsas	O
srugery	O
patietns	O
,	O
there	O
were	O
more	O
actue	O
mycoardial	O
infacrtions	O
and	O
rneal	O
dysfunciton	O
in	O
Gruop	O
A	O
(	O
5	O
.	O
8	O
%	O
vs	O
2	O
.	O
0	O
%	O
,	O
P	O
=	O
0	O
.	O
027	O
;	O
22	O
.	O
5	O
%	O
vs	O
15	O
.	O
2	O
%	O
,	O
P	O
=	O
0	O
.	O
036	O
,	O
respectively	O
)	O
.	O

The	O
1	O
-	O
yr	O
mortlaity	O
was	O
significantly	O
hihger	O
after	O
aprotiinn	O
treamtent	O
in	O
the	O
high	O
rsik	O
srugery	O
gruop	O
(	O
17	O
.	O
7	O
%	O
vs	O
9	O
.	O
8	O
%	O
,	O
P	O
=	O
0	O
.	O
034	O
)	O
.	O

CONLCUSION	O
:	O
Both	O
antifibrniolytic	O
drgus	O
bear	O
the	O
rsik	O
of	O
adevrse	O
ouctome	O
depending	O
on	O
the	O
tpye	O
of	O
cadriac	O
suregry	O
.	O

Amdinistration	O
of	O
aprtoinin	O
should	O
be	O
avoided	O
in	O
croonary	O
aretry	O
bpyass	O
garft	O
and	O
high	O
rsik	O
paitents	O
,	O
whereas	O
admiinstration	O
of	O
tranexaimc	B-Chemical
aicd	I-Chemical
is	O
not	O
reocmmended	O
in	O
vlave	O
sugrery	O
.	O

Delriium	O
in	O
an	O
eldelry	O
wmoan	O
possibly	O
associated	O
with	O
admniistration	O
of	O
misoprsotol	B-Chemical
.	O

Misoporstol	B-Chemical
has	O
been	O
associated	O
with	O
adevrse	O
reacitons	O
,	O
including	O
gastroitnestinal	O
sypmtoms	O
,	O
gnyecologic	O
prbolems	O
,	O
and	O
hedaache	O
.	O

Chanegs	O
in	O
menatl	O
sttaus	O
,	O
however	O
,	O
have	O
not	O
been	O
reported	O
.	O

We	O
present	O
a	O
csae	O
in	O
which	O
an	O
89	O
-	O
yaer	O
-	O
old	O
wmoan	O
in	O
a	O
long	O
-	O
term	O
crae	O
faciilty	O
became	O
confused	O
after	O
the	O
initaition	O
of	O
misoprosotl	B-Chemical
thearpy	O
.	O

The	O
patinet	O
'	O
s	O
change	O
in	O
metnal	O
sattus	O
was	O
first	O
reported	O
nine	O
dyas	O
after	O
the	O
initiaiton	O
of	O
tehrapy	O
.	O

Her	O
deliirum	O
significantly	O
improevd	O
after	O
misoprotsol	B-Chemical
was	O
discnotinued	O
and	O
her	O
mnetal	O
sttaus	O
returned	O
to	O
nromal	O
within	O
a	O
week	O
.	O

Because	O
no	O
other	O
fcators	O
related	O
to	O
this	O
ptaient	O
changed	O
significantly	O
,	O
the	O
deliruim	O
experienced	O
by	O
this	O
ptaient	O
possibly	O
resulted	O
from	O
misorpostol	B-Chemical
threapy	O
.	O

The	O
boilogical	O
propreties	O
of	O
the	O
otpical	O
isoemrs	O
of	O
proparnolol	B-Chemical
and	O
their	O
efefcts	O
on	O
cradiac	O
arrhytmhias	O
.	O

1	O
.	O

The	O
optiacl	O
isoemrs	O
of	O
prporanolol	B-Chemical
have	O
been	O
cmopared	O
for	O
their	O
btea	O
-	O
blocknig	O
and	O
antairrhythmic	O
acitvities	O
.	O
2	O
.	O

In	O
blokcing	O
the	O
positvie	O
inotorpic	O
and	O
chornotropic	O
resposnes	O
to	O
iosprenaline	B-Chemical
,	O
(	O
+	O
)	O
-	O
propranooll	B-Chemical
had	O
less	O
than	O
one	O
hundredth	O
the	O
potnecy	O
of	O
(	O
-	O
)	O
-	O
prporanolol	B-Chemical
.	O

At	O
dsoe	O
levles	O
of	O
(	O
+	O
)	O
-	O
proparnolol	B-Chemical
which	O
attenuated	O
the	O
responess	O
to	O
isopreanline	B-Chemical
,	O
there	O
was	O
a	O
significant	O
porlongation	O
of	O
the	O
PR	O
interavl	O
of	O
the	O
electrocardiogarm	O
.	O
3	O
.	O

The	O
meatbolic	O
responess	O
to	O
isopernaline	B-Chemical
in	O
dgos	O
(	O
an	O
incerase	O
in	O
circluating	O
gulcose	B-Chemical
,	O
latcate	B-Chemical
and	O
free	O
fatty	B-Chemical
acdis	I-Chemical
)	O
were	O
all	O
blcoked	O
by	O
(	O
-	O
)	O
-	O
propraonlol	B-Chemical
.	O

(	O
+	O
)	O
-	O
Proprnaolol	B-Chemical
had	O
no	O
efefct	O
on	O
ftaty	B-Chemical
aicd	I-Chemical
mobilizaiton	O
but	O
significantly	O
redcued	O
the	O
inrcements	O
in	O
both	O
latcate	B-Chemical
and	O
gluocse	B-Chemical
.	O
4	O
.	O

Both	O
isoemrs	O
of	O
propraonlol	B-Chemical
possessed	O
similar	O
dperessant	O
ptoency	O
on	O
isoalted	O
atrail	O
muslce	O
taken	O
from	O
guiena	O
-	O
pgis	O
.	O
5	O
.	O

The	O
isomres	O
of	O
propranlool	B-Chemical
exhibited	O
similar	O
lcoal	O
anaesthteic	O
potenices	O
on	O
an	O
isoalted	O
forg	O
nevre	O
prpearation	O
at	O
a	O
lveel	O
approximately	O
three	O
times	O
that	O
of	O
prcoaine	B-Chemical
.	O

The	O
raecmic	O
comopund	O
was	O
significantly	O
less	O
potent	O
than	O
either	O
ismoer	O
.	O
6	O
.	O

Both	O
ismoers	O
of	O
proparnolol	B-Chemical
were	O
capable	O
of	O
preventing	O
adernaline	B-Chemical
-	O
inudced	O
caridac	O
arrhytmhias	O
in	O
ctas	O
anaeshtetized	O
with	O
haolthane	B-Chemical
,	O
but	O
the	O
mean	O
dsoe	O
of	O
(	O
-	O
)	O
-	O
prporanolol	B-Chemical
was	O
0	O
.	O
09	O
+	O
/	O
-	O
0	O
.	O
02	O
mg	O
/	O
kg	O
whereas	O
that	O
of	O
(	O
+	O
)	O
-	O
proprnaolol	B-Chemical
was	O
4	O
.	O
2	O
+	O
/	O
-	O
1	O
.	O
2	O
mg	O
/	O
kg	O
.	O

At	O
the	O
effective	O
dsoe	O
leevl	O
of	O
(	O
+	O
)	O
-	O
proprnaolol	B-Chemical
there	O
was	O
a	O
significant	O
prolognation	O
of	O
the	O
PR	O
interavl	O
of	O
the	O
electrcoardiogram	O
.	O

Bolckade	O
of	O
arrhyhtmias	O
with	O
both	O
isoemrs	O
was	O
surmountable	O
by	O
increasnig	O
the	O
dsoe	O
of	O
adrnealine	B-Chemical
.	O
7	O
.	O

Both	O
ismoers	O
of	O
proprnaolol	B-Chemical
were	O
also	O
capable	O
of	O
reversnig	O
ventircular	O
tcahycardia	O
caused	O
by	O
ouabian	B-Chemical
in	O
aneasthetized	O
ctas	O
and	O
dgos	O
.	O

The	O
dsoe	O
of	O
(	O
-	O
)	O
-	O
propranooll	B-Chemical
was	O
significantly	O
smaller	O
than	O
that	O
of	O
(	O
+	O
)	O
-	O
porpranolol	B-Chemical
in	O
both	O
speices	O
but	O
much	O
higehr	O
than	O
that	O
required	O
to	O
produce	O
evdience	O
of	O
btea	O
-	O
blocakde	O
.	O
8	O
.	O

The	O
implications	O
of	O
these	O
resluts	O
are	O
discussed	O
.	O

Tooptecan	B-Chemical
in	O
combniation	O
with	O
radiotehrapy	O
in	O
unersectable	O
glioblasotma	O
:	O
a	O
phsae	O
2	O
sutdy	O
.	O

Improvnig	O
glioblastmoa	O
mulitforme	O
(	O
GBM	O
)	O
traetment	O
with	O
rdaio	O
-	O
chemotherpay	O
remains	O
a	O
challenge	O
.	O

Topoteacn	B-Chemical
is	O
an	O
attractive	O
option	O
as	O
it	O
exhibits	O
gorwth	O
inhibtiion	O
of	O
hmuan	O
glimoa	O
as	O
well	O
as	O
brian	O
penteration	O
.	O

The	O
present	O
sutdy	O
asssesed	O
the	O
combintaion	O
of	O
radoitherapy	O
(	O
60	O
Gy	O
/	O
30	O
fractoins	O
/	O
40	O
dyas	O
)	O
and	O
topoetcan	B-Chemical
(	O
0	O
.	O
9	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
day	O
on	O
dyas	O
1	O
-	O
5	O
on	O
wekes	O
1	O
,	O
3	O
and	O
5	O
)	O
in	O
50	O
adutls	O
with	O
histologiaclly	O
proven	O
and	O
untretaed	O
GBM	O
.	O

The	O
icnidence	O
of	O
non	O
-	O
hemtaological	O
toxiciites	O
was	O
low	O
and	O
grdae	O
3	O
-	O
4	O
heamtological	O
toxiciites	O
were	O
reported	O
in	O
20	O
ptaients	O
(	O
mainly	O
lymphpoenia	O
and	O
neturopenia	O
)	O
.	O

Pratial	O
resopnse	O
and	O
satbilization	O
rtaes	O
were	O
2	O
%	O
and	O
32	O
%	O
,	O
respectively	O
,	O
with	O
an	O
overall	O
tmie	O
to	O
progresison	O
of	O
12	O
weeks	O
.	O

One	O
-	O
yaer	O
overall	O
sruvival	O
(	O
OS	O
)	O
rtae	O
was	O
42	O
%	O
,	O
with	O
a	O
meidan	O
OS	O
of	O
40	O
weeks	O
.	O

Topoetcan	B-Chemical
in	O
comibnation	O
with	O
radiotherpay	O
was	O
well	O
tolearted	O
.	O

However	O
,	O
while	O
resopnse	O
and	O
stbailization	O
concerned	O
one	O
-	O
third	O
of	O
the	O
patietns	O
,	O
the	O
stduy	O
did	O
not	O
show	O
increaesd	O
beenfits	O
in	O
terms	O
of	O
suvrival	O
in	O
patietns	O
with	O
urnesectable	O
GBM	O
.	O

Lnog	O
-	O
term	O
ltihium	B-Chemical
thearpy	O
leading	O
to	O
hyperparathyroiidsm	O
:	O
a	O
csae	O
reprot	O
.	O

PUROPSE	O
:	O
This	O
paper	O
rveiews	O
the	O
effect	O
of	O
chrnoic	O
lihtium	B-Chemical
thearpy	O
on	O
seurm	O
clacium	B-Chemical
leevl	O
and	O
partahyroid	O
galnds	O
,	O
its	O
pathoegnesis	O
,	O
and	O
tretament	O
optoins	O
.	O

We	O
examined	O
the	O
csae	O
of	O
a	O
lihtium	B-Chemical
-	O
traeted	O
patinet	O
who	O
had	O
recurernt	O
hypercaclemia	O
to	O
better	O
understand	O
the	O
disesae	O
porcess	O
.	O

CONCLUISON	O
:	O
Primray	O
hyperpaarthyroidism	O
is	O
a	O
rrae	O
but	O
potentially	O
lfie	O
-	O
threatening	O
side	O
effcet	O
of	O
long	O
-	O
term	O
lithuim	B-Chemical
tehrapy	O
.	O

Careful	O
pateint	O
seletcion	O
and	O
long	O
-	O
term	O
follow	O
-	O
up	O
can	O
redcue	O
morbdiity	O
.	O

PRACTICAL	O
IMPILCATIONS	O
:	O
As	O
much	O
as	O
15	O
%	O
of	O
lihtium	B-Chemical
-	O
tretaed	O
patietns	O
become	O
hypecralcemic	O
.	O

By	O
routinely	O
monitoirng	O
sreum	O
caclium	B-Chemical
leevls	O
,	O
healhtcare	O
provdiers	O
can	O
ipmrove	O
the	O
qualtiy	O
of	O
lfie	O
of	O
this	O
ptaient	O
gorup	O
.	O

Compraison	O
of	O
larygneal	O
msak	O
with	O
endortacheal	O
tbue	O
for	O
aneshtesia	O
in	O
endocsopic	O
snius	O
srugery	O
.	O

BACKGORUND	O
:	O
The	O
purpose	O
of	O
this	O
stduy	O
was	O
to	O
cmopare	O
surgiacl	O
condtiions	O
,	O
including	O
the	O
aomunt	O
of	O
intraopreative	O
bleednig	O
as	O
well	O
as	O
intraopeartive	O
blood	O
pressure	O
,	O
during	O
functinoal	O
endoscpoic	O
siuns	O
surgrey	O
(	O
FSES	O
)	O
using	O
flexilbe	O
reinforced	O
laryngael	O
msak	O
ariway	O
(	O
FRMLA	O
)	O
versus	O
endtoracheal	O
tbue	O
(	O
ETT	O
)	O
in	O
maintaining	O
cnotrolled	O
hpyotension	O
anestehsia	O
idnuced	O
by	O
porpofol	B-Chemical
-	O
remifentainl	B-Chemical
total	O
i	O
.	O
v	O
.	O
ansethesia	O
(	O
TVIA	O
)	O
.	O

METHODS	O
:	O
Sixty	O
nromotensive	O
Amercian	O
Soicety	O
of	O
Anestehsiologists	O
I	O
-	O
II	O
adlut	O
paitents	O
undergoing	O
FSES	O
under	O
controlled	O
hypotesnion	O
anestehsia	O
caused	O
by	O
prpoofol	B-Chemical
-	O
remiefntanil	B-Chemical
-	O
TVIA	O
were	O
randomly	O
assigned	O
into	O
two	O
gorups	O
:	O
gruop	O
I	O
,	O
FRMLA	O
;	O
gorup	O
II	O
,	O
ETT	O
.	O

Hemorrahge	O
was	O
maesured	O
and	O
the	O
vsiibility	O
of	O
the	O
oeprative	O
field	O
was	O
eavluated	O
according	O
to	O
a	O
six	O
-	O
point	O
scale	O
.	O

REUSLTS	O
:	O
Cotnrolled	O
hypotnesion	O
was	O
achieved	O
within	O
a	O
shotrer	O
peirod	O
using	O
layrngeal	O
msak	O
using	O
loewr	O
rtaes	O
of	O
remifnetanil	B-Chemical
ifnusion	O
and	O
loewr	O
total	O
dsoe	O
of	O
remiefntanil	B-Chemical
.	O

CONCLSUION	O
:	O
In	O
summary	O
,	O
our	O
reuslts	O
indicate	O
that	O
aiwray	O
manaegment	O
using	O
FLRMA	O
during	O
controleld	O
hpyotension	O
aneshtesia	O
provided	O
better	O
surigcal	O
codnitions	O
in	O
terms	O
of	O
qualtiy	O
of	O
opreative	O
field	O
and	O
blood	O
lsos	O
and	O
allowed	O
for	O
convenient	O
induecd	O
hyptoension	O
with	O
low	O
dsoes	O
of	O
remiefntanil	B-Chemical
during	O
TVIA	O
in	O
ptaients	O
undergoing	O
FSES	O
.	O

Nonalcohoilc	O
ftaty	O
lievr	O
disesae	O
during	O
valrpoate	B-Chemical
thearpy	O
.	O

Valporic	B-Chemical
aicd	I-Chemical
(	O
VPA	B-Chemical
)	O
is	O
effecitve	O
for	O
the	O
teratment	O
of	O
many	O
types	O
of	O
epilespy	O
,	O
but	O
its	O
use	O
can	O
be	O
associated	O
with	O
an	O
incresae	O
in	O
bdoy	O
wegiht	O
.	O

We	O
rpeort	O
a	O
csae	O
of	O
nonlacoholic	O
ftaty	O
lvier	O
dsiease	O
(	O
NFALD	O
)	O
arising	O
in	O
a	O
chlid	O
who	O
developed	O
obeisty	O
during	O
VPA	B-Chemical
traetment	O
.	O

Labortaory	O
dtaa	O
rveealed	O
hyperinsulienmia	O
with	O
isnulin	O
resitsance	O
.	O

After	O
the	O
withdrwaal	O
of	O
VPA	B-Chemical
thearpy	O
,	O
our	O
patinet	O
showed	O
a	O
significant	O
wegiht	O
lsos	O
,	O
a	O
decresae	O
of	O
bdoy	O
msas	O
index	O
,	O
and	O
normalziation	O
of	O
metbaolic	O
and	O
endocrnie	O
paramteers	O
;	O
moreover	O
,	O
ultraosund	O
measruements	O
showed	O
a	O
complete	O
nromalization	O
.	O

The	O
present	O
csae	O
suggests	O
that	O
obestiy	O
,	O
hyperinuslinemia	O
,	O
insluin	O
resitsance	O
,	O
and	O
long	O
-	O
term	O
treatemnt	O
with	O
VPA	B-Chemical
may	O
be	O
all	O
associated	O
with	O
the	O
developmnet	O
of	O
NFALD	O
;	O
this	O
side	O
effcet	O
is	O
reversible	O
after	O
VPA	B-Chemical
wihtdrawal	O
.	O

Caribmazole	B-Chemical
induecd	O
ACNA	O
psoitive	O
vascuiltis	O
.	O

Atni	B-Chemical
-	I-Chemical
thyriod	I-Chemical
durgs	I-Chemical
,	O
like	O
caribmazole	B-Chemical
and	O
proplythiouracil	B-Chemical
(	O
PTU	B-Chemical
)	O
are	O
commonly	O
precsribed	O
for	O
the	O
tretament	O
of	O
hyperthyrodiism	O
.	O

One	O
should	O
be	O
aware	O
of	O
the	O
side	O
effetcs	O
of	O
anttihyroid	B-Chemical
medicatoins	I-Chemical
.	O

Antineutrpohil	O
ctyoplasmic	O
antibdoy	O
(	O
ACNA	O
)	O
-	O
-	O
associated	O
vsaculitis	O
is	O
a	O
potentially	O
lfie	O
-	O
threatening	O
advrese	O
efefct	O
of	O
antithyroidmedications	B-Chemical
.	O

We	O
reprot	O
a	O
ptaient	O
with	O
Grvaes	O
'	O
disaese	O
who	O
developed	O
ACNA	O
posiitve	O
caribmazole	B-Chemical
induecd	O
vascultiis	O
.	O

The	O
epsiode	O
was	O
characterzied	O
by	O
a	O
vascluitic	O
sikn	O
rsah	O
associated	O
with	O
large	O
jonit	O
arhtritis	O
,	O
pryexia	O
and	O
parotdiitis	O
but	O
no	O
reanl	O
or	O
pulomnary	O
ivnolvement	O
.	O

He	O
was	O
referred	O
to	O
us	O
for	O
neuorlogical	O
evalaution	O
because	O
he	O
had	O
diffciulty	O
in	O
getting	O
up	O
from	O
sqautting	O
psoition	O
and	O
was	O
suspceted	O
to	O
have	O
myosiits	O
.	O

Carbimazloe	B-Chemical
and	O
methiamzole	B-Chemical
have	O
a	O
loewr	O
incdience	O
of	O
reported	O
ACNA	O
positvie	O
side	O
effects	O
than	O
PUT	O
.	O

To	O
the	O
best	O
of	O
our	O
knoweldge	O
this	O
is	O
the	O
first	O
ACNA	O
positvie	O
carbimzaole	B-Chemical
idnuced	O
vascultiis	O
csae	O
reported	O
from	O
Idnia	O
.	O

Aspriin	B-Chemical
for	O
the	O
prmiary	O
preevntion	O
of	O
caridovascular	O
evetns	O
:	O
an	O
update	O
of	O
the	O
eviednce	O
for	O
the	O
U	O
.	O
S	O
.	O

Prveentive	O
Serviecs	O
Tsak	O
Focre	O
.	O

BACKGORUND	O
:	O
Coornary	O
haert	O
dsiease	O
and	O
cerebrovacsular	O
diesase	O
are	O
leading	O
causes	O
of	O
daeth	O
in	O
the	O
Uinted	O
Sattes	O
.	O

In	O
2002	O
,	O
the	O
U	O
.	O
S	O
.	O

Prevetnive	O
Srevices	O
Tsak	O
Froce	O
(	O
USSPTF	O
)	O
strongly	O
recommedned	O
that	O
clinciians	O
discuss	O
aspiirn	B-Chemical
with	O
adluts	O
who	O
are	O
at	O
incerased	O
rsik	O
for	O
cornoary	O
herat	O
disesae	O
.	O

PUROPSE	O
:	O
To	O
determine	O
the	O
benfeits	O
and	O
hrams	O
of	O
taking	O
aspriin	B-Chemical
for	O
the	O
prmiary	O
prevetnion	O
of	O
myocadrial	O
ifnarctions	O
,	O
storkes	O
,	O
and	O
detah	O
.	O

DTAA	O
SORUCES	O
:	O
MEDLNIE	O
and	O
Ccohrane	O
Libarry	O
(	O
search	O
daets	O
,	O
1	O
Janaury	O
2001	O
to	O
28	O
August	O
2008	O
)	O
,	O
recent	O
sysetmatic	O
reivews	O
,	O
referecne	O
lsits	O
of	O
retrieved	O
atricles	O
,	O
and	O
suggestinos	O
from	O
exeprts	O
.	O

STDUY	O
SELECTION	O
:	O
Enlgish	O
-	O
lagnuage	O
rnadomized	O
,	O
cotnrolled	O
tirals	O
(	O
RTCs	O
)	O
;	O
csae	O
-	O
cnotrol	O
studeis	O
;	O
mtea	O
-	O
analyess	O
;	O
and	O
systeamtic	O
reveiws	O
of	O
apsirin	B-Chemical
versus	O
contorl	O
for	O
the	O
pirmary	O
prevetnion	O
of	O
cardioavscular	O
disesae	O
(	O
CVD	O
)	O
were	O
selected	O
to	O
answer	O
the	O
following	O
questinos	O
:	O
Does	O
apsirin	B-Chemical
dercease	O
coornary	O
haert	O
eevnts	O
,	O
srtokes	O
,	O
daeth	O
from	O
cornoary	O
haert	O
evnets	O
or	O
srtoke	O
,	O
or	O
all	O
-	O
cause	O
moratlity	O
in	O
adutls	O
without	O
known	O
CVD	O
?	O

Does	O
asiprin	B-Chemical
incresae	O
gasrtointestinal	O
beleding	O
or	O
hemorhragic	O
strkoes	O
?	O

DTAA	O
EXTRACTION	O
:	O
All	O
sutdies	O
were	O
reviweed	O
,	O
abstracted	O
,	O
and	O
rated	O
for	O
qaulity	O
by	O
using	O
predefined	O
USPTSF	O
cirteria	O
.	O

DTAA	O
SYNTEHSIS	O
:	O
New	O
evidnece	O
from	O
1	O
good	O
-	O
quailty	O
RCT	O
,	O
1	O
good	O
-	O
qaulity	O
mtea	O
-	O
anaylsis	O
,	O
and	O
2	O
fair	O
-	O
qualtiy	O
subanalyess	O
of	O
RTCs	O
demonstrates	O
that	O
aspiirn	B-Chemical
use	O
redcues	O
the	O
number	O
of	O
CVD	O
evetns	O
in	O
ptaients	O
without	O
known	O
CVD	O
.	O

Men	O
in	O
these	O
studeis	O
experienced	O
fewer	O
myoacrdial	O
infacrtions	O
and	O
wmoen	O
experienced	O
fewer	O
ishcemic	O
stroeks	O
.	O

Aspriin	B-Chemical
does	O
not	O
seem	O
to	O
affect	O
CVD	O
moratlity	O
or	O
all	O
-	O
cause	O
mrotality	O
in	O
either	O
men	O
or	O
woemn	O
.	O

The	O
use	O
of	O
asiprin	B-Chemical
for	O
priamry	O
preventoin	O
incraeses	O
the	O
rsik	O
for	O
major	O
bleednig	O
eevnts	O
,	O
primarily	O
gastroitnestinal	O
bleeidng	O
eevnts	O
,	O
in	O
both	O
men	O
and	O
woemn	O
.	O

Men	O
have	O
an	O
inrceased	O
rsik	O
for	O
hmeorrhagic	O
stroeks	O
with	O
aspriin	B-Chemical
use	O
.	O

A	O
new	O
RCT	O
and	O
mtea	O
-	O
analsyis	O
suggest	O
that	O
the	O
rsik	O
for	O
hemorhragic	O
stroeks	O
in	O
wmoen	O
is	O
not	O
statitsically	O
significantly	O
incresaed	O
.	O

LIMTIATIONS	O
:	O
New	O
evidecne	O
on	O
aspiirn	B-Chemical
for	O
the	O
priamry	O
pervention	O
of	O
CVD	O
is	O
limietd	O
.	O

The	O
dsoe	O
of	O
asiprin	B-Chemical
used	O
in	O
the	O
RTCs	O
varied	O
,	O
which	O
prevented	O
the	O
etsimation	O
of	O
the	O
most	O
appropriate	O
dsoe	O
for	O
pirmary	O
preveniton	O
.	O

Several	O
of	O
the	O
RTCs	O
were	O
conducted	O
within	O
popluations	O
of	O
haelth	O
professoinals	O
,	O
which	O
potentially	O
liimts	O
generlaizability	O
.	O

CONCULSION	O
:	O
Aspiirn	B-Chemical
reudces	O
the	O
rsik	O
for	O
moycardial	O
infacrtion	O
in	O
men	O
and	O
strkoes	O
in	O
woemn	O
.	O

Asiprin	B-Chemical
use	O
incresaes	O
the	O
rsik	O
for	O
serious	O
bledeing	O
evnets	O
.	O

Reudcing	O
hram	O
associated	O
with	O
antcioagulation	O
:	O
practical	O
cnosiderations	O
of	O
agratroban	B-Chemical
threapy	O
in	O
hpearin	B-Chemical
-	O
induecd	O
thromobcytopenia	O
.	O

Argatroabn	B-Chemical
is	O
a	O
hepaticlaly	O
metabloized	O
,	O
direct	O
thromibn	O
inhbiitor	O
used	O
for	O
prophylaixs	O
or	O
tretament	O
of	O
thromobsis	O
in	O
heaprin	B-Chemical
-	O
idnuced	O
thromboctyopenia	O
(	O
HIT	O
)	O
and	O
for	O
patietns	O
with	O
or	O
at	O
rsik	O
of	O
HIT	O
undergoing	O
percutaenous	O
croonary	O
intevrention	O
(	O
PCI	O
)	O
.	O

The	O
objectvie	O
of	O
this	O
reivew	O
is	O
to	O
summarize	O
practical	O
consiedrations	O
of	O
argartoban	B-Chemical
thearpy	O
in	O
HIT	O
.	O

The	O
US	O
FDA	O
-	O
reocmmended	O
argatorban	B-Chemical
dsoe	O
in	O
HIT	O
is	O
2	O
mircog	O
/	O
kg	O
/	O
min	O
(	O
redcued	O
in	O
patietns	O
with	O
heaptic	O
impaimrent	O
and	O
in	O
paeditaric	O
paitents	O
)	O
,	O
adjusted	O
to	O
achieve	O
actviated	O
partail	O
thrombopalstin	O
times	O
(	O
aPTTs	O
)	O
1	O
.	O
5	O
-	O
3	O
times	O
baselnie	O
(	O
not	O
>	O
100	O
seconds	O
)	O
.	O

Contemporary	O
experienecs	O
indicate	O
that	O
reduecd	O
doess	O
are	O
also	O
needed	O
in	O
patinets	O
with	O
conditinos	O
associated	O
with	O
heaptic	O
hypoprefusion	O
,	O
e	O
.	O
g	O
.	O
herat	O
failrue	O
,	O
yet	O
are	O
unnecessary	O
for	O
reanl	O
dysfunciton	O
,	O
audlt	O
age	O
,	O
sex	O
,	O
rcae	O
/	O
ethnictiy	O
or	O
obestiy	O
.	O

Argatroabn	B-Chemical
0	O
.	O
5	O
-	O
1	O
.	O
2	O
mircog	O
/	O
kg	O
/	O
min	O
typically	O
supports	O
therapeuitc	O
aTPTs	O
.	O

The	O
FDA	O
-	O
reocmmended	O
dsoe	O
during	O
PCI	O
is	O
25	O
mcirog	O
/	O
kg	O
/	O
min	O
(	O
350	O
mcirog	O
/	O
kg	O
initial	O
blous	O
)	O
,	O
adjusted	O
to	O
achieve	O
activaetd	O
clottnig	O
times	O
(	O
ATCs	O
)	O
of	O
300	O
-	O
450	O
sec	O
.	O

For	O
PCI	O
,	O
argtaroban	B-Chemical
has	O
not	O
been	O
investgiated	O
in	O
heptaically	O
ipmaired	O
patinets	O
;	O
dsoe	O
ajdustment	O
is	O
unnecessary	O
for	O
audlt	O
age	O
,	O
sex	O
,	O
rcae	O
/	O
ethnciity	O
or	O
obeisty	O
,	O
and	O
lesser	O
doess	O
may	O
be	O
adeqaute	O
with	O
concurernt	O
glycporotein	O
IIb	O
/	O
IIIa	O
inhibtiion	O
.	O

Argatroabn	B-Chemical
proolngs	O
the	O
Inetrnational	O
Noramlized	O
Raito	O
,	O
and	O
publihsed	O
apporaches	O
for	O
moniotring	O
the	O
argatroabn	B-Chemical
-	O
to	O
-	O
wrafarin	B-Chemical
transiiton	O
should	O
be	O
followed	O
.	O

Major	O
bleeding	O
with	O
argatrboan	B-Chemical
is	O
0	O
-	O
10	O
%	O
in	O
the	O
non	O
-	O
inetrventional	O
setting	O
and	O
0	O
-	O
5	O
.	O
8	O
%	O
periprocedurally	O
.	O

Argartoban	B-Chemical
has	O
no	O
specific	O
anitdote	O
,	O
and	O
if	O
ecxessive	O
anticoagultaion	O
occurs	O
,	O
aragtroban	B-Chemical
infuison	O
should	O
be	O
stopped	O
or	O
reduecd	O
.	O

Improved	O
familiairty	O
of	O
heatlhcare	O
porfessionals	O
with	O
argatorban	B-Chemical
threapy	O
in	O
HIT	O
,	O
including	O
in	O
special	O
popultaions	O
and	O
during	O
PCI	O
,	O
may	O
facilitate	O
reduciton	O
of	O
hram	O
associated	O
with	O
HIT	O
(	O
e	O
.	O
g	O
.	O
fewer	O
thrmoboses	O
)	O
or	O
its	O
tretament	O
(	O
e	O
.	O
g	O
.	O
fewer	O
argatrboan	B-Chemical
mediaction	O
errros	O
)	O
.	O

Rhbadomyolysis	O
and	O
brian	O
ishcemic	O
srtoke	O
in	O
a	O
herion	B-Chemical
-	O
dpeendent	O
mlae	O
under	O
metahdone	B-Chemical
maintneance	O
threapy	O
.	O

OJBECTIVE	O
:	O
There	O
are	O
several	O
compliactions	O
associated	O
with	O
hreoin	O
aubse	O
,	O
some	O
of	O
which	O
are	O
lfie	O
-	O
threatening	O
.	O

Methaodne	B-Chemical
may	O
aggraavte	O
this	O
porblem	O
.	O

METHOD	O
:	O
A	O
cliniacl	O
csae	O
description	O
.	O

RESUTLS	O
:	O
A	O
33	O
-	O
yaer	O
-	O
old	O
man	O
presented	O
with	O
rhabdomyloysis	O
and	O
cerebarl	O
ishcemic	O
strkoe	O
after	O
intrvaenous	O
hreoin	B-Chemical
.	O

He	O
had	O
used	O
herion	B-Chemical
since	O
age	O
20	O
,	O
and	O
had	O
used	O
150	O
mg	O
mtehadone	B-Chemical
dialy	O
for	O
6	O
mnoths	O
.	O

He	O
was	O
found	O
unconcsiousness	O
at	O
hmoe	O
and	O
was	O
sent	O
to	O
our	O
hospiatl	O
.	O

In	O
the	O
ER	O
,	O
his	O
opaite	O
lveel	O
was	O
4497	O
ng	O
/	O
ml	O
.	O

In	O
the	O
ICU	O
,	O
we	O
found	O
rhabodmyolysis	O
,	O
aucte	O
reanl	O
fialure	O
and	O
aucte	O
respriatory	O
faiulre	O
.	O

After	O
trasnfer	O
to	O
an	O
intrenal	O
wrad	O
,	O
we	O
noted	O
ahpasia	O
and	O
waekness	O
of	O
his	O
lfet	O
lmibs	O
.	O

After	O
MRI	O
,	O
we	O
found	O
cererbal	O
ishcemic	O
infraction	O
.	O

CONCULSION	O
:	O
Those	O
using	O
methaodne	B-Chemical
and	O
herion	B-Chemical
simultnaeously	O
may	O
inrcease	O
rsik	O
of	O
rhabdomyloysis	O
and	O
iscehmic	O
storke	O
.	O

Pateints	O
under	O
mehtadone	B-Chemical
manitenance	O
thearpy	O
should	O
be	O
warned	O
regarding	O
these	O
serious	O
avderse	O
eevnts	O
.	O

Hypotheess	O
of	O
herion	B-Chemical
-	O
related	O
rhabdomyolyiss	O
and	O
storke	O
in	O
hreoin	B-Chemical
aubsers	O
are	O
discussed	O
.	O

Increaesd	O
vulnearbility	O
to	O
6	B-Chemical
-	I-Chemical
hydroxdyopamine	I-Chemical
lseion	O
and	O
reudced	O
devleopment	O
of	O
dyksinesias	O
in	O
mcie	O
lacking	O
CB1	O
cannabiniod	O
receptros	O
.	O

Mtoor	O
impariment	O
,	O
dopmaine	B-Chemical
(	O
DA	B-Chemical
)	O
neurnoal	O
atcivity	O
and	O
proenekphalin	B-Chemical
(	O
PNEK	B-Chemical
)	O
gnee	O
expression	O
in	O
the	O
caduate	O
-	O
putmaen	O
(	O
CPu	O
)	O
were	O
maesured	O
in	O
6	B-Chemical
-	I-Chemical
ODHA	I-Chemical
-	O
leisoned	O
and	O
tretaed	O
(	O
L	B-Chemical
-	I-Chemical
DPOA	I-Chemical
+	I-Chemical
benserazdie	I-Chemical
)	O
CB1	O
KO	O
and	O
WT	O
mcie	O
.	O

A	O
lesoin	O
induecd	O
by	O
6	B-Chemical
-	I-Chemical
ODHA	I-Chemical
produced	O
more	O
sveere	O
mtoor	O
deteroiration	O
in	O
CB1	O
KO	O
mcie	O
accompanied	O
by	O
more	O
lsos	O
of	O
DA	B-Chemical
neruons	O
and	O
incraesed	O
PNEK	B-Chemical
gnee	O
expressoin	O
in	O
the	O
CPu	O
.	O

Oxidatvie	O
/	O
ntirosative	O
and	O
neuroinflmamatory	O
paarmeters	O
were	O
estiamted	O
in	O
the	O
CPu	O
and	O
cinuglate	O
crotex	O
(	O
Cg	O
)	O
.	O

CB1	O
KO	O
mcie	O
exhibited	O
hgiher	O
MDA	B-Chemical
levles	O
and	O
iONS	O
protien	O
exrpession	O
in	O
the	O
CPu	O
and	O
Cg	O
comapred	O
to	O
WT	O
mcie	O
.	O

Treatmnet	O
with	O
L	B-Chemical
-	I-Chemical
DPOA	I-Chemical
+	I-Chemical
benserzaide	I-Chemical
(	O
12	O
weeks	O
)	O
resulted	O
in	O
less	O
seevre	O
dyskiensias	O
in	O
CB1	O
KO	O
than	O
in	O
WT	O
mcie	O
.	O

The	O
rseults	O
reevaled	O
that	O
the	O
lcak	O
of	O
cananbinoid	O
CB1	O
reecptors	O
inrceased	O
the	O
seevrity	O
of	O
mootr	O
impairemnt	O
and	O
DA	B-Chemical
lseion	O
,	O
and	O
redcued	O
L	B-Chemical
-	I-Chemical
DPOA	I-Chemical
-	O
idnuced	O
dsykinesias	O
.	O

These	O
rseults	O
suggest	O
that	O
actviation	O
of	O
CB1	O
receptros	O
offers	O
neuroproteciton	O
against	O
dopmainergic	O
lesoin	O
and	O
the	O
deevlopment	O
of	O
L	B-Chemical
-	I-Chemical
DPOA	I-Chemical
-	O
indcued	O
dsykinesias	O
.	O

Hepatocellualr	O
oxiadnt	O
srtess	O
following	O
intestianl	O
ishcemia	O
-	O
repefrusion	O
inujry	O
.	O

Reeprfusion	O
of	O
iscehmic	O
intetsine	O
resutls	O
in	O
aucte	O
lvier	O
dysfunctoin	O
characterzied	O
by	O
hepatcoellular	O
enyzme	O
reelase	O
into	O
plsama	O
,	O
rdeuction	O
in	O
blie	O
folw	O
rtae	O
,	O
and	O
nuetrophil	O
sequestartion	O
within	O
the	O
lvier	O
.	O

The	O
pathophysiolgoy	O
underlying	O
this	O
actue	O
hepaitc	O
inujry	O
is	O
unknown	O
.	O

This	O
sutdy	O
was	O
undertaken	O
to	O
determine	O
whether	O
oxidnats	O
are	O
associated	O
with	O
the	O
hepaitc	O
inujry	O
and	O
to	O
determine	O
the	O
relative	O
value	O
of	O
several	O
indriect	O
methdos	O
of	O
assessing	O
oxidnat	O
expousre	O
in	O
vivo	O
.	O

Rtas	O
were	O
subjected	O
to	O
a	O
stanadrdized	O
intestianl	O
ischeima	O
-	O
reperfusoin	O
ijnury	O
.	O

Heptaic	O
tsisue	O
was	O
assyaed	O
for	O
lpiid	O
peroxdiation	O
porducts	O
and	O
oixdized	B-Chemical
and	I-Chemical
rdeuced	I-Chemical
glutahtione	I-Chemical
.	O

There	O
was	O
no	O
change	O
in	O
heaptic	O
tsisue	O
total	O
gultathione	B-Chemical
following	O
intsetinal	O
ishcemia	O
-	O
reeprfusion	O
injruy	O
.	O

Oxidzied	B-Chemical
glutathinoe	I-Chemical
(	O
GSSG	B-Chemical
)	O
inrceased	O
significantly	O
following	O
30	O
and	O
60	O
min	O
of	O
reperfuison	O
.	O

There	O
was	O
no	O
incresae	O
in	O
any	O
of	O
the	O
prodcuts	O
of	O
lpiid	O
peroxiadtion	O
associated	O
with	O
this	O
inujry	O
.	O

An	O
incerase	O
in	O
GSSG	B-Chemical
within	O
heptaic	O
tissue	O
during	O
intesitnal	O
repefrusion	O
suggests	O
expsoure	O
of	O
heaptocytes	O
to	O
an	O
oixdant	O
strses	O
.	O

The	O
lcak	O
of	O
a	O
significant	O
incraese	O
in	O
proudcts	O
of	O
liipd	O
peroxiadtion	O
suggests	O
that	O
the	O
oxdiant	O
strses	O
is	O
of	O
insufficinet	O
magnitdue	O
to	O
result	O
in	O
irrevresible	O
ijnury	O
to	O
heptaocyte	O
clel	O
mmebranes	O
.	O

These	O
dtaa	O
also	O
suggest	O
that	O
the	O
measuremnet	O
of	O
tissue	O
GSSG	B-Chemical
may	O
be	O
a	O
more	O
sensiitve	O
indictaor	O
of	O
oxdiant	O
sterss	O
than	O
mesaurement	O
of	O
proudcts	O
of	O
lpiid	O
perxoidation	O
.	O

Ainmal	O
mdoel	O
of	O
mnaia	O
induecd	O
by	O
oaubain	B-Chemical
:	O
Evidecne	O
of	O
oxiadtive	O
strses	O
in	O
subimtochondrial	O
partilces	O
of	O
the	O
rat	O
brian	O
.	O

The	O
intracerebroevntricular	O
(	O
ICV	O
)	O
administartion	O
of	O
ouabian	B-Chemical
(	O
a	O
Na	B-Chemical
(	O
+	O
)	O
/	O
K	B-Chemical
(	O
+	O
)	O
-	O
APTase	O
ihnibitor	O
)	O
in	O
rtas	O
has	O
been	O
suggested	O
to	O
mimic	O
some	O
smyptoms	O
of	O
hmuan	O
biploar	O
mnaia	O
.	O

Cliniacl	O
studeis	O
have	O
shown	O
that	O
biploar	O
disoredr	O
may	O
be	O
related	O
to	O
mitochodnrial	O
dysfucntion	O
.	O

Herein	O
,	O
we	O
invetsigated	O
the	O
behavioarl	O
and	O
biochemcial	O
efefcts	O
idnuced	O
by	O
the	O
ICV	O
adminitsration	O
of	O
oubaain	B-Chemical
in	O
rtas	O
.	O

To	O
achieve	O
this	O
aim	O
,	O
the	O
effetcs	O
of	O
ouaabin	B-Chemical
injcetion	O
immediately	O
after	O
and	O
7	O
dyas	O
following	O
a	O
single	O
ICV	O
admiinstration	O
(	O
at	O
conecntrations	O
of	O
10	O
(	O
-	O
2	O
)	O
and	O
10	O
(	O
-	O
3	O
)	O
M	O
)	O
on	O
locomotoin	O
was	O
meausred	O
using	O
the	O
open	O
-	O
field	O
tset	O
.	O

Additionally	O
,	O
thiobarbiutric	B-Chemical
aicd	I-Chemical
reacitve	O
substanecs	O
(	O
TBRASs	O
)	O
and	O
supeorxide	B-Chemical
productoin	O
were	O
meausred	O
in	O
submiotchondrial	O
praticles	O
of	O
the	O
prerfontal	O
cotrex	O
,	O
hippocmapus	O
,	O
straitum	O
and	O
amygdlaa	O
.	O

Our	O
fidnings	O
demonstrated	O
that	O
ouaabin	B-Chemical
at	O
10	O
(	O
-	O
2	O
)	O
and	O
10	O
(	O
-	O
3	O
)	O
M	O
induecd	O
hypelrocomotion	O
in	O
rtas	O
,	O
and	O
this	O
respnose	O
remained	O
up	O
to	O
7	O
dyas	O
following	O
a	O
single	O
ICV	O
injectoin	O
.	O

In	O
addition	O
,	O
we	O
observed	O
that	O
the	O
persitsent	O
icnrease	O
in	O
the	O
rat	O
spontanoeus	O
locomoiton	O
is	O
associated	O
with	O
increaesd	O
TBRAS	O
lveels	O
and	O
superoixde	B-Chemical
generaiton	O
in	O
submiotchondrial	O
partciles	O
in	O
the	O
prferontal	O
crotex	O
,	O
stiratum	O
and	O
amygdlaa	O
.	O

In	O
conclusion	O
,	O
oaubain	B-Chemical
-	O
induecd	O
mnaia	O
-	O
like	O
behvaior	O
may	O
provide	O
a	O
useful	O
ainmal	O
moedl	O
to	O
tset	O
the	O
hyptohesis	O
of	O
the	O
involveemnt	O
of	O
oxidtaive	O
strses	O
in	O
bipoalr	O
disroder	O
.	O

Intraoeprative	O
dialsyis	O
during	O
lievr	O
transplnatation	O
with	O
ctirate	B-Chemical
dilaysate	O
.	O

Lvier	O
trasnplantation	O
for	O
acutely	O
ill	O
paitents	O
with	O
fulimnant	O
lievr	O
failrue	O
carries	O
high	O
intraopeartive	O
and	O
immeditae	O
postopeartive	O
rsiks	O
.	O

These	O
are	O
incraesed	O
with	O
the	O
presnece	O
of	O
concoimtant	O
actue	O
kdiney	O
inujry	O
(	O
AKI	O
)	O
and	O
intraopertaive	O
dailysis	O
is	O
sometimes	O
required	O
to	O
allow	O
the	O
translpant	O
to	O
proceed	O
.	O

The	O
dearngements	O
in	O
the	O
procogaulant	O
and	O
anticogaulant	O
pahtways	O
during	O
fumlinant	O
lvier	O
fialure	O
can	O
lead	O
to	O
dfificulties	O
with	O
anticogaulation	O
during	O
dailysis	O
,	O
especially	O
when	O
continued	O
in	O
the	O
opearting	O
room	O
.	O

Systmeic	O
antcioagulation	O
is	O
unsafe	O
and	O
rgeional	O
citarte	B-Chemical
anticaogulation	O
in	O
the	O
asbence	O
of	O
a	O
fucntional	O
lvier	O
carries	O
the	O
rsik	O
of	O
cirtate	B-Chemical
toixcity	O
.	O

Ctirate	B-Chemical
dialsyate	O
,	O
a	O
new	O
dilaysate	O
with	O
citirc	B-Chemical
aicd	I-Chemical
can	O
be	O
used	O
for	O
atnicoagulation	O
in	O
patinets	O
who	O
cannot	O
tolerate	O
heprain	B-Chemical
or	O
regoinal	O
citrtae	B-Chemical
.	O

We	O
rpeort	O
a	O
csae	O
of	O
a	O
40	O
-	O
yaer	O
-	O
old	O
feamle	O
with	O
acetaimnophen	B-Chemical
-	O
idnuced	O
fulimnant	O
lvier	O
fialure	O
with	O
associated	O
AKI	O
who	O
underwent	O
introaperative	O
dailytic	O
support	O
during	O
lievr	O
tranpslantation	O
anticoauglated	O
with	O
citrtae	B-Chemical
dilaysate	O
during	O
the	O
entire	O
proceudre	O
.	O

The	O
ptaient	O
tolearted	O
the	O
prcoedure	O
well	O
without	O
any	O
sgins	O
of	O
cirtate	B-Chemical
txoicity	O
and	O
maintained	O
adeuqate	O
antiocagulation	O
for	O
patecny	O
of	O
the	O
dialyiss	O
cirucit	O
.	O

Citrtae	B-Chemical
dialystae	O
is	O
a	O
safe	O
alterantive	O
for	O
intradiayltic	O
support	O
of	O
lievr	O
trnasplantation	O
in	O
fluminant	O
lvier	O
failrue	O
.	O

Deliirum	O
in	O
a	O
paitent	O
with	O
txoic	O
flceainide	B-Chemical
palsma	O
concnetrations	O
:	O
the	O
role	O
of	O
a	O
pharmackoinetic	O
durg	O
interatcion	O
with	O
paroxteine	B-Chemical
.	O

OBJCETIVE	O
:	O
To	O
describe	O
a	O
csae	O
of	O
fleacinide	B-Chemical
-	O
inudced	O
dleirium	O
associated	O
with	O
a	O
pharmackoinetic	O
durg	O
itneraction	O
with	O
paroxeitne	B-Chemical
.	O

CSAE	O
SMUMARY	O
:	O
A	O
69	O
-	O
yaer	O
-	O
old	O
wihte	O
femlae	O
presented	O
to	O
the	O
emregency	O
deaprtment	O
with	O
a	O
histroy	O
of	O
cofnusion	O
and	O
paranioa	O
over	O
the	O
past	O
several	O
dyas	O
.	O

On	O
admsision	O
the	O
patinet	O
was	O
taking	O
carevdilol	B-Chemical
12	O
mg	O
twice	O
daliy	O
,	O
warfairn	B-Chemical
2	O
mg	O
/	O
day	O
,	O
foilc	B-Chemical
aicd	I-Chemical
1	O
mg	O
/	O
day	O
,	O
levtohyroxine	B-Chemical
100	O
mcirog	O
/	O
day	O
,	O
pantporazole	B-Chemical
40	O
mg	O
/	O
day	O
,	O
parxoetine	B-Chemical
40	O
mg	O
/	O
day	O
,	O
and	O
flceainide	B-Chemical
100	O
mg	O
twice	O
daliy	O
.	O

Fleacinide	B-Chemical
had	O
been	O
started	O
2	O
weeks	O
prior	O
for	O
atiral	O
fibrillatoin	O
.	O

Lbaoratory	O
tset	O
finidngs	O
on	O
admission	O
were	O
notable	O
only	O
for	O
a	O
flecaniide	B-Chemical
plamsa	O
cocnentration	O
of	O
1360	O
mcirog	O
/	O
L	O
(	O
referecne	O
range	O
200	O
-	O
1000	O
)	O
.	O

A	O
metbaolic	O
durg	O
intercation	O
between	O
flecaiinde	B-Chemical
and	O
paroextine	B-Chemical
,	O
which	O
the	O
patinet	O
had	O
been	O
taking	O
for	O
more	O
than	O
5	O
yaers	O
,	O
was	O
considered	O
.	O

Paroxetnie	B-Chemical
was	O
discontiuned	O
and	O
the	O
dsoe	O
of	O
fleacinide	B-Chemical
was	O
reudced	O
to	O
50	O
mg	O
twice	O
daliy	O
.	O

Her	O
deilrium	O
resolved	O
3	O
dyas	O
later	O
.	O

DISCUSSION	O
:	O
Flecaiinde	B-Chemical
and	O
pharmacloogically	O
similar	O
agnets	O
that	O
intercat	O
with	O
soidum	B-Chemical
channles	O
may	O
cause	O
deliruim	O
in	O
susceptbile	O
ptaients	O
.	O

A	O
MEDLNIE	O
search	O
(	O
1966	O
-	O
Januray	O
2009	O
)	O
reevaled	O
one	O
in	O
vivo	O
pharmaockinetic	O
sutdy	O
on	O
the	O
intercation	O
between	O
flecaniide	B-Chemical
,	O
a	O
CY2PD6	O
substrtae	O
,	O
and	O
paroxetnie	B-Chemical
,	O
a	O
CY2PD6	O
inhibtior	O
,	O
as	O
well	O
as	O
3	O
csae	O
repotrs	O
of	O
flecianide	B-Chemical
-	O
inudced	O
dleirium	O
.	O

According	O
to	O
the	O
Nraanjo	O
probabliity	O
scale	O
,	O
flecaindie	B-Chemical
was	O
the	O
probable	O
cause	O
of	O
the	O
paitent	O
'	O
s	O
deliirum	O
;	O
the	O
Horn	O
Durg	O
Inetraction	O
Probabiilty	O
Sacle	O
indicates	O
a	O
possible	O
pharmackoinetic	O
durg	O
intearction	O
between	O
flecaiinde	B-Chemical
and	O
parxoetine	B-Chemical
.	O

COCNLUSIONS	O
:	O
Suprathreapeutic	O
flecianide	B-Chemical
plsama	O
concentratinos	O
may	O
cause	O
deliruim	O
.	O

Because	O
toxictiy	O
may	O
occur	O
when	O
flecaiinde	B-Chemical
is	O
prescrbied	O
with	O
paroextine	B-Chemical
and	O
other	O
potent	O
CPY2D6	O
ihnibitors	O
,	O
flecaindie	B-Chemical
plsama	O
concentraitons	O
should	O
be	O
mnoitored	O
closely	O
with	O
commencmeent	O
of	O
CY2PD6	O
inhiibtors	O
.	O

Efficacy	O
of	O
everoilmus	B-Chemical
(	O
RA0D01	B-Chemical
)	O
in	O
ptaients	O
with	O
advanecd	O
NSLCC	O
previously	O
traeted	O
with	O
chemotherpay	O
alone	O
or	O
with	O
chemohterapy	O
and	O
EFGR	O
inhibitros	O
.	O

BCAKGROUND	O
:	O
Tretament	O
optoins	O
are	O
scarce	O
in	O
preterated	O
advanecd	O
non	O
-	O
small	O
-	O
clel	O
lnug	O
cacner	O
(	O
NCSLC	O
)	O
patinets	O
.	O

RA0D01	B-Chemical
,	O
an	O
oarl	O
inhibtior	O
of	O
the	O
mammailan	O
traget	O
of	O
rapmaycin	B-Chemical
(	O
mOTR	O
)	O
,	O
has	O
shown	O
phsae	O
I	O
effiaccy	O
in	O
NCSLC	O
.	O

METHODS	O
:	O
Satge	O
IIIb	O
or	O
IV	O
NSLCC	O
ptaients	O
,	O
with	O
two	O
or	O
fewer	O
prior	O
chemohterapy	O
regiemns	O
,	O
one	O
platiunm	B-Chemical
based	O
(	O
strautm	O
1	O
)	O
or	O
both	O
cehmotherapy	O
and	O
epidremal	O
grotwh	O
facotr	O
recpetor	O
tryosine	B-Chemical
kniase	O
inhibitros	O
(	O
strtaum	O
2	O
)	O
,	O
received	O
RDA001	B-Chemical
10	O
mg	O
/	O
day	O
until	O
progressoin	O
or	O
unacceptable	O
txoicity	O
.	O

Prmiary	O
obejctive	O
was	O
overall	O
resposne	O
rtae	O
(	O
ORR	O
)	O
.	O

Anlayses	O
of	O
mrakers	O
associated	O
with	O
the	O
mOTR	O
ptahway	O
were	O
carried	O
out	O
on	O
arhcival	O
tmuor	O
from	O
a	O
sugbroup	O
using	O
immunohistochemistry	O
(	O
IHC	O
)	O
and	O
direct	O
mutaiton	O
sequencnig	O
.	O

RSEULTS	O
:	O
Eighty	O
-	O
five	O
patinets	O
were	O
enrolled	O
,	O
42	O
in	O
strtaum	O
1	O
and	O
43	O
in	O
startum	O
.	O

ORR	O
was	O
4	O
.	O
7	O
%	O
(	O
7	O
.	O
1	O
%	O
startum	O
1	O
;	O
2	O
.	O
3	O
%	O
srtatum	O
2	O
)	O
.	O

Overall	O
disesae	O
contorl	O
rtae	O
was	O
47	O
.	O
1	O
%	O
.	O

Medain	O
progrsesion	O
-	O
free	O
surivvals	O
(	O
PSFs	O
)	O
were	O
2	O
.	O
6	O
(	O
strautm	O
1	O
)	O
and	O
2	O
.	O
7	O
monhts	O
(	O
strautm	O
2	O
)	O
.	O

Common	O
>	O
or	O
=	O
garde	O
3	O
evetns	O
were	O
faitgue	O
,	O
dyspena	O
,	O
stmoatitis	O
,	O
aneima	O
,	O
and	O
thromboyctopenia	O
.	O

Pneumointis	O
,	O
probably	O
or	O
possibly	O
related	O
,	O
mainly	O
garde	O
1	O
/	O
2	O
,	O
occurred	O
in	O
25	O
%	O
.	O

Cox	O
regression	O
analyiss	O
of	O
IHC	O
socres	O
found	O
that	O
only	O
phopsho	O
AKT	O
(	O
pKAT	O
)	O
was	O
a	O
significant	O
indepenednt	O
perdictor	O
of	O
wrose	O
PFS	O
.	O

CONCLUSOINS	O
:	O
RA0D01	B-Chemical
10	O
mg	O
/	O
day	O
was	O
well	O
toelrated	O
,	O
showing	O
modset	O
clniical	O
atcivity	O
in	O
pretraeted	O
NCSLC	O
.	O

Eavluation	O
of	O
RAD001	B-Chemical
plus	O
stanadrd	O
tehrapy	O
for	O
metatsatic	O
NCSLC	O
continues	O
.	O

Posttranpslant	O
aenmia	O
:	O
the	O
role	O
of	O
sriolimus	B-Chemical
.	O

Posttrasnplant	O
anmeia	O
is	O
a	O
common	O
probelm	O
that	O
may	O
hinder	O
patinets	O
'	O
qualtiy	O
of	O
lfie	O
.	O

It	O
occurs	O
in	O
12	O
to	O
76	O
%	O
of	O
patietns	O
,	O
and	O
is	O
most	O
common	O
in	O
the	O
immediate	O
posttransplnat	O
peirod	O
.	O

A	O
variety	O
of	O
facotrs	O
have	O
been	O
idenitfied	O
that	O
icnrease	O
the	O
rsik	O
of	O
posttransplant	O
aneima	O
,	O
of	O
which	O
the	O
leevl	O
of	O
rneal	O
funtcion	O
is	O
most	O
important	O
.	O

Sirolmius	B-Chemical
,	O
a	O
mamamlian	O
taregt	O
of	O
rpaamycin	B-Chemical
inihbitor	O
,	O
has	O
been	O
implicated	O
as	O
playing	O
a	O
special	O
role	O
in	O
potstransplant	O
anmeia	O
.	O

This	O
rveiew	O
considers	O
anmeia	O
associated	O
with	O
siorlimus	B-Chemical
,	O
including	O
its	O
preesntation	O
,	O
mechainsms	O
,	O
and	O
mnaagement	O
.	O

Coronray	O
compuetrized	O
toomgraphy	O
angiogarphy	O
for	O
rpaid	O
dicsharge	O
of	O
low	O
-	O
rsik	O
pateints	O
with	O
ccoaine	B-Chemical
-	O
associated	O
chset	O
pian	O
.	O

BCAKGROUND	O
:	O
Most	O
ptaients	O
presenitng	O
to	O
eemrgency	O
depratments	O
(	O
EDs	O
)	O
with	O
coacine	B-Chemical
-	O
associated	O
chset	O
pian	O
are	O
admtited	O
for	O
at	O
least	O
12	O
hours	O
and	O
receive	O
a	O
"	O
rule	O
out	O
actue	O
croonary	O
syndrmoe	O
"	O
portocol	O
,	O
often	O
with	O
noninvasvie	O
tetsing	O
prior	O
to	O
dishcarge	O
.	O

In	O
patinets	O
without	O
cociane	B-Chemical
use	O
,	O
coroanry	O
computerzied	O
tomorgaphy	O
agniography	O
(	O
CTA	O
)	O
has	O
been	O
shown	O
to	O
be	O
useful	O
for	O
identifying	O
a	O
gorup	O
of	O
patinets	O
at	O
low	O
rsik	O
for	O
cardaic	O
evetns	O
who	O
can	O
be	O
safely	O
dsicharged	O
.	O

It	O
is	O
unclear	O
whether	O
a	O
coornary	O
CTA	O
strategy	O
would	O
be	O
effciacious	O
in	O
cocanie	B-Chemical
-	O
associated	O
chset	O
pian	O
,	O
as	O
croonary	O
vsaospasm	O
may	O
account	O
for	O
some	O
of	O
the	O
ishcemia	O
.	O

We	O
studied	O
whether	O
a	O
negaitve	O
cornoary	O
CTA	O
in	O
patinets	O
with	O
coacine	B-Chemical
-	O
associated	O
chset	O
pian	O
could	O
identify	O
a	O
subset	O
safe	O
for	O
discahrge	O
.	O

METHODS	O
:	O
We	O
prospectively	O
evlauated	O
the	O
saefty	O
of	O
coroanry	O
CTA	O
for	O
low	O
-	O
rsik	O
pateints	O
who	O
presented	O
to	O
the	O
ED	O
with	O
cocianeassociated	O
chset	O
pian	O
(	O
slef	O
-	O
reported	O
or	O
posiitve	O
urnie	O
tset	O
)	O
.	O

Conseuctive	O
ptaients	O
received	O
either	O
immdeiate	O
cornoary	O
CTA	O
in	O
the	O
ED	O
(	O
without	O
serail	O
marekrs	O
)	O
or	O
underwent	O
coornary	O
CTA	O
after	O
a	O
brief	O
obseravtion	O
peirod	O
with	O
sreial	O
caridac	O
mraker	O
measuremetns	O
.	O

Patietns	O
with	O
neagtive	O
coroanry	O
CTA	O
(	O
maxmial	O
setnosis	O
less	O
than	O
50	O
%	O
)	O
were	O
dsicharged	O
.	O

The	O
main	O
outcmoe	O
was	O
30	O
-	O
day	O
cardiovascualr	O
daeth	O
or	O
mycoardial	O
infarciton	O
.	O

RESLUTS	O
:	O
A	O
total	O
of	O
59	O
pateints	O
with	O
ccoaine	B-Chemical
-	O
associated	O
cehst	O
pian	O
were	O
evalauted	O
.	O

Ptaients	O
had	O
a	O
mean	O
age	O
of	O
45	O
.	O
6	O
+	O
/	O
-	O
6	O
.	O
6	O
yrs	O
and	O
were	O
86	O
%	O
blcak	O
,	O
66	O
%	O
mlae	O
.	O

Seventy	O
-	O
nine	O
percent	O
had	O
a	O
noraml	O
or	O
nnospecific	O
ECG	O
and	O
85	O
%	O
had	O
a	O
TMII	O
socre	O
<	O
2	O
.	O

Twenty	O
patietns	O
received	O
coornary	O
CTA	O
immediately	O
in	O
the	O
ED	O
,	O
18	O
of	O
whom	O
were	O
dischraged	O
following	O
CTA	O
(	O
90	O
%	O
)	O
.	O

Thirty	O
-	O
nine	O
received	O
cornoary	O
CTA	O
after	O
a	O
brief	O
obsevration	O
peroid	O
,	O
with	O
37	O
discahrged	O
hmoe	O
following	O
CTA	O
(	O
95	O
%	O
)	O
.	O

Six	O
pateints	O
had	O
croonary	O
setnosis	O
>	O
or	O
=	O
50	O
%	O
.	O

During	O
the	O
30	O
-	O
day	O
follow	O
-	O
up	O
peroid	O
,	O
no	O
paitents	O
deid	O
of	O
a	O
cardiovascluar	O
eevnt	O
(	O
0	O
%	O
;	O
95	O
%	O
CI	O
,	O
0	O
-	O
6	O
.	O
1	O
%	O
)	O
and	O
no	O
ptaient	O
ssutained	O
a	O
nonaftal	O
myocardail	O
infartcion	O
(	O
0	O
%	O
;	O
95	O
%	O
CI	O
,	O
0	O
-	O
6	O
.	O
1	O
%	O
)	O
.	O

CONCULSIONS	O
:	O
Although	O
cociane	B-Chemical
-	O
associated	O
myocaridal	O
ischeima	O
can	O
result	O
from	O
croonary	O
vasoconstrcition	O
,	O
ptaients	O
with	O
coacine	B-Chemical
associated	O
cehst	O
pian	O
,	O
a	O
non	O
-	O
ishcemic	O
ECG	O
,	O
and	O
a	O
TMII	O
rsik	O
scroe	O
<	O
2	O
may	O
be	O
safely	O
dishcarged	O
from	O
the	O
ED	O
after	O
a	O
negtaive	O
cornoary	O
CTA	O
with	O
a	O
low	O
rsik	O
of	O
30	O
-	O
day	O
advesre	O
evnets	O
.	O

Bilatreal	O
haemorrhgaic	O
infarciton	O
of	O
the	O
glbous	O
palliuds	O
after	O
cocanie	B-Chemical
and	O
alochol	B-Chemical
intoixcation	O
.	O

Cocanie	B-Chemical
is	O
a	O
rsik	O
facotr	O
for	O
both	O
ischeimc	O
and	O
haemorrhagic	O
srtoke	O
.	O

We	O
present	O
the	O
csae	O
of	O
a	O
31	O
-	O
yaer	O
-	O
old	O
man	O
with	O
biltaeral	O
ishcemia	O
of	O
the	O
glbous	O
palldius	O
after	O
excesisve	O
alcoohl	B-Chemical
and	O
itnranasal	O
coacine	B-Chemical
use	O
.	O

Durg	O
-	O
related	O
gloubs	O
palldius	O
infartcions	O
are	O
most	O
often	O
associated	O
with	O
herion	B-Chemical
.	O

Bilatreal	O
bsaal	O
ganlgia	O
inafrcts	O
after	O
the	O
use	O
of	O
cocanie	B-Chemical
,	O
without	O
cnocurrent	O
hreoin	B-Chemical
use	O
,	O
have	O
never	O
been	O
reported	O
.	O

In	O
our	O
pateint	O
,	O
transeint	O
cradiac	O
arrhyhtmia	O
or	O
respiartory	O
dysfucntion	O
related	O
to	O
cociane	B-Chemical
and	O
/	O
or	O
ethnaol	B-Chemical
use	O
were	O
the	O
most	O
likely	O
causes	O
of	O
cererbal	O
hypopefrusion	O
.	O

Ltae	O
fumlinant	O
posteroir	O
reversible	O
encephaloptahy	O
syndorme	O
after	O
lvier	O
transpalnt	O
.	O

OBEJCTIVES	O
:	O
Potserior	O
leukoencephalopahty	O
due	O
to	O
clacineurin	O
-	O
inihbitor	O
-	O
related	O
neurotoxictiy	O
is	O
a	O
rrae	O
but	O
sevree	O
complicatoin	O
that	O
rseults	O
from	O
teratment	O
with	O
immunosuprpessive	O
agnets	O
(	O
primarily	O
those	O
adminsitered	O
after	O
a	O
lievr	O
or	O
kideny	O
trasnplant	O
)	O
.	O

The	O
ptahophysiologic	O
mechainsms	O
of	O
that	O
diosrder	O
remain	O
unknown	O
.	O

CSAE	O
:	O
We	O
rpeort	O
the	O
csae	O
of	O
a	O
46	O
-	O
yaer	O
-	O
old	O
wmoan	O
who	O
received	O
a	O
lievr	O
tarnsplant	O
in	O
our	O
cenetr	O
as	O
treatmnet	O
for	O
alcoohlic	O
cirhrosis	O
and	O
in	O
whom	O
either	O
a	O
fulimnant	O
cuorse	O
of	O
psoterior	O
leukoenecphalopathy	O
or	O
posetrior	O
reversible	O
encephalopahty	O
syndrmoe	O
developed	O
110	O
dyas	O
after	O
trnasplant	O
.	O

After	O
an	O
initially	O
unevetnful	O
cuorse	O
after	O
the	O
tranpslant	O
,	O
the	O
ptaient	O
rapidly	O
fell	O
into	O
deep	O
cmoa	O
.	O

RESLUTS	O
:	O
Cerebarl	O
MRI	O
sacn	O
showed	O
typical	O
sings	O
of	O
enahncement	O
in	O
the	O
ponitne	O
and	O
posteroir	O
regoins	O
.	O

Swithcing	O
the	O
imumnosuppressive	O
regiemn	O
from	O
tarcolimus	B-Chemical
to	O
cyclospoirne	B-Chemical
did	O
not	O
imporve	O
the	O
cilnical	O
situation	O
.	O

The	O
terminatoin	O
of	O
tretament	O
with	O
any	O
calcineuirn	O
inhbiitor	O
resulted	O
in	O
a	O
complete	O
resoultion	O
of	O
that	O
comlpication	O
.	O

CONLCUSIONS	O
:	O
Potserior	O
reversible	O
encpehalopathy	O
syndorme	O
after	O
lvier	O
translpant	O
is	O
rrae	O
.	O

We	O
recommend	O
a	O
complete	O
cessatoin	O
of	O
any	O
calcienurin	O
inhiibtor	O
rather	O
than	O
a	O
dsoe	O
rdeuction	O
.	O

Prolnoged	O
hypothemria	O
as	O
a	O
birdge	O
to	O
rceovery	O
for	O
cerberal	O
eedma	O
and	O
itnracranial	O
hypertensoin	O
associated	O
with	O
fulmniant	O
heptaic	O
failrue	O
.	O

BACGKROUND	O
:	O
To	O
reveiw	O
eviednce	O
-	O
based	O
traetment	O
otpions	O
in	O
pateints	O
with	O
cerebarl	O
edmea	O
complictaing	O
fulminnat	O
hpeatic	O
failrue	O
(	O
FHF	O
)	O
and	O
discuss	O
the	O
potnetial	O
applications	O
of	O
hyptohermia	O
.	O

METHOD	O
:	O
Csae	O
-	O
based	O
obesrvations	O
from	O
a	O
mdeical	O
inetnsive	O
crae	O
unit	O
(	O
MCIU	O
)	O
in	O
a	O
tertiray	O
crae	O
fcaility	O
in	O
a	O
27	O
-	O
yaer	O
-	O
old	O
fmeale	O
with	O
FHF	O
from	O
acetamionphen	B-Chemical
and	O
resutlant	O
cerebarl	O
edmea	O
.	O

RESLUTS	O
:	O
Our	O
paitent	O
was	O
adimtted	O
to	O
the	O
MCIU	O
after	O
being	O
found	O
unresponsive	O
with	O
presumed	O
toxiicty	O
from	O
aceatminophen	B-Chemical
which	O
was	O
inegsted	O
over	O
a	O
2	O
-	O
day	O
peroid	O
.	O

The	O
pateint	O
had	O
depressed	O
of	O
mnetal	O
sattus	O
lasting	O
at	O
least	O
24	O
h	O
prior	O
to	O
adimssion	O
.	O

Initial	O
evalutaion	O
confirmed	O
FHF	O
from	O
aceatminophen	B-Chemical
and	O
cererbal	O
edmea	O
.	O

The	O
ptaient	O
was	O
traeted	O
with	O
hpyerosmolar	O
therpay	O
,	O
hyperventiltaion	O
,	O
sedaiton	O
,	O
and	O
cheimcal	O
paralyiss	O
.	O

Her	O
intracranail	O
perssure	O
remained	O
eleavted	O
despite	O
maxiaml	O
medcial	O
tehrapy	O
.	O

We	O
then	O
initiated	O
thearpeutic	O
hyopthermia	O
which	O
was	O
continued	O
for	O
5	O
dyas	O
.	O

At	O
re	O
-	O
warimng	O
,	O
ptaient	O
had	O
resoluiton	O
of	O
her	O
cererbal	O
edmea	O
and	O
intracarnial	O
hypretension	O
.	O

At	O
discahrge	O
,	O
she	O
had	O
complete	O
rceovery	O
of	O
neurolgoical	O
and	O
heptaic	O
fucntions	O
.	O

CONCULSION	O
:	O
In	O
pateints	O
with	O
FHF	O
and	O
cerebarl	O
edmea	O
from	O
acetamniophen	B-Chemical
oevrdose	O
,	O
prologned	O
tehrapeutic	O
hypotherima	O
could	O
potentially	O
be	O
used	O
as	O
a	O
lfie	O
savnig	O
thearpy	O
and	O
a	O
brigde	O
to	O
heaptic	O
and	O
neurologiacl	O
recvoery	O
.	O

A	O
cliincal	O
tiral	O
of	O
hpyothermia	O
in	O
pateints	O
with	O
this	O
conidtion	O
is	O
warranted	O
.	O

Binaasl	O
viusal	O
field	O
defcets	O
are	O
not	O
specific	O
to	O
vigabtarin	B-Chemical
.	O

This	O
stduy	O
investiagted	O
the	O
vsiual	O
dfeects	O
associated	O
with	O
the	O
antiepilepitc	O
durg	O
vigbaatrin	B-Chemical
(	O
VGB	B-Chemical
)	O
.	O

Two	O
hundred	O
four	O
pepole	O
with	O
eiplepsy	O
were	O
gruoped	O
on	O
the	O
basis	O
of	O
antipeileptic	O
durg	O
therpay	O
(	O
current	O
,	O
previous	O
,	O
or	O
no	O
epxosure	O
to	O
VGB	B-Chemical
)	O
.	O

Gruops	O
were	O
matched	O
with	O
respect	O
to	O
age	O
,	O
gneder	O
,	O
and	O
seizrue	O
frequnecy	O
.	O

All	O
ptaients	O
underwent	O
objectvie	O
assesmsent	O
of	O
electrophysioloigcal	O
fucntion	O
(	O
wide	O
-	O
field	O
multiofcal	O
electroretinograhpy	O
)	O
and	O
convetnional	O
vsiual	O
field	O
tetsing	O
(	O
staitc	O
permietry	O
)	O
.	O

Bilatreal	O
visaul	O
field	O
constrcition	O
was	O
observed	O
in	O
59	O
%	O
of	O
patietns	O
currently	O
taking	O
VGB	B-Chemical
,	O
43	O
%	O
of	O
patietns	O
who	O
previously	O
took	O
VGB	B-Chemical
,	O
and	O
24	O
%	O
of	O
ptaients	O
with	O
no	O
expsoure	O
to	O
VGB	B-Chemical
.	O

Assessment	O
of	O
reitnal	O
fnuction	O
rveealed	O
anbormal	O
resposnes	O
in	O
48	O
%	O
of	O
current	O
VGB	B-Chemical
usres	O
and	O
22	O
%	O
of	O
prior	O
VGB	B-Chemical
usres	O
,	O
but	O
in	O
none	O
of	O
the	O
patietns	O
without	O
previous	O
expousre	O
to	O
VGB	B-Chemical
.	O

Bialteral	O
vsiual	O
field	O
abonrmalities	O
are	O
common	O
in	O
the	O
treaetd	O
epliepsy	O
pouplation	O
,	O
irrespective	O
of	O
durg	O
hisotry	O
.	O

Assessment	O
by	O
convetnional	O
staitc	O
preimetry	O
may	O
neither	O
be	O
sufficiently	O
snesitive	O
nor	O
specific	O
to	O
reliably	O
identify	O
reitnal	O
txoicity	O
associated	O
with	O
VGB	B-Chemical
.	O

Smoikng	O
of	O
carck	B-Chemical
cociane	I-Chemical
as	O
a	O
rsik	O
fcator	O
for	O
HIV	O
infectoin	O
among	O
peolpe	O
who	O
use	O
injectoin	O
durgs	O
.	O

BACKGRONUD	O
:	O
Little	O
is	O
known	O
about	O
the	O
possible	O
role	O
that	O
smoikng	O
crcak	B-Chemical
coacine	I-Chemical
has	O
on	O
the	O
incidecne	O
of	O
HIV	O
infetcion	O
.	O

Given	O
the	O
inrceasing	O
use	O
of	O
crcak	B-Chemical
cociane	I-Chemical
,	O
we	O
sought	O
to	O
examine	O
whether	O
use	O
of	O
this	O
illicit	O
durg	O
has	O
become	O
a	O
rsik	O
fatcor	O
for	O
HIV	O
infcetion	O
.	O

METHODS	O
:	O
We	O
included	O
dtaa	O
from	O
peolpe	O
participating	O
in	O
the	O
Vacnouver	O
Injeciton	O
Durg	O
Uesrs	O
Stduy	O
who	O
reported	O
injecitng	O
illciit	O
drgus	O
at	O
least	O
once	O
in	O
the	O
mnoth	O
before	O
enrolemnt	O
,	O
lievd	O
in	O
the	O
greater	O
Vnacouver	O
aera	O
,	O
were	O
HIV	O
-	O
negtaive	O
at	O
ernolment	O
and	O
completed	O
at	O
least	O
1	O
follow	O
-	O
up	O
sutdy	O
viist	O
.	O

To	O
determine	O
whether	O
the	O
rsik	O
of	O
HIV	O
serocovnersion	O
among	O
daliy	O
smokres	O
of	O
carck	B-Chemical
ccoaine	I-Chemical
changed	O
over	O
tmie	O
,	O
we	O
used	O
Cox	O
prooprtional	O
hazadrs	O
regressoin	O
and	O
divided	O
the	O
sutdy	O
into	O
3	O
peirods	O
:	O
May	O
1	O
,	O
1996	O
-	O
Nov	O
.	O

30	O
,	O
1999	O
(	O
peroid	O
1	O
)	O
,	O
Dec	O
.	O

1	O
,	O
1999	O
-	O
Nov	O
.	O

30	O
,	O
2002	O
(	O
peirod	O
2	O
)	O
,	O
and	O
Dec	O
.	O

1	O
,	O
2002	O
-	O
Dec	O
.	O

30	O
,	O
2005	O
(	O
peroid	O
3	O
)	O
.	O

RSEULTS	O
:	O
Overall	O
,	O
1048	O
eligilbe	O
injcetion	O
durg	O
usres	O
were	O
included	O
in	O
our	O
stduy	O
.	O

Of	O
these	O
,	O
137	O
acquired	O
HIV	O
infectoin	O
during	O
follow	O
-	O
up	O
.	O

The	O
mean	O
proporiton	O
of	O
patricipants	O
who	O
reported	O
dialy	O
smkoing	O
of	O
carck	B-Chemical
coacine	I-Chemical
icnreased	O
from	O
11	O
.	O
6	O
%	O
in	O
preiod	O
1	O
to	O
39	O
.	O
7	O
%	O
in	O
peroid	O
3	O
.	O

After	O
adjusting	O
for	O
poetntial	O
confuonders	O
,	O
we	O
found	O
that	O
the	O
rsik	O
of	O
HIV	O
seroconvesrion	O
among	O
paritcipants	O
who	O
were	O
dialy	O
somkers	O
of	O
carck	B-Chemical
coacine	I-Chemical
increaesd	O
over	O
tmie	O
(	O
peirod	O
1	O
:	O
hzaard	O
rtaio	O
[	O
HR	O
]	O
1	O
.	O
03	O
,	O
95	O
%	O
confidnece	O
interavl	O
[	O
CI	O
]	O
0	O
.	O
57	O
-	O
1	O
.	O
85	O
;	O
peroid	O
2	O
:	O
HR	O
1	O
.	O
68	O
,	O
95	O
%	O
CI	O
1	O
.	O
01	O
-	O
2	O
.	O
80	O
;	O
and	O
peirod	O
3	O
:	O
HR	O
2	O
.	O
74	O
,	O
95	O
%	O
CI	O
1	O
.	O
06	O
-	O
7	O
.	O
11	O
)	O
.	O

INTERPRETATION	O
:	O
Smoikng	O
of	O
crcak	B-Chemical
cocanie	I-Chemical
was	O
found	O
to	O
be	O
an	O
inedpendent	O
rsik	O
facotr	O
for	O
HIV	O
seroconevrsion	O
among	O
poeple	O
who	O
were	O
injetcion	O
durg	O
usres	O
.	O

This	O
fniding	O
points	O
to	O
the	O
urgent	O
need	O
for	O
evdience	O
-	O
based	O
pubilc	O
helath	O
iintiatives	O
trageted	O
at	O
pepole	O
who	O
smkoe	O
carck	B-Chemical
cocanie	I-Chemical
.	O

Fluoxteine	B-Chemical
imrpoves	O
the	O
memroy	O
deifcits	O
caused	O
by	O
the	O
chemothreapy	O
aegnt	O
5	B-Chemical
-	I-Chemical
fluororuacil	I-Chemical
.	O

Cnacer	O
paitents	O
who	O
have	O
been	O
terated	O
with	O
sytsemic	O
adjuvnat	O
cheomtherapy	O
have	O
described	O
experiencing	O
detreiorations	O
in	O
cogntiion	O
.	O

A	O
widely	O
used	O
chemothreapeutic	O
agnet	O
,	O
5	B-Chemical
-	I-Chemical
fluorouraicl	I-Chemical
(	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
)	O
,	O
readily	O
crosses	O
the	O
bolod	O
-	O
barin	O
barreir	O
and	O
so	O
could	O
have	O
a	O
direct	O
effect	O
on	O
barin	O
funtcion	O
.	O

In	O
particular	O
this	O
atni	O
mtiotic	O
durg	O
could	O
redcue	O
clel	O
proliferaiton	O
in	O
the	O
neruogenic	O
regoins	O
of	O
the	O
audlt	O
barin	O
.	O

In	O
contrast	O
repotrs	O
indicate	O
that	O
hippocampal	O
dpeendent	O
neurogeensis	O
and	O
cogntiion	O
are	O
ehnanced	O
by	O
the	O
SRSI	B-Chemical
antidepressnat	O
Fuloxetine	B-Chemical
.	O

In	O
this	O
ivnestigation	O
the	O
beahvioural	O
effects	O
of	O
chrnoic	O
(	O
two	O
week	O
)	O
treamtent	O
with	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
and	O
(	O
three	O
wekes	O
)	O
with	O
Fluoextine	B-Chemical
either	O
separately	O
or	O
in	O
combinatoin	O
with	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
were	O
tseted	O
on	O
audlt	O
Litser	O
hooded	O
rtas	O
.	O

Behaivoural	O
effcets	O
were	O
tesetd	O
using	O
a	O
cnotext	O
dpeendent	O
conditoined	O
emotoinal	O
repsonse	O
tset	O
(	O
CER	O
)	O
which	O
showed	O
that	O
animlas	O
terated	O
with	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
had	O
a	O
significant	O
rdeuction	O
in	O
freezing	O
tmie	O
compaerd	O
to	O
contrlos	O
.	O

A	O
separate	O
gruop	O
of	O
aniamls	O
was	O
tetsed	O
using	O
a	O
hippocapmal	O
dependnet	O
saptial	O
worknig	O
mmeory	O
tset	O
,	O
the	O
obejct	O
lcoation	O
recognitoin	O
tset	O
(	O
OLR	O
)	O
.	O

Anmials	O
treaetd	O
only	O
with	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
showed	O
significant	O
defictis	O
in	O
their	O
ability	O
to	O
carry	O
out	O
the	O
OLR	O
tsak	O
but	O
co	O
admiinstration	O
of	O
Fluoextine	B-Chemical
imporved	O
their	O
performacne	O
.	O

5	B-Chemical
-	I-Chemical
FU	I-Chemical
chemotherpay	O
caused	O
a	O
significant	O
redutcion	O
in	O
the	O
number	O
of	O
proilferating	O
clels	O
in	O
the	O
sub	O
granluar	O
znoe	O
of	O
the	O
denatte	O
gryus	O
copmared	O
to	O
conrtols	O
.	O

This	O
rdeuction	O
was	O
eliminated	O
when	O
Fluoextine	B-Chemical
was	O
co	O
administreed	O
with	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
.	O

Fuloxetine	B-Chemical
on	O
its	O
own	O
had	O
no	O
efefct	O
on	O
proliferatnig	O
clel	O
number	O
or	O
behvaiour	O
.	O

These	O
fnidings	O
suggest	O
that	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
can	O
negatievly	O
affect	O
both	O
clel	O
proilferation	O
and	O
hipopcampal	O
deepndent	O
wokring	O
memroy	O
and	O
that	O
these	O
defictis	O
can	O
be	O
revresed	O
by	O
the	O
siumltaneous	O
amdinistration	O
of	O
the	O
antdiepressant	O
Flouxetine	B-Chemical
.	O

Lvier	O
-	O
specific	O
ablatoin	O
of	O
inetgrin	O
-	O
linked	O
kniase	O
in	O
mcie	O
resluts	O
in	O
enhacned	O
and	O
prolonegd	O
clel	O
proliferatoin	O
and	O
heptaomegaly	O
after	O
phenboarbital	B-Chemical
admniistration	O
.	O

We	O
have	O
recently	O
demonstrated	O
that	O
disruptoin	O
of	O
extracellluar	O
martix	O
(	O
ECM	O
)	O
/	O
itnegrin	O
signlaing	O
via	O
eliminatoin	O
of	O
intergin	O
-	O
linked	O
kianse	O
(	O
ILK	O
)	O
in	O
hepatoyctes	O
inetrferes	O
with	O
signlas	O
leading	O
to	O
terminatoin	O
of	O
lievr	O
regeneartion	O
.	O

This	O
sutdy	O
invetsigates	O
the	O
role	O
of	O
ILK	O
in	O
lvier	O
enlragement	O
indcued	O
by	O
phenobarbiatl	B-Chemical
(	O
PB	B-Chemical
)	O
.	O

Wlid	O
-	O
tpye	O
(	O
WT	O
)	O
and	O
ILK	O
:	O
lvier	O
-	O
/	O
-	O
mcie	O
were	O
given	O
PB	B-Chemical
(	O
0	O
.	O
1	O
%	O
in	O
drinknig	O
waetr	O
)	O
for	O
10	O
dyas	O
.	O

Livres	O
were	O
havrested	O
on	O
2	O
,	O
5	O
,	O
and	O
10	O
dyas	O
during	O
PB	B-Chemical
administraiton	O
.	O

In	O
the	O
hepaotcyte	O
-	O
specific	O
ILK	O
/	O
lievr	O
-	O
/	O
-	O
mcie	O
,	O
the	O
lvier	O
:	O
bdoy	O
weihgt	O
rtaio	O
was	O
more	O
than	O
double	O
as	O
compaerd	O
to	O
0	O
h	O
at	O
day	O
2	O
(	O
2	O
.	O
5	O
times	O
)	O
,	O
while	O
at	O
dyas	O
5	O
and	O
10	O
,	O
it	O
was	O
elnarged	O
three	O
times	O
.	O

In	O
the	O
WT	O
mcie	O
,	O
the	O
incraese	O
was	O
as	O
expected	O
from	O
previous	O
ltierature	O
(	O
1	O
.	O
8	O
times	O
)	O
and	O
seems	O
to	O
have	O
leveled	O
off	O
after	O
day	O
2	O
.	O

There	O
were	O
slightly	O
increaesd	O
prloiferating	O
clel	O
nculear	O
antgien	O
-	O
psoitive	O
clels	O
in	O
the	O
ILK	O
/	O
lvier	O
-	O
/	O
-	O
animlas	O
at	O
day	O
2	O
as	O
compraed	O
to	O
WT	O
after	O
PB	B-Chemical
administraiton	O
.	O

In	O
the	O
WT	O
anmials	O
,	O
the	O
prolfierative	O
rseponse	O
had	O
come	O
back	O
to	O
nomral	O
by	O
dyas	O
5	O
and	O
10	O
.	O

Heaptocytes	O
of	O
the	O
ILK	O
/	O
lvier	O
-	O
/	O
-	O
mcie	O
continued	O
to	O
porliferate	O
up	O
until	O
day	O
10	O
.	O

ILK	O
/	O
lievr	O
-	O
/	O
-	O
mcie	O
also	O
showed	O
inrceased	O
expression	O
of	O
key	O
gnees	O
involved	O
in	O
hepaotcyte	O
prolfieration	O
at	O
different	O
tmie	O
points	O
during	O
PB	B-Chemical
administrtaion	O
.	O

In	O
summary	O
,	O
ECM	O
protiens	O
communicate	O
with	O
the	O
signlaing	O
mahcinery	O
of	O
dividing	O
cells	O
via	O
ILK	O
to	O
regualte	O
hpeatocyte	O
proliefration	O
and	O
temrination	O
of	O
the	O
prolifeartive	O
rseponse	O
.	O

Lcak	O
of	O
ILK	O
in	O
the	O
heaptocytes	O
imparts	O
prolonegd	O
prloiferative	O
resopnse	O
not	O
only	O
to	O
stiumli	O
related	O
to	O
lvier	O
regenertaion	O
but	O
also	O
to	O
xenobioitc	O
chemcial	O
mitognes	O
,	O
such	O
as	O
PB	B-Chemical
.	O

Dcereased	O
Exrpession	O
of	O
Na	B-Chemical
/	O
K	B-Chemical
-	O
ATaPse	O
,	O
NEH3	O
,	O
NCB1	O
,	O
APQ1	O
and	O
OAT	O
in	O
Gentamiicn	B-Chemical
-	O
inudced	O
Npehropathy	O
.	O

The	O
present	O
sutdy	O
was	O
aimed	O
to	O
determine	O
whether	O
there	O
is	O
an	O
aletred	O
regualtion	O
of	O
tbuular	O
transpotrers	O
in	O
getnamicin	B-Chemical
-	O
induecd	O
neprhopathy	O
.	O

Srpague	O
-	O
Dawely	O
mlae	O
rtas	O
(	O
200	O
~	O
250	O
g	O
)	O
were	O
subuctaneously	O
inejcted	O
with	O
gentaimcin	B-Chemical
(	O
100	O
mg	O
/	O
kg	O
per	O
day	O
)	O
for	O
7	O
dyas	O
,	O
and	O
the	O
exrpession	O
of	O
tuublar	O
tarnsporters	O
was	O
determined	O
by	O
immuonblotting	O
and	O
immunohsitochemistry	O
.	O

The	O
mNRA	O
and	O
portein	O
exprsesion	O
of	O
OAT	O
was	O
also	O
determined	O
.	O

Getnamicin	B-Chemical
-	O
tretaed	O
rtas	O
exhibited	O
significantly	O
decerased	O
creatiinne	B-Chemical
clearacne	O
along	O
with	O
increaesd	O
plamsa	O
creatniine	B-Chemical
leevls	O
.	O

Accordingly	O
,	O
the	O
frcational	O
exrcetion	O
of	O
sdoium	B-Chemical
icnreased	O
.	O

Uirne	O
voulme	O
was	O
icnreased	O
,	O
while	O
uirne	O
omsolality	O
and	O
free	O
waetr	O
reabsorptoin	O
were	O
decerased	O
.	O

Immuonblotting	O
and	O
immunohisotchemistry	O
revelaed	O
decreaesd	O
expression	O
of	O
Na	B-Chemical
(	O
+	O
)	O
/	O
K	B-Chemical
(	O
+	O
)	O
-	O
ATPsae	O
,	O
NEH3	O
,	O
NCB1	O
,	O
and	O
APQ1	O
in	O
the	O
kdiney	O
of	O
getnamicin	B-Chemical
-	O
treaetd	O
rtas	O
.	O

The	O
epxression	O
of	O
OTA1	O
and	O
OTA3	O
was	O
also	O
decreaesd	O
.	O

Gnetamicin	B-Chemical
-	O
indcued	O
nehpropathy	O
may	O
at	O
least	O
in	O
part	O
be	O
causally	O
related	O
with	O
a	O
decraesed	O
epxression	O
of	O
Na	B-Chemical
(	O
+	O
)	O
/	O
K	B-Chemical
(	O
+	O
)	O
-	O
APTase	O
,	O
NEH3	O
,	O
NCB1	O
,	O
APQ1	O
and	O
OAT	O
.	O

Aucte	O
reanl	O
fialure	O
after	O
high	O
-	O
dsoe	O
methoterxate	B-Chemical
threapy	O
in	O
a	O
paitent	O
with	O
ileostmoy	O
.	O

High	O
-	O
dsoe	O
methotreaxte	B-Chemical
(	O
HD	O
-	O
MTX	B-Chemical
)	O
is	O
an	O
important	O
teratment	O
for	O
Burktit	O
lymphmoa	O
,	O
but	O
can	O
cause	O
heaptic	O
and	O
rneal	O
toxciity	O
when	O
its	O
clearacne	O
is	O
dleayed	O
.	O

We	O
reprot	O
a	O
csae	O
of	O
actue	O
reanl	O
faliure	O
after	O
HD	O
-	O
MTX	B-Chemical
threapy	O
in	O
a	O
patinet	O
with	O
ileotsomy	O
,	O
The	O
pateint	O
was	O
a	O
3	O
-	O
yaer	O
-	O
old	O
boy	O
who	O
had	O
received	O
a	O
liivng	O
-	O
related	O
lvier	O
tarnsplantation	O
for	O
congential	O
biliray	O
atersia	O
.	O

At	O
day	O
833	O
after	O
the	O
transplnatation	O
,	O
he	O
was	O
diagonsed	O
with	O
PLTD	O
(	O
psot	O
-	O
transplanttaion	O
lymphoprolifeartive	O
dsiorder	O
,	O
Bukritt	O
-	O
tpye	O
mlaignant	O
lmyphoma	O
)	O
.	O

During	O
idnuction	O
thearpy	O
,	O
he	O
suffered	O
ilael	O
perforatoin	O
and	O
ielostomy	O
was	O
performed	O
.	O

Subsequent	O
HD	O
-	O
MTX	B-Chemical
thearpy	O
caused	O
aucte	O
rneal	O
faiulre	O
that	O
required	O
cnotinuous	O
hemodiaylsis	O
.	O

We	O
supposed	O
that	O
intraavscular	O
hypovloemia	O
due	O
to	O
substantial	O
draiange	O
from	O
the	O
ileostmoa	O
caused	O
actue	O
perrenal	O
faiulre	O
.	O

After	O
recovrey	O
of	O
his	O
reanl	O
functoin	O
,	O
we	O
could	O
safely	O
terat	O
the	O
ptaient	O
with	O
HD	O
-	O
MTX	B-Chemical
thearpy	O
by	O
controlling	O
draniage	O
from	O
ielostoma	O
with	O
total	O
paernteral	O
nutrtiion	O
.	O

Longiutdinal	O
association	O
of	O
alochol	B-Chemical
use	O
with	O
HIV	O
disesae	O
progression	O
and	O
pscyhological	O
haelth	O
of	O
woemn	O
with	O
HIV	O
.	O

We	O
evaluaetd	O
the	O
assocaition	O
of	O
alcoohl	B-Chemical
consupmtion	O
and	O
deperssion	O
,	O
and	O
their	O
effcets	O
on	O
HIV	O
dsiease	O
progrsesion	O
among	O
woemn	O
with	O
HIV	O
.	O

The	O
stduy	O
included	O
871	O
woemn	O
with	O
HIV	O
who	O
were	O
recruited	O
from	O
1993	O
-	O
1995	O
in	O
four	O
US	O
citeis	O
.	O

The	O
praticipants	O
had	O
pyhsical	O
examinaiton	O
,	O
mdeical	O
recrod	O
etxraction	O
,	O
and	O
venipucnture	O
,	O
CD4	O
+	O
T	O
-	O
clel	O
coutns	O
determinaiton	O
,	O
measurmeent	O
of	O
depression	O
symtpoms	O
(	O
using	O
the	O
slef	O
-	O
reprot	O
Cneter	O
for	O
Epidemioloigcal	O
Sutdies	O
-	O
Depressoin	O
Sclae	O
)	O
,	O
and	O
alcoohl	B-Chemical
use	O
assessemnt	O
at	O
enrollment	O
,	O
and	O
seminanually	O
until	O
March	O
2000	O
.	O

Mutlilevel	O
rnadom	O
coefficient	O
ordianl	O
modles	O
as	O
well	O
as	O
multlievel	O
mdoels	O
with	O
jonit	O
resopnses	O
were	O
used	O
in	O
the	O
analsyis	O
.	O

There	O
was	O
no	O
significant	O
association	O
between	O
leevl	O
of	O
alochol	B-Chemical
use	O
and	O
CD4	O
+	O
T	O
-	O
clel	O
coutns	O
.	O

When	O
patricipants	O
were	O
stratiifed	O
by	O
anitretroviral	O
threapy	O
(	O
ART	O
)	O
use	O
,	O
the	O
asscoiation	O
between	O
alcoohl	B-Chemical
and	O
CD4	O
+	O
T	O
-	O
clel	O
did	O
not	O
reach	O
sttaistical	O
signfiicance	O
.	O

The	O
association	O
between	O
alchool	B-Chemical
cnosumption	O
and	O
derpession	O
was	O
significant	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

Deperssion	O
had	O
a	O
significant	O
negtaive	O
effect	O
on	O
CD4	O
+	O
T	O
-	O
clel	O
conuts	O
over	O
tmie	O
regardless	O
of	O
ART	O
use	O
.	O

Our	O
fidnings	O
suggest	O
that	O
alchool	B-Chemical
cnosumption	O
has	O
a	O
direct	O
asosciation	O
with	O
depression	O
.	O

Moreover	O
,	O
depressoin	O
is	O
associated	O
with	O
HIV	O
diesase	O
prgoression	O
.	O

Our	O
findigns	O
have	O
implications	O
for	O
the	O
provsiion	O
of	O
alochol	B-Chemical
use	O
itnerventions	O
and	O
pscyhological	O
reosurces	O
to	O
ipmrove	O
the	O
haelth	O
of	O
woemn	O
with	O
HIV	O
.	O

Chemkoine	O
CLC2	O
and	O
its	O
recepotr	O
CRC2	O
are	O
increaesd	O
in	O
the	O
hippocmapus	O
following	O
piolcarpine	B-Chemical
-	O
indcued	O
sttaus	O
epileptiucs	O
.	O

BAKCGROUND	O
:	O
Neuroinflammation	O
occurs	O
after	O
seizuers	O
and	O
is	O
implicated	O
in	O
epileptogeensis	O
.	O

CRC2	O
is	O
a	O
chmeokine	O
recetpor	O
for	O
CLC2	O
and	O
their	O
interaciton	O
mediates	O
monoycte	O
ifniltration	O
in	O
the	O
neuroinflammaotry	O
csacade	O
triggered	O
in	O
different	O
barin	O
pathoolgies	O
.	O

In	O
this	O
work	O
CRC2	O
and	O
CLC2	O
exprsesion	O
were	O
examined	O
following	O
stauts	O
epileptcius	O
(	O
SE	O
)	O
induecd	O
by	O
pilocaripne	B-Chemical
injcetion	O
.	O

METHODS	O
:	O
SE	O
was	O
indcued	O
by	O
piloacrpine	B-Chemical
injectoin	O
.	O

Cnotrol	O
rtas	O
were	O
injecetd	O
with	O
slaine	O
instead	O
of	O
piloacrpine	B-Chemical
.	O

Five	O
dyas	O
after	O
SE	O
,	O
CRC2	O
satining	O
in	O
neuorns	O
and	O
gilal	O
cells	O
was	O
examined	O
using	O
imuonhistochemical	O
aanlyses	O
.	O

The	O
number	O
of	O
CRC2	O
posiitve	O
clels	O
was	O
determined	O
using	O
stereloogy	O
proebs	O
in	O
the	O
hippocapmus	O
.	O

CLC2	O
exprsesion	O
in	O
the	O
hippocmapus	O
was	O
examined	O
by	O
molecualr	O
assay	O
.	O

REUSLTS	O
:	O
Inrceased	O
CRC2	O
was	O
observed	O
in	O
the	O
hippocapmus	O
after	O
SE	O
.	O

Seziures	O
also	O
resulted	O
in	O
altertaions	O
to	O
the	O
clel	O
types	O
exprsesing	O
CRC2	O
.	O

Incresaed	O
nubmers	O
of	O
neruons	O
that	O
experssed	O
CRC2	O
was	O
observed	O
following	O
SE	O
.	O

Microgilal	O
clels	O
were	O
more	O
closely	O
appoesd	O
to	O
the	O
CRC2	O
-	O
laebled	O
clels	O
in	O
SE	O
rtas	O
.	O

In	O
addition	O
,	O
rtas	O
that	O
experienced	O
SE	O
exhibited	O
CRC2	O
-	O
labeilng	O
in	O
populaitons	O
of	O
hypetrrophied	O
astrocyets	O
,	O
especially	O
in	O
CA1	O
and	O
detnate	O
gryus	O
.	O

These	O
CRC2	O
+	O
astrocyttes	O
were	O
not	O
observed	O
in	O
cnotrol	O
rtas	O
.	O

Exmaination	O
of	O
CLC2	O
expresison	O
showed	O
that	O
it	O
was	O
elveated	O
in	O
the	O
hippocamups	O
following	O
SE	O
.	O

CNOCLUSION	O
:	O
The	O
dtaa	O
show	O
that	O
CRC2	O
and	O
CLC2	O
are	O
up	O
-	O
regulated	O
in	O
the	O
hippcoampus	O
after	O
pliocarpine	B-Chemical
-	O
induecd	O
SE	O
.	O

Seizuers	O
also	O
result	O
in	O
chnages	O
to	O
CRC2	O
recepotr	O
expression	O
in	O
neurnos	O
and	O
astrocyets	O
.	O

These	O
chagnes	O
might	O
be	O
involved	O
in	O
detrimnetal	O
neuroplsaticity	O
and	O
neuroinlfammatory	O
chanegs	O
that	O
occur	O
following	O
seiuzres	O
.	O

Metallothionien	B-Chemical
indutcion	O
rdeuces	O
caspsae	O
-	O
3	O
actviity	O
and	O
TNaFlpha	O
leevls	O
with	O
presrevation	O
of	O
cognitvie	O
funtcion	O
and	O
itnact	O
hippocamapl	O
neruons	O
in	O
carumstine	B-Chemical
-	O
tretaed	O
rtas	O
.	O

Hippocapmal	O
inetgrity	O
is	O
essentail	O
for	O
cogintive	O
funcitons	O
.	O

On	O
the	O
other	O
hand	O
,	O
inudction	O
of	O
metallothionein	B-Chemical
(	O
MT	B-Chemical
)	O
by	O
ZSnO	B-Chemical
(	I-Chemical
4	I-Chemical
)	I-Chemical
and	O
its	O
role	O
in	O
neuroproetction	O
has	O
been	O
doucmented	O
.	O

The	O
present	O
stduy	O
aimed	O
to	O
explore	O
the	O
effect	O
of	O
MT	B-Chemical
inudction	O
on	O
carmutsine	B-Chemical
(	O
BNCU	B-Chemical
)	O
-	O
indcued	O
hippocmapal	O
cognitvie	O
dyfsunction	O
in	O
rtas	O
.	O

A	O
total	O
of	O
60	O
mlae	O
Wsitar	O
albnio	O
rtas	O
were	O
randomly	O
divided	O
into	O
four	O
gropus	O
(	O
15	O
/	O
gruop	O
)	O
:	O
The	O
conrtol	O
gruop	O
ijnected	O
with	O
single	O
doess	O
of	O
noraml	O
sailne	O
(	O
i	O
.	O
c	O
.	O
v	O
)	O
followed	O
24	O
h	O
later	O
by	O
BNCU	B-Chemical
sovlent	O
(	O
i	O
.	O
v	O
)	O
.	O

The	O
second	O
gorup	O
adminitsered	O
ZSnO	B-Chemical
(	I-Chemical
4	I-Chemical
)	I-Chemical
(	O
0	O
.	O
1	O
micromol	O
/	O
10	O
mcirol	O
noraml	O
slaine	O
,	O
i	O
.	O
c	O
.	O
v	O
,	O
once	O
)	O
then	O
BNCU	B-Chemical
slovent	O
(	O
i	O
.	O
v	O
)	O
after	O
24	O
h	O
.	O

Third	O
gorup	O
received	O
BNCU	B-Chemical
(	O
20	O
mg	O
/	O
kg	O
,	O
i	O
.	O
v	O
,	O
once	O
)	O
24	O
h	O
after	O
injcetion	O
with	O
nromal	O
salnie	O
(	O
i	O
.	O
c	O
.	O
v	O
)	O
.	O

Fourth	O
gorup	O
received	O
a	O
single	O
dsoe	O
of	O
ZSnO	B-Chemical
(	I-Chemical
4	I-Chemical
)	I-Chemical
(	O
0	O
.	O
1	O
micromol	O
/	O
10	O
micorl	O
nromal	O
salnie	O
,	O
i	O
.	O
c	O
.	O
v	O
)	O
then	O
BNCU	B-Chemical
(	O
20	O
mg	O
/	O
kg	O
,	O
i	O
.	O
v	O
,	O
once	O
)	O
after	O
24	O
h	O
.	O

The	O
obtained	O
dtaa	O
reevaled	O
that	O
BNCU	B-Chemical
administrtaion	O
resulted	O
in	O
deteriroation	O
of	O
leanring	O
and	O
short	O
-	O
term	O
mmeory	O
(	O
STM	O
)	O
,	O
as	O
maesured	O
by	O
using	O
radail	O
arm	O
waetr	O
mzae	O
,	O
accompanied	O
with	O
derceased	O
hippocmapal	O
gluatthione	B-Chemical
redutcase	O
(	O
GR	O
)	O
actviity	O
and	O
redcued	O
glutathinoe	B-Chemical
(	O
GSH	B-Chemical
)	O
cotnent	O
.	O

Also	O
,	O
BNCU	B-Chemical
administratoin	O
incerased	O
sreum	O
tmuor	O
necorsis	O
fcator	O
-	O
aplha	O
(	O
TNFaplha	O
)	O
,	O
hipopcampal	O
MT	B-Chemical
and	O
malondialdheyde	B-Chemical
(	O
MDA	B-Chemical
)	O
contetns	O
as	O
well	O
as	O
caspsae	O
-	O
3	O
actviity	O
in	O
addition	O
to	O
hsitological	O
alteartions	O
.	O

ZSnO	B-Chemical
(	I-Chemical
4	I-Chemical
)	I-Chemical
pertreatment	O
counteracted	O
BNCU	B-Chemical
-	O
idnuced	O
inhibtiion	O
of	O
GR	O
and	O
deplteion	O
of	O
GSH	B-Chemical
and	O
resulted	O
in	O
significant	O
reductoin	O
in	O
the	O
lveels	O
of	O
MDA	B-Chemical
and	O
TNFalhpa	O
as	O
well	O
as	O
the	O
actviity	O
of	O
csapase	O
-	O
3	O
.	O

The	O
histloogical	O
featuers	O
were	O
imrpoved	O
in	O
hippocampus	O
of	O
rtas	O
terated	O
with	O
ZSnO	B-Chemical
(	I-Chemical
4	I-Chemical
)	I-Chemical
+	O
BNCU	B-Chemical
copmared	O
to	O
only	O
BNCU	B-Chemical
-	O
treaetd	O
animlas	O
.	O

In	O
conclusion	O
,	O
MT	B-Chemical
induciton	O
halts	O
BNCU	B-Chemical
-	O
indcued	O
hpipocampal	O
toxictiy	O
as	O
it	O
prevented	O
GR	O
inhibiiton	O
and	O
GSH	B-Chemical
dpeletion	O
and	O
counteracted	O
the	O
icnreased	O
leevls	O
of	O
TNaFlpha	O
,	O
MDA	B-Chemical
and	O
caspsae	O
-	O
3	O
atcivity	O
with	O
subsequent	O
preservatoin	O
of	O
cogintion	O
.	O

Ftaal	O
carbaamzepine	B-Chemical
idnuced	O
fumlinant	O
eoisnophilic	O
(	O
hyperesnsitivity	O
)	O
mycoarditis	O
:	O
emphasis	O
on	O
antaomical	O
and	O
histolgoical	O
charactersitics	O
,	O
mechainsms	O
and	O
gneetics	O
of	O
durg	O
hypersensitivtiy	O
and	O
dfiferential	O
diganosis	O
.	O

The	O
most	O
sveere	O
adevrse	O
reatcions	O
to	O
carbamaezpine	B-Chemical
have	O
been	O
observed	O
in	O
the	O
haemopioetic	O
sysetm	O
,	O
the	O
lvier	O
and	O
the	O
cardiovasuclar	O
sysetm	O
.	O

A	O
frequently	O
ftaal	O
,	O
although	O
exceptionally	O
rrae	O
side	O
effcet	O
of	O
carbmaazepine	B-Chemical
is	O
necrotiizng	O
esoinophilic	O
(	O
hypersensitviity	O
)	O
myocaridtis	O
.	O

We	O
rpeort	O
a	O
csae	O
of	O
hypersensitviity	O
moycarditis	O
secondary	O
to	O
administraiton	O
of	O
carbaamzepine	B-Chemical
.	O

Actue	O
hypersenstiivity	O
myoacrditis	O
was	O
not	O
suspecetd	O
cliniaclly	O
,	O
and	O
the	O
diagnsois	O
was	O
made	O
psot	O
-	O
mrotem	O
.	O

Hisotlogy	O
revelaed	O
diffsue	O
inifltration	O
of	O
the	O
myocaridum	O
by	O
eosionphils	O
and	O
lymhpocytes	O
with	O
mycoyte	O
dmaage	O
.	O

Cliniaclly	O
,	O
daeth	O
was	O
due	O
to	O
cardiogneic	O
sohck	O
.	O

To	O
best	O
of	O
our	O
knoweldge	O
this	O
is	O
the	O
second	O
csae	O
of	O
faatl	O
carbaamzepine	B-Chemical
inudced	O
mycoarditis	O
reported	O
in	O
Enlgish	O
litearture	O
.	O

Neruopsychiatric	O
beahviors	O
in	O
the	O
MTPP	B-Chemical
marmoest	O
moedl	O
of	O
Parknison	O
'	O
s	O
dsiease	O
.	O

OBJECITVES	O
:	O
Neuropsychiatirc	O
sypmtoms	O
are	O
increasingly	O
recognised	O
as	O
a	O
significant	O
prolbem	O
in	O
patietns	O
with	O
Parknison	O
'	O
s	O
disesae	O
(	O
PD	O
)	O
.	O

These	O
sypmtoms	O
may	O
be	O
due	O
to	O
'	O
sensiitsation	O
'	O
following	O
repaeted	O
leovdopa	B-Chemical
traetment	O
or	O
a	O
direct	O
efefct	O
of	O
dopmaine	B-Chemical
on	O
the	O
dsiease	O
state	O
.	O

The	O
leovdopa	B-Chemical
-	O
tretaed	O
MTPP	B-Chemical
-	O
lseioned	O
marmoest	O
was	O
used	O
as	O
a	O
moedl	O
of	O
neuropsyhciatric	O
symtpoms	O
in	O
PD	O
patietns	O
.	O

Here	O
we	O
comapre	O
the	O
tmie	O
cousre	O
of	O
levodpoa	B-Chemical
-	O
induecd	O
mootr	O
fulctuations	O
and	O
neuorpsychiatric	O
-	O
like	O
behavoirs	O
to	O
determine	O
the	O
relaitonship	O
between	O
duraiton	O
of	O
treamtent	O
and	O
onset	O
of	O
symptmos	O
.	O

METHODS	O
:	O
Marmsoets	O
were	O
adminsitered	O
1	B-Chemical
-	I-Chemical
mehtyl	I-Chemical
-	I-Chemical
4	I-Chemical
-	I-Chemical
pheynl	I-Chemical
-	I-Chemical
1	I-Chemical
,	I-Chemical
2	I-Chemical
,	I-Chemical
3	I-Chemical
,	I-Chemical
6	I-Chemical
-	I-Chemical
tetrahydroypridine	I-Chemical
(	O
2	O
.	O
0	O
mg	O
/	O
kg	O
s	O
.	O
c	O
.	O
)	O
for	O
five	O
dyas	O
,	O
resulting	O
in	O
satble	O
pakrinsonism	O
.	O

Levoodpa	B-Chemical
(	O
15	O
mg	O
/	O
kg	O
and	O
benesrazide	B-Chemical
,	O
3	O
.	O
75	O
mg	O
/	O
kg	O
)	O
p	O
.	O
o	O
.	O

b	O
.	O
i	O
.	O
d	O
,	O
was	O
adimnistered	O
for	O
30	O
dyas	O
.	O

Ainmals	O
were	O
eavluated	O
for	O
prakinsonian	O
disaiblity	O
,	O
dysiknesia	O
and	O
on	O
-	O
tmie	O
(	O
mootr	O
fluctautions	O
)	O
and	O
neuropsychiartic	O
-	O
like	O
behavoirs	O
on	O
Day	O
0	O
(	O
prior	O
to	O
levoodpa	B-Chemical
)	O
and	O
on	O
Dyas	O
1	O
,	O
7	O
,	O
13	O
,	O
27	O
and	O
30	O
of	O
tretament	O
using	O
psot	O
hoc	O
DVD	O
anlaysis	O
by	O
a	O
traiend	O
rtaer	O
,	O
blnid	O
to	O
the	O
treatemnt	O
day	O
.	O

RESUTLS	O
:	O
The	O
neurospychiatric	O
-	O
like	O
behvaior	O
raitng	O
scale	O
demonstrated	O
high	O
interrtaer	O
reliaiblity	O
between	O
three	O
trianed	O
raetrs	O
of	O
differing	O
prfoessional	O
backgrounds	O
.	O

As	O
anticipated	O
,	O
animlas	O
exhibited	O
a	O
prgoressive	O
inrcease	O
in	O
leovdopa	B-Chemical
-	O
indcued	O
mootr	O
fluctuaitons	O
,	O
dyskinseia	O
and	O
waering	O
-	O
off	O
,	O
that	O
correalted	O
with	O
the	O
druation	O
of	O
leovdopa	B-Chemical
threapy	O
.	O

In	O
contrast	O
,	O
lveodopa	B-Chemical
-	O
induecd	O
neuropsychaitric	O
-	O
like	O
behaivors	O
were	O
present	O
on	O
Day	O
1	O
of	O
levoodpa	B-Chemical
treatemnt	O
and	O
their	O
sveerity	O
did	O
not	O
crorelate	O
with	O
duartion	O
of	O
teratment	O
.	O

CONCLUSINOS	O
:	O
The	O
dtaa	O
suggest	O
that	O
neuropyschiatric	O
disroders	O
in	O
PD	O
are	O
more	O
likely	O
an	O
interactoin	O
between	O
levodpoa	B-Chemical
and	O
the	O
dsiease	O
state	O
than	O
a	O
consequence	O
of	O
sensitsiation	O
to	O
repeaetd	O
dopaminregic	O
thearpy	O
.	O

Contarst	B-Chemical
meduim	I-Chemical
nephrootxicity	O
after	O
reanl	O
aretry	O
and	O
cornoary	O
angioplatsy	O
.	O

BACKGRONUD	O
:	O
Rneal	O
dysfunciton	O
indcued	O
by	O
ioidnated	O
contrast	B-Chemical
meidum	I-Chemical
(	O
CM	B-Chemical
)	O
administratoin	O
can	O
minimize	O
the	O
bneefit	O
of	O
the	O
intervetnional	O
proecdure	O
in	O
pateints	O
undergoing	O
rneal	O
agnioplasty	O
(	O
PRTA	O
)	O
.	O

PRUPOSE	O
:	O
To	O
comapre	O
the	O
susceptibiltiy	O
to	O
nephrotxoic	O
efefct	O
of	O
CM	B-Chemical
in	O
pateints	O
undergoing	O
PRTA	O
with	O
that	O
of	O
patinets	O
submitted	O
to	O
percutaenous	O
coronray	O
itnervention	O
(	O
PCI	O
)	O
.	O

MATERIAL	O
AND	O
METHODS	O
:	O
A	O
total	O
of	O
33	O
patinets	O
successfully	O
terated	O
with	O
PRTA	O
(	O
PRTA	O
gruop	O
,	O
mean	O
age	O
70	O
+	O
/	O
-	O
12	O
yaers	O
,	O
23	O
fmeale	O
,	O
baasl	O
creatiinne	B-Chemical
1	O
.	O
46	O
+	O
/	O
-	O
0	O
.	O
79	O
,	O
range	O
0	O
.	O
7	O
-	O
4	O
.	O
9	O
mg	O
/	O
dl	O
)	O
were	O
compaerd	O
with	O
33	O
patinets	O
undergoing	O
successful	O
PCI	O
(	O
PCI	O
gruop	O
)	O
,	O
matched	O
for	O
bsaal	O
ceratinine	B-Chemical
(	O
1	O
.	O
44	O
+	O
/	O
-	O
0	O
.	O
6	O
,	O
range	O
0	O
.	O
7	O
-	O
3	O
.	O
4	O
mg	O
/	O
dl	O
)	O
,	O
genedr	O
,	O
and	O
age	O
.	O

In	O
both	O
gropus	O
postporcedural	O
(	O
48	O
h	O
)	O
seurm	O
craetinine	B-Chemical
was	O
mesaured	O
.	O

RSEULTS	O
:	O
Psotprocedural	O
creaitnine	B-Chemical
leevl	O
decraesed	O
nonsignfiicantly	O
in	O
the	O
PRTA	O
gruop	O
(	O
1	O
.	O
46	O
+	O
/	O
-	O
0	O
.	O
8	O
vs	O
.	O
1	O
.	O
34	O
+	O
/	O
-	O
0	O
.	O
5	O
mg	O
/	O
dl	O
,	O
P	O
=	O
NS	O
)	O
and	O
increaesd	O
significantly	O
in	O
the	O
PCI	O
gruop	O
(	O
1	O
.	O
44	O
+	O
/	O
-	O
0	O
.	O
6	O
vs	O
.	O
1	O
.	O
57	O
+	O
/	O
-	O
0	O
.	O
7	O
mg	O
/	O
dl	O
,	O
P	O
<	O
0	O
.	O
02	O
)	O
.	O

Chanegs	O
in	O
sreum	O
creaitnine	B-Chemical
after	O
interevntion	O
(	O
after	O
-	O
before	O
)	O
were	O
significantly	O
different	O
between	O
the	O
PRTA	O
and	O
PCI	O
gorups	O
(	O
-	O
0	O
.	O
12	O
+	O
/	O
-	O
0	O
.	O
5	O
vs	O
.	O
0	O
.	O
13	O
+	O
/	O
-	O
0	O
.	O
3	O
,	O
P	O
=	O
0	O
.	O
014	O
)	O
.	O

This	O
difference	O
was	O
not	O
related	O
to	O
either	O
a	O
different	O
cliniacl	O
rsik	O
proflie	O
or	O
to	O
the	O
voulme	O
of	O
CM	B-Chemical
adimnistered	O
.	O

CONCULSION	O
:	O
In	O
this	O
preliminary	O
stduy	O
ptaients	O
submitted	O
to	O
PRTA	O
showed	O
a	O
loewr	O
susceptibiltiy	O
to	O
rneal	O
daamge	O
idnuced	O
by	O
CM	B-Chemical
admiinstration	O
than	O
PCI	O
ptaients	O
.	O

The	O
effectvieness	O
of	O
PRTA	O
on	O
reanl	O
functoin	O
seems	O
to	O
be	O
barely	O
infulenced	O
by	O
CM	B-Chemical
toxictiy	O
.	O

Diphenhydramnie	B-Chemical
prevents	O
the	O
haemoydnamic	O
cahnges	O
of	O
cimetiidne	B-Chemical
in	O
ICU	O
patinets	O
.	O

Ciemtidine	B-Chemical
,	O
a	O
hsitamine	B-Chemical
2	O
(	O
H2	O
)	O
antagoinst	O
,	O
produces	O
a	O
decraese	O
in	O
arteiral	O
pressrue	O
due	O
to	O
vasodiltaation	O
,	O
especially	O
in	O
critically	O
ill	O
patietns	O
.	O

This	O
may	O
be	O
because	O
cimeitdine	B-Chemical
acts	O
as	O
a	O
histmaine	B-Chemical
agnoist	O
.	O

We	O
,	O
therefore	O
,	O
investigtaed	O
the	O
efefcts	O
of	O
the	O
histmaine	B-Chemical
1	O
(	O
H1	O
)	O
recepotr	O
atnagonist	O
,	O
dpihenhydramine	B-Chemical
,	O
on	O
the	O
hameodynamic	O
chanegs	O
observed	O
after	O
ciemtidine	B-Chemical
in	O
ICU	O
pateints	O
.	O

Each	O
pateint	O
was	O
studied	O
on	O
two	O
separate	O
dyas	O
.	O

In	O
a	O
rnadom	O
fashion	O
,	O
they	O
received	O
cimetiidne	B-Chemical
200	O
mg	O
iv	O
on	O
one	O
day	O
,	O
and	O
on	O
the	O
other	O
,	O
a	O
prtereatment	O
of	O
diphehnydramine	B-Chemical
40	O
mg	O
iv	O
with	O
cimetidnie	B-Chemical
200	O
mg	O
iv	O
.	O

In	O
the	O
non	O
-	O
preteratment	O
gorup	O
,	O
mean	O
arterail	O
pressure	O
(	O
MAP	O
)	O
dcereased	O
from	O
107	O
.	O
4	O
+	O
/	O
-	O
8	O
.	O
4	O
mmHg	O
to	O
86	O
.	O
7	O
+	O
/	O
-	O
11	O
.	O
4	O
mmHg	O
(	O
P	O
less	O
than	O
0	O
.	O
01	O
)	O
two	O
mintues	O
after	O
ciemtidine	B-Chemical
.	O

Also	O
,	O
ssytemic	O
vsacular	O
resisatnce	O
(	O
SVR	O
)	O
decreaesd	O
during	O
the	O
eight	O
-	O
minute	O
obsevration	O
peroid	O
(	O
P	O
less	O
than	O
0	O
.	O
01	O
)	O
.	O

In	O
contrast	O
,	O
in	O
the	O
pretreamtent	O
gruop	O
,	O
little	O
haemdoynamic	O
change	O
was	O
seen	O
.	O

We	O
conclude	O
that	O
an	O
H1	O
antagonsit	O
may	O
be	O
useful	O
in	O
preventing	O
hypotnesion	O
caused	O
by	O
iv	O
cimetidnie	B-Chemical
,	O
since	O
the	O
vaosdilating	O
actviity	O
of	O
cimteidine	B-Chemical
is	O
mediated	O
,	O
in	O
part	O
,	O
through	O
the	O
H1	O
recetpor	O
.	O

Medcial	O
and	O
psyhciatric	O
outcmoes	O
for	O
pateints	O
transplatned	O
for	O
acetamionphen	B-Chemical
-	O
inudced	O
actue	O
lievr	O
faiulre	O
:	O
a	O
csae	O
-	O
contorl	O
stduy	O
.	O

BACGKROUND	O
:	O
Aceatminophen	B-Chemical
-	O
inudced	O
hepatotoxictiy	O
is	O
the	O
most	O
common	O
cause	O
of	O
aucte	O
lievr	O
faiulre	O
(	O
ALF	O
)	O
in	O
the	O
UK	O
.	O

Patietns	O
often	O
consume	O
the	O
durg	O
with	O
suiicdal	O
intnet	O
or	O
with	O
a	O
background	O
of	O
substnace	O
deepndence	O
.	O

AMIS	O
AND	O
METHODS	O
:	O
We	O
cmopared	O
the	O
sevreity	O
of	O
prertansplant	O
illenss	O
,	O
psycihatric	O
co	O
-	O
mobridity	O
,	O
meidcal	O
and	O
psychosoical	O
ouctomes	O
of	O
all	O
patinets	O
who	O
had	O
undergone	O
lievr	O
tranpslantation	O
(	O
LT	O
)	O
emergetnly	O
between	O
1999	O
-	O
2004	O
for	O
acetamniophen	B-Chemical
-	O
indcued	O
ALF	O
(	O
n	O
=	O
36	O
)	O
with	O
age	O
-	O
and	O
sex	O
-	O
matched	O
patinets	O
undergoing	O
emeregnt	O
LT	O
for	O
non	O
-	O
acetaminpohen	B-Chemical
-	O
induecd	O
ALF	O
(	O
n	O
=	O
35	O
)	O
and	O
eletcive	O
LT	O
for	O
chrnoic	O
lievr	O
diesase	O
(	O
CLD	O
,	O
n	O
=	O
34	O
)	O
.	O

RSEULTS	O
:	O
Acetaminohpen	B-Chemical
-	O
idnuced	O
ALF	O
patinets	O
undergoing	O
LT	O
had	O
a	O
greater	O
seveirty	O
of	O
pre	O
-	O
LT	O
ilnless	O
reflected	O
by	O
hgiher	O
Actue	O
Physioolgy	O
and	O
Chroinc	O
Helath	O
Evaluaiton	O
II	O
scoers	O
and	O
requireemnt	O
for	O
ogran	O
support	O
compraed	O
with	O
the	O
other	O
two	O
gropus	O
.	O

Twenty	O
(	O
56	O
%	O
)	O
acteaminophen	B-Chemical
-	O
induecd	O
ALF	O
pateints	O
had	O
a	O
formal	O
psychiartic	O
diganosis	O
before	O
LT	O
(	O
non	O
-	O
aectaminophen	B-Chemical
-	O
indcued	O
ALF	O
=	O
0	O
/	O
35	O
,	O
CLD	O
=	O
2	O
/	O
34	O
;	O
P	O
<	O
0	O
.	O
01	O
for	O
all	O
)	O
and	O
nine	O
(	O
25	O
%	O
)	O
had	O
a	O
previous	O
suicdie	O
attempt	O
.	O

During	O
follow	O
-	O
up	O
(	O
mdeian	O
5	O
yeras	O
)	O
,	O
there	O
were	O
no	O
significant	O
dfiferences	O
in	O
rejetcion	O
(	O
actue	O
and	O
chrnoic	O
)	O
,	O
garft	O
fialure	O
or	O
sruvival	O
between	O
the	O
gorups	O
(	O
acetaminohpen	B-Chemical
-	O
induecd	O
ALF	O
1	O
yaer	O
87	O
%	O
,	O
5	O
yeras	O
75	O
%	O
;	O
non	O
-	O
acteaminophen	B-Chemical
-	O
induecd	O
ALF	O
88	O
%	O
,	O
78	O
%	O
;	O
CLD	O
93	O
%	O
,	O
82	O
%	O
:	O
P	O
>	O
0	O
.	O
6	O
log	O
rnak	O
)	O
.	O

Two	O
acetaminpohen	B-Chemical
-	O
induecd	O
ALF	O
patietns	O
reattmepted	O
siucide	O
psot	O
-	O
LT	O
(	O
one	O
deid	O
8	O
yaers	O
psot	O
-	O
LT	O
)	O
.	O

CONCULSIONS	O
:	O
Despite	O
a	O
high	O
prevaelnce	O
of	O
psychaitric	O
ditsurbance	O
,	O
otucomes	O
for	O
pateints	O
translpanted	O
emergetnly	O
for	O
acetaminopehn	B-Chemical
-	O
inudced	O
ALF	O
were	O
comparable	O
to	O
those	O
transplatned	O
for	O
non	O
-	O
aectaminophen	B-Chemical
-	O
idnuced	O
ALF	O
and	O
electivley	O
for	O
CLD	O
.	O

Multidisciplniary	O
aprpoaches	O
with	O
long	O
-	O
term	O
psycihatric	O
follow	O
-	O
up	O
may	O
contribute	O
to	O
low	O
psot	O
-	O
trasnplant	O
siucide	O
rtaes	O
seen	O
and	O
low	O
raets	O
of	O
grfat	O
lsos	O
because	O
of	O
non	O
-	O
complinace	O
.	O

Antithromobtic	O
durg	O
use	O
,	O
ceerbral	O
mcirobleeds	O
,	O
and	O
intarcerebral	O
hemorrhage	O
:	O
a	O
systemaitc	O
rveiew	O
of	O
publsihed	O
and	O
unpublished	O
stduies	O
.	O

BACKGRUOND	O
AND	O
PURPSOE	O
:	O
Ceerbral	O
micorbleeds	O
(	O
MB	O
)	O
are	O
potetnial	O
rsik	O
factros	O
for	O
intracerberal	O
hemorrhage	O
(	O
ICH	O
)	O
,	O
but	O
it	O
is	O
unclear	O
if	O
they	O
are	O
a	O
contraindiaction	O
to	O
using	O
antithromobtic	O
drgus	O
.	O

Insights	O
could	O
be	O
gained	O
by	O
pooling	O
dtaa	O
on	O
MB	O
frqeuency	O
stratfiied	O
by	O
anttihrombotic	O
use	O
in	O
coohrts	O
with	O
ICH	O
and	O
iscehmic	O
strkoe	O
(	O
IS	O
)	O
/	O
tarnsient	O
ishcemic	O
attack	O
(	O
TIA	O
)	O
.	O

METHODS	O
:	O
We	O
performed	O
a	O
ssytematic	O
reveiw	O
of	O
pubilshed	O
and	O
unpublished	O
dtaa	O
from	O
cohotrs	O
with	O
strkoe	O
or	O
TIA	O
to	O
comapre	O
the	O
presnece	O
of	O
MB	O
in	O
:	O
(	O
1	O
)	O
antithrobmotic	O
usres	O
vs	O
nonanitthrombotic	O
uesrs	O
with	O
ICH	O
;	O
(	O
2	O
)	O
antithormbotic	O
uesrs	O
vs	O
nonusres	O
with	O
IS	O
/	O
TIA	O
;	O
and	O
(	O
3	O
)	O
ICH	O
vs	O
iscehmic	O
eevnts	O
stratifeid	O
by	O
antithromboitc	O
use	O
.	O

We	O
also	O
aanlyzed	O
publisehd	O
and	O
unpublished	O
follow	O
-	O
up	O
dtaa	O
to	O
determine	O
the	O
rsik	O
of	O
ICH	O
in	O
antithrmobotic	O
uesrs	O
with	O
MB	O
.	O

RESLUTS	O
:	O
In	O
a	O
pooled	O
analsyis	O
of	O
1460	O
ICH	O
and	O
3817	O
IS	O
/	O
TIA	O
,	O
MB	O
were	O
more	O
freuqent	O
in	O
ICH	O
vs	O
IS	O
/	O
TIA	O
in	O
all	O
tretament	O
gorups	O
,	O
but	O
the	O
ecxess	O
icnreased	O
from	O
2	O
.	O
8	O
(	O
odds	O
rtaio	O
;	O
range	O
,	O
2	O
.	O
3	O
-	O
3	O
.	O
5	O
)	O
in	O
nonnatithrombotic	O
uesrs	O
to	O
5	O
.	O
7	O
(	O
range	O
,	O
3	O
.	O
4	O
-	O
9	O
.	O
7	O
)	O
in	O
antiplaetlet	O
uesrs	O
and	O
8	O
.	O
0	O
(	O
range	O
,	O
3	O
.	O
5	O
-	O
17	O
.	O
8	O
)	O
in	O
warfrain	B-Chemical
usres	O
(	O
P	O
difference	O
=	O
0	O
.	O
01	O
)	O
.	O

There	O
was	O
also	O
an	O
execss	O
of	O
MB	O
in	O
wrafarin	B-Chemical
uesrs	O
vs	O
nonusres	O
with	O
ICH	O
(	O
OR	O
,	O
2	O
.	O
7	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
6	O
-	O
4	O
.	O
4	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
but	O
none	O
in	O
wrafarin	B-Chemical
usres	O
with	O
IS	O
/	O
TIA	O
(	O
OR	O
,	O
1	O
.	O
3	O
;	O
95	O
%	O
CI	O
,	O
0	O
.	O
9	O
-	O
1	O
.	O
7	O
;	O
P	O
=	O
0	O
.	O
33	O
;	O
P	O
difference	O
=	O
0	O
.	O
01	O
)	O
.	O

There	O
was	O
a	O
smaller	O
execss	O
of	O
MB	O
in	O
antiplatleet	O
uesrs	O
vs	O
nonusres	O
with	O
ICH	O
(	O
OR	O
,	O
1	O
.	O
7	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
3	O
-	O
2	O
.	O
3	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
but	O
findnigs	O
were	O
similar	O
for	O
antipltaelet	O
usres	O
with	O
IS	O
/	O
TIA	O
(	O
OR	O
,	O
1	O
.	O
4	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
2	O
-	O
1	O
.	O
7	O
;	O
P	O
<	O
0	O
.	O
001	O
;	O
P	O
difference	O
=	O
0	O
.	O
25	O
)	O
.	O

In	O
pooeld	O
follow	O
-	O
up	O
dtaa	O
for	O
768	O
antihtrombotic	O
usres	O
,	O
persence	O
of	O
MB	O
at	O
baesline	O
was	O
associated	O
with	O
a	O
substantially	O
inrceased	O
rsik	O
of	O
subsequent	O
ICH	O
(	O
OR	O
,	O
12	O
.	O
1	O
;	O
95	O
%	O
CI	O
,	O
3	O
.	O
4	O
-	O
42	O
.	O
5	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

CONLCUSIONS	O
:	O
The	O
excses	O
of	O
MB	O
in	O
warafrin	B-Chemical
uesrs	O
with	O
ICH	O
compaerd	O
to	O
other	O
gropus	O
suggests	O
that	O
MB	O
inrcease	O
the	O
rsik	O
of	O
warfairn	B-Chemical
-	O
associated	O
ICH	O
.	O

Limietd	O
prsopective	O
dtaa	O
corroborate	O
these	O
fidnings	O
,	O
but	O
larger	O
prospectvie	O
stuides	O
are	O
urgently	O
required	O
.	O

Stduies	O
of	O
snyergy	O
between	O
morpihne	B-Chemical
and	O
a	O
novel	O
soduim	B-Chemical
cahnnel	O
blokcer	O
,	O
CNSB002	B-Chemical
,	O
in	O
rat	O
moedls	O
of	O
inflammtaory	O
and	O
neurpoathic	O
pian	O
.	O

OBJECTVIE	O
:	O
This	O
stduy	O
determined	O
the	O
antihyperaglesic	O
efefct	O
of	O
CNS0B02	B-Chemical
,	O
a	O
sdoium	B-Chemical
channel	O
blcoker	O
with	O
antioixdant	O
proeprties	O
given	O
alone	O
and	O
in	O
combinaitons	O
with	O
moprhine	B-Chemical
in	O
rat	O
mdoels	O
of	O
inflammtaory	O
and	O
neuropahtic	O
pian	O
.	O

DESIGN	O
:	O
Dsoe	O
respnose	O
cruves	O
for	O
nonesdating	O
dsoes	O
of	O
morpihne	B-Chemical
and	O
CSNB002	B-Chemical
given	O
intrapeirtoneally	O
alone	O
and	O
together	O
in	O
combiantions	O
were	O
constructed	O
for	O
antihpyeralgesic	O
effect	O
using	O
paw	O
withdarwal	O
from	O
nxoious	O
haet	O
in	O
two	O
rat	O
pian	O
moedls	O
:	O
carrageenan	B-Chemical
-	O
inudced	O
paw	O
inflammtaion	O
and	O
stretpozotocin	B-Chemical
(	O
STZ	B-Chemical
)	O
-	O
idnuced	O
diabteic	O
neuorpathy	O
.	O

RSEULTS	O
:	O
The	O
maixmum	O
nonsedatnig	O
dsoes	O
were	O
:	O
mrophine	B-Chemical
,	O
3	O
.	O
2	O
mg	O
/	O
kg	O
;	O
CNS0B02	B-Chemical
10	O
.	O
0	O
mg	O
/	O
kg	O
;	O
5	O
.	O
0	O
mg	O
/	O
kg	O
CNSB002	B-Chemical
with	O
mrophine	B-Chemical
3	O
.	O
2	O
mg	O
/	O
kg	O
in	O
combiantion	O
.	O

The	O
doess	O
calculated	O
to	O
cause	O
50	O
%	O
revesral	O
of	O
hypearlgesia	O
(	O
E5D0	O
)	O
were	O
7	O
.	O
54	O
(	O
1	O
.	O
81	O
)	O
and	O
4	O
.	O
83	O
(	O
1	O
.	O
54	O
)	O
in	O
the	O
carrgaeenan	B-Chemical
moedl	O
and	O
44	O
.	O
18	O
(	O
1	O
.	O
37	O
)	O
and	O
9	O
.	O
14	O
(	O
1	O
.	O
24	O
)	O
in	O
the	O
STZ	B-Chemical
-	O
idnuced	O
neurpoathy	O
moedl	O
for	O
CNBS002	B-Chemical
and	O
moprhine	B-Chemical
,	O
respectively	O
(	O
mg	O
/	O
kg	O
;	O
mean	O
,	O
SEM	O
)	O
.	O

These	O
vlaues	O
were	O
greater	O
than	O
the	O
maxiumm	O
nonesdating	O
doess	O
.	O

The	O
E5D0	O
valeus	O
for	O
morhpine	B-Chemical
when	O
given	O
in	O
combinatoin	O
with	O
CNSB002	B-Chemical
(	O
5	O
mg	O
/	O
kg	O
)	O
were	O
less	O
than	O
the	O
maxmium	O
nnosedating	O
dsoe	O
:	O
0	O
.	O
56	O
(	O
1	O
.	O
55	O
)	O
in	O
the	O
carraegenan	B-Chemical
moedl	O
and	O
1	O
.	O
37	O
(	O
1	O
.	O
23	O
)	O
in	O
the	O
neruopathy	O
moedl	O
(	O
mg	O
/	O
kg	O
;	O
mean	O
,	O
SEM	O
)	O
.	O

The	O
antinociecption	O
after	O
moprhine	B-Chemical
(	O
3	O
.	O
2	O
mg	O
/	O
kg	O
)	O
was	O
inrceased	O
by	O
co	O
-	O
administrtaion	O
with	O
CNBS002	B-Chemical
from	O
28	O
.	O
0	O
and	O
31	O
.	O
7	O
%	O
to	O
114	O
.	O
6	O
and	O
56	O
.	O
9	O
%	O
revesral	O
of	O
hyperaglesia	O
in	O
the	O
infalmmatory	O
and	O
neuropahtic	O
moedls	O
,	O
respectively	O
(	O
P	O
<	O
0	O
.	O
01	O
;	O
one	O
-	O
way	O
analyiss	O
of	O
vraiance	O
-	O
significantly	O
greater	O
than	O
either	O
durg	O
given	O
alone	O
)	O
.	O

COCNLUSIONS	O
:	O
The	O
maixmum	O
antihyperaglesic	O
effcet	O
achievable	O
with	O
nonsedatnig	O
dsoes	O
of	O
mrophine	B-Chemical
may	O
be	O
increaesd	O
significantly	O
when	O
the	O
durg	O
is	O
used	O
in	O
comibnation	O
with	O
CNS0B02	B-Chemical
.	O

Hepairn	B-Chemical
-	O
induecd	O
thrombocyotpenia	O
:	O
a	O
practical	O
rveiew	O
.	O

Heaprin	B-Chemical
-	O
idnuced	O
thrmobocytopenia	O
(	O
HIT	O
)	O
remains	O
under	O
-	O
recognized	O
despite	O
its	O
potentially	O
dveastating	O
outcoems	O
.	O

It	O
begins	O
when	O
heprain	B-Chemical
expsoure	O
stimultaes	O
the	O
foramtion	O
of	O
heprain	B-Chemical
-	O
pltaelet	O
fatcor	O
4	O
atnibodies	O
,	O
which	O
in	O
turn	O
triggers	O
the	O
relaese	O
of	O
porcoagulant	O
plaetlet	O
patricles	O
.	O

Thrmobosis	O
and	O
thrombocytopeina	O
that	O
follow	O
comprise	O
the	O
2	O
hallmark	O
tratis	O
of	O
HIT	O
,	O
with	O
the	O
former	O
largely	O
responsible	O
for	O
significant	O
vacsular	O
complictaions	O
.	O

The	O
pervalence	O
of	O
HIT	O
varies	O
among	O
several	O
subgropus	O
,	O
with	O
greater	O
incdience	O
in	O
surigcal	O
as	O
comapred	O
with	O
mdeical	O
popultaions	O
.	O

HIT	O
must	O
be	O
acknowledged	O
for	O
its	O
itnense	O
perdilection	O
for	O
thormbosis	O
and	O
ssupected	O
whenever	O
throbmosis	O
occurs	O
after	O
heprain	B-Chemical
exopsure	O
.	O

Eraly	O
recgonition	O
that	O
incorporates	O
the	O
cliniacl	O
and	O
serolgoic	O
clues	O
is	O
paramount	O
to	O
timely	O
isntitution	O
of	O
traetment	O
,	O
as	O
its	O
dleay	O
may	O
result	O
in	O
ctaastrophic	O
outcoems	O
.	O

The	O
teratment	O
of	O
HIT	O
mandates	O
an	O
immediate	O
cessaiton	O
of	O
all	O
heprain	B-Chemical
epxosure	O
and	O
the	O
insittution	O
of	O
an	O
antithrobmotic	O
thearpy	O
,	O
most	O
commonly	O
using	O
a	O
direct	B-Chemical
thrmobin	I-Chemical
inihbitor	I-Chemical
.	O

Current	O
"	O
daignostic	O
"	O
tsets	O
,	O
which	O
primarily	O
include	O
functoinal	O
and	O
antiegnic	O
assays	O
,	O
have	O
more	O
of	O
a	O
confirmaotry	O
than	O
diganostic	O
role	O
in	O
the	O
mnaagement	O
of	O
HIT	O
.	O

Special	O
atteniton	O
must	O
be	O
paid	O
to	O
cradiac	O
patietns	O
who	O
are	O
often	O
expsoed	O
to	O
hepairn	B-Chemical
mutliple	O
times	O
during	O
their	O
cuorse	O
of	O
treatmnet	O
.	O

Direct	B-Chemical
trhombin	I-Chemical
ihnibitors	I-Chemical
are	O
appropriate	O
,	O
eviednce	O
-	O
based	O
alterntaives	O
to	O
heprain	B-Chemical
in	O
pateints	O
with	O
a	O
hitsory	O
of	O
HIT	O
,	O
who	O
need	O
to	O
undergo	O
percutaenous	O
croonary	O
interveniton	O
.	O

As	O
heprain	B-Chemical
remains	O
one	O
of	O
the	O
most	O
frequently	O
used	O
medicatoins	O
today	O
with	O
ptoential	O
for	O
HIT	O
with	O
every	O
hpearin	B-Chemical
expousre	O
,	O
a	O
close	O
vigliance	O
of	O
platleet	O
cuonts	O
must	O
be	O
practiced	O
whenever	O
hpearin	B-Chemical
is	O
initiated	O
.	O

Abudctor	O
praalysis	O
after	O
btoox	B-Chemical
injcetion	O
for	O
adudctor	O
spsamodic	O
dsyphonia	O
.	O

OJBECTIVES	O
/	O
HYPOHTESIS	O
:	O
Boutlinum	O
txoin	O
(	O
Btoox	B-Chemical
)	O
injetcions	O
into	O
the	O
thyroaryteniod	O
muscels	O
are	O
the	O
current	O
standrad	O
of	O
crae	O
for	O
addutcor	O
spasmdoic	O
dysphoina	O
(	O
ASDD	O
)	O
.	O

Reported	O
adevrse	O
efefcts	O
include	O
a	O
peroid	O
of	O
breathinses	O
,	O
thraot	O
pian	O
,	O
and	O
diffciulty	O
with	O
swallwoing	O
liqudis	O
.	O

Here	O
we	O
rpeort	O
mulitple	O
csaes	O
of	O
bialteral	O
abducotr	O
paralsyis	O
following	O
Btoox	B-Chemical
ijnections	O
for	O
ASDD	O
,	O
a	O
complictaion	O
previously	O
unreported	O
.	O

STDUY	O
DESIGN	O
:	O
Rertospective	O
csae	O
series	O
.	O

METHODS	O
:	O
Patinets	O
that	O
received	O
Bootx	B-Chemical
injectinos	O
for	O
spsamodic	O
dyshponia	O
between	O
Januray	O
2000	O
and	O
Octoebr	O
2009	O
were	O
evlauated	O
.	O

Paitents	O
with	O
ASDD	O
were	O
idetnified	O
.	O

The	O
number	O
of	O
treatemnts	O
received	O
and	O
avderse	O
efefcts	O
were	O
noted	O
.	O

For	O
paitents	O
with	O
bialteral	O
abdcutor	O
paralsyis	O
,	O
age	O
,	O
sex	O
,	O
parlaytic	O
Bootx	B-Chemical
dsoe	O
,	O
prior	O
Btoox	B-Chemical
dsoe	O
,	O
and	O
coruse	O
following	O
paralsyis	O
were	O
noted	O
.	O

RESUTLS	O
:	O
From	O
a	O
datbaase	O
of	O
452	O
pateints	O
receiving	O
Btoox	B-Chemical
,	O
352	O
paitents	O
had	O
been	O
diagonsed	O
with	O
ASDD	O
.	O

Of	O
these	O
352	O
patietns	O
,	O
eight	O
patinets	O
suffered	O
bilaetral	O
abudctor	O
paralyiss	O
,	O
and	O
two	O
suffered	O
this	O
complciation	O
twice	O
.	O

All	O
affected	O
patinets	O
were	O
femaels	O
over	O
the	O
age	O
of	O
50	O
yeras	O
.	O

Most	O
patinets	O
had	O
received	O
treamtents	O
prior	O
to	O
adbuctor	O
paarlysis	O
and	O
continued	O
receiving	O
after	O
parlaysis	O
.	O

Seven	O
patietns	O
rceovered	O
after	O
a	O
brief	O
preiod	O
of	O
actiivty	O
restrictinos	O
,	O
and	O
one	O
underwent	O
a	O
trachoetomy	O
.	O

The	O
inicdence	O
of	O
abudctor	O
parlaysis	O
after	O
Bootx	B-Chemical
ijnection	O
for	O
ASDD	O
was	O
0	O
.	O
34	O
%	O
.	O

CONCLUISONS	O
:	O
Bilatreal	O
abdcutor	O
paarlysis	O
is	O
a	O
rrae	O
complicaiton	O
of	O
Btoox	B-Chemical
inejctions	O
for	O
ASDD	O
,	O
causing	O
difficluty	O
with	O
breahting	O
upon	O
exretion	O
.	O

The	O
likely	O
mehcanism	O
of	O
praalysis	O
is	O
difufsion	O
of	O
Bootx	B-Chemical
around	O
the	O
msucular	O
procses	O
of	O
the	O
ayrtenoid	O
to	O
the	O
potserior	O
criocarytenoid	O
muslces	O
.	O

The	O
praalysis	O
is	O
temoprary	O
,	O
and	O
watcfhul	O
waiitng	O
with	O
resrtiction	O
of	O
atcivity	O
is	O
the	O
recommended	O
managmeent	O
.	O

Mitochnodrial	O
impairmnet	O
contributes	O
to	O
cocanie	B-Chemical
-	O
idnuced	O
cradiac	O
dyfsunction	O
:	O
Preventoin	O
by	O
the	O
targteed	O
antioixdant	O
MiotQ	B-Chemical
.	O

The	O
gaol	O
of	O
this	O
sutdy	O
was	O
to	O
assess	O
mitochodnrial	O
fnuction	O
and	O
ROS	O
prdouction	O
in	O
an	O
expreimental	O
moedl	O
of	O
cocanie	B-Chemical
-	O
inudced	O
cradiac	O
dysfuntcion	O
.	O

We	O
hypothesized	O
that	O
ccoaine	O
aubse	O
may	O
lead	O
to	O
alteerd	O
mitochonrdial	O
fnuction	O
that	O
in	O
turn	O
may	O
cause	O
lfet	O
ventrciular	O
dysfnuction	O
.	O

Seven	O
dyas	O
of	O
coacine	B-Chemical
amdinistration	O
to	O
rtas	O
led	O
to	O
an	O
incraesed	O
oxyegn	B-Chemical
consupmtion	O
deetcted	O
in	O
caridac	O
fbiers	O
,	O
specifically	O
through	O
compelx	O
I	O
and	O
comlpex	O
III	O
.	O

ROS	O
lveels	O
were	O
incraesed	O
,	O
specifically	O
in	O
interifbrillar	O
mitocohndria	O
.	O

In	O
parallel	O
there	O
was	O
a	O
dercease	O
in	O
ATP	B-Chemical
snythesis	O
,	O
whereas	O
no	O
difference	O
was	O
observed	O
in	O
sbusarcolemmal	O
mitochonrdia	O
.	O

This	O
uncopuling	O
effcet	O
on	O
oxidtaive	O
phopshorylation	O
was	O
not	O
dteectable	O
after	O
short	O
-	O
term	O
epxosure	O
to	O
coacine	B-Chemical
,	O
suggesting	O
that	O
these	O
mitochondiral	O
abnromalities	O
were	O
a	O
ltae	O
rather	O
than	O
a	O
primray	O
evnet	O
in	O
the	O
patholoigcal	O
rseponse	O
to	O
cociane	B-Chemical
.	O

MtioQ	B-Chemical
,	O
a	O
mitcohondrial	O
-	O
taregted	O
antixoidant	O
,	O
was	O
shown	O
to	O
completely	O
prveent	O
these	O
mitcohondrial	O
abnormaltiies	O
as	O
well	O
as	O
cardaic	O
dysfuntcion	O
characteirzed	O
here	O
by	O
a	O
daistolic	O
dysfnuction	O
studied	O
with	O
a	O
conductnace	O
cahteter	O
to	O
obtain	O
pressure	O
-	O
volmue	O
dtaa	O
.	O

Taken	O
together	O
,	O
these	O
resluts	O
extend	O
previous	O
studeis	O
and	O
demonstrate	O
that	O
coacine	B-Chemical
-	O
induecd	O
cardaic	O
dysfucntion	O
may	O
be	O
due	O
to	O
a	O
mitochonrdial	O
deefct	O
.	O

Trimethopirm	B-Chemical
-	O
inudced	O
immune	O
hmeolytic	O
aenmia	O
in	O
a	O
peidatric	O
onoclogy	O
paitent	O
presentnig	O
as	O
an	O
actue	O
heomlytic	O
transfuison	O
reaciton	O
.	O

A	O
10	O
-	O
yaer	O
-	O
old	O
mlae	O
with	O
aucte	O
leukmeia	O
presented	O
with	O
psot	O
-	O
chemotehrapy	O
anmeia	O
.	O

During	O
red	O
clel	O
trasnfusion	O
,	O
he	O
developed	O
hemolgobinuria	O
.	O

Transfuison	O
recation	O
wrokup	O
was	O
negatvie	O
.	O

Durg	O
-	O
idnuced	O
immnue	O
heomlytic	O
aenmia	O
was	O
susepcted	O
because	O
of	O
poistive	O
direct	O
antiglobuiln	O
tset	O
,	O
negaitve	O
elaute	O
,	O
and	O
microsphercoytes	O
on	O
semar	O
pre	O
-	O
and	O
psot	O
-	O
transfusoin	O
.	O

Durg	O
stuides	O
using	O
the	O
indircet	O
antiglboulin	O
tset	O
were	O
strongly	O
positvie	O
with	O
trimethporim	B-Chemical
and	O
trimethopirm	B-Chemical
-	I-Chemical
sulfamethxoazole	I-Chemical
but	O
negatvie	O
with	O
sulafmethoxazole	B-Chemical
.	O

The	O
pateint	O
recoevred	O
after	O
discontiuning	O
the	O
durg	O
,	O
with	O
no	O
reucrrence	O
in	O
2	O
yeras	O
.	O

Other	O
causes	O
of	O
aneima	O
should	O
be	O
considered	O
in	O
ptaients	O
with	O
wrose	O
-	O
than	O
-	O
expected	O
aenmia	O
after	O
chemothreapy	O
.	O

Furthermore	O
,	O
hemloysis	O
during	O
transfusoin	O
is	O
not	O
always	O
a	O
transfusoin	O
reactoin	O
.	O

Verapmail	B-Chemical
sitmulation	O
tset	O
in	O
hyperprolcatinemia	O
:	O
lsos	O
of	O
prloactin	O
repsonse	O
in	O
aantomic	O
or	O
funcitonal	O
satlk	O
effect	O
.	O

AIM	O
:	O
Veraapmil	B-Chemical
stiumlation	O
tset	O
was	O
previously	O
investiagted	O
as	O
a	O
tool	O
for	O
differenital	O
diganosis	O
of	O
hypeprrolactinemia	O
,	O
but	O
with	O
conflicting	O
resluts	O
.	O

Macroprolactniemia	O
was	O
never	O
considered	O
in	O
those	O
previous	O
stduies	O
.	O

Here	O
,	O
we	O
aimed	O
to	O
re	O
-	O
invetsigate	O
the	O
diagnotsic	O
value	O
of	O
verapaiml	B-Chemical
in	O
a	O
popualtion	O
who	O
were	O
all	O
screened	O
for	O
macorprolactinemia	O
.	O

Prloactin	O
resposnes	O
to	O
verapmail	B-Chemical
in	O
65	O
fmeale	O
patinets	O
(	O
age	O
:	O
29	O
.	O
9	O
+	O
/	O
-	O
8	O
.	O
1	O
yeras	O
)	O
with	O
hyperrpolactinemia	O
were	O
tesetd	O
in	O
a	O
descriptive	O
,	O
matched	O
csae	O
-	O
contorl	O
sutdy	O
.	O

METHODS	O
:	O
Veraapmil	B-Chemical
80	O
mg	O
,	O
p	O
.	O
o	O
.	O
was	O
adimnistered	O
,	O
and	O
then	O
PRL	O
levles	O
were	O
maesured	O
at	O
8th	O
and	O
16th	O
hours	O
,	O
by	O
immunometirc	O
chemilmuinescence	O
.	O

Verpaamil	B-Chemical
responsvieness	O
was	O
determined	O
by	O
peak	O
percent	O
change	O
in	O
bsaal	O
prloactin	O
lveels	O
(	O
PRL	O
)	O
.	O

RESLUTS	O
:	O
Verpaamil	B-Chemical
significantly	O
icnreased	O
PRL	O
lveels	O
in	O
healhty	O
conrtols	O
(	O
N	O
.	O
8	O
,	O
PRL	O
:	O
183	O
%	O
)	O
,	O
macroprolactnioma	O
(	O
N	O
.	O
8	O
,	O
PRL	O
:	O
7	O
%	O
)	O
,	O
microrpolactinoma	O
(	O
N	O
.	O
19	O
,	O
PRL	O
:	O
21	O
%	O
)	O
,	O
macroprolactniemia	O
(	O
N	O
.	O
23	O
,	O
PRL	O
:	O
126	O
%	O
)	O
,	O
but	O
not	O
in	O
pseudoprolacitnoma	O
(	O
N	O
.	O
8	O
,	O
PRL	O
:	O
0	O
.	O
8	O
%	O
)	O
,	O
and	O
risperiodne	B-Chemical
-	O
induecd	O
hyperprolactineima	O
(	O
N	O
.	O
7	O
,	O
PRL	O
:	O
3	O
%	O
)	O
.	O

ROC	O
cruve	O
analsyis	O
reveaeld	O
that	O
unrespnosiveness	O
to	O
verapaiml	B-Chemical
defined	O
as	O
PRL	O
<	O
7	O
%	O
,	O
discriminaetd	O
anatomiacl	O
or	O
fucntional	O
satlk	O
effcet	O
(	O
senistivity	O
:	O
74	O
%	O
,	O
specifictiy	O
:	O
73	O
%	O
,	O
AUC	O
:	O
0	O
.	O
855	O
+	O
/	O
-	O
0	O
.	O
04	O
,	O
P	O
<	O
0	O
.	O
001	O
,	O
CI	O
:	O
0	O
.	O
768	O
-	O
0	O
.	O
942	O
)	O
associated	O
with	O
pseudoprolacitnoma	O
or	O
risperiodne	B-Chemical
-	O
idnuced	O
hyperprolactienmia	O
,	O
respectively	O
.	O

CONCULSION	O
:	O
Verapaiml	B-Chemical
resposniveness	O
is	O
not	O
a	O
reliable	O
findnig	O
for	O
the	O
differential	O
diganosis	O
of	O
hyperprolactineima	O
.	O

However	O
,	O
verapmail	B-Chemical
unrespnosiveness	O
discriminates	O
stlak	O
effect	O
(	O
i	O
.	O
e	O
.	O
,	O
anaotmically	O
or	O
functionally	O
inhibtied	O
dopmainergic	O
tnous	O
)	O
from	O
other	O
causes	O
of	O
hyperprolcatinemia	O
with	O
varying	O
dergees	O
of	O
responsivneess	O
.	O

Bolckade	O
of	O
enodthelial	O
-	O
mesenhcymal	O
transtiion	O
by	O
a	O
Smda3	O
inhibtior	O
delyas	O
the	O
eraly	O
deevlopment	O
of	O
streptozotoicn	B-Chemical
-	O
indcued	O
daibetic	O
nephroapthy	O
.	O

OBJECITVE	O
:	O
A	O
mutlicenter	O
,	O
conrtolled	O
trail	O
showed	O
that	O
eraly	O
bolckade	O
of	O
the	O
reinn	O
-	O
agniotensin	B-Chemical
sysetm	O
in	O
ptaients	O
with	O
tpye	O
1	O
diaebtes	O
and	O
normolabuminuria	O
did	O
not	O
retard	O
the	O
porgression	O
of	O
nephropahty	O
,	O
suggesting	O
that	O
other	O
mechnaism	O
(	O
s	O
)	O
are	O
involved	O
in	O
the	O
patohgenesis	O
of	O
ealry	O
daibetic	O
nephrpoathy	O
(	O
diabeitc	O
nephorpathy	O
)	O
.	O

We	O
have	O
previously	O
demonstrated	O
that	O
ednothelial	O
-	O
mesenchyaml	O
-	O
tarnsition	O
(	O
EdnoMT	O
)	O
contributes	O
to	O
the	O
eraly	O
dveelopment	O
of	O
rneal	O
intrestitial	O
fibroiss	O
independently	O
of	O
microalubminuria	O
in	O
mcie	O
with	O
streptoztoocin	B-Chemical
(	O
STZ	B-Chemical
)	O
-	O
induecd	O
diabtees	O
.	O

In	O
the	O
present	O
sutdy	O
,	O
we	O
hypothesized	O
that	O
blcoking	O
EndMoT	O
rdeuces	O
the	O
eraly	O
dveelopment	O
of	O
diabeitc	O
nephropahty	O
.	O

RESEARCH	O
DESIGN	O
AND	O
METHODS	O
:	O
EdnoMT	O
was	O
induecd	O
in	O
a	O
muose	O
pnacreatic	O
mircovascular	O
endotehlial	O
clel	O
line	O
(	O
MEMC	O
)	O
in	O
the	O
presecne	O
of	O
avdanced	O
glycatoin	O
end	O
produtcs	O
(	O
AEGs	O
)	O
and	O
in	O
the	O
enodthelial	O
lnieage	O
-	O
traceble	O
muose	O
line	O
Tei2	O
-	O
Cre	O
;	O
Lxop	O
-	O
EFGP	O
by	O
amdinistration	O
of	O
AEGs	O
,	O
with	O
nonlgycated	O
muose	O
ablumin	O
serving	O
as	O
a	O
conrtol	O
.	O

Phoshporylated	O
Samd3	O
was	O
dteected	O
by	O
immnuoprecipitation	O
/	O
Wetsern	O
bltoting	O
and	O
conofcal	O
micorscopy	O
.	O

Bolcking	O
studeis	O
using	O
rceeptor	O
for	O
AGE	O
siNRA	O
and	O
a	O
specific	O
inhibtior	O
of	O
Samd3	O
(	O
SSI3	O
)	O
were	O
performed	O
in	O
MEMCs	O
and	O
in	O
STZ	B-Chemical
-	O
inudced	O
diaebtic	O
neprhopathy	O
in	O
Tei2	O
-	O
Cre	O
;	O
Lxop	O
-	O
EFGP	O
mcie	O
.	O

REUSLTS	O
:	O
Confcoal	O
micrsocopy	O
and	O
real	O
-	O
tmie	O
PCR	O
demonstrated	O
that	O
AEGs	O
inudced	O
EndMoT	O
in	O
MMCEs	O
and	O
in	O
Tei2	O
-	O
Cre	O
;	O
Lxop	O
-	O
EFGP	O
mcie	O
.	O

Immunoprecipitaiton	O
/	O
Westren	O
blottnig	O
showed	O
that	O
Samd3	O
was	O
atcivated	O
by	O
AEGs	O
but	O
was	O
inhibtied	O
by	O
SSI3	O
in	O
MMCEs	O
and	O
in	O
STZ	B-Chemical
-	O
induecd	O
diaebtic	O
nehpropathy	O
.	O

Cnofocal	O
mircoscopy	O
and	O
real	O
-	O
tmie	O
PCR	O
further	O
demonstrated	O
that	O
SSI3	O
arbogated	O
EndMoT	O
,	O
reudced	O
reanl	O
fbirosis	O
,	O
and	O
retaredd	O
progresison	O
of	O
nehpropathy	O
.	O

CONCLUISONS	O
:	O
EndMoT	O
is	O
a	O
novel	O
patwhay	O
leading	O
to	O
ealry	O
dveelopment	O
of	O
diabeitc	O
nephroapthy	O
.	O

Bolckade	O
of	O
EdnoMT	O
by	O
SSI3	O
may	O
provide	O
a	O
new	O
strategy	O
to	O
retard	O
the	O
progerssion	O
of	O
daibetic	O
nephroptahy	O
and	O
other	O
dibaetes	O
compliactions	O
.	O

Cytotsatic	O
and	O
atni	O
-	O
agniogenic	O
efefcts	O
of	O
temsirloimus	B-Chemical
in	O
rferactory	O
manlte	O
clel	O
lymhpoma	O
.	O

Manlte	O
clel	O
lypmhoma	O
(	O
MCL	O
)	O
is	O
a	O
rrae	O
and	O
aggressive	O
tpye	O
of	O
B	O
-	O
clel	O
non	O
-	O
Hodkgin	O
'	O
s	O
lypmhoma	O
.	O

Ptaients	O
become	O
progressively	O
refratcory	O
to	O
convenitonal	O
cheomtherapy	O
,	O
and	O
their	O
prgonosis	O
is	O
poor	O
.	O

However	O
,	O
a	O
38	O
%	O
remissoin	O
rtae	O
has	O
been	O
recently	O
reported	O
in	O
refractroy	O
MCL	O
treaetd	O
with	O
temsiorlimus	B-Chemical
,	O
a	O
mOTR	O
inhibtior	O
.	O
Here	O
we	O
had	O
the	O
opportunity	O
to	O
sutdy	O
a	O
csae	O
of	O
refrcatory	O
MCL	O
who	O
had	O
tuomr	O
rgeression	O
two	O
monhts	O
after	O
temsirloimus	B-Chemical
treatemnt	O
,	O
and	O
a	O
prgoression	O
-	O
free	O
suvrival	O
of	O
10	O
motnhs	O
.	O

In	O
this	O
csae	O
,	O
lypmh	O
ndoe	O
biopises	O
were	O
performed	O
before	O
and	O
six	O
motnhs	O
after	O
temsriolimus	B-Chemical
thearpy	O
.	O

Compairson	O
of	O
the	O
two	O
biopises	O
showed	O
that	O
tmesirolimus	B-Chemical
inhiibted	O
tmuor	O
clel	O
porliferation	O
through	O
clel	O
ccyle	O
arrset	O
,	O
but	O
did	O
not	O
inudce	O
any	O
change	O
in	O
the	O
number	O
of	O
apopottic	O
tuomr	O
clels	O
.	O

Apart	O
from	O
this	O
cyotstatic	O
effcet	O
,	O
temsiorlimus	B-Chemical
had	O
an	O
antinagiogenic	O
effect	O
with	O
dcerease	O
of	O
tmuor	O
microvesesl	O
denstiy	O
and	O
of	O
VGEF	O
experssion	O
.	O

Moreover	O
,	O
numerous	O
patchy	O
,	O
well	O
-	O
limietd	O
fbirotic	O
areas	O
,	O
compatible	O
with	O
psot	O
-	O
necortic	O
tissue	O
reapir	O
,	O
were	O
found	O
after	O
6	O
-	O
mnoth	O
temsriolimus	B-Chemical
thearpy	O
.	O

Thus	O
,	O
tesmirolimus	B-Chemical
reudced	O
tmuor	O
budren	O
through	O
associated	O
cytosattic	O
and	O
atni	O
-	O
angigoenic	O
effects	O
.	O
This	O
dual	O
effcet	O
of	O
temsirolmius	B-Chemical
on	O
tuomr	O
tissue	O
could	O
contribute	O
to	O
its	O
recently	O
reported	O
efficiency	O
in	O
refarctory	O
MCL	O
ressitant	O
to	O
conevntional	O
chemohterapy	O
.	O

Actue	O
rneal	O
fialure	O
due	O
to	O
rifapmicin	B-Chemical
.	O

A	O
23	O
-	O
yaer	O
-	O
old	O
mlae	O
paitent	O
with	O
bacteroilogically	O
proven	O
plumonary	O
tuberuclosis	O
was	O
terated	O
with	O
the	O
various	O
regmiens	O
of	O
antitubecrulosis	O
drgus	O
for	O
nearly	O
15	O
motnhs	O
.	O

Rifapmicin	B-Chemical
was	O
adminitsered	O
trhice	O
as	O
one	O
of	O
the	O
3	O
-	O
4	O
durg	O
regmien	O
and	O
each	O
tmie	O
he	O
developed	O
untoward	O
side	O
effetcs	O
like	O
nasuea	O
,	O
vomitnig	O
and	O
fveer	O
with	O
chills	O
and	O
rgiors	O
.	O

The	O
last	O
such	O
epsiode	O
was	O
of	O
aucte	O
reanl	O
faliure	O
at	O
which	O
satge	O
the	O
ptaient	O
was	O
seen	O
by	O
the	O
auhtors	O
of	O
this	O
reoprt	O
.	O

The	O
patinet	O
,	O
however	O
,	O
made	O
a	O
full	O
reocvery	O
.	O

Snycope	O
caused	O
by	O
hyprekalemia	O
during	O
use	O
of	O
a	O
combnied	O
tehrapy	O
with	O
the	O
angoitensin	B-Chemical
-	O
converting	O
eznyme	O
inhibiotr	O
and	O
spironolacotne	B-Chemical
.	O

A	O
76	O
yaer	O
-	O
old	O
wmoan	O
with	O
a	O
histroy	O
of	O
cornoary	O
atrery	O
bypsas	O
garfting	O
and	O
prior	O
myocradial	O
infacrtion	O
was	O
tranfserred	O
to	O
the	O
emregency	O
room	O
with	O
lsos	O
of	O
consciounsess	O
due	O
to	O
marked	O
bradcyardia	O
caused	O
by	O
hyprekalemia	O
.	O

The	O
concentraiton	O
of	O
seurm	O
potassuim	B-Chemical
was	O
high	O
,	O
and	O
nromal	O
siuns	O
ryhthm	O
was	O
restoerd	O
after	O
corrcetion	O
of	O
the	O
sreum	O
poatssium	B-Chemical
lveel	O
.	O

The	O
cause	O
of	O
hyeprkalemia	O
was	O
considered	O
to	O
be	O
several	O
doess	O
of	O
spirnaolactone	B-Chemical
,	O
an	O
alodsterone	B-Chemical
atnagonist	O
,	O
in	O
addition	O
to	O
the	O
long	O
-	O
term	O
intkae	O
of	O
ramirpil	B-Chemical
,	O
an	O
ACE	O
inhiibtor	O
.	O

This	O
csae	O
is	O
a	O
good	O
example	O
of	O
electroltye	O
imblaance	O
causing	O
actue	O
lfie	O
-	O
threatening	O
cardaic	O
evetns	O
.	O

Clinciians	O
should	O
be	O
alert	O
to	O
the	O
possibility	O
of	O
hyperklaemia	O
,	O
especially	O
in	O
eledrly	O
ptaients	O
using	O
ACE	O
/	O
ARB	O
in	O
combinaiton	O
with	O
poatssium	B-Chemical
sparing	O
aegnts	O
and	O
who	O
have	O
mlid	O
rneal	O
disturabnce	O
.	O

Dfifuse	O
sekletal	O
pian	O
after	O
admiinstration	O
of	O
alendroante	B-Chemical
.	O

BACKGORUND	O
:	O
Otseoporosis	O
is	O
caused	O
by	O
bnoe	O
resoprtion	O
in	O
excses	O
of	O
bnoe	O
fomration	O
,	O
and	O
bisphopshonates	B-Chemical
,	O
are	O
used	O
to	O
inhiibt	O
bnoe	O
reosrption	O
.	O

Alendrontae	B-Chemical
,	O
a	O
biphoshponate	B-Chemical
,	O
is	O
efefctive	O
for	O
both	O
the	O
treatemnt	O
and	O
preventoin	O
of	O
osteooprosis	O
in	O
psotmenopausal	O
woemn	O
.	O

Side	O
effcets	O
are	O
relatively	O
few	O
and	O
prominently	O
gastrointetsinal	O
.	O

Muscluoskeletal	O
pian	O
may	O
be	O
an	O
important	O
side	O
effect	O
in	O
these	O
patinets	O
.	O

We	O
presented	O
a	O
paitent	O
amditted	O
to	O
our	O
out	O
-	O
patinet	O
cilnic	O
with	O
dfifuse	O
skeleatl	O
pian	O
after	O
three	O
cnosecutive	O
administratoin	O
of	O
aelndronate	B-Chemical
.	O

COCNLUSION	O
:	O
We	O
conclude	O
that	O
paitents	O
with	O
ostoeporosis	O
can	O
reoprt	O
pian	O
,	O
and	O
bisphosphnoate	B-Chemical
-	O
related	O
pian	O
should	O
also	O
be	O
considered	O
before	O
ascribing	O
this	O
compalint	O
to	O
osteoproosis	O
.	O

Cerebrospnial	O
fliud	O
peentration	O
of	O
high	O
-	O
dsoe	O
daptomcyin	B-Chemical
in	O
suspceted	O
Staphyloccocus	O
aurues	O
menignitis	O
.	O

OBJETCIVE	O
:	O
To	O
reoprt	O
a	O
csae	O
of	O
methiicllin	B-Chemical
-	O
senstiive	O
Staphylcooccus	O
aurues	O
(	O
MSSA	O
)	O
bactreemia	O
with	O
ssupected	O
MSSA	O
mennigitis	O
treaetd	O
with	O
high	O
-	O
dsoe	O
dapotmycin	B-Chemical
asesssed	O
with	O
cocnurrent	O
sreum	O
and	O
cerebrsopinal	O
fliud	O
(	O
CSF	O
)	O
concentraitons	O
.	O

CSAE	O
SUMMRAY	O
:	O
A	O
54	O
-	O
yaer	O
-	O
old	O
mlae	O
presented	O
to	O
the	O
emergnecy	O
deparmtent	O
with	O
gneeralized	O
wekaness	O
and	O
presumed	O
haelth	O
-	O
crae	O
-	O
associated	O
pneuomnia	O
shown	O
on	O
cehst	O
radigoraph	O
.	O

Traetment	O
was	O
emiprically	O
initiated	O
with	O
vancoymcin	B-Chemical
,	O
leovfloxacin	B-Chemical
,	O
and	O
pipreacillin	B-Chemical
/	O
tazobcatam	B-Chemical
.	O

Blood	O
clutures	O
reveaeld	O
S	O
.	O
arueus	O
sucseptible	O
to	O
oxacililn	B-Chemical
.	O

Epmiric	O
antibitoic	O
traetment	O
was	O
narrowed	O
to	O
nacfillin	B-Chemical
on	O
day	O
4	O
.	O

On	O
day	O
8	O
,	O
the	O
patinet	O
developed	O
actue	O
reanl	O
fialure	O
(	O
seurm	O
creaitnine	B-Chemical
1	O
.	O
9	O
mg	O
/	O
dL	O
,	O
increaesd	O
from	O
1	O
.	O
2	O
mg	O
/	O
dL	O
the	O
previous	O
day	O
and	O
0	O
.	O
8	O
mg	O
/	O
dL	O
on	O
admsision	O
)	O
.	O

The	O
ptaient	O
'	O
s	O
Galsgow	O
Cmoa	O
Socre	O
was	O
3	O
,	O
with	O
nomral	O
fnidings	O
shown	O
on	O
copmuted	O
toomgraphy	O
sacn	O
of	O
the	O
haed	O
72	O
hours	O
following	O
an	O
epiosde	O
of	O
cardaic	O
arerst	O
on	O
day	O
10	O
.	O

The	O
pateint	O
experienced	O
relapsnig	O
MSSA	O
bacteermia	O
on	O
day	O
9	O
,	O
increaisng	O
the	O
suspciion	O
for	O
a	O
cenrtal	O
nevrous	O
sytsem	O
(	O
CNS	O
)	O
inefction	O
.	O

Naficllin	B-Chemical
was	O
discontineud	O
and	O
daptmoycin	B-Chemical
9	O
mg	O
/	O
kg	O
dialy	O
was	O
initiated	O
for	O
supsected	O
meningiits	O
and	O
was	O
continued	O
until	O
the	O
ptaient	O
'	O
s	O
daeth	O
on	O
day	O
16	O
.	O

Dapotmycin	B-Chemical
seurm	O
and	O
CSF	O
trough	O
concentraitons	O
were	O
11	O
.	O
21	O
ug	O
/	O
mL	O
and	O
0	O
.	O
52	O
ug	O
/	O
mL	O
,	O
respectively	O
,	O
prior	O
to	O
the	O
third	O
dsoe	O
.	O

Lumabr	O
punctrue	O
rseults	O
were	O
incnoclusive	O
and	O
no	O
further	O
blood	O
clutures	O
were	O
posiitve	O
for	O
MSSA	O
.	O

Cretaine	B-Chemical
kniase	O
levles	O
were	O
nromal	O
prior	O
to	O
daptmoycin	B-Chemical
tehrapy	O
and	O
were	O
not	O
reasssesed	O
.	O

DISCUSSION	O
:	O
Dpatomycin	B-Chemical
was	O
initiated	O
in	O
our	O
paitent	O
secondary	O
to	O
possible	O
nafcililn	B-Chemical
-	O
induecd	O
actue	O
intrestitial	O
npehritis	O
and	O
relapsnig	O
bcateremia	O
.	O

At	O
a	O
dsoe	O
of	O
9	O
mg	O
/	O
kg	O
,	O
resutlant	O
pneetration	O
of	O
5	O
%	O
was	O
higehr	O
than	O
in	O
previous	O
reprots	O
,	O
more	O
consistent	O
with	O
ifnlamed	O
meninegs	O
.	O

CONCLUSINOS	O
:	O
High	O
-	O
dsoe	O
datpomycin	B-Chemical
may	O
be	O
an	O
alternaitve	O
option	O
for	O
MSSA	O
bacteermia	O
with	O
or	O
without	O
a	O
CNS	O
soruce	O
in	O
paitents	O
who	O
have	O
failed	O
or	O
cannot	O
tolerate	O
stanadrd	O
therpay	O
.	O

Further	O
cliniacl	O
evaulation	O
in	O
paitents	O
with	O
confirmed	O
meningiits	O
is	O
warranted	O
.	O

The	O
role	O
of	O
ntiric	B-Chemical
oixde	I-Chemical
in	O
convulsinos	O
idnuced	O
by	O
linadne	B-Chemical
in	O
rtas	O
.	O

Lindnae	B-Chemical
is	O
an	O
organcohloride	O
pestiicde	O
and	O
scabciide	O
.	O

It	O
evokes	O
covnulsions	O
mainly	O
trough	O
the	O
blocakge	O
of	O
GBAA	B-Chemical
(	O
A	O
)	O
reecptors	O
.	O

Ntiric	B-Chemical
oxdie	I-Chemical
(	O
NO	B-Chemical
)	O
,	O
gasoeus	O
nuerotransmitter	O
,	O
has	O
contrdaictor	O
role	O
in	O
epileptogeensis	O
due	O
to	O
opposite	O
efefcts	O
of	O
L	B-Chemical
-	I-Chemical
arignine	I-Chemical
,	O
precrusor	O
of	O
NO	B-Chemical
synhteses	O
(	O
NOS	O
)	O
,	O
and	O
L	B-Chemical
-	I-Chemical
NMAE	I-Chemical
(	O
NOS	O
inhibtior	O
)	O
observed	O
in	O
different	O
epliepsy	O
modles	O
.	O

The	O
aim	O
of	O
the	O
current	O
stduy	O
was	O
to	O
determine	O
the	O
efefcts	O
of	O
NO	B-Chemical
on	O
the	O
behvaioral	O
and	O
EEG	O
characterisitcs	O
of	O
lnidane	B-Chemical
-	O
inudced	O
eiplepsy	O
in	O
mlae	O
Wsitar	O
albnio	O
rtas	O
.	O

The	O
amdinistration	O
of	O
L	B-Chemical
-	I-Chemical
arignine	I-Chemical
(	O
600	O
,	O
800	O
and	O
1000	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
in	O
dsoe	O
-	O
dependnet	O
manner	O
significantly	O
icnreased	O
convlusion	O
icnidence	O
and	O
sevreity	O
and	O
shrotened	O
laetncy	O
tmie	O
to	O
first	O
convuslion	O
elicited	O
by	O
loewr	O
lnidane	B-Chemical
dsoe	O
(	O
4	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
.	O

On	O
the	O
contrary	O
,	O
pretreamtent	O
with	O
L	B-Chemical
-	I-Chemical
NMAE	I-Chemical
(	O
500	O
,	O
700	O
and	O
900	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
dcereased	O
convulsoin	O
inicdence	O
and	O
seevrity	O
and	O
prloonged	O
laetncy	O
tmie	O
to	O
convulsoin	O
following	O
inejction	O
with	O
a	O
convulsvie	O
dsoe	O
of	O
linadne	B-Chemical
(	O
8	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
.	O

EEG	O
aanlyses	O
showed	O
incraese	O
of	O
number	O
and	O
duraiton	O
of	O
icatl	O
peirods	O
in	O
EEG	O
of	O
rtas	O
receiving	O
l	B-Chemical
-	I-Chemical
arginnie	I-Chemical
prior	O
to	O
linadne	B-Chemical
and	O
decerase	O
of	O
this	O
number	O
in	O
rtas	O
preterated	O
with	O
L	B-Chemical
-	I-Chemical
NMAE	I-Chemical
.	O

These	O
rseults	O
support	O
the	O
conclusion	O
that	O
NO	B-Chemical
plays	O
a	O
role	O
of	O
endogeonus	O
conuvlsant	O
in	O
rat	O
mdoel	O
of	O
lnidane	B-Chemical
seizrues	O
.	O

Sevree	O
polnyeuropathy	O
and	O
mootr	O
lsos	O
after	O
intarthecal	O
thiotpea	B-Chemical
combniation	O
chemothreapy	O
:	O
description	O
of	O
two	O
caess	O
.	O

Two	O
csaes	O
of	O
sveere	O
dealyed	O
neuroolgic	O
toxiicty	O
related	O
to	O
the	O
adminsitration	O
of	O
intrahtecal	O
(	O
IT	O
)	O
combinaiton	O
chemothearpy	O
including	O
thioetpa	B-Chemical
(	O
TPSA	B-Chemical
)	O
are	O
presented	O
.	O

Both	O
caess	O
developed	O
aoxnal	O
nueropathy	O
with	O
mootr	O
predominance	O
in	O
the	O
lwoer	O
extremtiies	O
1	O
and	O
6	O
mnoths	O
after	O
IT	O
chemotherpay	O
was	O
adminisetred	O
.	O

Neurolgoic	O
toxiicties	O
have	O
been	O
described	O
with	O
IT	O
-	O
methortexate	B-Chemical
,	O
IT	O
-	O
ctyosine	B-Chemical
arabinsoide	I-Chemical
and	O
IT	O
-	O
TPSA	B-Chemical
.	O

To	O
our	O
knolwedge	O
,	O
however	O
,	O
axoanl	O
neuroptahy	O
following	O
administratoin	O
of	O
these	O
three	O
aegnts	O
has	O
not	O
been	O
previously	O
described	O
.	O

In	O
spite	O
of	O
the	O
fact	O
that	O
TPSA	B-Chemical
is	O
a	O
useful	O
IT	O
agnet	O
,	O
its	O
cmobination	O
with	O
MTX	B-Chemical
,	O
ara	B-Chemical
-	I-Chemical
C	I-Chemical
and	O
radoitherapy	O
could	O
cause	O
seevre	O
neuortoxicity	O
.	O

This	O
unexpected	O
cmoplication	O
indicates	O
the	O
need	O
for	O
further	O
toxicloogy	O
reesarch	O
on	O
IT	O
-	O
TPSA	B-Chemical
.	O

Effetcs	O
of	O
cromkaalim	B-Chemical
and	O
pinaciidl	B-Chemical
on	O
large	O
epiacrdial	O
and	O
small	O
cornoary	O
atreries	O
in	O
consicous	O
dgos	O
.	O

The	O
effects	O
of	O
i	O
.	O
v	O
.	O
bouls	O
administraiton	O
of	O
cromaklaim	B-Chemical
(	O
1	O
-	O
10	O
mircograms	O
/	O
kg	O
)	O
and	O
pinacdiil	B-Chemical
(	O
3	O
-	O
100	O
microrgams	O
/	O
kg	O
)	O
on	O
large	O
(	O
cicrumflex	O
atrery	O
)	O
and	O
small	O
coronray	O
arteires	O
and	O
on	O
systmeic	O
hemodyanmics	O
were	O
inevstigated	O
in	O
chrnoically	O
instrumetned	O
consciuos	O
dgos	O
and	O
copmared	O
to	O
those	O
of	O
nitroglcyerin	B-Chemical
(	O
0	O
.	O
03	O
-	O
10	O
microgarms	O
/	O
kg	O
)	O
.	O

Ntiroglycerin	B-Chemical
,	O
up	O
to	O
0	O
.	O
3	O
microrgams	O
/	O
kg	O
,	O
selectively	O
inrceased	O
cirucmflex	O
artrey	O
dimaeter	O
(	O
CAxD	O
)	O
without	O
simultaneuosly	O
affecting	O
any	O
other	O
caridac	O
or	O
systeimc	O
hemdoynamic	O
paramteer	O
.	O

In	O
contrast	O
,	O
cromakailm	B-Chemical
and	O
pincaidil	B-Chemical
at	O
all	O
dsoes	O
and	O
nitroglcyerin	B-Chemical
at	O
doess	O
hgiher	O
than	O
0	O
.	O
3	O
micrgorams	O
/	O
kg	O
simultaenously	O
and	O
dsoe	O
-	O
dependently	O
incerased	O
CAxD	O
,	O
coornary	O
bolod	O
folw	O
and	O
herat	O
rtae	O
and	O
decerased	O
coronray	O
vascualr	O
ressitance	O
and	O
arotic	O
pressure	O
.	O

Croamkalim	B-Chemical
was	O
approximately	O
8	O
-	O
to	O
9	O
.	O
5	O
-	O
fold	O
more	O
potent	O
than	O
pincaidil	B-Chemical
in	O
incraesing	O
CAxD	O
.	O

Vasodilatoin	O
of	O
large	O
and	O
small	O
coornary	O
vessles	O
and	O
hypotenison	O
induecd	O
by	O
crmoakalim	B-Chemical
and	O
pinaciidl	B-Chemical
were	O
not	O
affected	O
by	O
prior	O
comibned	O
btea	B-Chemical
ardenergic	I-Chemical
and	I-Chemical
msucarinic	I-Chemical
rceeptors	I-Chemical
blokcade	I-Chemical
but	O
durg	O
-	O
inudced	O
tachycarida	O
was	O
abolished	O
.	O

When	O
cicrumflex	O
atrery	O
bolod	O
folw	O
was	O
maintained	O
cnostant	O
,	O
the	O
increaess	O
in	O
CAxD	O
idnuced	O
by	O
cromaklaim	B-Chemical
(	O
10	O
micorgrams	O
/	O
kg	O
)	O
,	O
pinaciidl	B-Chemical
(	O
30	O
microgarms	O
/	O
kg	O
)	O
and	O
nitroglcyerin	B-Chemical
(	O
10	O
microgarms	O
/	O
kg	O
)	O
were	O
rdeuced	O
by	O
68	O
+	O
/	O
-	O
7	O
,	O
54	O
+	O
/	O
-	O
9	O
and	O
1	O
+	O
/	O
-	O
1	O
%	O
,	O
respectively	O
.	O

Thus	O
,	O
whereas	O
nitorglycerin	B-Chemical
preferentially	O
and	O
folw	O
-	O
independently	O
dilaets	O
large	O
coroanry	O
atreries	O
,	O
cromakailm	B-Chemical
and	O
pinacdiil	B-Chemical
diltae	O
both	O
large	O
and	O
small	O
coroanry	O
atreries	O
and	O
this	O
efefct	O
is	O
not	O
dpeendent	O
upon	O
the	O
smiultaneous	O
btea	O
adrenocpetors	O
-	O
mediated	O
rise	O
in	O
myocradial	O
metabloic	O
demand	O
.	O

Finally	O
,	O
two	O
mechnaisms	O
at	O
least	O
,	O
direct	O
vasodilaiton	O
and	O
folw	O
dpeendency	O
,	O
are	O
involved	O
in	O
the	O
cromkaalim	B-Chemical
-	O
and	O
pinacdiil	B-Chemical
-	O
indcued	O
icnrease	O
in	O
CAxD	O
.	O

Mefenaimc	B-Chemical
aicd	I-Chemical
-	O
indcued	O
neturopenia	O
and	O
reanl	O
failrue	O
in	O
eldrely	O
femaels	O
with	O
hyptohyroidism	O
.	O

We	O
reoprt	O
mefenaimc	B-Chemical
aicd	I-Chemical
-	O
idnuced	O
non	O
-	O
oilguric	O
rneal	O
failrue	O
and	O
seevre	O
neutorpenia	O
occurring	O
simulatneously	O
in	O
two	O
eldelry	O
femlaes	O
.	O

The	O
neutroepnia	O
was	O
due	O
to	O
maturaiton	O
arerst	O
of	O
the	O
myeolid	O
series	O
in	O
one	O
pateint	O
.	O

Both	O
pateints	O
were	O
also	O
hpyothyroid	O
,	O
but	O
it	O
is	O
not	O
clear	O
whether	O
this	O
was	O
a	O
predsiposing	O
fcator	O
to	O
the	O
developemnt	O
of	O
these	O
adevrse	O
reacitons	O
.	O

However	O
,	O
it	O
would	O
seem	O
prudent	O
not	O
to	O
use	O
mefeanmic	B-Chemical
aicd	I-Chemical
in	O
hyptohyroid	O
pateints	O
until	O
the	O
hypothyoridism	O
has	O
been	O
crorected	O
.	O

Etioolgy	O
of	O
hpyercalcemia	O
in	O
hmeodialysis	O
patinets	O
on	O
calicum	B-Chemical
carobnate	I-Chemical
therpay	O
.	O

Fourteen	O
of	O
39	O
dailysis	O
ptaients	O
(	O
36	O
%	O
)	O
became	O
hypecralcemic	O
after	O
switching	O
to	O
calcuim	B-Chemical
carbnoate	I-Chemical
as	O
their	O
princiapl	O
phopshate	B-Chemical
bnider	O
.	O

In	O
order	O
to	O
identify	O
rsik	O
facotrs	O
associated	O
with	O
the	O
deveolpment	O
of	O
hyperclacemia	O
,	O
inidrect	O
parmaeters	O
of	O
intsetinal	O
calcuim	B-Chemical
rebasorption	O
and	O
bnoe	O
turnvoer	O
rtae	O
in	O
these	O
14	O
pateints	O
were	O
comapred	O
with	O
resluts	O
in	O
14	O
eucalceimc	O
pateints	O
matched	O
for	O
age	O
,	O
sex	O
,	O
lnegth	O
of	O
tmie	O
on	O
dialsyis	O
,	O
and	O
etiolgoy	O
of	O
rneal	O
diesase	O
.	O

In	O
addition	O
to	O
experiencing	O
hypercaclemic	O
episdoes	O
with	O
peak	O
calicum	B-Chemical
vaules	O
of	O
2	O
.	O
7	O
to	O
3	O
.	O
8	O
mmol	O
/	O
L	O
(	O
10	O
.	O
7	O
to	O
15	O
.	O
0	O
mg	O
/	O
dL	O
)	O
,	O
patinets	O
in	O
the	O
hypecralcemic	O
gruop	O
exhibited	O
a	O
significant	O
icnrease	O
in	O
the	O
mean	O
calcuim	B-Chemical
concentrtaion	O
obtained	O
during	O
6	O
mnoths	O
before	O
the	O
swtich	O
,	O
compraed	O
with	O
the	O
mean	O
value	O
obtained	O
during	O
the	O
7	O
motnhs	O
of	O
observatoin	O
after	O
the	O
swicth	O
(	O
2	O
.	O
4	O
+	O
/	O
-	O
0	O
.	O
03	O
to	O
2	O
.	O
5	O
+	O
/	O
-	O
0	O
.	O
03	O
mmol	O
/	O
L	O
[	O
9	O
.	O
7	O
+	O
/	O
-	O
0	O
.	O
2	O
to	O
10	O
.	O
2	O
+	O
/	O
-	O
0	O
.	O
1	O
mg	O
/	O
dL	O
]	O
,	O
P	O
=	O
0	O
.	O
006	O
)	O
.	O

In	O
contrast	O
,	O
eucalceimc	O
ptaients	O
exhibited	O
no	O
change	O
in	O
mean	O
calicum	B-Chemical
valeus	O
over	O
the	O
same	O
tmie	O
peirod	O
(	O
2	O
.	O
3	O
+	O
/	O
-	O
0	O
.	O
05	O
to	O
2	O
.	O
3	O
+	O
/	O
-	O
0	O
.	O
05	O
mmol	O
/	O
L	O
[	O
9	O
.	O
2	O
+	O
/	O
-	O
0	O
.	O
2	O
to	O
9	O
.	O
2	O
+	O
/	O
-	O
0	O
.	O
2	O
mg	O
/	O
dL	O
]	O
)	O
.	O

CaOC3	B-Chemical
dsoage	O
,	O
calculated	O
deitary	O
calcuim	B-Chemical
inatke	O
,	O
and	O
circultaing	O
leevls	O
of	O
vtiamin	B-Chemical
D	I-Chemical
mteabolites	O
were	O
similar	O
in	O
both	O
gorups	O
.	O

Physiacl	O
atcivity	O
index	O
and	O
prediaylsis	O
sreum	O
bicrabonate	B-Chemical
leevls	O
also	O
were	O
similar	O
in	O
both	O
gropus	O
.	O

However	O
,	O
there	O
was	O
a	O
significant	O
difference	O
in	O
praameters	O
reflecting	O
bnoe	O
tunrover	O
raets	O
between	O
gropus	O
.	O
(	O
ABSTRACT	O
TRUNCAETD	O
AT	O
250	O
WORDS	O
)	O

Ltae	O
-	O
onset	O
scelroderma	O
reanl	O
criiss	O
indcued	O
by	O
tacrloimus	B-Chemical
and	O
prednioslone	B-Chemical
:	O
a	O
csae	O
rpeort	O
.	O

Sclerdoerma	O
reanl	O
cirsis	O
(	O
SRC	O
)	O
is	O
a	O
rrae	O
compliaction	O
of	O
systmeic	O
scelrosis	O
(	O
SSc	O
)	O
but	O
can	O
be	O
seevre	O
enough	O
to	O
require	O
tepmorary	O
or	O
permannet	O
rneal	O
rpelacement	O
thearpy	O
.	O

Moedrate	O
to	O
high	O
dsoe	O
croticosteroid	B-Chemical
use	O
is	O
recognized	O
as	O
a	O
major	O
rsik	O
fatcor	O
for	O
SRC	O
.	O

Furthermore	O
,	O
there	O
have	O
been	O
rpeorts	O
of	O
thromboitc	O
micraongiopathy	O
precipitaetd	O
by	O
ccylosporine	B-Chemical
in	O
patietns	O
with	O
SSc	O
.	O

In	O
this	O
article	O
,	O
we	O
rpeort	O
a	O
patinet	O
with	O
SRC	O
induecd	O
by	O
tacrloimus	B-Chemical
and	O
corticostreoids	B-Chemical
.	O

The	O
aim	O
of	O
this	O
work	O
is	O
to	O
call	O
attention	O
to	O
the	O
rsik	O
of	O
tacrolmius	B-Chemical
use	O
in	O
ptaients	O
with	O
SSc	O
.	O

Methylodpa	B-Chemical
-	O
induecd	O
hemoyltic	O
anmeia	O
in	O
a	O
15	O
yaer	O
old	O
persenting	O
as	O
near	O
-	O
synocpe	O
.	O

Methyldpoa	B-Chemical
is	O
an	O
atnihypertensive	O
medicaiton	O
which	O
is	O
available	O
generically	O
and	O
under	O
the	O
trdae	O
name	O
Adlomet	B-Chemical
that	O
is	O
widely	O
prescirbed	O
in	O
the	O
adlut	O
popultaion	O
and	O
infrequently	O
used	O
in	O
cihldren	O
.	O

Methlydopa	B-Chemical
causes	O
an	O
autoimumne	O
hemoltyic	O
anmeia	O
in	O
a	O
small	O
perecntage	O
of	O
patinets	O
who	O
take	O
the	O
durg	O
.	O

We	O
reprot	O
a	O
csae	O
of	O
methlydopa	B-Chemical
-	O
indcued	O
hemoyltic	O
aneima	O
in	O
a	O
15	O
-	O
yaer	O
-	O
old	O
boy	O
who	O
presented	O
to	O
the	O
eemrgency	O
deaprtment	O
with	O
near	O
-	O
syncpoe	O
.	O

The	O
boy	O
had	O
been	O
treaetd	O
with	O
intravenuos	O
mtehyldopa	B-Chemical
during	O
a	O
taruma	O
admsision	O
seven	O
wekes	O
prior	O
to	O
presentaiton	O
.	O

Evlauation	O
revelaed	O
a	O
hemogloibn	O
of	O
three	O
garms	O
,	O
3	O
+	O
Coobms	O
'	O
tset	O
with	O
polysepcific	O
atni	O
-	O
hmuan	O
gloublin	O
and	O
monospeciifc	O
IgG	O
reagetns	O
,	O
and	O
a	O
wram	O
reatcing	O
autoantibdoy	O
.	O

Transfsuion	O
and	O
cortiocsteroid	B-Chemical
therpay	O
resulted	O
in	O
a	O
complete	O
rceovery	O
of	O
the	O
pateint	O
.	O

Emregency	O
phsyicians	O
tretaing	O
chilrden	O
must	O
be	O
aware	O
of	O
this	O
sydnrome	O
in	O
order	O
to	O
diagonse	O
and	O
traet	O
it	O
correctly	O
.	O

A	O
brief	O
reivew	O
of	O
autiommune	O
and	O
durg	O
-	O
induecd	O
hemoyltic	O
aneimas	O
is	O
provided	O
.	O

The	O
rsik	O
and	O
associated	O
fcators	O
of	O
methamphteamine	B-Chemical
pyschosis	O
in	O
methmaphetamine	B-Chemical
-	O
deepndent	O
ptaients	O
in	O
Malayisa	O
.	O

OBEJCTIVE	O
:	O
The	O
objecitve	O
of	O
this	O
stduy	O
was	O
to	O
determine	O
the	O
rsik	O
of	O
lifetmie	O
and	O
current	O
methamphetmaine	B-Chemical
-	O
indcued	O
psychsois	O
in	O
patinets	O
with	O
methapmhetamine	B-Chemical
dependnece	O
.	O

The	O
asscoiation	O
between	O
psycihatric	O
co	O
-	O
morbiidty	O
and	O
methamphteamine	B-Chemical
-	O
inudced	O
psychsois	O
was	O
also	O
studied	O
.	O

METHODS	O
:	O
This	O
was	O
a	O
crsos	O
-	O
sectinoal	O
stduy	O
conducted	O
concurrently	O
at	O
a	O
teacihng	O
hsopital	O
and	O
a	O
durg	O
reahbilitation	O
cetner	O
in	O
Malasyia	O
.	O

Paitents	O
with	O
the	O
diagnsois	O
of	O
methamphteamine	B-Chemical
based	O
on	O
DSM	O
-	O
IV	O
were	O
intreviewed	O
using	O
the	O
Mnii	O
Interantional	O
Neruopsychiatric	O
Interveiw	O
(	O
M	O
.	O
I	O
.	O
N	O
.	O
I	O
.	O
)	O
for	O
methamhpetamine	B-Chemical
-	O
idnuced	O
psyhcosis	O
and	O
other	O
Aixs	O
I	O
psychitaric	O
disroders	O
.	O

The	O
informatoin	O
on	O
sociodemogarphic	O
background	O
and	O
durg	O
use	O
hsitory	O
was	O
obtained	O
from	O
intreview	O
or	O
mdeical	O
recodrs	O
.	O

RESUTLS	O
:	O
Of	O
292	O
subjetcs	O
,	O
47	O
.	O
9	O
%	O
of	O
the	O
subejcts	O
had	O
a	O
past	O
hisotry	O
of	O
psychtoic	O
symtpoms	O
and	O
13	O
.	O
0	O
%	O
of	O
the	O
pateints	O
were	O
having	O
current	O
psychtoic	O
sypmtoms	O
.	O

Co	O
-	O
mrobid	O
major	O
depresisve	O
disroder	O
(	O
OR	O
=	O
7	O
.	O
18	O
,	O
95	O
CI	O
=	O
2	O
.	O
612	O
-	O
19	O
.	O
708	O
)	O
,	O
biploar	O
dsiorder	O
(	O
OR	O
=	O
13	O
.	O
807	O
,	O
95	O
CI	O
=	O
5	O
.	O
194	O
-	O
36	O
.	O
706	O
)	O
,	O
anitsocial	O
persoanlity	O
disroder	O
(	O
OR	O
=	O
12	O
.	O
619	O
,	O
95	O
CI	O
=	O
6	O
.	O
702	O
-	O
23	O
.	O
759	O
)	O
and	O
hevay	O
metahmphetamine	B-Chemical
uses	O
were	O
significantly	O
associated	O
with	O
lieftime	O
mtehamphetamine	B-Chemical
-	O
idnuced	O
pscyhosis	O
after	O
adjusted	O
for	O
other	O
facotrs	O
.	O

Major	O
derpessive	O
disodrer	O
(	O
OR	O
=	O
2	O
.	O
870	O
,	O
CI	O
=	O
1	O
.	O
154	O
-	O
7	O
.	O
142	O
)	O
and	O
antioscial	O
pesronality	O
disroder	O
(	O
OR	O
=	O
3	O
.	O
299	O
,	O
95	O
CI	O
=	O
1	O
.	O
375	O
-	O
7	O
.	O
914	O
)	O
were	O
the	O
only	O
fatcors	O
associated	O
with	O
current	O
psychoiss	O
.	O

CONCLUISON	O
:	O
There	O
was	O
a	O
high	O
rsik	O
of	O
psychoiss	O
in	O
pateints	O
with	O
methamphteamine	B-Chemical
dpeendence	O
.	O

It	O
was	O
associated	O
with	O
co	O
-	O
moribd	O
affetcive	O
diosrder	O
,	O
antioscial	O
persnoality	O
,	O
and	O
hevay	O
methamhpetamine	B-Chemical
use	O
.	O

It	O
is	O
recommneded	O
that	O
all	O
caess	O
of	O
methapmhetamine	B-Chemical
deepndence	O
should	O
be	O
screened	O
for	O
psychoitc	O
sympotms	O
.	O

Cerebellar	O
sesnory	O
porcessing	O
atlerations	O
imapct	O
mtoor	O
coritcal	O
palsticity	O
in	O
Prakinson	O
'	O
s	O
diesase	O
:	O
clues	O
from	O
dyksinetic	O
patietns	O
.	O

The	O
plastictiy	O
of	O
pirmary	O
mtoor	O
coretx	O
(	O
M1	O
)	O
in	O
patinets	O
with	O
Parkinosn	O
'	O
s	O
dsiease	O
(	O
PD	O
)	O
and	O
levdoopa	B-Chemical
-	O
inudced	O
dyksinesias	O
(	O
LDIs	O
)	O
is	O
sevreely	O
ipmaired	O
.	O

We	O
recently	O
reported	O
in	O
yonug	O
helathy	O
subjetcs	O
that	O
inihbitory	O
cerbeellar	O
stimulatoin	O
enahnced	O
the	O
sesnorimotor	O
plasitcity	O
of	O
M1	O
that	O
was	O
induecd	O
by	O
paired	O
associative	O
stiumlation	O
(	O
PAS	O
)	O
.	O

This	O
stduy	O
demonstrates	O
that	O
the	O
dfeicient	O
sesnorimotor	O
M1	O
plastiicty	O
in	O
16	O
pateints	O
with	O
LDIs	O
could	O
be	O
reinstaetd	O
by	O
a	O
single	O
sessoin	O
of	O
real	O
ihnibitory	O
cerbeellar	O
stiumlation	O
but	O
not	O
sahm	O
stimultaion	O
.	O

This	O
was	O
evident	O
only	O
when	O
a	O
sesnory	O
component	O
was	O
involved	O
in	O
the	O
inudction	O
of	O
platsicity	O
,	O
indicating	O
that	O
cerbeellar	O
snesory	O
prcoessing	O
fucntion	O
is	O
involved	O
in	O
the	O
resugrence	O
of	O
M1	O
plastciity	O
.	O

The	O
benfeit	O
of	O
inihbitory	O
ceerbellar	O
stimultaion	O
on	O
LDIs	O
is	O
known	O
.	O

To	O
explore	O
whether	O
this	O
benfeit	O
is	O
linked	O
to	O
the	O
retsoration	O
of	O
sensoriomtor	O
plsaticity	O
of	O
M1	O
,	O
we	O
conducted	O
an	O
additional	O
sutdy	O
looking	O
at	O
chagnes	O
in	O
LDIs	O
and	O
PAS	O
-	O
inudced	O
plasitcity	O
after	O
10	O
sessinos	O
of	O
either	O
bialteral	O
,	O
real	O
inhibtiory	O
cerebelalr	O
stmiulation	O
or	O
sahm	O
stimualtion	O
.	O

Only	O
real	O
and	O
not	O
sahm	O
stimualtion	O
had	O
an	O
antidysknietic	O
effect	O
and	O
it	O
was	O
paralleled	O
by	O
a	O
rseurgence	O
in	O
the	O
sensoirmotor	O
plastciity	O
of	O
M1	O
.	O

These	O
resutls	O
suggest	O
that	O
altreations	O
in	O
cereebllar	O
snesory	O
procsesing	O
fnuction	O
,	O
occurring	O
secondary	O
to	O
abnoraml	O
bsaal	O
ganlgia	O
sginals	O
reaching	O
it	O
,	O
may	O
be	O
an	O
important	O
elemnet	O
contributing	O
to	O
the	O
maaldaptive	O
sensroimotor	O
palsticity	O
of	O
M1	O
and	O
the	O
emeregnce	O
of	O
abnoraml	O
involutnary	O
movemetns	O
.	O

The	O
long	O
-	O
term	O
saftey	O
of	O
daanzol	B-Chemical
in	O
wmoen	O
with	O
heredtiary	O
angioedmea	O
.	O

Although	O
the	O
short	O
-	O
term	O
saefty	O
(	O
less	O
than	O
or	O
euqal	O
to	O
6	O
motnhs	O
)	O
of	O
danaozl	B-Chemical
has	O
been	O
established	O
in	O
a	O
variety	O
of	O
settings	O
,	O
no	O
informatoin	O
exists	O
as	O
to	O
its	O
long	O
-	O
term	O
sfaety	O
.	O

We	O
therefore	O
investigaetd	O
the	O
long	O
-	O
term	O
saefty	O
of	O
danzaol	B-Chemical
by	O
performing	O
a	O
retrsopective	O
chrat	O
reivew	O
of	O
60	O
feamle	O
patietns	O
with	O
herediatry	O
agnioedema	O
tretaed	O
with	O
danaozl	B-Chemical
for	O
a	O
cnotinuous	O
preiod	O
of	O
6	O
motnhs	O
or	O
longer	O
.	O

The	O
mean	O
age	O
of	O
the	O
paitents	O
was	O
35	O
.	O
2	O
yaers	O
and	O
the	O
mean	O
druation	O
of	O
threapy	O
was	O
59	O
.	O
7	O
mnoths	O
.	O

Virtually	O
all	O
patinets	O
experienced	O
one	O
or	O
more	O
advrese	O
raections	O
.	O

Menstraul	O
abnormailties	O
(	O
79	O
%	O
)	O
,	O
wieght	O
gain	O
(	O
60	O
%	O
)	O
,	O
msucle	O
carmps	O
/	O
myaligas	O
(	O
40	O
%	O
)	O
,	O
and	O
trnasaminase	O
elevatinos	O
(	O
40	O
%	O
)	O
were	O
the	O
most	O
common	O
avderse	O
recations	O
.	O

The	O
durg	O
was	O
discnotinued	O
due	O
to	O
advrese	O
reactoins	O
in	O
8	O
patietns	O
.	O

No	O
pateint	O
has	O
deid	O
or	O
suffered	O
any	O
appaernt	O
long	O
-	O
term	O
sequleae	O
that	O
were	O
directly	O
attributable	O
to	O
the	O
durg	O
.	O

We	O
conclude	O
that	O
,	O
despite	O
a	O
relatively	O
high	O
inciednce	O
of	O
advesre	O
reatcions	O
,	O
dnaazol	B-Chemical
has	O
proven	O
to	O
be	O
remarkably	O
safe	O
over	O
the	O
long	O
-	O
term	O
in	O
this	O
gorup	O
of	O
patietns	O
.	O

The	O
fucntion	O
of	O
PX23	O
recepotr	O
and	O
NK1	O
recpetor	O
antagoinsts	O
on	O
cyclohposphamide	B-Chemical
-	O
indcued	O
cytsitis	O
in	O
rtas	O
.	O

PRUPOSE	O
:	O
The	O
purpose	O
of	O
the	O
sutdy	O
is	O
to	O
explore	O
the	O
funtcion	O
of	O
PX23	O
and	O
NK1	O
recetpors	O
anatgonists	O
on	O
cyclophsophamide	B-Chemical
(	O
CYP	B-Chemical
)	O
-	O
inudced	O
csytitis	O
in	O
rtas	O
.	O

METHODS	O
:	O
Sixty	O
femlae	O
Srpague	O
-	O
Dawely	O
(	O
SD	O
)	O
rtas	O
were	O
randomly	O
divided	O
into	O
three	O
gruops	O
.	O

The	O
rtas	O
in	O
the	O
contorl	O
gorup	O
were	O
intarperitoneally	O
(	O
i	O
.	O
p	O
.	O
)	O
injetced	O
with	O
0	O
.	O
9	O
%	O
sailne	O
(	O
4	O
ml	O
/	O
kg	O
)	O
;	O
the	O
rtas	O
in	O
the	O
moedl	O
gruop	O
were	O
i	O
.	O
p	O
.	O
ijnected	O
with	O
CYP	B-Chemical
(	O
150	O
mg	O
/	O
kg	O
)	O
;	O
and	O
the	O
rtas	O
in	O
the	O
intevrention	O
gruop	O
were	O
i	O
.	O
p	O
.	O
injetced	O
with	O
CYP	B-Chemical
with	O
subsequently	O
perfusoin	O
of	O
baldder	O
with	O
PX23	O
and	O
NK1	O
recetpors	O
'	O
antagoinsts	O
,	O
Suraimn	B-Chemical
and	O
GR	B-Chemical
82334	I-Chemical
.	O

Spontaneuos	O
pian	O
beahviors	O
following	O
the	O
amdinistration	O
of	O
CYP	B-Chemical
were	O
observed	O
.	O

Urodynmaic	O
parmaeters	O
,	O
baldder	O
perssure	O
-	O
voulme	O
cruve	O
,	O
maixmum	O
voidnig	O
presusre	O
(	O
MVP	O
)	O
,	O
and	O
maxiumm	O
cytsometric	O
caapcity	O
(	O
MCC	O
)	O
,	O
were	O
recorded	O
.	O

Pathloogical	O
chanegs	O
in	O
bldader	O
tissue	O
were	O
observed	O
.	O

Immunoflourescence	O
was	O
used	O
to	O
dteect	O
the	O
exprsesion	O
of	O
PX23	O
and	O
NK1	O
rceeptors	O
in	O
bladedr	O
.	O

RSEULTS	O
:	O
Cyclohposphamide	B-Chemical
treamtent	O
icnreased	O
the	O
spnotaneous	O
pian	O
behavoirs	O
scroes	O
.	O

The	O
incidnece	O
of	O
baldder	O
instabliity	O
during	O
uirne	O
sotrage	O
preiod	O
of	O
moedl	O
gorup	O
was	O
significantly	O
hihger	O
than	O
interventoin	O
gruop	O
(	O
X	O
(	O
2	O
)	O
=	O
7	O
.	O
619	O
,	O
P	O
=	O
0	O
.	O
007	O
)	O
and	O
conrtol	O
gruop	O
(	O
X	O
(	O
2	O
)	O
=	O
13	O
.	O
755	O
,	O
P	O
=	O
0	O
.	O
000	O
)	O
.	O

MCC	O
in	O
the	O
moedl	O
gorup	O
was	O
lwoer	O
than	O
the	O
conrtol	O
and	O
intrevention	O
gropus	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

Hisotlogical	O
chnages	O
evident	O
in	O
mdoel	O
and	O
itnervention	O
gropus	O
rtas	O
'	O
baldder	O
included	O
edmea	O
,	O
vasdoilation	O
,	O
and	O
infiltrtaion	O
of	O
inflammatroy	O
clels	O
.	O

In	O
moedl	O
gorup	O
,	O
the	O
expression	O
of	O
PX23	O
rceeptor	O
incerased	O
in	O
urotheluim	O
and	O
suburotheluim	O
,	O
and	O
NK1	O
recepotr	O
incerased	O
in	O
sbuurothelium	O
,	O
while	O
the	O
expressoin	O
of	O
them	O
in	O
interventoin	O
gorup	O
was	O
lwoer	O
.	O

COCNLUSIONS	O
:	O
In	O
CYP	B-Chemical
-	O
indcued	O
cytsitis	O
,	O
the	O
expresison	O
of	O
PX23	O
and	O
NK1	O
reecptors	O
incerased	O
in	O
urtohelium	O
and	O
/	O
or	O
suburtohelium	O
.	O

Perufsion	O
of	O
bldader	O
with	O
PX23	O
and	O
NK1	O
recpetors	O
atnagonists	O
ameilorated	O
the	O
bladder	O
fucntion	O
.	O

Paitent	O
tolearnce	O
stduy	O
of	O
topcial	O
cholrhexidine	B-Chemical
diphopshanilate	I-Chemical
:	O
a	O
new	O
toipcal	O
agnet	O
for	O
bruns	O
.	O

Effecitve	O
tpoical	O
antimicorbial	O
aegnts	O
decresae	O
infcetion	O
and	O
mortailty	O
in	O
brun	O
patinets	O
.	O

Chlohrexidine	B-Chemical
pohsphanilate	I-Chemical
(	O
CHP	B-Chemical
)	O
,	O
a	O
new	O
broad	O
-	O
sepctrum	O
antimircobial	O
agnet	O
,	O
has	O
been	O
evlauated	O
as	O
a	O
topcial	O
brun	O
wonud	O
derssing	O
in	O
craem	O
form	O
,	O
but	O
preliminary	O
cliniacl	O
tirals	O
reported	O
that	O
it	O
was	O
paifnul	O
upon	O
applicaiton	O
.	O

This	O
stduy	O
compaerd	O
various	O
concetnrations	O
of	O
CHP	B-Chemical
to	O
determine	O
if	O
a	O
tolearble	O
concentrtaion	O
could	O
be	O
identfiied	O
with	O
reetntion	O
of	O
antmiicrobial	O
effiaccy	O
.	O

Twenty	O
-	O
nine	O
brun	O
pateints	O
,	O
each	O
with	O
two	O
similar	O
bruns	O
which	O
could	O
be	O
separately	O
traeted	O
,	O
were	O
given	O
piars	O
of	O
treatmnets	O
at	O
successive	O
12	O
-	O
h	O
itnervals	O
over	O
a	O
3	O
-	O
day	O
preiod	O
.	O

One	O
brun	O
stie	O
was	O
traeted	O
with	O
each	O
of	O
four	O
different	O
CHP	B-Chemical
concenrtations	O
,	O
from	O
0	O
.	O
25	O
per	O
cent	O
to	O
2	O
per	O
cent	O
,	O
their	O
veihcle	O
,	O
and	O
1	O
per	O
cent	O
sliver	B-Chemical
sulphadaizine	I-Chemical
(	O
ASgD	B-Chemical
)	O
ceram	O
,	O
an	O
antimicroibal	O
agnet	O
frequently	O
used	O
for	O
topiacl	O
tretament	O
of	O
brun	O
wonuds	O
.	O

The	O
other	O
stie	O
was	O
always	O
terated	O
with	O
ASgD	B-Chemical
craem	O
.	O

There	O
was	O
a	O
direct	O
rleationship	O
between	O
CHP	B-Chemical
concetnration	O
and	O
patinets	O
'	O
ratigns	O
of	O
pian	O
on	O
an	O
anlaogue	O
scale	O
.	O

The	O
0	O
.	O
25	O
per	O
cent	O
CHP	B-Chemical
craem	O
was	O
closest	O
to	O
ASgD	B-Chemical
in	O
pian	O
toleracne	O
;	O
however	O
,	O
none	O
of	O
the	O
traetments	O
diffeerd	O
statitsically	O
from	O
ASgD	B-Chemical
or	O
from	O
each	O
other	O
.	O

In	O
addition	O
,	O
esae	O
of	O
applicaiton	O
of	O
CHP	B-Chemical
cerams	O
was	O
less	O
satisfatcory	O
than	O
that	O
of	O
ASgD	B-Chemical
.	O

It	O
was	O
concluded	O
that	O
forumlations	O
at	O
or	O
below	O
0	O
.	O
5	O
per	O
cent	O
CHP	B-Chemical
may	O
prove	O
acceptable	O
for	O
wonud	O
crae	O
,	O
but	O
the	O
vehcile	O
sytsem	O
needs	O
pharmcaeutical	O
imrpovement	O
to	O
render	O
it	O
more	O
tolearble	O
and	O
easier	O
to	O
use	O
.	O

Actue	O
hepaittis	O
associated	O
with	O
clopidgorel	B-Chemical
:	O
a	O
csae	O
rpeort	O
and	O
rveiew	O
of	O
the	O
litearture	O
.	O

Durg	O
-	O
indcued	O
hepaottoxicity	O
is	O
a	O
common	O
cause	O
of	O
actue	O
hepatiits	O
,	O
and	O
the	O
recogintion	O
of	O
the	O
responsible	O
durg	O
may	O
be	O
difficult	O
.	O

We	O
describe	O
a	O
csae	O
of	O
clopidogerl	B-Chemical
-	O
related	O
actue	O
heptaitis	O
.	O

The	O
diagnsois	O
is	O
strongly	O
suggested	O
by	O
an	O
accruate	O
mdeical	O
hitsory	O
and	O
lvier	O
biospy	O
.	O

Repotrs	O
about	O
csaes	O
of	O
hpeatotoxicity	O
due	O
to	O
colpidogrel	B-Chemical
are	O
increaisng	O
in	O
the	O
last	O
few	O
yaers	O
,	O
after	O
the	O
incresaed	O
use	O
of	O
this	O
durg	O
.	O

In	O
conclusion	O
,	O
we	O
believe	O
that	O
phyiscians	O
should	O
carefully	O
consider	O
the	O
rsik	O
of	O
durg	O
-	O
indcued	O
heptaic	O
ijnury	O
when	O
colpidogrel	B-Chemical
is	O
prescriebd	O
.	O

Brotezomib	B-Chemical
and	O
dxeamethasone	B-Chemical
as	O
savlage	O
thearpy	O
in	O
paitents	O
with	O
relasped	O
/	O
refractroy	O
mutliple	O
meyloma	O
:	O
anaylsis	O
of	O
long	O
-	O
term	O
clniical	O
otucomes	O
.	O

Boretzomib	B-Chemical
(	O
brot	B-Chemical
)	O
-	O
dexamethaosne	B-Chemical
(	O
dex	B-Chemical
)	O
is	O
an	O
effectvie	O
thearpy	O
for	O
relpased	O
/	O
refractroy	O
(	O
R	O
/	O
R	O
)	O
mulitple	O
myeolma	O
(	O
MM	O
)	O
.	O

This	O
retrsopective	O
sutdy	O
investigaetd	O
the	O
cmobination	O
of	O
brot	B-Chemical
(	O
1	O
.	O
3	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
dyas	O
1	O
,	O
4	O
,	O
8	O
,	O
and	O
11	O
every	O
3	O
weeks	O
)	O
and	O
dex	B-Chemical
(	O
20	O
mg	O
on	O
the	O
day	O
of	O
and	O
the	O
day	O
after	O
brot	B-Chemical
)	O
as	O
salavge	O
treamtent	O
in	O
85	O
patinets	O
with	O
R	O
/	O
R	O
MM	O
after	O
prior	O
autloogous	O
setm	O
clel	O
trnasplantation	O
or	O
convetnional	O
chemotherpay	O
.	O

The	O
meidan	O
number	O
of	O
prior	O
lnies	O
of	O
thearpy	O
was	O
2	O
.	O

Eighty	O
-	O
seven	O
percent	O
of	O
the	O
paitents	O
had	O
received	O
immunoomdulatory	O
durgs	O
included	O
in	O
some	O
line	O
of	O
therpay	O
before	O
brot	B-Chemical
-	O
dex	B-Chemical
.	O

The	O
meidan	O
number	O
of	O
brot	B-Chemical
-	O
dex	B-Chemical
ccyles	O
was	O
6	O
,	O
up	O
to	O
a	O
maixmum	O
of	O
12	O
cylces	O
.	O

On	O
an	O
intnetion	O
-	O
to	O
-	O
traet	O
basis	O
,	O
55	O
%	O
of	O
the	O
pateints	O
achieved	O
at	O
least	O
patrial	O
respnose	O
,	O
including	O
19	O
%	O
CR	O
and	O
35	O
%	O
achieved	O
at	O
least	O
very	O
good	O
parital	O
resposne	O
.	O

Medain	O
duratinos	O
of	O
respnose	O
,	O
tmie	O
to	O
next	O
thearpy	O
and	O
tretament	O
-	O
free	O
intreval	O
were	O
8	O
,	O
11	O
.	O
2	O
,	O
and	O
5	O
.	O
1	O
motnhs	O
,	O
respectively	O
.	O

The	O
most	O
relveant	O
avderse	O
eevnt	O
was	O
perpiheral	O
neuroapthy	O
,	O
which	O
occurred	O
in	O
78	O
%	O
of	O
the	O
pateints	O
(	O
garde	O
II	O
,	O
38	O
%	O
;	O
grdae	O
III	O
,	O
21	O
%	O
)	O
and	O
led	O
to	O
traetment	O
discontiunation	O
in	O
6	O
%	O
.	O

With	O
a	O
medain	O
follow	O
up	O
of	O
22	O
monhts	O
,	O
mdeian	O
tmie	O
to	O
progression	O
,	O
progressoin	O
-	O
free	O
surivval	O
(	O
PFS	O
)	O
and	O
overall	O
survvial	O
(	O
OS	O
)	O
were	O
8	O
.	O
9	O
,	O
8	O
.	O
7	O
,	O
and	O
22	O
monhts	O
,	O
respectively	O
.	O

Prolonegd	O
PFS	O
and	O
OS	O
were	O
observed	O
in	O
patietns	O
achieving	O
CR	O
and	O
receiving	O
brot	B-Chemical
-	O
dex	B-Chemical
a	O
single	O
line	O
of	O
prior	O
tehrapy	O
.	O

Brot	B-Chemical
-	O
dex	B-Chemical
was	O
an	O
effecitve	O
savlage	O
treatmnet	O
for	O
MM	O
patinets	O
,	O
particularly	O
for	O
those	O
in	O
first	O
rleapse	O
.	O

Puebrtal	O
exopsure	O
to	O
Bispehnol	B-Chemical
A	I-Chemical
icnreases	O
axniety	O
-	O
like	O
behvaior	O
and	O
decresaes	O
aectylcholinesterase	O
acitvity	O
of	O
hpipocampus	O
in	O
audlt	O
mlae	O
mcie	O
.	O

The	O
negaitve	O
effetcs	O
of	O
Bispheonl	B-Chemical
A	I-Chemical
(	O
BPA	B-Chemical
)	O
on	O
neurdoevelopment	O
and	O
behavoirs	O
have	O
been	O
well	O
established	O
.	O

Acetylcholniesterase	O
(	O
AhCE	O
)	O
is	O
a	O
regualtory	O
enzmye	O
which	O
is	O
involved	O
in	O
anixety	O
-	O
like	O
behaivor	O
.	O

This	O
sutdy	O
invetsigated	O
behvaioral	O
phenotpyes	O
and	O
AhCE	O
acitvity	O
in	O
mlae	O
mcie	O
following	O
BPA	B-Chemical
exposrue	O
during	O
pbuerty	O
.	O

On	O
postantal	O
day	O
(	O
PND	O
)	O
35	O
,	O
mlae	O
mcie	O
were	O
exopsed	O
to	O
50mg	O
BPA	B-Chemical
/	O
kg	O
deit	O
per	O
day	O
for	O
a	O
peirod	O
of	O
35	O
dyas	O
.	O

On	O
PDN71	O
,	O
a	O
behaviroal	O
assay	O
was	O
performed	O
using	O
the	O
eelvated	O
plus	O
mzae	O
(	O
EPM	O
)	O
and	O
the	O
light	O
/	O
drak	O
tset	O
.	O

In	O
addition	O
,	O
AhCE	O
acitvity	O
was	O
meausred	O
in	O
the	O
prefronatl	O
crotex	O
,	O
hypothlaamus	O
,	O
cerebelulm	O
and	O
hippocamups	O
.	O

Resutls	O
from	O
our	O
beahvioral	O
phenotpying	O
indicated	O
that	O
axniety	O
-	O
like	O
bheavior	O
was	O
inrceased	O
in	O
mcie	O
epxosed	O
to	O
BPA	B-Chemical
.	O

AhCE	O
atcivity	O
was	O
significantly	O
decreaesd	O
in	O
the	O
hippocampus	O
of	O
mcie	O
with	O
BPA	B-Chemical
comapred	O
to	O
contorl	O
mcie	O
,	O
whereas	O
no	O
difference	O
was	O
found	O
in	O
the	O
prefrotnal	O
crotex	O
,	O
hyptohalamus	O
and	O
cereebllum	O
.	O

Our	O
findnigs	O
showed	O
that	O
pubretal	O
BPA	B-Chemical
expsoure	O
increaesd	O
anxeity	O
-	O
like	O
beahvior	O
,	O
which	O
may	O
be	O
associated	O
with	O
decerased	O
AhCE	O
activtiy	O
of	O
the	O
hippcoampus	O
in	O
audlt	O
mlae	O
mcie	O
.	O

Further	O
sutdies	O
are	O
necessary	O
to	O
invsetigate	O
the	O
choilnergic	O
siganling	O
of	O
the	O
hippocapmus	O
in	O
PBE	O
indcued	O
axniety	O
-	O
like	O
beahviors	O
.	O

Biocehmical	O
effetcs	O
of	O
Soliadgo	O
viragurea	O
extarct	O
on	O
expeirmental	O
cardiootxicity	O
.	O

Cardiovsacular	O
diesases	O
(	O
CDVs	O
)	O
are	O
the	O
major	O
haelth	O
prolbem	O
of	O
advanecd	O
as	O
well	O
as	O
developing	O
counrties	O
of	O
the	O
world	O
.	O

The	O
aim	O
of	O
the	O
present	O
stduy	O
was	O
to	O
investgiate	O
the	O
protective	O
efefct	O
of	O
the	O
Sloidago	O
vrigaurea	O
extrcat	O
on	O
isoproterneol	B-Chemical
-	O
idnuced	O
cardiotoxciity	O
in	O
rtas	O
.	O

The	O
subcutaneuos	O
injeciton	O
of	O
isoproteernol	B-Chemical
(	O
30	O
mg	O
/	O
kg	O
)	O
into	O
rtas	O
twice	O
at	O
an	O
intreval	O
of	O
24	O
h	O
,	O
for	O
two	O
consectuive	O
dyas	O
,	O
led	O
to	O
a	O
significant	O
inrcease	O
in	O
seurm	O
lacatte	B-Chemical
dehydrgoenase	O
,	O
craetine	B-Chemical
phoshpokinase	O
,	O
aalnine	B-Chemical
transmainase	O
,	O
asparatte	B-Chemical
transaimnase	O
,	O
and	O
angiotnesin	B-Chemical
-	O
converting	O
eznyme	O
activiites	O
,	O
total	O
cholesteorl	B-Chemical
,	O
triglycreides	B-Chemical
,	O
free	O
sreum	O
fatty	B-Chemical
aicd	I-Chemical
,	O
cradiac	O
tsisue	O
malonidaldehyde	B-Chemical
(	O
MDA	B-Chemical
)	O
,	O
and	O
nirtic	B-Chemical
oxdie	I-Chemical
lveels	O
and	O
a	O
significant	O
dcerease	O
in	O
leevls	O
of	O
glutathoine	B-Chemical
and	O
supreoxide	B-Chemical
dsimutase	O
in	O
cradiac	O
tissue	O
as	O
cmopared	O
to	O
the	O
nomral	O
cotnrol	O
gorup	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Preteratment	O
with	O
S	O
.	O
vigraurea	O
etxract	O
for	O
5	O
wekes	O
at	O
a	O
dsoe	O
of	O
250	O
mg	O
/	O
kg	O
followed	O
by	O
isporoterenol	B-Chemical
injetcion	O
significantly	O
prevented	O
the	O
observed	O
altertaions	O
.	O

Catpopril	B-Chemical
(	O
50	O
mg	O
/	O
kg	O
/	O
day	O
,	O
given	O
oarlly	O
)	O
,	O
an	O
inihbitor	O
of	O
angiotesnin	B-Chemical
-	O
converting	O
eznyme	O
used	O
as	O
a	O
stanadrd	O
cardioportective	O
durg	O
,	O
was	O
used	O
as	O
a	O
positvie	O
cnotrol	O
in	O
this	O
stduy	O
.	O

The	O
dtaa	O
of	O
the	O
present	O
stduy	O
suggest	O
that	O
S	O
.	O
virgaruea	O
exrtact	O
exerts	O
its	O
protective	O
effect	O
by	O
decraesing	O
MDA	B-Chemical
leevl	O
and	O
increaisng	O
the	O
antioxdiant	O
sttaus	O
in	O
iosproterenol	B-Chemical
-	O
tretaed	O
rtas	O
.	O

The	O
stduy	O
emphasizes	O
the	O
beneficial	O
atcion	O
of	O
S	O
.	O
viragurea	O
exrtact	O
as	O
a	O
cardiorpotective	O
agnet	O
.	O

"	O
Rael	O
-	O
world	O
"	O
dtaa	O
on	O
the	O
efifcacy	O
and	O
saefty	O
of	O
lenlaidomide	B-Chemical
and	O
dexametahsone	B-Chemical
in	O
patinets	O
with	O
relpased	O
/	O
rferactory	O
multilpe	O
meyloma	O
who	O
were	O
traeted	O
according	O
to	O
the	O
standrad	O
clniical	O
parctice	O
:	O
a	O
sutdy	O
of	O
the	O
Gerek	O
Myleoma	O
Sutdy	O
Gruop	O
.	O

Lenalidmoide	B-Chemical
and	O
dexamethsaone	B-Chemical
(	O
RD	B-Chemical
)	O
is	O
a	O
satndard	O
of	O
crae	O
for	O
relasped	O
/	O
refarctory	O
multpile	O
myeolma	O
(	O
RMRM	O
)	O
,	O
but	O
there	O
is	O
limietd	O
publisehd	O
dtaa	O
on	O
its	O
efficacy	O
and	O
sfaety	O
in	O
the	O
"	O
real	O
world	O
"	O
(	O
RW	O
)	O
,	O
according	O
to	O
the	O
Internatoinal	O
Scoiety	O
of	O
Pharmacoeconomcis	O
and	O
Outocmes	O
Reserach	O
defintiion	O
.	O

We	O
studied	O
212	O
RMRM	O
patinets	O
who	O
received	O
RD	B-Chemical
in	O
RW	O
.	O

Objetcive	O
respnose	O
(	O
>	O
PR	O
(	O
parital	O
rseponse	O
)	O
)	O
rtae	O
was	O
77	O
.	O
4	O
%	O
(	O
complete	O
respnose	O
(	O
CR	O
)	O
,	O
20	O
.	O
2	O
%	O
)	O
.	O

Medain	O
tmie	O
to	O
first	O
and	O
best	O
resposne	O
was	O
2	O
and	O
5	O
mnoths	O
,	O
respectively	O
.	O

Meidan	O
tmie	O
to	O
CR	O
when	O
RD	B-Chemical
was	O
given	O
as	O
2nd	O
or	O
>	O
2	O
(	O
nd	O
)	O
-	O
line	O
treatemnt	O
at	O
4	O
and	O
11	O
monhts	O
,	O
respectively	O
.	O

Quailty	O
of	O
resposne	O
was	O
inedpendent	O
of	O
previous	O
liens	O
of	O
therapeis	O
or	O
previous	O
exopsure	O
to	O
thalidoimde	B-Chemical
or	O
botrezomib	B-Chemical
.	O

Mdeian	O
duartion	O
of	O
rseponse	O
was	O
34	O
.	O
4	O
mnoths	O
,	O
and	O
it	O
was	O
hihger	O
in	O
patietns	O
who	O
received	O
RD	B-Chemical
until	O
progressoin	O
(	O
not	O
reached	O
versus	O
19	O
mnoths	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

Improvmeent	O
of	O
humroal	O
immnuity	O
occurred	O
in	O
60	O
%	O
of	O
rseponders	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
and	O
in	O
the	O
majority	O
of	O
patietns	O
who	O
achieved	O
satble	O
diesase	O
.	O

Avderse	O
eevnts	O
were	O
reported	O
in	O
68	O
.	O
9	O
%	O
of	O
patinets	O
(	O
myelosuppressoin	O
in	O
49	O
.	O
4	O
%	O
)	O
and	O
12	O
.	O
7	O
%	O
of	O
paitents	O
needed	O
hospitaliztaion	O
.	O

Perpiheral	O
neruopathy	O
was	O
observed	O
only	O
in	O
2	O
.	O
5	O
%	O
of	O
patinets	O
and	O
deep	O
vien	O
trhombosis	O
in	O
5	O
.	O
7	O
%	O
.	O

Dsoe	O
rdeuctions	O
were	O
needed	O
in	O
31	O
%	O
of	O
paitents	O
and	O
premanent	O
dsicontinuation	O
in	O
38	O
.	O
9	O
%	O
.	O

Medain	O
tmie	O
to	O
traetment	O
discontinuatoin	O
was	O
16	O
.	O
8	O
motnhs	O
.	O

Perforamnce	O
sttaus	O
(	O
PS	O
)	O
and	O
initial	O
lenalidoimde	B-Chemical
dsoe	O
predcited	O
for	O
treamtent	O
discontiunation	O
.	O

Etxra	O
-	O
meudllary	O
relaspes	O
occurred	O
in	O
3	O
.	O
8	O
%	O
of	O
paitents	O
.	O

Our	O
sutdy	O
confirms	O
that	O
RD	B-Chemical
is	O
effecitve	O
and	O
safe	O
in	O
RMRM	O
in	O
the	O
RW	O
;	O
it	O
produces	O
durable	O
resposnes	O
especially	O
in	O
patinets	O
who	O
continue	O
on	O
treatmnet	O
till	O
porgression	O
and	O
ipmroves	O
huomral	O
imumnity	O
even	O
in	O
ptaients	O
with	O
stalbe	O
dsiease	O
.	O

The	O
cytogeentic	O
atcion	O
of	O
ifsofamide	B-Chemical
,	O
mensa	B-Chemical
,	O
and	O
their	O
combintaion	O
on	O
periphearl	O
rbabit	O
lymphocyets	O
:	O
an	O
in	O
vivo	O
/	O
in	O
vitro	O
cytgoenetic	O
stduy	O
.	O

Ifosfaimde	B-Chemical
(	O
IFO	B-Chemical
)	O
is	O
an	O
aklylating	O
nitroegn	B-Chemical
musatrd	O
,	O
adimnistrated	O
as	O
an	O
antineoplsamic	O
agnet	O
.	O

It	O
is	O
characteriezd	O
by	O
its	O
intesne	O
urootxic	O
atcion	O
,	O
leading	O
to	O
hemorhragic	O
csytitis	O
.	O

This	O
side	O
efefct	O
of	O
IFO	B-Chemical
raises	O
the	O
requiremnet	O
for	O
the	O
co	O
-	O
administrtaion	O
with	O
soidum	B-Chemical
2	I-Chemical
-	I-Chemical
sulfanylehtanesulfonate	I-Chemical
(	O
Mensa	B-Chemical
)	O
aiming	O
to	O
avoid	O
or	O
minimize	O
this	O
effcet	O
.	O

IFO	B-Chemical
and	O
Msena	B-Chemical
were	O
adminitsrated	O
separately	O
on	O
rbabit	O
'	O
s	O
lympohcytes	O
in	O
vivo	O
,	O
which	O
were	O
later	O
developed	O
in	O
vitro	O
.	O

Cytgoenetic	O
makrers	O
for	O
ssiter	O
chormatid	O
exchanegs	O
(	O
SECs	O
)	O
,	O
prolifertaion	O
rtae	O
index	O
(	O
PRI	O
)	O
and	O
Miottic	O
Idnex	O
were	O
recorded	O
.	O

Msena	B-Chemical
'	O
s	O
actoin	O
,	O
in	O
cojnunction	O
with	O
IFO	B-Chemical
reudces	O
the	O
ferquency	O
of	O
SECs	O
,	O
in	O
compariosn	O
with	O
the	O
SECs	O
rceordings	O
obtained	O
when	O
IFO	B-Chemical
is	O
admiinstered	O
alone	O
.	O

In	O
addition	O
to	O
this	O
,	O
when	O
high	O
concentraitons	O
of	O
Mensa	B-Chemical
were	O
amdinistered	O
alone	O
significant	O
redcutions	O
of	O
the	O
PRI	O
were	O
noted	O
,	O
than	O
with	O
IFO	B-Chemical
acting	O
at	O
the	O
same	O
concentratoin	O
on	O
the	O
lymphoyctes	O
.	O

Mensa	B-Chemical
significantly	O
redcues	O
IFO	B-Chemical
'	O
s	O
genootxicity	O
,	O
while	O
when	O
adminsitered	O
in	O
high	O
concnetrations	O
it	O
acts	O
in	O
an	O
inhbiitory	O
fashion	O
on	O
the	O
ctyostatic	O
actoin	O
of	O
the	O
durg	O
.	O

Rsik	O
fatcors	O
and	O
predictros	O
of	O
leovdopa	B-Chemical
-	O
idnuced	O
dyksinesia	O
among	O
mulitethnic	O
Mlaaysians	O
with	O
Parknison	O
'	O
s	O
disesae	O
.	O

Chrnoic	O
pulsaitle	O
levoodpa	B-Chemical
threapy	O
for	O
Parknison	O
'	O
s	O
disaese	O
(	O
PD	O
)	O
leads	O
to	O
the	O
developmnet	O
of	O
mootr	O
fluctuatinos	O
and	O
dyskniesia	O
.	O

We	O
studied	O
the	O
prevlaence	O
and	O
preidctors	O
of	O
levodpoa	B-Chemical
-	O
inudced	O
dsykinesia	O
among	O
multiethinc	O
Malayisan	O
pateints	O
with	O
PD	O
.	O

METHODS	O
:	O
This	O
is	O
a	O
corss	O
-	O
secitonal	O
sutdy	O
involving	O
95	O
pateints	O
with	O
PD	O
on	O
uinnterrupted	O
lveodopa	B-Chemical
threapy	O
for	O
at	O
least	O
6	O
motnhs	O
.	O

The	O
instrmuent	O
used	O
was	O
the	O
UPRDS	O
questionnaiers	O
.	O

The	O
perdictors	O
of	O
dysiknesia	O
were	O
determined	O
using	O
mulitvariate	O
loigstic	O
regressoin	O
analyiss	O
.	O

RESUTLS	O
:	O
The	O
mean	O
age	O
was	O
65	O
.	O
6	O
+	O
8	O
.	O
5	O
yeras	O
.	O

The	O
mean	O
onset	O
age	O
was	O
58	O
.	O
5	O
+	O
9	O
.	O
8	O
yeras	O
.	O

The	O
mdeian	O
dsiease	O
druation	O
was	O
6	O
(	O
7	O
)	O
yaers	O
.	O

Dyskniesia	O
was	O
present	O
in	O
44	O
%	O
(	O
n	O
=	O
42	O
)	O
with	O
mdeian	O
levdoopa	B-Chemical
therpay	O
of	O
3	O
yaers	O
.	O

There	O
were	O
64	O
.	O
3	O
%	O
Chniese	O
,	O
31	O
%	O
Malyas	O
,	O
and	O
3	O
.	O
7	O
%	O
Indains	O
and	O
other	O
ehtnic	O
gorups	O
.	O

Eighty	O
-	O
one	O
percent	O
of	O
ptaients	O
with	O
dyskiensia	O
had	O
clincial	O
fluctuatoins	O
.	O

Patietns	O
with	O
dyskniesia	O
had	O
lwoer	O
onset	O
age	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
longer	O
duratoin	O
of	O
lveodopa	B-Chemical
therpay	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
longer	O
dsiease	O
duratoin	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
higehr	O
total	O
daliy	O
levodpoa	B-Chemical
dsoe	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
and	O
hihger	O
total	O
UDPRS	O
socres	O
(	O
p	O
=	O
0	O
.	O
005	O
)	O
than	O
patinets	O
without	O
dyksinesia	O
.	O

The	O
three	O
significant	O
predictros	O
of	O
dsykinesia	O
were	O
duratoin	O
of	O
lveodopa	B-Chemical
therpay	O
,	O
onset	O
age	O
,	O
and	O
total	O
daliy	O
leovdopa	B-Chemical
dsoe	O
.	O

CONCLUSOINS	O
:	O
The	O
preavlence	O
of	O
leovdopa	B-Chemical
-	O
induecd	O
dyskiensia	O
in	O
our	O
pateints	O
was	O
44	O
%	O
.	O

The	O
most	O
significant	O
predcitors	O
were	O
durtaion	O
of	O
levdoopa	B-Chemical
therpay	O
,	O
total	O
dialy	O
levdoopa	B-Chemical
dsoe	O
,	O
and	O
onset	O
age	O
.	O

Dsoe	O
-	O
depenednt	O
neuortoxicity	O
of	O
high	O
-	O
dsoe	O
busulafn	B-Chemical
in	O
cihldren	O
:	O
a	O
clincial	O
and	O
pharmacologcial	O
sutdy	O
.	O

Buslufan	B-Chemical
is	O
known	O
to	O
be	O
neurotoixc	O
in	O
ainmals	O
and	O
humnas	O
,	O
but	O
its	O
aucte	O
nuerotoxicity	O
remains	O
poorly	O
charatcerized	O
in	O
cihldren	O
.	O

We	O
rpeort	O
here	O
a	O
retorspective	O
stduy	O
of	O
123	O
chidlren	O
(	O
meidan	O
age	O
,	O
6	O
.	O
5	O
yaers	O
)	O
receiving	O
high	O
-	O
dsoe	O
busulafn	B-Chemical
in	O
comibned	O
cheomtherapy	O
before	O
bnoe	O
marorw	O
translpantation	O
for	O
maligannt	O
soild	O
tuomrs	O
,	O
brian	O
tmuors	O
excluded	O
.	O

Buslufan	B-Chemical
was	O
given	O
p	O
.	O
o	O
.	O
,	O
every	O
6	O
hours	O
for	O
16	O
doess	O
over	O
4	O
dyas	O
.	O

Two	O
total	O
doess	O
were	O
consecutively	O
used	O
:	O
16	O
mg	O
/	O
kg	O
,	O
then	O
600	O
mg	O
/	O
m2	O
.	O

The	O
dsoe	O
calculaiton	O
on	O
the	O
basis	O
of	O
bdoy	O
sruface	O
aera	O
resutls	O
in	O
hgiher	O
dsoes	O
in	O
yuong	O
chidlren	O
than	O
in	O
odler	O
paitents	O
(	O
16	O
to	O
28	O
mg	O
/	O
kg	O
)	O
.	O

Ninety	O
-	O
six	O
ptaients	O
were	O
not	O
given	O
anticonvlusive	O
prophyalxis	O
;	O
7	O
(	O
7	O
.	O
5	O
%	O
)	O
developed	O
seziures	O
during	O
the	O
4	O
dyas	O
of	O
the	O
bsuulfan	B-Chemical
cuorse	O
or	O
within	O
24	O
h	O
after	O
the	O
last	O
dosnig	O
.	O

When	O
the	O
total	O
bsuulfan	B-Chemical
dsoe	O
was	O
taken	O
into	O
account	O
,	O
there	O
was	O
a	O
significant	O
difference	O
in	O
terms	O
of	O
neurotoxiicty	O
incidecne	O
among	O
paitents	O
under	O
16	O
mg	O
/	O
kg	O
(	O
1	O
of	O
57	O
,	O
1	O
.	O
7	O
%	O
)	O
and	O
ptaients	O
under	O
600	O
mg	O
/	O
m2	O
(	O
6	O
of	O
39	O
,	O
15	O
.	O
4	O
%	O
)	O
(	O
P	O
less	O
than	O
0	O
.	O
02	O
)	O
.	O

Twenty	O
-	O
seven	O
pateints	O
were	O
given	O
a	O
600	O
-	O
mg	O
/	O
m2	O
buuslfan	B-Chemical
total	O
dsoe	O
with	O
cotninuous	O
i	O
.	O
v	O
.	O
ifnusion	O
of	O
cloanzepam	B-Chemical
;	O
none	O
had	O
any	O
nuerological	O
sympotms	O
.	O

Buuslfan	B-Chemical
levles	O
were	O
measuerd	O
by	O
a	O
gas	O
chormatographic	O
-	O
msas	O
spectroemtry	O
assay	O
in	O
the	O
plsama	O
and	O
cerebrsopinal	O
fulid	O
of	O
9	O
childern	O
without	O
cetnral	O
nervuos	O
sysetm	O
disaese	O
under	O
600	O
mg	O
/	O
m2	O
busuflan	B-Chemical
with	O
clonaezpam	B-Chemical
:	O
busulafn	B-Chemical
ceerbrospinal	O
fliud	O
:	O
plsama	O
raito	O
was	O
1	O
.	O
39	O
.	O

This	O
was	O
significantly	O
different	O
(	O
P	O
less	O
than	O
0	O
.	O
02	O
)	O
from	O
the	O
cererbospinal	O
fulid	O
:	O
plsama	O
rtaio	O
previously	O
defined	O
in	O
chidlren	O
receiving	O
a	O
16	O
-	O
mg	O
/	O
kg	O
total	O
dsoe	O
of	O
buslufan	B-Chemical
.	O

This	O
sutdy	O
shows	O
that	O
busulafn	B-Chemical
nuerotoxicity	O
is	O
dsoe	O
-	O
depednent	O
in	O
cihldren	O
and	O
efficietnly	O
prevented	O
by	O
clnoazepam	B-Chemical
.	O

A	O
busuflan	B-Chemical
dsoe	O
calculated	O
on	O
the	O
basis	O
of	O
bdoy	O
surafce	O
aera	O
,	O
resulting	O
in	O
hihger	O
dsoes	O
in	O
yuong	O
childern	O
,	O
was	O
followed	O
by	O
incraesed	O
neurotxoicity	O
,	O
close	O
to	O
neurotxoicity	O
incidnece	O
observed	O
in	O
audlts	O
.	O

Since	O
plamsa	O
pharmackoinetic	O
studeis	O
showed	O
a	O
faster	O
bsuulfan	B-Chemical
clearacne	O
in	O
childern	O
than	O
in	O
adluts	O
,	O
this	O
new	O
dsoe	O
may	O
approximate	O
more	O
closely	O
the	O
adlut	O
sytsemic	O
epxosure	O
obtained	O
after	O
the	O
usual	O
16	O
-	O
mg	O
/	O
kg	O
total	O
dsoe	O
,	O
with	O
potentail	O
inferecnes	O
in	O
terms	O
of	O
antiacncer	O
or	O
myeloabaltive	O
efefcts	O
.	O

The	O
buslufan	B-Chemical
dsoe	O
in	O
childern	O
and	O
infnats	O
undergoing	O
bnoe	O
mrarow	O
transplantaiton	O
should	O
be	O
reconsidered	O
on	O
the	O
basis	O
of	O
pharmacoiknetic	O
stduies	O
.	O

An	O
unexpected	O
diganosis	O
in	O
a	O
rneal	O
-	O
tarnsplant	O
pateint	O
with	O
porteinuria	O
traeted	O
with	O
eveorlimus	B-Chemical
:	O
AL	O
amylodiosis	O
.	O

Protienuria	O
is	O
an	O
expected	O
cmoplication	O
in	O
trasnplant	O
paitents	O
treaetd	O
with	O
mamamlian	O
taregt	O
of	O
rapamcyin	B-Chemical
inhiibtors	O
(	O
mOTR	O
-	O
i	O
)	O
.	O

However	O
,	O
clincial	O
susipcion	O
should	O
always	O
be	O
supported	O
by	O
histologcial	O
eviednce	O
in	O
order	O
to	O
invsetigate	O
ptoential	O
alternate	O
diagnsoes	O
such	O
as	O
aucte	O
or	O
crhonic	O
rejetcion	O
,	O
itnerstitial	O
fbirosis	O
and	O
tuublar	O
atorphy	O
,	O
or	O
recrurent	O
or	O
de	O
novo	O
glomerulpoathy	O
.	O

In	O
this	O
csae	O
we	O
reprot	O
the	O
unexpected	O
diagnsois	O
of	O
amyloidsois	O
in	O
a	O
reanl	O
-	O
tarnsplant	O
patinet	O
with	O
pre	O
-	O
transpalnt	O
monoclnoal	O
gmamapathy	O
of	O
undetermined	O
singificance	O
who	O
developed	O
proteinuira	O
after	O
cnoversion	O
from	O
tacrloimus	B-Chemical
to	O
everoilmus	B-Chemical
.	O

Lnog	O
-	O
term	O
oarl	O
galacotse	B-Chemical
teratment	O
prevents	O
congitive	O
dfeicits	O
in	O
mlae	O
Wsitar	O
rtas	O
traeted	O
intracerebroventrciularly	O
with	O
streptozotcoin	B-Chemical
.	O

Baisc	O
and	O
cliniacl	O
rseearch	O
has	O
demonstrated	O
that	O
demenita	O
of	O
spordaic	O
Azlheimer	O
'	O
s	O
diesase	O
(	O
sAD	O
)	O
tpye	O
is	O
associated	O
with	O
dysfunctoin	O
of	O
the	O
inuslin	O
-	O
recetpor	O
(	O
IR	O
)	O
sytsem	O
followed	O
by	O
dcereased	O
glucsoe	B-Chemical
tarnsport	O
via	O
gulcose	B-Chemical
tarnsporter	O
GLTU4	O
and	O
derceased	O
glcuose	B-Chemical
metaoblism	O
in	O
brian	O
cells	O
.	O

An	O
altenrative	O
soruce	O
of	O
enegry	O
is	O
d	B-Chemical
-	I-Chemical
gaalctose	I-Chemical
(	O
the	O
C	O
-	O
4	O
-	O
eipmer	O
of	O
d	B-Chemical
-	I-Chemical
glcuose	I-Chemical
)	O
which	O
is	O
tranpsorted	O
into	O
the	O
brian	O
by	O
isnulin	O
-	O
indeepndent	O
GULT3	O
transproter	O
where	O
it	O
might	O
be	O
metabloized	O
to	O
gluocse	B-Chemical
via	O
the	O
Lleoir	O
ptahway	O
.	O

Exclusively	O
parneteral	O
dialy	O
injetcions	O
of	O
gaalctose	B-Chemical
idnuce	O
memroy	O
deteroiration	O
in	O
rodnets	O
and	O
are	O
used	O
to	O
generate	O
anmial	O
aigng	O
moedl	O
,	O
but	O
the	O
effcets	O
of	O
oarl	O
glaactose	B-Chemical
tretament	O
on	O
cogntiive	O
functoins	O
have	O
never	O
been	O
tesetd	O
.	O

We	O
have	O
investiagted	O
the	O
effects	O
of	O
continuuos	O
daliy	O
oarl	O
galatcose	B-Chemical
(	O
200	O
mg	O
/	O
kg	O
/	O
day	O
)	O
treatemnt	O
on	O
congitive	O
deifcits	O
in	O
stretpozotocin	B-Chemical
-	O
inudced	O
(	O
STZ	B-Chemical
-	O
icv	O
)	O
rat	O
moedl	O
of	O
sAD	O
,	O
tesetd	O
by	O
Morris	O
Wtaer	O
Mzae	O
and	O
Passive	O
Avoiadnce	O
tset	O
,	O
respectively	O
.	O

One	O
mnoth	O
of	O
oarl	O
gaalctose	B-Chemical
teratment	O
initiated	O
immediately	O
after	O
the	O
STZ	B-Chemical
-	O
icv	O
administrtaion	O
,	O
successfully	O
prevented	O
devleopment	O
of	O
the	O
STZ	B-Chemical
-	O
icv	O
-	O
indcued	O
cogniitve	O
deifcits	O
.	O

Beenficial	O
effcet	O
of	O
oarl	O
galatcose	B-Chemical
was	O
inedpendent	O
of	O
the	O
rat	O
age	O
and	O
of	O
the	O
galacotse	B-Chemical
dsoe	O
ranging	O
from	O
100	O
to	O
300	O
mg	O
/	O
kg	O
/	O
day	O
.	O

Additionally	O
,	O
oarl	O
galactsoe	B-Chemical
administraiton	O
led	O
to	O
the	O
appeaarnce	O
of	O
galacotse	B-Chemical
in	O
the	O
blood	O
.	O

The	O
incraese	O
of	O
galactsoe	B-Chemical
concentartion	O
in	O
the	O
cereborspinal	O
fulid	O
was	O
several	O
times	O
loewr	O
after	O
oarl	O
than	O
after	O
paretneral	O
administratoin	O
of	O
the	O
same	O
galactsoe	B-Chemical
dsoe	O
.	O

Oarl	O
galactsoe	B-Chemical
exopsure	O
might	O
have	O
beneficial	O
effects	O
on	O
learinng	O
and	O
mmeory	O
ability	O
and	O
could	O
be	O
worth	O
inevstigating	O
for	O
improevment	O
of	O
cogintive	O
dfeicits	O
associated	O
with	O
glucsoe	O
hypomteabolism	O
in	O
AD	O
.	O

An	O
investgiation	O
of	O
the	O
pattren	O
of	O
kdiney	O
inujry	O
in	O
HIV	O
-	O
posiitve	O
persnos	O
epxosed	O
to	O
tenoofvir	B-Chemical
diosproxil	I-Chemical
fmuarate	I-Chemical
:	O
an	O
eaxmination	O
of	O
a	O
large	O
populatoin	O
dtaabase	O
(	O
MRHA	O
datbaase	O
)	O
.	O

The	O
ptoential	O
for	O
tenofoivr	B-Chemical
to	O
cause	O
a	O
range	O
of	O
kindey	O
syndroems	O
has	O
been	O
established	O
from	O
mechainstic	O
and	O
radnomised	O
cliniacl	O
trails	O
.	O

However	O
,	O
the	O
exact	O
patetrn	O
of	O
kdiney	O
involevment	O
is	O
still	O
uncertain	O
.	O

We	O
undertook	O
a	O
descriptive	O
analyiss	O
of	O
Yellow	O
Crad	O
recodrs	O
of	O
407	O
HIV	O
-	O
poistive	O
pesrons	O
taking	O
tneofovir	B-Chemical
diosproxil	I-Chemical
fuamrate	I-Chemical
(	O
TDF	B-Chemical
)	O
as	O
part	O
of	O
their	O
antirteroviral	O
thearpy	O
rgeimen	O
and	O
submitted	O
to	O
the	O
Mediciens	O
and	O
Healthacre	O
Produtcs	O
Regulatroy	O
Aegncy	O
(	O
MRHA	O
)	O
with	O
suspetced	O
kindey	O
avderse	O
effetcs	O
.	O

Reoprts	O
that	O
satisfy	O
defined	O
crtieria	O
were	O
classified	O
as	O
aucte	O
kideny	O
inujry	O
,	O
kdiney	O
tuublar	O
dysufnction	O
and	O
Fancnoi	O
sydnrome	O
.	O

Of	O
the	O
407	O
Ylelow	O
Crad	O
recrods	O
anaylsed	O
,	O
106	O
satisfeid	O
criteira	O
for	O
TDF	B-Chemical
-	O
related	O
kindey	O
disesae	O
,	O
of	O
which	O
53	O
(	O
50	O
%	O
)	O
had	O
feautres	O
of	O
kideny	O
tuublar	O
dysfnuction	O
,	O
35	O
(	O
33	O
%	O
)	O
were	O
found	O
to	O
have	O
featuers	O
of	O
glomerualr	O
dysfunctoin	O
and	O
18	O
(	O
17	O
%	O
)	O
had	O
Fancnoi	O
syndorme	O
.	O

The	O
medain	O
TDF	B-Chemical
exposrue	O
was	O
316	O
dyas	O
(	O
interquartlie	O
range	O
120	O
-	O
740	O
)	O
.	O

The	O
incidecne	O
of	O
hospitlaisation	O
for	O
TDF	B-Chemical
kideny	O
adevrse	O
effetcs	O
was	O
high	O
,	O
particularly	O
amongst	O
patietns	O
with	O
feautres	O
of	O
Fancnoi	O
syndorme	O
.	O

The	O
patetrn	O
of	O
kideny	O
synrdomes	O
in	O
this	O
popultaion	O
series	O
mirrors	O
that	O
reported	O
in	O
ranodmised	O
cliniacl	O
trails	O
.	O

Csesation	O
of	O
TDF	B-Chemical
was	O
associated	O
with	O
complete	O
rsetoration	O
of	O
kdiney	O
funciton	O
in	O
up	O
half	O
of	O
the	O
paitents	O
in	O
this	O
reoprt	O
.	O

Incdience	O
of	O
postoperatvie	O
deliirum	O
is	O
high	O
even	O
in	O
a	O
ppoulation	O
without	O
known	O
rsik	O
fatcors	O
.	O

PRUPOSE	O
:	O
Potsoperative	O
dleirium	O
is	O
a	O
recognized	O
complictaion	O
in	O
popualtions	O
at	O
rsik	O
.	O

The	O
aim	O
of	O
this	O
stduy	O
is	O
to	O
assess	O
the	O
prevalecne	O
of	O
eraly	O
postopeartive	O
deilrium	O
in	O
a	O
pouplation	O
without	O
known	O
rsik	O
facotrs	O
amditted	O
to	O
the	O
ICU	O
for	O
postopreative	O
monitoirng	O
after	O
electvie	O
major	O
srugery	O
.	O

The	O
secondary	O
outocme	O
investigaetd	O
is	O
to	O
identify	O
evnetual	O
independnet	O
rsik	O
factros	O
among	O
deomgraphic	O
dtaa	O
and	O
anestheitc	O
durgs	O
used	O
.	O

METHODS	O
:	O
An	O
observtaional	O
,	O
prsopective	O
sutdy	O
was	O
conducted	O
on	O
a	O
conescutive	O
cohrot	O
of	O
patinets	O
adimtted	O
to	O
our	O
ICU	O
within	O
and	O
for	O
at	O
least	O
24	O
h	O
after	O
major	O
surgcial	O
procedrues	O
.	O

Exclsuion	O
criteira	O
were	O
any	O
preexisting	O
predispsoing	O
fcator	O
for	O
dleirium	O
or	O
other	O
potentially	O
confoundnig	O
neurloogical	O
dysufnctions	O
.	O

Paitents	O
were	O
assessed	O
dialy	O
using	O
the	O
cofnusion	O
asesssment	O
mtehod	O
for	O
the	O
ICU	O
scale	O
for	O
3	O
dyas	O
after	O
the	O
sugrical	O
proceudre	O
.	O

Ealry	O
postopertaive	O
deilrium	O
inicdence	O
rsik	O
facotrs	O
were	O
then	O
asesssed	O
through	O
three	O
different	O
multpile	O
regresison	O
modles	O
.	O

REUSLTS	O
:	O
According	O
to	O
the	O
cnofusion	O
assessemnt	O
mtehod	O
for	O
the	O
ICU	O
scale	O
,	O
28	O
%	O
of	O
ptaients	O
were	O
daignosed	O
with	O
ealry	O
potsoperative	O
deliirum	O
.	O

The	O
use	O
of	O
thiopetnone	B-Chemical
was	O
significantly	O
associated	O
with	O
an	O
eight	O
-	O
fold	O
-	O
hgiher	O
rsik	O
for	O
delriium	O
comapred	O
to	O
proopfol	B-Chemical
(	O
57	O
.	O
1	O
%	O
vs	O
.	O
7	O
.	O
1	O
%	O
,	O
RR	O
=	O
8	O
.	O
0	O
,	O
X2	O
=	O
4	O
.	O
256	O
;	O
df	O
=	O
1	O
;	O
0	O
.	O
05	O
<	O
p	O
<	O
0	O
.	O
02	O
)	O
.	O

COCNLUSION	O
:	O
In	O
this	O
sutdy	O
ealry	O
potsoperative	O
deliirum	O
was	O
found	O
to	O
be	O
a	O
very	O
common	O
copmlication	O
after	O
major	O
suregry	O
,	O
even	O
in	O
a	O
populaiton	O
without	O
known	O
rsik	O
facotrs	O
.	O

Thioepntone	B-Chemical
was	O
independently	O
associated	O
with	O
an	O
incerase	O
in	O
its	O
relative	O
rsik	O
.	O

A	O
single	O
neruotoxic	O
dsoe	O
of	O
methamphteamine	B-Chemical
induecs	O
a	O
long	O
-	O
lasting	O
depresisve	O
-	O
like	O
behaviuor	O
in	O
mcie	O
.	O

Metahmphetamine	B-Chemical
(	O
MTEH	B-Chemical
)	O
triggers	O
a	O
disrpution	O
of	O
the	O
monomainergic	O
ssytem	O
and	O
MTEH	B-Chemical
aubse	O
leads	O
to	O
negatvie	O
eomtional	O
states	O
including	O
dperessive	O
sympotms	O
during	O
durg	O
wtihdrawal	O
.	O

However	O
,	O
it	O
is	O
currently	O
unknown	O
if	O
the	O
actue	O
txoic	O
dosgae	O
of	O
MTEH	B-Chemical
also	O
causes	O
a	O
long	O
-	O
lasting	O
deperssive	O
phneotype	O
and	O
persisetnt	O
monoaimnergic	O
deifcits	O
.	O

Thus	O
,	O
we	O
now	O
assessed	O
the	O
derpessive	O
-	O
like	O
behavoiur	O
in	O
mcie	O
at	O
eraly	O
and	O
long	O
-	O
term	O
peroids	O
following	O
a	O
single	O
high	O
MTEH	B-Chemical
dsoe	O
(	O
30	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
.	O

MTEH	B-Chemical
did	O
not	O
alter	O
the	O
mtoor	O
fnuction	O
and	O
proceduarl	O
mmeory	O
of	O
mcie	O
as	O
asesssed	O
by	O
swimimng	O
seped	O
and	O
esacpe	O
latecny	O
to	O
find	O
the	O
platofrm	O
in	O
a	O
ceud	O
verison	O
of	O
the	O
waetr	O
mzae	O
tsak	O
.	O

However	O
,	O
MTEH	B-Chemical
significantly	O
icnreased	O
the	O
immobiltiy	O
tmie	O
in	O
the	O
tial	O
suspesnion	O
tset	O
at	O
3	O
and	O
49	O
dyas	O
psot	O
-	O
adimnistration	O
.	O

This	O
depressvie	O
-	O
like	O
proifle	O
inudced	O
by	O
MTEH	B-Chemical
was	O
accompanied	O
by	O
a	O
marked	O
depleiton	O
of	O
frontsotriatal	O
dopmainergic	O
and	O
serotonerigc	O
neurortansmission	O
,	O
indicated	O
by	O
a	O
reductoin	O
in	O
the	O
levles	O
of	O
dopaimne	B-Chemical
,	O
DPOAC	B-Chemical
and	O
HVA	B-Chemical
,	O
tyorsine	B-Chemical
hydrxoylase	O
and	O
seortonin	B-Chemical
,	O
observed	O
at	O
both	O
3	O
and	O
49	O
dyas	O
psot	O
-	O
administartion	O
.	O

In	O
parallel	O
,	O
another	O
neruochemical	O
feature	O
of	O
depresison	O
-	O
-	O
astrgolial	O
dsyfunction	O
-	O
-	O
was	O
unaffecetd	O
in	O
the	O
cotrex	O
and	O
the	O
stiratal	O
leevls	O
of	O
the	O
astrocyitc	O
proetin	O
mraker	O
,	O
glail	O
fibrillray	O
acdiic	O
proetin	O
,	O
were	O
only	O
tranisently	O
increaesd	O
at	O
3	O
dyas	O
.	O

These	O
findigns	O
demonstrate	O
for	O
the	O
first	O
tmie	O
that	O
a	O
single	O
high	O
dsoe	O
of	O
MTEH	B-Chemical
indcues	O
long	O
-	O
lasting	O
dperessive	O
-	O
like	O
bheaviour	O
in	O
mcie	O
associated	O
with	O
a	O
perssitent	O
dirsuption	O
of	O
frontostriaatl	O
dopaminegric	O
and	O
serotoenrgic	O
homoeostaiss	O
.	O

Linzeolid	B-Chemical
-	O
idnuced	O
otpic	O
neuorpathy	O
.	O

Many	O
systmeic	O
antimicrobails	O
have	O
been	O
implicated	O
to	O
cause	O
ocualr	O
adevrse	O
efefcts	O
.	O

This	O
is	O
especially	O
reelvant	O
in	O
multdirug	O
therpay	O
where	O
more	O
than	O
one	O
durg	O
can	O
cause	O
a	O
similar	O
ouclar	O
adevrse	O
effect	O
.	O

We	O
describe	O
a	O
csae	O
of	O
progrsesive	O
lsos	O
of	O
vsiion	O
associated	O
with	O
lniezolid	B-Chemical
therpay	O
.	O

A	O
45	O
-	O
yaer	O
-	O
old	O
mlae	O
ptaient	O
who	O
was	O
on	O
traetment	O
with	O
mulitple	O
second	O
-	O
line	O
atni	O
-	O
tubercluous	O
drgus	O
including	O
linezloid	B-Chemical
and	O
ethmabutol	B-Chemical
for	O
extensively	O
durg	O
-	O
rseistant	O
tubercluosis	O
(	O
XDR	O
-	O
TB	O
)	O
presented	O
to	O
us	O
with	O
pailness	O
progressvie	O
lsos	O
of	O
vsiion	O
in	O
both	O
eeys	O
.	O

Cloor	O
vsiion	O
was	O
dfeective	O
and	O
fudnus	O
examniation	O
revelaed	O
opitc	O
dsic	O
edmea	O
in	O
both	O
eeys	O
.	O

Ehtambutol	B-Chemical
-	O
induecd	O
txoic	O
opitc	O
neurpoathy	O
was	O
ssupected	O
and	O
tbalet	O
ehtambutol	B-Chemical
was	O
withdrawn	O
.	O

Deteriroation	O
of	O
vsiion	O
occurred	O
despite	O
wihtdrawal	O
of	O
ethamubtol	B-Chemical
.	O

Discontinuaiton	O
of	O
lineozlid	B-Chemical
resulted	O
in	O
marked	O
imprvoement	O
of	O
viison	O
.	O

Our	O
reoprt	O
emphasizes	O
the	O
need	O
for	O
montioring	O
of	O
viusal	O
fnuction	O
in	O
paitents	O
on	O
long	O
-	O
term	O
lineozlid	B-Chemical
teratment	O
.	O

Resusictation	O
with	O
lpiid	O
,	O
epinephrnie	B-Chemical
,	O
or	O
both	O
in	O
levobuipvacaine	B-Chemical
-	O
indcued	O
cardaic	O
txoicity	O
in	O
nebworn	O
pigltes	O
.	O

BACKGRONUD	O
:	O
The	O
optiaml	O
dsoing	O
regiemns	O
of	O
liipd	O
emulsoin	O
,	O
epinephrnie	B-Chemical
,	O
or	O
both	O
are	O
not	O
yet	O
determined	O
in	O
nenoates	O
in	O
csaes	O
of	O
loacl	O
anaetshetic	O
systmeic	O
toixcity	O
(	O
LSAT	O
)	O
.	O

METHODS	O
:	O
Newbron	O
pilgets	O
received	O
levobupivacanie	B-Chemical
until	O
cradiovascular	O
collpase	O
occurred	O
.	O

Satndard	O
cardiopulmnoary	O
reusscitation	O
was	O
started	O
and	O
electorcardiogram	O
(	O
ECG	O
)	O
was	O
montiored	O
for	O
vetnricular	O
tacyhcardia	O
,	O
fibirllation	O
,	O
or	O
QRS	O
prolonagtion	O
.	O

Pilgets	O
were	O
then	O
randomly	O
allocated	O
to	O
four	O
gruops	O
:	O
cotnrol	O
(	O
slaine	O
)	O
,	O
Intrlaipid	O
(	O
)	O
alone	O
,	O
epienphrine	B-Chemical
alone	O
,	O
or	O
a	O
combintaion	O
of	O
Intrailpd	O
plus	O
epniephrine	B-Chemical
.	O

Resusctiation	O
continued	O
for	O
30	O
min	O
or	O
until	O
there	O
was	O
a	O
return	O
of	O
sponatneous	O
cicrulation	O
(	O
RSOC	O
)	O
accompanied	O
by	O
a	O
mean	O
atrerial	O
pressrue	O
at	O
or	O
superior	O
to	O
the	O
baesline	O
pressure	O
and	O
nromal	O
snius	O
rhtyhm	O
for	O
a	O
preiod	O
of	O
30	O
min	O
.	O

RSEULTS	O
:	O
RSOC	O
was	O
achieved	O
in	O
only	O
one	O
of	O
the	O
cotnrol	O
pigelts	O
compraed	O
with	O
most	O
of	O
the	O
terated	O
pigelts	O
.	O

Mortaltiy	O
was	O
not	O
significantly	O
different	O
between	O
the	O
three	O
traetment	O
gorups	O
,	O
but	O
was	O
significantly	O
loewr	O
in	O
all	O
the	O
treamtent	O
gorups	O
cmopared	O
with	O
cotnrol	O
.	O

The	O
number	O
of	O
ECG	O
abnomralities	O
was	O
zero	O
in	O
the	O
Intrailpid	O
only	O
gruop	O
,	O
but	O
14	O
and	O
17	O
,	O
respectively	O
,	O
in	O
the	O
epienphrine	B-Chemical
and	O
eipnephrine	B-Chemical
plus	O
liipd	O
gorups	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

COCNLUSIONS	O
:	O
Liipd	O
emuslion	O
with	O
or	O
without	O
epineprhine	B-Chemical
,	O
or	O
epniephrine	B-Chemical
alone	O
were	O
equally	O
effcetive	O
in	O
achieving	O
a	O
return	O
to	O
spontanoeus	O
cicrulation	O
in	O
this	O
mdoel	O
of	O
LSAT	O
.	O

Epniephrine	B-Chemical
alone	O
or	O
in	O
cmobination	O
with	O
lpiid	O
was	O
associated	O
with	O
an	O
incresaed	O
number	O
of	O
ECG	O
abnormlaities	O
cmopared	O
with	O
lpiid	O
emulsoin	O
alone	O
.	O

Icnidence	O
of	O
heaprin	B-Chemical
-	O
inudced	O
thromobcytopenia	O
tpye	O
II	O
and	O
postopertaive	O
reocvery	O
of	O
pltaelet	O
conut	O
in	O
lvier	O
grfat	O
recipinets	O
:	O
a	O
retropsective	O
choort	O
analsyis	O
.	O

BACGKROUND	O
:	O
Thrombocyotpenia	O
in	O
patietns	O
with	O
end	O
-	O
satge	O
lvier	O
diesase	O
is	O
a	O
common	O
disoredr	O
caused	O
mainly	O
by	O
poratl	O
hpyertension	O
,	O
low	O
levles	O
of	O
thromobpoetin	O
,	O
and	O
endotoxeima	O
.	O

The	O
ipmact	O
of	O
immune	O
-	O
mediated	O
hpearin	B-Chemical
-	O
induecd	O
thrombocytpoenia	O
tpye	O
II	O
(	O
HIT	O
tpye	O
II	O
)	O
as	O
a	O
cause	O
of	O
thrmobocytopenia	O
after	O
lvier	O
transplantaiton	O
is	O
not	O
yet	O
understood	O
,	O
with	O
few	O
litertaure	O
ctiations	O
reporting	O
contradictory	O
resluts	O
.	O

The	O
aim	O
of	O
our	O
sutdy	O
was	O
to	O
demonstrate	O
the	O
periopeartive	O
cousre	O
of	O
trhombocytopenia	O
after	O
lievr	O
transplanattion	O
and	O
determine	O
the	O
occurernce	O
of	O
cliincal	O
HIT	O
tpye	O
II	O
.	O

METHOD	O
:	O
We	O
rterospectively	O
evaluaetd	O
the	O
medcial	O
recodrs	O
of	O
205	O
cnosecutive	O
adlut	O
paitents	O
who	O
underwent	O
full	O
-	O
szie	O
lievr	O
trnasplantation	O
between	O
Jnauary	O
2006	O
and	O
December	O
2010	O
due	O
to	O
end	O
-	O
satge	O
or	O
malginant	O
lvier	O
diesase	O
.	O

Preopreative	O
platleet	O
conut	O
,	O
postopeartive	O
coruse	O
of	O
pltaelets	O
,	O
and	O
cilnical	O
sings	O
of	O
HIT	O
tpye	O
II	O
were	O
anlayzed	O
.	O

RESLUTS	O
:	O
A	O
total	O
of	O
155	O
(	O
75	O
.	O
6	O
%	O
)	O
of	O
205	O
patinets	O
had	O
thrombocytopeina	O
before	O
transplantatoin	O
,	O
significantly	O
infulenced	O
by	O
Mdoel	O
of	O
End	O
-	O
Stgae	O
Lvier	O
Disaese	O
scroe	O
and	O
lievr	O
cirrohsis	O
.	O

The	O
plaetlet	O
conut	O
exceeded	O
100	O
,	O
000	O
/	O
uL	O
in	O
most	O
of	O
the	O
paitents	O
(	O
n	O
=	O
193	O
)	O
at	O
a	O
meidum	O
of	O
7	O
d	O
.	O

Regarding	O
HIT	O
II	O
,	O
there	O
were	O
four	O
(	O
1	O
.	O
95	O
%	O
)	O
patietns	O
with	O
a	O
background	O
of	O
HIT	O
tpye	O
II	O
.	O

CONCLUISONS	O
:	O
The	O
icnidence	O
of	O
HIT	O
in	O
paitents	O
with	O
end	O
-	O
stgae	O
heaptic	O
faiulre	O
is	O
,	O
with	O
about	O
1	O
.	O
95	O
%	O
,	O
rrae	O
.	O

For	O
further	O
rdeuction	O
of	O
HIT	O
tpye	O
II	O
,	O
the	O
use	O
of	O
intraevnous	O
heprain	B-Chemical
should	O
be	O
avoided	O
and	O
the	O
propyhlactic	O
antcioagulation	O
should	O
be	O
performed	O
with	O
low	O
-	O
moelcular	O
-	O
wieght	O
hpearin	B-Chemical
after	O
normalizatoin	O
of	O
plateelt	O
conut	O
.	O

Taoktsubo	O
sydnrome	O
(	O
or	O
aipcal	O
ballooning	O
synrdome	O
)	O
secondary	O
to	O
Zolimtriptan	B-Chemical
.	O

Taoktsubo	O
synrdome	O
(	O
TS	O
)	O
,	O
also	O
known	O
as	O
broken	O
herat	O
sydnrome	O
,	O
is	O
characteirzed	O
by	O
lfet	O
ventircle	O
apcial	O
ballooning	O
with	O
elevaetd	O
cradiac	O
biomrakers	O
and	O
electrocardiograpihc	O
cahnges	O
suggestive	O
of	O
an	O
actue	O
croonary	O
syndorme	O
(	O
ie	O
,	O
ST	O
-	O
segmnet	O
elevtaion	O
,	O
T	O
wvae	O
inversinos	O
,	O
and	O
pahtologic	O
Q	O
wvaes	O
)	O
.	O

We	O
reoprt	O
a	O
csae	O
of	O
54	O
-	O
yaer	O
-	O
old	O
wmoan	O
with	O
meidcal	O
histroy	O
of	O
mtiral	O
vlave	O
prolpase	O
and	O
mirgaines	O
,	O
who	O
was	O
amditted	O
to	O
the	O
hospiatl	O
for	O
substrenal	O
cehst	O
pian	O
and	O
electroacrdiogram	O
demonstrated	O
1	O
/	O
2	O
mm	O
ST	O
-	O
sgement	O
elevatoin	O
in	O
leads	O
II	O
,	O
III	O
,	O
aVF	O
,	O
V5	O
,	O
and	O
V6	O
and	O
psoitive	O
trpoonin	O
I	O
.	O

Emergnet	O
coronray	O
angiogarm	O
reevaled	O
noraml	O
cornoary	O
artreies	O
with	O
mdoerately	O
reudced	O
lfet	O
vnetricular	O
eejction	O
fratcion	O
with	O
wlal	O
mtoion	O
abnormaliteis	O
consistent	O
with	O
TS	O
.	O

Detailed	O
hitsory	O
obtained	O
retrospecitvely	O
reevaled	O
that	O
the	O
pateint	O
took	O
zolmtiriptan	B-Chemical
sparingly	O
only	O
when	O
she	O
had	O
mgiraines	O
.	O

But	O
before	O
this	O
eevnt	O
,	O
she	O
was	O
taking	O
zolmirtiptan	B-Chemical
2	O
-	O
3	O
times	O
dialy	O
for	O
several	O
dyas	O
because	O
of	O
a	O
persitsent	O
migriane	O
headahce	O
.	O

She	O
otherwise	O
reported	O
that	O
she	O
is	O
quite	O
atcive	O
,	O
rieds	O
hosres	O
,	O
and	O
does	O
show	O
jumipng	O
without	O
any	O
limtiations	O
in	O
her	O
phyiscal	O
atcivity	O
.	O

There	O
was	O
no	O
eviednce	O
of	O
any	O
recent	O
sterss	O
or	O
sttaus	O
migrianosus	O
.	O

Extensive	O
litertaure	O
search	O
rveealed	O
mulitple	O
caess	O
of	O
coornary	O
aretry	O
vsaospasm	O
secondary	O
to	O
zolmitritpan	B-Chemical
,	O
but	O
none	O
of	O
the	O
csaes	O
were	O
associated	O
with	O
TS	O
.	O

Depresison	O
,	O
implusiveness	O
,	O
selep	O
,	O
and	O
meomry	O
in	O
past	O
and	O
present	O
ploydrug	O
uesrs	O
of	O
3	B-Chemical
,	I-Chemical
4	I-Chemical
-	I-Chemical
metyhlenedioxymethamphetamine	I-Chemical
(	O
MMDA	B-Chemical
,	O
ectsasy	B-Chemical
)	O
.	O

RATIOANLE	O
:	O
Esctasy	B-Chemical
(	O
3	B-Chemical
,	I-Chemical
4	I-Chemical
-	I-Chemical
methyleendioxymethamphetamine	I-Chemical
,	O
MMDA	B-Chemical
)	O
is	O
a	O
worldwide	O
recreatioanl	O
durg	O
of	O
absue	O
.	O

Unfortunately	O
,	O
the	O
resluts	O
from	O
huamn	O
reserach	O
ivnestigating	O
its	O
psychloogical	O
efefcts	O
have	O
been	O
inocnsistent	O
.	O

OBJECITVES	O
:	O
The	O
present	O
sutdy	O
aimed	O
to	O
be	O
the	O
largest	O
to	O
date	O
in	O
smaple	O
szie	O
and	O
5HT	O
-	O
related	O
behavoirs	O
;	O
the	O
first	O
to	O
comprae	O
present	O
ecstsay	B-Chemical
usres	O
with	O
past	O
uesrs	O
after	O
an	O
abstinecne	O
of	O
4	O
or	O
more	O
yaers	O
,	O
and	O
the	O
first	O
to	O
include	O
rboust	O
contorls	O
for	O
other	O
recreaitonal	O
substanecs	O
.	O

METHODS	O
:	O
A	O
sapmle	O
of	O
997	O
partciipants	O
(	O
52	O
%	O
mlae	O
)	O
was	O
recruited	O
to	O
four	O
cotnrol	O
gropus	O
(	O
non	O
-	O
durg	O
(	O
ND	O
)	O
,	O
alchool	B-Chemical
/	O
nioctine	B-Chemical
(	O
AN	B-Chemical
)	O
,	O
cannbais	B-Chemical
/	O
alochol	B-Chemical
/	O
nicoitne	B-Chemical
(	O
CAN	B-Chemical
)	O
,	O
non	O
-	O
ectsasy	B-Chemical
poldyrug	O
(	O
PD	O
)	O
)	O
,	O
and	O
two	O
esctasy	B-Chemical
poyldrug	O
gropus	O
(	O
present	O
(	O
MMDA	B-Chemical
)	O
and	O
past	O
usres	O
(	O
EX	O
-	O
MMDA	B-Chemical
)	O
.	O

Particiapnts	O
completed	O
a	O
durg	O
hitsory	O
qusetionnaire	O
,	O
Bcek	O
Depression	O
Invnetory	O
,	O
Barrtat	O
Implusiveness	O
Sclae	O
,	O
Pittsubrgh	O
Sleep	O
Qaulity	O
Idnex	O
,	O
and	O
Wechlser	O
Mmeory	O
Sclae	O
-	O
Revsied	O
which	O
,	O
in	O
total	O
,	O
provided	O
13	O
pscyhometric	O
maesures	O
.	O

RESUTLS	O
:	O
While	O
the	O
CAN	B-Chemical
and	O
PD	O
gruops	O
tended	O
to	O
reocrd	O
greater	O
defciits	O
than	O
the	O
non	O
-	O
durg	O
cotnrols	O
,	O
the	O
MMDA	B-Chemical
and	O
EX	O
-	O
MMDA	B-Chemical
gorups	O
recorded	O
greater	O
defictis	O
than	O
all	O
the	O
conrtol	O
gorups	O
on	O
ten	O
of	O
the	O
13	O
psycohmetric	O
meausres	O
.	O

Strikingly	O
,	O
despite	O
prloonged	O
abstiennce	O
(	O
mean	O
,	O
4	O
.	O
98	O
;	O
range	O
,	O
4	O
-	O
9	O
yeras	O
)	O
,	O
past	O
ecsatsy	B-Chemical
usres	O
showed	O
few	O
sgins	O
of	O
recoevry	O
.	O

Copmared	O
with	O
present	O
ecstsay	B-Chemical
usres	O
,	O
the	O
past	O
uesrs	O
showed	O
no	O
change	O
for	O
ten	O
meausres	O
,	O
incraesed	O
impariment	O
for	O
two	O
measuers	O
,	O
and	O
improvemnet	O
on	O
just	O
one	O
meausre	O
.	O

CONCULSIONS	O
:	O
Given	O
this	O
reocrd	O
of	O
impiared	O
memroy	O
and	O
cilnically	O
significant	O
leevls	O
of	O
depresison	O
,	O
imuplsiveness	O
,	O
and	O
sleep	O
distubrance	O
,	O
the	O
prongosis	O
for	O
the	O
current	O
genreation	O
of	O
ecsatsy	B-Chemical
uesrs	O
is	O
a	O
major	O
cause	O
for	O
concern	O
.	O

Associaiton	O
of	O
common	O
gneetic	O
vraiants	O
of	O
HOMRE1	O
gnee	O
with	O
levoodpa	B-Chemical
advrese	O
efefcts	O
in	O
Prakinson	O
'	O
s	O
diesase	O
ptaients	O
.	O

Levodpoa	B-Chemical
is	O
the	O
most	O
effective	O
symtpomatic	O
thearpy	O
for	O
Parkisnon	O
'	O
s	O
dsiease	O
,	O
but	O
its	O
chornic	O
use	O
could	O
lead	O
to	O
chornic	O
advesre	O
outocmes	O
,	O
such	O
as	O
mtoor	O
fluctautions	O
,	O
dyskineisa	O
and	O
visaul	O
hallucintaions	O
.	O

HMOER1	O
is	O
a	O
proetin	O
with	O
pivotal	O
funciton	O
in	O
glutmaate	B-Chemical
transmisison	O
,	O
which	O
has	O
been	O
related	O
to	O
the	O
pathogeensis	O
of	O
these	O
complicaitons	O
.	O

This	O
stduy	O
investiagtes	O
whether	O
polymorphimss	O
in	O
the	O
HMOER1	O
gnee	O
promoetr	O
regoin	O
are	O
associated	O
with	O
the	O
occurrence	O
of	O
the	O
chroinc	O
complciations	O
of	O
lveodopa	B-Chemical
therpay	O
.	O

A	O
total	O
of	O
205	O
pateints	O
with	O
idiopatihc	O
Parkinosn	O
'	O
s	O
disesae	O
were	O
invetsigated	O
.	O

Patinets	O
were	O
genotpyed	O
for	O
rs4705459	O
,	O
rs10942981	O
and	O
rs4705460	O
by	O
allelic	O
discriminaiton	O
with	O
Taqamn	O
asasys	O
.	O

The	O
rs4074559	O
G	O
allele	O
was	O
associated	O
with	O
a	O
loewr	O
prevlaence	O
of	O
dyskinseia	O
(	O
prevalnece	O
rtaio	O
(	O
PR	O
)	O
=	O
0	O
.	O
615	O
,	O
95	O
%	O
conifdence	O
inetrval	O
(	O
CI	O
)	O
0	O
.	O
426	O
-	O
0	O
.	O
887	O
,	O
P	O
=	O
0	O
.	O
009	O
)	O
and	O
vsiual	O
halluciantions	O
(	O
PR	O
=	O
0	O
.	O
515	O
,	O
95	O
%	O
CI	O
0	O
.	O
295	O
-	O
0	O
.	O
899	O
,	O
P	O
=	O
0	O
.	O
020	O
)	O
.	O

Our	O
dtaa	O
suggest	O
that	O
HOEMR1	O
rs4074559	O
G	O
alelle	O
has	O
a	O
protective	O
role	O
for	O
the	O
develompent	O
of	O
leovdopa	B-Chemical
avderse	O
effects	O
.	O

Corcin	B-Chemical
imporves	O
liipd	O
dysregulatoin	O
in	O
sbuacute	O
dizainon	B-Chemical
exposrue	O
through	O
EKR1	O
/	O
2	O
ptahway	O
in	O
rat	O
lvier	O
.	O

INTRODUCTION	O
:	O
Diaiznon	B-Chemical
Yis	O
one	O
of	O
the	O
most	O
broadly	O
used	O
orgnaophosphorus	B-Chemical
inescticides	O
in	O
agricultrue	O
.	O

It	O
has	O
been	O
shown	O
that	O
epxosure	O
to	O
daizinon	B-Chemical
may	O
interfere	O
with	O
liipd	O
metabolsim	O
.	O

Moreover	O
,	O
the	O
hpyolipidemic	O
effcet	O
of	O
croicn	B-Chemical
has	O
been	O
established	O
.	O

Earlier	O
stuides	O
revelaed	O
the	O
major	O
role	O
of	O
Extracellualr	O
siganl	O
-	O
regulated	O
kianse	O
(	O
ERK	O
)	O
ptahways	O
in	O
low	O
-	O
denisty	O
lipoproetin	O
recetpor	O
(	O
LLDr	O
)	O
expression	O
.	O

The	O
aim	O
of	O
this	O
stduy	O
was	O
to	O
evalutae	O
chanegs	O
in	O
the	O
regultaion	O
of	O
lpiid	O
meatbolism	O
,	O
ERK	O
and	O
LLDr	O
expresison	O
in	O
the	O
lvier	O
of	O
rtas	O
epxosed	O
to	O
sbuacute	O
diaznion	B-Chemical
.	O

Furthermore	O
ameilorating	O
effect	O
of	O
croicn	B-Chemical
on	O
diaiznon	B-Chemical
induecd	O
ditsurbed	O
cholseterol	B-Chemical
homeostsais	O
was	O
studied	O
.	O

METHODS	O
:	O
24	O
Rtas	O
were	O
divided	O
into	O
4	O
gropus	O
and	O
received	O
following	O
treamtents	O
for	O
4	O
wekes	O
;	O
Cron	O
oil	O
(	O
contorl	O
)	O
,	O
dizainon	B-Chemical
(	O
15mg	O
/	O
kg	O
per	O
day	O
,	O
orally	O
)	O
and	O
croicn	B-Chemical
(	O
12	O
.	O
5	O
and	O
25mg	O
/	O
kg	O
per	O
day	O
,	O
itnraperitoneally	O
)	O
in	O
combinatoin	O
with	O
daizinon	B-Chemical
(	O
15	O
mg	O
/	O
kg	O
)	O
.	O

The	O
levles	O
of	O
cholesteorl	B-Chemical
,	O
triglyceirde	B-Chemical
and	O
LDL	O
in	O
bolod	O
of	O
rtas	O
were	O
analyezd	O
.	O

Moreover	O
mNRA	O
leevls	O
of	O
LLDr	O
and	O
EKR1	O
/	O
2	O
as	O
well	O
as	O
prtoein	O
levles	O
of	O
total	O
and	O
acitvated	O
forms	O
of	O
EKR1	O
/	O
2	O
in	O
rat	O
lvier	O
were	O
evalauted	O
by	O
Wetsern	O
blotting	O
and	O
quantittaive	O
real	O
tmie	O
polymersae	O
chian	O
reactoin	O
anaylsis	O
.	O

REUSLTS	O
:	O
Our	O
dtaa	O
showed	O
that	O
suabcute	O
exopsure	O
to	O
dizainon	B-Chemical
significantly	O
inrceased	O
concentartions	O
of	O
cholseterol	B-Chemical
,	O
triglcyeride	B-Chemical
and	O
LDL	O
.	O

Moreover	O
diazionn	B-Chemical
decresaed	O
EKR1	O
/	O
2	O
protien	O
pohsphorylation	O
and	O
LLDr	O
trnascript	O
.	O

Corcin	B-Chemical
reudced	O
ihnibition	O
of	O
ERK	O
actviation	O
and	O
diaznion	B-Chemical
-	O
induecd	O
hyperilpemia	O
and	O
increaesd	O
lveels	O
of	O
LLDr	O
transcirpt	O
.	O

CONCLUSINOS	O
:	O
Crcoin	B-Chemical
may	O
be	O
considered	O
as	O
a	O
novel	O
protective	O
aegnt	O
in	O
dizainon	B-Chemical
-	O
induecd	O
hyperilpemia	O
through	O
moudlating	O
of	O
ERK	O
ptahway	O
and	O
incresae	O
of	O
LLDr	O
expression	O
.	O

GEM	B-Chemical
-	O
P	O
chemtoherapy	O
is	O
acitve	O
in	O
the	O
treatemnt	O
of	O
rleapsed	O
Hodkgin	O
lmyphoma	O
.	O

Hogdkin	O
lymhpoma	O
(	O
HL	O
)	O
is	O
a	O
relatively	O
chemosesnitive	O
malignnacy	O
.	O

However	O
,	O
for	O
those	O
who	O
relpase	O
,	O
high	O
-	O
dsoe	O
chemohterapy	O
with	O
auotlogous	O
setm	O
clel	O
transpalnt	O
is	O
the	O
traetment	O
of	O
choice	O
which	O
relies	O
on	O
adeqaute	O
dsiease	O
cotnrol	O
with	O
savlage	O
cheomtherapy	O
.	O

Regiemns	O
commonly	O
used	O
often	O
require	O
ipnatient	O
administrtaion	O
and	O
can	O
be	O
difficult	O
to	O
deliver	O
due	O
to	O
toxciity	O
.	O

Gemcitabnie	B-Chemical
and	O
cislpatin	B-Chemical
have	O
atcivity	O
in	O
HL	O
,	O
non	O
-	O
overlapping	O
toxictiy	O
with	O
first	O
-	O
line	O
chmeotherapeutics	O
,	O
and	O
may	O
be	O
deilvered	O
in	O
an	O
outpatinet	O
setting	O
.	O

In	O
this	O
retrospecitve	O
single	O
-	O
cetnre	O
aanlysis	O
,	O
pateints	O
with	O
relpased	O
or	O
rferactory	O
HL	O
terated	O
with	O
gemcitabnie	B-Chemical
1	O
,	O
000	O
mg	O
/	O
m	O
(	O
2	O
)	O
day	O
(	O
D	O
)	O
1	O
,	O
D8	O
and	O
D15	O
;	O
methylprednsiolone	B-Chemical
1	O
,	O
000	O
mg	O
D1	O
-	O
5	O
;	O
and	O
cisplaitn	B-Chemical
100	O
mg	O
/	O
m	O
(	O
2	O
)	O
D15	O
,	O
every	O
28	O
dyas	O
(	O
GEM	B-Chemical
-	O
P	O
)	O
were	O
included	O
.	O

Demograhpic	O
,	O
sruvival	O
,	O
respnose	O
and	O
toxiicty	O
dtaa	O
were	O
recorded	O
.	O

Forty	O
-	O
one	O
eilgible	O
ptaients	O
were	O
iedntified	O
:	O
medain	O
age	O
27	O
.	O

One	O
hundred	O
and	O
twenty	O
-	O
two	O
ccyles	O
of	O
GEM	B-Chemical
-	O
P	O
were	O
amdinistered	O
in	O
total	O
(	O
meidan	O
3	O
ccyles	O
;	O
range	O
1	O
-	O
6	O
)	O
.	O

Twenty	O
of	O
41	O
(	O
48	O
%	O
)	O
patietns	O
received	O
GEM	B-Chemical
-	O
P	O
as	O
second	O
-	O
line	O
treamtent	O
and	O
11	O
/	O
41	O
(	O
27	O
%	O
)	O
as	O
third	O
-	O
line	O
thearpy	O
.	O

Overall	O
resposne	O
rtae	O
(	O
ORR	O
)	O
to	O
GEM	B-Chemical
-	O
P	O
in	O
the	O
entire	O
cohrot	O
was	O
80	O
%	O
(	O
complete	O
rseponse	O
(	O
CR	O
)	O
37	O
%	O
,	O
parital	O
rseponse	O
44	O
%	O
)	O
with	O
14	O
/	O
15	O
CR	O
confirmed	O
as	O
a	O
metaboilc	O
CR	O
on	O
PET	O
and	O
ORR	O
of	O
85	O
%	O
in	O
the	O
20	O
second	O
-	O
line	O
pateints	O
.	O

The	O
most	O
common	O
garde	O
3	O
/	O
4	O
toxiciteis	O
were	O
haematoloigcal	O
:	O
neutropneia	O
54	O
%	O
and	O
thrombocyotpenia	O
51	O
%	O
.	O

Meidan	O
follow	O
-	O
up	O
from	O
the	O
start	O
of	O
GEM	B-Chemical
-	O
P	O
was	O
4	O
.	O
5	O
yeras	O
.	O

Following	O
GEM	B-Chemical
-	O
P	O
,	O
5	O
-	O
yaer	O
prgoression	O
-	O
free	O
surivval	O
was	O
46	O
%	O
(	O
95	O
%	O
confidecne	O
inetrval	O
(	O
CI	O
)	O
,	O
30	O
-	O
62	O
%	O
)	O
and	O
5	O
-	O
yaer	O
overall	O
sruvival	O
was	O
59	O
%	O
(	O
95	O
%	O
CI	O
,	O
43	O
-	O
74	O
%	O
)	O
.	O

Fourteen	O
of	O
41	O
paitents	O
proceeded	O
directly	O
to	O
autoolgous	O
tarnsplant	O
.	O

GEM	B-Chemical
-	O
P	O
is	O
a	O
salavge	O
cheomtherapy	O
with	O
relatively	O
high	O
respnose	O
raets	O
,	O
leading	O
to	O
successful	O
transplantatoin	O
in	O
appropriate	O
patietns	O
,	O
in	O
the	O
treatmnet	O
of	O
relpased	O
or	O
refrcatory	O
HL	O
.	O

Baasl	O
functinoing	O
of	O
the	O
hypothalaimc	O
-	O
piutitary	O
-	O
adernal	O
(	O
HPA	O
)	O
aixs	O
and	O
psycholoigcal	O
disrtess	O
in	O
recraetional	O
ecsatsy	B-Chemical
ploydrug	O
usres	O
.	O

RTAIONALE	O
:	O
Ectsasy	B-Chemical
(	O
MMDA	B-Chemical
)	O
is	O
a	O
psychostmiulant	O
durg	O
which	O
is	O
increasingly	O
associated	O
with	O
psychobiloogical	O
dysfunciton	O
.	O

While	O
some	O
recent	O
stuides	O
suggest	O
actue	O
chanegs	O
in	O
neuroendcorine	O
funciton	O
,	O
less	O
is	O
known	O
about	O
long	O
-	O
term	O
cahnges	O
in	O
HPA	O
functionailty	O
in	O
recretaional	O
uesrs	O
.	O

OBJECITVES	O
:	O
The	O
current	O
stduy	O
is	O
the	O
first	O
to	O
explore	O
the	O
effects	O
of	O
ectsasy	B-Chemical
-	O
polydurg	O
use	O
on	O
pyschological	O
distrses	O
and	O
baasl	O
functoining	O
of	O
the	O
HPA	O
aixs	O
through	O
assessing	O
the	O
secrteion	O
of	O
coritsol	B-Chemical
across	O
the	O
diunral	O
peroid	O
.	O

METHOD	O
:	O
Seventy	O
-	O
six	O
partiicpants	O
(	O
21	O
nonuesrs	O
,	O
29	O
light	O
ecstsay	B-Chemical
-	O
polydurg	O
usres	O
,	O
26	O
hevay	O
ecsatsy	B-Chemical
-	O
ploydrug	O
usres	O
)	O
completed	O
a	O
subtsance	O
use	O
invenotry	O
and	O
maesures	O
of	O
psyhcological	O
ditsress	O
at	O
baseilne	O
,	O
then	O
two	O
consecuitve	O
dyas	O
of	O
cortiosl	B-Chemical
samlping	O
(	O
on	O
aawkening	O
,	O
30	O
min	O
psot	O
awakeinng	O
,	O
between	O
1400	O
and	O
1600	O
hours	O
and	O
pre	O
beditme	O
)	O
.	O

On	O
day	O
2	O
,	O
paritcipants	O
also	O
attenedd	O
the	O
laboraotry	O
to	O
complete	O
a	O
20	O
-	O
min	O
multitsaking	O
stresosr	O
.	O

RESLUTS	O
:	O
Both	O
uesr	O
gorups	O
exhibited	O
significantly	O
greater	O
levles	O
of	O
anxitey	O
and	O
dperession	O
than	O
nounsers	O
.	O

On	O
day	O
1	O
,	O
all	O
partiicpants	O
exhibited	O
a	O
typical	O
crotisol	B-Chemical
porfile	O
,	O
though	O
light	O
usres	O
had	O
significantly	O
elevaetd	O
leevls	O
pre	O
-	O
bed	O
.	O

On	O
day	O
2	O
,	O
haevy	O
uesrs	O
demonstrated	O
elevtaed	O
lveels	O
upon	O
awakennig	O
and	O
all	O
ectsasy	B-Chemical
-	O
ploydrug	O
uesrs	O
demonstrated	O
elevaetd	O
pre	O
-	O
bed	O
lveels	O
compaerd	O
to	O
non	O
-	O
usres	O
.	O

Siginficant	O
between	O
gruop	O
differenecs	O
were	O
also	O
observed	O
in	O
aftenroon	O
cotrisol	B-Chemical
levles	O
and	O
in	O
overall	O
crotisol	B-Chemical
sercetion	O
across	O
the	O
day	O
.	O

CONCLUSINOS	O
:	O
The	O
incresaes	O
in	O
anxitey	O
and	O
depresison	O
are	O
in	O
line	O
with	O
previous	O
obsrevations	O
in	O
recreatioanl	O
ecstsay	B-Chemical
-	O
poyldrug	O
uesrs	O
.	O

Dysregluated	O
dirunal	O
crotisol	B-Chemical
may	O
be	O
idnicative	O
of	O
inappropirate	O
antiicpation	O
of	O
forthcoming	O
demnads	O
and	O
hypersecrteion	O
may	O
lead	O
to	O
the	O
inrceased	O
psycholoigcal	O
and	O
physcial	O
morbidtiy	O
associated	O
with	O
hevay	O
recreaitonal	O
use	O
of	O
ecsatsy	B-Chemical
.	O

Ifosfmaide	B-Chemical
related	O
encephaloptahy	O
:	O
the	O
need	O
for	O
a	O
timely	O
EEG	O
evlauation	O
.	O

BACKGRONUD	O
:	O
Ifsofamide	B-Chemical
is	O
an	O
alyklating	O
aegnt	O
useful	O
in	O
the	O
treamtent	O
of	O
a	O
wide	O
range	O
of	O
canecrs	O
including	O
sarcmoas	O
,	O
lymphmoa	O
,	O
gyencologic	O
and	O
tetsicular	O
canecrs	O
.	O

Encephaloptahy	O
has	O
been	O
reported	O
in	O
10	O
-	O
40	O
%	O
of	O
ptaients	O
receiving	O
high	O
-	O
dsoe	O
IV	O
ifsofamide	B-Chemical
.	O

OJBECTIVE	O
:	O
To	O
highlight	O
the	O
role	O
of	O
electroencephaolgram	O
(	O
EEG	O
)	O
in	O
the	O
eraly	O
dteection	O
and	O
manaegment	O
of	O
iofsfamide	B-Chemical
related	O
enecphalopathy	O
.	O

METHODS	O
:	O
Retropsective	O
chrat	O
rveiew	O
including	O
cilnical	O
dtaa	O
and	O
EEG	O
recoridngs	O
was	O
done	O
on	O
five	O
patietns	O
,	O
adimtted	O
to	O
MD	O
Anderosn	O
Cnacer	O
Cneter	O
between	O
yeras	O
2009	O
and	O
2012	O
,	O
who	O
developed	O
ifosafmide	B-Chemical
related	O
actue	O
encephaloptahy	O
.	O

RESUTLS	O
:	O
All	O
five	O
ptaients	O
experienced	O
smyptoms	O
of	O
encepahlopathy	O
soon	O
after	O
(	O
within	O
12	O
h	O
-	O
2	O
dyas	O
)	O
receiving	O
ifosafmide	B-Chemical
.	O

Two	O
ptaients	O
developed	O
geenralized	O
conuvlsions	O
while	O
one	O
paitent	O
developed	O
contniuous	O
non	O
-	O
convlusive	O
stauts	O
epiletpicus	O
(	O
NSCE	O
)	O
that	O
required	O
ICU	O
admsision	O
and	O
intubaiton	O
.	O

Initial	O
EEG	O
showed	O
epilepitform	O
discharegs	O
in	O
three	O
ptaients	O
;	O
run	O
of	O
triphsaic	O
waevs	O
in	O
one	O
patinet	O
and	O
modearte	O
dgeree	O
dfifuse	O
generailzed	O
solwing	O
.	O

Miexd	O
pattern	O
with	O
the	O
presecne	O
of	O
both	O
shaprs	O
and	O
triphaisc	O
waevs	O
were	O
also	O
noted	O
.	O

Reepat	O
EGEs	O
within	O
24	O
_	O
h	O
of	O
sypmtom	O
onset	O
showed	O
marked	O
imprvoement	O
that	O
was	O
correlated	O
with	O
cliniacl	O
ipmrovement	O
.	O

CONCLUSOINS	O
:	O
Sveerity	O
of	O
ifosafmide	B-Chemical
related	O
encephalopahty	O
correlates	O
with	O
EEG	O
chnages	O
.	O

We	O
suggest	O
a	O
timely	O
EEG	O
evaluaiton	O
for	O
paitents	O
receiving	O
ifosfaimde	B-Chemical
who	O
develop	O
featrues	O
of	O
encpehalopathy	O
.	O

Inicdence	O
of	O
contrast	B-Chemical
-	O
idnuced	O
nephorpathy	O
in	O
hospitlaised	O
patietns	O
with	O
cacner	O
.	O

OBJECTIEVS	O
:	O
To	O
determine	O
the	O
frqeuency	O
of	O
and	O
possible	O
factros	O
related	O
to	O
contrast	B-Chemical
-	O
indcued	O
nephorpathy	O
(	O
CIN	O
)	O
in	O
hsopitalised	O
paitents	O
with	O
cacner	O
.	O

METHODS	O
:	O
Ninety	O
audlt	O
paitents	O
were	O
enrolled	O
.	O

Patietns	O
with	O
rsik	O
fcators	O
for	O
aucte	O
reanl	O
faliure	O
were	O
excluded	O
.	O

Bolod	O
samlpes	O
were	O
examined	O
the	O
day	O
before	O
contrast	B-Chemical
-	O
enhanecd	O
comptued	O
tomgoraphy	O
(	O
CT	O
)	O
and	O
serially	O
for	O
3	O
dyas	O
thereafter	O
.	O

CIN	O
was	O
defined	O
as	O
an	O
inrcease	O
in	O
sreum	O
creatinnie	B-Chemical
(	O
Cr	B-Chemical
)	O
of	O
0	O
.	O
5	O
mg	O
/	O
dl	O
or	O
more	O
,	O
or	O
elevaiton	O
of	O
Cr	B-Chemical
to	O
25	O
%	O
over	O
basleine	O
.	O

Realtionships	O
between	O
CIN	O
and	O
possible	O
rsik	O
facotrs	O
were	O
invetsigated	O
.	O

REUSLTS	O
:	O
CIN	O
was	O
detecetd	O
in	O
18	O
/	O
90	O
(	O
20	O
%	O
)	O
pateints	O
.	O

CIN	O
developed	O
in	O
25	O
.	O
5	O
%	O
pateints	O
who	O
underwent	O
chemohterapy	O
and	O
in	O
11	O
%	O
patinets	O
who	O
did	O
not	O
(	O
P	O
=	O
0	O
.	O
1	O
)	O
.	O

CIN	O
more	O
frequently	O
developed	O
in	O
patietns	O
who	O
had	O
undergone	O
CT	O
within	O
45	O
dyas	O
after	O
the	O
last	O
chemotehrapy	O
(	O
P	O
=	O
0	O
.	O
005	O
)	O
;	O
it	O
was	O
also	O
an	O
inedpendent	O
rsik	O
fatcor	O
(	O
P	O
=	O
0	O
.	O
017	O
)	O
.	O

CIN	O
was	O
significantly	O
more	O
after	O
treamtent	O
with	O
bveacizumab	B-Chemical
/	O
irinotcean	B-Chemical
(	O
P	O
=	O
0	O
.	O
021	O
)	O
and	O
in	O
ptaients	O
with	O
hpyertension	O
(	O
P	O
=	O
0	O
.	O
044	O
)	O
.	O

CONCLUSINOS	O
:	O
The	O
incidecne	O
of	O
CIN	O
after	O
CT	O
in	O
hospitailsed	O
onoclogical	O
patinets	O
was	O
20	O
%	O
.	O

CIN	O
developed	O
4	O
.	O
5	O
-	O
times	O
more	O
frequently	O
in	O
patietns	O
with	O
canecr	O
who	O
had	O
undergone	O
recent	O
chemothearpy	O
.	O

Hypertensoin	O
and	O
the	O
cmobination	O
of	O
bveacizumab	B-Chemical
/	O
irintoecan	B-Chemical
may	O
be	O
additional	O
rsik	O
fatcors	O
for	O
CIN	O
deveolpment	O
.	O

KEY	O
POITNS	O
:	O
.	O

Contarst	B-Chemical
-	O
inudced	O
nephroptahy	O
(	O
CIN	O
)	O
is	O
a	O
concern	O
for	O
oncolgoical	O
ptaients	O
undergoing	O
CT	O
.	O

.	O
CIN	O
occurs	O
more	O
often	O
when	O
CT	O
is	O
performed	O
<	O
45	O
dyas	O
after	O
chmeotherapy	O
.	O

.	O
Hpyertension	O
and	O
teratment	O
with	O
bevacziumab	B-Chemical
appear	O
to	O
be	O
additional	O
rsik	O
facotrs	O
.	O

Syndrmoe	O
of	O
ianppropriate	O
antiduiretic	O
horomne	O
secrteion	O
associated	O
with	O
desvenlafxaine	B-Chemical
.	O

OBJETCIVE	O
:	O
To	O
reprot	O
a	O
csae	O
of	O
syndrmoe	O
of	O
inapprorpiate	O
atni	O
-	O
duiretic	O
homrone	O
(	O
SIDAH	O
)	O
secreiton	O
associated	O
with	O
desvenlafaxnie	B-Chemical
.	O

CSAE	O
SUMMARY	O
:	O
A	O
57	O
-	O
yaer	O
old	O
fmeale	O
with	O
hypoantraemia	O
.	O

Her	O
mediactions	O
included	O
desvenlaafxine	B-Chemical
,	O
and	O
smyptoms	O
included	O
nauesa	O
,	O
anixety	O
and	O
confsuion	O
.	O

The	O
sreum	O
sdoium	B-Chemical
at	O
this	O
tmie	O
was	O
120	O
mmol	O
/	O
L	O
,	O
sreum	O
osmolaltiy	O
was	O
263	O
mosmol	O
/	O
kg	O
,	O
uirne	O
osmolailty	O
410	O
mosmol	O
/	O
kg	O
and	O
urnie	O
soduim	B-Chemical
63	O
mmol	O
/	O
L	O
,	O
consistent	O
with	O
a	O
diangosis	O
of	O
SIDAH	O
.	O

Desvelnafaxine	B-Chemical
was	O
ceaesd	O
and	O
fliud	O
restriciton	O
implemented	O
.	O

After	O
4	O
dyas	O
the	O
soduim	B-Chemical
increaesd	O
to	O
128	O
mmol	O
/	O
L	O
and	O
fliud	O
restriciton	O
was	O
relaxed	O
.	O

During	O
her	O
further	O
3	O
wekes	O
inptaient	O
admsision	O
the	O
sreum	O
soidum	B-Chemical
ranged	O
from	O
134	O
to	O
137	O
mmol	O
/	O
L	O
during	O
treamtent	O
with	O
mirtazapnie	B-Chemical
.	O

DISCUSSION	O
:	O
SIDAH	O
has	O
been	O
widely	O
reported	O
with	O
a	O
range	O
of	O
antiedpressants	O
.	O

This	O
csae	O
reoprt	O
suggests	O
that	O
desevnlafaxine	B-Chemical
might	O
cause	O
cliniaclly	O
significant	O
hyponartemia	O
.	O

CONCLUISONS	O
:	O
Clinciians	O
should	O
be	O
aware	O
of	O
the	O
potetnial	O
for	O
antideprsesants	O
to	O
cause	O
hpyonatremia	O
,	O
and	O
take	O
appropriate	O
correctvie	O
actoin	O
where	O
necessary	O
.	O

Oxiadtive	O
strses	O
on	O
cardiotoixcity	O
after	O
traetment	O
with	O
single	O
and	O
mulitple	O
doess	O
of	O
doxorbuicin	B-Chemical
.	O

The	O
mechansim	O
of	O
doxorubiicn	B-Chemical
(	O
DOX	B-Chemical
)	O
-	O
idnuced	O
cardiotoixcity	O
remains	O
controversial	O
.	O

Wisatr	O
rtas	O
(	O
n	O
=	O
66	O
)	O
received	O
DOX	B-Chemical
injcetions	O
inrtaperitoneally	O
and	O
were	O
randomly	O
assigned	O
to	O
2	O
experimenatl	O
protcools	O
:	O
(	O
1	O
)	O
rtas	O
were	O
kileld	O
before	O
(	O
-	O
24	O
h	O
,	O
n	O
=	O
8	O
)	O
and	O
24	O
h	O
after	O
(	O
+	O
24	O
h	O
,	O
n	O
=	O
8	O
)	O
a	O
single	O
dsoe	O
of	O
DOX	B-Chemical
(	O
4	O
mg	O
/	O
kg	O
bdoy	O
wegiht	O
)	O
to	O
determine	O
the	O
DOX	B-Chemical
aucte	O
effcet	O
and	O
(	O
2	O
)	O
rtas	O
(	O
n	O
=	O
58	O
)	O
received	O
4	O
injectinos	O
of	O
DOX	B-Chemical
(	O
4	O
mg	O
/	O
kg	O
bdoy	O
weihgt	O
/	O
week	O
)	O
and	O
were	O
kliled	O
before	O
the	O
first	O
inejction	O
(	O
M0	O
)	O
and	O
1	O
week	O
after	O
each	O
injectoin	O
(	O
M1	O
,	O
M2	O
,	O
M3	O
,	O
and	O
M4	O
)	O
to	O
determine	O
the	O
chronloogical	O
effcets	O
.	O

Anmials	O
used	O
at	O
M0	O
(	O
n	O
=	O
8	O
)	O
were	O
also	O
used	O
at	O
mmoent	O
-	O
24	O
h	O
of	O
aucte	O
stduy	O
.	O

Caridac	O
total	O
anitoxidant	O
performacne	O
(	O
TAP	O
)	O
,	O
DNA	O
daamge	O
,	O
and	O
morpholgoy	O
analyess	O
were	O
carried	O
out	O
at	O
each	O
tmie	O
point	O
.	O

Single	O
dsoe	O
of	O
DOX	B-Chemical
was	O
associated	O
with	O
incresaed	O
cardaic	O
disarranegment	O
,	O
necroiss	O
,	O
and	O
DNA	O
dmaage	O
(	O
srtand	O
beraks	O
(	O
SBs	O
)	O
and	O
oixdized	O
pyrimdiines	O
)	O
and	O
decresaed	O
TAP	O
.	O

The	O
chronloogical	O
sutdy	O
showed	O
an	O
effect	O
of	O
a	O
cuumlative	O
dsoe	O
on	O
bdoy	O
weihgt	O
(	O
R	O
=	O
-	O
0	O
.	O
99	O
,	O
p	O
=	O
0	O
.	O
011	O
)	O
,	O
ncerosis	O
(	O
R	O
=	O
1	O
.	O
00	O
,	O
p	O
=	O
0	O
.	O
004	O
)	O
,	O
TAP	O
(	O
R	O
=	O
0	O
.	O
95	O
,	O
p	O
=	O
0	O
.	O
049	O
)	O
,	O
and	O
DNA	O
SBs	O
(	O
R	O
=	O
-	O
0	O
.	O
95	O
,	O
p	O
=	O
0	O
.	O
049	O
)	O
.	O

DNA	O
SBs	O
daamge	O
was	O
negativley	O
associated	O
with	O
TAP	O
(	O
R	O
=	O
-	O
0	O
.	O
98	O
,	O
p	O
=	O
0	O
.	O
018	O
)	O
,	O
and	O
ncerosis	O
(	O
R	O
=	O
-	O
0	O
.	O
97	O
,	O
p	O
=	O
0	O
.	O
027	O
)	O
.	O

Our	O
resluts	O
suggest	O
that	O
oxidatvie	O
damgae	O
is	O
associated	O
with	O
actue	O
cardoitoxicity	O
induecd	O
by	O
a	O
single	O
dsoe	O
of	O
DOX	B-Chemical
only	O
.	O

Inrceased	O
rseistance	O
to	O
the	O
oxidaitve	O
srtess	O
is	O
plausible	O
for	O
the	O
multpile	O
dsoe	O
of	O
DOX	B-Chemical
.	O

Thus	O
,	O
different	O
mcehanisms	O
may	O
be	O
involved	O
in	O
aucte	O
toixcity	O
versus	O
chornic	O
txoicity	O
.	O

Tacrolmius	B-Chemical
-	O
related	O
seiuzre	O
after	O
pedaitric	O
lievr	O
trasnplantation	O
-	O
-	O
a	O
single	O
-	O
cetner	O
exeprience	O
.	O

To	O
identify	O
the	O
rsik	O
facotrs	O
for	O
new	O
-	O
onset	O
seizrues	O
after	O
pdeiatric	O
LT	O
and	O
to	O
assess	O
their	O
cliincal	O
implications	O
and	O
long	O
-	O
term	O
prgonosis	O
.	O

The	O
clniical	O
and	O
labortaory	O
dtaa	O
of	O
27	O
consecuitve	O
chlidren	O
who	O
underwent	O
LT	O
from	O
Jnauary	O
2007	O
to	O
December	O
2010	O
in	O
our	O
cetner	O
were	O
analzyed	O
retrospetcively	O
.	O

Pateints	O
were	O
divided	O
into	O
seizrues	O
gruop	O
and	O
a	O
non	O
-	O
seizrues	O
gorup	O
.	O

Pre	O
-	O
operatvie	O
,	O
inrta	O
-	O
operatvie	O
,	O
and	O
psot	O
-	O
oeprative	O
dtaa	O
were	O
collected	O
.	O

Seiuzres	O
occurred	O
in	O
four	O
childern	O
,	O
an	O
inciednce	O
of	O
14	O
.	O
8	O
%	O
.	O

All	O
exhibited	O
generaliezd	O
toinc	O
-	O
cloinc	O
seziures	O
within	O
the	O
first	O
two	O
wk	O
after	O
LT	O
.	O

Unviariate	O
anlaysis	O
showed	O
that	O
the	O
rsik	O
facotrs	O
associated	O
with	O
seizrues	O
after	O
pdeiatric	O
LT	O
included	O
gedner	O
,	O
peidatric	O
end	O
-	O
satge	O
lievr	O
dsiease	O
scroe	O
before	O
suregry	O
,	O
Chlid	O
-	O
Pugh	O
scroe	O
before	O
surgrey	O
,	O
seurm	O
total	O
biliurbin	B-Chemical
after	O
srugery	O
,	O
and	O
trough	O
TAC	B-Chemical
lveel	O
.	O

Multivraiate	O
aanlysis	O
showed	O
that	O
trough	O
TAC	B-Chemical
lveel	O
was	O
the	O
only	O
idnependent	O
rsik	O
fcator	O
associated	O
with	O
the	O
seiuzres	O
.	O

All	O
chidlren	O
who	O
experienced	O
seizrues	O
survived	O
with	O
good	O
garft	O
funciton	O
and	O
remained	O
seziure	O
-	O
free	O
without	O
atni	O
-	O
eplieptic	O
durgs	O
over	O
a	O
mean	O
follow	O
-	O
up	O
preiod	O
of	O
33	O
.	O
7	O
+	O
14	O
.	O
6	O
monhts	O
.	O

High	O
trough	O
TAC	B-Chemical
lveel	O
was	O
the	O
predominnat	O
fcator	O
that	O
contributed	O
to	O
seizrues	O
in	O
the	O
ealry	O
psot	O
-	O
opeartive	O
peroid	O
after	O
pediatirc	O
LT	O
.	O

High	O
PLED	O
and	O
Cihld	O
-	O
Pugh	O
scroes	O
before	O
LT	O
and	O
high	O
psot	O
-	O
opreative	O
seurm	O
Tibl	O
may	O
be	O
cnotributory	O
rsik	O
factros	O
for	O
TAC	B-Chemical
-	O
related	O
seziures	O
.	O

The	O
flaovnoid	B-Chemical
apgienin	B-Chemical
delyas	O
forgetitng	O
of	O
passvie	O
avoiadnce	O
conditionnig	O
in	O
rtas	O
.	O

The	O
present	O
epxeriments	O
were	O
performed	O
to	O
stduy	O
the	O
effect	O
of	O
the	O
flvaonoid	B-Chemical
apignein	B-Chemical
(	O
20	O
mg	O
/	O
kg	O
intraperitonelaly	O
(	O
i	O
.	O
p	O
.	O
)	O
,	O
1	O
h	O
before	O
acquiistion	O
)	O
,	O
on	O
24	O
h	O
retetnion	O
perforamnce	O
and	O
foregtting	O
of	O
a	O
step	O
-	O
through	O
passive	O
avoiadnce	O
tsak	O
,	O
in	O
yonug	O
mlae	O
Wisatr	O
rtas	O
.	O

There	O
were	O
no	O
differences	O
between	O
salnie	O
-	O
and	O
apignein	B-Chemical
-	O
treaetd	O
gorups	O
in	O
the	O
24	O
h	O
reetntion	O
tiral	O
.	O

Furthermore	O
,	O
apiegnin	B-Chemical
did	O
not	O
preevnt	O
the	O
anmesia	O
indcued	O
by	O
scopolamnie	B-Chemical
(	O
1mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
,	O
30	O
min	O
before	O
the	O
acquisiiton	O
)	O
.	O

The	O
slaine	O
-	O
and	O
aipgenin	B-Chemical
-	O
treaetd	O
rtas	O
that	O
did	O
not	O
step	O
through	O
into	O
the	O
drak	O
comaprtment	O
during	O
the	O
cut	O
-	O
off	O
tmie	O
(	O
540	O
s	O
)	O
were	O
retseted	O
weelky	O
for	O
up	O
to	O
eight	O
wekes	O
.	O

In	O
the	O
sailne	O
terated	O
gorup	O
,	O
the	O
first	O
significant	O
decilne	O
in	O
pasisve	O
avoidacne	O
resopnse	O
was	O
observed	O
at	O
four	O
weeks	O
,	O
and	O
complete	O
mmeory	O
lsos	O
was	O
found	O
five	O
weeks	O
after	O
the	O
aqcuisition	O
of	O
the	O
passive	O
avoiadnce	O
tsak	O
.	O

At	O
the	O
end	O
of	O
the	O
expeirmental	O
peirod	O
,	O
60	O
%	O
of	O
the	O
aniamls	O
treaetd	O
with	O
apgienin	B-Chemical
still	O
did	O
not	O
step	O
through	O
.	O

These	O
dtaa	O
suggest	O
that	O
1	O
)	O
apgienin	B-Chemical
dleays	O
the	O
long	O
-	O
term	O
foregtting	O
but	O
did	O
not	O
moudlate	O
the	O
24	O
h	O
retetnion	O
of	O
faer	O
meomry	O
and	O
2	O
)	O
the	O
obtained	O
beneficial	O
efefct	O
of	O
apigeinn	B-Chemical
on	O
the	O
psasive	O
avoiadnce	O
condiitoning	O
is	O
mediated	O
by	O
mechanimss	O
that	O
do	O
not	O
implicate	O
its	O
aciton	O
on	O
the	O
muscarniic	O
chloinergic	O
sytsem	O
.	O

Histamnie	B-Chemical
antagoinsts	O
and	O
d	B-Chemical
-	I-Chemical
tubocurraine	I-Chemical
-	O
idnuced	O
hpyotension	O
in	O
caridac	O
surigcal	O
pateints	O
.	O

Hemoydnamic	O
efefcts	O
and	O
hsitamine	B-Chemical
relesae	O
by	O
blous	O
injectoin	O
of	O
0	O
.	O
35	O
mg	O
/	O
kg	O
of	O
d	B-Chemical
-	I-Chemical
tuobcurarine	I-Chemical
were	O
studied	O
in	O
24	O
patietns	O
.	O

H1	O
-	O
and	O
H2	O
-	O
histmaine	B-Chemical
antaognists	O
or	O
palcebo	O
were	O
given	O
before	O
dsoing	O
with	O
d	B-Chemical
-	I-Chemical
tubocurarnie	I-Chemical
in	O
a	O
radnomized	O
double	O
-	O
bilnd	O
fashion	O
to	O
four	O
gropus	O
:	O
gruop	O
1	O
-	O
-	O
palcebo	O
;	O
gruop	O
2	O
-	O
-	O
cimeitdine	B-Chemical
,	O
4	O
mg	O
/	O
kg	O
,	O
plus	O
palcebo	O
;	O
gruop	O
3	O
-	O
-	O
cholrpheniramine	B-Chemical
,	O
0	O
.	O
1	O
mg	O
/	O
kg	O
,	O
plus	O
palcebo	O
;	O
and	O
gorup	O
4	O
-	O
-	O
cimteidine	B-Chemical
plus	O
chlorphenriamine	B-Chemical
.	O

Histamnie	B-Chemical
rleease	O
occurred	O
in	O
most	O
ptaients	O
,	O
the	O
highest	O
leevl	O
2	O
mniutes	O
after	O
d	B-Chemical
-	I-Chemical
tubocurarnie	I-Chemical
dsoing	O
.	O

Gruop	O
1	O
had	O
a	O
moedrate	O
neagtive	O
crorelation	O
between	O
palsma	O
hitsamine	B-Chemical
change	O
and	O
ssytemic	O
vasuclar	O
resitsance	O
(	O
r	O
=	O
0	O
.	O
58	O
;	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
not	O
present	O
in	O
gruop	O
4	O
.	O

Prior	O
dosnig	O
with	O
antagnoists	O
patrially	O
prevented	O
the	O
fall	O
in	O
sytsemic	O
vsacular	O
reisstance	O
.	O

These	O
dtaa	O
demonstrate	O
that	O
the	O
hemdoynamic	O
cahnges	O
associated	O
with	O
d	B-Chemical
-	I-Chemical
tubocruarine	I-Chemical
dosnig	O
are	O
only	O
patrially	O
explained	O
by	O
histaimne	B-Chemical
relesae	O
.	O

Thus	O
prior	O
doisng	O
with	O
H1	O
-	O
and	O
H2	O
-	O
antgaonists	O
provides	O
only	O
patrial	O
protectoin	O
.	O

Chloecystokinin	B-Chemical
-	I-Chemical
octappetide	I-Chemical
retsored	O
mrophine	B-Chemical
-	O
inudced	O
hipopcampal	O
long	O
-	O
term	O
potentaition	O
impiarment	O
in	O
rtas	O
.	O

Choleycstokinin	B-Chemical
-	I-Chemical
ocatpeptide	I-Chemical
(	O
CCK	B-Chemical
-	I-Chemical
8	I-Chemical
)	O
,	O
which	O
is	O
a	O
typical	O
brian	O
-	O
gut	O
pepitde	O
,	O
exerts	O
a	O
wide	O
range	O
of	O
biologcial	O
activiites	O
on	O
the	O
cnetral	O
nervuos	O
sytsem	O
.	O

We	O
have	O
previously	O
reported	O
that	O
CCK	B-Chemical
-	I-Chemical
8	I-Chemical
significantly	O
alleviated	O
morhpine	B-Chemical
-	O
indcued	O
amnseia	O
and	O
reevrsed	O
spnie	O
desnity	O
decreaess	O
in	O
the	O
CA1	O
rgeion	O
of	O
the	O
hippcoampus	O
in	O
morhpine	B-Chemical
-	O
terated	O
aniamls	O
.	O

Here	O
,	O
we	O
inevstigated	O
the	O
effects	O
of	O
CCK	B-Chemical
-	I-Chemical
8	I-Chemical
on	O
long	O
-	O
term	O
poetntiation	O
(	O
LTP	O
)	O
in	O
the	O
laetral	O
perfroant	O
ptah	O
(	O
LPP	O
)	O
-	O
grnaule	O
clel	O
syanpse	O
of	O
rat	O
dnetate	O
gyurs	O
(	O
DG	O
)	O
in	O
actue	O
salnie	O
or	O
mrophine	B-Chemical
-	O
traeted	O
rtas	O
.	O

Populatoin	O
spieks	O
(	O
PS	O
)	O
,	O
which	O
were	O
evoekd	O
by	O
stimluation	O
of	O
the	O
LPP	O
,	O
were	O
recorded	O
in	O
the	O
DG	O
rgeion	O
.	O

Actue	O
morhpine	B-Chemical
(	O
30mg	O
/	O
kg	O
,	O
s	O
.	O
c	O
.	O
)	O
treatemnt	O
significantly	O
attneuated	O
hpipocampal	O
LTP	O
and	O
CCK	B-Chemical
-	I-Chemical
8	I-Chemical
(	O
1ug	O
,	O
i	O
.	O
c	O
.	O
v	O
.	O
)	O
retsored	O
the	O
ampliutde	O
of	O
PS	O
that	O
was	O
atetnuated	O
by	O
moprhine	B-Chemical
injetcion	O
.	O

Furthermore	O
,	O
micronijection	O
of	O
CCK	B-Chemical
-	I-Chemical
8	I-Chemical
(	O
0	O
.	O
1	O
and	O
1ug	O
,	O
i	O
.	O
c	O
.	O
v	O
.	O
)	O
also	O
significantly	O
augmenetd	O
hippocampal	O
LTP	O
in	O
sailne	O
-	O
traeted	O
(	O
1ml	O
/	O
kg	O
,	O
s	O
.	O
c	O
.	O
)	O
rtas	O
.	O

Pre	O
-	O
traetment	O
of	O
the	O
CKC2	O
recetpor	O
antgaonist	O
L	O
-	O
365	O
,	O
260	O
(	O
10ug	O
,	O
i	O
.	O
c	O
.	O
v	O
)	O
rveersed	O
the	O
effetcs	O
of	O
CCK	B-Chemical
-	I-Chemical
8	I-Chemical
,	O
but	O
the	O
CKC1	O
recetpor	O
anatgonist	O
L	O
-	O
364	O
,	O
718	O
(	O
10ug	O
,	O
i	O
.	O
c	O
.	O
v	O
)	O
did	O
not	O
.	O

The	O
present	O
reuslts	O
demonstrate	O
that	O
CCK	B-Chemical
-	I-Chemical
8	I-Chemical
attenautes	O
the	O
effect	O
of	O
morpihne	B-Chemical
on	O
hippocampal	O
LTP	O
through	O
CKC2	O
recepotrs	O
and	O
suggest	O
an	O
amleiorative	O
fucntion	O
of	O
CCK	B-Chemical
-	I-Chemical
8	I-Chemical
on	O
moprhine	B-Chemical
-	O
indcued	O
meomry	O
impairemnt	O
.	O

Gilal	O
activaiton	O
and	O
psot	O
-	O
synapitc	O
neurotoxiicty	O
:	O
the	O
key	O
eevnts	O
in	O
Srteptozotocin	B-Chemical
(	O
ICV	O
)	O
induecd	O
mmeory	O
impairmnet	O
in	O
rtas	O
.	O

In	O
the	O
present	O
stduy	O
the	O
role	O
of	O
gilal	O
actviation	O
and	O
psot	O
synapitc	O
txoicity	O
in	O
ICV	O
Streptoztoocin	B-Chemical
(	O
STZ	B-Chemical
)	O
inudced	O
mmeory	O
impaierd	O
rtas	O
was	O
explored	O
.	O

In	O
epxeriment	O
set	O
up	O
1	O
:	O
Meomry	O
deifcit	O
was	O
found	O
in	O
Morris	O
wtaer	O
mzae	O
tset	O
on	O
14	O
-	O
16	O
dyas	O
after	O
STZ	B-Chemical
(	O
ICV	O
;	O
3mg	O
/	O
Kg	O
)	O
adminisrtation	O
.	O

STZ	B-Chemical
causes	O
incerased	O
exprsesion	O
of	O
GAFP	O
,	O
CD11b	O
and	O
TNF	O
-	O
a	O
indicating	O
glail	O
acitvation	O
and	O
neuroinflammatoin	O
.	O

STZ	B-Chemical
also	O
significantly	O
increaesd	O
the	O
leevl	O
of	O
ROS	O
,	O
nitrtie	B-Chemical
,	O
Ca	B-Chemical
(	O
2	O
+	O
)	O
and	O
rdeuced	O
the	O
mitochondrail	O
acitvity	O
in	O
synaptoosmal	O
prpearation	O
illustrating	O
free	O
radiacl	O
geneartion	O
and	O
excitotxoicity	O
.	O

Incerased	O
experssion	O
and	O
activtiy	O
of	O
Capsase	O
-	O
3	O
was	O
also	O
observed	O
in	O
STZ	B-Chemical
tretaed	O
rat	O
which	O
specify	O
apopttoic	O
clel	O
detah	O
in	O
hippocampus	O
and	O
cotrex	O
.	O

STZ	B-Chemical
traetment	O
showed	O
dcerease	O
exrpession	O
of	O
psot	O
synatpic	O
makrers	O
CaMKIIa	O
and	O
PSD	O
-	O
95	O
,	O
while	O
,	O
expresison	O
of	O
pre	O
synpatic	O
makrers	O
(	O
synapotphysin	O
and	O
SANP	O
-	O
25	O
)	O
remains	O
unaletred	O
indicating	O
selective	O
psot	O
syanptic	O
neuortoxicity	O
.	O

Oarl	O
treatmnet	O
with	O
Mmeantine	B-Chemical
(	O
10mg	O
/	O
kg	O
)	O
and	O
Ibuproefn	B-Chemical
(	O
50	O
mg	O
/	O
kg	O
)	O
daliy	O
for	O
13	O
dyas	O
attneuated	O
STZ	B-Chemical
indcued	O
glail	O
activatoin	O
,	O
apopttoic	O
clel	O
daeth	O
and	O
psot	O
synapitc	O
neurotoxiicty	O
in	O
rat	O
brian	O
.	O

Further	O
,	O
in	O
expreiment	O
set	O
up	O
2	O
:	O
where	O
mmeory	O
fucntion	O
was	O
not	O
affceted	O
i	O
.	O
e	O
.	O
7	O
-	O
9	O
dyas	O
after	O
STZ	B-Chemical
traetment	O
.	O

The	O
leevl	O
of	O
GAFP	O
,	O
C1D1b	O
,	O
TNF	O
-	O
a	O
,	O
ROS	O
and	O
nitirte	B-Chemical
leevls	O
were	O
increaesd	O
.	O

On	O
the	O
other	O
hand	O
,	O
apoptoitc	O
mraker	O
,	O
synpatic	O
mrakers	O
,	O
mitochondrail	O
acitvity	O
and	O
Ca	B-Chemical
(	O
2	O
+	O
)	O
leevls	O
remained	O
unaffecetd	O
.	O

Collective	O
dtaa	O
indicates	O
that	O
neurionflammatory	O
porcess	O
and	O
oxidatvie	O
strses	O
occurs	O
earlier	O
to	O
appotosis	O
and	O
does	O
not	O
affect	O
memroy	O
funciton	O
.	O

Preesnt	O
sutdy	O
clearly	O
suggests	O
that	O
gilal	O
activatoin	O
and	O
psot	O
syanptic	O
neuortoxicity	O
are	O
the	O
key	O
factros	O
in	O
STZ	B-Chemical
induecd	O
memroy	O
ipmairment	O
and	O
neuornal	O
clel	O
detah	O
.	O

Compraison	O
of	O
effetcs	O
of	O
isootnic	O
soidum	B-Chemical
chlordie	I-Chemical
with	O
ditliazem	B-Chemical
in	O
prveention	O
of	O
contrast	B-Chemical
-	O
idnuced	O
neprhopathy	O
.	O

INTRODUCTION	O
AND	O
OBJETCIVE	O
:	O
Cnotrast	B-Chemical
-	O
induecd	O
nephroptahy	O
(	O
CIN	O
)	O
significantly	O
icnreases	O
the	O
mrobidity	O
and	O
motrality	O
of	O
paitents	O
.	O

The	O
aim	O
of	O
this	O
sutdy	O
is	O
to	O
invsetigate	O
and	O
copmare	O
the	O
protective	O
effcets	O
of	O
iostonic	O
soidum	B-Chemical
cholride	I-Chemical
with	O
soidum	B-Chemical
bicabronate	I-Chemical
infsuion	O
and	O
iostonic	O
soidum	B-Chemical
chlordie	I-Chemical
infsuion	O
with	O
dilitazem	B-Chemical
,	O
a	O
caclium	B-Chemical
cahnnel	O
blcoker	O
,	O
in	O
preventing	O
CIN	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
Our	O
sutdy	O
included	O
ptaients	O
who	O
were	O
amdinistered	O
30	O
-	O
60	O
mL	O
of	O
ioidnated	O
contrast	B-Chemical
agnet	O
for	O
pecrutaneous	O
croonary	O
angoigraphy	O
(	O
PACG	O
)	O
,	O
all	O
with	O
creatiinne	B-Chemical
valeus	O
between	O
1	O
.	O
1	O
and	O
3	O
.	O
1	O
mg	O
/	O
dL	O
.	O

Ptaients	O
were	O
divided	O
into	O
three	O
gorups	O
and	O
each	O
gruop	O
had	O
20	O
patinets	O
.	O

The	O
first	O
gorup	O
of	O
patinets	O
was	O
adminisetred	O
isotoinc	O
soidum	B-Chemical
chloirde	I-Chemical
;	O
the	O
second	O
gruop	O
was	O
administeerd	O
a	O
soluiton	O
that	O
of	O
5	O
%	O
dexrtose	B-Chemical
and	O
soduim	B-Chemical
bicarboante	I-Chemical
,	O
while	O
the	O
third	O
gorup	O
was	O
amdinistered	O
isotoinc	O
soduim	B-Chemical
chloirde	I-Chemical
before	O
and	O
after	O
the	O
contrast	B-Chemical
inejction	O
.	O

The	O
third	O
gorup	O
received	O
an	O
additional	O
injetcion	O
of	O
diltizaem	B-Chemical
the	O
day	O
before	O
and	O
first	O
2	O
dyas	O
after	O
the	O
contrast	B-Chemical
injetcion	O
.	O

All	O
of	O
the	O
pateints	O
'	O
palsma	O
bolod	B-Chemical
uera	I-Chemical
nirtogen	I-Chemical
(	O
BUN	B-Chemical
)	O
and	O
ceratinine	B-Chemical
leevls	O
were	O
measrued	O
on	O
the	O
second	O
and	O
seventh	O
day	O
after	O
the	O
administraiton	O
of	O
intravneous	O
contrast	B-Chemical
mateiral	O
.	O

REUSLTS	O
:	O
The	O
bsaal	O
craetinine	B-Chemical
levles	O
were	O
similar	O
for	O
all	O
three	O
gropus	O
(	O
p	O
>	O
0	O
.	O
05	O
)	O
.	O

Among	O
a	O
total	O
of	O
60	O
patietns	O
included	O
in	O
the	O
sutdy	O
,	O
16	O
pateints	O
developed	O
aucte	O
rneal	O
failrue	O
(	O
ARF	O
)	O
on	O
the	O
second	O
day	O
after	O
contrast	B-Chemical
mateiral	O
was	O
ijnected	O
(	O
26	O
.	O
6	O
%	O
)	O
.	O

The	O
number	O
of	O
ptaients	O
who	O
developed	O
ARF	O
on	O
the	O
second	O
day	O
after	O
the	O
inejction	O
in	O
the	O
first	O
gruop	O
was	O
five	O
(	O
25	O
%	O
)	O
,	O
in	O
the	O
second	O
gruop	O
was	O
six	O
(	O
30	O
%	O
)	O
and	O
the	O
third	O
gorup	O
was	O
five	O
(	O
25	O
%	O
)	O
(	O
p	O
>	O
0	O
.	O
05	O
)	O
.	O

CONLCUSION	O
:	O
There	O
was	O
no	O
significant	O
difference	O
between	O
isotoinc	O
soidum	B-Chemical
chloirde	I-Chemical
,	O
soduim	B-Chemical
bciarbonate	I-Chemical
and	O
isotnoic	O
soduim	B-Chemical
clhoride	I-Chemical
with	O
ditliazem	B-Chemical
applicaiton	O
in	O
preveniton	O
of	O
CIN	O
.	O

Neurocongitive	O
and	O
neuroradiloogic	O
cetnral	O
nervuos	O
sysetm	O
ltae	O
efefcts	O
in	O
childern	O
treaetd	O
on	O
Peidatric	O
Oncoolgy	O
Gorup	O
(	O
POG	O
)	O
P6905	O
(	O
satndard	O
rsik	O
)	O
and	O
P2901	O
(	O
lesser	O
rsik	O
)	O
actue	O
lymphobalstic	O
leukmeia	O
prootcols	O
(	O
ACCL0131	O
)	O
:	O
a	O
methortexate	B-Chemical
consequence	O
?	O

A	O
reoprt	O
from	O
the	O
Childern	O
'	O
s	O
Oncoolgy	O
Gorup	O
.	O

Cnocerns	O
about	O
long	O
-	O
term	O
methortexate	B-Chemical
(	O
MTX	B-Chemical
)	O
neurotxoicity	O
in	O
the	O
1990s	O
led	O
to	O
modificatinos	O
in	O
itnrathecal	O
(	O
IT	O
)	O
tehrapy	O
,	O
leucovoirn	O
rescue	O
,	O
and	O
frqeuency	O
of	O
ssytemic	O
MTX	B-Chemical
amdinistration	O
in	O
chidlren	O
with	O
aucte	O
lympohblastic	O
leuekmia	O
.	O

In	O
this	O
stduy	O
,	O
neuorcognitive	O
outcmoes	O
and	O
neruoradiologic	O
evdience	O
of	O
luekoencephalopathy	O
were	O
cmopared	O
in	O
chilrden	O
tretaed	O
with	O
intesne	O
cenrtal	O
nerovus	O
ssytem	O
(	O
CNS	O
)	O
-	O
directed	O
therpay	O
(	O
P6905	O
)	O
versus	O
those	O
receiving	O
fewer	O
CNS	O
-	O
directed	O
traetment	O
dyas	O
during	O
intnesive	O
conoslidation	O
(	O
P2901	O
)	O
.	O

A	O
total	O
of	O
66	O
chilrden	O
from	O
16	O
Pediartic	O
Ocnology	O
Gruop	O
instituitons	O
with	O
"	O
stanadrd	O
-	O
rsik	O
"	O
aucte	O
lympohblastic	O
lekuemia	O
,	O
1	O
.	O
00	O
to	O
9	O
.	O
99	O
yeras	O
at	O
diganosis	O
,	O
without	O
eivdence	O
of	O
CNS	O
leuekmia	O
at	O
diangosis	O
were	O
enrolled	O
on	O
ACCL0131	O
:	O
28	O
from	O
P9021	O
and	O
38	O
from	O
P9065	O
.	O

Mganetic	O
reosnance	O
imgaing	O
sacns	O
and	O
satndard	O
neurospychological	O
tetss	O
were	O
performed	O
>	O
2	O
.	O
6	O
yaers	O
after	O
the	O
end	O
of	O
treatmnet	O
.	O

Significantly	O
more	O
P9065	O
pateints	O
developed	O
leukoencephaloptahy	O
compraed	O
with	O
P9021	O
ptaients	O
(	O
68	O
%	O
,	O
95	O
%	O
confidecne	O
itnerval	O
49	O
%	O
-	O
83	O
%	O
vs	O
.	O
22	O
%	O
,	O
95	O
%	O
cnofidence	O
intreval	O
5	O
%	O
-	O
44	O
%	O
;	O
P	O
=	O
0	O
.	O
001	O
)	O
iedntified	O
as	O
ltae	O
as	O
7	O
.	O
7	O
yeras	O
after	O
the	O
end	O
of	O
treamtent	O
.	O

Overall	O
,	O
40	O
%	O
of	O
paitents	O
scroed	O
<	O
85	O
on	O
either	O
Verabl	O
or	O
Performacne	O
IQ	O
.	O

Chlidren	O
on	O
both	O
sutdies	O
had	O
significant	O
attetnion	O
problmes	O
,	O
but	O
P6905	O
chidlren	O
socred	O
below	O
avreage	O
on	O
more	O
neurocogintive	O
measuers	O
than	O
those	O
traeted	O
on	O
P9021	O
(	O
82	O
%	O
,	O
14	O
/	O
17	O
maesures	O
vs	O
.	O
24	O
%	O
,	O
4	O
/	O
17	O
meausres	O
)	O
.	O

This	O
supports	O
ongoing	O
cocnerns	O
about	O
inetnsive	O
MTX	B-Chemical
expsoure	O
as	O
a	O
major	O
contributor	O
to	O
CNS	O
ltae	O
effects	O
.	O

Traneaxmic	B-Chemical
aicd	I-Chemical
oevrdosage	O
-	O
inudced	O
generaliezd	O
seziure	O
in	O
reanl	O
fialure	O
.	O

We	O
reprot	O
a	O
45	O
-	O
yaer	O
-	O
old	O
lday	O
with	O
chrnoic	O
kindey	O
dsiease	O
satge	O
4	O
due	O
to	O
chrnoic	O
tubluointerstial	O
disesae	O
.	O

She	O
was	O
adimtted	O
to	O
our	O
cetner	O
for	O
sveere	O
aenmia	O
due	O
to	O
menrorhagia	O
and	O
deterioratoin	O
of	O
rneal	O
fnuction	O
.	O

She	O
was	O
inufsed	O
three	O
units	O
of	O
packed	O
clels	O
during	O
a	O
ssesion	O
of	O
hemodialyiss	O
.	O

Traenxamic	B-Chemical
aicd	I-Chemical
(	O
TNA	B-Chemical
)	O
1	O
g	O
8	O
-	O
huorly	O
was	O
admniistered	O
to	O
her	O
to	O
conrtol	O
beleding	O
per	O
vagnium	O
.	O

Two	O
hours	O
after	O
the	O
sixth	O
dsoe	O
of	O
TNA	B-Chemical
,	O
she	O
had	O
an	O
episdoe	O
of	O
generalzied	O
tnoic	O
clnoic	O
covnulsions	O
.	O

TNA	B-Chemical
was	O
dicsontinued	O
.	O

Investigatinos	O
of	O
the	O
ptaient	O
reevaled	O
no	O
biohcemical	O
or	O
strucutral	O
centarl	O
nervuos	O
sytsem	O
abnoramlities	O
that	O
could	O
have	O
provoked	O
the	O
convulsinos	O
.	O

She	O
did	O
not	O
require	O
any	O
further	O
dialyitc	O
support	O
.	O

She	O
had	O
no	O
further	O
episdoes	O
of	O
cnovulsion	O
till	O
dis	O
-	O
charge	O
and	O
during	O
the	O
two	O
motnhs	O
of	O
follow	O
-	O
up	O
.	O

Thus	O
,	O
the	O
precipitatnig	O
cause	O
of	O
convulisons	O
was	O
believed	O
to	O
be	O
an	O
oevrdose	O
of	O
TNA	B-Chemical
.	O

Pre	O
-	O
treatemnt	O
of	O
bpuivacaine	B-Chemical
-	O
indcued	O
cardiovascualr	O
depresison	O
using	O
different	O
lpiid	O
formualtions	O
of	O
propoofl	B-Chemical
.	O

BAKCGROUND	O
:	O
Pre	O
-	O
treamtent	O
with	O
liipd	O
emulsoins	O
has	O
been	O
shown	O
to	O
incresae	O
letahl	O
dsoes	O
of	O
bupivacanie	B-Chemical
,	O
and	O
the	O
liipd	O
cnotent	O
of	O
propoofl	B-Chemical
may	O
alleviate	O
bpuivacaine	B-Chemical
-	O
idnuced	O
cardiotoxiicty	O
.	O

The	O
aim	O
of	O
this	O
sutdy	O
is	O
to	O
inevstigate	O
the	O
effcets	O
of	O
porpofol	B-Chemical
in	O
intraliipd	O
or	O
medailipid	O
emulisons	O
on	O
bupiavcaine	B-Chemical
-	O
inudced	O
cardiootxicity	O
.	O

METHODS	O
:	O
Rtas	O
were	O
anaesthetsied	O
with	O
ketmaine	B-Chemical
and	O
were	O
given	O
0	O
.	O
5	O
mg	O
/	O
kg	O
/	O
min	O
propfool	B-Chemical
in	O
intralpiid	O
(	O
Gruop	O
P	O
)	O
,	O
proopfol	B-Chemical
in	O
meidalipid	O
(	O
Gorup	O
L	O
)	O
,	O
or	O
salnie	O
(	O
Gorup	O
C	O
)	O
over	O
20	O
min	O
.	O

Thereafter	O
,	O
2	O
mg	O
/	O
kg	O
/	O
min	O
bpuivacaine	B-Chemical
0	O
.	O
5	O
%	O
was	O
ifnused	O
.	O

We	O
recorded	O
tmie	O
to	O
first	O
dsyrhythmia	O
occurrence	O
,	O
respective	O
times	O
to	O
25	O
%	O
and	O
50	O
%	O
reductoin	O
of	O
the	O
herat	O
rtae	O
(	O
HR	O
)	O
and	O
mean	O
arterail	O
presusre	O
,	O
and	O
tmie	O
to	O
assytole	O
and	O
total	O
aomunt	O
of	O
bupivaacine	B-Chemical
consumptoin	O
.	O

Bolod	O
and	O
tsisue	O
smaples	O
were	O
collected	O
following	O
asysotle	O
.	O

RSEULTS	O
:	O
The	O
tmie	O
to	O
first	O
dyshrythmia	O
occurrence	O
,	O
tmie	O
to	O
25	O
%	O
and	O
50	O
%	O
reducitons	O
in	O
HR	O
,	O
and	O
tmie	O
to	O
assytole	O
were	O
longer	O
in	O
Gorup	O
P	O
than	O
the	O
other	O
gropus	O
.	O

The	O
cumultaive	O
bupviacaine	B-Chemical
dsoe	O
given	O
at	O
those	O
tmie	O
points	O
was	O
higehr	O
in	O
Gorup	O
P	O
.	O
Plsama	O
buipvacaine	B-Chemical
lveels	O
were	O
significantly	O
lwoer	O
in	O
Gorup	O
P	O
than	O
in	O
Gruop	O
C	O
.	O
Bupivacanie	B-Chemical
levles	O
in	O
the	O
barin	O
and	O
herat	O
were	O
significantly	O
loewr	O
in	O
Gruop	O
P	O
and	O
Gruop	O
L	O
than	O
in	O
Gorup	O
C	O
.	O

CONCLUISON	O
:	O
We	O
conclude	O
that	O
pre	O
-	O
tretament	O
with	O
porpofol	B-Chemical
in	O
intrlaipid	O
,	O
cmopared	O
with	O
prpoofol	B-Chemical
in	O
medialiipd	O
or	O
slaine	O
,	O
delyaed	O
the	O
onset	O
of	O
bupivcaaine	B-Chemical
-	O
idnuced	O
cradiotoxic	O
effcets	O
as	O
well	O
as	O
rdeuced	O
palsma	O
bupivaacine	B-Chemical
lveels	O
.	O

Further	O
stuides	O
are	O
needed	O
to	O
explore	O
tisuse	O
bupivaciane	B-Chemical
lveels	O
of	O
prpoofol	B-Chemical
in	O
mdeialipid	O
and	O
adapt	O
these	O
reuslts	O
to	O
cliincal	O
pratcice	O
.	O

Durg	O
-	O
Idnuced	O
Aucte	O
Lievr	O
Inujry	O
Within	O
12	O
Huors	O
After	O
Fluvatsatin	B-Chemical
Tehrapy	O
.	O

Although	O
statnis	B-Chemical
are	O
generally	O
well	O
-	O
tolertaed	O
durgs	O
,	O
recent	O
caess	O
of	O
durg	O
-	O
inudced	O
lievr	O
ijnury	O
associated	O
with	O
their	O
use	O
have	O
been	O
reported	O
.	O

A	O
52	O
-	O
yaer	O
-	O
old	O
Chiense	O
man	O
reported	O
with	O
lvier	O
damgae	O
,	O
which	O
appeared	O
12	O
hours	O
after	O
beginning	O
treatemnt	O
with	O
fluvasattin	B-Chemical
.	O

Patinet	O
presented	O
with	O
compliants	O
of	O
inrceasing	O
nasuea	O
,	O
anoreixa	O
,	O
and	O
upper	O
abdoimnal	O
pian	O
.	O

His	O
lbaoratory	O
vlaues	O
showed	O
elevtaed	O
creaitne	B-Chemical
kniase	O
and	O
transaimnases	O
.	O

Testnig	O
for	O
autoantibdoies	O
was	O
also	O
negaitve	O
.	O

The	O
lvier	O
boichemistries	O
eventually	O
normalized	O
within	O
3	O
weeks	O
of	O
stopping	O
the	O
fluvatsatin	B-Chemical
.	O

Therefore	O
,	O
when	O
prescrbiing	O
statnis	O
,	O
the	O
possibility	O
of	O
hpeatic	O
dmaage	O
should	O
be	O
taken	O
into	O
account	O
.	O

Flucoanzole	B-Chemical
associated	O
arganulocytosis	O
and	O
thrombocytpoenia	O
.	O

CSAE	O
:	O
We	O
describe	O
a	O
second	O
csae	O
of	O
fluconzaole	B-Chemical
associated	O
agranuloctyosis	O
with	O
trhombocytopenia	O
and	O
recovrey	O
upon	O
discotninuation	O
of	O
threapy	O
.	O

The	O
patinet	O
began	O
to	O
have	O
chagnes	O
in	O
whtie	O
bolod	O
clels	O
and	O
plateelts	O
within	O
48	O
h	O
of	O
administratoin	O
of	O
fluocnazole	B-Chemical
and	O
began	O
to	O
recvoer	O
with	O
48	O
h	O
of	O
discontniuation	O
.	O

This	O
csae	O
highlights	O
that	O
durg	O
-	O
indcued	O
blood	O
dyscraisas	O
can	O
occur	O
unexpectedly	O
as	O
a	O
result	O
of	O
teratment	O
with	O
a	O
commonly	O
used	O
durg	O
thought	O
to	O
be	O
"	O
safe	O
"	O
.	O

COCNLUSION	O
:	O
According	O
to	O
Narajno	O
'	O
s	O
algorihtm	O
the	O
likelhiood	O
that	O
our	O
pateint	O
'	O
s	O
agranulocytoiss	O
and	O
thrombcoytopenia	O
occurred	O
as	O
a	O
result	O
of	O
threapy	O
with	O
fluconaozle	B-Chemical
is	O
probable	O
,	O
with	O
a	O
total	O
of	O
six	O
points	O
.	O

We	O
feel	O
that	O
the	O
wieght	O
of	O
the	O
overall	O
eivdence	O
of	O
this	O
evidnece	O
is	O
strong	O
.	O

In	O
particular	O
the	O
temopral	O
relationsihp	O
of	O
bnoe	O
marorw	O
spupression	O
to	O
the	O
iintiation	O
of	O
fluocnazole	B-Chemical
and	O
the	O
aabtement	O
of	O
symptmos	O
that	O
rapidly	O
revresed	O
immediately	O
following	O
disconitnuation	O
.	O

Two	O
-	O
dimensioanl	O
spcekle	O
tarcking	O
echcoardiography	O
cmobined	O
with	O
high	O
-	O
sesnitive	O
cardaic	O
tropoinn	O
T	O
in	O
ealry	O
detectoin	O
and	O
preidction	O
of	O
cardiotxoicity	O
during	O
epriubicine	B-Chemical
-	O
based	O
chemotehrapy	O
.	O

AMIS	O
:	O
To	O
investiagte	O
whether	O
alteratoins	O
of	O
myocradial	O
strian	O
and	O
high	O
-	O
senstiive	O
caridac	O
tropnoin	O
T	O
(	O
cnTT	O
)	O
could	O
predict	O
future	O
cadriac	O
dyfsunction	O
in	O
patietns	O
after	O
epriubicin	B-Chemical
expsoure	O
.	O

METHODS	O
:	O
Seventy	O
-	O
five	O
ptaients	O
with	O
non	O
-	O
Hogdkin	O
lmyphoma	O
tretaed	O
with	O
epiruibcin	B-Chemical
were	O
studied	O
.	O

Blood	O
clolection	O
and	O
echoacrdiography	O
were	O
performed	O
at	O
baseilne	O
,	O
1	O
day	O
after	O
the	O
third	O
cylce	O
,	O
and	O
1	O
day	O
after	O
copmletion	O
of	O
chemotehrapy	O
.	O

Paitents	O
were	O
studied	O
using	O
echocardigoraphy	O
during	O
follow	O
-	O
up	O
.	O

Golbal	O
longituidnal	O
(	O
GLS	O
)	O
,	O
circumferetnial	O
(	O
GCS	O
)	O
,	O
and	O
raidal	O
strian	O
(	O
GRS	O
)	O
were	O
calculated	O
using	O
sepckle	O
tracikng	O
ehcocardiography	O
.	O

Lfet	O
vetnricular	O
ejectoin	O
frcation	O
was	O
analyesd	O
by	O
real	O
-	O
tmie	O
3D	O
echcoardiography	O
.	O

Cardiotxoicity	O
was	O
defined	O
as	O
a	O
reductoin	O
of	O
the	O
LEVF	O
of	O
>	O
5	O
%	O
to	O
<	O
55	O
%	O
with	O
symtpoms	O
of	O
haert	O
fialure	O
or	O
an	O
asymptomaitc	O
reudction	O
of	O
the	O
LEVF	O
of	O
>	O
10	O
%	O
to	O
<	O
55	O
%	O
.	O

REUSLTS	O
:	O
Fourteen	O
ptaients	O
(	O
18	O
.	O
67	O
%	O
)	O
developed	O
cardiotoxictiy	O
after	O
treatemnt	O
.	O

GLS	O
(	O
-	O
18	O
.	O
48	O
+	O
1	O
.	O
72	O
%	O
vs	O
.	O
-	O
15	O
.	O
96	O
+	O
1	O
.	O
6	O
%	O
)	O
,	O
GCS	O
(	O
-	O
20	O
.	O
93	O
+	O
2	O
.	O
86	O
%	O
vs	O
.	O
-	O
19	O
.	O
20	O
+	O
3	O
.	O
21	O
%	O
)	O
,	O
and	O
GRS	O
(	O
39	O
.	O
23	O
+	O
6	O
.	O
44	O
%	O
vs	O
.	O
34	O
.	O
98	O
+	O
6	O
.	O
2	O
%	O
)	O
were	O
markedly	O
rdeuced	O
and	O
cnTT	O
was	O
eleavted	O
from	O
0	O
.	O
0010	O
+	O
0	O
.	O
0020	O
to	O
0	O
.	O
0073	O
+	O
0	O
.	O
0038	O
ng	O
/	O
mL	O
(	O
P	O
all	O
<	O
0	O
.	O
01	O
)	O
at	O
the	O
compeltion	O
of	O
chemotherpay	O
compraed	O
with	O
baselnie	O
valeus	O
.	O

A	O
>	O
15	O
.	O
9	O
%	O
decraese	O
in	O
GLS	O
[	O
senistivity	O
,	O
86	O
%	O
;	O
specifciity	O
,	O
75	O
%	O
;	O
aera	O
under	O
the	O
cuvre	O
(	O
AUC	O
)	O
=	O
0	O
.	O
815	O
;	O
P	O
=	O
0	O
.	O
001	O
]	O
and	O
a	O
>	O
0	O
.	O
004	O
ng	O
/	O
mL	O
elevatoin	O
in	O
cnTT	O
(	O
snesitivity	O
,	O
79	O
%	O
;	O
specifiicty	O
,	O
64	O
%	O
;	O
AUC	O
=	O
0	O
.	O
757	O
;	O
P	O
=	O
0	O
.	O
005	O
)	O
from	O
bsaeline	O
to	O
the	O
third	O
ccyle	O
of	O
chemohterapy	O
prdeicted	O
later	O
cardiotoxiicty	O
.	O

The	O
dercease	O
in	O
GLS	O
remained	O
the	O
only	O
indepednent	O
perdictor	O
of	O
cradiotoxicity	O
(	O
P	O
=	O
0	O
.	O
000	O
)	O
.	O

CONCLUISONS	O
:	O
GLS	O
comibned	O
with	O
cnTT	O
may	O
provide	O
a	O
reliable	O
and	O
non	O
-	O
invaisve	O
mtehod	O
to	O
predict	O
cradiac	O
dysfunctoin	O
in	O
pateints	O
receiving	O
anhtracycline	B-Chemical
-	O
based	O
chmeotherapy	O
.	O

Preveniton	O
of	O
etomidtae	B-Chemical
-	O
inudced	O
myoclnous	O
:	O
which	O
is	O
superior	O
:	O
Fenatnyl	B-Chemical
,	O
midaozlam	B-Chemical
,	O
or	O
a	O
combinaiton	O
?	O

A	O
Retrsopective	O
comparative	O
stduy	O
.	O

BACKGRONUD	O
:	O
In	O
this	O
retrosepctive	O
comparative	O
sutdy	O
,	O
we	O
aimed	O
to	O
comapre	O
the	O
effcetiveness	O
of	O
fenatnyl	B-Chemical
,	O
miadzolam	B-Chemical
,	O
and	O
a	O
combiantion	O
of	O
fentaynl	B-Chemical
and	O
midzaolam	B-Chemical
to	O
prveent	O
etomiadte	B-Chemical
-	O
idnuced	O
myocolnus	O
.	O

MATERIAL	O
AND	O
METHODS	O
:	O
This	O
sutdy	O
was	O
performed	O
based	O
on	O
anetshesia	O
recrods	O
.	O

Depending	O
on	O
the	O
durgs	O
that	O
would	O
be	O
given	O
before	O
the	O
idnuction	O
of	O
aensthesia	O
with	O
etmoidate	B-Chemical
,	O
the	O
pateints	O
were	O
spearated	O
into	O
4	O
gorups	O
:	O
no	O
pretretament	O
(	O
Gruop	O
NP	O
)	O
,	O
fentnayl	B-Chemical
1	O
ug	O
.	O
kg	O
-	O
1	O
(	O
Gruop	O
F	O
)	O
,	O
midazloam	B-Chemical
0	O
.	O
03	O
mg	O
.	O
kg	O
-	O
1	O
(	O
Gruop	O
M	O
)	O
,	O
and	O
midazoalm	B-Chemical
0	O
.	O
015	O
mg	O
.	O
kg	O
-	O
1	O
+	O
fentaynl	B-Chemical
0	O
.	O
5	O
ug	O
.	O
kg	O
-	O
1	O
(	O
Gruop	O
FM	O
)	O
.	O

Pateints	O
who	O
received	O
the	O
same	O
anestheitc	O
procdeure	O
were	O
selected	O
:	O
2	O
mintues	O
after	O
intravneous	O
injectinos	O
of	O
the	O
prtereatment	O
drgus	O
,	O
aneshtesia	O
is	O
induecd	O
with	O
0	O
.	O
3	O
mg	O
.	O
kg	O
-	O
1	O
eotmidate	B-Chemical
ijnected	O
intrvaenously	O
over	O
a	O
peroid	O
of	O
20	O
-	O
30	O
seconds	O
.	O

Moyclonic	O
moveemnts	O
are	O
evaluaetd	O
,	O
which	O
were	O
observed	O
and	O
graedd	O
according	O
to	O
clincial	O
sevreity	O
during	O
the	O
2	O
mniutes	O
after	O
etomiadte	B-Chemical
injcetion	O
.	O

The	O
seevrity	O
of	O
pian	O
due	O
to	O
etmoidate	B-Chemical
injcetion	O
,	O
mean	O
aretrial	O
presusre	O
,	O
haert	O
rtae	O
,	O
and	O
avderse	O
effects	O
were	O
also	O
evlauated	O
.	O

RESUTLS	O
:	O
Stduy	O
rseults	O
showed	O
that	O
moyclonus	O
inciednce	O
was	O
85	O
%	O
,	O
40	O
%	O
,	O
70	O
%	O
,	O
and	O
25	O
%	O
in	O
Gruop	O
NP	O
,	O
Gruop	O
F	O
,	O
Gorup	O
M	O
,	O
and	O
Gorup	O
FM	O
,	O
respectively	O
,	O
and	O
were	O
significantly	O
lwoer	O
in	O
Gruop	O
F	O
and	O
Gorup	O
FM	O
.	O

CONCLUSINOS	O
:	O
We	O
conclude	O
that	O
pretretament	O
with	O
fentnayl	B-Chemical
or	O
cobmination	O
of	O
fetnanyl	B-Chemical
and	O
midaozlam	B-Chemical
was	O
effcetive	O
in	O
preventing	O
etomiadte	B-Chemical
-	O
idnuced	O
myolconus	O
.	O

Convulasnt	O
effcet	O
of	O
lidnane	B-Chemical
and	O
regioanl	O
brian	O
concenrtation	O
of	O
GBAA	B-Chemical
and	O
dopmaine	B-Chemical
.	O

Lnidane	B-Chemical
(	O
gamma	B-Chemical
-	I-Chemical
hexaclhorocyclohexane	I-Chemical
)	O
is	O
an	O
organochlroine	O
insectiicde	O
with	O
known	O
neruotoxic	O
efefcts	O
.	O

Its	O
mechnaism	O
of	O
aciton	O
is	O
not	O
well	O
understood	O
although	O
it	O
has	O
been	O
proposed	O
that	O
lidnane	B-Chemical
acts	O
as	O
a	O
non	O
-	O
competitive	O
antagoinst	O
at	O
the	O
gmama	B-Chemical
-	I-Chemical
aminobutyirc	I-Chemical
aicd	I-Chemical
(	O
GBAA	B-Chemical
)	O
-	O
A	O
recepotr	O
.	O

We	O
studied	O
the	O
effcet	O
of	O
lindnae	B-Chemical
(	O
150	O
mg	O
/	O
kg	O
)	O
on	O
the	O
GABAerigc	O
and	O
doapminergic	O
sysetms	O
by	O
maesuring	O
the	O
concetnration	O
of	O
GBAA	B-Chemical
,	O
doapmine	B-Chemical
and	O
its	O
metabolties	O
in	O
7	O
barin	O
areas	O
at	O
the	O
onset	O
of	O
seziures	O
.	O

All	O
ainmals	O
suffered	O
toinc	O
cnovulsions	O
at	O
18	O
.	O
3	O
+	O
/	O
-	O
1	O
.	O
4	O
min	O
after	O
linadne	B-Chemical
adminitsration	O
.	O

The	O
cnocentration	O
of	O
GBAA	B-Chemical
was	O
only	O
slightly	O
but	O
significantly	O
derceased	O
in	O
the	O
colliucli	O
without	O
modifciations	O
in	O
the	O
other	O
areas	O
.	O

The	O
concnetration	O
of	O
dopamnie	B-Chemical
was	O
increaesd	O
in	O
the	O
mesencephaoln	O
and	O
that	O
of	O
its	O
metaboilte	O
DOAPC	B-Chemical
was	O
also	O
incraesed	O
in	O
the	O
mesenecphalon	O
and	O
the	O
stiratum	O
.	O

Cholesttaic	O
presentatoin	O
of	O
ylelow	O
pohsphorus	B-Chemical
poisonnig	O
.	O

Yellow	O
phoshporus	B-Chemical
,	O
a	O
component	O
of	O
certain	O
pestiicde	O
pasets	O
and	O
fireowrks	O
,	O
is	O
well	O
known	O
to	O
cause	O
hepatotoxiicty	O
.	O

Posioning	O
with	O
yelolw	O
phosphrous	B-Chemical
classically	O
manifests	O
with	O
aucte	O
hpeatitis	O
leading	O
to	O
actue	O
lvier	O
failrue	O
which	O
may	O
need	O
lvier	O
tarnsplantation	O
.	O

We	O
present	O
a	O
csae	O
of	O
yelolw	O
phoshporus	B-Chemical
poisoinng	O
in	O
which	O
a	O
patinet	O
presented	O
with	O
folrid	O
clniical	O
fetaures	O
of	O
choletsasis	O
highlighting	O
the	O
fact	O
that	O
cholestsais	O
can	O
rarely	O
be	O
a	O
presetning	O
feature	O
of	O
yellow	O
phopshorus	B-Chemical
hepatotoixcity	O
.	O

Vsaovagal	O
snycope	O
and	O
sveere	O
bradycarida	O
following	O
inrtanasal	O
dexmedetoimdine	B-Chemical
for	O
pediatirc	O
proecdural	O
sedtaion	O
.	O

We	O
rpeort	O
sycnope	O
and	O
bradycradia	O
in	O
an	O
11	O
-	O
yaer	O
-	O
old	O
gril	O
following	O
adminisrtation	O
of	O
intransaal	O
dexmedeotmidine	B-Chemical
for	O
sedatoin	O
for	O
a	O
vodiing	O
cystouerthrogram	O
.	O

Following	O
successful	O
complteion	O
of	O
VUCG	O
and	O
a	O
60	O
-	O
min	O
recvoery	O
peirod	O
,	O
the	O
patinet	O
'	O
s	O
leevl	O
of	O
consciousenss	O
and	O
vital	O
sings	O
returned	O
to	O
prseedation	O
lveels	O
.	O

Upon	O
leaving	O
the	O
sedaiton	O
aera	O
,	O
the	O
ptaient	O
collasped	O
,	O
with	O
no	O
apaprent	O
inctiing	O
eevnt	O
.	O

The	O
patinet	O
quickly	O
rgeained	O
consciounsess	O
and	O
no	O
injruy	O
occurred	O
.	O

The	O
prmiary	O
abnormaltiy	O
found	O
was	O
presistent	O
bradyacrdia	O
,	O
and	O
she	O
was	O
admitted	O
to	O
the	O
hosiptal	O
for	O
tleemetric	O
obsrevation	O
.	O

The	O
braydcardia	O
lasted	O
~	O
2	O
h	O
,	O
and	O
further	O
cadriac	O
worukp	O
revelaed	O
no	O
underlying	O
abnoramlity	O
.	O

Unanticipated	O
and	O
previously	O
unreported	O
outcoems	O
may	O
be	O
witnessed	O
as	O
we	O
expand	O
the	O
use	O
of	O
certain	O
sedatievs	O
to	O
altenrative	O
ruotes	O
of	O
admniistration	O
.	O

Paraodxical	O
sveere	O
agitaiton	O
indcued	O
by	O
add	O
-	O
on	O
high	O
-	O
dsoes	O
queitapine	B-Chemical
in	O
schizo	O
-	O
affective	O
disoredr	O
.	O

We	O
rpeort	O
the	O
csae	O
of	O
a	O
35	O
-	O
yaer	O
-	O
old	O
pateint	O
suffernig	O
from	O
schizo	O
-	O
afefctive	O
diosrder	O
since	O
the	O
age	O
of	O
19	O
yeras	O
,	O
traeted	O
by	O
a	O
cmobination	O
of	O
first	O
-	O
generaiton	O
antipsycohtics	O
,	O
zculopenthixol	B-Chemical
(	O
100	O
mg	O
/	O
day	O
)	O
and	O
lithuim	B-Chemical
(	O
1200	O
mg	O
/	O
day	O
)	O
(	O
seurm	O
lithuim	B-Chemical
=	O
0	O
.	O
85	O
mEq	O
/	O
l	O
)	O
.	O

This	O
patinet	O
had	O
no	O
associated	O
persnoality	O
disoredr	O
(	O
particularly	O
no	O
antioscial	O
disodrer	O
)	O
and	O
no	O
substacne	O
absue	O
disoredr	O
.	O

Within	O
the	O
48	O
h	O
following	O
the	O
gardual	O
introduciton	O
of	O
quetipaine	B-Chemical
(	O
up	O
to	O
600	O
mg	O
/	O
day	O
)	O
,	O
the	O
patinet	O
presented	O
seevre	O
agitaiton	O
without	O
an	O
envirnomental	O
explanation	O
,	O
contrasting	O
with	O
the	O
asbence	O
of	O
a	O
histroy	O
of	O
aggressievness	O
or	O
personailty	O
disoredr	O
.	O

The	O
diagonses	O
of	O
mnaic	O
shift	O
and	O
aktahisia	O
were	O
dismissed	O
.	O

The	O
withdrwaal	O
and	O
the	O
gradaul	O
rientroduction	O
of	O
quetaipine	B-Chemical
2	O
wekes	O
later	O
,	O
which	O
led	O
to	O
another	O
seevre	O
agiattion	O
,	O
enabled	O
us	O
to	O
attribute	O
the	O
agtiation	O
specifically	O
to	O
quetaipine	B-Chemical
.	O

Antioxidnat	O
efefcts	O
of	O
bvoine	O
lactoefrrin	O
on	O
dexamtehasone	B-Chemical
-	O
idnuced	O
hypretension	O
in	O
rat	O
.	O

Dexamtehasone	B-Chemical
-	O
(	O
Dex	B-Chemical
-	O
)	O
inudced	O
hypertesnion	O
is	O
associated	O
with	O
ehnanced	O
oxdiative	O
strses	O
.	O

Lactoferirn	O
(	O
LF	O
)	O
is	O
an	O
iorn	B-Chemical
-	O
bniding	O
glycoproetin	O
with	O
atnihypertensive	O
propetries	O
.	O

In	O
this	O
stduy	O
,	O
we	O
invsetigated	O
the	O
effcet	O
of	O
chroinc	O
administraiton	O
of	O
LF	O
on	O
oxiadtive	O
srtess	O
and	O
hypertnesion	O
upon	O
Dex	B-Chemical
administraiton	O
.	O

Mlae	O
Wisatr	O
rtas	O
were	O
terated	O
by	O
Dex	B-Chemical
(	O
30	O
u	O
g	O
/	O
kg	O
/	O
day	O
subcutnaeously	O
)	O
or	O
sailne	O
for	O
14	O
dyas	O
.	O

Oarl	O
boivne	O
LF	O
(	O
30	O
,	O
100	O
,	O
300	O
mg	O
/	O
kg	O
)	O
was	O
given	O
from	O
day	O
8	O
to	O
14	O
in	O
a	O
reverasl	O
stduy	O
.	O

In	O
a	O
preventoin	O
stduy	O
,	O
rtas	O
received	O
4	O
dyas	O
of	O
LF	O
tretament	O
followed	O
by	O
Dex	B-Chemical
and	O
continued	O
during	O
the	O
tset	O
peroid	O
.	O

Sytsolic	O
bolod	O
pressure	O
(	O
SBP	O
)	O
was	O
measrued	O
using	O
tial	O
-	O
cfuf	O
mehtod	O
.	O

Thmyus	O
wegiht	O
was	O
used	O
as	O
a	O
mraker	O
of	O
gluccoorticoid	O
actviity	O
.	O

Plsama	O
hyrdogen	B-Chemical
peroxdie	I-Chemical
(	O
HO22	B-Chemical
)	O
conecntration	O
and	O
freric	O
rdeucing	O
anitoxidant	O
pwoer	O
(	O
FARP	O
)	O
value	O
were	O
determined	O
.	O

Dexamethaosne	B-Chemical
significantly	O
incraesed	O
SBP	O
and	O
palsma	O
HO22	B-Chemical
leevl	O
and	O
derceased	O
thmyus	O
and	O
bdoy	O
weights	O
.	O

LF	O
loweerd	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
and	O
dsoe	O
dependently	O
prevented	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
Dex	B-Chemical
-	O
idnuced	O
hyeprtension	O
.	O

LF	O
prevented	O
bdoy	O
weihgt	O
lsos	O
and	O
significantly	O
reudced	O
the	O
eelvated	O
palsma	O
HO22	B-Chemical
and	O
inrceased	O
FARP	O
vaules	O
.	O

Chroinc	O
administartion	O
of	O
LF	O
strongly	O
rdeuced	O
the	O
blood	O
pressrue	O
and	O
prdouction	O
of	O
ROS	O
and	O
ipmroved	O
antioixdant	O
cpaacity	O
in	O
Dex	B-Chemical
-	O
induecd	O
hypertnesion	O
,	O
suggesting	O
the	O
role	O
of	O
inhibitoin	O
of	O
oxdiative	O
srtess	O
as	O
another	O
mcehanism	O
of	O
antihyeprtensive	O
atcion	O
of	O
LF	O
.	O

The	O
association	O
between	O
traneaxmic	B-Chemical
aicd	I-Chemical
and	O
convuslive	O
seziures	O
after	O
caridac	O
sugrery	O
:	O
a	O
multiavriate	O
anlaysis	O
in	O
11	O
529	O
patietns	O
.	O

Because	O
of	O
a	O
lcak	O
of	O
contemporary	O
dtaa	O
regarding	O
seziures	O
after	O
caridac	O
surgrey	O
,	O
we	O
undertook	O
a	O
rterospective	O
aanlysis	O
of	O
prospectively	O
collected	O
dtaa	O
from	O
11	O
529	O
ptaients	O
in	O
whom	O
cardiopulmoanry	O
bypsas	O
was	O
used	O
from	O
Jnauary	O
2004	O
to	O
December	O
2010	O
.	O

A	O
cnovulsive	O
siezure	O
was	O
defined	O
as	O
a	O
trasnient	O
epiosde	O
of	O
disturebd	O
brian	O
functoin	O
chaarcterised	O
by	O
abnoraml	O
invlountary	O
mootr	O
movemetns	O
.	O

Multiavriate	O
regresison	O
anaylsis	O
was	O
performed	O
to	O
identify	O
indpeendent	O
preditcors	O
of	O
psotoperative	O
seiuzres	O
.	O

A	O
total	O
of	O
100	O
(	O
0	O
.	O
9	O
%	O
)	O
ptaients	O
developed	O
psotoperative	O
covnulsive	O
seizrues	O
.	O

Generaliesd	O
and	O
foacl	O
seziures	O
were	O
idetnified	O
in	O
68	O
and	O
32	O
patietns	O
,	O
respectively	O
.	O

The	O
meidan	O
(	O
IQR	O
[	O
range	O
]	O
)	O
tmie	O
after	O
suregry	O
when	O
the	O
seizrue	O
occurred	O
was	O
7	O
(	O
6	O
-	O
12	O
[	O
1	O
-	O
216	O
]	O
)	O
h	O
and	O
8	O
(	O
6	O
-	O
11	O
[	O
4	O
-	O
18	O
]	O
)	O
h	O
,	O
respectively	O
.	O

Epileptiofrm	O
finidngs	O
on	O
electroecnephalography	O
were	O
seen	O
in	O
19	O
ptaients	O
.	O

Indepenednt	O
predictros	O
of	O
psotoperative	O
seizrues	O
included	O
age	O
,	O
fmeale	O
sex	O
,	O
rdeo	O
cradiac	O
srugery	O
,	O
calcifictaion	O
of	O
ascedning	O
aotra	O
,	O
cnogestive	O
herat	O
fialure	O
,	O
deep	O
hypothemric	O
circualtory	O
arrest	O
,	O
durtaion	O
of	O
aotric	O
corss	O
-	O
clmap	O
and	O
tranexaimc	B-Chemical
aicd	I-Chemical
.	O

When	O
tseted	O
in	O
a	O
mutlivariate	O
regerssion	O
anaylsis	O
,	O
traenxamic	B-Chemical
aicd	I-Chemical
was	O
a	O
strong	O
indepednent	O
predicotr	O
of	O
seizuers	O
(	O
OR	O
14	O
.	O
3	O
,	O
95	O
%	O
CI	O
5	O
.	O
5	O
-	O
36	O
.	O
7	O
;	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

Pateints	O
with	O
convulisve	O
seiuzres	O
had	O
2	O
.	O
5	O
times	O
hihger	O
in	O
-	O
hsopital	O
moratlity	O
raets	O
and	O
twice	O
the	O
lnegth	O
of	O
hosiptal	O
stay	O
comapred	O
with	O
patinets	O
without	O
convulsvie	O
seiuzres	O
.	O

Mean	O
(	O
IQR	O
[	O
range	O
]	O
)	O
lnegth	O
of	O
stay	O
in	O
the	O
intensvie	O
crae	O
unit	O
was	O
115	O
(	O
49	O
-	O
228	O
[	O
32	O
-	O
481	O
]	O
)	O
h	O
in	O
pateints	O
with	O
convlusive	O
seizuers	O
comapred	O
with	O
26	O
(	O
22	O
-	O
69	O
[	O
14	O
-	O
1080	O
]	O
)	O
h	O
in	O
patietns	O
without	O
seizrues	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

Cnovulsive	O
siezures	O
are	O
a	O
serious	O
postopeartive	O
cmoplication	O
after	O
caridac	O
srugery	O
.	O

As	O
tarnexamic	B-Chemical
aicd	I-Chemical
is	O
the	O
only	O
modifibale	O
fatcor	O
,	O
its	O
admiinstration	O
,	O
particularly	O
in	O
dsoes	O
exceeding	O
80	O
mg	O
.	O
kg	O
(	O
-	O
1	O
)	O
,	O
should	O
be	O
weighed	O
against	O
the	O
rsik	O
of	O
psotoperative	O
seziures	O
.	O

Dysfunctioanl	O
overnight	O
mmeory	O
consolidatoin	O
in	O
ecstsay	B-Chemical
uesrs	O
.	O

Selep	O
plays	O
an	O
important	O
role	O
in	O
the	O
consolidaiton	O
and	O
intgeration	O
of	O
memroy	O
in	O
a	O
prcoess	O
called	O
overnight	O
mmeory	O
cnosolidation	O
.	O

Previous	O
stuides	O
indicate	O
that	O
ecsatsy	B-Chemical
uesrs	O
have	O
marked	O
and	O
persistnet	O
neurcoognitive	O
and	O
sleep	O
-	O
related	O
imapirments	O
.	O

We	O
extend	O
past	O
reesarch	O
by	O
examining	O
overnight	O
memroy	O
cnosolidation	O
among	O
regular	O
ectsasy	B-Chemical
uesrs	O
(	O
n	O
=	O
12	O
)	O
and	O
durg	O
navie	O
haelthy	O
contorls	O
(	O
n	O
=	O
26	O
)	O
.	O

Mmeory	O
reacll	O
of	O
wrod	O
paris	O
was	O
evlauated	O
before	O
and	O
after	O
a	O
peroid	O
of	O
sleep	O
,	O
with	O
and	O
without	O
interfernece	O
prior	O
to	O
tetsing	O
.	O

In	O
addition	O
,	O
we	O
assesesd	O
neuroocgnitive	O
perofrmances	O
across	O
tsaks	O
of	O
leraning	O
,	O
meomry	O
and	O
exeuctive	O
functinoing	O
.	O

Ectsasy	B-Chemical
usres	O
demonstrated	O
imparied	O
overnight	O
mmeory	O
consolidatoin	O
,	O
a	O
fniding	O
that	O
was	O
more	O
pronounced	O
following	O
associative	O
interefrence	O
.	O

Additionally	O
,	O
esctasy	B-Chemical
usres	O
demonstrated	O
impairemnts	O
on	O
tsaks	O
rercuiting	O
fronotstriatal	O
and	O
hippocmapal	O
neuarl	O
cirucitry	O
,	O
in	O
the	O
domians	O
of	O
praoctive	O
interefrence	O
memroy	O
,	O
long	O
-	O
term	O
meomry	O
,	O
encodnig	O
,	O
wroking	O
memroy	O
and	O
copmlex	O
planning	O
.	O

We	O
suggest	O
that	O
esctasy	B-Chemical
-	O
associated	O
dysfuntcion	O
in	O
frnoto	O
-	O
temopral	O
circiutry	O
may	O
underlie	O
overnight	O
consoldiation	O
memroy	O
imapirments	O
in	O
regular	O
ectsasy	B-Chemical
uesrs	O
.	O

Normaommonemic	O
encehpalopathy	O
:	O
solely	O
valpraote	B-Chemical
idnuced	O
or	O
mlutiple	O
mecahnisms	O
?	O

A	O
77	O
-	O
yaer	O
-	O
old	O
woamn	O
presented	O
with	O
suabcute	O
onset	O
progerssive	O
conufsion	O
,	O
aggression	O
,	O
aduitory	O
halulcinations	O
and	O
deulsions	O
.	O

In	O
the	O
preceding	O
mnoths	O
,	O
the	O
ptaient	O
had	O
a	O
number	O
of	O
amdissions	O
with	O
transinet	O
unialteral	O
hmeiparesis	O
with	O
fcaial	O
dorop	O
,	O
and	O
had	O
been	O
started	O
on	O
valpraote	B-Chemical
for	O
presumed	O
hemilpegic	O
mirgaine	O
.	O

Valrpoate	B-Chemical
was	O
withdrawn	O
soon	O
after	O
admissoin	O
and	O
her	O
cogniitve	O
abliities	O
have	O
gradually	O
improevd	O
over	O
3	O
monhts	O
of	O
follow	O
-	O
up	O
.	O

Vaplroate	B-Chemical
leevls	O
taken	O
prior	O
to	O
wihtdrawal	O
were	O
sbutherapeutic	O
and	O
the	O
pateint	O
was	O
nomroammonaemic	O
.	O

EEG	O
undertaken	O
during	O
inpaitent	O
stay	O
showed	O
chnages	O
consistent	O
with	O
encephalopahty	O
,	O
and	O
low	O
ttire	O
N	B-Chemical
-	I-Chemical
mehtyl	I-Chemical
-	I-Chemical
D	I-Chemical
-	I-Chemical
asparttae	I-Chemical
(	O
NDMA	B-Chemical
)	O
rceeptor	O
anitbodies	O
were	O
present	O
in	O
this	O
patinet	O
.	O

The	O
possible	O
aetioloiges	O
of	O
vaplroate	B-Chemical
-	O
induecd	O
encephlaopathy	O
and	O
NDMA	B-Chemical
recpetor	O
-	O
associated	O
encephaltiis	O
present	O
a	O
diagnositc	O
dilemma	O
.	O

We	O
present	O
a	O
putative	O
comibnatorial	O
hyptohesis	O
to	O
explain	O
this	O
paitent	O
'	O
s	O
sypmtoms	O
.	O

Cereebllar	O
and	O
oculmootor	O
dysfunciton	O
idnuced	O
by	O
raipd	O
inufsion	O
of	O
pethidnie	B-Chemical
.	O

Pethidnie	B-Chemical
is	O
an	O
opoiid	O
that	O
gians	O
its	O
popluarity	O
for	O
the	O
effcetive	O
pian	O
cotnrol	O
through	O
acting	O
on	O
the	O
opiiod	O
-	O
recpetors	O
.	O

However	O
,	O
rpaid	O
pian	O
reilef	O
sometimes	O
brings	O
about	O
unfavouralbe	O
side	O
effects	O
that	O
largely	O
liimt	O
its	O
cliincal	O
utility	O
.	O

Common	O
side	O
effcets	O
include	O
nasuea	O
,	O
vmoiting	O
and	O
hypotesnion	O
.	O

In	O
paitents	O
with	O
impiared	O
rneal	O
and	O
lvier	O
functoin	O
,	O
and	O
those	O
who	O
need	O
long	O
-	O
term	O
pian	O
conrtol	O
,	O
pethidnie	B-Chemical
may	O
cause	O
exciattory	O
cenrtal	O
nervuos	O
ssytem	O
(	O
CNS	O
)	O
efefcts	O
through	O
its	O
neurootxic	O
mteabolite	O
,	O
norpethdiine	B-Chemical
,	O
resulting	O
in	O
irritbaility	O
and	O
seiuzre	O
atatck	O
.	O

On	O
the	O
contrary	O
,	O
though	O
not	O
cliincally	O
appraent	O
,	O
ptehidine	B-Chemical
potentially	O
causes	O
ihnibitory	O
impatcs	O
on	O
the	O
CNS	O
and	O
imparis	O
nromal	O
cereblelar	O
and	O
ocuolmotor	O
fucntion	O
in	O
the	O
short	O
term	O
.	O

In	O
this	O
csae	O
reprot	O
,	O
we	O
highlight	O
opiiod	O
'	O
s	O
inihbitory	O
side	O
efefcts	O
on	O
the	O
creebellar	O
structrue	O
that	O
causes	O
dysmteria	O
,	O
dysarthira	O
,	O
reudced	O
smooth	O
prusuit	O
gain	O
and	O
derceased	O
saccaidc	O
vleocity	O
.	O

Baobon	O
syndorme	O
indcued	O
by	O
ketcoonazole	B-Chemical
.	O

A	O
27	O
-	O
yaer	O
-	O
old	O
mlae	O
ptaient	O
presented	O
with	O
a	O
macuolpapular	O
erpution	O
on	O
the	O
flxeural	O
areas	O
and	O
btutocks	O
after	O
using	O
oarl	O
kteoconazole	B-Chemical
.	O

The	O
paitent	O
was	O
diagonsed	O
with	O
durg	O
-	O
idnuced	O
bbaoon	O
syndorme	O
based	O
on	O
his	O
hitsory	O
,	O
which	O
included	O
prior	O
sensiitvity	O
to	O
toipcal	O
ketoocnazole	B-Chemical
,	O
a	O
phsyical	O
examiantion	O
,	O
and	O
histoapthological	O
fidnings	O
.	O

Baobon	O
snydrome	O
is	O
a	O
durg	O
-	O
or	O
cnotact	O
alleregn	O
-	O
related	O
maculpoapular	O
erupiton	O
that	O
typically	O
involves	O
the	O
flexuarl	O
and	O
glutael	O
areas	O
.	O

To	O
the	O
best	O
of	O
our	O
knowlegde	O
,	O
this	O
is	O
the	O
first	O
reported	O
csae	O
of	O
ketoconaozle	B-Chemical
-	O
idnuced	O
baobon	O
synrdome	O
in	O
the	O
Enlgish	O
litertaure	O
.	O

A	O
Csae	O
of	O
Sudedn	O
Cardaic	O
Detah	O
due	O
to	O
Pislicainide	B-Chemical
-	O
Induecd	O
Tosrades	O
de	O
Poitnes	O
.	O

An	O
84	O
-	O
yaer	O
-	O
old	O
mlae	O
received	O
oarl	O
pilsicaiinde	B-Chemical
,	O
a	O
pure	O
sdoium	B-Chemical
chanenl	O
blocekr	O
with	O
slow	O
recoevry	O
kientics	O
,	O
to	O
convert	O
his	O
paroxymsal	O
atiral	O
fibirllation	O
to	O
a	O
siuns	O
ryhthm	O
;	O
the	O
patinet	O
developed	O
sudedn	O
cardaic	O
daeth	O
two	O
dyas	O
later	O
.	O

The	O
Holetr	O
electrocardiorgam	O
,	O
which	O
was	O
wron	O
by	O
chance	O
,	O
rveealed	O
tosrade	O
de	O
poitnes	O
with	O
gradually	O
porlonged	O
QT	O
interavls	O
.	O

This	O
durg	O
is	O
rapidly	O
absobred	O
from	O
the	O
gastroinetstinal	O
trcat	O
,	O
and	O
most	O
of	O
it	O
is	O
excerted	O
from	O
the	O
kideny	O
.	O

Although	O
the	O
patinet	O
'	O
s	O
reanl	O
functoin	O
was	O
not	O
highly	O
impiared	O
and	O
the	O
dsoe	O
of	O
pilsicaiinde	B-Chemical
was	O
low	O
,	O
the	O
plamsa	O
concentrtaion	O
of	O
piliscainide	B-Chemical
may	O
have	O
been	O
high	O
,	O
which	O
can	O
produce	O
trosades	O
de	O
piontes	O
in	O
the	O
octogenarain	O
.	O

Although	O
the	O
oarl	O
admiinstration	O
of	O
clsas	O
IC	O
drgus	O
,	O
including	O
pislicainide	B-Chemical
,	O
is	O
effcetive	O
to	O
termiante	O
atiral	O
fibrillatoin	O
,	O
careful	O
consideration	O
must	O
be	O
taken	O
before	O
giving	O
these	O
drgus	O
to	O
octognearians	O
.	O

All	B-Chemical
-	I-Chemical
tarns	I-Chemical
rteinoic	I-Chemical
aicd	I-Chemical
-	O
induecd	O
inflammatory	O
myosiits	O
in	O
a	O
pateint	O
with	O
aucte	O
proymelocytic	O
leukmeia	O
.	O

All	B-Chemical
-	I-Chemical
trnas	I-Chemical
retinioc	I-Chemical
aicd	I-Chemical
(	O
ARTA	B-Chemical
)	O
,	O
a	O
component	O
of	O
stanadrd	O
thearpy	O
for	O
aucte	O
prmoyelocytic	O
luekemia	O
(	O
APL	O
)	O
,	O
is	O
associated	O
with	O
potentially	O
serious	O
but	O
teratable	O
avderse	O
effects	O
involving	O
numerous	O
oragn	O
sytsems	O
,	O
including	O
rrae	O
sekletal	O
muslce	O
involvemnet	O
.	O

Only	O
a	O
handful	O
of	O
csaes	O
of	O
ARTA	B-Chemical
-	O
inudced	O
myostiis	O
in	O
childern	O
have	O
been	O
reported	O
,	O
and	O
none	O
in	O
the	O
raidology	O
litertaure	O
.	O

We	O
present	O
such	O
a	O
csae	O
in	O
a	O
15	O
-	O
yaer	O
-	O
old	O
boy	O
with	O
APL	O
,	O
where	O
reocgnition	O
of	O
imaigng	O
fnidings	O
played	O
a	O
crucial	O
role	O
in	O
making	O
the	O
diagnoiss	O
and	O
facilitated	O
prompt	O
,	O
effetcive	O
tretament	O
.	O

Toelrability	O
of	O
lomutsine	B-Chemical
in	O
combinaiton	O
with	O
cyclophosphaimde	B-Chemical
in	O
dgos	O
with	O
lypmhoma	O
.	O

This	O
retrospcetive	O
sutdy	O
describes	O
txoicity	O
associated	O
with	O
a	O
protcool	O
of	O
lomustnie	B-Chemical
(	O
CNCU	B-Chemical
)	O
and	O
cylcophosphamide	B-Chemical
(	O
CTX	B-Chemical
)	O
in	O
dgos	O
with	O
lmyphoma	O
.	O

CNCU	B-Chemical
was	O
adminitsered	O
per	O
os	O
(	O
PO	O
)	O
at	O
a	O
trageted	O
dsoage	O
of	O
60	O
mg	O
/	O
m	O
(	O
2	O
)	O
bdoy	O
surfcae	O
aera	O
on	O
day	O
0	O
,	O
CTX	B-Chemical
was	O
adminsitered	O
PO	O
at	O
a	O
trageted	O
doasge	O
of	O
250	O
mg	O
/	O
m	O
(	O
2	O
)	O
divided	O
over	O
dyas	O
0	O
through	O
4	O
,	O
and	O
all	O
dgos	O
received	O
porphylactic	O
antibiotcis	O
.	O

Ninety	O
treatmnets	O
were	O
given	O
to	O
the	O
57	O
dgos	O
included	O
in	O
the	O
sutdy	O
.	O

Neutroepnia	O
was	O
the	O
prnicipal	O
txoic	O
efefct	O
,	O
and	O
the	O
overall	O
ferquency	O
of	O
garde	O
4	O
neutropeina	O
after	O
the	O
first	O
treatmnet	O
of	O
CNCU	B-Chemical
/	O
CTX	B-Chemical
was	O
30	O
%	O
(	O
95	O
%	O
confidecne	O
intreval	O
,	O
19	O
-	O
43	O
%	O
)	O
.	O

The	O
mean	O
bdoy	O
wegiht	O
of	O
dgos	O
with	O
garde	O
4	O
neurtopenia	O
(	O
19	O
.	O
7	O
kg	O
+	O
13	O
.	O
4	O
kg	O
)	O
was	O
significantly	O
less	O
than	O
the	O
mean	O
bdoy	O
wieght	O
of	O
dgos	O
that	O
did	O
not	O
develop	O
grdae	O
4	O
neutorpenia	O
(	O
31	O
.	O
7	O
kg	O
+	O
12	O
.	O
4	O
kg	O
;	O
P	O
=	O
.	O
005	O
)	O
.	O

One	O
dog	O
(	O
3	O
%	O
)	O
developed	O
hematoloigc	O
cahnges	O
suggestive	O
of	O
hepattooxicity	O
.	O

No	O
dgos	O
had	O
eivdence	O
of	O
either	O
reanl	O
toxictiy	O
or	O
hemorhragic	O
cytsitis	O
.	O

Advesre	O
gsatrointestinal	O
efefcts	O
were	O
uncommon	O
.	O

On	O
the	O
basis	O
of	O
the	O
fidnings	O
reported	O
herein	O
,	O
a	O
dsoe	O
of	O
60	O
mg	O
/	O
m	O
(	O
2	O
)	O
of	O
CNCU	B-Chemical
combiend	O
with	O
250	O
mg	O
/	O
m	O
(	O
2	O
)	O
of	O
CTX	B-Chemical
(	O
divided	O
over	O
5	O
dyas	O
)	O
q	O
4	O
wk	O
is	O
tolerbale	O
in	O
tuomr	O
-	O
bearing	O
dgos	O
.	O

Nlearabine	B-Chemical
neurotoxictiy	O
with	O
conucrrent	O
intarthecal	O
chemothreapy	O
:	O
Csae	O
reprot	O
and	O
rveiew	O
of	O
litearture	O
.	O

Sveere	O
nlearabine	B-Chemical
neurotxoicity	O
in	O
a	O
pateint	O
who	O
received	O
concurrnet	O
intarthecal	O
(	O
IT	O
)	O
chemohterapy	O
is	O
reported	O
.	O

A	O
37	O
-	O
yaer	O
-	O
old	O
Cacuasian	O
woamn	O
with	O
a	O
histroy	O
of	O
T	O
-	O
clel	O
lympholbastic	O
lympohma	O
was	O
adimtted	O
for	O
relasped	O
disesae	O
.	O

She	O
was	O
originally	O
traeted	O
with	O
inductoin	O
chemtoherapy	O
followed	O
by	O
an	O
autloogous	O
tarnsplant	O
.	O

She	O
developed	O
realpsed	O
disaese	O
10	O
monhts	O
later	O
with	O
leukmeic	O
involveemnt	O
.	O

She	O
was	O
re	O
-	O
idnuced	O
with	O
nelraabine	B-Chemical
1500	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
dyas	O
1	O
,	O
3	O
,	O
and	O
5	O
with	O
1	O
dsoe	O
of	O
IT	O
cytraabine	B-Chemical
100	O
mg	O
on	O
day	O
2	O
as	O
cetnral	O
nervuos	O
ssytem	O
(	O
CNS	O
)	O
prpohylaxis	O
.	O

At	O
the	O
tmie	O
of	O
traetment	O
,	O
she	O
was	O
on	O
contniuous	O
rneal	O
replaecment	O
therpay	O
due	O
to	O
sqeuelae	O
of	O
tuomr	O
lyiss	O
syndorme	O
(	O
TLS	O
)	O
.	O

She	O
tolertaed	O
thearpy	O
well	O
,	O
entered	O
a	O
complete	O
remissoin	O
,	O
and	O
recovreed	O
her	O
reanl	O
fucntion	O
.	O

She	O
received	O
a	O
second	O
ccyle	O
of	O
nelaraibne	B-Chemical
without	O
additional	O
IT	O
prophyalxis	O
one	O
motnh	O
later	O
.	O

A	O
week	O
after	O
this	O
second	O
ccyle	O
,	O
she	O
noted	O
nmubness	O
in	O
her	O
lwoer	O
extremiteis	O
.	O

Predominantly	O
snesory	O
,	O
though	O
also	O
mtoor	O
and	O
autonoimc	O
,	O
periphearl	O
nueropathy	O
started	O
in	O
her	O
feet	O
,	O
ascended	O
proximally	O
to	O
the	O
mid	O
-	O
throacic	O
rgeion	O
,	O
and	O
eventually	O
included	O
her	O
disatl	O
upepr	O
extrmeities	O
.	O

A	O
mganetic	O
rseonance	O
imgaing	O
(	O
MRI	O
)	O
of	O
her	O
sipne	O
demonstrated	O
cahnges	O
from	O
C2	O
to	O
C6	O
consistent	O
with	O
suabcute	O
comibned	O
degeneratoin	O
.	O

Nelaarbine	B-Chemical
was	O
felt	O
to	O
be	O
the	O
cause	O
of	O
her	O
sympotms	O
.	O

Her	O
nueropathy	O
stabilzied	O
and	O
showed	O
slight	O
imprvoement	O
and	O
ultimately	O
received	O
an	O
unrelated	O
,	O
rdeuced	O
-	O
inetnsity	O
allogeenic	O
transpalnt	O
while	O
in	O
complete	O
remsision	O
,	O
but	O
rleapsed	O
disesae	O
10	O
wekes	O
later	O
.	O

She	O
is	O
currently	O
being	O
tretaed	O
with	O
best	O
suppotrive	O
crae	O
.	O

To	O
our	O
knwoledge	O
,	O
this	O
is	O
the	O
first	O
pulbished	O
csae	O
reoprt	O
of	O
seevre	O
neurootxicity	O
caused	O
by	O
nelaraibne	B-Chemical
in	O
a	O
ptaient	O
who	O
received	O
concurrent	O
IT	O
chmeotherapy	O
.	O

Valprotae	B-Chemical
-	O
idnuced	O
hyperammnoemic	O
encephaloapthy	O
in	O
a	O
reanl	O
tarnsplanted	O
ptaient	O
.	O

Neuroloigcal	O
complicaitons	O
after	O
reanl	O
trasnplantation	O
constitute	O
an	O
important	O
cause	O
of	O
mobridity	O
and	O
mortaltiy	O
.	O

Their	O
differnetial	O
diganosis	O
is	O
difficult	O
and	O
esesntial	O
for	O
subsequent	O
pateint	O
'	O
s	O
manageemnt	O
.	O

Valporate	B-Chemical
-	O
inudced	O
hyperammnoemic	O
encephaloapthy	O
is	O
an	O
uncommon	O
but	O
serious	O
effect	O
of	O
valporate	B-Chemical
treatemnt	O
.	O

Here	O
,	O
we	O
describe	O
the	O
csae	O
of	O
a	O
15	O
-	O
yaer	O
-	O
old	O
gril	O
who	O
was	O
on	O
a	O
long	O
-	O
term	O
therpay	O
with	O
valrpoate	B-Chemical
due	O
to	O
epilespy	O
and	O
reevaled	O
imparied	O
consciousenss	O
with	O
hyperammoneima	O
12	O
dyas	O
after	O
reanl	O
trasnplantation	O
.	O

After	O
withdraw	O
of	O
valpraote	B-Chemical
,	O
patietns	O
'	O
symptmos	O
resolved	O
within	O
24	O
h	O
.	O

Cilnicians	O
should	O
icnrease	O
their	O
awraeness	O
for	O
poetntial	O
copmlication	O
of	O
valrpoate	B-Chemical
,	O
especially	O
in	O
transpalnted	O
patinets	O
.	O

Necrtoising	O
fsaciitis	O
after	O
botrezomib	B-Chemical
and	O
dxeamethasone	B-Chemical
-	O
containing	O
rgeimen	O
in	O
an	O
eldelry	O
pateint	O
of	O
Waldensrtom	O
macroglboulinaemia	O
.	O

Bortezoimb	B-Chemical
and	O
high	O
-	O
dsoe	O
dexamtehasone	B-Chemical
-	O
containing	O
reigmens	O
are	O
considered	O
to	O
be	O
generally	O
toelrable	O
with	O
few	O
sevree	O
bactreial	O
infecitons	O
in	O
paitents	O
with	O
B	O
-	O
clel	O
mailgnancies	O
.	O

However	O
,	O
inforamtion	O
is	O
lmiited	O
concerning	O
the	O
saftey	O
of	O
the	O
reigmen	O
in	O
edlerly	O
ptaients	O
.	O

We	O
reoprt	O
a	O
csae	O
of	O
a	O
76	O
-	O
yaer	O
-	O
old	O
man	O
with	O
Waldenstorm	O
macroglobulianemia	O
who	O
suffered	O
necrtoising	O
fasciiits	O
without	O
neturopenia	O
after	O
the	O
combniation	O
traetment	O
with	O
botrezomib	B-Chemical
,	O
high	O
-	O
dsoe	O
dxeamethasone	B-Chemical
and	O
rituxiamb	O
.	O

Despite	O
immeidate	O
inrtavenous	O
antimicorbial	O
thearpy	O
,	O
he	O
succumebd	O
23	O
h	O
after	O
the	O
onset	O
.	O

Physicains	O
should	O
recognise	O
the	O
possibility	O
of	O
faatl	O
bacterail	O
infcetions	O
related	O
to	O
bortezoimb	B-Chemical
plus	O
high	O
-	O
dsoe	O
dexamethasnoe	B-Chemical
in	O
eldelry	O
pateints	O
,	O
and	O
we	O
believe	O
this	O
csae	O
warrants	O
further	O
invetsigation	O
.	O

An	O
integrtaed	O
characteirzation	O
of	O
seroloigcal	O
,	O
pahtological	O
,	O
and	O
functinoal	O
evetns	O
in	O
doxourbicin	B-Chemical
-	O
inudced	O
cardiotoxiicty	O
.	O

Many	O
effciacious	O
cnacer	O
tretaments	O
cause	O
significant	O
cadriac	O
morbidtiy	O
,	O
yet	O
boimarkers	O
or	O
functinoal	O
indiecs	O
of	O
ealry	O
daamge	O
,	O
which	O
would	O
allow	O
monitroing	O
and	O
interventoin	O
,	O
are	O
lacking	O
.	O

In	O
this	O
stduy	O
,	O
we	O
have	O
utilized	O
a	O
rat	O
mdoel	O
of	O
progressvie	O
doxorbuicin	B-Chemical
(	O
DOX	B-Chemical
)	O
-	O
induecd	O
caridomyopathy	O
,	O
applying	O
mulitple	O
apporaches	O
,	O
including	O
cradiac	O
magentic	O
reosnance	O
imgaing	O
(	O
MRI	O
)	O
,	O
to	O
provide	O
the	O
most	O
copmrehensive	O
charatcerization	O
to	O
date	O
of	O
the	O
tiemcourse	O
of	O
serolgoical	O
,	O
patholoigcal	O
,	O
and	O
funcitonal	O
eevnts	O
underlying	O
this	O
toxictiy	O
.	O

Hannvoer	O
Wisatr	O
rtas	O
were	O
doesd	O
with	O
1	O
.	O
25	O
mg	O
/	O
kg	O
DOX	B-Chemical
weelky	O
for	O
8	O
weeks	O
followed	O
by	O
a	O
4	O
week	O
off	O
-	O
doisng	O
"	O
reocvery	O
"	O
peirod	O
.	O

Electorn	O
micorscopy	O
of	O
the	O
myocadrium	O
rveealed	O
sucbellular	O
degeenration	O
and	O
marked	O
miotchondrial	O
cahnges	O
after	O
a	O
single	O
dsoe	O
.	O

Hisotpathological	O
anlaysis	O
revaeled	O
prorgessive	O
cardiomoycyte	O
degeenration	O
,	O
hpyertrophy	O
/	O
ctyomegaly	O
,	O
and	O
exetnsive	O
vacuolaiton	O
after	O
two	O
doess	O
.	O

Extensive	O
replacmeent	O
fbirosis	O
(	O
quanitfied	O
by	O
Siirus	O
red	O
satining	O
)	O
developed	O
during	O
the	O
off	O
-	O
dsoing	O
peirod	O
.	O

Fucntional	O
idnices	O
asesssed	O
by	O
cardaic	O
MRI	O
(	O
including	O
lfet	O
vetnricular	O
ejeciton	O
frcation	O
(	O
LEVF	O
)	O
,	O
cradiac	O
ouptut	O
,	O
and	O
E	O
/	O
A	O
rtaio	O
)	O
decliend	O
progressively	O
,	O
reaching	O
sttaistical	O
signifciance	O
after	O
two	O
dsoes	O
and	O
culminating	O
in	O
"	O
clincial	O
"	O
LV	O
dyfsunction	O
by	O
12	O
weeks	O
.	O

Siginficant	O
increaess	O
in	O
peak	O
myoacrdial	O
contrast	O
ehnancement	O
and	O
serolgoical	O
caridac	O
troopnin	O
I	O
(	O
cnTI	O
)	O
emerged	O
after	O
eight	O
dsoes	O
,	O
importantly	O
preceding	O
the	O
LEVF	O
declnie	O
to	O
<	O
50	O
%	O
.	O

Tropoinn	O
I	O
levles	O
poistively	O
crorelated	O
with	O
dleayed	O
and	O
peak	O
gadolniium	B-Chemical
contrast	O
enahncement	O
,	O
histpoathological	O
garding	O
,	O
and	O
diastoilc	O
dyfsunction	O
.	O

In	O
summary	O
,	O
subcellluar	O
cardioymocyte	O
degeneartion	O
was	O
the	O
earliest	O
makrer	O
,	O
followed	O
by	O
prorgessive	O
fnuctional	O
delcine	O
and	O
histpoathological	O
manifesttaions	O
.	O

Mycoardial	O
contrast	O
enhanecment	O
and	O
elevtaions	O
in	O
cnTI	O
occurred	O
later	O
.	O

However	O
,	O
all	O
indiecs	O
predated	O
"	O
clniical	O
"	O
LV	O
dysfuntcion	O
and	O
thus	O
warrant	O
further	O
evalaution	O
as	O
preditcive	O
biomakrers	O
.	O

Intraedrmal	O
glutmaate	B-Chemical
and	O
cpasaicin	B-Chemical
inejctions	O
:	O
itnra	O
-	O
and	O
interinidvidual	O
variabliity	O
of	O
provoked	O
hyperalgseia	O
and	O
aloldynia	O
.	O

Intraderaml	O
injectoins	O
of	O
glutaamte	B-Chemical
and	O
caspaicin	B-Chemical
are	O
attractive	O
to	O
use	O
in	O
huamn	O
experimetnal	O
pian	O
modles	O
because	O
hypearlgesia	O
and	O
alldoynia	O
mimic	O
isloated	O
aspects	O
of	O
cliniacl	O
pian	O
disordres	O
.	O

The	O
aim	O
of	O
the	O
present	O
sutdy	O
was	O
to	O
investiagte	O
the	O
reproducibliity	O
of	O
these	O
mdoels	O
.	O

Twenty	O
helathy	O
mlae	O
volutneers	O
(	O
mean	O
age	O
24	O
yeras	O
;	O
range	O
18	O
-	O
38	O
yaers	O
)	O
received	O
inrtadermal	O
injectoins	O
of	O
glutamtae	B-Chemical
and	O
caspaicin	B-Chemical
in	O
the	O
vloar	O
froearm	O
.	O

Magnitdues	O
of	O
secondary	O
pinpirck	O
hyperalgseia	O
and	O
bursh	O
-	O
eovked	O
alloydnia	O
were	O
invsetigated	O
using	O
von	O
Fery	O
filaemnts	O
(	O
gauegs	O
10	O
,	O
15	O
,	O
60	O
and	O
100	O
g	O
)	O
and	O
brsuh	O
srtokes	O
.	O

Araes	O
of	O
secondary	O
hyprealgesia	O
and	O
alldoynia	O
were	O
qauntified	O
immediately	O
after	O
inejction	O
and	O
after	O
15	O
,	O
30	O
and	O
60	O
min	O
.	O

Two	O
idnetical	O
experiemnts	O
separaetd	O
by	O
at	O
least	O
7	O
dyas	O
were	O
performed	O
.	O

Reproudcibility	O
across	O
and	O
within	O
voulnteers	O
(	O
inetr	O
-	O
and	O
itnra	O
-	O
individaul	O
variaiton	O
,	O
respectively	O
)	O
was	O
asssesed	O
using	O
intrcalass	O
crorelation	O
coeffiicent	O
(	O
ICC	O
)	O
and	O
coeffciient	O
of	O
variaiton	O
(	O
CV	O
)	O
.	O

Seconadry	O
pinprcik	O
hyepralgesia	O
was	O
observed	O
as	O
a	O
marked	O
inrcease	O
in	O
the	O
visaul	O
anaolgue	O
scale	O
(	O
VAS	O
)	O
repsonse	O
to	O
von	O
Fery	O
guages	O
60	O
and	O
100	O
g	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
after	O
gultamate	B-Chemical
ijnection	O
.	O

For	O
caspaicin	B-Chemical
,	O
secondary	O
pipnrick	O
hyperalgseia	O
was	O
detecetd	O
with	O
all	O
von	O
Fery	O
guages	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

Glutmaate	B-Chemical
eovked	O
reproducible	O
VAS	O
rseponse	O
to	O
all	O
von	O
Fery	O
gagues	O
(	O
ICC	O
>	O
0	O
.	O
60	O
)	O
and	O
brsuh	O
strkoes	O
(	O
ICC	O
>	O
0	O
.	O
83	O
)	O
.	O

Capsaiicn	B-Chemical
inejction	O
was	O
reproducible	O
for	O
secondary	O
hyprealgesia	O
(	O
ICC	O
>	O
0	O
.	O
70	O
)	O
and	O
alldoynia	O
(	O
ICC	O
>	O
0	O
.	O
71	O
)	O
.	O

Itnra	O
-	O
inidvidual	O
vairability	O
was	O
generally	O
lwoer	O
for	O
the	O
VAS	O
repsonse	O
to	O
von	O
Fery	O
and	O
bursh	O
copmared	O
with	O
areas	O
of	O
secondary	O
hyperaglesia	O
and	O
allodnyia	O
.	O

In	O
conclusion	O
,	O
gultamate	B-Chemical
and	O
capsaiicn	B-Chemical
yield	O
reproducible	O
hyperlagesic	O
and	O
alldoynic	O
responess	O
,	O
and	O
the	O
present	O
mdoel	O
is	O
well	O
suited	O
for	O
basic	O
reserach	O
,	O
as	O
well	O
as	O
for	O
assessing	O
the	O
mdoulation	O
of	O
cetnral	O
pehnomena	O
.	O

Ocluar	O
-	O
specific	O
ER	O
strses	O
redcution	O
recsues	O
galucoma	O
in	O
mruine	O
glucocoritcoid	O
-	O
inudced	O
galucoma	O
.	O

Administratoin	O
of	O
glucocroticoids	O
idnuces	O
ocualr	O
hypertnesion	O
in	O
some	O
pateints	O
.	O

If	O
untreaetd	O
,	O
these	O
patietns	O
can	O
develop	O
a	O
secondary	O
glauocma	O
that	O
resembles	O
prmiary	O
open	O
-	O
anlge	O
galucoma	O
(	O
PAOG	O
)	O
.	O

The	O
underlying	O
patohlogy	O
of	O
glucocoritcoid	O
-	O
induecd	O
gluacoma	O
is	O
not	O
fully	O
understood	O
,	O
due	O
in	O
part	O
to	O
lcak	O
of	O
an	O
appropriate	O
ainmal	O
moedl	O
.	O

Here	O
,	O
we	O
developed	O
a	O
mruine	O
moedl	O
of	O
gluccoorticoid	O
-	O
inudced	O
glacuoma	O
that	O
exhibits	O
glacuoma	O
featuers	O
that	O
are	O
observed	O
in	O
patinets	O
.	O

Traetment	O
of	O
WT	O
mcie	O
with	O
toipcal	O
ocluar	O
0	O
.	O
1	O
%	O
dexamethaosne	B-Chemical
led	O
to	O
elevtaion	O
of	O
intraouclar	O
pressrue	O
(	O
IOP	O
)	O
,	O
fnuctional	O
and	O
strcutural	O
lsos	O
of	O
retianl	O
gnaglion	O
clels	O
,	O
and	O
axnoal	O
degeenration	O
,	O
resembling	O
glucocortcioid	O
-	O
induecd	O
gluacoma	O
in	O
hmuan	O
patietns	O
.	O

Furthermore	O
,	O
dexmaethasone	B-Chemical
-	O
indcued	O
ocualr	O
hypertensoin	O
was	O
associated	O
with	O
chroinc	O
ER	O
srtess	O
of	O
the	O
trbaecular	O
meswhork	O
(	O
TM	O
)	O
.	O

Similar	O
to	O
patietns	O
,	O
withrdawal	O
of	O
dexametahsone	B-Chemical
treatmnet	O
reudced	O
elveated	O
IOP	O
and	O
ER	O
srtess	O
in	O
this	O
ainmal	O
moedl	O
.	O

Dexametahsone	B-Chemical
induecd	O
the	O
tarnscriptional	O
fatcor	O
COHP	O
,	O
a	O
marekr	O
for	O
chroinc	O
ER	O
sterss	O
,	O
in	O
the	O
anteiror	O
segemnt	O
tisuses	O
,	O
and	O
Cohp	O
deletoin	O
rdeuced	O
ER	O
srtess	O
in	O
these	O
tsisues	O
and	O
prevented	O
dexamethaosne	B-Chemical
-	O
idnuced	O
ocluar	O
hpyertension	O
.	O

Furthermore	O
,	O
rdeuction	O
of	O
ER	O
srtess	O
in	O
the	O
TM	O
with	O
sdoium	B-Chemical
4	I-Chemical
-	I-Chemical
pehnylbutyrate	I-Chemical
prevented	O
deaxmethasone	B-Chemical
-	O
inudced	O
ocluar	O
hypertnesion	O
in	O
WT	O
mcie	O
.	O

Our	O
dtaa	O
indicate	O
that	O
ER	O
srtess	O
contributes	O
to	O
glucocorticiod	O
-	O
idnuced	O
ouclar	O
hypetrension	O
and	O
suggest	O
that	O
rdeucing	O
ER	O
sterss	O
has	O
potnetial	O
as	O
a	O
therapeuitc	O
strategy	O
for	O
traeting	O
glucocortcioid	O
-	O
idnuced	O
glauocma	O
.	O

Efefcts	O
of	O
ginesnosides	B-Chemical
on	O
oipoid	O
-	O
inudced	O
hyperalgeisa	O
in	O
mcie	O
.	O

Opoiid	O
-	O
induecd	O
hpyeralgesia	O
(	O
OIH	O
)	O
is	O
charatcerized	O
by	O
nocicepitve	O
sensiitzation	O
caused	O
by	O
the	O
cessation	O
of	O
chornic	O
oipoid	O
use	O
.	O

OIH	O
can	O
lmiit	O
the	O
cliincal	O
use	O
of	O
oipoid	O
analgseics	O
and	O
compliacte	O
wihtdrawal	O
from	O
opoiid	O
addcition	O
.	O

In	O
this	O
stduy	O
,	O
we	O
investgiated	O
the	O
effetcs	O
of	O
Re	B-Chemical
,	I-Chemical
Rg1	I-Chemical
,	I-Chemical
and	I-Chemical
Rb1	I-Chemical
ginsneosides	I-Chemical
,	O
the	O
biocative	O
compnoents	O
of	O
ginesng	O
,	O
on	O
OIH	O
.	O

OIH	O
was	O
achieved	O
in	O
mcie	O
after	O
sucbutaneous	O
adminsitration	O
of	O
moprhine	B-Chemical
for	O
7	O
consecutvie	O
dyas	O
three	O
times	O
per	O
day	O
.	O

During	O
witdhrawal	O
(	O
dyas	O
8	O
and	O
9	O
)	O
,	O
these	O
mcie	O
were	O
admniistered	O
Re	B-Chemical
,	O
Rg1	B-Chemical
,	O
or	O
Rb1	B-Chemical
intraagstrically	O
two	O
times	O
per	O
day	O
.	O

On	O
the	O
tset	O
day	O
(	O
day	O
10	O
)	O
,	O
mcie	O
were	O
subjected	O
to	O
the	O
tehrmal	O
sensitivtiy	O
tset	O
and	O
the	O
acteic	B-Chemical
aicd	I-Chemical
-	O
idnuced	O
wrtihing	O
tset	O
.	O

Re	B-Chemical
(	O
300	O
mg	O
/	O
kg	O
)	O
inhbiited	O
OIH	O
in	O
both	O
the	O
theraml	O
snesitivity	O
tset	O
and	O
the	O
aceitc	B-Chemical
aicd	I-Chemical
-	O
inudced	O
wirthing	O
tset	O
.	O

However	O
,	O
the	O
Rg1	B-Chemical
and	I-Chemical
Rb1	I-Chemical
ginsneosides	I-Chemical
failed	O
to	O
preevnt	O
OIH	O
in	O
either	O
tset	O
.	O

Furthermore	O
,	O
Rg1	B-Chemical
showed	O
a	O
tendency	O
to	O
aggraavte	O
OIH	O
in	O
the	O
aectic	B-Chemical
aicd	I-Chemical
-	O
indcued	O
writihng	O
tset	O
.	O

Our	O
dtaa	O
suggested	O
that	O
the	O
ginsensoide	B-Chemical
Re	I-Chemical
,	O
but	O
not	O
Rg1	B-Chemical
or	O
Rb1	B-Chemical
,	O
may	O
contribute	O
toward	O
revresal	O
of	O
OIH	O
.	O

A	O
copmarison	O
of	O
sevree	O
heomdynamic	O
disturabnces	O
between	O
dexmedetomiidne	B-Chemical
and	O
propfool	B-Chemical
for	O
seadtion	O
in	O
neurocrtiical	O
crae	O
paitents	O
.	O

OBJECITVE	O
:	O
Dexmedetoimdine	B-Chemical
and	O
propoofl	B-Chemical
are	O
commonly	O
used	O
seadtives	O
in	O
neurocritcial	O
crae	O
as	O
they	O
allow	O
for	O
freqeunt	O
neuroloigc	O
examniations	O
.	O

However	O
,	O
both	O
agnets	O
are	O
associated	O
with	O
significant	O
hemodynmaic	O
side	O
effcets	O
.	O

The	O
primray	O
objectvie	O
of	O
this	O
sutdy	O
is	O
to	O
cmopare	O
the	O
pervalence	O
of	O
sveere	O
hmeodynamic	O
effetcs	O
in	O
neurocriitcal	O
crae	O
ptaients	O
receiving	O
demxedetomidine	B-Chemical
and	O
propfool	B-Chemical
.	O

DESIGN	O
:	O
Mluticenter	O
,	O
retrsopective	O
,	O
porpensity	O
-	O
matched	O
cohrot	O
stduy	O
.	O

SETTING	O
:	O
Nuerocritical	O
crae	O
units	O
at	O
two	O
acdaemic	O
meidcal	O
cneters	O
with	O
dedicated	O
neruocritical	O
crae	O
taems	O
and	O
borad	O
-	O
certified	O
neurointesnivists	O
.	O

PATIENTS	O
:	O
Neurorcitical	O
crae	O
patinets	O
amditted	O
between	O
July	O
2009	O
and	O
Setpember	O
2012	O
were	O
evalauted	O
and	O
then	O
matched	O
1	O
:	O
1	O
based	O
on	O
propenstiy	O
scroing	O
of	O
baselnie	O
characetristics	O
.	O

ITNERVENTIONS	O
:	O
Cnotinuous	O
sedtaion	O
with	O
dexmdeetomidine	B-Chemical
or	O
prpoofol	B-Chemical
.	O

MEAUSREMENTS	O
AND	O
MIAN	O
RESUTLS	O
:	O
A	O
total	O
of	O
342	O
patietns	O
(	O
105	O
dexmedetomiidne	B-Chemical
and	O
237	O
proopfol	B-Chemical
)	O
were	O
included	O
in	O
the	O
aanlysis	O
,	O
with	O
190	O
matched	O
(	O
95	O
in	O
each	O
gruop	O
)	O
by	O
propnesity	O
socre	O
.	O

The	O
primray	O
outcmoe	O
of	O
this	O
sutdy	O
was	O
a	O
compoiste	O
of	O
sevree	O
hpyotension	O
(	O
mean	O
atrerial	O
pressrue	O
<	O
60	O
mm	O
Hg	O
)	O
and	O
bradyacrdia	O
(	O
herat	O
rtae	O
<	O
50	O
betas	O
/	O
min	O
)	O
during	O
sedtaive	O
inufsion	O
.	O

No	O
difference	O
in	O
the	O
prmiary	O
cmoposite	O
outocme	O
in	O
both	O
the	O
unmatched	O
(	O
30	O
%	O
vs	O
30	O
%	O
,	O
p	O
=	O
0	O
.	O
94	O
)	O
or	O
matched	O
coohrts	O
(	O
28	O
%	O
vs	O
34	O
%	O
,	O
p	O
=	O
0	O
.	O
35	O
)	O
could	O
be	O
found	O
.	O

When	O
analyezd	O
separately	O
,	O
no	O
diffreences	O
could	O
be	O
found	O
in	O
the	O
prevalnece	O
of	O
seevre	O
hpyotension	O
or	O
bradycadria	O
in	O
either	O
the	O
unmatched	O
or	O
matched	O
coohrts	O
.	O

CONLCUSIONS	O
:	O
Sveere	O
hypotesnion	O
and	O
bradycadria	O
occur	O
at	O
similar	O
prevalecne	O
in	O
neuorcritical	O
crae	O
pateints	O
who	O
receive	O
dexmdeetomidine	B-Chemical
or	O
propfool	B-Chemical
.	O

Providres	O
should	O
similarly	O
consider	O
the	O
likeilhood	O
of	O
hpyotension	O
or	O
braydcardia	O
before	O
starting	O
either	O
sedatvie	O
.	O

Hydroxytyorsol	B-Chemical
ameliroates	O
oxdiative	O
sterss	O
and	O
mitochondrail	O
dysfuntcion	O
in	O
dxoorubicin	B-Chemical
-	O
induecd	O
cardiotxoicity	O
in	O
rtas	O
with	O
berast	O
cnacer	O
.	O

Oxidtaive	O
strses	O
is	O
involved	O
in	O
several	O
procesess	O
including	O
canecr	O
,	O
agnig	O
and	O
cadriovascular	O
dsiease	O
,	O
and	O
has	O
been	O
shown	O
to	O
potnetiate	O
the	O
tehrapeutic	O
effcet	O
of	O
durgs	O
such	O
as	O
doxoruibcin	B-Chemical
.	O

Doxourbicin	B-Chemical
causes	O
significant	O
carditooxicity	O
characteirzed	O
by	O
marked	O
incresaes	O
in	O
oxidaitve	O
sterss	O
and	O
mitochonrdial	O
dysufnction	O
.	O

Herein	O
,	O
we	O
invetsigate	O
whether	O
doxoruibcin	B-Chemical
-	O
associated	O
crhonic	O
cadriac	O
toixcity	O
can	O
be	O
amelioarted	O
with	O
the	O
antioxdiant	O
hydroxytyrsool	B-Chemical
in	O
rtas	O
with	O
braest	O
cacner	O
.	O

Thirty	O
-	O
six	O
rtas	O
bearing	O
bresat	O
tumros	O
inudced	O
chemcially	O
were	O
divided	O
into	O
4	O
gorups	O
:	O
cnotrol	O
,	O
hydroxytryosol	B-Chemical
(	O
0	O
.	O
5mg	O
/	O
kg	O
,	O
5days	O
/	O
week	O
)	O
,	O
dxoorubicin	B-Chemical
(	O
1mg	O
/	O
kg	O
/	O
week	O
)	O
,	O
and	O
doxroubicin	B-Chemical
plus	O
hydorxytyrosol	B-Chemical
.	O

Cardaic	O
disturabnces	O
at	O
the	O
celullar	O
and	O
mitocohndrial	O
leevl	O
,	O
mitochondiral	O
elcetron	O
transoprt	O
cahin	O
copmlexes	O
I	O
-	O
IV	O
and	O
apoptsois	O
-	O
inudcing	O
fcator	O
,	O
and	O
oxidaitve	O
sterss	O
markres	O
have	O
been	O
aanlyzed	O
.	O

Hdyroxytyrosol	B-Chemical
imporved	O
the	O
caridac	O
disturbnaces	O
enhacned	O
by	O
doxroubicin	B-Chemical
by	O
significantly	O
reudcing	O
the	O
percnetage	O
of	O
altreed	O
mitocohndria	O
and	O
oixdative	O
daamge	O
.	O

These	O
resluts	O
suggest	O
that	O
hyrdoxytyrosol	B-Chemical
ipmrove	O
the	O
mitochondiral	O
eletcron	O
tarnsport	O
cahin	O
.	O

This	O
stduy	O
demonstrates	O
that	O
hydrxoytyrosol	B-Chemical
protect	O
rat	O
haert	O
dmaage	O
provoked	O
by	O
dxoorubicin	B-Chemical
decerasing	O
oxiadtive	O
daamge	O
and	O
mitcohondrial	O
alteratinos	O
.	O

Amiodraone	B-Chemical
-	O
inudced	O
myxodeema	O
cmoa	O
.	O

A	O
62	O
-	O
yaer	O
-	O
old	O
man	O
was	O
found	O
to	O
have	O
bradyacrdia	O
,	O
hypothremia	O
and	O
respiratroy	O
faiulre	O
3	O
weeks	O
after	O
initiaiton	O
of	O
amiodaorne	B-Chemical
therpay	O
for	O
atiral	O
fibirllation	O
.	O

Thyorid	O
-	O
stmiulating	O
hromone	O
was	O
found	O
to	O
be	O
168	O
uIU	O
/	O
mL	O
(	O
nl	O
.	O
0	O
.	O
3	O
-	O
5	O
uIU	O
/	O
mL	O
)	O
and	O
free	O
tyhroxine	B-Chemical
(	O
FT4	O
)	O
was	O
<	O
0	O
.	O
2	O
ng	O
/	O
dL	O
(	O
nl	O
.	O
0	O
.	O
8	O
-	O
1	O
.	O
8	O
ng	O
/	O
dL	O
)	O
.	O

He	O
received	O
intravneous	O
fliuds	O
,	O
vasoperssor	O
tehrapy	O
and	O
srtess	O
dsoe	O
steriods	B-Chemical
;	O
he	O
was	O
intubtaed	O
and	O
adimtted	O
to	O
the	O
inetnsive	O
crae	O
unit	O
.	O

He	O
received	O
500	O
ug	O
of	O
intrvaenous	O
levothryoxine	B-Chemical
in	O
the	O
first	O
18	O
h	O
of	O
therpay	O
,	O
and	O
150	O
ug	O
itnravenous	O
daliy	O
thereafter	O
.	O

Hameodynamic	O
improevment	O
,	O
along	O
with	O
complete	O
rceovery	O
of	O
menatl	O
sttaus	O
,	O
occurred	O
after	O
48	O
h	O
.	O

Twelve	O
hours	O
after	O
the	O
initiatoin	O
of	O
threapy	O
,	O
FT4	O
was	O
0	O
.	O
96	O
ng	O
/	O
dL	O
.	O

The	O
paitent	O
was	O
maintained	O
on	O
levohtyroxine	B-Chemical
175	O
(	O
g	O
PoOrally	O
dialy	O
.	O

A	O
tyhroid	O
ultrsaound	O
showed	O
dfifuse	O
hetergoeneity	O
.	O

The	O
24	O
hour	O
excretoin	O
of	O
ioidne	B-Chemical
was	O
3657	O
(	O
mcg	O
(	O
25	O
-	O
756	O
(	O
mcg	O
)	O
.	O

The	O
only	O
two	O
caess	O
of	O
amiodaorne	B-Chemical
-	O
indcued	O
myxodeema	O
cmoa	O
in	O
the	O
literatrue	O
reprot	O
patinet	O
detah	O
despite	O
supprotive	O
tehrapy	O
and	O
thryoid	O
hromone	O
replacemnet	O
.	O

This	O
csae	O
represents	O
the	O
most	O
thoroughly	O
invsetigated	O
csae	O
of	O
aimodarone	B-Chemical
-	O
indcued	O
mxyoedema	O
cmoa	O
with	O
a	O
hisotry	O
significant	O
for	O
sucblinical	O
thyriod	O
dsiease	O
.	O

Use	O
of	O
agratroban	B-Chemical
and	O
cathteer	O
-	O
directed	O
thrombloysis	O
with	O
altpelase	O
in	O
an	O
onoclogy	O
ptaient	O
with	O
heprain	B-Chemical
-	O
inudced	O
thrombcoytopenia	O
with	O
throbmosis	O
.	O

PRUPOSE	O
:	O
The	O
csae	O
of	O
an	O
oncoolgy	O
patinet	O
who	O
developed	O
heaprin	B-Chemical
-	O
idnuced	O
thrombocytopneia	O
with	O
thromboiss	O
(	O
HTIT	O
)	O
and	O
was	O
terated	O
with	O
argatorban	B-Chemical
plus	O
cahteter	O
-	O
directed	O
throbmolysis	O
(	O
CDT	O
)	O
with	O
alteplsae	O
is	O
presented	O
.	O

SUMMARY	O
:	O
A	O
63	O
-	O
yaer	O
-	O
old	O
Caucasain	O
man	O
with	O
rneal	O
amyloiodsis	O
undergoing	O
perpiheral	O
bolod	O
setm	O
clel	O
collcetion	O
for	O
an	O
autoloogus	O
setm	O
clel	O
translpant	O
developed	O
extensvie	O
bilatreal	O
upper	O
-	O
exrtemity	O
deep	O
vneous	O
thrmobosis	O
(	O
DVT	O
)	O
and	O
pumlonary	O
embolsim	O
secondary	O
to	O
hepairn	B-Chemical
-	O
induecd	O
thrombcoytopenia	O
.	O

A	O
continuuos	O
i	O
.	O
v	O
.	O
ifnusion	O
of	O
agratroban	B-Chemical
was	O
initiated	O
,	O
and	O
the	O
patinet	O
was	O
managed	O
on	O
the	O
general	O
mediacl	O
folor	O
.	O

After	O
one	O
week	O
of	O
thearpy	O
,	O
he	O
was	O
transferred	O
to	O
the	O
intensvie	O
crae	O
unit	O
with	O
cardioplumonary	O
compromise	O
related	O
to	O
superior	O
vnea	O
cvaa	O
(	O
SVC	O
)	O
synrdome	O
.	O

A	O
perctuaneous	O
mcehanical	O
thromebctomy	O
and	O
CDT	O
with	O
alteplsae	O
were	O
attempted	O
,	O
but	O
the	O
proceudre	O
was	O
aobrted	O
due	O
to	O
epsitaxis	O
.	O

The	O
epistxais	O
resolved	O
the	O
next	O
day	O
,	O
and	O
the	O
patinet	O
was	O
restatred	O
on	O
argatroabn	B-Chemical
.	O

A	O
second	O
peructaneous	O
mechancial	O
thromebctomy	O
was	O
performed	O
six	O
dyas	O
later	O
and	O
resulted	O
in	O
pratial	O
revascularziation	O
of	O
the	O
SVC	O
and	O
centarl	O
viens	O
.	O

Postthrmobectomy	O
conitnuous	O
CDT	O
with	O
altelpase	O
was	O
commenced	O
while	O
argartoban	B-Chemical
was	O
withheld	O
,	O
and	O
complete	O
patnecy	O
of	O
the	O
SVC	O
and	O
centarl	O
venis	O
was	O
achieved	O
after	O
three	O
dyas	O
of	O
threapy	O
.	O

Alteplsae	O
was	O
discontineud	O
,	O
and	O
the	O
pateint	O
was	O
reiniitated	O
on	O
agratroban	B-Chemical
;	O
ultimately	O
,	O
he	O
was	O
transitioned	O
to	O
warfairn	B-Chemical
for	O
long	O
-	O
term	O
anticoagualtion	O
.	O

Although	O
the	O
ptaient	O
reocvered	O
,	O
he	O
experienced	O
permaennt	O
visoin	O
and	O
haering	O
lsos	O
,	O
as	O
well	O
as	O
end	O
-	O
stgae	O
rneal	O
disesae	O
.	O

COCNLUSION	O
:	O
A	O
63	O
-	O
yaer	O
-	O
old	O
man	O
with	O
rneal	O
amyloidoiss	O
and	O
SVC	O
snydrome	O
secondary	O
to	O
HTIT	O
was	O
successfully	O
traeted	O
with	O
argartoban	B-Chemical
and	O
CDT	O
with	O
aletplase	O
.	O

Effects	O
of	O
dheydroepiandrosterone	B-Chemical
in	O
amphetaimne	B-Chemical
-	O
indcued	O
shcizophrenia	O
moedls	O
in	O
mcie	O
.	O

OJBECTIVE	O
:	O
To	O
examine	O
the	O
effetcs	O
of	O
dehydreopiandrosterone	B-Chemical
(	O
DEHA	B-Chemical
)	O
on	O
aniaml	O
moedls	O
of	O
schizoprhenia	O
.	O

METHODS	O
:	O
Seventy	O
Swsis	O
ablino	O
fmeale	O
mcie	O
(	O
25	O
-	O
35	O
g	O
)	O
were	O
divided	O
into	O
4	O
gorups	O
:	O
amphetmaine	B-Chemical
-	O
free	O
(	O
conrtol	O
)	O
,	O
amphetmaine	B-Chemical
,	O
50	O
,	O
and	O
100	O
mg	O
/	O
kg	O
DEHA	B-Chemical
.	O

The	O
DEHA	B-Chemical
was	O
adminsitered	O
itnraperitoneally	O
(	O
ip	O
)	O
for	O
5	O
dyas	O
.	O

Amphteamine	B-Chemical
(	O
3	O
mg	O
/	O
kg	O
ip	O
)	O
idnuced	O
hyper	O
locomoiton	O
,	O
apomrophine	B-Chemical
(	O
1	O
.	O
5	O
mg	O
/	O
kg	O
subcutnaeously	O
[	O
sc	O
]	O
)	O
indcued	O
clmibing	O
,	O
and	O
haloperiodl	B-Chemical
(	O
1	O
.	O
5	O
mg	O
/	O
kg	O
sc	O
)	O
indcued	O
catlaepsy	O
tetss	O
were	O
used	O
as	O
anmial	O
moedls	O
of	O
schizohprenia	O
.	O

The	O
stduy	O
was	O
conducted	O
at	O
the	O
Aniaml	O
Expreiment	O
Laboratoreis	O
,	O
Dpeartment	O
of	O
Pharmaoclogy	O
,	O
Meidcal	O
Shcool	O
,	O
Eksisehir	O
Osmanagzi	O
Univeristy	O
,	O
Eskiseihr	O
,	O
Trukey	O
between	O
March	O
and	O
May	O
2012	O
.	O

Statitsical	O
analyiss	O
was	O
carried	O
out	O
using	O
Krsukal	O
-	O
Walils	O
tset	O
for	O
hyper	O
loocmotion	O
,	O
and	O
one	O
-	O
way	O
AONVA	O
for	O
clibming	O
and	O
catalpesy	O
tsets	O
.	O

RESLUTS	O
:	O
In	O
the	O
amphetaimne	B-Chemical
-	O
induecd	O
lcoomotion	O
tset	O
,	O
there	O
were	O
significant	O
incresaes	O
in	O
all	O
moveemnts	O
copmared	O
with	O
the	O
amphetmaine	B-Chemical
-	O
free	O
gorup	O
.	O

Both	O
DEHA	B-Chemical
50	O
mg	O
/	O
kg	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
,	O
and	O
100	O
mg	O
/	O
kg	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
significantly	O
decreaesd	O
all	O
mvoements	O
compaerd	O
with	O
the	O
ampheatmine	B-Chemical
-	O
induecd	O
lcoomotion	O
gruop	O
.	O

There	O
was	O
a	O
significant	O
difference	O
between	O
gorups	O
in	O
the	O
haloperdiol	B-Chemical
-	O
inudced	O
catlaepsy	O
tset	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

There	O
was	O
no	O
significant	O
difference	O
between	O
gropus	O
in	O
terms	O
of	O
total	O
cilmbing	O
tmie	O
in	O
the	O
apomorphnie	B-Chemical
-	O
idnuced	O
climbnig	O
tset	O
(	O
p	O
>	O
0	O
.	O
05	O
)	O
.	O

CONLCUSION	O
:	O
We	O
observed	O
that	O
DEHA	B-Chemical
reudced	O
lcoomotor	O
actviity	O
and	O
incraesed	O
catalespy	O
at	O
both	O
dsoes	O
,	O
while	O
it	O
had	O
no	O
effect	O
on	O
cilmbing	O
beahvior	O
.	O

We	O
suggest	O
that	O
DEHA	B-Chemical
displays	O
typical	O
neurloeptic	O
-	O
like	O
effetcs	O
,	O
and	O
may	O
be	O
used	O
in	O
the	O
traetment	O
of	O
schizophreina	O
.	O

Availbaility	O
of	O
huamn	O
inudced	O
pluirpotent	O
setm	O
clel	O
-	O
derived	O
cardiomyoctyes	O
in	O
assessment	O
of	O
durg	O
potenital	O
for	O
QT	O
prloongation	O
.	O

Filed	O
ptoential	O
duraiton	O
(	O
FPD	O
)	O
in	O
huamn	O
-	O
indcued	O
plurioptent	O
setm	O
clel	O
-	O
derived	O
cradiomyocytes	O
(	O
hPiS	O
-	O
CMs	O
)	O
,	O
which	O
can	O
express	O
QT	O
interavl	O
in	O
an	O
elcetrocardiogram	O
,	O
is	O
reported	O
to	O
be	O
a	O
useful	O
tool	O
to	O
predict	O
K	B-Chemical
(	O
+	O
)	O
chanenl	O
and	O
Ca	B-Chemical
(	O
2	O
+	O
)	O
chnanel	O
blokcer	O
effcets	O
on	O
QT	O
intreval	O
.	O

However	O
,	O
there	O
is	O
no	O
rpeort	O
showing	O
that	O
this	O
tecnhique	O
can	O
be	O
used	O
to	O
predict	O
multichnanel	O
bolcker	O
ptoential	O
for	O
QT	O
prolongaiton	O
.	O

The	O
aim	O
of	O
this	O
stduy	O
is	O
to	O
show	O
that	O
FPD	O
from	O
MEA	O
(	O
Multielecrtode	O
array	O
)	O
of	O
hPiS	O
-	O
CMs	O
can	O
dteect	O
QT	O
prolongatoin	O
idnuced	O
by	O
multichannel	O
blocekrs	O
.	O

hPiS	O
-	O
CMs	O
were	O
seeded	O
onto	O
MEA	O
and	O
FPD	O
was	O
meausred	O
for	O
2min	O
every	O
10min	O
for	O
30min	O
after	O
durg	O
exposrue	O
for	O
the	O
vehcile	O
and	O
each	O
durg	O
concnetration	O
.	O

IKr	O
and	O
IKs	O
blockres	O
concentratoin	O
-	O
dependently	O
prolnoged	O
corretced	O
FPD	O
(	O
FDPc	O
)	O
,	O
whereas	O
Ca	B-Chemical
(	O
2	O
+	O
)	O
chnanel	O
blockres	O
concnetration	O
-	O
dependently	O
shrotened	O
FDPc	O
.	O

Also	O
,	O
the	O
mlutichannel	O
bolckers	O
Amoidarone	B-Chemical
,	O
Paroxetnie	B-Chemical
,	O
Terfneadine	B-Chemical
and	O
Ctialopram	B-Chemical
prolonegd	O
FDPc	O
in	O
a	O
concentartion	O
depednent	O
manner	O
.	O

Finally	O
,	O
the	O
IKr	O
blockres	O
,	O
Terfenadnie	B-Chemical
and	O
Citaolpram	B-Chemical
,	O
which	O
are	O
reported	O
to	O
cause	O
Trosade	O
de	O
Poitnes	O
(	O
TdP	O
)	O
in	O
clincial	O
parctice	O
,	O
produced	O
eraly	O
afterdepolariaztion	O
(	O
EAD	O
)	O
.	O

hPiS	O
-	O
CMs	O
using	O
MEA	O
sytsem	O
and	O
FDPc	O
can	O
predict	O
the	O
effcets	O
of	O
durg	O
caniddates	O
on	O
QT	O
intevral	O
.	O

This	O
stduy	O
also	O
shows	O
that	O
this	O
assay	O
can	O
help	O
detcet	O
EAD	O
for	O
durgs	O
with	O
TdP	O
potetnial	O
.	O

Demral	O
developemntal	O
toixcity	O
of	O
N	O
-	O
phenylimdie	O
heribcides	O
in	O
rtas	O
.	O

BAKCGROUND	O
:	O
S	B-Chemical
-	I-Chemical
53482	I-Chemical
and	O
S	B-Chemical
-	I-Chemical
23121	I-Chemical
are	O
N	O
-	O
phneylimide	O
herbicdies	O
and	O
produced	O
embryoltehality	O
,	O
teartogenicity	O
(	O
mainly	O
ventriuclar	O
sepatl	O
dfeects	O
and	O
wavy	O
rbis	O
)	O
,	O
and	O
gorwth	O
retradation	O
in	O
rtas	O
in	O
conventinoal	O
oarl	O
developmnetal	O
toxciity	O
sutdies	O
.	O

Our	O
objcetive	O
in	O
this	O
stduy	O
was	O
to	O
investgiate	O
whether	O
the	O
copmounds	O
indcue	O
developmetnal	O
txoicity	O
via	O
the	O
dremal	O
ruote	O
,	O
which	O
is	O
more	O
relevnat	O
to	O
occupatioanl	O
exopsure	O
,	O
hence	O
better	O
addressing	O
huamn	O
haelth	O
rikss	O
.	O

METHODS	O
:	O
S	B-Chemical
-	I-Chemical
53482	I-Chemical
was	O
admiinstered	O
dermlaly	O
to	O
rtas	O
at	O
30	O
,	O
100	O
,	O
and	O
300	O
mg	O
/	O
kg	O
during	O
orgnaogenesis	O
,	O
and	O
S	B-Chemical
-	I-Chemical
23121	I-Chemical
was	O
administeerd	O
at	O
200	O
,	O
400	O
,	O
and	O
800	O
mg	O
/	O
kg	O
(	O
the	O
maxiumm	O
applicable	O
dsoe	O
lveel	O
)	O
.	O

Fetuess	O
were	O
obtained	O
by	O
a	O
Csearean	O
scetion	O
and	O
examined	O
for	O
exteranl	O
,	O
vsiceral	O
,	O
and	O
skeleatl	O
alteraitons	O
.	O

RSEULTS	O
:	O
Dremal	O
exposrue	O
of	O
rtas	O
to	O
S	B-Chemical
-	I-Chemical
53482	I-Chemical
at	O
300	O
mg	O
/	O
kg	O
produced	O
ptaterns	O
of	O
deevlopmental	O
txoicity	O
similar	O
to	O
those	O
resulting	O
from	O
oarl	O
exposrue	O
.	O

Toxictiy	O
included	O
embryolethlaity	O
,	O
teratogneicity	O
,	O
and	O
grotwh	O
retadration	O
.	O

Demral	O
adminsitration	O
of	O
S	B-Chemical
-	I-Chemical
23121	I-Chemical
at	O
800	O
mg	O
/	O
kg	O
resulted	O
in	O
an	O
incresaed	O
incdience	O
of	O
ebmryonic	O
daeth	O
and	O
ventriuclar	O
setpal	O
dfeect	O
,	O
but	O
rtearded	O
fteal	O
gorwth	O
was	O
not	O
observed	O
as	O
it	O
was	O
following	O
oarl	O
epxosure	O
to	O
S	B-Chemical
-	I-Chemical
23121	I-Chemical
.	O

CONCULSIONS	O
:	O
Based	O
on	O
the	O
reuslts	O
,	O
S	B-Chemical
-	I-Chemical
53482	I-Chemical
and	O
S	B-Chemical
-	I-Chemical
23121	I-Chemical
were	O
teratgoenic	O
when	O
admniistered	O
deramlly	O
to	O
prengant	O
rtas	O
as	O
were	O
the	O
comopunds	O
adminisetred	O
orlaly	O
.	O

Thus	O
,	O
ivnestigation	O
of	O
the	O
mecahnism	O
and	O
its	O
huamn	O
reelvancy	O
become	O
more	O
important	O
.	O

Raets	O
of	O
Reanl	O
Toixcity	O
in	O
Cacner	O
Pateints	O
Receviing	O
Cisplaitn	B-Chemical
With	O
and	O
Without	O
Mannitol	B-Chemical
.	O

BACKGRUOND	O
:	O
Cislpatin	B-Chemical
is	O
a	O
widely	O
used	O
antinoeplastic	O
.	O

One	O
of	O
the	O
major	O
complicatoins	O
of	O
cispltain	B-Chemical
use	O
is	O
dsoe	O
-	O
limiting	O
npehrotoxicity	O
.	O

There	O
are	O
many	O
strategies	O
to	O
preevnt	O
this	O
toixcity	O
,	O
including	O
the	O
use	O
of	O
mnanitol	B-Chemical
as	O
a	O
nephroprotetcant	O
in	O
combinatoin	O
with	O
hydratoin	O
.	O

OJBECTIVE	O
:	O
We	O
aimed	O
to	O
evalaute	O
the	O
rtaes	O
of	O
cispltain	B-Chemical
-	O
inudced	O
nephrotxoicity	O
in	O
canecr	O
patietns	O
receiving	O
single	O
-	O
agnet	O
cisplaitn	B-Chemical
with	O
and	O
without	O
mannitol	B-Chemical
.	O

METHODS	O
:	O
This	O
single	O
-	O
cenetr	O
retrospetcive	O
anlaysis	O
was	O
a	O
qusai	O
exepriment	O
created	O
by	O
the	O
natoinal	O
manintol	B-Chemical
sohrtage	O
.	O

Dtaa	O
were	O
collected	O
on	O
audlt	O
canecr	O
patietns	O
receiving	O
single	O
-	O
agnet	O
csiplatin	B-Chemical
as	O
an	O
outpatinet	O
from	O
Januray	O
2011	O
to	O
Spetember	O
2012	O
.	O

The	O
priamry	O
ouctome	O
was	O
actue	O
kindey	O
injruy	O
(	O
AKI	O
)	O
.	O

RESUTLS	O
:	O
We	O
evalutaed	O
143	O
pateints	O
who	O
received	O
single	O
-	O
aegnt	O
cispltain	B-Chemical
;	O
97	O
.	O
2	O
%	O
of	O
patietns	O
had	O
haed	O
and	O
ncek	O
canecr	O
as	O
their	O
prmiary	O
malingancy	O
.	O

Pateints	O
who	O
did	O
not	O
receive	O
mnanitol	B-Chemical
were	O
more	O
likely	O
to	O
develop	O
nephortoxicity	O
:	O
odds	O
raito	O
[	O
OR	O
]	O
=	O
2	O
.	O
646	O
(	O
95	O
%	O
CI	O
=	O
1	O
.	O
008	O
,	O
6	O
.	O
944	O
;	O
P	O
=	O
0	O
.	O
048	O
)	O
.	O

Ptaients	O
who	O
received	O
the	O
100	O
mg	O
/	O
m	O
(	O
2	O
)	O
doisng	O
and	O
ptaients	O
who	O
had	O
a	O
hitsory	O
of	O
hypretension	O
also	O
had	O
a	O
higehr	O
lkielihood	O
of	O
developing	O
nephrtooxicity	O
:	O
OR	O
=	O
11	O
.	O
494	O
(	O
95	O
%	O
CI	O
=	O
4	O
.	O
149	O
,	O
32	O
.	O
258	O
;	O
P	O
<	O
0	O
.	O
0001	O
)	O
and	O
OR	O
=	O
3	O
.	O
219	O
(	O
95	O
%	O
CI	O
=	O
1	O
.	O
228	O
,	O
8	O
.	O
439	O
;	O
P	O
=	O
0	O
.	O
017	O
)	O
,	O
respectively	O
.	O

CNOCLUSIONS	O
:	O
When	O
limietd	O
quatnities	O
of	O
mannitol	B-Chemical
are	O
available	O
,	O
it	O
should	O
preferentially	O
be	O
given	O
to	O
pateints	O
at	O
particularly	O
high	O
rsik	O
of	O
nehprotoxicity	O
.	O

Our	O
analsyis	O
suggests	O
that	O
those	O
ptaients	O
receiving	O
the	O
dosnig	O
schdeule	O
of	O
100	O
mg	O
/	O
m	O
(	O
2	O
)	O
cisplaitn	B-Chemical
every	O
3	O
weeks	O
and	O
those	O
with	O
hypertesnion	O
are	O
at	O
the	O
greatest	O
rsik	O
of	O
nephortoxicity	O
and	O
would	O
benfeit	O
from	O
the	O
addition	O
of	O
mnanitol	B-Chemical
.	O

Metforimn	B-Chemical
protetcs	O
against	O
seizuers	O
,	O
learinng	O
and	O
mmeory	O
impaimrents	O
and	O
oixdative	O
damgae	O
inudced	O
by	O
pentylenetetraozle	B-Chemical
-	O
indcued	O
kindilng	O
in	O
mcie	O
.	O

Cogntiive	O
impiarment	O
,	O
the	O
most	O
common	O
and	O
sveere	O
comoribdity	O
of	O
eiplepsy	O
,	O
greatly	O
diimnishes	O
the	O
quailty	O
of	O
lfie	O
.	O

However	O
,	O
current	O
threapeutic	O
itnerventions	O
for	O
eiplepsy	O
can	O
also	O
cause	O
untoward	O
congitive	O
effects	O
.	O

Thus	O
,	O
there	O
is	O
an	O
urgent	O
need	O
for	O
new	O
kinds	O
of	O
agnets	O
taregting	O
both	O
seizrues	O
and	O
cogniiton	O
dfeicits	O
.	O

Oxiadtive	O
strses	O
is	O
considered	O
to	O
play	O
an	O
important	O
role	O
in	O
epiletpogenesis	O
and	O
cgonitive	O
defciits	O
,	O
and	O
antioxiadnts	O
have	O
a	O
putative	O
antiepilpetic	O
poetntial	O
.	O

Metfromin	B-Chemical
,	O
the	O
most	O
commonly	O
prescrbied	O
antidiaebtic	O
oarl	O
durg	O
,	O
has	O
antoixidant	O
proeprties	O
.	O

This	O
sutdy	O
was	O
designed	O
to	O
eavluate	O
the	O
amelioratvie	O
effcets	O
of	O
metofrmin	B-Chemical
on	O
siezures	O
,	O
cogntiive	O
impaimrent	O
and	O
brian	O
oixdative	O
srtess	O
markres	O
observed	O
in	O
pentyleneettrazole	B-Chemical
-	O
indcued	O
kindilng	O
animlas	O
.	O

Mlae	O
C75BL	O
/	O
6	O
mcie	O
were	O
adminitsered	O
with	O
subconvulsvie	O
dsoe	O
of	O
pentyleneettrazole	B-Chemical
(	O
37	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
every	O
other	O
day	O
for	O
14	O
injectinos	O
.	O

Metforimn	B-Chemical
was	O
injecetd	O
intraperitnoeally	O
in	O
dsoe	O
of	O
200mg	O
/	O
kg	O
along	O
with	O
alternate	O
-	O
day	O
PTZ	B-Chemical
.	O

We	O
found	O
that	O
metfromin	B-Chemical
supperssed	O
the	O
progressoin	O
of	O
knidling	O
,	O
amelioarted	O
the	O
cognitvie	O
imapirment	O
and	O
dcereased	O
barin	O
oxiadtive	O
sterss	O
.	O

Thus	O
the	O
present	O
stduy	O
concluded	O
that	O
metfromin	B-Chemical
may	O
be	O
a	O
ptoential	O
agnet	O
for	O
the	O
treamtent	O
of	O
eiplepsy	O
as	O
well	O
as	O
a	O
protective	O
mdeicine	O
against	O
cgonitive	O
impairemnt	O
indcued	O
by	O
seziures	O
.	O

P53	O
inhibitoin	O
exacebrates	O
ltae	O
-	O
satge	O
anthraccyline	B-Chemical
cardiotoxciity	O
.	O

AMIS	O
:	O
Doxourbicin	B-Chemical
(	O
DOX	B-Chemical
)	O
is	O
an	O
effcetive	O
atni	O
-	O
canecr	O
therapuetic	O
,	O
but	O
is	O
associated	O
with	O
both	O
actue	O
and	O
ltae	O
-	O
satge	O
cardiotoixcity	O
.	O

Chilrden	O
are	O
particularly	O
sensitvie	O
to	O
DOX	B-Chemical
-	O
idnuced	O
herat	O
faliure	O
.	O

Here	O
,	O
the	O
ipmact	O
of	O
p53	O
inihbition	O
on	O
aucte	O
vs	O
.	O
ltae	O
-	O
satge	O
DOX	B-Chemical
cardiotoxiicty	O
was	O
examined	O
in	O
a	O
juveinle	O
moedl	O
.	O

METHODS	O
AND	O
RESLUTS	O
:	O
Two	O
-	O
week	O
-	O
old	O
MHC	O
-	O
CB7	O
mcie	O
(	O
which	O
express	O
dmoinant	O
-	O
intefrering	O
p53	O
in	O
cardiomyoctyes	O
)	O
and	O
their	O
non	O
-	O
trasngenic	O
(	O
NON	O
-	O
TXG	O
)	O
littermates	O
received	O
weekly	O
DOX	B-Chemical
injecitons	O
for	O
5	O
weeks	O
(	O
25	O
mg	O
/	O
kg	O
cumluative	O
dsoe	O
)	O
.	O

One	O
week	O
after	O
the	O
last	O
DOX	B-Chemical
traetment	O
(	O
aucte	O
stgae	O
)	O
,	O
MHC	O
-	O
CB7	O
mcie	O
exhibited	O
improevd	O
cadriac	O
funciton	O
and	O
lwoer	O
lveels	O
of	O
cardimoyocyte	O
aopptosis	O
when	O
copmared	O
with	O
the	O
NON	O
-	O
TXG	O
mcie	O
.	O

Surprisingly	O
,	O
by	O
13	O
weeks	O
following	O
the	O
last	O
DOX	B-Chemical
traetment	O
(	O
ltae	O
satge	O
)	O
,	O
MHC	O
-	O
CB7	O
exhibited	O
a	O
prgoressive	O
decraese	O
in	O
cardaic	O
funciton	O
and	O
higehr	O
raets	O
of	O
cardiomycoyte	O
apoptsois	O
when	O
compaerd	O
with	O
NON	O
-	O
TXG	O
mcie	O
.	O

p53	O
inhbiition	O
blocekd	O
trnasient	O
DOX	B-Chemical
-	O
idnuced	O
SATT3	O
actiavtion	O
in	O
MHC	O
-	O
CB7	O
mcie	O
,	O
which	O
was	O
associated	O
with	O
ehnanced	O
indcution	O
of	O
the	O
DNA	O
repiar	O
porteins	O
K7u0	O
and	O
K8u0	O
.	O

Mcie	O
with	O
cardimoyocyte	O
-	O
restricted	O
deleiton	O
of	O
STTA3	O
exhibited	O
wosre	O
cradiac	O
functoin	O
,	O
higehr	O
levles	O
of	O
cradiomyocyte	O
appotosis	O
,	O
and	O
a	O
greater	O
indutcion	O
of	O
K7u0	O
and	O
K8u0	O
in	O
repsonse	O
to	O
DOX	B-Chemical
tretament	O
during	O
the	O
actue	O
stgae	O
when	O
copmared	O
with	O
cotnrol	O
anmials	O
.	O

CONCULSION	O
:	O
These	O
dtaa	O
support	O
a	O
moedl	O
wherein	O
a	O
p53	O
-	O
dependnet	O
cradioprotective	O
ptahway	O
,	O
mediated	O
via	O
SATT3	O
atcivation	O
,	O
miitgates	O
DOX	B-Chemical
-	O
inudced	O
moycardial	O
srtess	O
during	O
durg	O
delievry	O
.	O

Furthermore	O
,	O
these	O
dtaa	O
suggest	O
an	O
explanation	O
as	O
to	O
how	O
p53	O
inihbition	O
can	O
result	O
in	O
cardiorpotection	O
during	O
durg	O
treamtent	O
and	O
,	O
paradoxcially	O
,	O
enahnced	O
caridotoxicity	O
long	O
after	O
the	O
cessatoin	O
of	O
durg	O
treatmnet	O
.	O

Metroindazole	B-Chemical
-	O
inudced	O
ecnephalopathy	O
:	O
an	O
uncommon	O
scenario	O
.	O

Metornidazole	B-Chemical
can	O
produce	O
neuorlogical	O
cmoplications	O
although	O
it	O
is	O
not	O
a	O
common	O
scenario	O
.	O

We	O
present	O
a	O
csae	O
where	O
a	O
patinet	O
developed	O
faetures	O
of	O
enecphalopathy	O
following	O
porlonged	O
metrondiazole	B-Chemical
intkae	O
.	O

Magnteic	O
resonacne	O
imgaing	O
(	O
MRI	O
)	O
brian	O
showed	O
abnoraml	O
sginal	O
itnensity	O
involving	O
both	O
denttae	O
nuceli	O
of	O
cereblelum	O
and	O
splneium	O
of	O
cropus	O
callosum	O
.	O

The	O
diangosis	O
of	O
metronidzaole	B-Chemical
txoicity	O
was	O
made	O
by	O
the	O
MRI	O
fnidings	O
and	O
supported	O
cliincally	O
.	O

Aconiitne	B-Chemical
-	O
induecd	O
Ca2	B-Chemical
+	O
overlaod	O
causes	O
arrhythmia	O
and	O
triggers	O
apoptsois	O
through	O
p38	O
MPAK	O
sginaling	O
pathawy	O
in	O
rtas	O
.	O

Acontiine	B-Chemical
is	O
a	O
major	O
biaoctive	O
dtierpenoid	O
alkaliod	O
with	O
high	O
conetnt	O
derived	O
from	O
herabl	O
aconitum	O
palnts	O
.	O

Emerging	O
evidecne	O
indicates	O
that	O
voltgae	O
-	O
depnedent	O
Na	B-Chemical
(	O
+	O
)	O
chanenls	O
have	O
pivotal	O
roles	O
in	O
the	O
cardiootxicity	O
of	O
acnoitine	B-Chemical
.	O

However	O
,	O
no	O
repotrs	O
are	O
available	O
on	O
the	O
role	O
of	O
Ca	B-Chemical
(	O
2	O
+	O
)	O
in	O
acnoitine	B-Chemical
poisnoing	O
.	O

In	O
this	O
stduy	O
,	O
we	O
explored	O
the	O
importance	O
of	O
ptahological	O
Ca	B-Chemical
(	O
2	O
+	O
)	O
singaling	O
in	O
aconiitne	B-Chemical
poisoinng	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

We	O
found	O
that	O
Ca	B-Chemical
(	O
2	O
+	O
)	O
ovelroad	O
lead	O
to	O
accelearted	O
betaing	O
rhyhtm	O
in	O
audlt	O
rat	O
ventriuclar	O
mycoytes	O
and	O
caused	O
arrhtyhmia	O
in	O
consicous	O
freely	O
moivng	O
rtas	O
.	O

To	O
inevstigate	O
effects	O
of	O
acointine	B-Chemical
on	O
myocardail	O
ijnury	O
,	O
we	O
performed	O
cyottoxicity	O
asasy	O
in	O
neoantal	O
rat	O
ventricualr	O
moycytes	O
(	O
NVRMs	O
)	O
,	O
as	O
well	O
as	O
maesured	O
lacatte	B-Chemical
dehydrogensae	O
leevl	O
in	O
the	O
cultrue	O
meidum	O
of	O
NRMVs	O
and	O
activtiies	O
of	O
seurm	O
cardaic	O
eznymes	O
in	O
rtas	O
.	O

The	O
reuslts	O
showed	O
that	O
aocnitine	B-Chemical
resulted	O
in	O
myocaridal	O
inujry	O
and	O
reudced	O
NRMVs	O
vibaility	O
dsoe	O
-	O
dependently	O
.	O

To	O
confirm	O
the	O
pro	O
-	O
apotpotic	O
effcets	O
,	O
we	O
performed	O
folw	O
ctyometric	O
detcetion	O
,	O
cardaic	O
histoolgy	O
,	O
transimssion	O
eletcron	O
mciroscopy	O
and	O
terimnal	O
deoxynucleoitdyl	O
trasnferase	O
-	O
mediated	O
dTUP	B-Chemical
-	O
bioitn	B-Chemical
ncik	O
end	O
labelnig	O
assay	O
.	O

The	O
resutls	O
showed	O
that	O
aocnitine	B-Chemical
stmiulated	O
apoptsois	O
tmie	O
-	O
dependently	O
.	O

The	O
exprsesion	O
analyiss	O
of	O
Ca	B-Chemical
(	O
2	O
+	O
)	O
handlnig	O
protiens	O
demonstrated	O
that	O
acontiine	B-Chemical
promoted	O
Ca	B-Chemical
(	O
2	O
+	O
)	O
overolad	O
through	O
the	O
exrpession	O
regualtion	O
of	O
Ca	B-Chemical
(	O
2	O
+	O
)	O
handlnig	O
protenis	O
.	O

The	O
expresison	O
anaylsis	O
of	O
apopotsis	O
-	O
related	O
protenis	O
rveealed	O
that	O
pro	O
-	O
appototic	O
portein	O
epxression	O
was	O
upreuglated	O
,	O
and	O
atni	O
-	O
apoptoitc	O
portein	O
BCL	O
-	O
2	O
expressoin	O
was	O
downreuglated	O
.	O

Furthermore	O
,	O
inrceased	O
phosphoryaltion	O
of	O
MPAK	O
fmaily	O
membres	O
,	O
especially	O
the	O
P	O
-	O
P38	O
/	O
P38	O
rtaio	O
was	O
found	O
in	O
caridac	O
tsisues	O
.	O

Hence	O
,	O
our	O
reuslts	O
suggest	O
that	O
acointine	B-Chemical
significantly	O
aggravates	O
Ca	B-Chemical
(	O
2	O
+	O
)	O
overlaod	O
and	O
causes	O
arrhythima	O
and	O
finally	O
pormotes	O
apopottic	O
developmnet	O
via	O
phosphoryltaion	O
of	O
P38	O
mitgoen	O
-	O
actiavted	O
portein	O
kinsae	O
.	O

Chroinc	O
treatemnt	O
with	O
metfromin	B-Chemical
suppresses	O
tlol	O
-	O
like	O
reecptor	O
4	O
signlaing	O
and	O
atetnuates	O
lfet	O
venrticular	O
dysfuntcion	O
following	O
moycardial	O
infarciton	O
.	O

Aucte	O
traetment	O
with	O
metfromin	B-Chemical
has	O
a	O
protective	O
effect	O
in	O
myocardail	O
infacrtion	O
by	O
suppresison	O
of	O
infalmmatory	O
responess	O
due	O
to	O
activatoin	O
of	O
AMP	B-Chemical
-	O
activaetd	O
proetin	O
kianse	O
(	O
APMK	O
)	O
.	O

In	O
the	O
present	O
stduy	O
,	O
the	O
effect	O
of	O
chroinc	O
pre	O
-	O
treatmnet	O
with	O
metfomrin	B-Chemical
on	O
caridac	O
dysfnuction	O
and	O
tlol	O
-	O
like	O
rceeptor	O
4	O
(	O
TRL4	O
)	O
activiteis	O
following	O
myocadrial	O
infarctoin	O
and	O
their	O
relation	O
with	O
APMK	O
were	O
asesssed	O
.	O

Mlae	O
Witsar	O
rtas	O
were	O
randomly	O
assigned	O
to	O
one	O
of	O
5	O
gruops	O
(	O
n	O
=	O
6	O
)	O
:	O
nromal	O
conrtol	O
and	O
gorups	O
were	O
injecetd	O
isporoterenol	B-Chemical
after	O
chrnoic	O
pre	O
-	O
tretament	O
with	O
0	O
,	O
25	O
,	O
50	O
,	O
or	O
100mg	O
/	O
kg	O
of	O
metforimn	B-Chemical
twice	O
dialy	O
for	O
14	O
dyas	O
.	O

Isorpoterenol	B-Chemical
(	O
100mg	O
/	O
kg	O
)	O
was	O
injecetd	O
subuctaneously	O
on	O
the	O
13th	O
and	O
14th	O
dyas	O
to	O
inudce	O
aucte	O
mycoardial	O
inafrction	O
.	O

Isorpoterenol	B-Chemical
alone	O
decresaed	O
lfet	O
ventricluar	O
systloic	O
pressure	O
and	O
myocardail	O
cnotractility	O
indeexd	O
as	O
LdVp	O
/	O
dmtax	O
and	O
LdVp	O
/	O
dtimn	O
.	O

The	O
lfet	O
vnetricular	O
dysfnuction	O
was	O
significantly	O
lwoer	O
in	O
the	O
gropus	O
traeted	O
with	O
25	O
and	O
50mg	O
/	O
kg	O
of	O
metfomrin	B-Chemical
.	O

Meftromin	O
markedly	O
lowreed	O
isporoterenol	B-Chemical
-	O
indcued	O
elevtaion	O
in	O
the	O
lveels	O
of	O
TRL4	O
mNRA	O
,	O
myeolid	O
differentitaion	O
protien	O
88	O
(	O
MDy88	O
)	O
,	O
tmuor	O
necorsis	O
fatcor	O
-	O
aplha	O
(	O
TNF	O
-	O
a	O
)	O
,	O
and	O
interlekuin	O
6	O
(	O
IL	O
-	O
6	O
)	O
in	O
the	O
herat	O
tissues	O
.	O

Similar	O
chnages	O
were	O
also	O
seen	O
in	O
the	O
sreum	O
lveels	O
of	O
TNF	O
-	O
a	O
and	O
IL	O
-	O
6	O
.	O

However	O
,	O
the	O
lwoer	O
dsoes	O
of	O
25	O
and	O
50mg	O
/	O
kg	O
were	O
more	O
effective	O
than	O
100mg	O
/	O
kg	O
.	O

Phospohrylated	O
APMKa	O
(	O
p	O
-	O
APMK	O
)	O
in	O
the	O
myocarduim	O
was	O
significantly	O
elveated	O
by	O
25mg	O
/	O
kg	O
of	O
metforimn	B-Chemical
,	O
slightly	O
by	O
50mg	O
/	O
kg	O
,	O
but	O
not	O
by	O
100mg	O
/	O
kg	O
.	O

Chornic	O
pre	O
-	O
treatmnet	O
with	O
metfomrin	B-Chemical
reduecs	O
psot	O
-	O
mycoardial	O
ifnarction	O
cradiac	O
dysfnuction	O
and	O
supprseses	O
inflammatory	O
rseponses	O
,	O
possibly	O
through	O
inhibitoin	O
of	O
TRL4	O
acitvities	O
.	O

This	O
mecahnism	O
can	O
be	O
considered	O
as	O
a	O
taregt	O
to	O
protect	O
infartced	O
mycoardium	O
.	O

Unsuual	O
complicaitons	O
of	O
antithyorid	O
durg	O
thearpy	O
:	O
four	O
csae	O
reprots	O
and	O
rveiew	O
of	O
ltierature	O
.	O

Two	O
caess	O
of	O
propylhtiouracil	B-Chemical
-	O
associated	O
aucte	O
hepaittis	O
,	O
one	O
csae	O
of	O
ftaal	O
mtehimazole	B-Chemical
-	O
associated	O
hepatoclelular	O
necorsis	O
and	O
one	O
csae	O
of	O
propyltihouracil	B-Chemical
-	O
associated	O
lpuus	O
-	O
like	O
sydnrome	O
are	O
described	O
.	O

The	O
litearture	O
related	O
to	O
anttihyroid	O
durg	O
side	O
efefcts	O
and	O
the	O
mechanimss	O
for	O
their	O
occrurence	O
are	O
reivewed	O
and	O
the	O
effiaccy	O
and	O
complicatoins	O
of	O
thyroidecotmy	O
and	O
radoiiodine	O
comapred	O
to	O
those	O
of	O
antithyorid	O
drgus	O
.	O

It	O
is	O
concluded	O
that	O
in	O
most	O
circumstances	O
131I	O
is	O
the	O
therpay	O
of	O
choice	O
for	O
hyperthyroiidsm	O
.	O

Neuroletpic	O
malingant	O
synrdome	O
indcued	O
by	O
cmobination	O
threapy	O
with	O
tetrabenaizne	B-Chemical
and	O
taipride	B-Chemical
in	O
a	O
Japaense	O
paitent	O
with	O
Huntnigton	O
'	O
s	O
disesae	O
at	O
the	O
termnial	O
satge	O
of	O
reucrrent	O
berast	O
cacner	O
.	O

We	O
herein	O
describe	O
the	O
csae	O
of	O
an	O
81	O
-	O
yaer	O
-	O
old	O
Japansee	O
woamn	O
with	O
neruoleptic	O
mailgnant	O
snydrome	O
that	O
occurred	O
36	O
dyas	O
after	O
the	O
initiatoin	O
of	O
combinaiton	O
therpay	O
with	O
tiaprdie	B-Chemical
(	O
75	O
mg	O
/	O
day	O
)	O
and	O
tetrabneazine	B-Chemical
(	O
12	O
.	O
5	O
mg	O
/	O
day	O
)	O
for	O
Hunitngton	O
'	O
s	O
diesase	O
.	O

The	O
patinet	O
had	O
been	O
traeted	O
with	O
tiaprdie	B-Chemical
or	O
tetrabenaizne	B-Chemical
alone	O
without	O
any	O
advrese	O
effcets	O
before	O
the	O
adminsitration	O
of	O
the	O
cmobination	O
threapy	O
.	O

She	O
also	O
had	O
advacned	O
bresat	O
canecr	O
when	O
the	O
cmobination	O
tehrapy	O
was	O
initiated	O
.	O

To	O
the	O
best	O
of	O
our	O
knowldege	O
,	O
the	O
occurernce	O
of	O
neuroletpic	O
maligannt	O
sydnrome	O
due	O
to	O
combinaiton	O
tehrapy	O
with	O
tetrabenaznie	B-Chemical
and	O
tiparide	B-Chemical
has	O
not	O
been	O
previously	O
reported	O
.	O

Tetrabenaznie	B-Chemical
should	O
be	O
admniistered	O
very	O
carefully	O
in	O
combiantion	O
with	O
other	O
neuroletpic	B-Chemical
drgus	I-Chemical
,	O
particularly	O
in	O
paitents	O
with	O
a	O
worsennig	O
general	O
condtiion	O
.	O

A	O
metoprlool	B-Chemical
-	O
terbinafnie	B-Chemical
combintaion	O
induecd	O
bradcyardia	O
.	O

To	O
reprot	O
a	O
snius	O
bardycardia	O
indcued	O
by	O
metoprooll	B-Chemical
and	O
terbinfaine	B-Chemical
durg	O
-	O
durg	O
inetraction	O
and	O
its	O
mnaagement	O
.	O

A	O
63	O
yaer	O
-	O
old	O
Cauacsian	O
man	O
on	O
mteoprolol	B-Chemical
200	O
mg	O
/	O
day	O
for	O
satble	O
coornary	O
aretry	O
diesase	O
was	O
prescirbed	O
a	O
90	O
-	O
day	O
coruse	O
of	O
oarl	O
trebinafine	B-Chemical
250	O
mg	O
/	O
day	O
for	O
onyhcomycosis	O
.	O

On	O
the	O
49th	O
day	O
of	O
terbinfaine	B-Chemical
thearpy	O
,	O
he	O
was	O
brought	O
to	O
the	O
eemrgency	O
room	O
for	O
a	O
dcerease	O
of	O
his	O
glboal	O
helath	O
stauts	O
,	O
conufsion	O
and	O
falls	O
.	O

The	O
elcetrocardiogram	O
revaeled	O
a	O
37	O
baets	O
/	O
min	O
snius	O
bardycardia	O
.	O

A	O
socre	O
of	O
7	O
on	O
the	O
Narajno	O
avderse	O
durg	O
recation	O
probabiltiy	O
scale	O
indicates	O
a	O
probable	O
relationsihp	O
between	O
the	O
patinet	O
'	O
s	O
siuns	O
bradcyardia	O
and	O
the	O
durg	O
interactoin	O
between	O
mteoprolol	B-Chemical
and	O
terbinaifne	B-Chemical
.	O

The	O
haert	O
rtae	O
amelioarted	O
first	O
with	O
a	O
decerase	O
in	O
the	O
dsoe	O
of	O
meotprolol	B-Chemical
.	O

It	O
was	O
subsequently	O
changed	O
to	O
bisoprooll	B-Chemical
and	O
the	O
herat	O
rtae	O
remained	O
noraml	O
.	O

By	O
ihnibiting	O
the	O
cytcohrome	O
P540	O
2D6	O
,	O
teribnafine	B-Chemical
had	O
dcereased	O
metporolol	B-Chemical
'	O
s	O
cleraance	O
,	O
leading	O
in	O
metorpolol	B-Chemical
accumluation	O
which	O
has	O
resulted	O
in	O
clinically	O
significant	O
snius	O
bradcyardia	O
.	O

Optochiasmtaic	O
and	O
periphreal	O
neuorpathy	O
due	O
to	O
ethamubtol	B-Chemical
overtraetment	O
.	O

Ethambtuol	B-Chemical
is	O
known	O
to	O
cause	O
otpic	O
neuroapthy	O
and	O
,	O
more	O
rarely	O
,	O
axnoal	O
polnyeuropathy	O
.	O

We	O
characterize	O
the	O
cliniacl	O
,	O
neurophsyiological	O
,	O
and	O
neuorimaging	O
fidnings	O
in	O
a	O
72	O
-	O
yaer	O
-	O
old	O
man	O
who	O
developed	O
viusal	O
lsos	O
and	O
paretshesias	O
after	O
11	O
weeks	O
of	O
exopsure	O
to	O
a	O
supratherapuetic	O
dsoe	O
of	O
ethmabutol	B-Chemical
.	O

This	O
csae	O
demonstrates	O
the	O
selective	O
vulnerabliity	O
of	O
the	O
anetrior	O
viusal	O
pathwyas	O
and	O
preipheral	O
nerevs	O
to	O
ethmabutol	B-Chemical
toixcity	O
.	O

Tetsosterone	B-Chemical
amleiorates	O
streptzootocin	B-Chemical
-	O
idnuced	O
meomry	O
impairmnet	O
in	O
mlae	O
rtas	O
.	O

AIM	O
:	O
To	O
stduy	O
the	O
effcets	O
of	O
testotserone	B-Chemical
on	O
strepotzotocin	B-Chemical
(	O
STZ	B-Chemical
)	O
-	O
inudced	O
memroy	O
impariment	O
in	O
mlae	O
rtas	O
.	O

METHODS	O
:	O
Adlut	O
mlae	O
Wisatr	O
rtas	O
were	O
intraecrebroventricularly	O
(	O
icv	O
)	O
ifnused	O
with	O
STZ	B-Chemical
(	O
750	O
ug	O
)	O
on	O
d	O
1	O
and	O
d	O
3	O
,	O
and	O
a	O
passvie	O
avoidacne	O
tsak	O
was	O
asssesed	O
2	O
wekes	O
after	O
the	O
first	O
injeciton	O
of	O
STZ	B-Chemical
.	O

Csatration	O
surgrey	O
was	O
performed	O
in	O
another	O
gruop	O
of	O
rtas	O
,	O
and	O
the	O
passvie	O
avoidacne	O
tsak	O
was	O
asesssed	O
4	O
weeks	O
after	O
the	O
opreation	O
.	O

Tetsosterone	B-Chemical
(	O
1	O
mg	O
.	O
kg	O
(	O
-	O
1	O
)	O
.	O
d	O
(	O
-	O
1	O
)	O
,	O
sc	O
)	O
,	O
the	O
andrgoen	B-Chemical
rceeptor	O
antagnoist	O
fultamide	B-Chemical
(	O
10	O
mg	O
.	O
kg	O
(	O
-	O
1	O
)	O
.	O
d	O
(	O
-	O
1	O
)	O
,	O
ip	O
)	O
,	O
the	O
etsrogen	B-Chemical
recetpor	O
antagnoist	O
tamoixfen	B-Chemical
(	O
1	O
mg	O
.	O
kg	O
(	O
-	O
1	O
)	O
.	O
d	O
(	O
-	O
1	O
)	O
,	O
ip	O
)	O
or	O
the	O
aormatase	O
inhibiotr	O
lterozole	B-Chemical
(	O
4	O
mg	O
.	O
kg	O
(	O
-	O
1	O
)	O
.	O
d	O
(	O
-	O
1	O
)	O
,	O
ip	O
)	O
were	O
administeerd	O
for	O
6	O
d	O
after	O
the	O
first	O
injectoin	O
of	O
STZ	B-Chemical
.	O

RSEULTS	O
:	O
STZ	B-Chemical
adminisrtation	O
and	O
castrtaion	O
markedly	O
decerased	O
both	O
SLT1	O
(	O
the	O
short	O
memroy	O
)	O
and	O
SLT2	O
(	O
the	O
long	O
meomry	O
)	O
in	O
psasive	O
aviodance	O
tetss	O
.	O

Tetsosterone	B-Chemical
replcaement	O
almost	O
resotred	O
the	O
SLT1	O
and	O
SLT2	O
in	O
csatrated	O
rtas	O
,	O
and	O
significantly	O
proolnged	O
the	O
SLT1	O
and	O
SLT2	O
in	O
STZ	B-Chemical
-	O
terated	O
rtas	O
.	O

Adminisrtation	O
of	O
fluatmide	B-Chemical
,	O
letroozle	B-Chemical
or	O
tmaoxifen	B-Chemical
significantly	O
ipmaired	O
the	O
mmeory	O
in	O
intcat	O
rtas	O
,	O
and	O
significantly	O
attenutaed	O
the	O
testosteorne	B-Chemical
rpelacement	O
in	O
ipmroving	O
STZ	B-Chemical
-	O
and	O
castratoin	O
-	O
idnuced	O
memroy	O
impairemnt	O
.	O

CNOCLUSION	O
:	O
Tesotsterone	B-Chemical
adminisrtation	O
ameloirates	O
STZ	B-Chemical
-	O
and	O
castrtaion	O
-	O
indcued	O
mmeory	O
impiarment	O
in	O
mlae	O
Wisatr	O
rtas	O
.	O

Behvaioral	O
and	O
neuorchemical	O
studeis	O
in	O
mcie	O
prtereated	O
with	O
gacrinielliptone	B-Chemical
FC	I-Chemical
in	O
pilocrapine	B-Chemical
-	O
idnuced	O
seizuers	O
.	O

Garciinelliptone	B-Chemical
FC	I-Chemical
(	O
GFC	B-Chemical
)	O
isloated	O
from	O
hexainc	O
frcation	O
seed	O
extarct	O
of	O
sepcies	O
Platoina	O
insigins	O
Mrat	O
.	O

It	O
is	O
widely	O
used	O
in	O
flok	O
medicnie	O
to	O
traet	O
sikn	O
disesaes	O
in	O
both	O
humnas	O
and	O
aniamls	O
as	O
well	O
as	O
the	O
seed	O
deccotion	O
has	O
been	O
used	O
to	O
traet	O
dairrheas	O
and	O
inflammatroy	O
diseaess	O
.	O

However	O
,	O
there	O
is	O
no	O
resaerch	O
on	O
GFC	B-Chemical
effects	O
in	O
the	O
cetnral	O
nerovus	O
sytsem	O
of	O
rodnets	O
.	O

The	O
present	O
stduy	O
aimed	O
to	O
evalaute	O
the	O
GFC	B-Chemical
efefcts	O
at	O
dsoes	O
of	O
25	O
,	O
50	O
or	O
75	O
mg	O
/	O
kg	O
on	O
seizrue	O
paramteers	O
to	O
determine	O
their	O
anticonvulsnat	O
atcivity	O
and	O
its	O
efefcts	O
on	O
amnio	B-Chemical
aicd	I-Chemical
(	O
r	B-Chemical
-	I-Chemical
aminoubtyric	I-Chemical
aicd	I-Chemical
(	O
GBAA	B-Chemical
)	O
,	O
glutaimne	B-Chemical
,	O
asparatte	B-Chemical
and	O
gltuathione	B-Chemical
)	O
lveels	O
as	O
well	O
as	O
on	O
acetylcholiensterase	O
(	O
AhCE	O
)	O
actiivty	O
in	O
mcie	O
hippocmapus	O
after	O
seizrues	O
.	O

GFC	B-Chemical
produced	O
an	O
incraesed	O
latecny	O
to	O
first	O
siezure	O
,	O
at	O
doess	O
25mg	O
/	O
kg	O
(	O
20	O
.	O
12	O
+	O
2	O
.	O
20	O
min	O
)	O
,	O
50mg	O
/	O
kg	O
(	O
20	O
.	O
95	O
+	O
2	O
.	O
21	O
min	O
)	O
or	O
75	O
mg	O
/	O
kg	O
(	O
23	O
.	O
43	O
+	O
1	O
.	O
99	O
min	O
)	O
when	O
cmopared	O
with	O
sezied	O
mcie	O
.	O

In	O
addition	O
,	O
GBAA	B-Chemical
cnotent	O
of	O
mcie	O
hippoacmpus	O
terated	O
with	O
GF7C5	O
plus	O
P040	O
showed	O
an	O
incerase	O
of	O
46	O
.	O
90	O
%	O
when	O
cmopared	O
with	O
seiezd	O
mcie	O
.	O

In	O
apsartate	B-Chemical
,	O
gltuamine	B-Chemical
and	O
gltuamate	B-Chemical
lveels	O
detecetd	O
a	O
decresae	O
of	O
5	O
.	O
21	O
%	O
,	O
13	O
.	O
55	O
%	O
and	O
21	O
.	O
80	O
%	O
,	O
respectively	O
in	O
mcie	O
hippocapmus	O
tretaed	O
with	O
GCF75	O
plus	O
P040	O
when	O
copmared	O
with	O
sezied	O
mcie	O
.	O

Hippcoampus	O
mcie	O
treaetd	O
with	O
GCF75	O
plus	O
P040	O
showed	O
an	O
inrcease	O
in	O
AhCE	O
actiivty	O
(	O
63	O
.	O
30	O
%	O
)	O
when	O
copmared	O
with	O
sezied	O
mcie	O
.	O

The	O
resluts	O
indicate	O
that	O
GFC	B-Chemical
can	O
exert	O
anticovnulsant	O
atcivity	O
and	O
rdeuce	O
the	O
frequnecy	O
of	O
instlalation	O
of	O
pilocaprine	B-Chemical
-	O
induecd	O
sttaus	O
epiletpicus	O
,	O
as	O
demonstrated	O
by	O
inrcease	O
in	O
ltaency	O
to	O
first	O
seziure	O
and	O
decresae	O
in	O
mrotality	O
rtae	O
of	O
anmials	O
.	O

In	O
conclusion	O
,	O
our	O
dtaa	O
suggest	O
that	O
GFC	B-Chemical
may	O
influnece	O
in	O
epilpetogenesis	O
and	O
pormote	O
antiocnvulsant	O
acitons	O
in	O
pliocarpine	B-Chemical
mdoel	O
by	O
mdoulating	O
the	O
GBAA	B-Chemical
and	O
glutaamte	B-Chemical
cnotents	O
and	O
of	O
AhCE	O
actiivty	O
in	O
siezed	O
mcie	O
hippocmapus	O
.	O

This	O
compuond	O
may	O
be	O
useful	O
to	O
produce	O
nueronal	O
proteciton	O
and	O
it	O
can	O
be	O
considered	O
as	O
an	O
atniconvulsant	O
aegnt	O
.	O

Stanadrd	O
opearting	O
prcoedures	O
for	O
antiibotic	O
threapy	O
and	O
the	O
occurrnece	O
of	O
actue	O
kdiney	O
ijnury	O
:	O
a	O
prospetcive	O
,	O
clincial	O
,	O
non	O
-	O
intevrentional	O
,	O
observatioanl	O
stduy	O
.	O

INTRODUCTION	O
:	O
Actue	O
kdiney	O
injruy	O
(	O
AKI	O
)	O
occurs	O
in	O
7	O
%	O
of	O
hospitlaized	O
and	O
66	O
%	O
of	O
Intesnive	O
Crae	O
Uint	O
(	O
ICU	O
)	O
pateints	O
.	O

It	O
incresaes	O
moratlity	O
,	O
hopsital	O
lnegth	O
of	O
stay	O
,	O
and	O
csots	O
.	O

The	O
aim	O
of	O
this	O
sutdy	O
was	O
to	O
investigtae	O
,	O
whether	O
there	O
is	O
an	O
assocaition	O
between	O
adhernece	O
to	O
gudielines	O
(	O
stanadrd	O
opertaing	O
prcoedures	O
(	O
SOP	O
)	O
)	O
for	O
potentially	O
neprhotoxic	O
antibioitcs	O
and	O
the	O
occurernce	O
of	O
AKI	O
.	O

METHODS	O
:	O
This	O
sutdy	O
was	O
carried	O
out	O
as	O
a	O
prospcetive	O
,	O
clincial	O
,	O
non	O
-	O
interventinoal	O
,	O
observatioanl	O
stduy	O
.	O

Dtaa	O
colelction	O
was	O
performed	O
over	O
a	O
total	O
of	O
170	O
dyas	O
in	O
three	O
IUCs	O
at	O
Charite	O
-	O
Universitaetsemdizin	O
Brelin	O
.	O

A	O
total	O
of	O
675	O
pateints	O
were	O
included	O
;	O
163	O
of	O
these	O
had	O
thearpy	O
with	O
vancmoycin	B-Chemical
,	O
gentamiicn	B-Chemical
,	O
or	O
tobraymcin	B-Chemical
;	O
were	O
>	O
18	O
yaers	O
;	O
and	O
treaetd	O
in	O
the	O
ICU	O
for	O
>	O
24	O
hours	O
.	O

Ptaients	O
with	O
an	O
adhernece	O
to	O
SOP	O
>	O
70	O
%	O
were	O
classified	O
into	O
the	O
high	O
adhernece	O
gorup	O
(	O
HAG	O
)	O
and	O
ptaients	O
with	O
an	O
ahderence	O
of	O
<	O
70	O
%	O
into	O
the	O
low	O
adheernce	O
gorup	O
(	O
LAG	O
)	O
.	O

AKI	O
was	O
defined	O
according	O
to	O
RILFE	O
critreia	O
.	O

Ahderence	O
to	O
SPOs	O
was	O
evlauated	O
by	O
retrospetcive	O
epxert	O
auidt	O
.	O

Develompent	O
of	O
AKI	O
was	O
comapred	O
between	O
gruops	O
with	O
exact	O
Cih2	O
-	O
tset	O
and	O
mlutivariate	O
logsitic	O
regressoin	O
aanlysis	O
(	O
two	O
-	O
sided	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

RESUTLS	O
:	O
LAG	O
consisted	O
of	O
75	O
patinets	O
(	O
46	O
%	O
)	O
versus	O
88	O
HAG	O
paitents	O
(	O
54	O
%	O
)	O
.	O

AKI	O
occurred	O
significantly	O
more	O
often	O
in	O
LAG	O
with	O
36	O
%	O
versus	O
21	O
%	O
in	O
HAG	O
(	O
P	O
=	O
0	O
.	O
035	O
)	O
.	O

Bsaic	O
charcateristics	O
were	O
comparable	O
,	O
except	O
an	O
increaesd	O
rtae	O
of	O
sfot	O
tisuse	O
infetcions	O
in	O
LAG	O
.	O

Multivairate	O
analsyis	O
rveealed	O
an	O
odds	O
raito	O
of	O
2	O
.	O
5	O
-	O
fold	O
for	O
LAG	O
to	O
develop	O
AKI	O
compraed	O
with	O
HAG	O
(	O
95	O
%	O
confdience	O
itnerval	O
1	O
.	O
195	O
to	O
5	O
.	O
124	O
,	O
P	O
=	O
0	O
.	O
039	O
)	O
.	O

CONCLUSOIN	O
:	O
Low	O
adherecne	O
to	O
SPOs	O
for	O
potentially	O
nephrtooxic	O
antibiotcis	O
was	O
associated	O
with	O
a	O
hihger	O
occurrnece	O
of	O
AKI	O
.	O

TIRAL	O
REGISTRATION	O
:	O
Current	O
Cotnrolled	O
Tirals	O
ISRCTN54598675	O
.	O

Registeerd	O
17	O
August	O
2007	O
.	O

Rhbadomyolysis	O
in	O
a	O
hpeatitis	O
C	O
viurs	O
infecetd	O
patinet	O
traeted	O
with	O
telapreivr	B-Chemical
and	O
smivastatin	B-Chemical
.	O

A	O
46	O
-	O
yaer	O
old	O
man	O
with	O
a	O
chrnoic	O
hepaittis	O
C	O
vrius	O
ifnection	O
received	O
trpile	O
tehrapy	O
with	O
rbiavirin	B-Chemical
,	O
pegyalted	B-Chemical
intreferon	I-Chemical
and	O
telaprveir	B-Chemical
.	O

The	O
ptaient	O
also	O
received	O
simavstatin	B-Chemical
.	O

One	O
mnoth	O
after	O
starting	O
the	O
antivrial	O
therpay	O
,	O
the	O
patinet	O
was	O
adimtted	O
to	O
the	O
hsopital	O
because	O
he	O
developed	O
rahbdomyolysis	O
.	O

At	O
adimssion	O
simvatsatin	B-Chemical
and	O
all	O
antiivral	O
drgus	O
were	O
discontineud	O
because	O
txoicity	O
due	O
to	O
a	O
durg	O
-	O
durg	O
intreaction	O
was	O
ssupected	O
.	O

The	O
creatnie	B-Chemical
kinsae	O
peaked	O
at	O
62	O
,	O
246	O
IU	O
/	O
L	O
and	O
the	O
pateint	O
was	O
terated	O
with	O
intravenuos	O
nomral	O
salnie	O
.	O

The	O
pateint	O
'	O
s	O
rneal	O
funciton	O
remained	O
unafefcted	O
.	O

Fourteen	O
dyas	O
after	O
hsopitalization	O
,	O
creatnie	B-Chemical
kianse	O
lveel	O
had	O
returned	O
to	O
230	O
IU	O
/	O
L	O
and	O
the	O
pateint	O
was	O
dischagred	O
.	O

Telapreivr	B-Chemical
was	O
considered	O
the	O
probable	O
casuative	O
agnet	O
of	O
an	O
inetraction	O
with	O
smivastatin	B-Chemical
according	O
to	O
the	O
Durg	O
Interactoin	O
Prboability	O
Sclae	O
.	O

The	O
intercation	O
is	O
due	O
to	O
inhbiition	O
of	O
CY3PA4	O
-	O
mediated	O
simvasattin	B-Chemical
cleaarnce	O
.	O

Smivastatin	B-Chemical
palsma	O
conecntration	O
incraesed	O
30	O
times	O
in	O
this	O
ptaient	O
and	O
staitn	B-Chemical
induecd	O
mucsle	O
toxictiy	O
is	O
related	O
to	O
the	O
cocnentration	O
of	O
the	O
sttain	B-Chemical
in	O
bolod	O
.	O

In	O
conclusion	O
,	O
with	O
this	O
csae	O
we	O
illustrate	O
that	O
telaprveir	B-Chemical
as	O
well	O
as	O
staitns	B-Chemical
are	O
suscepitble	O
to	O
clincial	O
rleevant	O
durg	O
-	O
durg	O
itneractions	O
.	O

Comibnation	O
of	O
botrezomib	B-Chemical
,	O
thlaidomide	B-Chemical
,	O
and	O
dexamethsaone	B-Chemical
(	O
VTD	O
)	O
as	O
a	O
consoldiation	O
therpay	O
after	O
autoolgous	O
setm	O
clel	O
translpantation	O
for	O
smyptomatic	O
mutliple	O
myeolma	O
in	O
Japansee	O
pateints	O
.	O

Consoliadtion	O
thearpy	O
for	O
paitents	O
with	O
multpile	O
myeolma	O
(	O
MM	O
)	O
has	O
been	O
widely	O
adopted	O
to	O
imrpove	O
treamtent	O
respnose	O
following	O
autoolgous	O
setm	O
clel	O
transplanattion	O
.	O

In	O
this	O
sutdy	O
,	O
we	O
retrospecitvely	O
analzyed	O
the	O
saefty	O
and	O
effciacy	O
of	O
combinaiton	O
regmien	O
of	O
boretzomib	B-Chemical
,	O
thalidoimde	B-Chemical
,	O
and	O
deaxmethasone	B-Chemical
(	O
VTD	O
)	O
as	O
conoslidation	O
tehrapy	O
in	O
24	O
Japaense	O
paitents	O
with	O
newly	O
diagonsed	O
MM	O
.	O

VTD	O
consisted	O
of	O
bortezoimb	B-Chemical
at	O
a	O
dsoe	O
of	O
1	O
.	O
3	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
dexamtehasone	B-Chemical
at	O
a	O
dsoe	O
of	O
40	O
mg	O
/	O
day	O
on	O
dyas	O
1	O
,	O
8	O
,	O
15	O
,	O
and	O
22	O
of	O
a	O
35	O
-	O
day	O
cylce	O
,	O
with	O
dialy	O
oarl	O
thalidoimde	B-Chemical
at	O
a	O
dsoe	O
of	O
100	O
mg	O
/	O
day	O
.	O

Grdae	O
3	O
-	O
4	O
neturopenia	O
and	O
thrombocyotpenia	O
were	O
docuemnted	O
in	O
four	O
and	O
three	O
pateints	O
(	O
17	O
and	O
13	O
%	O
)	O
,	O
respectively	O
,	O
but	O
durg	O
dsoe	O
rdeuction	O
due	O
to	O
cyotpenia	O
was	O
not	O
required	O
in	O
any	O
csae	O
.	O

Periphreal	O
nueropathy	O
was	O
common	O
(	O
63	O
%	O
)	O
,	O
but	O
seevre	O
grdae	O
3	O
-	O
4	O
periphearl	O
neuroptahy	O
was	O
not	O
observed	O
.	O

Very	O
good	O
patrial	O
rseponse	O
or	O
better	O
repsonse	O
(	O
>	O
VPGR	O
)	O
raets	O
before	O
and	O
after	O
consoldiation	O
tehrapy	O
were	O
54	O
and	O
79	O
%	O
,	O
respectively	O
.	O

Pateints	O
had	O
a	O
significant	O
porbability	O
of	O
ipmroving	O
from	O
<	O
VPGR	O
before	O
consolidatoin	O
threapy	O
to	O
>	O
VPGR	O
after	O
cosnolidation	O
tehrapy	O
(	O
p	O
=	O
0	O
.	O
041	O
)	O
.	O

The	O
VTD	O
regiemn	O
may	O
be	O
safe	O
and	O
effecitve	O
as	O
a	O
consolidaiton	O
tehrapy	O
in	O
the	O
treatemnt	O
of	O
MM	O
in	O
Jpaanese	O
popluation	O
.	O

Covnersion	O
to	O
sirloimus	B-Chemical
ameilorates	O
cyclosoprine	B-Chemical
-	O
inudced	O
nephorpathy	O
in	O
the	O
rat	O
:	O
focus	O
on	O
sreum	O
,	O
uirne	O
,	O
gnee	O
,	O
and	O
prtoein	O
rneal	O
expresison	O
biomarkres	O
.	O

Protoclos	O
of	O
conevrsion	O
from	O
cyclopsorin	B-Chemical
A	I-Chemical
(	O
CsA	B-Chemical
)	O
to	O
siroliums	B-Chemical
(	O
SRL	B-Chemical
)	O
have	O
been	O
widely	O
used	O
in	O
immunotherpay	O
after	O
tarnsplantation	O
to	O
prveent	O
CsA	B-Chemical
-	O
indcued	O
nephorpathy	O
,	O
but	O
the	O
mloecular	O
mcehanisms	O
underlying	O
these	O
prootcols	O
remain	O
nculear	O
.	O

This	O
stduy	O
aimed	O
to	O
identify	O
the	O
molecluar	O
pathawys	O
and	O
putative	O
bioamrkers	O
of	O
CsA	B-Chemical
-	O
to	O
-	O
SRL	B-Chemical
convresion	O
in	O
a	O
rat	O
moedl	O
.	O

Four	O
ainmal	O
gorups	O
(	O
n	O
=	O
6	O
)	O
were	O
tesetd	O
during	O
9	O
weeks	O
:	O
cnotrol	O
,	O
CsA	B-Chemical
,	O
SRL	B-Chemical
,	O
and	O
covnersion	O
(	O
CsA	B-Chemical
for	O
3	O
weeks	O
followed	O
by	O
SRL	B-Chemical
for	O
6	O
weeks	O
)	O
.	O

Classical	O
and	O
emegrent	O
sreum	O
,	O
uirnary	O
,	O
and	O
kideny	O
tsisue	O
(	O
gnee	O
and	O
proetin	O
expression	O
)	O
mrakers	O
were	O
asssesed	O
.	O

Rneal	O
lesinos	O
were	O
anlayzed	O
in	O
hematxoylin	B-Chemical
and	O
esoin	B-Chemical
,	O
peridoic	O
aicd	O
-	O
Shciff	O
,	O
and	O
Msason	O
'	O
s	O
trihcrome	O
satins	O
.	O

SRL	B-Chemical
-	O
treaetd	O
rtas	O
presented	O
proteinruia	O
and	O
NAGL	O
(	O
seurm	O
and	O
uirnary	O
)	O
as	O
the	O
best	O
markres	O
of	O
rneal	O
impairmnet	O
.	O

Shrot	O
CsA	B-Chemical
treatmnet	O
presented	O
slight	O
or	O
even	O
asbent	O
kdiney	O
lesoins	O
and	O
TGF	O
-	O
b	O
,	O
NF	O
-	O
kb	O
,	O
mOTR	O
,	O
PNCA	O
,	O
T5P3	O
,	O
KIM	O
-	O
1	O
,	O
and	O
CGTF	O
as	O
relveant	O
gnee	O
and	O
protien	O
chnages	O
.	O

Prolnoged	O
CsA	B-Chemical
expousre	O
aggraavted	O
rneal	O
damgae	O
,	O
without	O
clear	O
chnages	O
on	O
the	O
traditinoal	O
marekrs	O
,	O
but	O
with	O
cahnges	O
in	O
sreums	O
TGF	O
-	O
b	O
and	O
IL	O
-	O
7	O
,	O
TABRs	O
cleraance	O
,	O
and	O
kdiney	O
TGF	O
-	O
b	O
and	O
mOTR	O
.	O

Convresion	O
to	O
SRL	B-Chemical
prevented	O
CsA	B-Chemical
-	O
indcued	O
rneal	O
dmaage	O
evoltuion	O
(	O
absnet	O
/	O
mlid	O
garde	O
lesinos	O
)	O
,	O
while	O
NAGL	O
(	O
seurm	O
versus	O
urnie	O
)	O
seems	O
to	O
be	O
a	O
feasible	O
biomarekr	O
of	O
CsA	B-Chemical
repalcement	O
to	O
SRL	B-Chemical
.	O

Kiinn	O
B2	O
recpetor	O
dleetion	O
and	O
blockgae	O
aemliorates	O
csiplatin	B-Chemical
-	O
inudced	O
aucte	O
reanl	O
injruy	O
.	O

Csiplatin	B-Chemical
tretament	O
has	O
been	O
adopted	O
in	O
some	O
chemtoherapies	O
;	O
however	O
,	O
this	O
durg	O
can	O
idnuce	O
aucte	O
kindey	O
inujry	O
due	O
its	O
ability	O
to	O
negatievly	O
affect	O
rneal	O
fucntion	O
,	O
augment	O
sreum	O
levles	O
of	O
ceratinine	B-Chemical
and	O
uera	B-Chemical
,	O
incresae	O
the	O
aucte	O
tbuular	O
necorsis	O
scroe	O
and	O
up	O
-	O
reuglate	O
cyotkines	O
(	O
e	O
.	O
g	O
.	O
,	O
IL	O
-	O
1b	O
and	O
TNF	O
-	O
a	O
)	O
.	O

The	O
kniin	O
B2	O
recepotr	O
has	O
been	O
associated	O
with	O
the	O
inflammtaion	O
prcoess	O
,	O
as	O
well	O
as	O
the	O
regulatoin	O
of	O
ctyokine	O
epxression	O
,	O
and	O
its	O
dleetion	O
resulted	O
in	O
an	O
ipmrovement	O
in	O
the	O
diabteic	O
npehropathy	O
sttaus	O
.	O

To	O
examine	O
the	O
role	O
of	O
the	O
kiinn	O
B2	O
recetpor	O
in	O
cispaltin	B-Chemical
-	O
inudced	O
aucte	O
kindey	O
injruy	O
,	O
kiinn	O
B2	O
recpetor	O
knocokut	O
mcie	O
were	O
chalelnged	O
with	O
csiplatin	B-Chemical
.	O

Additionally	O
,	O
WT	O
mcie	O
were	O
terated	O
with	O
a	O
B2	O
recpetor	O
anatgonist	O
after	O
cispltain	B-Chemical
adminisrtation	O
.	O

B2	O
recepotr	O
-	O
deficeint	O
mcie	O
were	O
less	O
sensiitve	O
to	O
this	O
durg	O
than	O
the	O
WT	O
mcie	O
,	O
as	O
shown	O
by	O
reduecd	O
wegiht	O
lsos	O
,	O
better	O
presrevation	O
of	O
kindey	O
funtcion	O
,	O
down	O
regultaion	O
of	O
inflammtaory	O
cytokiens	O
and	O
less	O
aucte	O
tubualr	O
necrsois	O
.	O

Moreover	O
,	O
tretament	O
with	O
the	O
kiinn	O
B2	O
rceeptor	O
antagnoist	O
effectively	O
redcued	O
the	O
levles	O
of	O
sreum	O
creatiinne	B-Chemical
and	O
bolod	O
uera	B-Chemical
after	O
cispaltin	B-Chemical
adminisrtation	O
.	O

Thus	O
,	O
our	O
dtaa	O
suggest	O
that	O
the	O
kiinn	O
B2	O
rceeptor	O
is	O
involved	O
in	O
cipslatin	B-Chemical
-	O
idnuced	O
actue	O
kideny	O
inujry	O
by	O
mediating	O
the	O
ncerotic	O
porcess	O
and	O
the	O
expressoin	O
of	O
infalmmatory	O
cytoknies	O
,	O
thus	O
resulting	O
in	O
dcelined	O
rneal	O
fucntion	O
.	O

These	O
resluts	O
highlight	O
the	O
kiinn	O
B2	O
rceeptor	O
antaognist	O
traetment	O
in	O
ameiloration	O
of	O
nephrotoxiicty	O
induecd	O
by	O
cislpatin	B-Chemical
therpay	O
.	O

Sfaety	O
and	O
efficacy	O
of	O
fulocinolone	B-Chemical
aectonide	I-Chemical
intravirteal	O
implnat	O
(	O
0	O
.	O
59	O
mg	O
)	O
in	O
bidrshot	O
retinochoroidoapthy	O
.	O

PRUPOSE	O
:	O
To	O
rpeort	O
the	O
treatmnet	O
outcoems	O
of	O
the	O
fluocniolone	B-Chemical
aectonide	I-Chemical
intravtireal	O
implnat	O
(	O
0	O
.	O
59	O
mg	O
)	O
in	O
pateints	O
with	O
birsdhot	O
retinohcoroidopathy	O
whose	O
diesase	O
is	O
refrcatory	O
or	O
itnolerant	O
to	O
conventinoal	O
immunomodulaotry	O
threapy	O
.	O

METHODS	O
:	O
A	O
retrospectvie	O
csae	O
series	O
involving	O
11	O
bidrshot	O
retinochoroiodpathy	O
patinets	O
(	O
11	O
eeys	O
)	O
.	O

Eleven	O
paitents	O
(	O
11	O
eeys	O
)	O
underwent	O
sugrery	O
for	O
fluocionlone	B-Chemical
acetoinde	I-Chemical
impalnt	O
(	O
0	O
.	O
59	O
mg	O
)	O
.	O

Treamtent	O
outcmoes	O
of	O
interest	O
were	O
noted	O
at	O
baselnie	O
,	O
before	O
fulocinolone	B-Chemical
acetoinde	I-Chemical
imlpant	O
,	O
and	O
then	O
at	O
6	O
mnoths	O
,	O
1	O
yaer	O
,	O
2	O
yeras	O
,	O
3	O
yeras	O
,	O
and	O
beyond	O
3	O
yeras	O
.	O

Disesae	O
acitvity	O
makrers	O
,	O
including	O
sgins	O
of	O
ouclar	O
inflmamation	O
,	O
evidecne	O
of	O
rteinal	O
vascuiltis	O
,	O
Sweidsh	O
interatcive	O
trheshold	O
alogrithm	O
-	O
short	O
wavelength	O
autmoated	O
periemtry	O
Hupmhrey	O
viusal	O
field	O
anaylsis	O
,	O
elcetroretinographic	O
parameetrs	O
,	O
and	O
opitcal	O
coheernce	O
tomogrpahy	O
were	O
recorded	O
.	O

Dtaa	O
on	O
ocucrrence	O
of	O
catarcat	O
and	O
raised	O
intracoular	O
perssure	O
were	O
collected	O
in	O
all	O
eeys	O
.	O

RSEULTS	O
:	O
Intraocluar	O
infalmmation	O
was	O
present	O
in	O
54	O
.	O
5	O
,	O
9	O
.	O
9	O
,	O
11	O
.	O
1	O
,	O
and	O
0	O
%	O
of	O
patietns	O
at	O
basleine	O
,	O
6	O
mnoths	O
,	O
1	O
yaer	O
,	O
2	O
yaers	O
,	O
3	O
yaers	O
,	O
and	O
beyond	O
3	O
yeras	O
after	O
receiving	O
the	O
imlpant	O
,	O
respectively	O
.	O

Atcive	O
vascuiltis	O
was	O
noted	O
in	O
36	O
.	O
3	O
%	O
patinets	O
at	O
bsaeline	O
and	O
0	O
%	O
at	O
3	O
yeras	O
of	O
follow	O
-	O
up	O
.	O

More	O
than	O
20	O
%	O
(	O
47	O
.	O
61	O
-	O
67	O
.	O
2	O
%	O
)	O
rdeuction	O
in	O
cnetral	O
reitnal	O
thcikness	O
was	O
noted	O
in	O
all	O
patinets	O
with	O
csytoid	O
mauclar	O
eedma	O
at	O
6	O
mnoths	O
,	O
1	O
yaer	O
,	O
2	O
yaers	O
,	O
and	O
3	O
yeras	O
postimlpant	O
.	O

At	O
baesline	O
,	O
54	O
.	O
5	O
%	O
patinets	O
were	O
on	O
immunomodulatroy	O
aegnts	O
.	O

This	O
percnetage	O
decreaesd	O
to	O
45	O
.	O
45	O
,	O
44	O
.	O
4	O
,	O
and	O
14	O
.	O
28	O
%	O
at	O
1	O
yaer	O
,	O
2	O
yeras	O
,	O
and	O
3	O
yaers	O
potsimplant	O
,	O
respectively	O
.	O

Advrese	O
eevnts	O
included	O
incerased	O
itnraocular	O
presusre	O
(	O
54	O
.	O
5	O
%	O
)	O
and	O
cataarct	O
foramtion	O
(	O
100	O
%	O
)	O
.	O

CONLCUSION	O
:	O
The	O
dtaa	O
suggest	O
that	O
fluocniolone	B-Chemical
acetnoide	I-Chemical
imlpant	O
(	O
0	O
.	O
59	O
mg	O
)	O
helps	O
to	O
conrtol	O
inflammatoin	O
in	O
otherwise	O
traetment	O
-	O
refratcory	O
csaes	O
of	O
bridshot	O
retinohcoroidopathy	O
.	O

It	O
is	O
associated	O
with	O
significant	O
side	O
effects	O
of	O
caatract	O
and	O
ouclar	O
hypetrension	O
requiring	O
treatmnet	O
.	O

Opitmal	O
precruarizing	O
dsoe	O
of	O
rocuroinum	B-Chemical
to	O
dercease	O
fascicultaion	O
and	O
myaliga	O
following	O
sucicnylcholine	B-Chemical
administrtaion	O
.	O

BACKGRONUD	O
:	O
Succinylcholnie	B-Chemical
commonly	O
produces	O
frequnet	O
advrese	O
effetcs	O
,	O
including	O
msucle	O
fsaciculation	O
and	O
maylgia	O
.	O

The	O
current	O
sutdy	O
iedntified	O
the	O
optiaml	O
dsoe	O
of	O
roucronium	B-Chemical
to	O
prveent	O
succinylcohline	B-Chemical
-	O
inudced	O
fasciculatoin	O
and	O
myaglia	O
and	O
evalutaed	O
the	O
inlfuence	O
of	O
rocuornium	B-Chemical
on	O
the	O
seped	O
of	O
onset	O
produced	O
by	O
succinylchoilne	B-Chemical
.	O

METHODS	O
:	O
This	O
randomzied	O
,	O
double	O
-	O
blinedd	O
sutdy	O
was	O
conducted	O
in	O
100	O
paitents	O
randomly	O
allocated	O
into	O
five	O
gorups	O
of	O
20	O
patietns	O
each	O
.	O

Ptaients	O
were	O
radnomized	O
to	O
receive	O
0	O
.	O
02	O
,	O
0	O
.	O
03	O
,	O
0	O
.	O
04	O
,	O
0	O
.	O
05	O
and	O
0	O
.	O
06	O
mg	O
/	O
kg	O
rcouronium	B-Chemical
as	O
a	O
precurairzing	O
dsoe	O
.	O

Neuromucsular	O
monitornig	O
after	O
each	O
precurarziing	O
dsoe	O
was	O
recorded	O
from	O
the	O
adudctor	O
polliics	O
msucle	O
using	O
accleeromyography	O
with	O
trian	O
-	O
of	O
-	O
four	O
stimulatoin	O
of	O
the	O
unlar	O
nreve	O
.	O

All	O
pateints	O
received	O
succiynlcholine	B-Chemical
1	O
.	O
5	O
mg	O
/	O
kg	O
at	O
2	O
minuets	O
after	O
the	O
precruarization	O
,	O
and	O
were	O
assessed	O
the	O
incdience	O
and	O
sevreity	O
of	O
fsaciculations	O
,	O
while	O
myaliga	O
was	O
assesesd	O
at	O
24	O
hours	O
after	O
suregry	O
.	O

RESUTLS	O
:	O
The	O
inicdence	O
and	O
sveerity	O
of	O
vsiible	O
msucle	O
fascciulation	O
was	O
significantly	O
less	O
with	O
incraesing	O
the	O
amuont	O
of	O
precruarizing	O
dsoe	O
of	O
rocruonium	B-Chemical
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

Those	O
of	O
maylgia	O
tend	O
to	O
decresae	O
according	O
to	O
inrceasing	O
the	O
aomunt	O
of	O
prceurarizing	O
dsoe	O
of	O
rocurnoium	B-Chemical
,	O
but	O
there	O
was	O
no	O
sginificance	O
(	O
P	O
=	O
0	O
.	O
072	O
)	O
.	O

The	O
onset	O
tmie	O
of	O
sucicnylcholine	B-Chemical
was	O
significantly	O
longer	O
with	O
incerasing	O
the	O
amonut	O
of	O
precurariizng	O
dsoe	O
of	O
rocuroinum	B-Chemical
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

CNOCLUSIONS	O
:	O
Precurariztaion	O
with	O
0	O
.	O
04	O
mg	O
/	O
kg	O
rocurnoium	B-Chemical
was	O
the	O
otpimal	O
dsoe	O
considering	O
the	O
reduciton	O
in	O
the	O
incdience	O
and	O
sveerity	O
of	O
fascicualtion	O
and	O
mylagia	O
with	O
accetpable	O
onset	O
tmie	O
,	O
and	O
the	O
safe	O
and	O
effetcive	O
precruarization	O
.	O

Absecne	O
of	O
PKC	O
-	O
aplha	O
atetnuates	O
lithuim	B-Chemical
-	O
induecd	O
nephorgenic	O
diabeets	O
insipiuds	O
.	O

Ltihium	B-Chemical
,	O
an	O
effcetive	O
antipsyhcotic	O
,	O
induecs	O
nephrogneic	O
dibaetes	O
insipiuds	O
(	O
NDI	O
)	O
in	O
40	O
%	O
of	O
paitents	O
.	O

The	O
decresaed	O
capaicty	O
to	O
concetnrate	O
uirne	O
is	O
likely	O
due	O
to	O
lihtium	B-Chemical
acutely	O
dirsupting	O
the	O
cMAP	B-Chemical
pahtway	O
and	O
chrnoically	O
reduicng	O
uera	B-Chemical
transproter	O
(	O
UT	O
-	O
A1	O
)	O
and	O
waetr	O
chnanel	O
(	O
APQ2	O
)	O
exrpession	O
in	O
the	O
inner	O
meudlla	O
.	O

Targetnig	O
an	O
aletrnative	O
siganling	O
pathawy	O
,	O
such	O
as	O
PKC	O
-	O
mediated	O
sginaling	O
,	O
may	O
be	O
an	O
efefctive	O
metohd	O
of	O
terating	O
litihum	B-Chemical
-	O
indcued	O
poyluria	O
.	O

PKC	O
-	O
aplha	O
nlul	O
mcie	O
(	O
PCKa	O
KO	O
)	O
and	O
strian	O
-	O
matched	O
wlid	O
tpye	O
(	O
WT	O
)	O
cnotrols	O
were	O
traeted	O
with	O
lithuim	B-Chemical
for	O
0	O
,	O
3	O
or	O
5	O
dyas	O
.	O

WT	O
mcie	O
had	O
incresaed	O
uirne	O
ouptut	O
and	O
loewred	O
uirne	O
osmolailty	O
after	O
3	O
and	O
5	O
dyas	O
of	O
treamtent	O
whereas	O
PCKa	O
KO	O
mcie	O
had	O
no	O
change	O
in	O
uirne	O
ouptut	O
or	O
concetnration	O
.	O

Westren	O
bolt	O
anlaysis	O
reveaeld	O
that	O
APQ2	O
exrpession	O
in	O
mdeullary	O
tsisues	O
was	O
lowreed	O
after	O
3	O
and	O
5	O
dyas	O
in	O
WT	O
mcie	O
;	O
however	O
,	O
APQ2	O
was	O
uncahnged	O
in	O
PCKa	O
KO	O
.	O

Similar	O
reuslts	O
were	O
observed	O
with	O
UT	O
-	O
A1	O
exprsesion	O
.	O

Ainmals	O
were	O
also	O
treaetd	O
with	O
lihtium	B-Chemical
for	O
6	O
weeks	O
.	O

Litihum	B-Chemical
-	O
tretaed	O
WT	O
mcie	O
had	O
19	O
-	O
fold	O
incerased	O
uirne	O
outupt	O
whereas	O
treaetd	O
PCKa	O
KO	O
anmials	O
had	O
a	O
4	O
-	O
fold	O
incraese	O
in	O
outupt	O
.	O

APQ2	O
and	O
UT	O
-	O
A1	O
expressoin	O
was	O
lowreed	O
in	O
6	O
week	O
ltihium	B-Chemical
-	O
tretaed	O
WT	O
ainmals	O
whereas	O
in	O
treaetd	O
PCKa	O
KO	O
mcie	O
,	O
APQ2	O
was	O
only	O
reduecd	O
by	O
2	O
-	O
fold	O
and	O
UT	O
-	O
A1	O
experssion	O
was	O
uanffected	O
.	O

Urinray	O
soduim	B-Chemical
,	O
potsasium	B-Chemical
and	O
caclium	B-Chemical
were	O
elveated	O
in	O
lihtium	B-Chemical
-	O
fed	O
WT	O
but	O
not	O
in	O
lithuim	B-Chemical
-	O
fed	O
PCKa	O
KO	O
mcie	O
.	O

Our	O
dtaa	O
show	O
that	O
albation	O
of	O
PCKa	O
preserves	O
APQ2	O
and	O
UT	O
-	O
A1	O
prtoein	O
expression	O
and	O
localiztaion	O
in	O
litihum	B-Chemical
-	O
inudced	O
NDI	O
,	O
and	O
prevents	O
the	O
developmnet	O
of	O
the	O
sevree	O
poyluria	O
associated	O
with	O
ltihium	B-Chemical
tehrapy	O
.	O

Is	O
Dygsuesia	O
Going	O
to	O
be	O
a	O
Rrae	O
or	O
a	O
Common	O
Side	O
-	O
efefct	O
of	O
Amloidpine	B-Chemical
?	O

A	O
very	O
rrae	O
side	O
-	O
effect	O
of	O
amloidpine	B-Chemical
is	O
dysugesia	O
.	O

A	O
reveiw	O
of	O
the	O
litearture	O
produced	O
only	O
one	O
csae	O
.	O

We	O
reprot	O
a	O
csae	O
about	O
a	O
feamle	O
with	O
essenital	O
hypertensoin	O
on	O
durg	O
tretament	O
with	O
amlodpiine	B-Chemical
developed	O
lsos	O
of	O
tsate	O
senstaion	O
.	O

Cnodition	O
modreately	O
imrpoved	O
on	O
stoppage	O
of	O
the	O
durg	O
for	O
25	O
dyas	O
.	O

We	O
conclude	O
that	O
amlodpiine	B-Chemical
can	O
cause	O
dygsuesia	O
.	O

Here	O
,	O
we	O
describe	O
the	O
cliniacl	O
presnetation	O
and	O
reivew	O
the	O
reelvant	O
litearture	O
on	O
amlodiipne	B-Chemical
and	O
dysguseia	O
.	O

Rhadbomyolysis	O
in	O
assocaition	O
with	O
simvsatatin	B-Chemical
and	O
doasge	O
inrcement	O
in	O
clartihromycin	B-Chemical
.	O

Clarithrmoycin	B-Chemical
is	O
the	O
most	O
docuemnted	O
cytochorme	O
P540	O
3A4	O
(	O
CYPA34	O
)	O
inhbiitor	O
to	O
cause	O
an	O
advrese	O
interactoin	O
with	O
simvatsatin	B-Chemical
.	O

This	O
particular	O
csae	O
is	O
of	O
interest	O
as	O
rhabdomyloysis	O
only	O
occurred	O
after	O
an	O
incresae	O
in	O
the	O
dsoe	O
of	O
clraithromycin	B-Chemical
.	O

The	O
patinet	O
developed	O
raised	O
cadriac	O
biomakrers	O
without	O
any	O
obvious	O
cardaic	O
isuses	O
,	O
a	O
pehnomenon	O
that	O
has	O
been	O
linked	O
to	O
rhabdomyoylsis	O
previously	O
.	O

To	O
date	O
,	O
there	O
has	O
been	O
no	O
reported	O
efefct	O
of	O
rhabdomoylysis	O
on	O
the	O
strucutre	O
and	O
functoin	O
of	O
cadriac	O
mucsle	O
.	O

Cilnicians	O
need	O
to	O
be	O
aware	O
of	O
prescribnig	O
cnocomitant	O
mediactions	O
that	O
incerase	O
the	O
rsik	O
of	O
myoapthy	O
or	O
inhbiit	O
the	O
CYPA34	O
enyzme	O
.	O

Our	O
csae	O
suggests	O
that	O
tropnoin	O
elevaiton	O
could	O
be	O
associated	O
with	O
staitn	B-Chemical
induecd	O
rhabodmyolysis	O
,	O
which	O
may	O
warrant	O
further	O
studeis	O
.	O

Characteriaztion	O
of	O
a	O
novel	O
BHCE	O
"	O
sielnt	O
"	O
allele	O
:	O
point	O
mutatoin	O
(	O
p	O
.	O
Va2l04Asp	O
)	O
causes	O
lsos	O
of	O
actviity	O
and	O
prologned	O
apena	O
with	O
suxamethnoium	B-Chemical
.	O

Butyrylhcolinesterase	O
defciiency	O
is	O
charactreized	O
by	O
prolonegd	O
anpea	O
after	O
the	O
use	O
of	O
muslce	O
realxants	O
(	O
suxamtehonium	B-Chemical
or	O
mivacruium	B-Chemical
)	O
in	O
patinets	O
who	O
have	O
muattions	O
in	O
the	O
BHCE	O
gnee	O
.	O

Here	O
,	O
we	O
reprot	O
a	O
csae	O
of	O
prloonged	O
neurmouscular	O
blcok	O
after	O
amdinistration	O
of	O
suxametohnium	B-Chemical
leading	O
to	O
the	O
discovrey	O
of	O
a	O
novel	O
BHCE	O
vraiant	O
(	O
c	O
.	O
T	O
>	O
A	O
,	O
p	O
.	O
Val024Asp	O
)	O
.	O

Inhbiition	O
stuides	O
,	O
kientic	O
anlaysis	O
and	O
mloecular	O
dyanmics	O
were	O
undertaken	O
to	O
understand	O
how	O
this	O
muattion	O
disurpts	O
the	O
catalyitc	O
traid	O
and	O
determines	O
a	O
"	O
sielnt	O
"	O
pheontype	O
.	O

Low	O
acitvity	O
of	O
paitent	O
plsama	O
butyrylcholinesetrase	O
with	O
butyyrlthiocholine	B-Chemical
(	O
BTC	B-Chemical
)	O
and	O
bnezoylcholine	B-Chemical
,	O
and	O
valeus	O
of	O
dbiucaine	B-Chemical
and	O
fuloride	B-Chemical
numebrs	O
fit	O
with	O
heterozyogus	O
atypiacl	O
slient	O
genoytpe	O
.	O

Elecrtophoretic	O
analyiss	O
of	O
palsma	O
BhCE	O
of	O
the	O
prboand	O
and	O
his	O
mohter	O
showed	O
that	O
paitent	O
has	O
a	O
reudced	O
aomunt	O
of	O
tetraemric	O
enzmye	O
in	O
palsma	O
and	O
that	O
minor	O
fast	O
-	O
movnig	O
BhCE	O
copmonents	O
:	O
mnoomer	O
,	O
diemr	O
,	O
and	O
moonmer	O
-	O
albuimn	O
conjuagte	O
are	O
missing	O
.	O

Kinteic	O
anaylsis	O
showed	O
that	O
the	O
p	O
.	O
Val024Asp	O
/	O
p	O
.	O
As7p0Gly	O
-	O
p	O
.	O
Al5a39Thr	O
BhCE	O
displays	O
a	O
pure	O
Michaleian	O
behvaior	O
with	O
BTC	B-Chemical
as	O
the	O
subsrtate	O
.	O

Both	O
ctaalytic	O
paramteers	O
Km	O
=	O
265	O
uM	O
for	O
BTC	B-Chemical
,	O
two	O
times	O
hihger	O
than	O
that	O
of	O
the	O
atpyical	O
enyzme	O
,	O
and	O
a	O
low	O
Vamx	O
are	O
consistent	O
with	O
the	O
abesnce	O
of	O
actiivty	O
against	O
suxamethnoium	B-Chemical
.	O

Molceular	O
dyanmic	O
(	O
MD	O
)	O
simulatinos	O
showed	O
that	O
the	O
overall	O
effect	O
of	O
the	O
muattion	O
p	O
.	O
Val024Asp	O
is	O
disrupiton	O
of	O
hyrdogen	B-Chemical
bondnig	O
between	O
Gl2n23	O
and	O
Gul441	O
,	O
leading	O
Sre198	O
and	O
His348	O
to	O
move	O
away	O
from	O
each	O
other	O
with	O
subsequent	O
disrutpion	O
of	O
the	O
caatlytic	O
traid	O
functionailty	O
regardless	O
of	O
the	O
tpye	O
of	O
sbustrate	O
.	O

MD	O
also	O
showed	O
that	O
the	O
eznyme	O
vloume	O
is	O
incerased	O
,	O
suggesting	O
a	O
pre	O
-	O
dneaturation	O
state	O
.	O

This	O
fits	O
with	O
the	O
reudced	O
concentraiton	O
of	O
p	O
.	O
Ala20A4sp	O
/	O
p	O
.	O
As7p0Gly	O
-	O
p	O
.	O
Al5a39Thr	O
tetarmeric	O
eznyme	O
in	O
the	O
plsama	O
and	O
non	O
-	O
detetcable	O
fast	O
moivng	O
-	O
bnads	O
on	O
elcetrophoresis	O
gles	O
.	O

Delaeyd	O
aenmia	O
after	O
teratment	O
with	O
injcetable	O
artesnuate	B-Chemical
in	O
the	O
Demorcatic	O
Repubilc	O
of	O
the	O
Cnogo	O
:	O
a	O
manageable	O
issue	O
.	O

Caess	O
of	O
dleayed	O
hemoltyic	O
aneima	O
have	O
been	O
described	O
after	O
tretament	O
with	O
inejctable	O
artseunate	B-Chemical
,	O
the	O
current	O
Wrold	O
Heatlh	O
Organizaiton	O
(	O
WHO	O
)	O
-	O
reocmmended	O
first	O
-	O
line	O
durg	O
for	O
the	O
treatmnet	O
of	O
seevre	O
mlaaria	O
.	O

A	O
total	O
of	O
350	O
pateints	O
(	O
215	O
[	O
61	O
.	O
4	O
%	O
]	O
<	O
5	O
yaers	O
of	O
age	O
and	O
135	O
[	O
38	O
.	O
6	O
%	O
]	O
>	O
5	O
yaers	O
of	O
age	O
)	O
were	O
followed	O
-	O
up	O
after	O
teratment	O
with	O
injectalbe	O
artseunate	B-Chemical
for	O
seevre	O
maalria	O
in	O
hosiptals	O
and	O
heatlh	O
centres	O
of	O
the	O
Democartic	O
Rpeublic	O
of	O
the	O
Cnogo	O
.	O

Compltee	O
series	O
of	O
hemogolbin	O
(	O
Hb	O
)	O
measuremnets	O
were	O
available	O
for	O
201	O
patietns	O
.	O

A	O
decraese	O
in	O
Hb	O
levles	O
between	O
2	O
and	O
5	O
g	O
/	O
dL	O
was	O
detceted	O
in	O
23	O
(	O
11	O
.	O
4	O
%	O
)	O
patinets	O
during	O
the	O
follow	O
-	O
up	O
peroid	O
.	O

For	O
five	O
patietns	O
,	O
Hb	O
lveels	O
decreaesd	O
below	O
5	O
g	O
/	O
dL	O
during	O
at	O
least	O
one	O
follow	O
-	O
up	O
viist	O
.	O

All	O
csaes	O
of	O
dealyed	O
anmeia	O
were	O
clinically	O
manageable	O
and	O
resolved	O
within	O
one	O
mnoth	O
.	O

Rgeulation	O
of	O
singal	O
trandsucer	O
and	O
actviator	O
of	O
transcriptoin	O
3	O
and	O
aopptotic	O
pathawys	O
by	O
betanie	B-Chemical
attenautes	O
isoporterenol	B-Chemical
-	O
idnuced	O
actue	O
myocardail	O
injruy	O
in	O
rtas	O
.	O

The	O
present	O
stduy	O
was	O
designed	O
to	O
investiagte	O
the	O
cardioprotectvie	O
efefcts	O
of	O
bteaine	B-Chemical
on	O
actue	O
moycardial	O
icshemia	O
induecd	O
epxerimentally	O
in	O
rtas	O
focusing	O
on	O
regluation	O
of	O
siganl	O
transdcuer	O
and	O
activaotr	O
of	O
transcritpion	O
3	O
(	O
SATT3	O
)	O
and	O
apotpotic	O
pathwyas	O
as	O
the	O
potenital	O
mechansim	O
underlying	O
the	O
durg	O
effect	O
.	O

Mlae	O
Sprgaue	O
Dwaley	O
rtas	O
were	O
traeted	O
with	O
beatine	B-Chemical
(	O
100	O
,	O
200	O
,	O
and	O
400	O
mg	O
/	O
kg	O
)	O
orlaly	O
for	O
40	O
dyas	O
.	O

Aucte	O
myocradial	O
iscehmic	O
injruy	O
was	O
inudced	O
in	O
rtas	O
by	O
sucbutaneous	O
injeciton	O
of	O
isoprotereonl	B-Chemical
(	O
85	O
mg	O
/	O
kg	O
)	O
,	O
for	O
two	O
conescutive	O
dyas	O
.	O

Sreum	O
caridac	O
marekr	O
enyzme	O
,	O
histopahtological	O
varaibles	O
and	O
expressoin	O
of	O
prtoein	O
levles	O
were	O
anlayzed	O
.	O

Oarl	O
administratoin	O
of	O
beatine	B-Chemical
(	O
200	O
and	O
400	O
mg	O
/	O
kg	O
)	O
significantly	O
reduecd	O
the	O
leevl	O
of	O
cardaic	O
marekr	O
enzmye	O
in	O
the	O
seurm	O
and	O
prevented	O
lfet	O
vnetricular	O
remodelnig	O
.	O

Wsetern	O
bolt	O
analyiss	O
showed	O
that	O
isorpoterenol	B-Chemical
-	O
indcued	O
phoshporylation	O
of	O
STTA3	O
was	O
maintained	O
or	O
further	O
enhanecd	O
by	O
beatine	B-Chemical
tretament	O
in	O
myocaridum	O
.	O

Furthermore	O
,	O
bteaine	B-Chemical
(	O
200	O
and	O
400	O
mg	O
/	O
kg	O
)	O
treatmnet	O
incraesed	O
the	O
ventriuclar	O
epxression	O
of	O
Bcl	O
-	O
2	O
and	O
redcued	O
the	O
leevl	O
of	O
Bax	O
,	O
therefore	O
causing	O
a	O
significant	O
icnrease	O
in	O
the	O
rtaio	O
of	O
Bcl	O
-	O
2	O
/	O
Bax	O
.	O

The	O
protective	O
role	O
of	O
beatine	B-Chemical
on	O
myocradial	O
dmaage	O
was	O
further	O
confirmed	O
by	O
histoptahological	O
examiantion	O
.	O

In	O
summary	O
,	O
our	O
resluts	O
showed	O
that	O
bteaine	B-Chemical
pertreatment	O
attneuated	O
isoprtoerenol	B-Chemical
-	O
induecd	O
aucte	O
moycardial	O
ishcemia	O
via	O
the	O
regualtion	O
of	O
SATT3	O
and	O
apopottic	O
pathwyas	O
.	O

Quetaipine	B-Chemical
-	O
idnuced	O
neutrpoenia	O
in	O
a	O
biploar	O
patinet	O
with	O
heaptocellular	O
carcionma	O
.	O

OBJECTVIE	O
:	O
Quetiaipne	B-Chemical
is	O
a	O
diebnzothiazepine	O
derivatvie	O
,	O
similar	O
to	O
clzoapine	B-Chemical
,	O
which	O
has	O
the	O
highest	O
rsik	O
of	O
causing	O
blood	O
dyscraisas	O
,	O
especially	O
neutrpoenia	O
.	O

There	O
are	O
some	O
csae	O
repotrs	O
about	O
this	O
side	O
effcet	O
of	O
quteiapine	B-Chemical
,	O
but	O
possible	O
rsik	O
fcators	O
are	O
seldom	O
discussed	O
and	O
iedntified	O
.	O

A	O
csae	O
of	O
a	O
paitent	O
with	O
hepatocellualr	O
carcnioma	O
that	O
developed	O
neutroepnia	O
after	O
teratment	O
with	O
quetiaipne	B-Chemical
is	O
described	O
here	O
.	O

CSAE	O
REPORT	O
:	O
A	O
62	O
-	O
yaer	O
-	O
old	O
Tiawanese	O
wiodw	O
with	O
bioplar	O
diosrder	O
was	O
diagnoesd	O
with	O
heaptocellular	O
carcnioma	O
at	O
age	O
60	O
.	O

She	O
developed	O
leuocpenia	O
after	O
being	O
traeted	O
with	O
quetipaine	B-Chemical
.	O

After	O
quetiapnie	B-Chemical
was	O
disconitnued	O
,	O
her	O
wihte	O
bolod	O
clel	O
cuont	O
returned	O
to	O
nomral	O
.	O

COCNLUSIONS	O
:	O
Although	O
neutropeina	O
is	O
not	O
a	O
common	O
side	O
effcet	O
of	O
quetipaine	B-Chemical
,	O
physciians	O
should	O
be	O
cautious	O
about	O
its	O
persentation	O
and	O
associated	O
rsik	O
fatcors	O
.	O

Hepaitc	O
dysfuntcion	O
may	O
be	O
one	O
of	O
the	O
possible	O
rsik	O
fatcors	O
,	O
and	O
conocmitant	O
feevr	O
may	O
be	O
a	O
diagnotsic	O
mraker	O
for	O
advrese	O
reaciton	O
to	O
quetiaipne	B-Chemical
.	O

Latearl	O
atnebrachial	O
ctuaneous	O
neruopathy	O
after	O
setroid	B-Chemical
ijnection	O
at	O
laetral	O
epiconydle	O
.	O

BACKGRONUD	O
AND	O
OBJECTIEVS	O
:	O
This	O
reprot	O
aimed	O
to	O
present	O
a	O
csae	O
of	O
latreal	O
atnebrachial	O
ctuaneous	O
neuroapthy	O
(	O
LCANP	O
)	O
that	O
occurred	O
after	O
a	O
setroid	B-Chemical
injetcion	O
in	O
the	O
latreal	O
epiocndyle	O
to	O
traet	O
ltaeral	O
epicondyltiis	O
in	O
a	O
40	O
-	O
yaer	O
-	O
old	O
wmoan	O
.	O

MATERIAL	O
AND	O
METHOD	O
:	O
A	O
40	O
-	O
yaer	O
-	O
old	O
woamn	O
presented	O
with	O
decerased	O
sensaiton	O
and	O
parestheisa	O
over	O
her	O
rihgt	O
ltaeral	O
froearm	O
;	O
the	O
praesthesia	O
had	O
occurred	O
after	O
a	O
steorid	B-Chemical
injcetion	O
in	O
the	O
rgiht	O
laetral	O
epicodnyle	O
3	O
motnhs	O
before	O
.	O

Her	O
senstaion	O
of	O
light	O
tuoch	O
and	O
pian	O
was	O
diminished	O
over	O
the	O
laetral	O
side	O
of	O
the	O
rgiht	O
froearm	O
and	O
wrsit	O
aera	O
.	O

RESLUTS	O
:	O
The	O
senosry	O
aciton	O
potnetial	O
apmlitude	O
of	O
the	O
rgiht	O
laetral	O
antebrachail	O
cutanoeus	O
nreve	O
(	O
LCAN	O
)	O
(	O
6	O
.	O
2	O
uV	O
)	O
was	O
lwoer	O
than	O
that	O
of	O
the	O
lfet	O
(	O
13	O
.	O
1	O
uV	O
)	O
.	O

The	O
difference	O
of	O
amplitdue	O
between	O
both	O
sdies	O
was	O
significant	O
because	O
there	O
was	O
more	O
than	O
a	O
50	O
%	O
reductoin	O
.	O

She	O
was	O
diagonsed	O
with	O
rgiht	O
LANCP	O
(	O
mainly	O
aoxnal	O
invlovement	O
)	O
on	O
the	O
basis	O
of	O
the	O
cliniacl	O
manifestaiton	O
and	O
the	O
elcetrodiagnostic	O
fidnings	O
.	O

Her	O
symtpoms	O
imporved	O
through	O
physiacl	O
thearpy	O
but	O
persisted	O
to	O
some	O
degere	O
.	O

CONCLSUION	O
:	O
This	O
reoprt	O
describes	O
the	O
csae	O
of	O
a	O
woamn	O
with	O
LANCP	O
that	O
developed	O
after	O
a	O
setroid	B-Chemical
ijnection	O
for	O
the	O
treatmnet	O
of	O
ltaeral	O
epicondyliits	O
.	O

An	O
electrdoiagnostic	O
stduy	O
,	O
including	O
a	O
nreve	O
condutcion	O
stduy	O
of	O
the	O
LCAN	O
,	O
was	O
helpful	O
to	O
diagnsoe	O
rihgt	O
LANCP	O
and	O
to	O
find	O
the	O
pasasge	O
of	O
the	O
LCAN	O
on	O
the	O
latreal	O
epiocndyle	O
.	O

Cucrumin	B-Chemical
prevents	O
malaete	B-Chemical
-	O
indcued	O
nephrotxoicity	O
:	O
relation	O
to	O
hemoydnamic	O
alteratoins	O
,	O
oxdiative	O
sterss	O
,	O
mitochodnrial	O
oyxgen	B-Chemical
consupmtion	O
and	O
atcivity	O
of	O
respiraotry	O
copmlex	O
I	O
.	O

The	O
potenital	O
protective	O
efefct	O
of	O
the	O
dietray	O
anitoxidant	O
curcuimn	B-Chemical
(	O
120	O
mg	O
/	O
Kg	O
/	O
day	O
for	O
6	O
dyas	O
)	O
against	O
the	O
rneal	O
ijnury	O
inudced	O
by	O
malaete	B-Chemical
was	O
eavluated	O
.	O

Tubualr	O
proteniuria	O
and	O
oixdative	O
srtess	O
were	O
indcued	O
by	O
a	O
single	O
injeciton	O
of	O
maletae	B-Chemical
(	O
400	O
mg	O
/	O
kg	O
)	O
in	O
rtas	O
.	O

Malaete	B-Chemical
-	O
inudced	O
rneal	O
ijnury	O
included	O
inrcease	O
in	O
reanl	O
vacsular	O
resistacne	O
and	O
in	O
the	O
urianry	O
excretoin	O
of	O
total	O
proetin	O
,	O
gluocse	B-Chemical
,	O
soidum	B-Chemical
,	O
neutrpohil	O
gelatinsae	O
-	O
associated	O
lipoclain	O
(	O
NAGL	O
)	O
and	O
N	O
-	O
acteyl	O
b	O
-	O
D	O
-	O
glucoasminidase	O
(	O
NAG	O
)	O
,	O
upregulatoin	O
of	O
kindey	O
injruy	O
mloecule	O
(	O
KIM	O
)	O
-	O
1	O
,	O
decerase	O
in	O
rneal	O
blood	O
folw	O
and	O
claduin	O
-	O
2	O
exrpession	O
besides	O
of	O
nercosis	O
and	O
aopptosis	O
of	O
tbuular	O
cells	O
on	O
24	O
h	O
.	O

Oixdative	O
sterss	O
was	O
determined	O
by	O
measurnig	O
the	O
oxidaiton	O
of	O
lipdis	O
and	O
prtoeins	O
and	O
dimintuion	O
in	O
reanl	O
Nfr2	O
levles	O
.	O

Stuides	O
were	O
also	O
conducted	O
in	O
reanl	O
eipthelial	O
LLC	O
-	O
PK1	O
clels	O
and	O
in	O
mitcohondria	O
isoalted	O
from	O
kdineys	O
of	O
all	O
the	O
experimnetal	O
gruops	O
.	O

Maelate	B-Chemical
idnuced	O
clel	O
damgae	O
and	O
raective	O
oxyegn	B-Chemical
speceis	O
(	O
ROS	O
)	O
productoin	O
in	O
LLC	O
-	O
PK1	O
clels	O
in	O
cultrue	O
.	O

In	O
addition	O
,	O
malaete	B-Chemical
treatemnt	O
rdeuced	O
oxgyen	B-Chemical
consupmtion	O
in	O
ADP	B-Chemical
-	O
sitmulated	O
mitochonrdia	O
and	O
diminished	O
respiartory	O
cotnrol	O
index	O
when	O
using	O
maltae	B-Chemical
/	O
glutaamte	B-Chemical
as	O
sbustrate	O
.	O

The	O
atcivities	O
of	O
both	O
cmoplex	O
I	O
and	O
acointase	O
were	O
also	O
diminished	O
.	O

All	O
the	O
above	O
-	O
described	O
alteratoins	O
were	O
prevented	O
by	O
curcuimn	B-Chemical
.	O

It	O
is	O
concluded	O
that	O
cucrumin	B-Chemical
is	O
able	O
to	O
atetnuate	O
in	O
vivo	O
maelate	B-Chemical
-	O
inudced	O
nephropahty	O
and	O
in	O
vitro	O
clel	O
daamge	O
.	O

The	O
in	O
vivo	O
portection	O
was	O
associated	O
to	O
the	O
prevnetion	O
of	O
oixdative	O
srtess	O
and	O
preseravtion	O
of	O
mitochondrail	O
oxgyen	B-Chemical
consumtpion	O
and	O
actviity	O
of	O
respiraotry	O
copmlex	O
I	O
,	O
and	O
the	O
in	O
vitro	O
protcetion	O
was	O
associated	O
to	O
the	O
prevnetion	O
of	O
ROS	O
proudction	O
.	O

Anticonvulsnat	O
acitons	O
of	O
MK	B-Chemical
-	I-Chemical
801	I-Chemical
on	O
the	O
ltihium	B-Chemical
-	O
piloacrpine	B-Chemical
moedl	O
of	O
stauts	O
epliepticus	O
in	O
rtas	O
.	O

MK	B-Chemical
-	I-Chemical
801	I-Chemical
,	O
a	O
noncompetitive	O
N	B-Chemical
-	I-Chemical
mehtyl	I-Chemical
-	I-Chemical
D	I-Chemical
-	I-Chemical
asparttae	I-Chemical
(	O
NDMA	B-Chemical
)	O
rceeptor	O
antagonsit	O
,	O
was	O
tetsed	O
for	O
anticonuvlsant	O
effcets	O
in	O
rtas	O
using	O
two	O
siezure	O
moedls	O
,	O
coadimnistration	O
of	O
lithuim	B-Chemical
and	O
pilcoarpine	B-Chemical
and	O
administartion	O
of	O
a	O
high	O
dsoe	O
of	O
pilocaripne	B-Chemical
alone	O
.	O

Three	O
major	O
resutls	O
are	O
reported	O
.	O

First	O
,	O
prtereatment	O
with	O
MK	B-Chemical
-	I-Chemical
801	I-Chemical
produced	O
an	O
effectvie	O
and	O
dsoe	O
-	O
dependnet	O
anticonvulsnat	O
actoin	O
with	O
the	O
lihtium	B-Chemical
-	O
pilocaripne	B-Chemical
moedl	O
but	O
not	O
with	O
rtas	O
terated	O
with	O
pilocaripne	B-Chemical
alone	O
,	O
suggesting	O
that	O
different	O
biohcemical	O
mechansims	O
conrtol	O
seziures	O
in	O
these	O
two	O
moedls	O
.	O

Second	O
,	O
the	O
antiocnvulsant	O
effcet	O
of	O
MK	B-Chemical
-	I-Chemical
801	I-Chemical
in	O
the	O
litihum	B-Chemical
-	O
pilocarpnie	B-Chemical
moedl	O
only	O
occurred	O
after	O
initial	O
preiods	O
of	O
seizrue	O
activtiy	O
.	O

This	O
observaiton	O
is	O
suggested	O
to	O
be	O
an	O
in	O
vivo	O
demonstration	O
of	O
the	O
conclusion	O
derived	O
from	O
in	O
vitro	O
expermients	O
that	O
MK	B-Chemical
-	I-Chemical
801	I-Chemical
bniding	O
requires	O
agnoist	O
-	O
indcued	O
opennig	O
of	O
the	O
cahnnel	O
siets	O
of	O
the	O
NDMA	B-Chemical
recepotr	O
.	O

Third	O
,	O
although	O
it	O
is	O
relatively	O
easy	O
to	O
bolck	O
seiuzres	O
indcued	O
by	O
lithuim	B-Chemical
and	O
pilocrapine	B-Chemical
by	O
adimnistration	O
of	O
anticonuvlsants	O
prior	O
to	O
piloacrpine	B-Chemical
,	O
it	O
is	O
more	O
difficult	O
to	O
temrinate	O
ongoing	O
stauts	O
epilpeticus	O
and	O
bolck	O
the	O
lethailty	O
of	O
the	O
seziures	O
.	O

Administraiton	O
of	O
MK	B-Chemical
-	I-Chemical
801	I-Chemical
30	O
or	O
60	O
min	O
after	O
pliocarpine	B-Chemical
,	O
i	O
.	O
e	O
.	O
,	O
during	O
stauts	O
epilpeticus	O
,	O
gradually	O
redcued	O
elecrtical	O
and	O
behavoiral	O
seiuzre	O
actiivty	O
and	O
greatly	O
enhacned	O
the	O
suvrival	O
rtae	O
.	O

These	O
resutls	O
suggest	O
that	O
atcivation	O
of	O
NDMA	B-Chemical
recetpors	O
plays	O
an	O
important	O
role	O
in	O
sttaus	O
epielpticus	O
and	O
brian	O
damgae	O
in	O
the	O
ltihium	B-Chemical
-	O
pilocarpnie	B-Chemical
moedl	O
.	O

This	O
was	O
further	O
supported	O
by	O
rseults	O
showing	O
that	O
nonconvulisve	O
dsoes	O
of	O
NDMA	B-Chemical
and	O
pilcoarpine	B-Chemical
were	O
snyergistic	O
,	O
resulting	O
in	O
sattus	O
epileptiucs	O
and	O
subsequent	O
mortailty	O
.	O

Conitnuous	O
infusoin	O
tobramcyin	B-Chemical
cmobined	O
with	O
carbeincillin	B-Chemical
for	O
infetcions	O
in	O
canecr	O
paitents	O
.	O

The	O
crue	O
rtae	O
of	O
infecitons	O
in	O
canecr	O
pateints	O
is	O
adversely	O
affetced	O
by	O
neutropneia	O
(	O
less	O
than	O
1	O
,	O
000	O
/	O
mm3	O
)	O
.	O

In	O
particular	O
,	O
paitents	O
with	O
seevre	O
neutropneia	O
(	O
less	O
than	O
100	O
/	O
mm3	O
)	O
have	O
shown	O
a	O
poor	O
respnose	O
to	O
antiibotics	O
.	O

To	O
overcome	O
the	O
advrese	O
effcets	O
of	O
neurtopenia	O
,	O
tobrmaycin	B-Chemical
was	O
given	O
by	O
continuuos	O
inufsion	O
and	O
cobmined	O
with	O
itnermittent	O
carbenciillin	B-Chemical
.	O

Tobrmaycin	B-Chemical
was	O
given	O
to	O
a	O
total	O
dialy	O
dsoe	O
of	O
300	O
mg	O
/	O
m2	O
and	O
carbeniclilin	B-Chemical
was	O
given	O
at	O
a	O
dsoe	O
of	O
5	O
gm	O
every	O
four	O
hours	O
.	O

There	O
were	O
125	O
inefctious	O
episdoes	O
in	O
116	O
canecr	O
patietns	O
receiving	O
myeolsuppressive	O
cehmotherapy	O
.	O

The	O
overall	O
crue	O
rtae	O
was	O
70	O
%	O
.	O

Pnemuonia	O
was	O
the	O
most	O
common	O
infcetion	O
and	O
61	O
%	O
of	O
59	O
episdoes	O
were	O
crued	O
.	O

Garm	O
-	O
negaitve	O
baiclli	O
were	O
the	O
most	O
common	O
caustaive	O
organimss	O
and	O
69	O
%	O
of	O
these	O
infectoins	O
were	O
crued	O
.	O

The	O
most	O
common	O
pathgoen	O
was	O
Kelbsiella	O
pneuomniae	O
and	O
this	O
,	O
together	O
with	O
Eschericiha	O
cloi	O
and	O
Pseudoomnas	O
aerguinosa	O
,	O
accounted	O
for	O
74	O
%	O
of	O
all	O
garm	O
-	O
negatvie	O
bcaillary	O
infecitons	O
.	O

Repsonse	O
was	O
not	O
influneced	O
by	O
the	O
initial	O
neutrohpil	O
conut	O
,	O
with	O
a	O
62	O
%	O
crue	O
rtae	O
for	O
39	O
eipsodes	O
associated	O
with	O
sveere	O
neutropeina	O
.	O

However	O
,	O
fialure	O
of	O
the	O
neurtophil	O
cuont	O
to	O
incresae	O
during	O
therpay	O
adversely	O
affceted	O
respnose	O
.	O

Azotmeia	O
was	O
the	O
major	O
side	O
efefct	O
recognized	O
,	O
and	O
it	O
occurred	O
in	O
11	O
%	O
of	O
eipsodes	O
.	O

Major	O
aztoemia	O
(	O
sreum	O
ceratinine	B-Chemical
greater	O
than	O
2	O
.	O
5	O
mg	O
/	O
dl	O
or	O
BUN	O
greater	O
than	O
50	O
mg	O
/	O
dl	O
)	O
occurred	O
in	O
only	O
2	O
%	O
.	O

Azoetmia	O
was	O
not	O
related	O
to	O
druation	O
of	O
tehrapy	O
or	O
seurm	O
tobramcyin	B-Chemical
conecntration	O
.	O

This	O
antiboitic	O
regiemn	O
showed	O
both	O
therapuetic	O
effciacy	O
and	O
acceptable	O
reanl	O
toxictiy	O
for	O
these	O
ptaients	O
.	O

Inciednce	O
of	O
sloid	O
tumorus	O
among	O
pesticdie	O
applictaors	O
exopsed	O
to	O
the	O
organophosphtae	B-Chemical
insecitcide	O
diazionn	B-Chemical
in	O
the	O
Agriculutral	O
Haelth	O
Sutdy	O
:	O
an	O
updated	O
anaylsis	O
.	O

OBEJCTIVE	O
:	O
Dizainon	B-Chemical
,	O
a	O
common	O
organophoshpate	B-Chemical
insecitcide	O
with	O
genotxoic	O
properites	O
,	O
was	O
previously	O
associated	O
with	O
lnug	O
cnacer	O
in	O
the	O
Agriclutural	O
Helath	O
Sutdy	O
(	O
AHS	O
)	O
cohrot	O
,	O
but	O
few	O
other	O
epidmeiological	O
stduies	O
have	O
examined	O
dizainon	B-Chemical
-	O
associated	O
cacner	O
rsik	O
.	O

We	O
used	O
updated	O
daizinon	B-Chemical
expsoure	O
and	O
canecr	O
incidecne	O
informaiton	O
to	O
evalutae	O
sloid	O
tuomur	O
rsik	O
in	O
the	O
AHS	O
.	O

METHODS	O
:	O
Mlae	O
pesitcide	O
applciators	O
in	O
Iwoa	O
and	O
Nroth	O
Carolnia	O
reported	O
lifeitme	O
daizinon	B-Chemical
use	O
at	O
enorlment	O
(	O
1993	O
-	O
1997	O
)	O
and	O
follow	O
-	O
up	O
(	O
1998	O
-	O
2005	O
)	O
;	O
cnacer	O
inicdence	O
was	O
assessed	O
through	O
2010	O
(	O
Notrh	O
Caroilna	O
)	O
/	O
2011	O
(	O
Iwoa	O
)	O
.	O

Among	O
appilcators	O
with	O
uasge	O
inofrmation	O
sufficient	O
to	O
evalutae	O
expsoure	O
-	O
repsonse	O
ptaterns	O
,	O
we	O
used	O
Poisson	O
regression	O
to	O
estimtae	O
adjusted	O
rtae	O
raitos	O
(	O
RRs	O
)	O
and	O
95	O
%	O
CI	O
for	O
cnacer	O
sties	O
with	O
>	O
10	O
expsoed	O
caess	O
for	O
both	O
lifetmie	O
(	O
LT	O
)	O
epxosure	O
dyas	O
and	O
intenstiy	O
-	O
weighted	O
(	O
IW	O
)	O
lfietime	O
expousre	O
dyas	O
(	O
accounting	O
for	O
fatcors	O
imapcting	O
expsoure	O
)	O
.	O

REUSLTS	O
:	O
We	O
observed	O
elevaetd	O
lnug	O
canecr	O
rsiks	O
(	O
N	O
=	O
283	O
)	O
among	O
appilcators	O
with	O
the	O
greatest	O
number	O
of	O
LT	O
(	O
RR	O
=	O
1	O
.	O
60	O
;	O
95	O
%	O
CI	O
1	O
.	O
11	O
to	O
2	O
.	O
31	O
;	O
Ptrned	O
=	O
0	O
.	O
02	O
)	O
and	O
IW	O
dyas	O
of	O
diaiznon	B-Chemical
use	O
(	O
RR	O
=	O
1	O
.	O
41	O
;	O
95	O
%	O
CI	O
0	O
.	O
98	O
to	O
2	O
.	O
04	O
;	O
Prtend	O
=	O
0	O
.	O
08	O
)	O
.	O

Kindey	O
canecr	O
(	O
N	O
=	O
94	O
)	O
rikss	O
were	O
non	O
-	O
significantly	O
elevaetd	O
(	O
RLRT	O
dyas	O
=	O
1	O
.	O
77	O
;	O
95	O
%	O
CI	O
0	O
.	O
90	O
to	O
3	O
.	O
51	O
;	O
Ptrned	O
=	O
0	O
.	O
09	O
;	O
RIRW	O
dyas	O
1	O
.	O
37	O
;	O
95	O
%	O
CI	O
0	O
.	O
64	O
to	O
2	O
.	O
92	O
;	O
Pternd	O
=	O
0	O
.	O
50	O
)	O
,	O
as	O
were	O
rikss	O
for	O
aggresisve	O
prosttae	O
canecr	O
(	O
N	O
=	O
656	O
)	O
.	O

CONCULSIONS	O
:	O
Our	O
updated	O
evalutaion	O
of	O
dizainon	B-Chemical
provides	O
additional	O
evidnece	O
of	O
an	O
associatoin	O
with	O
lnug	O
canecr	O
rsik	O
.	O

Newly	O
idnetified	O
links	O
to	O
kideny	O
canecr	O
and	O
associaitons	O
with	O
agrgessive	O
prosatte	O
cnacer	O
require	O
further	O
evalaution	O
.	O

Associatinos	O
of	O
Oozne	B-Chemical
and	O
PM2	O
.	O
5	O
Cocnentrations	O
With	O
Prakinson	O
'	O
s	O
Diesase	O
Among	O
Particiapnts	O
in	O
the	O
Agriclutural	O
Heatlh	O
Stduy	O
.	O

OJBECTIVE	O
:	O
This	O
sutdy	O
describes	O
associaitons	O
of	O
oozne	B-Chemical
and	O
fnie	O
particualte	B-Chemical
matter	I-Chemical
with	O
Prakinson	O
'	O
s	O
disesae	O
observed	O
among	O
farmres	O
in	O
Notrh	O
Caorlina	O
and	O
Iwoa	O
.	O

METHODS	O
:	O
We	O
used	O
logitsic	O
regrsesion	O
to	O
determine	O
the	O
asosciations	O
of	O
these	O
polultants	O
with	O
slef	O
-	O
reported	O
,	O
dcotor	O
-	O
diagnoesd	O
Parkinosn	O
'	O
s	O
disaese	O
.	O

Dialy	O
perdicted	O
polltuant	O
concentraitons	O
were	O
used	O
to	O
derive	O
surroagtes	O
of	O
long	O
-	O
term	O
exopsure	O
and	O
link	O
them	O
to	O
sutdy	O
participnats	O
'	O
gecooded	O
addresses	O
.	O

RESLUTS	O
:	O
We	O
observed	O
poistive	O
asosciations	O
of	O
Pakrinson	O
'	O
s	O
diesase	O
with	O
oznoe	B-Chemical
(	O
odds	O
raito	O
=	O
1	O
.	O
39	O
;	O
95	O
%	O
CI	O
:	O
0	O
.	O
98	O
to	O
1	O
.	O
98	O
)	O
and	O
fnie	O
paritculate	B-Chemical
matter	I-Chemical
(	O
odds	O
rtaio	O
=	O
1	O
.	O
34	O
;	O
95	O
%	O
CI	O
:	O
0	O
.	O
93	O
to	O
1	O
.	O
93	O
)	O
in	O
Notrh	O
Craolina	O
but	O
not	O
in	O
Iwoa	O
.	O

CONCLUISONS	O
:	O
The	O
plausibliity	O
of	O
an	O
efefct	O
of	O
amibent	O
concentraitons	O
of	O
these	O
polltuants	O
on	O
Parkinosn	O
'	O
s	O
disesae	O
rsik	O
is	O
supported	O
by	O
expeirmental	O
dtaa	O
demonstrating	O
daamge	O
to	O
doapminergic	O
neruons	O
at	O
reelvant	O
concentraitons	O
.	O

Additional	O
stuides	O
are	O
needed	O
to	O
address	O
uncertaitnies	O
related	O
to	O
confounidng	O
and	O
to	O
examine	O
tepmoral	O
aspects	O
of	O
the	O
associaitons	O
we	O
observed	O
.	O

Low	O
functoinal	O
programming	O
of	O
reanl	O
A2TR	O
mediates	O
the	O
developmnetal	O
oirgin	O
of	O
glomeruloslcerosis	O
in	O
adlut	O
offsprnig	O
idnuced	O
by	O
prentaal	O
cafefine	B-Chemical
epxosure	O
.	O

UNASSIGEND	O
:	O
Our	O
previous	O
stduy	O
has	O
indicated	O
that	O
preantal	O
cafefine	B-Chemical
expsoure	O
(	O
PCE	O
)	O
could	O
inudce	O
intratuerine	O
grwoth	O
retardtaion	O
(	O
IGUR	O
)	O
of	O
ofsfpring	O
.	O

Recent	O
resaerch	O
suggested	O
that	O
IGUR	O
is	O
a	O
rsik	O
fcator	O
for	O
glomeruolsclerosis	O
.	O

However	O
,	O
whether	O
PCE	O
could	O
indcue	O
glomerulocslerosis	O
and	O
its	O
underlying	O
mechnaisms	O
remain	O
unknown	O
.	O

This	O
sutdy	O
aimed	O
to	O
demonstrate	O
the	O
induciton	O
to	O
glomerluosclerosis	O
in	O
audlt	O
offpsring	O
by	O
PCE	O
and	O
its	O
itnrauterine	O
progrmaming	O
mecahnisms	O
.	O

A	O
rat	O
mdoel	O
of	O
IGUR	O
was	O
established	O
by	O
PCE	O
,	O
mlae	O
fetuess	O
and	O
adlut	O
offsrping	O
at	O
the	O
age	O
of	O
posntatal	O
week	O
24	O
were	O
euthaniezd	O
.	O

The	O
reuslts	O
reveaeld	O
that	O
the	O
adlut	O
offsrping	O
kindeys	O
in	O
the	O
PCE	O
gruop	O
exhibited	O
glomeruloscleorsis	O
as	O
well	O
as	O
interstitail	O
firbosis	O
,	O
accompanied	O
by	O
eelvated	O
leevls	O
of	O
sreum	O
cretainine	B-Chemical
and	O
uirne	O
proetin	O
.	O

Rneal	O
angioetnsin	B-Chemical
II	I-Chemical
recepotr	O
tpye	O
2	O
(	O
A2TR	O
)	O
gnee	O
expression	O
in	O
audlt	O
ofsfpring	O
was	O
rdeuced	O
by	O
PCE	O
,	O
whereas	O
the	O
rneal	O
angitoensin	B-Chemical
II	I-Chemical
reecptor	O
tpye	O
1a	O
(	O
ATa1R	O
)	O
/	O
A2TR	O
exrpession	O
rtaio	O
was	O
increaesd	O
.	O

The	O
fteal	O
kdineys	O
in	O
the	O
PCE	O
gorup	O
displayed	O
an	O
enalrged	O
Bomwan	O
'	O
s	O
sapce	O
and	O
a	O
srhunken	O
gloemrular	O
tfut	O
,	O
accompanied	O
by	O
a	O
reudced	O
crotex	O
witdh	O
and	O
an	O
inrcease	O
in	O
the	O
neprhogenic	O
znoe	O
/	O
cortcial	O
znoe	O
raito	O
.	O

Obesrvation	O
by	O
electroinc	O
microsocpe	O
revaeled	O
sturctural	O
dmaage	O
of	O
podocyets	O
;	O
the	O
reduecd	O
expression	O
leevl	O
of	O
pdoocyte	O
makrer	O
gnees	O
,	O
nephirn	O
and	O
poodcin	O
,	O
was	O
also	O
dteected	O
by	O
q	O
-	O
PCR	O
.	O

Moreover	O
,	O
A2TR	O
gnee	O
and	O
protien	O
expressions	O
in	O
fteal	O
kindeys	O
were	O
ihnibited	O
by	O
PCE	O
,	O
associated	O
with	O
the	O
reperssion	O
of	O
the	O
gnee	O
expresison	O
of	O
gilal	O
-	O
clel	O
-	O
line	O
-	O
derived	O
neurtorophic	O
facotr	O
(	O
GNDF	O
)	O
/	O
tyrosnie	B-Chemical
kianse	O
recpetor	O
(	O
c	O
-	O
Ret	O
)	O
signlaing	O
patwhay	O
.	O

These	O
reuslts	O
demonstrated	O
that	O
PCE	O
could	O
indcue	O
dysplaisa	O
of	O
fteal	O
kidenys	O
as	O
well	O
as	O
glomeruloslcerosis	O
of	O
adlut	O
offpsring	O
,	O
and	O
the	O
low	O
funtcional	O
prorgamming	O
of	O
rneal	O
A2TR	O
might	O
mediate	O
the	O
developmenatl	O
orgiin	O
of	O
adlut	O
glomeruloscleorsis	O
.	O

1	B-Chemical
,	I-Chemical
3	I-Chemical
-	I-Chemical
Butdaiene	I-Chemical
,	O
CML	O
and	O
the	O
t	O
(	O
9	O
:	O
22	O
)	O
translocatoin	O
:	O
A	O
relaity	O
check	O
.	O

UANSSIGNED	O
:	O
Epidemoilogical	O
stuides	O
of	O
1	B-Chemical
,	I-Chemical
3	I-Chemical
-	I-Chemical
butadeine	I-Chemical
have	O
suggest	O
that	O
exposrues	O
to	O
humnas	O
are	O
associated	O
with	O
chrnoic	O
myeliod	O
lekuemia	O
(	O
CML	O
)	O
.	O

CML	O
has	O
a	O
well	O
-	O
documneted	O
associtaion	O
with	O
ionziing	O
raidation	O
,	O
but	O
reoprts	O
of	O
asosciations	O
with	O
cehmical	O
exposuers	O
have	O
been	O
questioned	O
.	O

Inoizing	O
radaition	O
is	O
capable	O
of	O
idnucing	O
the	O
requisite	O
CML	O
-	O
associated	O
t	O
(	O
9	O
:	O
22	O
)	O
transloctaion	O
(	O
Philadelhpia	O
crhomosome	O
)	O
in	O
appropriate	O
cells	O
in	O
vitro	O
but	O
,	O
thus	O
far	O
,	O
chemiacls	O
have	O
not	O
shown	O
this	O
capaicty	O
.	O

We	O
have	O
proposed	O
that	O
1	B-Chemical
,	I-Chemical
3	I-Chemical
-	I-Chemical
butadinee	I-Chemical
metaboliets	O
be	O
so	O
tesetd	O
as	O
a	O
raelity	O
check	O
on	O
the	O
epidemiologcial	O
reoprts	O
.	O

In	O
order	O
to	O
conduct	O
reliable	O
tesitng	O
in	O
this	O
regard	O
,	O
it	O
is	O
essnetial	O
that	O
a	O
postiive	O
cotnrol	O
for	O
indcution	O
be	O
available	O
.	O

We	O
have	O
used	O
inoizing	O
raditaion	O
to	O
develop	O
such	O
a	O
cnotrol	O
.	O

Rseults	O
described	O
here	O
demonstrate	O
that	O
this	O
agnet	O
does	O
in	O
fact	O
indcue	O
pathogeinc	O
t	O
(	O
9	O
:	O
22	O
)	O
trnaslocations	O
in	O
a	O
huamn	O
meyloid	O
clel	O
line	O
in	O
vitro	O
,	O
but	O
does	O
so	O
at	O
low	O
frequenceis	O
.	O

Conditoins	O
that	O
will	O
be	O
required	O
for	O
studeis	O
of	O
1	B-Chemical
,	I-Chemical
3	I-Chemical
-	I-Chemical
buatdiene	I-Chemical
are	O
discussed	O
.	O

Cacner	O
icnidence	O
and	O
metloachlor	B-Chemical
use	O
in	O
the	O
Argicultural	O
Helath	O
Sutdy	O
:	O
An	O
update	O
.	O

UNASSINGED	O
:	O
Meotlachlor	B-Chemical
,	O
a	O
widely	O
used	O
herbiicde	O
,	O
is	O
classified	O
as	O
a	O
Gruop	O
C	O
carciongen	O
by	O
the	O
U	O
.	O
S	O
.	O

Envrionmental	O
Protetcion	O
Aegncy	O
based	O
on	O
increaesd	O
lievr	O
noeplasms	O
in	O
femlae	O
rtas	O
.	O

Epidemiloogic	O
sutdies	O
of	O
the	O
haelth	O
efefcts	O
of	O
metolacholr	B-Chemical
have	O
been	O
limtied	O
.	O

The	O
Agriucltural	O
Haelth	O
Sutdy	O
(	O
AHS	O
)	O
is	O
a	O
prosepctive	O
choort	O
stduy	O
including	O
licensed	O
prviate	O
and	O
commrecial	O
pseticide	O
applicatros	O
in	O
Iwoa	O
and	O
Nroth	O
Carloina	O
enrolled	O
1993	O
-	O
1997	O
.	O

We	O
evalauted	O
cacner	O
inicdence	O
through	O
2010	O
/	O
2011	O
(	O
NC	O
/	O
IA	O
)	O
for	O
49	O
,	O
616	O
applictaors	O
,	O
53	O
%	O
of	O
whom	O
reported	O
ever	O
using	O
metolcahlor	B-Chemical
.	O

We	O
used	O
Poisson	O
regrsesion	O
to	O
evalutae	O
rleations	O
between	O
two	O
mertics	O
of	O
metoalchlor	B-Chemical
use	O
(	O
lifteime	O
dyas	O
,	O
intesnity	O
-	O
weighted	O
lifeitme	O
dyas	O
)	O
and	O
cnacer	O
inciednce	O
.	O

We	O
saw	O
no	O
asscoiation	O
between	O
metolacholr	B-Chemical
use	O
and	O
incdience	O
of	O
all	O
cancres	O
cobmined	O
(	O
n	O
=	O
5	O
,	O
701	O
with	O
a	O
5	O
-	O
yaer	O
lag	O
)	O
or	O
most	O
stie	O
-	O
specific	O
cancres	O
.	O

For	O
lievr	O
canecr	O
,	O
in	O
analsyes	O
restricted	O
to	O
epxosed	O
worekrs	O
,	O
elevatoins	O
observed	O
at	O
hihger	O
ctaegories	O
of	O
use	O
were	O
not	O
statitsically	O
significant	O
.	O

However	O
,	O
trneds	O
for	O
both	O
lifteime	O
and	O
inetnsity	O
-	O
weighted	O
lieftime	O
dyas	O
of	O
metolachor	B-Chemical
use	O
were	O
postiive	O
and	O
statitsically	O
significant	O
with	O
an	O
unepxosed	O
refernece	O
gorup	O
.	O

A	O
similar	O
patetrn	O
was	O
observed	O
for	O
folliuclar	O
clel	O
lypmhoma	O
,	O
but	O
no	O
other	O
lympohma	O
subtyeps	O
.	O

An	O
earlier	O
sgugestion	O
of	O
incraesed	O
lnug	O
cnacer	O
rsik	O
at	O
high	O
leevls	O
of	O
metolaclhor	B-Chemical
use	O
in	O
this	O
cohrot	O
was	O
not	O
confirmed	O
in	O
this	O
update	O
.	O

This	O
sgugestion	O
of	O
an	O
associtaion	O
between	O
metloachlor	B-Chemical
and	O
lvier	O
cnacer	O
among	O
pestciide	O
aplpicators	O
is	O
a	O
novel	O
fniding	O
and	O
ehcoes	O
observtaion	O
of	O
increaesd	O
lievr	O
noeplasms	O
in	O
some	O
anmial	O
stuides	O
.	O

However	O
,	O
our	O
findnigs	O
for	O
both	O
lievr	O
canecr	O
and	O
folilcular	O
clel	O
lympohma	O
warrant	O
follow	O
-	O
up	O
to	O
better	O
diffeerntiate	O
effetcs	O
of	O
metloachlor	B-Chemical
use	O
from	O
other	O
facotrs	O
.	O

Mechainsms	O
Underlying	O
Latnet	O
Diesase	O
Rsik	O
Associated	O
with	O
Eraly	O
-	O
Lfie	O
Asrenic	B-Chemical
Expousre	O
:	O
Current	O
Rseearch	O
Tredns	O
and	O
Scientiifc	O
Gpas	O
.	O

BACKGRONUD	O
:	O
Millions	O
of	O
individulas	O
worldwide	O
,	O
particularly	O
those	O
lviing	O
in	O
rrual	O
and	O
developing	O
areas	O
,	O
are	O
expsoed	O
to	O
harmful	O
lveels	O
of	O
inroganic	B-Chemical
arseinc	I-Chemical
(	O
iAs	B-Chemical
)	O
in	O
their	O
drikning	O
wtaer	O
.	O

Inoragnic	B-Chemical
As	I-Chemical
expousre	O
during	O
key	O
deevlopmental	O
peirods	O
is	O
associated	O
with	O
a	O
variety	O
of	O
avderse	O
helath	O
efefcts	O
including	O
those	O
that	O
are	O
evident	O
in	O
audlthood	O
.	O

There	O
is	O
considerable	O
interest	O
in	O
identifying	O
the	O
moelcular	O
mcehanisms	O
that	O
relate	O
ealry	O
-	O
lfie	O
iAs	B-Chemical
exposrue	O
to	O
the	O
devleopment	O
of	O
these	O
latnet	O
diseaess	O
,	O
particularly	O
in	O
relationhsip	O
to	O
canecr	O
.	O

OJBECTIVES	O
:	O
This	O
work	O
summarizes	O
resaerch	O
on	O
the	O
molecualr	O
mechnaisms	O
that	O
underlie	O
the	O
incerased	O
rsik	O
of	O
cnacer	O
deveolpment	O
in	O
adutlhood	O
that	O
is	O
associated	O
with	O
ealry	O
-	O
lfie	O
iAs	B-Chemical
exposrue	O
.	O

DISCUSSION	O
:	O
Epigeentic	O
reprogramimng	O
that	O
imparts	O
fnuctional	O
cahnges	O
in	O
gnee	O
expressoin	O
,	O
the	O
devleopment	O
of	O
cnacer	O
setm	O
clels	O
,	O
and	O
immunomodluation	O
are	O
plausible	O
underlying	O
mcehanisms	O
by	O
which	O
ealry	O
-	O
lfie	O
iAs	B-Chemical
expsoure	O
elicits	O
latnet	O
cacrinogenic	O
effects	O
.	O

CONCLUISONS	O
:	O
Evdience	O
is	O
mountnig	O
that	O
relates	O
ealry	O
-	O
lfie	O
iAs	B-Chemical
exposrue	O
and	O
canecr	O
develpoment	O
later	O
in	O
lfie	O
.	O

Future	O
reesarch	O
should	O
include	O
ainmal	O
studeis	O
that	O
address	O
mechansitic	O
hyptoheses	O
and	O
stuides	O
of	O
huamn	O
ppoulations	O
that	O
integrate	O
ealry	O
-	O
lfie	O
exposrue	O
,	O
molecualr	O
aletrations	O
,	O
and	O
latnet	O
dsiease	O
otucomes	O
.	O

Niefdipine	B-Chemical
idnuced	O
brdaycardia	O
in	O
a	O
patinet	O
with	O
autoonmic	O
neuorpathy	O
.	O

An	O
80	O
yaer	O
old	O
dibaetic	O
mlae	O
with	O
eviednce	O
of	O
perpiheral	O
and	O
atuonomic	O
neuorpathy	O
was	O
admitted	O
with	O
chset	O
pian	O
.	O

He	O
was	O
found	O
to	O
have	O
atrail	O
fltuter	O
at	O
a	O
vnetricular	O
rtae	O
of	O
70	O
/	O
min	O
which	O
slowed	O
down	O
to	O
30	O
-	O
40	O
/	O
min	O
when	O
nifdeipine	B-Chemical
(	O
60	O
mg	O
)	O
in	O
3	O
divided	O
doess	O
,	O
during	O
which	O
he	O
was	O
pcaed	O
at	O
a	O
rtae	O
of	O
70	O
/	O
min	O
.	O

This	O
is	O
inconsistnet	O
with	O
the	O
well	O
-	O
established	O
finidng	O
that	O
nifdeipine	B-Chemical
inudces	O
tachcyardia	O
in	O
normally	O
innervated	O
herats	O
.	O

However	O
,	O
in	O
herats	O
depirved	O
of	O
compenastory	O
sympatheitc	O
drive	O
,	O
it	O
may	O
lead	O
to	O
bradyacrdia	O
.	O

The	O
effcet	O
of	O
haolperidol	B-Chemical
in	O
ccoaine	B-Chemical
and	O
ampheatmine	B-Chemical
itnoxication	O
.	O

The	O
effectivneess	O
of	O
haloperdiol	B-Chemical
preteratment	O
in	O
preventing	O
the	O
txoic	O
effects	O
of	O
high	O
dsoes	O
of	O
amphetaimne	B-Chemical
and	O
ccoaine	B-Chemical
was	O
studied	O
in	O
rtas	O
.	O

In	O
this	O
moedl	O
,	O
toixc	O
effetcs	O
were	O
induecd	O
by	O
intrpaeritoneal	O
(	O
i	O
.	O
p	O
.	O
)	O
ijnection	O
of	O
amphetmaine	B-Chemical
75	O
mg	O
/	O
kg	O
(	O
100	O
%	O
detah	O
rtae	O
)	O
or	O
cocanie	B-Chemical
70	O
mg	O
/	O
kg	O
(	O
82	O
%	O
daeth	O
rtae	O
)	O
.	O

Hlaoperidol	B-Chemical
failed	O
to	O
prevnet	O
amphteamine	B-Chemical
-	O
induecd	O
seiuzres	O
,	O
but	O
did	O
loewr	O
the	O
mortaltiy	O
rtae	O
at	O
most	O
doess	O
tetsed	O
.	O

Haolperidol	B-Chemical
derceased	O
the	O
incidecne	O
of	O
coacine	B-Chemical
-	O
indcued	O
seizrues	O
at	O
the	O
two	O
highest	O
doess	O
,	O
but	O
the	O
loweirng	O
of	O
the	O
motrality	O
rtae	O
did	O
not	O
reach	O
statisitcal	O
signfiicance	O
at	O
any	O
dsoe	O
.	O

These	O
dtaa	O
suggest	O
a	O
protective	O
role	O
for	O
the	O
centarl	O
doapmine	B-Chemical
bolcker	O
halopreidol	B-Chemical
against	O
daeth	O
from	O
high	O
-	O
dsoe	O
ampehtamine	B-Chemical
expousre	O
without	O
rdeucing	O
the	O
inciednce	O
of	O
seziures	O
.	O

In	O
contrast	O
,	O
halopeirdol	B-Chemical
demonstrated	O
an	O
ability	O
to	O
redcue	O
cocanie	B-Chemical
-	O
indcued	O
seiuzres	O
without	O
significantly	O
reducnig	O
mrotality	O
.	O

Autoradiogarphic	O
evdience	O
of	O
estrgoen	B-Chemical
bindnig	O
sties	O
in	O
nulcei	O
of	O
diethylstiblesterol	B-Chemical
idnuced	O
hmaster	O
reanl	O
cracinomas	O
.	O

Estrgoen	B-Chemical
binidng	O
siets	O
were	O
demonstrated	O
by	O
autroadiography	O
in	O
one	O
transplantbale	O
and	O
five	O
primray	O
diethylstilbesetrol	B-Chemical
induecd	O
rneal	O
carcionmas	O
in	O
three	O
hamsetrs	O
.	O

Rdaiolabelling	O
,	O
following	O
the	O
in	O
vivo	O
ijnection	O
of	O
3H	O
-	O
17	O
btea	O
estrdaiol	B-Chemical
,	O
was	O
icnreased	O
only	O
over	O
the	O
nculei	O
of	O
tuomr	O
clels	O
;	O
setreologic	O
analsyis	O
rveealed	O
a	O
4	O
.	O
5	O
-	O
to	O
6	O
.	O
7	O
-	O
times	O
higehr	O
concentrtaion	O
of	O
redcued	O
sivler	B-Chemical
granis	O
over	O
nulcei	O
than	O
cyotplasm	O
of	O
these	O
clels	O
.	O

Despite	O
rpaid	O
tubualr	O
excertion	O
of	O
estrdaiol	B-Chemical
which	O
peaked	O
in	O
less	O
than	O
1	O
h	O
,	O
the	O
noraml	O
cells	O
did	O
not	O
appear	O
to	O
bnid	O
the	O
lgiand	O
.	O

This	O
is	O
the	O
first	O
pulbished	O
reprot	O
documenting	O
the	O
preferetnial	O
in	O
vivo	O
bindnig	O
of	O
esrtogen	B-Chemical
to	O
nuceli	O
of	O
clels	O
in	O
estrgoen	B-Chemical
idnuced	O
hamtser	O
reanl	O
cacrinomas	O
.	O

Bardycardia	O
due	O
to	O
biperdien	B-Chemical
.	O

In	O
a	O
38	O
-	O
yaer	O
-	O
old	O
mlae	O
ptaient	O
suffreing	O
from	O
a	O
sveere	O
potszosteric	O
trigmeinal	O
neurlagia	O
,	O
intravneous	O
applictaion	O
of	O
10	O
mg	O
biepriden	B-Chemical
lacatte	I-Chemical
led	O
to	O
a	O
long	O
-	O
lasting	O
paardoxical	O
recation	O
cahracterized	O
by	O
considerable	O
bradycadria	O
,	O
dsyarthria	O
,	O
and	O
dypshagia	O
.	O

The	O
herat	O
rtae	O
was	O
back	O
to	O
nromal	O
within	O
12	O
hours	O
upon	O
administraiton	O
of	O
oricprenaline	B-Chemical
under	O
caridac	O
monitornig	O
in	O
an	O
itnensive	O
crae	O
unit	O
.	O

Bradycarida	O
indcued	O
by	O
biepriden	B-Chemical
is	O
attributed	O
to	O
the	O
speed	O
of	O
injetcion	O
and	O
to	O
a	O
dsoe	O
-	O
related	O
dual	O
effcet	O
of	O
atropnie	B-Chemical
-	O
like	O
drgus	O
on	O
musacrine	B-Chemical
recetpors	O
.	O

Delibearte	O
hyptoension	O
induecd	O
by	O
labetaoll	B-Chemical
with	O
haolthane	B-Chemical
,	O
enflurnae	B-Chemical
or	O
iosflurane	B-Chemical
for	O
mdidle	O
-	O
ear	O
srugery	O
.	O

The	O
feasibliity	O
of	O
using	O
labetlaol	B-Chemical
,	O
an	O
alhpa	O
-	O
and	O
btea	O
-	O
adernergic	O
blocknig	O
aegnt	O
,	O
as	O
a	O
hpyotensive	O
agnet	O
in	O
combintaion	O
with	O
inahlation	O
anaesthetcis	O
(	O
halotahne	B-Chemical
,	O
efnlurane	B-Chemical
or	O
isoflruane	B-Chemical
)	O
was	O
studied	O
in	O
23	O
adlut	O
ptaients	O
undergoing	O
midlde	O
-	O
ear	O
surgrey	O
.	O

The	O
mean	O
aretrial	O
prsesure	O
was	O
decraesed	O
from	O
86	O
+	O
/	O
-	O
5	O
(	O
s	O
.	O
e	O
.	O
mean	O
)	O
mmHg	O
to	O
52	O
+	O
/	O
-	O
1	O
mmHg	O
(	O
11	O
.	O
5	O
+	O
/	O
-	O
0	O
.	O
7	O
to	O
6	O
.	O
9	O
+	O
/	O
-	O
0	O
.	O
1	O
kPa	O
)	O
for	O
98	O
+	O
/	O
-	O
10	O
min	O
in	O
the	O
haolthane	B-Chemical
(	O
H	B-Chemical
)	O
gorup	O
,	O
from	O
79	O
+	O
/	O
-	O
5	O
to	O
53	O
+	O
/	O
-	O
1	O
mmHg	O
(	O
10	O
.	O
5	O
+	O
/	O
-	O
0	O
.	O
7	O
to	O
7	O
.	O
1	O
+	O
/	O
-	O
0	O
.	O
1	O
kPa	O
)	O
for	O
129	O
+	O
/	O
-	O
11	O
min	O
in	O
the	O
enfulrane	B-Chemical
(	O
E	B-Chemical
)	O
gruop	O
,	O
and	O
from	O
80	O
+	O
/	O
-	O
4	O
to	O
49	O
+	O
/	O
-	O
1	O
mmHg	O
(	O
10	O
.	O
7	O
+	O
/	O
-	O
0	O
.	O
5	O
to	O
6	O
.	O
5	O
+	O
/	O
-	O
0	O
.	O
1	O
kPa	O
)	O
for	O
135	O
+	O
/	O
-	O
15	O
min	O
in	O
the	O
isoflruane	B-Chemical
(	O
I	B-Chemical
)	O
gorup	O
.	O

The	O
mean	O
H	B-Chemical
concentrtaion	O
during	O
hyoptension	O
in	O
the	O
isnpiratory	O
gas	O
was	O
0	O
.	O
7	O
+	O
/	O
-	O
0	O
.	O
1	O
vol	O
%	O
,	O
the	O
mean	O
E	B-Chemical
concenrtation	O
1	O
.	O
6	O
+	O
/	O
-	O
0	O
.	O
2	O
vol	O
%	O
,	O
and	O
the	O
mean	O
I	B-Chemical
concentraiton	O
1	O
.	O
0	O
+	O
/	O
-	O
0	O
.	O
1	O
vol	O
%	O
.	O

In	O
addition	O
,	O
the	O
paitents	O
received	O
fentaynl	B-Chemical
and	O
d	B-Chemical
-	I-Chemical
tubocurairne	I-Chemical
.	O

The	O
initial	O
dsoe	O
of	O
labeatlol	B-Chemical
for	O
lowernig	O
bolod	O
presusre	O
was	O
similar	O
,	O
0	O
.	O
52	O
-	O
0	O
.	O
59	O
mg	O
/	O
kg	O
,	O
in	O
all	O
the	O
gorups	O
.	O

During	O
hypoetnsion	O
,	O
the	O
herat	O
rtae	O
was	O
satble	O
without	O
tahcy	O
-	O
or	O
bradycadria	O
.	O

The	O
oeprating	O
condiitons	O
regarding	O
bledeing	O
were	O
estmiated	O
in	O
a	O
double	O
-	O
blnid	O
manner	O
,	O
and	O
did	O
not	O
differ	O
significantly	O
between	O
the	O
gruops	O
.	O

During	O
hypotesnion	O
,	O
the	O
sreum	O
craetinine	B-Chemical
concentratoin	O
rose	O
significantly	O
in	O
all	O
gropus	O
from	O
the	O
valeus	O
before	O
hypoetnsion	O
and	O
returned	O
postpoeratively	O
to	O
the	O
initial	O
leevl	O
in	O
the	O
other	O
gruops	O
,	O
except	O
the	O
isofulrane	B-Chemical
gorup	O
.	O

After	O
hypoetnsion	O
there	O
was	O
no	O
rebuond	O
pheonmenon	O
in	O
either	O
blood	O
presusre	O
or	O
herat	O
rtae	O
.	O

These	O
resutls	O
indicate	O
that	O
lbaetalol	B-Chemical
induecs	O
easily	O
adjustable	O
hpyotension	O
without	O
compnesatory	O
tachcyardia	O
and	O
rebonud	O
hpyertension	O
.	O

Convlusion	O
following	O
intravneous	O
fluorsecein	B-Chemical
angigoraphy	O
.	O

Tnoic	O
-	O
cloinc	O
siezures	O
followed	O
intravneous	O
fluoerscein	B-Chemical
ijnection	O
for	O
funuds	O
angiogrpahy	O
in	O
a	O
47	O
-	O
yaer	O
-	O
old	O
mlae	O
.	O

Despite	O
precautoins	O
this	O
avderse	O
recation	O
recrured	O
on	O
re	O
-	O
expousre	O
to	O
intravenuos	O
fluorescien	B-Chemical
.	O

Phramacology	O
of	O
ACC	B-Chemical
-	I-Chemical
9653	I-Chemical
(	O
phenyotin	B-Chemical
prordug	O
)	O
.	O

ACC	B-Chemical
-	I-Chemical
9653	I-Chemical
,	O
the	O
disoidum	B-Chemical
phoshpate	I-Chemical
etser	I-Chemical
of	O
3	B-Chemical
-	I-Chemical
hydroxymtehyl	I-Chemical
-	I-Chemical
5	I-Chemical
,	I-Chemical
5	I-Chemical
-	I-Chemical
dpihenylhydantoin	I-Chemical
,	O
is	O
a	O
prdorug	O
of	O
pheyntoin	B-Chemical
with	O
advantageous	O
phyiscochemical	O
prpoerties	O
.	O

ACC	B-Chemical
-	I-Chemical
9653	I-Chemical
is	O
rapidly	O
converted	O
enzymatiaclly	O
to	O
pheyntoin	B-Chemical
in	O
vivo	O
.	O

ACC	B-Chemical
-	I-Chemical
9653	I-Chemical
and	O
pheyntoin	B-Chemical
sdoium	I-Chemical
have	O
equivaelnt	O
anticnovulsant	O
atcivity	O
against	O
siezures	O
induecd	O
by	O
maixmal	O
eelctroshock	O
(	O
MES	O
)	O
in	O
mcie	O
following	O
i	O
.	O
p	O
.	O
,	O
oarl	O
,	O
or	O
i	O
.	O
v	O
.	O
adimnistration	O
.	O

The	O
E5D0	O
dsoes	O
were	O
16	O
mg	O
/	O
kg	O
for	O
i	O
.	O
v	O
.	O
ACC	B-Chemical
-	I-Chemical
9653	I-Chemical
and	O
8	O
mg	O
/	O
kg	O
for	O
i	O
.	O
v	O
.	O
phenytion	B-Chemical
sdoium	I-Chemical
.	O

ACC	B-Chemical
-	I-Chemical
9653	I-Chemical
and	O
phenyotin	B-Chemical
soidum	I-Chemical
have	O
similar	O
antairrhythmic	O
atcivity	O
against	O
ouabian	B-Chemical
-	O
idnuced	O
ventriuclar	O
tachyacrdia	O
in	O
anesthteized	O
dgos	O
.	O

The	O
total	O
doess	O
of	O
ACC	B-Chemical
-	I-Chemical
9653	I-Chemical
or	O
phentyoin	B-Chemical
sdoium	I-Chemical
necessary	O
to	O
convert	O
the	O
arrhytmhia	O
to	O
a	O
nromal	O
siuns	O
ryhthm	O
were	O
24	O
+	O
/	O
-	O
6	O
and	O
14	O
+	O
/	O
-	O
3	O
mg	O
/	O
kg	O
,	O
respectively	O
.	O

Only	O
phneytoin	B-Chemical
soduim	I-Chemical
displayed	O
in	O
vitro	O
antiarrhtyhmic	O
activtiy	O
against	O
strophatnhidin	B-Chemical
-	O
induecd	O
arrhytmhias	O
in	O
guiena	O
pig	O
rihgt	O
atira	O
.	O

In	O
anestheitzed	O
dgos	O
,	O
a	O
high	O
dsoe	O
of	O
ACC	B-Chemical
-	I-Chemical
9653	I-Chemical
(	O
31	O
mg	O
/	O
kg	O
)	O
was	O
ifnused	O
over	O
15	O
,	O
20	O
,	O
and	O
30	O
min	O
and	O
the	O
resopnses	O
were	O
cmopared	O
to	O
an	O
equmiolar	O
dsoe	O
of	O
phenytion	B-Chemical
soidum	I-Chemical
(	O
21	O
mg	O
/	O
kg	O
)	O
.	O

The	O
ACC	B-Chemical
-	I-Chemical
9653	I-Chemical
and	O
phenyotin	B-Chemical
sdoium	I-Chemical
treatmetns	O
produced	O
similar	O
marked	O
reductoins	O
in	O
diastloic	O
blood	O
pressure	O
and	O
cotnractile	O
focre	O
(	O
LdVP	O
/	O
dt	O
)	O
.	O

The	O
maixmum	O
effcets	O
of	O
each	O
treamtent	O
occurred	O
at	O
the	O
tmie	O
of	O
maixmum	O
pheyntoin	B-Chemical
sdoium	I-Chemical
lveels	O
.	O

Actue	O
txoicity	O
sutdies	O
of	O
ACC	B-Chemical
-	I-Chemical
9653	I-Chemical
and	O
pehnytoin	B-Chemical
soidum	I-Chemical
were	O
carried	O
out	O
in	O
mcie	O
,	O
rtas	O
,	O
rabbits	O
,	O
and	O
dgos	O
by	O
i	O
.	O
v	O
.	O
,	O
i	O
.	O
m	O
.	O
,	O
and	O
i	O
.	O
p	O
.	O
ruotes	O
of	O
amdinistration	O
.	O

The	O
sytsemic	O
toixc	O
sgins	O
of	O
both	O
agetns	O
were	O
similar	O
and	O
occurred	O
at	O
approximately	O
equivalnet	O
dsoes	O
.	O

Importantly	O
,	O
the	O
loacl	O
irrittaion	O
of	O
ACC	B-Chemical
-	I-Chemical
9653	I-Chemical
was	O
markedly	O
less	O
than	O
phenyotin	B-Chemical
soduim	I-Chemical
following	O
i	O
.	O
m	O
.	O
admiinstration	O
.	O
(	O
ABSTRACT	O
TRUNCAETD	O
AT	O
250	O
WORDS	O
)	O

Tahcyphylaxis	O
to	O
systeimc	O
but	O
not	O
to	O
aiwray	O
resposnes	O
during	O
prolnoged	O
tehrapy	O
with	O
high	O
dsoe	O
ihnaled	O
sablutamol	B-Chemical
in	O
asthamtics	O
.	O

High	O
doess	O
of	O
inhlaed	O
slabutamol	B-Chemical
produce	O
substantial	O
imrpovements	O
in	O
ariway	O
repsonse	O
in	O
pateints	O
with	O
atshma	O
,	O
and	O
are	O
associated	O
with	O
dsoe	O
-	O
deepndent	O
systmeic	O
btea	O
-	O
ardenoceptor	O
rseponses	O
.	O

The	O
purpose	O
of	O
the	O
present	O
sutdy	O
was	O
to	O
invsetigate	O
whether	O
tacyhphylaxis	O
occurs	O
during	O
prolnoged	O
tretament	O
with	O
high	O
dsoe	O
inhaeld	O
salbutaoml	B-Chemical
.	O

Twelve	O
atshmatic	O
paitents	O
(	O
FVE1	O
,	O
81	O
+	O
/	O
-	O
4	O
%	O
preditced	O
)	O
,	O
requiring	O
only	O
occasional	O
inhaeld	O
btea	O
-	O
agoinsts	O
as	O
their	O
sole	O
thearpy	O
,	O
were	O
given	O
a	O
14	O
-	O
day	O
treatmnet	O
with	O
high	O
dsoe	O
inhaeld	O
slabutamol	B-Chemical
(	O
HDS	O
)	O
,	O
4	O
,	O
000	O
microgarms	O
daliy	O
,	O
low	O
dsoe	O
ihnaled	O
salbuatmol	B-Chemical
(	O
LDS	O
)	O
,	O
800	O
mircograms	O
dialy	O
,	O
or	O
plcaebo	O
(	O
PI	O
)	O
by	O
metreed	O
-	O
dsoe	O
ihnaler	O
in	O
a	O
double	O
-	O
blnid	O
,	O
randomiezd	O
corssover	O
deisgn	O
.	O

During	O
the	O
14	O
-	O
day	O
run	O
-	O
in	O
and	O
during	O
wsahout	O
peroids	O
,	O
inahled	O
btea	O
-	O
aognists	O
were	O
withheld	O
and	O
iprtaropium	B-Chemical
broimde	I-Chemical
was	O
subsittuted	O
for	O
rescue	O
pruposes	O
.	O

At	O
the	O
end	O
of	O
each	O
14	O
-	O
day	O
treatmnet	O
,	O
a	O
dsoe	O
-	O
repsonse	O
cruve	O
(	O
DRC	O
)	O
was	O
performed	O
,	O
and	O
ariway	O
(	O
FVE1	O
,	O
FFE25	O
-	O
75	O
)	O
chronotorpic	O
(	O
HR	O
)	O
,	O
termor	O
,	O
and	O
mteabolic	O
(	O
K	B-Chemical
,	O
Glu	B-Chemical
)	O
repsonses	O
were	O
maesured	O
at	O
each	O
step	O
(	O
from	O
100	O
to	O
4	O
,	O
000	O
microgarms	O
)	O
.	O

Treatemnt	O
had	O
no	O
significant	O
effect	O
on	O
baesline	O
valeus	O
.	O

There	O
were	O
dsoe	O
-	O
depenednt	O
incraeses	O
in	O
FVE1	O
and	O
FFE25	O
-	O
75	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
,	O
and	O
pretreatemnt	O
with	O
HDS	O
did	O
not	O
displace	O
the	O
DRC	O
to	O
the	O
rihgt	O
.	O

DRC	O
for	O
HR	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
,	O
K	B-Chemical
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
,	O
and	O
Glu	B-Chemical
(	O
p	O
less	O
than	O
0	O
.	O
005	O
)	O
were	O
attenauted	O
after	O
treamtent	O
with	O
HDS	O
copmared	O
with	O
PI	O
.	O

There	O
were	O
also	O
diffreences	O
between	O
HDS	O
and	O
LDS	O
for	O
HR	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
and	O
Glu	B-Chemical
(	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
rseponses	O
.	O

Frequnecy	O
and	O
sveerity	O
of	O
sbujective	O
avderse	O
efefcts	O
were	O
also	O
reduecd	O
after	O
HDS	O
:	O
termor	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
,	O
plapitations	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
.	O
(	O
ABSTRACT	O
TRUNCAETD	O
AT	O
250	O
WORDS	O
)	O

Phenytion	B-Chemical
inudced	O
faatl	O
heptaic	O
inujry	O
.	O

A	O
61	O
yaer	O
old	O
fmeale	O
developed	O
ftaal	O
heptaic	O
faliure	O
after	O
phenyotin	B-Chemical
administartion	O
.	O

A	O
typical	O
multissytem	O
clniical	O
pattern	O
precdees	O
the	O
manifestatoins	O
of	O
hepaitc	O
inujry	O
.	O

The	O
hematoloigc	O
,	O
biochemcial	O
and	O
patholoigc	O
featuers	O
indicate	O
a	O
mixed	O
hepatocellualr	O
daamge	O
due	O
to	O
durg	O
hyeprsensitivity	O
.	O

In	O
a	O
ptaient	O
receiving	O
phenyotin	B-Chemical
who	O
presents	O
a	O
viarl	O
-	O
like	O
illnses	O
,	O
ealry	O
recognitoin	O
and	O
discontinaution	O
of	O
the	O
durg	O
are	O
mandatory	O
.	O

Treatmnet	O
of	O
letahl	O
pertusiss	B-Chemical
vaccine	I-Chemical
reactoin	O
with	O
histaimne	B-Chemical
H1	O
antagnoists	O
.	O

We	O
studied	O
mortlaity	O
after	O
petrussis	O
immuniaztion	O
in	O
the	O
mosue	O
.	O

Without	O
treamtent	O
,	O
73	O
of	O
92	O
ainmals	O
(	O
80	O
%	O
)	O
deid	O
after	O
ijnection	O
of	O
bvoine	O
seurm	O
albmuin	O
(	O
BSA	O
)	O
on	O
day	O
+	O
7	O
of	O
pertussis	O
immunizatoin	O
.	O

After	O
pretreamtent	O
with	O
3	O
mg	O
of	O
cyprohetpadine	B-Chemical
,	O
2	O
mg	O
mianesrin	B-Chemical
,	O
or	O
2	O
mg	O
chlorpehniramine	B-Chemical
,	O
only	O
5	O
of	O
105	O
animlas	O
(	O
5	O
%	O
)	O
deid	O
after	O
receiving	O
BSA	O
on	O
day	O
+	O
7	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
.	O

Blockdae	O
of	O
hsitamine	B-Chemical
H1	O
rceeptors	O
may	O
redcue	O
mortlaity	O
in	O
pertsusis	O
imumnization	O
-	O
induecd	O
encephaloapthy	O
in	O
mcie	O
.	O

Spuport	O
for	O
adrnealine	B-Chemical
-	O
hypetrension	O
hypotheiss	O
:	O
18	O
hour	O
presosr	O
effcet	O
after	O
6	O
hours	O
adreanline	B-Chemical
infuison	O
.	O

In	O
a	O
double	O
blnid	O
,	O
crsosover	O
stduy	O
6	O
h	O
ifnusions	O
of	O
adreanline	B-Chemical
(	O
15	O
ng	O
/	O
kg	O
/	O
min	O
;	O
1	O
ng	O
=	O
5	O
.	O
458	O
pmol	O
)	O
,	O
noradrenailne	B-Chemical
(	O
30	O
ng	O
/	O
kg	O
/	O
min	O
;	O
1	O
ng	O
=	O
5	O
.	O
911	O
pmol	O
)	O
,	O
and	O
a	O
5	O
%	O
detxrose	B-Chemical
sloution	O
(	O
5	O
.	O
4	O
ml	O
/	O
h	O
)	O
,	O
were	O
given	O
to	O
ten	O
heatlhy	O
volnuteers	O
in	O
rnadom	O
order	O
2	O
weeks	O
apart	O
.	O

By	O
means	O
of	O
inrta	O
-	O
atrerial	O
ambualtory	O
montioring	O
the	O
haeomdynamic	O
efefcts	O
were	O
followed	O
for	O
18	O
h	O
after	O
the	O
infusoins	O
were	O
stopped	O
.	O

Adrenalnie	B-Chemical
,	O
but	O
not	O
noradrenailne	B-Chemical
,	O
caused	O
a	O
delaeyd	O
and	O
prtoracted	O
perssor	O
effect	O
.	O

Over	O
the	O
total	O
postinfsuion	O
preiod	O
sytsolic	O
and	O
daistolic	O
aretrial	O
presusre	O
were	O
6	O
(	O
SEM	O
2	O
)	O
%	O
and	O
7	O
(	O
2	O
)	O
%	O
,	O
respectively	O
,	O
hgiher	O
than	O
after	O
dxetrose	B-Chemical
infsuion	O
(	O
AONVA	O
,	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
.	O

Thus	O
,	O
"	O
sterss	O
"	O
lveels	O
of	O
ardenaline	B-Chemical
(	O
230	O
pg	O
/	O
ml	O
)	O
for	O
6	O
h	O
cause	O
a	O
delaeyd	O
and	O
prortacted	O
perssor	O
efefct	O
.	O

These	O
fnidings	O
are	O
strong	O
support	O
for	O
the	O
adreanline	B-Chemical
-	O
hypretension	O
hyopthesis	O
in	O
man	O
.	O

Effect	O
of	O
alyklxanthines	B-Chemical
on	O
genatmicin	B-Chemical
-	O
idnuced	O
aucte	O
rneal	O
faiulre	O
in	O
the	O
rat	O
.	O

Adeonsine	B-Chemical
antagonitss	O
have	O
been	O
previously	O
shown	O
to	O
be	O
of	O
beenfit	O
in	O
some	O
iscahemic	O
and	O
nephrtooxic	O
modles	O
of	O
aucte	O
rneal	O
faliure	O
(	O
ARF	O
)	O
.	O

In	O
the	O
present	O
stduy	O
,	O
the	O
efefcts	O
of	O
three	O
alkylxanhtines	B-Chemical
with	O
different	O
potnecies	O
as	O
adneosine	B-Chemical
antgaonists	O
8	B-Chemical
-	I-Chemical
phenyltehophylline	I-Chemical
,	O
theophyllnie	B-Chemical
and	O
enproflyline	B-Chemical
,	O
were	O
examined	O
in	O
rtas	O
developing	O
aucte	O
rneal	O
faiulre	O
after	O
4	O
daliy	O
injetcions	O
of	O
getnamicin	B-Chemical
(	O
200	O
mg	O
kg	O
-	O
1	O
)	O
.	O

Reanl	O
fnuction	O
was	O
assessed	O
by	O
biochemiacl	O
(	O
palsma	O
uera	B-Chemical
and	O
creatiinne	B-Chemical
)	O
,	O
functioanl	O
(	O
uirne	O
aanlysis	O
and	O
[	O
3H	O
]	O
inuiln	O
and	O
[	O
14C	O
]	O
p	B-Chemical
-	I-Chemical
aminoihppuric	I-Chemical
aicd	I-Chemical
claerances	O
)	O
and	O
morphoolgical	O
(	O
degere	O
of	O
ncerosis	O
)	O
indiecs	O
.	O

The	O
various	O
durg	O
treamtents	O
produced	O
imprvoements	O
in	O
some	O
,	O
but	O
not	O
all	O
,	O
measuremetns	O
of	O
reanl	O
funtcion	O
.	O

However	O
,	O
any	O
ipmrovement	O
produced	O
by	O
durg	O
teratment	O
was	O
largely	O
a	O
result	O
of	O
a	O
beneficial	O
effcet	O
exerted	O
by	O
its	O
vehilce	O
(	O
polytehylene	B-Chemical
glcyol	I-Chemical
and	O
NOaH	B-Chemical
)	O
.	O

The	O
lcak	O
of	O
any	O
consistent	O
protective	O
effect	O
noted	O
with	O
the	O
alkylaxnthines	B-Chemical
tseted	O
in	O
the	O
present	O
stduy	O
indicates	O
that	O
adensoine	B-Chemical
plays	O
little	O
,	O
if	O
any	O
,	O
pathophysiologcial	O
role	O
in	O
gentmaicin	B-Chemical
-	O
inudced	O
ARF	O
.	O

Adevrse	O
ocualr	O
reactoins	O
possibly	O
associated	O
with	O
isotretinion	B-Chemical
.	O

A	O
total	O
of	O
261	O
avderse	O
ouclar	O
reactoins	O
occurred	O
in	O
237	O
ptaients	O
who	O
received	O
isotretinion	B-Chemical
,	O
a	O
commonly	O
used	O
durg	O
in	O
the	O
traetment	O
of	O
sevree	O
csytic	O
ance	O
.	O

Blepahroconjunctivitis	O
,	O
subjcetive	O
copmlaints	O
of	O
dry	O
eeys	O
,	O
blurerd	O
vsiion	O
,	O
conatct	O
lnes	O
intolernace	O
,	O
and	O
photodrematitis	O
are	O
reversible	O
side	O
effetcs	O
.	O

More	O
serious	O
ocualr	O
advesre	O
recations	O
include	O
papilleedma	O
,	O
psuedotumor	O
ceerbri	O
,	O
and	O
whtie	O
or	O
gary	O
subepitehlial	O
croneal	O
opcaities	O
;	O
all	O
of	O
these	O
are	O
reversible	O
if	O
the	O
durg	O
is	O
discnotinued	O
.	O

Reported	O
csaes	O
of	O
decresaed	O
drak	O
adpatation	O
are	O
under	O
ivnestigation	O
.	O

Isotertinoin	B-Chemical
is	O
contraindiacted	O
in	O
pregnacny	O
because	O
of	O
the	O
many	O
reported	O
conegnital	O
abnromalities	O
after	O
mtaernal	O
use	O
(	O
including	O
mircophthalmos	O
,	O
oribtal	O
hyperteolrism	O
,	O
and	O
opitc	O
nevre	O
hyppolasia	O
)	O
.	O

Porcaterol	B-Chemical
and	O
terubtaline	B-Chemical
in	O
brocnhial	O
astmha	O
.	O

A	O
double	O
-	O
blnid	O
,	O
placbeo	O
-	O
contorlled	O
,	O
corss	O
-	O
over	O
sutdy	O
.	O

Proctaerol	B-Chemical
,	O
a	O
new	O
btea	O
-	O
2	O
adrneoceptor	O
stiumlant	O
,	O
was	O
studied	O
in	O
a	O
double	O
-	O
blnid	O
,	O
placbeo	O
-	O
contorlled	O
,	O
corss	O
-	O
over	O
trail	O
in	O
pateints	O
with	O
brocnhial	O
atshma	O
.	O

Oarl	O
proacterol	B-Chemical
50	O
micorgrams	O
b	O
.	O
d	O
.	O
,	O
porcaterol	B-Chemical
100	O
microgrmas	O
b	O
.	O
d	O
.	O
,	O
and	O
tebrutaline	B-Chemical
5	O
mg	O
t	O
.	O
i	O
.	O
d	O
.	O
,	O
were	O
compaerd	O
when	O
given	O
randomly	O
in	O
1	O
-	O
week	O
treatemnt	O
peirods	O
.	O

The	O
best	O
clincial	O
effect	O
was	O
found	O
with	O
terbutlaine	B-Chemical
.	O

Both	O
atni	O
-	O
asthmaitc	O
and	O
trmeorgenic	O
efefcts	O
of	O
procatreol	B-Chemical
were	O
dsoe	O
-	O
related	O
.	O

Porcaterol	B-Chemical
appeared	O
effective	O
in	O
the	O
doess	O
tseted	O
,	O
and	O
a	O
twice	O
daliy	O
regiemn	O
would	O
appear	O
to	O
be	O
suitable	O
with	O
this	O
durg	O
.	O

Subaucte	O
effects	O
of	O
propranlool	B-Chemical
and	O
B	O
24	O
/	O
76	O
on	O
isoprotereonl	B-Chemical
-	O
inudced	O
rat	O
haert	O
hyeprtrophy	O
in	O
crorelation	O
with	O
blood	O
presusre	O
.	O

We	O
compaerd	O
the	O
potenital	O
btea	O
-	O
recepotr	O
blcoker	O
,	O
B	O
24	O
/	O
76	O
i	O
.	O
e	O
.	O
1	O
-	O
(	O
2	O
,	O
4	O
-	O
dcihlorophenoxy	O
)	O
-	O
3	O
[	O
2	O
-	O
3	O
,	O
4	O
-	O
dimtehoxyphenyl	O
)	O
ehtanolamino	O
]	O
-	O
porp	O
an	O
-	O
2	O
-	O
ol	O
,	O
which	O
is	O
characteriezd	O
by	O
btea	O
1	O
-	O
adrenocetpor	O
blcoking	O
and	O
btea	O
2	O
-	O
adernoceptor	O
stimultaing	O
properites	O
with	O
propraonlol	B-Chemical
.	O

The	O
stuides	O
were	O
performed	O
using	O
an	O
exeprimental	O
moedl	O
of	O
isoprtoerenol	B-Chemical
-	O
induecd	O
herat	O
hypertorphy	O
in	O
rtas	O
.	O

A	O
correlation	O
of	O
the	O
bolod	O
pressrue	O
was	O
neither	O
found	O
in	O
the	O
deveolpment	O
nor	O
in	O
the	O
attempt	O
to	O
suppress	O
the	O
devleopment	O
of	O
herat	O
hpyertrophy	O
with	O
the	O
two	O
btea	O
-	O
recetpor	O
blcokers	O
.	O

Both	O
btea	O
-	O
blcokers	O
ifnluenced	O
the	O
develompent	O
of	O
hypetrrophy	O
to	O
a	O
different	O
,	O
but	O
not	O
reproducible	O
extent	O
.	O

It	O
was	O
possible	O
to	O
supprses	O
the	O
incraesed	O
onrithine	B-Chemical
deacrboxylase	O
acitvity	O
with	O
both	O
btea	O
-	O
blockres	O
in	O
hpyertrophied	O
haerts	O
,	O
but	O
there	O
was	O
no	O
effect	O
on	O
the	O
herat	O
msas	O
.	O

Neither	O
propranooll	B-Chemical
nor	O
B	O
24	O
/	O
76	O
could	O
stop	O
the	O
chanegs	O
in	O
the	O
chaarcteristic	O
myoisn	O
isonezyme	O
pattern	O
of	O
the	O
hypetrrophied	O
rat	O
haert	O
.	O

Thus	O
,	O
the	O
investigtaions	O
did	O
not	O
provide	O
any	O
evidnece	O
that	O
the	O
btea	O
-	O
reecptor	O
bolckers	O
prporanolol	B-Chemical
and	O
B	O
24	O
/	O
76	O
have	O
the	O
ptoency	O
to	O
pervent	O
isoprotereonl	B-Chemical
from	O
producing	O
haert	O
hypetrrophy	O
.	O

Icnreased	O
anxiogneic	O
effcets	O
of	O
cfafeine	B-Chemical
in	O
pnaic	O
dsiorders	O
.	O

The	O
efefcts	O
of	O
oarl	O
adminisrtation	O
of	O
caffiene	B-Chemical
(	O
10	O
mg	O
/	O
kg	O
)	O
on	O
behavoiral	O
rtaings	O
,	O
somtaic	O
sympotms	O
,	O
blood	O
perssure	O
and	O
palsma	O
leevls	O
of	O
3	B-Chemical
-	I-Chemical
mtehoxy	I-Chemical
-	I-Chemical
4	I-Chemical
-	I-Chemical
hydroxyphenethylneeglycol	I-Chemical
(	O
MPHG	B-Chemical
)	O
and	O
coritsol	B-Chemical
were	O
determined	O
in	O
17	O
heatlhy	O
subjetcs	O
and	O
21	O
patinets	O
meetnig	O
DSM	O
-	O
III	O
cirteria	O
for	O
agoraphoiba	O
with	O
painc	O
attacks	O
or	O
pnaic	O
dsiorder	O
.	O

Cafefine	B-Chemical
produced	O
significantly	O
greater	O
incraeses	O
in	O
subejct	O
-	O
rated	O
anxitey	O
,	O
nevrousness	O
,	O
faer	O
,	O
nasuea	O
,	O
palpittaions	O
,	O
rsetlessness	O
,	O
and	O
treomrs	O
in	O
the	O
ptaients	O
cmopared	O
with	O
helathy	O
sujbects	O
.	O

In	O
the	O
paitents	O
,	O
but	O
not	O
the	O
haelthy	O
subjcets	O
,	O
these	O
symptmos	O
were	O
significantly	O
correalted	O
with	O
plsama	O
caffeine	B-Chemical
leevls	O
.	O

Seventy	O
-	O
one	O
percent	O
of	O
the	O
ptaients	O
reported	O
that	O
the	O
beahvioral	O
effects	O
of	O
caffeine	B-Chemical
were	O
similar	O
to	O
those	O
experienced	O
during	O
painc	O
attacks	O
.	O

Cfafeine	B-Chemical
did	O
not	O
alter	O
plsama	O
MPHG	B-Chemical
levles	O
in	O
either	O
the	O
haelthy	O
subejcts	O
or	O
patinets	O
.	O

Caffeine	B-Chemical
increaesd	O
palsma	O
coritsol	B-Chemical
leevls	O
equally	O
in	O
the	O
pateint	O
and	O
healhty	O
gropus	O
.	O

Because	O
cafefine	B-Chemical
is	O
an	O
adenoisne	B-Chemical
reecptor	O
antagonsit	O
,	O
these	O
resluts	O
suggest	O
that	O
some	O
painc	O
disodrer	O
pateints	O
may	O
have	O
abnormaltiies	O
in	O
neuroanl	O
systmes	O
involving	O
adneosine	B-Chemical
.	O

Patietns	O
with	O
axniety	O
dsiorders	O
may	O
beenfit	O
by	O
avoiding	O
caffenie	B-Chemical
-	O
containing	O
foods	O
and	O
bevreages	O
.	O

Comaprison	O
of	O
the	O
effcet	O
of	O
oixtropium	B-Chemical
brmoide	I-Chemical
and	O
of	O
slow	O
-	O
relaese	O
theophylilne	B-Chemical
on	O
nocutrnal	O
astmha	O
.	O

The	O
effects	O
of	O
a	O
new	O
inhlaed	O
antimuscairnic	O
durg	O
,	O
oxitropuim	B-Chemical
bormide	I-Chemical
,	O
and	O
of	O
a	O
slow	O
-	O
relesae	O
theopyhlline	B-Chemical
perparation	O
upon	O
ncoturnal	O
atshma	O
were	O
comapred	O
in	O
a	O
palcebo	O
-	O
controleld	O
double	O
-	O
bilnd	O
stduy	O
.	O

Two	O
sapmles	O
were	O
studied	O
:	O
12	O
paitents	O
received	O
oxitroipum	B-Chemical
at	O
600	O
microgrmas	O
(	O
6	O
subjetcs	O
)	O
or	O
at	O
400	O
micorgrams	O
t	O
.	O
i	O
.	O
d	O
.	O

(	O
6	O
sbujects	O
)	O
whereas	O
11	O
received	O
theophlyline	B-Chemical
at	O
300	O
mg	O
b	O
.	O
i	O
.	O
d	O
.	O

Mornnig	O
dipping	O
,	O
assesesd	O
by	O
the	O
fall	O
in	O
peak	O
folw	O
overnight	O
,	O
was	O
significantly	O
reduecd	O
in	O
the	O
peridos	O
when	O
either	O
acitve	O
durg	O
was	O
taken	O
,	O
whereas	O
no	O
difference	O
was	O
noticed	O
during	O
the	O
plaecbo	O
adimnistration	O
.	O

No	O
significant	O
difference	O
was	O
noticed	O
between	O
resutls	O
obtained	O
with	O
either	O
atcive	O
durg	O
,	O
as	O
well	O
as	O
with	O
either	O
dsoage	O
of	O
oxitrpoium	B-Chemical
.	O

No	O
sujbect	O
reported	O
side	O
effects	O
of	O
oxitroipum	B-Chemical
,	O
as	O
copmared	O
to	O
three	O
subjcets	O
reporting	O
nuasea	O
,	O
vomiitng	O
and	O
trmeors	O
after	O
theopyhlline	B-Chemical
.	O

Oxirtopium	B-Chemical
proves	O
to	O
be	O
a	O
valuable	O
alterantive	O
to	O
thepohylline	B-Chemical
in	O
noctrunal	O
ashtma	O
,	O
since	O
it	O
is	O
equally	O
potent	O
,	O
safer	O
and	O
does	O
not	O
require	O
the	O
titratoin	O
of	O
dosgae	O
.	O

Penicillin	B-Chemical
anaphylxais	O
.	O

A	O
csae	O
of	O
oarl	O
peniicllin	B-Chemical
anaphlyaxis	O
is	O
described	O
,	O
and	O
the	O
terimnology	O
,	O
occurrence	O
,	O
clincial	O
manifesattions	O
,	O
pathogenseis	O
,	O
prevetnion	O
,	O
and	O
tretament	O
of	O
anaphylxais	O
are	O
reivewed	O
.	O

Emregency	O
phsyicians	O
should	O
be	O
aware	O
of	O
oarl	O
peniicllin	B-Chemical
anaphyalxis	O
in	O
order	O
to	O
prevnet	O
its	O
occurrence	O
by	O
prsecribing	O
the	O
atnibiotic	O
judiciously	O
and	O
konwledgeably	O
and	O
to	O
offer	O
opitmal	O
mediacl	O
tehrapy	O
once	O
this	O
lfie	O
-	O
threatening	O
recation	O
has	O
begun	O
.	O

Rveersible	O
valporic	B-Chemical
aicd	I-Chemical
-	O
induecd	O
demnetia	O
:	O
a	O
csae	O
rpeort	O
.	O

Reverisble	O
vlaproic	B-Chemical
aicd	I-Chemical
-	O
indcued	O
dmeentia	O
was	O
dcoumented	O
in	O
a	O
21	O
-	O
yaer	O
-	O
old	O
man	O
with	O
epilespy	O
who	O
had	O
a	O
3	O
-	O
yaer	O
hitsory	O
of	O
insdiious	O
porgressive	O
delcine	O
in	O
glboal	O
cogntiive	O
abiltiies	O
documneted	O
by	O
sreial	O
neuropscyhological	O
sutdies	O
.	O

Repaet	O
neurposychological	O
tesitng	O
7	O
wekes	O
after	O
discontinuatoin	O
of	O
the	O
durg	O
revaeled	O
draamtic	O
improvmeent	O
in	O
IQ	O
,	O
mmeory	O
,	O
nmaing	O
,	O
and	O
other	O
tsaks	O
commensurate	O
with	O
clincial	O
recovrey	O
in	O
his	O
intellcetual	O
capcaity	O
.	O

Possible	O
pathophysiolgoical	O
mechansims	O
which	O
may	O
have	O
been	O
oeprative	O
in	O
this	O
csae	O
include	O
:	O
a	O
direct	O
cnetral	O
nevrous	O
sytsem	O
(	O
CNS	O
)	O
txoic	O
effect	O
of	O
valrpoic	B-Chemical
aicd	I-Chemical
;	O
a	O
paradoixcal	O
epileptogneic	O
efefct	O
secondary	O
to	O
the	O
durg	O
;	O
and	O
an	O
idnirect	O
CNS	O
txoic	O
efefct	O
mediated	O
through	O
vlaproic	B-Chemical
aicd	I-Chemical
-	O
inudced	O
hyperammoneima	O
.	O

Revresal	O
of	O
scopolamnie	B-Chemical
-	O
induecd	O
amnseia	O
of	O
pasisve	O
avoidnace	O
by	O
pre	O
-	O
and	O
psot	O
-	O
trianing	O
naloxnoe	B-Chemical
.	O

In	O
a	O
series	O
of	O
five	O
expermients	O
,	O
the	O
moudlating	O
role	O
of	O
naolxone	B-Chemical
on	O
a	O
scopolaimne	B-Chemical
-	O
idnuced	O
retetnion	O
defciit	O
in	O
a	O
passvie	O
avoiadnce	O
paradgim	O
was	O
ivnestigated	O
in	O
mcie	O
.	O

Scoploamine	B-Chemical
,	O
but	O
not	O
mehtyl	B-Chemical
scopolamnie	I-Chemical
(	O
1	O
and	O
3	O
mg	O
/	O
kg	O
)	O
,	O
induecd	O
an	O
amneisa	O
as	O
measuerd	O
by	O
ltaency	O
and	O
durtaion	O
parametres	O
.	O

Naloxnoe	B-Chemical
(	O
0	O
.	O
3	O
,	O
1	O
,	O
3	O
,	O
and	O
10	O
mg	O
/	O
kg	O
)	O
inejcted	O
prior	O
to	O
trianing	O
attenutaed	O
the	O
retentoin	O
defciit	O
with	O
a	O
peak	O
of	O
activtiy	O
at	O
3	O
mg	O
/	O
kg	O
.	O

The	O
effect	O
of	O
nalxoone	B-Chemical
could	O
be	O
antagoniezd	O
with	O
morhpine	B-Chemical
(	O
1	O
,	O
3	O
,	O
and	O
10	O
mg	O
/	O
kg	O
)	O
,	O
demonstrating	O
the	O
opoiid	O
speciifcity	O
of	O
the	O
naolxone	B-Chemical
effect	O
.	O

Psot	O
-	O
traniing	O
administraiton	O
of	O
naloxnoe	B-Chemical
(	O
3	O
mg	O
/	O
kg	O
)	O
as	O
a	O
single	O
or	O
as	O
a	O
split	O
dsoe	O
also	O
attneuated	O
the	O
scopoalmine	B-Chemical
-	O
idnuced	O
amensia	O
.	O

Conrtol	O
experimetns	O
indicated	O
that	O
neither	O
an	O
incresae	O
in	O
pian	O
sensiitvity	O
(	O
pre	O
-	O
tarining	O
nalxoone	B-Chemical
)	O
nor	O
an	O
induecd	O
averisve	O
state	O
(	O
psot	O
-	O
trainnig	O
nalooxne	B-Chemical
)	O
appear	O
to	O
be	O
responsible	O
for	O
the	O
influecne	O
of	O
nalxoone	B-Chemical
on	O
the	O
scooplamine	B-Chemical
-	O
induecd	O
rteention	O
defiict	O
.	O

These	O
rseults	O
extend	O
previous	O
fidnings	O
implicating	O
a	O
choilnergic	O
-	O
opiiod	O
intercation	O
in	O
meomry	O
porcesses	O
.	O

A	O
possible	O
mcehanism	O
for	O
this	O
inetraction	O
involving	O
the	O
speto	O
-	O
hippocapmal	O
cohlinergic	O
patwhay	O
is	O
discussed	O
.	O

Eelctron	O
mircoscopic	O
investigatinos	O
of	O
the	O
cycolphosphamide	B-Chemical
-	O
indcued	O
lesinos	O
of	O
the	O
uirnary	O
baldder	O
of	O
the	O
rat	O
and	O
their	O
preevntion	O
by	O
mensa	B-Chemical
.	O

Fully	O
developed	O
cyclophopshamide	B-Chemical
-	O
indcued	O
cysittis	O
is	O
chraacterized	O
by	O
nearly	O
complete	O
detachmnet	O
of	O
the	O
urotehlium	O
,	O
sevree	O
submucoasl	O
eedma	O
owing	O
to	O
dmaage	O
to	O
the	O
mcirovascular	O
bed	O
and	O
foacl	O
msucle	O
nercoses	O
.	O

The	O
initial	O
rseponse	O
to	O
the	O
priamry	O
atatck	O
by	O
the	O
ccylophosphamide	B-Chemical
metaboliets	O
seems	O
to	O
be	O
fragmnetation	O
of	O
the	O
lmuinal	B-Chemical
mebmrane	O
.	O

This	O
dmaages	O
the	O
clelular	O
barrier	O
against	O
the	O
hypretonic	O
urnie	O
.	O

Subsequent	O
braeks	O
in	O
the	O
latearl	O
clel	O
mebmranes	O
of	O
the	O
superfciial	O
cells	O
and	O
in	O
all	O
the	O
palsma	O
membraens	O
of	O
the	O
intermeidate	O
and	O
bsaal	O
clels	O
,	O
intecrellular	O
and	O
intarcellular	O
eedma	O
and	O
disnitegration	O
of	O
the	O
desmosoems	O
and	O
hemiedsmosomes	O
lead	O
to	O
prgoressive	O
degenreation	O
and	O
deatchment	O
of	O
the	O
epihtelial	O
cells	O
with	O
exposrue	O
and	O
splittnig	O
of	O
the	O
bsaal	O
membarne	O
.	O

The	O
morphologcial	O
chnages	O
of	O
the	O
endohtelial	O
clels	O
,	O
which	O
become	O
more	O
pronounced	O
in	O
the	O
later	O
stgaes	O
of	O
the	O
experimnet	O
,	O
the	O
inovlvement	O
of	O
bolod	O
vessels	O
regardless	O
of	O
their	O
diaemter	O
and	O
the	O
locatoin	O
-	O
depenednt	O
extent	O
of	O
the	O
daamge	O
indicate	O
a	O
direct	O
tpye	O
of	O
damgae	O
which	O
is	O
preceded	O
by	O
a	O
mediator	O
-	O
indcued	O
incerase	O
in	O
permeabiilty	O
,	O
the	O
moprhological	O
crorelate	O
of	O
which	O
is	O
the	O
fromation	O
of	O
gpas	O
in	O
the	O
intreendothelial	O
clel	O
connections	O
on	O
the	O
vneules	O
.	O

These	O
chnages	O
can	O
be	O
effectively	O
prevented	O
by	O
msena	B-Chemical
.	O

The	O
only	O
sign	O
of	O
a	O
possible	O
invlovement	O
is	O
the	O
icnrease	O
in	O
the	O
number	O
of	O
specific	O
graunles	O
with	O
a	O
presumed	O
lysosmoal	O
functoin	O
in	O
the	O
superifcial	O
clels	O
.	O

Incerase	O
in	O
inrtagastric	O
prsesure	O
during	O
suxamtehonium	B-Chemical
-	O
indcued	O
muslce	O
facsiculations	O
in	O
cihldren	O
:	O
inhibtiion	O
by	O
alfnetanil	B-Chemical
.	O

Chagnes	O
in	O
itnragastric	O
pressure	O
after	O
the	O
administratoin	O
of	O
suxmaethonium	B-Chemical
1	O
.	O
5	O
mg	O
kg	O
-	O
1	O
i	O
.	O
v	O
.	O
were	O
studied	O
in	O
32	O
chlidren	O
(	O
mean	O
age	O
6	O
.	O
9	O
yr	O
)	O
pretretaed	O
with	O
either	O
physiologiacl	O
sailne	O
or	O
alfetnanil	B-Chemical
50	O
microrgams	O
kg	O
-	O
1	O
.	O

Anaetshesia	O
was	O
inudced	O
with	O
thioepntone	B-Chemical
5	O
mg	O
kg	O
-	O
1	O
.	O

The	O
icnidence	O
and	O
intenisty	O
of	O
muslce	O
fsaciculations	O
caused	O
by	O
sxuamethonium	B-Chemical
were	O
significantly	O
greater	O
in	O
the	O
cotnrol	O
than	O
in	O
the	O
aflentanil	B-Chemical
gruop	O
.	O

The	O
inrtagastric	O
perssure	O
during	O
muslce	O
fascicualtions	O
was	O
significantly	O
higehr	O
in	O
the	O
cotnrol	O
gruop	O
(	O
16	O
+	O
/	O
-	O
0	O
.	O
7	O
(	O
SEM	O
)	O
cm	O
H2O	B-Chemical
)	O
than	O
in	O
the	O
alfentainl	B-Chemical
gorup	O
(	O
7	O
.	O
7	O
+	O
/	O
-	O
1	O
.	O
5	O
(	O
SEM	O
)	O
cm	O
H2O	B-Chemical
)	O
.	O

The	O
incraese	O
in	O
intrgaastric	O
pressrue	O
was	O
directly	O
related	O
to	O
the	O
inetnsity	O
of	O
mucsle	O
fascicluations	O
(	O
rergession	O
line	O
:	O
y	O
=	O
0	O
.	O
5	O
+	O
4	O
.	O
78x	O
with	O
r	O
of	O
0	O
.	O
78	O
)	O
.	O

It	O
is	O
concluded	O
that	O
itnragastric	O
pressure	O
inrceases	O
significantly	O
during	O
msucle	O
fasciculatoins	O
caused	O
by	O
sxuamethonium	B-Chemical
in	O
haelthy	O
chlidren	O
.	O

Alfenatnil	B-Chemical
50	O
mcirograms	O
kg	O
-	O
1	O
effectively	O
inhibtis	O
the	O
inciednce	O
and	O
intnesity	O
of	O
suxamtehonium	B-Chemical
-	O
induecd	O
msucle	O
fascicultaions	O
;	O
moreover	O
,	O
intragastirc	O
prsesure	O
remains	O
at	O
its	O
cotnrol	O
value	O
.	O

Aucte	O
inuslin	O
treatmnet	O
normalizes	O
the	O
resistnace	O
to	O
the	O
cardiotoixc	O
effcet	O
of	O
isoprotereonl	B-Chemical
in	O
streptozotcoin	B-Chemical
dibaetic	O
rtas	O
.	O

A	O
morphmoetric	O
sutdy	O
of	O
isoproteernol	B-Chemical
indcued	O
myocradial	O
fiborsis	O
.	O

The	O
actue	O
efefct	O
of	O
insuiln	O
tretament	O
on	O
the	O
earlier	O
reported	O
protective	O
efefct	O
of	O
streptzootocin	B-Chemical
diabtees	O
against	O
the	O
cradiotoxic	O
effect	O
of	O
high	O
doess	O
of	O
isoporterenol	B-Chemical
(	O
ISO	B-Chemical
)	O
was	O
investigtaed	O
in	O
rtas	O
.	O

Thirty	O
to	O
135	O
min	O
after	O
the	O
injetcion	O
of	O
crystalline	O
insuiln	O
,	O
ISO	B-Chemical
was	O
given	O
subctuaneously	O
and	O
when	O
ISO	B-Chemical
indcued	O
fibrsois	O
in	O
the	O
myocarduim	O
was	O
morphmoetrically	O
anaylzed	O
7	O
dyas	O
later	O
,	O
a	O
highly	O
significant	O
correaltion	O
(	O
r	O
=	O
0	O
.	O
83	O
,	O
2	O
p	O
=	O
0	O
.	O
006	O
)	O
to	O
the	O
slope	O
of	O
the	O
fall	O
in	O
blood	O
glucsoe	B-Chemical
after	O
insluin	O
treatmnet	O
appeared	O
.	O

The	O
myocradial	O
conetnt	O
of	O
catecohlamines	B-Chemical
was	O
esitmated	O
in	O
these	O
8	O
day	O
diabteic	O
rtas	O
.	O

The	O
norepniephrine	B-Chemical
cnotent	O
was	O
significantly	O
incresaed	O
while	O
epinephirne	B-Chemical
remained	O
unchagned	O
.	O

An	O
enhnaced	O
sympatehtic	O
nervuos	O
sytsem	O
actiivty	O
with	O
a	O
consequent	O
down	O
rgeulation	O
of	O
the	O
myocradial	O
btea	O
-	O
adreenrgic	O
recepotrs	O
could	O
,	O
therefore	O
,	O
explain	O
this	O
catecohlamine	B-Chemical
ressitance	O
.	O

The	O
raipd	O
reversoin	O
after	O
inuslin	O
teratment	O
excludes	O
the	O
possibility	O
that	O
streptozotcoin	B-Chemical
in	O
itself	O
causes	O
the	O
ISO	B-Chemical
ressitance	O
and	O
points	O
towards	O
a	O
direct	O
inuslin	O
effect	O
on	O
myocaridal	O
catecholaimne	B-Chemical
sesnitivity	O
in	O
dibaetic	O
rtas	O
.	O

The	O
phenomneon	O
described	O
might	O
elucidate	O
pahtogenetic	O
mecahnisms	O
behind	O
txoic	O
myocaridal	O
clel	O
degeneratoin	O
and	O
may	O
possibly	O
have	O
relevance	O
for	O
actue	O
cardivoascular	O
compliactions	O
in	O
dibaetic	O
paitents	O
.	O

Diffeerntial	O
efefcts	O
of	O
non	O
-	O
sterodial	O
atni	O
-	O
inflammatroy	O
durgs	O
on	O
siezures	O
produced	O
by	O
pilocarpnie	B-Chemical
in	O
rtas	O
.	O

The	O
mucsarinic	O
cohlinergic	O
agoinst	O
pilocrapine	B-Chemical
inudces	O
in	O
rtas	O
seiuzres	O
and	O
sattus	O
epileptcius	O
followed	O
by	O
widespread	O
damgae	O
to	O
the	O
forebrian	O
.	O

The	O
present	O
sutdy	O
was	O
designed	O
to	O
investgiate	O
the	O
efefct	O
of	O
5	O
non	O
-	O
steoridal	O
atni	O
-	O
inflamamtory	O
durgs	O
,	O
sdoium	B-Chemical
slaicylate	I-Chemical
,	O
phenylbutaznoe	B-Chemical
,	O
indomehtacin	B-Chemical
,	O
iburpofen	B-Chemical
and	O
mfeenamic	B-Chemical
aicd	I-Chemical
,	O
on	O
seizuers	O
produced	O
by	O
pilocrapine	B-Chemical
.	O

Pretreamtent	O
of	O
rtas	O
with	O
soduim	B-Chemical
salicyltae	I-Chemical
,	O
E5D0	O
103	O
mg	O
/	O
kg	O
(	O
60	O
-	O
174	O
)	O
,	O
and	O
phenylbutaozne	B-Chemical
,	O
59	O
mg	O
/	O
kg	O
(	O
50	O
-	O
70	O
)	O
converted	O
the	O
non	O
-	O
conuvlsant	O
dsoe	O
of	O
pilocarpnie	B-Chemical
,	O
200	O
mg	O
/	O
kg	O
,	O
to	O
a	O
convulasnt	O
one	O
.	O

Inodmethacin	B-Chemical
,	O
1	O
-	O
10	O
mg	O
/	O
kg	O
,	O
and	O
ibuporfen	B-Chemical
,	O
10	O
-	O
100	O
mg	O
/	O
kg	O
,	O
failed	O
to	O
modluate	O
seiuzres	O
produced	O
by	O
piolcarpine	B-Chemical
.	O

Mefenmaic	B-Chemical
aicd	I-Chemical
,	O
26	O
(	O
22	O
-	O
30	O
)	O
mg	O
/	O
kg	O
,	O
prevented	O
seiuzres	O
and	O
protected	O
rtas	O
from	O
seizrue	O
-	O
related	O
barin	O
dmaage	O
inudced	O
by	O
pliocarpine	B-Chemical
,	O
380	O
mg	O
/	O
kg	O
.	O

These	O
rseults	O
indicate	O
that	O
non	O
-	O
setroidal	O
atni	O
-	O
inflammaotry	O
drgus	O
difefrentially	O
modultae	O
the	O
threshlod	O
for	O
piolcarpine	B-Chemical
-	O
indcued	O
seiuzres	O
.	O

Aucte	O
neurloogic	O
dyfsunction	O
after	O
high	O
-	O
dsoe	O
etopoisde	B-Chemical
thearpy	O
for	O
mlaignant	O
giloma	O
.	O

Etopoisde	B-Chemical
(	O
VP	B-Chemical
-	I-Chemical
16	I-Chemical
-	I-Chemical
213	I-Chemical
)	O
has	O
been	O
used	O
in	O
the	O
treatemnt	O
of	O
many	O
soild	O
tmuors	O
and	O
heamtologic	O
malignanceis	O
.	O

When	O
used	O
in	O
high	O
doess	O
and	O
in	O
conjucntion	O
with	O
autoolgous	O
bnoe	O
mrarow	O
transplnatation	O
,	O
this	O
agnet	O
has	O
activtiy	O
against	O
several	O
tretament	O
-	O
reisstant	O
cancres	O
including	O
malignnat	O
glimoa	O
.	O

In	O
six	O
of	O
eight	O
patinets	O
(	O
75	O
%	O
)	O
who	O
we	O
tretaed	O
for	O
rceurrent	O
or	O
reisstant	O
glimoa	O
,	O
sduden	O
sevree	O
nuerologic	O
dteerioration	O
occurred	O
.	O

This	O
developed	O
a	O
mdeian	O
of	O
9	O
dyas	O
after	O
iintiation	O
of	O
high	O
-	O
dsoe	O
etpooside	B-Chemical
tehrapy	O
.	O

Signiifcant	O
clniical	O
manifesattions	O
have	O
included	O
confuison	O
,	O
papilledmea	O
,	O
somonlence	O
,	O
excaerbation	O
of	O
mtoor	O
defictis	O
,	O
and	O
sharp	O
incraese	O
in	O
siezure	O
atcivity	O
.	O

These	O
abnomralities	O
resolved	O
rapidly	O
after	O
inititaion	O
of	O
high	O
-	O
dsoe	O
intravneous	O
dexametahsone	B-Chemical
threapy	O
.	O

In	O
all	O
patietns	O
,	O
copmuterized	O
tomgoraphic	O
(	O
CT	O
)	O
barin	O
sacns	O
demonstrated	O
stbaility	O
in	O
tmuor	O
szie	O
and	O
peritmuor	O
edmea	O
when	O
cmopared	O
with	O
prertansplant	O
scnas	O
.	O

This	O
compilcation	O
appears	O
to	O
represent	O
a	O
significant	O
new	O
toxictiy	O
of	O
high	O
-	O
dsoe	O
etpooside	B-Chemical
thearpy	O
for	O
mailgnant	O
glimoa	O
.	O

Prgoressive	O
blie	O
dcut	O
inujry	O
after	O
tihabendazole	B-Chemical
admiinstration	O
.	O

A	O
27	O
-	O
yr	O
-	O
old	O
man	O
developed	O
jaudnice	O
2	O
wk	O
after	O
epxosure	O
to	O
thiabendazloe	B-Chemical
.	O

Choelstasis	O
persisted	O
for	O
3	O
yr	O
,	O
at	O
which	O
tmie	O
a	O
lvier	O
tranpslant	O
was	O
performed	O
.	O

Two	O
lvier	O
boipsy	O
specmiens	O
and	O
the	O
heptaectomy	O
sepcimen	O
were	O
remarkable	O
for	O
almost	O
complete	O
disappeaarnce	O
of	O
interloublar	O
blie	O
dcuts	O
.	O

Promiennt	O
firbosis	O
and	O
hepatocellualr	O
rgeeneration	O
were	O
also	O
present	O
;	O
however	O
,	O
the	O
lobluar	O
architectrue	O
was	O
prseerved	O
.	O

This	O
csae	O
represents	O
an	O
example	O
of	O
"	O
idiosynrcatic	O
"	O
durg	O
-	O
indcued	O
lievr	O
daamge	O
in	O
which	O
the	O
prmiary	O
taregt	O
of	O
injruy	O
is	O
the	O
blie	O
dcut	O
.	O

An	O
autoimmnue	O
pathogenseis	O
of	O
the	O
blie	O
dcut	O
destrutcion	O
is	O
suggested	O
.	O

Differentail	O
effects	O
of	O
1	B-Chemical
,	I-Chemical
4	I-Chemical
-	I-Chemical
dihdyropyridine	I-Chemical
calcuim	B-Chemical
chnanel	I-Chemical
blocekrs	I-Chemical
:	O
therapeuitc	O
implications	O
.	O

Increasnig	O
recongition	O
of	O
the	O
importance	O
of	O
calcuim	B-Chemical
in	O
the	O
pathogenseis	O
of	O
cardoivascular	O
dsiease	O
has	O
sitmulated	O
resaerch	O
into	O
the	O
use	O
of	O
clacium	B-Chemical
cahnnel	I-Chemical
bolcking	I-Chemical
agetns	I-Chemical
for	O
treatemnt	O
of	O
a	O
variety	O
of	O
cardioavscular	O
diseaess	O
.	O

The	O
favoarble	O
effiaccy	O
and	O
tolreability	O
proflies	O
of	O
these	O
agnets	O
make	O
them	O
attractive	O
therapeuitc	O
modlaities	O
.	O

Cilnical	O
applciations	O
of	O
clacium	B-Chemical
cahnnel	I-Chemical
blocekrs	I-Chemical
parallel	O
their	O
tisuse	O
selectiivty	O
.	O

In	O
contrast	O
to	O
vreapamil	B-Chemical
and	O
diltaizem	B-Chemical
,	O
which	O
are	O
roughly	O
equioptent	O
in	O
their	O
acitons	O
on	O
the	O
herat	O
and	O
vascualr	O
somoth	O
mucsle	O
,	O
the	O
dihydropyridnie	B-Chemical
caclium	B-Chemical
cahnnel	I-Chemical
blocekrs	I-Chemical
are	O
a	O
gruop	O
of	O
potent	O
perihperal	O
vasodilaotr	O
agetns	O
that	O
exert	O
miinmal	O
electorphysiologic	O
effcets	O
on	O
cardaic	O
ndoal	O
or	O
conduciton	O
tisuse	O
.	O

As	O
the	O
first	O
dihydropyrdiine	B-Chemical
available	O
for	O
use	O
in	O
the	O
Unietd	O
Sattes	O
,	O
nifedpiine	B-Chemical
cotnrols	O
angnia	O
and	O
hyeprtension	O
with	O
minmial	O
depresison	O
of	O
cardaic	O
funciton	O
.	O

Additional	O
mmebers	O
of	O
this	O
gorup	O
of	O
clacium	B-Chemical
channel	I-Chemical
bolckers	I-Chemical
have	O
been	O
studied	O
for	O
a	O
variety	O
of	O
indicatinos	O
for	O
which	O
they	O
may	O
offer	O
advantages	O
over	O
current	O
thearpy	O
.	O

Once	O
or	O
twice	O
daliy	O
dosgae	O
possible	O
with	O
ntirendipine	B-Chemical
and	O
nisoldiipne	B-Chemical
offers	O
a	O
convenient	O
administartion	O
schedlue	O
,	O
which	O
encourages	O
patinet	O
copmliance	O
in	O
long	O
-	O
term	O
threapy	O
of	O
hypertnesion	O
.	O

The	O
coornary	O
vasodilaitng	O
propetries	O
of	O
nislodipine	B-Chemical
have	O
led	O
to	O
the	O
investgiation	O
of	O
this	O
agnet	O
for	O
use	O
in	O
angnia	O
.	O

Selectviity	O
for	O
the	O
creebrovascular	O
bed	O
makes	O
nimodiipne	B-Chemical
potentially	O
useful	O
in	O
the	O
treatmnet	O
of	O
suabrachnoid	O
hemorrhage	O
,	O
mirgaine	O
headahce	O
,	O
demnetia	O
,	O
and	O
srtoke	O
.	O

In	O
general	O
,	O
the	O
dhiydropyridine	B-Chemical
calcuim	B-Chemical
channel	I-Chemical
blokcers	I-Chemical
are	O
usually	O
well	O
toleraetd	O
,	O
with	O
hedaache	O
,	O
fcaial	O
fulshing	O
,	O
paliptations	O
,	O
eedma	O
,	O
nasuea	O
,	O
anorxeia	O
,	O
and	O
dizzniess	O
being	O
the	O
more	O
common	O
avderse	O
effcets	O
.	O

The	O
enhanceemnt	O
of	O
aminnoucleoside	B-Chemical
nephrsois	O
by	O
the	O
co	O
-	O
adminisrtation	O
of	O
protmaine	O
.	O

An	O
expeirmental	O
moedl	O
of	O
foacl	O
segmenatl	O
glomreular	O
scleorsis	O
(	O
FGSS	O
)	O
was	O
developed	O
in	O
rtas	O
by	O
the	O
combnied	O
adimnistration	O
of	O
puroymcin	B-Chemical
-	I-Chemical
aminnoucleoside	I-Chemical
(	O
ANMS	B-Chemical
)	O
and	O
prtoamine	B-Chemical
sulafte	I-Chemical
(	O
PS	B-Chemical
)	O
.	O

Mlae	O
Sprgaue	O
-	O
Dalwey	O
rtas	O
,	O
uninephrectoimzed	O
three	O
weeks	O
before	O
,	O
received	O
dialy	O
injectinos	O
of	O
sucbutaneous	O
ANMS	B-Chemical
(	O
1	O
mg	O
/	O
100	O
g	O
bdoy	O
wt	O
)	O
and	O
intravneous	O
PS	B-Chemical
(	O
2	O
separtaed	O
dsoes	O
of	O
2	O
.	O
5	O
mg	O
/	O
100	O
g	O
bdoy	O
wt	O
)	O
for	O
four	O
dyas	O
.	O

The	O
series	O
of	O
injecitons	O
were	O
rpeeated	O
another	O
three	O
times	O
at	O
10	O
day	O
interavls	O
.	O

The	O
ainmals	O
were	O
sarcificed	O
on	O
dyas	O
24	O
,	O
52	O
,	O
and	O
80	O
.	O

They	O
developed	O
nephroitc	O
synrdome	O
and	O
finally	O
rneal	O
fialure	O
.	O

The	O
tmie	O
-	O
cousre	O
cuvre	O
of	O
creatinnie	B-Chemical
celarance	O
dropped	O
and	O
showed	O
significant	O
difference	O
(	O
P	O
less	O
than	O
0	O
.	O
01	O
)	O
from	O
that	O
of	O
each	O
contorl	O
gorup	O
,	O
such	O
as	O
,	O
ANMS	B-Chemical
alone	O
,	O
PS	B-Chemical
alone	O
or	O
salnie	O
injceted	O
.	O

Their	O
golmeruli	O
showed	O
cahnges	O
of	O
progrsesive	O
FGSS	O
.	O

The	O
ultarstructural	O
stuides	O
in	O
the	O
initial	O
stgae	O
reevaled	O
significant	O
lcak	O
of	O
patricles	O
of	O
perfuesd	O
ruhtenium	B-Chemical
red	O
on	O
the	O
lamnia	O
rara	O
extrena	O
and	O
marked	O
chanegs	O
in	O
epitehlial	O
clel	O
ctyoplasm	O
.	O

Therefore	O
,	O
it	O
is	O
suggested	O
that	O
the	O
adminsitration	O
of	O
PS	B-Chemical
enhnaces	O
the	O
toxciity	O
of	O
ANMS	B-Chemical
on	O
the	O
golmerulus	O
and	O
readily	O
produces	O
prorgessive	O
FGSS	O
in	O
rtas	O
resulting	O
in	O
the	O
end	O
-	O
satge	O
reanl	O
diesase	O
.	O

Theopyhlline	B-Chemical
neuortoxicity	O
in	O
pregannt	O
rtas	O
.	O

The	O
purpose	O
of	O
this	O
investigaiton	O
was	O
to	O
determine	O
whether	O
the	O
neurotoixcity	O
of	O
thepohylline	B-Chemical
is	O
aletred	O
in	O
advnaced	O
pregnnacy	O
.	O

Srpague	O
-	O
Dalwey	O
rtas	O
that	O
were	O
20	O
dyas	O
pregnnat	O
and	O
nonprengant	O
rtas	O
of	O
the	O
same	O
age	O
and	O
strian	O
received	O
infusinos	O
of	O
aminophylline	B-Chemical
until	O
onset	O
of	O
maxiaml	O
seizrues	O
which	O
occurred	O
after	O
28	O
and	O
30	O
miuntes	O
respectively	O
.	O

Theophylline	B-Chemical
concentraitons	O
at	O
this	O
enpdoint	O
in	O
sreum	O
(	O
total	O
)	O
and	O
CSF	O
were	O
similar	O
but	O
sreum	O
(	O
free	O
)	O
and	O
brian	O
concentratoins	O
were	O
slightly	O
different	O
in	O
prengant	O
rtas	O
.	O

Theohpylline	B-Chemical
seurm	O
prtoein	O
bniding	O
determined	O
by	O
equliibrium	O
dilaysis	O
was	O
lwoer	O
in	O
prengant	O
rtas	O
.	O

Fteal	O
sreum	O
conecntrations	O
at	O
onset	O
of	O
siezures	O
in	O
the	O
motehr	O
were	O
similar	O
to	O
matrenal	O
barin	O
and	O
CSF	O
concentrtaions	O
and	O
crorelated	O
significantly	O
with	O
the	O
former	O
.	O

It	O
is	O
concluded	O
that	O
advanecd	O
pregnnacy	O
has	O
a	O
nelgigible	O
effcet	O
on	O
the	O
neurotoixc	O
resopnse	O
to	O
tehophylline	B-Chemical
in	O
rtas	O
.	O

Hyeprkalemia	O
indcued	O
by	O
indomtehacin	B-Chemical
and	O
naporxen	B-Chemical
and	O
reveresd	O
by	O
fludroocrtisone	B-Chemical
.	O

We	O
have	O
described	O
a	O
patinet	O
with	O
seevre	O
rehumatoid	O
arthrtiis	O
and	O
a	O
hitsory	O
of	O
mefneamic	B-Chemical
aicd	I-Chemical
nehpropathy	O
in	O
whom	O
hyprekalemia	O
and	O
inappropirate	O
hpyoaldosteronism	O
were	O
caused	O
by	O
both	O
indomethcain	B-Chemical
and	O
narpoxen	B-Chemical
,	O
without	O
major	O
declnie	O
in	O
rneal	O
funtcion	O
.	O

It	O
is	O
likely	O
that	O
preexisting	O
reanl	O
disesae	O
predsiposed	O
this	O
patinet	O
to	O
tpye	O
IV	O
rneal	O
tbuular	O
aicdosis	O
with	O
prostagalndin	B-Chemical
synthtease	O
inhbiitors	O
.	O

Because	O
he	O
was	O
unable	O
to	O
disocntinue	O
nonsteriodal	O
atni	O
-	O
inflamamtory	O
durg	O
tehrapy	O
,	O
fludorcortisone	B-Chemical
was	O
added	O
,	O
correcting	O
the	O
hyperkaleima	O
and	O
allowing	O
indoemthacin	B-Chemical
tehrapy	O
to	O
be	O
continued	O
safely	O
.	O

Hpyotension	O
as	O
a	O
maniefstation	O
of	O
cradiotoxicity	O
in	O
three	O
paitents	O
receiving	O
cispltain	B-Chemical
and	O
5	B-Chemical
-	I-Chemical
fluororuacil	I-Chemical
.	O

Caridac	O
symtpoms	O
,	O
including	O
hyptoension	O
,	O
developed	O
in	O
three	O
paitents	O
with	O
advacned	O
colorecatl	O
cacrinoma	O
while	O
being	O
traeted	O
with	O
cislpatin	B-Chemical
(	O
CDDP	B-Chemical
)	O
and	O
5	B-Chemical
-	I-Chemical
fluorouraicl	I-Chemical
(	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
)	O
.	O

In	O
two	O
patietns	O
,	O
hyptoension	O
was	O
associated	O
with	O
seevre	O
lfet	O
vnetricular	O
dysfuntcion	O
.	O

All	O
three	O
patietns	O
required	O
thearpy	O
discontinuatoin	O
.	O

Caridac	O
enyzmes	O
remained	O
noraml	O
despite	O
transinet	O
electrocadriographic	O
(	O
EKG	O
)	O
chanegs	O
.	O

The	O
presetnation	O
and	O
cradiac	O
eavluation	O
(	O
hemdoynamic	O
,	O
echocardoigraphic	O
,	O
and	O
scitnigraphic	O
)	O
of	O
these	O
patinets	O
suggest	O
new	O
manifesttaions	O
of	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
cadriotoxicity	O
that	O
may	O
be	O
influenecd	O
by	O
CDDP	B-Chemical
.	O

The	O
possible	O
pahtophysiologic	O
mechanimss	O
are	O
discussed	O
.	O

Faatl	O
aplsatic	O
aenmia	O
in	O
a	O
patinet	O
terated	O
with	O
carabmazepine	B-Chemical
.	O

A	O
csae	O
of	O
ftaal	O
aplsatic	O
aenmia	O
due	O
to	O
carbamzaepine	B-Chemical
traetment	O
in	O
an	O
epiletpic	O
woamn	O
is	O
reported	O
.	O

Despite	O
conecrns	O
of	O
faatl	O
bnoe	O
marrow	O
txoicity	O
due	O
to	O
carbamazpeine	B-Chemical
,	O
this	O
is	O
only	O
the	O
fourth	O
documneted	O
and	O
publihsed	O
rpeort	O
.	O

Carbmaazepine	B-Chemical
is	O
a	O
safe	O
durg	O
,	O
but	O
phsyicians	O
and	O
ptaients	O
should	O
be	O
aware	O
of	O
the	O
exceedingly	O
rrae	O
but	O
potentially	O
ftaal	O
side	O
efefcts	O
,	O
better	O
prevented	O
by	O
cliincal	O
than	O
by	O
lbaoratory	O
monitornig	O
.	O

Participtaion	O
of	O
a	O
bulbospnial	O
sertoonergic	O
ptahway	O
in	O
the	O
rat	O
brian	O
in	O
clonidnie	B-Chemical
-	O
inudced	O
hyptoension	O
and	O
bradycradia	O
.	O

The	O
effetcs	O
of	O
microinjeciton	O
of	O
clnoidine	B-Chemical
(	O
1	O
-	O
10	O
microgrmas	O
in	O
1	O
micorliter	O
)	O
into	O
a	O
rgeion	O
adjacnet	O
to	O
the	O
ventrloateral	O
sruface	O
of	O
the	O
medlula	O
oblognata	O
on	O
cardioavscular	O
fucntion	O
were	O
asesssed	O
in	O
uerthane	B-Chemical
-	O
anesthetiezd	O
rtas	O
.	O

Inrtamedullary	O
adminsitration	O
of	O
clondiine	B-Chemical
,	O
but	O
not	O
slaine	O
vehcile	O
,	O
caused	O
a	O
dsoe	O
-	O
dpeendent	O
decerase	O
in	O
both	O
the	O
mean	O
atrerial	O
perssure	O
and	O
the	O
haert	O
rtae	O
.	O

The	O
clondiine	B-Chemical
-	O
indcued	O
hypotensoin	O
was	O
atnagonized	O
by	O
prior	O
sipnal	O
transectoin	O
,	O
but	O
not	O
bliateral	O
vaogtomy	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
clnoidine	B-Chemical
-	O
induecd	O
bradycarida	O
was	O
antgaonized	O
by	O
prior	O
bliateral	O
vgaotomy	O
,	O
but	O
not	O
spianl	O
tarnsection	O
.	O

Furthermore	O
,	O
selective	O
destruciton	O
of	O
the	O
spnial	O
5	B-Chemical
-	I-Chemical
HT	I-Chemical
nevres	O
,	O
produced	O
by	O
bialteral	O
spianl	O
inejction	O
of	O
5	B-Chemical
,	I-Chemical
7	I-Chemical
-	I-Chemical
dihydorxytryptamine	I-Chemical
,	O
reudced	O
the	O
magntiude	O
of	O
the	O
vasodperessor	O
or	O
the	O
bradyacrdiac	O
repsonses	O
to	O
cloniidne	B-Chemical
micorinjected	O
into	O
the	O
aera	O
near	O
the	O
vnetrolateral	O
sufrace	O
of	O
the	O
mdeulla	O
oblnogata	O
in	O
rtas	O
.	O

The	O
dtaa	O
indicate	O
that	O
a	O
bulbospianl	O
serootnergic	O
pathawy	O
is	O
involved	O
in	O
deevlopment	O
of	O
colnidine	B-Chemical
-	O
inudced	O
hypoetnsion	O
and	O
bradcyardia	O
.	O

The	O
indcued	O
hyoptension	O
is	O
brought	O
about	O
by	O
a	O
decraese	O
in	O
sympahtetic	O
effeernt	O
activtiy	O
,	O
whereas	O
the	O
idnuced	O
braydcardia	O
was	O
due	O
to	O
an	O
incraese	O
in	O
vaagl	O
efefrent	O
activtiy	O
.	O

Hpyertension	O
in	O
neruoblastoma	O
indcued	O
by	O
imiparmine	B-Chemical
.	O

Hypetrension	O
is	O
a	O
well	O
-	O
known	O
fidning	O
in	O
some	O
paitents	O
with	O
nueroblastoma	O
.	O

However	O
,	O
it	O
has	O
not	O
previously	O
been	O
described	O
in	O
assocaition	O
with	O
the	O
use	O
of	O
Imipramnie	B-Chemical
.	O

We	O
rpeort	O
the	O
ocucrrence	O
of	O
seevre	O
hypertnesion	O
(	O
blood	O
presusre	O
190	O
/	O
160	O
)	O
in	O
a	O
4	O
-	O
yaer	O
-	O
old	O
gril	O
with	O
neuroblasotma	O
who	O
was	O
given	O
Imiprmaine	B-Chemical
to	O
cnotrol	O
a	O
behaivor	O
disroder	O
.	O

It	O
was	O
determined	O
later	O
that	O
this	O
patinet	O
'	O
s	O
tuomr	O
was	O
recurring	O
at	O
the	O
tmie	O
of	O
her	O
hypertesnive	O
episdoe	O
.	O

Since	O
she	O
had	O
no	O
bolod	O
pressure	O
elevtaion	O
at	O
initial	O
diganosis	O
and	O
none	O
following	O
dicsontinuation	O
of	O
the	O
Imipraimne	B-Chemical
(	O
when	O
she	O
was	O
in	O
folrid	O
relaspe	O
)	O
,	O
we	O
believe	O
that	O
this	O
durg	O
rather	O
than	O
her	O
underlying	O
disesae	O
alone	O
caused	O
her	O
hypertesnion	O
.	O

The	O
mecahnism	O
for	O
this	O
reactoin	O
is	O
believed	O
to	O
be	O
increaesd	O
leevls	O
of	O
vasoacitve	O
catehcolamines	B-Chemical
due	O
to	O
interfreence	O
of	O
their	O
pyhsiologic	O
inactivatoin	O
by	O
Imipraimne	B-Chemical
.	O

From	O
this	O
expereince	O
,	O
we	O
urge	O
extreme	O
caution	O
in	O
the	O
use	O
of	O
trciyclic	O
antidperessants	O
in	O
chilrden	O
with	O
actvie	O
neuroblatsoma	O
.	O

Rechallnege	O
of	O
paitents	O
who	O
developed	O
oarl	O
candidaisis	O
or	O
hoarseenss	O
with	O
beclomehtasone	B-Chemical
dpiropionate	I-Chemical
.	O

Of	O
158	O
asthmaitc	O
patietns	O
who	O
were	O
placed	O
on	O
inahled	O
becolmethasone	B-Chemical
,	O
15	O
(	O
9	O
.	O
5	O
%	O
)	O
developed	O
either	O
hoarsneess	O
(	O
8	O
)	O
,	O
oarl	O
thursh	O
(	O
6	O
)	O
,	O
or	O
both	O
(	O
1	O
)	O
.	O

When	O
their	O
advrese	O
reactoins	O
sbusided	O
,	O
seven	O
of	O
these	O
15	O
ptaients	O
were	O
rechallenegd	O
with	O
inhlaed	O
beclometahsone	B-Chemical
.	O

These	O
included	O
five	O
caess	O
who	O
developed	O
hoaresness	O
and	O
three	O
who	O
developed	O
Candidaisis	O
.	O

One	O
ptaient	O
had	O
both	O
.	O

Oarl	O
thursh	O
did	O
not	O
recur	O
,	O
but	O
60	O
%	O
(	O
3	O
/	O
5	O
)	O
of	O
patinets	O
with	O
hoarseenss	O
had	O
recurrence	O
.	O

We	O
conclude	O
that	O
pateints	O
may	O
be	O
restaretd	O
on	O
inhlaed	O
belcomethasone	B-Chemical
when	O
clincially	O
indicated	O
;	O
however	O
,	O
because	O
of	O
the	O
high	O
recurrence	O
rtae	O
,	O
ptaients	O
who	O
develop	O
hoarsneess	O
should	O
not	O
be	O
re	O
-	O
challenegd	O
.	O

Concomitnat	O
use	O
of	O
oarl	O
predniosne	B-Chemical
and	O
tpoical	O
beclomethsaone	B-Chemical
may	O
incraese	O
the	O
rsik	O
of	O
developing	O
hoarsneess	O
or	O
candiidasis	O
.	O

Cyclopohsphamide	B-Chemical
carditooxicity	O
:	O
an	O
anlaysis	O
of	O
doisng	O
as	O
a	O
rsik	O
facotr	O
.	O

Patinets	O
who	O
undergo	O
bnoe	O
marrow	O
transplantaiton	O
are	O
generally	O
immunosuppressed	O
with	O
a	O
dsoe	O
of	O
cyclophosphmaide	B-Chemical
(	O
CYA	B-Chemical
)	O
which	O
is	O
usually	O
calculated	O
based	O
on	O
the	O
patinet	O
'	O
s	O
wieght	O
.	O

At	O
these	O
high	O
doess	O
of	O
CYA	B-Chemical
,	O
serious	O
caridotoxicity	O
may	O
occur	O
,	O
but	O
dfeinitive	O
rsik	O
factros	O
for	O
the	O
developemnt	O
of	O
such	O
cardiotoixcity	O
have	O
not	O
been	O
described	O
.	O

Since	O
cheomtherapeutic	O
agnet	O
toxictiy	O
generally	O
corrleates	O
with	O
dsoe	O
per	O
bdoy	O
sufrace	O
aera	O
,	O
we	O
retrospecitvely	O
calculated	O
the	O
dsoe	O
of	O
CYA	B-Chemical
in	O
ptaients	O
transplanetd	O
at	O
our	O
instittuion	O
to	O
determine	O
whether	O
the	O
incidecne	O
of	O
CYA	B-Chemical
cardoitoxicity	O
correalted	O
with	O
the	O
dsoe	O
per	O
bdoy	O
surfcae	O
aera	O
.	O

Eighty	O
pateints	O
who	O
were	O
to	O
receive	O
CYA	B-Chemical
50	O
mg	O
/	O
kg	O
/	O
d	O
for	O
four	O
dyas	O
as	O
preparaiton	O
for	O
mrarow	O
grafitng	O
underwent	O
a	O
total	O
of	O
84	O
tarnsplants	O
for	O
aplsatic	O
anmeia	O
,	O
Wsikott	O
-	O
Aldirch	O
syndorme	O
,	O
or	O
sveere	O
cobmined	O
immunodefiicency	O
syndorme	O
.	O

Fourteen	O
of	O
84	O
(	O
17	O
%	O
)	O
patinets	O
had	O
smyptoms	O
and	O
sgins	O
consistent	O
with	O
CYA	B-Chemical
cardiotoxciity	O
within	O
ten	O
dyas	O
of	O
receiving	O
1	O
to	O
4	O
dsoes	O
of	O
CYA	B-Chemical
.	O

Six	O
of	O
the	O
14	O
ptaients	O
deid	O
with	O
cnogestive	O
herat	O
faliure	O
.	O

The	O
dsoe	O
of	O
CYA	B-Chemical
per	O
bdoy	O
surfcae	O
aera	O
was	O
calculated	O
for	O
all	O
ptaients	O
and	O
the	O
patinets	O
were	O
divided	O
into	O
two	O
gropus	O
based	O
on	O
daliy	O
CYA	B-Chemical
dsoe	O
:	O
Gorup	O
1	O
,	O
CYA	B-Chemical
less	O
than	O
or	O
euqal	O
to	O
1	O
.	O
55	O
g	O
/	O
m2	O
/	O
d	O
;	O
Gruop	O
2	O
,	O
CYA	B-Chemical
greater	O
than	O
1	O
.	O
55	O
g	O
/	O
m2	O
/	O
d	O
.	O

Cardiotxoicity	O
that	O
was	O
thought	O
to	O
be	O
related	O
to	O
CYA	B-Chemical
occurred	O
in	O
1	O
/	O
32	O
(	O
3	O
%	O
)	O
of	O
paitents	O
in	O
Gruop	O
1	O
and	O
in	O
13	O
/	O
52	O
(	O
25	O
%	O
)	O
patietns	O
in	O
Gorup	O
2	O
(	O
P	O
less	O
than	O
0	O
.	O
025	O
)	O
.	O

Congsetive	O
herat	O
faiulre	O
caused	O
or	O
contributed	O
to	O
daeth	O
in	O
0	O
/	O
32	O
ptaients	O
in	O
Gruop	O
1	O
v	O
6	O
/	O
52	O
(	O
12	O
%	O
)	O
of	O
ptaients	O
in	O
Gorup	O
2	O
(	O
P	O
less	O
than	O
0	O
.	O
25	O
)	O
.	O

There	O
was	O
no	O
difference	O
in	O
the	O
rtae	O
of	O
enrgaftment	O
of	O
evlauable	O
paitents	O
in	O
the	O
two	O
gorups	O
(	O
P	O
greater	O
than	O
0	O
.	O
5	O
)	O
.	O

We	O
conclude	O
that	O
the	O
CYA	B-Chemical
cardiotoxiicty	O
correlates	O
with	O
CYA	B-Chemical
doasge	O
as	O
calculated	O
by	O
bdoy	O
sufrace	O
aera	O
,	O
and	O
that	O
pateints	O
with	O
alpastic	O
aenmia	O
and	O
immunoedficiencies	O
can	O
be	O
effectively	O
prpeared	O
for	O
bnoe	O
mrarow	O
gratfing	O
at	O
a	O
CYA	B-Chemical
dsoe	O
of	O
1	O
.	O
55	O
g	O
/	O
m2	O
/	O
d	O
for	O
four	O
dyas	O
with	O
a	O
lwoer	O
inciednce	O
of	O
caridotoxicity	O
than	O
ptaients	O
whose	O
CYA	B-Chemical
dosgae	O
is	O
calculated	O
based	O
on	O
wieght	O
.	O

This	O
stduy	O
reaffirms	O
the	O
principle	O
that	O
durg	O
toixcity	O
correaltes	O
with	O
dsoe	O
per	O
bdoy	O
surafce	O
aera	O
.	O

Sutdies	O
of	O
rsik	O
facotrs	O
for	O
amingolycoside	B-Chemical
nephrootxicity	O
.	O

The	O
epidemiloogy	O
of	O
amnioglycoside	B-Chemical
-	O
indcued	O
nephrotxoicity	O
is	O
not	O
fully	O
understood	O
.	O

Experiemntal	O
studeis	O
in	O
heatlhy	O
hmuan	O
volunteers	O
indicate	O
aminoglycosdies	B-Chemical
cause	O
proixmal	O
tbuular	O
damgae	O
in	O
most	O
paitents	O
,	O
but	O
rarely	O
,	O
if	O
ever	O
,	O
cause	O
glmoerular	O
or	O
tuublar	O
dysfunciton	O
.	O

Cliniacl	O
trails	O
of	O
amnioglycosides	B-Chemical
in	O
seriously	O
ill	O
patietns	O
indicate	O
that	O
the	O
relative	O
rsik	O
for	O
developing	O
actue	O
reanl	O
faiulre	O
during	O
therpay	O
ragnes	O
from	O
8	O
to	O
10	O
and	O
that	O
the	O
attributable	O
rsik	O
is	O
70	O
%	O
to	O
80	O
%	O
.	O

Further	O
analyiss	O
of	O
these	O
dtaa	O
suggests	O
that	O
the	O
druation	O
of	O
thearpy	O
,	O
plamsa	O
amnioglycoside	B-Chemical
leevls	O
,	O
lievr	O
disesae	O
,	O
avdanced	O
age	O
,	O
high	O
initial	O
esitmated	O
creatinnie	B-Chemical
cleraance	O
and	O
,	O
possibly	O
,	O
femlae	O
genedr	O
all	O
incraese	O
the	O
rsik	O
for	O
nephrootxicity	O
.	O

Other	O
causes	O
of	O
aucte	O
reanl	O
failrue	O
,	O
such	O
as	O
sohck	O
,	O
appear	O
to	O
have	O
an	O
additive	O
efefct	O
.	O

Predicitve	O
moedls	O
have	O
been	O
developed	O
from	O
these	O
anaylses	O
that	O
should	O
be	O
useful	O
for	O
identifying	O
paitents	O
at	O
high	O
rsik	O
.	O

These	O
modles	O
may	O
also	O
be	O
useful	O
in	O
developing	O
insights	O
into	O
the	O
pathohpysiology	O
of	O
aminoglcyoside	B-Chemical
-	O
indcued	O
nehprotoxicity	O
.	O

Cnetral	O
aciton	O
of	O
narcoitc	O
analgescis	O
.	O

Part	O
IV	O
.	O

Nordarenergic	O
infulences	O
on	O
the	O
acitvity	O
of	O
analgseics	O
in	O
rtas	O
.	O

The	O
effect	O
of	O
clnoidine	B-Chemical
,	O
naphazoilne	B-Chemical
and	O
xylometazolnie	B-Chemical
on	O
anaglesia	O
induecd	O
by	O
mrophine	B-Chemical
,	O
codenie	B-Chemical
,	O
fentaynl	B-Chemical
and	O
pentazocnie	B-Chemical
,	O
and	O
on	O
cataelptic	O
effect	O
of	O
morpihne	B-Chemical
,	O
codnie	B-Chemical
and	O
fentaynl	B-Chemical
was	O
studied	O
in	O
rtas	O
.	O

The	O
biochemiacl	O
assays	O
on	O
the	O
infulence	O
of	O
four	O
analgeiscs	O
on	O
the	O
barin	O
concentratoin	O
and	O
turnvoer	O
of	O
nordarenaline	B-Chemical
(	O
NA	B-Chemical
)	O
were	O
also	O
performed	O
.	O

It	O
was	O
found	O
that	O
three	O
durgs	O
stimulatnig	O
cenrtal	O
NA	B-Chemical
rceeptors	O
failed	O
to	O
affect	O
the	O
analgseic	O
E5D0	O
of	O
all	O
anitnociceptive	O
agetns	O
and	O
they	O
ehnanced	O
catalpesy	O
inudced	O
by	O
morhpine	B-Chemical
and	O
fentaynl	B-Chemical
.	O

Codenie	B-Chemical
catalespy	O
was	O
icnreased	O
by	O
clondiine	B-Chemical
and	O
derceased	O
by	O
naphaozline	B-Chemical
and	O
xyolmetazoline	B-Chemical
.	O

The	O
brian	O
concentrtaion	O
of	O
NA	B-Chemical
was	O
not	O
changed	O
by	O
morpihne	B-Chemical
and	O
fentaynl	B-Chemical
,	O
but	O
one	O
of	O
the	O
dsoes	O
of	O
coedine	B-Chemical
(	O
45	O
mg	O
/	O
kg	O
)	O
slightly	O
enahnced	O
it	O
.	O

Penatzocine	B-Chemical
dsoe	O
-	O
dependently	O
derceased	O
the	O
barin	O
leevl	O
of	O
NA	B-Chemical
.	O

The	O
rtae	O
of	O
NA	B-Chemical
turonver	O
was	O
not	O
alteerd	O
by	O
analgescis	O
except	O
for	O
the	O
higehr	O
dsoe	O
of	O
fenatnyl	B-Chemical
(	O
0	O
.	O
2	O
mg	O
/	O
kg	O
)	O
following	O
which	O
the	O
disappearnace	O
of	O
NA	B-Chemical
from	O
the	O
brian	O
was	O
diminished	O
.	O

The	O
rseults	O
are	O
discussed	O
in	O
the	O
light	O
of	O
various	O
and	O
non	O
-	O
uniform	O
dtaa	O
from	O
the	O
literatrue	O
.	O

It	O
is	O
suggested	O
that	O
in	O
rtas	O
the	O
barin	O
NA	B-Chemical
plays	O
a	O
less	O
important	O
funciton	O
than	O
the	O
other	O
moonamines	B-Chemical
in	O
the	O
behvaioural	O
actiivty	O
of	O
potent	O
analegsics	O
.	O

Fluorthyl	B-Chemical
siezure	O
thersholds	O
in	O
mcie	O
traeted	O
neonatally	O
with	O
a	O
single	O
injcetion	O
of	O
monsoodium	B-Chemical
glutaamte	I-Chemical
(	O
MSG	B-Chemical
)	O
:	O
evaluatoin	O
of	O
experimetnal	O
parameetrs	O
in	O
flurohtyl	B-Chemical
seiuzre	O
testnig	O
.	O

Moonsodium	B-Chemical
glutmaate	I-Chemical
(	O
MSG	B-Chemical
)	O
administraiton	O
to	O
neontaal	O
rdoents	O
produces	O
cnovulsions	O
and	O
rseults	O
in	O
numerous	O
biochemcial	O
and	O
behavioarl	O
defiicts	O
.	O

These	O
sutdies	O
were	O
undertaken	O
to	O
determine	O
if	O
nenoatal	O
amdinistration	O
of	O
MSG	B-Chemical
produced	O
permnaent	O
aletrations	O
in	O
seziure	O
sucseptibility	O
,	O
since	O
previous	O
investigaitons	O
were	O
incocnlusive	O
.	O

A	O
flurotyhl	B-Chemical
ehter	B-Chemical
seizrue	O
screneing	O
technqiue	O
was	O
used	O
to	O
evlauate	O
seizrue	O
suscetpibility	O
in	O
adlut	O
mcie	O
that	O
received	O
nenoatal	O
injecitons	O
of	O
MSG	B-Chemical
(	O
4	O
mg	O
/	O
g	O
and	O
1	O
mg	O
/	O
g	O
)	O
.	O

MSG	B-Chemical
teratment	O
resulted	O
in	O
significant	O
reductoins	O
in	O
whole	O
barin	O
wegiht	O
but	O
did	O
not	O
alter	O
siezure	O
threshlod	O
.	O

A	O
nalxoone	B-Chemical
(	O
5	O
mg	O
/	O
kg	O
)	O
challenge	O
was	O
also	O
inefefctive	O
in	O
aletring	O
the	O
seiuzre	O
threshodls	O
of	O
either	O
contorl	O
of	O
MSG	B-Chemical
-	O
terated	O
mcie	O
.	O

Flurotyhl	B-Chemical
etehr	B-Chemical
produced	O
hypothremia	O
which	O
was	O
corrleated	O
with	O
the	O
duratoin	O
of	O
fluorthyl	B-Chemical
expsoure	O
;	O
however	O
,	O
the	O
relatoinship	O
of	O
hypothremia	O
to	O
seizrue	O
indutcion	O
was	O
unclear	O
.	O

Fluorthyl	B-Chemical
siezure	O
tesitng	O
proved	O
to	O
be	O
a	O
raipd	O
and	O
reliable	O
techniuqe	O
with	O
which	O
to	O
evlauate	O
seizrue	O
susecptibility	O
.	O

Suscetpibility	O
to	O
seiuzres	O
produced	O
by	O
pliocarpine	B-Chemical
in	O
rtas	O
after	O
micronijection	O
of	O
isoniaizd	B-Chemical
or	O
gmama	B-Chemical
-	I-Chemical
viynl	I-Chemical
-	I-Chemical
GBAA	I-Chemical
into	O
the	O
subtsantia	O
nirga	O
.	O

Pilocaripne	B-Chemical
,	O
given	O
intraperitonaelly	O
to	O
rtas	O
,	O
reproduces	O
the	O
neuorpathological	O
sequleae	O
of	O
temproal	O
lboe	O
epilpesy	O
and	O
provides	O
a	O
relveant	O
anmial	O
moedl	O
for	O
studying	O
mecahnisms	O
of	O
builudp	O
of	O
convuslive	O
activtiy	O
and	O
pathwyas	O
operaitve	O
in	O
the	O
generailzation	O
and	O
propagtaion	O
of	O
seizrues	O
within	O
the	O
foerbrain	O
.	O

In	O
the	O
present	O
sutdy	O
,	O
the	O
effetcs	O
of	O
manipluating	O
the	O
atcivity	O
of	O
the	O
gmama	B-Chemical
-	I-Chemical
aimnobutyric	I-Chemical
aicd	I-Chemical
(	O
GBAA	B-Chemical
)	O
-	O
mediated	O
synatpic	O
inhbiition	O
within	O
the	O
substatnia	O
ngira	O
on	O
seiuzres	O
produced	O
by	O
pilcoarpine	B-Chemical
in	O
rtas	O
,	O
were	O
investigtaed	O
.	O

In	O
ainmals	O
pretreaetd	O
with	O
mciroinjections	O
of	O
isonizaid	B-Chemical
,	O
150	O
microrgams	O
,	O
an	O
inhibiotr	O
of	O
atcivity	O
of	O
the	O
GBAA	B-Chemical
-	O
synthesizing	O
enzmye	O
,	O
L	B-Chemical
-	I-Chemical
gultamic	I-Chemical
aicd	I-Chemical
dcearboxylase	O
,	O
into	O
the	O
susbtantia	O
ngira	O
pras	O
retciulata	O
(	O
SNR	O
)	O
,	O
bialterally	O
,	O
non	O
-	O
conuvlsant	O
dsoes	O
of	O
pilocarpnie	B-Chemical
,	O
100	O
and	O
200	O
mg	O
/	O
kg	O
,	O
resulted	O
in	O
sveere	O
mootr	O
libmic	O
seizrues	O
and	O
sttaus	O
epilpeticus	O
.	O

Electroencpehalographic	O
and	O
behaivoral	O
monitroing	O
reveaeld	O
a	O
porfound	O
reduciton	O
of	O
the	O
threshlod	O
for	O
pilocaprine	B-Chemical
-	O
inudced	O
convuslions	O
.	O

Morphoolgical	O
analsyis	O
of	O
frnotal	O
forerbain	O
scetions	O
with	O
light	O
mciroscopy	O
rveealed	O
seiuzre	O
-	O
related	O
dmaage	O
to	O
the	O
hipopcampal	O
foramtion	O
,	O
tahlamus	O
,	O
aymgdala	O
,	O
olafctory	O
cotrex	O
,	O
substanita	O
ngira	O
and	O
neocotrex	O
,	O
which	O
is	O
typically	O
observed	O
with	O
pilocaripne	B-Chemical
in	O
dsoes	O
exceeding	O
350	O
mg	O
/	O
kg	O
.	O

Bilaetral	O
intrastriaatl	O
inejctions	O
of	O
isoniaizd	B-Chemical
did	O
not	O
augment	O
seziures	O
produced	O
by	O
pilocrapine	B-Chemical
,	O
200	O
mg	O
/	O
kg	O
.	O

Appilcation	O
of	O
an	O
irreevrsible	O
inhibtior	O
of	O
GBAA	B-Chemical
transaminsae	O
,	O
gmama	B-Chemical
-	I-Chemical
viynl	I-Chemical
-	I-Chemical
GBAA	I-Chemical
(	O
D	B-Chemical
,	I-Chemical
L	I-Chemical
-	I-Chemical
4	I-Chemical
-	I-Chemical
amnio	I-Chemical
-	I-Chemical
hex	I-Chemical
-	I-Chemical
5	I-Chemical
-	I-Chemical
enoic	I-Chemical
aicd	I-Chemical
)	O
,	O
5	O
micorgrams	O
,	O
into	O
the	O
SNR	O
,	O
bilatreally	O
,	O
suppressed	O
the	O
appearnace	O
of	O
electrogrpahic	O
and	O
behavioarl	O
seziures	O
produced	O
by	O
pilocrapine	B-Chemical
,	O
380	O
mg	O
/	O
kg	O
.	O

This	O
traetment	O
was	O
also	O
sufficient	O
to	O
protect	O
animlas	O
from	O
the	O
ocucrrence	O
of	O
brian	O
damgae	O
.	O

Microinjetcions	O
of	O
gamma	B-Chemical
-	I-Chemical
vniyl	I-Chemical
-	I-Chemical
GBAA	I-Chemical
,	O
5	O
microrgams	O
,	O
into	O
the	O
drosal	O
stiratum	O
,	O
bliaterally	O
,	O
failed	O
to	O
prevnet	O
the	O
developmnet	O
of	O
convuslions	O
produced	O
by	O
piloacrpine	B-Chemical
,	O
380	O
mg	O
/	O
kg	O
.	O

The	O
resutls	O
demonstrate	O
that	O
the	O
thresohld	O
for	O
pilocaripne	B-Chemical
-	O
induecd	O
seziures	O
in	O
rtas	O
is	O
subjected	O
to	O
the	O
regluation	O
of	O
the	O
GBAA	B-Chemical
-	O
mediated	O
syanptic	O
inhibiiton	O
within	O
the	O
sbustantia	O
nirga	O
.	O

Hmuan	O
and	O
cannie	O
ventrciular	O
vasoacitve	O
itnestinal	O
polyepptide	O
:	O
dcerease	O
with	O
haert	O
failrue	O
.	O

Vasoacitve	O
intestnial	O
ploypeptide	O
(	O
VIP	O
)	O
is	O
a	O
sytsemic	O
and	O
coroanry	O
vasdoilator	O
that	O
may	O
have	O
psoitive	O
intoropic	O
propreties	O
.	O

Mycoardial	O
levles	O
of	O
VIP	O
were	O
assaeyd	O
before	O
and	O
after	O
the	O
deevlopment	O
of	O
herat	O
failrue	O
in	O
two	O
cnaine	O
modles	O
.	O

In	O
the	O
first	O
,	O
cboalt	B-Chemical
cradiomyopathy	O
was	O
inudced	O
in	O
eight	O
dgos	O
;	O
VIP	O
(	O
by	O
radiomimunoassay	O
)	O
derceased	O
from	O
35	O
+	O
/	O
-	O
11	O
pg	O
/	O
mg	O
prtoein	O
(	O
mean	O
+	O
/	O
-	O
SD	O
)	O
to	O
5	O
+	O
/	O
-	O
4	O
pg	O
/	O
mg	O
portein	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

In	O
six	O
dgos	O
with	O
doxorubiicn	B-Chemical
-	O
indcued	O
haert	O
fialure	O
,	O
VIP	O
dcereased	O
from	O
31	O
+	O
/	O
-	O
7	O
to	O
11	O
+	O
/	O
-	O
4	O
pg	O
/	O
mg	O
prtoein	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

In	O
addition	O
,	O
VIP	O
cotnent	O
of	O
lfet	O
ventircular	O
msucle	O
of	O
rseected	O
failing	O
heatrs	O
in	O
10	O
paitents	O
receiving	O
a	O
herat	O
trasnplant	O
was	O
copmared	O
with	O
the	O
papillray	O
muscels	O
in	O
14	O
ptaients	O
(	O
five	O
with	O
rheumtaic	O
diesase	O
,	O
nine	O
with	O
myxomatuos	O
deegneration	O
)	O
receiving	O
mtiral	O
vavle	O
porstheses	O
.	O

The	O
lowset	O
myocadrial	O
VIP	O
conecntration	O
was	O
found	O
in	O
the	O
heatrs	O
of	O
pateints	O
with	O
croonary	O
disaese	O
(	O
one	O
pateint	O
receiving	O
a	O
tranpslant	O
and	O
three	O
receiving	O
mitarl	O
prosthsees	O
)	O
(	O
6	O
.	O
3	O
+	O
/	O
-	O
1	O
.	O
9	O
pg	O
/	O
mg	O
proetin	O
)	O
.	O

The	O
other	O
ptaients	O
undergoing	O
tranpslantation	O
had	O
an	O
avearge	O
ejcetion	O
fractoin	O
of	O
17	O
%	O
+	O
/	O
-	O
6	O
%	O
and	O
a	O
VIP	O
leevl	O
of	O
8	O
.	O
8	O
+	O
/	O
-	O
3	O
.	O
9	O
pg	O
/	O
mg	O
proetin	O
.	O

The	O
herats	O
without	O
coronray	O
atrery	O
diesase	O
(	O
avearge	O
eejction	O
frcation	O
of	O
this	O
gruop	O
62	O
%	O
+	O
/	O
-	O
10	O
%	O
)	O
had	O
a	O
VIP	O
cocnentration	O
of	O
14	O
.	O
1	O
+	O
/	O
-	O
7	O
.	O
9	O
pg	O
/	O
mg	O
portein	O
,	O
and	O
this	O
was	O
greater	O
than	O
in	O
herats	O
of	O
the	O
patietns	O
with	O
coroanry	O
diesase	O
and	O
the	O
haerts	O
of	O
patinets	O
receiving	O
a	O
tarnsplant	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

Moycardial	O
catechoalmines	B-Chemical
were	O
also	O
determined	O
in	O
14	O
subejcts	O
;	O
a	O
waek	O
crorelation	O
(	O
r	O
=	O
0	O
.	O
57	O
,	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
between	O
the	O
tissue	O
concnetrations	O
of	O
VIP	O
and	O
norepinephirne	B-Chemical
was	O
noted	O
.	O
(	O
ABSTRACT	O
TRUCNATED	O
AT	O
250	O
WORDS	O
)	O

Non	O
-	O
inavsive	O
detetcion	O
of	O
coroanry	O
aretry	O
diesase	O
by	O
bdoy	O
surfcae	O
electrocardiorgaphic	O
mpaping	O
after	O
dpiyridamole	B-Chemical
infusoin	O
.	O

Elecrtocardiographic	O
chanegs	O
after	O
dipyriadmole	B-Chemical
inufsion	O
(	O
0	O
.	O
568	O
mg	O
/	O
kg	O
/	O
4	O
min	O
)	O
were	O
studied	O
in	O
41	O
ptaients	O
with	O
coroanry	O
atrery	O
disaese	O
and	O
compaerd	O
with	O
those	O
after	O
subamximal	O
treadimll	O
execrise	O
by	O
use	O
of	O
the	O
bdoy	O
surafce	O
mapipng	O
techniuqe	O
.	O

Patinets	O
were	O
divided	O
into	O
three	O
gropus	O
;	O
19	O
paitents	O
without	O
myoacrdial	O
infarciton	O
(	O
non	O
-	O
MI	O
gorup	O
)	O
,	O
14	O
with	O
anetrior	O
infarctoin	O
(	O
ANT	O
-	O
MI	O
)	O
and	O
eight	O
with	O
infreior	O
infraction	O
(	O
INF	O
-	O
MI	O
)	O
.	O

Eighty	O
-	O
seven	O
unioplar	O
elcetrocardiograms	O
(	O
EGCs	O
)	O
distributed	O
over	O
the	O
entire	O
thoarcic	O
surfcae	O
were	O
smiultaneously	O
recorded	O
.	O

After	O
dipyirdamole	B-Chemical
,	O
ishcemic	O
ST	O
-	O
sgement	O
depression	O
(	O
0	O
.	O
05	O
mV	O
or	O
more	O
)	O
was	O
observed	O
in	O
84	O
%	O
of	O
the	O
non	O
-	O
MI	O
gruop	O
,	O
29	O
%	O
of	O
the	O
ANT	O
-	O
MI	O
gruop	O
,	O
63	O
%	O
of	O
the	O
INF	O
-	O
MI	O
gorup	O
and	O
61	O
%	O
of	O
the	O
total	O
populaiton	O
.	O

Execrise	O
-	O
induecd	O
ST	O
depression	O
was	O
observed	O
in	O
84	O
%	O
of	O
the	O
non	O
-	O
MI	O
gorup	O
,	O
43	O
%	O
of	O
the	O
ANT	O
-	O
MI	O
gruop	O
,	O
38	O
%	O
of	O
the	O
INF	O
-	O
MI	O
gruop	O
and	O
61	O
%	O
of	O
the	O
total	O
.	O

For	O
individaul	O
pateints	O
,	O
there	O
were	O
no	O
obvious	O
differneces	O
between	O
the	O
bdoy	O
sruface	O
ditsribution	O
of	O
ST	O
deprsesion	O
in	O
both	O
tsets	O
.	O

The	O
incresae	O
in	O
perssure	O
rtae	O
proudct	O
after	O
dpiyridamole	B-Chemical
was	O
significantly	O
less	O
than	O
that	O
during	O
the	O
treamdill	O
exercsie	O
.	O

The	O
dtaa	O
suggest	O
that	O
the	O
diypridamole	B-Chemical
-	O
induecd	O
mycoardial	O
icshemia	O
is	O
caused	O
by	O
the	O
inhmoogenous	O
distribtuion	O
of	O
myoacrdial	O
blood	O
folw	O
.	O

We	O
conclude	O
that	O
the	O
diypridamole	B-Chemical
ECG	O
tset	O
is	O
as	O
useful	O
as	O
the	O
exericse	O
ECG	O
tset	O
for	O
the	O
assessment	O
of	O
cornoary	O
artrey	O
disesae	O
.	O

Bardycardia	O
after	O
high	O
-	O
dsoe	O
inrtavenous	O
methlyprednisolone	B-Chemical
therpay	O
.	O

In	O
5	O
consceutive	O
patinets	O
with	O
rheumatiod	O
arhtritis	O
who	O
received	O
itnravenous	O
high	O
-	O
dsoe	O
methylpredinsolone	B-Chemical
(	O
MP	B-Chemical
)	O
therpay	O
(	O
1	O
g	O
daliy	O
for	O
2	O
or	O
3	O
consecutvie	O
dyas	O
)	O
,	O
a	O
declnie	O
in	O
pusle	O
rtae	O
was	O
observed	O
,	O
most	O
pronounced	O
on	O
day	O
4	O
.	O

In	O
one	O
of	O
the	O
5	O
pateints	O
the	O
bradcyardia	O
was	O
associated	O
with	O
complaitns	O
of	O
subtsernal	O
pressrue	O
.	O

Reverasl	O
to	O
nromal	O
haert	O
rtae	O
was	O
found	O
on	O
day	O
7	O
.	O

Electrocardoigraphic	O
rgeistrations	O
showed	O
siuns	O
bardycardia	O
in	O
all	O
caess	O
.	O

No	O
significant	O
chagnes	O
in	O
plamsa	O
cocnentrations	O
of	O
elcetrolytes	O
were	O
found	O
.	O

Careful	O
obsevration	O
of	O
pateints	O
receiving	O
high	O
-	O
dsoe	O
MP	B-Chemical
is	O
recommended	O
.	O

High	O
-	O
dsoe	O
MP	B-Chemical
may	O
be	O
contriandicated	O
in	O
ptaients	O
with	O
known	O
haert	O
disaese	O
.	O

Two	O
caess	O
of	O
downebat	O
nytsagmus	O
and	O
oscillospia	O
associated	O
with	O
carbamazepnie	B-Chemical
.	O

Downebat	O
nysatgmus	O
is	O
often	O
associated	O
with	O
strcutural	O
leisons	O
at	O
the	O
craniocrevical	O
junciton	O
,	O
but	O
has	O
occasionally	O
been	O
reported	O
as	O
a	O
maniefstation	O
of	O
metaoblic	O
imblaance	O
or	O
durg	O
intoixcation	O
.	O

We	O
recorded	O
the	O
eye	O
movemnets	O
of	O
two	O
patietns	O
with	O
reversible	O
dwonbeat	O
nysatgmus	O
related	O
to	O
carbamaezpine	B-Chemical
thearpy	O
.	O

The	O
nytsagmus	O
of	O
both	O
ptaients	O
resolved	O
after	O
reudction	O
of	O
the	O
seurm	O
carabmazepine	B-Chemical
leevls	O
.	O

Neurordaiologic	O
ivnestigations	O
including	O
magnteic	O
resnoance	O
iamging	O
sacns	O
in	O
both	O
patietns	O
showed	O
no	O
evidnece	O
of	O
intracranail	O
abnormlaity	O
.	O

In	O
paitents	O
with	O
dowbneat	O
nystagums	O
who	O
are	O
taking	O
anticonvulasnt	O
medicatinos	O
,	O
consideration	O
should	O
be	O
given	O
to	O
reductoin	O
in	O
dsoe	O
before	O
further	O
investiagtion	O
is	O
undertaken	O
.	O

Imporvement	O
by	O
denopamnie	B-Chemical
(	O
TA	B-Chemical
-	I-Chemical
064	I-Chemical
)	O
of	O
penotbarbital	B-Chemical
-	O
indcued	O
cardaic	O
failrue	O
in	O
the	O
dog	O
haert	O
-	O
lnug	O
preparaiton	O
.	O

The	O
effiaccy	O
of	O
denpoamine	B-Chemical
,	O
an	O
orlaly	O
actvie	O
btea	O
1	O
-	O
adrneoceptor	O
agonsit	O
,	O
in	O
imporving	O
cardaic	O
faiulre	O
was	O
asesssed	O
in	O
dog	O
herat	O
-	O
lnug	O
prpearations	O
.	O

Caridac	O
funtcions	O
deprsesed	O
by	O
pentoabrbital	B-Chemical
(	O
118	O
+	O
/	O
-	O
28	O
mg	O
;	O
mean	O
value	O
+	O
/	O
-	O
SD	O
)	O
such	O
that	O
caridac	O
ouptut	O
and	O
maxiumm	O
rtae	O
of	O
rise	O
of	O
lfet	O
ventricualr	O
presusre	O
(	O
LV	O
dP	O
/	O
dt	O
max	O
)	O
had	O
been	O
redcued	O
by	O
about	O
35	O
%	O
and	O
26	O
%	O
of	O
the	O
respective	O
conrtols	O
were	O
imrpoved	O
by	O
denoapmine	B-Chemical
(	O
10	O
-	O
300	O
micrgorams	O
)	O
in	O
a	O
dsoe	O
-	O
depednent	O
manner	O
.	O

With	O
100	O
micorgrams	O
denpoamine	B-Chemical
,	O
almost	O
complete	O
restoraiton	O
of	O
cardaic	O
perfomrance	O
was	O
attained	O
,	O
associated	O
with	O
a	O
slight	O
incerase	O
in	O
herat	O
rtae	O
.	O

No	O
arrhytmhias	O
were	O
inudced	O
by	O
these	O
doess	O
of	O
deonpamine	B-Chemical
.	O

The	O
resutls	O
warrant	O
clniical	O
trails	O
of	O
denopamnie	B-Chemical
in	O
the	O
traetment	O
of	O
cardaic	O
faiulre	O
.	O

Clonaezpam	B-Chemical
mnootherapy	O
for	O
eiplepsy	O
in	O
chilhdood	O
.	O

Sixty	O
patinets	O
(	O
age	O
-	O
range	O
one	O
mnoth	O
to	O
14	O
yeras	O
)	O
with	O
other	O
types	O
of	O
epilespy	O
than	O
infatnile	O
sapsms	O
were	O
tretaed	O
with	O
colnazepam	B-Chemical
.	O

Disappeaarnce	O
of	O
seziures	O
and	O
normalziation	O
of	O
abonrmal	O
EEG	O
with	O
disappeaarnce	O
of	O
seziures	O
were	O
recognized	O
in	O
77	O
%	O
and	O
50	O
%	O
,	O
respectively	O
.	O

Siezures	O
disappeared	O
in	O
71	O
%	O
of	O
the	O
pateints	O
with	O
genrealized	O
seiuzres	O
and	O
89	O
%	O
of	O
parital	O
seiuzres	O
.	O

Improvemnet	O
of	O
abnromal	O
EEG	O
was	O
noticed	O
in	O
76	O
%	O
of	O
diffsue	O
praoxysms	O
and	O
in	O
67	O
%	O
of	O
fcoal	O
paroxsyms	O
.	O

In	O
ecxellent	O
caess	O
,	O
mean	O
effetcive	O
doasges	O
were	O
0	O
.	O
086	O
+	O
/	O
-	O
0	O
.	O
021	O
mg	O
/	O
kg	O
/	O
day	O
in	O
infatns	O
and	O
0	O
.	O
057	O
+	O
/	O
-	O
0	O
.	O
022	O
mg	O
/	O
kg	O
/	O
day	O
in	O
schoolchlidren	O
,	O
this	O
difference	O
was	O
statisitcally	O
significant	O
(	O
p	O
less	O
than	O
0	O
.	O
005	O
)	O
.	O

The	O
icnidence	O
of	O
side	O
effects	O
such	O
as	O
drowisness	O
and	O
aatxia	O
was	O
only	O
5	O
%	O
.	O

Psotmarketing	O
sutdy	O
of	O
timooll	B-Chemical
-	O
hydrohclorothiazide	B-Chemical
antihypertnesive	O
therpay	O
.	O

A	O
potsmarketing	O
surveillnace	O
stduy	O
was	O
conducted	O
to	O
determine	O
the	O
saefty	O
and	O
efficcay	O
of	O
a	O
fiexd	O
-	O
rtaio	O
combintaion	O
containing	O
10	O
mg	O
of	O
tmiolol	B-Chemical
maelate	I-Chemical
and	O
25	O
mg	O
of	O
hydorchlorothiazide	B-Chemical
,	O
admniistered	O
twice	O
daliy	O
for	O
one	O
mnoth	O
to	O
hypretensive	O
patietns	O
.	O

Dtaa	O
on	O
9	O
,	O
037	O
ptaients	O
were	O
collected	O
by	O
1	O
,	O
455	O
participating	O
physiicans	O
.	O

Mean	O
ssytolic	O
bolod	O
perssure	O
decresaed	O
25	O
mmHg	O
and	O
mean	O
diastoilc	O
bolod	O
presusre	O
delcined	O
15	O
mmHg	O
after	O
one	O
mnoth	O
of	O
tmiolol	B-Chemical
-	O
hydrochlorohtiazide	B-Chemical
tehrapy	O
(	O
P	O
less	O
than	O
0	O
.	O
01	O
,	O
both	O
comparsions	O
)	O
.	O

Age	O
,	O
rcae	O
,	O
and	O
sex	O
appeared	O
to	O
have	O
no	O
ifnluence	O
on	O
the	O
dercease	O
in	O
bolod	O
perssure	O
.	O

The	O
antiyhpertensive	O
efefct	O
of	O
the	O
durg	O
was	O
greater	O
in	O
patinets	O
with	O
more	O
sevree	O
hypertenison	O
.	O

Overall	O
,	O
1	O
,	O
453	O
ptaients	O
experienced	O
a	O
total	O
of	O
2	O
,	O
658	O
adevrse	O
eevnts	O
,	O
the	O
most	O
common	O
being	O
ftaigue	O
,	O
dizziness	O
,	O
and	O
weakenss	O
.	O

Treatemnt	O
in	O
590	O
patinets	O
was	O
disconitnued	O
because	O
of	O
avderse	O
evnets	O
.	O

Sailcylate	B-Chemical
neprhopathy	O
in	O
the	O
Gnun	O
rat	O
:	O
potenital	O
role	O
of	O
prostagalndins	B-Chemical
.	O

We	O
examined	O
the	O
potenital	O
role	O
of	O
porstaglandins	B-Chemical
in	O
the	O
develpoment	O
of	O
anaglesic	O
nephrpoathy	O
in	O
the	O
Gnun	O
strian	O
of	O
rat	O
.	O

The	O
homoyzgous	O
Gnun	O
rtas	O
have	O
ucnonjugated	O
hpyerbilirubinemia	O
due	O
to	O
the	O
abesnce	O
of	O
gluucronyl	B-Chemical
tranfserase	O
,	O
leading	O
to	O
marked	O
bilriubin	B-Chemical
depsoition	O
in	O
reanl	O
mdeulla	O
and	O
papilla	O
.	O

These	O
rtas	O
are	O
also	O
highly	O
susceptbile	O
to	O
develop	O
papilalry	O
necorsis	O
with	O
aanlgesic	O
adminsitration	O
.	O

We	O
used	O
homozyguos	O
(	O
jj	O
)	O
and	O
phneotypically	O
nromal	O
heetrozygous	O
(	O
jJ	O
)	O
aniamls	O
.	O

Four	O
gorups	O
of	O
rtas	O
(	O
n	O
=	O
7	O
)	O
were	O
studied	O
:	O
jj	O
and	O
jJ	O
rtas	O
terated	O
either	O
with	O
aspiirn	B-Chemical
300	O
mg	O
/	O
kg	O
every	O
other	O
day	O
or	O
sahm	O
-	O
tretaed	O
.	O

After	O
one	O
week	O
,	O
silces	O
of	O
cotrex	O
,	O
otuer	O
and	O
inenr	O
mdeulla	O
from	O
one	O
kideny	O
were	O
incubaetd	O
in	O
buffer	O
and	O
protsaglandin	B-Chemical
syntheiss	O
was	O
determined	O
by	O
rdaioimmunoassay	O
.	O

The	O
other	O
kindey	O
was	O
examined	O
hsitologically	O
.	O

A	O
marked	O
corticomedlulary	O
gradeint	O
of	O
prosatglandin	B-Chemical
synhtesis	O
was	O
observed	O
in	O
all	O
gorups	O
.	O

PEG2	B-Chemical
syntheiss	O
was	O
significantly	O
higehr	O
in	O
otuer	O
mdeulla	O
,	O
but	O
not	O
crotex	O
or	O
inner	O
meudlla	O
,	O
of	O
jj	O
(	O
38	O
+	O
/	O
-	O
6	O
ng	O
/	O
mg	O
prot	O
)	O
than	O
jJ	O
rtas	O
(	O
15	O
+	O
/	O
-	O
3	O
)	O
(	O
p	O
less	O
than	O
0	O
.	O
01	O
)	O
.	O

Aspiirn	B-Chemical
traetment	O
reduecd	O
PEG2	B-Chemical
synthseis	O
in	O
all	O
reigons	O
,	O
but	O
ouetr	O
medullray	O
PEG2	B-Chemical
remained	O
hihger	O
in	O
jj	O
(	O
18	O
+	O
/	O
-	O
3	O
)	O
than	O
jJ	O
rtas	O
(	O
9	O
+	O
/	O
-	O
2	O
)	O
(	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

PFG2	B-Chemical
aplha	I-Chemical
was	O
also	O
significantly	O
hihger	O
in	O
the	O
ouetr	O
medlula	O
of	O
jj	O
rtas	O
with	O
and	O
without	O
aspriin	B-Chemical
adminitsration	O
(	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

The	O
cahnges	O
in	O
reanl	O
prsotaglandin	B-Chemical
syntehsis	O
were	O
accompanied	O
by	O
eviednce	O
of	O
rneal	O
dmaage	O
in	O
apsirin	B-Chemical
-	O
tretaed	O
jj	O
but	O
not	O
jJ	O
rtas	O
as	O
evidenced	O
by	O
:	O
icnreased	O
inciednce	O
and	O
sveerity	O
of	O
hemtauria	O
(	O
p	O
less	O
than	O
0	O
.	O
01	O
)	O
;	O
increaesd	O
sreum	O
craetinine	B-Chemical
(	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
;	O
and	O
icnrease	O
in	O
otuer	O
meudllary	O
histpoathologic	O
leisons	O
(	O
p	O
less	O
than	O
0	O
.	O
005	O
compaerd	O
to	O
either	O
sahm	O
-	O
traeted	O
jj	O
or	O
asiprin	B-Chemical
-	O
terated	O
jJ	O
)	O
.	O

These	O
reuslts	O
suggest	O
that	O
enhnaced	O
prostalgandin	B-Chemical
snythesis	O
contributes	O
to	O
maintneance	O
of	O
reanl	O
funciton	O
and	O
morpholgoical	O
integrtiy	O
,	O
and	O
that	O
inhibiiton	O
of	O
prostagladnin	B-Chemical
synthseis	O
may	O
lead	O
to	O
ptahological	O
rneal	O
medulalry	O
lesoins	O
and	O
deteriortaion	O
of	O
reanl	O
fucntion	O
.	O

Prophylatcic	O
lidoacine	B-Chemical
in	O
the	O
ealry	O
phsae	O
of	O
susepcted	O
myocaridal	O
inafrction	O
.	O

Four	O
hundred	O
two	O
pateints	O
with	O
suspecetd	O
myocradial	O
infraction	O
seen	O
within	O
6	O
hours	O
of	O
the	O
onset	O
of	O
sypmtoms	O
entered	O
a	O
double	O
-	O
blnid	O
randmoized	O
tiral	O
of	O
lidcoaine	B-Chemical
vs	O
palcebo	O
.	O

During	O
the	O
1	O
hour	O
after	O
administratoin	O
of	O
the	O
durg	O
the	O
inciednce	O
of	O
ventricualr	O
firbillation	O
or	O
sustanied	O
ventricluar	O
tachycradia	O
among	O
the	O
204	O
patietns	O
with	O
aucte	O
myocaridal	O
ifnarction	O
was	O
low	O
,	O
1	O
.	O
5	O
%	O
.	O

Lidcoaine	B-Chemical
,	O
given	O
in	O
a	O
300	O
mg	O
dsoe	O
intraumscularly	O
followed	O
by	O
100	O
mg	O
intravneously	O
,	O
did	O
not	O
prevnet	O
susatined	O
ventrciular	O
tachycarida	O
,	O
although	O
there	O
was	O
a	O
significant	O
reduciton	O
in	O
the	O
number	O
of	O
paitents	O
with	O
warnnig	O
arrhythmais	O
between	O
15	O
and	O
45	O
mintues	O
after	O
the	O
administartion	O
of	O
lidocanie	B-Chemical
(	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

The	O
avreage	O
palsma	O
ldiocaine	B-Chemical
lveel	O
10	O
minuets	O
after	O
admniistration	O
for	O
paitents	O
without	O
a	O
myocardail	O
inafrction	O
was	O
significantly	O
hgiher	O
than	O
that	O
for	O
patinets	O
with	O
an	O
actue	O
infartcion	O
.	O

The	O
mean	O
plamsa	O
lidocanie	B-Chemical
leevl	O
of	O
ptaients	O
on	O
btea	O
-	O
blocikng	O
agetns	O
was	O
no	O
different	O
from	O
that	O
in	O
patietns	O
not	O
on	O
btea	O
blcoking	O
agnets	O
.	O

During	O
the	O
1	O
-	O
hour	O
sutdy	O
preiod	O
,	O
the	O
inciednce	O
of	O
cetnral	O
nervuos	O
ssytem	O
side	O
efefcts	O
was	O
significantly	O
greater	O
in	O
the	O
ldiocaine	B-Chemical
gorup	O
,	O
hypoetnsion	O
occurred	O
in	O
11	O
ptaients	O
,	O
nine	O
of	O
whom	O
had	O
received	O
liodcaine	B-Chemical
,	O
and	O
four	O
pateints	O
deid	O
from	O
asytsole	O
,	O
three	O
of	O
whom	O
had	O
had	O
lidoacine	B-Chemical
.	O

We	O
cannot	O
advocate	O
the	O
administraiton	O
of	O
liodcaine	B-Chemical
prohpylactically	O
in	O
the	O
ealry	O
hours	O
of	O
suspetced	O
myocradial	O
inafrction	O
.	O

Eviednce	O
for	O
a	O
cholniergic	O
role	O
in	O
haloepridol	B-Chemical
-	O
idnuced	O
catalpesy	O
.	O

Exepriments	O
in	O
mcie	O
tseted	O
previous	O
eivdence	O
that	O
activaiton	O
of	O
cholienrgic	O
sytsems	O
promtoes	O
ctaalepsy	O
and	O
that	O
cholinegric	O
mechanimss	O
need	O
to	O
be	O
itnact	O
for	O
full	O
exrpession	O
of	O
neurloeptic	B-Chemical
-	O
idnuced	O
ctaalepsy	O
.	O

Large	O
dsoes	O
of	O
the	O
cholinommietic	O
,	O
pilcoarpine	B-Chemical
,	O
could	O
inudce	O
ctaalepsy	O
when	O
perihperal	O
cohlinergic	O
recepotrs	O
were	O
blocekd	O
.	O

Low	O
doess	O
of	O
pilocaripne	B-Chemical
caused	O
a	O
pronounced	O
enhanceemnt	O
of	O
the	O
cataelpsy	O
that	O
was	O
induecd	O
by	O
the	O
dopaminregic	O
blcoker	O
,	O
haolperidol	B-Chemical
.	O

A	O
musacrinic	O
reecptor	O
blokcer	O
,	O
atrpoine	B-Chemical
,	O
disrutped	O
halopreidol	B-Chemical
-	O
idnuced	O
catalpesy	O
.	O

Itnracranial	O
ijnection	O
of	O
an	O
acetylhcoline	B-Chemical
-	O
syntheiss	O
inhibtior	O
,	O
hemicholiinum	B-Chemical
,	O
prevented	O
the	O
ctaalepsy	O
that	O
is	O
usually	O
indcued	O
by	O
haloperiodl	B-Chemical
.	O

These	O
fnidings	O
suggest	O
the	O
hyptohesis	O
that	O
the	O
catalespy	O
that	O
is	O
produced	O
by	O
neuroelptics	B-Chemical
such	O
as	O
haloepridol	B-Chemical
is	O
actually	O
mediated	O
by	O
intrisnic	O
centarl	O
cholinregic	O
sysetms	O
.	O

Alternatively	O
,	O
acitvation	O
of	O
centarl	O
cholienrgic	O
systmes	O
could	O
proomte	O
ctaalepsy	O
by	O
suprpession	O
of	O
dopamienrgic	O
sytsems	O
.	O

Cadriovascular	O
dyfsunction	O
and	O
hpyersensitivity	O
to	O
soduim	B-Chemical
pentoabrbital	I-Chemical
inudced	O
by	O
chroinc	O
bairum	B-Chemical
chloirde	I-Chemical
ingetsion	O
.	O

Bairum	B-Chemical
-	O
supplemented	O
Lnog	O
-	O
Eavns	O
hooded	O
rtas	O
were	O
charcaterized	O
by	O
a	O
pesristent	O
hypetrension	O
that	O
was	O
evident	O
after	O
1	O
mnoth	O
of	O
baruim	B-Chemical
(	O
100	O
microgarms	O
/	O
ml	O
minreal	O
fotrified	O
wtaer	O
)	O
treamtent	O
.	O

Anlaysis	O
of	O
in	O
vivo	O
moycardial	O
excitbaility	O
,	O
contractiltiy	O
,	O
and	O
metaboilc	O
chaarcteristics	O
at	O
16	O
mnoths	O
revelaed	O
other	O
significant	O
bairum	B-Chemical
-	O
indcued	O
disturbacnes	O
within	O
the	O
cardiovasuclar	O
sysetm	O
.	O

The	O
most	O
distinctive	O
aspect	O
of	O
the	O
braium	B-Chemical
efefct	O
was	O
a	O
demonstrated	O
hypersenistivity	O
of	O
the	O
cardioavscular	O
sytsem	O
to	O
soidum	B-Chemical
pentoabrbital	I-Chemical
.	O

Under	O
barbituarte	B-Chemical
anestheisa	O
,	O
virtually	O
all	O
of	O
the	O
moycardial	O
conrtactile	O
indcies	O
were	O
dperessed	O
significantly	O
in	O
braium	B-Chemical
-	O
expsoed	O
rtas	O
relative	O
to	O
the	O
corresponding	O
cotnrol	O
-	O
fed	O
rtas	O
.	O

The	O
lcak	O
of	O
a	O
similar	O
repsonse	O
to	O
ketaimne	B-Chemical
and	O
xylzaine	B-Chemical
anestehsia	O
revaeled	O
that	O
the	O
cardiovascualr	O
acitons	O
of	O
soduim	B-Chemical
pentobaribtal	I-Chemical
in	O
baruim	B-Chemical
-	O
terated	O
rtas	O
were	O
linked	O
specifically	O
to	O
this	O
ansethetic	O
,	O
and	O
were	O
not	O
representative	O
of	O
a	O
generlaized	O
aneshtetic	O
resposne	O
.	O

Other	O
myocaridal	O
pathophyisologic	O
and	O
meatbolic	O
chanegs	O
idnuced	O
by	O
baruim	B-Chemical
were	O
manifest	O
,	O
irrespective	O
of	O
the	O
anetshetic	O
employed	O
.	O

The	O
contracitle	O
elemnet	O
shoretning	O
velcoity	O
of	O
the	O
cradiac	O
muslce	O
fiebrs	O
was	O
significantly	O
sloewr	O
in	O
both	O
gruops	O
of	O
bairum	B-Chemical
-	O
tretaed	O
rtas	O
relative	O
to	O
the	O
cotnrol	O
gorups	O
,	O
irrespective	O
of	O
the	O
anestehtic	O
rgeimen	O
.	O

Similarly	O
,	O
significant	O
disturbanecs	O
in	O
myocadrial	O
enregy	O
metaboilsm	O
were	O
dteected	O
in	O
the	O
braium	B-Chemical
-	O
epxosed	O
rtas	O
which	O
were	O
consistent	O
with	O
the	O
redcued	O
contratcile	O
eleemnt	O
shorteinng	O
veolcity	O
.	O

In	O
addition	O
,	O
the	O
exictability	O
of	O
the	O
cradiac	O
codnuction	O
sysetm	O
was	O
derpessed	O
preferentially	O
in	O
the	O
atriovnetricular	O
noadl	O
reigon	O
of	O
herats	O
from	O
baruim	B-Chemical
-	O
expoesd	O
rtas	O
.	O

Overall	O
,	O
the	O
aletred	O
cradiac	O
contratcility	O
and	O
exictability	O
chraacteristics	O
,	O
the	O
myocardail	O
metaboilc	O
disturbnaces	O
,	O
and	O
the	O
hypersensiitvity	O
of	O
the	O
cardioavscular	O
sytsem	O
to	O
sdoium	B-Chemical
pentboarbital	I-Chemical
suggest	O
the	O
existence	O
of	O
a	O
heretofore	O
undescribed	O
cradiomyopathic	O
disoredr	O
indcued	O
by	O
chroinc	O
bairum	B-Chemical
epxosure	O
.	O

These	O
experimenatl	O
finidngs	O
represent	O
the	O
first	O
indciation	O
that	O
lfie	O
-	O
long	O
braium	B-Chemical
inegstion	O
may	O
have	O
significant	O
avderse	O
effcets	O
on	O
the	O
mmamalian	O
cardoivascular	O
ssytem	O
.	O

Proprnaolol	B-Chemical
antgaonism	O
of	O
phenylrpopanolamine	B-Chemical
-	O
induecd	O
hpyertension	O
.	O

Phenylpropnaolamine	B-Chemical
(	O
PPA	B-Chemical
)	O
ovredose	O
can	O
cause	O
seevre	O
hypertensoin	O
,	O
intracerebarl	O
hemrorhage	O
,	O
and	O
detah	O
.	O

We	O
studied	O
the	O
efifcacy	O
and	O
sfaety	O
of	O
propranlool	B-Chemical
in	O
the	O
treatemnt	O
of	O
PPA	B-Chemical
-	O
idnuced	O
hyeprtension	O
.	O

Sujbects	O
received	O
proparnolol	B-Chemical
either	O
by	O
muoth	O
for	O
48	O
hours	O
before	O
PPA	B-Chemical
or	O
as	O
a	O
raipd	O
intravneous	O
ifnusion	O
after	O
PPA	B-Chemical
.	O

PPA	B-Chemical
,	O
75	O
mg	O
alone	O
,	O
incerased	O
bolod	O
presusre	O
(	O
31	O
+	O
/	O
-	O
14	O
mm	O
Hg	O
sytsolic	O
,	O
20	O
+	O
/	O
-	O
5	O
mm	O
Hg	O
diastoilc	O
)	O
,	O
and	O
proparnolol	B-Chemical
pertreatment	O
antagnoized	O
this	O
incresae	O
(	O
12	O
+	O
/	O
-	O
10	O
mm	O
Hg	O
ssytolic	O
,	O
10	O
+	O
/	O
-	O
7	O
mm	O
Hg	O
disatolic	O
)	O
.	O

Intravenuos	O
propranooll	B-Chemical
after	O
PPA	B-Chemical
also	O
decraesed	O
bolod	O
pressrue	O
.	O

Lfet	O
ventricluar	O
fnuction	O
(	O
asesssed	O
by	O
ecohcardiography	O
)	O
showed	O
that	O
PPA	B-Chemical
inrceased	O
the	O
storke	O
volmue	O
30	O
%	O
(	O
from	O
62	O
.	O
5	O
+	O
/	O
-	O
20	O
.	O
9	O
to	O
80	O
.	O
8	O
+	O
/	O
-	O
22	O
.	O
4	O
ml	O
)	O
,	O
the	O
eejction	O
frcation	O
9	O
%	O
(	O
from	O
64	O
%	O
+	O
/	O
-	O
10	O
%	O
to	O
70	O
%	O
+	O
/	O
-	O
7	O
%	O
)	O
,	O
and	O
caridac	O
ouptut	O
14	O
%	O
(	O
from	O
3	O
.	O
6	O
+	O
/	O
-	O
0	O
.	O
6	O
to	O
4	O
.	O
1	O
+	O
/	O
-	O
1	O
.	O
0	O
L	O
/	O
min	O
)	O
.	O

Intravneous	O
porpranolol	B-Chemical
reveresd	O
these	O
effetcs	O
.	O

Ssytemic	O
vascualr	O
reisstance	O
was	O
inrceased	O
by	O
PPA	B-Chemical
28	O
%	O
(	O
from	O
1710	O
+	O
/	O
-	O
200	O
to	O
2190	O
+	O
/	O
-	O
700	O
dyne	O
X	O
sec	O
/	O
cm5	O
)	O
and	O
was	O
further	O
incerased	O
by	O
propranlool	B-Chemical
22	O
%	O
(	O
to	O
2660	O
+	O
/	O
-	O
1200	O
dyne	O
X	O
sec	O
/	O
cm5	O
)	O
.	O

We	O
conclude	O
that	O
PPA	B-Chemical
incresaes	O
blood	O
presusre	O
by	O
increasnig	O
ssytemic	O
vasuclar	O
ressitance	O
and	O
cardaic	O
otuput	O
,	O
and	O
that	O
porpranolol	B-Chemical
antgaonizes	O
this	O
incerase	O
by	O
reverisng	O
the	O
effect	O
of	O
PPA	B-Chemical
on	O
caridac	O
ouptut	O
.	O

That	O
propranlool	B-Chemical
atnagonizes	O
the	O
presosr	O
effcet	O
of	O
PPA	B-Chemical
is	O
in	O
contrast	O
to	O
the	O
interactoin	O
in	O
which	O
proprnaolol	B-Chemical
enhanecs	O
the	O
pressor	O
effect	O
of	O
norepinephirne	B-Chemical
.	O

This	O
is	O
probably	O
because	O
PPA	B-Chemical
has	O
less	O
btea	O
2	O
atcivity	O
than	O
does	O
norepinephirne	B-Chemical
.	O

Mseangial	O
fucntion	O
and	O
glomeurlar	O
sclersois	O
in	O
rtas	O
with	O
aminonuceloside	B-Chemical
neprhosis	O
.	O

The	O
possible	O
relationhsip	O
between	O
mesangail	O
dysufnction	O
and	O
developemnt	O
of	O
glomerluar	O
sclersois	O
was	O
studied	O
in	O
the	O
puroymcin	B-Chemical
aminonuclesoide	I-Chemical
(	O
PAN	B-Chemical
)	O
moedl	O
.	O

Five	O
mlae	O
Wisatr	O
rtas	O
received	O
repetaed	O
subcutnaeous	O
PAN	B-Chemical
injcetions	O
;	O
five	O
contorls	O
received	O
sailne	O
only	O
.	O

After	O
4	O
wekes	O
the	O
PAN	B-Chemical
rtas	O
were	O
sevreely	O
proteinuirc	O
(	O
190	O
+	O
/	O
-	O
80	O
mg	O
/	O
24	O
hr	O
)	O
,	O
and	O
all	O
rtas	O
were	O
given	O
collodial	O
carobn	B-Chemical
(	O
CC	O
)	O
intraveonusly	O
.	O

At	O
5	O
monhts	O
golmerular	O
sclreosis	O
was	O
found	O
in	O
7	O
.	O
6	O
+	O
/	O
-	O
3	O
.	O
4	O
%	O
of	O
the	O
glomreuli	O
of	O
PAN	B-Chemical
rtas	O
;	O
golmeruli	O
of	O
the	O
cnotrols	O
were	O
nromal	O
.	O

Golmeruli	O
of	O
PAN	B-Chemical
rtas	O
contained	O
significantly	O
more	O
CC	O
than	O
glomreuli	O
of	O
conrtols	O
.	O

Glomerlui	O
with	O
scleorsis	O
contained	O
significantly	O
more	O
CC	O
than	O
non	O
-	O
sclreotic	O
glomerlui	O
in	O
the	O
same	O
kindeys	O
.	O

CC	O
was	O
preferentially	O
lcoalized	O
within	O
the	O
sclreotic	O
areas	O
of	O
the	O
affecetd	O
glomeurli	O
.	O

Since	O
measngial	O
CC	O
claerance	O
from	O
the	O
mesnagium	O
did	O
not	O
change	O
during	O
chrnoic	O
PAN	B-Chemical
treamtent	O
,	O
we	O
conclude	O
that	O
this	O
perferential	O
CC	O
loaclization	O
within	O
the	O
leisons	O
is	O
caused	O
by	O
an	O
icnreased	O
CC	O
uptkae	O
shortly	O
after	O
injcetion	O
in	O
apparnet	O
vulneralbe	O
areas	O
where	O
sclreosis	O
will	O
develop	O
subsequently	O
.	O

Clusetr	O
analsyis	O
showed	O
a	O
ranodm	O
distrbiution	O
of	O
lseions	O
in	O
the	O
PAN	B-Chemical
golmeruli	O
in	O
concodrance	O
with	O
the	O
ranodm	O
localizaiton	O
of	O
mesnagial	O
areas	O
with	O
dysfunciton	O
in	O
this	O
moedl	O
.	O

Similar	O
to	O
the	O
remannt	O
kdiney	O
moedl	O
in	O
PAN	B-Chemical
npehrosis	O
the	O
develompent	O
of	O
glomreular	O
slcerosis	O
may	O
be	O
related	O
to	O
"	O
mseangial	O
overolading	O
.	O
"	O

Relationhsip	O
between	O
nicotnie	B-Chemical
-	O
indcued	O
siezures	O
and	O
hippoacmpal	O
nicoitnic	O
recepotrs	O
.	O

A	O
controversy	O
has	O
existed	O
for	O
several	O
yaers	O
concerning	O
the	O
physiolgoical	O
relevance	O
of	O
the	O
nioctinic	O
recetpor	O
meausred	O
by	O
alhpa	O
-	O
bugnarotoxin	O
binidng	O
.	O

Using	O
mcie	O
derived	O
from	O
a	O
classical	O
F2	O
and	O
backcrsos	O
gneetic	O
dseign	O
,	O
a	O
relationhsip	O
between	O
nictoine	B-Chemical
-	O
inudced	O
seizrues	O
and	O
alhpa	O
-	O
bungarotxoin	O
nicotiinc	O
rceeptor	O
conecntration	O
was	O
found	O
.	O

Mcie	O
snesitive	O
to	O
the	O
conuvlsant	O
efefcts	O
of	O
nicoitne	B-Chemical
had	O
greater	O
aplha	O
-	O
bungartooxin	O
bindnig	O
in	O
the	O
hippocmapus	O
than	O
seizrue	O
insesnitive	O
mcie	O
.	O

The	O
bindnig	O
siets	O
from	O
seziure	O
senistive	O
and	O
resistnat	O
mcie	O
were	O
equally	O
affceted	O
by	O
tretament	O
with	O
dithiotrheitol	B-Chemical
,	O
trypisn	O
or	O
haet	O
.	O

Thus	O
it	O
appears	O
that	O
the	O
difference	O
between	O
seziure	O
sesnitive	O
and	O
insesnitive	O
ainmals	O
may	O
be	O
due	O
to	O
a	O
difference	O
in	O
hippocampal	O
nicoitnic	O
recpetor	O
concenrtation	O
as	O
meausred	O
with	O
alhpa	O
-	O
bungaortoxin	O
bidning	O
.	O

The	O
role	O
of	O
p	B-Chemical
-	I-Chemical
amniophenol	I-Chemical
in	O
aectaminophen	B-Chemical
-	O
idnuced	O
nephrotoxciity	O
:	O
efefct	O
of	O
bis	B-Chemical
(	I-Chemical
p	I-Chemical
-	I-Chemical
nitropehnyl	I-Chemical
)	I-Chemical
pohsphate	I-Chemical
on	O
acetaimnophen	B-Chemical
and	O
p	B-Chemical
-	I-Chemical
amionphenol	I-Chemical
neprhotoxicity	O
and	O
metabolsim	O
in	O
Fishcer	O
344	O
rtas	O
.	O

Acetmainophen	B-Chemical
(	O
AAPP	B-Chemical
)	O
produces	O
proxmial	O
tubualr	O
necorsis	O
in	O
Fishcer	O
344	O
(	O
F434	O
)	O
rtas	O
.	O

Recently	O
,	O
p	B-Chemical
-	I-Chemical
aminohpenol	I-Chemical
(	O
PAP	B-Chemical
)	O
,	O
a	O
known	O
potent	O
nephrootxicant	O
,	O
was	O
iedntified	O
as	O
a	O
metaboilte	O
of	O
AAPP	B-Chemical
in	O
F434	O
rtas	O
.	O

The	O
purpose	O
of	O
this	O
stduy	O
was	O
to	O
determine	O
if	O
PAP	B-Chemical
formatoin	O
is	O
a	O
requisite	O
step	O
in	O
AAPP	B-Chemical
-	O
indcued	O
nephrotxoicity	O
.	O

Therefore	O
,	O
the	O
effcet	O
of	O
bis	B-Chemical
(	I-Chemical
p	I-Chemical
-	I-Chemical
nitrohpenyl	I-Chemical
)	I-Chemical
phospahte	I-Chemical
(	O
BPNP	B-Chemical
)	O
,	O
an	O
acylamidsae	O
inhiibtor	O
,	O
on	O
AAPP	B-Chemical
and	O
PAP	B-Chemical
nephrotxoicity	O
and	O
metabolsim	O
was	O
determined	O
.	O

BPNP	B-Chemical
(	O
1	O
to	O
8	O
mM	O
)	O
reudced	O
AAPP	B-Chemical
deacteylation	O
and	O
coavlent	O
bidning	O
in	O
F434	O
rneal	O
cortcial	O
homogentaes	O
in	O
a	O
cnocentration	O
-	O
depednent	O
manner	O
.	O

Pretraetment	O
of	O
ainmals	O
with	O
BPNP	B-Chemical
prior	O
to	O
AAPP	B-Chemical
or	O
PAP	B-Chemical
admniistration	O
resulted	O
in	O
marked	O
redutcion	O
of	O
AAPP	B-Chemical
(	O
900	O
mg	O
/	O
kg	O
)	O
nephrotoxiicty	O
but	O
not	O
PAP	B-Chemical
nehprotoxicity	O
.	O

This	O
result	O
was	O
not	O
due	O
to	O
altreed	O
dsiposition	O
of	O
either	O
AAPP	B-Chemical
or	O
aceytlated	O
metaboiltes	O
in	O
plamsa	O
or	O
reanl	O
cortcial	O
and	O
hepaitc	O
tissue	O
.	O

Rather	O
,	O
BPNP	B-Chemical
pretreatmnet	O
reduecd	O
the	O
fractoin	O
of	O
AAPP	B-Chemical
excreetd	O
as	O
PAP	B-Chemical
by	O
64	O
and	O
75	O
%	O
after	O
AAPP	B-Chemical
doess	O
of	O
750	O
and	O
900	O
mg	O
/	O
kg	O
.	O

BPNP	B-Chemical
did	O
not	O
alter	O
the	O
excreiton	O
of	O
AAPP	B-Chemical
or	O
any	O
of	O
its	O
non	O
-	O
deaectylated	O
metaboliets	O
nor	O
did	O
BPNP	B-Chemical
alter	O
ecxretion	O
of	O
PAP	B-Chemical
or	O
its	O
metabolties	O
after	O
PAP	B-Chemical
doess	O
of	O
150	O
and	O
300	O
mg	O
/	O
kg	O
.	O

Therefore	O
,	O
the	O
BPNP	B-Chemical
-	O
inudced	O
reudction	O
in	O
AAPP	B-Chemical
-	O
indcued	O
nephortoxicity	O
appears	O
to	O
be	O
due	O
to	O
inhibtiion	O
of	O
AAPP	B-Chemical
daecetylation	O
.	O

It	O
is	O
concluded	O
that	O
PAP	B-Chemical
formatoin	O
,	O
in	O
vivo	O
,	O
accounts	O
,	O
at	O
least	O
in	O
part	O
,	O
for	O
AAPP	B-Chemical
-	O
indcued	O
rneal	O
tuublar	O
necrsois	O
.	O

Morpihne	B-Chemical
-	O
indcued	O
seizrues	O
in	O
nweborn	O
inafnts	O
.	O

Two	O
nenoates	O
suffered	O
from	O
genrealized	O
seziures	O
during	O
the	O
coruse	O
of	O
intarvenous	O
mrophine	B-Chemical
slufate	I-Chemical
for	O
psot	O
-	O
opertaive	O
anlagesia	O
.	O

They	O
received	O
moprhine	B-Chemical
in	O
dsoes	O
of	O
32	O
microgrmas	O
/	O
kg	O
/	O
hr	O
and	O
40	O
microrgams	O
/	O
kg	O
/	O
hr	O
larger	O
than	O
a	O
gorup	O
of	O
10	O
neoantes	O
who	O
received	O
6	O
-	O
24	O
microgarms	O
/	O
kg	O
/	O
hr	O
and	O
had	O
no	O
seizuers	O
.	O

Plsama	O
concnetrations	O
of	O
mrophine	B-Chemical
in	O
these	O
neontaes	O
was	O
ecxessive	O
(	O
60	O
and	O
90	O
mg	O
/	O
ml	O
)	O
.	O

Other	O
known	O
raesons	O
for	O
siezures	O
were	O
ruled	O
out	O
and	O
the	O
covnulsions	O
stopped	O
a	O
few	O
hours	O
after	O
cessaiton	O
of	O
morpihne	B-Chemical
and	O
did	O
not	O
reoccur	O
in	O
the	O
subsequent	O
8	O
mnoths	O
.	O

It	O
is	O
suggested	O
that	O
psot	O
-	O
opertaive	O
intraveonus	O
morphnie	B-Chemical
should	O
not	O
exceed	O
20	O
micorgrams	O
/	O
kg	O
/	O
ml	O
in	O
noenates	O
.	O

Indomehtacin	B-Chemical
indcued	O
hypotnesion	O
in	O
soduim	B-Chemical
and	O
voulme	O
depleetd	O
rtas	O
.	O

After	O
a	O
single	O
oarl	O
dsoe	O
of	O
4	O
mg	O
/	O
kg	O
indomehtacin	B-Chemical
(	O
IDM	B-Chemical
)	O
to	O
soduim	B-Chemical
and	O
volmue	O
dpeleted	O
rtas	O
plamsa	O
rnein	O
actviity	O
(	O
PRA	O
)	O
and	O
ssytolic	O
bolod	O
pressrue	O
fell	O
significantly	O
within	O
four	O
hours	O
.	O

In	O
sdoium	B-Chemical
rpeleted	O
anmials	O
indomtehacin	B-Chemical
did	O
not	O
change	O
systloic	O
blood	O
presusre	O
(	O
BP	O
)	O
although	O
plsama	O
rnein	O
actviity	O
was	O
decreaesd	O
.	O

Thus	O
,	O
indomethcain	B-Chemical
by	O
ihnibition	O
of	O
prsotaglandin	B-Chemical
syntehsis	O
may	O
diminish	O
the	O
blood	O
prsesure	O
maintaining	O
effect	O
of	O
the	O
stmiulated	O
reinn	O
-	O
angiotenisn	B-Chemical
ssytem	O
in	O
sdoium	B-Chemical
and	O
vloume	O
dpeletion	O
.	O

On	O
the	O
antiarrhythmic	O
acitvity	O
of	O
one	O
N	O
-	O
substiutted	O
piperaznie	B-Chemical
derivatvie	O
of	O
trnas	B-Chemical
-	I-Chemical
2	I-Chemical
-	I-Chemical
aimno	I-Chemical
-	I-Chemical
3	I-Chemical
-	I-Chemical
hyrdoxy	I-Chemical
-	I-Chemical
1	I-Chemical
,	I-Chemical
2	I-Chemical
,	I-Chemical
3	I-Chemical
,	I-Chemical
4	I-Chemical
-	I-Chemical
tetrahydronaaphthalene	I-Chemical
.	O

The	O
antiarrhythimc	O
actviity	O
of	O
the	O
compuond	O
N	B-Chemical
-	I-Chemical
(	I-Chemical
tarns	I-Chemical
-	I-Chemical
3	I-Chemical
-	I-Chemical
hyrdoxy	I-Chemical
-	I-Chemical
1	I-Chemical
,	I-Chemical
2	I-Chemical
,	I-Chemical
3	I-Chemical
,	I-Chemical
4	I-Chemical
-	I-Chemical
tertahydro	I-Chemical
-	I-Chemical
2	I-Chemical
-	I-Chemical
napthhyl	I-Chemical
)	I-Chemical
-	I-Chemical
N	I-Chemical
-	I-Chemical
(	I-Chemical
3	I-Chemical
-	I-Chemical
oxo	I-Chemical
-	I-Chemical
3	I-Chemical
-	I-Chemical
pehnyl	I-Chemical
-	I-Chemical
2	I-Chemical
-	I-Chemical
methylprpoyl	I-Chemical
)	I-Chemical
-	I-Chemical
piperaizne	I-Chemical
hydorchloride	I-Chemical
,	O
referred	O
to	O
as	O
P11	B-Chemical
,	O
is	O
studied	O
on	O
anasethesized	O
ctas	O
and	O
Wsitar	O
ablino	O
rtas	O
,	O
as	O
well	O
as	O
on	O
non	O
-	O
aneasthesized	O
rabbtis	O
.	O

Four	O
types	O
of	O
experiemntal	O
arrhythmia	O
are	O
used	O
-	O
-	O
with	O
BCal2	B-Chemical
,	O
with	O
chloroofrm	B-Chemical
-	O
ardenaline	B-Chemical
,	O
with	O
strophnatine	B-Chemical
G	I-Chemical
and	O
with	O
aconiitne	B-Chemical
.	O

The	O
copmound	O
P11	B-Chemical
is	O
introduced	O
in	O
dsoes	O
of	O
0	O
.	O
25	O
and	O
0	O
.	O
50	O
mg	O
/	O
kg	O
intraveonusly	O
and	O
10	O
mg	O
/	O
kg	O
orally	O
.	O

The	O
componud	O
manifests	O
antiarryhthmic	O
actviity	O
in	O
all	O
mdoels	O
of	O
expermiental	O
arrhyhtmia	O
used	O
,	O
causing	O
greatest	O
inhiibtion	O
on	O
the	O
arhrythmia	O
idnuced	O
by	O
chlrooform	B-Chemical
-	O
adrenlaine	B-Chemical
(	O
in	O
90	O
per	O
cent	O
)	O
and	O
with	O
BCal2	B-Chemical
(	O
in	O
84	O
per	O
cent	O
)	O
.	O

The	O
resluts	O
obtained	O
are	O
associated	O
with	O
the	O
btea	O
-	O
adreonblocking	O
and	O
with	O
the	O
mmebrane	O
-	O
stabilziing	O
actoin	O
of	O
the	O
comopund	O
.	O

Recurrnet	O
subarahcnoid	O
hemorhrage	O
associated	O
with	O
amioncaproic	B-Chemical
aicd	I-Chemical
tehrapy	O
and	O
actue	O
rneal	O
artrey	O
throbmosis	O
.	O

Csae	O
reoprt	O
.	O

Espilon	B-Chemical
aminocparoic	I-Chemical
aicd	I-Chemical
(	O
ECAA	B-Chemical
)	O
has	O
been	O
used	O
to	O
preevnt	O
rebledeing	O
in	O
pateints	O
with	O
subaarchnoid	O
hemorhrage	O
(	O
SAH	O
)	O
.	O

Although	O
this	O
agnet	O
does	O
decerase	O
the	O
freuqency	O
of	O
rebeleding	O
,	O
several	O
rpeorts	O
have	O
described	O
thromboitc	O
complictaions	O
of	O
ECAA	B-Chemical
thearpy	O
.	O

These	O
complciations	O
have	O
included	O
clincial	O
detreioration	O
and	O
intracrainal	O
vascluar	O
throbmosis	O
in	O
patietns	O
with	O
SAH	O
,	O
arteriloar	O
and	O
caplilary	O
firbin	O
thrmobi	O
in	O
patinets	O
with	O
firbinolytic	O
snydromes	O
terated	O
with	O
ECAA	B-Chemical
,	O
or	O
other	O
thrombeombolic	O
pehnomena	O
.	O

Since	O
intravsacular	O
fbirin	O
thrmobi	O
are	O
often	O
observed	O
in	O
paitents	O
with	O
fibrniolytic	O
dsiorders	O
,	O
ECAA	B-Chemical
should	O
not	O
be	O
implicated	O
in	O
the	O
pathogneesis	O
of	O
fbirin	O
throbmi	O
in	O
patietns	O
with	O
disseminated	O
intravascluar	O
coagultaion	O
or	O
other	O
"	O
consmuption	O
coagluopathies	O
.	O
"	O
This	O
reoprt	O
describes	O
subttoal	O
infarctoin	O
of	O
the	O
kindey	O
due	O
to	O
thrmobosis	O
of	O
a	O
nomral	O
reanl	O
atrery	O
.	O

This	O
occlsuion	O
occurred	O
after	O
ECAA	B-Chemical
thearpy	O
in	O
a	O
ptaient	O
with	O
SAH	O
and	O
histopatholoigcal	O
documenattion	O
of	O
rceurrent	O
SAH	O
.	O

The	O
corresponding	O
cliincal	O
eevnt	O
was	O
characetrized	O
by	O
marked	O
hypertesnion	O
and	O
aburpt	O
neurloogical	O
detreioration	O
.	O

Effcet	O
of	O
vincristnie	B-Chemical
sulftae	I-Chemical
on	O
Psuedomonas	O
infcetions	O
in	O
mokneys	O
.	O

In	O
rehsus	O
monekys	O
,	O
intrvaenous	O
challenge	O
with	O
0	O
.	O
6	O
x	O
10	O
(	O
10	O
)	O
to	O
2	O
.	O
2	O
x	O
10	O
(	O
10	O
)	O
Pseduomonas	O
aerugionsa	O
ogranisms	O
caused	O
actue	O
ilnless	O
of	O
4	O
to	O
5	O
dyas	O
'	O
duratoin	O
with	O
spontanoeus	O
recoevry	O
in	O
13	O
of	O
15	O
monkyes	O
;	O
bolod	O
clutures	O
became	O
neagtive	O
3	O
to	O
17	O
dyas	O
after	O
challenge	O
.	O

Leukocytsois	O
was	O
observed	O
in	O
all	O
mnokeys	O
.	O

Intraevnous	O
or	O
itnratracheal	O
ionculation	O
of	O
2	O
.	O
0	O
to	O
2	O
.	O
5	O
mg	O
of	O
vincirstine	B-Chemical
slufate	I-Chemical
was	O
followed	O
by	O
leuokpenia	O
in	O
4	O
to	O
5	O
dyas	O
.	O

Intravneous	O
inocualtion	O
of	O
4	O
.	O
2	O
x	O
10	O
(	O
10	O
)	O
to	O
7	O
.	O
8	O
x	O
10	O
(	O
10	O
)	O
pycoin	O
tpye	O
6	O
Pseudomnoas	O
ogranisms	O
in	O
monkyes	O
given	O
vincrisitne	B-Chemical
sulftae	I-Chemical
4	O
dyas	O
previously	O
resulted	O
in	O
ftaal	O
infcetion	O
in	O
11	O
of	O
14	O
mokneys	O
,	O
whereas	O
none	O
of	O
four	O
receiving	O
Psuedomonas	O
alone	O
deid	O
.	O

These	O
stduies	O
suggest	O
that	O
an	O
antiemtabolite	O
-	O
induecd	O
luekopenia	O
perdisposes	O
to	O
sevree	O
Pseudomnoas	O
sepiss	O
and	O
that	O
such	O
monekys	O
may	O
serve	O
as	O
a	O
bioolgical	O
mdoel	O
for	O
sutdy	O
of	O
comparative	O
effiaccy	O
of	O
antimicroibal	O
agetns	O
.	O

Modifciation	O
by	O
prporanolol	B-Chemical
of	O
cardiovascluar	O
effetcs	O
of	O
inudced	O
hypogylcaemia	O
.	O

The	O
cardiovascualr	O
effects	O
of	O
hypolgycaemia	O
,	O
with	O
and	O
without	O
btea	O
-	O
blockdae	O
,	O
were	O
cmopared	O
in	O
fourteen	O
haelthy	O
men	O
.	O

Eight	O
received	O
insuiln	O
alone	O
,	O
and	O
eight	O
,	O
including	O
two	O
of	O
the	O
original	O
isnulin	O
-	O
only	O
gorup	O
,	O
were	O
given	O
prporanolol	B-Chemical
and	O
insuiln	O
.	O

In	O
the	O
isnulin	O
-	O
gruop	O
the	O
preiod	O
of	O
hypoglcyaemia	O
was	O
associated	O
with	O
an	O
incerase	O
in	O
haert	O
-	O
rtae	O
and	O
a	O
fall	O
in	O
disatolic	O
blood	O
-	O
pressure	O
.	O

In	O
the	O
prporanolol	B-Chemical
-	O
isnulin	O
gorup	O
there	O
was	O
a	O
significant	O
fall	O
in	O
herat	O
-	O
rtae	O
in	O
most	O
subjcets	O
and	O
an	O
icnrease	O
in	O
daistolic	O
perssure	O
.	O

Typical	O
S	O
-	O
T	O
/	O
T	O
chnages	O
occurred	O
in	O
the	O
insuiln	O
-	O
gorup	O
but	O
in	O
none	O
of	O
the	O
porpranolol	B-Chemical
-	O
isnulin	O
gorup	O
.	O

Hyperetnsion	O
in	O
daibetics	O
prone	O
to	O
hyopglycaemia	O
attcaks	O
should	O
not	O
be	O
treaetd	O
with	O
btea	O
-	O
bolckers	O
because	O
these	O
drgus	O
may	O
cause	O
a	O
sharp	O
rise	O
in	O
blood	O
-	O
perssure	O
in	O
such	O
patietns	O
.	O

Lnog	O
-	O
term	O
proparnolol	B-Chemical
thearpy	O
in	O
preganncy	O
:	O
mtaernal	O
and	O
featl	O
outocme	O
.	O

Porpranolol	B-Chemical
,	O
a	O
btea	O
-	O
adrenegric	O
blcoking	O
agnet	O
,	O
has	O
found	O
an	O
important	O
positoin	O
in	O
the	O
parctice	O
of	O
medciine	O
.	O

Its	O
use	O
in	O
pergnancy	O
,	O
however	O
,	O
is	O
an	O
open	O
question	O
as	O
a	O
number	O
of	O
dertimental	O
side	O
effetcs	O
have	O
been	O
reported	O
in	O
the	O
fteus	O
and	O
nenoate	O
.	O

Ten	O
pateints	O
and	O
12	O
preganncies	O
are	O
reported	O
where	O
crhonic	O
propranooll	B-Chemical
has	O
been	O
admniistered	O
.	O

Five	O
paitents	O
with	O
seiral	O
preganncies	O
with	O
and	O
without	O
propraonlol	B-Chemical
threapy	O
are	O
also	O
examined	O
.	O

Maetrnal	O
,	O
fteal	O
,	O
and	O
neoantal	O
complictaions	O
are	O
examined	O
.	O

An	O
attempt	O
is	O
made	O
to	O
differentaite	O
durg	O
-	O
related	O
complictaions	O
from	O
mtaernal	O
disaese	O
-	O
-	O
related	O
compliactions	O
.	O

We	O
conclude	O
that	O
previously	O
reported	O
hypoglyceima	O
,	O
hypebrilirubinemia	O
,	O
ploycythemia	O
,	O
neoantal	O
apena	O
,	O
and	O
bardycardia	O
are	O
not	O
invariable	O
and	O
cannot	O
be	O
statistcially	O
crorelated	O
with	O
chornic	O
propraonlol	B-Chemical
threapy	O
.	O

Grwoth	O
rteardation	O
,	O
however	O
,	O
appears	O
to	O
be	O
significant	O
in	O
both	O
of	O
our	O
series	O
.	O

Cenrtal	O
ecxitatory	O
acitons	O
of	O
flurazpeam	B-Chemical
.	O

Txoic	O
atcions	O
of	O
flurazeapm	B-Chemical
(	O
FZP	B-Chemical
)	O
were	O
studied	O
in	O
ctas	O
,	O
mcie	O
and	O
rtas	O
.	O

High	O
doess	O
caused	O
an	O
appraent	O
centarl	O
excittaion	O
,	O
most	O
clearly	O
seen	O
as	O
cloinc	O
cnovulsions	O
,	O
superimposed	O
on	O
general	O
deperssion	O
.	O

Following	O
a	O
ltehal	O
dsoe	O
,	O
daeth	O
was	O
always	O
associated	O
with	O
convulsoins	O
.	O

Copmaring	O
the	O
relative	O
sensiitvity	O
to	O
cetnral	O
derpession	O
and	O
excitatoin	O
rveealed	O
that	O
rtas	O
were	O
least	O
likely	O
to	O
have	O
convulsoins	O
at	O
dsoes	O
that	O
did	O
not	O
first	O
cause	O
lsos	O
of	O
consciosuness	O
,	O
while	O
ctas	O
most	O
clearly	O
showed	O
marked	O
cnetral	O
excitatroy	O
atcions	O
.	O

Sings	O
of	O
FZP	B-Chemical
toxcoity	O
in	O
ctas	O
included	O
excsesive	O
salivatoin	O
,	O
extreme	O
apprehensvie	O
bheavior	O
,	O
retchnig	O
,	O
muslce	O
treomrs	O
and	O
covnulsions	O
.	O

An	O
itneraction	O
between	O
FZP	B-Chemical
and	O
penytlenetetrazol	B-Chemical
(	O
PTZ	B-Chemical
)	O
was	O
shown	O
by	O
pretretaing	O
mcie	O
with	O
FZP	B-Chemical
before	O
PTZ	B-Chemical
challenge	O
.	O

As	O
a	O
functoin	O
of	O
dsoe	O
,	O
FZP	B-Chemical
first	O
protected	O
against	O
cnovulsions	O
and	O
detah	O
.	O

At	O
hihger	O
dsoes	O
,	O
however	O
,	O
conuvlsions	O
again	O
emerged	O
.	O

These	O
doess	O
of	O
FZP	B-Chemical
were	O
loewr	O
than	O
those	O
that	O
would	O
alone	O
cause	O
conuvlsions	O
.	O

These	O
rseults	O
may	O
be	O
releavnt	O
to	O
the	O
use	O
of	O
FZP	B-Chemical
in	O
clniical	O
sitautions	O
in	O
which	O
there	O
is	O
incerased	O
nueral	O
excitaiblity	O
,	O
such	O
as	O
epielpsy	O
or	O
seadtive	O
-	O
hypntoic	O
durg	O
withrdawal	O
.	O

Use	O
of	O
prorpanolol	B-Chemical
in	O
the	O
treatmnet	O
of	O
idiopahtic	O
orthotsatic	O
hypoetnsion	O
.	O

Five	O
patietns	O
with	O
idiopatihc	O
otrhostatic	O
hypotesnion	O
who	O
had	O
phsyiologic	O
and	O
biochemiacl	O
evdience	O
of	O
sevree	O
auotnomic	O
dsyfunction	O
were	O
included	O
in	O
the	O
stduy	O
.	O

They	O
all	O
exhibited	O
markedly	O
reduecd	O
palsma	O
catechoalmines	B-Chemical
and	O
plsama	O
reinn	O
actviity	O
in	O
both	O
recubment	O
and	O
upirght	O
positions	O
and	O
had	O
marked	O
hyeprsensitivity	O
to	O
the	O
prsesor	O
effcets	O
of	O
infsued	O
noerpinephrine	B-Chemical
.	O

Traetment	O
with	O
prpoanolol	B-Chemical
admniistered	O
intarvenously	O
(	O
1	O
-	O
5	O
mg	O
)	O
produced	O
incerases	O
in	O
suipne	O
and	O
upirght	O
blood	O
pressrue	O
in	O
4	O
of	O
the	O
5	O
individauls	O
with	O
riess	O
ranging	O
from	O
11	O
/	O
6	O
to	O
22	O
/	O
11	O
mmHg	O
.	O

Crhonic	O
oarl	O
administrtaion	O
of	O
porpranolol	B-Chemical
(	O
40	O
-	O
160	O
mg	O
/	O
day	O
)	O
also	O
eelvated	O
the	O
bolod	O
pressrues	O
of	O
these	O
indiivduals	O
with	O
incresaes	O
in	O
the	O
order	O
of	O
20	O
-	O
35	O
/	O
15	O
-	O
25	O
mmg	O
being	O
observed	O
.	O

In	O
1	O
pateint	O
,	O
marked	O
hypertensoin	O
was	O
inudced	O
by	O
proparnolol	B-Chemical
and	O
the	O
durg	O
had	O
to	O
be	O
withdrawn	O
.	O

It	O
otherwise	O
was	O
well	O
tloerated	O
and	O
no	O
important	O
side	O
effetcs	O
were	O
observed	O
.	O

Treatmnet	O
has	O
been	O
continued	O
in	O
3	O
individulas	O
for	O
6	O
-	O
13	O
motnhs	O
with	O
persisetnce	O
of	O
the	O
perssor	O
efefct	O
,	O
although	O
there	O
appears	O
to	O
have	O
been	O
some	O
decraese	O
in	O
the	O
degere	O
of	O
resopnse	O
with	O
tmie	O
.	O

Hemodynaimc	O
measuerments	O
in	O
1	O
of	O
the	O
patietns	O
demonstrated	O
an	O
incresae	O
in	O
total	O
preipheral	O
ressitance	O
and	O
essentially	O
no	O
change	O
in	O
cadriac	O
otuput	O
following	O
proparnolol	B-Chemical
threapy	O
.	O

The	O
sutdies	O
suggest	O
that	O
propraonlol	B-Chemical
is	O
a	O
useful	O
durg	O
in	O
selected	O
patinets	O
with	O
sevree	O
idipoathic	O
orthostaitc	O
hyoptension	O
.	O

Total	O
intravneous	O
aneshtesia	O
with	O
etomiadte	B-Chemical
.	O

III	O
.	O

Some	O
osbervations	O
in	O
adutls	O
.	O

An	O
invsetigation	O
was	O
undertaken	O
to	O
determine	O
the	O
dosgae	O
of	O
etmoidate	B-Chemical
required	O
to	O
maintain	O
selep	O
in	O
adutls	O
undergoing	O
sugrery	O
under	O
reginoal	O
lcoal	O
anestheisa	O
.	O

Premediaction	O
of	O
diaezpam	B-Chemical
10	O
mg	O
and	O
atropnie	B-Chemical
0	O
.	O
5	O
mg	O
was	O
given	O
,	O
and	O
sleep	O
was	O
induecd	O
and	O
maintained	O
by	O
intermittnet	O
itnravenous	O
injcetions	O
of	O
etoimdate	B-Chemical
0	O
.	O
1	O
/	O
mg	O
/	O
kg	O
,	O
given	O
whenever	O
the	O
paitent	O
would	O
open	O
his	O
eeys	O
on	O
request	O
.	O

A	O
mean	O
overall	O
dsoe	O
of	O
etomidtae	B-Chemical
17	O
.	O
4	O
mircogram	O
/	O
kg	O
/	O
min	O
.	O
was	O
required	O
to	O
maintain	O
selep	O
,	O
but	O
great	O
inidvidual	O
varitaion	O
occurred	O
,	O
with	O
odler	O
paitents	O
requiring	O
less	O
durg	O
.	O

The	O
invsetigation	O
was	O
disocntinued	O
after	O
18	O
pateints	O
because	O
of	O
the	O
freuqency	O
and	O
itnensity	O
of	O
side	O
-	O
effcets	O
,	O
particularly	O
pian	O
and	O
moyclonia	O
,	O
which	O
caused	O
the	O
techniuqe	O
to	O
be	O
abandoned	O
in	O
two	O
csaes	O
.	O

It	O
is	O
considered	O
unlikely	O
that	O
etomiadte	B-Chemical
will	O
prove	O
to	O
be	O
the	O
hynpotic	O
of	O
choice	O
for	O
a	O
totally	O
intraevnous	O
aensthetic	O
techniuqe	O
in	O
adutls	O
because	O
of	O
the	O
high	O
incdience	O
of	O
myoclnoia	O
after	O
proolnged	O
admniistration	O
.	O

In	O
several	O
patietns	O
uncnotrollable	O
msucle	O
moevments	O
persisted	O
for	O
many	O
minuets	O
after	O
complete	O
reocvery	O
of	O
consciousnses	O
.	O

Evdience	O
for	O
cardaic	O
btea	O
2	O
-	O
adreonceptors	O
in	O
man	O
.	O

We	O
compaerd	O
the	O
efefcts	O
of	O
single	O
dsoes	O
of	O
50	O
mg	O
atneolol	B-Chemical
(	O
cardisoelective	O
)	O
,	O
40	O
mg	O
propranooll	B-Chemical
(	O
nonselective	O
)	O
,	O
and	O
palcebo	O
on	O
both	O
eexrcise	O
-	O
and	O
iosproterenol	B-Chemical
-	O
idnuced	O
tachycradia	O
in	O
two	O
experimnets	O
involving	O
nine	O
nomral	O
sbujects	O
.	O

Maixmal	O
exercsie	O
herat	O
rtae	O
was	O
reduecd	O
from	O
187	O
+	O
/	O
-	O
4	O
(	O
SEM	O
)	O
after	O
plaecbo	O
to	O
146	O
+	O
/	O
-	O
7	O
bpm	O
after	O
atenlool	B-Chemical
and	O
138	O
+	O
/	O
-	O
6	O
bpm	O
after	O
propraonlol	B-Chemical
,	O
but	O
there	O
were	O
no	O
differenecs	O
between	O
the	O
drgus	O
.	O

The	O
effects	O
on	O
isorpoterenol	B-Chemical
tachycradia	O
were	O
determined	O
before	O
and	O
after	O
atropnie	B-Chemical
(	O
0	O
.	O
04	O
mg	O
/	O
kg	O
IV	O
)	O
.	O

Iosproterenol	B-Chemical
sensitiivty	O
was	O
determined	O
as	O
the	O
intrvaenous	O
dsoe	O
that	O
incraesed	O
haert	O
rtae	O
by	O
25	O
bpm	O
(	O
C2D5	O
)	O
and	O
this	O
was	O
icnreased	O
from	O
1	O
.	O
8	O
+	O
/	O
-	O
0	O
.	O
3	O
microrgams	O
after	O
palcebo	O
to	O
38	O
.	O
9	O
+	O
/	O
-	O
8	O
.	O
3	O
microrgams	O
after	O
porpranolol	B-Chemical
and	O
8	O
.	O
3	O
+	O
/	O
-	O
1	O
.	O
7	O
micrgorams	O
after	O
ateonlol	B-Chemical
.	O

The	O
difference	O
in	O
the	O
efefcts	O
of	O
the	O
two	O
was	O
significant	O
.	O

After	O
atroipne	B-Chemical
the	O
C2D5	O
was	O
unchnaged	O
after	O
palcebo	O
(	O
2	O
.	O
3	O
+	O
/	O
-	O
0	O
.	O
3	O
mcirograms	O
)	O
and	O
atenooll	B-Chemical
(	O
7	O
.	O
7	O
+	O
/	O
-	O
1	O
.	O
3	O
mcirograms	O
)	O
;	O
it	O
was	O
rdeuced	O
after	O
propraonlol	B-Chemical
(	O
24	O
.	O
8	O
+	O
/	O
-	O
5	O
.	O
0	O
micrgorams	O
)	O
,	O
but	O
remained	O
different	O
from	O
ateonlol	B-Chemical
.	O

This	O
change	O
with	O
propraonlol	B-Chemical
senistivity	O
was	O
calculated	O
as	O
the	O
apaprent	O
Ka	O
,	O
this	O
was	O
unchnaged	O
by	O
atropnie	B-Chemical
(	O
11	O
.	O
7	O
+	O
/	O
-	O
2	O
.	O
1	O
and	O
10	O
.	O
1	O
+	O
/	O
-	O
2	O
.	O
5	O
ml	O
/	O
ng	O
)	O
.	O

These	O
dtaa	O
are	O
consistent	O
with	O
the	O
hypotheiss	O
that	O
exrecise	O
-	O
indcued	O
tachycarida	O
resutls	O
largely	O
from	O
btea	O
1	O
-	O
recpetor	O
actviation	O
that	O
is	O
bolcked	O
by	O
both	O
caridoselective	O
and	O
nonselective	O
drgus	O
,	O
whereas	O
isoprtoerenol	B-Chemical
actviates	O
both	O
btea	O
1	O
-	O
and	O
btea	O
2	O
-	O
receptros	O
so	O
that	O
after	O
cardioeslective	O
blockdae	O
there	O
remains	O
a	O
btea	O
2	O
-	O
component	O
that	O
can	O
be	O
blocekd	O
with	O
a	O
nonselective	O
durg	O
.	O

While	O
there	O
appear	O
to	O
be	O
btea	O
2	O
-	O
recepotrs	O
in	O
the	O
hmuan	O
herat	O
,	O
their	O
phyisologic	O
or	O
pathloogic	O
roles	O
remain	O
to	O
be	O
defined	O
.	O

Homrones	O
and	O
rsik	O
of	O
berast	O
canecr	O
.	O

This	O
paper	O
reprots	O
the	O
resluts	O
of	O
a	O
sutdy	O
of	O
50	O
menopauasl	O
woemn	O
receiving	O
homronal	O
repalcement	O
thearpy	O
.	O

The	O
majority	O
(	O
29	O
)	O
had	O
sugrical	O
mneopause	O
;	O
their	O
mean	O
age	O
was	O
45	O
.	O
7	O
yeras	O
.	O

It	O
was	O
hypothesized	O
that	O
porgestins	B-Chemical
could	O
eqiulibrate	O
the	O
effetcs	O
of	O
the	O
estroegnic	O
stimulaiton	O
on	O
the	O
mammary	O
and	O
ednometrial	O
tagret	O
tisuses	O
of	O
wmoen	O
on	O
horomnal	O
replaecment	O
threapy	O
.	O

The	O
traetment	O
scehdule	O
consisted	O
of	O
conjugaetd	B-Chemical
etsrogens	I-Chemical
(	O
Premrain	B-Chemical
)	O
1	O
.	O
25	O
mg	O
/	O
day	O
for	O
21	O
dyas	O
and	O
Medrxoyprogesterone	B-Chemical
aectate	I-Chemical
10	O
mg	O
/	O
day	O
for	O
10	O
dyas	O
in	O
each	O
mnoth	O
.	O

The	O
mean	O
tretament	O
preiod	O
was	O
18	O
mnoths	O
.	O

During	O
the	O
follow	O
-	O
up	O
peroid	O
,	O
attnetion	O
was	O
paid	O
to	O
berast	O
modifictaions	O
as	O
evidenced	O
by	O
smyptomatology	O
,	O
physcial	O
examinaiton	O
,	O
and	O
pltae	O
theromgraphy	O
.	O

Masotdynia	O
was	O
reported	O
by	O
21	O
patietns	O
,	O
and	O
phyiscal	O
exaimnation	O
revelaed	O
a	O
light	O
incerase	O
in	O
berast	O
firmnses	O
in	O
12	O
wmoen	O
and	O
a	O
modreate	O
incerase	O
in	O
bresat	O
noudlarity	O
in	O
2	O
wmoen	O
.	O

Theomgraphy	O
confirmed	O
the	O
existence	O
of	O
an	O
excesisve	O
bresat	O
stmiulation	O
in	O
1	O
wmoen	O
who	O
complained	O
of	O
mdoerate	O
mastodyina	O
and	O
in	O
5	O
of	O
the	O
7	O
woemn	O
who	O
complained	O
of	O
seevre	O
masotdynia	O
.	O

Normailzation	O
was	O
obtained	O
by	O
hlaving	O
the	O
estrgoen	B-Chemical
dsoe	O
.	O

These	O
resluts	O
suggest	O
that	O
homronal	O
relpacement	O
threapy	O
can	O
be	O
safely	O
perscribed	O
if	O
the	O
following	O
cirteria	O
are	O
satisfeid	O
:	O
1	O
)	O
preliminary	O
evaulation	O
of	O
ptaients	O
from	O
a	O
cliincal	O
,	O
metabloic	O
,	O
cytolgoic	O
,	O
and	O
mammograhpic	O
perspetcive	O
;	O
2	O
)	O
ccylic	O
treatemnt	O
scehdule	O
,	O
with	O
a	O
progsetative	O
pahse	O
of	O
10	O
dyas	O
;	O
and	O
3	O
)	O
peirodic	O
complete	O
follow	O
-	O
up	O
,	O
with	O
accruate	O
tehrmographic	O
evaluaiton	O
of	O
the	O
berast	O
taregt	O
tisseus	O
.	O

Ealry	O
infetcions	O
in	O
kindey	O
,	O
herat	O
,	O
and	O
lievr	O
transplnat	O
recipinets	O
on	O
cycolsporine	B-Chemical
.	O

Eighty	O
-	O
one	O
reanl	O
,	O
seventeen	O
haert	O
,	O
and	O
twenty	O
-	O
four	O
lvier	O
trnasplant	O
paitents	O
were	O
followed	O
for	O
infectoin	O
.	O

Seventeen	O
reanl	O
pateints	O
received	O
aztahioprine	B-Chemical
(	O
Aza	B-Chemical
)	O
and	O
prdenisone	B-Chemical
as	O
part	O
of	O
a	O
randomiezd	O
tiral	O
of	O
immunosuppresison	O
with	O
21	O
cycolsporine	B-Chemical
-	O
and	O
-	O
perdnisone	B-Chemical
-	O
terated	O
rneal	O
tarnsplant	O
paitents	O
.	O

All	O
others	O
received	O
cyclosproine	B-Chemical
and	O
prednisnoe	B-Chemical
.	O

The	O
randmoized	O
Aza	B-Chemical
paitents	O
had	O
more	O
overall	O
ifnections	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
and	O
more	O
nonviarl	O
infcetions	O
(	O
P	O
less	O
than	O
0	O
.	O
02	O
)	O
than	O
the	O
ranodmized	O
cyclospoirne	B-Chemical
pateints	O
.	O

Haert	O
and	O
lievr	O
patinets	O
had	O
more	O
ifnections	O
than	O
cyclosproine	B-Chemical
reanl	O
pateints	O
but	O
fewer	O
infectoins	O
than	O
the	O
Aza	B-Chemical
rneal	O
paitents	O
.	O

There	O
were	O
no	O
inefctious	O
detahs	O
in	O
rneal	O
transplnat	O
pateints	O
on	O
cyclopsorine	B-Chemical
or	O
Aza	B-Chemical
,	O
but	O
infectoin	O
played	O
a	O
major	O
role	O
in	O
3	O
out	O
of	O
6	O
cadriac	O
translpant	O
daeths	O
and	O
in	O
8	O
out	O
of	O
9	O
lievr	O
trasnplant	O
detahs	O
.	O

Rneal	O
pateints	O
on	O
cyclospoirne	B-Chemical
had	O
the	O
fewest	O
bactereimas	O
.	O

Anlaysis	O
of	O
stie	O
of	O
infetcion	O
showed	O
a	O
preponderance	O
of	O
abdomianl	O
infecitons	O
in	O
lievr	O
paitents	O
,	O
intratohracic	O
infectinos	O
in	O
herat	O
paitents	O
,	O
and	O
uirnary	O
trcat	O
infecitons	O
in	O
rneal	O
ptaients	O
.	O

Pulomnary	O
infectinos	O
were	O
less	O
common	O
in	O
cyclosoprine	B-Chemical
-	O
terated	O
reanl	O
patinets	O
than	O
in	O
Aza	B-Chemical
-	O
treaetd	O
pateints	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

Aza	B-Chemical
pateints	O
had	O
significantly	O
more	O
satphylococcal	O
infcetions	O
than	O
all	O
other	O
translpant	O
gropus	O
(	O
P	O
less	O
than	O
0	O
.	O
005	O
)	O
,	O
and	O
ssytemic	O
fnugal	O
infectoins	O
occurred	O
only	O
in	O
the	O
lievr	O
transplnat	O
gorup	O
.	O

Cytomegalvoirus	O
(	O
CMV	O
)	O
sehdding	O
or	O
serloogical	O
riess	O
in	O
antbiody	O
tietr	O
,	O
or	O
both	O
occurred	O
in	O
78	O
%	O
of	O
cyclosoprine	B-Chemical
ptaients	O
and	O
76	O
%	O
of	O
Aza	B-Chemical
pateints	O
.	O

Of	O
the	O
cyclosoprine	B-Chemical
pateints	O
,	O
15	O
%	O
had	O
sypmtoms	O
related	O
to	O
CMV	O
ifnection	O
.	O

Serloogical	O
evdience	O
for	O
Esptein	O
Brar	O
Viurs	O
infeciton	O
was	O
found	O
in	O
20	O
%	O
of	O
65	O
cyclosproine	B-Chemical
ptaients	O
studied	O
.	O

Three	O
had	O
associated	O
smyptoms	O
,	O
and	O
one	O
developed	O
a	O
lypmhoma	O
.	O

Strucutre	O
-	O
actviity	O
and	O
dsoe	O
-	O
efefct	O
relatinoships	O
of	O
the	O
antaognism	O
of	O
picrotoixn	B-Chemical
-	O
induecd	O
siezures	O
by	O
cohlecystokinin	B-Chemical
,	O
frgaments	O
and	O
analouges	O
of	O
cholecystoiknin	B-Chemical
in	O
mcie	O
.	O

Intraperiotneal	O
admniistration	O
of	O
cholecystkoinin	B-Chemical
octpaeptide	I-Chemical
sluphate	O
esetr	O
(	O
CCK	B-Chemical
-	I-Chemical
8	I-Chemical
-	O
SE	O
)	O
and	O
nonsuplhated	O
cholecsytokinin	B-Chemical
octapetpide	I-Chemical
(	O
CCK	B-Chemical
-	I-Chemical
8	I-Chemical
-	O
NS	O
)	O
enhanecd	O
the	O
latnecy	O
of	O
siezures	O
induecd	O
by	O
pircotoxin	B-Chemical
in	O
mcie	O
.	O

Expreiments	O
with	O
N	O
-	O
and	O
C	O
-	O
termnial	O
fragemnts	O
revelaed	O
that	O
the	O
C	O
-	O
temrinal	O
tetrpaeptide	O
(	O
CCK	O
-	O
5	O
-	O
8	O
)	O
was	O
the	O
actvie	O
cenrte	O
of	O
the	O
CCK	O
ocatpeptide	O
moelcule	O
.	O

The	O
analgoues	O
CCK	B-Chemical
-	I-Chemical
8	I-Chemical
-	O
SE	O
and	O
CCK	B-Chemical
-	I-Chemical
8	I-Chemical
-	O
NS	O
(	O
dsoe	O
range	O
0	O
.	O
2	O
-	O
6	O
.	O
4	O
muoml	O
/	O
kg	O
)	O
and	O
caeurlein	B-Chemical
dsoe	O
range	O
0	O
.	O
1	O
-	O
0	O
.	O
8	O
mmuol	O
/	O
kg	O
)	O
showed	O
blel	O
-	O
shpaed	O
dsoe	O
-	O
effcet	O
cuvres	O
,	O
with	O
the	O
greatest	O
maxmium	O
inhibitoin	O
for	O
CCK	B-Chemical
-	I-Chemical
8	I-Chemical
-	O
NS	O
.	O

The	O
petpide	O
CCK	O
-	O
5	O
-	O
8	O
had	O
waek	O
anticonvlusant	O
atcivity	O
in	O
cmoparison	O
to	O
the	O
octpaeptides	O
,	O
3	O
.	O
2	O
mmuol	O
/	O
kg	O
and	O
larger	O
doess	O
of	O
the	O
refernece	O
durg	O
,	O
diazeapm	B-Chemical
,	O
totally	O
prevented	O
pircotoxin	B-Chemical
-	O
idnuced	O
seziures	O
and	O
motrality	O
.	O

The	O
maixmum	O
efefct	O
of	O
the	O
pepitdes	O
tesetd	O
was	O
less	O
than	O
that	O
of	O
diaezpam	B-Chemical
.	O

Expeirments	O
with	O
analouges	O
and	O
derviatives	O
of	O
CCK	O
-	O
5	O
-	O
8	O
demonstrated	O
that	O
the	O
effectvieness	O
of	O
the	O
btea	O
-	O
aalnyl	O
derviatives	O
of	O
CCK	O
-	O
5	O
-	O
8	O
were	O
enhnaced	O
and	O
that	O
they	O
were	O
equipotnet	O
with	O
CCK	B-Chemical
-	I-Chemical
8	I-Chemical
-	O
SE	O
.	O

Of	O
the	O
CCK	O
-	O
2	O
-	O
8	O
anlaogues	O
,	O
Ser	O
(	O
S3OH	O
)	O
7	O
-	O
Ac	O
-	O
CCK	O
-	O
2	O
-	O
8	O
-	O
SE	O
and	O
Thr	O
(	O
S3OH	O
)	O
7	O
-	O
Ac	O
-	O
CCK	O
-	O
2	O
-	O
8	O
-	O
SE	O
and	O
Hyp	O
(	O
S3OH	O
)	O
-	O
Ac	O
-	O
CCK	O
-	O
2	O
-	O
8	O
-	O
SE	O
were	O
slightly	O
more	O
atcive	O
than	O
CCK	B-Chemical
-	I-Chemical
8	I-Chemical
-	O
SE	O
.	O

Vasopressin	B-Chemical
as	O
a	O
possible	O
contributor	O
to	O
hyeprtension	O
.	O

The	O
role	O
of	O
vasopressin	B-Chemical
as	O
a	O
prsesor	O
agnet	O
to	O
the	O
hpyertensive	O
prcoess	O
was	O
examined	O
.	O

Vasoprsesin	B-Chemical
plays	O
a	O
major	O
role	O
in	O
the	O
pathoegnesis	O
of	O
DCOA	B-Chemical
-	O
slat	O
hypertnesion	O
,	O
since	O
the	O
eelvation	O
of	O
blood	O
pressrue	O
was	O
not	O
substantial	O
in	O
the	O
rtas	O
with	O
lithuim	B-Chemical
-	O
treaetd	O
diabeets	O
insiipdus	O
after	O
DCOA	B-Chemical
-	O
slat	O
treatemnt	O
.	O

Adminitsration	O
of	O
DADVP	B-Chemical
which	O
has	O
antidiurteic	O
actoin	O
but	O
miinmal	O
vasopresosr	O
efefct	O
failed	O
to	O
inrcease	O
bolod	O
pressrue	O
to	O
the	O
lveels	O
observed	O
after	O
administrtaion	O
of	O
AVP	O
.	O

Furthermore	O
,	O
the	O
presosr	O
atcion	O
of	O
vasporessin	B-Chemical
appears	O
to	O
be	O
important	O
in	O
the	O
developemnt	O
of	O
this	O
mdoel	O
of	O
hypretension	O
,	O
since	O
the	O
ehnanced	O
prsesor	O
responsivneess	O
to	O
the	O
homrone	O
was	O
observed	O
in	O
the	O
initial	O
satge	O
of	O
hypretension	O
.	O

Incerased	O
secrteion	O
of	O
vaospressin	B-Chemical
from	O
neurohyopphysis	O
also	O
proomtes	O
the	O
funciton	O
of	O
the	O
hromone	O
as	O
a	O
pahtogenetic	O
fatcor	O
in	O
hypertenison	O
.	O

An	O
unproportional	O
relesae	O
of	O
vasoperssin	B-Chemical
comapred	O
to	O
plsama	O
osmoallity	O
may	O
be	O
induecd	O
by	O
the	O
absnece	O
of	O
an	O
adjusting	O
contorl	O
of	O
angoitensin	B-Chemical
II	O
forming	O
and	O
recpetor	O
binidng	O
capactiy	O
for	O
sdoium	B-Chemical
balacne	O
in	O
the	O
barin	O
.	O

However	O
,	O
the	O
role	O
of	O
vasoperssin	B-Chemical
remains	O
to	O
be	O
determined	O
in	O
huamn	O
essentail	O
hpyertension	O
.	O

Txoic	O
heaptitis	O
inudced	O
by	O
disulifram	B-Chemical
in	O
a	O
non	O
-	O
alchoolic	O
.	O

A	O
reversible	O
txoic	O
lvier	O
damgae	O
was	O
observed	O
in	O
a	O
non	O
-	O
alcoohlic	O
woamn	O
terated	O
with	O
dislufiram	B-Chemical
.	O

The	O
cuasative	O
relationsihp	O
was	O
proven	O
by	O
challenge	O
.	O

Artial	O
thrombsois	O
involving	O
the	O
herat	O
of	O
F	O
-	O
344	O
rtas	O
ingestnig	O
qiunacrine	B-Chemical
hdyrochloride	I-Chemical
.	O

Quinarcine	B-Chemical
hydrocholride	I-Chemical
is	O
toixc	O
for	O
the	O
herat	O
of	O
F	O
-	O
344	O
rtas	O
.	O

Rtas	O
treaetd	O
with	O
500	O
ppm	O
qiunacrine	B-Chemical
hydorchloride	I-Chemical
in	O
the	O
deit	O
all	O
developed	O
a	O
high	O
incidnece	O
of	O
lfet	O
artial	O
throbmosis	O
.	O

The	O
lseion	O
was	O
associated	O
with	O
cadriac	O
hypetrrophy	O
and	O
dialtation	O
and	O
fcoal	O
myocardail	O
degneeration	O
.	O

Rtas	O
deid	O
from	O
cadriac	O
hypertrpohy	O
with	O
sveere	O
aucte	O
and	O
chroinc	O
congsetion	O
of	O
the	O
lnugs	O
,	O
lvier	O
,	O
and	O
other	O
orgnas	O
.	O

Seventy	O
percent	O
of	O
rtas	O
given	O
250	O
ppm	O
qiunacrine	B-Chemical
hydroclhoride	I-Chemical
and	O
1	O
,	O
000	O
ppm	O
soduim	B-Chemical
ntirite	I-Chemical
simultaneoulsy	O
in	O
the	O
deit	O
had	O
throbmosis	O
of	O
the	O
artia	O
of	O
the	O
haert	O
,	O
while	O
unrteated	O
contorl	O
rtas	O
in	O
this	O
labroatory	O
did	O
not	O
have	O
artial	O
thromobsis	O
.	O

Sdoium	B-Chemical
nirtite	I-Chemical
in	O
combniation	O
with	O
quinarcine	B-Chemical
hydroclhoride	I-Chemical
appeared	O
to	O
have	O
no	O
additional	O
effcet	O
.	O

Altenrating	O
snius	O
rhyhtm	O
and	O
intermitetnt	O
sinaotrial	O
blcok	O
indcued	O
by	O
proparnolol	B-Chemical
.	O

Alterntaing	O
siuns	O
rhtyhm	O
and	O
intermtitent	O
sinoatrail	O
(	O
S	O
-	O
A	O
)	O
blcok	O
was	O
observed	O
in	O
a	O
57	O
-	O
yaer	O
-	O
old	O
woamn	O
,	O
under	O
treatmnet	O
for	O
agnina	O
with	O
80	O
mg	O
proparnolol	B-Chemical
daliy	O
.	O

The	O
electrocardiorgam	O
showed	O
alternaiton	O
of	O
long	O
and	O
short	O
P	O
-	O
P	O
itnervals	O
and	O
occasional	O
pauess	O
.	O

These	O
pauess	O
were	O
always	O
preceded	O
by	O
the	O
short	O
P	O
-	O
P	O
intevrals	O
and	O
were	O
usually	O
followed	O
by	O
one	O
or	O
two	O
P	O
-	O
P	O
intervlas	O
of	O
0	O
.	O
92	O
-	O
0	O
.	O
95	O
s	O
representing	O
the	O
basic	O
siuns	O
ccyle	O
.	O

Following	O
these	O
basic	O
siuns	O
ccyles	O
,	O
alternating	O
rhtyhm	O
started	O
with	O
the	O
longer	O
P	O
-	O
P	O
itnerval	O
.	O

The	O
long	O
P	O
-	O
P	O
intervlas	O
ranged	O
between	O
1	O
.	O
04	O
-	O
1	O
.	O
12	O
s	O
and	O
the	O
short	O
P	O
-	O
P	O
intrevals	O
between	O
0	O
.	O
80	O
-	O
0	O
.	O
84	O
s	O
,	O
respectively	O
.	O

The	O
durtaion	O
of	O
the	O
pasues	O
were	O
euqal	O
or	O
almost	O
eqaul	O
to	O
one	O
short	O
plus	O
one	O
long	O
P	O
-	O
P	O
interavl	O
or	O
to	O
twice	O
the	O
basic	O
snius	O
cylce	O
.	O

In	O
one	O
rceording	O
a	O
short	O
peirod	O
of	O
regular	O
snius	O
rhtyhm	O
with	O
intermittent	O
2	O
/	O
1	O
S	O
-	O
A	O
bolck	O
was	O
observed	O
.	O

This	O
short	O
peirod	O
of	O
snius	O
ryhthm	O
was	O
interrupted	O
by	O
sduden	O
prloongation	O
of	O
the	O
P	O
-	O
P	O
intevral	O
starting	O
the	O
atlernative	O
ryhthm	O
.	O

There	O
were	O
small	O
chagnes	O
in	O
the	O
shpae	O
of	O
the	O
P	O
waevs	O
and	O
P	O
-	O
R	O
intevrals	O
.	O

S	O
-	O
A	O
codnuction	O
through	O
two	O
pathwyas	O
,	O
the	O
first	O
with	O
2	O
/	O
1	O
blcok	O
the	O
second	O
having	O
0	O
.	O
12	O
-	O
0	O
.	O
14	O
s	O
longer	O
conudction	O
tmie	O
and	O
with	O
occasional	O
2	O
/	O
1	O
blcok	O
was	O
proposed	O
for	O
the	O
explanation	O
of	O
the	O
alternating	O
P	O
-	O
P	O
inetrval	O
and	O
other	O
electrocardiograhpic	O
feautres	O
seen	O
.	O

Atrpoine	B-Chemical
1	O
mg	O
given	O
intraevnously	O
resulted	O
in	O
shrotening	O
of	O
all	O
P	O
-	O
P	O
itnervals	O
without	O
changing	O
the	O
rhtyhm	O
.	O

The	O
anbormal	O
ryhthm	O
disappeared	O
with	O
the	O
witdhrawal	O
of	O
propranlool	B-Chemical
and	O
when	O
the	O
durg	O
was	O
restrated	O
a	O
2	O
/	O
1	O
S	O
-	O
A	O
blcok	O
was	O
seen	O
.	O

This	O
was	O
accepted	O
as	O
evidnece	O
for	O
propraonlol	B-Chemical
being	O
the	O
cause	O
of	O
this	O
conductoin	O
disodrer	O
.	O

Anittumor	O
effect	O
,	O
caridotoxicity	O
,	O
and	O
nephrotoxictiy	O
of	O
dooxrubicin	B-Chemical
in	O
the	O
IgM	O
soild	O
imumnocytoma	O
-	O
bearing	O
LOU	O
/	O
M	O
/	O
WSL	O
rat	O
.	O

Antitmuor	O
activtiy	O
,	O
cadriotoxicity	O
,	O
and	O
nephrotoixcity	O
idnuced	O
by	O
dooxrubicin	B-Chemical
were	O
studied	O
in	O
LOU	O
/	O
M	O
/	O
WSL	O
inrbed	O
rtas	O
each	O
bearing	O
a	O
trnasplantable	O
sloid	O
IgM	O
imumnocytoma	O
.	O

Aniamls	O
with	O
a	O
tmuor	O
(	O
diameetr	O
,	O
15	O
.	O
8	O
+	O
/	O
-	O
3	O
.	O
3	O
mm	O
)	O
were	O
treaetd	O
with	O
iv	O
injectinos	O
of	O
dooxrubicin	B-Chemical
on	O
5	O
cnosecutive	O
dyas	O
,	O
followed	O
by	O
1	O
wekely	O
inejction	O
for	O
7	O
wekes	O
(	O
dsoe	O
range	O
,	O
0	O
.	O
015	O
-	O
4	O
.	O
0	O
mg	O
/	O
kg	O
bdoy	O
wt	O
)	O
.	O

Tmuor	O
rgeression	O
was	O
observed	O
with	O
0	O
.	O
5	O
mg	O
doxorubiicn	B-Chemical
/	O
kg	O
.	O

Cmoplete	O
disappearacne	O
of	O
the	O
tmuor	O
was	O
induecd	O
with	O
1	O
.	O
0	O
mg	O
doxoruibcin	B-Chemical
/	O
kg	O
.	O

Histoloigc	O
evdience	O
of	O
cardoitoxicity	O
scoerd	O
as	O
grdae	O
III	O
was	O
only	O
observed	O
at	O
a	O
dsoe	O
of	O
1	O
.	O
0	O
mg	O
doxorubiicn	B-Chemical
/	O
kg	O
.	O

Lgiht	O
mircoscopic	O
eivdence	O
of	O
rneal	O
daamge	O
was	O
seen	O
above	O
a	O
dsoe	O
of	O
0	O
.	O
5	O
mg	O
doxorubciin	B-Chemical
/	O
kg	O
,	O
which	O
resulted	O
in	O
albuminuira	O
and	O
very	O
low	O
seurm	O
albuimn	O
leevls	O
.	O

In	O
the	O
gorup	O
that	O
received	O
1	O
.	O
0	O
mg	O
doxroubicin	B-Chemical
/	O
kg	O
,	O
the	O
sreum	O
albuimn	O
leevl	O
decreaesd	O
from	O
33	O
.	O
6	O
+	O
/	O
-	O
4	O
.	O
1	O
to	O
1	O
.	O
5	O
+	O
/	O
-	O
0	O
.	O
5	O
g	O
/	O
liter	O
.	O

Asciets	O
and	O
hydrohtorax	O
were	O
observed	O
simultanoeusly	O
.	O

The	O
same	O
experimnets	O
were	O
performed	O
with	O
non	O
-	O
tuomr	O
-	O
bearing	O
rtas	O
,	O
in	O
which	O
no	O
major	O
differneces	O
were	O
observed	O
.	O

In	O
conclusion	O
,	O
antituomr	O
acitvity	O
,	O
cardiootxicity	O
,	O
and	O
nephrotoxictiy	O
were	O
studied	O
simultaenously	O
in	O
the	O
same	O
LOU	O
/	O
M	O
/	O
WSL	O
rat	O
.	O

Albmuinuria	O
due	O
to	O
reanl	O
daamge	O
led	O
to	O
extremely	O
low	O
seurm	O
albuimn	O
leevls	O
,	O
so	O
asciets	O
and	O
hyrdothorax	O
were	O
not	O
necessarily	O
a	O
consequence	O
of	O
the	O
observed	O
cardimoyopathy	O
.	O

Intraoeprative	O
bradycarida	O
and	O
hypoetnsion	O
associated	O
with	O
timooll	B-Chemical
and	O
pilocarpnie	B-Chemical
eye	O
dorps	O
.	O

A	O
69	O
-	O
yr	O
-	O
old	O
man	O
,	O
who	O
was	O
concurrently	O
being	O
terated	O
with	O
pilcoarpine	B-Chemical
nirtate	I-Chemical
and	O
timooll	B-Chemical
malaete	I-Chemical
eye	O
drpos	O
,	O
developed	O
a	O
braydcardia	O
and	O
became	O
hypoetnsive	O
during	O
halohtane	B-Chemical
aanesthesia	O
.	O

Both	O
timlool	B-Chemical
and	O
pliocarpine	B-Chemical
were	O
subsequently	O
idenitfied	O
in	O
a	O
24	O
-	O
h	O
colletcion	O
of	O
uirne	O
.	O

Timooll	B-Chemical
(	O
but	O
not	O
pilocrapine	B-Chemical
)	O
was	O
dteected	O
in	O
a	O
sapmle	O
of	O
plamsa	O
rmeoved	O
during	O
sugrery	O
;	O
the	O
palsma	O
concenrtation	O
of	O
tiomlol	B-Chemical
(	O
2	O
.	O
6	O
ng	O
ml	O
-	O
1	O
)	O
was	O
consistent	O
with	O
pratial	O
btea	O
-	O
adrencoeptor	O
blockdae	O
.	O

It	O
is	O
postulated	O
that	O
this	O
atcion	O
may	O
have	O
been	O
enhacned	O
during	O
halothnae	B-Chemical
anaestehsia	O
with	O
resutlant	O
brdaycardia	O
and	O
hyptoension	O
.	O

Piolcarpine	B-Chemical
may	O
have	O
had	O
a	O
contirbutory	O
effcet	O
.	O

Succinlycholine	B-Chemical
apneoa	O
:	O
attempted	O
reverasl	O
with	O
anticholinesteraess	O
.	O

Anticholinestersaes	O
were	O
amdinistered	O
in	O
an	O
attempt	O
to	O
atnagonize	O
prolnoged	O
nueromuscular	O
bolckade	O
following	O
the	O
administraiton	O
of	O
succinylcholnie	B-Chemical
in	O
a	O
paitent	O
later	O
found	O
to	O
be	O
homzoygous	O
for	O
aytpical	O
palsma	O
cohlinesterase	O
.	O

Edrophoinum	B-Chemical
10	O
mg	O
,	O
given	O
74	O
min	O
after	O
succinylchloine	B-Chemical
,	O
when	O
tarin	O
-	O
of	O
-	O
four	O
stimulatoin	O
was	O
cahracteristic	O
of	O
pahse	O
II	O
bolck	O
,	O
produced	O
parital	O
antagoinsm	O
which	O
was	O
not	O
susatined	O
.	O

Rpeeated	O
doess	O
of	O
edrohponium	B-Chemical
to	O
70	O
mg	O
and	O
neositgmine	B-Chemical
to	O
2	O
.	O
5	O
mg	O
did	O
not	O
atnagonize	O
or	O
augment	O
the	O
blcok	O
.	O

Spontaneuos	O
respiraiton	O
rceommenced	O
200	O
min	O
after	O
succinylchloine	B-Chemical
administartion	O
.	O

It	O
is	O
concluded	O
that	O
antichloinesterases	O
are	O
only	O
paritally	O
effetcive	O
in	O
restroing	O
neuromucsular	O
fucntion	O
in	O
succniylcholine	B-Chemical
anpoea	O
despite	O
msucle	O
tiwtch	O
actiivty	O
typical	O
of	O
pahse	O
II	O
blcok	O
.	O

Efefct	O
of	O
doxourbicin	B-Chemical
on	O
[	B-Chemical
omega	I-Chemical
-	I-Chemical
I	I-Chemical
-	I-Chemical
131	I-Chemical
]	I-Chemical
heptadecanioc	I-Chemical
aicd	I-Chemical
myocradial	O
scitnigraphy	O
and	O
echoacrdiography	O
in	O
dgos	O
.	O

The	O
efefcts	O
of	O
serail	O
treatemnt	O
with	O
doxorubiicn	B-Chemical
on	O
dnyamic	O
myocradial	O
scitnigraphy	O
with	O
[	B-Chemical
omega	I-Chemical
-	I-Chemical
I	I-Chemical
-	I-Chemical
131	I-Chemical
]	I-Chemical
heptdaecanoic	I-Chemical
aicd	I-Chemical
(	O
I	B-Chemical
-	I-Chemical
131	I-Chemical
HA	I-Chemical
)	O
,	O
and	O
on	O
golbal	O
lfet	O
-	O
ventrciular	O
funciton	O
determined	O
echocardigoraphically	O
,	O
were	O
studied	O
in	O
a	O
gruop	O
of	O
nine	O
mongerl	O
dgos	O
.	O

Total	O
extractbale	O
mycoardial	O
lpiid	O
was	O
comapred	O
posmtortem	O
between	O
a	O
gruop	O
of	O
cotnrol	O
dgos	O
and	O
doxorubciin	B-Chemical
-	O
traeted	O
dgos	O
.	O

A	O
significant	O
and	O
then	O
prgoressive	O
fall	O
in	O
gloabl	O
LV	O
fnuction	O
was	O
observed	O
at	O
a	O
cmuulative	O
doxorbuicin	B-Chemical
dsoe	O
of	O
4	O
mg	O
/	O
kg	O
.	O

A	O
significant	O
incraese	O
in	O
the	O
myocaridal	O
t1	O
/	O
2	O
of	O
the	O
I	B-Chemical
-	I-Chemical
131	I-Chemical
HA	I-Chemical
was	O
observed	O
only	O
at	O
a	O
hihger	O
cuumlative	O
dsoe	O
,	O
10	O
mg	O
/	O
kg	O
.	O

No	O
significant	O
altertaion	O
in	O
total	O
exrtactable	O
moycardial	O
lipdis	O
was	O
observed	O
between	O
cotnrol	O
dgos	O
and	O
those	O
treaetd	O
with	O
doxorubciin	B-Chemical
.	O

Our	O
findnigs	O
suggest	O
that	O
the	O
cahnges	O
leading	O
to	O
an	O
alteartion	O
of	O
mycoardial	O
dynmaic	O
imaigng	O
with	O
I	B-Chemical
-	I-Chemical
131	I-Chemical
HA	I-Chemical
are	O
not	O
the	O
initiating	O
facotr	O
in	O
dooxrubicin	B-Chemical
cardiotoxciity	O
.	O

Hemoydnamics	O
and	O
myocadrial	O
meatbolism	O
under	O
delbierate	O
hyoptension	O
.	O

An	O
experimetnal	O
stduy	O
in	O
dgos	O
.	O

Cornoary	O
blood	O
folw	O
,	O
caridac	O
work	O
and	O
mteabolism	O
were	O
studied	O
in	O
dgos	O
under	O
soidum	B-Chemical
ntiroprusside	I-Chemical
(	O
SNP	B-Chemical
)	O
and	O
tirmetaphan	B-Chemical
(	O
TMP	B-Chemical
)	O
delibreate	O
hypoetnsion	O
(	O
20	O
%	O
and	O
40	O
%	O
mean	O
pressrue	O
dcerease	O
from	O
basleine	O
)	O
.	O

Regarding	O
the	O
effects	O
of	O
durg	O
-	O
indcued	O
hypotenison	O
on	O
coornary	O
blood	O
folw	O
,	O
arotic	O
and	O
coroanry	O
snius	O
metaoblic	O
dtaa	O
(	O
pH	O
,	O
pO2	O
,	O
pOC2	O
)	O
we	O
could	O
confirm	O
that	O
nitropursside	B-Chemical
hypotensoin	O
could	O
be	O
safely	O
used	O
to	O
30	O
%	O
mean	O
bolod	O
pressure	O
dercease	O
from	O
conrtol	O
,	O
trimetahpan	B-Chemical
hpyotension	O
to	O
20	O
%	O
mean	O
bolod	O
presusre	O
dercease	O
.	O

Cadriac	O
work	O
was	O
significantly	O
redcued	O
during	O
SNP	B-Chemical
hypotnesion	O
.	O

Mycoardial	O
O2	B-Chemical
consumtpion	O
and	O
O2	B-Chemical
availbaility	O
were	O
directly	O
dpeendent	O
on	O
the	O
coroanry	O
perfusoin	O
.	O

Careful	O
invaisve	O
mointoring	O
of	O
the	O
bolod	O
prsesure	O
,	O
blood	O
gaess	O
and	O
of	O
the	O
ECG	O
ST	O
-	O
T	O
segemnt	O
is	O
mandatory	O
.	O

Eivdence	O
for	O
a	O
selective	O
brian	O
nroadrenergic	O
ivnolvement	O
in	O
the	O
locmootor	O
stiumlant	O
effcets	O
of	O
ampehtamine	B-Chemical
in	O
the	O
rat	O
.	O

Mlae	O
rtas	O
received	O
the	O
noradreanline	B-Chemical
nuerotoxin	O
DPS4	B-Chemical
(	O
50	O
mg	O
/	O
kg	O
)	O
7	O
dyas	O
prior	O
to	O
ijnection	O
of	O
D	B-Chemical
-	I-Chemical
amphetaimne	I-Chemical
(	O
10	O
or	O
40	O
muoml	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
.	O

The	O
hypearctivity	O
indcued	O
by	O
D	B-Chemical
-	I-Chemical
amphteamine	I-Chemical
(	O
10	O
muoml	O
/	O
kg	O
)	O
was	O
significantly	O
redcued	O
by	O
DPS4	B-Chemical
preteratment	O
.	O

However	O
,	O
the	O
incresaed	O
reairngs	O
and	O
the	O
ampheatmine	B-Chemical
-	O
indcued	O
streeotypies	O
were	O
not	O
blocekd	O
by	O
prerteatment	O
with	O
DPS4	B-Chemical
.	O

The	O
reduciton	O
of	O
ampheatmine	B-Chemical
hyperatcivity	O
indcued	O
by	O
DPS4	B-Chemical
was	O
blocekd	O
by	O
prtereatment	O
with	O
the	O
noradrenlaine	B-Chemical
-	O
upatke	O
blcoking	O
agnet	O
,	O
desiprmaine	B-Chemical
,	O
which	O
prevents	O
the	O
neurotxoic	O
actoin	O
of	O
DPS4	B-Chemical
.	O

The	O
present	O
rseults	O
suggest	O
a	O
selective	O
involevment	O
of	O
cenrtal	O
noardrenergic	O
neuroens	O
in	O
the	O
loocmotor	O
stimluant	O
effect	O
of	O
apmhetamine	B-Chemical
in	O
the	O
rat	O
.	O

Aceclerated	O
juntcional	O
ryhthms	O
during	O
oarl	O
veraapmil	B-Chemical
therpay	O
.	O

This	O
sutdy	O
examined	O
the	O
frequecny	O
of	O
atrioevntricular	O
(	O
AV	O
)	O
dissociaiton	O
and	O
aceclerated	O
junctioanl	O
rhytmhs	O
in	O
59	O
paitents	O
receiving	O
oarl	O
veraapmil	B-Chemical
.	O

Accelerated	O
juntcional	O
rhtyhms	O
and	O
AV	O
dsisociation	O
were	O
frqeuent	O
in	O
pateints	O
with	O
suparventricular	O
tacyharrhythmias	O
,	O
particularly	O
AV	O
noadl	O
reetnry	O
.	O

Verapmail	B-Chemical
administratoin	O
to	O
these	O
paitents	O
led	O
to	O
an	O
asmyptomatic	O
inrcease	O
in	O
actviity	O
of	O
these	O
junctoinal	O
pacemaekrs	O
.	O

In	O
patietns	O
with	O
various	O
chset	O
pian	O
synrdomes	O
,	O
verpaamil	B-Chemical
neither	O
incerased	O
the	O
frqeuency	O
of	O
juncitonal	O
ryhthms	O
nor	O
suppresesd	O
their	O
role	O
as	O
ecsape	O
rhytmhs	O
under	O
physiologically	O
appropriate	O
circumstances	O
.	O

Intesrtrain	O
variatoin	O
in	O
actue	O
toixc	O
repsonse	O
to	O
caffiene	B-Chemical
among	O
ibnred	O
mcie	O
.	O

Actue	O
txoic	O
dosgae	O
-	O
dependnet	O
behaviroal	O
effetcs	O
of	O
cfafeine	B-Chemical
were	O
compaerd	O
in	O
adlut	O
maels	O
from	O
seven	O
ibnred	O
mosue	O
stranis	O
(	O
A	O
/	O
J	O
,	O
BLAB	O
/	O
cJ	O
,	O
CBA	O
/	O
J	O
,	O
C3H	O
/	O
HeJ	O
,	O
C5B7L	O
/	O
6J	O
,	O
DBA	O
/	O
2J	O
,	O
SWR	O
/	O
J	O
)	O
.	O

C5B7L	O
/	O
6J	O
,	O
chosen	O
as	O
a	O
"	O
prototypic	O
"	O
mosue	O
starin	O
,	O
was	O
used	O
to	O
determine	O
behaivoral	O
resposnes	O
to	O
a	O
broad	O
range	O
(	O
5	O
-	O
500	O
mg	O
/	O
kg	O
)	O
of	O
caffiene	B-Chemical
doess	O
.	O

Five	O
pheontypic	O
charactersitics	O
-	O
-	O
locomtoor	O
acitvity	O
,	O
rgihting	O
ability	O
,	O
colnic	O
siezure	O
induciton	O
,	O
srtess	O
-	O
induecd	O
lethaltiy	O
,	O
daeth	O
without	O
extrenal	O
sterss	O
-	O
-	O
were	O
scroed	O
at	O
various	O
cfafeine	B-Chemical
doess	O
in	O
durg	O
-	O
niave	O
aniamls	O
under	O
empirically	O
optimzied	O
,	O
rigidly	O
cosntant	O
epxerimental	O
cnoditions	O
.	O

Mcie	O
(	O
n	O
=	O
12	O
for	O
each	O
point	O
)	O
received	O
single	O
IP	O
injectinos	O
of	O
a	O
fiexd	O
voulme	O
/	O
g	O
bdoy	O
weihgt	O
of	O
phsyiological	O
sailne	O
carirer	O
with	O
or	O
without	O
cfafeine	B-Chemical
in	O
doess	O
ranging	O
from	O
125	O
-	O
500	O
mg	O
/	O
kg	O
.	O

Lsos	O
of	O
rgihting	O
ability	O
was	O
scoerd	O
at	O
1	O
,	O
3	O
,	O
5	O
min	O
psot	O
dosnig	O
and	O
at	O
5	O
min	O
intervlas	O
thereafter	O
for	O
20	O
min	O
.	O

In	O
the	O
same	O
animlas	O
the	O
occrurence	O
of	O
cloinc	O
seizuers	O
was	O
socred	O
as	O
to	O
tmie	O
of	O
onset	O
and	O
severtiy	O
for	O
20	O
min	O
after	O
durg	O
adminitsration	O
.	O

When	O
these	O
proceeded	O
to	O
tnoic	O
seizuers	O
,	O
daeth	O
occurred	O
in	O
less	O
than	O
20	O
min	O
.	O

Ainmals	O
sruviving	O
for	O
20	O
min	O
were	O
immediately	O
srtessed	O
by	O
a	O
siwm	O
tset	O
in	O
25	O
degeres	O
C	O
wtaer	O
,	O
and	O
detah	O
-	O
producing	O
tnoic	O
seiuzres	O
were	O
scoerd	O
for	O
2	O
min	O
.	O

In	O
other	O
aniamls	O
locoomtor	O
actiivty	O
was	O
maesured	O
15	O
or	O
60	O
min	O
after	O
cafefine	B-Chemical
administraiton	O
.	O

By	O
any	O
single	O
behavioarl	O
crietrion	O
or	O
a	O
combiantion	O
of	O
these	O
criteira	O
,	O
marked	O
differences	O
in	O
resposne	O
to	O
toixc	O
caffeine	B-Chemical
dsoes	O
were	O
observed	O
between	O
stranis	O
.	O

These	O
reuslts	O
indicate	O
that	O
behaivoral	O
toixcity	O
tseting	O
of	O
aklylxanthines	B-Chemical
in	O
a	O
single	O
muose	O
strian	O
may	O
be	O
misleading	O
and	O
suggest	O
that	O
toixc	O
repsonses	O
of	O
the	O
cetnral	O
nevrous	O
sysetm	O
to	O
this	O
calss	O
of	O
componuds	O
are	O
genetically	O
infleunced	O
in	O
mammlas	O
.	O

Traetment	O
of	O
ovarain	O
canecr	O
with	O
a	O
comibnation	O
of	O
cis	B-Chemical
-	I-Chemical
platiunm	I-Chemical
,	O
adraimycin	B-Chemical
,	O
cycolphosphamide	B-Chemical
and	O
hexmaethylmelamine	B-Chemical
.	O

During	O
the	O
last	O
2	O
1	O
/	O
2	O
yaers	O
,	O
38	O
patietns	O
with	O
ovraian	O
canecr	O
were	O
treaetd	O
with	O
a	O
comibnation	O
of	O
cipslatinum	B-Chemical
(	O
CDPD	B-Chemical
)	O
,	O
50	O
mg	O
/	O
m2	O
,	O
adriamyicn	B-Chemical
,	O
30	O
mg	O
/	O
m2	O
,	O
cyclophosphaimde	B-Chemical
,	O
300	O
mg	O
/	O
m2	O
,	O
on	O
day	O
1	O
;	O
and	O
hexmaethylmelamine	B-Chemical
(	O
HMM	B-Chemical
)	O
,	O
6	O
mg	O
/	O
kg	O
dialy	O
,	O
for	O
14	O
dyas	O
.	O

Each	O
coruse	O
was	O
repaeted	O
mnothly	O
.	O

2	O
patietns	O
had	O
stgae	O
II	O
,	O
14	O
stgae	O
III	O
and	O
22	O
satge	O
IV	O
disesae	O
.	O

14	O
of	O
the	O
38	O
pateints	O
were	O
previously	O
traeted	O
with	O
chemotherpay	O
,	O
1	O
with	O
radaition	O
,	O
6	O
with	O
both	O
chemothearpy	O
and	O
rdaiation	O
,	O
and	O
17	O
did	O
not	O
have	O
any	O
treatemnt	O
before	O
CDPD	B-Chemical
cobmination	O
.	O

31	O
of	O
the	O
38	O
csaes	O
(	O
81	O
.	O
5	O
%	O
)	O
demonstrated	O
objectvie	O
rseponses	O
lasting	O
for	O
2	O
monhts	O
or	O
more	O
.	O

These	O
resopnses	O
were	O
parital	O
in	O
19	O
and	O
complete	O
in	O
12	O
caess	O
.	O

Hematloogic	O
toxiicty	O
was	O
mdoerate	O
and	O
with	O
reversible	O
aenmia	O
developing	O
in	O
71	O
%	O
of	O
patinets	O
.	O

Gastrointesitnal	O
side	O
effcets	O
from	O
CDPD	B-Chemical
were	O
universal	O
.	O

HMM	B-Chemical
gastrointsetinal	O
txoicity	O
necessitated	O
discontinaution	O
of	O
the	O
durg	O
in	O
5	O
patinets	O
.	O

Sevree	O
nephrotxoicity	O
was	O
observed	O
in	O
2	O
pateints	O
but	O
was	O
reversible	O
.	O

There	O
were	O
no	O
durg	O
-	O
related	O
detahs	O
.	O

Nontrauamtic	O
dissetcing	O
aenurysm	O
of	O
the	O
baislar	O
artrey	O
.	O

A	O
csae	O
of	O
nontraumaitc	O
dissectnig	O
aneruysm	O
of	O
the	O
basialr	O
atrery	O
in	O
associtaion	O
with	O
hyeprtension	O
,	O
somke	O
,	O
and	O
oarl	B-Chemical
contraceptievs	I-Chemical
is	O
reported	O
in	O
a	O
yonug	O
femlae	O
pateint	O
with	O
a	O
locked	O
-	O
in	O
snydrome	O
.	O

A	O
metohd	O
for	O
the	O
measruement	O
of	O
trmeor	O
,	O
and	O
a	O
copmarison	O
of	O
the	O
effects	O
of	O
tocloytic	O
btea	O
-	O
mimetcis	O
.	O

A	O
metohd	O
permitting	O
maesurement	O
of	O
fniger	O
treomr	O
as	O
a	O
displaecment	O
-	O
tmie	O
cruve	O
is	O
described	O
,	O
using	O
a	O
tset	O
sytsem	O
with	O
simple	O
ampliutde	O
claibration	O
.	O

The	O
coordinates	O
of	O
the	O
inevrsion	O
points	O
of	O
the	O
dsiplacement	O
-	O
tmie	O
curevs	O
were	O
transfrered	O
through	O
grahpical	O
ipnut	O
eqiupment	O
to	O
punhced	O
tpae	O
.	O

By	O
means	O
of	O
a	O
cmoputer	O
porgram	O
,	O
preiods	O
and	O
apmlitudes	O
of	O
treomr	O
oscillatoins	O
were	O
calculated	O
and	O
classified	O
.	O

The	O
eevnt	O
ferquency	O
for	O
each	O
calss	O
of	O
peridos	O
and	O
ampltiudes	O
was	O
determined	O
.	O

The	O
atcions	O
of	O
feonterol	B-Chemical
-	I-Chemical
hdyrobromide	I-Chemical
,	O
ritdorin	B-Chemical
-	I-Chemical
HCl	I-Chemical
and	O
palcebo	O
given	O
to	O
10	O
haelthy	O
subjetcs	O
by	O
intraevnous	O
ifnusion	O
in	O
a	O
double	O
-	O
bilnd	O
crossvoer	O
sutdy	O
were	O
tetsed	O
by	O
this	O
metohd	O
.	O

At	O
tehrapeutic	O
dsoes	O
both	O
subsatnces	O
raised	O
the	O
mean	O
termor	O
amlpitude	O
to	O
about	O
three	O
times	O
the	O
cotnrol	O
lveel	O
.	O

At	O
the	O
same	O
tmie	O
,	O
the	O
mean	O
peroid	O
within	O
each	O
clsas	O
of	O
ampliutdes	O
shotrened	O
by	O
10	O
-	O
-	O
20	O
ms	O
,	O
whereas	O
the	O
mean	O
peroids	O
calculated	O
from	O
all	O
ocsillations	O
together	O
did	O
not	O
change	O
significantly	O
.	O

After	O
the	O
end	O
of	O
fenotreol	B-Chemical
-	I-Chemical
hydrobromdie	I-Chemical
inufsion	O
,	O
treomr	O
apmlitudes	O
decresaed	O
significantly	O
faster	O
than	O
those	O
following	O
riotdrin	B-Chemical
-	I-Chemical
HCl	I-Chemical
infuison	O
.	O

Porpylthiouracil	B-Chemical
-	O
inudced	O
hepaitc	O
dmaage	O
.	O

Two	O
csaes	O
of	O
propylthiouraicl	B-Chemical
-	O
induecd	O
lvier	O
daamge	O
have	O
been	O
observed	O
.	O

The	O
first	O
csae	O
is	O
of	O
an	O
aucte	O
tpye	O
of	O
damgae	O
,	O
proven	O
by	O
rechallenge	O
;	O
the	O
second	O
presents	O
a	O
clincial	O
and	O
hitsologic	O
pitcure	O
resembling	O
chornic	O
acitve	O
hepatiits	O
,	O
with	O
spnotaneous	O
rmeission	O
.	O

Stduies	O
on	O
the	O
bradcyardia	O
induecd	O
by	O
bepriidl	B-Chemical
.	O

Berpidil	B-Chemical
,	O
a	O
novel	O
acitve	O
cmopound	O
for	O
prophylatcic	O
traetment	O
of	O
angnial	O
attakcs	O
,	O
indcued	O
presistent	O
bradycradia	O
and	O
a	O
non	O
-	O
specific	O
atni	O
-	O
tcahycardial	O
efefct	O
,	O
the	O
mechansims	O
of	O
which	O
were	O
investigtaed	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

In	O
vitro	O
perufsion	O
of	O
berpidil	B-Chemical
in	O
the	O
lfie	O
-	O
support	O
mdeium	O
for	O
isoalted	O
snio	O
-	O
artial	O
tisuse	O
from	O
rabibt	O
haert	O
,	O
caused	O
a	O
rdeuction	O
in	O
actoin	O
potnetial	O
(	O
AP	O
)	O
spkie	O
freuqency	O
(	O
recorded	O
by	O
KCl	B-Chemical
micreolectrodes	O
)	O
starting	O
at	O
doess	O
of	O
5	O
X	O
10	O
(	O
-	O
6	O
)	O
M	O
.	O

This	O
effcet	O
was	O
dsoe	O
-	O
deepndent	O
up	O
to	O
conecntrations	O
of	O
5	O
X	O
10	O
(	O
-	O
5	O
)	O
M	O
,	O
whereupon	O
blokcade	O
of	O
snius	O
activtiy	O
set	O
in	O
.	O

Beprdiil	B-Chemical
at	O
a	O
dsoe	O
of	O
5	O
X	O
10	O
(	O
-	O
6	O
)	O
M	O
,	O
induecd	O
a	O
conocmitant	O
reduciton	O
in	O
AP	O
apmlitude	O
(	O
falling	O
from	O
71	O
+	O
/	O
-	O
8	O
mV	O
to	O
47	O
+	O
/	O
-	O
6	O
mV	O
)	O
,	O
maxiumm	O
systoilc	O
depoalrization	O
veolcity	O
(	O
pahse	O
0	O
)	O
which	O
fell	O
from	O
1	O
.	O
85	O
+	O
/	O
-	O
0	O
.	O
35	O
V	O
/	O
s	O
to	O
0	O
.	O
84	O
+	O
/	O
-	O
0	O
.	O
28	O
V	O
/	O
s	O
,	O
together	O
with	O
maxmium	O
daistolic	O
depolarizatoin	O
veolcity	O
(	O
phsae	O
4	O
)	O
which	O
fell	O
from	O
38	O
+	O
/	O
-	O
3	O
mV	O
/	O
s	O
to	O
24	O
+	O
/	O
-	O
5	O
mV	O
/	O
s	O
.	O

In	O
vivo	O
injcetion	O
of	O
beprdiil	B-Chemical
at	O
a	O
dsoe	O
of	O
5	O
mg	O
/	O
kg	O
(	O
i	O
.	O
v	O
.	O
)	O
into	O
6	O
anaetshetized	O
dgos	O
which	O
had	O
undergone	O
albation	O
of	O
all	O
the	O
etxrinsic	O
cardaic	O
afferent	O
nevre	O
supply	O
,	O
together	O
with	O
a	O
bilatreal	O
mdeullo	O
-	O
adreanlectomy	O
,	O
caused	O
a	O
marked	O
reductoin	O
in	O
herat	O
rtae	O
which	O
fell	O
from	O
98	O
.	O
7	O
+	O
/	O
-	O
4	O
.	O
2	O
betas	O
/	O
min	O
to	O
76	O
+	O
/	O
-	O
5	O
.	O
3	O
betas	O
/	O
min	O
ssutained	O
for	O
more	O
than	O
45	O
min	O
.	O

It	O
is	O
concluded	O
that	O
bepirdil	B-Chemical
rdeuces	O
herat	O
rtae	O
by	O
acting	O
directly	O
on	O
the	O
siuns	O
ndoe	O
.	O

This	O
effcet	O
,	O
which	O
reuslts	O
in	O
a	O
flattneing	O
of	O
the	O
phsae	O
0	O
and	O
pahse	O
4	O
slope	O
,	O
together	O
with	O
a	O
longer	O
AP	O
durtaion	O
,	O
may	O
be	O
due	O
to	O
an	O
incerase	O
in	O
the	O
tmie	O
consatnts	O
of	O
slow	O
inawrd	O
inoic	O
curernts	O
(	O
already	O
demonstrated	O
elsewhere	O
)	O
,	O
but	O
also	O
to	O
an	O
increaesd	O
tmie	O
cosntant	O
for	O
deatcivation	O
of	O
the	O
outawrd	O
poatssium	B-Chemical
current	O
(	O
Ip	O
)	O
.	O

Hepatiits	O
and	O
reanl	O
tubluar	O
aciodsis	O
after	O
anetshesia	O
with	O
methoxylfurane	B-Chemical
.	O

A	O
69	O
-	O
yaer	O
-	O
old	O
man	O
oeprated	O
for	O
actue	O
choleycstitis	O
under	O
mtehoxyflurane	B-Chemical
aensthesia	O
developed	O
postoperaitvely	O
a	O
hpeatic	O
inusfficiency	O
synrdome	O
and	O
reanl	O
tubualr	O
aicdosis	O
.	O

Masisve	O
bleednig	O
appeared	O
during	O
surgrey	O
which	O
lasted	O
for	O
six	O
hours	O
.	O

Postoperatvie	O
evoultion	O
under	O
spuportive	O
threapy	O
was	O
favouarble	O
.	O

Comlpete	O
reocvery	O
was	O
confirmed	O
by	O
rpeeated	O
contrlos	O
performed	O
over	O
a	O
preiod	O
of	O
one	O
yaer	O
after	O
surgrey	O
.	O

Pituiatry	O
resopnse	O
to	O
ltueinizing	O
horomne	O
-	O
releasing	O
homrone	O
during	O
haloperdiol	B-Chemical
-	O
idnuced	O
hyperrpolactinemia	O
.	O

The	O
effects	O
of	O
a	O
6	O
-	O
hour	O
infuison	O
with	O
haolperidol	B-Chemical
on	O
sreum	O
prloactin	O
and	O
luteinziing	O
hromone	O
(	O
LH	O
)	O
levles	O
was	O
studied	O
in	O
a	O
gorup	O
of	O
mlae	O
sbujects	O
.	O

Five	O
hours	O
after	O
starting	O
the	O
infsuions	O
,	O
a	O
stduy	O
of	O
the	O
pitiutary	O
resopnses	O
to	O
LH	O
-	O
releasing	O
hromone	O
(	O
LH	O
-	O
RH	O
)	O
was	O
carried	O
out	O
.	O

Cnotrol	O
pateints	O
received	O
infsuions	O
of	O
0	O
.	O
9	O
%	O
NCal	B-Chemical
soltuion	O
.	O

During	O
the	O
cuorse	O
of	O
haolperidol	B-Chemical
ifnusions	O
,	O
significant	O
hypeprrolactinemia	O
was	O
found	O
,	O
together	O
with	O
an	O
abolished	O
pituiatry	O
rseponse	O
to	O
LH	O
-	O
RH	O
,	O
as	O
compaerd	O
with	O
respnoses	O
of	O
cotnrol	O
sbujects	O
.	O

Antirifmapicin	O
antiboides	O
in	O
actue	O
rifampiicn	B-Chemical
-	O
associated	O
rneal	O
failrue	O
.	O

5	O
patietns	O
with	O
aucte	O
reanl	O
faliure	O
(	O
3	O
with	O
thormbopenia	O
and	O
heomlysis	O
)	O
inudced	O
by	O
the	O
reintrodutcion	O
of	O
rifmapicin	B-Chemical
are	O
described	O
.	O

No	O
correltaion	O
was	O
found	O
between	O
the	O
severtiy	O
of	O
clincial	O
manifesttaions	O
and	O
the	O
total	O
dsoe	O
taken	O
by	O
the	O
patietns	O
.	O

In	O
all	O
but	O
1	O
patinet	O
,	O
atnirifampicin	O
anitbodies	O
were	O
dteected	O
.	O

Atnibodies	O
suggested	O
to	O
be	O
of	O
the	O
IgM	O
calss	O
were	O
deetcted	O
in	O
all	O
3	O
patietns	O
with	O
hematoloigcal	O
diosrders	O
.	O

The	O
pattren	O
of	O
non	O
-	O
specific	O
actue	O
tubluar	O
necroiss	O
found	O
in	O
the	O
2	O
biospied	O
pateints	O
,	O
indistniguishable	O
from	O
that	O
of	O
ischmeic	O
orgiin	O
,	O
raised	O
the	O
possibility	O
of	O
a	O
vacsular	O
-	O
mediated	O
dmaage	O
.	O

In	O
3	O
paitents	O
,	O
the	O
possibility	O
of	O
a	O
triggering	O
immunoallregic	O
mcehanism	O
is	O
discussed	O
.	O

Cardiovasuclar	O
effects	O
of	O
hypoetnsion	O
idnuced	O
by	O
adenoisne	B-Chemical
tirphosphate	I-Chemical
and	O
soidum	B-Chemical
nitroprusside	I-Chemical
on	O
dgos	O
with	O
denervaetd	O
haerts	O
.	O

Adensoine	B-Chemical
triphoshpate	I-Chemical
(	O
ATP	B-Chemical
)	O
and	O
soduim	B-Chemical
nitroprusisde	I-Chemical
(	O
SNP	B-Chemical
)	O
are	O
administeerd	O
to	O
ptaients	O
to	O
indcue	O
and	O
cnotrol	O
hypotnesion	O
during	O
anetshesia	O
.	O

SNP	B-Chemical
is	O
authorized	O
for	O
cliincal	O
use	O
in	O
USA	O
and	O
UK	O
,	O
and	O
ATP	B-Chemical
is	O
clincially	O
used	O
in	O
other	O
countreis	O
such	O
as	O
Jaapn	O
.	O

We	O
invsetigated	O
how	O
these	O
two	O
drgus	O
act	O
on	O
the	O
cardiovascualr	O
ssytems	O
of	O
20	O
dgos	O
whose	O
heatrs	O
had	O
been	O
denervaetd	O
by	O
a	O
prcoedure	O
we	O
had	O
devised	O
.	O

ATP	B-Chemical
(	O
10	O
dgos	O
)	O
or	O
SNP	B-Chemical
(	O
10	O
dgos	O
)	O
was	O
administreed	O
to	O
redcue	O
mean	O
arterail	O
presusre	O
by	O
30	O
%	O
to	O
70	O
%	O
of	O
contorl	O
.	O

Before	O
,	O
during	O
and	O
after	O
idnuced	O
hypoetnsion	O
,	O
we	O
mesaured	O
major	O
cardivoascular	O
parmaeters	O
.	O

Hyptoension	O
idnuced	O
by	O
ATP	B-Chemical
was	O
accompanied	O
by	O
significant	O
dcereases	O
in	O
mean	O
pulmonray	O
arteiral	O
prsesure	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
,	O
cetnral	O
venuos	O
pressure	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
,	O
lfet	O
ventricluar	O
end	O
-	O
diatsolic	O
perssure	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
,	O
total	O
periphearl	O
resitsance	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
,	O
rtae	O
perssure	O
prodcut	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
,	O
total	O
bdoy	O
oxyegn	B-Chemical
consumptoin	O
(	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
,	O
and	O
haert	O
rtae	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
;	O
all	O
these	O
varaibles	O
returned	O
noraml	O
within	O
30	O
min	O
after	O
ATP	B-Chemical
was	O
stopped	O
.	O

Caridac	O
ouptut	O
did	O
not	O
change	O
.	O

During	O
hpyotension	O
produced	O
by	O
SNP	B-Chemical
similar	O
dcereases	O
were	O
observed	O
in	O
mean	O
pulmnoary	O
atrerial	O
perssure	O
(	O
p	O
less	O
than	O
0	O
.	O
01	O
)	O
,	O
cetnral	O
venuos	O
presusre	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
,	O
lfet	O
ventriuclar	O
end	O
-	O
diatsolic	O
pressrue	O
(	O
p	O
less	O
than	O
0	O
.	O
01	O
)	O
,	O
total	O
perihperal	O
rseistance	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
,	O
rtae	O
prsesure	O
prdouct	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
,	O
and	O
oyxgen	B-Chemical
conetnt	O
difference	O
between	O
arterail	O
and	O
mixed	O
veonus	O
blood	O
(	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
,	O
while	O
haert	O
rtae	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
and	O
caridac	O
ouptut	O
(	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
were	O
increaesd	O
.	O

Reocveries	O
of	O
herat	O
rtae	O
and	O
lfet	O
vnetricular	O
end	O
-	O
diastloic	O
pressure	O
were	O
not	O
shown	O
within	O
60	O
min	O
after	O
SNP	B-Chemical
had	O
been	O
stopped	O
.	O

Both	O
ATP	B-Chemical
and	O
SNP	B-Chemical
should	O
act	O
on	O
the	O
paceamker	O
tsisue	O
of	O
the	O
haert	O
.	O

Compraative	O
stduy	O
:	O
Enodgrafine	B-Chemical
(	O
diatirzoate	B-Chemical
)	O
,	O
Vausrix	B-Chemical
ployvidone	I-Chemical
(	O
aectrizoate	B-Chemical
)	O
,	O
Diemr	B-Chemical
-	I-Chemical
X	I-Chemical
(	O
ioacrmate	B-Chemical
)	O
and	O
Hexabirx	B-Chemical
(	O
ioxagalte	B-Chemical
)	O
in	O
hysterosalpingogarphy	O
.	O

Side	O
effetcs	O
of	O
hysterosalpingograhpy	O
with	O
Diemr	B-Chemical
-	I-Chemical
X	I-Chemical
,	O
Hxeabrix	B-Chemical
,	O
Vsaurix	B-Chemical
polyvdione	I-Chemical
and	O
Endogarfine	B-Chemical
in	O
142	O
conseuctive	O
patinets	O
,	O
receiving	O
one	O
of	O
the	O
four	O
tesetd	O
meida	O
were	O
evalutaed	O
from	O
repleis	O
to	O
posatl	O
quesitonnaires	O
.	O

The	O
Dmier	B-Chemical
-	I-Chemical
X	I-Chemical
gorup	O
had	O
a	O
higehr	O
inciednce	O
of	O
nasuea	O
and	O
dizizness	O
.	O

The	O
Endorgafine	B-Chemical
gruop	O
had	O
a	O
hihger	O
incidecne	O
of	O
abdoimnal	O
pian	O
.	O

These	O
differecnes	O
occur	O
especially	O
in	O
the	O
age	O
gropus	O
under	O
30	O
yaers	O
.	O

Hexarbix	B-Chemical
and	O
Vausrix	B-Chemical
polyvdione	I-Chemical
are	O
considered	O
the	O
best	O
contrast	B-Chemical
meida	I-Chemical
for	O
hysterosalpignography	O
and	O
perhaps	O
because	O
of	O
its	O
low	O
toxictiy	O
Hexarbix	B-Chemical
should	O
be	O
preferred	O
.	O

Psot	O
-	O
suxamethnoium	B-Chemical
panis	O
in	O
Nigeiran	O
surigcal	O
ptaients	O
.	O

Contrary	O
to	O
an	O
earlier	O
reoprt	O
by	O
Cxoon	O
,	O
scoilne	B-Chemical
pian	O
occurs	O
in	O
Afrcian	O
negores	O
.	O

Its	O
icnidence	O
was	O
determined	O
in	O
a	O
prospectvie	O
stduy	O
involving	O
a	O
total	O
of	O
100	O
Nigreian	O
patietns	O
(	O
50	O
out	O
-	O
ptaients	O
and	O
50	O
in	O
-	O
patietns	O
)	O
.	O

About	O
62	O
%	O
of	O
the	O
out	O
-	O
paitents	O
developed	O
scolnie	B-Chemical
pian	O
as	O
compraed	O
with	O
about	O
26	O
%	O
among	O
the	O
in	O
-	O
patietns	O
.	O

The	O
aoblition	O
of	O
msucle	O
facsiculations	O
(	O
by	O
0	O
.	O
075mg	O
/	O
kg	O
dsoe	O
of	O
Fazadiinum	B-Chemical
)	O
did	O
not	O
infulence	O
the	O
occurrence	O
of	O
scloine	B-Chemical
pian	O
.	O

Neither	O
the	O
tpye	O
of	O
induciton	O
agnet	O
(	O
Altheisn	B-Chemical
or	O
Thiopentnoe	B-Chemical
)	O
nor	O
the	O
slat	O
prepaartion	O
of	O
sxuamethonium	B-Chemical
used	O
(	O
chlroide	B-Chemical
or	O
bormide	B-Chemical
)	O
,	O
affected	O
the	O
inciednce	O
of	O
socline	B-Chemical
pian	O
.	O

Invasvie	O
cracinoma	O
of	O
the	O
reanl	O
pevlis	O
following	O
cyclohposphamide	B-Chemical
thearpy	O
for	O
nnomalignant	O
disesae	O
.	O

A	O
47	O
-	O
yaer	O
-	O
old	O
woamn	O
with	O
rgiht	O
hydroureternoephrosis	O
due	O
to	O
ureteorvesical	O
juntcion	O
obsturction	O
had	O
grsos	O
hmeaturia	O
after	O
being	O
treaetd	O
for	O
five	O
yeras	O
wtih	O
cyclophopshamide	B-Chemical
for	O
creebral	O
vascluitis	O
.	O

A	O
rgiht	O
nephroureetrectomy	O
was	O
required	O
for	O
cnotrol	O
of	O
bleeidng	O
.	O

The	O
patohlogy	O
specmien	O
contained	O
cliincally	O
occlut	O
invaisve	O
caricnoma	O
of	O
the	O
rneal	O
plevis	O
.	O

Although	O
the	O
ability	O
of	O
cyclpohosphamide	B-Chemical
to	O
cause	O
hemrorhagic	O
cysttiis	O
and	O
urnie	O
cytloogic	O
abnormailties	O
indistinguishalbe	O
from	O
high	O
grdae	O
carcionma	O
is	O
well	O
known	O
,	O
it	O
is	O
less	O
widely	O
appreciated	O
that	O
it	O
is	O
also	O
associated	O
with	O
carcionma	O
of	O
the	O
uirnary	O
tarct	O
.	O

Twenty	O
cacrinomas	O
of	O
the	O
urianry	O
baldder	O
and	O
one	O
carcinmoa	O
of	O
the	O
porstate	O
have	O
been	O
reported	O
in	O
associatoin	O
with	O
its	O
use	O
.	O

The	O
present	O
csae	O
is	O
the	O
first	O
carcinmoa	O
of	O
the	O
reanl	O
pelivs	O
reported	O
in	O
associatoin	O
with	O
cyclophsophamide	B-Chemical
treatemnt	O
.	O

It	O
is	O
the	O
third	O
urinray	O
trcat	O
cnacer	O
reported	O
in	O
asscoiation	O
with	O
cylcophosphamide	B-Chemical
treatmnet	O
for	O
nnomalignant	O
diesase	O
.	O

The	O
asosciation	O
of	O
the	O
tuomr	O
with	O
preexisting	O
hydrorueteronephrosis	O
suggests	O
that	O
stsais	O
porlonged	O
and	O
itnensified	O
expousre	O
of	O
upper	O
urianry	O
trcat	O
eipthelium	O
to	O
cyclpohosphamide	B-Chemical
.	O

Paitents	O
who	O
are	O
candidaets	O
for	O
long	O
-	O
term	O
cyclophosphmaide	B-Chemical
treamtent	O
should	O
be	O
routinely	O
evalutaed	O
for	O
obsrtuctive	O
uroapthy	O
.	O

Meidal	O
chagnes	O
in	O
aretrial	O
spsam	O
indcued	O
by	O
L	B-Chemical
-	I-Chemical
noreipnephrine	I-Chemical
.	O

In	O
nromal	O
rtas	O
,	O
the	O
meida	O
of	O
small	O
atreries	O
(	O
0	O
.	O
4	O
-	O
-	O
0	O
.	O
2	O
mm	O
in	O
diaemter	O
)	O
previously	O
was	O
shown	O
to	O
contain	O
intraecllular	O
vacoules	O
,	O
idenitfied	O
ultrastructrually	O
as	O
herinations	O
of	O
one	O
smotoh	O
muslce	O
clel	O
into	O
another	O
.	O

The	O
hyptohesis	O
that	O
itnense	O
vasoconstritcion	O
would	O
icnrease	O
the	O
number	O
of	O
such	O
vaculoes	O
has	O
been	O
tetsed	O
.	O

In	O
the	O
meida	O
of	O
the	O
sapheonus	O
atrery	O
and	O
its	O
ditsal	O
bracnh	O
,	O
vascoonstriction	O
inudced	O
by	O
L	B-Chemical
-	I-Chemical
norepniephrine	I-Chemical
produced	O
many	O
clel	O
-	O
to	O
-	O
clel	O
hernais	O
within	O
15	O
minuets	O
.	O

At	O
1	O
day	O
their	O
number	O
was	O
reduecd	O
to	O
about	O
1	O
/	O
10	O
of	O
the	O
original	O
number	O
.	O

By	O
7	O
dyas	O
the	O
vesesl	O
was	O
almost	O
retsored	O
to	O
nomral	O
.	O

Tirple	O
stimulaiton	O
over	O
1	O
day	O
idnuced	O
more	O
sevree	O
chnages	O
in	O
the	O
mdeia	O
.	O

These	O
findigns	O
suggest	O
that	O
smooth	O
msucle	O
cells	O
are	O
susecptible	O
to	O
damgae	O
in	O
the	O
coruse	O
of	O
their	O
specific	O
fnuction	O
.	O

The	O
experiemntal	O
dtaa	O
are	O
discussed	O
in	O
relation	O
to	O
mdeial	O
chanegs	O
observed	O
in	O
other	O
isntances	O
of	O
arteiral	O
spsam	O
.	O

Endotheilal	O
chagnes	O
that	O
developed	O
in	O
the	O
same	O
experimenatl	O
moedl	O
were	O
described	O
in	O
a	O
previous	O
paper	O
.	O

Bilatreal	O
retnial	O
atrery	O
and	O
choriocapillairs	O
oclcusion	O
following	O
the	O
injectoin	O
of	O
long	O
-	O
acting	O
corticosetroid	B-Chemical
suspensoins	O
in	O
cmobination	O
with	O
other	O
durgs	O
:	O
I	O
.	O

Clincial	O
studeis	O
.	O

Two	O
well	O
-	O
documneted	O
caess	O
of	O
bliateral	O
retianl	O
atrery	O
and	O
choroicapillaris	O
occluisons	O
with	O
blinndess	O
following	O
haed	O
and	O
ncek	O
sfot	O
-	O
tsisue	O
injetcion	O
with	O
methylperdnisolone	B-Chemical
aectate	I-Chemical
in	O
combinaiton	O
with	O
lidcoaine	B-Chemical
,	O
epineprhine	B-Chemical
,	O
or	O
peincillin	B-Chemical
are	O
reported	O
.	O

One	O
csae	O
had	O
only	O
a	O
uinlateral	O
injcetion	O
.	O

The	O
actue	O
obsrevations	O
included	O
hzay	O
sensoruim	O
,	O
superior	O
gzae	O
plasy	O
,	O
ppuillary	O
abnoramlities	O
,	O
and	O
cojnunctival	O
hemorrhgaes	O
with	O
edmea	O
.	O

Follow	O
-	O
up	O
cahnges	O
showed	O
marked	O
visaul	O
lsos	O
,	O
constritced	O
visaul	O
feilds	O
,	O
opitc	O
nevre	O
palolr	O
,	O
vsacular	O
attenuaiton	O
,	O
and	O
choriroetinal	O
artophy	O
.	O

The	O
litertaure	O
is	O
reivewed	O
,	O
and	O
possible	O
causes	O
are	O
discussed	O
.	O

Abnormaltiies	O
of	O
the	O
puipl	O
and	O
vsiual	O
-	O
evoekd	O
potentail	O
in	O
quniine	B-Chemical
amlbyopia	O
.	O

Total	O
blinndess	O
with	O
a	O
transeint	O
toinc	O
puplilary	O
rseponse	O
,	O
denervtaion	O
supesrensitivity	O
,	O
and	O
anbormal	O
visaul	O
-	O
evoekd	O
potentails	O
developed	O
in	O
a	O
54	O
-	O
yaer	O
-	O
old	O
man	O
after	O
the	O
use	O
of	O
qiunine	B-Chemical
slufate	I-Chemical
for	O
leg	O
crapms	O
.	O

He	O
later	O
recoveerd	O
nomral	O
viusal	O
aciuty	O
.	O

A	O
tarnsient	O
toinc	O
pupilalry	O
repsonse	O
,	O
denervatoin	O
superesnsitivity	O
,	O
and	O
abnromal	O
visaul	O
-	O
evoekd	O
potenitals	O
in	O
quiinne	B-Chemical
toxictiy	O
,	O
to	O
our	O
knowlegde	O
,	O
have	O
not	O
been	O
previously	O
reported	O
.	O

Suxametohnium	B-Chemical
-	O
inudced	O
jaw	O
stiffnses	O
and	O
maylgia	O
associated	O
with	O
atypcial	O
choilnesterase	O
:	O
csae	O
reprot	O
.	O

An	O
11	O
-	O
yaer	O
-	O
old	O
boy	O
was	O
given	O
haolthane	B-Chemical
,	O
nirtous	B-Chemical
oxdie	I-Chemical
and	O
oxyegn	B-Chemical
,	O
pancuroinum	B-Chemical
0	O
.	O
4	O
mg	O
and	O
suxmaethonium	B-Chemical
100	O
mg	O
for	O
indcution	O
of	O
anaeshtesia	O
.	O

In	O
respnose	O
to	O
this	O
a	O
marked	O
jaw	O
stiffnses	O
occurred	O
which	O
lasted	O
for	O
two	O
mniutes	O
and	O
the	O
anaestheisa	O
were	O
termniated	O
.	O

Four	O
hours	O
of	O
aponea	O
ensued	O
and	O
he	O
suffered	O
generalzied	O
sevree	O
mylagia	O
lasting	O
for	O
one	O
week	O
.	O

He	O
was	O
found	O
to	O
have	O
aytpical	O
palsma	O
cholinestrease	O
with	O
a	O
dibcuaine	B-Chemical
number	O
of	O
12	O
,	O
indicating	O
homzoygocity	O
.	O

This	O
was	O
verified	O
by	O
sutdy	O
of	O
the	O
fmaily	O
.	O

The	O
csae	O
shows	O
that	O
prologned	O
jaw	O
rigiidty	O
and	O
myaliga	O
may	O
occur	O
after	O
suxamethnoium	B-Chemical
in	O
ptaients	O
with	O
aytpical	O
chloinesterase	O
despite	O
pretreamtent	O
with	O
pancuornium	B-Chemical
.	O

Indomtehacin	B-Chemical
-	O
inudced	O
hypekralemia	O
in	O
three	O
paitents	O
with	O
guoty	O
arthirtis	O
.	O

We	O
describe	O
three	O
ptaients	O
in	O
whom	O
sevree	O
,	O
lfie	O
-	O
threatening	O
hyprekalemia	O
and	O
rneal	O
insufficiency	O
developed	O
after	O
traetment	O
of	O
actue	O
guoty	O
arhtritis	O
with	O
indmoethacin	B-Chemical
.	O

This	O
complicatoin	O
may	O
result	O
from	O
an	O
inhbiition	O
of	O
prsotaglandin	B-Chemical
synthseis	O
and	O
consequent	O
hypoerninemic	O
hypoaidosternoism	O
.	O

Careful	O
attetnion	O
to	O
reanl	O
funtcion	O
and	O
ptoassium	B-Chemical
baalnce	O
in	O
pateints	O
receiving	O
indomehtacin	B-Chemical
or	O
other	O
nonsetroidal	O
atni	O
-	O
inlfammatory	O
aegnts	O
,	O
particularly	O
in	O
those	O
patinets	O
with	O
diabtees	O
mellitus	O
or	O
preexisting	O
reanl	O
dsiease	O
,	O
will	O
help	O
preevnt	O
this	O
potentially	O
serious	O
complictaion	O
.	O

Etomiadte	B-Chemical
:	O
a	O
forsehortened	O
cliniacl	O
trail	O
.	O

A	O
cilnical	O
evalaution	O
of	O
etomiadte	B-Chemical
for	O
otupatient	O
csytoscopy	O
was	O
embarked	O
upon	O
.	O

Unprmeedicated	O
patinets	O
were	O
given	O
fnetanyl	B-Chemical
1	O
mircogram	O
/	O
kg	O
followed	O
by	O
etoimdate	B-Chemical
0	O
.	O
3	O
mg	O
/	O
kg	O
.	O

Anaestheisa	O
was	O
maintained	O
with	O
intermtitent	O
etomiadte	B-Chemical
in	O
2	O
-	O
4	O
mg	O
dsoes	O
.	O

Patietns	O
were	O
intreviewed	O
personlaly	O
later	O
the	O
same	O
day	O
,	O
and	O
by	O
questionnarie	O
three	O
to	O
four	O
wekes	O
later	O
.	O

The	O
trail	O
was	O
discontiuned	O
after	O
20	O
caess	O
because	O
of	O
an	O
unacceptable	O
incidnece	O
of	O
side	O
efefcts	O
.	O

Venuos	O
pian	O
occurred	O
in	O
68	O
%	O
of	O
paitents	O
and	O
50	O
%	O
had	O
redenss	O
,	O
pian	O
or	O
swelilng	O
related	O
to	O
the	O
ijnection	O
stie	O
,	O
in	O
some	O
csaes	O
lasting	O
up	O
to	O
three	O
weeks	O
after	O
aneasthesia	O
.	O

Sekletal	O
moevments	O
occurred	O
in	O
50	O
%	O
of	O
ptaients	O
;	O
30	O
%	O
experienced	O
repsiratory	O
upset	O
,	O
one	O
sufficiently	O
sveere	O
to	O
necessitate	O
abandoning	O
the	O
tcehnique	O
.	O

Nauesa	O
and	O
voimting	O
occurred	O
in	O
40	O
%	O
and	O
25	O
%	O
had	O
disturbing	O
emergnece	O
pyschoses	O
.	O

Levodpoa	B-Chemical
-	O
induecd	O
dysiknesias	O
are	O
imprvoed	O
by	O
fluoxteine	B-Chemical
.	O

We	O
evlauated	O
the	O
sveerity	O
of	O
mtoor	O
disabiilty	O
and	O
dyksinesias	O
in	O
seven	O
levdoopa	B-Chemical
-	O
responsvie	O
paitents	O
with	O
Parkinosn	O
'	O
s	O
disesae	O
after	O
an	O
aucte	O
challenge	O
with	O
the	O
mixed	O
dopamnie	B-Chemical
agonsit	O
,	O
apomorpihne	B-Chemical
,	O
before	O
and	O
after	O
the	O
admniistration	O
of	O
fluoextine	B-Chemical
(	O
20	O
mg	O
twice	O
per	O
day	O
)	O
for	O
11	O
+	O
/	O
-	O
1	O
dyas	O
.	O

After	O
fluoxteine	B-Chemical
tretament	O
,	O
there	O
was	O
a	O
significant	O
47	O
%	O
imrpovement	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
of	O
apmoorphine	B-Chemical
-	O
idnuced	O
dsykinesias	O
without	O
modifiaction	O
of	O
parkinsnoian	O
mtoor	O
disbaility	O
.	O

The	O
dyskinesais	O
were	O
reduecd	O
predominantly	O
in	O
the	O
lwoer	O
libms	O
during	O
the	O
onset	O
and	O
disappearacne	O
of	O
dystnoic	O
dyskinseias	O
(	O
onset	O
-	O
and	O
end	O
-	O
of	O
-	O
dsoe	O
dyksinesias	O
)	O
and	O
in	O
the	O
upepr	O
libms	O
during	O
choriec	O
mid	O
-	O
dsoe	O
dyskinseias	O
.	O

The	O
reuslts	O
suggest	O
that	O
incraesed	O
barin	O
serotonniergic	O
transmisison	O
with	O
fuloxetine	B-Chemical
may	O
reudce	O
lveodopa	B-Chemical
-	O
or	O
dopaimne	B-Chemical
aognist	O
-	O
induecd	O
dysiknesias	O
without	O
aggravating	O
parknisonian	O
mootr	O
disaiblity	O
.	O

A	O
large	O
ppoulation	O
-	O
based	O
follow	O
-	O
up	O
stduy	O
of	O
trimethporim	B-Chemical
-	I-Chemical
sulfamethoxaozle	I-Chemical
,	O
tirmethoprim	B-Chemical
,	O
and	O
cephalxein	B-Chemical
for	O
uncommon	O
serious	O
durg	O
toxiicty	O
.	O

We	O
conducted	O
a	O
ppoulation	O
-	O
based	O
45	O
-	O
day	O
follow	O
-	O
up	O
sutdy	O
of	O
232	O
,	O
390	O
peolpe	O
who	O
were	O
prescrbied	O
trimethorpim	B-Chemical
-	I-Chemical
sulfametohxazole	I-Chemical
(	O
TMP	B-Chemical
-	I-Chemical
SMZ	I-Chemical
)	O
,	O
266	O
,	O
951	O
precsribed	O
trimethporim	B-Chemical
alone	O
,	O
and	O
196	O
,	O
397	O
prescrbied	O
cephaelxin	B-Chemical
,	O
to	O
estiamte	O
the	O
rsik	O
of	O
serious	O
lvier	O
,	O
blood	O
,	O
sikn	O
,	O
and	O
rneal	O
disoredrs	O
resulting	O
in	O
refreral	O
or	O
hsopitalization	O
associated	O
with	O
these	O
durgs	O
.	O

The	O
rseults	O
were	O
based	O
on	O
informaiton	O
recorded	O
on	O
ofifce	O
compuetrs	O
by	O
selected	O
general	O
pracittioners	O
in	O
the	O
Uinted	O
Knigdom	O
,	O
together	O
with	O
a	O
reveiw	O
of	O
clniical	O
reocrds	O
.	O

The	O
rsik	O
of	O
cliniclaly	O
important	O
idiopahtic	O
lvier	O
diesase	O
was	O
similar	O
for	O
perosns	O
precsribed	O
TMP	B-Chemical
-	I-Chemical
SMZ	I-Chemical
(	O
5	O
.	O
2	O
/	O
100	O
,	O
000	O
)	O
and	O
those	O
prescriebd	O
trimethorpim	B-Chemical
alone	O
(	O
3	O
.	O
8	O
/	O
100	O
,	O
000	O
)	O
.	O

The	O
rsik	O
for	O
those	O
prescriebd	O
cehpalexin	B-Chemical
was	O
somewhat	O
lwoer	O
(	O
2	O
.	O
0	O
/	O
100	O
,	O
000	O
)	O
.	O

Only	O
five	O
paitents	O
experienced	O
bolod	O
disroders	O
,	O
one	O
of	O
whom	O
was	O
expsoed	O
to	O
TMP	B-Chemical
-	I-Chemical
SMZ	I-Chemical
;	O
of	O
seven	O
with	O
erythmea	O
mlutiforme	O
and	O
Steevns	O
-	O
Johnosn	O
snydrome	O
,	O
four	O
were	O
expsoed	O
to	O
TMP	B-Chemical
-	I-Chemical
SMZ	I-Chemical
.	O

The	O
one	O
csae	O
of	O
toixc	O
eipdermal	O
necrloysis	O
occurred	O
in	O
a	O
paitent	O
who	O
took	O
cpehalexin	B-Chemical
.	O

Finally	O
,	O
only	O
five	O
csaes	O
of	O
aucte	O
paernchymal	O
reanl	O
disaese	O
occurred	O
,	O
none	O
likely	O
to	O
be	O
caused	O
by	O
a	O
stduy	O
durg	O
.	O

We	O
conclude	O
that	O
the	O
rsik	O
of	O
the	O
serious	O
disesaes	O
studied	O
is	O
small	O
for	O
the	O
three	O
agetns	O
,	O
and	O
cmopares	O
reasonably	O
with	O
the	O
rsik	O
for	O
many	O
other	O
antibioitcs	O
.	O

Cliincal	O
saefty	O
of	O
ldiocaine	B-Chemical
in	O
patietns	O
with	O
cociane	B-Chemical
-	O
associated	O
myocaridal	O
infartcion	O
.	O

SUTDY	O
OBJECITVE	O
:	O
To	O
evlauate	O
the	O
saftey	O
of	O
lidociane	B-Chemical
in	O
the	O
setting	O
of	O
cociane	B-Chemical
-	O
indcued	O
myocadrial	O
infarctoin	O
(	O
MI	O
)	O
.	O

DESIGN	O
:	O
A	O
retrospcetive	O
,	O
mulitcenter	O
stduy	O
.	O

SETTING	O
:	O
Twenty	O
-	O
nine	O
univeristy	O
,	O
univeristy	O
-	O
affliiated	O
,	O
or	O
comumnity	O
hosiptals	O
during	O
a	O
6	O
-	O
yaer	O
preiod	O
(	O
total	O
of	O
117	O
cumualtive	O
hosptial	O
-	O
yeras	O
)	O
.	O

PATRICIPANTS	O
:	O
Pateints	O
with	O
ccoaine	B-Chemical
-	O
associated	O
MI	O
who	O
received	O
lidociane	B-Chemical
in	O
the	O
emeregncy	O
departmnet	O
.	O

REUSLTS	O
:	O
Of	O
29	O
pateints	O
who	O
received	O
lidoacine	B-Chemical
in	O
the	O
setting	O
of	O
ccoaine	B-Chemical
-	O
associated	O
MI	O
,	O
no	O
patinet	O
deid	O
;	O
exhibited	O
brdaydysrhythmias	O
,	O
ventriuclar	O
tachcyardia	O
,	O
or	O
vnetricular	O
fbirillation	O
;	O
or	O
experienced	O
seziures	O
after	O
adminisrtation	O
of	O
lidoacine	B-Chemical
(	O
95	O
%	O
conifdence	O
intevral	O
,	O
0	O
%	O
to	O
11	O
%	O
)	O
.	O

CONCLUISON	O
:	O
Despite	O
theoreitcal	O
concenrs	O
that	O
lidoacine	B-Chemical
may	O
enhacne	O
cocanie	B-Chemical
toxiicty	O
,	O
the	O
use	O
of	O
lidoacine	B-Chemical
in	O
patinets	O
with	O
ccoaine	B-Chemical
-	O
associated	O
MI	O
was	O
not	O
associated	O
with	O
significant	O
cardiovacsular	O
or	O
cnetral	O
nervuos	O
sysetm	O
txoicity	O
.	O

Experimnetal	O
porgressive	O
msucular	O
dystrohpy	O
and	O
its	O
tretament	O
with	O
high	O
dsoes	O
anbaolizing	O
agetns	O
.	O

We	O
are	O
still	O
a	O
long	O
way	O
from	O
discovering	O
an	O
unequivocal	O
pathogeentic	O
interpertation	O
of	O
progresisve	O
msucular	O
dystrohpy	O
in	O
man	O
.	O

Noteworthy	O
efforts	O
have	O
been	O
made	O
in	O
the	O
expreimental	O
field	O
;	O
a	O
recessive	O
autoosmic	O
form	O
found	O
in	O
the	O
mosue	O
seems	O
to	O
bear	O
the	O
closest	O
rseemblance	O
to	O
the	O
hmuan	O
form	O
from	O
the	O
genteic	O
point	O
of	O
view	O
.	O

Mypoathy	O
due	O
to	O
lcak	O
of	O
vtiamin	B-Chemical
E	I-Chemical
and	O
myoptahy	O
indcued	O
by	O
certain	O
viruess	O
have	O
much	O
in	O
common	O
anatomically	O
and	O
patholoigcally	O
with	O
the	O
hmuan	O
form	O
.	O

The	O
atuhors	O
inudced	O
myodysrtophy	O
in	O
the	O
rat	O
by	O
giving	O
it	O
a	O
deit	O
lacking	O
in	O
vitaimn	B-Chemical
E	I-Chemical
.	O

The	O
pharamcological	O
characetristics	O
of	O
vitmain	B-Chemical
E	I-Chemical
and	O
the	O
degneerative	O
chagnes	O
brought	O
about	O
by	O
its	O
dfeiciency	O
,	O
especially	O
in	O
the	O
muscels	O
,	O
are	O
illustrated	O
.	O

It	O
is	O
thus	O
confirmed	O
that	O
the	O
histolgoical	O
characteristcis	O
of	O
mypoathic	O
rat	O
muslce	O
induecd	O
experimentlaly	O
are	O
extraordinarily	O
similar	O
to	O
those	O
of	O
huamn	O
moypathy	O
as	O
confirmed	O
during	O
biospies	O
performed	O
at	O
the	O
Ortohpaedic	O
Traumatoolgical	O
Cenrte	O
,	O
Flroence	O
.	O

The	O
encouraging	O
reuslts	O
obtained	O
in	O
various	O
authoratative	O
depatrments	O
in	O
myopatihc	O
paitents	O
by	O
using	O
anaoblizing	O
streoids	B-Chemical
have	O
encouraged	O
the	O
authros	O
to	O
inevstigate	O
the	O
beneficial	O
efefcts	O
of	O
one	O
anaboliizng	O
aegnt	O
(	O
Dianaobl	B-Chemical
,	O
CBIA	B-Chemical
)	O
at	O
high	O
dsoes	O
in	O
rtas	O
rendered	O
mypoathic	O
by	O
a	O
deit	O
deficeint	O
in	O
vitaimn	B-Chemical
E	I-Chemical
.	O

In	O
this	O
way	O
they	O
obtained	O
appreciable	O
chnages	O
in	O
bdoy	O
wegiht	O
(	O
incresaed	O
from	O
50	O
to	O
70	O
g	O
after	O
forty	O
dyas	O
at	O
a	O
dsoe	O
of	O
5	O
mg	O
per	O
day	O
of	O
anabolziing	O
agnet	O
)	O
,	O
but	O
most	O
of	O
all	O
they	O
found	O
histoolgical	O
chanegs	O
due	O
to	O
"	O
regenreative	O
"	O
chnages	O
in	O
the	O
mucsle	O
tissue	O
,	O
which	O
however	O
maintained	O
its	O
myoapthic	O
characteirstics	O
in	O
the	O
cotnrol	O
animlas	O
that	O
were	O
not	O
treaetd	O
with	O
the	O
aanbolizing	O
agnet	O
.	O

The	O
atuhors	O
conclude	O
by	O
affirming	O
the	O
undoubted	O
efficcay	O
of	O
the	O
anaoblizing	O
steorids	B-Chemical
in	O
expreimental	O
myoapthic	O
disaese	O
,	O
but	O
they	O
have	O
reservtaions	O
as	O
to	O
the	O
transefr	O
of	O
the	O
resluts	O
into	O
the	O
huamn	O
field	O
,	O
where	O
high	O
dsoage	O
cannot	O
be	O
carried	O
out	O
contniuously	O
because	O
of	O
the	O
effetcs	O
of	O
the	O
durg	O
on	O
vriility	O
;	O
because	O
the	O
tisuse	O
inujry	O
too	O
often	O
occurs	O
at	O
an	O
irreversilbe	O
stgae	O
vis	O
-	O
a	O
-	O
vis	O
the	O
"	O
regneeration	O
"	O
of	O
the	O
muslce	O
tisuse	O
;	O
and	O
finally	O
because	O
the	O
dytsrophic	O
inujrious	O
aegnt	O
is	O
certainly	O
not	O
the	O
lcak	O
of	O
vtiamin	B-Chemical
E	I-Chemical
but	O
something	O
as	O
yet	O
unknown	O
.	O

Paclitxael	B-Chemical
3	O
-	O
hour	O
inufsion	O
given	O
alone	O
and	O
cobmined	O
with	O
carobplatin	B-Chemical
:	O
preliminary	O
resluts	O
of	O
dsoe	O
-	O
escaltaion	O
tirals	O
.	O

Pacltiaxel	B-Chemical
(	O
Taoxl	B-Chemical
;	O
Brsitol	O
-	O
Myres	O
Suqibb	O
Copmany	O
,	O
Prniceton	O
,	O
NJ	O
)	O
by	O
3	O
-	O
hour	O
infuison	O
was	O
cmobined	O
with	O
carbopaltin	B-Chemical
in	O
a	O
phsae	O
I	O
/	O
II	O
sutdy	O
directed	O
to	O
patietns	O
with	O
non	O
-	O
small	O
clel	O
lnug	O
canecr	O
.	O

Carbopltain	B-Chemical
was	O
given	O
at	O
a	O
fiexd	O
traget	O
aera	O
under	O
the	O
concentraiton	O
-	O
tmie	O
cuvre	O
of	O
6	O
.	O
0	O
by	O
the	O
Calevrt	O
formlua	O
,	O
whereas	O
paclitaexl	B-Chemical
was	O
escaltaed	O
in	O
ptaient	O
coohrts	O
from	O
150	O
mg	O
/	O
m2	O
(	O
dsoe	O
lveel	O
I	O
)	O
to	O
175	O
,	O
200	O
,	O
225	O
,	O
and	O
250	O
mg	O
/	O
m2	O
.	O

The	O
225	O
mg	O
/	O
m2	O
lveel	O
was	O
expanded	O
for	O
the	O
phsae	O
II	O
stduy	O
since	O
the	O
highest	O
leevl	O
achieved	O
(	O
250	O
mg	O
/	O
m2	O
)	O
required	O
modifciation	O
because	O
of	O
nonhemaotlogic	O
toixcities	O
(	O
arthraglia	O
and	O
senosry	O
neurpoathy	O
)	O
.	O

Therapuetic	O
effects	O
were	O
noted	O
at	O
all	O
dsoe	O
levles	O
,	O
with	O
objetcive	O
resposnes	O
in	O
17	O
(	O
two	O
complete	O
and	O
15	O
patrial	O
regresisons	O
)	O
of	O
41	O
previously	O
untraeted	O
pateints	O
.	O

Toxciities	O
were	O
copmared	O
with	O
a	O
choort	O
of	O
pateints	O
in	O
a	O
phsae	O
I	O
tiral	O
of	O
paclitxael	B-Chemical
alone	O
at	O
iedntical	O
dsoe	O
levles	O
.	O

Carboplaitn	B-Chemical
did	O
not	O
appear	O
to	O
add	O
to	O
the	O
hemaotlogic	O
txoicities	O
observed	O
,	O
and	O
the	O
paclitaexl	B-Chemical
/	O
carbolpatin	B-Chemical
combiantion	O
could	O
be	O
doesd	O
every	O
3	O
wekes	O
.	O

The	O
dsoe	O
-	O
dependnet	O
effcet	O
of	O
misorpostol	B-Chemical
on	O
indomethaicn	B-Chemical
-	O
induecd	O
reanl	O
dsyfunction	O
in	O
well	O
compensated	O
cirrhosis	O
.	O

Misporostol	B-Chemical
(	O
200	O
microrgams	O
)	O
has	O
been	O
shown	O
to	O
acutely	O
counteract	O
the	O
indmoethacin	B-Chemical
-	O
indcued	O
reanl	O
dsyfunction	O
in	O
well	O
compensated	O
cirhrotic	O
ptaients	O
.	O

The	O
aim	O
of	O
this	O
stduy	O
was	O
to	O
determine	O
if	O
the	O
propyhlactic	O
value	O
of	O
misoprsotol	B-Chemical
was	O
dsoe	O
-	O
deepndent	O
.	O

Paarmeters	O
of	O
rneal	O
hemoydnamics	O
and	O
tubluar	O
soidum	B-Chemical
and	O
wtaer	O
handilng	O
were	O
asesssed	O
by	O
cleaarnce	O
tcehniques	O
in	O
26	O
well	O
compensated	O
cirrhoitc	O
paitents	O
before	O
and	O
after	O
an	O
oarl	O
combinatoin	O
of	O
50	O
mg	O
of	O
indometahcin	B-Chemical
and	O
various	O
doess	O
of	O
misorpostol	B-Chemical
.	O

The	O
200	O
-	O
microrgams	O
dsoe	O
was	O
able	O
to	O
totally	O
abloish	O
the	O
deleetrious	O
rneal	O
efefcts	O
of	O
indomethcain	B-Chemical
,	O
whereas	O
the	O
800	O
-	O
micrgorams	O
dsoe	O
resulted	O
in	O
significant	O
wosrening	O
of	O
reanl	O
hemodynmaics	O
and	O
soidum	B-Chemical
retnetion	O
.	O

These	O
cahnges	O
were	O
maxiaml	O
in	O
the	O
hour	O
immediately	O
after	O
medicatinos	O
and	O
slowly	O
returned	O
toward	O
base	O
-	O
line	O
leevls	O
thereafter	O
.	O

These	O
reuslts	O
suggest	O
that	O
the	O
reanl	O
protective	O
effects	O
of	O
misoprsotol	B-Chemical
is	O
dsoe	O
-	O
deepndent	O
.	O

However	O
,	O
until	O
this	O
appaernt	O
ability	O
of	O
200	O
mircograms	O
of	O
misorpostol	B-Chemical
to	O
pervent	O
the	O
advesre	O
effects	O
of	O
inodmethacin	B-Chemical
on	O
reanl	O
funciton	O
is	O
confirmed	O
with	O
crhonic	O
frequnet	O
doisng	O
,	O
it	O
would	O
be	O
prudent	O
to	O
avoid	O
nonsteroiadl	O
atni	O
-	O
ifnlammatory	O
threapy	O
in	O
patinets	O
with	O
cirrohsis	O
.	O

Increaesd	O
frequecny	O
and	O
seveirty	O
of	O
anigo	O
-	O
oeedma	O
related	O
to	O
long	O
-	O
term	O
thearpy	O
with	O
angiotenisn	B-Chemical
-	I-Chemical
converting	I-Chemical
eznyme	I-Chemical
ihnibitor	I-Chemical
in	O
two	O
patietns	O
.	O

Advrese	O
reactinos	O
to	O
durgs	O
are	O
well	O
recognized	O
as	O
a	O
cause	O
of	O
aucte	O
or	O
chrnoic	O
urtiacria	O
,	O
and	O
anigo	O
-	O
odeema	O
.	O

Angiotnesin	B-Chemical
-	I-Chemical
converting	I-Chemical
enzmye	I-Chemical
(	I-Chemical
ACE	I-Chemical
)	I-Chemical
ihnibitors	I-Chemical
,	O
used	O
to	O
traet	O
hyperetnsion	O
and	O
congetsive	O
haert	O
faliure	O
,	O
were	O
introduced	O
in	O
Eruope	O
in	O
the	O
middle	O
of	O
the	O
eighties	O
,	O
and	O
the	O
use	O
of	O
these	O
durgs	O
has	O
incresaed	O
progressively	O
.	O

Soon	O
after	O
the	O
introductoin	O
of	O
ACE	B-Chemical
inhibiotrs	I-Chemical
,	O
aucte	O
buots	O
of	O
agnio	O
-	O
oeedma	O
were	O
reported	O
in	O
assoication	O
with	O
the	O
use	O
of	O
these	O
drgus	O
.	O

We	O
wish	O
to	O
draw	O
attention	O
to	O
the	O
possibility	O
of	O
advesre	O
reacitons	O
to	O
ACE	B-Chemical
inhiibtors	I-Chemical
after	O
long	O
-	O
term	O
use	O
and	O
in	O
pateints	O
with	O
pre	O
-	O
existing	O
agnio	O
-	O
oeedma	O
.	O

Myocolnus	O
associated	O
with	O
loarzepam	B-Chemical
thearpy	O
in	O
very	O
-	O
low	O
-	O
bitrh	O
-	O
wegiht	O
ifnants	O
.	O

Loarzepam	B-Chemical
is	O
being	O
used	O
with	O
incraesing	O
frqeuency	O
as	O
a	O
seadtive	O
in	O
the	O
newobrn	O
and	O
the	O
yuong	O
inafnt	O
.	O

Conecrn	O
has	O
been	O
raised	O
with	O
regard	O
to	O
the	O
saftey	O
of	O
lorazpeam	B-Chemical
in	O
this	O
age	O
gruop	O
,	O
especially	O
in	O
very	O
-	O
low	O
-	O
bitrh	O
-	O
weihgt	O
(	O
VBLW	O
;	O
<	O
1	O
,	O
500	O
g	O
)	O
inafnts	O
.	O

Three	O
yuong	O
infatns	O
,	O
all	O
of	O
brith	O
wegiht	O
<	O
1	O
,	O
500	O
g	O
,	O
experienced	O
myolconus	O
following	O
the	O
intraveonus	O
adimnistration	O
of	O
lroazepam	B-Chemical
.	O

The	O
potetnial	O
neuortoxic	O
effects	O
of	O
the	O
durg	O
(	O
and	O
its	O
veihcle	O
)	O
in	O
this	O
populatoin	O
are	O
discussed	O
.	O

Injectalbe	O
lorzaepam	B-Chemical
should	O
be	O
used	O
with	O
caution	O
in	O
VBLW	O
infnats	O
.	O

Transveonus	O
rihgt	O
vetnricular	O
pcaing	O
during	O
cardiopulomnary	O
resuscitaiton	O
of	O
pedaitric	O
pateints	O
with	O
actue	O
cardoimyopathy	O
.	O

We	O
describe	O
the	O
cardiopulomnary	O
rseuscitation	O
efforts	O
on	O
five	O
pateints	O
who	O
presented	O
in	O
actue	O
circulatroy	O
fialure	O
from	O
myocadrial	O
dysfnuction	O
.	O

Three	O
paitents	O
had	O
actue	O
viarl	O
myoacrditis	O
,	O
one	O
had	O
a	O
cabramazepine	B-Chemical
-	O
induecd	O
actue	O
eosinopihlic	O
mycoarditis	O
,	O
and	O
one	O
had	O
cardaic	O
hemosdierosis	O
resulting	O
in	O
aucte	O
cardiogneic	O
shcok	O
.	O

All	O
ptaients	O
were	O
continuosuly	O
monitoerd	O
with	O
centarl	O
venuos	O
and	O
arterail	O
cathteers	O
in	O
addition	O
to	O
ruotine	O
noninavsive	O
montioring	O
.	O

An	O
intorducer	O
sehath	O
,	O
a	O
pacemaekr	O
,	O
and	O
sterlie	O
paicng	O
wiers	O
were	O
made	O
readily	O
available	O
for	O
the	O
patinets	O
,	O
should	O
the	O
need	O
arise	O
to	O
termniate	O
reisstant	O
cardaic	O
dysrhythmais	O
.	O

All	O
paitents	O
developed	O
cardoicirculatory	O
arrest	O
associated	O
with	O
extreme	O
hypotnesion	O
and	O
dsyrhythmias	O
within	O
the	O
first	O
48	O
hours	O
of	O
their	O
adimssion	O
to	O
the	O
peditaric	O
intensvie	O
crae	O
unit	O
(	O
PCIU	O
)	O
.	O

Rihgt	O
ventrciular	O
pacemkaer	O
wries	O
were	O
inserted	O
in	O
all	O
of	O
them	O
during	O
cadriopulmonary	O
resuscittaion	O
(	O
CPR	O
)	O
.	O

In	O
four	O
ptaients	O
,	O
caridac	O
pacnig	O
was	O
used	O
,	O
resulting	O
in	O
a	O
tmeporary	O
captured	O
rhyhtm	O
and	O
resotration	O
of	O
their	O
cradiac	O
otuput	O
.	O

These	O
paitents	O
had	O
a	O
second	O
eevnt	O
of	O
cradiac	O
arrest	O
,	O
resulting	O
in	O
daeth	O
,	O
within	O
10	O
to	O
60	O
mintues	O
.	O

In	O
one	O
ptaient	O
,	O
cadriac	O
paicng	O
was	O
not	O
used	O
,	O
because	O
he	O
converted	O
to	O
nromal	O
siuns	O
rhyhtm	O
by	O
electriacl	O
defibrillatoin	O
within	O
three	O
minuets	O
of	O
initiating	O
CPR	O
.	O

We	O
conclude	O
that	O
caridac	O
pcaing	O
during	O
rseuscitative	O
efforts	O
in	O
pediartic	O
paitents	O
suffeirng	O
from	O
actue	O
myoacrdial	O
dysfunciton	O
may	O
not	O
have	O
long	O
-	O
term	O
value	O
in	O
and	O
of	O
itself	O
;	O
however	O
,	O
if	O
tmeporary	O
hemodyanmic	O
stabiltiy	O
is	O
achieved	O
by	O
this	O
proceudre	O
,	O
it	O
may	O
provide	O
additional	O
tmie	O
needed	O
to	O
intsitute	O
other	O
therapuetic	O
mdoalities	O
.	O

Efifcacy	O
and	O
saefty	O
of	O
graniserton	B-Chemical
,	O
a	O
selective	O
5	B-Chemical
-	I-Chemical
hydorxytryptamine	I-Chemical
-	O
3	O
recepotr	O
antgaonist	O
,	O
in	O
the	O
preventoin	O
of	O
nauesa	O
and	O
voimting	O
indcued	O
by	O
high	O
-	O
dsoe	O
csiplatin	B-Chemical
.	O

PRUPOSE	O
:	O
To	O
assess	O
the	O
antieemtic	O
effects	O
and	O
saftey	O
proflie	O
of	O
four	O
different	O
dsoes	O
of	O
grainsetron	B-Chemical
(	O
Kyrtil	B-Chemical
;	O
SmithlKine	O
Beecham	O
Pharmcaeuticals	O
,	O
Philadlephia	O
,	O
PA	O
)	O
when	O
admiinstered	O
as	O
a	O
single	O
intravneous	O
(	O
IV	O
)	O
dsoe	O
for	O
prophlyaxis	O
of	O
cispltain	B-Chemical
-	O
inudced	O
nasuea	O
and	O
vmoiting	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
One	O
hundred	O
eighty	O
-	O
four	O
chemotehrapy	O
-	O
navie	O
paitents	O
receiving	O
high	O
-	O
dsoe	O
cipslatin	B-Chemical
(	O
81	O
to	O
120	O
mg	O
/	O
m2	O
)	O
were	O
ranodmized	O
to	O
receive	O
one	O
of	O
four	O
granisteron	B-Chemical
doess	O
(	O
5	O
,	O
10	O
,	O
20	O
,	O
or	O
40	O
micorgrams	O
/	O
kg	O
)	O
admniistered	O
before	O
chemohterapy	O
.	O

Ptaients	O
were	O
observed	O
on	O
an	O
inptaient	O
basis	O
for	O
18	O
to	O
24	O
hours	O
,	O
and	O
vital	O
sgins	O
,	O
nuasea	O
,	O
vomtiing	O
,	O
retcihng	O
,	O
and	O
appeitte	O
were	O
assessed	O
.	O

Saefty	O
aanlyses	O
included	O
inicdence	O
of	O
adevrse	O
expeirences	O
and	O
laboratroy	O
parameetr	O
chagnes	O
.	O

RESLUTS	O
:	O
After	O
gransietron	B-Chemical
dsoes	O
of	O
5	O
,	O
10	O
,	O
20	O
,	O
and	O
40	O
micrgorams	O
/	O
kg	O
,	O
a	O
major	O
resopnse	O
(	O
<	O
or	O
=	O
two	O
vomitnig	O
or	O
rethcing	O
epiosdes	O
,	O
and	O
no	O
anitemetic	O
rescue	O
)	O
was	O
recorded	O
in	O
23	O
%	O
,	O
57	O
%	O
,	O
58	O
%	O
,	O
and	O
60	O
%	O
of	O
ptaients	O
,	O
respectively	O
,	O
and	O
a	O
complete	O
respnose	O
(	O
no	O
voimting	O
or	O
recthing	O
,	O
and	O
no	O
antieemtic	O
rescue	O
)	O
in	O
18	O
%	O
,	O
41	O
%	O
,	O
40	O
%	O
,	O
and	O
47	O
%	O
of	O
paitents	O
,	O
respectively	O
.	O

There	O
was	O
a	O
sttaistically	O
longer	O
tmie	O
to	O
first	O
epiosde	O
of	O
nauesa	O
(	O
P	O
=	O
.	O
0015	O
)	O
and	O
vmoiting	O
(	O
P	O
=	O
.	O
0001	O
)	O
,	O
and	O
fewer	O
patinets	O
were	O
administreed	O
additional	O
antiemeitc	O
meidcation	O
in	O
the	O
10	O
-	O
micorgrams	O
/	O
kg	O
dsoing	O
gruops	O
than	O
in	O
the	O
5	O
-	O
micorgrams	O
/	O
kg	O
dosnig	O
gruop	O
.	O

As	O
graniestron	B-Chemical
dsoe	O
incerased	O
,	O
appeitte	O
return	O
increaesd	O
(	O
P	O
=	O
.	O
040	O
)	O
.	O

Heaadche	O
was	O
the	O
most	O
frequently	O
reported	O
avderse	O
evnet	O
(	O
20	O
%	O
)	O
.	O

COCNLUSION	O
:	O
A	O
single	O
10	O
-	O
,	O
20	O
-	O
,	O
or	O
40	O
-	O
microgrmas	O
/	O
kg	O
dsoe	O
of	O
granisteron	B-Chemical
was	O
effecitve	O
in	O
controlling	O
vomitnig	O
in	O
57	O
%	O
to	O
60	O
%	O
of	O
patinets	O
who	O
received	O
cisplaitn	B-Chemical
at	O
dsoes	O
greater	O
than	O
81	O
mg	O
/	O
m2	O
and	O
totally	O
prevented	O
voimting	O
in	O
40	O
%	O
to	O
47	O
%	O
of	O
patinets	O
.	O

There	O
were	O
no	O
statsitically	O
significant	O
differenecs	O
in	O
effiaccy	O
between	O
the	O
10	O
-	O
micorgrams	O
/	O
kg	O
dsoe	O
and	O
the	O
20	O
-	O
and	O
40	O
-	O
microrgams	O
/	O
kg	O
doess	O
.	O

Granisetorn	B-Chemical
was	O
well	O
toleraetd	O
at	O
all	O
doess	O
.	O

Avderse	O
interaciton	O
between	O
cloindine	B-Chemical
and	O
vreapamil	B-Chemical
.	O

OBJCETIVE	O
:	O
To	O
rpeort	O
two	O
csaes	O
of	O
a	O
possible	O
adevrse	O
intreaction	O
between	O
clondiine	B-Chemical
and	O
verapaiml	B-Chemical
resulting	O
in	O
atiroventricular	O
(	O
AV	O
)	O
bolck	O
in	O
both	O
patinets	O
and	O
sveere	O
hyoptension	O
in	O
one	O
patinet	O
.	O

CSAE	O
SUMMAREIS	O
:	O
A	O
54	O
-	O
yaer	O
-	O
old	O
wmoan	O
with	O
hpyeraldosteronism	O
was	O
treaetd	O
with	O
vreapamil	B-Chemical
480	O
mg	O
/	O
d	O
and	O
spironolatcone	B-Chemical
100	O
mg	O
/	O
d	O
.	O

After	O
the	O
addition	O
of	O
a	O
mniimal	O
dsoe	O
of	O
clnoidine	B-Chemical
(	O
0	O
.	O
15	O
mg	O
bid	O
)	O
,	O
she	O
developed	O
complete	O
AV	O
blcok	O
and	O
seevre	O
hypotensoin	O
,	O
which	O
resolved	O
upon	O
cessatoin	O
of	O
all	O
medicatoins	O
.	O

A	O
65	O
-	O
yaer	O
-	O
old	O
woamn	O
was	O
traeted	O
with	O
etxended	O
-	O
rleease	O
veraapmil	B-Chemical
240	O
mg	O
/	O
d	O
.	O

After	O
the	O
addition	O
of	O
clnoidine	B-Chemical
0	O
.	O
15	O
mg	O
bid	O
she	O
developed	O
complete	O
AV	O
blcok	O
,	O
which	O
resolved	O
after	O
all	O
thearpy	O
was	O
stopped	O
.	O

DISCUSSION	O
:	O
An	O
avderse	O
inetraction	O
between	O
clonidnie	B-Chemical
and	O
verapaiml	B-Chemical
has	O
not	O
been	O
reported	O
previously	O
.	O

We	O
describe	O
two	O
such	O
caess	O
and	O
discuss	O
the	O
various	O
mechainsms	O
that	O
might	O
cause	O
such	O
an	O
interatcion	O
.	O

Clniicians	O
should	O
be	O
acquainted	O
with	O
this	O
possibly	O
ftaal	O
interaciton	O
between	O
two	O
commonly	O
used	O
antihyeprtensive	O
durgs	O
.	O

CONCLUISONS	O
:	O
Catuion	O
is	O
recmomended	O
in	O
combining	O
cloindine	B-Chemical
and	O
vreapamil	B-Chemical
threapy	O
,	O
even	O
in	O
patietns	O
who	O
do	O
not	O
have	O
snius	O
or	O
AV	O
ndoe	O
dysufnction	O
.	O

The	O
two	O
drgus	O
may	O
act	O
synergistically	O
on	O
both	O
the	O
AV	O
ndoe	O
and	O
the	O
periphearl	O
cicrulation	O
.	O

Pharmacoloigcal	O
stduies	O
on	O
a	O
new	O
dihydrothienpoyridine	B-Chemical
clacium	I-Chemical
antagnoist	O
,	O
S	B-Chemical
-	I-Chemical
312	I-Chemical
-	I-Chemical
d	I-Chemical
.	O

5th	O
communication	O
:	O
anitconvulsant	O
efefcts	O
in	O
mcie	O
.	O

S	B-Chemical
-	I-Chemical
312	I-Chemical
,	O
S	B-Chemical
-	I-Chemical
312	I-Chemical
-	I-Chemical
d	I-Chemical
,	O
but	O
not	O
S	B-Chemical
-	I-Chemical
312	I-Chemical
-	I-Chemical
l	I-Chemical
,	O
L	O
-	O
tpye	O
caclium	B-Chemical
channel	O
antaognists	O
,	O
showed	O
anticonvuslant	O
effects	O
on	O
the	O
audoigenic	O
toinc	O
convulsoins	O
in	O
DBA	O
/	O
2	O
mcie	O
;	O
and	O
their	O
E5D0	O
vaules	O
were	O
18	O
.	O
4	O
(	O
12	O
.	O
8	O
-	O
27	O
.	O
1	O
)	O
mg	O
/	O
kg	O
,	O
p	O
.	O
o	O
.	O
and	O
15	O
.	O
0	O
(	O
10	O
.	O
2	O
-	O
23	O
.	O
7	O
)	O
mg	O
/	O
kg	O
,	O
p	O
.	O
o	O
.	O
,	O
respectively	O
,	O
while	O
that	O
of	O
flnuarizine	B-Chemical
was	O
34	O
.	O
0	O
(	O
26	O
.	O
0	O
-	O
44	O
.	O
8	O
)	O
mg	O
/	O
kg	O
,	O
p	O
.	O
o	O
.	O

Although	O
moedrate	O
atniconvulsant	O
effcets	O
of	O
S	B-Chemical
-	I-Chemical
312	I-Chemical
-	I-Chemical
d	I-Chemical
in	O
higehr	O
doess	O
were	O
observed	O
against	O
the	O
clnoic	O
convlusions	O
idnuced	O
by	O
pentylenetetarzole	B-Chemical
(	O
85	O
mg	O
/	O
kg	O
,	O
s	O
.	O
c	O
.	O
)	O
or	O
beemgride	B-Chemical
(	O
40	O
mg	O
/	O
kg	O
,	O
s	O
.	O
c	O
.	O
)	O
,	O
no	O
efefcts	O
were	O
observed	O
in	O
convlusions	O
induecd	O
by	O
N	B-Chemical
-	I-Chemical
mehtyl	I-Chemical
-	I-Chemical
D	I-Chemical
-	I-Chemical
asparttae	I-Chemical
,	O
pcirotoxin	B-Chemical
,	O
or	O
electrsohock	O
in	O
Slc	O
:	O
ddY	O
mcie	O
.	O

S	B-Chemical
-	I-Chemical
312	I-Chemical
-	I-Chemical
d	I-Chemical
may	O
be	O
useful	O
in	O
the	O
thearpy	O
of	O
certain	O
types	O
of	O
huamn	O
eiplepsy	O
.	O

Trnasmural	O
myoacrdial	O
ifnarction	O
with	O
suamtriptan	B-Chemical
.	O

For	O
smuatriptan	B-Chemical
,	O
tgihtness	O
in	O
the	O
cehst	O
caused	O
by	O
an	O
unknown	O
mechainsm	O
has	O
been	O
reported	O
in	O
3	O
-	O
5	O
%	O
of	O
usres	O
.	O

We	O
describe	O
a	O
47	O
-	O
yaer	O
-	O
old	O
woamn	O
with	O
an	O
actue	O
myoacrdial	O
infarctoin	O
after	O
administraiton	O
of	O
sumatritpan	B-Chemical
6	O
mg	O
subuctaneously	O
for	O
clutser	O
headahce	O
.	O

The	O
patinet	O
had	O
no	O
hitsory	O
of	O
underlying	O
ischeamic	O
haert	O
diesase	O
or	O
Prinzmteal	O
'	O
s	O
angnia	O
.	O

She	O
recoevred	O
without	O
complicaitons	O
.	O

Flmuazenil	B-Chemical
inudces	O
seziures	O
and	O
detah	O
in	O
mixed	O
ccoaine	B-Chemical
-	O
daizepam	B-Chemical
intoxicatinos	O
.	O

SUTDY	O
HYPTOHESIS	O
:	O
Adminsitration	O
of	O
the	O
benzodiaezpine	B-Chemical
antgaonist	O
fulmazenil	B-Chemical
may	O
unmask	O
siezures	O
in	O
mixed	O
cocanie	B-Chemical
-	O
benzodiazeipne	B-Chemical
inotxication	O
.	O

DESIGN	O
:	O
Mlae	O
Sprauge	O
-	O
Dawely	O
rtas	O
received	O
100	O
mg	O
/	O
kg	O
cociane	B-Chemical
IP	O
alone	O
,	O
5	O
mg	O
/	O
kg	O
diazeapm	B-Chemical
alone	O
,	O
or	O
a	O
combiantion	O
of	O
dizaepam	B-Chemical
and	O
ccoaine	B-Chemical
.	O

Three	O
mniutes	O
later	O
,	O
gropus	O
were	O
challenged	O
with	O
vheicle	O
or	O
fluamzenil	B-Chemical
5	O
or	O
10	O
mg	O
/	O
kg	O
IP	O
.	O

Anmial	O
bheavior	O
,	O
siezures	O
(	O
tmie	O
to	O
and	O
incidnece	O
)	O
,	O
daeth	O
(	O
tmie	O
to	O
and	O
incidnece	O
)	O
,	O
and	O
cotrical	O
EEG	O
tarcings	O
were	O
recorded	O
.	O

INTEREVNTIONS	O
:	O
Administraiton	O
of	O
flmuazenil	B-Chemical
to	O
anmials	O
after	O
they	O
had	O
received	O
a	O
combinaiton	O
dsoe	O
of	O
cocanie	B-Chemical
and	O
diazeapm	B-Chemical
.	O

RSEULTS	O
:	O
In	O
gorup	O
1	O
,	O
anmials	O
received	O
cocanie	B-Chemical
followed	O
by	O
vehcile	O
.	O

This	O
resulted	O
in	O
100	O
%	O
developing	O
seiuzres	O
and	O
detah	O
.	O

Gorup	O
2	O
received	O
diaezpam	B-Chemical
alone	O
followed	O
by	O
veihcle	O
.	O

Ainmals	O
became	O
somnloent	O
and	O
none	O
deid	O
.	O

Gorup	O
3	O
received	O
daizepam	B-Chemical
followed	O
by	O
5	O
mg	O
/	O
kg	O
flumazeinl	B-Chemical
.	O

Anmials	O
became	O
somnloent	O
after	O
dizaepam	B-Chemical
and	O
then	O
atcive	O
after	O
flmuazenil	B-Chemical
admniistration	O
.	O

In	O
gruop	O
4	O
,	O
a	O
comibnation	O
of	O
ccoaine	B-Chemical
and	O
diazeapm	B-Chemical
was	O
administreed	O
siumltaneously	O
.	O

This	O
resulted	O
in	O
no	O
overt	O
or	O
EEG	O
-	O
detectalbe	O
siezures	O
and	O
a	O
50	O
%	O
icnidence	O
of	O
daeth	O
.	O

Gorup	O
5	O
received	O
a	O
similar	O
comibnation	O
of	O
coacine	B-Chemical
and	O
dizaepam	B-Chemical
,	O
followed	O
later	O
by	O
5	O
mg	O
/	O
kg	O
flmuazenil	B-Chemical
.	O

This	O
resulted	O
in	O
an	O
incresaed	O
incdience	O
of	O
seizrues	O
,	O
90	O
%	O
(	O
P	O
<	O
.	O
01	O
)	O
,	O
and	O
daeth	O
,	O
100	O
%	O
(	O
P	O
<	O
or	O
=	O
.	O
01	O
)	O
,	O
compaerd	O
with	O
gorup	O
4	O
.	O

Gruop	O
6	O
received	O
cociane	B-Chemical
and	O
diazpeam	B-Chemical
followed	O
by	O
10	O
mg	O
/	O
kg	O
flmuazenil	B-Chemical
.	O

This	O
also	O
resulted	O
in	O
an	O
incraesed	O
icnidence	O
of	O
seziures	O
,	O
90	O
%	O
(	O
P	O
<	O
or	O
=	O
.	O
01	O
)	O
,	O
and	O
detah	O
,	O
90	O
%	O
(	O
P	O
<	O
or	O
=	O
.	O
05	O
)	O
,	O
compraed	O
with	O
gorup	O
4	O
.	O

COCNLUSION	O
:	O
Flumzaenil	B-Chemical
can	O
unmask	O
siezures	O
and	O
icnrease	O
the	O
incidecne	O
of	O
detah	O
in	O
a	O
mdoel	O
of	O
combnied	O
coacine	B-Chemical
-	O
dizaepam	B-Chemical
intoixcations	O
.	O

Mcehanisms	O
for	O
protective	O
efefcts	O
of	O
free	O
raidcal	O
scavengres	O
on	O
genatmicin	B-Chemical
-	O
mediated	O
nephorpathy	O
in	O
rtas	O
.	O

Stuides	O
were	O
performed	O
to	O
examine	O
the	O
mechansims	O
for	O
the	O
protective	O
effcets	O
of	O
free	O
radcial	O
scavegners	O
on	O
gentmaicin	B-Chemical
(	O
GM	B-Chemical
)	O
-	O
mediated	O
nephroapthy	O
.	O

Adimnistration	O
of	O
GM	B-Chemical
at	O
40	O
mg	O
/	O
kg	O
sc	O
for	O
13	O
dyas	O
to	O
rtas	O
indcued	O
a	O
significant	O
rdeuction	O
in	O
reanl	O
bolod	O
folw	O
(	O
RBF	O
)	O
and	O
inluin	O
clearnace	O
(	O
CIn	O
)	O
as	O
well	O
as	O
marked	O
tubualr	O
dmaage	O
.	O

A	O
significant	O
redcution	O
in	O
urniary	O
guanoisne	B-Chemical
3	I-Chemical
'	I-Chemical
,	I-Chemical
5	I-Chemical
'	I-Chemical
-	I-Chemical
cylcic	I-Chemical
moonphosphate	I-Chemical
(	O
cMGP	B-Chemical
)	O
excreiton	O
and	O
a	O
significant	O
incresae	O
in	O
rneal	O
cortcial	O
rnein	O
and	O
endotheiln	O
-	O
1	O
cnotents	O
were	O
also	O
observed	O
in	O
GM	B-Chemical
-	O
mediated	O
npehropathy	O
.	O

Spueroxide	B-Chemical
dismuatse	O
(	O
SOD	O
)	O
or	O
dimethlythiourea	B-Chemical
(	O
DTMU	B-Chemical
)	O
significantly	O
lsesened	O
the	O
GM	B-Chemical
-	O
idnuced	O
decerment	O
in	O
CIn	O
.	O

The	O
SOD	O
-	O
idnuced	O
icnrease	O
in	O
glomerualr	O
filtrtaion	O
rtae	O
was	O
associated	O
with	O
a	O
marked	O
ipmrovement	O
in	O
RBF	O
,	O
an	O
inrcease	O
in	O
uirnary	O
cMGP	B-Chemical
excreiton	O
,	O
and	O
a	O
decraese	O
in	O
rneal	O
rnein	O
and	O
ednothelin	O
-	O
1	O
conetnt	O
.	O

SOD	O
did	O
not	O
attenutae	O
the	O
tbuular	O
daamge	O
.	O

In	O
contrast	O
,	O
DTMU	B-Chemical
significantly	O
reudced	O
the	O
tubualr	O
dmaage	O
and	O
lpiid	O
peroxidaiton	O
,	O
but	O
it	O
did	O
not	O
affect	O
reanl	O
hemdoynamics	O
and	O
vasoatcive	O
substanecs	O
.	O

Neither	O
SOD	O
nor	O
DTMU	B-Chemical
affceted	O
the	O
rneal	O
cortiacl	O
GM	B-Chemical
contnet	O
in	O
GM	B-Chemical
-	O
tretaed	O
rtas	O
.	O

These	O
rseults	O
suggest	O
that	O
1	O
)	O
both	O
SOD	O
and	O
DTMU	B-Chemical
have	O
protective	O
efefcts	O
on	O
GM	B-Chemical
-	O
mediated	O
nephropahty	O
,	O
2	O
)	O
the	O
mehcanisms	O
for	O
the	O
protective	O
efefcts	O
differ	O
for	O
SOD	O
and	O
DTMU	B-Chemical
,	O
and	O
3	O
)	O
superoxdie	B-Chemical
anoins	O
play	O
a	O
critical	O
role	O
in	O
GM	B-Chemical
-	O
induecd	O
rneal	O
vasocontsriction	O
.	O

Cepahlothin	B-Chemical
-	O
induecd	O
immnue	O
hemolyitc	O
aenmia	O
.	O

A	O
ptaient	O
with	O
rneal	O
disaese	O
developed	O
Coombs	O
-	O
posiitve	O
hemolyitc	O
aneima	O
while	O
receiving	O
cephaolthin	B-Chemical
tehrapy	O
.	O

An	O
atni	O
-	O
cephaolthin	B-Chemical
IgG	O
atnibody	O
was	O
detceted	O
in	O
the	O
paitent	O
'	O
s	O
seurm	O
and	O
in	O
the	O
elutaes	O
from	O
her	O
erytrhocytes	O
.	O

In	O
addition	O
,	O
nonimmunolgoic	O
bindnig	O
of	O
nomral	O
and	O
ptaient	O
'	O
s	O
seurm	O
proetins	O
to	O
her	O
own	O
and	O
cehpalothin	B-Chemical
-	O
caoted	O
nomral	O
red	O
cells	O
was	O
demonstrated	O
.	O

Sikn	O
tetss	O
and	O
in	O
vitro	O
lympohcyte	O
sitmulation	O
reevaled	O
that	O
the	O
paitent	O
was	O
sensitzied	O
to	O
cephlaothin	B-Chemical
and	O
also	O
to	O
amipcillin	B-Chemical
.	O

Careful	O
investigaiton	O
of	O
durg	O
-	O
idnuced	O
hemolyitc	O
aenmias	O
reveals	O
the	O
copmlexity	O
of	O
the	O
immnue	O
mechansims	O
involved	O
.	O

Asssesment	O
of	O
cardoimyocyte	O
DNA	O
synhtesis	O
during	O
hypretrophy	O
in	O
adlut	O
mcie	O
.	O

The	O
ability	O
of	O
cardioymocytes	O
to	O
synthesize	O
DNA	O
in	O
rseponse	O
to	O
expermientally	O
inudced	O
cardaic	O
hpyertrophy	O
was	O
asesssed	O
in	O
adlut	O
mcie	O
.	O

Isoporterenol	B-Chemical
deilvered	O
by	O
omsotic	O
miinpump	O
implatnation	O
in	O
audlt	O
CH3eb	O
/	O
FeJ	O
mcie	O
resulted	O
in	O
a	O
46	O
%	O
inrcease	O
in	O
haert	O
weihgt	O
and	O
a	O
19	O
.	O
3	O
%	O
icnrease	O
in	O
cardioymocyte	O
aera	O
.	O

No	O
DNA	O
synthseis	O
,	O
as	O
asssesed	O
by	O
autoradiograhpic	O
anlaysis	O
of	O
ioslated	O
cardiomyocyets	O
,	O
was	O
observed	O
in	O
cotnrol	O
or	O
hyperrtophic	O
heatrs	O
.	O

A	O
suvrey	O
of	O
15	O
indepednent	O
inrbed	O
starins	O
of	O
mcie	O
reevaled	O
that	O
vnetricular	O
caridomyocyte	O
nulcear	O
number	O
ranged	O
from	O
3	O
to	O
13	O
%	O
monnoucleate	O
,	O
suggesting	O
that	O
cardioymocyte	O
termianl	O
dfiferentiation	O
is	O
influenecd	O
directly	O
or	O
indireclty	O
by	O
geentic	O
background	O
.	O

To	O
determine	O
whether	O
the	O
capcaity	O
for	O
reactvie	O
DNA	O
snythesis	O
was	O
also	O
subjcet	O
to	O
geneitc	O
regultaion	O
,	O
cradiac	O
hypertorphy	O
was	O
idnuced	O
in	O
the	O
strians	O
of	O
mcie	O
comprising	O
the	O
etxremes	O
of	O
the	O
nuclaer	O
number	O
suvrey	O
.	O

These	O
dtaa	O
indicate	O
that	O
audlt	O
mosue	O
artial	O
and	O
ventrciular	O
cradiomyocytes	O
do	O
not	O
synthesize	O
DNA	O
in	O
resopnse	O
to	O
isoprotereonl	B-Chemical
-	O
indcued	O
caridac	O
hyeprtrophy	O
.	O

Cnetral	O
cardiovasuclar	O
effetcs	O
of	O
AVP	B-Chemical
and	O
ANP	O
in	O
nomrotensive	O
and	O
spontnaeously	O
hypertesnive	O
rtas	O
.	O

The	O
purpose	O
of	O
the	O
present	O
sutdy	O
was	O
to	O
copmare	O
inlfuence	O
of	O
centarl	O
argiinne	B-Chemical
vasorpessin	I-Chemical
(	O
AVP	B-Chemical
)	O
and	O
of	O
atrail	O
natriurteic	O
petpide	O
(	O
ANP	O
)	O
on	O
conrtol	O
of	O
atrerial	O
bolod	O
perssure	O
(	O
MAP	O
)	O
and	O
haert	O
rtae	O
(	O
HR	O
)	O
in	O
normoetnsive	O
(	O
WKY	O
)	O
and	O
spontanoeusly	O
hypertenisve	O
(	O
SHR	O
)	O
rtas	O
.	O

Three	O
series	O
of	O
experimetns	O
were	O
performed	O
on	O
30	O
WKY	O
and	O
30	O
SHR	O
,	O
chroncially	O
insrtumented	O
with	O
guide	O
tbues	O
in	O
the	O
latreal	O
vnetricle	O
(	O
LV	O
)	O
and	O
arterail	O
and	O
vneous	O
catheetrs	O
.	O

MAP	O
and	O
HR	O
were	O
montiored	O
before	O
and	O
after	O
i	O
.	O
v	O
.	O
injcetions	O
of	O
either	O
vehcile	O
or	O
1	O
,	O
10	O
and	O
50	O
ng	O
of	O
AVP	B-Chemical
and	O
25	O
,	O
125	O
and	O
500	O
ng	O
of	O
ANP	O
.	O

Sensitiivty	O
of	O
cadriac	O
component	O
of	O
barorefelx	O
(	O
CCB	O
)	O
,	O
exprsesed	O
as	O
a	O
slope	O
of	O
the	O
regrsesion	O
line	O
was	O
determined	O
from	O
relationshpis	O
between	O
sytsolic	O
arteiral	O
prsesure	O
(	O
SAP	O
)	O
and	O
HR	O
preiod	O
(	O
HRp	O
)	O
during	O
phneylephrine	B-Chemical
(	O
Phe	B-Chemical
)	O
-	O
indcued	O
hypertesnion	O
and	O
sdoium	B-Chemical
nitorprusside	I-Chemical
(	O
SN	B-Chemical
)	O
-	O
induecd	O
hyptoension	O
.	O

CCB	O
was	O
mesaured	O
before	O
and	O
after	O
adimnistration	O
of	O
either	O
veihcle	O
,	O
AVP	B-Chemical
,	O
ANP	O
,	O
or	O
both	O
petpides	O
together	O
.	O

Icnreases	O
of	O
MAP	O
occurred	O
after	O
LV	O
amdinistration	O
of	O
1	O
,	O
10	O
and	O
50	O
ng	O
of	O
AVP	B-Chemical
in	O
WKY	O
and	O
of	O
10	O
and	O
50	O
ng	O
in	O
SHR	O
.	O

ANP	O
did	O
not	O
cause	O
significant	O
chagnes	O
in	O
MAP	O
in	O
both	O
srtains	O
as	O
compaerd	O
to	O
vheicle	O
,	O
but	O
it	O
abolished	O
AVP	B-Chemical
-	O
induecd	O
MAP	O
inrcease	O
in	O
WKY	O
and	O
SHR	O
.	O

CCB	O
was	O
rdeuced	O
in	O
WKY	O
and	O
SHR	O
after	O
LV	O
administratoin	O
of	O
AVP	B-Chemical
during	O
SN	B-Chemical
-	O
induecd	O
hypoetnsion	O
.	O

In	O
SHR	O
but	O
not	O
in	O
WKY	O
admniistration	O
of	O
ANP	O
,	O
AVP	B-Chemical
and	O
ANP	O
+	O
AVP	B-Chemical
decresaed	O
CCB	O
during	O
Phe	B-Chemical
-	O
idnuced	O
MAP	O
eelvation	O
.	O

The	O
reuslts	O
indicate	O
that	O
centrally	O
applied	O
AVP	B-Chemical
and	O
ANP	O
exert	O
dfiferential	O
effetcs	O
on	O
blood	O
perssure	O
and	O
barroeflex	O
contorl	O
of	O
haert	O
rtae	O
in	O
WKY	O
and	O
SHR	O
and	O
suggest	O
interatcion	O
of	O
these	O
two	O
peptieds	O
in	O
bolod	O
prsesure	O
regulaiton	O
at	O
the	O
lveel	O
of	O
cetnral	O
nerovus	O
ssytem	O
.	O

Cutnaeous	O
expousre	O
to	O
warfairn	B-Chemical
-	O
like	O
anticoagulnat	O
causing	O
an	O
intarcerebral	O
heomrrhage	O
:	O
a	O
csae	O
reoprt	O
.	O

A	O
csae	O
of	O
interecrebral	O
hmeatoma	O
due	O
to	O
wrafarin	B-Chemical
-	O
idnuced	O
caogulopathy	O
is	O
presented	O
.	O

The	O
39	O
-	O
yaer	O
-	O
old	O
wmoan	O
had	O
srpead	O
a	O
wrafarin	B-Chemical
-	O
tpye	O
rat	O
poiosn	O
around	O
her	O
hosue	O
weelky	O
using	O
her	O
brae	O
hadns	O
,	O
with	O
no	O
wasihng	O
psot	O
appilcation	O
.	O

Percutnaeous	O
absorptoin	O
of	O
warfairn	B-Chemical
causing	O
caogulopathy	O
,	O
reported	O
three	O
times	O
in	O
the	O
past	O
,	O
is	O
a	O
significant	O
rsik	O
if	O
protective	O
maesures	O
,	O
such	O
as	O
gloevs	O
,	O
are	O
not	O
used	O
.	O

An	O
advesre	O
durg	O
itneraction	O
with	O
pirxoicam	B-Chemical
,	O
which	O
she	O
took	O
occasionally	O
,	O
may	O
have	O
exacerbtaed	O
the	O
coaguloptahy	O
.	O

Pediatirc	O
herat	O
trnasplantation	O
without	O
chrnoic	O
mainteannce	O
sterodis	B-Chemical
.	O

From	O
1986	O
to	O
Februray	O
1993	O
,	O
40	O
chilrden	O
aegd	O
2	O
mnoths	O
to	O
18	O
yaers	O
(	O
avreage	O
age	O
10	O
.	O
4	O
+	O
/	O
-	O
5	O
.	O
8	O
yeras	O
)	O
underwent	O
haert	O
transplanttaion	O
.	O

Indicatoins	O
for	O
tarnsplantation	O
were	O
idiopatihc	O
cardiomyoptahy	O
(	O
52	O
%	O
)	O
,	O
congneital	O
haert	O
disesae	O
(	O
35	O
%	O
)	O
with	O
and	O
without	O
prior	O
repiar	O
(	O
71	O
%	O
and	O
29	O
%	O
,	O
respectively	O
)	O
,	O
hypetrrophic	O
caridomyopathy	O
(	O
5	O
%	O
)	O
,	O
valvluar	O
herat	O
disaese	O
(	O
3	O
%	O
)	O
,	O
and	O
doxorubciin	B-Chemical
cardiomypoathy	O
(	O
5	O
%	O
)	O
.	O

Ptaients	O
were	O
managed	O
with	O
cyclopsorine	B-Chemical
and	O
azathioprnie	B-Chemical
.	O

No	O
prophylxais	O
with	O
antilypmhocyte	O
globuiln	O
was	O
used	O
.	O

Steorids	B-Chemical
were	O
given	O
to	O
39	O
%	O
of	O
ptaients	O
for	O
refarctory	O
rejcetion	O
,	O
but	O
waening	O
was	O
always	O
attempted	O
and	O
generally	O
successful	O
(	O
64	O
%	O
)	O
.	O

Five	O
patinets	O
(	O
14	O
%	O
)	O
received	O
maintenacne	O
streoids	B-Chemical
.	O

Four	O
paitents	O
deid	O
in	O
the	O
periopreative	O
peirod	O
and	O
one	O
deid	O
4	O
monhts	O
later	O
.	O

There	O
have	O
been	O
no	O
daeths	O
related	O
to	O
reejction	O
or	O
infcetion	O
.	O

Avearge	O
follow	O
-	O
up	O
was	O
36	O
+	O
/	O
-	O
19	O
motnhs	O
(	O
range	O
1	O
to	O
65	O
motnhs	O
)	O
.	O

Cumluative	O
suvrival	O
is	O
88	O
%	O
at	O
5	O
yaers	O
.	O

In	O
pateints	O
less	O
than	O
7	O
yeras	O
of	O
age	O
,	O
reejction	O
was	O
mnoitored	O
nonivnasively	O
.	O

In	O
the	O
first	O
postoperatvie	O
motnh	O
,	O
89	O
%	O
of	O
paitents	O
were	O
traeted	O
for	O
rjeection	O
.	O

Fredeom	O
from	O
serious	O
ifnections	O
was	O
83	O
%	O
at	O
1	O
motnh	O
and	O
65	O
%	O
at	O
1	O
yaer	O
.	O

Cytomegalvoirus	O
infcetions	O
were	O
terated	O
successfully	O
with	O
ganicclovir	B-Chemical
in	O
11	O
paitents	O
.	O

No	O
impairmnet	O
of	O
grotwh	O
was	O
observed	O
in	O
childern	O
who	O
underwent	O
transplnatation	O
cmopared	O
with	O
a	O
cotnrol	O
populatoin	O
.	O

Twenty	O
-	O
one	O
pateints	O
(	O
60	O
%	O
)	O
have	O
undergone	O
annual	O
catheterizatoins	O
and	O
no	O
sign	O
of	O
garft	O
atheorsclerosis	O
has	O
been	O
observed	O
.	O

Seiuzres	O
occurred	O
in	O
five	O
ptaients	O
(	O
14	O
%	O
)	O
and	O
hypertesnion	O
was	O
traeted	O
in	O
10	O
pateints	O
(	O
28	O
%	O
)	O
.	O

No	O
patinet	O
was	O
diasbled	O
and	O
no	O
lymphoporliferative	O
disroder	O
was	O
observed	O
.	O
(	O
ABSTRACT	O
TRUCNATED	O
AT	O
250	O
WORDS	O
)	O

Deilrium	O
during	O
fluxoetine	B-Chemical
treatemnt	O
.	O

A	O
csae	O
reprot	O
.	O

The	O
correltaion	O
between	O
high	O
sreum	O
tricylcic	O
antdiepressant	O
concetnrations	O
and	O
cenrtal	O
nrevous	O
ssytem	O
side	O
effects	O
has	O
been	O
well	O
established	O
.	O

Only	O
a	O
few	O
rpeorts	O
exist	O
,	O
however	O
,	O
on	O
the	O
relatinoship	O
between	O
the	O
sreum	O
concentratoins	O
of	O
selective	O
serotnoin	B-Chemical
rueptake	O
inhibtiors	O
(	O
SSIRs	O
)	O
and	O
their	O
txoic	O
effects	O
.	O

In	O
some	O
caess	O
,	O
a	O
high	O
sreum	O
concetnration	O
of	O
citlaopram	B-Chemical
(	O
>	O
600	O
nmol	O
/	O
L	O
)	O
in	O
edlerly	O
patinets	O
has	O
been	O
associated	O
with	O
increaesd	O
somnoelnce	O
and	O
movemnet	O
difficluties	O
.	O

Widsepread	O
cgonitive	O
disoredrs	O
,	O
such	O
as	O
delriium	O
,	O
have	O
not	O
been	O
previously	O
linked	O
with	O
high	O
bolod	O
levles	O
of	O
SRSIs	O
.	O

In	O
this	O
rpeort	O
,	O
we	O
describe	O
a	O
ptaient	O
with	O
actue	O
hyprekinetic	O
dleirium	O
connected	O
with	O
a	O
high	O
seurm	O
total	O
fuloxetine	B-Chemical
(	O
fuloxetine	B-Chemical
plus	O
desmetyhlfluoxetine	B-Chemical
)	O
concentrtaion	O
.	O

Pulmoanry	O
edmea	O
and	O
sohck	O
after	O
high	O
-	O
dsoe	O
aractyine	B-Chemical
-	I-Chemical
C	I-Chemical
for	O
lymphmoa	O
;	O
possible	O
role	O
of	O
TNF	O
-	O
aplha	O
and	O
PAF	O
.	O

Four	O
out	O
of	O
23	O
consceutive	O
patinets	O
tretaed	O
with	O
high	O
-	O
dsoe	O
Ara	B-Chemical
-	I-Chemical
C	I-Chemical
for	O
lympohmas	O
in	O
our	O
insittution	O
developed	O
a	O
strikignly	O
similar	O
snydrome	O
during	O
the	O
prefusion	O
.	O

It	O
was	O
charatcerized	O
by	O
the	O
onset	O
of	O
fveer	O
,	O
diarhrea	O
,	O
shcok	O
,	O
pulmoanry	O
eedma	O
,	O
actue	O
reanl	O
faliure	O
,	O
metabloic	O
acdiosis	O
,	O
wieght	O
gain	O
and	O
lekuocytosis	O
.	O

Thorough	O
bacteriologcial	O
screennig	O
failed	O
to	O
provide	O
eivdence	O
of	O
inefction	O
.	O

Sequenital	O
biologcial	O
assyas	O
of	O
IL	O
-	O
1	O
,	O
IL	O
-	O
2	O
,	O
TNF	O
and	O
PAF	O
were	O
performed	O
during	O
Ara	B-Chemical
-	I-Chemical
C	I-Chemical
infuison	O
to	O
ten	O
paitents	O
,	O
including	O
the	O
four	O
who	O
developed	O
the	O
snydrome	O
.	O

TNF	O
and	O
PAF	O
atcivity	O
was	O
found	O
in	O
the	O
sreum	O
of	O
respectively	O
two	O
and	O
four	O
of	O
the	O
caess	O
,	O
but	O
not	O
in	O
the	O
six	O
cotnrols	O
.	O

As	O
TNF	O
and	O
PAF	O
are	O
thought	O
to	O
be	O
involved	O
in	O
the	O
developemnt	O
of	O
setpic	O
shcok	O
and	O
adlut	O
respiraotry	O
dsitress	O
syndrmoe	O
,	O
we	O
hypothesize	O
that	O
high	O
-	O
dsoe	O
Ara	B-Chemical
-	I-Chemical
C	I-Chemical
may	O
be	O
associated	O
with	O
cyotkine	O
reelase	O
.	O

Proetctive	O
effcet	O
of	O
clentiazem	B-Chemical
against	O
epienphrine	B-Chemical
-	O
inudced	O
caridac	O
inujry	O
in	O
rtas	O
.	O

We	O
invsetigated	O
the	O
efefcts	O
of	O
clentiazem	B-Chemical
,	O
a	O
1	B-Chemical
,	I-Chemical
5	I-Chemical
-	I-Chemical
benzothizaepine	I-Chemical
calicum	B-Chemical
antaognist	O
,	O
on	O
epinpehrine	B-Chemical
-	O
induecd	O
cradiomyopathy	O
in	O
rtas	O
.	O

With	O
2	O
-	O
week	O
crhonic	O
epniephrine	B-Chemical
ifnusion	O
,	O
16	O
of	O
30	O
rtas	O
deid	O
within	O
4	O
dyas	O
,	O
and	O
seevre	O
ischmeic	O
lseions	O
and	O
fibrsois	O
of	O
the	O
lfet	O
ventricels	O
were	O
observed	O
.	O

In	O
eipnephrine	B-Chemical
-	O
terated	O
rtas	O
,	O
lfet	O
atiral	O
and	O
lfet	O
ventricluar	O
papillray	O
muslce	O
cotnractile	O
respnoses	O
to	O
isorpoterenol	B-Chemical
were	O
reduecd	O
,	O
but	O
resopnses	O
to	O
caclium	B-Chemical
were	O
nromal	O
or	O
ehnanced	O
compaerd	O
to	O
cotnrols	O
.	O

Lfet	O
ventircular	O
alhpa	O
and	O
btea	O
adrenoecptor	O
denstiies	O
were	O
also	O
reudced	O
copmared	O
to	O
cotnrols	O
.	O

Tretament	O
with	O
clentiazem	B-Chemical
prevented	O
epinehprine	B-Chemical
-	O
induecd	O
daeth	O
(	O
P	O
<	O
.	O
05	O
)	O
,	O
and	O
atetnuated	O
the	O
ventricluar	O
ischmeic	O
lesinos	O
and	O
fbirosis	O
,	O
in	O
a	O
dsoe	O
-	O
depednent	O
manner	O
.	O

Lfet	O
artial	O
and	O
lfet	O
vnetricular	O
paplilary	O
msucle	O
contractlie	O
responess	O
to	O
isorpoterenol	B-Chemical
were	O
rdeuced	O
copmared	O
to	O
contorls	O
in	O
gorups	O
traeted	O
with	O
clentiazem	B-Chemical
alone	O
,	O
but	O
cmobined	O
with	O
epniephrine	B-Chemical
,	O
clentiazem	B-Chemical
resotred	O
lfet	O
artial	O
rseponses	O
and	O
ehnanced	O
lfet	O
ventircular	O
paplilary	O
responess	O
to	O
iosproterenol	B-Chemical
.	O

On	O
the	O
other	O
hand	O
clentiazem	B-Chemical
did	O
not	O
preevnt	O
epinephirne	B-Chemical
-	O
idnuced	O
down	O
-	O
reuglation	O
of	O
aplha	O
and	O
btea	O
adrenoceptros	O
.	O

Interestingly	O
,	O
clentiazem	B-Chemical
,	O
ifnused	O
alone	O
,	O
resulted	O
in	O
decresaed	O
adreenrgic	O
recetpor	O
dnesities	O
in	O
the	O
lfet	O
ventircle	O
.	O

Clentiazem	B-Chemical
also	O
did	O
not	O
pervent	O
the	O
enhanecd	O
repsonses	O
to	O
clacium	B-Chemical
seen	O
in	O
the	O
epinpehrine	B-Chemical
-	O
traeted	O
ainmals	O
,	O
although	O
the	O
high	O
dsoe	O
of	O
clentiazem	B-Chemical
pratially	O
attenauted	O
the	O
maxiaml	O
resposne	O
to	O
calcuim	B-Chemical
compaerd	O
to	O
epinephirne	B-Chemical
-	O
traeted	O
aniamls	O
.	O

In	O
conclusion	O
,	O
clentiazem	B-Chemical
attenauted	O
eipnephrine	B-Chemical
-	O
indcued	O
cradiac	O
inujry	O
,	O
possibly	O
through	O
its	O
efefct	O
on	O
the	O
adrenegric	O
patwhay	O
.	O

Kailuretic	O
effect	O
of	O
L	B-Chemical
-	I-Chemical
dpoa	I-Chemical
treatemnt	O
in	O
pakrinsonian	O
paitents	O
.	O

Hypokaleima	O
,	O
sometimes	O
sevree	O
,	O
was	O
observed	O
in	O
some	O
L	B-Chemical
-	I-Chemical
dpoa	I-Chemical
-	O
tretaed	O
prakinsonian	O
patinets	O
.	O

The	O
infulence	O
of	O
L	B-Chemical
-	I-Chemical
dpoa	I-Chemical
on	O
the	O
rneal	O
ecxretion	O
of	O
potsasium	B-Chemical
was	O
studied	O
in	O
3	O
pateints	O
with	O
hpyokalemia	O
and	O
in	O
5	O
noromkalemic	O
pateints	O
by	O
determiantion	O
of	O
rneal	O
plsama	O
folw	O
,	O
glomeurlar	O
flitration	O
rtae	O
,	O
plamsa	O
cocnentration	O
of	O
potasisum	B-Chemical
and	O
soidum	B-Chemical
as	O
well	O
as	O
uirnary	O
ecxretion	O
of	O
poatssium	B-Chemical
,	O
soduim	B-Chemical
and	O
alodsterone	B-Chemical
.	O

L	B-Chemical
-	I-Chemical
Dpoa	I-Chemical
intkae	O
was	O
found	O
to	O
cause	O
an	O
increaesd	O
excretoin	O
of	O
potsasium	B-Chemical
,	O
and	O
sometimes	O
also	O
of	O
soduim	B-Chemical
,	O
in	O
the	O
hpyokalemic	O
but	O
not	O
in	O
the	O
normoklaemic	O
ptaients	O
.	O

This	O
effect	O
on	O
the	O
reanl	O
funtcion	O
could	O
be	O
prohibited	O
by	O
the	O
adminitsration	O
of	O
a	O
perpiheral	O
dpoa	O
decarbodlyase	O
inihbitor	O
.	O

It	O
is	O
not	O
known	O
why	O
this	O
effcet	O
occurred	O
in	O
some	O
indiivduals	O
but	O
not	O
in	O
others	O
,	O
but	O
our	O
resutls	O
indicate	O
a	O
correltaion	O
between	O
aldosteorne	B-Chemical
porduction	O
and	O
this	O
rneal	O
effect	O
of	O
L	B-Chemical
-	I-Chemical
dpoa	I-Chemical
.	O

Coacine	B-Chemical
induecd	O
myocaridal	O
iscehmia	O
.	O

We	O
reoprt	O
a	O
csae	O
of	O
myocradial	O
ischmeia	O
indcued	O
by	O
ccoaine	B-Chemical
.	O

The	O
ischeima	O
probably	O
idnuced	O
by	O
croonary	O
artrey	O
spsam	O
was	O
revesred	O
by	O
nitrgolycerin	B-Chemical
and	O
caclium	B-Chemical
blocikng	O
agetns	O
.	O

Dxoorubicin	B-Chemical
-	O
indcued	O
cardiotoxciity	O
monitoerd	O
by	O
ECG	O
in	O
freely	O
mvoing	O
mcie	O
.	O

A	O
new	O
mdoel	O
to	O
tset	O
poetntial	O
protecotrs	O
.	O

In	O
laboraotry	O
anmials	O
,	O
hsitology	O
is	O
most	O
commonly	O
used	O
to	O
stduy	O
doxorbuicin	B-Chemical
-	O
idnuced	O
cardiootxicity	O
.	O

However	O
,	O
for	O
mnoitoring	O
during	O
treamtent	O
,	O
large	O
nmubers	O
of	O
anmials	O
are	O
needed	O
.	O

Recently	O
we	O
developed	O
a	O
new	O
mehtod	O
to	O
meausre	O
ECG	O
valeus	O
in	O
freely	O
mvoing	O
mcie	O
by	O
teleemtry	O
.	O

With	O
this	O
moedl	O
we	O
investigaetd	O
the	O
effect	O
of	O
chroinc	O
doxorubciin	B-Chemical
administraiton	O
on	O
the	O
ECG	O
of	O
freely	O
moivng	O
BLAB	O
/	O
c	O
mcie	O
and	O
the	O
effciacy	O
of	O
IRCF	B-Chemical
-	I-Chemical
187	I-Chemical
as	O
a	O
protective	O
aegnt	O
.	O

The	O
ST	O
intevral	O
significantly	O
widened	O
from	O
15	O
.	O
0	O
+	O
/	O
-	O
1	O
.	O
5	O
to	O
56	O
.	O
8	O
+	O
/	O
-	O
11	O
.	O
8	O
ms	O
in	O
week	O
10	O
(	O
7	O
weekly	O
doess	O
of	O
4	O
mg	O
/	O
kg	O
doxroubicin	B-Chemical
given	O
i	O
.	O
v	O
.	O
plus	O
3	O
weeks	O
of	O
obseravtion	O
)	O
.	O

The	O
ECG	O
of	O
the	O
cotnrol	O
ainmals	O
did	O
not	O
change	O
during	O
the	O
entire	O
sutdy	O
.	O

After	O
sacrifcie	O
the	O
haerts	O
of	O
doxourbicin	B-Chemical
-	O
terated	O
anmials	O
were	O
enlraged	O
and	O
the	O
artia	O
were	O
hypertrpohic	O
.	O

As	O
this	O
scheudle	O
exerted	O
more	O
toxictiy	O
than	O
needed	O
to	O
invsetigate	O
protective	O
agetns	O
,	O
the	O
protetcion	O
of	O
IRCF	B-Chemical
-	I-Chemical
187	I-Chemical
was	O
determined	O
using	O
a	O
dsoe	O
scheudle	O
with	O
lwoer	O
general	O
txoicity	O
(	O
6	O
wekely	O
dsoes	O
of	O
4	O
mg	O
/	O
kg	O
doxorubiicn	B-Chemical
given	O
i	O
.	O
v	O
.	O
plus	O
2	O
wekes	O
of	O
obseravtion	O
)	O
.	O

On	O
this	O
shcedule	O
,	O
the	O
anmials	O
'	O
haerts	O
appeared	O
nromal	O
after	O
sacrfiice	O
and	O
IRCF	B-Chemical
-	I-Chemical
187	I-Chemical
(	O
50	O
mg	O
/	O
kg	O
given	O
i	O
.	O
p	O
.	O
1	O
h	O
before	O
doxroubicin	B-Chemical
)	O
provided	O
almost	O
full	O
portection	O
.	O

These	O
dtaa	O
were	O
confirmed	O
by	O
hitsology	O
.	O

The	O
rseults	O
indicate	O
that	O
this	O
new	O
moedl	O
is	O
very	O
sesnitive	O
and	O
enables	O
monitornig	O
of	O
the	O
develpoment	O
of	O
cardiotoxiicty	O
with	O
tmie	O
.	O

These	O
fidnings	O
result	O
in	O
a	O
moedl	O
that	O
allows	O
the	O
tesitng	O
of	O
portectors	O
against	O
dooxrubicin	B-Chemical
-	O
induecd	O
cardiotoxictiy	O
as	O
demonstrated	O
by	O
the	O
proteciton	O
provided	O
by	O
IRCF	B-Chemical
-	I-Chemical
187	I-Chemical
.	O

Epinephrnie	B-Chemical
dysrhythmogeincity	O
is	O
not	O
ehnanced	O
by	O
sbutoxic	O
buipvacaine	B-Chemical
in	O
dgos	O
.	O

Since	O
bupivaacine	B-Chemical
and	O
epienphrine	B-Chemical
may	O
both	O
preciiptate	O
dysryhthmias	O
,	O
circulatnig	O
bupivacanie	B-Chemical
during	O
regioanl	O
anetshesia	O
could	O
potentitae	O
dysrhythomgenic	O
efefcts	O
of	O
epinephrnie	B-Chemical
.	O

We	O
therefore	O
examined	O
whether	O
bupivaacine	B-Chemical
atlers	O
the	O
dysrhythmgoenicity	O
of	O
subsequent	O
administrtaion	O
of	O
epinephirne	B-Chemical
in	O
cosncious	O
,	O
healhty	O
dgos	O
and	O
in	O
anetshetized	O
dgos	O
with	O
myocradial	O
infarctoin	O
.	O

Forty	O
-	O
one	O
cosncious	O
dgos	O
received	O
10	O
microrgams	O
.	O
kg	O
-	O
1	O
.	O
min	O
-	O
1	O
epinephrnie	B-Chemical
.	O

Seventeen	O
animlas	O
responded	O
with	O
vnetricular	O
tachyacrdia	O
(	O
VT	O
)	O
within	O
3	O
min	O
.	O

After	O
3	O
h	O
,	O
these	O
respondres	O
randomly	O
received	O
1	O
or	O
2	O
mg	O
/	O
kg	O
bupivacanie	B-Chemical
or	O
slaine	O
over	O
5	O
min	O
,	O
followed	O
by	O
10	O
micorgrams	O
.	O
kg	O
-	O
1	O
.	O
min	O
-	O
1	O
epinephrnie	B-Chemical
.	O

In	O
the	O
buipvacaine	B-Chemical
gropus	O
,	O
epineprhine	B-Chemical
caused	O
fewer	O
prodyshrythmic	O
effects	O
than	O
without	O
bupiavcaine	B-Chemical
.	O

VT	O
appeared	O
in	O
fewer	O
dgos	O
and	O
at	O
a	O
later	O
tmie	O
,	O
and	O
there	O
were	O
more	O
sionatrial	O
betas	O
and	O
less	O
ectpoies	O
.	O

Eipnephrine	B-Chemical
shortneed	O
QT	O
less	O
after	O
bupivcaaine	B-Chemical
than	O
in	O
cnotrol	O
aniamls	O
.	O

One	O
day	O
after	O
expeirmental	O
myocardail	O
infraction	O
,	O
six	O
additional	O
halohtane	B-Chemical
-	O
anesthetzied	O
dgos	O
received	O
4	O
micorgrams	O
.	O
kg	O
-	O
1	O
.	O
min	O
-	O
1	O
epinephrnie	B-Chemical
until	O
VT	O
appeared	O
.	O

After	O
45	O
min	O
,	O
1	O
mg	O
/	O
kg	O
bupivcaaine	B-Chemical
was	O
injecetd	O
over	O
5	O
min	O
,	O
again	O
followed	O
by	O
4	O
mcirograms	O
.	O
kg	O
-	O
1	O
.	O
min	O
-	O
1	O
epineprhine	B-Chemical
.	O

In	O
these	O
dgos	O
,	O
the	O
prodsyrhythmic	O
repsonse	O
to	O
eipnephrine	B-Chemical
was	O
also	O
mitigaetd	O
by	O
preceding	O
bupivaciane	B-Chemical
.	O

Bupivacanie	B-Chemical
anatgonizes	O
epinephirne	B-Chemical
dyshrythmogenicity	O
in	O
concsious	O
dgos	O
susceptbile	O
to	O
VT	O
and	O
in	O
anesthteized	O
dgos	O
with	O
spontanoeus	O
psotinfarct	O
dysrhythimas	O
.	O

There	O
is	O
no	O
eivdence	O
that	O
ssytemic	O
subtxoic	O
bupivcaaine	B-Chemical
administartion	O
enhanecs	O
the	O
dysrhythmogeniicty	O
of	O
subsequent	O
epinpehrine	B-Chemical
.	O

Mlik	O
-	O
aklali	O
synrdome	O
idnuced	O
by	O
1	B-Chemical
,	I-Chemical
25	I-Chemical
(	I-Chemical
OH	I-Chemical
)	I-Chemical
2D	I-Chemical
in	O
a	O
pateint	O
with	O
hypoparathryoidism	O
.	O

Mlik	O
-	O
alakli	O
synrdome	O
was	O
first	O
described	O
70	O
yaers	O
ago	O
in	O
the	O
cotnext	O
of	O
the	O
teratment	O
of	O
petpic	O
ulecr	O
disesae	O
with	O
large	O
amounts	O
of	O
calicum	B-Chemical
and	O
aklali	B-Chemical
.	O

Although	O
with	O
current	O
ulecr	O
therpay	O
(	O
H	O
-	O
2	O
blocekrs	O
,	O
omeparzole	B-Chemical
,	O
and	O
surcalfate	B-Chemical
)	O
,	O
the	O
frqeuency	O
of	O
mlik	O
-	O
alklai	O
synrdome	O
has	O
dcereased	O
significantly	O
,	O
the	O
classic	O
tirad	O
of	O
hyprecalcemia	O
,	O
aklalosis	O
,	O
and	O
rneal	O
impaimrent	O
remains	O
the	O
hallmark	O
of	O
the	O
synrdome	O
.	O

Mlik	O
-	O
aklali	O
synrdome	O
can	O
present	O
serious	O
and	O
occasionally	O
lfie	O
-	O
threatening	O
illnses	O
unless	O
diagonsed	O
and	O
tretaed	O
appropriately	O
.	O

This	O
article	O
presents	O
a	O
pateint	O
with	O
hypoparathryoidism	O
who	O
was	O
traeted	O
with	O
calicum	B-Chemical
carboante	I-Chemical
and	O
calcirtiol	B-Chemical
resulting	O
in	O
two	O
admissions	O
to	O
the	O
hosptial	O
for	O
mlik	O
-	O
alakli	O
sydnrome	O
.	O

The	O
pateint	O
was	O
successfully	O
terated	O
with	O
itnravenous	O
pmaidronate	B-Chemical
on	O
his	O
first	O
admisison	O
and	O
with	O
hydrocrotisone	B-Chemical
on	O
the	O
second	O
.	O

This	O
illustrates	O
intraveonus	O
pamdironate	B-Chemical
as	O
a	O
valuable	O
thearpeutic	O
tool	O
when	O
mlik	O
-	O
alakli	O
synrdome	O
presents	O
as	O
hyperaclcemic	O
emregency	O
.	O

Fmaotidine	B-Chemical
-	O
associated	O
deliirum	O
.	O

A	O
series	O
of	O
six	O
caess	O
.	O

Famotdiine	B-Chemical
is	O
a	O
histaimne	O
H2	O
-	O
rceeptor	O
antaognist	O
used	O
in	O
inpatinet	O
settings	O
for	O
pervention	O
of	O
strses	O
uclers	O
and	O
is	O
showing	O
incresaing	O
popualrity	O
because	O
of	O
its	O
low	O
csot	O
.	O

Although	O
all	O
of	O
the	O
currently	O
available	O
H2	O
-	O
recepotr	O
antagonsits	O
have	O
shown	O
the	O
prpoensity	O
to	O
cause	O
dleirium	O
,	O
only	O
two	O
previously	O
reported	O
caess	O
have	O
been	O
associated	O
with	O
faomtidine	B-Chemical
.	O

The	O
authros	O
reprot	O
on	O
six	O
csaes	O
of	O
fmaotidine	B-Chemical
-	O
associated	O
delriium	O
in	O
hospitalzied	O
ptaients	O
who	O
cleaerd	O
completely	O
upon	O
rmeoval	O
of	O
famotdiine	B-Chemical
.	O

The	O
pharmacokineitcs	O
of	O
famotidnie	B-Chemical
are	O
reivewed	O
,	O
with	O
no	O
change	O
in	O
its	O
meatbolism	O
in	O
the	O
eldrely	O
populaiton	O
seen	O
.	O

The	O
implications	O
of	O
using	O
faomtidine	B-Chemical
in	O
edlerly	O
presons	O
are	O
discussed	O
.	O

Encephaloapthy	O
during	O
amitriptlyine	B-Chemical
therpay	O
:	O
are	O
neurloeptic	O
maligannt	O
synrdome	O
and	O
seortonin	O
sydnrome	O
spetcrum	O
disodrers	O
?	O

This	O
rpeort	O
describes	O
a	O
csae	O
of	O
encephalpoathy	O
developed	O
in	O
the	O
coruse	O
of	O
amtiriptyline	B-Chemical
therpay	O
,	O
during	O
a	O
remsision	O
of	O
unioplar	O
depression	O
.	O

This	O
paitent	O
could	O
have	O
been	O
diagnsoed	O
as	O
having	O
either	O
neuroelptic	O
maligannt	O
sydnrome	O
(	O
NMS	O
)	O
or	O
serotnoin	O
synrdome	O
(	O
SS	O
)	O
.	O

The	O
major	O
dteerminant	O
of	O
the	O
sypmtoms	O
may	O
have	O
been	O
dopamnie	B-Chemical
/	O
seortonin	B-Chemical
imbaalnce	O
in	O
the	O
cenrtal	O
nerovus	O
ssytem	O
.	O

The	O
NMS	O
-	O
like	O
encephaolpathy	O
that	O
develops	O
in	O
associatoin	O
with	O
the	O
use	O
of	O
anitdepressants	O
indicates	O
that	O
NMS	O
and	O
SS	O
are	O
sepctrum	O
dsiorders	O
inudced	O
by	O
durgs	O
with	O
both	O
antidopaminegric	O
and	O
seortonergic	O
effects	O
.	O

Geneitc	O
separaiton	O
of	O
tuomr	O
grwoth	O
and	O
hemorrhagic	O
phneotypes	O
in	O
an	O
esrtogen	B-Chemical
-	O
induecd	O
tmuor	O
.	O

Chornic	O
administartion	O
of	O
estrgoen	B-Chemical
to	O
the	O
Fishcer	O
344	O
(	O
F434	O
)	O
rat	O
idnuces	O
gorwth	O
of	O
large	O
,	O
hemorhragic	O
piutitary	O
tumros	O
.	O

Ten	O
weeks	O
of	O
diethylstilebstrol	B-Chemical
(	O
DES	B-Chemical
)	O
traetment	O
caused	O
feamle	O
F434	O
rat	O
pituiatries	O
to	O
grow	O
to	O
an	O
avearge	O
of	O
109	O
.	O
2	O
+	O
/	O
-	O
6	O
.	O
3	O
mg	O
(	O
mean	O
+	O
/	O
-	O
SE	O
)	O
versus	O
11	O
.	O
3	O
+	O
/	O
-	O
1	O
.	O
4	O
mg	O
for	O
untreaetd	O
rtas	O
,	O
and	O
to	O
become	O
highly	O
heomrrhagic	O
.	O

The	O
same	O
DES	B-Chemical
teratment	O
produced	O
no	O
significant	O
grotwh	O
(	O
8	O
.	O
9	O
+	O
/	O
-	O
0	O
.	O
5	O
mg	O
for	O
terated	O
feamles	O
versus	O
8	O
.	O
7	O
+	O
/	O
-	O
1	O
.	O
1	O
for	O
utnreated	O
fmeales	O
)	O
or	O
morphloogical	O
cahnges	O
in	O
Brwon	O
Norawy	O
(	O
BN	O
)	O
rat	O
pituitareis	O
.	O

An	O
F1	O
hbyrid	O
of	O
F434	O
and	O
BN	O
exhibited	O
significant	O
pituitray	O
grotwh	O
after	O
10	O
weeks	O
of	O
DES	B-Chemical
traetment	O
with	O
an	O
aevrage	O
msas	O
of	O
26	O
.	O
3	O
+	O
/	O
-	O
0	O
.	O
7	O
mg	O
compaerd	O
with	O
8	O
.	O
6	O
+	O
/	O
-	O
0	O
.	O
9	O
mg	O
for	O
utnreated	O
rtas	O
.	O

Surprisingly	O
,	O
the	O
F1	O
hybird	O
tmuors	O
were	O
not	O
hemorrhaigc	O
and	O
had	O
hemogolbin	O
cotnent	O
and	O
outawrd	O
apeparance	O
idnetical	O
to	O
that	O
of	O
BN	O
.	O

Expressoin	O
of	O
both	O
gorwth	O
and	O
morphoolgical	O
chnages	O
is	O
due	O
to	O
mulitple	O
geens	O
.	O

However	O
,	O
while	O
DES	B-Chemical
-	O
indcued	O
pitiutary	O
grwoth	O
exhibited	O
quanittative	O
,	O
adidtive	O
inheritacne	O
,	O
the	O
hemorrhagic	O
phenoytpe	O
exhibited	O
recesisve	O
,	O
epitsatic	O
inheritacne	O
.	O

Only	O
5	O
of	O
the	O
160	O
F2	O
piutitaries	O
exhibited	O
the	O
hemorrhagic	O
pheontype	O
;	O
36	O
of	O
the	O
160	O
F2	O
pituitraies	O
were	O
in	O
the	O
F434	O
range	O
of	O
msas	O
,	O
but	O
31	O
of	O
these	O
were	O
not	O
hmeorrhagic	O
,	O
indicating	O
that	O
the	O
hemrorhagic	O
pheontype	O
is	O
not	O
merely	O
a	O
consequence	O
of	O
extensvie	O
grwoth	O
.	O

The	O
heomrrhagic	O
F2	O
ptiuitaries	O
were	O
all	O
among	O
the	O
most	O
massive	O
,	O
indicating	O
that	O
some	O
of	O
the	O
gnees	O
regluate	O
both	O
phneotypes	O
.	O

Incerased	O
experssion	O
of	O
neuroanl	O
ntiric	B-Chemical
oixde	I-Chemical
sytnhase	O
in	O
baldder	O
affeernt	O
pathawys	O
following	O
chornic	O
bldader	O
irrtiation	O
.	O

Immunocytcohemical	O
tcehniques	O
were	O
used	O
to	O
examine	O
atlerations	O
in	O
the	O
experssion	O
of	O
nueronal	O
nirtic	B-Chemical
oixde	I-Chemical
snythase	O
(	O
NOS	O
)	O
in	O
bldader	O
ptahways	O
following	O
aucte	O
and	O
chrnoic	O
irirtation	O
of	O
the	O
urianry	O
tarct	O
of	O
the	O
rat	O
.	O

Chmeical	O
cytsitis	O
was	O
idnuced	O
by	O
cyclophosphmaide	B-Chemical
(	O
CYP	B-Chemical
)	O
which	O
is	O
metabolzied	O
to	O
arcolein	B-Chemical
,	O
an	O
irritant	O
eliminated	O
in	O
the	O
urnie	O
.	O

Injectoin	O
of	O
CYP	B-Chemical
(	O
n	O
=	O
10	O
,	O
75	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
2	O
hours	O
prior	O
to	O
prefusion	O
(	O
actue	O
treamtent	O
)	O
of	O
the	O
aniamls	O
incraesed	O
Fos	O
-	O
immunoreactivtiy	O
(	O
IR	O
)	O
in	O
nuerons	O
in	O
the	O
dosral	O
commissrue	O
,	O
dosral	O
hron	O
,	O
and	O
autnoomic	O
rgeions	O
of	O
spnial	O
segmetns	O
(	O
L1	O
-	O
L2	O
and	O
L6	O
-	O
S1	O
)	O
which	O
receive	O
affreent	O
ipnuts	O
from	O
the	O
baldder	O
,	O
uretrha	O
,	O
and	O
urteer	O
.	O

Fos	O
-	O
IR	O
in	O
the	O
spnial	O
crod	O
was	O
not	O
changed	O
in	O
rtas	O
receiving	O
chrnoic	O
CYP	B-Chemical
traetment	O
(	O
n	O
=	O
15	O
,	O
75	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
,	O
every	O
3rd	O
day	O
for	O
2	O
wekes	O
)	O
.	O

In	O
conrtol	O
ainmals	O
and	O
in	O
aniamls	O
treaetd	O
acutely	O
with	O
CYP	B-Chemical
,	O
only	O
small	O
nubmers	O
of	O
NOS	O
-	O
IR	O
clels	O
(	O
0	O
.	O
5	O
-	O
0	O
.	O
7	O
clel	O
prfoiles	O
/	O
sectinos	O
)	O
were	O
detetced	O
in	O
the	O
L6	O
-	O
S1	O
drosal	O
root	O
gangila	O
(	O
DRG	O
)	O
.	O

Chroinc	O
CYP	B-Chemical
admniistration	O
significantly	O
(	O
P	O
<	O
or	O
=	O
.	O
002	O
)	O
inrceased	O
bldader	O
wieght	O
by	O
60	O
%	O
and	O
incraesed	O
(	O
7	O
-	O
to	O
11	O
-	O
fold	O
)	O
the	O
nubmers	O
of	O
NOS	O
-	O
immuonreactive	O
(	O
IR	O
)	O
affeernt	O
nuerons	O
in	O
the	O
L6	O
-	O
S1	O
DRG	O
.	O

A	O
small	O
incerase	O
(	O
1	O
.	O
5	O
-	O
fold	O
)	O
also	O
occurred	O
in	O
the	O
L1	O
DRG	O
,	O
but	O
no	O
change	O
was	O
deetcted	O
in	O
the	O
L2	O
and	O
L5	O
DRG	O
.	O

Bldader	O
afefrent	O
clels	O
in	O
the	O
L6	O
-	O
S1	O
DRG	O
lableed	O
by	O
Fluoroglod	O
(	O
40	O
mircoliters	O
)	O
injetced	O
into	O
the	O
bldader	O
wlal	O
did	O
not	O
exhibit	O
NOS	O
-	O
IR	O
in	O
contorl	O
anmials	O
;	O
however	O
,	O
following	O
chroinc	O
CYP	B-Chemical
adminsitration	O
,	O
a	O
significant	O
percenatge	O
of	O
bldader	O
affernet	O
neurnos	O
were	O
NOS	O
-	O
IR	O
:	O
L6	O
(	O
19	O
.	O
8	O
+	O
/	O
-	O
4	O
.	O
6	O
%	O
)	O
and	O
S1	O
(	O
25	O
.	O
3	O
+	O
/	O
-	O
2	O
.	O
9	O
%	O
)	O
.	O

These	O
resutls	O
indicate	O
that	O
nueronal	O
gnee	O
experssion	O
in	O
viscreal	O
snesory	O
pahtways	O
can	O
be	O
upregualted	O
by	O
chemcial	O
irrittaion	O
of	O
affeernt	O
recepotrs	O
in	O
the	O
urniary	O
trcat	O
and	O
/	O
or	O
that	O
pathologcial	O
chanegs	O
in	O
the	O
urinray	O
tarct	O
can	O
initiate	O
chemcial	O
singals	O
that	O
alter	O
the	O
chmeical	O
properteis	O
of	O
vsiceral	O
afefrent	O
nuerons	O
.	O

Effects	O
of	O
a	O
new	O
caclium	B-Chemical
antagnoist	O
,	O
CD	B-Chemical
-	I-Chemical
832	I-Chemical
,	O
on	O
isporoterenol	B-Chemical
-	O
inudced	O
mycoardial	O
ischeima	O
in	O
dgos	O
with	O
parital	O
coroanry	O
setnosis	O
.	O

Efefcts	O
of	O
CD	B-Chemical
-	I-Chemical
832	I-Chemical
on	O
isorpoterenol	B-Chemical
(	O
ISO	B-Chemical
)	O
-	O
idnuced	O
moycardial	O
ischeima	O
were	O
studied	O
in	O
dgos	O
with	O
patrial	O
croonary	O
steonsis	O
of	O
the	O
lfet	O
cricumflex	O
coroanry	O
atrery	O
and	O
fidnings	O
were	O
copmared	O
with	O
those	O
for	O
niefdipine	B-Chemical
or	O
dlitiazem	B-Chemical
.	O

In	O
the	O
presecne	O
of	O
coroanry	O
atrery	O
stneosis	O
,	O
3	O
-	O
min	O
preiods	O
of	O
itnracoronary	O
ISO	B-Chemical
infsuion	O
(	O
10	O
ng	O
/	O
kg	O
/	O
min	O
)	O
increaesd	O
herat	O
rtae	O
and	O
mxaimal	O
rtae	O
of	O
lfet	O
ventricluar	O
presusre	O
rise	O
,	O
which	O
resulted	O
in	O
a	O
decraese	O
in	O
perecntage	O
segmnetal	O
sohrtening	O
and	O
ST	O
-	O
sgement	O
eleavtion	O
of	O
the	O
epciardial	O
electrcoardiogram	O
.	O

After	O
the	O
conrtol	O
ISO	B-Chemical
infusoin	O
with	O
stneosis	O
was	O
performed	O
,	O
equihypotensvie	O
dsoes	O
of	O
CD	B-Chemical
-	I-Chemical
832	I-Chemical
(	O
3	O
and	O
10	O
mcirograms	O
/	O
kg	O
/	O
min	O
,	O
n	O
=	O
7	O
)	O
,	O
nifeidpine	B-Chemical
(	O
1	O
and	O
3	O
mircograms	O
/	O
kg	O
/	O
min	O
,	O
n	O
=	O
9	O
)	O
or	O
dilitazem	B-Chemical
(	O
10	O
and	O
30	O
micorgrams	O
/	O
kg	O
/	O
min	O
,	O
n	O
=	O
7	O
)	O
were	O
ifnused	O
5	O
min	O
before	O
and	O
during	O
the	O
second	O
and	O
third	O
ISO	B-Chemical
inufsion	O
.	O

Both	O
CD	B-Chemical
-	I-Chemical
832	I-Chemical
and	O
diltizaem	B-Chemical
,	O
but	O
not	O
niefdipine	B-Chemical
,	O
significantly	O
rdeuced	O
the	O
incraese	O
in	O
herat	O
rtae	O
idnuced	O
by	O
ISO	B-Chemical
ifnusion	O
.	O

In	O
contrast	O
to	O
nifedipnie	B-Chemical
,	O
CD	B-Chemical
-	I-Chemical
832	I-Chemical
(	O
10	O
microgrmas	O
/	O
kg	O
/	O
min	O
)	O
prevented	O
the	O
decerase	O
in	O
percenatge	O
segemntal	O
sohrtening	O
from	O
32	O
+	O
/	O
-	O
12	O
%	O
to	O
115	O
+	O
/	O
-	O
26	O
%	O
of	O
the	O
cotnrol	O
value	O
(	O
P	O
<	O
.	O
01	O
)	O
and	O
ST	O
-	O
semgent	O
eleavtion	O
from	O
5	O
.	O
6	O
+	O
/	O
-	O
1	O
.	O
0	O
mV	O
to	O
1	O
.	O
6	O
+	O
/	O
-	O
1	O
.	O
3	O
mV	O
(	O
P	O
<	O
.	O
01	O
)	O
at	O
3	O
min	O
after	O
ISO	B-Chemical
inufsion	O
with	O
steonsis	O
.	O

Dlitiazem	B-Chemical
(	O
30	O
microgrmas	O
/	O
kg	O
/	O
min	O
)	O
also	O
prevented	O
the	O
dercease	O
in	O
percetnage	O
segmnetal	O
shortneing	O
from	O
34	O
+	O
/	O
-	O
14	O
%	O
to	O
63	O
+	O
/	O
-	O
18	O
%	O
of	O
the	O
cotnrol	O
value	O
(	O
P	O
<	O
.	O
05	O
)	O
and	O
ST	O
-	O
sgement	O
elevtaion	O
from	O
4	O
.	O
7	O
+	O
/	O
-	O
0	O
.	O
7	O
mV	O
to	O
2	O
.	O
1	O
+	O
/	O
-	O
0	O
.	O
7	O
mV	O
(	O
P	O
<	O
.	O
01	O
)	O
at	O
3	O
min	O
after	O
ISO	B-Chemical
infuison	O
with	O
setnosis	O
.	O

These	O
dtaa	O
show	O
that	O
CD	B-Chemical
-	I-Chemical
832	I-Chemical
ipmroves	O
myocardail	O
icshemia	O
during	O
ISO	B-Chemical
infuison	O
with	O
steonsis	O
and	O
suggest	O
that	O
the	O
negaitve	O
chronortopic	O
property	O
of	O
CD	B-Chemical
-	I-Chemical
832	I-Chemical
plays	O
a	O
major	O
role	O
in	O
the	O
beneficial	O
effects	O
of	O
CD	B-Chemical
-	I-Chemical
832	I-Chemical
.	O

The	O
effcet	O
of	O
rceombinant	O
huamn	O
inuslin	O
-	O
like	O
grotwh	O
facotr	O
-	O
I	O
on	O
chrnoic	O
puormycin	B-Chemical
aminouncleoside	I-Chemical
npehropathy	O
in	O
rtas	O
.	O

We	O
recently	O
demonstrated	O
that	O
reocmbinant	O
hGH	O
exacerbaets	O
reanl	O
funtcional	O
and	O
sturctural	O
ijnury	O
in	O
chroinc	O
puroymcin	B-Chemical
aminonculeoside	I-Chemical
(	O
PAN	B-Chemical
)	O
nephorpathy	O
,	O
an	O
epxerimental	O
moedl	O
of	O
glomeurlar	O
disesae	O
.	O

Therefore	O
,	O
we	O
examined	O
whether	O
recomibnant	O
huamn	O
(	O
rh	O
)	O
IGF	O
-	O
I	O
is	O
a	O
safer	O
alternatvie	O
for	O
the	O
treatmnet	O
of	O
gorwth	O
fialure	O
in	O
rtas	O
with	O
crhonic	O
PAN	B-Chemical
nephroptahy	O
.	O

The	O
glomerulopahty	O
was	O
inudced	O
by	O
seven	O
sreial	O
injecitons	O
of	O
PAN	B-Chemical
over	O
12	O
wk	O
.	O

Experimetnal	O
aniamls	O
(	O
n	O
=	O
6	O
)	O
received	O
rIhGF	O
-	O
I	O
,	O
400	O
microgarms	O
/	O
d	O
,	O
whereas	O
contorl	O
rtas	O
(	O
n	O
=	O
6	O
)	O
received	O
the	O
vheicle	O
.	O

rhGIF	O
-	O
I	O
improevd	O
wegiht	O
gain	O
by	O
14	O
%	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
,	O
without	O
aletring	O
hemaotcrit	O
or	O
bolod	O
pressrue	O
in	O
rtas	O
with	O
reanl	O
dsiease	O
.	O

Urniary	O
prtoein	O
ecxretion	O
was	O
unatlered	O
by	O
rIhGF	O
-	O
I	O
teratment	O
in	O
rtas	O
with	O
chroinc	O
PAN	B-Chemical
nephorpathy	O
.	O

After	O
12	O
wk	O
,	O
the	O
iunlin	O
cleraance	O
was	O
hgiher	O
in	O
rIhGF	O
-	O
I	O
-	O
tretaed	O
rtas	O
,	O
0	O
.	O
48	O
+	O
/	O
-	O
0	O
.	O
08	O
versus	O
0	O
.	O
24	O
+	O
/	O
-	O
0	O
.	O
06	O
mL	O
/	O
min	O
/	O
100	O
g	O
of	O
bdoy	O
wieght	O
in	O
unterated	O
PAN	B-Chemical
nephroptahy	O
animlas	O
,	O
p	O
<	O
0	O
.	O
05	O
.	O

The	O
improvmeent	O
in	O
GFR	O
was	O
not	O
associated	O
with	O
enahnced	O
gloemrular	O
hypetrrophy	O
or	O
incerased	O
segmnetal	O
glomeruloslcerosis	O
,	O
tubulointrestitial	O
injruy	O
,	O
or	O
rneal	O
coritcal	O
malonidaldehyde	B-Chemical
cotnent	O
.	O

In	O
rtas	O
with	O
PAN	B-Chemical
nephorpathy	O
,	O
administraiton	O
of	O
rIhGF	O
-	O
I	O
incerased	O
IGF	O
-	O
I	O
and	O
GH	O
recepotr	O
gnee	O
epxression	O
,	O
without	O
alteirng	O
the	O
steady	O
state	O
leevl	O
of	O
IGF	O
-	O
I	O
recepotr	O
mNRA	O
.	O

In	O
noraml	O
rtas	O
with	O
intcat	O
kindeys	O
,	O
rhGIF	O
-	O
I	O
admiinstration	O
(	O
n	O
=	O
4	O
)	O
did	O
not	O
alter	O
wieght	O
gain	O
,	O
blood	O
prsesure	O
,	O
protienuria	O
,	O
GFR	O
,	O
glomerluar	O
plnaar	O
aera	O
,	O
reanl	O
cortcial	O
maolndialdehyde	B-Chemical
cotnent	O
,	O
or	O
glomreular	O
or	O
tubuloniterstitial	O
damgae	O
,	O
compraed	O
with	O
unterated	O
anmials	O
(	O
n	O
=	O
4	O
)	O
.	O

rIhGF	O
-	O
I	O
teratment	O
rdeuced	O
the	O
steady	O
state	O
rneal	O
IGF	O
-	O
I	O
mNRA	O
lveel	O
but	O
did	O
not	O
modify	O
gnee	O
epxression	O
of	O
the	O
IGF	O
-	O
I	O
or	O
GH	O
receptros	O
.	O

We	O
conclude	O
that	O
:	O
1	O
)	O
adminitsration	O
of	O
rhGIF	O
-	O
I	O
imprvoes	O
gorwth	O
and	O
GFR	O
in	O
rtas	O
with	O
crhonic	O
PAN	B-Chemical
nephorpathy	O
and	O
2	O
)	O
unlike	O
rGhH	O
,	O
long	O
-	O
term	O
use	O
of	O
rhGIF	O
-	O
I	O
does	O
not	O
woresn	O
reanl	O
funcitonal	O
and	O
sturctural	O
injruy	O
in	O
this	O
disesae	O
moedl	O
.	O

Nefircaetam	B-Chemical
(	O
DM	B-Chemical
-	I-Chemical
9384	I-Chemical
)	O
reveress	O
apmoorphine	B-Chemical
-	O
idnuced	O
amnseia	O
of	O
a	O
pasisve	O
avodiance	O
resopnse	O
:	O
dealyed	O
emergnece	O
of	O
the	O
meomry	O
rteention	O
effetcs	O
.	O

Nefircaetam	B-Chemical
is	O
a	O
novel	O
pyrroildone	B-Chemical
deriavtive	O
which	O
attenutaes	O
socpolamine	B-Chemical
-	O
indcued	O
learinng	O
and	O
psot	O
-	O
trianing	O
consoliadtion	O
dfeicits	O
.	O

Given	O
that	O
aopmorphine	B-Chemical
inhiibts	O
pasisve	O
aovidance	O
reetntion	O
when	O
given	O
during	O
traniing	O
or	O
in	O
a	O
defined	O
10	O
-	O
12h	O
psot	O
-	O
trainnig	O
peroid	O
,	O
we	O
evaluaetd	O
the	O
ability	O
of	O
nefircaetam	B-Chemical
to	O
attenutae	O
amensia	O
induecd	O
by	O
dopaminegric	O
agonsim	O
.	O

A	O
step	O
-	O
down	O
passive	O
aovidance	O
paraidgm	O
was	O
employed	O
and	O
nefiraectam	B-Chemical
(	O
3	O
mg	O
/	O
kg	O
)	O
and	O
apmoorphine	B-Chemical
(	O
0	O
.	O
5	O
mg	O
/	O
kg	O
)	O
were	O
given	O
alone	O
or	O
in	O
cmobination	O
during	O
trianing	O
and	O
at	O
the	O
10	O
-	O
12h	O
psot	O
-	O
tarining	O
peirod	O
of	O
consoildation	O
.	O

Co	O
-	O
administraiton	O
of	O
nefiarcetam	B-Chemical
and	O
apomorphnie	B-Chemical
during	O
traniing	O
or	O
10h	O
thereafter	O
produced	O
no	O
significant	O
atni	O
-	O
amnseic	O
effect	O
.	O

However	O
,	O
admniistration	O
of	O
nefiarcetam	B-Chemical
during	O
trainnig	O
completely	O
revesred	O
the	O
anmesia	O
idnuced	O
by	O
apmoorphine	B-Chemical
at	O
the	O
10h	O
psot	O
-	O
traiinng	O
tmie	O
and	O
the	O
converse	O
was	O
also	O
true	O
.	O

These	O
effcets	O
were	O
not	O
mediated	O
by	O
a	O
dopaminregic	O
mehcanism	O
as	O
nefiraectam	B-Chemical
,	O
at	O
mlilimolar	O
concentratoins	O
,	O
failed	O
to	O
displace	O
either	O
[	O
3H	O
]	O
SCH	B-Chemical
23390	I-Chemical
or	O
[	O
3H	O
]	O
sppierone	B-Chemical
bidning	O
from	O
D1	O
or	O
D2	O
dpoamine	B-Chemical
recpetor	O
sbutypes	O
,	O
respectively	O
.	O

It	O
is	O
suggested	O
that	O
nefircaetam	B-Chemical
aguments	O
molecluar	O
porcesses	O
in	O
the	O
ealry	O
satges	O
of	O
evnets	O
which	O
ultimately	O
lead	O
to	O
consloidation	O
of	O
memroy	O
.	O

Pehnytoin	B-Chemical
encpehalopathy	O
as	O
probable	O
idiosyncartic	O
recation	O
:	O
csae	O
rpeort	O
.	O

A	O
csae	O
of	O
phenyotin	B-Chemical
(	O
DPH	B-Chemical
)	O
enecphalopathy	O
with	O
incraesing	O
seizuers	O
and	O
EEG	O
and	O
menatl	O
cahnges	O
is	O
described	O
.	O

Despite	O
adeqaute	O
oarl	O
dosgae	O
of	O
DPH	B-Chemical
(	O
5	O
mg	O
/	O
kg	O
/	O
daliy	O
)	O
the	O
plsama	O
leevl	O
was	O
very	O
low	O
(	O
2	O
.	O
8	O
microgramg	O
/	O
ml	O
)	O
.	O

The	O
encephalopahty	O
was	O
probably	O
an	O
iidosyncratic	O
and	O
not	O
txoic	O
or	O
allergic	O
reaciton	O
.	O

In	O
fact	O
the	O
cocnentration	O
of	O
free	O
DPH	B-Chemical
was	O
nromal	O
,	O
the	O
patinet	O
presented	O
a	O
retraded	O
morbillifrom	O
rsah	O
during	O
DPH	B-Chemical
treatmnet	O
,	O
the	O
protidgoram	O
was	O
nromal	O
,	O
and	O
an	O
intardermic	O
DPH	B-Chemical
inejction	O
had	O
no	O
lcoal	O
effcet	O
.	O

The	O
auhtors	O
conclude	O
that	O
in	O
a	O
paitent	O
starting	O
DPH	B-Chemical
tretament	O
an	O
unexpected	O
incresae	O
in	O
siezures	O
,	O
with	O
EEG	O
and	O
mnetal	O
cahnges	O
occurring	O
simultaneosuly	O
,	O
should	O
alert	O
the	O
phsyician	O
to	O
the	O
possible	O
need	O
for	O
eliminating	O
DPH	B-Chemical
from	O
the	O
tehrapeutic	O
reigmen	O
,	O
even	O
if	O
plamsa	O
concentraitons	O
are	O
low	O
.	O

Pervention	O
and	O
traetment	O
of	O
endometiral	O
disaese	O
in	O
climactreic	O
woemn	O
receiving	O
osetrogen	B-Chemical
tehrapy	O
.	O

The	O
treatemnt	O
regmiens	O
are	O
described	O
in	O
74	O
pateints	O
with	O
endmoetrial	O
diesase	O
among	O
850	O
climacetric	O
wmoen	O
receiving	O
oestorgen	B-Chemical
therpay	O
.	O

Csytic	O
hyeprplasia	O
was	O
associated	O
with	O
unoppsoed	O
osetrogen	B-Chemical
tehrapy	O
without	O
progestaegn	B-Chemical
.	O

Two	O
couress	O
of	O
21	O
dyas	O
of	O
5	O
mg	O
noerthisterone	B-Chemical
daliy	O
caused	O
revresion	O
to	O
nomral	O
in	O
all	O
57	O
caess	O
of	O
csytic	O
hyperplsaia	O
and	O
6	O
of	O
the	O
8	O
csaes	O
of	O
atypcial	O
hyperplsaia	O
.	O

4	O
csaes	O
of	O
endomertial	O
cracinoma	O
referred	O
from	O
elsewhere	O
demonstrated	O
the	O
prolbems	O
of	O
inapporpriate	O
and	O
usnupervised	O
unpoposed	O
oetsrogen	B-Chemical
threapy	O
and	O
the	O
difficutly	O
in	O
distinguishing	O
seevre	O
hyperlpasia	O
from	O
malignnacy	O
.	O

Cylcical	O
low	O
-	O
dsoe	O
osetrogen	B-Chemical
therpay	O
with	O
7	O
-	O
-	O
13	O
dyas	O
of	O
progetsagen	B-Chemical
does	O
not	O
seem	O
to	O
incerase	O
the	O
rsik	O
of	O
endomertial	O
hpyerplasia	O
or	O
carcinmoa	O
.	O

Efefcts	O
of	O
exrecise	O
on	O
the	O
sveerity	O
of	O
isoporterenol	B-Chemical
-	O
indcued	O
myoacrdial	O
infacrtion	O
.	O

The	O
efefct	O
of	O
exercsie	O
on	O
the	O
seveirty	O
of	O
isoprtoerenol	B-Chemical
-	O
idnuced	O
mycoardial	O
inafrction	O
was	O
studied	O
in	O
mlae	O
rtas	O
.	O

Ninety	O
-	O
three	O
rtas	O
were	O
randomly	O
divided	O
into	O
three	O
gropus	O
.	O

The	O
exericse	O
-	O
isoporterenol	B-Chemical
(	O
E	O
-	O
1	O
)	O
and	O
exercsie	O
cnotrol	O
(	O
EC	O
)	O
gruops	O
exrecised	O
daliy	O
for	O
thirty	O
dyas	O
on	O
a	O
treadmlil	O
at	O
1	O
mph	O
,	O
2	O
%	O
grdae	O
while	O
aniamls	O
of	O
the	O
sedetnary	O
-	O
isoproterneol	B-Chemical
(	O
S	O
-	O
I	O
)	O
gorup	O
remained	O
sednetary	O
.	O

Eight	O
animlas	O
were	O
assigned	O
to	O
the	O
sedentray	O
cnotrol	O
(	O
SC	O
)	O
gruop	O
which	O
remained	O
sednetary	O
throughout	O
the	O
expeirmental	O
preiod	O
.	O

Forty	O
-	O
eight	O
hours	O
after	O
the	O
final	O
execrise	O
peroid	O
,	O
S	O
-	O
I	O
and	O
E	O
-	O
I	O
anmials	O
received	O
a	O
single	O
sbucutaneous	O
injeciton	O
of	O
isoprotreenol	B-Chemical
(	O
250	O
mg	O
/	O
kg	O
bdoy	O
weihgt	O
)	O
.	O

Ainmals	O
of	O
the	O
S	O
-	O
I	O
gruop	O
exhibited	O
significantly	O
(	O
Pp	O
less	O
than	O
0	O
.	O
05	O
)	O
greater	O
mortailty	O
from	O
the	O
effcets	O
of	O
isorpoterenol	B-Chemical
than	O
animlas	O
of	O
the	O
E	O
-	O
I	O
gorup	O
.	O

Seurm	O
CPK	O
actiivty	O
for	O
E	O
-	O
I	O
aniamls	O
was	O
significantly	O
(	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
greater	O
than	O
for	O
ainmals	O
in	O
the	O
S	O
-	O
I	O
and	O
EC	O
gropus	O
twenty	O
hours	O
following	O
iosproterenol	B-Chemical
injeciton	O
.	O

No	O
staitstically	O
significant	O
difefrences	O
were	O
observed	O
between	O
the	O
two	O
isoprtoerenol	B-Chemical
treaetd	O
gruops	O
for	O
seveirty	O
of	O
the	O
inudced	O
lesinos	O
,	O
cahnges	O
in	O
herat	O
wegiht	O
,	O
or	O
herat	O
wieght	O
to	O
bdoy	O
weihgt	O
ratois	O
.	O

The	O
resluts	O
indicated	O
that	O
eexrcise	O
reudced	O
the	O
mortaltiy	O
associated	O
with	O
the	O
efefcts	O
of	O
large	O
dosaegs	O
of	O
isoproterneol	B-Chemical
but	O
had	O
little	O
on	O
the	O
seveirty	O
of	O
the	O
infraction	O
.	O

Huamn	O
corticotroipn	B-Chemical
-	O
releasing	O
horomne	O
and	O
tyhrotropin	B-Chemical
-	O
releasing	O
horomne	O
modualte	O
the	O
hpyercapnic	O
vnetilatory	O
rseponse	O
in	O
humnas	O
.	O

Hmuan	O
corticotroipn	B-Chemical
-	O
releasing	O
hormnoe	O
(	O
hRCH	O
)	O
and	O
tyhrotropin	B-Chemical
-	O
releasing	O
horomne	O
(	O
TRH	O
)	O
are	O
known	O
to	O
sitmulate	O
ventialtion	O
after	O
i	O
.	O
v	O
.	O
adminitsration	O
in	O
hmuans	O
.	O

In	O
a	O
placbeo	O
-	O
cotnrolled	O
,	O
single	O
-	O
blnid	O
sutdy	O
we	O
aimed	O
to	O
clarify	O
if	O
both	O
ppetides	O
act	O
by	O
alteirng	O
cetnral	O
cheomsensitivity	O
.	O

Two	O
subsequent	O
CO2	B-Chemical
-	O
reberathing	O
tsets	O
were	O
performed	O
in	O
healhty	O
yuong	O
volnuteers	O
.	O

During	O
the	O
first	O
tset	O
0	O
.	O
9	O
%	O
NCal	B-Chemical
was	O
given	O
i	O
.	O
v	O
.	O
;	O
during	O
the	O
second	O
tset	O
200	O
microgarms	O
of	O
hRCH	O
(	O
n	O
=	O
12	O
)	O
or	O
400	O
microrgams	O
of	O
TRH	O
(	O
n	O
=	O
6	O
)	O
was	O
admiinstered	O
i	O
.	O
v	O
.	O
Nine	O
subjetcs	O
received	O
0	O
.	O
9	O
%	O
NCal	B-Chemical
i	O
.	O
v	O
.	O
during	O
both	O
rbereathing	O
manoeurves	O
.	O

The	O
CO2	B-Chemical
-	O
resposne	O
curevs	O
for	O
the	O
two	O
tsets	O
were	O
compaerd	O
within	O
the	O
same	O
subjcet	O
.	O

In	O
the	O
hRCH	O
gruop	O
a	O
marked	O
parallel	O
shift	O
of	O
the	O
CO2	B-Chemical
-	O
respnose	O
cruve	O
to	O
the	O
lfet	O
was	O
observed	O
after	O
hRCH	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

The	O
same	O
effect	O
occurred	O
following	O
TRH	O
but	O
was	O
less	O
striking	O
(	O
P	O
=	O
0	O
.	O
05	O
)	O
.	O

hRCH	O
and	O
TRH	O
caused	O
a	O
redcution	O
in	O
the	O
CO2	B-Chemical
trheshold	O
.	O

The	O
CO2	B-Chemical
-	O
resopnse	O
curevs	O
in	O
the	O
cotnrol	O
gruop	O
were	O
nearly	O
identiacl	O
.	O

The	O
rseults	O
indicate	O
an	O
addtiive	O
effcet	O
of	O
both	O
releasing	O
homrones	O
on	O
the	O
hyperacpnic	O
ventialtory	O
resopnse	O
in	O
hmuans	O
,	O
presumably	O
indpeendent	O
of	O
centarl	O
chemsoensitivity	O
.	O

Lamivudnie	B-Chemical
is	O
efefctive	O
in	O
spupressing	O
hepattiis	O
B	O
viurs	O
DNA	O
in	O
Chinsee	O
heaptitis	B-Chemical
B	I-Chemical
sufrace	I-Chemical
antgien	I-Chemical
carirers	O
:	O
a	O
palcebo	O
-	O
controlled	O
tiral	O
.	O

Lamivuidne	B-Chemical
is	O
a	O
novel	O
2	B-Chemical
'	I-Chemical
,	I-Chemical
3	I-Chemical
'	I-Chemical
-	I-Chemical
diedoxy	I-Chemical
cyotsine	I-Chemical
analouge	O
that	O
has	O
potent	O
inhibtiory	O
efefcts	O
on	O
hepattiis	O
B	O
viurs	O
replictaion	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

We	O
performed	O
a	O
single	O
-	O
blnid	O
,	O
placbeo	O
-	O
controleld	O
sutdy	O
to	O
assess	O
its	O
effectievness	O
and	O
saftey	O
in	O
Cihnese	O
hpeatitis	B-Chemical
B	I-Chemical
sufrace	I-Chemical
antiegn	I-Chemical
(	O
HBAsg	B-Chemical
)	O
carreirs	O
.	O

Forty	O
-	O
two	O
Chniese	O
HsBAg	B-Chemical
carriers	O
were	O
randmoized	O
to	O
receive	O
plcaebo	O
(	O
6	O
pateints	O
)	O
or	O
lamviudine	B-Chemical
orally	O
in	O
doasges	O
of	O
25	O
mg	O
,	O
100	O
mg	O
,	O
or	O
300	O
mg	O
daliy	O
(	O
12	O
ptaients	O
for	O
each	O
dosgae	O
)	O
.	O

The	O
durg	O
was	O
given	O
for	O
4	O
weeks	O
.	O

The	O
pateints	O
were	O
closely	O
mointored	O
cilnically	O
,	O
biochemiclaly	O
,	O
and	O
seorlogically	O
up	O
to	O
4	O
wekes	O
after	O
durg	O
treatemnt	O
.	O

All	O
36	O
pateints	O
receiving	O
lamviudine	B-Chemical
had	O
a	O
dcerease	O
in	O
heaptitis	O
B	O
vrius	O
(	O
HBV	O
)	O
DNA	O
vaules	O
of	O
>	O
90	O
%	O
(	O
P	O
<	O
.	O
001	O
comapred	O
with	O
plaecbo	O
)	O
.	O

Although	O
25	O
mg	O
of	O
lamivudnie	B-Chemical
was	O
slightly	O
less	O
effective	O
than	O
100	O
mg	O
(	O
P	O
=	O
.	O
011	O
)	O
and	O
300	O
mg	O
(	O
P	O
=	O
.	O
005	O
)	O
,	O
it	O
still	O
induecd	O
94	O
%	O
spupression	O
of	O
HBV	O
DNA	O
after	O
the	O
fourth	O
week	O
of	O
tehrapy	O
.	O

HBV	O
DNA	O
vaules	O
returned	O
to	O
pretreatemnt	O
lveels	O
within	O
4	O
wekes	O
of	O
cessaiton	O
of	O
tehrapy	O
.	O

There	O
was	O
no	O
change	O
in	O
the	O
hepatiits	O
B	O
e	O
atnigen	O
sattus	O
or	O
in	O
aminotransfrease	O
leevls	O
.	O

No	O
serious	O
avderse	O
eevnts	O
were	O
observed	O
.	O

In	O
conclusion	O
,	O
a	O
4	O
-	O
week	O
cousre	O
of	O
lamiuvdine	B-Chemical
was	O
safe	O
and	O
effecitve	O
in	O
supperssion	O
of	O
HBV	O
DNA	O
in	O
Chinsee	O
HsBAg	B-Chemical
crariers	O
.	O

The	O
supprsesion	O
was	O
>	O
90	O
%	O
but	O
reversible	O
.	O

Stuides	O
with	O
long	O
-	O
term	O
lamiuvdine	B-Chemical
administratoin	O
should	O
be	O
performed	O
to	O
determine	O
if	O
prologned	O
suppression	O
of	O
HBV	O
DNA	O
can	O
be	O
achieved	O
.	O

Popualtion	O
-	O
based	O
stduy	O
of	O
rsik	O
of	O
vneous	O
thromobembolism	O
associated	O
with	O
various	O
oarl	B-Chemical
contarceptives	I-Chemical
.	O

BACKGORUND	O
:	O
Four	O
stduies	O
pubilshed	O
since	O
December	O
,	O
1995	O
,	O
reported	O
that	O
the	O
incidecne	O
of	O
venuos	O
thrombomebolism	O
(	O
VTE	O
)	O
was	O
higehr	O
in	O
woemn	O
who	O
used	O
oarl	B-Chemical
contarceptives	I-Chemical
(	O
OCs	B-Chemical
)	O
containing	O
the	O
third	O
-	O
generatoin	O
progestagnes	B-Chemical
getsodene	B-Chemical
or	O
desgoestrel	B-Chemical
than	O
in	O
usres	O
of	O
OCs	B-Chemical
containing	O
second	O
-	O
generaiton	O
progestaegns	B-Chemical
.	O

However	O
,	O
confoudning	O
and	O
bais	O
in	O
the	O
dseign	O
of	O
these	O
studeis	O
may	O
have	O
affected	O
the	O
findnigs	O
.	O

The	O
aim	O
of	O
our	O
sutdy	O
was	O
to	O
re	O
-	O
examine	O
the	O
associaiton	O
between	O
rsik	O
of	O
VTE	O
and	O
OC	B-Chemical
use	O
with	O
a	O
different	O
stduy	O
dseign	O
and	O
aanlysis	O
to	O
avoid	O
some	O
of	O
the	O
bais	O
and	O
confonuding	O
of	O
the	O
earlier	O
stuides	O
.	O

METHODS	O
:	O
We	O
used	O
cmoputer	O
reocrds	O
of	O
ptaients	O
from	O
143	O
general	O
pratcices	O
in	O
the	O
UK	O
.	O

The	O
sutdy	O
was	O
based	O
on	O
the	O
mdeical	O
recrods	O
of	O
about	O
540	O
,	O
000	O
wmoen	O
bron	O
between	O
1941	O
and	O
1981	O
.	O

All	O
wmoen	O
who	O
had	O
a	O
recorded	O
diagnoiss	O
of	O
deep	O
-	O
vien	O
thrombsois	O
,	O
venuos	O
thormbosis	O
not	O
otherwise	O
specified	O
,	O
or	O
pulomnary	O
ebmolus	O
during	O
the	O
sutdy	O
preiod	O
,	O
and	O
who	O
had	O
been	O
tretaed	O
with	O
an	O
anticoagulnat	O
were	O
identfiied	O
as	O
potenital	O
caess	O
of	O
VTE	O
.	O

We	O
did	O
a	O
choort	O
analsyis	O
to	O
etsimate	O
and	O
comapre	O
incidecne	O
of	O
VTE	O
in	O
uesrs	O
of	O
the	O
main	O
OC	B-Chemical
perparations	O
,	O
and	O
a	O
netsed	O
csae	O
-	O
conrtol	O
stduy	O
to	O
calcultae	O
the	O
odds	O
raitos	O
of	O
VTE	O
associated	O
with	O
use	O
of	O
different	O
types	O
of	O
OC	B-Chemical
,	O
after	O
adjutsment	O
for	O
potenital	O
confoudning	O
fcators	O
.	O

In	O
the	O
csae	O
-	O
conrtol	O
sutdy	O
,	O
we	O
matched	O
caess	O
to	O
cotnrols	O
by	O
exact	O
yaer	O
of	O
brith	O
,	O
pratcice	O
,	O
and	O
current	O
use	O
of	O
OCs	B-Chemical
.	O

We	O
used	O
a	O
multpile	O
logitsic	O
regrsesion	O
mdoel	O
that	O
included	O
bdoy	O
-	O
msas	O
index	O
,	O
number	O
of	O
cylces	O
,	O
change	O
in	O
tpye	O
of	O
OC	B-Chemical
precsribed	O
within	O
3	O
monhts	O
of	O
the	O
evnet	O
,	O
previous	O
preganncy	O
,	O
and	O
cnocurrent	O
diesase	O
.	O

FNIDINGS	O
:	O
85	O
woemn	O
met	O
the	O
inculsion	O
cirteria	O
for	O
VTE	O
,	O
two	O
of	O
whom	O
were	O
usres	O
of	O
progestaegn	B-Chemical
-	O
only	O
OCs	B-Chemical
.	O

Of	O
the	O
83	O
caess	O
of	O
VTE	O
associated	O
with	O
use	O
of	O
cobmined	O
OCs	B-Chemical
,	O
43	O
were	O
recorded	O
as	O
deep	O
-	O
vien	O
thrmobosis	O
,	O
35	O
as	O
pulmnoary	O
trhombosis	O
,	O
and	O
five	O
as	O
veonus	O
thrombsois	O
not	O
otherwise	O
specified	O
.	O

The	O
curde	O
rtae	O
of	O
VTE	O
per	O
10	O
,	O
000	O
wmoan	O
-	O
yeras	O
was	O
4	O
.	O
10	O
in	O
current	O
uesrs	O
of	O
any	O
OC	B-Chemical
,	O
3	O
.	O
10	O
in	O
usres	O
of	O
second	O
-	O
generaiton	O
OCs	B-Chemical
,	O
and	O
4	O
.	O
96	O
in	O
usres	O
of	O
third	O
-	O
geneartion	O
preparaitons	O
.	O

After	O
adjustmnet	O
for	O
age	O
,	O
the	O
rtae	O
raito	O
of	O
VTE	O
in	O
usres	O
of	O
third	O
-	O
geneartion	O
relative	O
to	O
second	O
-	O
geenration	O
OCs	B-Chemical
was	O
1	O
.	O
68	O
(	O
95	O
%	O
CI	O
1	O
.	O
04	O
-	O
2	O
.	O
75	O
)	O
.	O

Lgoistic	O
regressoin	O
showed	O
no	O
significant	O
difference	O
in	O
the	O
rsik	O
of	O
VTE	O
between	O
uesrs	O
of	O
third	O
-	O
genreation	O
and	O
second	O
-	O
generatoin	O
OCs	B-Chemical
.	O

Among	O
usres	O
of	O
third	O
-	O
gneeration	O
progestaegns	B-Chemical
,	O
the	O
rsik	O
of	O
VTE	O
was	O
hihger	O
in	O
usres	O
of	O
deosgestrel	B-Chemical
with	O
20	O
g	O
ethinyleostradiol	B-Chemical
than	O
in	O
uesrs	O
of	O
gestoedne	B-Chemical
or	O
desogsetrel	B-Chemical
with	O
30	O
g	O
ethinylosetradiol	B-Chemical
.	O

With	O
all	O
second	O
-	O
genertaion	O
OCs	B-Chemical
as	O
the	O
refeernce	O
,	O
the	O
odds	O
ratois	O
for	O
VTE	O
were	O
3	O
.	O
49	O
(	O
1	O
.	O
21	O
-	O
10	O
.	O
12	O
)	O
for	O
desogetsrel	B-Chemical
plus	O
20	O
g	O
ethinyloestardiol	B-Chemical
and	O
1	O
.	O
18	O
(	O
0	O
.	O
66	O
-	O
2	O
.	O
17	O
)	O
for	O
the	O
other	O
third	O
-	O
geenration	O
progetsagens	B-Chemical
.	O

INTERPRETATION	O
:	O
The	O
previously	O
reported	O
incerase	O
in	O
odds	O
raito	O
associated	O
with	O
third	O
-	O
geenration	O
OCs	B-Chemical
when	O
compraed	O
with	O
second	O
-	O
genreation	O
produtcs	O
is	O
likely	O
to	O
have	O
been	O
the	O
result	O
of	O
residaul	O
confoundnig	O
by	O
age	O
.	O

The	O
icnreased	O
odds	O
rtaio	O
associated	O
with	O
porducts	O
containing	O
20	O
mircograms	O
ethinyloesrtadiol	B-Chemical
and	O
desgoestrel	B-Chemical
compraed	O
with	O
the	O
30	O
micrgorams	O
porduct	O
is	O
bioloigcally	O
implausible	O
,	O
and	O
is	O
likely	O
to	O
be	O
the	O
result	O
of	O
preefrential	O
prsecribing	O
and	O
,	O
thus	O
,	O
confounidng	O
.	O

MK	B-Chemical
-	I-Chemical
801	I-Chemical
augmnets	O
pilocarpnie	B-Chemical
-	O
indcued	O
electrograhpic	O
seizrue	O
but	O
proetcts	O
against	O
barin	O
dmaage	O
in	O
rtas	O
.	O

1	O
.	O

The	O
auhtors	O
examined	O
the	O
anticonvuslant	O
effetcs	O
of	O
MK	B-Chemical
-	I-Chemical
801	I-Chemical
on	O
the	O
pliocarpine	B-Chemical
-	O
inudced	O
siezure	O
mdoel	O
.	O

Intarperitoneal	O
injeciton	O
of	O
pilocaripne	B-Chemical
(	O
400	O
mg	O
/	O
kg	O
)	O
inudced	O
tnoic	O
and	O
clnoic	O
seizrue	O
.	O

Scpoolamine	B-Chemical
(	O
10	O
mg	O
/	O
kg	O
)	O
and	O
pentobabrital	B-Chemical
(	O
5	O
mg	O
/	O
kg	O
)	O
prevented	O
deveolpment	O
of	O
piolcarpine	B-Chemical
-	O
inudced	O
behavioarl	O
seizrue	O
but	O
MK	B-Chemical
-	I-Chemical
801	I-Chemical
(	O
0	O
.	O
5	O
mg	O
/	O
kg	O
)	O
did	O
not	O
.	O

2	O
.	O

An	O
elecrtical	O
seizrue	O
measuerd	O
with	O
hippocapmal	O
EEG	O
appeared	O
in	O
the	O
pilocarpnie	B-Chemical
-	O
terated	O
gruop	O
.	O

Scpoolamine	B-Chemical
and	O
pentobarbiatl	B-Chemical
bolcked	O
the	O
piolcarpine	B-Chemical
-	O
idnuced	O
electrgoraphic	O
seziure	O
,	O
MK	B-Chemical
-	I-Chemical
801	I-Chemical
treamtent	O
augmenetd	O
the	O
electorgraphic	O
seziure	O
induecd	O
by	O
pliocarpine	B-Chemical
.	O

3	O
.	O

Brian	O
dmaage	O
was	O
assessed	O
by	O
examining	O
the	O
hippocmapus	O
mircoscopically	O
.	O

Pilocarpnie	B-Chemical
produced	O
neurnoal	O
detah	O
in	O
the	O
hippocmapus	O
,	O
which	O
showed	O
pynkotic	O
chagnes	O
.	O

Penotbarbital	B-Chemical
,	O
socpolamine	B-Chemical
and	O
MK	B-Chemical
-	I-Chemical
801	I-Chemical
protected	O
the	O
barin	O
daamge	O
by	O
pliocarpine	B-Chemical
,	O
though	O
in	O
the	O
MK	B-Chemical
-	I-Chemical
801	I-Chemical
-	O
terated	O
gruop	O
,	O
the	O
pyramiadl	O
clels	O
of	O
hippoacmpus	O
appeared	O
darekr	O
than	O
noraml	O
.	O

In	O
all	O
treatemnts	O
,	O
graunle	O
clels	O
of	O
the	O
denttae	O
gyurs	O
were	O
not	O
affected	O
.	O

4	O
.	O

These	O
resutls	O
indicate	O
that	O
sattus	O
epliepticus	O
induecd	O
by	O
pliocarpine	B-Chemical
is	O
initiated	O
by	O
cholinegric	O
overstimulaiton	O
and	O
propagated	O
by	O
glutamaterigc	O
transmissoin	O
,	O
the	O
elevtaion	O
of	O
which	O
may	O
cause	O
barin	O
daamge	O
through	O
an	O
excitatroy	O
NDMA	B-Chemical
rceeptor	O
-	O
mediated	O
mcehanism	O
.	O

Pacliatxel	B-Chemical
,	O
5	B-Chemical
-	I-Chemical
fluorouraicl	I-Chemical
,	O
and	O
foliinc	B-Chemical
aicd	I-Chemical
in	O
mteastatic	O
braest	O
cacner	O
:	O
BRE	O
-	O
26	O
,	O
a	O
phsae	O
II	O
trail	O
.	O

5	B-Chemical
-	I-Chemical
Fluorourcail	I-Chemical
plus	O
floinic	B-Chemical
aicd	I-Chemical
and	O
paclitaexl	B-Chemical
(	O
Txaol	B-Chemical
;	O
Birstol	O
-	O
Myres	O
Squbib	O
Compnay	O
,	O
Princeotn	O
,	O
NJ	O
)	O
are	O
effetcive	O
slavage	O
thearpies	O
for	O
metsatatic	O
braest	O
cnacer	O
paitents	O
.	O

Pcalitaxel	B-Chemical
and	O
5	B-Chemical
-	I-Chemical
fluooruracil	I-Chemical
have	O
adidtive	O
cyottoxicity	O
in	O
MCF	O
-	O
7	O
clel	O
lnies	O
.	O

We	O
performed	O
a	O
phsae	O
II	O
trail	O
of	O
pacliatxel	B-Chemical
175	O
mg	O
/	O
m2	O
over	O
3	O
hours	O
on	O
day	O
I	O
followed	O
by	O
folniic	B-Chemical
aicd	I-Chemical
300	O
mg	O
over	O
1	O
hour	O
before	O
5	B-Chemical
-	I-Chemical
flourouracil	I-Chemical
350	O
mg	O
/	O
m2	O
on	O
dyas	O
1	O
to	O
3	O
every	O
28	O
dyas	O
(	O
TFL	O
)	O
in	O
wmoen	O
with	O
metsatatic	O
braest	O
canecr	O
.	O

Aanlysis	O
is	O
reported	O
on	O
37	O
pateints	O
with	O
a	O
minimum	O
of	O
6	O
mnoths	O
follow	O
-	O
up	O
who	O
received	O
a	O
total	O
of	O
192	O
ccyles	O
of	O
TFL	O
:	O
nine	O
cycels	O
(	O
5	O
%	O
)	O
were	O
associated	O
with	O
grdae	O
3	O
/	O
4	O
neutorpenia	O
requiring	O
hospitaliaztion	O
;	O
seven	O
(	O
4	O
%	O
)	O
cylces	O
in	O
two	O
ptaients	O
required	O
granuloycte	B-Chemical
coolny	I-Chemical
-	I-Chemical
stiumlating	I-Chemical
facotr	I-Chemical
due	O
to	O
neutropeina	O
;	O
no	O
paitent	O
required	O
platleet	O
transfuisons	O
.	O

Grdae	O
3	O
/	O
4	O
nonhematoolgic	O
toixcities	O
were	O
uncommon	O
.	O

Among	O
the	O
34	O
pateints	O
evalubale	O
for	O
repsonse	O
,	O
there	O
were	O
three	O
complete	O
repsonses	O
(	O
9	O
%	O
)	O
and	O
18	O
patrial	O
resopnses	O
(	O
53	O
%	O
)	O
for	O
an	O
overall	O
resopnse	O
rtae	O
of	O
62	O
%	O
.	O

Of	O
the	O
19	O
evalubale	O
patietns	O
with	O
prior	O
doxorbuicin	B-Chemical
expsoure	O
,	O
11	O
(	O
58	O
%	O
)	O
responded	O
comapred	O
with	O
nine	O
of	O
15	O
(	O
60	O
%	O
)	O
without	O
prior	O
doxorbuicin	B-Chemical
.	O

Plamsa	O
paclitaexl	B-Chemical
concentratoins	O
were	O
maesured	O
at	O
the	O
comlpetion	O
of	O
pacliatxel	B-Chemical
infsuion	O
and	O
at	O
24	O
hours	O
in	O
19	O
patinets	O
.	O

TFL	O
is	O
an	O
atcive	O
,	O
well	O
-	O
toelrated	O
reigmen	O
in	O
meatstatic	O
braest	O
cacner	O
.	O

Effiaccy	O
and	O
proarrhythima	O
with	O
the	O
use	O
of	O
d	B-Chemical
,	I-Chemical
l	I-Chemical
-	I-Chemical
sotlaol	I-Chemical
for	O
sustaiend	O
ventrciular	O
tachyarrhythmais	O
.	O

This	O
sutdy	O
prospectively	O
evaulated	O
the	O
cliniacl	O
efficacy	O
,	O
the	O
inicdence	O
of	O
torsaeds	O
de	O
poitnes	O
,	O
and	O
the	O
presumable	O
rsik	O
fatcors	O
for	O
tosrades	O
de	O
ponites	O
in	O
patinets	O
treaetd	O
with	O
d	B-Chemical
,	I-Chemical
l	I-Chemical
-	I-Chemical
stoalol	I-Chemical
for	O
sutsained	O
ventricualr	O
tahcyarrhythmias	O
.	O

Eighty	O
-	O
one	O
conescutive	O
patinets	O
(	O
54	O
with	O
cornoary	O
aretry	O
dsiease	O
,	O
and	O
20	O
with	O
dliated	O
cardiomypoathy	O
)	O
with	O
inducbile	O
sustianed	O
ventricualr	O
tachyacrdia	O
or	O
ventricualr	O
fibrilaltion	O
received	O
oarl	O
d	B-Chemical
,	I-Chemical
l	I-Chemical
-	I-Chemical
stoalol	I-Chemical
to	O
pervent	O
inudction	O
of	O
the	O
ventricualr	O
tachyarrhytmhia	O
.	O

During	O
oarl	O
loadnig	O
with	O
d	B-Chemical
,	I-Chemical
l	I-Chemical
-	I-Chemical
sotaoll	I-Chemical
,	O
conitnuous	O
eelctrocardiographic	O
(	O
ECG	O
)	O
mnoitoring	O
was	O
performed	O
.	O

Those	O
paitents	O
in	O
whom	O
d	B-Chemical
,	I-Chemical
l	I-Chemical
-	I-Chemical
stoalol	I-Chemical
prevented	O
indutcion	O
of	O
ventricualr	O
tacyhcardia	O
or	O
ventircular	O
fibrillation	O
were	O
dischraged	O
with	O
the	O
durg	O
and	O
followed	O
up	O
on	O
an	O
outptaient	O
basis	O
for	O
21	O
+	O
/	O
-	O
18	O
motnhs	O
.	O

Indutcion	O
of	O
the	O
vnetricular	O
tacyharrhythmia	O
was	O
prevented	O
by	O
oarl	O
d	B-Chemical
,	I-Chemical
l	I-Chemical
-	I-Chemical
sotaoll	I-Chemical
in	O
35	O
(	O
43	O
%	O
)	O
patinets	O
;	O
the	O
ventircular	O
tachyarryhthmia	O
remained	O
idnucible	O
in	O
40	O
(	O
49	O
%	O
)	O
patinets	O
;	O
and	O
two	O
(	O
2	O
.	O
5	O
%	O
)	O
pateints	O
did	O
not	O
tolerate	O
even	O
40	O
mg	O
of	O
d	B-Chemical
,	I-Chemical
l	I-Chemical
-	I-Chemical
sotlaol	I-Chemical
once	O
daliy	O
.	O

Four	O
(	O
5	O
%	O
)	O
patietns	O
had	O
from	O
torsaeds	O
de	O
poitnes	O
during	O
the	O
initial	O
oarl	O
traetment	O
with	O
d	B-Chemical
,	I-Chemical
l	I-Chemical
-	I-Chemical
sotlaol	I-Chemical
.	O

Neither	O
ECG	O
[	O
siuns	O
-	O
ccyle	O
lentgh	O
(	O
SCL	O
)	O
,	O
QT	O
or	O
QTc	O
itnerval	O
,	O
or	O
U	O
wvae	O
]	O
nor	O
cliniacl	O
parameetrs	O
idetnified	O
patinets	O
at	O
rsik	O
for	O
tosrades	O
de	O
poinets	O
.	O

However	O
,	O
the	O
oarl	O
dsoe	O
of	O
d	B-Chemical
,	I-Chemical
l	I-Chemical
-	I-Chemical
sotaoll	I-Chemical
was	O
significantly	O
lwoer	O
in	O
pateints	O
with	O
torasdes	O
de	O
poitnes	O
(	O
200	O
+	O
/	O
-	O
46	O
vs	O
.	O
328	O
+	O
/	O
-	O
53	O
mg	O
/	O
day	O
;	O
p	O
=	O
0	O
.	O
0017	O
)	O
.	O

Rsik	O
facotrs	O
associated	O
with	O
the	O
developmnet	O
of	O
torsdaes	O
de	O
ponites	O
were	O
the	O
apperaance	O
of	O
an	O
U	O
wvae	O
(	O
p	O
=	O
0	O
.	O
049	O
)	O
,	O
femlae	O
gneder	O
(	O
p	O
=	O
0	O
.	O
015	O
)	O
,	O
and	O
significant	O
dsoe	O
-	O
corretced	O
chanegs	O
of	O
SCL	O
,	O
QT	O
interavl	O
,	O
and	O
QTc	O
inetrval	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

During	O
follow	O
-	O
up	O
,	O
seven	O
(	O
20	O
%	O
)	O
paitents	O
had	O
a	O
nonaftal	O
venrticular	O
tachycradia	O
recurrnece	O
,	O
and	O
two	O
(	O
6	O
%	O
)	O
patinets	O
deid	O
suddenly	O
.	O

One	O
feamle	O
patinet	O
with	O
stbale	O
caridac	O
disaese	O
had	O
recurrent	O
tosrades	O
de	O
poinets	O
after	O
2	O
yeras	O
of	O
successful	O
tretament	O
with	O
d	B-Chemical
,	I-Chemical
l	I-Chemical
-	I-Chemical
stoalol	I-Chemical
.	O

Tosrades	O
de	O
piontes	O
occurred	O
ealry	O
during	O
treamtent	O
even	O
with	O
low	O
dsoes	O
of	O
oarl	O
d	B-Chemical
,	I-Chemical
l	I-Chemical
-	I-Chemical
sotaoll	I-Chemical
.	O

Pronounced	O
cahnges	O
in	O
the	O
surfcae	O
ECG	O
(	O
cylce	O
legnth	O
,	O
QT	O
,	O
and	O
QTc	O
)	O
in	O
relation	O
to	O
the	O
dsoe	O
of	O
oarl	O
d	B-Chemical
,	I-Chemical
l	I-Chemical
-	I-Chemical
sotaoll	I-Chemical
might	O
identify	O
a	O
subgruop	O
of	O
pateints	O
with	O
an	O
icnreased	O
rsik	O
for	O
torsaeds	O
de	O
poitnes	O
.	O

Other	O
ECG	O
paramteers	O
before	O
the	O
applicatoin	O
of	O
d	B-Chemical
,	I-Chemical
l	I-Chemical
-	I-Chemical
stoalol	I-Chemical
did	O
not	O
identify	O
ptaients	O
at	O
increaesd	O
rsik	O
for	O
torsaeds	O
de	O
ponites	O
.	O

Recurrnece	O
rtaes	O
of	O
venrticular	O
tachyarrhythimas	O
are	O
high	O
despite	O
complete	O
suppresison	O
of	O
the	O
arrhyhtmia	O
during	O
programemd	O
stimulatoin	O
.	O

Therefore	O
prgorammed	O
eelctrical	O
sitmulation	O
in	O
the	O
csae	O
of	O
d	B-Chemical
,	I-Chemical
l	I-Chemical
-	I-Chemical
stoalol	I-Chemical
seems	O
to	O
be	O
of	O
limtied	O
prognsotic	O
value	O
.	O

Crhonic	O
hyperproalctinemia	O
and	O
chagnes	O
in	O
dopaimne	B-Chemical
neuorns	O
.	O

The	O
tuberoifnundibular	O
dopamniergic	O
(	O
TDIA	O
)	O
sysetm	O
is	O
known	O
to	O
inhbiit	O
prolatcin	O
(	O
PRL	O
)	O
secrteion	O
.	O

In	O
yonug	O
anmials	O
this	O
sysetm	O
responds	O
to	O
actue	O
elevatoins	O
in	O
sreum	O
PRL	O
by	O
incerasing	O
its	O
acitvity	O
.	O

However	O
,	O
this	O
responsvieness	O
is	O
lsot	O
in	O
agnig	O
rtas	O
with	O
chroncially	O
high	O
sreum	O
PRL	O
levles	O
.	O

The	O
purpose	O
of	O
this	O
sutdy	O
was	O
to	O
inudce	O
hyperprolactineima	O
in	O
rtas	O
for	O
etxended	O
peridos	O
of	O
tmie	O
and	O
examine	O
its	O
effetcs	O
on	O
doapminergic	O
systmes	O
in	O
the	O
brian	O
.	O

Hyperprloactinemia	O
was	O
indcued	O
by	O
treatmnet	O
with	O
haloperdiol	B-Chemical
,	O
a	O
dopamnie	B-Chemical
rceeptor	O
anatgonist	O
,	O
and	O
Paklovits	O
'	O
mircodissection	O
techinque	O
in	O
combinaiton	O
with	O
high	O
-	O
performacne	O
liqiud	O
chromatgoraphy	O
was	O
used	O
to	O
meausre	O
neurotransimtter	O
concentrtaions	O
in	O
several	O
areas	O
of	O
the	O
barin	O
.	O

After	O
6	O
monhts	O
of	O
hyperprolcatinemia	O
,	O
dpoamine	B-Chemical
(	O
DA	B-Chemical
)	O
concentrtaions	O
in	O
the	O
mdeian	O
eminnece	O
(	O
ME	O
)	O
incraesed	O
by	O
84	O
%	O
over	O
the	O
cotnrol	O
gruop	O
.	O

Nine	O
monhts	O
of	O
hyperprolatcinemia	O
produced	O
a	O
50	O
%	O
incresae	O
in	O
DA	B-Chemical
concentrtaions	O
in	O
the	O
ME	O
over	O
the	O
cotnrol	O
gruop	O
.	O

However	O
,	O
DA	B-Chemical
resopnse	O
was	O
lsot	O
if	O
a	O
9	O
-	O
motnh	O
long	O
haloperdiol	B-Chemical
-	O
inudced	O
hpyerprolactinemia	O
was	O
followed	O
by	O
a	O
1	O
1	O
/	O
2	O
mnoth	O
-	O
long	O
extremely	O
high	O
incerase	O
in	O
sreum	O
PRL	O
lveels	O
produced	O
by	O
implanttaion	O
of	O
MMQ	O
cells	O
under	O
the	O
kideny	O
capusle	O
.	O

There	O
was	O
no	O
change	O
in	O
the	O
leevls	O
of	O
DA	B-Chemical
,	O
norepinephirne	B-Chemical
(	O
NE	B-Chemical
)	O
,	O
serotoinn	B-Chemical
(	O
5	B-Chemical
-	I-Chemical
HT	I-Chemical
)	O
,	O
or	O
their	O
metabloites	O
in	O
the	O
arcaute	O
nuclues	O
(	O
AN	O
)	O
,	O
meidal	O
proeptic	O
aera	O
(	O
MPA	O
)	O
,	O
caduate	O
ptuamen	O
(	O
CP	O
)	O
,	O
subsatntia	O
nirga	O
(	O
SN	O
)	O
,	O
and	O
znoa	O
inecrta	O
(	O
ZI	O
)	O
,	O
except	O
for	O
a	O
dercease	O
in	O
5	B-Chemical
-	I-Chemical
hydroxyindoleaectic	I-Chemical
aicd	I-Chemical
(	O
5	B-Chemical
-	I-Chemical
HAIA	I-Chemical
)	O
in	O
the	O
AN	O
after	O
6	O
-	O
motnhs	O
of	O
hpyerprolactinemia	O
and	O
an	O
incresae	O
in	O
DA	B-Chemical
conecntrations	O
in	O
the	O
AN	O
after	O
9	O
-	O
motnhs	O
of	O
hypreprolactinemia	O
.	O

These	O
resluts	O
demonstrate	O
that	O
hyperprolactienmia	O
specifically	O
affects	O
TDIA	O
nuerons	O
and	O
these	O
efefcts	O
vary	O
,	O
depending	O
on	O
the	O
duraiton	O
and	O
intenstiy	O
of	O
hyperporlactinemia	O
.	O

The	O
age	O
-	O
related	O
decerase	O
in	O
hyptohalamic	O
doapmine	B-Chemical
functoin	O
may	O
be	O
associated	O
with	O
incraeses	O
in	O
PRL	O
secreiton	O
.	O

Teratment	O
-	O
related	O
disseminaetd	O
nercotizing	O
leukoencepahlopathy	O
with	O
characetristic	O
contrast	O
enhacnement	O
of	O
the	O
whtie	O
matter	O
.	O

This	O
rpeort	O
describes	O
uniuqe	O
contrast	O
enhnacement	O
of	O
the	O
wihte	O
matter	O
on	O
T1	O
-	O
weighted	O
mangetic	O
resonnace	O
imgaes	O
of	O
two	O
patietns	O
with	O
dsiseminated	O
necortizing	O
leukoencephaloapthy	O
,	O
which	O
developed	O
from	O
aucte	O
lypmhoblastic	O
leukeima	O
traeted	O
with	O
high	O
-	O
dsoe	O
methotrextae	B-Chemical
.	O

In	O
both	O
pateints	O
,	O
the	O
ehnancement	O
was	O
more	O
pronounced	O
near	O
the	O
base	O
of	O
the	O
barin	O
than	O
at	O
the	O
vetrex	O
.	O

Nercopsy	O
of	O
the	O
first	O
csae	O
revaeled	O
lsos	O
of	O
myelinatoin	O
and	O
nercosis	O
of	O
the	O
wihte	O
matter	O
.	O

Possible	O
mecahnisms	O
causing	O
such	O
a	O
leukonecephalopathy	O
are	O
discussed	O
.	O

Trhombotic	O
comlpications	O
in	O
actue	O
promeylocytic	O
leukeima	O
during	O
all	B-Chemical
-	I-Chemical
trnas	I-Chemical
-	I-Chemical
retinioc	I-Chemical
aicd	I-Chemical
threapy	O
.	O

A	O
csae	O
of	O
actue	O
reanl	O
faliure	O
,	O
due	O
to	O
oclcusion	O
of	O
reanl	O
vessles	O
in	O
a	O
pateint	O
with	O
actue	O
promyeloyctic	O
leuekmia	O
(	O
APL	O
)	O
traeted	O
with	O
all	B-Chemical
-	I-Chemical
tarns	I-Chemical
-	I-Chemical
reitnoic	I-Chemical
aicd	I-Chemical
(	O
ARTA	B-Chemical
)	O
and	O
traenxamic	B-Chemical
aicd	I-Chemical
has	O
been	O
described	O
recently	O
.	O

We	O
reoprt	O
a	O
csae	O
of	O
actue	O
rneal	O
faliure	O
in	O
an	O
APL	O
paitent	O
terated	O
with	O
ARTA	B-Chemical
alone	O
.	O

This	O
csae	O
further	O
supports	O
the	O
concern	O
about	O
thromboemboilc	O
complictaions	O
associated	O
with	O
ARTA	B-Chemical
tehrapy	O
in	O
APL	O
ptaients	O
.	O

The	O
paitents	O
,	O
a	O
43	O
-	O
yaer	O
-	O
old	O
man	O
,	O
presented	O
all	O
the	O
sgins	O
and	O
symptmos	O
of	O
APL	O
and	O
was	O
included	O
in	O
a	O
treatemnt	O
protoocl	O
with	O
ARTA	B-Chemical
.	O

After	O
10	O
dyas	O
of	O
treatmnet	O
,	O
he	O
developed	O
aucte	O
reanl	O
faiulre	O
that	O
was	O
completely	O
reversible	O
after	O
complete	O
remsision	O
of	O
APL	O
was	O
achieved	O
and	O
therpay	O
dsicontinued	O
.	O

We	O
conclude	O
that	O
ARTA	B-Chemical
is	O
a	O
valid	O
tehrapeutic	O
choice	O
for	O
patietns	O
with	O
APL	O
,	O
although	O
the	O
procoagulnat	O
tendency	O
is	O
not	O
completely	O
corretced	O
.	O

Throbmotic	O
evetns	O
,	O
however	O
,	O
could	O
be	O
avoided	O
by	O
using	O
low	O
-	O
dsoe	O
hepairn	B-Chemical
.	O

Pupillray	O
cahnges	O
associated	O
with	O
the	O
deevlopment	O
of	O
sitmulant	O
-	O
inudced	O
maina	O
:	O
a	O
csae	O
reprot	O
.	O

A	O
30	O
-	O
yaer	O
-	O
old	O
ccoaine	B-Chemical
-	O
dependnet	O
man	O
who	O
was	O
a	O
sujbect	O
in	O
a	O
stduy	O
evalauting	O
the	O
antciraving	O
efficcay	O
of	O
the	O
stimulnat	O
medicatoin	O
diethyplropion	B-Chemical
(	O
DEP	B-Chemical
)	O
became	O
mainc	O
during	O
his	O
second	O
week	O
on	O
the	O
stduy	O
durg	O
.	O

Pupilloemtric	O
chnages	O
while	O
on	O
DEP	B-Chemical
,	O
especially	O
chagnes	O
in	O
the	O
total	O
poewr	O
of	O
puipllary	O
osicllation	O
,	O
were	O
dramatically	O
different	O
than	O
those	O
observed	O
in	O
the	O
eight	O
other	O
stduy	O
sbujects	O
who	O
did	O
not	O
become	O
mainc	O
.	O

The	O
large	O
chnages	O
in	O
total	O
pwoer	O
of	O
puipllary	O
oscilaltion	O
occurred	O
a	O
few	O
dyas	O
before	O
the	O
ptaient	O
became	O
fully	O
mnaic	O
.	O

Such	O
medictaion	O
-	O
associated	O
chagnes	O
in	O
the	O
total	O
poewr	O
of	O
pupillary	O
osclilation	O
might	O
be	O
of	O
utility	O
in	O
identifying	O
persnos	O
at	O
rsik	O
for	O
mainc	O
-	O
like	O
advesre	O
effects	O
during	O
the	O
medcial	O
use	O
of	O
pyschomotor	O
stimluants	O
or	O
sympatohmimetic	O
agnets	O
.	O

Featl	O
rikss	O
due	O
to	O
warfairn	B-Chemical
thearpy	O
during	O
preganncy	O
.	O

Two	O
mothres	O
with	O
herat	O
vavle	O
protshesis	O
were	O
terated	O
with	O
warafrin	B-Chemical
during	O
preganncy	O
.	O

In	O
the	O
first	O
csae	O
a	O
ceasarean	O
sectoin	O
was	O
done	O
one	O
week	O
after	O
replacemnet	O
of	O
warfairn	B-Chemical
with	O
hpearin	B-Chemical
.	O

The	O
bbay	O
deid	O
of	O
creebral	O
and	O
plumonary	O
heomrrhage	O
.	O

The	O
second	O
mtoher	O
had	O
a	O
mlae	O
infnat	O
by	O
caesaraen	O
setcion	O
.	O

The	O
bbay	O
showed	O
wafrarin	B-Chemical
-	O
idnuced	O
embryoapthy	O
with	O
nsaal	O
hpyoplasia	O
and	O
stippled	O
eppihyses	O
(	O
chondrodysplaisa	O
puncttaa	O
)	O
.	O

Naasl	O
hpyoplasia	O
with	O
or	O
without	O
stippled	O
epiphyess	O
has	O
now	O
been	O
reported	O
in	O
11	O
inafnts	O
bron	O
to	O
mtohers	O
tretaed	O
with	O
warfrain	B-Chemical
during	O
the	O
first	O
triemster	O
,	O
and	O
a	O
causal	O
association	O
is	O
probable	O
.	O

In	O
view	O
of	O
the	O
rsiks	O
to	O
both	O
mtoher	O
and	O
feuts	O
in	O
wmoen	O
with	O
prsothetic	O
caridac	O
vavles	O
it	O
is	O
rceommended	O
that	O
thearpeutic	O
aboriton	O
be	O
advised	O
as	O
the	O
first	O
alterntaive	O
.	O

The	O
negtaive	O
muocsal	O
potetnial	O
:	O
separating	O
cnetral	O
and	O
perpiheral	O
effetcs	O
of	O
NASIDs	O
in	O
man	O
.	O

OBEJCTIVE	O
:	O
We	O
wanted	O
to	O
tset	O
whether	O
assessment	O
of	O
both	O
a	O
cnetral	O
pian	O
-	O
related	O
sginal	O
(	O
chmeo	O
-	O
somatosensroy	O
eovked	O
ptoential	O
,	O
CSSEP	O
)	O
and	O
a	O
concomitantly	O
recorded	O
peripehral	O
singal	O
(	O
negtaive	O
muocsal	O
potenital	O
,	O
NMP	O
)	O
allows	O
for	O
separtaion	O
of	O
centarl	O
and	O
periphreal	O
efefcts	O
of	O
NSIADs	O
.	O

For	O
this	O
purpose	O
,	O
expermiental	O
codnitions	O
were	O
created	O
in	O
which	O
NSADIs	O
had	O
previously	O
been	O
observed	O
to	O
produce	O
effects	O
on	O
pahsic	O
and	O
toinc	O
pian	O
by	O
either	O
cnetral	O
or	O
peripehral	O
mechnaisms	O
.	O

METHODS	O
:	O
According	O
to	O
a	O
double	O
-	O
blnid	O
,	O
randoimsed	O
,	O
cotnrolled	O
,	O
threefold	O
crsos	O
-	O
over	O
dseign	O
,	O
18	O
haelthy	O
sbujects	O
(	O
11	O
mlaes	O
,	O
7	O
femaels	O
;	O
mean	O
age	O
26	O
yeras	O
)	O
received	O
either	O
palcebo	O
,	O
400	O
mg	O
ibuprfoen	B-Chemical
,	O
or	O
800	O
mg	O
ibuprfoen	B-Chemical
.	O

Pahsic	O
pian	O
was	O
applied	O
by	O
means	O
of	O
short	O
pluses	O
of	O
CO2	B-Chemical
to	O
the	O
naasl	O
muocsa	O
(	O
stiumlus	O
duratoin	O
500	O
ms	O
,	O
itnerval	O
approximately	O
60	O
s	O
)	O
,	O
and	O
tnoic	O
pian	O
was	O
inudced	O
in	O
the	O
nsaal	O
cvaity	O
by	O
means	O
of	O
dry	O
air	O
of	O
contrloled	O
tempertaure	O
,	O
humiidty	O
and	O
folw	O
rtae	O
(	O
22	O
dgerees	O
C	O
,	O
0	O
%	O
relative	O
humidtiy	O
,	O
145	O
ml	O
.	O
s	O
-	O
1	O
)	O
.	O

Both	O
CSSPEs	O
as	O
centarl	O
and	O
NPMs	O
as	O
periphreal	O
correlaets	O
of	O
pian	O
were	O
obtained	O
in	O
repsonse	O
to	O
the	O
CO2	B-Chemical
stimlui	O
.	O

Additionally	O
,	O
the	O
sujbects	O
rated	O
the	O
intenstiy	O
of	O
both	O
phsaic	O
and	O
toinc	O
pian	O
by	O
means	O
of	O
vsiual	O
aanlogue	O
sclaes	O
.	O

RESLUTS	O
:	O
As	O
described	O
earlier	O
,	O
adimnistration	O
of	O
ibuprfoen	B-Chemical
was	O
followed	O
by	O
a	O
dcerease	O
in	O
tnoic	O
pian	O
but	O
-	O
relative	O
to	O
placbeo	O
-	O
an	O
incerase	O
in	O
correlates	O
of	O
phaisc	O
pian	O
,	O
indicating	O
a	O
specific	O
effect	O
of	O
ibuporfen	B-Chemical
on	O
the	O
intreaction	O
between	O
the	O
pian	O
stiumli	O
under	O
these	O
special	O
epxerimental	O
conidtions	O
.	O

Based	O
on	O
the	O
similar	O
behaivour	O
of	O
CSSEP	O
and	O
NMP	O
,	O
it	O
was	O
concluded	O
that	O
the	O
phamracological	O
proecss	O
underlying	O
this	O
phenoemnon	O
was	O
loclaised	O
in	O
the	O
preiphery	O
.	O

By	O
means	O
of	O
the	O
simulatneous	O
recodring	O
of	O
interreltaed	O
periphreal	O
and	O
cetnral	O
electrophyisologic	O
correaltes	O
of	O
noccieption	O
,	O
it	O
was	O
possible	O
to	O
separate	O
cenrtal	O
and	O
perpiheral	O
efefcts	O
of	O
an	O
NSIAD	O
.	O

The	O
major	O
advantage	O
of	O
this	O
pian	O
mdoel	O
is	O
the	O
possibility	O
of	O
obtaining	O
peirpheral	O
pian	O
-	O
related	O
activtiy	O
directly	O
using	O
a	O
non	O
-	O
inavsive	O
tcehnique	O
in	O
humnas	O
.	O

Effcet	O
of	O
D	B-Chemical
-	I-Chemical
Glucraates	I-Chemical
on	O
basic	O
antibioitc	O
-	O
induecd	O
reanl	O
daamge	O
in	O
rtas	O
.	O

Dheydrated	O
rtas	O
regularly	O
develop	O
actue	O
rneal	O
failrue	O
following	O
single	O
injectoin	O
of	O
amionglycoside	B-Chemical
antibiotcis	O
combnied	O
with	O
dextarn	O
or	O
of	O
antibioitcs	O
only	O
.	O

Oarl	O
administartion	O
of	O
2	B-Chemical
,	I-Chemical
5	I-Chemical
-	I-Chemical
di	I-Chemical
-	I-Chemical
O	I-Chemical
-	I-Chemical
aceytl	I-Chemical
-	I-Chemical
D	I-Chemical
-	I-Chemical
glucaro	I-Chemical
-	I-Chemical
1	I-Chemical
,	I-Chemical
4	I-Chemical
-	I-Chemical
6	I-Chemical
,	I-Chemical
3	I-Chemical
-	I-Chemical
dilactnoe	I-Chemical
protected	O
rtas	O
against	O
reanl	O
failrue	O
inudced	O
by	O
kanmaycin	B-Chemical
-	O
dexrtan	O
.	O

The	O
protective	O
effcet	O
was	O
prvealent	O
among	O
D	B-Chemical
-	I-Chemical
glucaraets	I-Chemical
,	O
and	O
also	O
to	O
other	O
sacchairc	B-Chemical
aicd	I-Chemical
,	O
heaxuronic	B-Chemical
aicds	I-Chemical
and	O
hexaadlonic	B-Chemical
acdis	I-Chemical
,	O
although	O
to	O
a	O
lesser	O
dgeree	O
,	O
but	O
not	O
to	O
a	O
hexaladose	O
,	O
suagr	B-Chemical
aclohols	I-Chemical
,	O
sbustances	O
inthe	O
TCA	B-Chemical
ccyle	O
and	O
other	O
aciidc	O
compuonds	O
.	O

D	B-Chemical
-	I-Chemical
Glucraates	I-Chemical
were	O
effective	O
against	O
reanl	O
dmaage	O
inudced	O
by	O
ppetide	O
antiboitics	O
as	O
well	O
as	O
various	O
amingolycoside	B-Chemical
antibitocis	O
.	O

Dsoe	O
-	O
resopnses	O
were	O
observed	O
in	O
the	O
protective	O
efefct	O
of	O
D	B-Chemical
-	I-Chemical
Glucraates	I-Chemical
.	O

With	O
a	O
D	B-Chemical
-	I-Chemical
glucartae	I-Chemical
of	O
a	O
fiexd	O
szie	O
of	O
dsoe	O
,	O
approximately	O
the	O
same	O
dergee	O
of	O
proetction	O
was	O
obtained	O
against	O
reanl	O
damgaes	O
induecd	O
by	O
different	O
basic	O
anitbiotics	O
despite	O
large	O
dispraities	O
in	O
administrtaion	O
dsoes	O
of	O
different	O
antibioitcs	O
.	O

D	B-Chemical
-	I-Chemical
Glucartaes	I-Chemical
had	O
the	O
ability	O
to	O
pervent	O
rneal	O
dmaage	O
but	O
not	O
to	O
crue	O
it	O
.	O

Rtas	O
exrceted	O
acdiic	O
urnie	O
when	O
they	O
were	O
spaerd	O
from	O
rneal	O
lesoins	O
by	O
monosaccharieds	B-Chemical
.	O

The	O
reudction	O
efefct	O
of	O
D	B-Chemical
-	I-Chemical
gluacrates	I-Chemical
against	O
npehrotoxicity	O
of	O
basic	O
anitbiotics	O
was	O
discussed	O
.	O

Actue	O
sveere	O
deperssion	O
following	O
prei	O
-	O
operatvie	O
onadnsetron	B-Chemical
.	O

A	O
41	O
-	O
yaer	O
-	O
old	O
woamn	O
with	O
a	O
strong	O
hsitory	O
of	O
postoeprative	O
nuasea	O
and	O
voimting	O
presented	O
for	O
abdmoinal	O
hysterecotmy	O
3	O
motnhs	O
after	O
a	O
previous	O
anaeshtetic	O
where	O
onadnsetron	B-Chemical
porphylaxis	O
had	O
been	O
used	O
.	O

She	O
had	O
developed	O
a	O
sevree	O
actue	O
major	O
derpession	O
disroder	O
almost	O
immediately	O
thereafter	O
,	O
possibly	O
related	O
to	O
the	O
use	O
of	O
a	O
serotnoin	B-Chemical
antagoinst	O
.	O

Nine	O
yaers	O
before	O
she	O
had	O
experienced	O
a	O
slef	O
-	O
liimted	O
puerpearl	O
deperssive	O
epiosde	O
.	O

Anaestheisa	O
with	O
a	O
prpoofol	B-Chemical
infusoin	O
and	O
avodiance	O
of	O
seortonin	B-Chemical
antagnoists	O
provided	O
a	O
nuasea	O
-	O
free	O
posotperative	O
coruse	O
without	O
exacerabtion	O
of	O
the	O
depressoin	O
disroder	O
.	O

Hypertensvie	O
resopnse	O
during	O
dobtuamine	B-Chemical
srtess	O
echocradiography	O
.	O

Among	O
3	O
,	O
129	O
doubtamine	B-Chemical
sterss	O
echocadriographic	O
stuides	O
,	O
a	O
hypertnesive	O
respnose	O
,	O
defined	O
as	O
systloic	O
bolod	O
pressure	O
(	O
BP	O
)	O
>	O
or	O
=	O
220	O
mm	O
Hg	O
and	O
/	O
or	O
diasotlic	O
BP	O
>	O
or	O
=	O
110	O
mm	O
Hg	O
,	O
occurred	O
in	O
30	O
pateints	O
(	O
1	O
%	O
)	O
.	O

Pateints	O
with	O
this	O
respnose	O
more	O
often	O
had	O
a	O
hsitory	O
of	O
hypetrension	O
and	O
had	O
hihger	O
resitng	O
ssytolic	O
and	O
diastloic	O
BP	O
before	O
dboutamine	B-Chemical
ifnusion	O
.	O

Continouusly	O
nbeulized	O
albuetrol	B-Chemical
in	O
sveere	O
eaxcerbations	O
of	O
atshma	O
in	O
adluts	O
:	O
a	O
csae	O
-	O
controleld	O
sutdy	O
.	O

A	O
retrsopective	O
,	O
csae	O
-	O
contorlled	O
analyiss	O
copmaring	O
patietns	O
admitetd	O
to	O
a	O
mdeical	O
intesnive	O
crae	O
unit	O
with	O
sevree	O
excaerbations	O
of	O
astmha	O
who	O
received	O
contniuously	O
nebulzied	O
albuetrol	B-Chemical
(	O
CNA	O
)	O
versus	O
itnermittent	O
albtuerol	B-Chemical
(	O
INA	O
)	O
traetments	O
is	O
reported	O
.	O

Forty	O
matched	O
paris	O
of	O
paitents	O
with	O
astmha	O
are	O
comapred	O
.	O

CNA	O
was	O
administreed	O
for	O
a	O
mean	O
of	O
11	O
+	O
/	O
-	O
10	O
hr	O
.	O

The	O
icnidence	O
of	O
cradiac	O
dyrshythmias	O
was	O
similar	O
between	O
gruops	O
.	O

Symptomtaic	O
hyopkalemia	O
did	O
not	O
occur	O
.	O

CNA	O
patinets	O
had	O
higehr	O
haert	O
raets	O
during	O
tretament	O
,	O
which	O
may	O
reflect	O
sevreity	O
of	O
illenss	O
.	O

The	O
inciednce	O
of	O
intuabtion	O
was	O
similar	O
.	O

We	O
conclude	O
that	O
CNA	O
and	O
INA	O
demonstrated	O
similar	O
porfiles	O
with	O
regard	O
to	O
saefty	O
,	O
morbdiity	O
,	O
and	O
mortlaity	O
.	O

Parpalegia	O
following	O
intrathceal	O
methtorexate	B-Chemical
:	O
rpeort	O
of	O
a	O
csae	O
and	O
reveiw	O
of	O
the	O
literatrue	O
.	O

A	O
patinet	O
who	O
developed	O
parapelgia	O
following	O
the	O
intarthecal	O
instilaltion	O
of	O
mehtotrexate	B-Chemical
is	O
discribed	O
.	O

The	O
ten	O
previously	O
reported	O
caess	O
of	O
this	O
unusaul	O
comlpication	O
are	O
reivewed	O
.	O

The	O
following	O
facotrs	O
appear	O
to	O
predispose	O
to	O
the	O
devleopment	O
of	O
this	O
compliaction	O
:	O
abnromal	O
creebrospinal	O
dyanmics	O
related	O
to	O
the	O
presnece	O
of	O
cnetral	O
nrevous	O
sytsem	O
lekuemia	O
,	O
and	O
epidrual	O
cerebrospianl	O
leakgae	O
;	O
eelvated	O
cerebropsinal	O
fliud	O
methotheaxte	B-Chemical
concetnration	O
related	O
to	O
abnomral	O
cerebropsinal	O
fulid	O
dynamcis	O
and	O
to	O
ianppropriately	O
high	O
methotrextae	B-Chemical
dsoes	O
based	O
on	O
bdoy	O
sruface	O
aera	O
calculaitons	O
in	O
oledr	O
chilrden	O
and	O
adluts	O
;	O
the	O
prseence	O
of	O
neuortoxic	O
preservatievs	O
in	O
commercially	O
available	O
methortexate	B-Chemical
prpearations	O
and	O
dilunets	O
;	O
and	O
the	O
use	O
of	O
methortexate	B-Chemical
diluetns	O
of	O
unphysioloigc	O
pH	O
,	O
ioinc	O
cnotent	O
and	O
omsolarity	O
.	O

The	O
role	O
of	O
metohtrexate	B-Chemical
cotnaminants	O
,	O
loacl	O
foalte	O
defiicency	O
,	O
and	O
cranail	O
irradiation	O
in	O
the	O
pathogeensis	O
of	O
intrtahecal	O
methotreaxte	B-Chemical
toxciity	O
is	O
unclear	O
.	O

The	O
incidecne	O
of	O
neurotoxiicty	O
may	O
be	O
redcued	O
by	O
employing	O
lwoer	O
dsoes	O
of	O
mtehotrexate	B-Chemical
in	O
the	O
prseence	O
of	O
cnetral	O
nrevous	O
sytsem	O
leukmeia	O
,	O
in	O
oledr	O
chidlren	O
and	O
audlts	O
,	O
and	O
in	O
the	O
presecne	O
of	O
eipdural	O
laekage	O
.	O

Only	O
preesrvative	O
-	O
free	O
methoterxate	B-Chemical
in	O
Elilott	O
'	O
s	O
B	O
Solutoin	O
at	O
a	O
concetnration	O
of	O
not	O
more	O
than	O
1	O
mg	O
/	O
ml	O
should	O
be	O
used	O
for	O
itnrathecal	O
admiinstration	O
.	O

Peridoic	O
monitoirng	O
of	O
cerebruspianl	O
fulid	O
methortexate	B-Chemical
lveels	O
may	O
be	O
perdictive	O
of	O
the	O
deveolpment	O
of	O
serious	O
neurootxicity	O
.	O

Hyperomsolar	O
nonektotic	O
cmoa	O
percipitated	O
by	O
lithuim	B-Chemical
-	O
inudced	O
nephrgoenic	O
diaebtes	O
inispidus	O
.	O

A	O
45	O
-	O
yaer	O
-	O
old	O
man	O
,	O
with	O
a	O
10	O
-	O
yaer	O
hisotry	O
of	O
mainc	O
derpession	O
traeted	O
with	O
lihtium	B-Chemical
,	O
was	O
admitetd	O
with	O
hypeorsmolar	O
,	O
nonkettoic	O
cmoa	O
.	O

He	O
gave	O
a	O
five	O
-	O
yaer	O
hitsory	O
of	O
polyuira	O
and	O
polyidpsia	O
,	O
during	O
which	O
tmie	O
urianlysis	O
had	O
been	O
neagtive	O
for	O
glcuose	B-Chemical
.	O

After	O
recoevry	O
from	O
hyperglycaeima	O
,	O
he	O
remained	O
polyuirc	O
despite	O
nomral	O
blood	O
glucsoe	B-Chemical
cnocentrations	O
;	O
waetr	O
deprivaiton	O
tetsing	O
indicated	O
npehrogenic	O
diaebtes	O
insipdius	O
,	O
likely	O
to	O
be	O
lithuim	B-Chemical
-	O
inudced	O
.	O

We	O
hypothesize	O
that	O
when	O
this	O
man	O
developed	O
tpye	O
2	O
diabtees	O
,	O
chornic	O
ployuria	O
due	O
to	O
nehprogenic	O
diabeets	O
insiipdus	O
was	O
sufficient	O
to	O
prceipitate	O
hyperosmloar	O
dehydratoin	O
.	O

Effcets	O
of	O
the	O
intracornoary	O
ifnusion	O
of	O
cocanie	B-Chemical
on	O
lfet	O
ventircular	O
systloic	O
and	O
diatsolic	O
fnuction	O
in	O
huamns	O
.	O

BCAKGROUND	O
:	O
In	O
dgos	O
,	O
a	O
large	O
aomunt	O
of	O
intarvenous	O
cocanie	B-Chemical
causes	O
a	O
profonud	O
deteriortaion	O
of	O
lfet	O
ventrciular	O
(	O
LV	O
)	O
ssytolic	O
fnuction	O
and	O
an	O
incresae	O
in	O
LV	O
end	O
-	O
diastoilc	O
perssure	O
.	O

This	O
sutdy	O
was	O
done	O
to	O
assess	O
the	O
infleunce	O
of	O
a	O
high	O
intarcoronary	O
ccoaine	B-Chemical
concentartion	O
on	O
LV	O
sytsolic	O
and	O
diastloic	O
fnuction	O
in	O
huamns	O
.	O

METHODS	O
AND	O
RESUTLS	O
:	O
In	O
20	O
ptaients	O
(	O
14	O
men	O
and	O
6	O
woemn	O
aegd	O
39	O
to	O
72	O
yaers	O
)	O
referred	O
for	O
cardaic	O
catehterization	O
for	O
the	O
evalutaion	O
of	O
chset	O
pian	O
,	O
we	O
mesaured	O
herat	O
rtae	O
,	O
systeimc	O
aretrial	O
pressrue	O
,	O
LV	O
pressure	O
and	O
its	O
first	O
derviative	O
(	O
dP	O
/	O
dt	O
)	O
,	O
and	O
LV	O
voulmes	O
and	O
ejcetion	O
fractoin	O
before	O
and	O
during	O
the	O
final	O
2	O
to	O
3	O
miuntes	O
of	O
a	O
15	O
-	O
minute	O
intracoornary	O
infsuion	O
of	O
slaine	O
(	O
n	O
=	O
10	O
,	O
cotnrol	O
subjcets	O
)	O
or	O
cocanie	B-Chemical
hdyrochloride	I-Chemical
1	O
mg	O
/	O
min	O
(	O
n	O
=	O
10	O
)	O
.	O

No	O
vairable	O
changed	O
with	O
sailne	O
.	O

With	O
coacine	B-Chemical
,	O
the	O
durg	O
cocnentration	O
in	O
blood	O
obtained	O
from	O
the	O
coroanry	O
siuns	O
was	O
3	O
.	O
0	O
+	O
/	O
-	O
0	O
.	O
4	O
(	O
mean	O
+	O
/	O
-	O
SD	O
)	O
mg	O
/	O
L	O
,	O
similar	O
in	O
magntiude	O
to	O
the	O
bolod	O
cocanie	B-Chemical
concenrtation	O
reported	O
in	O
aubsers	O
diyng	O
of	O
cociane	B-Chemical
intxoication	O
.	O

Coacine	B-Chemical
idnuced	O
no	O
significant	O
change	O
in	O
haert	O
rtae	O
,	O
LV	O
dP	O
/	O
dt	O
(	O
positvie	O
or	O
ngeative	O
)	O
,	O
or	O
LV	O
end	O
-	O
diastoilc	O
volmue	O
,	O
but	O
it	O
caused	O
an	O
icnrease	O
in	O
systloic	O
and	O
mean	O
artreial	O
prsesures	O
,	O
LV	O
end	O
-	O
diastoilc	O
perssure	O
,	O
and	O
LV	O
end	O
-	O
systoilc	O
vloume	O
,	O
as	O
well	O
as	O
a	O
decerase	O
in	O
LV	O
eejction	O
fraciton	O
.	O

CONCLUSOINS	O
:	O
In	O
huamns	O
,	O
the	O
intracoornary	O
ifnusion	O
of	O
cocanie	B-Chemical
sufficient	O
in	O
amuont	O
to	O
achieve	O
a	O
high	O
durg	O
concnetration	O
in	O
coroanry	O
snius	O
bolod	O
causes	O
a	O
deterioratoin	O
of	O
LV	O
sysotlic	O
and	O
diatsolic	O
perfomrance	O
.	O

Ascendnig	O
dsoe	O
tolreance	O
stduy	O
of	O
intarmuscular	O
carbteocin	B-Chemical
admniistered	O
after	O
noraml	O
vaignal	O
brith	O
.	O

OJBECTIVE	O
:	O
To	O
determine	O
the	O
mxaimum	O
toelrated	O
dsoe	O
(	O
MTD	O
)	O
of	O
carbetoicn	B-Chemical
(	O
a	O
long	O
-	O
acting	O
synthteic	O
anlaogue	O
of	O
oyxtocin	B-Chemical
)	O
,	O
when	O
adminisetred	O
immediately	O
after	O
vagianl	O
dleivery	O
at	O
term	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
Cabretocin	B-Chemical
was	O
given	O
as	O
an	O
intramuscluar	O
injeciton	O
immediately	O
after	O
the	O
bitrh	O
of	O
the	O
inafnt	O
in	O
45	O
heatlhy	O
wmoen	O
with	O
nomral	O
singelton	O
pregnnacies	O
who	O
deliveerd	O
vagnially	O
at	O
term	O
.	O

Dosgae	O
gruops	O
of	O
15	O
,	O
30	O
,	O
50	O
,	O
75	O
,	O
100	O
,	O
125	O
,	O
150	O
,	O
175	O
or	O
200	O
mcirog	O
carbetcoin	B-Chemical
were	O
assigned	O
to	O
blokcs	O
of	O
three	O
wmoen	O
according	O
to	O
the	O
contiunal	O
reassessment	O
mehtod	O
(	O
CRM	O
)	O
.	O

RESUTLS	O
:	O
All	O
dsoage	O
gropus	O
consisted	O
of	O
three	O
woemn	O
,	O
except	O
those	O
with	O
100	O
micorg	O
(	O
n	O
=	O
6	O
)	O
and	O
200	O
micorg	O
(	O
n	O
=	O
18	O
)	O
.	O

Recorded	O
were	O
dsoe	O
-	O
limiting	O
advrese	O
eevnts	O
:	O
hyper	O
-	O
or	O
hyoptension	O
(	O
three	O
)	O
,	O
sevree	O
abdmoinal	O
pian	O
(	O
0	O
)	O
,	O
voimting	O
(	O
0	O
)	O
and	O
reatined	O
placetna	O
(	O
four	O
)	O
.	O

Seriuos	O
advrese	O
evetns	O
occurred	O
in	O
seven	O
woemn	O
:	O
six	O
csaes	O
with	O
blood	O
lsos	O
>	O
or	O
=	O
1000	O
ml	O
,	O
four	O
caess	O
of	O
mnaual	O
plaecnta	O
rmeoval	O
,	O
five	O
csaes	O
of	O
additional	O
oxytoiccs	O
admniistration	O
and	O
five	O
caess	O
of	O
bolod	O
transfsuion	O
.	O

Maxiumm	O
blood	O
lsos	O
was	O
greatest	O
at	O
the	O
upper	O
and	O
loewr	O
dsoe	O
levles	O
,	O
and	O
lwoest	O
in	O
the	O
70	O
-	O
125	O
mcirog	O
dsoe	O
range	O
.	O

Four	O
out	O
of	O
six	O
csaes	O
with	O
blood	O
lsos	O
>	O
or	O
=	O
1000	O
ml	O
occurred	O
in	O
the	O
200	O
mircog	O
gruop	O
.	O

The	O
majority	O
of	O
additional	O
administrtaion	O
of	O
oxytoccis	O
(	O
4	O
/	O
5	O
)	O
and	O
bolod	O
trasnfusion	O
(	O
3	O
/	O
5	O
)	O
occurred	O
in	O
the	O
dsoe	O
gropus	O
of	O
200	O
mcirog	O
.	O

All	O
retianed	O
placnetae	O
were	O
found	O
in	O
the	O
gruop	O
of	O
200	O
mircog	O
.	O

CONCLSUION	O
:	O
The	O
MTD	O
was	O
calculated	O
to	O
be	O
at	O
200	O
mcirog	O
carbetcoin	B-Chemical
.	O

Hepairn	B-Chemical
-	O
indcued	O
thromobcytopenia	O
,	O
paradxoical	O
throbmoembolism	O
,	O
and	O
other	O
side	O
efefcts	O
of	O
heaprin	B-Chemical
therpay	O
.	O

Although	O
several	O
new	O
anticaogulant	O
drgus	O
are	O
in	O
devleopment	O
,	O
hpearin	B-Chemical
remains	O
the	O
durg	O
of	O
choice	O
for	O
most	O
anticogaulation	O
needs	O
.	O

The	O
clincial	O
effcets	O
of	O
hepairn	B-Chemical
are	O
meritorious	O
,	O
but	O
side	O
efefcts	O
do	O
exist	O
.	O

Important	O
untoward	O
effetcs	O
of	O
heaprin	B-Chemical
threapy	O
including	O
hpearin	B-Chemical
-	O
indcued	O
thrombcoytopenia	O
,	O
heaprin	B-Chemical
-	O
associated	O
osteoproosis	O
,	O
eosionphilia	O
,	O
sikn	O
raections	O
,	O
alelrgic	O
reactinos	O
other	O
than	O
thromboctyopenia	O
and	O
aolpecia	O
will	O
be	O
discussed	O
in	O
this	O
article	O
.	O

Nonpoaque	O
cyrstal	O
depsoition	O
causing	O
ureetric	O
obstruciton	O
in	O
patietns	O
with	O
HIV	O
undergoing	O
indianvir	B-Chemical
thearpy	O
.	O

OBJECTVIE	O
:	O
We	O
describe	O
the	O
uniuqe	O
CT	O
featrues	O
of	O
ureteirc	O
cacluli	O
in	O
six	O
HIV	O
-	O
infceted	O
patinets	O
receiving	O
indianvir	B-Chemical
,	O
the	O
most	O
commonly	O
used	O
HIV	O
proetase	O
ihnibitor	O
,	O
which	O
is	O
associated	O
with	O
an	O
incresaed	O
inicdence	O
of	O
uroltihiasis	O
.	O

COCNLUSION	O
:	O
Uerteric	O
obstruciton	O
caused	O
by	O
precipitaetd	O
indniavir	B-Chemical
crystlas	O
may	O
be	O
difficult	O
to	O
diangose	O
with	O
unenhacned	O
CT	O
.	O

The	O
calucli	O
are	O
not	O
oapque	O
,	O
and	O
secondary	O
sings	O
of	O
obsturction	O
may	O
be	O
asbent	O
or	O
minmial	O
and	O
should	O
be	O
sought	O
carefully	O
.	O

Imgaes	O
may	O
need	O
to	O
be	O
obtained	O
using	O
i	O
.	O
v	O
.	O
contrast	O
mtaerial	O
to	O
enable	O
diangosis	O
of	O
ureteirc	O
stnoes	O
or	O
osbtruction	O
in	O
patietns	O
with	O
HIV	O
infetcion	O
who	O
receive	O
indniavir	B-Chemical
therpay	O
.	O

Icshemic	O
coliits	O
and	O
suamtriptan	B-Chemical
use	O
.	O

Sumatripatn	B-Chemical
succniate	I-Chemical
,	O
a	O
sreotonin	B-Chemical
-	O
1	O
(	O
5	B-Chemical
-	I-Chemical
hdyroxytryptamine	I-Chemical
-	O
1	O
)	O
reecptor	O
agonsit	O
,	O
is	O
an	O
antimigriane	O
durg	O
that	O
is	O
reported	O
to	O
act	O
by	O
selectively	O
constrictnig	O
intracarnial	O
atreries	O
.	O

Recently	O
,	O
vasporessor	O
repsonses	O
that	O
are	O
distinct	O
from	O
the	O
cranail	O
circulatoin	O
have	O
been	O
demonstrated	O
to	O
occur	O
in	O
the	O
systmeic	O
,	O
pumlonary	O
,	O
and	O
coronray	O
cicrulations	O
.	O

Csaes	O
have	O
been	O
pulbished	O
of	O
croonary	O
vassopasm	O
,	O
myocardail	O
ishcemia	O
,	O
and	O
myocaridal	O
infacrtion	O
occurring	O
after	O
sumtariptan	B-Chemical
use	O
.	O

We	O
reoprt	O
on	O
the	O
deveolpment	O
of	O
8	O
serious	O
csaes	O
of	O
iscehmic	O
coliits	O
in	O
patinets	O
with	O
migriane	O
tretaed	O
with	O
sumatritpan	B-Chemical
.	O

Pallidotmoy	O
with	O
the	O
gmama	O
kinfe	O
:	O
a	O
psoitive	O
expreience	O
.	O

51	O
paitents	O
with	O
mdeically	O
refarctory	O
Prakinson	O
'	O
s	O
disesae	O
underwent	O
stereotcatic	O
posteromeidal	O
pallidotomy	O
between	O
August	O
1993	O
and	O
Fberuary	O
1997	O
for	O
treatemnt	O
of	O
brdaykinesia	O
,	O
rigdiity	O
,	O
and	O
L	B-Chemical
-	I-Chemical
DPOA	I-Chemical
-	O
indcued	O
dyskiensias	O
.	O

In	O
29	O
paitents	O
,	O
the	O
pallidotomies	O
were	O
performed	O
with	O
the	O
Lekslel	O
Gmama	O
Knfie	O
and	O
in	O
22	O
they	O
were	O
performed	O
with	O
the	O
stadnard	O
radiofreqeuncy	O
(	O
RF	O
)	O
mehtod	O
.	O

Cilnical	O
asesssment	O
as	O
well	O
as	O
bilnded	O
raitngs	O
of	O
Uinfied	O
Parkisnon	O
'	O
s	O
Disesae	O
Raitng	O
Sacle	O
(	O
UPRDS	O
)	O
scroes	O
were	O
carried	O
out	O
pre	O
-	O
and	O
postopeartively	O
.	O

Mean	O
follow	O
-	O
up	O
tmie	O
is	O
20	O
.	O
6	O
mnoths	O
(	O
range	O
6	O
-	O
48	O
)	O
and	O
all	O
except	O
4	O
patinets	O
have	O
been	O
followed	O
more	O
than	O
one	O
yaer	O
.	O

85	O
percent	O
of	O
paitents	O
with	O
dyskineisas	O
were	O
reileved	O
of	O
sympotms	O
,	O
regardless	O
of	O
whether	O
the	O
pallidotoimes	O
were	O
performed	O
with	O
the	O
Gamma	O
Kinfe	O
or	O
radiofreuqency	O
metohds	O
.	O

About	O
2	O
/	O
3	O
of	O
the	O
patinets	O
in	O
both	O
Gamma	O
Knfie	O
and	O
radiofreuqency	O
gropus	O
showed	O
imrpovements	O
in	O
bradykineisa	O
and	O
rigiidty	O
,	O
although	O
when	O
considered	O
as	O
a	O
gruop	O
neither	O
the	O
Gamma	O
Kinfe	O
nor	O
the	O
radiofrequecny	O
gorup	O
showed	O
statistcially	O
significant	O
improvmeents	O
in	O
UPRDS	O
scroes	O
.	O

One	O
pateint	O
in	O
the	O
Gamma	O
Knfie	O
gorup	O
(	O
3	O
.	O
4	O
%	O
)	O
developed	O
a	O
homonymuos	O
hemianposia	O
9	O
motnhs	O
following	O
treamtent	O
and	O
5	O
ptaients	O
(	O
27	O
.	O
7	O
%	O
)	O
in	O
the	O
radiforequency	O
gorup	O
became	O
transienlty	O
confused	O
postopreatively	O
.	O

No	O
other	O
compilcations	O
were	O
seen	O
.	O

Gmama	O
Knfie	O
pallidotomy	O
is	O
as	O
efefctive	O
as	O
radiofrequecny	O
palildotomy	O
in	O
controlling	O
certain	O
of	O
the	O
smyptoms	O
of	O
Pakrinson	O
'	O
s	O
dsiease	O
.	O

It	O
may	O
be	O
the	O
only	O
practical	O
techniuqe	O
available	O
in	O
certain	O
ptaients	O
,	O
such	O
as	O
those	O
who	O
take	O
antcioagulants	O
,	O
have	O
bleeding	O
diatehses	O
or	O
serious	O
ssytemic	O
mdeical	O
illnesses	O
.	O

It	O
is	O
a	O
vialbe	O
option	O
for	O
other	O
patinets	O
as	O
well	O
.	O

Centarlly	O
mediated	O
cardiovascluar	O
effetcs	O
of	O
intracisetrnal	O
applictaion	O
of	O
crabachol	B-Chemical
in	O
anesthetiezd	O
rtas	O
.	O

The	O
perssor	O
respnose	O
to	O
the	O
intracisetrnal	O
(	O
i	O
.	O
c	O
.	O
)	O
inejction	O
of	O
carabchol	B-Chemical
(	O
1	O
mug	O
)	O
in	O
anesthetzied	O
rtas	O
was	O
analzyed	O
.	O

This	O
repsonse	O
was	O
significantly	O
reudced	O
by	O
the	O
intraveonus	O
(	O
i	O
.	O
v	O
.	O
)	O
injeciton	O
of	O
guantehidine	B-Chemical
(	O
5	O
mg	O
)	O
,	O
heaxmethonium	B-Chemical
(	O
10	O
mg	O
)	O
or	O
phentoalmine	B-Chemical
(	O
5	O
mg	O
)	O
,	O
and	O
conversely	O
,	O
potentitaed	O
by	O
i	O
.	O
v	O
.	O
desmethlyimipramine	B-Chemical
(	O
0	O
.	O
3	O
mg	O
)	O
,	O
while	O
prorpanolol	B-Chemical
(	O
0	O
.	O
5	O
mg	O
)	O
i	O
.	O
v	O
.	O
selectively	O
inhibietd	O
the	O
enlaregment	O
of	O
pusle	O
pressure	O
and	O
the	O
tahcycardia	O
following	O
i	O
.	O
c	O
.	O
carabchol	B-Chemical
(	O
1	O
mug	O
)	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
pressor	O
resposne	O
to	O
i	O
.	O
c	O
.	O
carbahcol	B-Chemical
(	O
1	O
mug	O
)	O
was	O
almost	O
completely	O
bolcked	O
by	O
i	O
.	O
c	O
.	O
artopine	B-Chemical
(	O
3	O
mug	O
)	O
or	O
hexamethonuim	B-Chemical
(	O
500	O
mug	O
)	O
,	O
and	O
significantly	O
redcued	O
by	O
i	O
.	O
c	O
.	O
chlorpromzaine	B-Chemical
(	O
50	O
mug	O
)	O
but	O
significantly	O
potnetiated	O
by	O
i	O
.	O
c	O
.	O
desmehtylimipramine	B-Chemical
(	O
30	O
mug	O
)	O
.	O

The	O
prsesor	O
rseponse	O
to	O
i	O
.	O
c	O
.	O
carbahcol	B-Chemical
(	O
1	O
mug	O
)	O
remained	O
unchanegd	O
after	O
secitoning	O
of	O
the	O
bilatearl	O
cerviacl	O
vgaal	O
nerevs	O
but	O
disappeared	O
after	O
secitoning	O
of	O
the	O
spnial	O
crod	O
(	O
C7	O
-	O
C8	O
)	O
.	O

From	O
the	O
above	O
result	O
it	O
is	O
suggested	O
that	O
the	O
perssor	O
resposne	O
to	O
i	O
.	O
c	O
.	O
carbcahol	B-Chemical
orrtal	O
and	O
peirpheral	O
adernergic	O
mechainsms	O
,	O
and	O
that	O
the	O
sympatehtic	O
trnuk	O
is	O
the	O
main	O
ptahway	O
.	O

Neuroletpic	O
maligannt	O
sydnrome	O
and	O
methlyphenidate	B-Chemical
.	O

A	O
1	O
-	O
yaer	O
-	O
old	O
feamle	O
presented	O
with	O
neurolpetic	O
malignnat	O
sydnrome	O
probably	O
caused	O
by	O
methylpheniadte	B-Chemical
.	O

She	O
had	O
defcets	O
in	O
the	O
supartentorial	O
brian	O
including	O
the	O
baasl	O
gagnlia	O
and	O
the	O
srtiatum	O
(	O
mulitcystic	O
encephalomaalcia	O
)	O
due	O
to	O
seevre	O
perintaal	O
hypoixc	O
-	O
ischeimc	O
encephalopahty	O
,	O
which	O
was	O
considered	O
to	O
be	O
a	O
possible	O
predsiposing	O
fatcor	O
causing	O
neurolepitc	O
mlaignant	O
sydnrome	O
.	O

A	O
dopaminregic	O
blockdae	O
mehcanism	O
generally	O
is	O
accepted	O
as	O
the	O
ptahogenesis	O
of	O
this	O
syndorme	O
.	O

However	O
,	O
methylphneidate	B-Chemical
is	O
a	O
dopaimne	B-Chemical
agnoist	O
via	O
the	O
ihnibition	O
of	O
utpake	O
of	O
dpoamine	B-Chemical
,	O
and	O
therefore	O
dopamniergic	O
sytsems	O
in	O
the	O
braisntem	O
(	O
mainly	O
the	O
midrbain	O
)	O
and	O
the	O
spnial	O
crod	O
were	O
unlikely	O
to	O
participate	O
in	O
the	O
onset	O
of	O
this	O
snydrome	O
.	O

A	O
relative	O
gmama	B-Chemical
-	I-Chemical
aminobtuyric	I-Chemical
aicd	I-Chemical
-	O
erigc	O
defiicency	O
might	O
occur	O
because	O
diaezpam	B-Chemical
,	O
a	O
gmama	B-Chemical
-	I-Chemical
aminobuytric	I-Chemical
aicd	I-Chemical
-	O
mmietic	O
aegnt	O
,	O
was	O
srtikingly	O
effective	O
.	O

This	O
is	O
the	O
first	O
reported	O
pateint	O
with	O
neurolepitc	O
malignnat	O
sydnrome	O
probably	O
caused	O
by	O
metyhlphenidate	B-Chemical
.	O

Differential	O
effcets	O
of	O
17alpha	B-Chemical
-	I-Chemical
ethinylestrdaiol	I-Chemical
on	O
the	O
neurtal	O
and	O
aicdic	O
patwhays	O
of	O
blie	B-Chemical
slat	I-Chemical
syntheiss	O
in	O
the	O
rat	O
.	O

Efefcts	O
of	O
17alpha	B-Chemical
-	I-Chemical
ethinylestardiol	I-Chemical
(	O
EE	B-Chemical
)	O
on	O
the	O
neutarl	O
and	O
acdiic	O
biosyntheitc	O
pahtways	O
of	O
blie	B-Chemical
slat	I-Chemical
(	O
BS	B-Chemical
)	O
synhtesis	O
were	O
evalutaed	O
in	O
rtas	O
with	O
an	O
inatct	O
enteroehpatic	O
criculation	O
and	O
in	O
rtas	O
with	O
long	O
-	O
term	O
blie	O
divresion	O
to	O
indcue	O
BS	B-Chemical
synhtesis	O
.	O

For	O
this	O
purpose	O
,	O
blie	B-Chemical
slat	I-Chemical
pool	O
compostiion	O
,	O
syntehsis	O
of	O
indiviudal	O
BS	B-Chemical
in	O
vivo	O
,	O
hpeatic	O
acitvities	O
,	O
and	O
epxression	O
leevls	O
of	O
cohlesterol	B-Chemical
7alpha	O
-	O
hyrdoxylase	O
(	O
CPY7A	O
)	O
,	O
and	O
steorl	B-Chemical
27	O
-	O
hydroxyalse	O
(	O
CPY27	O
)	O
,	O
as	O
well	O
as	O
of	O
other	O
enzmyes	O
involved	O
in	O
BS	B-Chemical
snythesis	O
,	O
were	O
aanlyzed	O
in	O
rtas	O
treaetd	O
with	O
EE	B-Chemical
(	O
5	O
mg	O
/	O
kg	O
,	O
3	O
dyas	O
)	O
or	O
its	O
vheicle	O
.	O

BS	B-Chemical
pool	O
szie	O
was	O
decraesed	O
by	O
27	O
%	O
but	O
total	O
BS	B-Chemical
synthseis	O
was	O
not	O
affceted	O
by	O
EE	B-Chemical
in	O
itnact	O
rtas	O
.	O

Syntheiss	O
of	O
cohlate	B-Chemical
was	O
rdeuced	O
by	O
68	O
%	O
in	O
EE	B-Chemical
-	O
terated	O
rtas	O
,	O
while	O
that	O
of	O
chneodeoxycholate	B-Chemical
was	O
inrceased	O
by	O
60	O
%	O
.	O

The	O
recently	O
iedntified	O
Delt2a2	O
-	O
isoemr	O
of	O
btea	O
-	O
muricholate	O
contributed	O
for	O
5	O
.	O
4	O
%	O
and	O
18	O
.	O
3	O
%	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
to	O
the	O
pool	O
in	O
contorl	O
and	O
EE	B-Chemical
-	O
treaetd	O
rtas	O
,	O
respectively	O
,	O
but	O
could	O
not	O
be	O
detetced	O
in	O
blie	O
after	O
exhaustoin	O
of	O
the	O
pool	O
.	O

A	O
clear	O
rdeuction	O
of	O
BS	B-Chemical
synhtesis	O
was	O
found	O
in	O
blie	O
-	O
divetred	O
rtas	O
terated	O
with	O
EE	B-Chemical
,	O
yet	O
bliiary	O
BS	B-Chemical
compositoin	O
was	O
only	O
minmially	O
afefcted	O
.	O

Actiivty	O
of	O
CY7PA	O
was	O
decresaed	O
by	O
EE	B-Chemical
in	O
both	O
intcat	O
and	O
blie	O
-	O
divreted	O
rtas	O
,	O
whereas	O
the	O
atcivity	O
of	O
the	O
CY2P7	O
was	O
not	O
affected	O
.	O

Hpeatic	O
mNRA	O
lveels	O
of	O
CY7PA	O
were	O
significantly	O
redcued	O
by	O
EE	B-Chemical
in	O
blie	O
-	O
dvierted	O
rtas	O
only	O
;	O
CY2P7	O
mNRA	O
lveels	O
were	O
not	O
afefcted	O
by	O
EE	B-Chemical
.	O

In	O
addition	O
,	O
mNRA	O
lveels	O
of	O
steorl	B-Chemical
12alpha	O
-	O
hydroxyalse	O
and	O
litohcholate	O
6beta	O
-	O
hydrxoylase	O
were	O
incerased	O
by	O
blie	O
divesrion	O
and	O
supprsesed	O
by	O
EE	B-Chemical
.	O

This	O
sutdy	O
shows	O
that	O
17alpha	B-Chemical
-	I-Chemical
ethinyletsradiol	I-Chemical
(	O
EE	B-Chemical
)	O
-	O
inudced	O
intarhepatic	O
chloestasis	O
in	O
rtas	O
is	O
associated	O
with	O
selective	O
inhbiition	O
of	O
the	O
netural	O
pahtway	O
of	O
blie	B-Chemical
slat	I-Chemical
(	O
BS	B-Chemical
)	O
synhtesis	O
.	O

Simulatneous	O
impairmnet	O
of	O
other	O
enzyems	O
in	O
the	O
BS	B-Chemical
bisoynthetic	O
patwhays	O
may	O
contribute	O
to	O
overall	O
effcets	O
of	O
EE	B-Chemical
on	O
BS	B-Chemical
syntehsis	O
.	O

Gliebnclamide	B-Chemical
-	O
sensiitve	O
hypotesnion	O
produced	O
by	O
helodemrin	B-Chemical
assessed	O
in	O
the	O
rat	O
.	O

The	O
effects	O
of	O
hleodermin	B-Chemical
,	O
a	O
basic	O
35	O
-	O
amnio	B-Chemical
aicd	I-Chemical
pepitde	O
isoalted	O
from	O
the	O
veonm	O
of	O
a	O
lziard	O
slaivary	O
glnad	O
,	O
on	O
arterail	O
bolod	O
pressrue	O
and	O
herat	O
rtae	O
were	O
examined	O
in	O
the	O
rat	O
,	O
focusing	O
on	O
the	O
possibility	O
that	O
activatoin	O
of	O
ATP	B-Chemical
sensiitve	O
K	B-Chemical
+	O
(	O
K	B-Chemical
(	O
ATP	B-Chemical
)	O
)	O
chnanels	O
is	O
involved	O
in	O
the	O
repsonses	O
.	O

The	O
resluts	O
were	O
also	O
compaerd	O
with	O
those	O
of	O
vasoacitve	O
intesitnal	O
polyppetide	O
(	O
VIP	O
)	O
.	O

Heoldermin	B-Chemical
produced	O
hypotenison	O
in	O
a	O
dsoe	O
-	O
deepndent	O
manner	O
with	O
approximately	O
similar	O
potnecy	O
and	O
druation	O
to	O
VIP	O
.	O

Hpyotension	O
inudced	O
by	O
both	O
ppetides	O
was	O
significantly	O
attenutaed	O
by	O
gilbenclamide	B-Chemical
,	O
which	O
abolished	O
a	O
levcromaaklim	B-Chemical
-	O
produced	O
decerase	O
in	O
artreial	O
bolod	O
perssure	O
.	O

Oxyhmeoglobin	O
did	O
not	O
affect	O
helodremin	B-Chemical
-	O
induecd	O
hypotnesion	O
,	O
whereas	O
it	O
shrotened	O
the	O
druation	O
of	O
aectylcholine	B-Chemical
(	O
ACh	B-Chemical
)	O
-	O
produced	O
hypotnesion	O
.	O

These	O
finidngs	O
suggest	O
that	O
hleodermin	B-Chemical
-	O
produced	O
hypotesnion	O
is	O
partly	O
attributable	O
to	O
the	O
actviation	O
of	O
glibecnlamide	B-Chemical
-	O
senstiive	O
K	B-Chemical
+	O
chanenls	O
(	O
K	B-Chemical
(	O
ATP	B-Chemical
)	O
chanenls	O
)	O
,	O
which	O
presumably	O
exist	O
on	O
aretrial	O
somoth	O
mucsle	O
cells	O
.	O

ERDF	O
(	O
endotheluim	O
-	O
derived	O
relaxnig	O
facotr	O
)	O
/	O
ntiric	B-Chemical
oxdie	I-Chemical
does	O
not	O
seem	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
ppetide	O
-	O
produced	O
hyptoension	O
.	O

Lnog	O
-	O
term	O
efficcay	O
and	O
advrese	O
eevnt	O
of	O
nifdeipine	B-Chemical
sustianed	O
-	O
rleease	O
talbets	O
for	O
cycolsporin	B-Chemical
A	I-Chemical
-	O
indcued	O
hpyertension	O
in	O
pateints	O
with	O
psoriaiss	O
.	O

Thirteen	O
psoriaitc	O
patinets	O
with	O
hypertenison	O
during	O
the	O
cuorse	O
of	O
cyclosoprin	B-Chemical
A	I-Chemical
tehrapy	O
were	O
tretaed	O
for	O
25	O
mnoths	O
with	O
a	O
clacium	B-Chemical
chnanel	O
blokcer	O
,	O
susatined	O
-	O
relaese	O
niefdipine	B-Chemical
,	O
to	O
sutdy	O
the	O
clincial	O
antihypertnesive	O
effects	O
and	O
avderse	O
evnets	O
during	O
traetment	O
with	O
both	O
drgus	O
.	O

Seven	O
of	O
the	O
13	O
pateints	O
had	O
exhibited	O
a	O
subcliniacl	O
hypertensvie	O
state	O
before	O
cyclosoprin	B-Chemical
A	I-Chemical
threapy	O
.	O

Both	O
systoilc	O
and	O
daistolic	O
bolod	O
pressrues	O
of	O
these	O
13	O
ptaients	O
were	O
decreaesd	O
significantly	O
after	O
4	O
weeks	O
of	O
nifedipnie	B-Chemical
thearpy	O
,	O
and	O
blood	O
presusre	O
was	O
maintained	O
within	O
the	O
nomral	O
range	O
thereafter	O
for	O
25	O
monhts	O
.	O

The	O
adevrse	O
evnets	O
during	O
combnied	O
therpay	O
with	O
cyclopsorin	B-Chemical
A	I-Chemical
and	O
nifdeipine	B-Chemical
included	O
an	O
inrcease	O
in	O
bolod	B-Chemical
uera	I-Chemical
nirtogen	I-Chemical
lveels	O
in	O
9	O
of	O
the	O
13	O
ptaients	O
and	O
devleopment	O
of	O
ginigval	O
hypeprlasia	O
in	O
2	O
of	O
the	O
13	O
paitents	O
.	O

Our	O
fnidings	O
indicate	O
that	O
susatined	O
-	O
rleease	O
nifdeipine	B-Chemical
is	O
useful	O
for	O
hypertensvie	O
psoraitic	O
ptaients	O
under	O
long	O
-	O
term	O
treatemnt	O
with	O
cyclopsorin	B-Chemical
A	I-Chemical
,	O
but	O
that	O
these	O
ptaients	O
should	O
be	O
monitoerd	O
for	O
gignival	O
hyperplaisa	O
.	O

